<SEC-DOCUMENT>0000882095-21-000013.txt : 20210506
<SEC-HEADER>0000882095-21-000013.hdr.sgml : 20210506
<ACCEPTANCE-DATETIME>20210506161156
ACCESSION NUMBER:		0000882095-21-000013
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		91
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210506
DATE AS OF CHANGE:		20210506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GILEAD SCIENCES INC
		CENTRAL INDEX KEY:			0000882095
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943047598
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19731
		FILM NUMBER:		21897876

	BUSINESS ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6505743000

	MAIL ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>gild-20210331.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:62245928-4256-4115-b52c-a224301f8b52,g:d7709fc8-9a45-40b0-bb7e-3c2cb616ef14,d:5e8b0e18419843159ec07e1b794d0d87--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:gild="http://www.gilead.com/20210331" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>gild-20210331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180L2ZyYWc6YWMwZWVmMDk0N2U0NDE0NWEzYjkyNTc4NWE5NjgwMDAvdGFibGU6ZjQ3YzM2MjUyYzZkNDAwYzg3MmJlZDViMjEyMDBlYzkvdGFibGVyYW5nZTpmNDdjMzYyNTJjNmQ0MDBjODcyYmVkNWIyMTIwMGVjOV80LTEtMS0xLTA_fc272212-66ff-4d92-b214-19df2a24189e">0000882095</ix:nonNumeric><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180L2ZyYWc6YWMwZWVmMDk0N2U0NDE0NWEzYjkyNTc4NWE5NjgwMDAvdGFibGU6ZjQ3YzM2MjUyYzZkNDAwYzg3MmJlZDViMjEyMDBlYzkvdGFibGVyYW5nZTpmNDdjMzYyNTJjNmQ0MDBjODcyYmVkNWIyMTIwMGVjOV81LTEtMS0xLTA_fde70f86-f517-4697-9a8a-5b723368a602">12/31</ix:nonNumeric><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180L2ZyYWc6YWMwZWVmMDk0N2U0NDE0NWEzYjkyNTc4NWE5NjgwMDAvdGFibGU6ZjQ3YzM2MjUyYzZkNDAwYzg3MmJlZDViMjEyMDBlYzkvdGFibGVyYW5nZTpmNDdjMzYyNTJjNmQ0MDBjODcyYmVkNWIyMTIwMGVjOV85LTEtMS0xLTA_af1809d0-f2be-4f87-9f86-a8f8ea3ba598">2021</ix:nonNumeric><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180L2ZyYWc6YWMwZWVmMDk0N2U0NDE0NWEzYjkyNTc4NWE5NjgwMDAvdGFibGU6ZjQ3YzM2MjUyYzZkNDAwYzg3MmJlZDViMjEyMDBlYzkvdGFibGVyYW5nZTpmNDdjMzYyNTJjNmQ0MDBjODcyYmVkNWIyMTIwMGVjOV8xMC0xLTEtMS0w_169a8f30-a9e0-4259-9cf3-6d54c74801a2">Q1</ix:nonNumeric><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180L2ZyYWc6YWMwZWVmMDk0N2U0NDE0NWEzYjkyNTc4NWE5NjgwMDAvdGFibGU6ZjQ3YzM2MjUyYzZkNDAwYzg3MmJlZDViMjEyMDBlYzkvdGFibGVyYW5nZTpmNDdjMzYyNTJjNmQ0MDBjODcyYmVkNWIyMTIwMGVjOV8xMy0xLTEtMS0w_d3354405-e710-45b1-ae0e-30990961483c">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="gild-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i59d6a509af4b42e1a99d44dee3d8c20f_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if18ad61a4d694b84a567b29c22cd074c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i869fada8dc15440fb186758025e4ea38_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i888db709f4bb4306aecd55be57d43e9e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d0a665778d14bbb912aa93b2b6e4f2e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e94052ecbb3480d9dda10de813ecacb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4491879c7fcd415288701f6b62e40e51_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13bf16e2c0cc414ca0e4618b4219c2cb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id315795d1e774a6a845a09bd3c23f669_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i631a0304196e455e9a985f2aed12a21c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ceb4b2138664055958fd36c771ef719_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22e6def1ee614c1f88a734ccf8b57339_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49ed492a453846c298f340cfb12aea93_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f56585e4ce041a0a4818371afd20608_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e9ec92ee61543dbb61d2f855c0a785c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33e7b278cf744482b55f1a9184b9c0fb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cad2b62afdf497cb6d680783df2564b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e12da2f502648b1b1cfe3c2ce745770_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideb5f8dc0c4442658f18eab50f25a677_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aa770dc5dd844ef8a4c9f16bbad3843_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59a30e5469c84cd78e03499a820d4cfa_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0e06ce8778849a79902920387c413c1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic27cb3c440c3422fbad61655cb15c60c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c7b9ebee1f549d198ceb53ea6813141_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58c9bc44b74c412ea8a63c832add3283_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0484fdf9aa034ecd94e3797e7f978bdf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a8779a54fef4be683c8d4f7e5b601ac_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17fa9a1c26714f1587a2aa325624b533_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="gild:CumulativeEffectPeriodOfAdoptionAxis">gild:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48b7a28e035547fa89fcfc8c0593b301_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:CumulativeEffectPeriodOfAdoptionAxis">gild:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2835b80e3c7a4d00b23cdd84912a90e9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f2d827efd2a4f4a91dee3811a501ecc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dce18c9540c42d6ae4ba9bd85b66896_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dd270c88164436597aad1b5ed3cb4ef_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6ecd38b92444ed38d13e95fbd53341a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ca6dc703a0d49718435076c33ed0dbc_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i887b76714c9c41c4a6db53d46bc0f6a7_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51b7741d7f0241a9a5987bf6c4f4f41c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaa5a801f01b483992e5c3baa5e7844b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i118f3a03d85d40aba97d7091b6ac999f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3f0f2350f9c47889d2e1afa48054b12_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>gild:segment</xbrli:measure></xbrli:unit><xbrli:context id="ie434694a2f304ecd94c3775324b4378d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied66863fda3841ad881df6b37123aec9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeff20e2f7ee495db92fa4c3484b89a8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0438c7b3d8b44618b0023cd7a41ed6d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5f03dade66d4049ac775a2ff2e95578_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaffbd58e1c6444dbbb5947207f1292df_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1af19a68a52f40feb3f105f7566f6acb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id77a0ac827ef47e490fe49f7648d3b55_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bcc8d5fc46645f296ca7a59cd624b53_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7754da6d6ec44b0e944fa8f87cfe572d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93ea9ae384744892b920c309bb2dc11b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b9480e8d66b4593ad97e4e5be56077d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i860dabfa33e143bbb52212212435f1ac_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32acee5874f9459b9252142abdad455c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8c9ead692aa4d9b810f9ec7db117251_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8c7336c5e6147e7adf7d7c7affa6881_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2462c72487a94e59b5caf6a5a319777f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i926db54afaa349f6af84a0c3e2544b96_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ec0f287f8ff4da3820bdba4ffc47bc2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3fd650f8abb4697adb1f0f30c929d64_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74acc5bbd8d34c738b16ae51a6075385_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15469494cca5432aa408d46c88acabf0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d5d49b7149047bab9ea616bba4640f0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8809e89136714bbbab87f233c9eadb83_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id32809760dcc4f69a8dab604473dba7f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib508419ccb58428e84530322853938fe_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25554b833ac44de8ae88e315443d09c8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78b9775b1d1b40319b1f9d7183321020_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63920a1a040e417891a03f303d3bbcad_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia590ce34497d4eaa86fa2b29038aabb5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eeed5ddca31468cb705d74685f56174_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64b13d2f087c45bd9fc1acd32cd1ef64_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63ae64a7b8094554852cb98b0a551090_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic110886142334d548f1d0723e44253d3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdcd081c4a4c46029ac68f60d58be6aa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0410e8fcd4043e490ebbf9c80ae64b1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib630252d0da14149adffcae74b86e4e7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bec6854dc6b4f04a8e737cd53521147_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0ebb14b7645429db55c7da591d24c92_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d00d8d104314587b42a25a2edff05da_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a6f431e5de642bba69f6328f2961f14_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99ccdd43f15d46bfbdc7e4ea02150055_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5661ce6a8f840d1850cebad529dc17c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8af148cdc07347ba838fdffde80857bb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie65015860c764edfbb86c8af349ccd93_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b044c57517f472a99248ee2666230e0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie915268dd561478f9d1b79082fe9e92c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c5a0930911c499688e99f6e08ca653c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4618b8d2431482ea6b2b45a2b50b865_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ed385b62afc49599835c73bd497620e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d7e6c0864674e51b116a0887e955135_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f3c8b7a52cf49be80972340697e8657_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a691facdde446d09127f1d0029b00a8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic621020502cb4461b3f507d17a78d96d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9944473064fa47dcbb264707adb1876b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2e742eaf2b342098a385d2addbe3722_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i588d3a5b64fd4b7080b0056b85ea0150_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33b30c8afa7d47e59e7da726ed9b9890_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03098f2d9e664ef285eee0bbed328af7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38535068021e4957bf196cb0586b1f95_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie91ab1070982497baf8fd021259bd6f4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77d7d1bcb69242afbb3209274bf2e205_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9079d3cc20b47f48f6dadc7048847b4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5c79c7043994738bad7f7620e19bd9c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib54f9224b2d046a7ba0fb1790721cc77_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f0e9b7992f04bd4b7a98d3c40e33e6c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1bfaa1d7b2047c8b0243a6fe75777de_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6a1884c73a14fabbeac29b5261925ce_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9213a6fb817f496f82175fdabab96f9f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id25b065da243414e834f92baa87571d1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd4289b827184b00ba7eb9735afd98c1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7f221d836804ac0ac5bf313e85fb6d7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38b3924c6f0c441c9eb7e6c652985a59_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i685ce820b15c48c5a1caa899b5612367_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica58dd4564944ece805e2d3c625a68a5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eac58164bb8445e95ecf5a632b200e5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5a9b0307d9f4396804a48e8a8842af3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i405af8d2ac694bcba3c274ea467fe4c5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4b1a067e082487a8eba535819944c84_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ad7557b78564109823d84b4134cb07c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19c918e9779d45728feb8d2f77e6f762_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84672c37600c456ab352a9bd8d1c0bc1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a8a43acfc2946a2bb710af0e9617ab5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61244f5bb1eb4b01a880be330bb43ca1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9695a806ea324bfd8dc16e1026c867b1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28b0923ec98c483796a4a281d6f4da09_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f3114f39eea433da4c3f4769d416586_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia68c505daaab4913bbd9dbc115125ca6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01820e105c11483b98e41dfe3ddbf458_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46a4791353fb4785b0fd7e420b2475dd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6903aaf9e2c46dd8097d605617899ff_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cedb25ca5664766987bf8d01722d958_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd6d40d2852e487fab1dc8033ea98643_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f2e37e070de443485aa360d17396ef9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i926b41607fcf4d478d80f477c8e14d41_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib18a279ca38b432890071110c7674594_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e7edf182cba4fe09b32a83db26b4422_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec3036fbf5cb40bc8c7e26870944ae22_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51bdb311ba0f467c84b98f56b3828ae6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92d6c64051da48a8a8e6f80486b979bc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb14461498914ac79e0457757c75dbd7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8d0518889a34fa2998643c6c7727744_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba550e7873fd45c6aff0245542583cad_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63580e96633b4a5e805fcfb22890f21f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbe86121ebc04ad2a0dac3152347a17c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3261f10427f747079f2363eba0693663_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f5059f19d2d404d9f5b485c545a5334_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if27f6ff654cf4f2aa404dd2e82fe05b3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb4b9a4d69dc4a5b969be42cf4ab5ab8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54a8ecbfe7104cffb328730f7e2f2ba8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icabba3a157cc4c89993c0a6f7b81fbf4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec98ee45e5ad401eb35c35717992014d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cab6459ae2e4342bcf14bb7f0922405_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if127a72225484fd3bd781db0b605a953_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d2f28f5774846bcaefb219a74d26197_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1df4119b39b941c5a676e0d6e2524da4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8d501a125774436b2320401b2dd5bfe_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id015d46967b94673ac7fb2ecc01b0237_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4660e6236c694b5ab8b1df8d62990e36_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0789c28a8de462d9aaa999b30d2860d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i675d50c435a342b58fa7e73781175e88_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i360f92e56eee4f9cace9fa5368873470_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bcf031777e242c49d6e3dcb11d0d8b4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1a9d40b8bca4c5ebf598872fea64e39_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if969bdf4b849499da19c7f7222a8956b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84671f49939d40bc886c4b2114546e68_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2772b321f6f54c0c86bea892e8380009_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic526ab60ae6e4f5793eb51c0321f5905_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id610eb3a322f41c8a749fe84d536e585_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica526b4aef3a494aa2733999ba191001_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bc50922e47b41d1ae940b37d4a22377_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88ec94f0555e4aebb035ebb5e2f4925a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cc4334126ed455ca10fd4f18e8f5b4c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ff242a9f3684b65bdac58944556d71a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab32fe9b37b248d29bd625882511a2bb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia54a8c84a9224b4aa1d3a5f8e35961cf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3432013787d441d5ac3a3a61b439dac3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib78feb1672bc421087bf1d5bd26b7f38_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b34a41296624040be895c5b6d3289a3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85236c36163f4119b8910a94fbd2562f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1912c5f855804d3eba84607a017c56ee_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b6a5426bf9c42a6acc2bf5e17b270af_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60e4866d36c54935ba04c29bb4fca09d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6db1d7fe6dbc4d6ca143fc475b93b204_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc5ca7d98d3244549154eef3bc1137b9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5777618eff474b979c73d1e5bb0bcd06_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20c40061142b4bff954eed33447b411c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib68625c89e0942cda48fef6469af6e0b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8c748ed1b844524849ec04f66244abe_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37dae4cebdb14befa776bdc7e3990bdc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37cc9d8c63b54982bdae48850a893359_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i897fee00cdd84fe19bcc2cc8dff383b3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b087aba23654283a5c4af9b69a0202e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeb98b603f06451ead95cabe282463e2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id37d8e541c21407bb4a5f8243c09f13e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7ec4f656f3842acbe27241f7f05ed2f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id69e1c2be46d4ab3b4309b0f917bbc46_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1667d7f2806e4f558140470b36628aa9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2328db06206c4fdd9af385e7c2173cc1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f4ecee25efe4513b99dc58abd0fe3a2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3005b97b85247b7bb0b10e165ad5a20_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf31979b82854addb363f690711744a9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c18a34a44ac4a6eb3e0df9bd9f9bbec_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5b81cbd589447aeb09c7c7271354585_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a2f8ebf252349c19b669e8c8082fec4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7413a3522244628851987c3f80b566e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13d9726cce774f76a579a5e8833f0a50_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id035c0dd020540dd9baeb1cf7dc147b5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieffdb1acfae64cf3893370c95966b40f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib75a2669840e4d33ba162e40920c2dd7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43c8f799fa3c418bb426643d8c44cd59_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i770b79af85df4a5682a9ba6a0d5ab1d8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie36eeb702c1740afbd92eef4087fa2b7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie528cd0b9cdf4dc5a97392412c208b8c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95f4d058a72e4ceeb60de778690ef7c2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie77a01ccaa114972a96aa9c83d1e2ae4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e328dc77d9945ddb8c8684f306018df_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i638557b5d8cb4470bf95e691ee5ce53b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05bbfb8bf6fe4d4db64e6f86903a3437_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id31fed8e97de4275a24d7c4b6bdcd1ae_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i895202346b1e4f8e9fb49025b720a3e9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a4bec7cd2a7469992b30486d0367128_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd6d31d7996e46edbb7ee6b98031d951_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia884a4d361c549379ff1a1b4a3e743d1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e124cdf64ce4d42808bbced06eee17f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94c157660993467d933768c8d2aace75_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i765af031a6b7456b87400772e5870fad_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9bec1aed1d4441e84196a0df4aef39e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a6c817b9881419c843a0c4e6dc181a7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72493ff81994417eb27d02d1509511da_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84bc3ed5f80d4988b11e429d726f932f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if726dadc7df94416b6c217bdf80c23dd_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6640c16387c47d3a3a2b9e3877f611f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9418ff206901445b9b29378a177c1078_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95a67a6c1c934a8191082d5f097351ab_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic787aa223d5c4f5da13f043035ca0c4d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbcfbd0d83fd490a88eb77e4164e8482_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56ccd5f7a01343d2a2c516f6e998e3bc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i830a223d4ff2496b95fa59aa0e3e4797_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a0e2be2410b432f83a8f28ad4956670_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56d0c83af6c24195b5bf3247fc3a2a1d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f5ba02898844d3ea4c5f499f95e5fb0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20275018e0d44c51a225e199b4c27700_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8ac1fc0d9b04f45841b68102ff7a077_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc55defcbcf045f4926fb48eb0af8237_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie794e67f1815485d87eb5b97b42e3a28_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4c01e5b99d04896a602aacda729c489_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb5ad85e55c34064accc690566b965df_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i060769bd1274459796e6b5d21c6d2fcf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8116a166d7b441d2956497a975f03511_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i240d967d6df04f7b960c8bd653ebf8b2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i217f335d6069466ab81d2c9226caf8aa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fd3a3dc901f42628f9c5cdcd8c7c6a8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i416394b51cde4930982ba7a31e497d29_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if80f651125c7457f9c03c5bae809f7df_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29de68ae484845bbbcc46d9cef9b77cc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9cafed727b04b61a40c05a62b4478bb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91466ff987d24072b25a05678b2c099c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27f5ef98b94448b0b24ea64ee73bc0bd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i993d7e955bc24b07ac282e4ab68a7571_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e949706c1134da999d6dae385652030_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ec3ba3a461c4bb9a085047222875988_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2a556c276af4966a1f10ac00b2afafe_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1608b354af974844a750d7bbff9d65bd_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie622129ad8eb43a190e8eff8fa687ae5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f5fae6c59274f0c9e41875005ba8c44_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e613c28bb364cccbb5a721e8f1d7d7a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e45a6235b364a4bb66ea5322ed6de0c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52538488633a4641a1fb75bd6ea77c00_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife67fb52d10a4d4a9dc24e6e584d9f8f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77b40277de7045d1be5c4072ff5a78d5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d26210a184b4926ac141ab337c6d073_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2bdbc28395e4c749de3966f3d490986_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31d850a622e9469497772ed09d38381a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1dde27099e04e999e1d57d292d9919d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddfef4e9b501477bb8ed2bdd6115418a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i633cffc37fba44c896afe1666617e27b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i696ccf6fee89419a892324e7301d6a33_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if03f06d9abbc4d33994c24916cad8f2a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2da7f309c165427aaa64cd0d24fc46ec_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0f41ed705fc47bdad91b627766f40c6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i242ad95eb87d4a50a40c74136ce45ce8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4208030b6e11411a8b65bb4461639e24_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26be40f7eb5247d2a40cf54a35c01a00_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53b279b4db0f4f1dbfbb9132a4d78da9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6a7bd7ae51244859339deec6090a256_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eb69f03734240adab1da5d621476341_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i718d3fcd575e4cfcb3f142a29edf8c39_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i776c29b6bd8246b799595de5c9c32a6c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2d224f161354feb9e09b4ebb8e0cd9c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i001045f707f44a6f80dd8a8ca22a4bf3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefd124be7cd14a8cb0d1429c3a487683_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i027a876acd5948e39aaa2a168d3de1fa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8517e6b14d3e4e059d8471ac0f54ff42_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c6a2a79dbe141ba9c759468a86cea51_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85cbcbbe9efe43c6b5e7ac96bb4d64c1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a72c3a2c01447b1ba0c68c97b289ee6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f8b4813eba0494e93eda89e8d1553c8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i0bd483f628534e979ee1ef8021838fb8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbcb2718a9a24054beb14bb7fd018345_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd0ff86989784672bbacbf1f772f25fa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7f6740c84514432ac4d19cf79c9a9e6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia65096122500425d94f26b129443d35e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8763f2000062414b96d9bc6531fe8ab1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77440dee8e4f4c28b9284a8c1b5ee20d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0658097ecd9f4ed7a6c2540f41f0c3ba_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c6858c51c1e4711938e993b04877b4e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if96617e7cd54426a8d62efdc0b500ca3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0ad9df8e3f742f8a9d13605d46cdb6f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31c0a79638a0401ca700e01bc980c823_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b3360b0081141b68f60fc04b739a94b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93e1474c09ed43708fdbb6b69bc558b3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief5d8a88cb0c498aa5bab8062cadc5e2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e340b8dc03c46e9847845ecc93cd50d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a5e98f04e5240d491e0cc8b9dddefdb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97d51408424340dda5bf1d3aa89904bb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb8af5d71f544b89bc874338694fa854_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied9f8a90eedf43f299e27e814d996911_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07d6a99463d548be91dccf3d8477c710_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00c48252b08b4726a781e4f7f1713886_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i555b95565b354fac92b93a98e20786a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7f7eb5d72aa41e389a203f002990378_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iade14a2b611b4dc4a1182a5853afb334_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4464d90589e45bda0d671fed402ff0e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b417832f6cc49f191f7192d1a823352_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc9df4486c8247a19dc93d1ed8ddc162_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic28662f110d3489097e5bfb6893f2427_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic05e70bbe4b3409dae83bc7d0776ac63_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e9200ff492148ae8c58c24ec1cd7a91_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d0c1157b3a14d309db0f095df92bde3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i152ea6395daa4d07b42285941bcfdf86_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52d21135f58b461f951b28b78af74777_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i377ef2a3c67e4eddb0210c423899d36b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25828069eb6f42dd8588993c039568a3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3222bce3d3fd40099ca0065f76398572_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7823458e96f5434ba771f22ab8eaabf9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64c79cd884d64f78bc716dbc267e3aaa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00681abd09ab444f83e854d3a2172b8e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0d37ded2b7640aa9128dac07431cd34_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a4a45ef79134c3eb7aefea81863cd66_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b6fb120815b4e528bfe5109cd7d6515_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3664faeffef41cf8c6784e97bf9f9e9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia462feb041e340b58c473503f10bf35b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1db9c8c7496f46a8a743dffc446c7a18_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f4efed1bea843dc869bb5263b87e2ad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00a4be1eea0d49da818f2dfc2e5cfec6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3fb2529cb7c446b9a528d1a8b7febe6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88a5a0a5260942a38c682ec567b73ed3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30f95952d5ad4c11a2bb8bfb311497de_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49e347d7180a4083bef177c0caac5662_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19b688ee3c124c99aecfd55f3756946d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0f6e93e4ace4564af67e889d7a1da32_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ab32a7541324448912a25d6eb8375b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a15e23f32af40a1b8c8859ebe00a14c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ee618b24da746db97c20d8ee326d75b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ecc557b23e64f7f8b3e28f3bb1e98a7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c9d39b9d99e449cb7beaed696f22f66_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a792f48d4514975b5fc1c1b4ed9d133_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b4ada8e24d54ee1b49c8cb41dc0bb2a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f6cb1f3baba4062821903054d8f7abe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc6563b6f71a489583fb4e031963948f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ad38733f4904e358d2e5a32c94b2371_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9ddc669c48f47d4bd4a8213c2574ab2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied694544bbe046f5abc557c39b011a0b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3bc6d62c5104b8c8d39a0ae9f7af156_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id19a8a5f19494cf0b1f5311d3e01397e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i679d3266010f46df9faca1c635a05771_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie908d94aad8a48da9603237735f6394b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia516bf91deb6424abb224de23f37284b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ea5455638c849c895022cdbce0f998c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49ae8bae833b4b0296c3d14e93ef42cc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4a3d53db4d24b249fa3b917fb325e05_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86cb4e206c9e40978c991361828e2661_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic136b1c243ab4833b7ff10d92f76ed3b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i676cb8c8931248afb9e78b6bc23fc50a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5e8131ea89e4f1490b4e83e0d880fa4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i972f4f0a16784ee889562e13a1463c5d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac1c2aeaca014e89ae0337e0d8ff78f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6227824f558c4cf0ba46ee925f4ba83c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafe8c56a47ec438f9d41105497550c3a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia740610ef9fb41c794dfff273c3759dd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id021fadde4cf4151b8857bcbfbaa339f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idef828ce7dea449aa7d5797f8b58b3f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63e11f3f2e3d40369f3e6bd198c01b8f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08cfe9d6b24b4cdfafdaa13b884170c0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e6608db0e98415cb580d29b81c635ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i985051c2ebfb41d0b2027dcd0777c115_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15435e6a628245f9a04322eb3570b28e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib612747a67f64d9b91c1ab19e54958ed_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8330bb360aa481b97cd6a1b14847b1d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief0436ce6e3d435288b49bb3c284e932_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5405c11586b401189e38d818eda683a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecff646d1fe84980876d9a9c81fd66c9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdf1d864d25b418bb9159fa7600a42ac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a23cea7a9ba48798f1fd6bbaffb4921_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fc48886b65840e5a1585ee67a7e5017_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86da9eb4322542f1b0071e4a1ce91218_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96f6368de4194af297dac9a63844f55e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i712971393ae14ae89870e173db5b2a1a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1244e3889c7843578e273ee679a43474_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i283158ca5b0642c59af33bc78f9e3655_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85636e0ea3524ff98a8b2e838f9c8141_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7819b77653554557af820a95339c1b48_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82dd65450f234374bcea4a2190eb3484_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69731411c56349848eae4d9b486db920_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dee5b3f2c69441494dc09dbd6b1224c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87d4f540cc2348449700aa4e9824ba95_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i842226164126495eb19a5f6e285f7a87_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i775975dd06c34a91977a0d26c3c7aad3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31a2c0299c3f47b68f2ee84425bd6ba4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4079e9eaf1b42a79cea9514877ac8eb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i707925a6e11e4e8b89cd1de5486dccd6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9ff815d16ad4190a3c3cc2de4b5e390_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2cfe856897d47a4a15c011727b132a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ccba16f84d64786acebdc56d30d2961_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b637184cf1d4fd595b58c5754beb956_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a4c7af7aa214730805797a174566133_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if73c04ebb10b4c1fb24efca2362f9a22_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89f38dcb82a5491dbb25812d7738c19b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffef8ea761174ff198789287afe52e44_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a97739a676441f385dd15bc5a05b29f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69e005c46bfd4e5c8cfa65d68167b7ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfa8675ac1aa4739beb924a027e71114_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f6999e94a9b47b8836b7e7d12120eb3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96932fa83e584390b3f1d56742823d34_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia27960115dde4e8db6988f723a792c47_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if12b94fde2df458b856419eb60f3749f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie29dcd6fa2fd430ab157b38ccbb28d3e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5174f6004a743eb845f20ac1490f61a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e49f98b54ce4b26af2d8166b46b66e9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2408fe312f9e4448b357064015614afc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91624599719d473faf279a33da7ef5be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1ff20f5b83944dba31b16c66a70e1a8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a1a8f49d74c45eeaa8823dd49a9aebc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ff3207761de4a358076755192646e75_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i278cbd93950247099589a8c54d16f788_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>gild:position</xbrli:measure></xbrli:unit><xbrli:context id="i2964d55b3b0243efb3f22c4eed834d5f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dcabcb1cbf9400c95b149a28f9172b6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0315ed156fa4a999a216e7bf46cb806_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15db68ece60c4907bce23168391fc549_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib316497f09074016814019469a1c5282_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b3659e23b9d46dc913b50eb69f837b7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a4bb5869b2a4a65965e0573d5a9fc0b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15df5ed6d62b49e8bf563f685962e609_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb9b9032e3424975b8d41437080d8fd9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37496332327e49d2bfd711461be5eee2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84d63f6e0c374aa6a0d94624a78f5b37_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d0edd02c9c343938d862442b6afc2af_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91c1249190d841d3ac8dc4919431731a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a21b040839549338b52418d18bb1e17_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia692393a1fd94bbb97576f97ccd34cce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb12e9542cfd4e90b2dcab8f7f4c58d5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8653fde001146e0bea68d8800992d8a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied6ece005700482abaa15b4b44d0acab_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i638cafe3b48a4a748be6d8f1b169f897_D20210304-20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-04</xbrli:startDate><xbrli:endDate>2021-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibedf080b94a2460fb4f0a3efc0a14793_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a98f90b07b94f6c86e128d20787701b_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad268a44b5f2496ba16a02c95c0952e9_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4833c72c785b491e8f5afc3f5e83a942_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexForHDVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33549bbb2e014a6ab92f613d389caaf5_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexForHDVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0db85f8bde2e48919fd0edfbb47844d6_D20210304-20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexForHDVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-04</xbrli:startDate><xbrli:endDate>2021-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b3e846287d144f5a57024a1a2aaa1f4_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f919867053e472aa6823a950ddff61b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19a0802804904e31ba6efd10f1f3ea4b_D20201023-20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-23</xbrli:startDate><xbrli:endDate>2020-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc1e9ade6e414ced9c63b109438a49e7_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bbcce56feb74fe6a616f350aa562468_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aa9165e8567484387ecc5acb5b3f1e9_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyForMTNBCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf62e749ffee4dcc9a54082aaa23c3b8_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05a08140a83742d99cfbd0fcb20b09fa_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d12086953934504ada4ca8bfb4497b1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia02e3e3eb61e4722a1d82ca5bfeafc26_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3231dad87cac437aaa04d35fce3d9824_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8222759ba26347c3a6f92ef2992fa9a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56a8801e286d4710aab30d8ef3145cc8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyForMTNBCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8a8bbb1048e4a4db06008d8d902d2a9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyForMTNBCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42d240b01e18486db9a4e93c058e1eb9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexForHDVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86ef6063e2dd483ebe6c5dcca3038c73_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexForHDVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if32750d98ae2460aa464be3d472d1042_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0ac0434166243fdbe064ef57c4cf330_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf9f311c0c5a450295b3455afad3eb99_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04105952f21b49fe8cd9befd11b8c28b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e6af3a3c95d4c1689521cc7dae5427c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bba91958aca44f293ca49c63fbaafef_D20210313-20210313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-13</xbrli:startDate><xbrli:endDate>2021-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37ff3780af8f4a3e8fb8ad3d11da24c2_D20210313-20210313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">gild:MerckMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-13</xbrli:startDate><xbrli:endDate>2021-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bb0786a7089452eab44f7d3f2844758_D20210313-20210313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OralFormulationProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-13</xbrli:startDate><xbrli:endDate>2021-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32ac5282522a4590be96101bc1e207b1_D20210313-20210313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:InjectableFormulationProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-13</xbrli:startDate><xbrli:endDate>2021-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id660245607b543dea4f85f3873880146_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdce32802a20413da082d4b864fd5089_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i410db304976646ba98567afb20cfa4a0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a3b8026d52f4290b417e3f5e019a0ff_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e3646c5f44b457faaf84b163f791ffc_D20200527-20200527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-27</xbrli:startDate><xbrli:endDate>2020-05-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a6c487393e2416988fed705f84d74ee_D20200527-20200527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:CommonStockPurchaseAgreementAndInvestorRightsAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-27</xbrli:startDate><xbrli:endDate>2020-05-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5fa445c6c284cf389eb387244e326c3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie247b2a21d0b41a8936b62106a17ef12_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id981d1fa90ad4e34a3646bf93d286389_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueApril2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddf64755f5544f55a023159b39cd796c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueApril2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ef8f9839275426e96e11272486fcf64_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i226f19faf322425f8f45de6324e4ddcc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0682f9735fe421db3f9c49bed1595fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e07919b5c964bd1a6f6261698386d5a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A440SeniorUnsecuredNotesDueDecember2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie96a1150c9f54ebbb4aeeeac86d5d0b4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A440SeniorUnsecuredNotesDueDecember2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4560703e7e434329b08f919b7ec93556_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A195SeniorUnsecuredNotesDueMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d7b8c0c53ce4856b17e0c17548ab01b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A195SeniorUnsecuredNotesDueMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42ab2dc4d1f3427799326322503aeb9f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A325SeniorUnsecuredNotesDueSeptember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e00b7d5eead42bcba3eb2cf1ac7ef4e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A325SeniorUnsecuredNotesDueSeptember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31c5d5f5c24240f88a2fbf3010130c04_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A250SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a5500ac6a4a40b4a0ce85e93cb1be81_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A250SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84c7098c5f6942d6aafc60e537b25ace_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d84c0793a654adc835292e4057e62af_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc91e8dffffa4c25b54f3376c5704709_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b064cf950804b14bb98c71681dbbe38_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1cfc9d0baa34e13b8b793bd53072677_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5caff279b30742e699b0222a2e09750d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:VariableTermLoanNoteDueOctober2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f01ef44785a49f0bc8f3ed2a594041b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:VariableTermLoanNoteDueOctober2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82712a6fb96b40d1ba7af885131644a8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A370SeniorUnsecuredNotesDueApril2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02153ca61e2240f8a5f4caff17673c80_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A370SeniorUnsecuredNotesDueApril2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd2dbc82577249dda35b4d5bf8355af9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A350SeniorUnsecuredNotesDueFebruary2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie93b3397067946b99b504b92e01bc73e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A350SeniorUnsecuredNotesDueFebruary2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie111efaeb3a5493fb1836bdd7dd01efa_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A365SeniorUnsecuredNotesDueMarch2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37798ead586444438d3256c1b09bc74c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A365SeniorUnsecuredNotesDueMarch2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ab5e1d8ed5a4d4ebb33b172197fddbc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A295SeniorUnsecuredNotesDueMarch2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cc4906eaff642878b6f94791e6e1015_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A295SeniorUnsecuredNotesDueMarch2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41f044c9e0ca469e8e21f44e347cf6f3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia277d47a2bbd47a4bda96e51633f0028_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06b11f61f1c147e092d508e568092b9d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0607a5570b824496986ded1619166b26_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bb341107e2a4b88b6060a86a8e386e2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A460SeniorUnsecuredNotesDueSeptember2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i649ba66e7c7f4344a91edbb3d0ed8c94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A460SeniorUnsecuredNotesDueSeptember2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i461c85d95d204d8b9943c1284aed4e98_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A400SeniorUnsecuredNotesDueSeptember2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic58ce72e2e4849669af1178aea5ff019_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A400SeniorUnsecuredNotesDueSeptember2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefd9e7139a3441e891c9c8d8134e4c6d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c5e44c87f514190914febaeb7ea34b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bb3588ac15b409787bad99b65f13969_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A565SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id64726640cdc49ae9944b3cafdf07c69_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A565SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7030cc99c6824dc0a8042a4bed018068_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A480SeniorUnsecuredNotesDueApril2044Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5dfe2f629c047abb4f613b421c5ea88_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A480SeniorUnsecuredNotesDueApril2044Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaf8c9742e0b4ece8d7b8394db2ca224_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueFebruary2045Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0aa69e4a48d34c5da5aab157a2293340_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueFebruary2045Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65459f3f8cdf4c0fbca4efc6938b38e0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A475SeniorUnsecuredNotesDueMarch2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7771d37672d44616baa7902fe05821c9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A475SeniorUnsecuredNotesDueMarch2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e2b6e7d9810413789463933aef23466_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A415SeniorUnsecuredNotesDueMarch2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae31ed5d6fdc4498b6a90dbfc8b86b3a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A415SeniorUnsecuredNotesDueMarch2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4e384c2073a40b39d85efcab4bf3ee9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81921ac030614d4f83c0267cd19a94f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id10bca8646004217ad83ef4814b3a4a9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie72718e6c6b44809858a4b6a4ec81ed3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3dbd1bb43e241408c3dee0863ca9f87_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9b223edf7794782b8bfe9faef909258_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i608d56f7947f4ed8a1369997dcdee599_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNoteIssuedNovember2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e2e8987386644709b5eece8fb454a57_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i970db95a26094960bfc48e49693d580f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16cafbaeadde42a9815b149e242ae829_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c3a790a1deb4b198ed2f54a96f31ccb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6d3b14fdf7c4b5eb29edbe4dd41290f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id74ea6000e4640078ac1bb187f3e6b5c_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibff1240b05f74e8bbf297b65247ec996_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2516fe8e62b244c1b6bc3ae3b23fb48c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43d6693463d944d28b68b70f837d5ae1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bf3308623744494a7125eb9515bdd4a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i190cbe2a2a9c446497a9e647b03a5b69_D20180207-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ViiVHealthcareCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-07</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>gild:agreement</xbrli:measure></xbrli:unit><xbrli:context id="ibee266afb5b04b4db218d2019292d0cd_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:PreExposureProphylaxisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>gild:patent</xbrli:measure></xbrli:unit><xbrli:context id="i9e2d7de5386e4c88ab9f4aaa94c77fe9_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="opposingparty"><xbrli:measure>gild:opposingParty</xbrli:measure></xbrli:unit><xbrli:context id="ib51fb29ce69647fcba6f2f052669fbed_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaimsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ae8970b904f49c99fc9ef1c33c59098_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaimsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d4fda0dfd5c44b09d04f6e618870a0a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaimsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="party"><xbrli:measure>gild:party</xbrli:measure></xbrli:unit><xbrli:context id="id9fd61e590a14210ba14b89a9af49a7a_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaimsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6905d9942f5a4f50abf9170409131c14_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaimsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>gild:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i39c4711339df49138fdbd03e8ed2571a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ProductLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>gild:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="i6e3291601bc74013bce40b293768f095_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:QuiTamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic57a1e59e1024277b33535c08ac1107b_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:QuiTamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i891c637afe3247688741c781d552db7a_I20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2016StockRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e485618ab80414bb2d0af91dc1e3dde_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2020StockRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90c7f28364e54993b67eae1023b738de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i157cdc9a965446c9969cd003d367f516_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i252e49a6c063428f959d1aefb1686cb7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i950fa40a56274ea0bb64105a4547be31_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i777694101d38407bb54ae3e8cd5cee81_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id773468e90654dd8b93c841e0cb1a4f1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74a3340bf967422db6145ae553899ded_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i841123aefd8d43d8a410b8754e996cf9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5050a35f97640609878001cc93224f3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d8ba4328011413291632383906e71c4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70187083484a4893bef3cc4b8f7bb49f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01bc5741de984cbc967d805c30a354d1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic65478d3665c420fb62c02fb229595b5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8ecd1344d59495b906912f07829d102_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea5ded2b35d44d24932e27a42a2fd41d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55db8ffa0e8944bfb28e03d449bbd545_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie621feabbb3c4e7e89573dd30bc4a6a9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1502d914c22f4785a00d85c5a6112310_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00cafa1b2c044278a85e4d45db30d3b1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gild:GileadFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gild:EquitySecuritiesDonationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5e8b0e18419843159ec07e1b794d0d87_1"></div><div style="min-height:33.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN184OQ_71f71220-e2fa-4221-b331-73ae96c371b8">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.862%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGFibGU6YmQxNTJlM2IwYTllNGM5OTk3OWQ5YmRjZTdmNWExZjMvdGFibGVyYW5nZTpiZDE1MmUzYjBhOWU0Yzk5OTc5ZDliZGNlN2Y1YTFmM18wLTAtMS0xLTA_4c9c53fa-9974-46dc-b7dd-832cacbef8f6">&#9746;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18xMTA_b812b608-6739-426c-bb31-45b161239c9c">March 31, 2021</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.076%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGFibGU6NWJhNDExYjhjOWI0NGY4Yjg5NDFiZGVhYjllZmEyYTYvdGFibGVyYW5nZTo1YmE0MTFiOGM5YjQ0ZjhiODk0MWJkZWFiOWVmYTJhNl8wLTAtMS0xLTA_2c4a7a4e-e97a-4e42-bd08-28ea303e19a6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">     For the transition period from ________ to ________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File No. <ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18xOTg_75466917-1bda-484a-a80c-f8eb60af5437">0-19731</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18yMDY_3e2f2de6-9862-4a4b-b0e4-2491214eaea5">GILEAD SCIENCES, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGFibGU6YzdkOGIyZWNkMTc3NGNlMTg0NTMzZGE3MDE5ZWJiN2EvdGFibGVyYW5nZTpjN2Q4YjJlY2QxNzc0Y2UxODQ1MzNkYTcwMTllYmI3YV8wLTAtMS0xLTA_bcc76d95-99d5-46cd-9d23-8067beb01b27">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGFibGU6YzdkOGIyZWNkMTc3NGNlMTg0NTMzZGE3MDE5ZWJiN2EvdGFibGVyYW5nZTpjN2Q4YjJlY2QxNzc0Y2UxODQ1MzNkYTcwMTllYmI3YV8wLTEtMS0xLTA_bacb7874-6c63-4acf-9bad-4dc31bfbb876">94-3047598</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18yNzI_6a7d16f7-d820-4193-af97-0b8c9b1c9a1b">333 Lakeside Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18yNzY_909a5f00-15a2-4581-b945-260896eb7ce8">Foster City</ix:nonNumeric>, <ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18yODA_0f83cc37-f648-41d7-92da-56f65bd1cd86">California</ix:nonNumeric> <ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18yODM_5a858634-d2c7-4d5d-ab01-3cab5fc435e7">94404</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18zMzk_28dece6e-31a9-465a-83bf-17ed012eebb6">650</ix:nonNumeric>-<ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18zNDI_a40183d4-b028-4365-9d35-0963b135f19c">574-3000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGFibGU6YTEwZThlMjA2MTdlNDQyYmE3M2NlOGE3YTIxNzJjMWEvdGFibGVyYW5nZTphMTBlOGUyMDYxN2U0NDJiYTczY2U4YTdhMjE3MmMxYV8xLTAtMS0xLTA_61c7c803-256f-469f-9774-45459d8adb5a">Common Stock, par value, $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGFibGU6YTEwZThlMjA2MTdlNDQyYmE3M2NlOGE3YTIxNzJjMWEvdGFibGVyYW5nZTphMTBlOGUyMDYxN2U0NDJiYTczY2U4YTdhMjE3MmMxYV8xLTItMS0xLTA_45614642-2464-41cf-87ba-47cb011c7d3f">GILD</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGFibGU6YTEwZThlMjA2MTdlNDQyYmE3M2NlOGE3YTIxNzJjMWEvdGFibGVyYW5nZTphMTBlOGUyMDYxN2U0NDJiYTczY2U4YTdhMjE3MmMxYV8xLTQtMS0xLTA_55cfb4a9-fd6b-4e94-a20a-5d0c9b2459f3">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN184MTI_b9dfc64e-7477-447c-8f2c-ef7c31ff51be">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant&#160;has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18xMTMx_3fe0ee81-8b77-4abb-8cd4-1d8232651394">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18yMTEx_a1f8fb1f-2e4a-4d37-adc0-899e7594fe6f">Large accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-accelerated&#160;filer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller&#160;reporting&#160;company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18yMTEy_69565f5c-2c29-4d36-9f7e-165f49027740">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18yMTEz_48b68f94-436a-48a9-b676-5519a14f4b33">&#9744;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18yMTE0_985a2533-6e13-49b4-841c-9d4c0fb15d20">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of shares outstanding of the issuer&#8217;s common stock, par value $0.001 per share, as of April&#160;30, 2021: <ix:nonFraction unitRef="shares" contextRef="i59d6a509af4b42e1a99d44dee3d8c20f_I20210430" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18yMTA3_9b29c6c3-867c-4f2b-bd58-bd83130fa405">1,254,178,166</ix:nonFraction></span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5e8b0e18419843159ec07e1b794d0d87_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-bottom:14pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_10">PART&#160;I.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_10">2</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_13">Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_13">2</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_16">Condensed Consolidated Balance Sheets at March 31, 2021 and December 31, 2020 (unaudited)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_16">2</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_19">Condensed Consolidated Statements of Income for the Three Months Ended March 31, 2021 and 2020 (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_19">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_22">Condensed Consolidated Statements of Comprehensive Income for the Three Months Ended March 31, 2021 and 2020 (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_22">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_25">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three Months Ended March 31, 2021 and 2020 (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_25">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_28">Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2021 and 2020 (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_28">6</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_31">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_31">7</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_73">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_73">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_73">29</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_94">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_94">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_94">38</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_97">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_97">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_97">39</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_100">PART&#160;II.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_100">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_100">40</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_103">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_103">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_103">40</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_106">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_106">Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_106">40</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_109">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_109">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_109">53</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_112">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_112">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_112">53</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_115">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_115">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_115">53</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_118">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_118">Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_118">53</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_121">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_121">Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_121">53</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_127">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5e8b0e18419843159ec07e1b794d0d87_127">57</a></span></div></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We own or have rights to various trademarks, copyrights and trade names used in our business, including the following: GILEAD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, GILEAD SCIENCES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, AMBISOME</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, ATRIPLA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, BIKTARVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, CAYSTON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, COMPLERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, DESCOVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, DESCOVY FOR PREP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, EMTRIVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, EPCLUSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, EVIPLERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, GENVOYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, HEPCLUDEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(BULEVIRTIDE), HARVONI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, HEPSERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, JYSELECA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, LETAIRIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, ODEFSEY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, RANEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, SOVALDI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, STRIBILD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, TECARTUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, TRODELVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, TRUVADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, TRUVADA FOR PREP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, TYBOST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, VEKLURY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, VEMLIDY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, VIREAD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, VOSEVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, YESCARTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and ZYDELIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. This report also includes other trademarks, service marks and trade names of other companies.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5e8b0e18419843159ec07e1b794d0d87_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I.&#160;&#160;&#160;&#160;FINANCIAL INFORMATION</span></div><div id="i5e8b0e18419843159ec07e1b794d0d87_13"></div><div style="margin-top:16.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i5e8b0e18419843159ec07e1b794d0d87_16"></div><div style="margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMy0xLTEtMS0w_93f621d5-46cb-4dfb-9528-a48f77c0e940">4,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMy0zLTEtMS0w_2fda4ce9-855a-4ef9-b140-5754f63f0d26">5,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfNC0xLTEtMS0w_58c05262-2b89-459f-a39f-3a9f5d3e7364">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfNC0zLTEtMS0w_b7672691-cce9-4bcb-beb4-74f1f8cc5010">1,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfNS0xLTEtMS0w_c64279e7-ef97-4963-b0c0-339894c1e002">3,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfNS0zLTEtMS0w_c73634a6-1916-464f-bee9-b381dcfde58e">4,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfNi0xLTEtMS0w_940694de-679f-4703-95d0-1092df9b1e85">1,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfNi0zLTEtMS0w_3eab0329-3699-4a63-a92c-16535f3de705">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfNy0xLTEtMS0w_3b2651d1-027e-4e6c-9f6f-1711dd0b6fda">1,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfNy0zLTEtMS0w_7bee398a-7ee2-43f5-a714-9b04754dfe3d">2,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfOC0xLTEtMS0w_be93d1a9-4a43-47f6-be15-37eaf84a636e">13,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfOC0zLTEtMS0w_0314f905-b3d6-43e5-8319-0803414d1844">15,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfOS0xLTEtMS0w_b73408af-7b51-442d-ab19-e99a5c1be1fe">4,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfOS0zLTEtMS0w_5581dbb5-6e66-4aab-a199-941e9d4e6b4f">4,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTAtMS0xLTEtMA_94a94646-b527-45b8-9ce8-d91abb4d95cb">579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTAtMy0xLTEtMA_347a9d2f-1e24-46a9-a208-4b7e78d9a441">502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTEtMS0xLTEtMA_d21d0e2a-9653-4b3d-a2b8-597c9787bae5">34,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTEtMy0xLTEtMA_f39f9692-e555-49fa-ad29-178caf3cfd95">33,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTItMS0xLTEtMA_b30e43ee-acfe-473a-8bf0-bf3c77cd59ee">8,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTItMy0xLTEtMA_829e67b5-ab5b-40eb-acba-5ea8066016fa">8,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTMtMS0xLTEtMA_aee62e7c-c3e8-4303-a1dd-2592662fc257">5,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTMtMy0xLTEtMA_b7934ada-080e-4125-9093-a63fbd5fd01d">5,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTQtMS0xLTEtMA_9cf33a0f-4387-4224-a568-8ff3ee7d1e83">67,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTQtMy0xLTEtMA_680c05ae-6627-440c-901d-083c19483599">68,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTctMS0xLTEtMA_c47e2410-2d86-43ec-8918-4d4fb3eae377">570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTctMy0xLTEtMA_c51eb5b7-fb4f-4b1b-b68d-795a20fe08f1">844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued government and other rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="gild:AccruedGovernmentAndOtherRebates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTgtMS0xLTEtMA_20ce39c1-6b8b-48e9-a40d-3ff56c39cfd9">3,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="gild:AccruedGovernmentAndOtherRebates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTgtMy0xLTEtMA_30498650-4bb6-4407-80e0-b3d74b3b773e">3,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTktMS0xLTEtMA_f026ace8-65ef-4c2a-bccc-d54be97758eb">3,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTktMy0xLTEtMA_0fb0e78b-4222-47ae-963f-b18e519b5fd2">4,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt and other obligations, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjAtMS0xLTEtMA_5850bb1a-6dcb-4548-a40f-8202855222c1">2,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjAtMy0xLTEtMA_99026f24-82ab-4bd8-b2fd-ea021a121092">2,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjEtMS0xLTEtMA_8ab86197-9a98-4a48-8944-dba652ed39e2">9,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjEtMy0xLTEtMA_8733d043-44b5-4ac8-9395-3fbafe02eebb">11,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjItMS0xLTEtMA_82ccac92-2b2f-4c2c-9900-2884e2779db1">27,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjItMy0xLTEtMA_13aa4064-2979-49ee-9575-c19ebe4b9a66">28,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjMtMS0xLTEtMA_d94412ac-5e98-4073-8ef3-fd9c3f016439">5,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjMtMy0xLTEtMA_da4434ba-c206-4a98-a9e4-50980ee4adcd">5,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjQtMi0xLTEtNjIzNw_567728a1-4d46-4b3f-a7c9-24c06bdf02a2">4,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjQtNC0xLTEtNjIzNw_62154c10-bf7d-4300-a71d-fe3b0fa80ac4">3,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjQtMS0xLTEtMA_4a7f746c-a174-4778-aee6-f8dcc4751acf">1,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjQtMy0xLTEtMA_7ada551c-26cd-4802-bd2a-7c5f347f98ff">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 11)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjUtMS0xLTEtMA_e9e3993d-d0eb-4ffa-adc0-f294e345563f"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjUtMy0xLTEtMA_1b1d72f5-d8c3-44fc-a2ae-c1736f2f6883"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjZjOTYxMjJhZjA4MTQxZDE5N2NiODU3ZTQzMWZlZGI4XzMx_72bce3da-4feb-4db0-b4f5-6131bcc2eb7c"><ix:nonFraction unitRef="usdPerShare" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjZjOTYxMjJhZjA4MTQxZDE5N2NiODU3ZTQzMWZlZGI4XzMx_d3b10a9f-6fdf-45dd-a6d4-a941421f84fa">0.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjZjOTYxMjJhZjA4MTQxZDE5N2NiODU3ZTQzMWZlZGI4XzQ1_632b6792-6e74-41b4-901f-981e2e32739d"><ix:nonFraction unitRef="shares" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjZjOTYxMjJhZjA4MTQxZDE5N2NiODU3ZTQzMWZlZGI4XzQ1_d5ac34ca-da14-4630-bf39-ee97ac0eb212">5</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjZjOTYxMjJhZjA4MTQxZDE5N2NiODU3ZTQzMWZlZGI4XzY3_0a831285-ff0f-4d1e-997b-3af30a9685c7"><ix:nonFraction unitRef="shares" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjZjOTYxMjJhZjA4MTQxZDE5N2NiODU3ZTQzMWZlZGI4XzY3_7d797de1-fc21-483f-9870-11606a2e3b71">no</ix:nonFraction></ix:nonFraction>ne outstanding</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjctMS0xLTEtMA_0a96520a-3254-4894-917c-b62afb7230c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjctMy0xLTEtMA_d8060898-f774-499b-9c4d-bc2b4c791f73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjZlMWUzMDRlYzAzNTQzY2JhMDJiZTJjMmFhODM0MmJiXzI4_0b67891e-94f4-4f96-b739-7b02459b5954"><ix:nonFraction unitRef="usdPerShare" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjZlMWUzMDRlYzAzNTQzY2JhMDJiZTJjMmFhODM0MmJiXzI4_19941b0c-5736-4310-a3a9-101badfefee6">0.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjZlMWUzMDRlYzAzNTQzY2JhMDJiZTJjMmFhODM0MmJiXzQy_49f702ac-7390-4f18-822c-65b29e4c99d0"><ix:nonFraction unitRef="shares" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjZlMWUzMDRlYzAzNTQzY2JhMDJiZTJjMmFhODM0MmJiXzQy_86e2dfa8-bb83-48f9-95ce-11dc2fda9981">5,600</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjZlMWUzMDRlYzAzNTQzY2JhMDJiZTJjMmFhODM0MmJiXzY0_2cfdeea7-2663-44f8-a71f-40a1b268af6f"><ix:nonFraction unitRef="shares" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjZlMWUzMDRlYzAzNTQzY2JhMDJiZTJjMmFhODM0MmJiXzY0_3d4155aa-1318-4d06-bbd3-4eb6af547bec"><ix:nonFraction unitRef="shares" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjZlMWUzMDRlYzAzNTQzY2JhMDJiZTJjMmFhODM0MmJiXzY0_9a992112-7685-47e7-8345-f5ddc7b07b3f"><ix:nonFraction unitRef="shares" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjZlMWUzMDRlYzAzNTQzY2JhMDJiZTJjMmFhODM0MmJiXzY0_d858bc28-e730-4af0-a940-eb2725709416">1,254</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjgtMS0xLTEtMA_faddfc89-4495-4bd1-9abc-3c6573803c2d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjgtMy0xLTEtMA_3eb66a81-e838-4b02-890b-185dfe36e454">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjktMS0xLTEtMA_2e74b642-2882-44b2-9d78-58b59334ed55">4,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjktMy0xLTEtMA_4b3a1dab-a15a-4ddd-882f-7eb402cd07d3">3,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzAtMS0xLTEtMA_e2ec33ea-72f7-4d7a-bd98-b8cff4fa22bd">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzAtMy0xLTEtMA_cba489cd-af93-4c9e-bd0c-397e667a8b00">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzEtMS0xLTEtMA_d0e074f6-2110-4599-8d65-1618bc4259a5">14,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzEtMy0xLTEtMA_cea355e0-67ab-4345-a045-7ba1db918534">14,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gilead stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzItMS0xLTEtMA_58a092df-d91d-47b2-9cf3-8ba2543ef339">18,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzItMy0xLTEtMA_b3ddf38b-8097-4c2c-a6a6-e3571aa9f299">18,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzMtMS0xLTEtMA_9b17c40b-7269-41ef-890a-a57607a97721">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzMtMy0xLTEtMA_17b618ee-eaad-4292-9e51-b532c8dfa6db">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzQtMS0xLTEtMA_19e703d1-6b59-4b40-aefd-6b57df527e33">18,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzQtMy0xLTEtMA_93358cef-37b2-4746-bbce-f5456767521d">18,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzUtMS0xLTEtMA_19937401-c7af-405e-a80d-96aae80189e8">67,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzUtMy0xLTEtMA_1f7bd31c-27e3-4c99-9431-2780c5788bd2">68,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i5e8b0e18419843159ec07e1b794d0d87_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> GILEAD SCIENCES,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i869fada8dc15440fb186758025e4ea38_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfNC0yLTEtMS0w_1539724c-3a59-4ecb-bcd1-55d8be7cd3fa">6,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i888db709f4bb4306aecd55be57d43e9e_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfNC00LTEtMS0w_2cb93b0f-f3bd-41c1-abe4-589694d872e1">5,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d0a665778d14bbb912aa93b2b6e4f2e_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfNS0yLTEtMS0w_9e2e8261-09e4-4748-bb4b-402f5d75fe51">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e94052ecbb3480d9dda10de813ecacb_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfNS00LTEtMS0w_85212ebf-ebfe-4fbf-8fa5-cf196f15aeb2">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfNi0yLTEtMS0w_aaa9c345-ce60-41c2-bd26-587c8d5ff9f4">6,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfNi00LTEtMS0w_09a7911a-5a61-4d4f-958a-315e6e926a5b">5,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfOC0yLTEtMS0w_46d27953-a66f-4796-9f01-d0785bf74ce9">1,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfOC00LTEtMS0w_e2fdf623-6af0-4acb-bfd1-8e5919bd606e">969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfOS0yLTEtMS0w_b796dfb9-5e54-4ba2-8b9d-b44e6f27166d">1,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfOS00LTEtMS0w_e61039ac-526d-4d9b-99ae-b53621856276">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTAtMi0xLTEtMA_23b463bf-f810-40d2-973a-ebbf560f6ffc">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTAtNC0xLTEtMA_2f87f07b-9fb1-4428-957a-69bb03908945">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTEtMi0xLTEtMA_af777257-8432-4a90-b610-c13895f6ff9f">1,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTEtNC0xLTEtMA_ed18d869-3692-498c-9d73-8c9246316ac1">1,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTItMi0xLTEtMA_065e2137-1938-4c32-aebb-3c09578f5431">3,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTItNC0xLTEtMA_a0b5c44c-359c-4c4c-be27-0a11ba044f4c">3,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTMtMi0xLTEtMA_87ee0016-6dcb-4cd3-b449-8c395007916e">2,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTMtNC0xLTEtMA_809ac0e2-1c99-430d-81d9-5a4fac403618">2,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTQtMi0xLTEtMA_e5509fdd-f6df-4b58-843b-2ce9cf51802b">257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTQtNC0xLTEtMA_cecdf21e-c6cc-455e-9232-12be392c5b6c">241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTUtMi0xLTEtMA_7409c852-f4e1-4fe1-b92c-24d425957988">369</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTUtNC0xLTEtMA_bd1df6df-0913-4ec9-9ee3-215f221039d2">158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTYtMi0xLTEtMA_b942bcab-1ff0-4474-bbaa-52cc5468f9f6"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTYtMi0xLTEtMA_c9777f9a-f878-420b-820f-b321e78079a1">2,264</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTYtNC0xLTEtMA_184ab219-dfdf-4bcb-b1d2-5efa84b0a24a"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTYtNC0xLTEtMA_7ba11f38-6c28-492a-a952-d1d7f3eb11ea">2,003</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTctMi0xLTEtMA_d1b97bb7-88cd-4b11-bb64-5011cf02b82f">542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTctNC0xLTEtMA_d1e7da64-5ce4-429a-9276-e3d404fd2381">465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTgtMi0xLTEtMA_3749c92d-1abd-4115-ac57-17bfa85c550a">1,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTgtNC0xLTEtMA_70cdd4af-de07-4c94-9132-4b6c472492eb">1,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTktMi0xLTEtMA_076d6056-c32f-418d-8786-72fafb71fecc">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTktNC0xLTEtMA_1c70eb5e-187b-4961-bbc2-5c123bba777d">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMjAtMi0xLTEtMA_10e882bf-6385-4a73-aced-c87aceefdcfb">1,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMjAtNC0xLTEtMA_60eb6653-2a1e-42fa-b3bc-f864e3b37e78">1,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMjEtMi0xLTEtMA_a2654a7b-059e-4993-ba09-4dc3d7951ea9">1.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMjEtNC0xLTEtMA_c29ef92a-ce5a-4d1f-9c12-9d87de5d715d">1.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMjItMi0xLTEtMA_a1ca49a0-6d74-4275-81cb-d05d9896884f">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMjItNC0xLTEtMA_2ba753a6-cef7-4ba4-8f1a-373404742060">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMjMtMi0xLTEtMA_8a558bff-3436-4104-8b6b-8a473594350b">1.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMjMtNC0xLTEtMA_20a09fa0-4927-4bfe-83dc-2d1d0c1d64ed">1.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMjQtMi0xLTEtMA_9b19c8e4-7223-45a0-b5d1-9899e0c163da">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMjQtNC0xLTEtMA_37f7c369-dc97-4596-bf78-6f6c4456d108">1,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i5e8b0e18419843159ec07e1b794d0d87_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> GILEAD SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMy0yLTEtMS0w_3749c92d-1abd-4115-ac57-17bfa85c550a">1,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMy00LTEtMS0w_70cdd4af-de07-4c94-9132-4b6c472492eb">1,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign currency translation gain (loss), net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfNS0yLTEtMS0w_9e7dbddb-fa44-44f9-9e52-83191323088c">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfNS00LTEtMS0w_87140515-c651-43e4-9ef6-a76a13777d6e">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfNy0yLTEtMS0w_93801c46-9704-4ef5-a432-4fdd8d040adf">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfNy00LTEtMS0w_e46b5f19-5820-4208-9441-f50acfaf97c0">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfOC0yLTEtMS0w_2ef1ac4b-a93e-4e51-ada1-a3ad25ff7dff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfOC00LTEtMS0w_399f0645-3958-425d-a04c-04feb61bce5c">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfOS0yLTEtMS0w_461b484b-ee9d-4474-9b5f-8d32e474707e">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfOS00LTEtMS0w_c971c920-a66e-43f1-bafa-c1ad8a60e0c6">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain, net of tax </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTEtMi0xLTEtMA_02519809-a917-40e0-8298-a509e0fd5675">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTEtNC0xLTEtMA_a2c4d067-f673-47ef-a447-8386df22c770">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTItMi0xLTEtMA_eda07862-e7bb-4f91-9554-bdf80a161937">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTItNC0xLTEtMA_a5c2b89c-c540-450a-b740-22335a14aaa4">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:42.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTMtMi0xLTEtMA_15474330-6aae-4946-ae74-c392370ee1be">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTMtNC0xLTEtMA_6c0d917a-d94d-4af0-b911-e16ccafb6cc4">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTQtMi0xLTEtMA_8defcab8-d7ac-413c-9042-15e4340e0035">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTQtNC0xLTEtMA_8aca2f57-f930-4708-8cf3-06d7f0df09f2">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTUtMi0xLTEtMA_4858d924-4f9f-4d94-8627-43e3ce331649">1,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTUtNC0xLTEtMA_33ffc505-a405-4b55-a320-e8158c34963c">1,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTYtMi0xLTEtMA_506b6f31-9481-4d98-9134-4b3e26396bbd">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTYtNC0xLTEtMA_268d496e-b589-4ab2-ab7d-f3510e2fa989">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTctMi0xLTEtMA_a7fe52b6-7bcf-4592-910e-5b13088c82d3">1,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTctNC0xLTEtMA_327e96f0-e0e8-46b4-89cb-359b57f9361f">1,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i5e8b0e18419843159ec07e1b794d0d87_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:30.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gilead Stockholders&#8217; Equity&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest</span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; <br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income (Loss)</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4491879c7fcd415288701f6b62e40e51_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNC0yLTEtMS0w_d54b098f-3fe4-42b7-a088-67f0968d943a">1,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4491879c7fcd415288701f6b62e40e51_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNC00LTEtMS0w_6513937e-d526-4d16-ac81-52fd7eb7a354">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13bf16e2c0cc414ca0e4618b4219c2cb_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNC02LTEtMS0w_31244ace-72ea-4cfa-8898-276d5292482f">3,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id315795d1e774a6a845a09bd3c23f669_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNC04LTEtMS0w_acd87442-58ae-4953-83ad-8e9c336b06e8">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i631a0304196e455e9a985f2aed12a21c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNC0xMC0xLTEtMA_9716f21c-27b7-4a91-a81f-ea1ec9236b4e">14,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ceb4b2138664055958fd36c771ef719_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNC0xMi0xLTEtMA_fd608a8a-a19d-4481-8ac4-01b8f52c04d3">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNC0xNC0xLTEtMA_c926702a-62cd-4014-8daf-a77a1a81be3a">18,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e6def1ee614c1f88a734ccf8b57339_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNi0xMC0xLTEtMA_10c21cfa-f294-46cd-8d19-aa7b45a55356">1,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49ed492a453846c298f340cfb12aea93_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNi0xMi0xLTEtMA_9423c53d-2b1f-4878-b048-3501a241b799">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNi0xNC0xLTEtMA_a8101b3c-20f2-42d9-8ea0-2be0cdca3a52">1,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f56585e4ce041a0a4818371afd20608_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNy04LTEtMS0w_8641458a-7241-4c72-aff6-9cac27fa2215">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNy0xNC0xLTEtMA_eb77ea4e-b20f-4f49-9576-18df511b0694">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e9ec92ee61543dbb61d2f855c0a785c_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfOC0yLTEtMS0w_3cc52a0e-5433-43ab-bd31-633a8c4c76b1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33e7b278cf744482b55f1a9184b9c0fb_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfOC02LTEtMS0w_fd521fe9-5958-4652-b590-45d48cd65e44">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfOC0xNC0xLTEtMA_8b9dbd74-e0f6-47c0-b93e-9b9a9e9b78dd">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e9ec92ee61543dbb61d2f855c0a785c_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfOS0yLTEtMS0w_e18bae09-3636-4308-a97c-214eaa6bee05">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33e7b278cf744482b55f1a9184b9c0fb_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfOS02LTEtMS0w_264034db-2704-4acc-9037-ecae43959613">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfOS0xNC0xLTEtMA_000c74d0-dd02-4a6a-b28d-eb8e5e1a9900">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33e7b278cf744482b55f1a9184b9c0fb_D20210101-20210331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTAtNi0xLTEtMA_15184ed4-17e7-40ec-9585-88f565d839fc">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTAtMTQtMS0xLTA_7c41d8cf-2f9f-41bc-9c0a-1519dd343d6d">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2e9ec92ee61543dbb61d2f855c0a785c_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTEtMi0xLTEtMA_ce3a90d8-8bfd-4217-b386-7f7490d985bf">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33e7b278cf744482b55f1a9184b9c0fb_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTEtNi0xLTEtMA_a3e0ebdd-00fb-470e-8f23-d6a9f0662c3e">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22e6def1ee614c1f88a734ccf8b57339_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTEtMTAtMS0xLTA_19186bde-c7af-46c2-aef6-cbd173248339">383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTEtMTQtMS0xLTA_9b291cd2-9e14-4b7d-ad9c-c3a726af4cdb">399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTItMC0xLTEtMC90ZXh0cmVnaW9uOjA4YzRmODQ1YThhNTRjMDU4OTUzZWExNmMzNTFhYzI0XzI0_834c6622-8706-4528-9440-091b76b3e92c">0.71</ix:nonFraction> per share)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22e6def1ee614c1f88a734ccf8b57339_D20210101-20210331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTItMTAtMS0xLTA_f0aaf4ed-882f-4cfc-a083-3e7874468ad3">906</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTItMTQtMS0xLTA_6c79d4de-a2fd-41f2-8ada-6f71bb6afcc7">906</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4cad2b62afdf497cb6d680783df2564b_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTMtMi0xLTEtMA_e16861b0-38e3-4ea1-8364-0fb6f6db0ea2">1,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cad2b62afdf497cb6d680783df2564b_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTMtNC0xLTEtMA_21116aee-bf95-45bf-9a3d-0a4f6ca2fff5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e12da2f502648b1b1cfe3c2ce745770_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTMtNi0xLTEtMA_c86eeedb-8d7a-49b2-8f15-dbfd3cb06351">4,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideb5f8dc0c4442658f18eab50f25a677_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTMtOC0xLTEtMA_e7fb750f-f102-4cf3-a9a6-37c2d31a5f20">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aa770dc5dd844ef8a4c9f16bbad3843_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTMtMTAtMS0xLTA_97270ab8-2600-4ca3-8df0-202c6841fc33">14,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59a30e5469c84cd78e03499a820d4cfa_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTMtMTItMS0xLTA_fc37bce0-8b98-4564-9ed3-33f182443737">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTMtMTQtMS0xLTA_b26df7ee-c67a-4341-92bf-0de3870a5232">18,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:30.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gilead Stockholders&#8217; Equity&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest</span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; <br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income (Loss)</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0e06ce8778849a79902920387c413c1_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNC0yLTEtMS0w_bee312ad-e958-432b-aa56-93582b1b0cd6">1,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e06ce8778849a79902920387c413c1_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNC00LTEtMS0w_3cb14b06-6143-4ee2-8f9b-75ac20207809">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic27cb3c440c3422fbad61655cb15c60c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNC02LTEtMS0w_6a45caf5-7f54-48ff-870f-ab82bf4e1625">3,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c7b9ebee1f549d198ceb53ea6813141_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNC04LTEtMS0w_f317667f-f407-44ab-98ec-81f1e1503a7e">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c9bc44b74c412ea8a63c832add3283_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNC0xMC0xLTEtMA_6afa2aa9-76e9-4583-8c66-e08d0dda05f0">19,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0484fdf9aa034ecd94e3797e7f978bdf_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNC0xMi0xLTEtMA_276dce5e-a505-4080-a602-893a5d509b0b">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a8779a54fef4be683c8d4f7e5b601ac_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNC0xNC0xLTEtMA_0d403869-083d-478e-92c5-2df8becac96b">22,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative effect from the adoption of new accounting standard</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17fa9a1c26714f1587a2aa325624b533_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNS0xMC0xLTEtNDQ3OA_e4fb8b59-d5f6-45d5-aadb-35bdfb6143c1">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48b7a28e035547fa89fcfc8c0593b301_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNS0xNC0xLTEtNDQ3OA_058fc938-715c-4c39-82c1-e3668466653e">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2835b80e3c7a4d00b23cdd84912a90e9_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNS0xMC0xLTEtMA_25154e3a-dc1d-4c5b-8958-3b4f99f13d63">1,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f2d827efd2a4f4a91dee3811a501ecc_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNS0xMi0xLTEtMA_dd9fdad7-27b7-4a9d-a17f-0b91bce20c65">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNS0xNC0xLTEtMA_58448976-8ac0-466f-8eaa-dcf6424407d1">1,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4dce18c9540c42d6ae4ba9bd85b66896_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNi04LTEtMS0w_91145e53-eac3-45c0-b765-d16cae0bebd5">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNi0xNC0xLTEtMA_a55219eb-4f67-4bc7-9670-66942f83f593">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6dd270c88164436597aad1b5ed3cb4ef_D20200101-20200331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNy0yLTEtMS0w_64ac541d-f100-4d1f-afcc-1d6c60ff2a13">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6ecd38b92444ed38d13e95fbd53341a_D20200101-20200331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNy02LTEtMS0w_3261fb2b-e0ba-4cab-ad8e-2884dd9ee195">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNy0xNC0xLTEtMA_b6ee1478-587d-4af5-8fc1-d6d2e99c3df6">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6dd270c88164436597aad1b5ed3cb4ef_D20200101-20200331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfOC0yLTEtMS0w_dfddce5e-73f7-4f92-b3a2-a7d2272209a6">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6ecd38b92444ed38d13e95fbd53341a_D20200101-20200331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfOC02LTEtMS0w_128f7d7e-914f-4653-b80f-483763e5f021">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfOC0xNC0xLTEtMA_ea8a3d81-984e-44ce-a540-7d50f2b243be">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6ecd38b92444ed38d13e95fbd53341a_D20200101-20200331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfOS02LTEtMS0w_3c0392c6-5deb-4eda-976d-cd598ee20dd5">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfOS0xNC0xLTEtMA_420bc3d8-88d9-42be-b29e-664608cb9092">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6dd270c88164436597aad1b5ed3cb4ef_D20200101-20200331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTAtMi0xLTEtMA_d7a9ebe1-9723-4c0c-ae96-6ade94b98c95">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6ecd38b92444ed38d13e95fbd53341a_D20200101-20200331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTAtNi0xLTEtMA_2507c1a3-6b68-4039-a7f3-aba3811a08e7">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2835b80e3c7a4d00b23cdd84912a90e9_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTAtMTAtMS0xLTA_08d9ba21-a5d8-42a3-be0d-cd6a5e8eb06b">1,356</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTAtMTQtMS0xLTA_27e0ded9-e495-45db-b43a-930ca0c55ac5">1,414</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOmZjMDcxZGM2ZjExNTQwM2Q5YzViODJmNDQzM2JjZmUzXzI0_eb074dde-ed6d-48ee-b620-f47ab16c68b4">0.68</ix:nonFraction> per share)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2835b80e3c7a4d00b23cdd84912a90e9_D20200101-20200331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTEtMTAtMS0xLTA_8abc657a-1b66-4cc1-92b7-88c5a484deb2">867</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTEtMTQtMS0xLTA_94e33e50-d395-4f30-9ea0-7dc6c8a27d84">867</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ca6dc703a0d49718435076c33ed0dbc_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTItMi0xLTEtMA_2953896f-f1ac-4c06-8842-66c1f0cb8b5d">1,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca6dc703a0d49718435076c33ed0dbc_I20200331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTItNC0xLTEtMA_c3e18d44-5f22-4e0a-833d-e2acc1a40429">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i887b76714c9c41c4a6db53d46bc0f6a7_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTItNi0xLTEtMA_bf5bb91f-af09-4f7e-a84d-08d109533e60">3,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51b7741d7f0241a9a5987bf6c4f4f41c_I20200331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTItOC0xLTEtMA_d6608818-d4fc-41cd-b7cb-d6f715f15a17">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaa5a801f01b483992e5c3baa5e7844b_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTItMTAtMS0xLTA_d335e586-b62f-44ae-90ac-2e679133bf33">18,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i118f3a03d85d40aba97d7091b6ac999f_I20200331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTItMTItMS0xLTA_536b29a9-899a-4b2e-83c5-6d0c5bd4d833">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3f0f2350f9c47889d2e1afa48054b12_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTItMTQtMS0xLTA_13b44247-b56f-415b-a1a5-063b720433cd">22,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i5e8b0e18419843159ec07e1b794d0d87_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Operating Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfNC0yLTEtMS0w_e439bcd0-e2a7-49fe-92d2-142d9a472e79">1,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfNC00LTEtMS0w_fb9fffe0-0dbb-4db8-8090-51f7ecfe97bc">1,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfNi0yLTEtMS0w_5b9d0eaa-94f3-4892-a090-e189d64a8a45">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfNi00LTEtMS0w_241cef25-d688-4516-ba37-4bdca23ec0aa">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfNy0yLTEtMS0w_3050d4cc-8fe1-4372-b7d1-cb102ab5db9a">395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfNy00LTEtMS0w_49870a82-89ed-4cb8-b686-ca8a774fe435">281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfOC0yLTEtMS0w_11fac12b-4f99-4e99-8f1b-7c31f1f8c3d3">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfOC00LTEtMS0w_f3ec40cc-6ad2-4ebf-a17d-142c18f9732e">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Acquired in-process research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfOS0yLTEtMS0w_3079cf48-06d8-4273-826b-4fc8c50a0425">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfOS00LTEtMS0w_87939393-3b81-4117-8b34-d287535aa83b">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTAtMi0xLTEtMA_d4b96577-20b0-481d-b105-539e6997c270">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTAtNC0xLTEtMA_b9de2a78-ee50-4577-935f-96af88cd39a9">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net losses from equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTEtMi0xLTEtMA_a281a611-e46e-46fe-84b8-4684db6ec90c">351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTEtNC0xLTEtMA_07082604-9388-43b2-8132-8f03400a8da6">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTItMi0xLTEtMA_3b7bcb56-4a26-4746-802d-e9e6dc8842ed">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTItNC0xLTEtMA_481ba22b-7777-44ef-ba6d-c5bbdb385ca4">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTQtMi0xLTEtMA_567d4669-0eb9-47b3-8ffb-ae1210bc23e9">975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTQtNC0xLTEtMA_b86b984d-1b3b-4eac-a2b2-8701928fa902">376</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTUtMi0xLTEtMA_b1e51967-ebab-4ce6-ad15-26875637072e">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTUtNC0xLTEtMA_6d0ef71a-20de-4800-bf75-0a7c5de99848">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTYtMi0xLTEtMA_3dfd0005-c405-4ae0-825d-68561ba38c7e">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTYtNC0xLTEtMA_adcd8474-c8c9-4e52-9f04-547c01931331">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTctMi0xLTEtMA_6e9a5e69-eafa-44a1-8e3e-3ea6b0b4a153">253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTctNC0xLTEtMA_a5f4f2c2-2a5c-46fb-a05c-15510bb81446">109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTgtMi0xLTEtMA_c90c9431-0567-43f8-84ff-e672927e55b3">316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTgtNC0xLTEtMA_86a32a02-6685-4556-8643-e9386b7e9f4f">127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued and other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTktMi0xLTEtMA_5e238241-718b-4abb-8ce6-6f6824225430">738</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTktNC0xLTEtMA_a966de69-6199-4509-adc1-06f1a5277ef0">550</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjAtMi0xLTEtMA_01d7f5a1-ced5-4e4b-8664-567809af9684">2,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjAtNC0xLTEtMA_e1d6b864-5112-4bb5-b0f8-086c249f77e2">1,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Purchases of marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjItMi0xLTEtMA_9f56f33e-aba3-4514-a650-6b421c59cfd4">931</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjItNC0xLTEtMA_59ce7352-89cf-4b43-8a7c-52402f8b5025">13,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from sales of marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjMtMi0xLTEtMA_ee411ae8-ee74-469f-b6d1-1df4171ff89b">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjMtNC0xLTEtMA_1933a687-70db-422f-9340-bcdd12c8c82b">9,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjQtMi0xLTEtMA_58f31152-34ff-4b43-be47-7051e0505a79">619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjQtNC0xLTEtMA_090b2908-1c4d-4560-bf86-8a4a68d1050f">3,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Acquisitions, including in-process research and development, net of cash acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjUtMi0xLTEtMA_eb8ea83d-4b43-4b7f-a024-f36231e19703">1,255</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjUtNC0xLTEtMA_3a82f379-6f13-4acf-b917-37daf466732c">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Purchases of equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjYtMi0xLTEtMA_39ea4e16-efda-41ea-803b-b41e5d5921ce">279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjYtNC0xLTEtMA_15d3610b-e75d-4c95-87fd-a3abd44c9aef">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjctMi0xLTEtMA_36e1907f-8c09-48ef-9b2c-48e6694c3ef1">165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjctNC0xLTEtMA_96057e36-c3c2-4f71-8d95-b15ed8af9d20">171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjgtMi0xLTEtMA_fc6e8759-3e98-4ee2-a23e-725a37f8173e">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjgtNC0xLTEtMA_8b5884bd-24f3-4c58-ba77-c6624c86e4c2">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjktMi0xLTEtMA_3136de1c-a373-4153-8c70-cd0c2c796993">2,042</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjktNC0xLTEtMA_04e8a874-40da-4d20-9b15-4f89e8b29d97">344</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Financing Activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from issuances of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzItMi0xLTEtMA_295f5d6b-f979-4585-9b70-7acc2126fd70">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzItNC0xLTEtMA_75eca535-4858-4005-858c-a79bab16a536">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzMtMi0xLTEtMA_27bbf088-53ff-40cd-80fd-b4445ba268b8">309</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzMtNC0xLTEtMA_ab258b4e-cedb-4bfb-825b-1347c2bf656f">1,328</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Repayments of debt and other obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzQtMi0xLTEtMA_ec7da4ae-ea43-4af0-a24a-6041427d9494">1,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzQtNC0xLTEtMA_ce382f2a-6283-4d56-90ca-cb7899063712">500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payments of dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzUtMi0xLTEtMA_dc909efd-cf89-439b-9e68-b178b3edf4ec">917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzUtNC0xLTEtMA_69840dec-7829-43d9-936e-aed6318e70aa">874</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzYtMi0xLTEtMA_d6d6e3ed-24cd-4313-b1f5-f06eda8fbb78">89</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzYtNC0xLTEtMA_22cb8f0c-4570-477e-9c8c-93f3cd7e3248">86</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzctMi0xLTEtMA_66e62d91-b29e-4982-8f5c-751f7190f319">2,477</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzctNC0xLTEtMA_c4f9de68-a59b-4703-acec-736ee6aba1cb">2,611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzgtMi0xLTEtMA_b1f68aa0-9935-4e59-a616-5dde4e8932a5">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzgtNC0xLTEtMA_1e99870d-6bbe-4e9b-a911-2688dc7d8158">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzktMi0xLTEtMA_02e9d9ef-aab0-4e8d-a513-2225ebc8dd37">1,932</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzktNC0xLTEtMA_089c1925-6fec-401b-b528-6c9f5cc762a3">1,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfNDAtMi0xLTEtMA_ee01aefc-2918-4f95-9133-1e83befd7a4f">5,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a8779a54fef4be683c8d4f7e5b601ac_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfNDAtNC0xLTEtMA_86f2975a-cf3f-41fd-b866-f6e201130865">11,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfNDEtMi0xLTEtMA_446728af-b053-4721-99d5-914a7cad0c1a">4,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3f0f2350f9c47889d2e1afa48054b12_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfNDEtNC0xLTEtMA_952ce7af-383b-43e2-8c54-82efb067c553">10,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i5e8b0e18419843159ec07e1b794d0d87_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div id="i5e8b0e18419843159ec07e1b794d0d87_34"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNC9mcmFnOjljYzQ3MTQ1ZmQyMzQzOTA5NzBjNDkzODBiYTFlMjAzL3RleHRyZWdpb246OWNjNDcxNDVmZDIzNDM5MDk3MGM0OTM4MGJhMWUyMDNfNzM1MA_df35cae8-7ded-472b-872c-c8f92de3ad29" continuedAt="ia0bf655ca3214045939b92875314e76a" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </ix:nonNumeric></span></div><ix:continuation id="ia0bf655ca3214045939b92875314e76a" continuedAt="ia744b073569e43cab0ed6b303cd349af"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNC9mcmFnOjljYzQ3MTQ1ZmQyMzQzOTA5NzBjNDkzODBiYTFlMjAzL3RleHRyZWdpb246OWNjNDcxNDVmZDIzNDM5MDk3MGM0OTM4MGJhMWUyMDNfNzMzNQ_23087276-63be-44dd-8e33-889b843fcc8b" continuedAt="i0b5d3e8565a044d68a43cae9b1b6fc39" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information. The financial statements include all adjustments consisting of normal recurring adjustments that the management of Gilead Sciences, Inc. (&#8220;Gilead&#8221;, &#8220;we&#8221;, &#8220;our&#8221; or &#8220;us&#8221;) believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and a variable interest entity (&#8220;VIE&#8221;) for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our Condensed Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether we are the primary beneficiary of a VIE at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. </span></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0b5d3e8565a044d68a43cae9b1b6fc39">The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission.</ix:continuation> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNC9mcmFnOjljYzQ3MTQ1ZmQyMzQzOTA5NzBjNDkzODBiYTFlMjAzL3RleHRyZWdpb246OWNjNDcxNDVmZDIzNDM5MDk3MGM0OTM4MGJhMWUyMDNfNzM2Mg_b1b6b8a0-ff10-46a2-8725-6ad2da0180ef" escape="true">We have <ix:nonFraction unitRef="segment" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNC9mcmFnOjljYzQ3MTQ1ZmQyMzQzOTA5NzBjNDkzODBiYTFlMjAzL3RleHRyZWdpb246OWNjNDcxNDVmZDIzNDM5MDk3MGM0OTM4MGJhMWUyMDNfMTgxMw_175aaa0a-3e26-4af8-9b00-df3c8e737a09">one</ix:nonFraction> operating segment, which focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (&#8220;CODM&#8221;), manages and allocates resources to the operations of the company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#8220;R&amp;D&#8221;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;D portfolio and external opportunities to best support the long-term growth of our business.</ix:nonNumeric> See Note 2. Revenues for a summary of disaggregated revenues by product and geographic region.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies, Estimates and Judgments</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNC9mcmFnOjljYzQ3MTQ1ZmQyMzQzOTA5NzBjNDkzODBiYTFlMjAzL3RleHRyZWdpb246OWNjNDcxNDVmZDIzNDM5MDk3MGM0OTM4MGJhMWUyMDNfNzM3Mw_8a7da416-826c-435f-8bf8-f022da2436b0" escape="true">The preparation of these Condensed Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the coronavirus disease (&#8220;COVID-19&#8221;) could have on our significant accounting estimates. Actual results may differ significantly from these estimates.</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNC9mcmFnOjljYzQ3MTQ1ZmQyMzQzOTA5NzBjNDkzODBiYTFlMjAzL3RleHRyZWdpb246OWNjNDcxNDVmZDIzNDM5MDk3MGM0OTM4MGJhMWUyMDNfNzMzOA_f44b09ab-cf01-47d3-babc-6b86ed1eee4b" escape="true">Certain amounts for the three months ended March 31, 2020 were reclassified to conform to the current period presentation. Beginning in the second quarter of 2020, acquired in-process research and development (&#8220;IPR&amp;D&#8221;) expenses are reported separately from Research and development expenses on our Condensed Consolidated Statements of Income. Our Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2020, has also been conformed to separately present acquired IPR&amp;D expenses.</ix:nonNumeric> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ia744b073569e43cab0ed6b303cd349af"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Risk </span></div><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNC9mcmFnOjljYzQ3MTQ1ZmQyMzQzOTA5NzBjNDkzODBiYTFlMjAzL3RleHRyZWdpb246OWNjNDcxNDVmZDIzNDM5MDk3MGM0OTM4MGJhMWUyMDNfNzM4Mw_e0c14bb0-9f1f-42f3-b7e2-da105f7c886a" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States, Europe and Japan. There were <ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNC9mcmFnOjljYzQ3MTQ1ZmQyMzQzOTA5NzBjNDkzODBiYTFlMjAzL3RleHRyZWdpb246OWNjNDcxNDVmZDIzNDM5MDk3MGM0OTM4MGJhMWUyMDNfNTc0Ng_73f8a0b9-de5b-4413-806e-17aef02ce2b8"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNC9mcmFnOjljYzQ3MTQ1ZmQyMzQzOTA5NzBjNDkzODBiYTFlMjAzL3RleHRyZWdpb246OWNjNDcxNDVmZDIzNDM5MDk3MGM0OTM4MGJhMWUyMDNfNTc0Ng_d63d930b-2a79-49e7-84da-22b103ad3418">no</ix:nonFraction></ix:nonFraction> material write-offs charged against the allowance for the three months ended March 31, 2021 and 2020. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the raw materials and components that we utilize in our operations are obtained through single suppliers. Certain of the raw materials that we utilize in our operations are made at only one facility. Since the suppliers of key components and raw materials must be named in a new drug application filed with U.S. Food and Drug Administration (&#8220;FDA&#8221;) for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from our suppliers is interrupted for any reason, we may be unable to ship our commercial products or to supply our product candidates for clinical trials.</span></div></ix:nonNumeric></ix:continuation><div id="i5e8b0e18419843159ec07e1b794d0d87_37"></div><div style="margin-top:13.5pt;padding-left:22.5pt;text-indent:-22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RleHRyZWdpb246NWJjODQ4YzM4NzdjNGU5N2JjNDYxYWJlYjRhMTdhNDFfMjA3OA_12d6fa51-19dc-4f74-be4c-83052a91dc77" continuedAt="i3d6e08d614094982ad36c9451a9ffcbc" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="i3d6e08d614094982ad36c9451a9ffcbc" continuedAt="if8f8d70fe1204b57abfa4b8ebceb6ae7"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenues</span></div><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RleHRyZWdpb246NWJjODQ4YzM4NzdjNGU5N2JjNDYxYWJlYjRhMTdhNDFfMjA3Mw_dba33174-2e36-4651-a7dd-1ecccbf5f8ef" continuedAt="i9285eadbf0314cfead8bf265fe6526f2" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.660%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product Sales:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">HIV</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Atripla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie434694a2f304ecd94c3775324b4378d_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNC0yLTEtMS0yNzcz_4e7eca08-65cc-4677-b069-b9bc256826bb">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied66863fda3841ad881df6b37123aec9_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNC00LTEtMS0yNzcz_36b6b515-90cb-43a4-8897-44f95b1e9797">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeff20e2f7ee495db92fa4c3484b89a8_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNC02LTEtMS0yNzcz_556f2e28-b11a-4cc7-8886-1e2478e53d33">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0438c7b3d8b44618b0023cd7a41ed6d_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNC04LTEtMS0yNzcz_1c39fb80-433a-404d-8ba9-7600bcbf2a97">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5f03dade66d4049ac775a2ff2e95578_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNC0xMC0xLTEtMjc3Mw_ed230a7e-bbe7-452d-b4a6-17148b3a1229">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaffbd58e1c6444dbbb5947207f1292df_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNC0xMi0xLTEtMjc3Mw_553c001d-85bb-4433-ab4a-c246be45bcb1">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af19a68a52f40feb3f105f7566f6acb_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNC0xNC0xLTEtMjc3Mw_a194d1f0-364a-402e-9ab7-a864b4b873b1">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id77a0ac827ef47e490fe49f7648d3b55_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNC0xNi0xLTEtMjc3Mw_69a32e2f-ab38-465c-87f6-a086053cd1aa">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bcc8d5fc46645f296ca7a59cd624b53_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNS0yLTEtMS0yNzcz_df73c08d-a49f-414e-9c14-d22d965111d8">1,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7754da6d6ec44b0e944fa8f87cfe572d_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNS00LTEtMS0yNzcz_d0c9ac2f-0071-4511-b02a-f34a6bcf71a1">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93ea9ae384744892b920c309bb2dc11b_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNS02LTEtMS0yNzcz_a5c51f55-0bd2-4d0f-a9b7-dbdbc429dc6b">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b9480e8d66b4593ad97e4e5be56077d_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNS04LTEtMS0yNzcz_2b7271c2-87c7-4dfa-8f9f-224c19d84048">1,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i860dabfa33e143bbb52212212435f1ac_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNS0xMC0xLTEtMjc3Mw_da9c308c-a835-45f5-9cb8-3ef2296fe9ee">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32acee5874f9459b9252142abdad455c_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNS0xMi0xLTEtMjc3Mw_bcaed904-ea85-4c3b-8497-978e62363a0e">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c9ead692aa4d9b810f9ec7db117251_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNS0xNC0xLTEtMjc3Mw_a8b32066-78a6-489d-8929-135efbcb43c4">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8c7336c5e6147e7adf7d7c7affa6881_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNS0xNi0xLTEtMjc3Mw_31a1e7d4-e92b-4a32-9ae0-10504deb0075">1,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2462c72487a94e59b5caf6a5a319777f_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNi0yLTEtMS0yNzcz_63911f95-0201-421a-9115-4abce9dbf6cd">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926db54afaa349f6af84a0c3e2544b96_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNi00LTEtMS0yNzcz_6a956961-bf69-4061-8e32-bd0caced510b">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec0f287f8ff4da3820bdba4ffc47bc2_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNi02LTEtMS0yNzcz_231ade34-e749-4c66-abbb-13d9dd6f723e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3fd650f8abb4697adb1f0f30c929d64_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNi04LTEtMS0yNzcz_1de62d71-94d5-41a7-b533-50e36e615f8d">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74acc5bbd8d34c738b16ae51a6075385_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNi0xMC0xLTEtMjc3Mw_2e9f9c6c-ce1c-4dfe-9a01-4da5a58ebf3b">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15469494cca5432aa408d46c88acabf0_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNi0xMi0xLTEtMjc3Mw_9a37030c-1966-42bf-8fa4-0c411beb5875">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d5d49b7149047bab9ea616bba4640f0_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNi0xNC0xLTEtMjc3Mw_56911ec1-cb42-4742-baf1-a7cc3113f30c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8809e89136714bbbab87f233c9eadb83_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNi0xNi0xLTEtMjc3Mw_763457af-2b96-4485-8b30-38a695676374">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id32809760dcc4f69a8dab604473dba7f_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNy0yLTEtMS0yNzcz_bbd36bc8-9b74-4cfc-a682-9338a64a4fa3">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib508419ccb58428e84530322853938fe_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNy00LTEtMS0yNzcz_da980173-7f78-4b31-a3cc-1deba3f6758a">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25554b833ac44de8ae88e315443d09c8_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNy02LTEtMS0yNzcz_36b8eb90-edd4-4061-a905-1b7553b18f3a">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78b9775b1d1b40319b1f9d7183321020_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNy04LTEtMS0yNzcz_644381e3-b24f-4950-a762-43fba008b027">359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63920a1a040e417891a03f303d3bbcad_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNy0xMC0xLTEtMjc3Mw_6d0e9e35-07ec-44e5-b7aa-339da9c32c06">363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia590ce34497d4eaa86fa2b29038aabb5_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNy0xMi0xLTEtMjc3Mw_ee1adf49-f2c4-4a38-85ac-a7c69dec5283">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eeed5ddca31468cb705d74685f56174_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNy0xNC0xLTEtMjc3Mw_43f2a462-2b53-4035-9c01-79a9ce4134e0">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64b13d2f087c45bd9fc1acd32cd1ef64_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNy0xNi0xLTEtMjc3Mw_920fedf1-b7f7-4ee2-a6fb-941157323b5f">458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63ae64a7b8094554852cb98b0a551090_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOC0yLTEtMS0yNzcz_40569ab4-641d-4bef-9b1a-5012b51f3588">506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic110886142334d548f1d0723e44253d3_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOC00LTEtMS0yNzcz_c0a9c7c8-d900-4842-9f01-599ee6ee3494">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdcd081c4a4c46029ac68f60d58be6aa_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOC02LTEtMS0yNzcz_eb911201-bfaa-40e1-8be6-6d7077d193af">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0410e8fcd4043e490ebbf9c80ae64b1_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOC04LTEtMS0yNzcz_4605ec8b-5562-4b10-be0e-b58a0077a6be">673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630252d0da14149adffcae74b86e4e7_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOC0xMC0xLTEtMjc3Mw_689015fe-aa03-43c5-bb35-984ad0e494d9">612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bec6854dc6b4f04a8e737cd53521147_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOC0xMi0xLTEtMjc3Mw_e60a43cc-9150-4446-96b8-80e120ec2789">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0ebb14b7645429db55c7da591d24c92_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOC0xNC0xLTEtMjc3Mw_645a57a8-1977-4bfd-b9d7-9080b5772630">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d00d8d104314587b42a25a2edff05da_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOC0xNi0xLTEtMjc3Mw_19aee80a-a55d-4dfa-97aa-7e05b73aed5d">824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a6f431e5de642bba69f6328f2961f14_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOS0yLTEtMS0yNzcz_c579baaf-9284-4b4c-9586-ae0209cb63e1">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99ccdd43f15d46bfbdc7e4ea02150055_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOS00LTEtMS0yNzcz_8ab40e74-beeb-4018-84ff-62fceaa114bc">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5661ce6a8f840d1850cebad529dc17c_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOS02LTEtMS0yNzcz_705e28f1-9d05-464e-b3ee-f441a4bd1f77">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8af148cdc07347ba838fdffde80857bb_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOS04LTEtMS0yNzcz_a29489ce-0872-48dc-a81f-6a7dc5e09ba9">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65015860c764edfbb86c8af349ccd93_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOS0xMC0xLTEtMjc3Mw_c0a7cc5a-f6de-40ea-a731-8d2747b6131f">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b044c57517f472a99248ee2666230e0_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOS0xMi0xLTEtMjc3Mw_cb45f3a4-9cf0-4d93-bf8e-cf66177c36ce">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie915268dd561478f9d1b79082fe9e92c_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOS0xNC0xLTEtMjc3Mw_9fe2994e-a39f-460a-a083-5d438d410127">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c5a0930911c499688e99f6e08ca653c_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOS0xNi0xLTEtMjc3Mw_cf51877a-e8d3-47e9-962b-ea399cff015d">409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4618b8d2431482ea6b2b45a2b50b865_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTAtMi0xLTEtMjc3Mw_7db08f94-d6a0-431c-84dd-f0e94c1616c3">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ed385b62afc49599835c73bd497620e_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTAtNC0xLTEtMjc3Mw_49cf0793-c20d-4c1c-a445-96e74ace779b">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d7e6c0864674e51b116a0887e955135_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTAtNi0xLTEtMjc3Mw_939c83f3-803e-49fc-8189-a92ff1089e3e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f3c8b7a52cf49be80972340697e8657_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTAtOC0xLTEtMjc3Mw_59587b6d-dcc5-4d9e-bbf5-dcd604bef9e5">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a691facdde446d09127f1d0029b00a8_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTAtMTAtMS0xLTI3NzM_1c5efb7a-5c5a-4677-8d85-78a6a2fc8038">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic621020502cb4461b3f507d17a78d96d_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTAtMTItMS0xLTI3NzM_23d867ec-f44c-41fb-9269-a2fe52217356">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9944473064fa47dcbb264707adb1876b_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTAtMTQtMS0xLTI3NzM_bcf40937-ad0c-4392-80c8-be349e11cbbf">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e742eaf2b342098a385d2addbe3722_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTAtMTYtMS0xLTI3NzM_d1baf5cb-5164-43d9-9f13-21511918ab49">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i588d3a5b64fd4b7080b0056b85ea0150_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTEtMi0xLTEtMjc3Mw_fc8feeea-6ede-48db-b082-21d9ee9ecfd9">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b30c8afa7d47e59e7da726ed9b9890_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTEtNC0xLTEtMjc3Mw_89ec95a1-b704-4655-8d47-586434449fe3">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03098f2d9e664ef285eee0bbed328af7_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTEtNi0xLTEtMjc3Mw_58baedaa-eef0-4749-8e2f-8a78e2497ea6">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38535068021e4957bf196cb0586b1f95_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTEtOC0xLTEtMjc3Mw_66a6c0ab-3d15-416b-be62-ea49da25bbdd">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie91ab1070982497baf8fd021259bd6f4_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTEtMTAtMS0xLTI3NzM_c7fbf4e6-b45d-44f8-aaa8-ca63ebb7fdf5">383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77d7d1bcb69242afbb3209274bf2e205_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTEtMTItMS0xLTI3NzM_66017622-9b4f-4959-84e8-57a2a055f543">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9079d3cc20b47f48f6dadc7048847b4_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTEtMTQtMS0xLTI3NzM_6e5cb3ab-f426-476f-b0b6-ea897e7a0567">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c79c7043994738bad7f7620e19bd9c_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTEtMTYtMS0xLTI3NzM_7313bd37-7c78-4c6a-a2e4-cf7dab6a65f9">406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib54f9224b2d046a7ba0fb1790721cc77_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTItMi0xLTEtMjc3Mw_0e0a3303-ab23-4c37-9f44-a327db9ba2d2">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f0e9b7992f04bd4b7a98d3c40e33e6c_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTItNC0xLTEtMjc3Mw_8e12ff06-0bd6-4032-81c6-4e864df54f57">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1bfaa1d7b2047c8b0243a6fe75777de_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTItNi0xLTEtMjc3Mw_311085c0-7196-4130-88d5-2c65b8352786">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6a1884c73a14fabbeac29b5261925ce_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTItOC0xLTEtMjc3Mw_a1177c27-f0f5-44f6-8e36-bcc07b2998fb">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9213a6fb817f496f82175fdabab96f9f_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTItMTAtMS0xLTI3NzM_1b421ea9-9a05-4cf7-97b4-45a796d9de51">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id25b065da243414e834f92baa87571d1_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTItMTItMS0xLTI3NzM_1f36b0ab-a1d5-4e84-b564-feda9aec6a29">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd4289b827184b00ba7eb9735afd98c1_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTItMTQtMS0xLTI3NzM_f5dbfba4-b793-4807-ad62-a531d2819f63">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7f221d836804ac0ac5bf313e85fb6d7_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTItMTYtMS0xLTI3NzM_93a8f6c9-5b19-428f-9961-f4a00fc2ebad">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue share - Symtuza </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38b3924c6f0c441c9eb7e6c652985a59_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTMtMi0xLTEtMjc3Mw_0958075f-bc77-46d4-9b7a-dbce2c3f9384">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i685ce820b15c48c5a1caa899b5612367_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTMtNC0xLTEtMjc3Mw_0cd3fd23-19c0-486c-a351-5da118f21de4">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica58dd4564944ece805e2d3c625a68a5_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTMtNi0xLTEtMjc3Mw_2ff0c1da-1eb6-4bf5-acd9-8017c24036a3">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eac58164bb8445e95ecf5a632b200e5_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTMtOC0xLTEtMjc3Mw_b6e5c0d8-a562-4d83-92d4-78d3bfca00c6">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5a9b0307d9f4396804a48e8a8842af3_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTMtMTAtMS0xLTI3NzM_c60a134b-8e2d-4461-9d1f-02c938a5488a">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i405af8d2ac694bcba3c274ea467fe4c5_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTMtMTItMS0xLTI3NzM_6f993038-26e7-4361-9b40-6e7a3ea96082">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4b1a067e082487a8eba535819944c84_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTMtMTQtMS0xLTI3NzM_9bae9ac5-8053-4c6b-9bb7-2e1b8554ec4a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ad7557b78564109823d84b4134cb07c_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTMtMTYtMS0xLTI3NzM_51677838-50bc-4f88-a733-63b81c020f6d">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HIV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19c918e9779d45728feb8d2f77e6f762_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTQtMi0xLTEtMjk5NA_8e39148a-5251-494f-900a-4a3d5d187c5f">2,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84672c37600c456ab352a9bd8d1c0bc1_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTQtNC0xLTEtMjk5Ng_1323a7f7-70c8-4a70-b95e-34d004e0738e">578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8a43acfc2946a2bb710af0e9617ab5_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTQtNi0xLTEtMjk5OA_6146020b-d49a-418a-b638-419397e209a8">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61244f5bb1eb4b01a880be330bb43ca1_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTQtOC0xLTEtMzAwMA_8fb2ffac-66a8-40ad-a7c8-23ff5c1c4cfb">3,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9695a806ea324bfd8dc16e1026c867b1_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTQtMTAtMS0xLTMwMDI_17def2a7-4d17-4d6c-a346-b5b6271d120c">3,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b0923ec98c483796a4a281d6f4da09_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTQtMTItMS0xLTMwMDQ_49e3febd-5e34-48af-aab4-e0943521fa4f">639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f3114f39eea433da4c3f4769d416586_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTQtMTQtMS0xLTMwMDY_bf9381ab-2e5a-4f94-a3fd-fb6cddb4f73e">242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68c505daaab4913bbd9dbc115125ca6_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTQtMTYtMS0xLTMwMDg_6c4856dc-1510-470d-b645-e7e2f665e51e">4,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Hepatitis C virus (&#8220;HCV&#8221;)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ledipasvir/Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01820e105c11483b98e41dfe3ddbf458_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTYtMi0xLTEtMjc3Mw_ae30d135-9cc3-4c62-8c00-6a53bbd78d13">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46a4791353fb4785b0fd7e420b2475dd_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTYtNC0xLTEtMjc3Mw_c7503eae-c684-475e-baf5-fdcf46352708">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6903aaf9e2c46dd8097d605617899ff_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTYtNi0xLTEtMjc3Mw_fc871686-3c76-44c3-8b48-27991e26a057">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cedb25ca5664766987bf8d01722d958_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTYtOC0xLTEtMjc3Mw_790ac4f3-33c4-4da4-a563-7a519016d3b2">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd6d40d2852e487fab1dc8033ea98643_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTYtMTAtMS0xLTI3NzM_cb5b3684-8809-48b8-b4b2-8bacf5813070">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2e37e070de443485aa360d17396ef9_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTYtMTItMS0xLTI3NzM_a1356533-d557-401a-998d-f73462e2b40d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926b41607fcf4d478d80f477c8e14d41_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTYtMTQtMS0xLTI3NzM_ab3e82c2-9ad2-4833-b934-dc3bd6211057">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18a279ca38b432890071110c7674594_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTYtMTYtMS0xLTI3NzM_33260c1e-b7d8-491a-9a41-6adc16f7034f">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e7edf182cba4fe09b32a83db26b4422_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTctMi0xLTEtMjc3Mw_0f321698-761e-41f1-971e-337c5abd69b8">214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec3036fbf5cb40bc8c7e26870944ae22_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTctNC0xLTEtMjc3Mw_f437a4ee-b5fc-4082-8e57-16861fff6fa0">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51bdb311ba0f467c84b98f56b3828ae6_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTctNi0xLTEtMjc3Mw_66b2d73a-f161-4e15-8bd9-df555499d4b9">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92d6c64051da48a8a8e6f80486b979bc_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTctOC0xLTEtMjc3Mw_78dfb53e-a86b-4595-8602-04d9561ddc79">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb14461498914ac79e0457757c75dbd7_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTctMTAtMS0xLTI3NzM_87628948-93c8-4bd5-a72a-f2190ef76764">311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8d0518889a34fa2998643c6c7727744_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTctMTItMS0xLTI3NzM_b83adb5c-0fdd-4ade-92cc-0ec7849dacce">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba550e7873fd45c6aff0245542583cad_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTctMTQtMS0xLTI3NzM_1880f558-2372-44cd-87cf-f9904e3babfb">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63580e96633b4a5e805fcfb22890f21f_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTctMTYtMS0xLTI3NzM_d0e4d302-5ebb-4e4a-9d49-47e6477c6424">564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbe86121ebc04ad2a0dac3152347a17c_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTgtMi0xLTEtMjc3Mw_ea44bcb3-363b-4ca8-92b1-9345a3ce6820">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3261f10427f747079f2363eba0693663_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTgtNC0xLTEtMjc3Mw_2dfdf4cd-8cff-46bd-9678-3237eb39bd45">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f5059f19d2d404d9f5b485c545a5334_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTgtNi0xLTEtMjc3Mw_0cec4da1-1d88-41b2-9b6d-31d02ed60855">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27f6ff654cf4f2aa404dd2e82fe05b3_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTgtOC0xLTEtMjc3Mw_8a170a75-0d75-458f-9b3a-3d0b7cfd5aa3">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb4b9a4d69dc4a5b969be42cf4ab5ab8_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTgtMTAtMS0xLTI3NzM_daba7b8f-66a4-4f97-b0d4-7bbf8c6dcf3d">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54a8ecbfe7104cffb328730f7e2f2ba8_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTgtMTItMS0xLTI3NzM_1cde2355-d11e-45ed-a24f-458a2abb8a0e">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icabba3a157cc4c89993c0a6f7b81fbf4_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTgtMTQtMS0xLTI3NzM_61134bd6-9028-40ba-a3ae-077434321fc9">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec98ee45e5ad401eb35c35717992014d_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTgtMTYtMS0xLTI3NzM_cb23620b-4d60-4d49-80c3-c4ebb28e87bb">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HCV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cab6459ae2e4342bcf14bb7f0922405_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTktMi0xLTEtMzA1OA_aa2ce4a8-1f58-4315-9f84-f62dac4afa85">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if127a72225484fd3bd781db0b605a953_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTktNC0xLTEtMzA2MA_97873bbc-69cd-475e-9039-4486a95a121d">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d2f28f5774846bcaefb219a74d26197_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTktNi0xLTEtMzA2Mg_db2862f0-4700-4b64-b184-a05f30730682">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df4119b39b941c5a676e0d6e2524da4_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTktOC0xLTEtMzA2NA_440f70dc-b419-492c-a4a6-6e5c3a825279">510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8d501a125774436b2320401b2dd5bfe_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTktMTAtMS0xLTMwNjY_40867b21-57fd-406f-800f-47795715b782">398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id015d46967b94673ac7fb2ecc01b0237_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTktMTItMS0xLTMwNjg_b6c1f888-a36c-4a56-88ac-1bd69d86b690">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4660e6236c694b5ab8b1df8d62990e36_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTktMTQtMS0xLTMwNzA_815596cd-91b2-4418-a153-85213cb5b6f3">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0789c28a8de462d9aaa999b30d2860d_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTktMTYtMS0xLTMwNzI_ea130f25-00d5-4f36-bf79-b672adcc7cd0">729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Hepatitis B virus (&#8220;HBV&#8221;) / Hepatitis Delta virus (&#8220;HDV&#8221;)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675d50c435a342b58fa7e73781175e88_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtMi0xLTEtNTk1Mw_63d86441-6227-4b0d-8a52-51d28f34a584">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i360f92e56eee4f9cace9fa5368873470_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtNC0xLTEtNTk1Mw_a633b0fd-e44e-4827-856f-cd7f20f8b7ce">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf031777e242c49d6e3dcb11d0d8b4_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtNi0xLTEtNTk1Mw_52ad593b-57e4-46fa-96a7-f6659c6a5102">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1a9d40b8bca4c5ebf598872fea64e39_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtOC0xLTEtNTk1Mw_160235b8-eb43-45aa-b019-71700f125506">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if969bdf4b849499da19c7f7222a8956b_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtMTAtMS0xLTU5NTM_94e3fd20-9f78-445b-a794-7d1a6ac7e677">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84671f49939d40bc886c4b2114546e68_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtMTItMS0xLTU5NTM_a95fd283-54ea-4f47-91e9-e17b4afb4895">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2772b321f6f54c0c86bea892e8380009_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtMTQtMS0xLTU5NTM_83d3a090-9f2b-42a0-b582-7b31c6db7c07">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic526ab60ae6e4f5793eb51c0321f5905_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtMTYtMS0xLTU5NTM_f81086d9-0821-4ab9-b513-8d2bf6170797">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id610eb3a322f41c8a749fe84d536e585_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjItMi0xLTEtNTk1Mw_b38b37e2-f06c-4686-aace-e97c38127446">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica526b4aef3a494aa2733999ba191001_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjItNC0xLTEtNTk1Mw_7a0fcd85-a4d9-46c7-bb35-d0bf8ff63ae8">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bc50922e47b41d1ae940b37d4a22377_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjItNi0xLTEtNTk1Mw_c8a10710-c97d-43e7-b133-c45f09935cc4">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ec94f0555e4aebb035ebb5e2f4925a_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjItOC0xLTEtNTk1Mw_c49ce4f2-2763-4285-a0c5-e63a133f19dd">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cc4334126ed455ca10fd4f18e8f5b4c_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjItMTAtMS0xLTU5NTM_6d0bb187-8f7b-4769-a75b-9700d93a0977">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff242a9f3684b65bdac58944556d71a_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjItMTItMS0xLTU5NTM_e7b85306-b923-45e6-b930-4dc24b173082">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab32fe9b37b248d29bd625882511a2bb_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjItMTQtMS0xLTU5NTM_83c13532-f960-4199-842c-9cdb08890feb">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia54a8c84a9224b4aa1d3a5f8e35961cf_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjItMTYtMS0xLTU5NTM_7bad535f-dd9a-42f1-b12b-3710c77f3ec6">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3432013787d441d5ac3a3a61b439dac3_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjMtMi0xLTEtNTk3Mg_0e802a50-c6e0-40be-9cd7-ebc52ecda825">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib78feb1672bc421087bf1d5bd26b7f38_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjMtNC0xLTEtNTk3NQ_00e1035f-6aa2-4a68-aee2-6688473dbb7b">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b34a41296624040be895c5b6d3289a3_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjMtNi0xLTEtNTk3Nw_5a215b40-b05d-4f66-bdbc-1b55344dcd6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85236c36163f4119b8910a94fbd2562f_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjMtOC0xLTEtNTk3OQ_6989764b-86c6-4938-9d3e-f3f8863ac2fb">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1912c5f855804d3eba84607a017c56ee_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjMtMTAtMS0xLTU5ODE_9b135bd8-b982-45c0-a230-8e4e5808aaf7">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b6a5426bf9c42a6acc2bf5e17b270af_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjMtMTItMS0xLTU5ODM_8bd1844a-7c33-4a3f-b982-18581cb24c21">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60e4866d36c54935ba04c29bb4fca09d_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjMtMTQtMS0xLTU5ODU_83baa7da-6805-4544-95ba-f5d249508149">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6db1d7fe6dbc4d6ca143fc475b93b204_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjMtMTYtMS0xLTU5ODc_4961d162-7327-4d96-a462-3bb620efe4cc">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc5ca7d98d3244549154eef3bc1137b9_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjQtMi0xLTEtNTk4OQ_edd4f4b3-6a68-4dd4-9f2f-31ab300f08f8">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5777618eff474b979c73d1e5bb0bcd06_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjQtNC0xLTEtNTk5MQ_5d83ee67-fa4f-4501-ac25-d82bed4254b8">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c40061142b4bff954eed33447b411c_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjQtNi0xLTEtNTk5Mw_cc1d7b66-a430-4504-ae23-549db8bc0735">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib68625c89e0942cda48fef6469af6e0b_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjQtOC0xLTEtNTk5NQ_316d1284-3e45-4cdc-b035-86f26212f334">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8c748ed1b844524849ec04f66244abe_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjQtMTAtMS0xLTU5OTc_76010098-72f5-4014-812b-ca5bcaf27e3c">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dae4cebdb14befa776bdc7e3990bdc_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjQtMTItMS0xLTU5OTk_11367815-8ec4-43b3-a2d5-0f77c573d6cb">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37cc9d8c63b54982bdae48850a893359_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjQtMTQtMS0xLTYwMDE_daa39985-3f8a-426a-bb7b-fb17bd4a4e08">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i897fee00cdd84fe19bcc2cc8dff383b3_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjQtMTYtMS0xLTYwMDM_91b01bd9-1058-41ca-884a-143150bbbb56">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b087aba23654283a5c4af9b69a0202e_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtMi0xLTEtMjc3Mw_715fdf9f-e139-488c-adcc-9858c4f780c7">820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeb98b603f06451ead95cabe282463e2_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtNC0xLTEtMjc3Mw_79d83096-2aaa-4e6c-86df-d285048502e7">388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id37d8e541c21407bb4a5f8243c09f13e_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtNi0xLTEtMjc3Mw_f38e2a71-2a57-459f-ba02-7d1d4c592389">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ec4f656f3842acbe27241f7f05ed2f_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtOC0xLTEtMjc3Mw_2d61f667-bc91-40a8-923e-0c78ede4fb5a">1,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id69e1c2be46d4ab3b4309b0f917bbc46_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtMTAtMS0xLTI3NzM_cd88938f-13d1-414a-9c35-89ec4e53bf76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1667d7f2806e4f558140470b36628aa9_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtMTItMS0xLTI3NzM_9bb820e7-5a57-43b8-b1d5-2f6a106658d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2328db06206c4fdd9af385e7c2173cc1_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtMTQtMS0xLTI3NzM_dc9eafd2-9792-449d-9aee-7869ea096053">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f4ecee25efe4513b99dc58abd0fe3a2_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtMTYtMS0xLTI3NzM_10c196ef-7e6a-4bae-9836-9e637725a051">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Cell Therapy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3005b97b85247b7bb0b10e165ad5a20_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjUtMi0xLTEtMjc3Mw_eb521c36-d767-4ea0-a16d-33b0515f4e5f">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf31979b82854addb363f690711744a9_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjUtNC0xLTEtMjc3Mw_3f18e9b6-e1cb-44d1-aa0f-31e819043ede">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c18a34a44ac4a6eb3e0df9bd9f9bbec_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjUtNi0xLTEtMjc3Mw_eff32e45-5831-4f1f-b136-e894d7aba59f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5b81cbd589447aeb09c7c7271354585_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjUtOC0xLTEtMjc3Mw_72e66b2f-1dcd-4499-bdff-18ceffa27969">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a2f8ebf252349c19b669e8c8082fec4_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjUtMTAtMS0xLTI3NzM_b686ef74-de91-4a4a-81fa-3dcf59aba8c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7413a3522244628851987c3f80b566e_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjUtMTItMS0xLTI3NzM_8ce0d7a8-63e9-4e5f-b358-acdd413061e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13d9726cce774f76a579a5e8833f0a50_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjUtMTQtMS0xLTI3NzM_66b4af77-ded0-4e59-8962-f6e2a224b135">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id035c0dd020540dd9baeb1cf7dc147b5_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjUtMTYtMS0xLTI3NzM_3b23f142-c4fc-4abc-9f78-255519373da3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieffdb1acfae64cf3893370c95966b40f_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtMi0xLTEtMTA2NDI_9f30b233-f188-4224-9119-7bb9c9cff99a">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib75a2669840e4d33ba162e40920c2dd7_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtNC0xLTEtMTA2NDI_38c56c32-72f2-4a97-9531-168380b86a84">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43c8f799fa3c418bb426643d8c44cd59_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtNi0xLTEtMTA2NDI_9a397537-924d-4f0b-a68b-5ac0c23a22d2">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b79af85df4a5682a9ba6a0d5ab1d8_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtOC0xLTEtMTA2NDI_efe6ea16-a90f-4513-8774-6a160bc20e1d">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36eeb702c1740afbd92eef4087fa2b7_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtMTAtMS0xLTEwNjQy_f87796b6-53d4-4453-94f1-d57d04e76374">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie528cd0b9cdf4dc5a97392412c208b8c_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtMTItMS0xLTEwNjQy_62faf937-d56b-423f-8867-18d9fb1a0427">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95f4d058a72e4ceeb60de778690ef7c2_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtMTQtMS0xLTEwNjQy_22ffa181-ece1-456b-bc31-f537903248ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie77a01ccaa114972a96aa9c83d1e2ae4_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtMTYtMS0xLTEwNjQy_8cada538-3938-4fd4-a8ec-386ba23e823e">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Cell Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e328dc77d9945ddb8c8684f306018df_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjYtMi0xLTEtMzE1NA_fdd3392b-cc89-4ffe-b881-51db71f7ccfc">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i638557b5d8cb4470bf95e691ee5ce53b_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjYtNC0xLTEtMzE1Ng_344a9387-6cba-4506-81b7-26eb155d82ac">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05bbfb8bf6fe4d4db64e6f86903a3437_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjYtNi0xLTEtMzE1OA_e367c3ac-8a63-47a1-8b14-d6452504d33c">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id31fed8e97de4275a24d7c4b6bdcd1ae_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjYtOC0xLTEtMzE2MA_edeb1106-b321-48be-a1bc-e46c725db8b7">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i895202346b1e4f8e9fb49025b720a3e9_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjYtMTAtMS0xLTMxNjI_c0eb5368-59fa-4261-a970-eee1c1c8317a">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a4bec7cd2a7469992b30486d0367128_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjYtMTItMS0xLTMxNjQ_820988d1-95de-4503-ab2b-b137c3e59769">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd6d31d7996e46edbb7ee6b98031d951_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjYtMTQtMS0xLTMxNjY_0211f545-c275-4543-9a96-1b006e820d2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia884a4d361c549379ff1a1b4a3e743d1_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjYtMTYtMS0xLTMxNjg_5cb224f9-ecea-4ace-8e4f-16661b7626e4">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e124cdf64ce4d42808bbced06eee17f_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjgtMi0xLTEtMjc3Mw_1a0874a8-e929-4ba5-97ae-e047e2e00a4b">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94c157660993467d933768c8d2aace75_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjgtNC0xLTEtMjc3Mw_2e2e1870-d56b-426a-b27e-a1e419383dd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i765af031a6b7456b87400772e5870fad_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjgtNi0xLTEtMjc3Mw_36a152e6-7947-4dee-8cef-db6658335e2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9bec1aed1d4441e84196a0df4aef39e_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjgtOC0xLTEtMjc3Mw_ff7ec639-f1b7-4472-934c-128edb0c2962">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a6c817b9881419c843a0c4e6dc181a7_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjgtMTAtMS0xLTI3NzM_d14c439b-5087-4c33-b673-d28a826633a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72493ff81994417eb27d02d1509511da_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjgtMTItMS0xLTI3NzM_f0d8e9b0-2c48-44f8-bf27-0b598b8d8c4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84bc3ed5f80d4988b11e429d726f932f_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjgtMTQtMS0xLTI3NzM_6c30689e-5e7a-4201-9435-0ac4cafa6e28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if726dadc7df94416b6c217bdf80c23dd_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjgtMTYtMS0xLTI3NzM_7a350fc2-709a-42c6-8f9f-c980863290ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6640c16387c47d3a3a2b9e3877f611f_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtMi0xLTEtMjc3Mw_952fd121-f002-48b2-9cee-2fd38a69ef04">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9418ff206901445b9b29378a177c1078_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtNC0xLTEtMjc3Mw_95ffc414-7a6e-49c4-a717-af137492d88a">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a67a6c1c934a8191082d5f097351ab_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtNi0xLTEtMjc3Mw_ebb0ccae-8a46-4e63-b26b-d57cf08cfd98">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic787aa223d5c4f5da13f043035ca0c4d_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtOC0xLTEtMjc3Mw_010574e8-bb1f-467e-8eda-d74ad39a0516">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbcfbd0d83fd490a88eb77e4164e8482_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtMTAtMS0xLTI3NzM_330f54b7-2c5f-42cf-9df6-16bf544e40b8">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ccd5f7a01343d2a2c516f6e998e3bc_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtMTItMS0xLTI3NzM_1a6769c3-c37b-4459-88d4-f19c5738055f">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830a223d4ff2496b95fa59aa0e3e4797_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtMTQtMS0xLTI3NzM_121418c8-8802-4896-bbdf-bf6800562824">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a0e2be2410b432f83a8f28ad4956670_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtMTYtMS0xLTI3NzM_a36ec084-12ad-4b2c-813a-acb6dcb984c9">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56d0c83af6c24195b5bf3247fc3a2a1d_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzItMi0xLTEtMjc3Mw_49f8389c-32ba-4bf6-9c13-8993474f86b2">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f5ba02898844d3ea4c5f499f95e5fb0_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctNC0xLTEtOTA2MQ_866801c3-8067-4b4c-8844-13d5ca0457ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20275018e0d44c51a225e199b4c27700_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctNi0xLTEtOTA2MQ_824634be-1072-4d0c-95dc-b56a79313512">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ac1fc0d9b04f45841b68102ff7a077_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzItOC0xLTEtMjc3Mw_6179c4f7-c8ad-43fc-a4bd-57f5b8a5f32b">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc55defcbcf045f4926fb48eb0af8237_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzItMTAtMS0xLTI3NzM_c71dd5a5-e6b1-4592-b8cd-7cb7457eb237">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie794e67f1815485d87eb5b97b42e3a28_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctMTItMS0xLTkwNjE_df03090a-aa2b-45a5-a51c-c15b80bbeead">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4c01e5b99d04896a602aacda729c489_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctMTQtMS0xLTkwNjE_9097ce8e-3aca-4b2c-81e8-1428b152082f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb5ad85e55c34064accc690566b965df_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzItMTYtMS0xLTI3NzM_81f5e0ca-6230-4234-bc5f-57ff32d637f9">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ranexa</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i060769bd1274459796e6b5d21c6d2fcf_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzMtMi0xLTEtMjc3Mw_ea0d2c38-26de-43da-aabb-c7ac2609646c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8116a166d7b441d2956497a975f03511_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtNC0xLTEtOTA2MQ_13e6c2a0-9765-4f6b-9208-06085bc808c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i240d967d6df04f7b960c8bd653ebf8b2_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtNi0xLTEtOTA2MQ_a8c920c6-15f0-42b8-9b32-48d1178812cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i217f335d6069466ab81d2c9226caf8aa_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzMtOC0xLTEtMjc3Mw_ce3495e7-6681-48b7-9223-a0039b2f5475">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fd3a3dc901f42628f9c5cdcd8c7c6a8_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzMtMTAtMS0xLTI3NzM_608cfe97-9251-429e-ae6e-009fd73d43c5">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416394b51cde4930982ba7a31e497d29_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtMTItMS0xLTkwNjE_02b61363-d391-4170-a878-046055d08613">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if80f651125c7457f9c03c5bae809f7df_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtMTQtMS0xLTkwNjE_752e6076-37a2-495f-b364-38f8f664ea7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29de68ae484845bbbcc46d9cef9b77cc_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzMtMTYtMS0xLTI3NzM_61bf19c5-0ee7-49e7-976e-0b7eae367737">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zydelig</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9cafed727b04b61a40c05a62b4478bb_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzYtMi0xLTEtMjc3Mw_6c03b870-021b-4f28-b6b4-a99e5ed28e3b">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91466ff987d24072b25a05678b2c099c_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzYtNC0xLTEtMjc3Mw_cc1f667e-6513-4912-b025-af1d8e522d22">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27f5ef98b94448b0b24ea64ee73bc0bd_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzYtNi0xLTEtMjc3Mw_659921d2-bd56-4821-9385-717a27418540">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i993d7e955bc24b07ac282e4ab68a7571_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzYtOC0xLTEtMjc3Mw_c3e0a5e3-f213-417d-a964-93e2cee17c42">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e949706c1134da999d6dae385652030_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzYtMTAtMS0xLTI3NzM_a504ef68-c814-4e72-94e7-682410b925a6">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec3ba3a461c4bb9a085047222875988_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzYtMTItMS0xLTI3NzM_a29604d9-ac47-472a-890f-7ddcbaba39c8">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2a556c276af4966a1f10ac00b2afafe_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzYtMTQtMS0xLTI3NzM_901c222b-f345-455b-8011-e40658d64b95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1608b354af974844a750d7bbff9d65bd_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzYtMTYtMS0xLTI3NzM_37b3af7f-23b0-40d2-bc4f-661c3dd6ac33">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie622129ad8eb43a190e8eff8fa687ae5_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctMi0xLTEtMjc3Mw_cc5754b2-43e9-4b23-a636-00ab48f29a9f">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f5fae6c59274f0c9e41875005ba8c44_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctNC0xLTEtMjc3Mw_3cb8c14e-52f2-4096-9dc5-9599f6438cfe">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e613c28bb364cccbb5a721e8f1d7d7a_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctNi0xLTEtMjc3Mw_dc2700ea-8a5f-47e8-8f7d-583c1705ec10">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e45a6235b364a4bb66ea5322ed6de0c_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctOC0xLTEtMjc3Mw_2b00c2f1-cd94-4fd4-8222-41b18a75cae5">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52538488633a4641a1fb75bd6ea77c00_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctMTAtMS0xLTI3NzM_1920aa08-f387-4ce5-bda1-0b0fe0ece2d1">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife67fb52d10a4d4a9dc24e6e584d9f8f_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctMTItMS0xLTI3NzM_af020626-5f6e-43ea-a340-d1d2b86c6962">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77b40277de7045d1be5c4072ff5a78d5_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctMTQtMS0xLTI3NzM_47c025b5-cd1c-4071-a5ab-bb9978fb4eaa">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d26210a184b4926ac141ab337c6d073_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctMTYtMS0xLTI3NzM_3d14a98a-4807-408b-a45f-b9101b4729ec">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2bdbc28395e4c749de3966f3d490986_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtMi0xLTEtMzI5MQ_93946360-66cd-4bfe-b15b-91d3d20f6a9d">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31d850a622e9469497772ed09d38381a_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtNC0xLTEtMzI5Mw_ec7253ee-b72a-477f-8163-4794a100302f">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1dde27099e04e999e1d57d292d9919d_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtNi0xLTEtMzI5NQ_52f4b023-32de-426a-b5ea-d1f8a9eea0b8">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddfef4e9b501477bb8ed2bdd6115418a_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtOC0xLTEtMzI5Nw_a4934e98-93ae-40b6-8387-17587b509cb8">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i633cffc37fba44c896afe1666617e27b_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtMTAtMS0xLTMyOTk_00a5369f-62ba-4223-b12e-c4f3906c6cb3">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i696ccf6fee89419a892324e7301d6a33_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtMTItMS0xLTMzMDE_b6cb3b6f-abd5-41fd-9fec-57abd3766faa">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03f06d9abbc4d33994c24916cad8f2a_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtMTQtMS0xLTMzMDM_5e1845c2-125f-4368-a1c5-919cbf5dc8d0">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da7f309c165427aaa64cd0d24fc46ec_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtMTYtMS0xLTMzMDU_3683b02e-6dbe-4541-942d-bed9ec36ae74">278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0f41ed705fc47bdad91b627766f40c6_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzktMi0xLTEtMzI3NQ_7804ffa7-24cb-43c2-ae6f-d363cb5c0f71">4,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i242ad95eb87d4a50a40c74136ce45ce8_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzktNC0xLTEtMzI3Nw_b195c513-27e4-4721-a766-2cc0715fb79d">1,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4208030b6e11411a8b65bb4461639e24_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzktNi0xLTEtMzI3OQ_f2db163d-e264-4407-a9e1-b0bab74e4f67">825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i869fada8dc15440fb186758025e4ea38_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzktOC0xLTEtMzI4MQ_9843dd8c-bbd0-4459-8c70-9a735cff98ba">6,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26be40f7eb5247d2a40cf54a35c01a00_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzktMTAtMS0xLTMyODM_bbe2ba4c-f61c-499c-aad3-d96619f7b373">3,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53b279b4db0f4f1dbfbb9132a4d78da9_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzktMTItMS0xLTMyODU_f5436bdd-ec4b-4750-9654-a061d2e00958">927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a7bd7ae51244859339deec6090a256_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzktMTQtMS0xLTMyODc_27ce2ffd-d19b-44ff-9e87-2ba1f830abaf">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i888db709f4bb4306aecd55be57d43e9e_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzktMTYtMS0xLTMyODk_72508094-60e5-4f6f-9a20-48290b511691">5,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eb69f03734240adab1da5d621476341_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDAtMi0xLTEtMjc3Mw_0682e97a-33f0-44bc-92e1-a0f62e5641c9">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i718d3fcd575e4cfcb3f142a29edf8c39_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDAtNC0xLTEtMjc3Mw_97894a78-17af-4425-b9e6-1e94f89139c1">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776c29b6bd8246b799595de5c9c32a6c_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDAtNi0xLTEtMjc3Mw_c07b3535-fc08-4a33-85ee-f1b81c4d373e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d0a665778d14bbb912aa93b2b6e4f2e_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDAtOC0xLTEtMjc3Mw_342185c1-4d8d-470a-bec7-488504b74b5e">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2d224f161354feb9e09b4ebb8e0cd9c_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDAtMTAtMS0xLTI3NzM_d62747ec-0e25-49e9-8abf-885b2c13551b">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i001045f707f44a6f80dd8a8ca22a4bf3_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDAtMTItMS0xLTI3NzM_e5d1e6f1-4cd5-408e-8341-6c7a4391b136">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefd124be7cd14a8cb0d1429c3a487683_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDAtMTQtMS0xLTI3NzM_eaa91a8a-792a-4107-9813-3e516df929a6">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e94052ecbb3480d9dda10de813ecacb_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDAtMTYtMS0xLTI3NzM_2e6317c4-23ea-47ef-a12e-8de5ac124874">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027a876acd5948e39aaa2a168d3de1fa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDEtMi0xLTEtMzMyNw_fde556d5-aeb5-4f2a-bc1f-7110f2c97654">4,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8517e6b14d3e4e059d8471ac0f54ff42_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDEtNC0xLTEtMzMyOQ_b8846581-d8dd-4e74-9447-e8ea28e9b813">1,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c6a2a79dbe141ba9c759468a86cea51_D20210101-20210331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDEtNi0xLTEtMzMzMQ_45b5e83a-1933-495a-a422-195a4ac33c1a">827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDEtOC0xLTEtMzMzMw_d1cfd366-ea75-4b60-b5a2-3fbe183290d7">6,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85cbcbbe9efe43c6b5e7ac96bb4d64c1_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDEtMTAtMS0xLTMzMzU_76f24eec-7767-4761-b913-3b61aca73025">4,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a72c3a2c01447b1ba0c68c97b289ee6_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDEtMTItMS0xLTMzMzg_ce923f21-4c67-4cc6-9e6b-6a7a35083d49">975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f8b4813eba0494e93eda89e8d1553c8_D20200101-20200331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDEtMTQtMS0xLTMzNDE_7587f29a-5d31-4b2a-8df7-6dd421c426cf">567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDEtMTYtMS0xLTMzNDQ_d524cecf-1960-432f-8bf7-df4ada0cd1b5">5,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="if8f8d70fe1204b57abfa4b8ebceb6ae7"><ix:continuation id="i9285eadbf0314cfead8bf265fe6526f2"><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#8220;C&#8221;), emtricitabine (&#8220;FTC&#8221;) and tenofovir alafenamide (&#8220;TAF&#8221;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Cayston and Jyseleca.</span></div></ix:continuation><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues from Major Customers</span></div><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RleHRyZWdpb246NWJjODQ4YzM4NzdjNGU5N2JjNDYxYWJlYjRhMTdhNDFfMjA2OQ_99167eec-709e-4e01-8805-5e697bef69ff" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:79.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(as a percentage of total revenues)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0bd483f628534e979ee1ef8021838fb8_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjA4NDY0NzRkMTRiZDRmMzZiNjFmM2UxM2FjNGM4YWM4L3RhYmxlcmFuZ2U6MDg0NjQ3NGQxNGJkNGYzNmI2MWYzZTEzYWM0YzhhYzhfMy0yLTEtMS0w_a74fb8b4-cd56-4f11-ac02-f21ac231bf7d">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icbcb2718a9a24054beb14bb7fd018345_D20200101-20200331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjA4NDY0NzRkMTRiZDRmMzZiNjFmM2UxM2FjNGM4YWM4L3RhYmxlcmFuZ2U6MDg0NjQ3NGQxNGJkNGYzNmI2MWYzZTEzYWM0YzhhYzhfMy00LTEtMS0w_796c172b-37d6-4eba-af9d-7524b941914b">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd0ff86989784672bbacbf1f772f25fa_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjA4NDY0NzRkMTRiZDRmMzZiNjFmM2UxM2FjNGM4YWM4L3RhYmxlcmFuZ2U6MDg0NjQ3NGQxNGJkNGYzNmI2MWYzZTEzYWM0YzhhYzhfNC0yLTEtMS0w_8bf224b5-2ac7-4ec5-a3a7-84b81fcae100">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id7f6740c84514432ac4d19cf79c9a9e6_D20200101-20200331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjA4NDY0NzRkMTRiZDRmMzZiNjFmM2UxM2FjNGM4YWM4L3RhYmxlcmFuZ2U6MDg0NjQ3NGQxNGJkNGYzNmI2MWYzZTEzYWM0YzhhYzhfNC00LTEtMS0w_0fc2c078-b03a-426a-90ec-fa57ae6c07c2">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia65096122500425d94f26b129443d35e_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjA4NDY0NzRkMTRiZDRmMzZiNjFmM2UxM2FjNGM4YWM4L3RhYmxlcmFuZ2U6MDg0NjQ3NGQxNGJkNGYzNmI2MWYzZTEzYWM0YzhhYzhfNS0yLTEtMS0w_d8529434-527f-45c6-babe-f338e98aae65">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8763f2000062414b96d9bc6531fe8ab1_D20200101-20200331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjA4NDY0NzRkMTRiZDRmMzZiNjFmM2UxM2FjNGM4YWM4L3RhYmxlcmFuZ2U6MDg0NjQ3NGQxNGJkNGYzNmI2MWYzZTEzYWM0YzhhYzhfNS00LTEtMS0w_cf55ddbb-3306-4d8c-bf2f-27f96b6e6df9">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues Recognized from Performance Obligations Satisfied in Prior Periods </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized from performance obligations satisfied in prior years related to royalties for licenses of our intellectual property were $<ix:nonFraction unitRef="usd" contextRef="i77440dee8e4f4c28b9284a8c1b5ee20d_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RleHRyZWdpb246NWJjODQ4YzM4NzdjNGU5N2JjNDYxYWJlYjRhMTdhNDFfNjUx_df18510d-2f0b-4ccd-b3b4-d945411e0d18">226</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0658097ecd9f4ed7a6c2540f41f0c3ba_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RleHRyZWdpb246NWJjODQ4YzM4NzdjNGU5N2JjNDYxYWJlYjRhMTdhNDFfMTA5OTUxMTYyOTk1Ng_6d6c2aaf-7428-4921-990d-9891d3af8ff1">188</ix:nonFraction> million for the three months ended March 31, 2021 and 2020, respectively. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable consideration is included in the net sales price only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with the variable consideration is subsequently resolved. Estimates are assessed each period and updated to reflect current information. Changes in estimates for variable consideration related to sales made in prior years resulted in a $<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RleHRyZWdpb246NWJjODQ4YzM4NzdjNGU5N2JjNDYxYWJlYjRhMTdhNDFfMTE3Mg_bf4bf008-72ac-47f1-9ce6-801a31b9161f">332</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RleHRyZWdpb246NWJjODQ4YzM4NzdjNGU5N2JjNDYxYWJlYjRhMTdhNDFfMTA5OTUxMTYzMDEwNg_8466e9dd-0e01-43c0-bcaf-ab4f7ff42c35">38</ix:nonFraction> million increase in revenues for the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $<ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RleHRyZWdpb246NWJjODQ4YzM4NzdjNGU5N2JjNDYxYWJlYjRhMTdhNDFfMTQ5OQ_9798345b-e647-40ba-b320-9f56839365f0">185</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RleHRyZWdpb246NWJjODQ4YzM4NzdjNGU5N2JjNDYxYWJlYjRhMTdhNDFfMTUwNg_2060e9a3-6e18-44ec-b71f-517071251ff7">198</ix:nonFraction> million as of March&#160;31, 2021 and December&#160;31, 2020, respectively. Contract liabilities, which generally result from receipt of advance payment before our performance under the contract, were $<ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RleHRyZWdpb246NWJjODQ4YzM4NzdjNGU5N2JjNDYxYWJlYjRhMTdhNDFfMTY2NQ_cda4ec68-c1a3-4b89-8752-21b577f39bba">91</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RleHRyZWdpb246NWJjODQ4YzM4NzdjNGU5N2JjNDYxYWJlYjRhMTdhNDFfMTY3Mg_fff4b9a7-5492-4536-8e29-a19039b7054b">97</ix:nonFraction>&#160;million as of March&#160;31, 2021 and December&#160;31, 2020, respectively. During the three months ended March 31, 2021 and 2020, revenue recognized that was included in the contract liability balance as of the beginning of the respective years was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div></ix:continuation><div id="i5e8b0e18419843159ec07e1b794d0d87_40"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfNDc5NQ_28742a32-856a-4f32-8aa8-5c2ec49d6cb0" continuedAt="i700a4594dfa4454388bbe62c3cdf09b2" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i700a4594dfa4454388bbe62c3cdf09b2" continuedAt="iee37d10b83714608bd28abd00b788784"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfNDc5Mw_298d15ae-c8e0-45ff-95f2-d119c2528a3b" continuedAt="ida49f9f0c034465b9f523694c01b4b5f" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 1 inputs include quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. For our marketable securities, we review trading activity and pricing as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data; and </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iee37d10b83714608bd28abd00b788784" continuedAt="i384846e1a2264f10988058b5d3697839"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ida49f9f0c034465b9f523694c01b4b5f" continuedAt="i5cf8fbb460fb40c38bcb7181d312e9bc">Our financial instruments consist primarily of cash and cash equivalents, marketable debt securities, accounts receivable, foreign currency exchange contracts, equity securities, accounts payable and short-term and long-term debt. Cash and cash equivalents, marketable debt securities, certain equity securities and foreign currency exchange contracts are reported at their respective fair values on our Condensed Consolidated Balance Sheets. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Short-term and long-term debt are reported at their amortized costs on our Condensed Consolidated Balance Sheets. The remaining financial instruments are reported on our Condensed Consolidated Balance Sheets at amounts that approximate current fair values.</ix:continuation> </span></div><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfNDgxNA_0390aa09-c3c1-47bc-9c5b-83f6a1e6553f" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6858c51c1e4711938e993b04877b4e_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNC0xLTEtMS0w_b671a63b-ddc3-4391-8b9c-b74fcabe9a4e">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96617e7cd54426a8d62efdc0b500ca3_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNC0zLTEtMS0w_fcd63d1a-4e67-40b4-b0b9-78cc4293dc42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0ad9df8e3f742f8a9d13605d46cdb6f_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNC01LTEtMS0w_ead00879-345b-4939-836d-ce9b55b7a58b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c0a79638a0401ca700e01bc980c823_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNC03LTEtMS0w_04c5c87b-da58-4b1b-913a-2e82d429e5f9">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3360b0081141b68f60fc04b739a94b_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNC05LTEtMS0w_3c91bb61-74a2-4b21-85d1-6effee925a43">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93e1474c09ed43708fdbb6b69bc558b3_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNC0xMS0xLTEtMA_da4475bd-daa4-486e-bc74-022cc6398110">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief5d8a88cb0c498aa5bab8062cadc5e2_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNC0xMy0xLTEtMA_15033581-4827-4372-9e92-84fedc00918a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e340b8dc03c46e9847845ecc93cd50d_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNC0xNS0xLTEtMA_0abce4cd-da47-4317-9105-d6a3b402e13a">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5e98f04e5240d491e0cc8b9dddefdb_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNS0xLTEtMS0w_33709120-8958-4192-a3e7-02c878fe8fa1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97d51408424340dda5bf1d3aa89904bb_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNS0zLTEtMS0w_fbfdfb28-a162-4362-a590-b00b542d5f29">358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb8af5d71f544b89bc874338694fa854_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNS01LTEtMS0w_0ccb63a9-7733-4415-9d3a-8d71b21619c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied9f8a90eedf43f299e27e814d996911_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNS03LTEtMS0w_cdd19b40-7cdc-4854-a3ce-5d3b3f007df1">358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d6a99463d548be91dccf3d8477c710_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNS05LTEtMS0w_ad359cd0-3c6c-453f-aad9-1fdb582c3b31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00c48252b08b4726a781e4f7f1713886_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNS0xMS0xLTEtMA_c07a31aa-3431-49f1-8187-fa4d97a9495e">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i555b95565b354fac92b93a98e20786a0_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNS0xMy0xLTEtMA_82f442ca-1c42-4ce5-aba4-02ea7b025f81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f7eb5d72aa41e389a203f002990378_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNS0xNS0xLTEtMA_5687f262-9576-4fa0-b44f-a3c0ba8cbf5c">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iade14a2b611b4dc4a1182a5853afb334_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNy0xLTEtMS0w_dc5aa362-dfc2-4fce-a6bb-e1935b4e7d11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4464d90589e45bda0d671fed402ff0e_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNy0zLTEtMS0w_59e6ed3b-2aac-4634-84a3-7c3e33408417">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b417832f6cc49f191f7192d1a823352_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNy01LTEtMS0w_100f0305-bd02-4abd-9a48-053b3df862a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc9df4486c8247a19dc93d1ed8ddc162_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNy03LTEtMS0w_733d16e6-cd24-4d8b-b539-a2f7051df7e9">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic28662f110d3489097e5bfb6893f2427_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNy05LTEtMS0w_bbf04743-0be3-4aa2-8789-d231cb270262">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic05e70bbe4b3409dae83bc7d0776ac63_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNy0xMS0xLTEtMA_f3a7a913-5af3-4aeb-b522-20c3bdcebac1">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e9200ff492148ae8c58c24ec1cd7a91_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNy0xMy0xLTEtMA_de7f33af-4432-481e-abc8-51c6ab2e24e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0c1157b3a14d309db0f095df92bde3_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNy0xNS0xLTEtMA_b9393e1e-d25b-4768-b06d-3eac3c62bff9">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152ea6395daa4d07b42285941bcfdf86_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOC0xLTEtMS0w_d40c60ff-8720-4d7c-8458-4c9a815aa181">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d21135f58b461f951b28b78af74777_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOC0zLTEtMS0w_ba4f916e-a04a-43e7-8bdf-4de081c1eba8">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i377ef2a3c67e4eddb0210c423899d36b_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOC01LTEtMS0w_741e432b-4d0a-43fe-a934-701375768725">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25828069eb6f42dd8588993c039568a3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOC03LTEtMS0w_f3c3daff-c64d-4bd5-871f-3cf1f94c7002">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3222bce3d3fd40099ca0065f76398572_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOC05LTEtMS0w_cacaa7c1-8ade-493d-aa31-77d1de37f792">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7823458e96f5434ba771f22ab8eaabf9_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOC0xMS0xLTEtMA_687245b2-f90d-4e0c-a3f7-2a62fd2c485b">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c79cd884d64f78bc716dbc267e3aaa_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOC0xMy0xLTEtMA_6090930d-9f64-4fd3-a932-e66f0586c7f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00681abd09ab444f83e854d3a2172b8e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOC0xNS0xLTEtMA_bf7989e7-ac9b-45a7-ad5c-9fc22163ac0f">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0d37ded2b7640aa9128dac07431cd34_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOS0xLTEtMS0w_20207623-4413-498d-b891-00dd0a0ed2ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a4a45ef79134c3eb7aefea81863cd66_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOS0zLTEtMS0w_16057d94-2ed1-4e75-87e3-6de6299fcc35">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b6fb120815b4e528bfe5109cd7d6515_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOS01LTEtMS0w_2abc5a0b-d3fa-4261-b024-63676ce31fe1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3664faeffef41cf8c6784e97bf9f9e9_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOS03LTEtMS0w_84cfcf26-9849-4130-b2c3-6b78c6d69099">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia462feb041e340b58c473503f10bf35b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOS05LTEtMS0w_f5832a5b-dbed-4752-8f8e-00027e2a33ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1db9c8c7496f46a8a743dffc446c7a18_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOS0xMS0xLTEtMA_1c632e66-09ba-4066-a287-35eb83079c64">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f4efed1bea843dc869bb5263b87e2ad_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOS0xMy0xLTEtMA_cee29fa2-e107-45d2-862d-02e22f95d80e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a4be1eea0d49da818f2dfc2e5cfec6_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOS0xNS0xLTEtMA_7708c30e-2730-4b7c-8e7c-6cb624038181">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3fb2529cb7c446b9a528d1a8b7febe6_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtMi0xLTEtNDc0Ng_31c82c7e-3871-41d1-870b-1d921f49b82f">2,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a5a0a5260942a38c682ec567b73ed3_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtNC0xLTEtNDc0Ng_d0beaee3-089c-4337-9d8f-6f6c321641b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30f95952d5ad4c11a2bb8bfb311497de_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtNi0xLTEtNDc0Ng_712d4d76-ea88-44d9-8c46-2d0f38692242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49e347d7180a4083bef177c0caac5662_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtOC0xLTEtNDc0Ng_6f35eae5-61a5-4273-b9e5-345bb98e65d5">2,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19b688ee3c124c99aecfd55f3756946d_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtMTAtMS0xLTQ3NDY_291d170d-2249-41a2-a141-cc0f406769b6">4,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0f6e93e4ace4564af67e889d7a1da32_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtMTItMS0xLTQ3NDY_e7ef12ed-d362-4542-8b09-98ff97a58342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ab32a7541324448912a25d6eb8375b8_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtMTQtMS0xLTQ3NDY_c01121cf-e579-45d9-9575-63211d3d6f3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a15e23f32af40a1b8c8859ebe00a14c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtMTYtMS0xLTQ3NDY_6d538192-c448-4107-8700-b852fba0efcb">4,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Galapagos</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ee618b24da746db97c20d8ee326d75b_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtMS0xLTEtMA_ea3f7d1d-aa6a-4f2f-9874-17b5b23acd4e">1,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ecc557b23e64f7f8b3e28f3bb1e98a7_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtMy0xLTEtMA_25150040-e3e1-4508-b935-c8f96c2473a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9d39b9d99e449cb7beaed696f22f66_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtNS0xLTEtMA_f1bb40ab-b972-41a7-ad3f-04b981fccd27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a792f48d4514975b5fc1c1b4ed9d133_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtNy0xLTEtMA_b3d310fc-b00b-4fa9-a308-30f24856f79e">1,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b4ada8e24d54ee1b49c8cb41dc0bb2a_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtOS0xLTEtMA_6b2a400b-e1fb-4798-94cc-b2ce4b8de36e">1,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6cb1f3baba4062821903054d8f7abe_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtMTEtMS0xLTA_a7df6b79-336d-408d-8475-72003e75b715">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc6563b6f71a489583fb4e031963948f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtMTMtMS0xLTA_560ab51c-c7d9-4c3e-8840-5777f02b5ca9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ad38733f4904e358d2e5a32c94b2371_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtMTUtMS0xLTA_20eb8e6d-c32d-454b-bab0-c52a0809c187">1,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9ddc669c48f47d4bd4a8213c2574ab2_I20210331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTMtMS0xLTEtMA_091ac2df-1258-44c6-b958-e4ed13a821a2">968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied694544bbe046f5abc557c39b011a0b_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTMtMy0xLTEtMA_a3a478c4-e5c5-4370-b42c-64fb3241dba4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3bc6d62c5104b8c8d39a0ae9f7af156_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTMtNS0xLTEtMA_a2f5fa12-70f6-41ac-8a14-dff26afd6713">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id19a8a5f19494cf0b1f5311d3e01397e_I20210331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTMtNy0xLTEtMA_75219eaa-1c37-41ad-b8ef-af41efd88839">968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i679d3266010f46df9faca1c635a05771_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTMtOS0xLTEtMA_864b085d-089e-43f7-8914-ef62112453b8">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie908d94aad8a48da9603237735f6394b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTMtMTEtMS0xLTA_6c09ef7b-d98f-4fda-baff-2e327bffcf3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia516bf91deb6424abb224de23f37284b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTMtMTMtMS0xLTA_3930317f-713c-4073-82c0-cf66eb4cf8df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ea5455638c849c895022cdbce0f998c_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTMtMTUtMS0xLTA_13cbd89b-ce25-4951-94bd-4faf5a7ee542">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ae8bae833b4b0296c3d14e93ef42cc_I20210331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTQtMS0xLTEtMA_3c16de01-881d-47ee-901f-b3b8cda3ddc0">235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4a3d53db4d24b249fa3b917fb325e05_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTQtMy0xLTEtMA_b20b7160-5a4e-48cc-aa6c-2a226309bbd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86cb4e206c9e40978c991361828e2661_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTQtNS0xLTEtMA_da8eea13-809c-4ecc-8d6d-2311745152ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic136b1c243ab4833b7ff10d92f76ed3b_I20210331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTQtNy0xLTEtMA_3bcc33e4-3146-47d7-ba1d-aafbbfee33b7">235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676cb8c8931248afb9e78b6bc23fc50a_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTQtOS0xLTEtMA_c9d1de4f-13b8-44ab-ab3b-02dc94da116a">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e8131ea89e4f1490b4e83e0d880fa4_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTQtMTEtMS0xLTA_275d529a-8f51-40a2-8e0b-2ea9333b311e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972f4f0a16784ee889562e13a1463c5d_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTQtMTMtMS0xLTA_f0cf8a25-11d7-4b3d-8d4f-3ec8754b33d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac1c2aeaca014e89ae0337e0d8ff78f8_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTQtMTUtMS0xLTA_ab9e40e6-e2b1-4704-9ff0-cae9d48284cd">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6227824f558c4cf0ba46ee925f4ba83c_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTUtMS0xLTEtMA_63d35edb-c409-4cd0-b34c-256520ede597">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe8c56a47ec438f9d41105497550c3a_I20210331" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTUtMy0xLTEtMA_b3545b9f-1b0d-4d08-a584-f41b545a0d81">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia740610ef9fb41c794dfff273c3759dd_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTUtNS0xLTEtMA_b98420e7-a173-472a-a865-2c1705a31e43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id021fadde4cf4151b8857bcbfbaa339f_I20210331" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTUtNy0xLTEtMA_f7c5af96-7eb2-4c28-a0c4-fb9d7cf7f2c1">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idef828ce7dea449aa7d5797f8b58b3f6_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTUtOS0xLTEtMA_73876431-5b7b-4eb3-b756-c275daac63f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e11f3f2e3d40369f3e6bd198c01b8f_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTUtMTEtMS0xLTA_e2aec4de-9ae9-44b7-a069-902f2ddacd2d">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08cfe9d6b24b4cdfafdaa13b884170c0_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTUtMTMtMS0xLTA_5389845f-ecd5-426e-9678-ffdeee96aef8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e6608db0e98415cb580d29b81c635ca_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTUtMTUtMS0xLTA_4f16d221-0fd5-464c-829f-ac1201a31d9d">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i985051c2ebfb41d0b2027dcd0777c115_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTYtMS0xLTEtMA_29309456-5a39-43ef-887d-aabf46af9b15">5,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15435e6a628245f9a04322eb3570b28e_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTYtMy0xLTEtMA_40ac7583-ea68-4d8d-a452-0a0aed729c71">2,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib612747a67f64d9b91c1ab19e54958ed_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTYtNS0xLTEtMA_c6c82094-5f0a-42db-b09d-c82ac266c605">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8330bb360aa481b97cd6a1b14847b1d_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTYtNy0xLTEtMA_f4632d56-10a7-4639-be96-e75acc227659">7,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief0436ce6e3d435288b49bb3c284e932_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTYtOS0xLTEtMA_a15d952c-f600-462c-89ca-021a7ad06657">7,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5405c11586b401189e38d818eda683a_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTYtMTEtMS0xLTA_d74e7875-05ca-46ea-821c-b9a2bedaaf55">1,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecff646d1fe84980876d9a9c81fd66c9_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTYtMTMtMS0xLTA_5698044a-922e-462b-8a79-7cbed5183dcf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf1d864d25b418bb9159fa7600a42ac_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTYtMTUtMS0xLTA_fd278263-7b43-4b6d-8d00-4433aefb25bd">9,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for MYR contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a23cea7a9ba48798f1fd6bbaffb4921_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtMi0xLTEtNjQxNw_7d2680ac-6889-480b-9abf-5bceb5fb0e93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fc48886b65840e5a1585ee67a7e5017_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtNC0xLTEtNjQxNw_1f15ba55-1014-4a07-9ea0-d2d7e6461a56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86da9eb4322542f1b0071e4a1ce91218_I20210331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtNi0xLTEtNjQxNw_4cb85237-fea7-42ea-8bcb-250f7a0c0f60">341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96f6368de4194af297dac9a63844f55e_I20210331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtOC0xLTEtNjQxNw_79bce34b-e081-462f-accb-323f46af583b">341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i712971393ae14ae89870e173db5b2a1a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtMTAtMS0xLTY0MTc_b3249ae1-576d-4d88-a38a-27579e97cc20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1244e3889c7843578e273ee679a43474_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtMTItMS0xLTY0MTc_c5ea76ed-0e68-40df-ad7a-bbc4ab6b284d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i283158ca5b0642c59af33bc78f9e3655_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtMTQtMS0xLTY0MTc_243bf6db-5ac5-487b-97c5-fe56d137a9b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85636e0ea3524ff98a8b2e838f9c8141_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtMTYtMS0xLTY0MTc_4d962893-0b29-4c97-9eda-f3dda8b2dd03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ae8bae833b4b0296c3d14e93ef42cc_I20210331" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtMS0xLTEtMA_4409fb88-4e7a-47cb-af70-f62a106c8863">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4a3d53db4d24b249fa3b917fb325e05_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtMy0xLTEtMA_ea1317f4-81f5-4582-bb46-34c539a582d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86cb4e206c9e40978c991361828e2661_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtNS0xLTEtMA_c942cac9-1b5c-4ed7-9dfb-afe28a16062c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic136b1c243ab4833b7ff10d92f76ed3b_I20210331" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtNy0xLTEtMA_3de4b75b-4802-438c-916d-291dac75ff7b">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676cb8c8931248afb9e78b6bc23fc50a_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtOS0xLTEtMA_b8cd6ba0-9fca-4ff6-b167-590433d3a728">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e8131ea89e4f1490b4e83e0d880fa4_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtMTEtMS0xLTA_d00131c4-fdce-4b64-9042-ed646a337447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972f4f0a16784ee889562e13a1463c5d_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtMTMtMS0xLTA_3021a8a7-2f33-4058-8c6f-88899230ec98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac1c2aeaca014e89ae0337e0d8ff78f8_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtMTUtMS0xLTA_b6d6a1b2-fd65-4b91-9bc6-926f742dcac0">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6227824f558c4cf0ba46ee925f4ba83c_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTktMS0xLTEtMA_9bff509d-6a9a-4fa4-b178-ca87ade1767e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafe8c56a47ec438f9d41105497550c3a_I20210331" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTktMy0xLTEtMA_980eaa6a-ab6b-494a-9126-a6dc36e3f733">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia740610ef9fb41c794dfff273c3759dd_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTktNS0xLTEtMA_e2e98c36-755b-4dc4-b79b-2eac9cefdf8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id021fadde4cf4151b8857bcbfbaa339f_I20210331" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTktNy0xLTEtMA_761bb0fb-ff86-49ca-a2e7-2c9135f51899">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idef828ce7dea449aa7d5797f8b58b3f6_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTktOS0xLTEtMA_420cea65-50c8-45c5-9a2d-d8c7fd25f841">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e11f3f2e3d40369f3e6bd198c01b8f_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTktMTEtMS0xLTA_b984346f-516d-4534-8eb4-bf4dfec19305">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08cfe9d6b24b4cdfafdaa13b884170c0_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTktMTMtMS0xLTA_303098f3-bc1b-443b-a623-96fc59b995c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e6608db0e98415cb580d29b81c635ca_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTktMTUtMS0xLTA_5a86def0-4641-4b2b-a464-126b1bda2af1">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i985051c2ebfb41d0b2027dcd0777c115_I20210331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMjAtMS0xLTEtMA_90cc32d9-7358-46dc-8849-921169e0a521">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15435e6a628245f9a04322eb3570b28e_I20210331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMjAtMy0xLTEtMA_9900458a-0c52-4f73-bac1-fde6f6c8e9bf">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib612747a67f64d9b91c1ab19e54958ed_I20210331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMjAtNS0xLTEtMA_0b13a6dc-cd76-4954-867d-723671c94ba6">341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8330bb360aa481b97cd6a1b14847b1d_I20210331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMjAtNy0xLTEtMA_9e89b42c-a376-4ce3-a5ab-0489c2e7ea16">617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief0436ce6e3d435288b49bb3c284e932_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMjAtOS0xLTEtMA_e0b74e86-9b14-46d5-8c8f-c47eb30dc9be">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5405c11586b401189e38d818eda683a_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMjAtMTEtMS0xLTA_2df2e355-fd9d-4366-9cea-b2634fc8383c">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecff646d1fe84980876d9a9c81fd66c9_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMjAtMTMtMS0xLTA_d69171d7-2ec9-4129-8941-4d31763be878">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf1d864d25b418bb9159fa7600a42ac_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMjAtMTUtMS0xLTA_9deccd9b-cbd0-44b0-b2b0-ca7611e521e4">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Securities</span></div><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfOTg5NTYwNDY2OTEyMg_70d95b97-fe56-46f6-b7f6-d0eac36d35ea" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity securities measured at fair value on a recurring basis on our Condensed Consolidated Balance Sheets:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7819b77653554557af820a95339c1b48_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOjgyYTk4MGI0ODU3OTQzYWJhODgyZTQ0ZGU4ZmNmMmQyL3RhYmxlcmFuZ2U6ODJhOTgwYjQ4NTc5NDNhYmE4ODJlNDRkZThmY2YyZDJfMS0yLTEtMS00Njkz_35ff8fe9-93ea-47a7-bd05-78c589ed1872">2,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dd65450f234374bcea4a2190eb3484_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOjgyYTk4MGI0ODU3OTQzYWJhODgyZTQ0ZGU4ZmNmMmQyL3RhYmxlcmFuZ2U6ODJhOTgwYjQ4NTc5NDNhYmE4ODJlNDRkZThmY2YyZDJfMS00LTEtMS00Njkz_2b32d83d-73dd-44e0-addf-46763c48e6dc">4,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69731411c56349848eae4d9b486db920_I20210331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOjgyYTk4MGI0ODU3OTQzYWJhODgyZTQ0ZGU4ZmNmMmQyL3RhYmxlcmFuZ2U6ODJhOTgwYjQ4NTc5NDNhYmE4ODJlNDRkZThmY2YyZDJfMi0yLTEtMS00Njkz_ae84953e-f655-4300-81fc-8005d6a28c14">797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dee5b3f2c69441494dc09dbd6b1224c_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOjgyYTk4MGI0ODU3OTQzYWJhODgyZTQ0ZGU4ZmNmMmQyL3RhYmxlcmFuZ2U6ODJhOTgwYjQ4NTc5NDNhYmE4ODJlNDRkZThmY2YyZDJfMi00LTEtMS00Njkz_b1afeaf7-469c-408e-861c-8bd52c75d3dc">853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d4f540cc2348449700aa4e9824ba95_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOjgyYTk4MGI0ODU3OTQzYWJhODgyZTQ0ZGU4ZmNmMmQyL3RhYmxlcmFuZ2U6ODJhOTgwYjQ4NTc5NDNhYmE4ODJlNDRkZThmY2YyZDJfMy0yLTEtMS00Njkz_2ddf770b-1236-4c02-82d8-68201fa9045b">1,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i842226164126495eb19a5f6e285f7a87_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOjgyYTk4MGI0ODU3OTQzYWJhODgyZTQ0ZGU4ZmNmMmQyL3RhYmxlcmFuZ2U6ODJhOTgwYjQ4NTc5NDNhYmE4ODJlNDRkZThmY2YyZDJfMy00LTEtMS00Njkz_5cfa89d3-2ef6-4882-a4af-9175eac81139">1,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i775975dd06c34a91977a0d26c3c7aad3_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOjgyYTk4MGI0ODU3OTQzYWJhODgyZTQ0ZGU4ZmNmMmQyL3RhYmxlcmFuZ2U6ODJhOTgwYjQ4NTc5NDNhYmE4ODJlNDRkZThmY2YyZDJfNC0yLTEtMS00Njkz_48d4c97a-df99-4aa5-830a-96abbcceb902">4,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31a2c0299c3f47b68f2ee84425bd6ba4_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOjgyYTk4MGI0ODU3OTQzYWJhODgyZTQ0ZGU4ZmNmMmQyL3RhYmxlcmFuZ2U6ODJhOTgwYjQ4NTc5NDNhYmE4ODJlNDRkZThmY2YyZDJfNC00LTEtMS00Njkz_24828fc1-215e-46bc-99be-9c56f184d45b">6,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-bottom:4.5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes equity investment in Galapagos NV (&#8220;Galapagos&#8221;)</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments not measured at fair value and excluded from the above tables were limited partnerships and other equity method investments of $<ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfMTA5OTUxMTYzNDc5NQ_aea03bf8-2e3e-4197-ab61-0d2400668053">69</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfMTA5OTUxMTYzNDc3OA_353eb7dd-9bf8-4c78-89ad-fcb2333c61e9">58</ix:nonFraction> million at March&#160;31, 2021 and December&#160;31, 2020, respectively, and other equity investments without readily determinable fair values of $<ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfMTA5OTUxMTYzNDgzMw_d5077442-1d61-4db6-9bb3-b29bf5f21378">225</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfMTA5OTUxMTYzNDgxNQ_de16daaf-84fe-4465-b334-1ad3378d6db9">204</ix:nonFraction> million at March&#160;31, 2021 and December&#160;31, 2020, respectively. These amounts were included in Other long-term assets on our Condensed Consolidated Balance Sheets.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i384846e1a2264f10988058b5d3697839"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of equity securities resulted in net unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfNDM5ODA0NjUzOTM2OQ_a281a611-e46e-46fe-84b8-4684db6ec90c">351</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfNDM5ODA0NjUzOTM3Nw_07082604-9388-43b2-8132-8f03400a8da6">283</ix:nonFraction>&#160;million for the three months ended March 31, 2021 and 2020, respectively, which were included in Other income (expense), net on our Condensed Consolidated Statements of Income.</span></div><div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale debt securities are classified as cash equivalents, short-term marketable securities and long-term marketable securities in our Condensed Consolidated Balance Sheets. See Note 4. Available-For-Sale Debt Securities for additional information. </span></div><div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Investment in Galapagos</span></div><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfOTg5NTYwNDY3ODI2Mw_b0a071bf-3ef1-4d79-a074-7057f13902d4" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity investment in Galapagos in our Condensed Consolidated Balance Sheets:</span></div><div style="margin-bottom:11pt;margin-top:9.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4079e9eaf1b42a79cea9514877ac8eb_I20210331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmVlNmU5YjU5MjU4ZTRkZTY5YjA4ZGEzN2ZiNGYzNGViL3RhYmxlcmFuZ2U6ZWU2ZTliNTkyNThlNGRlNjliMDhkYTM3ZmI0ZjM0ZWJfMS0yLTEtMS0xMDI0NA_270c67ef-fb9a-46dd-8f3b-959fb7a4885b">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707925a6e11e4e8b89cd1de5486dccd6_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmVlNmU5YjU5MjU4ZTRkZTY5YjA4ZGEzN2ZiNGYzNGViL3RhYmxlcmFuZ2U6ZWU2ZTliNTkyNThlNGRlNjliMDhkYTM3ZmI0ZjM0ZWJfMS00LTEtMS0xMDI0NA_e438fd05-5eda-454d-89e3-f0f8a3405d72">351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9ff815d16ad4190a3c3cc2de4b5e390_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmVlNmU5YjU5MjU4ZTRkZTY5YjA4ZGEzN2ZiNGYzNGViL3RhYmxlcmFuZ2U6ZWU2ZTliNTkyNThlNGRlNjliMDhkYTM3ZmI0ZjM0ZWJfMi0yLTEtMS0xMDI0NA_f22198b1-ad66-45cc-92ce-0a90f6a8358d">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2cfe856897d47a4a15c011727b132a4_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmVlNmU5YjU5MjU4ZTRkZTY5YjA4ZGEzN2ZiNGYzNGViL3RhYmxlcmFuZ2U6ZWU2ZTliNTkyNThlNGRlNjliMDhkYTM3ZmI0ZjM0ZWJfMi00LTEtMS0xMDI0NA_9a8dd7c9-bca6-4cff-8463-c4baf37d48be">1,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ccba16f84d64786acebdc56d30d2961_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmVlNmU5YjU5MjU4ZTRkZTY5YjA4ZGEzN2ZiNGYzNGViL3RhYmxlcmFuZ2U6ZWU2ZTliNTkyNThlNGRlNjliMDhkYTM3ZmI0ZjM0ZWJfMy0yLTEtMS0xMDI0NA_dfe9e179-8151-4f63-987b-b5c6b609da50">1,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b637184cf1d4fd595b58c5754beb956_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmVlNmU5YjU5MjU4ZTRkZTY5YjA4ZGEzN2ZiNGYzNGViL3RhYmxlcmFuZ2U6ZWU2ZTliNTkyNThlNGRlNjliMDhkYTM3ZmI0ZjM0ZWJfMy00LTEtMS0xMDI0NA_eddbf162-55ae-4fc2-aada-a08292f2b169">1,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:continuation id="i5cf8fbb460fb40c38bcb7181d312e9bc"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected and applied the fair value option to account for our equity investment in Galapagos whereby the investment is marked to market through earnings each reporting period based on the market price of Galapagos shares. We believe the fair value option best reflects the underlying economics of the investment. The portion of the investment subject to long-term contractual lock-up provisions is classified within Other long-term assets and the remainder is classified as Prepaid and other current assets on our Condensed Consolidated Balance Sheets. Subsequent to the first quarter of 2021, we amended the Galapagos subscription agreement to extend the initial lock-up provision for certain Galapagos shares from August 2021 to August 2024. As a result, all of our equity investment in Galapagos became subject to long-term contractual lock-up provisions and will be classified as Other long-term assets commencing in the second quarter of 2021. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2 Inputs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair values of Level 2 financial instruments by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;P Global Ratings, Moody&#8217;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, London Interbank Offered Rates and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.</span></div></ix:continuation><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated fair values of our aggregate short-term and long-term debt, determined using Level 2 inputs based on their quoted market values, were approximately $<ix:nonFraction unitRef="usd" contextRef="i5a4c7af7aa214730805797a174566133_I20210331" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfNDY3Mw_f3bc261a-06bb-4971-a797-d80c749032c9">31.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="if73c04ebb10b4c1fb24efca2362f9a22_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfNDY4MA_7fd11a31-18d7-40b3-b821-fa2a6fe3432d">34.6</ix:nonFraction> billion as of March&#160;31, 2021 and December&#160;31, 2020, respectively, and the carrying values were $<ix:nonFraction unitRef="usd" contextRef="i89f38dcb82a5491dbb25812d7738c19b_I20210331" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfNDc0Mw_de6c4b1d-e66e-4884-bbf3-1bf7750227e7">29.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="iffef8ea761174ff198789287afe52e44_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfNDc1MA_326587ca-64d0-4553-b1b2-c78ca939c07c">30.3</ix:nonFraction> billion as of March&#160;31, 2021 and December&#160;31, 2020, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3 Inputs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, we measured assets acquired and liabilities assumed at fair value on a nonrecurring basis, in connection with our acquisition of MYR GmbH (&#8220;MYR&#8221;). Total consideration for the MYR acquisition included a liability for contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i86da9eb4322542f1b0071e4a1ce91218_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfMTA5OTUxMTY0Mzk3Mw_fdf272d9-56e7-467b-8dce-2847e3c8f630">341</ix:nonFraction> million as of the acquisition date. This contingent liability was measured at fair value using probability-weighted scenarios for FDA approval. See Note 6. Acquisitions for additional information. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021 and December&#160;31, 2020, the carrying value of the liability related to future royalties assumed from the fourth quarter 2020 Immunomedics, Inc. (&#8220;Immunomedics&#8221;) acquisition approximated fair value, determined using Level 3 inputs. See Note 10. Debt and Credit Facilities for additional information.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i5e8b0e18419843159ec07e1b794d0d87_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RleHRyZWdpb246OTk1NjkwZmExZjI1NGY2ZDhhZTIyY2Q4ZjE0ZGI4ZTlfMTA2OQ_16c765be-fbb9-41a8-8393-8dc27d256258" continuedAt="i2d90be325eaf48718d5f0d6f3709a06a" escape="true">AVAILABLE-FOR-SALE DEBT SECURITIES</ix:nonNumeric></span></div><ix:continuation id="i2d90be325eaf48718d5f0d6f3709a06a" continuedAt="i0861c41456ba42769026c176b9ac4012"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RleHRyZWdpb246OTk1NjkwZmExZjI1NGY2ZDhhZTIyY2Q4ZjE0ZGI4ZTlfMTA4OQ_5c8f5c89-9ab2-4f66-ac4d-0cf9d91ab29d" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a97739a676441f385dd15bc5a05b29f_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMi0yLTEtMS0w_9ed8f495-9f2c-447b-8487-781257ea99b6">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a97739a676441f385dd15bc5a05b29f_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMi00LTEtMS0w_5c4eca4a-db58-4678-87ce-1e30d59512ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a97739a676441f385dd15bc5a05b29f_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMi02LTEtMS0w_7c0e148e-7153-4cac-a5fd-af617e6516de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a97739a676441f385dd15bc5a05b29f_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMi04LTEtMS0w_24370252-1095-4a37-8c41-3deeedf7e06e">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e005c46bfd4e5c8cfa65d68167b7ff_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMi0xMC0xLTEtMA_856d1588-9d16-4971-92ef-bc1ec2c9d57c">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e005c46bfd4e5c8cfa65d68167b7ff_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMi0xMi0xLTEtMA_1ad64496-b9d0-4318-b965-0507159279d9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e005c46bfd4e5c8cfa65d68167b7ff_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMi0xNC0xLTEtMA_f2458107-6303-4e1d-9470-094dfe95145a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e005c46bfd4e5c8cfa65d68167b7ff_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMi0xNi0xLTEtMA_5b9d9c2a-ddc7-45d9-a9e2-a1e711b924f7">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfa8675ac1aa4739beb924a027e71114_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMy0yLTEtMS0w_302e031e-7537-44e1-b0a0-2db1031dd616">358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfa8675ac1aa4739beb924a027e71114_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMy00LTEtMS0w_5d26f44e-81f9-436a-80ee-aa31fc21b505">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfa8675ac1aa4739beb924a027e71114_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMy02LTEtMS0w_9837c3b9-3102-4181-8f18-b7288834fca8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfa8675ac1aa4739beb924a027e71114_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMy04LTEtMS0w_cf9f2d21-5033-4ad2-a200-de1a2d152820">358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f6999e94a9b47b8836b7e7d12120eb3_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMy0xMC0xLTEtMA_ed2ae440-7d17-4469-acdb-8b530c954f9a">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f6999e94a9b47b8836b7e7d12120eb3_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMy0xMi0xLTEtMA_8a9826ca-987c-417d-a7cb-2fa14d5fc38a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f6999e94a9b47b8836b7e7d12120eb3_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMy0xNC0xLTEtMA_165703a4-b932-4cbb-8e08-d99f6b8279e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f6999e94a9b47b8836b7e7d12120eb3_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMy0xNi0xLTEtMA_47141dde-33c3-4d6c-afdc-108391dad515">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96932fa83e584390b3f1d56742823d34_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNS0yLTEtMS0w_8089b467-b69c-41c6-ba1f-c95e12743d74">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96932fa83e584390b3f1d56742823d34_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNS00LTEtMS0w_732443c1-535c-463e-9c48-6c9002f5ec9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96932fa83e584390b3f1d56742823d34_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNS02LTEtMS0w_f24c3ab9-1797-4d07-b106-bb9aaf390ca5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96932fa83e584390b3f1d56742823d34_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNS04LTEtMS0w_47c2dd41-9319-4f60-b6c7-2701023e02a8">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia27960115dde4e8db6988f723a792c47_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNS0xMC0xLTEtMA_bcb1d4d9-1e26-4749-8707-3d15b096b0b7">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia27960115dde4e8db6988f723a792c47_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNS0xMi0xLTEtMA_148772fe-370c-4a77-96d8-3340e504024d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia27960115dde4e8db6988f723a792c47_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNS0xNC0xLTEtMA_27c1b1b4-9082-4cc5-ae85-4042b3625b16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia27960115dde4e8db6988f723a792c47_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNS0xNi0xLTEtMA_8e01a46c-443a-4355-9e46-0c313fdfbd05">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if12b94fde2df458b856419eb60f3749f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNi0yLTEtMS0w_fcf1f3c0-7fbc-4ba7-b520-2e54aece2fe7">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if12b94fde2df458b856419eb60f3749f_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNi00LTEtMS0w_a2bfe9cd-9409-469a-a158-b35fd2c67f71">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if12b94fde2df458b856419eb60f3749f_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNi02LTEtMS0w_27beec84-e799-4556-89b4-24a4e58aaf38">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if12b94fde2df458b856419eb60f3749f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNi04LTEtMS0w_7bcada81-7219-485f-8663-e8c000ad2c59">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie29dcd6fa2fd430ab157b38ccbb28d3e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNi0xMC0xLTEtMA_ceb81169-9278-4ae5-9ba1-11fd20a184ae">1,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie29dcd6fa2fd430ab157b38ccbb28d3e_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNi0xMi0xLTEtMA_a5b86628-356c-41dd-8272-5b711faf51b0">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie29dcd6fa2fd430ab157b38ccbb28d3e_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNi0xNC0xLTEtMA_79f77cdb-dd07-44b1-a1c7-70490568abaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie29dcd6fa2fd430ab157b38ccbb28d3e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNi0xNi0xLTEtMA_2537e578-5f3b-4d8a-a375-39ef72399792">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5174f6004a743eb845f20ac1490f61a_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNy0yLTEtMS0w_1e12fd61-9403-4f1d-9700-39e6999fddcc">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5174f6004a743eb845f20ac1490f61a_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNy00LTEtMS0w_97a2228a-aa60-4d49-a3c9-d48ce48cab98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5174f6004a743eb845f20ac1490f61a_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNy02LTEtMS0w_59140796-5597-4e78-8e00-d7f6581e9866">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5174f6004a743eb845f20ac1490f61a_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNy04LTEtMS0w_09df1c63-0f3c-4288-b6b2-228e634c6489">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e49f98b54ce4b26af2d8166b46b66e9_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNy0xMC0xLTEtMA_ed16f134-7cf5-47cf-9ee4-f906c609d452">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e49f98b54ce4b26af2d8166b46b66e9_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNy0xMi0xLTEtMA_9facdbb6-01dc-4a93-a875-5e884e23c42b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e49f98b54ce4b26af2d8166b46b66e9_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNy0xNC0xLTEtMA_5c57e42b-9b17-478e-9667-5377b3ea2719">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e49f98b54ce4b26af2d8166b46b66e9_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNy0xNi0xLTEtMA_44248cfd-1e27-4847-8d76-051475443df8">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfOC0yLTEtMS0w_cce14dfc-11ec-40ec-b909-a72653cd84e3">2,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfOC00LTEtMS0w_e9972a80-1035-475b-8d71-c7f78ab11718">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfOC02LTEtMS0w_745e8dc6-a1fa-4aec-8a21-c7b5edfdf976">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfOC04LTEtMS0w_7cf0e2c3-6aa8-4b35-a217-b927381d60ae">2,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfOC0xMC0xLTEtMA_3ae9bec3-e744-47c8-b2f1-644c3318288b">2,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfOC0xMi0xLTEtMA_b4ff1cff-6edb-4a11-926f-0c863970ba0c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfOC0xNC0xLTEtMA_83ca511e-ddf0-44f6-a425-2bccc03d1969">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfOC0xNi0xLTEtMA_464cc5fe-8e8c-4842-9e0d-54b59b3b344c">2,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RleHRyZWdpb246OTk1NjkwZmExZjI1NGY2ZDhhZTIyY2Q4ZjE0ZGI4ZTlfMTA3OQ_44c58385-81bc-42f3-992c-df44be77a1e9" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets:</span></div><div style="margin-bottom:11pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2408fe312f9e4448b357064015614afc_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjk3ODQ2MGFlNGRiODQ3YTNiNDc0MmJjOGIzZmQ2MTVmL3RhYmxlcmFuZ2U6OTc4NDYwYWU0ZGI4NDdhM2I0NzQyYmM4YjNmZDYxNWZfMS0yLTEtMS0w_bcc2ffa5-d281-4422-aca3-6e683d5c8ef8">298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91624599719d473faf279a33da7ef5be_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjk3ODQ2MGFlNGRiODQ3YTNiNDc0MmJjOGIzZmQ2MTVmL3RhYmxlcmFuZ2U6OTc4NDYwYWU0ZGI4NDdhM2I0NzQyYmM4YjNmZDYxNWZfMS00LTEtMS0w_e354b82a-0189-4b65-ad0c-4be1abbd6d0a">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ff20f5b83944dba31b16c66a70e1a8_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjk3ODQ2MGFlNGRiODQ3YTNiNDc0MmJjOGIzZmQ2MTVmL3RhYmxlcmFuZ2U6OTc4NDYwYWU0ZGI4NDdhM2I0NzQyYmM4YjNmZDYxNWZfMi0yLTEtMS0w_4a473bab-cbda-4629-8a4a-fc090b8e46b9">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a1a8f49d74c45eeaa8823dd49a9aebc_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjk3ODQ2MGFlNGRiODQ3YTNiNDc0MmJjOGIzZmQ2MTVmL3RhYmxlcmFuZ2U6OTc4NDYwYWU0ZGI4NDdhM2I0NzQyYmM4YjNmZDYxNWZfMi00LTEtMS0w_190eacc4-e6b6-4dbd-a012-24918f8e6578">1,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ff3207761de4a358076755192646e75_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjk3ODQ2MGFlNGRiODQ3YTNiNDc0MmJjOGIzZmQ2MTVmL3RhYmxlcmFuZ2U6OTc4NDYwYWU0ZGI4NDdhM2I0NzQyYmM4YjNmZDYxNWZfMy0yLTEtMS0w_31fe3c2a-6ed4-4ef4-b8d9-28669c4e529e">579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i278cbd93950247099589a8c54d16f788_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjk3ODQ2MGFlNGRiODQ3YTNiNDc0MmJjOGIzZmQ2MTVmL3RhYmxlcmFuZ2U6OTc4NDYwYWU0ZGI4NDdhM2I0NzQyYmM4YjNmZDYxNWZfMy00LTEtMS0w_75d7931f-1b11-4089-a18e-6b3397de5667">502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjk3ODQ2MGFlNGRiODQ3YTNiNDc0MmJjOGIzZmQ2MTVmL3RhYmxlcmFuZ2U6OTc4NDYwYWU0ZGI4NDdhM2I0NzQyYmM4YjNmZDYxNWZfNC0yLTEtMS0w_3b43d9ee-74e2-466a-ba83-ae45b05706e2">2,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjk3ODQ2MGFlNGRiODQ3YTNiNDc0MmJjOGIzZmQ2MTVmL3RhYmxlcmFuZ2U6OTc4NDYwYWU0ZGI4NDdhM2I0NzQyYmM4YjNmZDYxNWZfNC00LTEtMS0w_2596c766-1ddc-4eb8-b4be-4ba959d60517">2,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable excluded from both the fair value and amortized cost basis of the available-for-sale debt securities was $<ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RleHRyZWdpb246OTk1NjkwZmExZjI1NGY2ZDhhZTIyY2Q4ZjE0ZGI4ZTlfMzUy_56328ccd-bb7e-4a24-86a9-542e216c4df0"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RleHRyZWdpb246OTk1NjkwZmExZjI1NGY2ZDhhZTIyY2Q4ZjE0ZGI4ZTlfMzUy_8435301b-a4b3-46d1-b8a8-5245424c646b">9</ix:nonFraction></ix:nonFraction> million as of March&#160;31, 2021 and December&#160;31, 2020 and is recorded in Prepaid and other current assets on our Condensed Consolidated Balance Sheets. There were <ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="gild:WriteOffsInAccruedInterestReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RleHRyZWdpb246OTk1NjkwZmExZjI1NGY2ZDhhZTIyY2Q4ZjE0ZGI4ZTlfNDY3_3e4bc755-8551-4a29-8c16-ef76321ce728"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="gild:WriteOffsInAccruedInterestReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RleHRyZWdpb246OTk1NjkwZmExZjI1NGY2ZDhhZTIyY2Q4ZjE0ZGI4ZTlfNDY3_a3b50a9d-d4d8-47fe-a84d-6f960f075383">no</ix:nonFraction></ix:nonFraction> write-offs of accrued interest receivable during the three months ended March 31, 2021 and 2020.</span></div><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RleHRyZWdpb246OTk1NjkwZmExZjI1NGY2ZDhhZTIyY2Q4ZjE0ZGI4ZTlfMTA5Ng_c3bc1a82-2979-4b8e-947e-67cc89e97096" escape="true"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity: </span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjdmOTc5YmUwMjJjYjQ1MTNhNTkxNDY5Y2MyZWM3YWIzL3RhYmxlcmFuZ2U6N2Y5NzliZTAyMmNiNDUxM2E1OTE0NjljYzJlYzdhYjNfMi0yLTEtMS0w_37942ee5-bfcb-4399-8be3-6105e3672f22">1,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjdmOTc5YmUwMjJjYjQ1MTNhNTkxNDY5Y2MyZWM3YWIzL3RhYmxlcmFuZ2U6N2Y5NzliZTAyMmNiNDUxM2E1OTE0NjljYzJlYzdhYjNfMi00LTEtMS0w_642fad6b-08cc-40df-868d-a154b9086a32">1,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjdmOTc5YmUwMjJjYjQ1MTNhNTkxNDY5Y2MyZWM3YWIzL3RhYmxlcmFuZ2U6N2Y5NzliZTAyMmNiNDUxM2E1OTE0NjljYzJlYzdhYjNfMy0yLTEtMS0w_2dc0f9a8-1aa8-48ce-8232-868dac6344d6">563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjdmOTc5YmUwMjJjYjQ1MTNhNTkxNDY5Y2MyZWM3YWIzL3RhYmxlcmFuZ2U6N2Y5NzliZTAyMmNiNDUxM2E1OTE0NjljYzJlYzdhYjNfMy00LTEtMS0w_dc918503-d329-49d3-aabe-ad1881895aa1">562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjdmOTc5YmUwMjJjYjQ1MTNhNTkxNDY5Y2MyZWM3YWIzL3RhYmxlcmFuZ2U6N2Y5NzliZTAyMmNiNDUxM2E1OTE0NjljYzJlYzdhYjNfNC0yLTEtMS0w_a11fbc5e-1960-49af-b958-68b7e1d839ab">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjdmOTc5YmUwMjJjYjQ1MTNhNTkxNDY5Y2MyZWM3YWIzL3RhYmxlcmFuZ2U6N2Y5NzliZTAyMmNiNDUxM2E1OTE0NjljYzJlYzdhYjNfNC00LTEtMS0w_d56ed335-78b4-4307-9834-8734194f0253">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjdmOTc5YmUwMjJjYjQ1MTNhNTkxNDY5Y2MyZWM3YWIzL3RhYmxlcmFuZ2U6N2Y5NzliZTAyMmNiNDUxM2E1OTE0NjljYzJlYzdhYjNfNS0yLTEtMS0w_7f5a186a-c17a-4ff2-8285-fecdfb19b159">2,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjdmOTc5YmUwMjJjYjQ1MTNhNTkxNDY5Y2MyZWM3YWIzL3RhYmxlcmFuZ2U6N2Y5NzliZTAyMmNiNDUxM2E1OTE0NjljYzJlYzdhYjNfNS00LTEtMS0w_ef246f36-c966-4021-9f70-b1134a2a63d0">2,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0861c41456ba42769026c176b9ac4012">We held a total of <ix:nonFraction unitRef="position" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RleHRyZWdpb246OTk1NjkwZmExZjI1NGY2ZDhhZTIyY2Q4ZjE0ZGI4ZTlfNzc2_87af183a-d4ee-44b4-8e8b-bf307a5f7e84">203</ix:nonFraction> positions which were in an unrealized loss position as of March&#160;31, 2021. The unrealized losses are largely due to changes in interest rates. Aggregated gross unrealized losses on available-for-sale debt securities were not material, and accordingly, <ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RleHRyZWdpb246OTk1NjkwZmExZjI1NGY2ZDhhZTIyY2Q4ZjE0ZGI4ZTlfMjc0ODc3OTA3MTA2MA_3fdc443a-76c6-4275-a395-6fc9784b4cc6"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RleHRyZWdpb246OTk1NjkwZmExZjI1NGY2ZDhhZTIyY2Q4ZjE0ZGI4ZTlfMjc0ODc3OTA3MTA2MA_d6b344df-8ef5-46b6-8200-838ce78cba74">no</ix:nonFraction></ix:nonFraction> impairment was recognized for the three months ended March 31, 2021. Gross realized gains and gross realized losses on available-for-sale debt securities were not material for the three months ended March 31, 2021.</ix:continuation> </span></div><div id="i5e8b0e18419843159ec07e1b794d0d87_46"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RleHRyZWdpb246MTg2ODNjNjU1ZDNkNDY1ZDk2Mjk3NmQwZTVjNjJjMDFfMzM2MQ_29d462ae-cc83-493f-b562-ca6a27d9cb75" continuedAt="i32c0d978432544dbb45a43cc699cd622" escape="true">DERIVATIVE FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i32c0d978432544dbb45a43cc699cd622" continuedAt="i1f11ccb9b021422895784b75e7242df8">Our operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we may hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward or option contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes. </ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1f11ccb9b021422895784b75e7242df8" continuedAt="ib86d9cd44c02426397f10990a9ec80de"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge our exposure to foreign currency exchange rate fluctuations for certain monetary assets and liabilities that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are not designated as hedges and, as a result, changes in their fair value are recorded in Other income (expense), net on our Condensed Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge our exposure to foreign currency exchange rate fluctuations for forecasted product sales that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are designated as cash flow hedges and have maturities of <ix:nonNumeric contextRef="i2964d55b3b0243efb3f22c4eed834d5f_D20210101-20210331" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RleHRyZWdpb246MTg2ODNjNjU1ZDNkNDY1ZDk2Mjk3NmQwZTVjNjJjMDFfMTg3Ng_dacab751-7dc4-4ad3-aedd-ff8945273a13">18</ix:nonNumeric> months or less. Upon executing a hedging contract and quarterly thereafter, we assess hedge effectiveness using regression analysis. The unrealized gains or losses in Accumulated other comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;AOCI&#8221;) are reclassified into product sales when the respective hedged transactions affect earnings. The majority of gains and losses related to the hedged forecasted transactions reported in AOCI as of March&#160;31, 2021 are expected to be reclassified to product sales within <ix:nonNumeric contextRef="i2964d55b3b0243efb3f22c4eed834d5f_D20210101-20210331" format="ixt-sec:durmonth" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RleHRyZWdpb246MTg2ODNjNjU1ZDNkNDY1ZDk2Mjk3NmQwZTVjNjJjMDFfMjM0MQ_62b78985-d651-4353-80f6-e7ecf2b87846">12</ix:nonNumeric> months.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flow effects of our derivative contracts for the three months ended March 31, 2021 and 2020 were included within Net cash provided by operating activities on our Condensed Consolidated Statements of Cash Flows.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had notional amounts on foreign currency exchange contracts outstanding of $<ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RleHRyZWdpb246MTg2ODNjNjU1ZDNkNDY1ZDk2Mjk3NmQwZTVjNjJjMDFfMjU2NQ_80e71220-e254-4bd2-aaf7-0b7c3d85f89c">3.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RleHRyZWdpb246MTg2ODNjNjU1ZDNkNDY1ZDk2Mjk3NmQwZTVjNjJjMDFfMjU3Mg_9ae4c43b-7e32-4608-bc55-3c65a616588a">2.4</ix:nonFraction> billion as of March&#160;31, 2021 and December&#160;31, 2020, respectively. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts on a gross basis. <ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RleHRyZWdpb246MTg2ODNjNjU1ZDNkNDY1ZDk2Mjk3NmQwZTVjNjJjMDFfMzM3Ng_018e4c09-223f-4e9a-a71d-0895095d4192" continuedAt="i73d2a5c0c8cb450291e4557ffe8a0e1c" escape="true">The following table summarizes the classification and fair values of derivative instruments on our Condensed Consolidated Balance Sheets:</ix:nonNumeric></span></div><ix:continuation id="i73d2a5c0c8cb450291e4557ffe8a0e1c"><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:33.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.380%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcabcb1cbf9400c95b149a28f9172b6_I20210331" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfNC00LTEtMS0w_8c2ff02c-10b6-43e1-b3f5-a4001c38f87a">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;accrued&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0315ed156fa4a999a216e7bf46cb806_I20210331" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfNC04LTEtMS0w_9e509380-201a-424f-865e-867ce66b8ade">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15db68ece60c4907bce23168391fc549_I20210331" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfNS00LTEtMS0w_450787ed-1891-4a19-8921-bd17ac61728e">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib316497f09074016814019469a1c5282_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfNS04LTEtMS0w_320d2659-225f-4d43-8576-95db538823fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b3659e23b9d46dc913b50eb69f837b7_I20210331" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfNi00LTEtMS0w_58d8d125-b815-43b4-bb7c-1fc7b89d60bb">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b3659e23b9d46dc913b50eb69f837b7_I20210331" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfNi04LTEtMS0w_f4513b49-f133-4609-a2de-e9fc8a726019">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a4bb5869b2a4a65965e0573d5a9fc0b_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfOC00LTEtMS0w_c01d5e70-13d4-4ad0-9493-172635986185">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15df5ed6d62b49e8bf563f685962e609_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfOC04LTEtMS0w_3e2c099d-4fe3-46ba-908f-1c26107f2282">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb9b9032e3424975b8d41437080d8fd9_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfOS00LTEtMS0w_f17e9418-f034-4819-b927-82b1d165c622">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb9b9032e3424975b8d41437080d8fd9_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfOS04LTEtMS0w_dc386720-2620-4875-b39a-f01b02013d52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfMTAtNC0xLTEtMA_9ae5474c-1973-45b7-a091-b0ca2325154e">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfMTAtOC0xLTEtMA_c64f8379-95f7-4cc5-82be-41464c83f536">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.508%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37496332327e49d2bfd711461be5eee2_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfNC00LTEtMS0w_42041b69-f45e-4a49-a1eb-47b1605b393c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;accrued&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84d63f6e0c374aa6a0d94624a78f5b37_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfNC04LTEtMS0w_7aa4cdd9-a769-41ac-93b0-8f069e3050fb">113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0edd02c9c343938d862442b6afc2af_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfNS00LTEtMS0w_47ea8131-1f92-410d-82a1-31061034c669">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91c1249190d841d3ac8dc4919431731a_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfNS04LTEtMS0w_ef012454-14d6-4051-be5f-980dcdfc23e6">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a21b040839549338b52418d18bb1e17_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfNi00LTEtMS0w_979840e7-d3a0-4fa8-a527-664c84d7b88f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a21b040839549338b52418d18bb1e17_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfNi04LTEtMS0w_1ca3f612-e4f7-4d61-9383-da8e6266c70d">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia692393a1fd94bbb97576f97ccd34cce_I20201231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfOC00LTEtMS0w_ba9467ed-8795-4fa5-9e53-535bb8336de3">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb12e9542cfd4e90b2dcab8f7f4c58d5_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfOC04LTEtMS0w_741eb00e-0fe8-479c-997d-c32663606287">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8653fde001146e0bea68d8800992d8a_I20201231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfOS00LTEtMS0w_3547033d-041a-40fe-9bce-2b78e648ce2e">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8653fde001146e0bea68d8800992d8a_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfOS04LTEtMS0w_b64f2f91-9943-4594-a2c8-1d368bb41b8c">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfMTAtNC0xLTEtMA_770fba41-b9cd-4460-8e7b-9ef96566b7b5">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfMTAtOC0xLTEtMA_dabfbdc2-a2e5-435b-8f2a-418be0055aa8">121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib86d9cd44c02426397f10990a9ec80de"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RleHRyZWdpb246MTg2ODNjNjU1ZDNkNDY1ZDk2Mjk3NmQwZTVjNjJjMDFfMzM2NA_c360e37b-ccc9-4080-8a16-451f4a777432" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our foreign currency exchange contracts on our Condensed Consolidated Financial Statements: </span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains recognized in AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjI0Y2JjZDRjMzY5ZTRkM2U4MDY1MzE0OTQ1ZmQ5Zjk3L3RhYmxlcmFuZ2U6MjRjYmNkNGMzNjllNGQzZTgwNjUzMTQ5NDVmZDlmOTdfNC0yLTEtMS0w_5ce00dbb-9609-4cb2-9706-8985135060f2">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjI0Y2JjZDRjMzY5ZTRkM2U4MDY1MzE0OTQ1ZmQ5Zjk3L3RhYmxlcmFuZ2U6MjRjYmNkNGMzNjllNGQzZTgwNjUzMTQ5NDVmZDlmOTdfNC00LTEtMS0w_bd515551-c142-4972-9078-e12af128b7fa">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) reclassified from AOCI into product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjI0Y2JjZDRjMzY5ZTRkM2U4MDY1MzE0OTQ1ZmQ5Zjk3L3RhYmxlcmFuZ2U6MjRjYmNkNGMzNjllNGQzZTgwNjUzMTQ5NDVmZDlmOTdfNS0yLTEtMS0w_b2b74ca5-c96c-47ae-a5cb-baf487bf52b3">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjI0Y2JjZDRjMzY5ZTRkM2U4MDY1MzE0OTQ1ZmQ5Zjk3L3RhYmxlcmFuZ2U6MjRjYmNkNGMzNjllNGQzZTgwNjUzMTQ5NDVmZDlmOTdfNS00LTEtMS0w_9ad3a012-13c6-4c47-91a1-e6f1e1bd988b">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains recognized in Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjI0Y2JjZDRjMzY5ZTRkM2U4MDY1MzE0OTQ1ZmQ5Zjk3L3RhYmxlcmFuZ2U6MjRjYmNkNGMzNjllNGQzZTgwNjUzMTQ5NDVmZDlmOTdfNy0yLTEtMS0w_d2720a8a-b38d-455d-aed1-155db2ad0aa1">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjI0Y2JjZDRjMzY5ZTRkM2U4MDY1MzE0OTQ1ZmQ5Zjk3L3RhYmxlcmFuZ2U6MjRjYmNkNGMzNjllNGQzZTgwNjUzMTQ5NDVmZDlmOTdfNy00LTEtMS0w_6e718b02-456f-4184-88c8-5fb203a786bc">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may discontinue cash flow hedges and, as a result, record related amounts in Other income (expense), net on our Condensed Consolidated Statements of Income. There were <ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RleHRyZWdpb246MTg2ODNjNjU1ZDNkNDY1ZDk2Mjk3NmQwZTVjNjJjMDFfMzA5OA_423875ec-52c5-4f6d-a65c-fc4230ea4e36"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RleHRyZWdpb246MTg2ODNjNjU1ZDNkNDY1ZDk2Mjk3NmQwZTVjNjJjMDFfMzA5OA_a6e0bce1-85f4-4f72-b081-e25848bb20ce">no</ix:nonFraction></ix:nonFraction> discontinuances of cash flow hedges for the three months ended March 31, 2021 and 2020. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021 and December&#160;31, 2020, we only held foreign currency exchange contracts. <ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RleHRyZWdpb246MTg2ODNjNjU1ZDNkNDY1ZDk2Mjk3NmQwZTVjNjJjMDFfMzM5MQ_a1858e49-be2f-497b-988c-f4671e314215" continuedAt="i626811f99fac4723ac834466c096ea67" escape="true">The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Condensed Consolidated Balance Sheets:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"><ix:continuation id="i626811f99fac4723ac834466c096ea67"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:22.507%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.899%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Amounts Not Offset <br/>on our Condensed <br/>Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Amounts<br/>&#160;of Recognized <br/>Assets/Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Amounts<br/>&#160;Offset on our <br/>Condensed <br/>Consolidated <br/>Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amounts of Assets/Liabilities Presented<br/>&#160;on our Condensed Consolidated<br/>Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Derivative <br/>Financial <br/>Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Cash Collateral <br/>Received/<br/>Pledged</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net Amount<br/>&#160;(Legal Offset)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline">As of March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNC0yLTEtMS0w_d3f0d1b2-4e59-4e75-b26f-427cb28d4920">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetFairValueGrossLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNC00LTEtMS0w_6212de37-33f4-4d1b-b85e-2cc47108d3cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNC02LTEtMS0w_efe5ac38-69d0-4ce2-8139-a2b699e3a53a">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNC04LTEtMS0w_b4c161b8-9d29-49ec-8db5-3ec4c3ea06bf">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNC0xMC0xLTEtMA_59c97449-d5e7-4c7e-bb52-4bc9a15139f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNC0xMi0xLTEtMA_072ed9d0-5785-4a6e-8521-71c23234592f">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNS0yLTEtMS0w_1fc2dee6-8046-463b-9cc2-bd3cbf405b40">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNS00LTEtMS0w_44feee46-8cde-4774-b8cf-98c3bf19a0b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNS02LTEtMS0w_dd4c346b-b639-471c-9d40-39738a7ea4b1">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNS04LTEtMS0w_b5cd9526-beac-4e61-9d24-b7db07dcf10a">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeCollateralRightToReclaimCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNS0xMC0xLTEtMA_e6e95bdc-12dc-4325-a661-f10816821cc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNS0xMi0xLTEtMA_9c80296c-6ba9-4dc3-b3a3-72188c1cdf93">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNy0yLTEtMS0w_6bf76e22-a3a6-4640-9037-c9228642105e">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetFairValueGrossLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNy00LTEtMS0w_d3351b49-e326-4ce1-908e-3c5b7780c1ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNy02LTEtMS0w_bbd6c2bc-9db6-42f8-b9d4-4a7e88c29c57">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNy04LTEtMS0w_62f70df2-1788-4042-84ed-d3866fc6d411">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNy0xMC0xLTEtMA_da815b89-8b10-4a81-8009-113326cbec90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNy0xMi0xLTEtMA_083489ab-6aa5-4474-8eb1-28836ca5d069">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfOC0yLTEtMS0w_ef48c9db-e678-4d1b-9065-d22e36474a6e">121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfOC00LTEtMS0w_4447c104-140b-43c3-83cf-5cb89b75655f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfOC02LTEtMS0w_9a72ff3c-3ba0-4d3e-98fc-843e87c5d587">121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfOC04LTEtMS0w_e4d23669-ff4e-4e8f-bd97-ba0caab945ea">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeCollateralRightToReclaimCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfOC0xMC0xLTEtMA_97a195ce-ccef-4799-8b36-88da13d04ad9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfOC0xMi0xLTEtMA_2dc88c46-11e8-4735-a62d-c5284eab8f0f">109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i5e8b0e18419843159ec07e1b794d0d87_49"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfMjA4OTg_e5e08a4a-5ceb-4c41-8f48-172e9bb77db6" continuedAt="i0dcf09435a4a43379030d2d4a5df61b4" escape="true">ACQUISITIONS</ix:nonNumeric></span></div><ix:continuation id="i0dcf09435a4a43379030d2d4a5df61b4" continuedAt="id780149dfa224dc48d60eaa93b32cedf"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired and liabilities assumed be recorded at their fair values as of the acquisition date. Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. Transaction costs associated with business combinations are expensed as they are incurred. The first quarter 2021 acquisition of MYR and the fourth quarter 2020 acquisition of Immunomedics were accounted for as business combinations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:155%">MYR </span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 4, 2021, we completed the acquisition of MYR, a German biotechnology company. MYR focuses on the development and commercialization of therapeutics for the treatment of HDV. The acquisition provides Gilead with Hepcludex, which was conditionally approved by the European Medicines Agency (&#8220;EMA&#8221;) in July 2020 for the treatment of chronic HDV infection in adults with compensated liver disease. Upon closing, MYR became a wholly-owned subsidiary of Gilead. The financial results of MYR were included in our Condensed Consolidated Financial Statements from the date of the acquisition. MYR contributed an immaterial net loss from the date of acquisition through March 31, 2021. We recorded other acquisition-related expenses of $<ix:nonFraction unitRef="usd" contextRef="ied6ece005700482abaa15b4b44d0acab_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjYzMTYzMg_72894e38-84f9-4aa7-a1bb-a375f6c7951c">11</ix:nonFraction> million, primarily representing closing costs and related fees, in Selling, general and administrative expenses on our Condensed Consolidated Statements of Income for the three months ended March 31, 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate consideration for this acquisition of approximately &#8364;<ix:nonFraction unitRef="eur" contextRef="i638cafe3b48a4a748be6d8f1b169f897_D20210304-20210304" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjYyNjE1OA_7a6d9ee9-c385-4220-a6a5-38177e23d797">1.3</ix:nonFraction> billion (or $<ix:nonFraction unitRef="usd" contextRef="i638cafe3b48a4a748be6d8f1b169f897_D20210304-20210304" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjYyNjE3NA_81dcf81b-839f-4123-8fc0-4b84fb790c7b">1.6</ix:nonFraction> billion) primarily consists of &#8364;<ix:nonFraction unitRef="eur" contextRef="i638cafe3b48a4a748be6d8f1b169f897_D20210304-20210304" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjU5MTY3NQ_c2f29176-63e3-4ab4-b50f-50fd2525ccd0">1.0</ix:nonFraction> billion (or approximately $<ix:nonFraction unitRef="usd" contextRef="i638cafe3b48a4a748be6d8f1b169f897_D20210304-20210304" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjU5MTY5MQ_2a2fa76d-2f7f-409d-b4f1-00bedab68204">1.2</ix:nonFraction> billion) paid upon closing and contingent consideration of up to &#8364;<ix:nonFraction unitRef="eur" contextRef="ibedf080b94a2460fb4f0a3efc0a14793_I20210304" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjU5MTY1Ng_2b9fde56-6897-4468-bda5-0e2f9ae828ee">300</ix:nonFraction> million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex. The estimated fair value of this contingent liability was $<ix:nonFraction unitRef="usd" contextRef="i3a98f90b07b94f6c86e128d20787701b_I20210304" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfMTA5OTUxMTc2NDE5Mg_4b9c3e8d-d822-4a09-88a1-47ecf8530fa1">341</ix:nonFraction> million as of the acquisition date and recorded in Other long-term obligations on our Condensed Consolidated Balance Sheets. The contingent consideration was estimated using probability-weighted scenarios for FDA approval. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id780149dfa224dc48d60eaa93b32cedf" continuedAt="ib718ec0ce5a04bb194964e1b5e2fd544"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value estimates for the assets acquired and liabilities assumed were based upon valuations using information known and knowable as of the date of this filing. Changes to these assumptions and estimates could cause an impact to the valuation of assets acquired, including intangible assets, goodwill and the related tax impacts of the acquisition, as well as legal and other contingencies. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date.</span></div><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfOTg5NTYwNDc3MTU1OA_652d7626-0603-46c9-a717-27cd9774c040" continuedAt="i5708f3d59a134f3298a2f177aa335e3a" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date: </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a98f90b07b94f6c86e128d20787701b_I20210304" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmRlMjI3ODg4ZWU1YTQ5NTg4MDFkZmJmNGQwNDI4NmJkL3RhYmxlcmFuZ2U6ZGUyMjc4ODhlZTVhNDk1ODgwMWRmYmY0ZDA0Mjg2YmRfMi0yLTEtMS01NTAz_0d4eedef-202c-4c46-b988-b612abbc3983">845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad268a44b5f2496ba16a02c95c0952e9_I20210304" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmRlMjI3ODg4ZWU1YTQ5NTg4MDFkZmJmNGQwNDI4NmJkL3RhYmxlcmFuZ2U6ZGUyMjc4ODhlZTVhNDk1ODgwMWRmYmY0ZDA0Mjg2YmRfMy0yLTEtMS01NTA3_ec9345a8-3dd9-4fa0-a0b1-8be4135e675a">1,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a98f90b07b94f6c86e128d20787701b_I20210304" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmRlMjI3ODg4ZWU1YTQ5NTg4MDFkZmJmNGQwNDI4NmJkL3RhYmxlcmFuZ2U6ZGUyMjc4ODhlZTVhNDk1ODgwMWRmYmY0ZDA0Mjg2YmRfNC0yLTEtMS01NTA3_31a21b32-b869-468e-8cce-826a771f6dbc">513</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a98f90b07b94f6c86e128d20787701b_I20210304" decimals="-6" sign="-" name="gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmRlMjI3ODg4ZWU1YTQ5NTg4MDFkZmJmNGQwNDI4NmJkL3RhYmxlcmFuZ2U6ZGUyMjc4ODhlZTVhNDk1ODgwMWRmYmY0ZDA0Mjg2YmRfNS0yLTEtMS01NTA3_ee1e3ae6-ead3-42a3-9999-db77cc2bf124">187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a98f90b07b94f6c86e128d20787701b_I20210304" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmRlMjI3ODg4ZWU1YTQ5NTg4MDFkZmJmNGQwNDI4NmJkL3RhYmxlcmFuZ2U6ZGUyMjc4ODhlZTVhNDk1ODgwMWRmYmY0ZDA0Mjg2YmRfNi0yLTEtMS01NTA3_da677983-1857-413d-b69d-abbba6666acf">1,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a98f90b07b94f6c86e128d20787701b_I20210304" decimals="-6" name="us-gaap:GoodwillGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmRlMjI3ODg4ZWU1YTQ5NTg4MDFkZmJmNGQwNDI4NmJkL3RhYmxlcmFuZ2U6ZGUyMjc4ODhlZTVhNDk1ODgwMWRmYmY0ZDA0Mjg2YmRfNy0yLTEtMS01MzU3_861b1a5a-472c-4f8c-907d-f382906b5e25">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a98f90b07b94f6c86e128d20787701b_I20210304" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmRlMjI3ODg4ZWU1YTQ5NTg4MDFkZmJmNGQwNDI4NmJkL3RhYmxlcmFuZ2U6ZGUyMjc4ODhlZTVhNDk1ODgwMWRmYmY0ZDA0Mjg2YmRfOC0yLTEtMS01NTA3_5e398c47-77a4-4159-90c0-5c831571458b">1,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The finite-lived intangible asset of $<ix:nonFraction unitRef="usd" contextRef="i4833c72c785b491e8f5afc3f5e83a942_I20210304" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjU5MTgwMw_38f1cafa-6d99-4c07-ab68-bbe7d5e1fa0a">845</ix:nonFraction> million represents the estimated fair value of Hepcludex for HDV in Europe as of the acquisition date. The fair value was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to Hepcludex for HDV in Europe and a discount rate of <ix:nonFraction unitRef="number" contextRef="i33549bbb2e014a6ab92f613d389caaf5_I20210304" decimals="2" name="gild:IntangibleAssetMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjU5MTgxMQ_f42e3e3a-7885-4970-855c-cb1e09c06415">12</ix:nonFraction>%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of <ix:nonNumeric contextRef="i0db85f8bde2e48919fd0edfbb47844d6_D20210304-20210304" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjU5MTgxNg_72b0516f-b462-4e9e-8c7e-d1b67532db17">10</ix:nonNumeric> years.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired intangible assets related to IPR&amp;D consist of Hepcludex for HDV in all other regions without regulatory approval, including the U.S. The estimated aggregate fair value of $<ix:nonFraction unitRef="usd" contextRef="iad268a44b5f2496ba16a02c95c0952e9_I20210304" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjU5MTgyOQ_4434cf07-b839-447a-ab20-1bfad96183b6">1.2</ix:nonFraction> billion as of the acquisition date was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to this asset and a discount rate of <ix:nonFraction unitRef="number" contextRef="i1b3e846287d144f5a57024a1a2aaa1f4_I20210304" decimals="2" name="gild:IntangibleAssetMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjU5MTgzOA_b0dd25e2-dea5-4e69-8de5-381222c606b0">12</ix:nonFraction>%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the more significant assumptions inherent in the development of intangible asset fair values include: estimates of projected future cash flows including revenues and operating profits; probability of success; the discount rate selected; the life of the potential commercialized products and the risks related to the viability of and potential alternative treatments in any future target markets, among other factors.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived assets until the completion or abandonment of the associated R&amp;D efforts. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The inputs used for valuing these identifiable intangibles are unobservable and considered Level 3 under the fair value measurement and disclosure guidance. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax liability was based upon the difference between the estimated book basis and tax basis of net assets acquired and an estimate for the final pre-acquisition net operating losses of MYR.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the consideration transferred over the fair values of assets acquired and liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="i3a98f90b07b94f6c86e128d20787701b_I20210304" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GoodwillGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjYxOTA3MA_e69cd742-6235-4110-b594-6134129a0e80">226</ix:nonFraction> million was recorded as goodwill, which primarily reflects the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill recognized for MYR is <ix:nonFraction unitRef="usd" contextRef="i9f919867053e472aa6823a950ddff61b_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfOTg5NTYwNDc3ODExMA_5072e403-bd98-409d-b4f4-05139a222957">no</ix:nonFraction>t expected to be deductible for income tax purposes.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Immunomedics</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we completed the acquisition of Immunomedics for cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i19a0802804904e31ba6efd10f1f3ea4b_D20201023-20201023" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNTQ5NzU1ODI2MDYwNA_d9d2a49a-ae22-4f57-88bf-df070cb344c7">20.6</ix:nonFraction> billion. Immunomedics is a wholly-owned subsidiary of Gilead. The acquisition was financed with the majority of the proceeds from the September 2020 senior unsecured notes offering, an additional $<ix:nonFraction unitRef="usd" contextRef="idc1e9ade6e414ced9c63b109438a49e7_D20201001-20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjYxMTA5MA_9d2c1e7d-92cc-4329-a428-bab7d2ebb277">1.0</ix:nonFraction> billion borrowing under a new senior unsecured term loan facility and cash on hand. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib718ec0ce5a04bb194964e1b5e2fd544"><ix:continuation id="i5708f3d59a134f3298a2f177aa335e3a"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbcce56feb74fe6a616f350aa562468_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmQ2MzQ5MmViZWI4OTRjYjI4YTQ2ZjlkZmEyYTlmMmU2L3RhYmxlcmFuZ2U6ZDYzNDkyZWJlYjg5NGNiMjhhNDZmOWRmYTJhOWYyZTZfMS0yLTEtMS05MTU3_1c789fce-a37c-4585-bae4-0a06e894523f">726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbcce56feb74fe6a616f350aa562468_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmQ2MzQ5MmViZWI4OTRjYjI4YTQ2ZjlkZmEyYTlmMmU2L3RhYmxlcmFuZ2U6ZDYzNDkyZWJlYjg5NGNiMjhhNDZmOWRmYTJhOWYyZTZfMi0yLTEtMS05MTU3_a3fb8aad-07ae-43ed-b074-9e6dead9404b">946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aa9165e8567484387ecc5acb5b3f1e9_I20201023" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmQ2MzQ5MmViZWI4OTRjYjI4YTQ2ZjlkZmEyYTlmMmU2L3RhYmxlcmFuZ2U6ZDYzNDkyZWJlYjg5NGNiMjhhNDZmOWRmYTJhOWYyZTZfNC0yLTEtMS05MTU3_7bb2e78f-4f8a-4a16-9e5b-31cb4ebf290c">4,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf62e749ffee4dcc9a54082aaa23c3b8_I20201023" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmQ2MzQ5MmViZWI4OTRjYjI4YTQ2ZjlkZmEyYTlmMmU2L3RhYmxlcmFuZ2U6ZDYzNDkyZWJlYjg5NGNiMjhhNDZmOWRmYTJhOWYyZTZfNS0yLTEtMS05MTU3_71ebd6de-a2f6-499a-b130-b2b76d586935">15,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outlicense contract</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05a08140a83742d99cfbd0fcb20b09fa_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmQ2MzQ5MmViZWI4OTRjYjI4YTQ2ZjlkZmEyYTlmMmU2L3RhYmxlcmFuZ2U6ZDYzNDkyZWJlYjg5NGNiMjhhNDZmOWRmYTJhOWYyZTZfNi0yLTEtMS05MTU3_33ed6a0d-6981-4623-b766-11b6c1f8e3c2">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bbcce56feb74fe6a616f350aa562468_I20201023" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmQ2MzQ5MmViZWI4OTRjYjI4YTQ2ZjlkZmEyYTlmMmU2L3RhYmxlcmFuZ2U6ZDYzNDkyZWJlYjg5NGNiMjhhNDZmOWRmYTJhOWYyZTZfNy0yLTEtMS05MTU3_47302010-39f8-4fb9-bd79-924f66b219b1">4,565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bbcce56feb74fe6a616f350aa562468_I20201023" decimals="-6" format="ixt:numdotdecimal" name="gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmQ2MzQ5MmViZWI4OTRjYjI4YTQ2ZjlkZmEyYTlmMmU2L3RhYmxlcmFuZ2U6ZDYzNDkyZWJlYjg5NGNiMjhhNDZmOWRmYTJhOWYyZTZfOC0yLTEtMS05MTU3_a35b2973-ff45-4ef5-b17c-a49520570942">1,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbcce56feb74fe6a616f350aa562468_I20201023" decimals="-6" name="gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmQ2MzQ5MmViZWI4OTRjYjI4YTQ2ZjlkZmEyYTlmMmU2L3RhYmxlcmFuZ2U6ZDYzNDkyZWJlYjg5NGNiMjhhNDZmOWRmYTJhOWYyZTZfOS0yLTEtMS05MTU3_9e4a3735-b5a7-4bac-af5f-5c0e15cd5832">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbcce56feb74fe6a616f350aa562468_I20201023" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmQ2MzQ5MmViZWI4OTRjYjI4YTQ2ZjlkZmEyYTlmMmU2L3RhYmxlcmFuZ2U6ZDYzNDkyZWJlYjg5NGNiMjhhNDZmOWRmYTJhOWYyZTZfMTAtMi0xLTEtOTE1Nw_4f1a144c-c508-45eb-ab80-9a1388a7386e">16,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbcce56feb74fe6a616f350aa562468_I20201023" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GoodwillGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmQ2MzQ5MmViZWI4OTRjYjI4YTQ2ZjlkZmEyYTlmMmU2L3RhYmxlcmFuZ2U6ZDYzNDkyZWJlYjg5NGNiMjhhNDZmOWRmYTJhOWYyZTZfMTEtMi0xLTEtOTE1Nw_209c2e3b-7b19-44dc-a65b-df46ab12eab2">3,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bbcce56feb74fe6a616f350aa562468_I20201023" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmQ2MzQ5MmViZWI4OTRjYjI4YTQ2ZjlkZmEyYTlmMmU2L3RhYmxlcmFuZ2U6ZDYzNDkyZWJlYjg5NGNiMjhhNDZmOWRmYTJhOWYyZTZfMTItMi0xLTEtOTE1Nw_a1676eea-9206-4c56-9695-337f0ad84ead">20,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no measurement period adjustments recorded to the fair values of assets acquired and liabilities assumed during the three months ended March 31, 2021.</span></div></ix:continuation><div id="i5e8b0e18419843159ec07e1b794d0d87_55"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RleHRyZWdpb246NDNlMTg4M2UwYTk0NDI4NDlmMGVjYzlkNjAxNTcyYjRfNDUx_76637063-d539-45b9-90ef-92defef75a59" continuedAt="i9d026aa3b7864aafbf75c555aef813e3" escape="true">GOODWILL AND INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="i9d026aa3b7864aafbf75c555aef813e3" continuedAt="id4959d8410464291b8b50c2d1b3491d4"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RleHRyZWdpb246NDNlMTg4M2UwYTk0NDI4NDlmMGVjYzlkNjAxNTcyYjRfOTg5NTYwNDY1NjYyNQ_d9aa6bef-9657-4e11-b599-45addac6ec07" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOmM1NTI4ZWYxOTBlNjQ3N2Q5ZDAwMWFiNDE4YjQ4MzMzL3RhYmxlcmFuZ2U6YzU1MjhlZjE5MGU2NDc3ZDlkMDAxYWI0MThiNDgzMzNfMS0yLTEtMS00NTg2_7360acdd-235f-4ed6-b595-464594e44bbe">8,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill resulting from the acquisition of MYR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOmM1NTI4ZWYxOTBlNjQ3N2Q5ZDAwMWFiNDE4YjQ4MzMzL3RhYmxlcmFuZ2U6YzU1MjhlZjE5MGU2NDc3ZDlkMDAxYWI0MThiNDgzMzNfMi0yLTEtMS00NTg2_eabf57f8-1074-4cc9-a3a4-3e4febaeedc5">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOmM1NTI4ZWYxOTBlNjQ3N2Q5ZDAwMWFiNDE4YjQ4MzMzL3RhYmxlcmFuZ2U6YzU1MjhlZjE5MGU2NDc3ZDlkMDAxYWI0MThiNDgzMzNfMy0yLTEtMS00NTg2_469dcf4c-19f1-41df-aea0-bc4bb5ded5c7">8,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RleHRyZWdpb246NDNlMTg4M2UwYTk0NDI4NDlmMGVjYzlkNjAxNTcyYjRfNDU5_2882025a-855b-4ec3-854b-f32d3715d655" escape="true"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RleHRyZWdpb246NDNlMTg4M2UwYTk0NDI4NDlmMGVjYzlkNjAxNTcyYjRfNDc2_dbc1966f-a9a5-4659-95b5-349c9daef52b" escape="true"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net: </span></div><div style="margin-top:1.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:22.360%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.524%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.524%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d12086953934504ada4ca8bfb4497b1_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfMy0yLTEtMS0w_5cfcc58e-a27c-4159-b5bc-d92aeba04491">10,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d12086953934504ada4ca8bfb4497b1_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfMy00LTEtMS0w_c14ef391-c180-452b-b7b1-bc78322cfa4b">5,127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d12086953934504ada4ca8bfb4497b1_I20210331" decimals="-6" format="ixt:zerodash" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfMy02LTEtMS0w_cb5950b8-992c-4f8c-8b6f-8f658c43abfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d12086953934504ada4ca8bfb4497b1_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfMy04LTEtMS0w_7a9b357b-7461-4fbc-bdc8-17d855be57f5">5,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia02e3e3eb61e4722a1d82ca5bfeafc26_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfMy0xMC0xLTEtMA_fecf73b3-c37c-4405-ad4e-0625f20341ed">10,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia02e3e3eb61e4722a1d82ca5bfeafc26_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfMy0xMi0xLTEtMA_35a592b2-cc6c-4413-aabf-c983a0158361">4,952</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia02e3e3eb61e4722a1d82ca5bfeafc26_I20201231" decimals="-6" format="ixt:zerodash" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfMy0xNC0xLTEtMA_87061e26-c0dc-4293-ac79-430a861360dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia02e3e3eb61e4722a1d82ca5bfeafc26_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfMy0xNi0xLTEtMA_6828d04b-1cc3-4b97-b122-3b87393f83ec">5,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - axicabtagene ciloleucel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3231dad87cac437aaa04d35fce3d9824_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNC0yLTEtMS0w_40b5d317-22a2-41c1-b932-1abbf10c5b83">7,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3231dad87cac437aaa04d35fce3d9824_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNC00LTEtMS0w_272890bf-29d9-45c8-af7c-6fc7cc3279d5">1,196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3231dad87cac437aaa04d35fce3d9824_I20210331" decimals="-6" format="ixt:zerodash" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNC02LTEtMS0w_069190e0-d9af-4d8e-9be9-8cfaa8638a59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3231dad87cac437aaa04d35fce3d9824_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNC04LTEtMS0w_c5f49d4e-b45e-43ab-8484-064cc123fef1">5,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8222759ba26347c3a6f92ef2992fa9a1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNC0xMC0xLTEtMA_6f1343fd-602d-4955-8bca-0fe7546f74bb">6,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8222759ba26347c3a6f92ef2992fa9a1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNC0xMi0xLTEtMA_63f46210-e1b9-4733-9668-5206143cca68">1,105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8222759ba26347c3a6f92ef2992fa9a1_I20201231" decimals="-6" format="ixt:zerodash" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNC0xNC0xLTEtMA_c2254a97-ae92-49a2-b489-227502a69dad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8222759ba26347c3a6f92ef2992fa9a1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNC0xNi0xLTEtMA_f3bc6ac9-6055-486c-ab4a-91ac164e18b3">5,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a8801e286d4710aab30d8ef3145cc8_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS0yLTEtMS0zNzQ5_b0d654c4-ed5e-4d3c-92b1-abef3213f81f">4,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a8801e286d4710aab30d8ef3145cc8_I20210331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS00LTEtMS0zNzQ5_6124bbec-6c15-4f52-9966-6b3fa3f315f5">158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a8801e286d4710aab30d8ef3145cc8_I20210331" decimals="-6" format="ixt:zerodash" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS02LTEtMS0zNzQ5_c14156ae-5240-4e91-a3cb-70f9d8fcc2c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a8801e286d4710aab30d8ef3145cc8_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS04LTEtMS0zNzQ5_eb256a17-7a58-4ca0-9c51-76e3925f7f2d">4,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8a8bbb1048e4a4db06008d8d902d2a9_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS0xMC0xLTEtMzc0Ng_604cece3-052e-4cf5-9c00-f3af6b701857">4,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8a8bbb1048e4a4db06008d8d902d2a9_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS0xMi0xLTEtMzc0Ng_d9851673-df8e-4198-98e4-1058dde35cbe">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8a8bbb1048e4a4db06008d8d902d2a9_I20201231" decimals="-6" format="ixt:zerodash" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS0xNC0xLTEtMzc0Ng_8955a580-e5d0-4096-afc1-a5e6b6108832">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8a8bbb1048e4a4db06008d8d902d2a9_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS0xNi0xLTEtMzc0Ng_5b2ebd28-b8ef-4846-ae01-9ee770107c73">4,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Hepcludex for HDV </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42d240b01e18486db9a4e93c058e1eb9_I20210331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi0yLTEtMS00ODk0_7ecf84d2-3a0c-41f3-9f23-fb8b27f33539">845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42d240b01e18486db9a4e93c058e1eb9_I20210331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi00LTEtMS00ODk0_3d119f37-433d-4c7c-b090-77771aa1d975">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42d240b01e18486db9a4e93c058e1eb9_I20210331" decimals="-6" format="ixt:zerodash" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi02LTEtMS00ODk0_a8a173fa-0617-4454-b360-9692741a00ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42d240b01e18486db9a4e93c058e1eb9_I20210331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi04LTEtMS00ODk0_4c6cafae-71ae-4dd5-a8c8-a989b3f9c4da">838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ef6063e2dd483ebe6c5dcca3038c73_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi0xMC0xLTEtNDg5NA_9933a911-2d75-4d33-b2b1-a3e5355d7b0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ef6063e2dd483ebe6c5dcca3038c73_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi0xMi0xLTEtNDg5NA_04262c26-8864-4aef-8078-d2930d5b6eb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ef6063e2dd483ebe6c5dcca3038c73_I20201231" decimals="-6" format="ixt:zerodash" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi0xNC0xLTEtNDg5NA_5b0e5169-a12d-4889-bebf-f4b4226daf65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ef6063e2dd483ebe6c5dcca3038c73_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi0xNi0xLTEtNDg5NA_e4c8db31-cd92-4e25-8504-8f0ba9feea1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if32750d98ae2460aa464be3d472d1042_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS0yLTEtMS0w_a74953e6-d3b2-44a2-8afb-e2bfcdc46af9">1,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if32750d98ae2460aa464be3d472d1042_I20210331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS00LTEtMS0w_3b06feb7-4848-43a9-a97c-ebc2518040a1">567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if32750d98ae2460aa464be3d472d1042_I20210331" decimals="-6" format="ixt:zerodash" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS02LTEtMS0w_b57f9d9e-2bb6-4a92-a8f2-e8a9b4c10bb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if32750d98ae2460aa464be3d472d1042_I20210331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS04LTEtMS0w_6eb99dc1-1d69-43ad-ae07-78108b75044c">824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ac0434166243fdbe064ef57c4cf330_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS0xMC0xLTEtMA_6cbf3cf8-755b-497c-b799-50e1cf4f1923">1,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0ac0434166243fdbe064ef57c4cf330_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS0xMi0xLTEtMA_95ea2d75-08b7-450d-9d9e-79c9b12a1aa3">540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0ac0434166243fdbe064ef57c4cf330_I20201231" decimals="-6" sign="-" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS0xNC0xLTEtMA_c3fc2494-7763-4e65-8aa7-344431ace8ab">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ac0434166243fdbe064ef57c4cf330_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS0xNi0xLTEtMA_960747d0-4830-4934-9077-e974cb5b07ea">836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi0yLTEtMS0w_c5730af7-cb74-4c33-9d1b-8f6f6cd127d7">24,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi00LTEtMS0w_b6d8aef3-e478-42e9-a5d0-946d177ca9da">7,055</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:zerodash" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi02LTEtMS0w_220c7248-a0d7-4e15-a337-31bf1e6a1ed7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi04LTEtMS0w_1989a335-8e55-4474-b044-ee33c413b70a">17,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi0xMC0xLTEtMA_cdd9daff-5cda-46db-aeab-2e82d6947a9f">22,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi0xMi0xLTEtMA_e778be42-1e02-405c-a333-9f15513f2800">6,660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" sign="-" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi0xNC0xLTEtMA_50008000-7489-4014-83d0-976661114d21">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi0xNi0xLTEtMA_16e19888-14be-49ec-9e75-a2d73b2d7d59">16,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets - IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf9f311c0c5a450295b3455afad3eb99_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNy0yLTEtMS0w_ea4a2484-4efd-4220-98ff-df3c762805d7">17,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf9f311c0c5a450295b3455afad3eb99_I20210331" decimals="-6" format="ixt:zerodash" name="gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNy02LTEtMS0w_bd574b63-f497-4a53-ad9b-e0d5fa512725">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf9f311c0c5a450295b3455afad3eb99_I20210331" decimals="-6" format="ixt:numdotdecimal" name="gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNy04LTEtMS0w_b0944680-c778-462e-ae94-a160fb999726">17,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04105952f21b49fe8cd9befd11b8c28b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNy0xMC0xLTEtMA_7e4e4565-7c3b-4f65-b498-9ab7647c19e5">16,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04105952f21b49fe8cd9befd11b8c28b_I20201231" decimals="-6" format="ixt:zerodash" name="gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNy0xNC0xLTEtMA_c9739caa-6120-4bfd-8445-4799f66501ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04105952f21b49fe8cd9befd11b8c28b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNy0xNi0xLTEtMA_5e6952ef-bd6c-4217-ab25-d27f42307d22">16,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfOC0yLTEtMS0w_e1992b89-7e3a-47d5-b994-22fd09ab129b">41,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfOC00LTEtMS0w_05d336fa-6569-4960-9206-4837628b4a6c">7,055</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:zerodash" name="gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfOC02LTEtMS0w_7700d5a8-e887-4952-88c7-d21e92de2edd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfOC04LTEtMS0w_e08fcbf0-cd8c-466d-be9b-0e5af6be5009">34,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfOC0xMC0xLTEtMA_6f364bb2-9b68-4cf8-ba45-1e1dfcfc5d39">39,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfOC0xMi0xLTEtMA_11464f85-07b2-48d6-a81c-665b209d3a5f">6,660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" sign="-" name="gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfOC0xNC0xLTEtMA_79f2d356-a072-4e5d-866a-79f2e4356481">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfOC0xNi0xLTEtMA_7924fa5c-4c55-4c6e-92a3-dd3a20a14666">33,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of March&#160;31, 2021 includes $<ix:nonFraction unitRef="usd" contextRef="iaf9f311c0c5a450295b3455afad3eb99_I20210331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="gild:FiniteLivedIntangibleAssetsGrossTransfers" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RleHRyZWdpb246NDNlMTg4M2UwYTk0NDI4NDlmMGVjYzlkNjAxNTcyYjRfNDM5ODA0NjUxNzA2OQ_3902499a-9b05-43b1-8a2a-ee0f1d4fee2c"><ix:nonFraction unitRef="usd" contextRef="i3231dad87cac437aaa04d35fce3d9824_I20210331" decimals="-6" format="ixt:numdotdecimal" name="gild:FiniteLivedIntangibleAssetsGrossTransfers" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RleHRyZWdpb246NDNlMTg4M2UwYTk0NDI4NDlmMGVjYzlkNjAxNTcyYjRfNDM5ODA0NjUxNzA2OQ_f554ffa3-69d4-4af0-b969-a99aa02d8c60">910</ix:nonFraction></ix:nonFraction>&#160;million reclassified from indefinite-lived assets - IPR&amp;D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts represent Trodelvy for metastatic triple-negative breast cancer.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of March&#160;31, 2021 includes $<ix:nonFraction unitRef="usd" contextRef="iad268a44b5f2496ba16a02c95c0952e9_I20210304" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RleHRyZWdpb246NDNlMTg4M2UwYTk0NDI4NDlmMGVjYzlkNjAxNTcyYjRfMTA5OTUxMTYzOTIyMQ_ec4eb230-8803-4a8a-9f89-9f419889e8e3">1.2</ix:nonFraction>&#160;billion recognized from the first quarter 2021 MYR acquisition. See Note 6. Acquisitions for additional information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;In April 2021, FDA granted accelerated approval of Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer, a new indication. Accordingly, the related amount of $<ix:nonFraction unitRef="usd" contextRef="i4e6af3a3c95d4c1689521cc7dae5427c_D20210401-20210630" decimals="-8" format="ixt:numdotdecimal" name="gild:FiniteLivedIntangibleAssetsGrossReclassified" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RleHRyZWdpb246NDNlMTg4M2UwYTk0NDI4NDlmMGVjYzlkNjAxNTcyYjRfMTA5OTUxMTYzNzE4OQ_833d3094-88fa-471d-a2e6-f06c3e2f9207">1.0</ix:nonFraction>&#160;billion will be reclassified to finite-lived assets in the second quarter of 2021.</span></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id4959d8410464291b8b50c2d1b3491d4"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense related to finite-lived intangible assets was $<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RleHRyZWdpb246NDNlMTg4M2UwYTk0NDI4NDlmMGVjYzlkNjAxNTcyYjRfMTY1_8f872083-eb26-4b45-8cee-5645e5cad050">395</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RleHRyZWdpb246NDNlMTg4M2UwYTk0NDI4NDlmMGVjYzlkNjAxNTcyYjRfMTY0OTI2NzQ0MjI0OQ_21435ae1-0399-4b3d-87f4-1f789855a962">281</ix:nonFraction> million for the three months ended March 31, 2021 and 2020, respectively, and was primarily included in Cost of goods sold on our Condensed Consolidated Statements of Income.</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RleHRyZWdpb246NDNlMTg4M2UwYTk0NDI4NDlmMGVjYzlkNjAxNTcyYjRfNDY0_6c0a3346-4db7-4eeb-b488-0c2f25c52c03" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of March&#160;31, 2021:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:86.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.191%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining nine months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjczOGVlNTBmYmM0YjRhYjc5ZDJjNjFhMGQwM2NjZWI4L3RhYmxlcmFuZ2U6NzM4ZWU1MGZiYzRiNGFiNzlkMmM2MWEwZDAzY2NlYjhfMS0yLTEtMS0w_2aa82c9e-3683-4135-9eea-47d1fb08e93a">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjczOGVlNTBmYmM0YjRhYjc5ZDJjNjFhMGQwM2NjZWI4L3RhYmxlcmFuZ2U6NzM4ZWU1MGZiYzRiNGFiNzlkMmM2MWEwZDAzY2NlYjhfMi0yLTEtMS0w_a39e7e92-8a5b-42f0-b15d-453529caac7c">1,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjczOGVlNTBmYmM0YjRhYjc5ZDJjNjFhMGQwM2NjZWI4L3RhYmxlcmFuZ2U6NzM4ZWU1MGZiYzRiNGFiNzlkMmM2MWEwZDAzY2NlYjhfMy0yLTEtMS0w_0169d22b-9db1-4353-b040-a1843ea209cb">1,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjczOGVlNTBmYmM0YjRhYjc5ZDJjNjFhMGQwM2NjZWI4L3RhYmxlcmFuZ2U6NzM4ZWU1MGZiYzRiNGFiNzlkMmM2MWEwZDAzY2NlYjhfNC0yLTEtMS0w_46741d72-c23c-47d3-8cb2-c9c3a3acdb76">1,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjczOGVlNTBmYmM0YjRhYjc5ZDJjNjFhMGQwM2NjZWI4L3RhYmxlcmFuZ2U6NzM4ZWU1MGZiYzRiNGFiNzlkMmM2MWEwZDAzY2NlYjhfNS0yLTEtMS0w_1a09d761-7fe0-4345-9f3c-1c602b2cb5f6">1,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjczOGVlNTBmYmM0YjRhYjc5ZDJjNjFhMGQwM2NjZWI4L3RhYmxlcmFuZ2U6NzM4ZWU1MGZiYzRiNGFiNzlkMmM2MWEwZDAzY2NlYjhfNi0yLTEtMS0w_01e6e724-e6b3-42cb-a83d-0efe0b0343e5">9,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjczOGVlNTBmYmM0YjRhYjc5ZDJjNjFhMGQwM2NjZWI4L3RhYmxlcmFuZ2U6NzM4ZWU1MGZiYzRiNGFiNzlkMmM2MWEwZDAzY2NlYjhfNy0yLTEtMS0w_c1bd463a-89d9-418e-841f-d14a651b09ba">17,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i5e8b0e18419843159ec07e1b794d0d87_52"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RleHRyZWdpb246ODkyNDc5YzcxNjMyNDY3NDk4OGViYWFiZTljZjg5YWZfMTg2_076e4ee3-fe00-41cc-9bc5-9caf1eda12f7" continuedAt="i55c684bbd23848b7988af6f93c075f08" escape="true">OTHER FINANCIAL INFORMATION</ix:nonNumeric></span></div><ix:continuation id="i55c684bbd23848b7988af6f93c075f08"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable, net</span></div><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RleHRyZWdpb246ODkyNDc5YzcxNjMyNDY3NDk4OGViYWFiZTljZjg5YWZfOTg5NTYwNDY1MDM5OA_1b68d03a-8f4d-4739-961d-596a653093df" escape="true"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Accounts receivable, net:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableGrossCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmExY2I2ZGY3YjdiNTRmODI4ZmVlMGI1NDNhYWJjNjNiL3RhYmxlcmFuZ2U6YTFjYjZkZjdiN2I1NGY4MjhmZWUwYjU0M2FhYmM2M2JfMS0yLTEtMS0zOTg_2dd79fb3-440d-4819-9c2b-49b6cde6b755">4,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableGrossCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmExY2I2ZGY3YjdiNTRmODI4ZmVlMGI1NDNhYWJjNjNiL3RhYmxlcmFuZ2U6YTFjYjZkZjdiN2I1NGY4MjhmZWUwYjU0M2FhYmM2M2JfMS00LTEtMS0zOTg_4a884701-6fd8-4ee4-9755-927770047e1e">5,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="gild:AccountsReceivableChargebacksCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmExY2I2ZGY3YjdiNTRmODI4ZmVlMGI1NDNhYWJjNjNiL3RhYmxlcmFuZ2U6YTFjYjZkZjdiN2I1NGY4MjhmZWUwYjU0M2FhYmM2M2JfMi0yLTEtMS0zOTg_8981a554-de6b-4a9c-993d-6ef0ab73f230">607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" name="gild:AccountsReceivableChargebacksCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmExY2I2ZGY3YjdiNTRmODI4ZmVlMGI1NDNhYWJjNjNiL3RhYmxlcmFuZ2U6YTFjYjZkZjdiN2I1NGY4MjhmZWUwYjU0M2FhYmM2M2JfMi00LTEtMS0zOTg_a9533c6a-a656-4a3f-96c0-7699872ffb8f">552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash discounts and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="gild:AccountsReceivableCashDiscountsAndOtherCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmExY2I2ZGY3YjdiNTRmODI4ZmVlMGI1NDNhYWJjNjNiL3RhYmxlcmFuZ2U6YTFjYjZkZjdiN2I1NGY4MjhmZWUwYjU0M2FhYmM2M2JfMy0yLTEtMS0zOTg_12a43dcd-805e-4f0b-bb2d-8dc168b0a300">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" name="gild:AccountsReceivableCashDiscountsAndOtherCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmExY2I2ZGY3YjdiNTRmODI4ZmVlMGI1NDNhYWJjNjNiL3RhYmxlcmFuZ2U6YTFjYjZkZjdiN2I1NGY4MjhmZWUwYjU0M2FhYmM2M2JfMy00LTEtMS0zOTg_06d21b53-fa28-4f0d-9124-ab360b6d15c3">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmExY2I2ZGY3YjdiNTRmODI4ZmVlMGI1NDNhYWJjNjNiL3RhYmxlcmFuZ2U6YTFjYjZkZjdiN2I1NGY4MjhmZWUwYjU0M2FhYmM2M2JfNC0yLTEtMS0zOTg_c3d487d6-d325-4d74-95f9-5193466c0cb7">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmExY2I2ZGY3YjdiNTRmODI4ZmVlMGI1NDNhYWJjNjNiL3RhYmxlcmFuZ2U6YTFjYjZkZjdiN2I1NGY4MjhmZWUwYjU0M2FhYmM2M2JfNC00LTEtMS0zOTg_992c1e7f-ce4f-4510-8049-018fbb865bf7">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmExY2I2ZGY3YjdiNTRmODI4ZmVlMGI1NDNhYWJjNjNiL3RhYmxlcmFuZ2U6YTFjYjZkZjdiN2I1NGY4MjhmZWUwYjU0M2FhYmM2M2JfNS0yLTEtMS0zOTg_e43e16f6-01d4-426a-8268-e81ebc0c3da9">3,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmExY2I2ZGY3YjdiNTRmODI4ZmVlMGI1NDNhYWJjNjNiL3RhYmxlcmFuZ2U6YTFjYjZkZjdiN2I1NGY4MjhmZWUwYjU0M2FhYmM2M2JfNS00LTEtMS0zOTg_116b653c-c673-4e53-b458-3c83bf8e870b">4,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RleHRyZWdpb246ODkyNDc5YzcxNjMyNDY3NDk4OGViYWFiZTljZjg5YWZfMTgx_3f45da58-044f-4980-9dd4-0c584d76013b" escape="true"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Inventories:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfMS0yLTEtMS0w_bcc441f8-6a9f-4777-adab-69ae63081603">1,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfMS00LTEtMS0w_4e9f5f62-3cd0-4481-b655-9b4fcc7486c7">1,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfMi0yLTEtMS0w_14c9559f-349f-42e8-bf9c-cfb0d0d1123b">856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfMi00LTEtMS0w_50c41fd3-7947-4d01-ad9b-b9110a8b04da">976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfMy0yLTEtMS0w_7862e286-a554-4617-bb5e-9312726848d7">1,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfMy00LTEtMS0w_e7c76f45-9f02-460e-8ebd-715570354469">958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="gild:InventoryNetAndInventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfNC0yLTEtMS0w_ce99ae1c-4895-437a-8a2b-bd1f2ca243e6">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="gild:InventoryNetAndInventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfNC00LTEtMS0w_a3a8f044-df17-4639-911f-f77ea44d295d">3,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfNy0yLTEtMS0w_940694de-679f-4703-95d0-1092df9b1e85">1,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfNy00LTEtMS0w_3eab0329-3699-4a63-a92c-16535f3de705">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfOC0yLTEtMS0w_92f91b23-ddd3-4f1f-bdb1-edeac93ce9ac">1,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfOC00LTEtMS0w_7b120dd1-6edf-407a-a44d-efc047962c01">1,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="gild:InventoryNetAndInventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfOS0yLTEtMS0w_48c757ed-4606-4b0f-b81a-67cfb7f6bc05">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="gild:InventoryNetAndInventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfOS00LTEtMS0w_7488bb6c-6057-45a9-ad22-cf436185c71d">3,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.415%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">________________________________</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts primarily consist of raw materials.</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued and other current liabilities </span></div><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RleHRyZWdpb246ODkyNDc5YzcxNjMyNDY3NDk4OGViYWFiZTljZjg5YWZfMTg3_eccb508d-0194-48c8-bfbb-8e028a8c58ff" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of Accrued and other current liabilities:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmQ1NGMyNzgyMTA4YTRjN2I5OWU0YzQ4MzgxZDdlNDFlL3RhYmxlcmFuZ2U6ZDU0YzI3ODIxMDhhNGM3Yjk5ZTRjNDgzODFkN2U0MWVfMS0yLTEtMS0w_bfc0065b-a2b5-41e2-ac1c-4c8b93e619ac">494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmQ1NGMyNzgyMTA4YTRjN2I5OWU0YzQ4MzgxZDdlNDFlL3RhYmxlcmFuZ2U6ZDU0YzI3ODIxMDhhNGM3Yjk5ZTRjNDgzODFkN2U0MWVfMS00LTEtMS0w_0d7dd8d1-936b-45f2-9691-79b67f336770">864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmQ1NGMyNzgyMTA4YTRjN2I5OWU0YzQ4MzgxZDdlNDFlL3RhYmxlcmFuZ2U6ZDU0YzI3ODIxMDhhNGM3Yjk5ZTRjNDgzODFkN2U0MWVfMi0yLTEtMS0w_9369320b-6733-4d73-8067-2b61f890c34a">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmQ1NGMyNzgyMTA4YTRjN2I5OWU0YzQ4MzgxZDdlNDFlL3RhYmxlcmFuZ2U6ZDU0YzI3ODIxMDhhNGM3Yjk5ZTRjNDgzODFkN2U0MWVfMi00LTEtMS0w_0e817143-3acf-4319-82f5-ea73e3f9df4c">598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmQ1NGMyNzgyMTA4YTRjN2I5OWU0YzQ4MzgxZDdlNDFlL3RhYmxlcmFuZ2U6ZDU0YzI3ODIxMDhhNGM3Yjk5ZTRjNDgzODFkN2U0MWVfMy0yLTEtMS0zNjI_49fb7116-e6e2-4015-9eb1-4e646772bf64">524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmQ1NGMyNzgyMTA4YTRjN2I5OWU0YzQ4MzgxZDdlNDFlL3RhYmxlcmFuZ2U6ZDU0YzI3ODIxMDhhNGM3Yjk5ZTRjNDgzODFkN2U0MWVfMy00LTEtMS0zNjI_e2c2f942-dc02-4bfc-86c8-5acb8c963694">587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmQ1NGMyNzgyMTA4YTRjN2I5OWU0YzQ4MzgxZDdlNDFlL3RhYmxlcmFuZ2U6ZDU0YzI3ODIxMDhhNGM3Yjk5ZTRjNDgzODFkN2U0MWVfMy0yLTEtMS0w_95dfbf41-3d4a-4b65-b5a1-95b5df4fb04c">2,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmQ1NGMyNzgyMTA4YTRjN2I5OWU0YzQ4MzgxZDdlNDFlL3RhYmxlcmFuZ2U6ZDU0YzI3ODIxMDhhNGM3Yjk5ZTRjNDgzODFkN2U0MWVfMy00LTEtMS0w_986c86b0-cbe5-4ab0-b804-e6e3a9a25c78">2,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmQ1NGMyNzgyMTA4YTRjN2I5OWU0YzQ4MzgxZDdlNDFlL3RhYmxlcmFuZ2U6ZDU0YzI3ODIxMDhhNGM3Yjk5ZTRjNDgzODFkN2U0MWVfNC0yLTEtMS0w_fee650db-5d69-41bf-8843-1008d63b607a">3,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmQ1NGMyNzgyMTA4YTRjN2I5OWU0YzQ4MzgxZDdlNDFlL3RhYmxlcmFuZ2U6ZDU0YzI3ODIxMDhhNGM3Yjk5ZTRjNDgzODFkN2U0MWVfNC00LTEtMS0w_77dfb11d-9f9a-419a-a405-bf6694c395d4">4,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i5e8b0e18419843159ec07e1b794d0d87_1103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="gild:CollaborativeAndOtherArrangementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF85ODk1NjA0NzA0MDQ0_c0430c72-7e7d-4c47-869f-0b8db12ad0af" continuedAt="i641e490be7fd494cbb726f70bc3b1324" escape="true">COLLABORATIONS AND OTHER ARRANGEMENTS</ix:nonNumeric></span></div><ix:continuation id="i641e490be7fd494cbb726f70bc3b1324" continuedAt="ibdcc1e1526204225bc7f871e9218f8f1"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to pursue licensing and strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain products and product candidates. These arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements and cost-sharing arrangements. We also continue to pursue equity investments in third parties focused on the development and commercialization of products and product candidates. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Merck Sharp &amp; Dohme Corp. (&#8220;Merck&#8221;) </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 13, 2021, we entered into a license and collaboration agreement with Merck, a subsidiary of Merck &amp; Co., Inc. to jointly develop and commercialize long-acting investigational treatments in HIV that combine Gilead&#8217;s investigational capsid inhibitor, lenacapavir, and Merck&#8217;s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir. The collaboration will initially focus on long-acting oral and injectable formulations. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Gilead and Merck will share global development and commercialization costs at <ix:nonFraction unitRef="number" contextRef="i9bba91958aca44f293ca49c63fbaafef_D20210313-20210313" decimals="2" name="gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF8xMDk5NTExNjgxODUw_92985a5f-8e5b-4f25-a09d-3c672316a21f">60</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i37ff3780af8f4a3e8fb8ad3d11da24c2_D20210313-20210313" decimals="2" name="gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF8xMDk5NTExNjgxODU1_c73bcef4-6e01-460a-aca7-628284332b37">40</ix:nonFraction>%, respectively, across the oral and injectable formulation programs. For long-acting oral products, Gilead will lead commercialization in the U.S. and Merck will lead commercialization in the European Union (&#8220;EU&#8221;) and rest of the world. For long-acting injectable products, Merck will lead commercialization in the U.S. and Gilead will lead commercialization in the EU and rest of the world. Gilead and Merck will jointly promote the combination products in the U.S. and certain other major markets. We will share global product revenues with Merck equally until product revenues surpass certain pre-determined per formulation revenue tiers. Upon passing $<ix:nonFraction unitRef="usd" contextRef="i2bb0786a7089452eab44f7d3f2844758_D20210313-20210313" decimals="INF" format="ixt:numdotdecimal" name="gild:CollaborationArrangementNetProductSalesThreshold" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF8xMDk5NTExNjgxODcx_5490fd21-b7e4-44be-aa95-7c00a7ca5b52">2.0</ix:nonFraction> billion in net product sales for the oral combination in a given calendar year, our share of revenue will increase to <ix:nonFraction unitRef="number" contextRef="i2bb0786a7089452eab44f7d3f2844758_D20210313-20210313" decimals="2" name="gild:CollaborationArrangementPercentOfGlobalProductRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF8xMDk5NTExNjgxODk1_839f2bec-3bc2-4309-ac5b-c4db82cb98ba">65</ix:nonFraction>% for any revenues above the threshold for such calendar year. Upon passing $<ix:nonFraction unitRef="usd" contextRef="i32ac5282522a4590be96101bc1e207b1_D20210313-20210313" decimals="INF" format="ixt:numdotdecimal" name="gild:CollaborationArrangementNetProductSalesThreshold" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF8xMDk5NTExNjgxODg3_20fd9541-9013-456c-86d3-4fc3e32b919a">3.5</ix:nonFraction> billion in net product sales for the injectable combination in a given calendar year, our share of revenue will increase to <ix:nonFraction unitRef="number" contextRef="i32ac5282522a4590be96101bc1e207b1_D20210313-20210313" decimals="2" name="gild:CollaborationArrangementPercentOfGlobalProductRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF8xMDk5NTExNjgxOTAx_874366f2-7497-4268-84bc-5348195bfb51">65</ix:nonFraction>% for any revenues above the threshold for such calendar year. There was no material impact from the agreement on our Condensed Consolidated Financial Statements for the three months ended March 31, 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also have the option to license certain of Merck&#8217;s investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of Gilead&#8217;s investigational oral integrase inhibitors to develop in combination with islatravir. Each company may exercise its option for such investigational oral integrase inhibitor of the other company within the first <ix:nonNumeric contextRef="i9bba91958aca44f293ca49c63fbaafef_D20210313-20210313" format="ixt-sec:durwordsen" name="gild:CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF85ODk1NjA0NzE0MDQx_fc9c39cb-4508-4e42-8516-804dd22651fa">five years</ix:nonNumeric> after execution of the agreement, following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon exercise of an option, the companies will split development cost and revenues, unless the non-exercising company decides to opt-out, in which case the non-exercising company will be paid a royalty.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arcus Biosciences, Inc. (&#8220;Arcus&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On&#160;May 27, 2020, we entered into a transaction with Arcus, which included entry into an option, license and collaboration agreement (the &#8220;Collaboration Agreement&#8221;) and a common stock purchase agreement and an investor rights agreement (together, and as subsequently amended the &#8220;Stock Purchase Agreements&#8221;). In 2020, pursuant to the Stock Purchase Agreements and a separate secondary equity offering, we acquired approximately <ix:nonFraction unitRef="shares" contextRef="id660245607b543dea4f85f3873880146_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="gild:EquitySecuritiesFVNISharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF80Mzk4MDQ2NTYyOTc3_34b6b31d-f4bb-4b8b-865c-a7c3100ac1d2">8.2</ix:nonFraction>&#160;million shares of Arcus common stock for approximately $<ix:nonFraction unitRef="usd" contextRef="id660245607b543dea4f85f3873880146_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="gild:PaymentsToAcquireEquitySecuritiesFVNI" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF80Mzk4MDQ2NTYyOTky_d6c2b08f-4645-41b8-8de7-5d0174484e67">261</ix:nonFraction> million. In the first quarter of 2021, we amended and restated the common stock purchase agreement and acquired approximately <ix:nonFraction unitRef="shares" contextRef="ibdce32802a20413da082d4b864fd5089_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="gild:EquitySecuritiesFVNISharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF80Mzk4MDQ2NTYyNjc1_332a5218-2f00-4005-9f26-679922c4e91d">5.7</ix:nonFraction>&#160;million additional shares of Arcus common stock for $<ix:nonFraction unitRef="usd" contextRef="ibdce32802a20413da082d4b864fd5089_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="gild:PaymentsToAcquireEquitySecuritiesFVNI" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF80Mzk4MDQ2NTYyNjkz_7c0cdb0b-ef24-4c30-8fca-ebd6b32904fe">220</ix:nonFraction> million. As a result, we currently own a total of <ix:nonFraction unitRef="shares" contextRef="i410db304976646ba98567afb20cfa4a0_I20210331" decimals="-5" format="ixt:numdotdecimal" name="gild:EquitySecuritiesFVNIShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF80Mzk4MDQ2NTYyNzA5_d5bdecfb-7008-4cab-8d44-1a646906eec8">13.8</ix:nonFraction>&#160;million shares of Arcus, which represented approximately <ix:nonFraction unitRef="number" contextRef="i2a3b8026d52f4290b417e3f5e019a0ff_I20210331" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF80Mzk4MDQ2NTYyNzI4_f70f23ff-8f28-4df8-a397-205e2ae26a45">19.5</ix:nonFraction>% of the issued and outstanding voting stock of Arcus immediately following the closing of the transaction. We recorded our equity investments in Arcus in Other long-term assets on our Condensed Consolidated Balance Sheets as the investments are subject to contractual lock-up provisions, subject to certain conditions. We account for our equity investments in Arcus at fair value with changes in fair value recognized in Other income (expense), net on our Condensed Consolidated Statements of Income for each reporting period. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Stock Purchase Agreements, we have the right to purchase additional shares of Arcus from Arcus over the <ix:nonNumeric contextRef="i8e3646c5f44b457faaf84b163f791ffc_D20200527-20200527" format="ixt-sec:durwordsen" name="gild:EquitySecuritiesFVNIPurchasePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF85ODk1NjA0NzA0MDQy_d7489cf6-2c8b-4baa-926a-bbf5d2fc6ec7">five year</ix:nonNumeric> period beginning on the closing of the Stock Purchase Agreements, up to a maximum of <ix:nonFraction unitRef="number" contextRef="i9a6c487393e2416988fed705f84d74ee_D20200527-20200527" decimals="2" name="gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF80Mzk4MDQ2NTU4MDgw_849166ad-312c-44f4-baf5-17c1e85d7c2d">35</ix:nonFraction>% of the outstanding voting stock. We are subject to a <ix:nonNumeric contextRef="i8e3646c5f44b457faaf84b163f791ffc_D20200527-20200527" format="ixt-sec:durwordsen" name="gild:EquitySecuritiesFVNIRestrictionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF85ODk1NjA0NzA0MDQz_71cafa10-5022-47be-939f-c6f3d417fd28">three year</ix:nonNumeric> standstill, which period began on the date the parties entered into the Stock Purchase Agreements, restricting our ability to acquire voting stock of Arcus exceeding more than <ix:nonFraction unitRef="number" contextRef="i9a6c487393e2416988fed705f84d74ee_D20200527-20200527" decimals="2" name="gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF80Mzk4MDQ2NTU4MjM0_849166ad-312c-44f4-baf5-17c1e85d7c2d">35</ix:nonFraction>% of the then issued and outstanding voting stock of Arcus, subject to certain exceptions. Additionally, we agreed not to dispose of any equity securities of Arcus prior to the second anniversary of the closing of the Stock Purchase Agreements without the prior consent of Arcus, subject to certain exceptions. The amendment and restatement of the common stock purchase agreement in the first quarter of 2021 did not modify any of these terms. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibdcc1e1526204225bc7f871e9218f8f1"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Arrangements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021 and 2020, we entered into several collaborations, equity investments and licensing arrangements as well as other similar arrangements that we do not consider to be individually material. We recorded upfront collaboration expenses related to these arrangements of $<ix:nonFraction unitRef="usd" contextRef="if5fa445c6c284cf389eb387244e326c3_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="gild:UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF8xNjQ5MjY3NDU3MTI4_116c3fb9-f5fb-4b55-9d02-e347c129593d">62</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie247b2a21d0b41a8936b62106a17ef12_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="gild:UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF80Mzk4MDQ2NTUxOTc3_eee563e2-0741-4be9-a76e-77020ec87d4d">97</ix:nonFraction> million for the three months ended March 31, 2021 and 2020, respectively, within Acquired in-process research and development expenses on our Condensed Consolidated Statements of Income. Cash payments made related to our equity investments were $<ix:nonFraction unitRef="usd" contextRef="if5fa445c6c284cf389eb387244e326c3_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="gild:CashPaymentsMadeRelatedToEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF80Mzk4MDQ2NTUyMDIy_5e0d1100-e118-469d-a024-c67de542f9c5">59</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie247b2a21d0b41a8936b62106a17ef12_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="gild:CashPaymentsMadeRelatedToEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF80Mzk4MDQ2NTUyMDMz_ef0f76c7-130a-473b-a4a2-9b6480f11d6d">8</ix:nonFraction> million for the three months ended March 31, 2021 and 2020, respectively, which were primarily recorded in Other long-term assets on our Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the financial terms of these arrangements, we may be required to make payments upon achievement of developmental, regulatory and commercial milestones, which could be significant. Future milestone payments, if any, will be reflected in our Condensed Consolidated Statements of Income when the corresponding events become probable. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurrence.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i5e8b0e18419843159ec07e1b794d0d87_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RleHRyZWdpb246NTNlYTE3Mjc0OWU2NDk0YmFjNDM3NGU0MWFjNmU4ZTdfNTA2MQ_44e70e10-3092-426d-8c6e-f1ea5a6182d7" continuedAt="ia1df649f7f5b43d9b7f2751ca17bc420" escape="true">DEBT AND CREDIT FACILITIES</ix:nonNumeric></span></div><ix:continuation id="ia1df649f7f5b43d9b7f2751ca17bc420"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RleHRyZWdpb246NTNlYTE3Mjc0OWU2NDk0YmFjNDM3NGU0MWFjNmU4ZTdfNTA2MA_45a9db6b-ef64-4065-9505-98c7b71c379b" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of our borrowings under various financing arrangements:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id981d1fa90ad4e34a3646bf93d286389_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNC00LTEtMS0w_66d23960-ed97-4ff6-8222-7044a3914602">4.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id981d1fa90ad4e34a3646bf93d286389_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNC02LTEtMS0w_b853b366-e466-4d8d-9c13-6bdd97a42a38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddf64755f5544f55a023159b39cd796c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNC04LTEtMS0w_b2c109dc-5c6c-4fa4-94cd-eb24edaed471">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + <ix:nonFraction unitRef="number" contextRef="i5ef8f9839275426e96e11272486fcf64_D20210101-20210331" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNS00LTEtMS0wL3RleHRyZWdpb246MjZiNjVlNzM5NmY5NDE4MTg5NTM2ZTUwYzQwZGFmMTVfMjA_abaaa2da-51e8-4dd6-aa4e-ef5dd7d8e07e">0.15</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i226f19faf322425f8f45de6324e4ddcc_I20210331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNS02LTEtMS0w_59145635-7fb5-4fe8-825d-22c654b7240b">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0682f9735fe421db3f9c49bed1595fe_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNS04LTEtMS0w_2ba67912-feeb-4a1e-af1a-f6b4a05d9a78">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e07919b5c964bd1a6f6261698386d5a_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNi00LTEtMS0w_d5c61b60-2b58-48b9-829c-b1ff46d58df2">4.40</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e07919b5c964bd1a6f6261698386d5a_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNi02LTEtMS0w_e3b03a3b-a7cc-4f24-a50a-50aacb17cd00">1,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie96a1150c9f54ebbb4aeeeac86d5d0b4_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNi04LTEtMS0w_f0726e64-056b-4f7c-bc2d-f188bed88f4e">1,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4560703e7e434329b08f919b7ec93556_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNy00LTEtMS0w_6110554d-62f1-4ca1-9ec0-8fe7343bdcb9">1.95</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4560703e7e434329b08f919b7ec93556_I20210331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNy02LTEtMS0w_dd1d5d95-2993-435a-b639-1dd2c9f88aa9">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d7b8c0c53ce4856b17e0c17548ab01b_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNy04LTEtMS0w_624cc6c0-2d5f-4821-9fb8-d9b67a343a69">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i42ab2dc4d1f3427799326322503aeb9f_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfOC00LTEtMS0w_079caba6-7b9f-430f-a2aa-d363f4908256">3.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42ab2dc4d1f3427799326322503aeb9f_I20210331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfOC02LTEtMS0w_cf619de8-4d04-494b-a8fd-53a8d0c92f21">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e00b7d5eead42bcba3eb2cf1ac7ef4e_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfOC04LTEtMS0w_91e68a58-a9ad-4cdf-9010-58c6fc493425">998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i31c5d5f5c24240f88a2fbf3010130c04_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfOS00LTEtMS0w_6f065a6a-56e4-462d-ae9f-88c16d2fa591">2.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c5d5f5c24240f88a2fbf3010130c04_I20210331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfOS02LTEtMS0w_bd6542bf-4685-4ef1-973a-653987bb7d53">748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a5500ac6a4a40b4a0ce85e93cb1be81_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfOS04LTEtMS0w_2925cc12-9db2-4e6d-aeda-b6486d3d3ae3">748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + <ix:nonFraction unitRef="number" contextRef="i84c7098c5f6942d6aafc60e537b25ace_D20210101-20210331" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTAtNC0xLTEtMC90ZXh0cmVnaW9uOmNlZjRhYjNiZTE5NzQ4NDI5YjQ0NjVjMzQ2OWM3MTUwXzIw_dfd0bebc-49f1-4bc3-a8e8-fc81d25a92b2">0.52</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d84c0793a654adc835292e4057e62af_I20210331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTAtNi0xLTEtMA_536f79ae-a382-414d-9152-e37871fbaa75">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc91e8dffffa4c25b54f3376c5704709_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTAtOC0xLTEtMA_42db4fc1-dda8-449a-9e45-8b8ddf9818b5">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b064cf950804b14bb98c71681dbbe38_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTEtNC0xLTEtMA_7e6f48d7-5bf4-4021-97f0-af1e53564690"><ix:nonFraction unitRef="number" contextRef="i7b064cf950804b14bb98c71681dbbe38_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTEtNC0xLTEtMA_c85dd233-9f86-46cc-87e4-7006ce2fd2ca">0.75</ix:nonFraction></ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b064cf950804b14bb98c71681dbbe38_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTEtNi0xLTEtMA_d0614edc-7068-4b24-8e7f-0b61a37d2c95">1,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1cfc9d0baa34e13b8b793bd53072677_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTEtOC0xLTEtMA_d8518a12-56f3-4d11-8b61-72337dcf7cf0">1,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">variable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5caff279b30742e699b0222a2e09750d_I20210331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTItOC0xLTEtMjAyMw_30aac413-4ba7-4e7d-8d5e-5be616583aa9">748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f01ef44785a49f0bc8f3ed2a594041b_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTItMTAtMS0xLTIwMjM_08a953c7-389e-4faf-888e-50ef30c54612">998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i82712a6fb96b40d1ba7af885131644a8_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTItNC0xLTEtMA_9452cae4-f745-4097-b48c-139a65a8a065">3.70</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82712a6fb96b40d1ba7af885131644a8_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTItNi0xLTEtMA_90d4be5c-f1fa-4c66-aef6-decf8d9a00a4">1,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02153ca61e2240f8a5f4caff17673c80_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTItOC0xLTEtMA_8452d44a-9441-42b4-9e2d-bfafbfab56ab">1,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd2dbc82577249dda35b4d5bf8355af9_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTMtNC0xLTEtMA_3f981ad1-60e7-4b46-ac5e-c4a41f986333">3.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd2dbc82577249dda35b4d5bf8355af9_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTMtNi0xLTEtMA_76ee837a-8a45-49f5-a88e-7fff68846f41">1,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie93b3397067946b99b504b92e01bc73e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTMtOC0xLTEtMA_5777c0ad-3a5f-442a-a297-9de6065f9acd">1,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie111efaeb3a5493fb1836bdd7dd01efa_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTQtNC0xLTEtMA_0ae17ea5-c560-4001-846c-b53c2e316866">3.65</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie111efaeb3a5493fb1836bdd7dd01efa_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTQtNi0xLTEtMA_e5ccc906-6671-4899-9aee-4a4e383a823a">2,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37798ead586444438d3256c1b09bc74c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTQtOC0xLTEtMA_a0be197a-c1e6-46ff-94b6-fe7c1f1d0ea1">2,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ab5e1d8ed5a4d4ebb33b172197fddbc_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTUtNC0xLTEtMA_189541da-8d01-4ac9-9a9b-81a666486629">2.95</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ab5e1d8ed5a4d4ebb33b172197fddbc_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTUtNi0xLTEtMA_00fc2a8b-b09e-443a-b9b7-3514b8203d1c">1,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cc4906eaff642878b6f94791e6e1015_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTUtOC0xLTEtMA_29505306-70d5-4ea6-9e58-cae9d57342c0">1,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41f044c9e0ca469e8e21f44e347cf6f3_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTYtNC0xLTEtMA_3f7299ff-d97f-406c-8e79-8e43ddda4e0e"><ix:nonFraction unitRef="number" contextRef="i41f044c9e0ca469e8e21f44e347cf6f3_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTYtNC0xLTEtMA_57e93a67-af39-4c59-aa90-9cc35cb1b6cf">1.20</ix:nonFraction></ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f044c9e0ca469e8e21f44e347cf6f3_I20210331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTYtNi0xLTEtMA_f6008f65-229b-4bd6-9303-0d56134cc140">746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia277d47a2bbd47a4bda96e51633f0028_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTYtOC0xLTEtMA_eb64f955-a923-4b93-a14f-fa91fb794ef7">745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i06b11f61f1c147e092d508e568092b9d_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTctNC0xLTEtMA_608b468b-036e-4056-9e5f-ef290c86ca79"><ix:nonFraction unitRef="number" contextRef="i06b11f61f1c147e092d508e568092b9d_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTctNC0xLTEtMA_69885d63-a034-4807-a08a-eda7cac65504">1.65</ix:nonFraction></ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b11f61f1c147e092d508e568092b9d_I20210331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTctNi0xLTEtMA_304d81df-e18d-49e6-b586-3216a5974eae">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0607a5570b824496986ded1619166b26_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTctOC0xLTEtMA_187c70e9-3f6e-47c2-b94e-49592bf953ae">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1bb341107e2a4b88b6060a86a8e386e2_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTgtNC0xLTEtMA_86d3393c-5946-4467-8a4a-04627d66fa42">4.60</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bb341107e2a4b88b6060a86a8e386e2_I20210331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTgtNi0xLTEtMA_35c903f4-fccf-4b8e-9175-af5a83ef966f">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i649ba66e7c7f4344a91edbb3d0ed8c94_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTgtOC0xLTEtMA_00f2f230-efc4-4a6d-89cd-aa45c21a39e9">991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2036</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i461c85d95d204d8b9943c1284aed4e98_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTktNC0xLTEtMA_ea7aa8a1-cd89-4e13-93e2-c650864b221e">4.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461c85d95d204d8b9943c1284aed4e98_I20210331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTktNi0xLTEtMA_ad5f158b-2a18-4101-a1e3-28005f119b61">742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic58ce72e2e4849669af1178aea5ff019_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTktOC0xLTEtMA_617e841c-07ed-45df-928e-7e947dd5d70b">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iefd9e7139a3441e891c9c8d8134e4c6d_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjAtNC0xLTEtMA_50d80719-12d4-4b0c-a5b7-b3d9a6c260c6"><ix:nonFraction unitRef="number" contextRef="iefd9e7139a3441e891c9c8d8134e4c6d_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjAtNC0xLTEtMA_e9495cc4-d7fb-4119-8bdf-1fdca4775612">2.60</ix:nonFraction></ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefd9e7139a3441e891c9c8d8134e4c6d_I20210331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjAtNi0xLTEtMA_812e8f77-898a-4b4b-960a-4fdd7ddd58da">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5e44c87f514190914febaeb7ea34b2_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjAtOC0xLTEtMA_4e90bbef-ccdb-4f40-9c9a-986d358dc167">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6bb3588ac15b409787bad99b65f13969_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjEtNC0xLTEtMA_9284187e-42df-4f3e-b468-78c0d4fb90a4">5.65</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bb3588ac15b409787bad99b65f13969_I20210331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjEtNi0xLTEtMA_59823b79-62af-48c6-94c5-93a758bc6945">996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id64726640cdc49ae9944b3cafdf07c69_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjEtOC0xLTEtMA_e0bd70cd-1a98-4111-a582-b615b01792fe">996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2044</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7030cc99c6824dc0a8042a4bed018068_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjItNC0xLTEtMA_f190c5a0-1225-4f1b-bfc3-edef9d5cb948">4.80</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7030cc99c6824dc0a8042a4bed018068_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjItNi0xLTEtMA_be0f43e2-d467-4cc6-9527-4fbc5ab67a8e">1,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5dfe2f629c047abb4f613b421c5ea88_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjItOC0xLTEtMA_8d92eafa-909f-44b4-8b70-ba141085ab55">1,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idaf8c9742e0b4ece8d7b8394db2ca224_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjMtNC0xLTEtMA_44079ef8-a613-47a2-977b-b744075ea33a">4.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaf8c9742e0b4ece8d7b8394db2ca224_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjMtNi0xLTEtMA_2ed0dcb2-a1a3-4f43-813f-177f31741f65">1,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aa69e4a48d34c5da5aab157a2293340_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjMtOC0xLTEtMA_cef56b93-ddc9-4cf3-8327-a1ee4f03a603">1,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2046</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i65459f3f8cdf4c0fbca4efc6938b38e0_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjQtNC0xLTEtMA_4c5d120f-81eb-410e-8fcd-7ca83aa42ca9">4.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65459f3f8cdf4c0fbca4efc6938b38e0_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjQtNi0xLTEtMA_9f6acf5c-895e-4e8a-a629-79eb08be9f2f">2,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7771d37672d44616baa7902fe05821c9_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjQtOC0xLTEtMA_45c98e23-cfa2-46d8-8ddc-3e18b3b99e1c">2,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2047</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1e2b6e7d9810413789463933aef23466_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjUtNC0xLTEtMA_a5113a7d-3e3e-4ea2-bd32-9dec3a720544">4.15</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e2b6e7d9810413789463933aef23466_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjUtNi0xLTEtMA_11c9d113-d760-4b82-9780-bd682b349956">1,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae31ed5d6fdc4498b6a90dbfc8b86b3a_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjUtOC0xLTEtMA_fae7ab97-c52f-4264-9278-d9682e4eaff3">1,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia4e384c2073a40b39d85efcab4bf3ee9_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjYtNC0xLTEtMA_6bfbac93-035d-4358-8ba2-f598625889c8"><ix:nonFraction unitRef="number" contextRef="ia4e384c2073a40b39d85efcab4bf3ee9_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjYtNC0xLTEtMA_b630c41f-180f-4543-a374-61ba444d697f">2.80</ix:nonFraction></ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e384c2073a40b39d85efcab4bf3ee9_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjYtNi0xLTEtMA_7f02984f-f548-41a0-b061-0c333f3247a6">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81921ac030614d4f83c0267cd19a94f9_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjYtOC0xLTEtMA_3aa13df9-ada1-4f21-808c-c9afcf59bc8a">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total senior unsecured notes and term loan facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id10bca8646004217ad83ef4814b3a4a9_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjctNi0xLTEtMA_eebad571-883f-453c-ac52-8d40b9b76fef">29,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie72718e6c6b44809858a4b6a4ec81ed3_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjctOC0xLTEtMA_f1a27f73-16fb-4b28-831e-7561847ef826">30,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3dbd1bb43e241408c3dee0863ca9f87_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjctOC0xLTEtMjA3Mg_59a84f01-ef31-45ed-aa77-eca9ecf68a39">1,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9b223edf7794782b8bfe9faef909258_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjctMTAtMS0xLTIwNzI_a6e58b69-f5f8-4244-af93-d963da2bde2d">1,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjgtOC0xLTEtMjA3Mg_59a3c3ba-75bd-4e84-aef3-19f87342bd7b">30,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjgtMTAtMS0xLTIwNzI_f336bb8d-0f24-411c-b7ed-7af72ac982e8">31,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: current portion of long-term debt and other obligations, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjgtNi0xLTEtMA_d4839ca2-e8ce-424b-830c-4c130b96ec75">2,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjgtOC0xLTEtMA_d6ab8526-4812-4750-a653-21eead48ae5f">2,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total long-term debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjktNi0xLTEtMA_ecd91c01-a467-4f61-92aa-70ff3212791f">27,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjktOC0xLTEtMA_7b8e3489-3f2b-4498-a5d9-856d5d98cf81">28,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, we repaid $<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RleHRyZWdpb246NTNlYTE3Mjc0OWU2NDk0YmFjNDM3NGU0MWFjNmU4ZTdfMTA5OTUxMTY0MDYzOQ_d26f18d7-a0c2-474f-8321-8456f10adf21">1.25</ix:nonFraction> billion of debt. In January 2021, we repaid $<ix:nonFraction unitRef="usd" contextRef="i608d56f7947f4ed8a1369997dcdee599_D20210101-20210131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfUnsecuredDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RleHRyZWdpb246NTNlYTE3Mjc0OWU2NDk0YmFjNDM3NGU0MWFjNmU4ZTdfMTY0OTI2NzQ1MzY1OQ_312e956e-6f38-4c1e-b643-6d6d6990fed1">1.0</ix:nonFraction> billion of senior unsecured notes prior to the April 2021 maturity, by exercising a 3-month par call. In March 2021, we repaid $<ix:nonFraction unitRef="usd" contextRef="i5e2e8987386644709b5eece8fb454a57_D20210301-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfUnsecuredDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RleHRyZWdpb246NTNlYTE3Mjc0OWU2NDk0YmFjNDM3NGU0MWFjNmU4ZTdfMTY0OTI2NzQ1MzY3Nw_0f3871c6-af9d-4850-8a23-38a98a01da00">250</ix:nonFraction> million principal amount under our <ix:nonNumeric contextRef="i5e2e8987386644709b5eece8fb454a57_D20210301-20210331" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RleHRyZWdpb246NTNlYTE3Mjc0OWU2NDk0YmFjNDM3NGU0MWFjNmU4ZTdfOTg5NTYwNDY2MjYxMg_be6239ef-e509-4503-8a1a-cdfee0cd49fd">three-year</ix:nonNumeric> $<ix:nonFraction unitRef="usd" contextRef="i970db95a26094960bfc48e49693d580f_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RleHRyZWdpb246NTNlYTE3Mjc0OWU2NDk0YmFjNDM3NGU0MWFjNmU4ZTdfMTA5OTUxMTY0MDcyOQ_5e585c87-c51c-4709-8ddc-b43083405228">1.0</ix:nonFraction> billion senior unsecured term loan facility, leaving $<ix:nonFraction unitRef="usd" contextRef="i970db95a26094960bfc48e49693d580f_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RleHRyZWdpb246NTNlYTE3Mjc0OWU2NDk0YmFjNDM3NGU0MWFjNmU4ZTdfMTA5OTUxMTY0MDg2Ng_0e45bc89-007a-4398-8d5f-beb60eb977bb">750</ix:nonFraction> million principal amount outstanding as of March&#160;31, 2021. No new debt was issued during the three months ended March 31, 2021. We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of March&#160;31, 2021, we were in compliance with all covenants.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021 and December&#160;31, 2020, there were <ix:nonFraction unitRef="usd" contextRef="i16cafbaeadde42a9815b149e242ae829_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LineOfCredit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RleHRyZWdpb246NTNlYTE3Mjc0OWU2NDk0YmFjNDM3NGU0MWFjNmU4ZTdfMTY0OTI2NzQ0NzMxMA_90b2296d-e303-4b73-a189-c17ea7f47a5c"><ix:nonFraction unitRef="usd" contextRef="i7c3a790a1deb4b198ed2f54a96f31ccb_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LineOfCredit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RleHRyZWdpb246NTNlYTE3Mjc0OWU2NDk0YmFjNDM3NGU0MWFjNmU4ZTdfMTY0OTI2NzQ0NzMxMA_98b22a2a-fe1d-4f9a-a9cb-e5dcedbd8ff0">no</ix:nonFraction></ix:nonFraction> amounts outstanding under our $<ix:nonFraction unitRef="usd" contextRef="id6d3b14fdf7c4b5eb29edbe4dd41290f_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RleHRyZWdpb246NTNlYTE3Mjc0OWU2NDk0YmFjNDM3NGU0MWFjNmU4ZTdfMTY0OTI2NzQ0NzQxMw_09d1d164-6782-4d8b-abf1-f9467aeb625d">2.5</ix:nonFraction> billion revolving credit facility maturing in June 2025, and we were in compliance with all covenants.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i5e8b0e18419843159ec07e1b794d0d87_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMjM5NDM_4338666e-7d42-4ce1-9955-c34223dcd241" continuedAt="i08aac71c423e4a9d8c9ddadc96b22f6b" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i08aac71c423e4a9d8c9ddadc96b22f6b" continuedAt="ib7bd24e3a5a94685910ac8ccb7afa882"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions. The most significant of these are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. Unless otherwise noted, it is not possible to determine the outcome of these matters or the outcome (including in excess of any accrual) is not expected to be material, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any material accruals for the matters described below on our Condensed Consolidated Balance Sheets as of March&#160;31, 2021 and December&#160;31, 2020. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Sofosbuvir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, we acquired Pharmasset, Inc. Through the acquisition, we acquired sofosbuvir, a nucleotide analog that acts to inhibit the replication of the HCV. In 2013, we received approval from FDA for sofosbuvir, now known commercially as Sovaldi. Sofosbuvir is also included in all of our marketed HCV products. We have received a number of litigation claims regarding sofosbuvir. While we have carefully considered these claims both prior to and following the acquisition and believe they are without merit, we cannot predict the ultimate outcome of such claims or range of loss.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patents and patent applications owned by third parties that have been or may in the future be alleged by such parties to cover the use of our HCV products. If third parties obtain valid and enforceable patents, and successfully prove infringement of those patents by our HCV products, we could be required to pay significant monetary damages. We cannot predict the ultimate outcome of intellectual property claims related to our HCV products. We have spent, and will continue to spend, significant resources defending against these claims.</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with Idenix Pharmaceuticals, Inc. (&#8220;Idenix&#8221;), Universita Degli Studi di Cagliari (&#8220;UDSG&#8221;), Centre National de la Recherche Scientifique and L&#8217;Universit&#233; Montpellier II</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2013, Idenix and UDSG sued us in the U.S. District Court for the District of Massachusetts alleging that the commercialization of sofosbuvir infringes U.S. Patent Nos. 6,914,054 (the &#8220;&#8217;054 patent&#8221;) and 7,608,597 (the &#8220;&#8217;597 patent&#8221;). In 2014, the court transferred the Massachusetts litigation to the U.S. District Court for the District of Delaware. Prior to trial in 2016, Idenix committed to give us a covenant not to sue with respect to any claims arising out of the &#8217;054 patent related to sofosbuvir and withdrew that patent from the trial. We prevailed at all phases of litigation concerning the &#8217;597 patent, and in January 2021, the U.S. Supreme Court denied Idenix&#8217;s petition for review, making the judgment against Idenix final. </span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with the University of Minnesota</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The University of Minnesota (the &#8220;University&#8221;) has obtained U.S. Patent No. 8,815,830 (the &#8220;&#8217;830 patent&#8221;), which purports to broadly cover nucleosides with antiviral and anticancer activity. In 2016, the University filed a lawsuit against us in the U.S. District Court for the District of Minnesota, alleging that the commercialization of sofosbuvir-containing products infringes the &#8217;830 patent. We believe the &#8217;830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir. In 2017, the court granted our motion to transfer the case to California. We have also filed petitions for inter partes review with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (&#8220;PTAB&#8221;) alleging that all asserted claims are invalid for anticipation and obviousness. The PTAB instituted one of these petitions and a merits hearing was held in February 2021. In 2018, the U.S. District Court for the Northern District of California stayed the litigation until after the PTAB concludes the inter partes review that it has initiated, which we expect will occur in 2021.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with NuCana plc. (&#8220;NuCana&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NuCana has obtained European Patent No. 2,955,190 (the &#8220;EP &#8217;190 patent&#8221;) that allegedly covers sofosbuvir. In Opposition proceedings before the European Patent Office (&#8220;EPO&#8221;) held in February 2021, the EPO Opposition Division upheld the validity of the EP &#8217;190 patent in amended form. We believe that the amended EP &#8217;190 patent claims are invalid. Subsequently, we initiated proceedings to invalidate the UK counterpart of the EP &#8217;190 patent in the High Court of England &amp; Wales. In March 2021, NuCana filed a counterclaim against us in the High Court of England &amp; Wales alleging patent infringement of the UK counterpart and seeking damages and other relief. In April 2021, NuCana also filed a lawsuit against us in Germany at the Landgericht D&#252;sseldorf alleging patent infringement of the German counterpart of the EP &#8217;190 patent and seeking damages and relief.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib7bd24e3a5a94685910ac8ccb7afa882" continuedAt="ic7b3d776c49f4fdf813d4a79cbc64c02"><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Axicabtagene Ciloleucel</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#8220;Juno&#8221;) filed a lawsuit against us in the U.S. District Court for the Central District of California, alleging that the commercialization of axicabtagene ciloleucel, sold commercially as Yescarta, infringes on U.S. Patent No. 7,446,190 (the &#8220;&#8217;190 patent&#8221;). A jury trial was held on the &#8217;190 patent, and in December 2019, the jury found that the asserted claims of the &#8217;190 patent were valid, and that we willfully infringed the asserted claims of the &#8217;190 patent. The jury also awarded Juno damages in amounts of $<ix:nonFraction unitRef="usd" contextRef="id74ea6000e4640078ac1bb187f3e6b5c_D20191201-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTA5OTUxMTgyMzIyNA_db350480-35eb-462f-939f-2c93fe5df077">585</ix:nonFraction> million in an up-front payment and a <ix:nonFraction unitRef="number" contextRef="id74ea6000e4640078ac1bb187f3e6b5c_D20191201-20191231" decimals="3" name="gild:JudgmentRoyaltyRateFromOctober2017" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTA5OTUxMTgyMzIzNQ_1171d0b8-a1f0-47c8-b0b7-ae7836f5bfa0">27.6</ix:nonFraction>% running royalty from October 2017 through the date of the jury&#8217;s verdict. The parties filed post-trial motions in the first quarter of 2020, and the trial judge entered a judgment in April 2020. The trial judge affirmed the jury&#8217;s verdict, enhanced the past damages by <ix:nonFraction unitRef="number" contextRef="ibff1240b05f74e8bbf297b65247ec996_I20200430" decimals="2" name="gild:JudgmentEnhancedDamagesOnPastSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTA5OTUxMTgyMzI1Nw_aa493e67-4432-47d7-a286-d5dc94e858f5">50</ix:nonFraction>% and maintained the royalties on future Yescarta sales at <ix:nonFraction unitRef="number" contextRef="ibff1240b05f74e8bbf297b65247ec996_I20200430" decimals="3" name="gild:JudgmentRoyaltyRateOnFutureSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTA5OTUxMTgyMzI0NA_5c4c3507-88a5-4247-a65a-1597f27ef9aa">27.6</ix:nonFraction>%. In April 2020, we filed an appeal seeking to reverse the judgment or obtain a new trial due to errors made by the trial judge.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing whether we should accrue a liability for this litigation in our Condensed Consolidated Financial Statements, we considered various factors, including the legal and factual circumstances of the case, the jury&#8217;s verdict, the district court&#8217;s pre- and post-trial orders, the current status of the proceedings, applicable law, the views of legal counsel and the likelihood that the judgment will be upheld on appeal. As a result of this review, we have determined, in accordance with applicable accounting standards, that it is not probable that we will incur a material loss as a result of this litigation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the judgment is reversed on appeal, the loss is expected to be <ix:nonFraction unitRef="usd" contextRef="i2516fe8e62b244c1b6bc3ae3b23fb48c_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTY0OTI2NzYzNzE1OA_a0876b49-d2da-4c60-9d39-ce530a1961f1">zero</ix:nonFraction>. If the judgment is upheld in its entirety on appeal, we estimate a loss through the first quarter of 2021 to be approximately $<ix:nonFraction unitRef="usd" contextRef="i43d6693463d944d28b68b70f837d5ae1_I20210331" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTY0OTI2NzYzNzE3Mw_f4b35ff8-69ef-45e6-843d-3bbade33baae">1.4</ix:nonFraction> billion, which consists primarily of (i) approximately $<ix:nonFraction unitRef="usd" contextRef="i7bf3308623744494a7125eb9515bdd4a_I20210331" decimals="-6" format="ixt:numdotdecimal" name="gild:LossContingencyEstimateOfPossibleLossPastSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTY0OTI2NzYzNzE5MA_fa03bd8b-dddf-4bcf-b56a-1b95147557e6">811</ix:nonFraction> million, which represents damages on Yescarta revenues through December 12, 2019, and prejudgment interest thereon, (ii) approximately $<ix:nonFraction unitRef="usd" contextRef="i7bf3308623744494a7125eb9515bdd4a_I20210331" decimals="-6" format="ixt:numdotdecimal" name="gild:LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTY0OTI2NzYzNzIwOA_56271423-79c2-402f-aced-6af9ea618f5f">389</ix:nonFraction> million, which represents a <ix:nonFraction unitRef="number" contextRef="ibff1240b05f74e8bbf297b65247ec996_I20200430" decimals="2" name="gild:JudgmentEnhancedDamagesOnPastSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTY0OTI2NzYzNzIxNA_aa493e67-4432-47d7-a286-d5dc94e858f5">50</ix:nonFraction>% enhancement of past damages and (iii) approximately $<ix:nonFraction unitRef="usd" contextRef="i7bf3308623744494a7125eb9515bdd4a_I20210331" decimals="-6" format="ixt:numdotdecimal" name="gild:LossContingencyEstimateOfPossibleLossRoyalties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTY0OTI2NzYzNzIyOQ_bee894b2-9872-48a2-b9a5-7927448b281d">225</ix:nonFraction> million for royalties on Yescarta revenues from December 13, 2019 to March&#160;31, 2021. The estimated loss does not include post-judgment interest on the foregoing, which is not estimated to be material as of March 31, 2021. Although we cannot predict with certainty the ultimate outcome of this litigation on appeal, we believe the jury&#8217;s verdict and the judgment to be in error. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Bictegravir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, ViiV Healthcare Company (&#8220;ViiV&#8221;) filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the commercialization of bictegravir, sold commercially in combination with tenofovir alafenamide and emtricitabine as Biktarvy, infringes ViiV&#8217;s U.S. Patent No. 8,129,385 (the &#8220;&#8217;385 patent&#8221;) covering ViiV&#8217;s dolutegravir. Bictegravir is structurally different from dolutegravir, and we believe that bictegravir does not infringe the claims of the &#8217;385 patent. The court has set a trial date of January 2022 for this lawsuit. ViiV is seeking billions of dollars for alleged damages comprised of ViiV&#8217;s lost profits and a royalty on sales of bictegravir from launch through the trial. ViiV calculates these damages based on the cumulative U.S. revenues from Biktarvy since launch, which have totaled $<ix:nonFraction unitRef="usd" contextRef="i190cbe2a2a9c446497a9e647b03a5b69_D20180207-20210331" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTA5OTUxMTgyMzExOQ_2eac2351-af2b-479b-94ce-9510d247deb5">12.9</ix:nonFraction> billion through March&#160;31, 2021. In addition, should a court find that we are liable for infringement, we expect ViiV will seek a royalty on sales after the trial. Although we cannot predict with certainty the ultimate outcome of this litigation, an adverse judgment could result in substantial monetary damages, including ViiV&#8217;s lost profits and royalties through trial, and a going-forward royalty stream on future sales. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, ViiV also filed a lawsuit against us in the Federal Court of Canada, alleging that our activities relating to our bictegravir compound have infringed ViiV&#8217;s Canadian Patent No. 2,606,282 (the &#8220;&#8217;282 patent&#8221;), which was issued to Shionogi &amp; Co. Ltd. and ViiV. The &#8217;282 patent is the compound patent covering ViiV&#8217;s dolutegravir. We believe that bictegravir does not infringe the claims of the &#8217;282 patent. In January 2020, the court held a summary trial to assess ViiV&#8217;s infringement allegations. In April 2020, the court determined that bictegravir does not infringe the claims of the &#8217;282 patent and dismissed the case. ViiV has appealed this decision. Argument on the appeal took place in April 2021, and a decision is expected in the second half of 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November and December 2019, ViiV filed lawsuits in France, Germany, Ireland and the UK asserting the relevant national designations of European Patent No. 3 045 206 (&#8220;EP &#8217;206&#8221;); in Australia asserting Australian Patent No. 2006239177; in Japan asserting Japanese Patent No. 4295353; and in Korea asserting Korean Patent Nos. 1848819 (&#8220;KR &#8217;819&#8221;) and 1363875. These patents all relate to molecules which ViiV claims would act as integrase inhibitors. We believe that bictegravir does not infringe the claims of any of ViiV&#8217;s patents. In 2019, we filed an opposition in the EPO requesting revocation of EP &#8217;206. The EPO hearing took place in January 2021, and the patent claims, which do not cover bictegravir, were maintained in amended form. Additionally, in 2020, we filed a petition in the Korean Intellectual Property Office requesting invalidation of KR &#8217;819. Following a trial, a tribunal of the Korean Intellectual Property Trial and Appeal Board found KR &#8217;819 to be invalid. In March 2021, ViiV appealed this decision. The court in Germany held a hearing on the issue of infringement in April 2021. In all jurisdictions, to the extent that the claims of ViiV&#8217;s patents are interpreted to cover bictegravir, we believe that those claims are invalid. We cannot predict the ultimate outcome of intellectual property claims related to bictegravir. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic7b3d776c49f4fdf813d4a79cbc64c02" continuedAt="i0cb34e566d234b0fbb85ec2c3f955aed"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Relating to Pre-Exposure Prophylaxis</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, &#8220;HHS Patents&#8221;) by PTAB. The HHS Patents are assigned to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of emtricitabine and tenofovir or TDF prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis (&#8220;PrEP&#8221;). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the sale of Truvada and Descovy for use as PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a breach of contract lawsuit against the U.S. federal government in the Court of Federal Claims, alleging violations of <ix:nonFraction unitRef="agreement" contextRef="ibee266afb5b04b4db218d2019292d0cd_I20200430" decimals="INF" format="ixt-sec:numwordsen" name="gild:LossContingencyMaterialTransferAgreementsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfOTg5NTYwNDg2MjYwNg_c125b14c-6bcd-46e2-a0af-a2b507595983">four</ix:nonFraction> material transfer agreements (&#8220;MTAs&#8221;) related to the research underlying the HHS Patents and a clinical trial agreement (&#8220;CTA&#8221;) by the U.S. Centers for Disease Control and Prevention related to PrEP research. Although we cannot predict with certainty the ultimate outcome of these litigation matters, we believe that the U.S. federal government breached the MTAs and CTA, that Truvada and Descovy do not infringe the HHS Patents and that the HHS Patents are invalid over prior art descriptions of Truvada&#8217;s use for PrEP and post-exposure prophylaxis as well because physicians and patients were using the claimed methods years before HHS filed the applications for the patents. A trial date for the lawsuit in the Court of Federal Claims has been set for June 2022, and a trial date for the lawsuit in the District Court of Delaware has been set for May 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Generic Manufacturers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the approval process for some of our products, FDA granted us a New Chemical Entity (&#8220;NCE&#8221;) exclusivity period during which other manufacturers&#8217; applications for approval of generic versions of our product will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (&#8220;ANDA&#8221;), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products earlier than their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product&#8217;s approval.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in December 2019, we received letters from Lupin Ltd., Apotex Inc., Shilpa Medicare Ltd., Sunshine Lake Pharma Co. Ltd., Laurus Labs, Natco Pharma Ltd., Macleods Pharma Ltd., Hetero Labs Ltd. and Cipla Ltd. (collectively, &#8220;generic manufacturers&#8221;) indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of certain of our tenofovir alafenamide (&#8220;TAF&#8221;)-containing products. Between them, these generic manufacturers seek to market generic versions of Odefsey, Descovy and Vemlidy. Some generic manufacturers have challenged the validity of <ix:nonFraction unitRef="patent" contextRef="i9e2d7de5386e4c88ab9f4aaa94c77fe9_D20191201-20191231" decimals="INF" format="ixt-sec:numwordsen" name="gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfOTg5NTYwNDg2MjU4Mg_2b4a3826-202f-4152-88fe-9f9946c4d5b4">four</ix:nonFraction> patents listed on the Orange Book and associated with TAF, while others have challenged the validity of <ix:nonFraction unitRef="patent" contextRef="i9e2d7de5386e4c88ab9f4aaa94c77fe9_D20191201-20191231" decimals="INF" format="ixt-sec:numwordsen" name="gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfOTg5NTYwNDg2NDI4Ng_dca9320f-2a6d-4953-8cd9-4162b13dffce">two</ix:nonFraction> of our Orange Book-listed patents associated with TAF. We filed lawsuits against the generic manufacturers, and we intend to enforce and defend our intellectual property.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Claims</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, several parties filed oppositions in the EPO requesting revocation of one of our granted European patents covering sofosbuvir that expires in 2028. In 2016, the EPO upheld the validity of certain claims of our sofosbuvir patent. We have appealed this decision, seeking to restore all of the original claims, and several of the original opposing parties have also appealed, requesting full revocation. The appeal hearing is scheduled for July 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to sofosbuvir that expires in 2024. The EPO conducted an oral hearing for this opposition in 2018 and upheld the claims. <ix:nonFraction unitRef="opposingparty" contextRef="ib51fb29ce69647fcba6f2f052669fbed_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="gild:LossContingencyPartiesAppealedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfOTg5NTYwNDg2MjU3Mw_994ab95d-08de-45e4-b439-fc582948f653">Two</ix:nonFraction> of the original opposing parties have appealed, requesting full revocation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, several parties filed oppositions in the EPO requesting revocation of our granted European patent covering TAF that expires in 2026. In 2017, the EPO upheld the validity of the claims of our TAF patent. <ix:nonFraction unitRef="opposingparty" contextRef="i5ae8970b904f49c99fc9ef1c33c59098_I20171231" decimals="INF" format="ixt-sec:numwordsen" name="gild:LossContingencyPartiesAppealedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfOTg5NTYwNDg2MjU2Mg_7bb11694-5eaa-42ad-b326-42bf45df97e9">Three</ix:nonFraction> parties have appealed this decision. The appeal hearing was held in March 2021, and the validity of all claims were upheld.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to TAF hemifumarate that expires in 2032. In 2019, the EPO upheld the validity of the claims of our TAF hemifumarate patent. <ix:nonFraction unitRef="opposingparty" contextRef="i0d4fda0dfd5c44b09d04f6e618870a0a_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="gild:LossContingencyPartiesAppealedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfOTg5NTYwNDg2MjU1MQ_089ce006-ed87-46ff-b8f9-367439248c95">Three</ix:nonFraction> parties have appealed this decision. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, <ix:nonFraction unitRef="party" contextRef="id9fd61e590a14210ba14b89a9af49a7a_D20160101-20161231" decimals="INF" format="ixt-sec:numwordsen" name="gild:LossContingencyPartiesFilingOppositionNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfOTg5NTYwNDg2MjUzMg_bbc42a23-b3eb-4a24-bffb-d545652c5111">three</ix:nonFraction> parties filed oppositions in the EPO requesting revocation of our granted European patent covering cobicistat that expires in 2027. In 2017, the EPO upheld the validity of the claims of our cobicistat patent. <ix:nonFraction unitRef="opposingparty" contextRef="i6905d9942f5a4f50abf9170409131c14_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="gild:LossContingencyPartiesAppealedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfOTg5NTYwNDg2MjU0Mg_ea8e452b-7285-4d91-8519-c924d808ffb9">Two</ix:nonFraction> parties have appealed this decision. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0cb34e566d234b0fbb85ec2c3f955aed" continuedAt="i9a74f38214b3481c8da2f1a37f705e0b"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The appeal process may take several years for all EPO opposition proceedings. While we are confident in the strength of our patents, we cannot predict the ultimate outcome of these oppositions. If we are unsuccessful in defending these oppositions, some or all of our patent claims may be narrowed or revoked and the patent protection for sofosbuvir, TAF, TAF hemifumarate and cobicistat in the European Union could be substantially shortened or eliminated entirely. If our patents are revoked, and no other European patents are granted covering these compounds, our exclusivity may be based entirely on regulatory exclusivity granted by EMA. If we lose patent protection for any of these compounds, our revenues and results of operations could be negatively impacted for the years including and succeeding the year in which such exclusivity is lost.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust and Consumer Protection</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We (along with Japan Tobacco, Inc. (&#8220;Japan Tobacco&#8221;), Bristol-Myers Squibb Company (&#8220;BMS&#8221;) and Johnson &amp; Johnson, Inc.)) have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV, including drugs used in combination antiretroviral therapy. Japan Tobacco was dismissed from the lawsuit after a favorable court ruling on the defendants&#8217; motion to dismiss. Plaintiffs allege that we (and the other remaining defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been or may be consolidated, are all pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of two nationwide classes - one of direct purchasers consisting largely of wholesales, and another of end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we along with generic manufacturers Cipla Ltd. and Cipla USA Inc. (&#8220;Cipla&#8221;) were named as defendants in a class action lawsuit filed in the U.S. District Court for the Northern District of California by Jacksonville Police Officers and Fire Fighters Health Insurance Trust (&#8220;Jacksonville Trust&#8221;) on behalf of end-payor purchasers. Jacksonville Trust claims that the 2014 settlement agreement between us and Cipla, which settled a patent dispute relating to patents covering our Emtriva, Truvada, and Atripla products and permitted generic entry prior to patent expiry, violates certain federal and state antitrust and consumer protection laws. Plaintiffs seek damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we along with BMS and generic manufacturer Teva Pharmaceuticals USA were named as defendants in a lawsuit filed in the First Judicial District Court for the State of New Mexico, county of Santa Fe by the New Mexico Attorney General. The New Mexico Attorney General alleges that we (and the other defendants) restrained competition in violation of New Mexico state antitrust and consumer protection laws. In March 2021, we removed the case to the U.S. District Court for the District of New Mexico. The New Mexico Attorney General seeks damages and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages or could be subject to permanent injunctive relief awarded in favor of plaintiffs.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="i39c4711339df49138fdbd03e8ed2571a_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfOTg5NTYwNDg2MjUwMg_15022762-34b4-473f-b499-bab55f6ded64">two</ix:nonFraction> class action lawsuits and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to experience kidney, bone and/or tooth injuries. The lawsuits, which are pending in state or federal court in California, Delaware, Florida, New Jersey and Missouri, involve more than <ix:nonFraction unitRef="plaintiff" contextRef="i39c4711339df49138fdbd03e8ed2571a_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTA5OTUxMTgyMzY4MA_6cd64715-aa04-4b44-9f29-b5fdba772fc2">21,000</ix:nonFraction> plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Investigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="plaintiff" contextRef="i6e3291601bc74013bce40b293768f095_D20170801-20170831" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfOTg5NTYwNDg2MjQ5Mw_c4fa3687-a8b3-41d8-94ab-816c9f974217">Two</ix:nonFraction> former sales employees filed a qui tam lawsuit against Gilead in August 2017 in the U.S. District Court for the Eastern District of Pennsylvania. Following the government&#8217;s decision not to intervene in the suit, the relators served us with a Second Amended Complaint in November 2019. The lawsuit alleges that Gilead&#8217;s HBV speaker programs and advisory boards violated the federal False Claims Act and various state false claims acts. The relators seek all available relief under these statutes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Another former sales employee also filed a qui tam lawsuit against Gilead in March 2017 in U.S. District Court for the Eastern District of Pennsylvania. Following the government&#8217;s decision not to intervene in the suit, the relator served us with a Second Amended Complaint in January 2021. The lawsuit alleges that Gilead&#8217;s HCV patient access programs, clinical educator programs, speaker programs, and other sales and marketing programs violated the federal False Claims Act and various state false claims acts. The relator seeks all available relief under these statutes.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9a74f38214b3481c8da2f1a37f705e0b"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="plaintiff" contextRef="ic57a1e59e1024277b33535c08ac1107b_D20200401-20200430" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfOTg5NTYwNDg2MzM5Ng_90e31b62-415d-43a7-9c50-4c1ec7c31c6a">Two</ix:nonFraction> former employees filed a qui tam lawsuit against Gilead in April 2020 in California state court. These same former employees had previously filed a qui tam lawsuit in federal court in California and the U.S. Department of Justice declined intervention and moved to dismiss relators&#8217; federal False Claims Act claims. Relators subsequently voluntarily dismissed their federal lawsuit and refiled their lawsuit in California state court. Following the California Attorney General&#8217;s Office&#8217;s decision not to intervene, relators served Gilead with their complaint in August 2020. The complaint alleges violations of the California False Claims Act (&#8221;CFCA&#8221;) and employment law claims. Relators seek all available relief under the CFCA.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice Advocates, LLC (&#8220;Health Choice&#8221;) filed a qui tam lawsuit against Gilead in April 2020 in New Jersey state court. Following the New Jersey Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in August 2020. The lawsuit alleges that Gilead violated the New Jersey False Claims Act through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the New Jersey False Claims Act. In April 2021, the trial court granted our motion to dismiss with prejudice.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice filed another qui tam lawsuit against Gilead in May 2020 making similar allegations in Texas state court. Following the Texas Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in October 2020. The lawsuit alleges that Gilead violated the Texas Medicare Fraud Prevention Act (&#8220;TMFPA&#8221;) through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the TMFPA.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcomes. If any of these plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunomedics and several of its former officers and directors have been named as defendants in putative class actions filed in 2018 and 2019. The lawsuits were consolidated in September 2019, and plaintiffs filed a consolidated complaint in November 2019. Plaintiffs allege that Immunomedics and the individual defendants violated the federal securities laws in connection with Immunomedics&#8217; Biologics License Application for Trodelvy, and seek certification of a class of shareholders, damages and other relief. The consolidated lawsuit is pending in the United States District Court for the District of New Jersey. While we believe this case is without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that these other legal actions will have a material adverse impact on our consolidated business, financial position or results of operations.</span></div></ix:continuation><div id="i5e8b0e18419843159ec07e1b794d0d87_64"></div><div style="margin-top:13.5pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RleHRyZWdpb246YWJkNDcxNjRhM2RhNDVlM2I5ZGEwMTNlZjM5ZWY0M2NfMTYxOA_4391a7d2-26d5-433a-9d52-95d40c8ccead" continuedAt="ib3bb682a17e94d9d85a70ca19f56bd86" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="ib3bb682a17e94d9d85a70ca19f56bd86" continuedAt="i2ba331422a694b8e959f7ce66fbc303d"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Repurchase Programs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2016, our Board of Directors authorized a $<ix:nonFraction unitRef="usd" contextRef="i891c637afe3247688741c781d552db7a_I20160331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RleHRyZWdpb246YWJkNDcxNjRhM2RhNDVlM2I5ZGEwMTNlZjM5ZWY0M2NfMTA0_93383c51-435d-4b2a-9487-eee902826b64">12.0</ix:nonFraction> billion stock repurchase program (&#8220;2016 Program&#8221;) under which repurchases may be made in the open market or in privately negotiated transactions. We started repurchases under the 2016 Program in April 2016. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, our Board of Directors authorized a new $<ix:nonFraction unitRef="usd" contextRef="i4e485618ab80414bb2d0af91dc1e3dde_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RleHRyZWdpb246YWJkNDcxNjRhM2RhNDVlM2I5ZGEwMTNlZjM5ZWY0M2NfMzU3_03011d68-f651-4e81-9202-65521c3e58d7">5.0</ix:nonFraction> billion&#160;stock repurchase program (&#8220;2020 Program&#8221;), which will commence upon the completion of the&#160;2016 Program. Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021 and 2020, we repurchased and retired <ix:nonFraction unitRef="shares" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RleHRyZWdpb246YWJkNDcxNjRhM2RhNDVlM2I5ZGEwMTNlZjM5ZWY0M2NfMTY0OTI2NzQ0MzQ3MA_f145facf-1fca-49dc-9e38-e58a68e52ef3">4.8</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RleHRyZWdpb246YWJkNDcxNjRhM2RhNDVlM2I5ZGEwMTNlZjM5ZWY0M2NfMTY0OTI2NzQ0MzQ3Nw_ebbd636c-3d3e-4d17-a88e-b91fffaf2cf8">18.7</ix:nonFraction> million shares of our common stock for $<ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RleHRyZWdpb246YWJkNDcxNjRhM2RhNDVlM2I5ZGEwMTNlZjM5ZWY0M2NfMTY0OTI2NzQ0MzQ4Mw_e632ad17-45bd-4064-bd93-7f63aadadfca">309</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RleHRyZWdpb246YWJkNDcxNjRhM2RhNDVlM2I5ZGEwMTNlZjM5ZWY0M2NfMTY0OTI2NzQ0MzQ5MA_1fbc4c46-30c7-4648-8fc7-40ced7de99c1">1.3</ix:nonFraction> billion, respectively, through open market transactions under the 2016 Program.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the remaining authorized repurchase amount under both programs was $<ix:nonFraction unitRef="usd" contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RleHRyZWdpb246YWJkNDcxNjRhM2RhNDVlM2I5ZGEwMTNlZjM5ZWY0M2NfODc5NjA5MzAyNDExNA_7546d6b0-ebd1-40d7-bca0-19a503345173">6.5</ix:nonFraction> billion.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2ba331422a694b8e959f7ce66fbc303d"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income</span></div><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RleHRyZWdpb246YWJkNDcxNjRhM2RhNDVlM2I5ZGEwMTNlZjM5ZWY0M2NfMTYwNg_6df6b650-ba86-4eb1-adb6-e84be551bd95" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in AOCI by component, net of tax:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90c7f28364e54993b67eae1023b738de_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMS0yLTEtMS0w_be037fda-fead-4451-ad31-e8bfc8575ca1">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i157cdc9a965446c9969cd003d367f516_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMS00LTEtMS0w_60eeac72-641c-4567-9ab7-8a024f4824eb">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i252e49a6c063428f959d1aefb1686cb7_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMS02LTEtMS0w_eeb17e99-1377-416b-8681-9d0ce4032d85">113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id315795d1e774a6a845a09bd3c23f669_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMS04LTEtMS0w_1dd71095-2d64-4cb8-a3c3-eeee25e825e0">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950fa40a56274ea0bb64105a4547be31_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMi0yLTEtMS0w_9536eb71-9976-431a-bed5-5c58c467a565">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i777694101d38407bb54ae3e8cd5cee81_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMi00LTEtMS0w_c10cd416-61b2-499f-92c6-a779fc653a42">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id773468e90654dd8b93c841e0cb1a4f1_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMi02LTEtMS0w_234fb14c-60ac-40e0-a875-d6ed38cebe03">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f56585e4ce041a0a4818371afd20608_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMi04LTEtMS0w_bbe505ea-1d2d-48b2-bc45-95c5d1c38aec">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950fa40a56274ea0bb64105a4547be31_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMy0yLTEtMS0w_1fe2c2d5-5343-48c5-8c61-f3320b944dc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i777694101d38407bb54ae3e8cd5cee81_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMy00LTEtMS0w_08250593-6a2b-4121-b91d-0f5db4a236c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id773468e90654dd8b93c841e0cb1a4f1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMy02LTEtMS0w_f74972c6-21cd-49b4-a5a7-17c8d76c7ae1">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f56585e4ce041a0a4818371afd20608_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMy04LTEtMS0w_922936fe-975e-49b6-bb0f-78d499100282">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950fa40a56274ea0bb64105a4547be31_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfNC0yLTEtMS0w_442534fd-b05d-40a8-b145-0860099939a2">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i777694101d38407bb54ae3e8cd5cee81_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfNC00LTEtMS0w_874a0098-cf5a-464b-9885-47154907ada2">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id773468e90654dd8b93c841e0cb1a4f1_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfNC02LTEtMS0w_d63a22d2-75ab-4d11-b3b6-b4d54c49c2f8">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f56585e4ce041a0a4818371afd20608_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfNC04LTEtMS0w_ea52c3e5-5f52-48ed-9917-19e87a03b90b">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a3340bf967422db6145ae553899ded_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfNS0yLTEtMS0w_46e7d534-e850-491a-a13a-3e0a670a47b8">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841123aefd8d43d8a410b8754e996cf9_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfNS00LTEtMS0w_7eb81692-69f4-4570-b532-26c27c4e4aa4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5050a35f97640609878001cc93224f3_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfNS02LTEtMS0w_fce385cc-a220-4a61-8eef-b77fe9ad0fe9">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideb5f8dc0c4442658f18eab50f25a677_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfNS04LTEtMS0w_80ee2ebf-e873-4218-b966-9fa57f588a2e">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:11pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d8ba4328011413291632383906e71c4_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMS0yLTEtMS0w_bbcdbbb4-617e-4532-b3de-5578a649da6a">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70187083484a4893bef3cc4b8f7bb49f_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMS00LTEtMS0w_b0243221-6c72-4db2-b57a-17aa0bfc56c3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01bc5741de984cbc967d805c30a354d1_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMS02LTEtMS0w_63f61294-bdb8-4327-a053-53d4ce44f7c5">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c7b9ebee1f549d198ceb53ea6813141_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMS04LTEtMS0w_d9781b8c-f74b-4198-b42e-53bf2f63beb5">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic65478d3665c420fb62c02fb229595b5_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMi0yLTEtMS0w_8f44492c-e1dc-45ca-9099-b7372ae4fad1">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8ecd1344d59495b906912f07829d102_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMi00LTEtMS0w_820d2d16-286e-4be4-89d5-86ab9dbc3717">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea5ded2b35d44d24932e27a42a2fd41d_D20200101-20200331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMi02LTEtMS0w_db2650ae-8451-42bf-8635-f8725489dbc9">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4dce18c9540c42d6ae4ba9bd85b66896_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMi04LTEtMS0w_58fa05c8-8ec7-4060-bf52-718c160324b2">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic65478d3665c420fb62c02fb229595b5_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMy0yLTEtMS0w_f830144f-8abe-42db-b523-ab83939d7dc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8ecd1344d59495b906912f07829d102_D20200101-20200331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMy00LTEtMS0w_898ffb0d-dbf2-4575-bcf6-5402c865d4a9">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea5ded2b35d44d24932e27a42a2fd41d_D20200101-20200331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMy02LTEtMS0w_654cc14e-e449-43b6-a48b-ffc4f4ca3b23">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4dce18c9540c42d6ae4ba9bd85b66896_D20200101-20200331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMy04LTEtMS0w_a24403f6-f724-4c7e-b492-61d63308dc2a">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic65478d3665c420fb62c02fb229595b5_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfNC0yLTEtMS0w_edf54034-bbd5-4db2-b17e-7c0cc4906e54">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8ecd1344d59495b906912f07829d102_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfNC00LTEtMS0w_cb24d851-42ad-4f95-93df-71f560b8947c">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea5ded2b35d44d24932e27a42a2fd41d_D20200101-20200331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfNC02LTEtMS0w_3f335a0b-bbf8-473f-96fc-469a511b5351">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4dce18c9540c42d6ae4ba9bd85b66896_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfNC04LTEtMS0w_15aa3e57-0418-447d-b4d2-78ef54d193d3">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55db8ffa0e8944bfb28e03d449bbd545_I20200331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfNS0yLTEtMS0w_e1a44c6c-68b5-4aa1-93d6-4a4f904460be">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie621feabbb3c4e7e89573dd30bc4a6a9_I20200331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfNS00LTEtMS0w_7f52f521-cfc9-4e61-880e-e87f09d33288">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1502d914c22f4785a00d85c5a6112310_I20200331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfNS02LTEtMS0w_b72c64c7-6b3e-41b4-9793-6dcc80efd9b4">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51b7741d7f0241a9a5987bf6c4f4f41c_I20200331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfNS04LTEtMS0w_ab22ac43-cd2d-460f-9e61-cdbd0fd78889">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts reclassified to net income for gains and losses on cash flow hedges are recorded as part of Product sales on our Condensed Consolidated Statements of Income. See Note 5. Derivative Financial Instruments for additional information. The amounts reclassified to net income for gains and losses on available-for-sale debt securities are recorded as part of Other income (expense), net on our Condensed Consolidated Statements of Income. Gross realized gains and losses on available-for-sale debt securities were not material for the three months ended March 31, 2021 and 2020. The income tax impact allocated to each component of other comprehensive income (loss) was not material for the periods presented.</span></div></ix:continuation><div id="i5e8b0e18419843159ec07e1b794d0d87_67"></div><div style="margin-top:13.5pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RleHRyZWdpb246ZTI2NzQ2MDBmMThiNGJlOTliY2RmZWI3ZDJjZDA1NjNfMTA3Nw_c00f55ed-bc31-407a-812d-4b72768194e0" continuedAt="ied50cee2d9e0446a86dc5c839b95c443" escape="true">NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS</ix:nonNumeric></span></div><ix:continuation id="ied50cee2d9e0446a86dc5c839b95c443"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share attributable to Gilead common stockholders is calculated based on the weighted average number of shares of our common stock outstanding during the period. Diluted net income per share attributable to Gilead common stockholders is calculated based on the weighted average number of shares of our common stock and other dilutive securities outstanding during the period. The potentially dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and equivalents were determined under the treasury stock metho</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential shares of common stock excluded from the computation of diluted net income per share attributable to Gilead common stockholders because their effect would have been antidilutive were <ix:nonFraction unitRef="shares" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RleHRyZWdpb246ZTI2NzQ2MDBmMThiNGJlOTliY2RmZWI3ZDJjZDA1NjNfODA1_e4e517d1-7abf-44fe-8fc7-8a4fbdb5b7c8">15</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RleHRyZWdpb246ZTI2NzQ2MDBmMThiNGJlOTliY2RmZWI3ZDJjZDA1NjNfODQ1_8f27e3bc-c2a6-4600-9c2a-83be38734490">14</ix:nonFraction> million, for the three months ended March 31, 2021 and 2020, respectively.</span></div><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RleHRyZWdpb246ZTI2NzQ2MDBmMThiNGJlOTliY2RmZWI3ZDJjZDA1NjNfMTA2OA_d69647d1-477f-4b20-a232-96e9570fe6ca" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the calculation of basic and diluted net income per share attributable to Gilead common stockholders:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.944%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfMy0yLTEtMS0w_10e882bf-6385-4a73-aced-c87aceefdcfb">1,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfMy00LTEtMS0w_60eb6653-2a1e-42fa-b3bc-f864e3b37e78">1,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfNC0yLTEtMS0w_d19ab1b8-0b2e-455e-91e5-c32c07e5c5ec">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfNC00LTEtMS0w_268e9f67-bfe9-4e60-aada-82ae05ea3500">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfNS0yLTEtMS0w_3c8a17d3-1ac6-4d8a-8d9b-45d1d5fb1d7f">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfNS00LTEtMS0w_3f278c78-979f-4558-a408-4ba8db1ca24e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfNi0yLTEtMS0w_6019ac81-85e4-4817-ada9-e43844116100">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfNi00LTEtMS0w_0bd47e82-ed7f-411f-9756-7e2637eb9f7d">1,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfOC0yLTEtMS0w_a2654a7b-059e-4993-ba09-4dc3d7951ea9">1.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfOC00LTEtMS0w_c29ef92a-ce5a-4d1f-9c12-9d87de5d715d">1.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfOS0yLTEtMS0w_8a558bff-3436-4104-8b6b-8a473594350b">1.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfOS00LTEtMS0w_20a09fa0-4927-4bfe-83dc-2d1d0c1d64ed">1.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i5e8b0e18419843159ec07e1b794d0d87_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RleHRyZWdpb246NDExYjk4YTRlN2I2NGFiM2JlZTAyNzBiMzgzMmMyMmJfMjQwMg_9aef0e05-ecf3-49b6-a697-391995c4ebf1" continuedAt="ib8e101adc41f447e99fae22d231a10ec" escape="true">INCOME TAXES </ix:nonNumeric></span></div><ix:continuation id="ib8e101adc41f447e99fae22d231a10ec"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RleHRyZWdpb246NDExYjk4YTRlN2I2NGFiM2JlZTAyNzBiMzgzMmMyMmJfMjM5NQ_20a91949-6545-453a-b3ff-9d7a4f204a0d" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our income tax expense:</span></div><div style="margin-bottom:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RhYmxlOjAwYzlhMzNjOGU3YjQ3NjdiMTI5YzMzZThmMjQ1YjA4L3RhYmxlcmFuZ2U6MDBjOWEzM2M4ZTdiNDc2N2IxMjljMzNlOGYyNDViMDhfMy0yLTEtMS0w_b942bcab-1ff0-4474-bbaa-52cc5468f9f6"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RhYmxlOjAwYzlhMzNjOGU3YjQ3NjdiMTI5YzMzZThmMjQ1YjA4L3RhYmxlcmFuZ2U6MDBjOWEzM2M4ZTdiNDc2N2IxMjljMzNlOGYyNDViMDhfMy0yLTEtMS0w_c9777f9a-f878-420b-820f-b321e78079a1">2,264</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RhYmxlOjAwYzlhMzNjOGU3YjQ3NjdiMTI5YzMzZThmMjQ1YjA4L3RhYmxlcmFuZ2U6MDBjOWEzM2M4ZTdiNDc2N2IxMjljMzNlOGYyNDViMDhfMy00LTEtMS0w_184ab219-dfdf-4bcb-b1d2-5efa84b0a24a"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RhYmxlOjAwYzlhMzNjOGU3YjQ3NjdiMTI5YzMzZThmMjQ1YjA4L3RhYmxlcmFuZ2U6MDBjOWEzM2M4ZTdiNDc2N2IxMjljMzNlOGYyNDViMDhfMy00LTEtMS0w_7ba11f38-6c28-492a-a952-d1d7f3eb11ea">2,003</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RhYmxlOjAwYzlhMzNjOGU3YjQ3NjdiMTI5YzMzZThmMjQ1YjA4L3RhYmxlcmFuZ2U6MDBjOWEzM2M4ZTdiNDc2N2IxMjljMzNlOGYyNDViMDhfNC0yLTEtMS0w_d1b97bb7-88cd-4b11-bb64-5011cf02b82f">542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RhYmxlOjAwYzlhMzNjOGU3YjQ3NjdiMTI5YzMzZThmMjQ1YjA4L3RhYmxlcmFuZ2U6MDBjOWEzM2M4ZTdiNDc2N2IxMjljMzNlOGYyNDViMDhfNC00LTEtMS0w_d1e7da64-5ce4-429a-9276-e3d404fd2381">465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RhYmxlOjAwYzlhMzNjOGU3YjQ3NjdiMTI5YzMzZThmMjQ1YjA4L3RhYmxlcmFuZ2U6MDBjOWEzM2M4ZTdiNDc2N2IxMjljMzNlOGYyNDViMDhfNS0yLTEtMS0w_d78fb845-bff4-4f01-91d1-84c20d389a2f">23.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RhYmxlOjAwYzlhMzNjOGU3YjQ3NjdiMTI5YzMzZThmMjQ1YjA4L3RhYmxlcmFuZ2U6MDBjOWEzM2M4ZTdiNDc2N2IxMjljMzNlOGYyNDViMDhfNS00LTEtMS0w_feea88ec-e6ba-4077-a992-d60cfdd06468">23.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate of <ix:nonFraction unitRef="number" contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RleHRyZWdpb246NDExYjk4YTRlN2I2NGFiM2JlZTAyNzBiMzgzMmMyMmJfMTQ4_d78fb845-bff4-4f01-91d1-84c20d389a2f">23.9</ix:nonFraction>% for the three months ended March 31, 2021 differed from the U.S. federal statutory rate of 21% primarily due to unfavorable changes in the fair value of our equity investment in Galapagos that are non-deductible for income tax purposes, partially offset by net discrete tax benefits related to settlements with taxing authorities.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate of <ix:nonFraction unitRef="number" contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RleHRyZWdpb246NDExYjk4YTRlN2I2NGFiM2JlZTAyNzBiMzgzMmMyMmJfOTQ2_feea88ec-e6ba-4077-a992-d60cfdd06468">23.2</ix:nonFraction>% for the three months ended March 31, 2020 differed from the U.S. federal statutory rate of 21% primarily due to the Global Intangible Low-Taxed Income tax, state taxes and our portion of the non-deductible branded prescription drug fee.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently under examination by the U.S. Internal Revenue Service for the tax years from 2016 to 2018 and by various state and foreign jurisdictions. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We regularly evaluate our exposures associated with our tax filing positions to determine our assessment of unrecognized tax benefits in accordance with the income tax guidance which clarifies the accounting for uncertainty in income taxes.</span></div></ix:continuation><div id="i5e8b0e18419843159ec07e1b794d0d87_1174"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTc0L2ZyYWc6ZTM4YzY4MGNmNWNkNGM4ZTllZjE2MzYwODg3MGExYTUvdGV4dHJlZ2lvbjplMzhjNjgwY2Y1Y2Q0YzhlOWVmMTYzNjA4ODcwYTFhNV85ODk1NjA0NjUwOTUz_c8280223-7005-4614-9bee-8a9b21a65f05" continuedAt="i00c129d5d3924fa7a00016614fe5cd07" escape="true">SUBSEQUENT EVENT</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i00c129d5d3924fa7a00016614fe5cd07">In April 2021, Gilead donated equity securities at fair value to the Gilead Foundation, a California nonprofit public benefit corporation (&#8220;Foundation&#8221;). The Foundation is a related party as certain officers of the Company also serve as directors of the Foundation. The donation expense of $<ix:nonFraction unitRef="usd" contextRef="i00cafa1b2c044278a85e4d45db30d3b1_D20210401-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTc0L2ZyYWc6ZTM4YzY4MGNmNWNkNGM4ZTllZjE2MzYwODg3MGExYTUvdGV4dHJlZ2lvbjplMzhjNjgwY2Y1Y2Q0YzhlOWVmMTYzNjA4ODcwYTFhNV80Mzk4MDQ2NTEyMDcw_a687ef81-fefd-4950-8790-2d9ccab0095e">206</ix:nonFraction> million will be recorded within Selling, general and administrative expenses on our Condensed Consolidated Statements of Income in the second quarter of 2021.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i5e8b0e18419843159ec07e1b794d0d87_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements regarding future events and our future results that are subject to the safe harbors created under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. The forward-looking statements are contained principally in this section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Risk Factors.&#8221; Words such as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;target,&#8221; &#8220;goal,&#8221; &#8220;project,&#8221; &#8220;hope,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;might,&#8221; and variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, any statements other than statements of historical fact are forward-looking statements, including statements regarding overall trends, operating cost and revenue trends, liquidity and capital needs, collaboration and licensing arrangements, ongoing litigation and investigation matters, statements regarding the anticipated future impact on our business of the ongoing coronavirus disease 2019 (&#8220;COVID-19&#8221;) and related public health measures, statements regarding the development, manufacturing and distribution of Veklury as a treatment for COVID-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> and other statements of expectations, beliefs, future plans and strategies, anticipated events or trends and similar expressions. We have based these forward-looking statements on our current expectations about future events. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Our actual results may differ materially from those suggested by these forward-looking statements for various reasons, including those identified below under Risk Factors. Given these risks and uncertainties, you are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements included in this report are made only as of the date hereof unless otherwise specified. Except as required under federal securities laws and the rules and regulations of the Securities and Exchange Commission, we do not undertake and specifically decline any obligation to update any of these statements or to publicly announce the results of any revisions to any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions or otherwise. In evaluating our business, you should carefully consider the risks described in the section entitled Risk Factors under Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020 and this Quarterly Report on Form 10-Q Part II, Item&#160;1A in addition to the other information in this Quarterly Report on Form&#160;10-Q. Any of the risks contained herein could materially and adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read the following management&#8217;s discussion and analysis of our financial condition and results of operations in conjunction with our audited Consolidated Financial Statements and related notes thereto included as part of our <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm">Annual Report on Form 10-K</a> for the year ended December&#160;31, 2020 and our unaudited Condensed Consolidated Financial Statements for the three months ended March 31, 2021 and other disclosures (including the disclosures under Part II, Item&#160;1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) included in this Quarterly Report on Form&#160;10-Q. Our Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles and are presented in U.S. dollars.</span></div><div id="i5e8b0e18419843159ec07e1b794d0d87_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT OVERVIEW</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. (&#8220;Gilead&#8221;, &#8220;we&#8221;, &#8220;our&#8221; or &#8220;us&#8221;) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of marketed products includes AmBisome</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Atripla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Biktarvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cayston</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Complera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/Eviplera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Descovy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Descovy for PrEP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Emtriva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Epclusa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Genvoya</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Harvoni</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Hepcludex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Bulevirtide), Hepsera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jyseleca</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Letairis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Odefsey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Ranexa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Sovaldi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Stribild</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tecartus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Truvada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Truvada for PrEP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tybost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Veklury</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vemlidy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Viread</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vosevi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Yescarta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zydelig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The approval status of Hepcludex and Jyseleca vary worldwide, and Hepcludex and Jyseleca are not approved in the United States. We also sell and distribute authorized generic versions of Epclusa and Harvoni in the United States through our separate subsidiary, Asegua Therapeutics, LLC. In addition, we sell and distribute certain products through our corporate partners under collaborative agreements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Highlights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oncology</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In March 2021, European Medicines Agency (&#8220;EMA&#8221;) validated the Marketing Authorization Application for sacituzumab govitecan-hziy for the treatment of metastatic triple-negative breast cancer (&#8220;mTNBC&#8221;).</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In April 2021, U.S. Food and Drug Administration (&#8220;FDA&#8221;) granted full approval of Trodelvy (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or mTNBC.</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In April 2021, FDA granted accelerated approval of Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer, a new indication.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In March 2021, FDA granted accelerated approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.</span></div><div style="margin-top:4.5pt;padding-left:11.25pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Viral Diseases</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.7pt">In March 2021, we completed the acquisition of MYR GmbH (&#8220;MYR&#8221;). The acquisition provides us with Hepcludex, which is conditionally approved by EMA for the treatment of chronic hepatitis delta virus (&#8220;HDV&#8221;) in adults with compensated liver disease.</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In March 2021, we entered into an agreement with Merck Sharp &amp; Dohme Corp (&#8220;Merck&#8221;), a subsidiary of Merck &amp; Co., Inc. to jointly develop and commercialize long-acting treatments in HIV that combine Gilead&#8217;s investigational capsid inhibitor, lenacapavir, and Merck&#8217;s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir.</span></div><div style="margin-top:4.5pt;padding-left:11.25pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.7pt">In April 2021, we announced we will provide assistance and support for expansion of local manufacturing capacity of remdesivir in India and donation of active pharmaceutical ingredient. In addition, we will donate a minimum of 450,000 vials of Veklury (remdesivir) to the government of India.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">______________________________________________________&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We announced and discussed these updates, subsequent to the issuance of our 2020 Annual Report on Form 10-K, in further detail in press releases available on our website at https://www.gilead.com/news-and-press/press-room/press-releases. Readers are also encouraged to review all other press releases available on our website mentioned above. Website references are provided throughout this document for convenience. The content on the referenced websites does not constitute a part of and is not incorporated by reference into this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Highlights</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages and per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues increased by 16% to $6.4 billion for the first quarter of 2021, compared to $5.5 billion for the same period in 2020, primarily due to Veklury sales.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to Gilead increased by 11% to $1.7 billion for the first quarter of 2021, compared to $1.6 billion for the same period in 2020. Diluted earnings per share increased 12% to $1.37 for the first quarter of 2021, compared to $1.22 for the same period in 2020. The increases from 2020 to 2021 were primarily due to revenue growth, partially offset by unfavorable changes in the fair value of our equity investments primarily in Galapagos NV (&#8220;Galapagos&#8221;) and lower interest income.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i5e8b0e18419843159ec07e1b794d0d87_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Revenues</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our revenues:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HIV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(12)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HCV</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(30)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">18%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cell Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">36%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(13)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,340&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,467&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">16%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">2%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 50.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,423&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,548&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">16%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">NM - Not Meaningful</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">For the first quarter of 2021 compared to the first quarter of 2020</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Total Product Sales</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total product sales increased by 16% to $6.3 billion for the first quarter of 2021, compared to $5.5 billion for the same period in 2020, primarily</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> due to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales of Veklury, our FDA-approved treatment for hospitalized patients with COVID-19. The first quarter of 2021 reflects growth in Cell Therapy, Trodelvy and hepatitis B virus (&#8220;HBV&#8221;)/hepatitis delta virus (&#8220;HDV&#8221;). We obtained Trodelvy through the acquisition of Immunomedics, Inc. (&#8220;Immunomedics&#8221;) in the fourth quarter of 2020. The increases were partially offset by lower HIV product sales primarily due to the continued generic competition following the October 2020 loss of exclusivity of Truvada and Atripla in the United States, in addition to higher channel inventory purchases in the first quarter of 2020 due to the COVID-19 pandemic. The decline in HCV sales was mainly driven by lower patient starts due to the continued impact of the pandemic.</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">HIV</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIV product sales decreased by 12% to $3.7 billion for the first quarter of 2021, compared to $4.1 billion for the same period in 2020. The decline was primarily due to the anticipated decline in sales volume of our Truvada (emtricitabine (&#8220;FTC&#8221;) and tenofovir disoproxil fumarate (&#8220;TDF&#8221;))-based products driven by the continued generic competition following the October 2020 loss of exclusivity of Truvada and Atripla in the United States, as well as the pull forward of channel inventory purchases in the first quarter of 2020 due to the COVID-19 pandemic. The decline was partially offset by market share increase and continued patient uptake of Biktarvy. We expect Truvada sales to continue to decline in 2021 and beyond as multiple generics are expected to enter the market starting in the second quarter of 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Descovy (FTC/TAF)-based product sales decreased in the first quarter of 2021, primarily driven by COVID-19 related channel inventory purchases in the first quarter of 2020, in addition to the impact of ongoing pandemic-related effects on the pre-exposure prophylaxis (&#8220;PrEP&#8221;) market, offset by Biktarvy growth. </span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">HCV</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HCV product sales decreased by 30% to $510 million for the first quarter of 2021, compared to $729 million for the same period in 2020, primarily due to lower volume driven by lower patient starts, which continued to be impacted by the COVID-19 pandemic. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">HBV/HDV</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HBV and HDV product sales increased by 18% to $220 million for the first quarter of 2021, compared to $186 million for the same period in 2020, primarily due to higher Vemlidy sales volume in certain international locations. The first quarter of 2021 also reflects $6 million of Hepcludex sales following the completion of our acquisition of MYR on March 4, 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Veklury</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Veklury generated $1.5 billion in sales in the first quarter of 2021. There were no Veklury sales in the first quarter of 2020. Sales of Veklury generally are affected by COVID-19 related rates of infections, hospitalizations and vaccinations, and will continue to be subject to significant volatility and uncertainty.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cell Therapy</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cell Therapy product sales, which include Tecartus and Yescarta, increased by 36% to $191 million for the first quarter of 2021, compared to $140 million for the same period in 2020. The growth was primarily due to the July 2020 launch of Tecartus in the United States and the continued uptake and geographic expansion of Yescarta in Europe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Trodelvy</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trodelvy generated $72 million in sales in the United States for the first quarter of 2021 following the completion of our acquisition of Immunomedics on October 23, 2020.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Product Sales</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other product sales, which include AmBisome, Cayston, Jyseleca, Letairis, Ranexa and Zydelig, decreased by 13% to $241 million in the first quarter of 2021, compared to $278 million for the same period in 2020. Letairis and Ranexa sales were lower in the first quarter of 2021, as anticipated, due to continued generic competition, following the losses of exclusivity in 2019.</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Sales by Geographic Area</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our total product sales, 33% and 27% were generated outside the United States for the first quarter of 2021 and 2020, respectively. We generally face exposure to movements in foreign currency exchange rates, primarily in the Euro. We use foreign currency exchange contracts to hedge a portion of our foreign currency exposures. Foreign currency exchange, net of hedges, had a favorable impact on our product sales of $80 million for the first quarter of 2021, based on a comparison using foreign currency exchange rates from the first quarter of 2020.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales in the United States increased by 6% to $4.2 billion in the first quarter of 2021, compared to $4.0 billion for the same period in 2020, primarily due to sales of Veklury as well as sales of Trodelvy and the launch of Tecartus in the third quarter of 2020. The increases were partially offset by continued generic competition from the loss of exclusivity of Truvada and Atripla, lower HCV sales and the anticipated decline in sales volume of Letairis and Ranexa following the losses of exclusivity in 2019.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales in Europe increased by 38% to $1.3 billion for the first quarter of 2021, compared to $927 million for the same period in 2020, primarily due to sales of Veklury, the continued patient uptake of Biktarvy, and the continued patient uptake and geographic expansion of Yescarta. The increase was partially offset by lower HCV sales driven by lower patient starts due to the continued impact from the COVID-19 pandemic. The lower HCV sales were partially offset by higher average net selling price due to a favorable government rebate adjustment. Foreign currency exchange, net of hedges, had a favorable impact on our Europe product sales of $52 million for the first quarter of 2021, based on a comparison using foreign currency exchange rates from the first quarter of 2020.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales in other locations increased by 50% to $825 million for the first quarter of 2021, compared to $551 million for the same period in 2020, primarily due to higher sales volumes of Veklury, Biktarvy and Vemlidy.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our product sales: </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">HIV Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Descovy (FTC/TAF) Based Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biktarvy &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biktarvy &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biktarvy &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,824&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descovy &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descovy &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descovy &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genvoya &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genvoya &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genvoya &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Odefsey &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Odefsey &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Odefsey &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue share &#8211; Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; U.S.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue share &#8211; Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Europe</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue share &#8211; Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Other International</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Descovy (FTC/TAF) Based Products &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Descovy (FTC/TAF) Based Products &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Descovy (FTC/TAF) Based Products &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,358&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,496&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Truvada (FTC/TDF) Based Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Atripla &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Atripla &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Atripla &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Complera / Eviplera &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Complera / Eviplera &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Complera / Eviplera &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stribild &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stribild &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stribild &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Truvada &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Truvada &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Truvada &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Truvada (FTC/TDF) Based Products &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Truvada (FTC/TDF) Based Products &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Truvada (FTC/TDF) Based Products &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; U.S.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Europe</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Other International</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HIV &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HIV &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HIV &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,134&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">HCV Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ledipasvir / Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; U.S.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ledipasvir / Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Europe</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ledipasvir / Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Other International</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(50)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sofosbuvir / Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; U.S.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sofosbuvir / Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Europe</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sofosbuvir / Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Other International</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(32)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; U.S.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Europe</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Other International</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HCV &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HCV &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HCV &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(30)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">HBV/HDV Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vemlidy &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vemlidy &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vemlidy &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Viread &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Viread &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Viread &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; U.S.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Europe</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Other International</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HBV/HDV &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HBV/HDV &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HBV/HDV &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Veklury</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Veklury &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Veklury &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Veklury &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,456&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Cell Therapy Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tecartus &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tecartus &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tecartus &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="padding:0 1pt 0 12.25pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Yescarta &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Yescarta &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Yescarta &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 12.25pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Cell Therapy &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Cell Therapy &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Cell Therapy &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Trodelvy - U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Other Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AmBisome &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AmBisome &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AmBisome &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Letairis &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ranexa &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Zydelig &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Zydelig &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Zydelig &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; U.S.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(7) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211; Europe</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Other International</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Other &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Other &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Other &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product sales &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product sales &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product sales &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,340&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,467&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">NM - Not Meaningful</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera. The first quarter of 2021 includes $6 million Hepcludex sales, following the completion of our acquisition of MYR on March 4, 2021.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Cayston and Jyseleca.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Costs and Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our costs and expenses:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Product gross margin</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">82.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">-380 bps</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development (&#8220;R&amp;D&#8221;) expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Goods Sold and Product Gross Margin</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold for the first quarter of 2021 increased by $392 million, or 40%, compared to the same period in 2020, primarily due to higher acquisition-related expenses from amortization of finite-lived intangible assets and inventory step-up charges of $506 million driven by our fourth quarter 2020 acquisition of Immunomedics, as well as increased product sales. The increase was partially offset by a decline in royalty expenses primarily due to lower sales of products containing emtricitabine and elvitegravir.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross margin for the first quarter of 2021 decreased primarily due to factors mentioned above and unfavorable product sales mix and an inventory reserve adjustment.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses consist primarily of clinical studies performed by contract research organizations, materials and supplies, payments under collaborative and other arrangements including milestone payments, licenses and fees, expense reimbursements to the collaboration partners, personnel costs including salaries, benefits and stock-based compensation expense, and overhead allocations including various support and infrastructure costs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not track total R&amp;D expenses by product candidate, therapeutic area or development phase. However, we manage our R&amp;D expenses by identifying the R&amp;D activities we anticipate will be performed during a given period and then prioritizing efforts based on scientific data, probability of technical and regulatory successful development, market potential, available human and capital resources and other considerations. We continually review our R&amp;D projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;D portfolio and external opportunities that we believe will best support the long-term growth of our business.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a breakout of our R&amp;D expenses by major cost type:</span></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical studies and outside services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel, infrastructure and other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,055&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses for the first quarter of 2021 increased by 5%, compared to the same period in 2020, primarily due to higher expenses driven by headcount growth due to the fourth quarter 2020 acquisition of Immunomedics and higher investments in oncology programs including magrolimab and Trodelvy. Partly offsetting these increases, we incurred lower expenses on other programs, including cancellations of certain filgotinib programs in connection with the December 2020 amended agreement with Galapagos. The first quarter 2020 R&amp;D expenses also reflected investments in remdesivir due to the manufacturing ramp-up and clinical trial costs prior to the commercialization of Veklury.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D expenses reflect IPR&amp;D impairments as well as the initial costs of externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront payments related to various collaborations and the initial costs of rights to IPR&amp;D projects. Beginning in the second quarter of 2020, acquired IPR&amp;D expenses were reported separately from Research and development expenses on our Condensed Consolidated Statements of Income. IPR&amp;D assets capitalized are tested for impairment in the fourth quarter of each year, or earlier if impairment indicators exist. No IPR&amp;D impairment charges were recorded during the three months ended March 31, 2021 and 2020.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D expenses of $62 million and $97 million for the first quarter of 2021 and 2020, were related to licensing, collaboration, investment and other arrangements we entered into during the periods. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses relate to sales and marketing, finance, human resources, legal and other administrative activities, including information technology investments. Expenses consist primarily of personnel costs, facilities and overhead costs, outside marketing, advertising and legal expenses and other general and administrative costs. SG&amp;A expenses also include the branded prescription drug fee. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses for the first quarter of 2021 decreased by $21 million or 2%, compared to the same period in 2020. The decrease was primarily due to lower corporate grants and lower promotional expenses in HIV and HCV, partially offset by higher costs associated with the commercialization efforts for Veklury, Trodelvy and Cell Therapy.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense), Net and Interest Expense</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our Other income (expense), net and Interest expense:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-bottom:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">NM - Not Meaningful</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in Other income (expense), net for the first quarter of 2021, compared to the same period in 2020, was primarily due to unfavorable changes in the fair value of investments in equity securities driven by our equity investment in Galapagos.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the first quarter of 2021 increased by $16 million or 7%, compared to the same period in 2020, primarily due to an increase in borrowing driven by the fourth quarter 2020 acquisition of Immunomedics, partially offset by favorable effects from debt maturities and repayments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our Income tax expense:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,003&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate and provision increased for the first quarter of 2021, compared to the same period in 2020, primarily due to unfavorable changes in the fair value of our equity investments primarily in Galapagos that are non-deductible for income tax purposes, partially offset by net discrete tax benefits related to favorable settlements with taxing authorities.</span></div><div id="i5e8b0e18419843159ec07e1b794d0d87_82"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing capital resources, supplemented by our cash flows generated from operating activities, will be adequate to satisfy our capital needs for the foreseeable future.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash, cash equivalents and marketable debt securities and working capital:</span></div><div style="margin-bottom:11pt;margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,599&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Debt Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable debt securities as of March 31, 2021 decreased by $1.7 billion, or 21%, compared to December&#160;31, 2020. During the first quarter of 2021, we generated $2.6 billion in operating cash flow, made early debt repayments of $1.25 billion, which included $1.0 billion principal amount of senior unsecured notes due in April 2021 and $250 million principal amount under our $1.0 billion three-year senior unsecured term loan facility. In addition, we utilized $1.2 billion on the MYR acquisition, including IPR&amp;D, net of cash acquired, paid cash dividends of $917 million and utilized $309 million on repurchases of our common stock.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Working Capital</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Working capital, which is current assets less current liabilities, decreased by $1.0 billion, or 22%, compared to December&#160;31, 2020, primarily due to the utilization of cash, cash equivalents and marketable debt securities for our acquisition of MYR as noted above. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable decreased by $1.0 billion, compared to December&#160;31, 2020, primarily due to collections of Veklury receivables during the first quarter of 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities decreased by $829 million compared to December&#160;31, 2020, primarily due to certain tax payments made to taxing authorities during the first quarter of 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activities:</span></div><div style="margin-bottom:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:75.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by (used in):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,042)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(344)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,477)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities represents the cash receipts and disbursements related to all activities other than investing and financing activities. Operating cash flow is derived by adjusting our net income for non-cash items and changes in operating assets and liabilities. Cash provided by operating activities increased by $1.2 billion to $2.6 billion for the first quarter of 2021, compared to the same period in 2020. The increase was primarily the result of changes in working capital reflecting collections of Veklury receivables during the first quarter of 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities primarily consists of purchases, sales and maturities of our marketable debt securities, capital expenditures, acquisitions, including IPR&amp;D, net of cash acquired, purchases of equity securities and other investments. Cash used in investing activities increased by $1.7 billion to $2.0 billion for the first quarter of 2021, compared to the same period in 2020, primarily due to our acquisition of MYR.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in cash used in financing activities for the first quarter of 2021, compared to the same period in 2020, was primarily due to $1.0 billion lower repurchases of our common stock, partially offset by $750 million higher repayments of debt during the first quarter of 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt and Credit Facilities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our borrowings under various financing arrangements is included in Note 10. Debt and Credit Facilities of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q. We may choose to repay certain of our long-term debt obligations prior to maturity dates based on our assessment of current and long-term liquidity and capital requirements.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, we repaid $1.25 billion of debt. In January 2021, we repaid $1.0 billion of senior unsecured notes prior to the April 2021 maturity, by exercising a 3-month par call. In March 2021, we repaid $250 million principal amount under our $1.0 billion three-year senior unsecured term loan facility, leaving $750 million principal amount outstanding as of March&#160;31, 2021. As of March&#160;31, 2021 and December&#160;31, 2020, there were no amounts outstanding under our $2.5 billion revolving credit facility maturing in June 2025. We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of March&#160;31, 2021, we were in compliance with all covenants.</span></div><div id="i5e8b0e18419843159ec07e1b794d0d87_85"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES, ESTIMATES AND JUDGMENTS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our Condensed Consolidated Financial Statements in accordance with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts in the financial statements and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the recent COVID-19 pandemic could have on our significant accounting estimates. Actual results may differ significantly from these estimates. A summary of our critical accounting policies and estimates is presented in Part II, Item 7 of our <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm">Annual Report on Form 10-K</a> for the year ended December&#160;31, 2020. There were no material changes to our critical accounting policies and estimates during the three months ended March 31, 2021.</span></div><div id="i5e8b0e18419843159ec07e1b794d0d87_88"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K.</span></div><div id="i5e8b0e18419843159ec07e1b794d0d87_91"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECENT ACCOUNTING PRONOUNCEMENTS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no new accounting pronouncements issued nor adopted during the three months ended March 31, 2021 that are of significance to us.</span></div><div id="i5e8b0e18419843159ec07e1b794d0d87_1159"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6. Acquisitions and Note 9. Collaborations and Other Arrangements of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q for additional information.</span></div><div id="i5e8b0e18419843159ec07e1b794d0d87_94"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our market risk during the three months ended March 31, 2021 compared to the disclosures in Part II, Item 7A of our <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm">Annual Report on Form 10-K</a> for the year ended December&#160;31, 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i5e8b0e18419843159ec07e1b794d0d87_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An evaluation as of March&#160;31, 2021 was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our &#8220;disclosure controls and procedures,&#8221; which are defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act), as controls and other procedures of a company that are designed to ensure that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March&#160;31, 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, has evaluated any changes in our internal control over financial reporting that occurred during the quarter ended March&#160;31, 2021, and has concluded that there was no change during such quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitations on the Effectiveness of Controls</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our Chief Executive Officer and Chief Financial Officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i5e8b0e18419843159ec07e1b794d0d87_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div id="i5e8b0e18419843159ec07e1b794d0d87_103"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL PROCEEDINGS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our significant pending legal proceedings, please see Note 11. Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q. </span></div><div id="i5e8b0e18419843159ec07e1b794d0d87_106"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. &#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In evaluating our business, you should carefully consider the following discussion of material risks, events and uncertainties that make an investment in us speculative or risky in addition to the other information in this Quarterly Report on Form 10-Q. A manifestation of any of the following risks and uncertainties could, in circumstances we may or may not be able to accurately predict, materially and adversely affect our business, growth, reputation (including the commercial or scientific reputation of our products), prospects, product pipeline and sales, operating and financial results, financial condition, cash flows, liquidity and stock price. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. It is not possible to predict or identify all such factors; our operations could also be affected by factors, events or uncertainties that are not presently known to us or that we currently do not consider to present significant risks to our operations. Therefore, you should not consider the following risks to be a complete statement of all the potential risks or uncertainties that we face.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Product and Commercialization Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain of our products subject us to additional or heightened risks.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HIV Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a substantial portion of our revenue from sales of our products for the treatment and prevention of HIV infection. During the three months ended March 31, 2021, sales of our HIV products accounted for approximately 58% of our total product sales. We may be unable to sustain or increase sales of our HIV products for any number of reasons, including market share gains by competitive products or the inability to introduce new HIV medications necessary to remain competitive. In such case, we may need to scale back our operations, including our future drug development and spending on research and development (&#8220;R&amp;D&#8221;) efforts. For example, most of our HIV products contain tenofovir alafenamide (&#8220;TAF&#8221;), tenofovir disoproxil fumarate (&#8220;TDF&#8221;) and/or emtricitabine (&#8220;FTC&#8221;), which belong to the nucleoside class of antiviral therapeutics, and any changes to the treatment paradigm for HIV may cause nucleoside-based therapeutics to fall out of favor.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Veklury (remdesivir)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks related to our significant investment in the rapid development, manufacturing and distribution of Veklury (remdesivir), which was approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in October 2020 as a treatment for hospitalized patients with COVID-19. Given the severity and urgency of the COVID-19 pandemic, we committed significant capital and resources for clinical trials and the scale-up of the production of remdesivir. We expect our investment will continue through 2021 and beyond, as we continue to manufacture large quantities of finished product and conduct additional studies of specific patient populations, and develop and evaluate new formulations and delivery methods and combinations with other therapies. While the utilization of remdesivir has largely tracked the level of infections, we are unable to accurately predict our revenues or supply needs over the short and long term due to the potential for new and better therapeutics, the availability and effectiveness of vaccines and fluctuating hospital utilization rates. For example, we have observed that the volume of Veklury sales in the first quarter of 2021 reflected lower infections and growing vaccination rates compared to the fourth quarter of 2020. If we are unable to accurately forecast demand or manufacture Veklury at levels to meet actual demand, then this may result in shortages or excess inventory that may be written off. We are subject to significant public attention and scrutiny over the complex decisions made regarding the clinical data, allocation, distribution and pricing of Veklury, all of which affects our corporate reputation. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Yescarta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advancing a novel and personalized therapy such as Yescarta, which is a Chimeric Antigen Receptor (&#8220;CAR&#8221;) T cell therapy, creates significant challenges, including:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">educating and certifying medical personnel regarding the procedures and the potential side effects, such as cytokine release syndrome and neurologic toxicities, in compliance with the Risk Evaluation and Mitigation Strategy program required by FDA;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">securing sufficient supply of other medications to manage side effects, such as tocilizumab and corticosteroids, which may not be available in sufficient quantities, may not adequately control the side effects and/or may have detrimental impacts on the efficacy of Yescarta;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and maintaining a robust and reliable process for engineering a patient&#8217;s T cells in our facilities and infusing them back into the patient; and</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditioning patients with chemotherapy in advance of administering our therapy, which may increase the risk of adverse side effects.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of engineered T cells as a potential cancer treatment is a recent development and may not be broadly accepted by physicians, patients, hospitals, cancer treatment centers, payers and others in the medical community. We may not be able to demonstrate to the medical community and payers the potential advantages of Yescarta compared to existing and future therapeutics. For challenges related to the reimbursement of Yescarta, see also &#8220;Our existing products are subject to reimbursement pressures from government agencies and other third parties, required rebates and other discounts on our products and other pricing pressures.&#8221;</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party sites to collect patients&#8217; white blood cells, known as apheresis centers, as well as shippers, couriers, and hospitals for the logistical collection of patients&#8217; white blood cells and ultimate delivery of Yescarta to patients. These vendors may encounter disruptions or difficulties that could result in product loss and regulatory action. Apheresis centers may also choose not to participate in our quality certification process, or we may be unable to complete such certification in a timely manner or at all, which could delay or constrain our manufacturing and commercialization efforts.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our success depends on developing and commercializing new products or expanding the indications for existing products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to launch commercially successful new products or new indications for existing products our business will be adversely impacted. The launch of commercially successful products is necessary to grow our business, cover our substantial R&amp;D expenses, and offset revenue losses when existing products lose market share due to factors such as competition and loss of patent exclusivity. There are many difficulties and uncertainties inherent in drug development and the introduction of new products. The product development cycle is characterized by significant investments of resources, long lead times and unpredictable outcomes due to the nature of developing medicines for human use. We expend significant time and resources on our product pipeline without any assurance that we will recoup our investments or that our efforts will be commercially successful. A high rate of failure is inherent in the discovery and development of new products, and failure can occur at any point in the process, including late in the process after substantial investment.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face challenges in accurately forecasting sales because of the difficulties in predicting demand for our products and fluctuations in purchasing patterns or wholesaler inventories. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to accurately predict demand for our products, including the uptake of new products, as demand depends on a number of factors. For example, product demand may be adversely affected if physicians do not see the benefit of our products. Additionally, the non-retail sector in the United States, which includes government institutions, including state AIDS Drug Assistance Programs, the U.S. Department of Veterans Affairs, correctional facilities and large health maintenance organizations, tends to be less consistent in terms of buying patterns and often causes quarter-over-quarter fluctuations that do not necessarily mirror patient demand for our products. Federal and state budget pressures, as well as the annual grant cycles for federal and state funds, may cause purchasing patterns to not reflect patient demand for our products. We expect to continue to experience fluctuations in the purchasing patterns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed variations in purchasing patterns induced by cost containment measures in Europe. We believe these measures have caused some government agencies and other purchasers to reduce inventory of our products in the distribution channels. We may continue to see this trend in the future. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell and distribute most of our products in the United States exclusively through the wholesale channel. For the three months ended March 31, 2021, approximately 94% of our product sales in the United States were to three wholesalers, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Corporation. The U.S. wholesalers with whom we have entered into inventory management agreements make estimates to determine end user demand and may not be completely effective in matching their inventory levels to actual end user demand. As a result, changes in inventory levels held by those wholesalers can cause our operating results to fluctuate unexpectedly if our sales to these wholesalers do not match end user demand. In addition, inventory is held at retail pharmacies and other non-wholesaler locations with whom we have no inventory management agreements and no control over buying patterns. Adverse changes in economic conditions, increased competition or other factors may cause retail pharmacies to reduce their inventories of our products, which would reduce their orders from wholesalers and, consequently, the wholesalers&#8217; orders from us, even if end user demand has not changed. In addition, we have observed that strong wholesaler and sub-wholesaler purchases of our products in the fourth quarter typically results in inventory draw-down by wholesalers and sub-wholesalers in the subsequent first quarter. As inventory in the distribution channel fluctuates from quarter to quarter, we may continue to see fluctuations in our earnings and a mismatch between prescription demand for our products and our revenues. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face significant competition from global pharmaceutical and biotechnology companies, specialized pharmaceutical firms and generic drug manufacturers.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New branded or generic products entering major markets affects our ability to maintain pricing and market share. Our products compete with other available products based primarily on efficacy, safety, tolerability, acceptance by doctors, ease of patient compliance, ease of use, price, insurance and other reimbursement coverage, distribution and marketing. A number of companies are pursuing the development of technologies which are competitive with our existing products or research programs. These competing companies include large pharmaceutical and biotechnology companies and specialized pharmaceutical firms acting either independently or together with other such companies. Furthermore, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection or may establish collaborative arrangements for competitive products or programs. We may be adversely impacted if any of these competitors gain market share as a result of new technologies, commercialization strategies or otherwise.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our existing products are subject to reimbursement pressures from government agencies and other third parties, required rebates and other discounts on our products and other pricing pressures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Reimbursements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful commercialization of our products depends, in part, on the availability of third-party payer reimbursement for the cost of such products and related treatments and medical services in the markets where we sell our products. Government health authorities, private health insurers and other organizations generally provide reimbursement. As our products mature, private insurers and government payers often reduce the amount they will reimburse patients for these products, which increases pressure on us to reduce prices. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory actions affecting government prescription drug procurement and reimbursement programs occur relatively frequently. For example, in September 2020, FDA issued a final rule implementing a pathway for the importation of certain prescription drugs from Canada. This rule is subject to ongoing litigation. In addition, in November 2020, the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) issued an interim final rule that would substantially alter the Medicare Part B reimbursement system for physician-administered medicines as of January 1, 2021. This rule is subject to ongoing litigation and CMS has been preliminarily enjoined from implementing the rule. We may be adversely impacted by any such legislative and regulatory actions, though it is difficult to predict the impact, if any, on the use and reimbursement of our products.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Pricing, Discounts and Rebates</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the European Union and other significant or potentially significant markets for our products and product candidates, government authorities and third-party payers are increasingly attempting to limit or regulate the price of medical products and services. In the United States, the volume of drug pricing-related bills has dramatically increased in recent years. For example, Congress proposed bills to change the Medicare Part D benefit to impose an inflation-based rebate when list prices for drugs grow faster than inflation and to increase manufacturer contributions in some or all of the benefit phases. In addition, many state legislatures are considering, or have already passed into law, legislation that seeks to indirectly or directly regulate pharmaceutical drug pricing, such as requiring manufacturers to publicly report proprietary pricing information, creating review boards for prices to state agencies, and encouraging the use of generic drugs. Such initiatives and legislation may cause added pricing pressures on our products, and the resulting impact on our business is uncertain. Many countries outside the United States, including the European Union member states, have established complex and lengthy procedures to obtain price approvals, coverage reimbursement and periodically review their pricing and reimbursement decisions. The outcome of this review cannot be predicted and could have an adverse effect on the pricing and reimbursement of our medicinal products in the European Union member states. Reductions in the pricing of our medicinal products in one member state could affect the price in other member states and have a negative impact on our financial results. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our product sales is subject to significant discounts from list price, including rebates that we may be required to pay state Medicaid agencies and discounts provided to 340B covered entities. Changes to the 340B program or the Medicaid program at the federal or state level could have a material adverse effect on our business. For example, in December 2020, CMS issued a final rule that will make certain changes to the calculation of rebates under the Medicaid Drug Rebate Program. Among other changes, effective January 1, 2023, the final rule will change the requirements for excluding manufacturer co-pay coupons from the Medicaid &#8220;best price.&#8221; If these changes go into effect, they could substantially increase our Medicaid rebate obligations and decrease the prices we charge 340B covered entities. The continued growth of the 340B program also limits the prices we may charge to an increasing number of customers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, standard reimbursement structures may not adequately reimburse for innovative therapies. For example, beginning in fiscal year 2021, CMS established a new severity adjusted diagnosis related group (&#8220;DRG&#8221;) 018 for Medicare inpatient reimbursement of CAR T products such as Yescarta and Tecartus. While the new DRG has a significantly higher base payment amount than the prior DRG 016, the payment available may not be sufficient to reimburse some hospitals for their cost of care for patients receiving Yescarta and Tecartus. When reimbursement is not aligned well to account for treatment costs, Medicare beneficiaries may be denied access as this misalignment could impact the willingness of some hospitals to offer the therapy and of doctors to recommend the therapy. Additionally, in the European Union, there are barriers to reimbursement in individual countries that could limit the uptake of Yescarta and Tecartus.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we estimate the rebates we will be required to pay in connection with sales during a particular quarter based on claims data from prior quarters. In the United States, actual rebate claims are typically made by payers one to three quarters in arrears. Actual claims and payments may vary significantly from our estimates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may experience adverse impacts resulting from imports from countries where our products are available at lower prices or imports of unapproved generic or counterfeit versions of our products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prices for our products are based on local market economics and competition and sometimes differ from country to country. Our sales in countries with relatively higher prices may be reduced if products can be imported and resold into those countries from lower price markets. For example, U.S. sales could also be affected if FDA permits importation of drugs from Canada. We have entered into agreements with generic drug manufacturers as well as licensing agreements with the Medicines Patent Pool, a United Nations-backed public health organization, which allows generic drug manufacturers to manufacture generic versions of certain of our products for distribution in certain low- and middle-income countries. We may be adversely affected if any generic versions of our products, whether or not produced and/or distributed under these agreements, are exported to the United States, Europe or markets with higher prices. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, we are required to permit products purchased in one European Union member state to be sold in another member state. Purchases of our products in countries where our selling prices are relatively low for resale in countries in which our selling prices are relatively high can affect the inventory level held by our wholesalers and can cause the relative sales levels in the various countries to fluctuate from quarter to quarter and not reflect the actual consumer demand in any given quarter. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, diverted products may be used in countries where they have not been approved and patients may source the diverted products outside the legitimate supply chain. These diverted products may be handled, shipped and stored inappropriately, which may affect the efficacy of the products and could harm patients, and adversely impact us.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also aware of the existence of various &#8220;Buyers Clubs&#8221; around the world that promote the personal importation of generic versions of our products that have not been approved for use in the countries into which they are imported. As a result, patients may be at risk of taking unapproved medications which may not be what they purport to be, may not have the potency they claim to have or may contain harmful substances, which could adversely impact us. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, third parties may illegally distribute and sell illegally diverted and counterfeit versions of our medicines, which do not meet the rigorous quality standards of our manufacturing and supply chain. Illegally diverted and counterfeit medicines pose a serious risk to patient health and safety and may raise the risk of product recalls. Our actions to discourage the distribution and sale of illegally diverted and counterfeit versions of our medicines around the world may not be successful, and we may be adversely affected as a result. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Product Development and Supply Chain Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face risks in our clinical trials, including the potential for unfavorable results, delays in anticipated timelines and disruption.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to demonstrate the safety and efficacy of products that we develop for each intended use through extensive preclinical studies and clinical trials. The results from preclinical and early clinical studies do not always accurately predict results in later, large-scale clinical trials. Even successfully completed large-scale clinical trials may not result in marketable products. If any of our product candidates fails to achieve its primary endpoint in clinical trials, if safety issues arise or if the results from our clinical trials are otherwise inadequate to support regulatory approval of our product candidates, commercialization of that product candidate could be delayed or halted. In addition, we may also face challenges in clinical trial protocol design.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be adversely impacted if the clinical trials for any of the product candidates in our pipeline are delayed or terminated. We face numerous risks and uncertainties with our product candidates that could prevent completion of development of these product candidates. These risks include our ability to enroll patients in clinical trials, the possibility of unfavorable results of our clinical trials, the need to modify or delay our clinical trials or to perform additional trials and the risk of failing to obtain FDA and other regulatory agency approvals. As a result, our product candidates may never be successfully commercialized. Further, we may make a strategic decision to discontinue development of our product candidates if, for example, we believe commercialization will be difficult relative to other opportunities in our pipeline. In 2021, our key anticipated milestones for our product candidates include, among others, Phase 3 data readouts for (1) sacituzumab govitecan-hziy for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative, metastatic breast cancer patients, (2) axicabtagene ciloleucel for the treatment of second line diffuse large B cell lymphoma and (3) bulevirtide for the treatment of chronic hepatitis delta virus. We may be adversely impacted if we do not have favorable results from these studies and other programs in our pipeline cannot be completed on a timely basis or at all. In addition, clinical trials involving our commercial products could raise new safety issues for our existing products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we extensively outsource our clinical trial activities and usually perform only a small portion of the start-up activities in-house. We rely on independent third-party contract research organizations (&#8220;CROs&#8221;) to perform most of our clinical studies, including document preparation, site identification, screening and preparation, pre-study visits, training, program management, patient enrollment, ongoing monitoring, site management and bioanalytical analysis. Many important aspects of the services performed for us by the CROs are out of our direct control. If there is any dispute or disruption in our relationship with our CROs, our clinical trials may be delayed. Moreover, in our regulatory submissions, we rely on the quality and validity of the clinical work performed by third-party CROs. If any of our CROs&#8217; processes, methodologies or results were determined to be invalid or inadequate, our own clinical data and results and related regulatory approvals may be adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may face manufacturing difficulties, delays or interruptions, including at our third-party manufacturers and corporate partners.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products, which are manufactured at our own facilities or by third-party manufacturers and corporate partners, are the result of complex, highly regulated manufacturing processes. We depend on third-party manufacturers and corporate partners to perform manufacturing activities effectively and on a timely basis for the majority of our active pharmaceutical ingredients and drug products. These third parties are independent entities subject to their own unique operational and financial risks that are out of our control. We and our third-party manufacturers and corporate partners are subject to Good Manufacturing Practices (&#8220;GMP&#8221;), which are extensive regulations governing manufacturing processes, stability testing, record keeping and quality standards as defined by FDA and the European Medicines Agency (&#8220;EMA&#8221;), as well as comparable regulations in other jurisdictions. Manufacturing operations are also subject to routine inspections by regulatory agencies.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting or resulting from our manufacturing operations or the operations of our third-party manufacturers and corporate partners may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also need to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications and quality standards, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenues or market share and damage our reputation. In addition, manufacturing issues may cause delays in our clinical trials and applications for regulatory approval. For example, if we are unable to remedy any deficiencies cited by FDA or other regulatory agencies in their inspections, our existing products and the timing of regulatory approval of product candidates in development could be adversely affected. Further, there is risk that regulatory agencies in other countries where marketing applications are pending will undertake similar additional reviews or apply a heightened standard of review, which could delay the regulatory approvals for products in those countries. Our business may be adversely affected if approval of any of our product candidates were delayed or if production of our products were interrupted.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may not be able to obtain materials or supplies necessary to conduct clinical trials or to manufacture and sell our products, which could limit our ability to generate revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need access to certain supplies and products to conduct our clinical trials and to manufacture and sell our products. If we are unable to purchase sufficient quantities of these materials or find suitable alternative materials in a timely manner, our development efforts for our product candidates may be delayed or our ability to manufacture and sell our products could be limited.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Suppliers of key components and materials must be named in the new drug application or marketing authorization application filed with the regulatory authority for any product candidate for which we are seeking marketing approval, and significant delays can occur if the qualification of a new supplier is required. Even after a manufacturer is qualified by the regulatory authority, the manufacturer must continue to expend time, money and effort in the area of production and quality control to maintain full compliance with GMP. Manufacturers are subject to regular periodic inspections by regulatory authorities following initial approval. If, as a result of these inspections, a regulatory authority determines that the equipment, facilities, laboratories or processes do not comply with applicable regulations and conditions of product approval, the regulatory authority may suspend the manufacturing operations. If the manufacturing operations of any of the single suppliers for our products are suspended, we may be unable to generate sufficient quantities of commercial or clinical supplies of product to meet market demand. In addition, if deliveries of materials from our suppliers were interrupted for any reason, we may be unable to ship certain of our products for commercial supply or to supply our product candidates in development for clinical trials. Also, some of our products and the materials that we utilize in our operations are manufactured by only one supplier or at only one facility, which we may not be able to replace in a timely manner and on commercially reasonable terms, or at all. Problems with any of the single suppliers or facilities we depend on, including in the event of a disaster, such as an earthquake, equipment failure or other difficulty, may negatively impact our development and commercialization efforts.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the raw materials and intermediates used to manufacture our antiviral products are supplied by third-party manufacturers and corporate partners outside of the United States. As a result, any political or economic factors in a specific country or region, including any changes in or interpretations of trade regulations, compliance requirements or tax legislation, that would limit or prevent third parties outside of the United States from supplying these materials could adversely affect our ability to manufacture and supply our antiviral products to meet market needs and have a material and adverse effect on our operating results.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to encounter any of these difficulties, our ability to conduct clinical trials on product candidates and to manufacture and sell our products could be impaired.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Regulatory and Other Legal Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our operations depend on compliance with complex FDA and comparable international regulations. Failure to obtain broad approvals on a timely basis or to maintain compliance could delay or halt commercialization of our products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The products we develop must be approved for marketing and sale by regulatory authorities and, once approved, are subject to extensive regulation by FDA, EMA and comparable regulatory agencies in other countries. We have filed, and anticipate that we will file, for marketing approval in additional countries and for additional indications and products over the next several years. These and any future marketing applications we file may not be approved by the regulatory authorities on a timely basis, or at all. Even if marketing approval is granted for these products, there may be significant limitations on their use. We cannot state with certainty when or whether any of our product candidates under development will be approved or launched; whether we will be able to develop, license or acquire additional product candidates or products; or whether any products, once launched, will be commercially successful. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, how we manufacture and sell our products is subject to extensive regulation and review. For example, under FDA rules, we are often required to conduct post-approval clinical studies to assess a known serious risk, signals of serious risk or to identify an unexpected serious risk. In certain circumstances, we may be required to implement a Risk Evaluation and Mitigation Strategy program for our products, which could include a medication guide, patient package insert, a communication plan to healthcare providers, restrictions on distribution or use of a product and other elements FDA deems necessary to assure safe use of the drug. Discovery of previously unknown problems with our marketed products or product candidates, including serious safety, resistance or drug interaction issues, or problems with our manufacturing, safety reporting or promotional activities may result in regulatory approvals being delayed, denied or granted with significant restrictions on our products, including limitations on or the withdrawal of the products from the market. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these or other requirements imposed by FDA could result in significant civil monetary penalties, fines suspensions of regulatory approvals, product recalls, seizure of products and criminal prosecutions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are impacted by evolving laws, regulations and legislative or regulatory actions applicable to the health care industry. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health care industry is subject to various federal, state and international laws and regulations pertaining to drug reimbursement, rebates, price reporting, health care fraud and abuse, and data privacy and security. In the United States, these laws include anti-kickback and false claims laws, laws and regulations relating to the Medicare and Medicaid programs and other federal and state programs, the Medicaid Rebate Statute, individual state laws relating to pricing and sales and marketing practices, the Health Insurance Portability and Accountability Act and other federal and state laws relating to the privacy and security of health information. Actual or alleged violations of these laws or any related regulations may be punishable by criminal and/or civil sanctions, including, in some instances, substantial fines, civil monetary penalties, exclusion from participation in federal and state health care programs, including Medicare, Medicaid and Department of Veterans Affairs and Department of Defense health programs, actions against executives overseeing our business and significant remediation measures, negative publicity or other consequences. These laws and regulations are broad in scope and subject to changing and evolving interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our sales or marketing practices. For example, in the United States, a challenge to the Affordable Care Act (&#8220;ACA&#8221;) is currently pending before the U.S. Supreme Court, which has resulted in uncertainty regarding the ACA&#8217;s future viability and destabilization of the health insurance market. The resulting impact on our business is uncertain and could be material.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, government price reporting and payment regulations are complex and we are continually assessing the methods by which we calculate and report pricing in accordance with these obligations. Our methodologies for calculations are inherently subjective and may be subject to review and challenge by various government agencies, which may disagree with our interpretation. If the government disagrees with our reported calculations, we may need to restate previously reported data and could be subject to additional financial and legal liability.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also continues to be enhanced scrutiny of company-sponsored patient assistance programs, including co-pay assistance programs, and manufacturer donations to third-party charities that provide such assistance. There has also been enhanced scrutiny by governments on reimbursement support offerings, clinical education programs and promotional speaker programs. If we, or our agents and vendors, are deemed to have failed to comply with laws, regulations or government guidance in any of these areas, we could be subject to criminal or civil sanctions. Any similar violations by our competitors could also negatively impact our industry reputation and increase scrutiny over our business and our products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our government investigations and related litigation, Note 11. Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to risks if significant safety issues arise for our marketed products or our product candidates.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As additional studies are conducted subsequent to obtaining marketing approval for our products, and as our products are used over longer periods of time by many patients, including patients with underlying health problems or patients taking other medicines, we expect to continue finding new issues related to safety, resistance or drug interactions. Any such issues may require changes to our product labels, such as additional warnings, contraindications or even narrowed indications, or to halt sales of a product.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities have been moving towards more active and transparent pharmacovigilance and are making greater amounts of stand-alone safety information and clinical trial data directly available to the public through websites and other means, such as periodic safety update report summaries, risk management plan summaries and various adverse event data. Safety information, without the appropriate context and expertise, may be misinterpreted and lead to misperception or legal action.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our success depends to a significant degree on our ability to obtain and defend our patents and other intellectual property rights both domestically and internationally, and to operate without infringing upon the patents or other proprietary rights of third parties. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and other proprietary rights are very important to our business. As part of our business strategy, we actively seek patent protection both in the United States and internationally and file additional patent applications, when appropriate, to cover improvements in our compounds, products and technology. Our success depends to a significant degree on our ability to:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain patents and licenses to patent rights;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preserve trade secrets and internal know-how;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">defend against infringement of our patents and efforts to invalidate them; and</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operate without infringing on the intellectual property of others.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since patent applications are confidential for a period of time before a patent is issued, we may not know if our competitors filed patent applications for technology covered by our pending applications or if we were the first to invent or first to file an application directed toward the technology that is the subject of our patent applications. If competitors file patent applications covering our technology, we may have to participate in litigation, post-grant proceedings before the U.S. Patent and Trademark Office or other proceedings to determine the right to a patent or validity of any patent granted. Such litigation and proceedings are unpredictable and expensive, and could divert management attention from other operations, such that, even if we are ultimately successful, we may be adversely impacted. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic manufacturers have sought, and may continue to seek, FDA approval to market generic versions of our products through an abbreviated new drug application (&#8220;ANDA&#8221;), the application process typically used by manufacturers seeking approval of a generic drug. For a description of our ANDA litigation, see Note 11. Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q. The entry of generic versions of our products has, and may in the future, lead to market share and price erosion. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are found to infringe the valid patents of third parties, we may be required to pay significant monetary damages or we may be prevented from commercializing products or may be required to obtain licenses from these third parties. We may not be able to obtain alternative technologies or any required license on commercially reasonable terms or at all. If we fail to obtain these licenses or alternative technologies, we may be unable to develop or commercialize some or all of our products. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patents and patent applications owned by third parties that such parties may claim cover the use of sofosbuvir, axicabtagene ciloleucel or bictegravir, as well as certain uses of combinations of FTC and TDF or TAF. For example, in February 2018, ViiV filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the commercialization of bictegravir, sold commercially in combination with TAF and FTC as Biktarvy, infringes on ViiV&#8217;s U.S. Patent No. 8,129,385 (the &#8220;&#8217;385 patent&#8221;), covering ViiV&#8217;s dolutegravir. Bictegravir is structurally different from dolutegravir, and we believe that bictegravir does not infringe the claims of the &#8217;385 patent. The court has set a trial date of January 2022 for this lawsuit. ViiV is seeking billions of dollars for alleged damages comprised of ViiV&#8217;s lost profits and a royalty on sales of bictegravir from launch through the trial. In addition, should a court find that we are liable for infringement, we expect ViiV will seek a royalty on sales after the trial. ViiV calculates these damages based on the cumulative U.S. revenues from Biktarvy since launch, which have totaled $12.9 billion through March&#160;31, 2021. Although we cannot predict with certainty the ultimate outcome of this litigation, an adverse judgment could result in substantial monetary damages, including ViiV&#8217;s lost profits and royalties through trial, and a going-forward royalty stream on future sales. See a description of our litigation related to these and other matters in Note 11. Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we also rely on unpatented trade secrets and improvements, unpatented internal know-how and technological innovation. For example, a great deal of our liposomal manufacturing expertise, which is a key component of our liposomal technology, is not covered by patents but is instead protected as a trade secret. We protect these rights mainly through confidentiality agreements with our corporate partners, employees, consultants and vendors. We cannot be certain that these parties will comply with these confidentiality agreements, that we have adequate remedies for any breach or that our trade secrets, internal know-how or technological innovation will not otherwise become known or be independently discovered by our competitors. Under some of our R&amp;D agreements, inventions become jointly owned by us and our corporate partner and in other cases become the exclusive property of one party. In certain circumstances, it can be difficult to determine who owns a particular invention and disputes could arise regarding those inventions. We could be adversely affected if our trade secrets, internal know-how, technological innovation or confidential information become known or independently discovered by competitors or if we enter into disputes over ownership of inventions. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face potentially significant liability and increased expenses from litigation and government investigations relating to our products and operations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in a number of litigation, investigation and other dispute-related matters that require us to expend substantial internal and financial resources, including ongoing litigation related to our Yescarta and Biktarvy products and ongoing product liability litigation related to our TDF-based products. These matters could require us to pay significant monetary damages, including royalty payments for past and future sales. We expect these matters will continue to require a high level of internal and financial resources for the foreseeable future. These matters have reduced, and are expected to continue to reduce, our earnings and require significant management attention. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the testing, manufacturing, marketing and use of our commercial products, as well as product candidates in development, involve substantial risk of product liability claims. These claims may be made directly by consumers, healthcare providers, pharmaceutical companies or others. We have limited insurance for product liabilities that may arise and claims may exceed our coverage.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our litigation, investigations and other dispute-related matters, see Note 11. Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q. The outcome of such legal proceedings or any other legal proceedings that may be brought against us, the investigations or any other investigations that may be initiated and any other dispute-related matters, are inherently uncertain, and adverse developments or outcomes can result in significant expenses, monetary damages, penalties or injunctive relief against us.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operational Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business has been, and may in the future be, adversely affected by outbreaks of epidemic, pandemic or contagious diseases, including the recent COVID-19 outbreak.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual or threatened outbreaks of epidemic, pandemic or contagious diseases, such as COVID-19, may significantly disrupt our global operations and adversely affect our business, financial condition and results of operations. For example, the COVID-19 pandemic has caused significant volatility and uncertainty in U.S. and international markets and has resulted in increased risks to our operations. In addition to the developments discussed in Part II, Item 7 &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations,&#8221; we are monitoring a number of risks related to the pandemic, including the following:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Supply Chain: The pandemic could result in disruptions to our supply chain and distribution in the future. For example, quarantines, shelter-in-place and other governmental orders and policies, travel restrictions, airline capacity and route reductions, safety guidelines and health impacts of the pandemic, could impact the availability or productivity of products and personnel at manufacturers, distributors, freight carriers and other necessary components of our supply chain. In addition, there may be unfavorable changes in the availability or cost of raw materials, intermediates and other materials necessary for production, which may result in higher costs, disruptions in our supply chain and interruptions in our distribution capabilities.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical Trials: This pandemic has adversely affected and may continue to adversely affect certain of our clinical trials, including our ability to initiate and complete our clinical trials within the anticipated timelines. For ongoing trials, clinical trial sites have imposed restrictions on patient visits to limit risks of possible COVID-19 exposure, and we may experience issues with participant compliance with clinical trial protocols as a result of quarantines, travel restrictions and interruptions to healthcare services. There is also a risk that closures at clinical sites may be necessary as the pandemic and related guidance and restrictions continue to evolve. For the foregoing reasons, we have experienced delays with new subject enrollment for most clinical trials, and may continue to experience overall delays in our clinical trials. There is also the risk of biased data collection if only certain clinical trial sites remain open. As a result of these challenges, our anticipated filing and marketing timelines for certain products may be adversely impacted.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory Reviews: The operations of FDA, EMA or other regulatory agencies may be adversely affected. We may also experience delays in necessary interactions with regulatory authorities around the world, including with respect to any anticipated filing, which together with other factors resulting from the pandemic may adversely impact our ability to launch new commercial products.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patient Access: The pandemic has limited patients&#8217; ability or willingness to access and seek care from healthcare providers and initiate new therapies, which has resulted in lower demand for our products, particularly with respect to HIV prevention and hepatitis C virus (&#8220;HCV&#8221;) treatment. For example, we have seen a reduction in prescription refills for HIV prevention as a result of higher discontinuations. In addition, with the rising unemployment, we have experienced a shift in payer mix towards more government-funded coverage and the uninsured segment.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Employees: We face risks related to the health, safety, morale and productivity of our employees, including the safe occupancy of our sites during the pandemic. Currently, most Gilead sites are requiring flexible location employees to work from home while physical location dependent workers and mixed location workers continue to work on Gilead sites. Our job site enhancements and risk protocols, which include health screenings and COVID-19 testing, do not guarantee that we can maintain the continued safe occupancy of our sites. On-site employees testing positive for COVID-19 could lead to mandatory quarantines and potential site shutdowns of office locations and manufacturing plants.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Financial: The pandemic has had, and may continue to have, an adverse financial impact in the short-term and potentially beyond. As a result of reduced patient access and a shift in payer mix, our HCV treatment and HIV businesses have been adversely impacted. For example, our product sales, excluding Veklury, for the full year 2020 and first quarter 2021 decreased 3% and 11%, respectively, compared to full year 2019 and first quarter 2020, respectively, due in part to the continued effects of the pandemic on our HCV and HIV franchises. We may continue to experience fluctuating revenues from these businesses as infection rates rise and fall and as shelter in place restrictions are periodically tightened and eased. We have also experienced, and may continue to experience, volatility in our short-term revenues due to fluctuations in inventory channel purchases during the pandemic. We could also have additional unexpected expenses related to the pandemic, which could negatively affect our results of operations. These factors together with the overall uncertainty and disruption caused by the pandemic could result in increased volatility and decreased predictability in our results of operations and volatility in our stock price.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pandemic may also amplify many of the other risks described throughout the &#8220;Risk Factors&#8221; section of this Quarterly Report on Form 10-Q. The extent to which the pandemic impacts our business and results will depend on future developments, which are uncertain and cannot be predicted with confidence, including any potential future waves of the pandemic, new variants of the virus that impact the severity and duration of the pandemic, the development, distribution, effectiveness and public acceptance of vaccines, and any other ongoing and future actions taken to contain the pandemic.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face risks associated with our global operations.</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global operations are accompanied by certain financial, political, economic and other risks, including those listed below:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foreign Currency Exchange: For the three months ended March 31, 2021, approximately 33% of our product sales were outside the United States. Because a significant percentage of our product sales is denominated in foreign currencies, primarily the Euro, we face exposure to adverse movements in foreign currency exchange rates. Overall, we are a net receiver of foreign currencies, and therefore, we benefit from a weaker U.S. dollar and are adversely affected by a stronger U.S. dollar. Our hedging program does not eliminate our exposure to currency fluctuations. We may be adversely impacted if the U.S. dollar appreciates significantly against certain currencies and our hedging program does not sufficiently offset the effects of such appreciation.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Anti-Bribery: We are subject to the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws that govern our international operations with respect to payments to government officials. Our international operations are heavily regulated and require significant interaction with foreign officials. We operate in parts of the world that have experienced governmental corruption to some degree. In certain circumstances, strict compliance with anti-bribery laws may conflict with local customs and practices or may require us to interact with doctors and hospitals, some of which may be state controlled, in a manner that is different than local custom. It is possible that certain of our practices may be challenged under these laws. In addition, our internal control policies and procedures may not protect us from reckless or criminal acts committed by our employees and agents. Enforcement activities under anti-bribery laws could subject us to administrative and legal proceedings and actions, which could result in civil and criminal sanctions, including monetary penalties and exclusion from healthcare programs.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other risks inherent in conducting a global business include:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restrictive government actions against our intellectual property and other foreign assets such as nationalization, expropriation, the imposition of compulsory licenses or similar actions, including waiver of intellectual property protections.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Protective economic policies taken by foreign governments, such as trade protection measures and import and export licensing requirements, which may result in the imposition of trade sanctions or similar restrictions by the United States or other governments.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Business interruptions stemming from natural or man-made disasters, such as climate change, earthquakes, hurricanes, flooding, fires or actual or threatened public health emergencies, or efforts taken by third parties to prevent or mitigate such disasters, such as public safety power shutoffs and facility shutdowns, for which we may be uninsured or inadequately insured. For example, our corporate headquarters in Foster City and certain R&amp;D and manufacturing facilities are located in California, a seismically active region. In the event of a major earthquake, we may not carry adequate earthquake insurance and significant recovery time could be required to resume operations. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Political instability or disruption in a geographic region where we operate, regardless of cause, including war, terrorism, social unrest and political changes. For example, on January 31, 2020, the United Kingdom withdrew from the European Union, which initiated a transition period during which the United Kingdom and the European Union will negotiate their future relationship. There is uncertainty concerning any changes in the laws and regulations governing the conduct of clinical trials and marketing of medicinal products in the United Kingdom following the country&#8217;s exit from the European Union. This uncertainty may lead to significant complexity and risks for our company and our ability to research, develop and market medicinal products in the European Union and the United Kingdom.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We depend on relationships with third parties for sales and marketing performance, technology, development, logistics and commercialization of products. Failure to maintain these relationships, poor performance by these companies or disputes with these third parties could negatively impact our business.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a number of collaborative relationships with third parties for our sales and marketing performance in certain territories. For example, we have collaboration arrangements with Janssen Sciences Ireland UC for Odefsey, Complera/Eviplera and Symtuza. In some countries, we rely on international distributors for sales of certain of our products. Some of these relationships also involve the clinical development of these products by our partners. Reliance on collaborative relationships poses a number of risks, including the risk that:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we are unable to control the resources our corporate partners devote to our programs or products;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise with respect to the ownership of rights to technology developed with our corporate partners;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with our corporate partners could cause delays in, or termination of, the research, development or commercialization of product candidates or result in litigation or arbitration;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contracts with our corporate partners may fail to provide significant protection or may fail to be effectively enforced if one of these partners fails to perform;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our corporate partners have considerable discretion in electing whether to pursue the development of any additional products and may pursue alternative technologies or products either on their own or in collaboration with our competitors;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our corporate partners with marketing rights may choose to pursue competing technologies or to devote fewer resources to the marketing of our products than they do to products of their own development; and</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our distributors and our corporate partners may be unable to pay us.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, there is a great deal of uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed or revenues from products could decline.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Due to the specialized and technical nature of our business, the failure to attract, develop and retain highly qualified personnel could adversely impact us.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success will depend in large part on our continued ability to attract, develop and retain highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, governmental regulation and commercialization. Our ability to do so also depends in part on how well we maintain a strong workplace culture that is attractive to employees. In addition, competition for qualified personnel in the biopharmaceutical field is intense, and there is a limited pool of qualified potential employees to recruit. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. Additionally, changes to U.S. immigration and work authorization laws and regulations could make it more difficult for employees to work in or transfer to one of the jurisdictions in which we operate. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are dependent on information technology systems, infrastructure and data, which may be subject to cyberattacks, security breaches and legal claims.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent upon information technology systems, infrastructure and data, including our Kite Konnect platform, which is critical to maintain chain of identity and chain of custody of Yescarta. The multitude and complexity of our computer systems make them inherently vulnerable to service interruption or destruction, malicious intrusion and random attack. Likewise, data privacy or security breaches by employees or others pose a risk that sensitive data, including our intellectual property or trade secrets or the personal information of our employees, patients, customers or other business partners may be exposed to unauthorized persons or to the public. Cyberattacks are increasing in their frequency, sophistication and intensity, including during the pandemic. Cyberattacks include, for example, the deployment of harmful malware, denial-of-service, social engineering and other means to affect service reliability and threaten data confidentiality, integrity and availability. Our business and technology partners face similar risks and any security breach of their systems could adversely affect our security posture. There can be no assurance that our efforts, or the efforts of our partners and vendors, to invest in the protection of information technology infrastructure and data will prevent future service interruptions or identify breaches in our systems. Such interruptions or breaches could cause the loss of critical or sensitive information, including personal information. In addition, our insurance may not be sufficient in type or amount to cover the losses that may result from an interruption or breach of our systems.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulators globally are also imposing new data privacy and security requirements, including new and greater monetary fines for privacy violations. For example, the General Data Protection Regulation (&#8220;GDPR&#8221;) that became effective in Europe in 2018 established regulations regarding the handling of personal data, and non-compliance with the GDPR may result in monetary penalties of up to four percent of worldwide revenue. In addition, new domestic data privacy and security laws, such as the California Consumer Privacy Act (&#8220;CCPA&#8221;) that became effective in January 2020, and others that may be passed, similarly introduce requirements with respect to personal information, and non-compliance with CCPA may result in liability through private actions (subject to statutorily defined damages in the event of certain data breaches) and enforcement. The GDPR, CCPA and other changes, or new laws or regulations associated with the enhanced protection of personal information, including in some cases healthcare data or other personal information, could greatly increase our cost of providing our products and services or even prevent us from offering certain services in jurisdictions in which we operate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Strategic and Financial Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to risks associated with engaging in business acquisitions, licensing arrangements, collaborations, options, equity investments, asset divestitures and other strategic transactions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have engaged in, and may in the future engage in, such transactions as part of our business strategy. We may not identify suitable transactions in the future and, if we do, we may not complete such transactions in a timely manner, on a cost-effective basis, or at all, and may not realize the expected benefits. If we are successful in making an acquisition or closing a licensing arrangement or collaboration, the products, intellectual property and technologies that are acquired or licensed may not be successful or may require significantly greater resources and investments than anticipated. As part of our annual impairment testing of our goodwill and other indefinite-lived intangible assets in the fourth quarter, and earlier if impairment indicators exist, as required under U.S. generally accepted accounting principles, we may need to recognize impairment charges if the products, intellectual property and technologies that are acquired or licensed are not successful. For option structured deals, there is no assurance that we will elect to exercise our option right, and it is possible that disagreements, uncertainties or other circumstances may arise, including with respect to whether our option rights have been appropriately triggered, which may hinder our ability to realize the expected benefits. For equity investments in our strategic transactions, such as in connection with our collaboration with Galapagos NV, the value of our equity investments may fluctuate and decline in value. If we are not successful in the execution or implementation of these transactions, our financial condition, cash flows and results of operations may be adversely affected, and our stock price could decline.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid substantial amounts of cash and incurred additional debt to finance our strategic transactions. Additional indebtedness and a lower cash balance could result in a downgrade of our credit ratings, limit our ability to borrow additional funds or refinance existing debt on favorable terms, increase our vulnerability to adverse economic or industry conditions, and reduce our financial flexibility to continue with our capital investments, stock repurchases and dividend payments. For example, as a result of the cash used and the debt issued in connection with our acquisition of Immunomedics in 2020, S&amp;P downgraded our credit rating. We may be adversely impacted by any failure to overcome these additional risks.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in our effective income tax rate could reduce our earnings.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes and tax return audits in the United States and various foreign jurisdictions including Ireland. Due to economic and political conditions, various countries are actively considering and have made changes to existing tax laws, and we cannot predict the form or timing of such changes. For example, the new U.S. Presidential administration has proposed to increase the U.S. corporate income tax rate from its current 21%, among numerous other corporate tax reform proposals. There are differing interpretations of tax laws and regulations and, as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We may be adversely affected by the resolution of one or more of these exposures in any reporting period.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, significant judgment is required in determining our worldwide provision for income taxes. Various factors may have favorable or unfavorable effects on our income tax rate including, but not limited to, our portion of the non-deductible annual branded prescription drug fee, the accounting for stock options and other share-based awards, mergers/acquisitions and restructurings, ability to maintain manufacturing and other operational activities in our Irish facilities, changes in the mix of earnings in the various tax jurisdictions in which we operate, changes in overall levels of pre-tax earnings, resolution of federal, state and foreign income tax audits. The impact on our income tax provision resulting from the above mentioned factors may be significant.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i5e8b0e18419843159ec07e1b794d0d87_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our stock repurchase activity for the three months ended March 31, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of Shares&#160;Purchased (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average&#160;Price&#160;Paid per Share (in dollars) </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;Total Number of Shares Purchased as Part of Publicly Announced Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maximum&#160;Approximate Dollar&#160;Value of&#160;Shares that&#160;May&#160;Yet&#160;Be Purchased&#160;Under the Plans or Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> (in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1 - January 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1 - February 28, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1 - March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,157&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,771&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.415%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">________________________________</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">In the first quarter of 2016, our Board of Directors authorized a $12.0 billion share repurchase program (&#8220;2016 Program&#8221;). Shares purchased during the period were made under the 2016 Program. In January 2020, our Board of Directors authorized a new $5.0 billion stock repurchase program, which will commence upon the completion of the 2016 Program. Share repurchases under both programs may be made in the open market or in privately negotiated transactions. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The difference between the total number of shares purchased and the total number of shares purchased as part of a publicly announced program is due to shares of common stock withheld by us from employee restricted stock awards in order to satisfy applicable tax withholding obligations.</span></div></td></tr></table></div><div id="i5e8b0e18419843159ec07e1b794d0d87_112"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i5e8b0e18419843159ec07e1b794d0d87_115"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i5e8b0e18419843159ec07e1b794d0d87_118"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i5e8b0e18419843159ec07e1b794d0d87_121"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reference is made to the Exhibit Index included herein.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="i5e8b0e18419843159ec07e1b794d0d87_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit Index</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.898%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.618%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Exhibit<br/>Footnote</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Description of Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000095010320017822/dp136480_ex0201.htm">Agreement and Plan of Merger, dated September 13, 2020, among Immunomedics, Inc., Gilead Sciences, Inc. and Maui Merger Sub, Inc.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465919028215/a19-9678_1ex3d2.htm">Restated Certificate of Incorporation of Registrant</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465919028215/a19-9678_1ex3d3.htm">Amended and Restated Bylaws of Registrant</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Reference is made to Exhibit 3.1 and Exhibit 3.2</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511086814/dex41.htm">Indenture related to Senior Notes, dated as of March&#160;30, 2011, between Registrant and Wells Fargo, National Association, as Trustee</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511086814/dex42.htm">First Supplemental Indenture related to Senior Notes, dated as of March 30, 2011, between Registrant and Wells Fargo, National Association, as Trustee (including form of Senior Notes)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511339157/d269235dex41.htm">Second Supplemental Indenture related to Senior Notes, dated as of December 13, 2011, between Registrant and Wells Fargo, National Association, as Trustee (including </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511339157/d269235dex41.htm">Form of 2041 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514089047/d688498dex41.htm">Third Supplemental Indenture related to Senior Notes, dated as of March 7, 2014, between Registrant and Wells Fargo, National Association, as Trustee (including Form of 2024 Note</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514089047/d688498dex41.htm"> a</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514089047/d688498dex41.htm">nd</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514089047/d688498dex41.htm"> Form of 2044 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514415184/d821656dex41.htm">Fourth Supplemental Indenture related to Senior Notes, dated as of November 17, 2014, between Registrant and Wells Fargo, National Association, as Trustee (including </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514415184/d821656dex41.htm">Form of 2025 Note</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514415184/d821656dex41.htm"> a</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514415184/d821656dex41.htm">nd</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514415184/d821656dex41.htm"> Form of 2045 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312515319560/d68529dex41.htm">Fifth Supplemental Indenture, dated as of September 14, 2015, between Registrant and Wells Fargo Bank, National Association, as Trustee (including</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312515319560/d68529dex41.htm"> Form of 2026 Note, Form of 2035 Note and Form of 2046 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312516714926/d259911dex41.htm">Sixth Supplemental Indenture, dated as of September 20, 2016, between Registrant and Wells Fargo Bank, National Association, as Trustee (including </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312516714926/d259911dex41.htm">Form of 2023 Note, Form of 2027 Note, Form of 2036 Note and Form of 2047 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465920110185/tm2031940d2_ex4-1.htm">Eighth Supplemental Indenture, dated as of September 30, 2020, between the Company and Wells Fargo Bank, National Association, as Trustee (including form of notes)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000006/gild2019form10-kex49.htm">Description of Registrant&#8217;s Securities</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(11)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312517168672/d396034dex101.htm">Gilead Sciences, Inc. 2004 Equity Incentive Plan, amended and restated May 10, 2017</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(12)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000008/gild20ormex102amendmentto2.htm">Amendment No. 1 to Gilead Sciences, Inc. 2004 Equity Incentive Plan, amended and restated May 10, 2017</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511132405/dex1042.htm">Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.4*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex104.htm">Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.5*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000027/gildq32019ex105.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.6*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex105.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex105.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex105.htm"> in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.7*,**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gildq12021ex1072021employe.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants commencing in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.8*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312509165506/dex1019.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2009 through 2012)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(18)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.9*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209513000038/gildq21310-qex1043.htm">Form of non-employee director stock option agreement (U.S.) under 2004 Equity Incentive Plan (for grants made in 2013)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(18)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.10*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209513000038/gildq21310-qex1044.htm">Form of non-employee director stock option agreement (non-U.S.) under 2004 Equity Incentive Plan (for grants made in 2013)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(19)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.11*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209514000038/ex1045-stockoptionagreement.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2014 through 2018)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.12*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex109.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex109.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex109.htm"> in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.13*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10112020no.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10112020no.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10112020no.htm"> in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.14*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1012.htm">Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.15*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1013.htm">Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1013.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1013.htm"> in 2020)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.16*,**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gildq12021ex10162021psuagr.htm">Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants commencing in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.17*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1015.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.18*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1017.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1017.htm">ma</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1017.htm">de</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1017.htm"> in 2020)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.19*,**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gildq12021ex10192021psuagr.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants commencing in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.20*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511132405/dex1057.htm">Form of employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.21*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1017.htm">Form of employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.22*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000027/gildq32019ex1020.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.23*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1024.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1024.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1024.htm"> in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.898%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.618%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.24*,**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gildq12021ex10242021employ.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants commencing in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.25*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10262020no.htm">Form of non-employee director restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10262020no.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10262020no.htm"> in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.26*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10272018eq.htm">Gilead Sciences, Inc. 2018 Equity Incentive Plan, amended and restated April 7, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(21) </span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.27*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209515000015/exhibit101-espp.htm">Gilead Sciences, Inc. Employee Stock Purchase Plan, amended and restated January 22, 2015</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.28*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1020.htm">Gilead Sciences, Inc. 2005 Deferred Compensation Plan, amended and restated April 19, 2016</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.29*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex1030severa.htm">Gilead Sciences, Inc. Severance Plan, amended and restated May 5, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.30*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1028.htm">Gilead Sciences, Inc. Corporate Annual Incentive Plan, amended and restated January 1, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(23)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.31*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465918072098/a18-41320_1ex99d2.htm">Offer Letter between Registrant and Daniel O&#8217;Day, dated November 30, 2018</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.32*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1027.htm">Stock option agreement for Daniel O&#8217;Day under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.33*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1028.htm">Performance share award agreement for Daniel O&#8217;Day (for TSR Goals in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.34*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1029.htm">Performance share award agreement for Daniel O&#8217;Day (for Revenue Goals in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.35*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1029.htm">Form of restricted stock unit issuance agreement for Daniel O&#8217;Day (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.36*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1026.htm">Offer Letter between Registrant and Johanna Mercier, dated May 21, 2019</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.37*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex1043housin.htm">Letter Agreement between Registrant and Johanna Mercier, dated May 4, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.38*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1040.htm">Global stock option agreement for Johanna Mercier (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.39*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1041.htm">Restricted stock unit issuance agreement for Johanna Mercier (for Performance Objectives in 2019-2020) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.40*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1042.htm">Global restricted stock unit issuance agreement for Johanna Mercier (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.41*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1043.htm">Offer Letter between Registrant and Merdad Parsey, dated September 29, 2019</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.42*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1044.htm">Global stock option agreement for Merdad Parsey (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.43*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1045.htm">Global restricted stock unit issuance agreement for Merdad Parsey (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(24)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.44*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Form of Indemnity Agreement entered into between Registrant and its directors and executive officers</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(24)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.45*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Form of Employee Proprietary Information and Invention Agreement entered into between Registrant and certain of its officers and key employees</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(25)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.46*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312507041203/dex103.htm">Form of Employee Proprietary Information and Invention Agreement entered into between Registrant and certain of its officers and key employees (revised September&#160;2006)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(26)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.47</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amendment Agreement, dated October&#160;25, 1993, between Registrant, the Institute of Organic Chemistry and Biochemistry (IOCB) and Rega Stichting v.z.w. (REGA), together with the following exhibits: the License Agreement, dated December&#160;15, 1991, between Registrant, IOCB and REGA (the 1991 License Agreement); the License Agreement, dated October&#160;15, 1992, between Registrant, IOCB and REGA (the October 1992 License Agreement); and the License Agreement, dated December&#160;1, 1992, between Registrant, IOCB and REGA (the December 1992 License Agreement)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(27)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.48</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000091205701007841/a2041233zex-10_13.txt">Amendment Agreement between Registrant and IOCB/REGA, dated December&#160;27, 2000, amending the 1991 License Agreement and the December 1992 License Agreement</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(28)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312506223996/dex103.htm">Sixth Amendment Agreement to the License Agreement, between IOCB/REGA and Registrant, dated August&#160;18, 2006, amending the October 1992 License Agreement and the December 1992 License Agreement</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(29)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.50</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209513000046/q313form10-qxexhibit1078.htm">Seventh Amendment Agreement to the License Agreement, between IOCB/REGA and Registrant, dated July 1, 2013, amending the October 1992 License Agreement and the December 1992 License Agreement</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(30)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.51</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022622/000091205799003190/0000912057-99-003190.txt">Exclusive License Agreement by and between Registrant (as successor to Triangle Pharmaceuticals, Inc.), Glaxo Group Limited, The Wellcome Foundation Limited, Glaxo Wellcome Inc. and Emory University, dated May&#160;6, 1999</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(31)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.52</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312505216649/dex102.htm">Royalty Sale Agreement by and among Registrant, Emory University and Investors Trust &amp; Custodial Services (Ireland) Limited, solely in its capacity as Trustee of Royalty Pharma, dated July&#160;18, 2005</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(31)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.53</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312505216649/dex102.htm">Amended and Restated License Agreement by and between Registrant, Emory University and Investors Trust &amp; Custodial Services (Ireland) Limited, solely in its capacity as Trustee of Royalty Pharma, dated July&#160;21, 2005</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;++(32)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.54</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000008/gild2018form10-kaexhibit1042.htm">Amended and Restated EVG License Agreement by and between Japan Tobacco Inc. and Registrant, dated November 29, 2018</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;++(32)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.55</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000008/gild2018form10-kaexhibit1043.htm">Master Agreement by and between Registrant, Gilead Sciences K.K. and Japan Tobacco Inc., dated November 29, 2018</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(33)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.56</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209515000008/ex1076-arcollaborationagre.htm">Amended and Restated Collaboration Agreement by and among Registrant, Gilead Sciences Ireland UC (formerly Gilead Sciences Limited) and Janssen R&amp;D Ireland, dated December 23, 2014</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(34)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.57</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1510580/000119312514239257/d705296dex1017.htm">License Agreement by and among Kite Pharma, Inc., Cabaret Biotech Ltd. and Dr. Zelig Eshhar, dated December 12, 2013</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;++(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.58</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000027/gildq32019ex1050.htm">Option, License and Collaboration Agreement by and between Galapagos NV and Registrant, dated July 14, 2019</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">31.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gildq12021ex311ceocertific.htm">Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.898%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.618%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">31.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gildq12021ex312cfocertific.htm">Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">32***</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gildq12021ex32section906ce.htm">Certifications of Chief Executive Officer and Chief Financial Officer, as required by Rule 13a-14(b) or Rule&#160;15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.INS**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.SCH**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.CAL**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.DEF**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.LAB**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.PRE**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cover Page Interactive Data File, formatted in Inline XBRL (included as Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 14, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on May 9, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on April&#160;1, 2011, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on December 13, 2011, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on March 7, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on November 17, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(7)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 14, 2015, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(8)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 20, 2016, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(9)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 30, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(10)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(11)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on May 12, 2017, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(12)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(13)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2011, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(14)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(15)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(16)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(17)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2009, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(18)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2013, and incorporated herein by reference</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(19)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(20)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(21)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on May 8, 2015, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(22)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(23)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on December 10, 2018, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(24)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Registration Statement on Form S-1 (No. 33-55680), as amended, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(25)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2006, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(26)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended March&#160;31, 1994, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(27)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2000, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(28)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2006, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(29)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(30)&#160;&#160;&#160;&#160;Filed as an exhibit to Triangle Pharmaceuticals, Inc.&#8217;s Quarterly Report on Form 10-Q/A filed on November&#160;3, 1999, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(31)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2005, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(32)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Amendment No. 1 to Annual Report on Form 10-K/A filed on April 18, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(33)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2014, and incorporated herein by reference.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(34)&#160;&#160;&#160;&#160;Filed as an exhibit to Kite Pharma, Inc.&#8217;s Registration Statement on Form S-1/A (No. 333-196081) filed on June 17, 2014, and incorporated herein by reference.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Filed herewith.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">***&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Certain confidential portions of this Exhibit were omitted by means of marking such portions with an asterisk (the Mark). This Exhibit has been filed separately with the Secretary of the Securities and Exchange Commission without the Mark pursuant to Registrant&#8217;s Application Requesting Confidential Treatment under Rule 24b-2 under the Securities Exchange Act of 1934, as amended.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Certain confidential portions of this Exhibit were omitted by means of marking such portions with the Mark because the identified confidential portions are (i) not material and (ii) would be competitively harmful if publicly disclosed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i5e8b0e18419843159ec07e1b794d0d87_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GILEAD SCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 6, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ DANIEL P. O&#8217;DAY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Daniel P. O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Day</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 6, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ ANDREW D. DICKINSON</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Andrew D. Dickinson<br/>Chief Financial Officer<br/>(Principal Financial Officer)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>2
<FILENAME>gildq12021ex1072021employe.htm
<DESCRIPTION>2021 EMPLOYEE STOCK OPTION AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib4ac2b42411e4e54a560352b4a59506f_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT 10.7</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">GLOBAL STOCK OPTION AGREEMENT </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">RECITALS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;This Agreement is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Company&#8217;s grant of an option to Optionee.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;All capitalized terms used but not otherwise defined in this Agreement shall have the meaning assigned to them in the attached Appendix.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company hereby grants an option to Optionee upon the following terms and conditions&#58;</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Grant of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company hereby grants to Optionee an option to purchase shares of Common Stock under the Plan. The Grant Date, the Option Shares, the Exercise Price, the Vesting Schedule and the Expiration Date are indicated on this Agreement. The option is a non-statutory option under the U.S. federal income tax laws. The remaining terms and conditions governing this option shall be as set forth in this Agreement.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OPTION GRANT SPECIFICS</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Name of Optionee&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Grant Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Number of Option Shares&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Vesting Schedule&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The options have a four-year vesting schedule. 25% vest on the first anniversary date of the Grant Date. The balance will vest 6.25% quarterly thereafter until fully vested. However, one or more Shares may be subject to accelerated vesting in accordance with the provisions of Paragraph 3 or 5 of this Agreement.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Expiration Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Option Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The term of this option shall commence on the Grant Date and continue to be in effect until the close of business on the last business day prior to the Expiration Date, unless sooner terminated in accordance with Paragraph 5 or 6 below.</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Transferability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> This option shall be neither transferable nor assignable by Optionee other than by will or the laws of inheritance following Optionee&#8217;s death and may be exercised, during Optionee&#8217;s lifetime, only by Optionee.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Dates of Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> This option shall vest and become exercisable for the Option Shares in a series of installments in accordance with the Vesting Schedule set forth under Option Grant Specifics. As the option vests and becomes exercisable for such installments, those installments shall accumulate, and the option shall remain exercisable for the accumulated installments until the last business day prior to the Expiration Date or any sooner termination of the option term under Paragraph 5 or 6 below.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Cessation of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The option term specified in Paragraph 2 above shall terminate (and this option shall cease to be outstanding) prior to the Expiration Date should any of the following provisions become applicable&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Except as otherwise expressly provided in subparagraphs (b) through (f) of this Paragraph 5, should Optionee cease to remain in Continuous Service for any reason while this option is outstanding, then Optionee shall have until the close of business on the last business day prior to the expiration of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the expiration of the three (3)-month period measured from the date of such cessation of Continuous Service, or (ii) the Expiration Date, during which to exercise this option for any or all of the Option Shares for which this option is vested and exercisable at the time of Optionee&#8217;s cessation of Continuous Service. Upon the expiration of such limited exercise period, this option shall terminate and cease to be outstanding for any exercisable Option Shares for which the option has not otherwise been exercised.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">In the event Optionee ceases Continuous Service by reason of his or her death while this option is outstanding, then this option may be exercised, for any or all of the Option Shares for which this option is vested and exercisable at the time of Optionee&#8217;s cessation of Continuous Service, by (i) the personal representative of Optionee&#8217;s estate or (ii) the person or persons to whom the option is transferred pursuant to Optionee&#8217;s will or the laws of inheritance following Optionee&#8217;s death. Any such right to exercise this option shall lapse, and this option shall cease to be outstanding, upon the close of business on the last business day prior to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (A) the expiration of the twelve (12)-month period measured from the date of Optionee&#8217;s death or (B) the Expiration Date. Upon the expiration of such limited exercise period, this option shall terminate and cease to be outstanding for any exercisable Option Shares for which the option has not otherwise been exercised.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Should Optionee cease Continuous Service by reason of Permanent Disability while this option is outstanding, then Optionee shall have until the close of business on the last business day prior to the earlier of (i) expiration of the twelve (12)-month period measured from the date of such cessation of Continuous Service, or (ii) the Expiration Date, during which to exercise this option for any or all of the Option Shares for which this option is vested and exercisable at the time of such cessation of Continuous Service. Upon the expiration of such limited exercise period, this option shall terminate and cease to be outstanding for any exercisable Option Shares for which the option has not otherwise been exercised.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Should Optionee (i) cease Continuous Service at least twelve (12) months following the Grant Date and (ii) (x) after attaining age 55 and completing at least ten (10) years of Continuous Service or (y) after attaining age 65, then Optionee shall (1) continue to vest in any unvested options granted hereunder in accordance with the Vesting Schedule set forth under Option Grant Specifics as if such Optionee had remained in Continuous Service&#59; and (2) have until the close of business on the last business day prior to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of&#58; (A) expiration of the five (5) year period measured from the date of such cessation of Continuous Service, or (B) the Expiration Date, during which to exercise this option for any or all of the Option Shares for which this option is vested and exercisable at the time of such cessation of Continuous Service or becomes vested and exercisable following such cessation of Continuous Service in accordance </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with this subparagraph (d). If Optionee, as of December 31, 2018, (I) is in Salary Grade 35 or above, (II) has completed at least three (3) years of Continuous Service, and (III) the sum of Optionee&#8217;s attained age and completed years of Continuous Service equals or exceeds seventy (70) years, he or she shall be deemed to satisfy the requirements of subparagraph (d)(ii) above. Notwithstanding the foregoing, if the Company receives an opinion of counsel that there has been a legal judgment and&#47;or legal development in Optionee&#8217;s jurisdiction that would likely result in the favorable treatment applicable to the option pursuant to this subparagraph (d) being deemed unlawful and&#47;or discriminatory, then the Company will not apply this favorable treatment at the time of Optionee&#8217;s cessation of Continuous Service, and the option will be treated as set forth in the other subparagraphs of this Paragraph 5, as applicable.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The applicable period of post-service exercisability in effect pursuant to the foregoing provisions of this Paragraph 5 shall automatically be extended by an additional period of time equal in duration to any interval within such post-service exercise period during which the exercise of this option or the immediate sale of the Option Shares acquired under this option cannot be effected in compliance with applicable federal, state and foreign securities laws, but in no event shall such an extension result in the continuation of this option beyond the close of business on the last business day prior to the Expiration Date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">Notwithstanding any other provision hereof, should Optionee&#8217;s Continuous Service be terminated for Cause (or for a reason that is comparable to termination for Cause under employment laws in the jurisdiction where Optionee is employed or the terms of Optionee&#8217;s employment agreement, if any), or should Optionee engage in any other conduct, while in Continuous Service or following cessation of Continuous Service, that is materially detrimental to the business or affairs of the Company (or any Related Entity), as determined in the sole discretion of the Administrator, then this option, whether or not vested and exercisable at the time, shall terminate immediately and cease to be outstanding.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">During the limited period of post-service exercisability provided under this Paragraph 5, this option may not be exercised in the aggregate for more than the number of Option Shares for which this option is at the time vested and exercisable. Except as set forth in Section 5(d) or to the extent (if any) specifically authorized by the Administrator pursuant to an express written agreement with Optionee, this option shall not vest or become exercisable for any additional Option Shares, whether pursuant to the normal Vesting Schedule set forth under Option Grant Specifics or the special vesting acceleration provisions of Paragraph 6 below, following Optionee&#8217;s cessation of Continuous Service. Upon the expiration of such limited exercise period or (if earlier) upon the close of business on the last business day prior to the Expiration Date, this option shall terminate and cease to be outstanding for any exercisable Option Shares for which the option has not otherwise been exercised.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Special Acceleration of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">This option, to the extent outstanding at the time of an actual Change in Control but not otherwise fully exercisable, shall automatically accelerate so that this option shall, immediately prior to the effective date of such Change in Control, become exercisable for all of the Option Shares at the time subject to this option and may be exercised </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">for any or all of those Option Shares as fully vested shares of Common Stock. However, this option shall not become exercisable on such an accelerated basis if and to the extent&#58; (i) this option is to be assumed by the successor corporation (or parent thereof) or is otherwise to continue in full force and effect pursuant to the terms of the Change in Control transaction, (ii) this option is to be replaced with an economically-equivalent substitute equity award or (iii) this option is to be replaced with a cash retention program of the successor corporation which preserves the spread existing at the time of the Change in Control on any Option Shares for which this option is not otherwise at that time vested and exercisable (the excess of the Fair Market Value of those Option Shares over the aggregate Exercise Price payable for such shares) and provides for the subsequent vesting and concurrent payout of that spread in accordance with the same Vesting Schedule for those Option Shares as set forth under Option Grant Specifics. Notwithstanding the foregoing, no such cash retention program shall be established for this option (or any other option granted to Optionee under the Plan) to the extent such program would otherwise be deemed to constitute a deferred compensation arrangement subject to the requirements of Code Section 409A and the Treasury Regulations thereunder.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Immediately following the consummation of the Change in Control, this option shall terminate and cease to be outstanding, except to the extent assumed by the successor corporation (or parent thereof) or otherwise continued in effect pursuant to the terms of the Change in Control transaction.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">If this option is assumed in connection with a Change in Control or otherwise continued in effect, then this option shall be appropriately adjusted, immediately after such Change in Control, to apply to the number and class of securities into which the shares of Common Stock subject to this option would have been converted in consummation of such Change in Control had those shares actually been outstanding at the time. Appropriate adjustments shall also be made to the Exercise Price, provided the aggregate Exercise Price shall remain the same. To the extent the actual holders of the Company&#8217;s outstanding Common Stock receive cash consideration for their Common Stock in consummation of the Change in Control, the successor corporation may, in connection with the assumption or continuation of this option but subject to the Administrator&#8217;s approval, substitute one or more shares of its own common stock with a fair market value equivalent to the cash consideration paid per share of Common Stock in such Change in Control, provided such common stock is readily tradable on an established U.S. securities exchange or market.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">If this option is assumed or otherwise continued in effect in connection with a Change in Control or replaced with an economically-equivalent equity award or a cash retention program in accordance with Paragraph 6(a) above, then&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:93.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)  the option (or such economically equivalent award) shall vest and become immediately exercisable for all of the Option Shares or other securities at the time subject to the option (or such award) and may, within the applicable exercise period under Paragraph 5, be exercised for any or all of those Option Shares or other securities as fully vested shares or securities, or</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:90.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) the balance credited to Optionee under any cash retention program established in accordance with Paragraph 6(a) shall immediately be paid to Optionee in a lump sum, subject to the Company&#8217;s collection of all applicable Withholding Taxes&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">if, within the period beginning with the execution date of the definitive agreement for the Change in Control transaction and ending with the earlier of (i) the termination of that definitive agreement without the consummation of such Change in Control or (ii) the expiration of the Applicable Acceleration Period following the consummation of such Change in Control, Optionee&#8217;s Continuous Service terminates due to an involuntary termination (other than for death or Permanent Disability) without Cause (or without a reason that is comparable to termination for Cause under employment laws in the jurisdiction where Optionee is employed or the terms of Optionee&#8217;s employment agreement, if any) or a voluntary termination by Optionee due to Constructive Termination.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">This Agreement shall not in any way affect the right of the Company to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Adjustment in Option Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Should any change be made to the Common Stock by reason of any stock split, stock dividend, recapitalization, combination of shares, exchange of shares, spin-off transaction, or other change affecting the outstanding Common Stock as a class without the Company&#8217;s receipt of consideration, or should the value of outstanding shares of Common Stock be substantially reduced as a result of a spin-off transaction or an extraordinary dividend or distribution, or should there occur any merger, consolidation or other reorganization, then equitable and proportional adjustments shall be made by the Administrator to (i) the total number and&#47;or class of securities subject to this option and (ii) the Exercise Price. The adjustments shall be made in such manner as the Administrator deems appropriate in order to reflect such change and thereby prevent the dilution or enlargement of benefits hereunder, and those adjustments shall be final, binding and conclusive upon Optionee and any other person or persons having an interest in the option. In the event of any Change in Control transaction, the adjustment provisions of Paragraph 6(c) above shall be controlling.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Stockholder Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The holder of this option shall not have any stockholder rights including voting, dividend or liquidation rights, with respect to the Option Shares until such person shall have exercised the option, paid the Exercise Price and become a holder of record of the purchased shares.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Manner of Exercising Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">In order to exercise this option with respect to all or any part of the Option Shares for which this option is at the time exercisable, Optionee (or any other person or persons exercising the option) must take the following actions&#58;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:96.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) Execute and deliver to the Company a Notice of Exercise as to the Option Shares for which the option is exercised or comply with such other procedures as the Company may establish for notifying the Company, either directly or through an on-line internet transaction with a brokerage firm authorized by the Company to effect such option exercises, of the exercise of this option for one or more Option Shares.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:93.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) Pay the aggregate Exercise Price for the purchased shares in one or more of the following forms&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.36pt">cash or check made payable to the Company&#59; or</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.02pt">through a special sale and remittance procedure pursuant to which Optionee (or any other person or persons exercising the option) shall concurrently provide irrevocable instructions (i) to a brokerage firm (reasonably satisfactory to the Company for purposes of administering such procedure in accordance with the Company&#8217;s pre-clearance&#47;pre- notification policies) to effect the immediate sale of all or a sufficient portion of the purchased shares so that such brokerage firm can remit to the Company, on the settlement date, sufficient funds out of the resulting sale proceeds to cover the aggregate Exercise Price payable for all the purchased shares plus all applicable Withholding Taxes and (ii) to the Company to deliver the purchased shares directly to such brokerage firm on such settlement date.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except to the extent the sale and remittance procedure is utilized in connection with the option exercise, payment of the Exercise Price must accompany the Notice of Exercise (or other notification procedure) delivered to the Company in connection with the option exercise.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Furnish to the Company appropriate documentation that the person or persons exercising the option (if other than Optionee) have the right to exercise this option.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Make appropriate arrangements with the Company (or the Employer) for the satisfaction of all applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">As soon as practical after the Exercise Date, the Company shall issue to or on behalf of Optionee (or any other person or persons exercising this option) the purchased Option Shares, subject to appropriate restrictions, if any.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">In no event may this option be exercised for any fractional shares.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Responsibility for Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Optionee acknowledges that, regardless of any action the Company and&#47;or the Employer take with respect to any or all Withholding Taxes, the ultimate liability for all Withholding Taxes is and remains Optionee&#8217;s responsibility and may exceed the amount actually withheld by the Company or the Employer. Optionee further acknowledges that the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company and&#47;or the Employer (i) make no representations or undertakings regarding the treatment of any Withholding Taxes in connection with any aspect of the option, including the grant, vesting or exercise of the options, the subsequent sale of any shares of Common Stock acquired at exercise and the receipt of any dividends&#59; and (ii) do not commit to, and are under no obligation to, structure the terms of the grant or any aspect of the option to reduce or eliminate Optionee&#8217;s liability for Withholding Taxes or achieve any particular tax result. Further, if Optionee is subject to Withholding Taxes in more than one jurisdiction, Optionee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Withholding Taxes in more than one jurisdiction.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Prior to the relevant taxable event, Optionee agrees to make arrangements satisfactory to the Company and&#47;or the Employer to satisfy all Withholding Taxes. In this regard, Optionee authorizes the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Withholding Taxes by one or a combination of the following&#58;</font></div><div style="margin-top:12pt;padding-left:112.5pt;text-align:justify;text-indent:60.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.5pt">withholding&#160;&#160;&#160;&#160;from&#160;&#160;&#160;&#160;any&#160;&#160;&#160;&#160;wages&#160;&#160;&#160;&#160;or&#160;&#160;&#160;&#160;other&#160;&#160;&#160;&#160;cash compensation paid to Optionee by the Company and&#47;or the Employer&#59; or</font></div><div style="margin-top:12pt;padding-left:112.5pt;text-align:justify;text-indent:57.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.5pt">withholding from the proceeds of the sale of shares of Common Stock acquired upon exercise of the option.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Depending on the withholding method, the Company may withhold or account for Withholding Taxes by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates, in which case Optionee will receive a refund of any over-withheld amount in cash and will have no entitlement to the Common Stock equivalent. Optionee shall pay to the Company and&#47;or the Employer any amount of Withholding Taxes that the Company and&#47;or the Employer may be required to withhold as a result of Optionee&#8217;s participation in the Plan that cannot be satisfied by the means previously described. The Company may refuse to deliver any purchased Option Shares or the proceeds of the sale of shares if Optionee fails to comply with Optionee&#8217;s obligations in connection with the Withholding Taxes</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Compliance with Laws and Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The exercise of this option and the issuance of the Option Shares upon such exercise shall be subject to compliance by the Company and Optionee with all Applicable Laws relating thereto, as determined by counsel for the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The inability of the Company to obtain approval from any regulatory body having authority deemed by the Company to be necessary to the lawful issuance and sale of any Common Stock pursuant to this option shall relieve the Company of any liability with respect to the non-issuance or sale of the Common Stock as to which such approval shall not have been obtained. The Company, however, shall use its reasonable best efforts to obtain all such approvals.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Optionee may be subject to insider trading restrictions and&#47;or market abuse laws based on the exchange on which the shares of Common Stock are listed and in applicable jurisdictions including the United States and Optionee&#8217;s country or his or her broker&#8217;s country, if different, which may affect Optionee&#8217;s ability to accept, acquire, sell or otherwise dispose of shares of Common Stock, rights to shares of Common Stock (e.g., options) or rights linked to the value of shares of Common Stock during such times as Optionee is considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws in applicable jurisdictions). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders Optionee placed before he or she possessed inside information. Furthermore, Optionee could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable insider trading policy of the Company. Optionee acknowledges that it is Optionee&#8217;s responsibility to comply with any applicable restrictions and Optionee should speak with his or her personal legal advisor on this matter.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Successors and Assigns.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Except to the extent otherwise provided in Paragraphs 3 and 6 above, the provisions of this Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns and Optionee, Optionee&#8217;s assigns, the legal representatives, heirs and legatees of Optionee&#8217;s estate.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and addressed to the Company at its principal corporate offices. Any notice required to be given or delivered to Optionee shall be in writing and addressed to Optionee at the most current address then indicated for Optionee on the Company&#8217;s employee records or shall be delivered electronically to Optionee through the Company&#8217;s electronic mail system or through an on-line brokerage firm authorized by the Company to effect option exercises through the internet. All notices shall be deemed effective upon personal delivery or delivery through the Company&#8217;s electronic mail system or upon deposit in the U.S. or local country mail, postage prepaid and properly addressed to the party to be notified.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement and the option evidenced hereby are made and granted pursuant to the Plan and are in all respects limited by and subject to the terms of the Plan. In the event of any conflict between the provisions of this Agreement and the terms of the Plan, the terms of the Plan shall be controlling. All decisions of the Administrator with respect to any question or issue arising under the Plan or this Agreement shall be conclusive and binding on all persons having an interest in this option.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The interpretation, performance and enforcement of this Agreement shall be governed by the laws of the State of Delaware without resort to Delaware&#8217;s conflict-of- laws rules.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this option and this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of the State of California and agree that such litigation shall be conducted only in the courts of San Mateo County, California, or the federal courts for the Northern District of California, and no other courts where the grant of this option is made and&#47;or to be performed.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Optionee acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by Optionee or other Optionees.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Excess Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> If the Option Shares covered by this Agreement exceed, as of the Grant Date, the number of shares of Common Stock which may without stockholder approval be issued under the Plan, then this option shall be void with respect to those excess shares, unless stockholder approval of an amendment sufficiently increasing the number of shares of Common Stock issuable under the Plan is obtained in accordance with the provisions of the Plan. In no event shall the option be exercisable with respect to any of the excess Option Shares unless and until such stockholder approval is obtained.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Leaves of Absence.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The following provisions shall govern leaves of absence, except to the extent the application of such provisions to Optionee would contravene employment laws in the jurisdiction where Optionee is employed or the terms of Optionee&#8217;s employment agreement, if any.</font></div><div style="margin-top:12pt;padding-left:40.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.2pt">For purposes of this Agreement, Optionee&#8217;s Continuous Service shall not be deemed to cease during any period for which Optionee is on a military leave, sick leave or other personal leave approved by the Company. However, Optionee shall not receive any Continuous Service credit, for purposes of vesting in this option and the Option Shares pursuant to the Vesting Schedule set forth under Option Grant Specifics, for any period of such leave of absence, except to the extent otherwise required by employment laws in the jurisdiction where Optionee is employed or the terms of Optionee&#8217;s employment agreement, if any or pursuant to the following policy&#58;</font></div><div style="margin-top:12pt;padding-left:76.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25.5pt">Optionee shall receive Continuous Service credit for such vesting purposes for (i) the first three (3) months of an approved personal leave of absence or (ii) the first seven (7) months of any bona fide leave of absence (other than an approved personal leave), but in no event beyond the expiration date of such leave of absence.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:40.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In no event shall Optionee be deemed to remain in Continuous Service at any time after the earlier of (i) the expiration date of his or her leave of absence, unless Optionee returns to active Continuous Service on or before that date, or (ii) the date Optionee&#8217;s Continuous Service actually terminates by reason of his or her voluntary or involuntary termination or by reason of his or her death or Permanent Disability.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Acknowledgment of Nature of Plan and Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In accepting the option, Optionee acknowledges, understands and agrees that&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the Plan is established voluntarily by the Company, it is discretionary in nature, and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the option is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of options, or benefits in lieu of options, even if options have been granted in the past&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">all decisions with respect to future options, if any, will be at the sole discretion of the Company&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the option grant and Optionee&#8217;s participation in the Plan shall not create a right to employment or be interpreted as forming or amending an employment or service contract with the Company, the Employer or any Related Entity and shall not interfere with the ability of the Company, the Employer or any Related Entity, as applicable, to terminate Optionee&#8217;s employment or service relationship (if any)&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Optionee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">the option and the Option Shares, and the income and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the option and the Option Shares, and the income and value of same, are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, holiday pay, bonuses, long-service awards, leave-related payments, pension or retirement or welfare benefits or similar payments&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the future value of the Option Shares is unknown, indeterminable and cannot be predicted with any certainty&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">if the Option Shares do not increase in value, the option will have no value&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">if Optionee exercises his or her option and obtains the Option Shares, the value of those Option Shares acquired upon exercise may increase or decrease in value, even below the Exercise Price&#59;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the option resulting from termination of Optionee&#8217;s Continuous Service by the Employer or the Company (or any Related Entity) (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Optionee is employed or the terms of Optionee&#8217;s employment agreement, if any), and in consideration of the Award, Optionee irrevocably agrees not to institute any claim against the Company, the Employer or any Related Entity, waives his or her ability, if any, to bring any such claim and releases the Company, the Employer and any Related Entity from any such claim&#59; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, Optionee shall be deemed irrevocably to have agreed not to pursue such claim and agrees to execute any and all documents necessary to request dismissal or withdrawal of such claim&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">unless otherwise agreed with the Company in writing, the option and the Option Shares, and the income and value of same, are not granted as consideration for, or in connection with, any service Optionee may provide as a director of the Company or a Related Entity&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">unless otherwise provided in the Plan or by the Company in its discretion, the option and the benefits evidenced by this Agreement do not create any entitlement to have the option or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Option Shares&#59; and</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the following provisions apply only if Optionee is providing services outside the United States&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">the option and the Option Shares, and the income and value of same, are not part of normal or expected compensation or salary for any purpose&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">Optionee acknowledges and agrees that neither the Company, the Employer nor any Related Entity shall be liable for any foreign exchange rate fluctuation between Optionee&#8217;s local currency and the United States Dollar that may affect the value of the option or of any amounts due to Optionee pursuant to the exercise of the option or the subsequent sale of any Option Shares acquired upon exercise.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Optionee&#8217;s participation in the Plan or Optionee&#8217;s acquisition or sale of the Option Shares. Optionee should consult with his or her personal tax, legal and financial advisors regarding his or her participation in the Plan before taking any action related to the Plan.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Data Privacy Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. By electing to participate in the Plan via the Company&#8217;s online acceptance procedure, Optionee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Personal Data (as defined below) by the Company and the transfer of Personal Data to the recipients mentioned herein, including recipients located in countries which do not adduce an adequate level of protection from a European (or other) data protection law perspective, for the purposes described herein.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that he or she needs to review the following information about the processing of his or her personal data by or on behalf of the Company, the Employer and&#47;or any Related Entity as described in the Agreement and any other Plan materials (the &#8220;Personal Data&#8221;) and declare his or her consent. As regards the processing of Optionee&#8217;s Personal Data in connection with the Plan and this Agreement, Optionee understands that the Company is the controller of his or her Personal Data.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">Data Processing and Legal Basis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. The Company collects, uses and otherwise processes Personal Data about Optionee for the purposes of allocating shares of Common Stock and implementing, administering and managing the Plan. Optionee understands that this Personal Data may include, without limitation, his or her name, home address and telephone number, email address, date of birth, social insurance number, passport number or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all options or any other entitlement to shares of stock or equivalent benefits awarded, cancelled, exercised, vested, unvested or outstanding in Optionee&#8217;s favor. The legal basis for the processing of Optionee&#8217;s Personal Data, where required, will be his or her consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that the Company transfers his or her Personal Data, or parts thereof, to E*TRADE Financial Services, Inc. (and its affiliated companies), an independent service provider based in the United States which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share Optionee&#8217;s Personal Data with such different service provider that serves the Company in a similar manner. Optionee understands and acknowledges that the Company&#8217;s service provider will open an account for him or her to receive and trade shares of Common Stock acquired under the Plan and that he or she will be asked to agree on separate terms and data processing practices with the service provider, which is a condition of Optionee&#8217;s ability to participate in the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that the Company and, as of the date hereof, any third parties assisting in the implementation, administration and management of the Plan, such as E*TRADE Financial Services, Inc., are based in the United States. Optionee understands and acknowledges that his or her country may have enacted data privacy laws that are different from the laws of the United States. For </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">example, the European Commission has issued only a limited adequacy finding with respect to the United States that applies solely if and to the extent that companies self-certify and remain self-certified under the EU&#47;U.S. Privacy Shield program. The Company does not currently participate in the EU&#47;U.S. Privacy Shield Program. The Company&#8217;s legal basis for the transfer of Optionee&#8217;s Personal Data is his or her consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:24.69pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that the Company will use his or her Personal Data only as long as is necessary to implement, administer and manage his or her participation in the Plan, or to comply with legal or regulatory obligations, including under tax and securities laws. In the latter case, Optionee understands and acknowledges that the Company&#8217;s legal basis for the processing of his or her Personal Data would be compliance with the relevant laws or regulations. When the Company no longer needs Optionee&#8217;s Personal Data for any of the above purposes, Optionee understands the Company will remove it from its systems.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Voluntariness and Consequences of Denial&#47;Withdrawal of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that his or her participation in the Plan and his or her consent is purely voluntary. Optionee may deny or later withdraw his or her consent at any time, with future effect and for any or no reason. If Optionee denies or later withdraws his or her consent, the Company can no longer offer Optionee participation in the Plan or offer other equity awards to Optionee or administer or maintain such awards and Optionee would no longer be able to participate in the Plan. Optionee further understands that denial or withdrawal of his or her consent would not affect his or her status or salary as an employee or his or her career and that Optionee would merely forfeit the opportunities associated with the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that data subject rights regarding the processing of Personal Data vary depending on the applicable law and that, depending on where Optionee is based and subject to the conditions set out in the applicable law, Optionee may have, without limitation, the rights to (i) inquire whether and what kind of Personal Data the Company holds about him or her and how it is processed, and to access or request copies of such Personal Data, (ii) request the correction or supplementation of Personal Data about him or her that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Personal Data no longer necessary for the purposes underlying the processing, processed based on withdrawn consent, processed for legitimate interests that, in the context of his or her objection, do not prove to be compelling, or processed in non-compliance with applicable legal requirements, (iv) request the Company to restrict the processing of his or her Personal Data in certain situations where Optionee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Personal Data for legitimate interests, and to (vi) request portability of Optionee&#8217;s Personal Data that he or she has actively or passively provided to the Company (which does not include data derived or inferred from the collected data), where the processing of such Personal Data is based on consent or his or her employment and is carried out by automated means. In case of concerns, Optionee understands that he or she may also have the right to lodge a complaint with the competent local data protection authority. </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Further, to receive clarification of, or to exercise any of, Optionee&#8217;s rights, Optionee understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Plan Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The official prospectus for the Plan is available on the Company&#8217;s intranet at&#58; GNet &#62; Employee Resources &#62; Stock Awards &#62; Plan Documents. Optionee may also obtain a printed copy of the prospectus by contacting Stock Plan Services at stockplanservices&#64;gilead.com.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By electing to accept this Agreement, Optionee acknowledges that he or she is sufficiently proficient in the English language, or has consulted with an advisor who is sufficiently proficient in English, so as to allow Optionee to understand the terms and conditions of this Agreement. Further, if Optionee has received this Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Electronic Delivery and Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. Optionee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through the electronic acceptance procedure established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Optionee Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Optionee must accept the terms and conditions of this Agreement either electronically through the electronic acceptance procedure established by the Company or through a written acceptance delivered to the Company in a form satisfactory to the Company. In no event shall this option be exercised in the absence of such acceptance. An exercise of any portion of the shares subject to this Option shall be deemed to be an acceptance by Optionee of the terms and conditions of this Agreement.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Foreign Account &#47; Assets Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Depending upon the country to which laws Optionee is subject, Optionee may have certain foreign asset and&#47;or account reporting requirements that may affect Optionee&#8217;s ability to acquire or hold shares of Common Stock under the Plan or cash received from participating in the Plan (including from any dividends or sale proceeds arising from the sale of shares of Common Stock) in a brokerage or bank account outside Optionee&#8217;s country. Optionee&#8217;s country may require that he or she report such accounts, assets or transactions to the applicable authorities in Optionee&#8217;s country. Optionee is responsible for knowledge of and compliance with any such regulations and should speak with his or her own personal tax, legal and financial advisors regarding same.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding any provision herein, Optionee&#8217;s participation in the Plan shall be subject to any additional terms and conditions as set forth in the Addendum for Optionee&#8217;s country of residence, if any. Moreover, if Optionee relocates to one of the countries included in the Addendum, the special terms and conditions for such country will apply to Optionee, to the extent the Company determines that the application of such terms and conditions is necessary for legal or administrative reasons. The Addendum constitutes part of this Agreement.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company reserves the right to impose other requirements on Optionee&#8217;s participation in the Plan, on the option and on any shares of Common Stock acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Optionee to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company has caused this Agreement to be executed on its behalf by its duly-authorized officer on the day and year first indicated above.</font></div><div style="margin-top:12pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.929%"><tr><td style="width:1.0%"></td><td style="width:21.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EVP, Human Resources</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By electronically accepting the option, Optionee agrees that this option is granted under and governed by the terms and conditions of the Plan and the Agreement, including the terms and conditions set forth in any Addendum to the Agreement for Optionee&#8217;s country. Optionee has reviewed the Plan and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting the Agreement and fully understands all provisions of the Plan and Agreement.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div><div><font><br></font></div></div></div><div id="ib4ac2b42411e4e54a560352b4a59506f_58"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">APPENDIX</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following definitions shall be in effect under the Agreement&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the addendum to this Agreement setting forth special terms and conditions for Optionee&#8217;s country.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt;text-decoration:underline">Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the Compensation Committee of the Board (or a subcommittee thereof) acting in its capacity as administrator of the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean this Global Stock Option Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Applicable Acceleration Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall have the meaning assigned to such term in Section 2(b) of the Plan and shall be determined on the basis of Optionee&#8217;s status on the Change in Control date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.67pt;text-decoration:underline">Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the legal requirements related to the Plan and the option under applicable provisions of the federal securities laws, state corporate and securities laws, the Code, the rules of any applicable Stock Exchange on which the Common Stock is listed for trading, and the rules of any non-U.S. jurisdiction applicable to options granted to residents therein.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.33pt;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the Company&#8217;s Board of Directors.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall have the meaning given to the term &#8220;Cause&#8221; in any effective employment agreement between the Optionee and the Company or a Related Entity, or if none the meaning set forth below. For purposes of Paragraph 5 of the Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the termination of Optionee&#8217;s Continuous Service as a result of Optionee&#8217;s (i) performance of any act, or failure to perform any act, in bad faith and to the detriment of the Company or a Related Entity&#59; (ii) dishonesty, intentional misconduct, material violation of any applicable Company or Related Entity policy, or material breach of any agreement with the Company or a Related Entity&#59; or (iii) commission of a crime involving dishonesty, breach of trust, or physical or emotional harm to any person. However, for purposes of Paragraph 6(d) of the Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the termination of Optionee&#8217;s Continuous Service as a result of Optionee&#8217;s (a) conviction of, a guilty plea with respect to, or a plea of nolo contendere to, a charge that Optionee has committed a felony under the laws of the United States or of any State or a crime involving moral turpitude, including (without limitation) fraud, theft, embezzlement or any crime that results in or is intended to result in personal enrichment to Optionee at the expense of the Company or a Related Entity&#59; (b) material breach of any agreement entered into between Optionee and the Company or a Related Entity that impairs the Company&#8217;s or the Related Entity&#8217;s interest therein&#59; (c) willful misconduct, significant failure to perform his or her duties or gross neglect of his or her duties&#59; or (d) engagement in any activity that constitutes a material conflict of interest with the Company or a Related Entity</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">H.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean a change in ownership or control of the Company effected through the consummation of any of the following transactions&#58;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">a sale, transfer or other disposition of all or substantially all of the Company&#8217;s assets&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">the closing of any transaction or series of related transactions pursuant to which any person or any group of persons comprising a &#8220;group&#8221; within the meaning of Rule 13d-5(b)(1) of the 1934 Act (other than the Company or a person that, prior to such transaction or series of related transactions, directly or indirectly controls, is controlled by or is under common control with, the Company) becomes directly or indirectly (whether as a result of a single acquisition or by reason of one or more acquisitions within the twelve (12)-month period ending with the most recent acquisition) the beneficial owner (within the meaning of Rule 13d- 3 of the 1934 Act) of securities possessing (or convertible into or exercisable for securities possessing) more than fifty percent (50%) of the total combined voting power of the Company&#8217;s outstanding securities (as measured in terms of the power to vote with respect to the election of Board members) outstanding immediately after the consummation of such transaction or series of related transactions, whether such transaction involves a direct issuance from the Company or the acquisition of outstanding securities held by one or more of the Company&#8217;s existing stockholders or an acquisition, consolidation or other reorganization to which the Company is a party&#59; or</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">a change in the composition of the Board over a period of twelve (12) consecutive months or less such that a majority of the Board members ceases, by reason of one or more contested elections for Board membership, to be comprised of individuals who either (a) have been Board members continuously since the beginning of such period or (b) have been elected or nominated for election as Board members during such period by at least a majority of the Board members described in clause (a) above who were still in office at the time the Board approved such election or nomination.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In no event, however, shall a Change in Control be deemed to occur upon a merger, consolidation or other reorganization effected primarily to change the State of the Company&#8217;s incorporation or to create a holding company structure pursuant to which the Company becomes a wholly-owned subsidiary of an entity whose outstanding voting securities immediately after its formation are beneficially owned, directly or indirectly and in substantially the same proportion, by the persons who beneficially owned the Company&#8217;s outstanding voting securities immediately prior to the formation of such entity.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:11.01pt;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the U.S. Internal Revenue Code of 1986, as amended.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">J.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:10.34pt;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean shares of the Company&#8217;s common stock.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">K.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean Gilead Sciences, Inc., a Delaware corporation, and any successor corporation to all or substantially all of the assets or voting stock of Gilead Sciences, Inc. which shall by appropriate action adopt the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">L.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.67pt;text-decoration:underline">Constructive Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall have the meaning assigned to such term in Section 11(d) of the Plan.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">M.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.34pt;text-decoration:underline">Consultant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean any person, including an advisor, who is compensated by the Company or any Related Entity for services performed as a non-employee consultant&#59; provided, however, that the term &#8220;Consultant&#8221; shall not include non-employee Directors serving in their capacity as Board members. The term &#8220;Consultant&#8221; shall include a member of the board of directors of a Related Entity.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">N.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Continuous Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean shall mean the performance of services for the Company or a Related Entity (whether now existing or subsequently established) by a person in the capacity of an Employee, Director or Consultant. For purposes of this Agreement, Optionee shall be deemed to cease Continuous Service immediately upon the occurrence of either of the following events&#58; (i) Optionee no longer performs services in any of the foregoing capacities for the Company or any Related Entity or (ii) the entity for which Optionee is performing such services ceases to remain a Related Entity of the Company, even though Optionee may subsequently continue to perform services for that entity. Subject to the foregoing and any applicable limitations of Code Section 409A, the Administrator shall have the exclusive discretion to determine when Optionee ceases Continuous Service for purposes of the Award.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">O.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean a member of the Board.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">P.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.33pt;text-decoration:underline">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean any person who is in the employ of the Company (or any Related Entity), subject to the control and direction of the Company or Related Entity as to both the work to be performed and the manner and method of performance.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Q.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the Company or the Related Entity employing or retaining Optionee.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">R.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt;text-decoration:underline">Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean the date on which the option shall have been exercised in accordance with Paragraph 9 of the Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.33pt;text-decoration:underline">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the exercise price payable per Option Share as specified under Option Grant Specifics.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">T.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.67pt;text-decoration:underline">Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the date specified under Option Grant Specifics for measuring the maximum term for which the option may remain outstanding.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">U.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Fair Market Valu</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e per share of Common Stock on any relevant date shall be the closing price per share of Common Stock (or the closing bid, if no sales were reported) on that date, as quoted on the Stock Exchange that is at the time serving as the primary trading market for the Common Stock&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that if there is no reported closing price or closing bid for that date, then the closing price or closing bid, as applicable, for the last trading date on which such closing price or closing bid was quoted shall be determinative of such Fair Market Value. The applicable quoted price shall be as reported in The Wall Street Journal or such other source as the Administrator deems reliable.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the date on which the option is granted, as specified under Option Grant Specifics.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">W.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:3.68pt;text-decoration:underline">1934 Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the U.S. Securities Exchange Act of 1934, as amended from time to time.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">X.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Non-Statutory Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean an option not intended to satisfy the requirements of Code Section 422.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Y.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Notice of Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the notice of option exercise in the form authorized by the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Z.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.67pt;text-decoration:underline">Option Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the number of shares of Common Stock subject to the option as specified under Option Grant Specifics.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">AA. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Optionee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the person identified under Option Grant Specifics to whom the option is granted pursuant to the Agreement. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BB. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean a &#8220;parent corporation,&#8221; whether now existing or hereafter established, as defined in Section 424(e) of the Code.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CC. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Permanent Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the inability of Optionee to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which is expected to result in death or to be of continuous duration of twelve (12) months or more. The Administrator shall have exclusive discretion to determine when Permanent Disability has occurred for purposes of this Agreement</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DD. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the Company&#8217;s 2004 Equity Incentive Plan, as amended from time to time.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EE. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Related Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean (i) any Parent or Subsidiary of the Company and (ii) any corporation in an unbroken chain of corporations beginning with the Company and ending with the corporation in the chain for which Optionee provides services as an Employee, Director or Consultant, provided each corporation in such chain owns securities representing at least twenty percent (20%) of the total outstanding voting power of the outstanding securities of another corporation or entity in such chain and there is a legitimate non-tax business purpose for making this option grant to Optionee.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FF. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Stock Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the American Stock Exchange, the Nasdaq Global or Global Select Market or the New York Stock Exchange.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">GG. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean a &#8220;subsidiary corporation,&#8221; whether now existing or hereafter established, as defined in Section 424(f) of the Code.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">HH. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the schedule set forth under Option Grant Specifics, pursuant to which the option is to vest and become exercisable for the Option Shares in a series of installments over Optionee&#8217;s period of Continuous Service.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">II. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean any and all income tax (including U.S. federal, state, and local tax and&#47;or foreign income taxes) and the employee portion of the federal, state, local and&#47;or foreign employment taxes (including social insurance, payroll tax, payment on account or other tax-related items) required or permitted to be withheld by the Company and&#47;or the Employer in connection with any taxable event attributable to the option or Optionee&#8217;s participation in the Plan.</font></div><div><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-5</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>3
<FILENAME>gildq12021ex10162021psuagr.htm
<DESCRIPTION>2021 PSU AGREEMENT-TSR GOALS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i6dfb92a218fc4fb9a870ae8c20d11f46_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 10.16</font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TSR PERFORMANCE GOAL</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">PERFORMANCE SHARE AWARD AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;Gilead Sciences, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) has implemented the Gilead Sciences, Inc. 2004 Equity Incentive Plan, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants to continue their service relationship with the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;This Agreement is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Company&#8217;s issuance of shares of Common Stock to Participant thereunder.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;All capitalized terms in this Performance Share Award Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall have the meaning assigned to them herein or in the attached Appendix A. Capitalized terms not defined herein or in the attached Appendix A shall have the meanings assigned to them in the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, it is hereby agreed as follows&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Grant of Performance Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company hereby awards to Participant, as of the Award Date indicated below, an award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of Performance Shares under the Plan. This Agreement provides the Participant with the right to receive one or more shares of Common Stock on the designated issuance date for those shares, based upon the extent to which each Performance Share vests pursuant to the terms hereof. The Target Shares subject to this Award, the applicable performance-vesting and Continuous Service vesting requirements for this Award, the date or dates on which the shares of Common Stock that vest hereunder shall become issuable and the remaining terms and conditions governing this Award, including the applicable vesting acceleration provisions, shall be as set forth in this Agreement.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AWARD SUMMARY</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Participant&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Award Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Target Number of Performance Shares&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The actual number of shares of Common Stock that may become issuable pursuant to the Performance Shares subject to this Agreement shall be determined in accordance with the performance-vesting and Continuous Service vesting provisions of attached Schedule I. For purposes of the applicable calculations under Schedule I, the target number of Performance Shares to be utilized is shares (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Target Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div></td></tr></table></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Vesting Requirements. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Performance Shares shall be subject to the performance-vesting and Continuous Service vesting requirements set forth in attached Schedule I and shall vest on the Certification Date (as defined in Appendix A). </font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Change in Control Vesting. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The shares of Common Stock underlying the Performance Shares may also vest on an accelerated basis in accordance with the applicable provisions of Paragraph 4 of this Agreement should a Change in Control occur after the start but prior to the completion of the Performance Period applicable to the Performance Shares or the Certification Date.</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Issuance Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The shares of Common Stock which actually vest and become issuable pursuant to the Performance Shares shall be issued in accordance with the provisions of this Agreement applicable to the particular circumstances under which such vesting occurs.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Limited Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Prior to the actual issuance of the shares of Common Stock which vest hereunder, Participant may not transfer any interest in the Performance Shares subject to this Award or the underlying shares of Common Stock or pledge or otherwise hedge the sale of those Performance Shares or underlying shares, including (without limitation) any short sale or any acquisition or disposition of any put or call option or other instrument tied to the value of the underlying shares of Common Stock. However, any shares of Common Stock which vest hereunder but otherwise remain unissued at the time of Participant&#8217;s death may be transferred pursuant to the provisions of Participant&#8217;s will or the laws of inheritance.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Stockholder Rights and Dividend Equivalents</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The holder of this Award shall not have any stockholder rights, including voting, dividend or liquidation rights, with respect to the shares of Common Stock subject to the Award until Participant becomes the record holder of those shares upon their actual issuance following the Company&#8217;s collection of the applicable Withholding Taxes. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding the foregoing, if and to the extent that this Award is outstanding on the record date for any dividend or other distribution, whether regular or extraordinary and whether payable in cash, securities (other than Common Stock) or other property, and one or more shares of Common Stock subject to this Award on such record date have not otherwise vested and been delivered as of the payment date for such dividend or distribution and do not otherwise receive such dividend or distribution (i.e., those shares of Common Stock are not otherwise treated as issued and outstanding for purposes of entitlement to the dividend or distribution pursuant to state law, the terms of such distribution or otherwise), then a special book account shall be established for Participant and credited with a phantom dividend that is equivalent to the actual dividend or distribution which would have been paid on such shares of Common Stock at the time subject to this Award had they been issued and outstanding and entitled to that dividend or distribution. As such shares of Common Stock subsequently vest hereunder, the phantom dividend equivalents so credited to those shares of </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Common Stock in the book account shall vest, and those vested dividend equivalents shall be distributed to Participant (in the form of additional shares of Common Stock or in such other form as the Administrator deems appropriate under the circumstances) concurrently with the issuance of the vested shares of Common Stock to which those phantom dividend equivalents relate and correspondingly as such shares of Common Stock are forfeited or cancelled under this Award the phantom dividend equivalents so credited to those shares of Common Stock in the book account shall be forfeited or cancelled.&#160;Each such distribution of phantom dividend equivalent amounts shall be subject to the Company&#8217;s collection of any Withholding Taxes applicable to that distribution. The Administrator shall have the sole discretion to determine the dollar value of any dividend or distribution paid other than in the form of cash, and its determination shall be controlling.&#160;No dividend equivalent amount shall be paid or distributed on shares of Common Stock under this Award that are forfeited or that otherwise are not vested and issued or issuable under this Award. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The following provisions shall apply only to the extent a Change in Control is consummated prior to the Certification Date and shall have no force or effect if the effective date of the Change in Control occurs after the Certification Date&#58; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Should (i) the Change in Control occur within the first twelve (12) months of the Performance Period and (ii) Participant remains in Continuous Service through the effective date of that Change in Control, then Participant shall immediately vest in that number of shares of Common Stock equal to the Target Shares subject to this Award, without any measurement of Performance Goal attainment to date and without regard to the Continuous Service vesting provisions.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Should (i) the Change in Control occur at any time on or after the completion of the first twelve (12) months of the Performance Period but prior to the Certification Date and (ii) Participant remains in Continuous Service through the effective date of that Change in Control, then Participant shall immediately vest in that number of shares of Common Stock equal to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">greater</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the Target Shares subject to this Award or (ii) the actual number of Performance-Qualified Shares determined by multiplying (A) the Target Shares subject to this Award by (B) the applicable percentage (determined in accordance with the payout slope set forth in attached Schedule I) for the level at which the TSR Performance Goal is attained over an abbreviated Performance Period ending with the close of the Company&#8217;s fiscal quarter coincident with or immediately preceding the effective date of the Change in Control, in either case, without regard to the Continuous Service vesting requirements. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The foregoing provisions of this Paragraph 4 shall also apply should Participant&#8217;s Continuous Service terminate, by reason of an involuntary termination (other than as a result of Retirement, death, or Permanent Disability) other than for Cause or his or her resignation due to Constructive Termination, at any time during the period beginning with the execution date of the definitive agreement for the Change in Control transaction and ending with the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the termination of the definitive agreement without the consummation of such Change in Control or (ii) the expiration of the Applicable Acceleration Period following the consummation of such Change in Control.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Should Participant cease Continuous Service during the Performance Period by reason of death or Permanent Disability and a Change in Control subsequently occurs prior to the Certification Date, then Participant shall, at the time of such Change in Control, vest in a pro-rated number of shares of Common Stock calculated by multiplying (i) the number of Target Shares or Performance-Qualified Shares determined in accordance with the applicable provisions of subparagraphs (a) and (b) of this Paragraph 4 by (ii) a fraction, the numerator of which is the number of months of Continuous Service actually completed by Participant in the Performance Period (rounded to the closest whole month), and the denominator of which is the number of months (rounded to the closest whole number) comprising the portion of such Performance Period ending with the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the effective date of the Change in Control or (ii) the last day of the abbreviated Performance Period (if any) taken into account under clause (ii) of Paragraph 4(b), which shall be settled and paid as provided in subparagraph (f) of this Paragraph 4 in lieu of any issuance of shares pursuant to Schedule I.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Should Participant cease Continuous Service by reason of his or her Retirement at least twelve (12) months following the Award Date but prior to the Certification Date and a Change in Control subsequently occurs prior to the Certification Date, then Participant shall, at the time of such Change in Control, immediately vest in that number of shares of Common Stock equal to the Target Shares subject to this Award, without any measurement of Performance Goal attainment to date and without regard to the Continuous Service vesting provisions.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">The number of shares of Common Stock in which Participant vests determined in accordance with the foregoing provisions of this Paragraph 4 shall be converted into the right to receive for each such share the same consideration per share of Common Stock payable to the other stockholders of the Company in consummation of the Change in Control, and such consideration shall be distributed to Participant on the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (i) the tenth (10th) business day following the effective date of the Change in Control, provided such Change in Control also constitutes a Qualifying Change in Control, or (ii) the date those shares would have been issued to Participant in accordance with Paragraph 6 in the absence of such Change in Control. Each issuance or distribution made under this Paragraph 4(f) shall be subject to the Company&#8217;s collection of the applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Except for the actual number of shares of Common Stock in which Participant vests in accordance with this Paragraph 4, Participant shall cease to have any further right or entitlement to any additional shares of Common Stock under this Agreement following the effective date of the Change in Control.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">This Agreement shall not in any way affect the right of the Company to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Adjustment in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Should any change be made to the Common Stock by reason of any stock split, stock dividend, recapitalization, combination of shares, </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">exchange of shares, spin-off transaction, extraordinary dividend or distribution or other change affecting the outstanding Common Stock as a class without the Company&#8217;s receipt of consideration, or should the value of the outstanding shares of Common Stock be substantially reduced as a result of a spin-off transaction or an extraordinary dividend or distribution, or should there occur any merger, consolidation or other reorganization, then equitable adjustments shall be made by the Administrator to the total number and&#47;or class of securities issuable pursuant to this Award in order to reflect such change. The determination of the Administrator shall be final, binding and conclusive. In the event of any Change in Control transaction, the provisions of Paragraph 4 shall also be applicable.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Issuance or Distribution of Vested Shares or Other Amounts.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Except as otherwise provided in Paragraph 4 or Paragraph 7, the shares of Common Stock in which Participant vests pursuant to the performance-vesting and Continuous Service vesting provisions of attached Schedule I shall be issued in accordance with the following provisions&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;The issuance of the shares of Common Stock shall be effected during the period beginning on the first (1st) business day of February of the calendar year immediately succeeding the end of the Performance Period and ending no later than March 15 of that calendar year.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Company shall, on the applicable issuance date, issue to or on behalf of Participant a certificate in electronic form for the shares of Common Stock in which Participant vests pursuant to the performance-vesting and Continuous Service vesting provisions of attached Schedule I and shall concurrently settle with Participant any phantom dividend equivalent amount with respect to those shares as provided in Paragraph 3.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Except as otherwise provided in Paragraph 4, no shares of Common Stock shall be issued prior to the Certification Date. No fractional shares of Common Stock shall be issued pursuant to this Award, and any fractional share resulting from any calculation made in accordance with the terms of this Agreement shall be rounded down to the next whole share.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Participant acknowledges that, regardless of any action the Employer may take with respect to any or all Withholding Taxes related to Participant&#8217;s participation in the Plan and legally applicable to Participant, the ultimate liability for all Withholding Taxes is and remains Participant&#8217;s responsibility and may exceed the amount actually withheld by the Employer. Participant further acknowledges that the Employer (i) makes no representations or undertakings regarding the treatment of any Withholding Taxes in connection with any aspect of the Award, including the grant, vesting or settlement of the Award, the issuance of shares of Common Stock or other property in settlement of the Award, the subsequent sale of the shares of Common Stock acquired pursuant to such issuance and the receipt of any dividends and&#47;or phantom dividend equivalent amount provided pursuant to Paragraph 3 and (ii) does not commit to, and is under no obligation to, structure the terms of the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">grant or any aspect of the Award to reduce or eliminate Participant&#8217;s liability for Withholding Taxes or achieve any particular tax result. Further, if Participant is or becomes subject to Withholding Taxes in more than one jurisdiction, Participant acknowledges that the Employer (or former employer, as applicable) may withhold or account for Withholding Taxes in more than one jurisdiction.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The Company shall collect, and Participant hereby authorizes the Company to collect, the Withholding Taxes with respect to the shares of Common Stock issued under this Agreement (including any shares of Common Stock issued in settlement of any phantom dividend equivalent amount as provided in Paragraph 3) through an automatic share withholding procedure pursuant to which the Company will withhold, immediately as the shares of Common Stock are issued under the Award, a portion of those shares with a Fair Market Value (measured as of the issuance date) equal to the amount of such Withholding Taxes (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Share Withholding Method</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Notwithstanding the foregoing, the Share Withholding Method shall not be utilized if (i) such method is not permissible or advisable under local law or (ii) the Company otherwise decides no longer to utilize such method and provides Participant with notice to such effect.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">If the Share Withholding Method is to be utilized for the collection of Withholding Taxes, then the Company shall withhold the number of otherwise issuable shares of Common Stock necessary to satisfy the applicable Withholding Taxes based on the applicable minimum statutory rate or other applicable withholding rate, including maximum applicable rates, as determined by the Company in its sole discretion. If the maximum rate is used, any over-withheld amount will be refunded to Participant in cash by the Employer (with no entitlement to the Common Stock equivalent) or if not refunded, Participant may seek a refund from the appropriate tax authorities. If the obligation for Withholding Taxes is satisfied by using the Share Withholding Method, then Participant will, for tax purposes, be deemed to have been issued the full number of shares of Common Stock subject to the vested Award, notwithstanding that a number of shares of Common Stock are withheld solely for the purpose of paying the applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Company shall have sole discretion to determine whether or not the Share Withholding Method shall be utilized for the collection of the applicable Withholding Taxes. Participant shall be notified (in writing or through the Company&#8217;s electronic mail system) in the event the Company no longer intends to utilize the Share Withholding Method. Should any shares of Common Stock become issuable under the Award (including any shares of Common Stock issued in settlement of any phantom dividend equivalent amount as provided in Paragraph 3) at a time when the Share Withholding Method is not being utilized by the Company, then the Withholding Taxes shall be collected from Participant through a sale-to-cover transaction authorized by Participant, pursuant to which an immediate open-market sale of a portion of the shares of Common Stock issued to Participant will be effected, for and on behalf of Participant, by the Company&#8217;s designated broker to cover the Withholding Tax liability estimated by the Company to be applicable to such issuance. Participant shall, promptly upon request from the Company, execute (whether manually or through electronic acceptance) an appropriate sales authorization (in form and substance reasonably satisfactory to the Company) that authorizes and directs the broker to effect such open-market, sale-to-cover transactions and </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">remit the sale proceeds, net of brokerage fees and other applicable charges, to the Company in satisfaction of the applicable Withholding Taxes. However, no sale-to-cover transaction shall be effected unless (i) such a sale is at the time permissible under the Company&#8217;s insider trading policies governing the sale of Common Stock and (ii) the transaction is not otherwise deemed to constitute a prohibited loan under Section 402 of the Sarbanes-Oxley Act of 2002.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">If the Company determines that such sale-to-cover transaction is not permissible or advisable at the time or if Participant otherwise fails to effect a timely sales authorization as required by this Agreement, then the Company may, in its sole discretion, elect either to defer the issuance of the shares of Common Stock until such sale-to-cover transaction can be effected in accordance with Participant&#8217;s executed sale directive or to collect the applicable Withholding Taxes through a wire transfer of funds from Participant to the Company in the amount of such Withholding Taxes or by withholding such amount from other wages payable to Participant. In no event shall any shares of Common Stock be issued in the absence of an arrangement reasonably satisfactory to the Company for the satisfaction of the applicable Withholding Taxes, and any such arrangement must be in compliance with any applicable requirements of Code Section 409A.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">The Company shall collect the Withholding Taxes with respect to any phantom dividend equivalent amount as provided in Paragraph 3 that is distributed in a form other than shares of Common Stock by withholding a portion of that distribution equal to the amount of the applicable Withholding Taxes, with the cash portion of the distribution to be the first portion so withheld, or through such other tax withholding arrangement as the Company deems appropriate, in its sole discretion.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding the foregoing provisions of Paragraphs 6(d) through 6(i), the employee portion of the federal, state and local employment taxes required to be withheld by the Company in connection with the vesting (as determined under applicable tax laws) of the shares of Common Stock or any other amounts hereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Employment Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall in all events be collected from Participant no later than the last business day of the calendar year in which those shares or other amounts vest (as determined under applicable tax laws) hereunder. Accordingly, to the extent the applicable issuance date for one or more vested shares of Common Stock or the distribution date for such other amounts is to occur in a year subsequent to the calendar year in which those shares or other amounts vest, Participant shall, if so requested by the Company, on or before the last business day of the calendar year in which such shares or other amounts vest, deliver to the Company a check payable to its order (or a wire transfer of funds to the Company ) in the dollar amount equal to the Employment Taxes required to be withheld with respect to those shares or other amounts. Alternatively, the Company may, in its sole discretion, elect to withhold the dollar amount equal to the Employment Taxes required to be withheld with respect to those shares or other amounts from other wages payable to Participant, or through such other tax withholding arrangement as the Company deems appropriate, in its sole discretion. The provisions of this Paragraph 6(j) shall be applicable only to the extent necessary to comply with the applicable tax withholding requirements of Code Section 3121(v).Except as otherwise provided in Paragraph 4 or this Paragraph 6, the settlement of all Performance Shares or Performance-Qualified Shares which vest under the Award shall be made solely in shares of Common Stock.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Special Deferral Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Provided Participant is a U.S. tax resident and Participant timely submits a properly completed deferral election in a form provided by the Company, any shares of Common Stock that become issuable pursuant to this Agreement shall be distributed in accordance with the terms of such deferral election, subject to Participant&#8217;s satisfaction of any applicable Withholding Taxes under Paragraph 6.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  For purposes of applying the various Continuous Service vesting provisions of this Agreement, Participant shall be deemed to cease Continuous Service on the commencement date of any leave of absence and not to remain in Continuous Service status during the period of that leave, except to the extent otherwise required under employment laws in the jurisdiction where Participant is employed or pursuant to the following policy&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Participant shall be deemed to remain in Continuous Service status during (i) the first three (3) months of an approved personal leave of absence or (ii) the first seven (7) months of any bona fide leave of absence (other than an approved personal leave) and shall be deemed to cease Continuous Service upon the expiration of the applicable three (3)-month or seven (7)-month period.</font></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;In no event, however, shall Participant be deemed, for vesting purposes hereunder, to remain in Continuous Service beyond the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of (i) the expiration date of that leave of absence, unless Participant returns to active Continuous Service or Employee status on or before that date, or (ii) the date Participant&#8217;s Continuous Service or Employee status actually terminates by reason of his or her voluntary or involuntary termination or by reason of his or her death or Permanent Disability. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Compliance with Laws and Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The issuance of shares of Common Stock pursuant to the Award shall be subject to compliance by the Company and Participant with all Applicable Laws relating thereto.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Nature of Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  In accepting the grant, Participant acknowledges, understands and agrees that&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan&#59;</font></div><div style="margin-bottom:0.12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the grant of the Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of Awards, or benefits in lieu of Awards, even if Awards have been granted in the past&#59; </font></div><div style="margin-bottom:0.12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">all decisions with respect to future Awards or other grants, if any, will be at the sole discretion of the Company&#59;</font></div><div style="margin-bottom:0.12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Participant is voluntarily participating in the Plan&#59; </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the Award and the shares of Common Stock subject to the Award, and the income and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">the Award and the shares of Common Stock subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including, without limitation, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, holiday pay, bonuses, long-service awards, leave-related payments, pension or retirement or welfare benefits or similar payments&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the future value of the underlying shares of Common Stock is unknown, indeterminable and cannot be predicted with certainty&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the termination of Participant&#8217;s Continuous Service (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s employment agreement, if any), and in consideration of the grant of the Award to which Participant is otherwise not entitled,&#160;Participant irrevocably agrees never to institute any claim against the Company, any Related Entity or the Employer, waives Participant&#8217;s ability, if any, to bring any such claim, and releases the Company, any Related Entity and the Employer from any such claim&#59; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, Participant shall be deemed irrevocably to have agreed not to pursue such claim and agreed to execute any and all documents necessary to request dismissal or withdrawal of such claim&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">unless otherwise agreed with the Company in writing, the Award and the shares of Common Stock subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, any service Participant may provide as a director of the Company or a Related Entity&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">unless otherwise provided in the Plan or by the Company in its discretion, the Award and the benefits evidenced by this Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the shares of the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Participant&#8217;s participation in the Plan, or Participant&#8217;s acquisition or sale of the underlying shares of Common Stock. Participant should consult with Participant&#8217;s own personal tax, legal and financial advisors regarding Participant&#8217;s participation in the Plan before taking any action related to the Plan or the Award.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and addressed to the Company at its </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">principal corporate offices. Any notice required to be given or delivered to Participant shall be in writing and addressed to Participant at the most current address then indicated for Participant on the Company&#8217;s employee records or shall be delivered electronically to Participant through the Company&#8217;s electronic mail system or through an on-line brokerage firm authorized by the Company to effect sales of the Common Stock issued hereunder. All notices shall be deemed effective upon personal delivery or delivery through the Company&#8217;s electronic mail system or upon deposit in the U.S. mail, postage prepaid and properly addressed to the party to be notified.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except to the extent otherwise provided in this Agreement, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the Company and its successors and assigns and Participant, the legal representatives, heirs and legatees of Participant&#8217;s estate.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Code Section 409A</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">It is the intention of the parties that the provisions of this Agreement shall, to the maximum extent permissible, comply with the requirements of the short-term deferral exception to Section 409A of the Code and Treasury Regulations Section 1.409A-1(b)(4) with respect to one or more shares of Common Stock underlying this Award. Accordingly, to the extent there is any ambiguity as to whether one or more provisions of this Agreement would otherwise contravene the requirements or limitations of Code Section 409A applicable to such short-term deferral exception, then those provisions, as they apply to such shares of Common Stock, shall be interpreted and applied in a manner that does not result in a violation of the requirements or limitations of Code Section 409A and the Treasury Regulations thereunder that apply to such exception.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">However, to the extent this Agreement should be deemed to create a deferred compensation arrangement subject to the requirements of Code Section 409A with respect to one or more shares of Common Stock underlying this Award, whether by reason of a deferral election that satisfies the requirements of Paragraph 7 above or the pro-rata Continuous Service vesting provisions of this Agreement, then the following provisions shall apply with respect to those shares, notwithstanding anything to the contrary set forth herein&#58; </font></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;None of those shares of Common Stock or other amounts which become issuable or distributable with respect to those shares by reason of Participant&#8217;s cessation of Continuous Service shall actually be issued or distributed to Participant until the date of Participant&#8217;s Separation from Service or as soon thereafter as administratively practicable, but in no event later than the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">later</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the close of the calendar year in which such Separation from Service occurs or (ii) the fifteenth (15th) day of the third (3rd) calendar month following the date of such Separation from Service.</font></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;None of those shares of Common Stock or other amounts which become issuable or distributable with respect to those shares by reason of Participant&#8217;s cessation of Continuous Service shall actually be issued or distributed to Participant prior to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the first (1st) day of the seventh </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(7th) month following the date of Participant&#8217;s Separation from Service or (ii) the date of Participant&#8217;s death, if Participant is deemed at the time of such Separation from Service to be a specified employee under Section 1.409A-1(i) of the Treasury Regulations issued under Code Section 409A, as determined by the Administrator in accordance with consistent and uniform standards applied to all other Code Section 409A arrangements of the Company, and such delayed commencement is otherwise required in order to avoid a prohibited distribution under Code Section 409A(a)(2). The deferred shares of Common Stock or other distributable amount shall be issued or distributed in a lump sum on the first (1st) day of the seventh (7th) month following the date of Participant&#8217;s Separation from Service or, if earlier, the first (1st) day of the month immediately following the date the Company receives proof of Participant&#8217;s death.</font></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;No amounts that vest and become payable under Paragraph 4 of this Agreement with respect to those shares of Common Stock by reason of a Change in Control shall be distributed to Participant at the time of such Change in Control, unless that transaction also constitutes a Qualifying Change in Control. In the absence of such a Qualifying Change in Control, the distribution shall not be made until the date on which the shares of Common Stock to which those amounts pertain would have become issuable in accordance with the provisions of Paragraph 6(a) of this Agreement. </font></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;If a deferral election under Paragraph 7 of this Agreement is in effect with respect to any shares of Common Stock underlying this Award, no amounts that vest and become payable under Paragraph 4 with respect to those shares by reason of a Change in Control shall be distributed to Participant at the time of that Change in Control unless the transaction also constitutes a Qualifying Change in Control. In the absence of such a Qualifying Change in Control, the distribution shall not be made until the date on which the shares of Common Stock to which those amounts pertain would have become issuable in accordance with Participant&#8217;s deferral election under Paragraph 7 of this Agreement. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement and the Award evidenced hereby are made and granted pursuant to the Plan and are in all respects limited by and subject to the terms of the Plan. In the event of any conflict between the provisions of this Agreement and the terms of the Plan, the terms of the Plan shall be controlling. All decisions of the Administrator with respect to any question or issue arising under the Plan or this Agreement shall be conclusive and binding on all persons having an interest in the Award.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Governing Law&#47;Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The interpretation, performance and enforcement of this Agreement shall be governed by the laws of the State of Delaware without resort to that State&#8217;s conflict-of-laws rules. For purposes of any action, lawsuit or other proceedings brought to enforce this Agreement or otherwise relating to or arising from this Agreement, the parties hereby submit to and consent to the sole and exclusive jurisdiction of the courts of San Mateo County, California, or the federal courts for the United States for the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Northern District of California, and no other courts, where this grant is made and&#47;or to be performed.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nothing in this Agreement or in the Plan shall confer upon Participant any right to remain in Continuous Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Employer or of Participant, which rights are hereby expressly reserved by each, to terminate Participant&#8217;s Continuous Service at any time for any reason, with or without Cause.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Plan Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The official prospectus for the Plan is available on the Company&#8217;s intranet at&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Stock Awards section on GNET</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Participant may also obtain a printed copy of the prospectus by contacting Stock Plan Services at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">stockplanservices&#64;gilead.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Electronic</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Delivery</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">and</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant may be subject to insider trading restrictions and&#47;or market abuse laws based on the exchange on which the shares of Common Stock are listed and in applicable jurisdictions including the United States and Participant&#8217;s country or his or her broker&#8217;s country, if different, which may affect Participant&#8217;s ability to accept, acquire, sell or otherwise dispose of shares, rights to shares (e.g., Performance Shares) or rights linked to the value of shares of Common Stock (e.g., dividend equivalents) during such times as Participant is considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws in applicable jurisdictions). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders Participant placed before he or she possessed inside information. Furthermore, Participant could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable insider trading policy of the Company. Participant acknowledges that it is Participant&#8217;s responsibility to comply with any applicable restrictions, and Participant should speak with his or her personal legal advisor on this matter.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Imposition of Other Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company reserves the right to impose other requirements on Participant&#8217;s participation in the Plan, on the Award and on any </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shares of Common Stock acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Participant Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant must accept the terms and conditions of this Agreement either electronically through the electronic acceptance procedure established by the Company or through a written acceptance delivered to the Company in a form satisfactory to the Company. In no event shall any shares of Common Stock be issued (or other securities or property distributed) under this Agreement in the absence of such acceptance. By accepting the Award, Participant agrees that this Award is granted under and governed by the terms and conditions of the Plan and this Agreement. Participant has reviewed the Plan and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting this Agreement and fully understands all provisions of the Plan and Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Gilead Sciences, Inc. has caused this Agreement to be executed on its behalf by its duly-authorized officer on the day and year first indicated above.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.608%"><tr><td style="width:1.0%"></td><td style="width:21.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EVP, Human Resources</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.769%"><tr><td style="width:1.0%"></td><td style="width:22.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PARTICIPANT</font></td></tr><tr style="height:41pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Signature</font></td></tr></table></div><div style="margin-bottom:7pt;text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:right;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>4
<FILENAME>gildq12021ex10192021psuagr.htm
<DESCRIPTION>2021 PSU AGREEMENT-REVENUE GOALS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i890e68332a1b4b3fbfc64d7c52abfda4_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:0.24pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 10.19</font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> REVENUE PERFORMANCE GOAL</font></div><div style="margin-bottom:0.24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></div><div style="margin-bottom:0.24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">PERFORMANCE SHARE AWARD AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.34pt">Gilead Sciences, Inc. (the &#8220;Company&#8221;) has implemented the Gilead Sciences, Inc. 2004 Equity Incentive Plan, as amended (the &#8220;Plan&#8221;) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants to continue their service relationship with the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;This Agreement is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Company&#8217;s issuance of shares of Common Stock to Participant thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;All capitalized terms in this Performance Share Award Agreement (this &#8220;Agreement&#8221;) shall have the meaning assigned to them herein or in the attached Appendix A. Capitalized terms not defined herein or in the attached Appendix A shall have the meanings assigned to them in the Plan.</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> it is hereby agreed as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Grant of Performance Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The Company hereby awards to Participant, as of the Award Date indicated below, an award (the &#8220;Award&#8221;) of Performance Shares under the Plan. This Agreement provides the Participant with the right to receive one or more shares of Common Stock on the designated issuance date for those shares, based upon the extent to which each Performance Share vests pursuant to the terms hereof. The Target Shares subject to this Award, the applicable performance-vesting and Continuous Service vesting requirements for each separate Tranche of this Award, the date or dates on which the shares of Common Stock that vest hereunder shall become issuable and the remaining terms and conditions governing this Award, including the applicable vesting acceleration provisions, shall be as set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AWARD SUMMARY</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Participant&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Award Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">March 10, 2021</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Target Number of Performance Shares&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The actual number of shares of Common Stock that may become issuable pursuant to the Performance Shares subject to this Agreement shall be determined in accordance with the performance-vesting and Continuous Service vesting provisions of attached Schedule I. For purposes of the applicable calculations under Schedule I, the target number of Performance Shares to be utilized is shares (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:125%">&#8220;Target Shares&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">).</font></div></td></tr></table></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The Performance Shares shall be divided into three separate Tranches with one third (1&#47;3) of the Target Shares allocated to each such Tranche.</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:125%">Vesting Requirements. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Each Tranche of Performance Shares shall be subject to the performance-vesting and Continuous Service vesting requirements set forth for that particular Tranche in attached Schedule I and shall vest on the Certification Date (as defined in Appendix A).</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:125%">Change in Control Vesting. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The shares of Common Stock underlying each Tranche of Performance Shares may also vest on an accelerated basis in accordance with the applicable provisions of Paragraph 4 of this Agreement should a Change in Control occur after the start but prior to the completion of the Performance Period applicable to that particular Tranche or the Certification Date.</font></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Issuance Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The shares of Common Stock which actually vest and become issuable pursuant to each Tranche of Performance Shares shall be issued in accordance with the provisions of this Agreement applicable to the particular circumstances under which such vesting occurs.</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Limited Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Prior to the actual issuance of the shares of Common Stock which vest hereunder, Participant may not transfer any interest in the Performance Shares subject to this Award or the underlying shares of Common Stock or pledge or otherwise hedge the sale of those Performance Shares or underlying shares, including (without limitation) any short sale or any acquisition or disposition of any put or call option or other instrument tied to the value of the underlying shares of Common Stock. However, any shares of Common Stock which vest hereunder but otherwise remain unissued at the time of Participant&#8217;s death may be transferred pursuant to the provisions of Participant&#8217;s will or the laws of inheritance.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Stockholder Rights and Dividend Equivalents</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The holder of this Award shall not have any stockholder rights, including voting, dividend or liquidation rights, with respect to the shares of Common Stock subject to the Award until Participant becomes the record holder of those shares upon their actual issuance following the Company&#8217;s collection of the applicable Withholding Taxes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding the foregoing, if and to the extent that this Award is outstanding on the record date for any dividend or other distribution, whether regular or extraordinary and whether payable in cash, securities (other than Common Stock) or other property, and one or more shares of Common Stock subject to this Award on such record date have not otherwise vested and been delivered as of the payment date for such dividend or distribution and do not otherwise receive such dividend or distribution (i.e., those shares of Common Stock are not otherwise treated as issued and outstanding for purposes of entitlement to </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the dividend or distribution pursuant to state law, the terms of such distribution or otherwise), then a special book account shall be established for Participant and credited with a phantom dividend that is equivalent to the actual dividend or distribution which would have been paid on such shares of Common Stock at the time subject to this Award had they been issued and outstanding and entitled to that dividend or distribution. As such shares of Common Stock subsequently vest hereunder, the phantom dividend equivalents so credited to those shares of Common Stock in the book account shall vest, and those vested dividend equivalents shall be distributed to Participant (in the form of additional shares of Common Stock or in such other form as the Administrator deems appropriate under the circumstances) concurrently with the issuance of the vested shares of Common Stock to which those phantom dividend equivalents relate and correspondingly as such shares of Common Stock are forfeited or cancelled under this Award the phantom dividend equivalents so credited to those shares of Common Stock in the book account shall be forfeited or cancelled. Each such distribution of phantom dividend equivalent amounts shall be subject to the Company&#8217;s collection of any Withholding Taxes applicable to that distribution. The Administrator shall have the sole discretion to determine the dollar value of any dividend or distribution paid other than in the form of cash, and its determination shall be controlling. No dividend equivalent amount shall be paid or distributed on shares of Common Stock under this Award that are forfeited or that otherwise are not vested and issued or issuable under this Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The following provisions shall apply only to the extent a Change in Control is consummated prior to the Certification Date and shall have no force or effect if the effective date of the Change in Control occurs after the Certification Date&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Should (i) the Change in Control occur during a Performance Period that is in effect at the time with respect to a particular Tranche of Performance Shares but prior to the completion of that Performance Period and (ii) Participant remains in Continuous Service through the effective date of that Change in Control, then Participant shall immediately vest in that number of shares of Common Stock equal to the Target Shares allocated to that particular Tranche, without any measurement of Performance Goal attainment to date with respect to that particular Tranche and without regard to the Continuous Service vesting provisions. To the extent a Performance Period for a particular Tranche of Performance Shares has not commenced prior to the effective date of the Change in Control, the Performance Shares allocated to that Tranche in accordance with Paragraph 1 of this Agreement and the provisions of attached Schedule I shall be cancelled, and Participant shall not have any further right or entitlement to receive any shares of Common Stock with respect to those cancelled Performance Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Should (i) the Change in Control occur at any time on or after the completion of the Performance Period applicable to a particular Tranche of Performance Shares but prior to the Certification Date and (ii) Participant remains in Continuous Service through the effective date of that Change in Control, then Participant shall immediately vest in that number of shares of Common Stock equal to the actual number of Performance-Qualified Shares (if any) at the time subject to that Tranche by reason of the level at which the Revenue Performance Goal for that Tranche was in fact attained for the Performance Period applicable to that Tranche, without regard to the Continuous Service vesting provisions.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The foregoing provisions of this Paragraph 4 shall also apply should Participant&#8217;s Continuous Service terminate, by reason of an involuntary termination (other than as a result of Retirement, death, or Permanent Disability) other than for Cause or his or her resignation due to Constructive Termination, at any time during the period beginning with the execution date of the definitive agreement for the Change in Control transaction and ending with the earlier of (i) the termination of the definitive agreement without the consummation of such Change in Control or (ii) the expiration of the Applicable Acceleration Period following the consummation of such Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Should Participant cease Continuous Service by reason of death or Permanent Disability during one or more Service Periods that are, pursuant to the provisions of attached Schedule I, in effect at that time with respect to one or more Tranches of Performance Shares and a Change in Control subsequently occurs prior to the Certification Date, then Participant shall, at the time of such Change in Control, vest in a pro-rated number of shares of Common Stock calculated by multiplying (i) the number of Target Shares or Performance- Qualified Shares (if any) determined for each such Tranche in accordance with the applicable provisions of subparagraphs (a) and (b) of this Paragraph 4 by (ii) a fraction, the numerator of which is the number of months of Continuous Service actually completed by Participant in the applicable Service Period for such Tranche (rounded to the closest whole month), and the denominator of which is the number of months (rounded to the closest whole number) comprising the portion of that Service Period ending with the effective date of the Change in Control, which shall be settled and paid as provided in subparagraph (f) of this Paragraph 4 in lieu of any issuance of shares pursuant to Schedule I.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Should Participant cease Continuous Service by reason of his or her Retirement at least twelve (12) months following the Award Date but prior to the Certification Date and during one or more Service Periods that are, pursuant to the provisions of attached Schedule I, in effect at that time with respect to one or more Tranches of Performance Shares and a Change in Control subsequently occurs prior to the Certification Date, then Participant shall, at the time of such Change in Control, immediately vest in that number of shares of Common Stock equal to the Target Shares allocated to that particular Tranche, without any measurement of Performance Goal attainment to date with respect to that particular Tranche and without regard to the Continuous Service vesting provisions. To the extent a Performance Period for a particular Tranche of Performance Shares has not commenced prior to the effective date of the Change in Control, the Performance Shares allocated to that Tranche in accordance with Paragraph 1 of this Agreement and the provisions of attached Schedule I shall be cancelled, and Participant shall not have any further right or entitlement to receive any shares of Common Stock with respect to those cancelled Performance Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;The number of shares of Common Stock in which Participant vests determined in accordance with the foregoing provisions of this Paragraph 4 shall be converted into the right to receive for each such share the same consideration per share of Common Stock payable to the other stockholders of the Company in consummation of the Change in Control, and such consideration shall be distributed to Participant on the earlier of (i) the tenth (10th) business day following the effective date of the Change in Control, provided such Change in Control also constitutes a Qualifying Change in Control, or (ii) the date those shares would have </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">been issued to Participant in accordance with Paragraph 6 in the absence of such Change in Control. Each issuance or distribution made under this Paragraph 4(f) shall be subject to the Company&#8217;s collection of the applicable Withholding Taxes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Except for the actual number of shares of Common Stock in which Participant vests in accordance with this Paragraph 4, Participant shall cease to have any further right or entitlement to any additional shares of Common Stock under this Agreement following the effective date of the Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;This Agreement shall not in any way affect the right of the Company to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Adjustment in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Should any change be made to the Common Stock by reason of any stock split, stock dividend, recapitalization, combination of shares, exchange of shares, spin-off transaction, extraordinary dividend or distribution or other change affecting the outstanding Common Stock as a class without the Company&#8217;s receipt of consideration, or should the value of the outstanding shares of Common Stock be substantially reduced as a result of a spin- off transaction or an extraordinary dividend or distribution, or should there occur any merger, consolidation or other reorganization, then equitable adjustments shall be made by the Administrator to the total number and&#47;or class of securities issuable pursuant to this Award in order to reflect such change. The determination of the Administrator shall be final, binding and conclusive. In the event of any Change in Control transaction, the provisions of Paragraph 4 shall also be applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Issuance or Distribution of Vested Shares or Other Amounts.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Except as otherwise provided in Paragraph 4 or Paragraph 7, the shares of Common Stock in which Participant vests pursuant to the performance-vesting and Continuous Service vesting provisions of attached Schedule I shall be issued in accordance with the following provisions&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;The issuance of the shares of Common Stock underlying each particular Tranche of Performance Shares shall be effected during the period beginning on the first (1st) business day of February of the calendar year immediately succeeding the end of the Tranche Three Performance Period and ending no later than March 15 of that calendar year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Company shall, on the applicable issuance date, issue to or on behalf of Participant a certificate in electronic form for the shares of Common Stock in which Participant vests pursuant to the performance-vesting and Continuous Service vesting provisions of attached Schedule I and shall concurrently settle with Participant any phantom dividend equivalent amount with respect to those shares as provided in Paragraph 3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Except as otherwise provided in Paragraph 4, no shares of Common Stock shall be issued prior to the Certification Date. No fractional shares of Common </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Stock shall be issued pursuant to this Award, and any fractional share resulting from any calculation made in accordance with the terms of this Agreement shall be rounded down to the next whole share.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Participant acknowledges that, regardless of any action the Employer may take with respect to any or all Withholding Taxes related to Participant&#8217;s participation in the Plan and legally applicable to Participant, the ultimate liability for all Withholding Taxes is and remains Participant&#8217;s responsibility and may exceed the amount actually withheld by the Employer. Participant further acknowledges that the Employer (i) makes no representations or undertakings regarding the treatment of any Withholding Taxes in connection with any aspect of the Award, including the grant, vesting or settlement of the Award, the issuance of shares of Common Stock or other property in settlement of the Award, the subsequent sale of the shares of Common Stock acquired pursuant to such issuance and the receipt of any dividends and&#47;or phantom dividend equivalent amount provided pursuant to Paragraph 3 and (ii) does not commit to, and is under no obligation to, structure the terms of the grant or any aspect of the Award to reduce or eliminate Participant&#8217;s liability for Withholding Taxes or achieve any particular tax result. Further, if Participant is or becomes subject to Withholding Taxes in more than one jurisdiction, Participant acknowledges that the Employer (or former employer, as applicable) may withhold or account for Withholding Taxes in more than one jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The Company shall collect, and Participant hereby authorizes the Company to collect, the Withholding Taxes with respect to the shares of Common Stock issued under this Agreement (including any shares of Common Stock issued in settlement of any phantom dividend equivalent amount as provided in Paragraph 3) through an automatic share withholding procedure pursuant to which the Company will withhold, immediately as the shares of Common Stock are issued under the Award, a portion of those shares with a Fair Market Value (measured as of the issuance date) equal to the amount of such Withholding Taxes (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Share Withholding Method</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Notwithstanding the foregoing, the Share Withholding Method shall not be utilized if (f) such method is not permissible or advisable under local law or (ii) the Company otherwise decides no longer to utilize such method and provides Participant with notice to such effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;If the Share Withholding Method is to be utilized for the collection of Withholding Taxes, then the Company shall withhold the number of otherwise issuable shares of Common Stock necessary to satisfy the applicable Withholding Taxes based on the applicable minimum statutory rate or other applicable withholding rate, including maximum applicable rates, as determined by the Company in its sole discretion. If the maximum rate is used, any over- withheld amount will be refunded to Participant in cash by the Employer (with no entitlement to the Common Stock equivalent) or if not refunded, Participant may seek a refund from the appropriate tax authorities. If the obligation for Withholding Taxes is satisfied by using the Share Withholding Method, then Participant will, for tax purposes, be deemed to have been issued the full number of shares of Common Stock subject to the vested Award, notwithstanding that a number of shares of Common Stock are withheld solely for the purpose of paying the applicable Withholding Taxes.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;The Company shall have sole discretion to determine whether or not the Share Withholding Method shall be utilized for the collection of the applicable Withholding Taxes. Participant shall be notified (in writing or through the Company&#8217;s electronic mail system) in the event the Company no longer intends to utilize the Share Withholding Method. Should any shares of Common Stock become issuable under the Award (including any shares of Common Stock issued in settlement of any phantom dividend equivalent amount as provided in Paragraph 3) at a time when the Share Withholding Method is not being utilized by the Company, then the Withholding Taxes shall be collected from Participant through a sale-to-cover transaction authorized by Participant, pursuant to which an immediate open-market sale of a portion of the shares of Common Stock issued to Participant will be effected, for and on behalf of Participant, by the Company&#8217;s designated broker to cover the Withholding Tax liability estimated by the Company to be applicable to such issuance. Participant shall, promptly upon request from the Company, execute (whether manually or through electronic acceptance) an appropriate sales authorization (in form and substance reasonably satisfactory to the Company) that authorizes and directs the broker to effect such open-market, sale-to-cover transactions and remit the sale proceeds, net of brokerage fees and other applicable charges, to the Company in satisfaction of the applicable Withholding Taxes. However, no sale-to-cover transaction shall be effected unless (i) such a sale is at the time permissible under the Company&#8217;s insider trading policies governing the sale of Common Stock and (ii) the transaction is not otherwise deemed to constitute a prohibited loan under Section 402 of the Sarbanes-Oxley Act of 2002.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;If the Company determines that such sale-to-cover transaction is not permissible or advisable at the time or if Participant otherwise fails to effect a timely sales authorization as required by this Agreement, then the Company may, in its sole discretion, elect either to defer the issuance of the shares of Common Stock until such sale-to-cover transaction can be effected in accordance with Participant&#8217;s executed sale directive or to collect the applicable Withholding Taxes through a wire transfer of funds from Participant to the Company in the amount of such Withholding Taxes or by withholding such amount from other wages payable to Participant. In no event shall any shares of Common Stock be issued in the absence of an arrangement reasonably satisfactory to the Company for the satisfaction of the applicable Withholding Taxes, and any such arrangement must be in compliance with any applicable requirements of Code Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;The Company shall collect the Withholding Taxes with respect to any phantom dividend equivalent amount as provided in Paragraph 3 that is distributed in a form other than shares of Common Stock by withholding a portion of that distribution equal to the amount of the applicable Withholding Taxes, with the cash portion of the distribution to be the first portion so withheld, or through such other tax withholding arrangement as the Company deems appropriate, in its sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;Notwithstanding the foregoing provisions of Paragraphs 6(d) through 6(i), the employee portion of the federal, state and local employment taxes required to be withheld by the Company in connection with the vesting (as determined under applicable tax laws) of the shares of Common Stock or any other amounts hereunder (the &#8220;Employment Taxes&#8221;) shall in all events be collected from Participant no later than the last business day of the calendar year in which those shares or other amounts vest (as determined under applicable tax </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">laws) hereunder. Accordingly, to the extent the applicable issuance date for one or more vested shares of Common Stock or the distribution date for such other amounts is to occur in a year subsequent to the calendar year in which those shares or other amounts vest, Participant shall, if so requested by the Company, on or before the last business day of the calendar year in which such shares or other amounts vest, deliver to the Company a check payable to its order (or a wire transfer of funds to the Company) in the dollar amount equal to the Employment Taxes required to be withheld with respect to those shares or other amounts. Alternatively, the Company may, in its sole discretion, elect to withhold the dollar amount equal to the Employment Taxes required to be withheld with respect to those shares or other amounts from other wages payable to Participant, or through such other tax withholding arrangement as the Company deems appropriate, in its sole discretion. The provisions of this Paragraph 6(j) shall be applicable only to the extent necessary to comply with the applicable tax withholding requirements of Code Section 3121(v).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;Except as otherwise provided in Paragraph 4 or this Paragraph 6, the settlement of all Performance Shares or Performance-Qualified Shares which vest under the Award shall be made solely in shares of Common Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Special Deferral Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Provided Participant is a U.S. tax resident and Participant timely submits a properly completed deferral election in a form provided by the Company, any shares of Common Stock that become issuable pursuant to this Agreement shall be distributed in accordance with the terms of such deferral election, subject to Participant&#8217;s satisfaction of any applicable Withholding Taxes under Paragraph 6.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For purposes of applying the various Continuous Service vesting provisions of this Agreement, Participant shall be deemed to cease Continuous Service on the commencement date of any leave of absence and not to remain in Continuous Service status during the period of that leave, except to the extent otherwise required under employment laws in the jurisdiction where Participant is employed or pursuant to the following policy&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;Participant shall be deemed to remain in Continuous Service status during (i) the first three (3) months of an approved personal leave of absence or (ii) the first seven (7) months of any bona fide leave of absence (other than an approved personal leave) and shall be deemed to cease Continuous Service upon the expiration of the applicable three (3)-month or seven (7)-month period.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;In no event, however, shall Participant be deemed, for vesting purposes hereunder, to remain in Continuous Service beyond the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the expiration date of that leave of absence, unless Participant returns to active Continuous Service or Employee status on or before that date, or (ii) the date Participant&#8217;s Continuous Service or Employee status actually terminates by reason of his or her voluntary or involuntary termination or by reason of his or her death or Permanent Disability.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Compliance with Laws and Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The issuance of shares of Common Stock pursuant to the Award shall be subject to compliance by the Company and Participant with all Applicable Laws relating thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Nature of Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accepting the grant, Participant acknowledges, understands and agrees that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the grant of the Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of Awards, or benefits in lieu of Awards, even if Awards have been granted in the past&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;all decisions with respect to future Awards or other grants, if any, will be at the sole discretion of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Participant is voluntarily participating in the Plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;the Award and the shares of Common Stock subject to the Award, and the income and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;the Award and the shares of Common Stock subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including, without limitation, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, holiday pay, bonuses, long-service awards, leave-related payments, pension or retirement or welfare benefits or similar payments&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;the future value of the underlying shares of Common Stock is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from the termination of Participant&#8217;s Continuous Service (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s employment agreement, if any), and in consideration of the grant of the Award to which Participant is otherwise not entitled, Participant irrevocably agrees never to institute any claim against the Company, any Related Entity or the Employer, waives Participant&#8217;s ability, if any, to bring any such claim, and releases the Company, any Related Entity and the Employer from any such claim&#59; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, Participant shall be deemed irrevocably to have agreed not to pursue such claim and agreed to execute any and all documents necessary to request dismissal or withdrawal of such claim&#59;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;unless otherwise agreed with the Company in writing, the Award and the shares of Common Stock subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, any service Participant may provide as a director of the Company or a Related Entity&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;unless otherwise provided in the Plan or by the Company in its discretion, the Award and the benefits evidenced by this Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the shares of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">No Advice Regarding Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Participant&#8217;s participation in the Plan, or Participant&#8217;s acquisition or sale of the underlying shares of Common Stock. Participant should consult with Participant&#8217;s own personal tax, legal and financial advisors regarding Participant&#8217;s participation in the Plan before taking any action related to the Plan or the Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Notices.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and addressed to the Company at its principal corporate offices. Any notice required to be given or delivered to Participant shall be in writing and addressed to Participant at the most current address then indicated for Participant on the Company&#8217;s employee records or shall be delivered electronically to Participant through the Company&#8217;s electronic mail system or through an on-line brokerage firm authorized by the Company to effect sales of the Common Stock issued hereunder. All notices shall be deemed effective upon personal delivery or delivery through the Company&#8217;s electronic mail system or upon deposit in the U.S. mail, postage prepaid and properly addressed to the party to be notified.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Successors and Assigns.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Except to the extent otherwise provided in this Agreement, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the Company and its successors and assigns and Participant, the legal representatives, heirs and legatees of Participant&#8217;s estate</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Code Section 409A</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">It is the intention of the parties that the provisions of this Agreement shall, to the maximum extent permissible, comply with the requirements of the short-term deferral exception to Section 409A of the Code and Treasury Regulations Section 1.409A-1(b)(4) with respect to each Tranche of Performance Shares under this Award. Accordingly, to the extent there is any ambiguity as to whether one or more provisions of this Agreement would otherwise contravene the requirements or limitations of Code Section 409A applicable to such short-term deferral exception, then those provisions, as they apply to each Tranche, shall be interpreted and applied in a manner that does not result in a violation of the requirements or limitations of Code Section 409A and the Treasury Regulations thereunder that apply to such exception.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">However, to the extent this Agreement should be deemed to create a deferred compensation arrangement subject to the requirements of Code Section 409A with respect to one or more Tranches of the Performance Shares, whether by reason of a deferral election that satisfies the requirements of Paragraph 7 above or the pro-rata Continuous Service vesting provisions of this Agreement, then the following provisions shall apply with respect to any such Tranche, notwithstanding anything to the contrary set forth herein&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:30pt">No shares of Common Stock or other amounts which become issuable or distributable with respect to such Tranche by reason of Participant&#8217;s cessation of Continuous Service shall actually be issued or distributed to Participant until the date of Participant&#8217;s Separation from Service or as soon thereafter as administratively practicable, but in no event later than the later of (i) the close of the calendar year in which such Separation from Service occurs or (ii) the fifteenth (15th) day of the third (3rd) calendar month following the date of such Separation from Service.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:30pt">No shares of Common Stock or other amounts which become issuable or distributable with respect to such Tranche by reason of Participant&#8217;s cessation of Continuous Service shall actually be issued or distributed to Participant prior to the earlier of (i) the first (1st) day of the seventh (7th) month following the date of Participant&#8217;s Separation from Service or (ii) the date of Participant&#8217;s death, if Participant is deemed at the time of such Separation from Service to be a specified employee under Section 1.409A-1(i) of the Treasury Regulations issued under Code Section 409A, as determined by the Administrator in accordance with consistent and uniform standards applied to all other Code Section 409A arrangements of the Company, and such delayed commencement is otherwise required in order to avoid a prohibited distribution under Code Section 409A(a)(2). The deferred shares of Common Stock or other distributable amount shall be issued or distributed in a lump sum on the first (1st) day of the seventh (7th) month following the date of Participant&#8217;s Separation from Service or, if earlier, the first (1st) day of the month immediately following the date the Company receives proof of Participant&#8217;s death.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:30pt">No amounts that vest and become payable under Paragraph 4 of this Agreement with respect to that Tranche by reason of a Change in Control shall be distributed to Participant at the time of such Change in Control, unless that transaction also constitutes a Qualifying Change in Control. In the absence of such a Qualifying Change in Control, the distribution shall not be made until the date on which the shares of Common Stock to which those amounts pertain would have become issuable in accordance with the provisions of Paragraph 6(a) of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:30pt">If a deferral election under Paragraph 7 of this Agreement is in effect with respect to any Tranche of Performance Shares under this Award, no amounts that vest and become payable under Paragraph 4 with respect to that particular Tranche by reason of a Change in Control shall be distributed to Participant at the time of that Change in Control unless the transaction also constitutes a Qualifying Change in Control. In the absence of such a Qualifying Change in Control, the distribution shall not be made until the date on which the shares of Common Stock to which those amounts pertain </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">would have become issuable in accordance with Participant&#8217;s deferral election under Paragraph 7 of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:30pt">The shares of Common Stock that are issuable pursuant to each Tranche of Performance Shares in accordance with the provisions of this Agreement and attached Schedule I shall be deemed a separate payment for purposes of Code Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement and the Award evidenced hereby are made and granted pursuant to the Plan and are in all respects limited by and subject to the terms of the Plan. In the event of any conflict between the provisions of this Agreement and the terms of the Plan, the terms of the Plan shall be controlling. All decisions of the Administrator with respect to any question or issue arising under the Plan or this Agreement shall be conclusive and binding on all persons having an interest in the Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Governing Law&#47;Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of the State of Delaware without resort to that State&#8217;s conflict-of-laws rules. For purposes of any action, lawsuit or other proceedings brought to enforce this Agreement or otherwise relating to or arising from this Agreement, the parties hereby submit to and consent to the sole and exclusive jurisdiction of the courts of San Mateo County, California, or the federal courts for the United States for the Northern District of California, and no other courts, where this grant is made and&#47;or to be performed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Nothing in this Agreement or in the Plan shall confer upon Participant any right to remain in Continuous Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Employer or of Participant, which rights are hereby expressly reserved by each, to terminate Participant&#8217;s Continuous Service at any time for any reason, with or without Cause.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Plan Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The official prospectus for the Plan is available on the Company&#8217;s intranet at&#58; Stock Awards section on GNET. Participant may also obtain a printed copy of the prospectus by contacting Stock Plan Services at stockplanservices&#64;gilead.com.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Electronic Delivery and Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Participant acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of this Agreement.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Participant may be subject to insider trading restrictions and&#47;or market abuse laws based on the exchange on which the shares of Common Stock are listed and in applicable jurisdictions including the United States and Participant&#8217;s country or his or her broker&#8217;s country, if different, which may affect Participant&#8217;s ability to accept, acquire, sell or otherwise dispose of shares, rights to shares (e.g., Performance Shares) or rights linked to the value of shares of Common Stock (e.g., dividend equivalents) during such times as Participant is considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws in applicable jurisdictions). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders Participant placed before he or she possessed inside information. Furthermore, Participant could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable insider trading policy of the Company. Participant acknowledges that it is Participant&#8217;s responsibility to comply with any applicable restrictions, and Participant should speak with his or her personal legal advisor on this matter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Imposition of Other Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The Company reserves the right to impose other requirements on Participant&#8217;s participation in the Plan, on the Award and on any shares of Common Stock acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Participant Acceptance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Participant must accept the terms and conditions of this Agreement either electronically through the electronic acceptance procedure established by the Company or through a written acceptance delivered to the Company in a form satisfactory to the Company. In no event shall any shares of Common Stock be issued (or other securities or property distributed) under this Agreement in the absence of such acceptance. By accepting the Award, Participant agrees that this Award is granted under and governed by the terms and conditions of the Plan and this Agreement. Participant has reviewed the Plan and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting this Agreement and fully understands all provisions of the Plan and Agreement.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div><div style="text-align:justify"><font><br></font></div></div></div><div id="i890e68332a1b4b3fbfc64d7c52abfda4_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Gilead Sciences, Inc. has caused this Agreement to be executed on its behalf by its duly-authorized officer on the day and year first indicated above.</font></div><div style="margin-bottom:7pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.608%"><tr><td style="width:1.0%"></td><td style="width:21.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">GILEAD SCIENCES, INC.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#47;s&#47; Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">EVP, Human Resources</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:7pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.769%"><tr><td style="width:1.0%"></td><td style="width:22.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">PARTICIPANT</font></td></tr><tr style="height:41pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Signature</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>5
<FILENAME>gildq12021ex10242021employ.htm
<DESCRIPTION>2021 EMPLOYEE RSU AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ie20661f5c6584f36a7b0794c5b5d9464_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 10.24</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">GLOBAL RESTRICTED STOCK UNIT ISSUANCE AGREEMENT</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">RECITALS</font></div><div style="margin-top:8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;The Board has adopted the Plan for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants.</font></div><div style="margin-top:8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;This Agreement is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Company&#8217;s issuance of shares of Common Stock to Participant thereunder.</font></div><div style="margin-top:8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;All capitalized terms in this Agreement shall have the meaning assigned to them herein and in the attached Appendix.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company hereby awards Restricted Stock Units to Participant upon the following terms and conditions&#58; </font></div><div style="margin-top:8pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Grant of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company hereby awards to Participant, as of the Award Date indicated below, Restricted Stock Units under the Plan. Each Restricted Stock Unit that vests hereunder will entitle Participant to receive one share of Common Stock on the specified issuance date for that unit. The number of Shares subject to the awarded Restricted Stock Units, the applicable vesting schedule for those Shares, the dates on which those vested Shares shall become issuable to Participant and the remaining terms and conditions governing the Award shall be as set forth in this Agreement.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AWARD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SUMMARY</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.266%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Participant&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Award Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Number of Shares Subject to Award&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">shares of Common Stock (the &#8220;Shares&#8221;)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Vesting Schedule&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Shares have a four-year vesting schedule. 25% vest on the first anniversary of the Award Date. The balance will vest 6.25% quarterly thereafter until fully vested. However, one or more Shares may be subject to accelerated vesting in accordance with the provisions of Paragraph 3 or 5 of this Agreement.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Issuance Schedule</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Shares in which Participant vests in accordance with the Normal Vesting Schedule shall become issuable pursuant to the Plan on the applicable annual vesting date, subject to the Company&#8217;s collection of the applicable Withholding Taxes. In no event will the Shares in which Participant so vests be issued after the later of (i) the close of the calendar year in which the Shares vest pursuant to the Normal Vesting Schedule or (ii) the fifteenth (15th) day of the third (3rd) calendar month following such vesting date. The procedures pursuant to which the applicable Withholding Taxes are to be collected are set forth in Paragraph 7 of this Agreement.</font></td></tr></table></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Limited Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Prior to actual receipt of the Shares which vest hereunder, Participant may not transfer any interest in the Award or the underlying Shares or pledge or otherwise hedge the sale of those Shares, including (without limitation) any short sale or any acquisition or disposition of any put or call option or other instrument tied to the value of the underlying Shares. However, any Shares which vest hereunder but which otherwise remain unissued at the time of Participant&#8217;s death may be transferred pursuant to the provisions of Participant&#8217;s will or the laws of inheritance. </font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Cessation of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Except as otherwise provided in this Paragraph 3 or in Paragraph 5 below, should Participant cease Continuous Service for any reason prior to vesting in one or more Shares pursuant to the Normal Vesting Schedule, then the Award will be immediately cancelled with respect to those unvested Shares, and the number of Restricted Stock Units will be reduced accordingly. Participant shall thereupon cease to have any right or entitlement to receive any Shares under those cancelled units.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Should Participant (i) cease Continuous Service at least twelve (12) months following the Award Date and (ii) (1) after attaining age 55 and completing at least ten (10) years of Continuous Service or (2) after attaining age 65, then Participant shall continue to vest in unvested Shares granted hereunder in accordance with the Normal Vesting Schedule as if such Participant had remained in Continuous Service. If Participant, as of December 31, 2018, (x) was in Salary Grade 35 or above, (y) had completed at least three (3) years of Continuous Service, and (z) the sum of Participant&#8217;s attained age and completed years of Continuous Service equals or exceeds seventy (70) years, he or she shall be deemed to satisfy the requirements of subparagraph (b)(ii). Any Shares which vest pursuant to this Subparagraph shall be issuable as set forth in Paragraph 1 above. Notwithstanding the foregoing, if the Company receives an opinion of counsel that there has been a legal judgment and&#47;or legal development in Participant&#8217;s jurisdiction that would likely result in the favorable treatment applicable to the Award pursuant to this subparagraph (b) being deemed unlawful and&#47;or discriminatory, then the Company will not apply this favorable treatment at the time of Participant&#8217;s cessation of Continuous Service, and the Award will be treated as set forth in Subparagraph 3(a). Furthermore, if Participant is located in Australia, Hong Kong, the Netherlands, or Taiwan, he or she shall not be eligible for the provisions of this Subparagraph 3(b) and the Award will be treated as set forth in the Subparagraph 3(a).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Notwithstanding any other provision hereof, should Participant&#8217;s Continuous Service be terminated for Cause (or for a reason that is comparable to termination for Cause under employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s employment agreement, if any), or should Participant engage in any other conduct, while in Continuous Service or following cessation of Continuous Service, that is materially detrimental to the business or affairs of the Company (or any Related Entity), as determined in the sole discretion of the Administrator, then this Award will be immediately cancelled with respect to all Shares, whether or not vested at the time. Participant shall thereupon cease to have any right or entitlement to receive any Shares under those cancelled units.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Stockholder Rights and Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The holder of this Award shall not have any stockholder rights, including voting, dividend or liquidation rights, with respect to the Shares subject to the Award until Participant becomes the record holder of those Shares upon their actual issuance following the Company&#8217;s collection of the applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding the foregoing, if and to the extent that this Award is outstanding on the record date for any dividend or other distribution, whether regular or extraordinary and whether payable in cash, securities (other than Common Stock) or other property, and one or more Shares subject to this Award on such record date have not otherwise vested and been delivered as of the payment date for such dividend or distribution and do not otherwise receive such dividend or distribution (i.e., those Shares are not otherwise treated as issued and outstanding for purposes of entitlement to the dividend or distribution pursuant to state law, the terms of such distribution or otherwise), then a special book account shall be established for Participant and credited with a phantom dividend that is equivalent to the actual dividend or distribution which would have been paid on such Shares at the time subject to this Award had they been issued and outstanding and entitled to that dividend or distribution. As such Shares subsequently vest hereunder, the phantom dividend equivalents so credited to those Shares in the book account shall vest, and those vested dividend equivalents shall be distributed to Participant (in the form of additional Shares or in such other form as the Administrator deems appropriate under the circumstances) concurrently with the issuance of the vested Shares to which those phantom dividend equivalents relate and correspondingly as such Shares are forfeited or cancelled under this Award the phantom dividend equivalents so credited to those Shares in the book account shall be forfeited or cancelled. Each such distribution of dividend equivalent amounts shall be subject to the Company&#8217;s collection of any Withholding Taxes applicable to that distribution. The Administrator shall have the sole discretion to determine the dollar value of any dividend or distribution paid other than in the form of cash, and its determination shall be controlling.&#160;No dividend equivalent amount shall be paid or distributed on shares of Common Stock under this Award that are forfeited or that otherwise do not vest and are not issued or issuable under this Award.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Should Participant cease Continuous Service without vesting in one or more of the Shares subject to this Award (including any Shares which do not or will not otherwise vest after taking into account any applicable vesting acceleration or continuation provisions set forth in Paragraph 3 or 5 of this Agreement), then the phantom dividend equivalents credited to those unvested Shares shall be cancelled, and Participant shall thereupon cease to have any further right or entitlement to those cancelled amounts.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Any Restricted Stock Units subject to this Award at the time of a Change in Control may be (i) assumed or otherwise continued in full force and effect by the surviving corporation, (ii) replaced with an economically-equivalent substitute award or (iii) replaced with a cash retention program of the successor corporation that is in a dollar amount equal to the Fair Market Value of the Shares underlying those Restricted Stock Units (as </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">measured immediately prior to the Change in Control) and provides for the subsequent vesting and payout of that dollar amount in accordance with the same vesting and issuance provisions that would otherwise be in effect for those Shares in the absence of the Change in Control. In the event of such assumption or continuation of the Award or such replacement of the Award with an economically-equivalent award or cash retention program, no accelerated vesting of the Restricted Stock Units shall occur at the time of the Change in Control. Notwithstanding the foregoing, no such cash retention program shall be established for the Restricted Stock Units subject to this Award to the extent such program would otherwise be deemed to constitute a deferred compensation arrangement subject to the requirements of Code Section 409A and the Treasury Regulations thereunder.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">In the event the Award is assumed or otherwise continued in effect, the Restricted Stock Units subject to the Award shall be adjusted immediately after the consummation of the Change in Control so as to apply to the number and class of securities into which the Shares underlying those units immediately prior to the Change in Control would have been converted in consummation of that Change in Control had those Shares actually been issued and outstanding at that time. To the extent the actual holders of the outstanding Common Stock receive cash consideration for their Common Stock in consummation of the Change in Control, the successor corporation (or parent entity) may, in connection with the assumption or continuation of the Restricted Stock Units subject to the Award at that time and with the approval of the Administrator, substitute one or more shares of its own common stock with a fair market value equivalent to the cash consideration paid per Share in the Change in Control transaction, provided the substituted common stock is readily tradable on an established U.S. securities exchange.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Any Restricted Stock Units which are to be assumed or otherwise continued in effect in connection with the Change in Control or are to be replaced with an economically equivalent award or cash retention program in accordance with Paragraph 5(a) shall be subject to accelerated vesting in accordance with the following provision&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If Participant&#8217;s Employee status is unilaterally terminated as a result of an involuntary termination (other than for death or Permanent Disability) without Cause, or if Participant resigns from such Employee status due to a Constructive Termination, at any time during the period beginning with the execution date of the definitive agreement for that Change in Control transaction and ending with the earlier of (i) the termination of that definitive agreement without the consummation of such Change in Control or (ii) the expiration of the Applicable Acceleration Period following the consummation of such Change in Control, then Participant shall immediately vest in all the unvested Shares (or any replacement securities or cash proceeds) at the time subject to this Award. The Shares (or any replacement securities or cash proceeds) that vest pursuant to this Paragraph 5(c) shall be issued or distributed on the date of Participant&#8217;s Separation from Service in connection with such termination of Employee status or as soon as administratively practicable thereafter, but in no event later than the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">later</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the close of the calendar year in which such Separation from Service occurs or (ii) the fifteenth (15th) day of the third (3rd) calendar month following the date of such Separation from </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Service. The applicable Withholding Taxes with respect to such issuance shall be collected in accordance with Paragraph 7 of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">If the Restricted Stock Units subject to this Award at the time of the Change in Control are not assumed or otherwise continued in effect in connection with the Change in Control or are not replaced with an economically equivalent award or cash incentive program in accordance with Paragraph 5(a), then those units will vest immediately prior to the closing of the Change in Control. The Shares subject to those vested units shall be converted into the right to receive for each such Share the same consideration per Share payable to the other stockholders of the Company in consummation of that Change in Control, and such consideration per Share shall be distributed to Participant upon the tenth (10th) business day following the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earliest </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to occur of (i) the date the Share would have otherwise vested and been issued pursuant to the Vesting and Issuance Schedules set forth in Paragraph 1 in the absence of such Change in Control, (ii) the date of Participant&#8217;s Separation from Service, or (iii) the first date following a Qualifying Change in Control on which the distribution can be made without contravention of any applicable provisions of Code Section 409A. Such distribution shall be subject to the Company&#8217;s collection of the applicable Withholding Taxes pursuant to the provisions of Paragraph 7.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">This Agreement shall not in any way affect the right of the Company to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Adjustment in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Should any change be made to the Common Stock by reason of any stock split, stock dividend, recapitalization, combination of shares, exchange of shares, spin-off transaction, extraordinary dividend or distribution or other change affecting the outstanding Common Stock as a class without the Company&#8217;s receipt of consideration, or should the value of outstanding Common Stock be substantially reduced as a result of a spin-off transaction or an extraordinary dividend or distribution, or should there occur any merger, consolidation or other reorganization, then equitable adjustments shall be made by the Administrator to the total number and&#47;or class of securities issuable pursuant to this Award in order to reflect such change. In making such adjustments, the Administrator shall take into account any amounts to be credited to Participant&#8217;s book account under Paragraph 4(b) in connection with the transaction, and the determination of the Administrator shall be final, binding and conclusive. In the event of a Change in Control, the provisions of Paragraph 5 shall be controlling. </font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Issuance of Shares or Other Amounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">On or after each date on which one or more Shares are to be issued in accordance with the express provisions of this Agreement, the Company shall issue to or on behalf of Participant a certificate (which may be in electronic form) for those Shares and shall concurrently distribute to Participant any phantom dividend equivalents with respect to those Shares (in the form of additional Shares or in such other form as the Administrator deems </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">appropriate under the circumstances), subject in each instance to the Company&#8217;s collection of the applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Participant acknowledges that, regardless of any action the Company and&#47;or the Employer take with respect to any or all Withholding Taxes related to Participant&#8217;s participation in the Plan and legally applicable to Participant, the ultimate liability for all Withholding Taxes is and remains Participant&#8217;s responsibility and may exceed the amount actually withheld by the Company or the Employer. Participant further acknowledges that the Company and&#47;or the Employer (i) make no representations or undertakings regarding the treatment of any Withholding Taxes in connection with any aspect of the Award, including the grant, vesting or settlement of the Award, the issuance of Shares (or other property) upon settlement of the Award, the subsequent sale of Shares acquired pursuant to such issuance and the receipt of any dividends and&#47;or phantom dividend equivalents&#59; and (ii) do not commit to, and are under no obligation to, structure the terms of the grant or any aspect of the Award to reduce or eliminate Participant&#8217;s liability for Withholding Taxes or achieve any particular tax result. Further, if Participant has become subject to Withholding Taxes in more than one jurisdiction, Participant acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Withholding Taxes in more than one jurisdiction.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The Company shall collect, and Participant hereby authorizes the Company to collect, the Withholding Taxes with respect to the Shares issued under this Agreement (including Shares issued in settlement of phantom dividend equivalents) through an automatic Share withholding procedure pursuant to which the Company will withhold, immediately as the Shares are issued under the Award, a portion of those Shares with a Fair Market Value (measured as of the issuance date) equal to the amount of such Withholding Taxes, unless such Share Withholding Method is not permissible or advisable under local law or until the Company otherwise decides to no longer utilize the Share Withholding Method and provides Participants with a corresponding notice.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">If the Share Withholding Method is to be utilized for the collection of Withholding Taxes, then the Company shall withhold the number of otherwise issuable Shares necessary to satisfy the applicable Withholding Taxes based on the applicable minimum statutory rate or other applicable withholding rate, including maximum applicable rates, as determined by the Company in its sole discretion. If the maximum rate is used, any over-withheld amount will be refunded to Participant in cash by the Company or Employer (with no entitlement to the Common Stock equivalent) or if not refunded, Participant may seek a refund from the local tax authorities. If the obligation for Withholding Taxes is satisfied by using the Share Withholding Method, then Participant will, for tax purposes, be deemed to have been issued the full number of Shares subject to the vested Award, notwithstanding that a number of the Shares are withheld solely for the purpose of paying the applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The Company shall have sole discretion to determine whether or not the Share Withholding Method shall be utilized for the collection of the applicable Withholding Taxes. Participant shall be notified (in writing or through the Company&#8217;s electronic mail system) in the event the Company no longer intends to utilize the Share Withholding </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Method. Should any Shares become issuable under the Award (including Shares issued in settlement of phantom dividend equivalents) at a time when the Share Withholding Method is not being utilized by the Company, then the Withholding Taxes shall be collected from Participant through a sale-to-cover transaction authorized by Participant, pursuant to which an immediate open-market sale of a portion of the Shares issued to Participant will be effected, for and on behalf of Participant, by the Company&#8217;s designated broker to cover the Withholding Tax liability estimated by the Company to be applicable to such issuance. Participant shall, promptly upon request from the Company, execute (whether manually or through electronic acceptance) an appropriate sales authorization (in form and substance reasonably satisfactory to the Company) that authorizes and directs the broker to effect such open-market, sale-to-cover transactions and remit the sale proceeds, net of brokerage fees and other applicable charges, to the Company in satisfaction of the applicable Withholding Taxes. However, no sale-to-cover transaction shall be effected unless (i) such a sale is at the time permissible under the Company&#8217;s insider trading policies governing the sale of Common Stock and (ii) the transaction is not otherwise deemed to constitute a prohibited loan under Section 402 of the Sarbanes-Oxley Act of 2002.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">If the Company determines that such sale-to-cover transaction is not permissible or advisable at the time or if Participant otherwise fails to effect a timely sales authorization as required by this Agreement, then the Company may, in its sole discretion, elect either to defer the issuance of the Shares until such sale-to-cover transaction can be effected in accordance with Participant&#8217;s executed sale directive or to collect the applicable Withholding Taxes through Participant&#8217;s delivery of his or her separate check payable to the Company in the amount of such Withholding Taxes or by withholding such amount from other wages payable to Participant. In no event shall any Shares be issued in the absence of an arrangement reasonably satisfactory to the Company for the satisfaction of the applicable Withholding Taxes and in compliance with any applicable requirements of Code Section 409A.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Except as otherwise provided in Paragraph 5, the settlement of all Restricted Stock Units which vest under the Award shall be made solely in Shares. In no event, however, shall any fractional Shares be issued. Accordingly, the total number of Shares to be issued at the time the Award vests (including any Shares issued in settlement of phantom dividend equivalents) shall, to the extent necessary, be rounded down to the next whole Share in order to avoid the issuance of a fractional Share.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt"> The Company shall collect the Withholding Taxes with respect to phantom dividend equivalents distributed in a form other than Shares by withholding a portion of that distribution equal to the amount of the applicable Withholding Taxes, with the cash portion of the distribution to be the first portion so withheld, or through such other tax withholding arrangement as the Company deems appropriate, in its sole discretion.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">Notwithstanding the foregoing provisions, to the extent Participant is subject to taxation in the United States, the employee portion of the federal, state and local employment taxes required to be withheld by the Company in connection with the vesting (as determined under applicable tax laws) of the Shares or any other amounts hereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Employment Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall in all events be collected from Participant no later than the last </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">business day of the calendar year in which those Shares or other amounts vest (as determined under applicable tax laws) hereunder. Accordingly, to the extent the applicable issuance date for one or more vested Shares or the distribution date for such other amounts is to occur in a year subsequent to the calendar year in which those Shares or other amounts vest, Participant shall, if so requested by the Company, on or before the last business day of the calendar year in which such Shares or other amounts vest, deliver to the Company a check payable to its order (or a wire transfer of funds to the Company) in the dollar amount equal to the Employment Taxes required to be withheld with respect to those Shares or other amounts. Alternatively, the Company may, in its sole discretion, elect to withhold the dollar amount equal to the Employment Taxes required to be withheld with respect to those Shares or other amounts from other wages payable to Participant, or through such other tax withholding arrangement as the Company deems appropriate, in its sole discretion. The provisions of this Paragraph 7(i) shall be applicable only to the extent necessary to comply with the applicable tax withholding requirements of Code Section 3121(v).</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For purposes of applying the various vesting provisions of this Agreement, the Administrator, in its sole discretion, may determine that Participant shall be deemed to cease Continuous Service and Employee status on the commencement date of any leave of absence and not remain in Continuous Service or Employee status during the period of that leave, except to the extent otherwise required under employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s employment agreement, if any or pursuant to the following policy&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Participant shall receive Continuous Service credit for such vesting purposes for (i) the first three (3) months of an approved personal leave of absence and (ii) the first seven (7) months of any bona fide leave of absence (other than an approved personal leave), but in no event beyond the expiration date of such leave of absence.</font></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In no event, however, shall Participant be deemed, for vesting purposes hereunder, to remain in Continuous Service or Employee status beyond the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earliest </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of (i) the expiration date of that leave of absence, unless Participant returns to active Continuous Service or Employee status on or before that date, (ii) the date Participant&#8217;s Continuous Service or Employee status actually terminates by reason of his or her voluntary or involuntary termination or by reason of his or her death or Permanent Disability or (iii) the date Participant is deemed to have a Separation from Service.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Compliance with Laws and Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The issuance of Shares pursuant to the Award shall be subject to compliance by the Company and Participant with all Applicable Laws relating thereto, as determined by counsel for the Company.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The inability of the Company to obtain approval from any regulatory body having authority deemed by the Company to be necessary to the lawful </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">issuance and sale of any Common Stock pursuant to this Award shall relieve the Company of any liability with respect to the non-issuance or sale of the Common Stock as to which such approval shall not have been obtained. The Company, however, shall use its reasonable best efforts to obtain all such approvals.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant may be subject to insider trading restrictions and&#47;or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions including the United States and Participant&#8217;s country or his or her broker&#8217;s country, if different, which may affect Participant&#8217;s ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (e.g., Restricted Stock Units) or rights linked to the value of Shares (e.g., dividend equivalents) during such times as Participant is considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws in applicable jurisdictions). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders Participant placed before he or she possessed inside information. Furthermore, Participant could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable insider trading policy of the Company. Participant acknowledges that it is Participant&#8217;s responsibility to comply with any applicable restrictions and Participant should speak with his or her personal legal advisor on this matter.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Deferred Issuance Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding any provision to the contrary in this Agreement, to the extent Participant is subject to taxation in the United States and this Award may be deemed to create a deferred compensation arrangement under Code Section 409A, then the following limitation shall apply&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No Shares or other amounts which become issuable or distributable under this Agreement upon Participant&#8217;s Separation from Service shall actually be issued or distributed to Participant prior to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the first day of the seventh (7th) month following the date of such Separation from Service or (ii) the date of Participant&#8217;s death, if Participant is deemed at the time of such Separation from Service to be a specified employee under Section 1.409A-1(i) of the Treasury Regulations issued under Code Section 409A, as determined by the Administrator in accordance with consistent and uniform standards applied to all other Code Section 409A arrangements of the Company, and such delayed commencement is otherwise required in order to avoid a prohibited distribution under Code Section 409A(a)(2). The deferred Shares or other distributable amount shall be issued or distributed in a lump sum on the first day of the seventh (7th) month following the date of Participant&#8217;s Separation from Service or, if earlier, the first day of the month immediately following the date the Company receives proof of Participant&#8217;s death.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To the extent there is any ambiguity as to whether any provision of this Agreement would otherwise contravene one or more requirements or limitations of Code Section 409A, such provisions shall be interpreted and applied in a manner that does not </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">result in a violation of the applicable requirements or limitations of Code Section 409A and the Treasury Regulations thereunder.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Each installment of Shares issuable pursuant to this Agreement shall be treated as a separate payment for purposes of Code Section 409A. </font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and addressed to the Company at its principal corporate offices. Any notice required to be given or delivered to Participant shall be in writing and addressed to Participant at the most current address then indicated for Participant on the Company&#8217;s employee records or shall be delivered electronically to Participant through the Company&#8217;s electronic mail system or through the on-line brokerage firm authorized by the Company to effect the sale of the Shares issued hereunder. All notices shall be deemed effective upon personal delivery or delivery through the Company&#8217;s electronic mail system or upon deposit in the U.S. or local country mail, postage prepaid and properly addressed to the party to be notified.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except to the extent otherwise provided in this Agreement, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the Company and its successors and assigns and Participant, Participant&#8217;s assigns, the legal representatives, heirs and legatees of Participant&#8217;s estate.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement and the Award evidenced hereby are made and granted pursuant to the Plan and are in all respects limited by and subject to the terms of the Plan. In the event of any conflict between the provisions of this Agreement and the terms of the Plan, the terms of the Plan shall be controlling. All decisions of the Administrator with respect to any question or issue arising under the Plan or this Agreement shall be conclusive and binding on all persons having an interest in the Award.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The interpretation, performance and enforcement of this Agreement shall be governed by the laws of the State of Delaware without resort to that State&#8217;s conflict-of-laws rules.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Award and this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of the State of California and agree that such litigation shall be conducted only in the courts of San Mateo County, California, or the federal courts for the Northern District of California, and no other courts where the grant of the Restricted Stock Units is made and&#47;or to be performed. </font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Acknowledgment of Nature of Plan and Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In accepting the Award, Participant acknowledges, understands and agrees that&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the Plan is established voluntarily by the Company, it is discretionary in nature, and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of Restricted Stock Units, or benefits in lieu of Restricted Stock Units, even if Restricted Stock Units have been granted in the past&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">all decisions with respect to future Awards or other grants, if any, will be at the sole discretion of the Company&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the Award and Participant&#8217;s participation in the Plan shall not create a right to employment or be interpreted as forming or amending an employment or service contract with the Company, the Employer or any Related Entity and shall not interfere with the ability of the Company, the Employer or any Related Entity, as applicable, to terminate Participant&#8217;s employment or service relationship (if any)&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Participant&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">the Award and the Shares subject to the Award, and the income and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the Award and the Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, holiday pay, bonuses, long-service awards, leave-related payments, pension or retirement or welfare benefits or similar payments&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with any certainty&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from termination of Participant&#8217;s Continuous Service by the Employer or the Company (or any Related Entity) (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s employment agreement, if any), and in consideration of the Award, Participant irrevocably agrees not to institute any claim against the Company, the Employer or any Related Entity, waives his or her ability, if any, to bring any such claim and releases the Company, the Employer and any Related Entity from any such claim&#59; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, Participant shall be deemed irrevocably to have agreed not to pursue such claim and agrees to execute any and all documents necessary to request dismissal or withdrawal of such claim&#59;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">unless otherwise agreed with the Company in writing, the Award and the Shares subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, any service Participant may provide as a director of the Company or a Related Entity&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">unless otherwise provided in the Plan or by the Company in its discretion, the Restricted Stock Units and the benefits evidenced by this Agreement do not create any entitlement to have the Restricted Stock Units or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">the following provisions apply only if Participant is providing services outside the United States&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">the Award and the Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation or salary for any purpose&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">Participant acknowledges and agrees that neither the Company, the Employer nor any Related Entity shall be liable for any foreign exchange rate fluctuation between Participant&#8217;s local currency and the United States Dollar that may affect the value of the Restricted Stock Units or of any amounts due to Participant pursuant to the settlement of the Restricted Stock Units or the subsequent sale of any Shares acquired upon settlement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Participant&#8217;s participation in the Plan or Participant&#8217;s acquisition or sale of the underlying Shares. Participant should consult with his or her personal tax, legal and financial advisors regarding his or her participation in the Plan before taking any action related to the Plan or the Restricted Stock Units.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by Participant or other Participants.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Data Privacy Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  By electing to participate in the Plan via the Company&#8217;s online acceptance procedure, Participant is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Personal Data (as defined below) by the Company and the transfer of Personal Data to the recipients mentioned herein, including recipients located in countries which do not adduce an adequate level of protection from a European (or other) data protection law perspective, for the purposes described herein.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that he or she needs to review the following information about the processing of his or her personal data by or on behalf of the Company, the Employer and&#47;or any Related Entity as described in the Agreement and any other Plan materials (the &#8220;Personal Data&#8221;) and declare his or her consent. As regards the processing of Participant&#8217;s Personal Data in connection with the Plan and this Agreement, Participant understands that the Company is the controller of his or her Personal Data.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">Data Processing and Legal Basis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  The Company collects, uses and otherwise processes Personal Data about Participant for the purposes of allocating Shares and implementing, administering and managing the Plan. Participant understands that this Personal Data may include, without limitation, his or her name, home address and telephone number, email address, date of birth, social insurance number, passport number or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Restricted Stock Units or any other entitlement to shares of stock or equivalent benefits awarded, cancelled, exercised, vested, unvested or outstanding in Participant&#8217;s favor. The legal basis for the processing of Participant&#8217;s Personal Data, where required, will be his or her consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that the Company transfers his or her Personal Data, or parts thereof, to E*TRADE Financial Services, Inc. (and its affiliated companies), an independent service provider based in the United States which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share Participant&#8217;s Personal Data with such different service provider that serves the Company in a similar manner. Participant understands and acknowledges that the Company&#8217;s service provider will open an account for him or her to receive and trade Shares acquired under the Plan and that he or she will be asked to agree on separate terms and data processing practices with the service provider, which is a condition of Participant&#8217;s ability to participate in the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that the Company and, as of the date hereof, any third parties assisting in the implementation, administration and management of the Plan, such as E*TRADE Financial Services, Inc., are based in the United States. Participant understands and acknowledges that his or her country may have enacted data privacy laws that are different from the laws of the United States. For example, the European Commission has issued only a limited adequacy finding with respect to the United States that applies solely if and to the extent that companies self-certify and remain self-certified under the EU&#47;U.S. Privacy Shield program. The Company does not currently participate in the EU&#47;U.S. Privacy Shield Program. The Company&#8217;s legal basis for the transfer of Participant&#8217;s Personal Data is his or her consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:24.69pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that the Company will use his or her Personal Data only as long as is necessary to implement, administer and manage his or her participation in the Plan, or to comply with legal or regulatory obligations, including under tax and securities laws. In the latter case, Participant understands and </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">acknowledges that the Company&#8217;s legal basis for the processing of his or her Personal Data would be compliance with the relevant laws or regulations. When the Company no longer needs Participant&#8217;s Personal Data for any of the above purposes, Participant understands the Company will remove it from its systems.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Voluntariness and Consequences of Denial&#47;Withdrawal of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that his or her participation in the Plan and his or her consent is purely voluntary. Participant may deny or later withdraw his or her consent at any time, with future effect and for any or no reason. If Participant denies or later withdraws his or her consent, the Company can no longer offer Participant participation in the Plan or offer other equity awards to Participant or administer or maintain such awards and Participant would no longer be able to participate in the Plan. Participant further understands that denial or withdrawal of his or her consent would not affect his or her status or salary as an employee or his or her career and that Participant would merely forfeit the opportunities associated with the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that data subject rights regarding the processing of Personal Data vary depending on the applicable law and that, depending on where Participant is based and subject to the conditions set out in the applicable law, Participant may have, without limitation, the rights to (i) inquire whether and what kind of Personal Data the Company holds about him or her and how it is processed, and to access or request copies of such Personal Data, (ii) request the correction or supplementation of Personal Data about him or her that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Personal Data no longer necessary for the purposes underlying the processing, processed based on withdrawn consent, processed for legitimate interests that, in the context of his or her objection, do not prove to be compelling, or processed in non-compliance with applicable legal requirements, (iv) request the Company to restrict the processing of his or her Personal Data in certain situations where Participant feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Personal Data for legitimate interests, and to (vi) request portability of Participant&#8217;s Personal Data that he or she has actively or passively provided to the Company (which does not include data derived or inferred from the collected data), where the processing of such Personal Data is based on consent or his or her employment and is carried out by automated means. In case of concerns, Participant understands that he or she may also have the right to lodge a complaint with the competent local data protection authority. Further, to receive clarification of, or to exercise any of, Participant&#8217;s rights, Participant understands that he or she should contact his or her local human resources representative.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Plan Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The official prospectus for the Plan is available on the Company&#8217;s intranet at&#58; GNet &#62; Employee Resources &#62; Stock Awards &#62; Plan Documents. Participant may also obtain a printed copy of the prospectus by contacting Stock Plan Services at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">stockplanservices&#64;gilead.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By electing to accept this Agreement, Participant acknowledges that he or she is sufficiently proficient in English, or has consulted with an </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">advisor who is sufficiently proficient in English so as to allow Participant, to understand the terms and conditions of this Agreement. Further, if Participant has received this Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Electronic Delivery and Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Participant Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant must accept the terms and conditions of this Agreement either electronically through the electronic acceptance procedure established by the Company or through a written acceptance delivered to the Company in a form satisfactory to the Company. In no event shall any Shares be issued (or other securities or property distributed) under this Agreement in the absence of such acceptance.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Foreign Account &#47; Assets Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Depending upon the country to which laws Participant is subject, Participant may have certain foreign asset and&#47;or account reporting requirements that may affect Participant&#8217;s ability to acquire or hold Shares under the Plan or cash received from participating in the Plan (including from any dividends or phantom dividend equivalents received or sale proceeds arising from the sale of Shares) in a brokerage or bank account outside Participant&#8217;s country. Participant&#8217;s country may require that he or she report such accounts, assets or transactions to the applicable authorities in Participant&#8217;s country. Participant is responsible for knowledge of and compliance with any such regulations and should speak with his or her own personal tax, legal and financial advisors regarding same.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any provisions in this Agreement, the Award shall be subject to any special terms and conditions set forth in any Addendum to this Agreement for Participant&#8217;s country. Moreover, if Participant relocates to one of the countries included in the Addendum, the special terms and conditions for such country will apply to Participant, to the extent the Company determines that the application of such terms and conditions is necessary for legal or administrative reasons. The Addendum constitutes part of this Agreement.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company reserves the right to impose other requirements on Participant&#8217;s participation in the Plan, on the Award and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Gilead Sciences, Inc. has caused this Agreement to be executed on its behalf by its duly-authorized officer on the day and year first indicated above.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:24pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.929%"><tr><td style="width:1.0%"></td><td style="width:21.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EVP, Human Resources</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By Participant&#8217;s electronic acceptance and the signature of the Company&#8217;s representative above, Participant and the Company agree that this Award is granted under and governed by the terms and conditions of the Plan and the Agreement, including the terms and conditions set forth in any Addendum to the Agreement for Participant&#8217;s country. Participant has reviewed the Plan and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting the Agreement and fully understands all provisions of the Plan and Agreement.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div></div></div><div id="ie20661f5c6584f36a7b0794c5b5d9464_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">APPENDIX</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">DEFINITIONS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following definitions shall be in effect under the Agreement&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the addendum to this Agreement setting forth special terms and conditions for Participant&#8217;s country.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt;text-decoration:underline">Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the Compensation Committee of the Board (or a subcommittee thereof) acting in its capacity as administrator of the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean this Global Restricted Stock Unit Issuance Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Applicable Acceleration Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall have the meaning assigned to such term in Section 2(b) of the Plan and shall be determined on the basis of Participant&#8217;s status on the Change in Control date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.67pt;text-decoration:underline">Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the legal requirements related to the Plan and the Award under applicable provisions of the federal securities laws, state corporate and securities laws, the Code, the rules of any applicable Stock Exchange on which the Common Stock is listed for trading, and the rules of any non-U.S. jurisdiction applicable to Awards granted to residents therein.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.33pt;text-decoration:underline">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the award of Restricted Stock Units made to Participant pursuant to the terms of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Award Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the date the Restricted Stock Units are awarded to Participant pursuant to the Agreement and shall be the date indicated in Paragraph 1 of the Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">H.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the Company&#8217;s Board of Directors.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:11.01pt;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall have the meaning given to the term &#8220;Cause&#8221; in any effective employment agreement between the Participant and the Company or a Related Entity, or if none, shall mean the termination of Participant&#8217;s Continuous Service as a result of Participant&#8217;s (i) conviction of, a guilty plea with respect to, or a plea of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">nolo contendere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to, a charge that Participant has committed a felony under the laws of the United States or of any State or a crime involving moral turpitude, including (without limitation) fraud, theft, embezzlement or any crime that results in or is intended to result in personal enrichment to Participant at the expense of the Company or a Related Entity&#59; (ii) material breach of any agreement entered into between Participant and the Company or a Related Entity that impairs the Company&#8217;s or the Related Entity&#8217;s interest therein&#59; (iii) willful misconduct, significant failure to perform his or her duties or gross neglect of his or her duties&#59; (iv) engagement in any activity that constitutes a material conflict of interest with the Company or a Related Entity&#59; or (v) reasons that are comparable to Cause under employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s employment agreement, if any.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">J.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:10.34pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean a change in ownership or control of the Company effected through the consummation of any of the following transactions&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">a sale, transfer or other disposition of all or substantially all of the Company&#8217;s assets&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">the closing of any transaction or series of related transactions pursuant to which any person or any group of persons comprising a &#8220;group&#8221; within the meaning of Rule 13d-5(b)(1) of the 1934 Act (other than the Company or a person that, prior to such transaction or series of related transactions, directly or indirectly controls, is controlled by or is under common control with, the Company) becomes directly or indirectly (whether as a result of a single acquisition or by reason of one or more acquisitions within the twelve (12)-month period ending with the most recent acquisition) the beneficial owner (within the meaning of Rule 13d-3 of the 1934 Act) of securities possessing (or convertible into or exercisable for securities possessing) more than fifty percent (50%) of the total combined voting power of the Company&#8217;s outstanding securities (as measured in terms of the power to vote with respect to the election of Board members) outstanding immediately after the consummation of such transaction or series of related transactions, whether such transaction involves a direct issuance from the Company or the acquisition of outstanding securities held by one or more of the Company&#8217;s existing stockholders or an acquisition, consolidation or other reorganization to which the Company is a party&#59; or</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">a change in the composition of the Board over a period of twelve (12) consecutive months or less such that a majority of the Board members ceases, by reason of one or more contested elections for Board membership, to be comprised of individuals who either (A) have been Board members continuously since the beginning of such period or (B) have been elected or nominated for election as Board members during such period by at least a majority of the Board members described in clause (A) who were still in office at the time the Board approved such election or nomination.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In no event, however, shall a Change in Control be deemed to occur upon a merger, consolidation or other reorganization effected primarily to change the State of the Company&#8217;s incorporation or to create a holding company structure pursuant to which the Company becomes a wholly-owned subsidiary of an entity whose outstanding voting securities immediately after its formation are beneficially owned, directly or indirectly and in substantially the same proportion, by the persons who beneficially owned the Company&#8217;s outstanding voting securities immediately prior to the formation of such entity.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">K.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the U.S. Internal Revenue Code of 1986, as amended.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">L.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.67pt;text-decoration:underline">Common Stock or Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean shares of the Company&#8217;s common stock.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">M.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.34pt;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean Gilead Sciences, Inc., a Delaware corporation, and any successor corporation to all or substantially all of the assets or voting stock of Gilead Sciences, Inc. which shall by appropriate action adopt the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">N.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Constructive Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall have the meaning assigned to such term in Section 11(d) of the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">O.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Consultant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean any person, including an advisor, who is compensated by the Company or any Related Entity for services performed as a non-employee consultant&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the term &#8220;Consultant&#8221; shall not include non-employee Directors serving in their capacity as Board members. The term &#8220;Consultant&#8221; shall include a member of the board of directors of a Related Entity.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">P.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.33pt;text-decoration:underline">Continuous Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall mean the performance of services for the Company or a Related Entity (whether now existing or subsequently established) by a person in the capacity of an Employee, Director or Consultant. For purposes of this Agreement, Participant shall be deemed to cease Continuous Service immediately upon the occurrence of either of the following events&#58; (i) Participant no longer performs services in any of the foregoing capacities for the Company or any Related Entity or (ii) the entity for which Participant is performing such services ceases to remain a Related Entity of the Company, even though Participant may subsequently continue to perform services for that entity. Subject to the foregoing and any applicable limitations of Code Section 409A, the Administrator shall have the exclusive discretion to determine when Participant ceases Continuous Service for purposes of the Award. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Q.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean a member of the Board.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">R.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt;text-decoration:underline">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean any person who is in the employ of the Company (or any Related Entity), subject to the control and direction of the Company or Related Entity as to both the work to be performed and the manner and method of performance.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.33pt;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the Company or the Related Entity employing or retaining Participant.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">T.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.67pt;text-decoration:underline">Fair Market Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">per share of Common Stock on any relevant date shall be the closing price per share of Common Stock (or the closing bid, if no sales were reported) on that date, as quoted on the Stock Exchange that is at the time serving as the primary trading market for the Common Stock&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that if there is no reported closing price or closing bid for that date, then the closing price or closing bid, as applicable, for the last trading date on which such closing price or closing bid was quoted shall be determinative of such Fair Market Value. The applicable quoted price shall be as reported in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">The Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or such other source as the Administrator deems reliable.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">U.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">1934 Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the U.S. Securities Exchange Act of 1934, as amended from time to time.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Normal Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the schedule set forth in Paragraph 1 of the Agreement, pursuant to which the Restricted Stock Units and the underlying Shares are to vest in a series of installments over Participant&#8217;s period of Continuous Service.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">W.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:3.68pt;text-decoration:underline">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean a &#8220;parent corporation,&#8221; whether now existing or hereafter established, as defined in Section 424(e) of the Code.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">X.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the person to whom the Award is made pursuant to the Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Y.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the Company&#8217;s 2004 Equity Incentive Plan, as amended and restated from time to time.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Z.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.67pt;text-decoration:underline">Permanent Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the inability of Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which is expected to result in death or to be of continuous duration of twelve (12) months or more. The Administrator shall have exclusive discretion to determine when Permanent Disability has occurred for purposes of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">AA. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Qualifying Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean a change in the ownership of the Company, a change in the effective control of the Company or a change in ownership of a substantial portion of the Company&#8217;s assets, with each such event to be determined in accordance with the requirements for a change in control event set forth in Section 1.409A-3(i)((5) of the Treasury Regulations&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that a change in the effective control of the Company will only be deemed to occur if there is an acquisition, within the applicable twelve (12)-month period, of ownership of securities possessing more than fifty percent (50%) of the total combined voting power of the Company&#8217;s outstanding securities. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BB. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Related Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean (i) any Parent or Subsidiary of the Company and (ii) any corporation in an unbroken chain of corporations beginning with the Company and ending with the corporation in the chain for which Participant provides services as an Employee, Director or Consultant, provided each corporation in such chain owns securities representing at least twenty percent (20%) of the total outstanding voting power of the outstanding securities of another corporation or entity in such chain and there is a legitimate non-tax business purpose for making this Award to Participant. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CC. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Restricted Stock Unit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the Award in the form of a contractual right to receive Shares under this Agreement which will entitle Participant to receive one actual share of Common Stock per Restricted Stock Unit upon the satisfaction of the Continuous Service vesting requirements applicable to such Award. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DD. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean Participant&#8217;s cessation of Employee status by reason of his or her death, retirement or termination of employment. Participant shall be deemed to have terminated employment for such purpose at such time as the level of his or her bona fide services to be performed as an Employee (or as a consultant or independent contractor) permanently decreases to a level that is not more than twenty percent (20%) of the average level of services such person rendered as an Employee during the immediately preceding thirty-six (36) months (or such shorter period for which he or she may have rendered such services). Solely for purposes of determining when a Separation from Service occurs, Participant will be deemed to continue in &#8220;Employee&#8221; status for so long as he remains in the employ of one or more </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">members of the Employer Group, subject to the control and direction of the employer entity as to both the work to be performed and the manner and method of performance. &#8220;Employer Group&#8221; means the Company and any Parent or Subsidiary and any other corporation or business controlled by, controlling or under common control with, the Company, as determined in accordance with Sections 414(b) and 414(c) of the Code and the Treasury Regulations thereunder, except that in applying Sections 1563(1), (2) and (3) of the Code for purposes of determining the controlled group of corporations under Section 414(b), the phrase &#8220;at least 50 percent&#8221; shall be used instead of &#8220;at least 80 percent&#8221; each place the latter phrase appears in such sections, and in applying Section 1.414(c)-2 of the Treasury Regulations for purposes of determining trades or businesses that are under common control for purposes of Section 414(c), the phrase &#8220;at least 50 percent&#8221; shall be used instead of &#8220;at least 80 percent&#8221; each place the latter phrase appears in Section 1.414(c)-2 of the Treasury Regulations. Any such determination as to Separation from Service, however, shall be made in accordance with the applicable standards of the Treasury Regulations issued under Section 409A of the Code. In addition, the following special provisions shall be in effect for any leave of absence taken by Participant while this Award is outstanding&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">Should the period of such leave (other than a disability leave) exceed six (6) months, then Participant shall be deemed to incur a Separation from Service upon the expiration of the initial six (6) - month period of that leave, unless Participant retains a right to re-employment under Applicable Law or by contract with the Company (or any Parent or Subsidiary or other Related Entity).</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">Should the period of a disability leave exceed twenty-nine (29) months, then Participant shall be deemed to incur a Separation from Service upon the expiration of the initial twenty-nine (29)-month period of that leave, unless Participant retains a right to re-employment under Applicable Law or by contract with the Company (or any Parent or Subsidiary or other Related Entity). For such purpose, a disability leave shall be a leave of absence due to any medically determinable physical or mental impairment that can be expected to result in death or to last for a continuous period of not less than six (6) months and causes Participant to be unable to perform the duties of his position of employment with the Company (or any Parent or Subsidiary or other Related Entity) or any substantially similar position of employment.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EE. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Share Withholding Method</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean an automatic Share withholding procedure pursuant to which the Company will withhold, immediately as the Shares are issued under the Award, a portion of those Shares with a Fair Market Value (measured as of the issuance date) equal to the amount of the applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FF. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Stock Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the American Stock Exchange, the Nasdaq Global or Global Select Market or the New York Stock Exchange.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">GG. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean a &#8220;subsidiary corporation,&#8221; whether now existing or hereafter established, as defined in Section 424(f) of the Code.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">HH. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean any and all income taxes (including U.S. federal, state, and local tax and&#47;or foreign income taxes) and the employee portion of the federal, state, local and&#47;or foreign employment taxes (including social insurance, payroll tax, payment on account or other tax-related items) required or permitted to be withheld by the Company in connection with any taxable or tax withholding event, as applicable, attributable to the Award or Participant&#8217;s participation in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>gildq12021ex311ceocertific.htm
<DESCRIPTION>CEO CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ifdf1203228864f32bdbff819b57d7af0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel P. O&#8217;Day, certify that&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this quarterly report on Form 10-Q of Gilead Sciences, Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;6, 2021 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:8pt;padding-left:288pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:41.959%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;DANIEL P. O&#8217;DAY</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Daniel P. O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8217;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Day</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>gildq12021ex312cfocertific.htm
<DESCRIPTION>CFO CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic80fa67a29a04e9cb99dbdb5a42eafdb_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Andrew D. Dickinson, certify that&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this quarterly report on Form 10-Q of Gilead Sciences, Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;6, 2021 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:11pt;padding-left:252pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:48.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;ANDREW D. DICKINSON</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Andrew D. Dickinson<br>Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>8
<FILENAME>gildq12021ex32section906ce.htm
<DESCRIPTION>SECTION 906 CERTIFICATIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i542a9db4e3024a26b1eb82a006da2f59_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. &#167; 1350, as adopted), Daniel P. O&#8217;Day, the Chairman and Chief Executive Officer of Gilead Sciences, Inc. (the Company), and Andrew D. Dickinson, the Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2021 (the Report) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;6, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:17pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.825%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;DANIEL P. O&#8217;DAY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;ANDREW D. DICKINSON</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Daniel P. O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8217;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Day</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Andrew D. Dickinson<br>Chief Financial Officer</font></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>gild-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:62245928-4256-4115-b52c-a224301f8b52,g:d7709fc8-9a45-40b0-bb7e-3c2cb616ef14-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:gild="http://www.gilead.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.gilead.com/20210331">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.gilead.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2101101 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>2403401 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUES" roleURI="http://www.gilead.com/role/REVENUES">
        <link:definition>2104102 - Disclosure - REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESTables" roleURI="http://www.gilead.com/role/REVENUESTables">
        <link:definition>2305301 - Disclosure - REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESDisaggregationofRevenuesDetails" roleURI="http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails">
        <link:definition>2406402 - Disclosure - REVENUES - Disaggregation of Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESRevenuesfromMajorCustomersDetails" roleURI="http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails">
        <link:definition>2407403 - Disclosure - REVENUES - Revenues from Major Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESAdditionalInformationDetails" roleURI="http://www.gilead.com/role/REVENUESAdditionalInformationDetails">
        <link:definition>2408404 - Disclosure - REVENUES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>2109103 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>2310302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails">
        <link:definition>2411405 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails" roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails">
        <link:definition>2412406 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Classification of Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSAdditionalInformationDetails" roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails">
        <link:definition>2413407 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails" roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails">
        <link:definition>2414408 - Disclosure - FAIR VALUE MEASUREMENTS - Equity Investment In Galapagos (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIES" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIES">
        <link:definition>2115104 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESTables" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESTables">
        <link:definition>2316303 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails">
        <link:definition>2417409 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails">
        <link:definition>2418410 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails">
        <link:definition>2419411 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails">
        <link:definition>2420412 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTS" roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS">
        <link:definition>2121105 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTSTables" roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables">
        <link:definition>2322304 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails" roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails">
        <link:definition>2423413 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails">
        <link:definition>2424414 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails" roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails">
        <link:definition>2425415 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails" roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails">
        <link:definition>2426416 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Potential Effect of Offsetting Derivatives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONS" roleURI="http://www.gilead.com/role/ACQUISITIONS">
        <link:definition>2127106 - Disclosure - ACQUISITIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSTables" roleURI="http://www.gilead.com/role/ACQUISITIONSTables">
        <link:definition>2328305 - Disclosure - ACQUISITIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSNarrativeDetails" roleURI="http://www.gilead.com/role/ACQUISITIONSNarrativeDetails">
        <link:definition>2429417 - Disclosure - ACQUISITIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>2430418 - Disclosure - ACQUISITIONS - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETS" roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS">
        <link:definition>2131107 - Disclosure - GOODWILL AND INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSTables" roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables">
        <link:definition>2332306 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSGoodwillDetails" roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails">
        <link:definition>2433419 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails" roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails">
        <link:definition>2434420 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails" roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails">
        <link:definition>2435421 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails" roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails">
        <link:definition>2436422 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATION" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATION">
        <link:definition>2137108 - Disclosure - OTHER FINANCIAL INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONTables" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables">
        <link:definition>2338307 - Disclosure - OTHER FINANCIAL INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails">
        <link:definition>2439423 - Disclosure - OTHER FINANCIAL INFORMATION - Accounts Receivable, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONInventoriesDetails" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails">
        <link:definition>2440424 - Disclosure - OTHER FINANCIAL INFORMATION - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONInventoriesDetails_1" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1">
        <link:definition>2440424 - Disclosure - OTHER FINANCIAL INFORMATION - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails">
        <link:definition>2441425 - Disclosure - OTHER FINANCIAL INFORMATION - Other Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONSANDOTHERARRANGEMENTS" roleURI="http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTS">
        <link:definition>2142109 - Disclosure - COLLABORATIONS AND OTHER ARRANGEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONSANDOTHERARRANGEMENTSDetails" roleURI="http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails">
        <link:definition>2443426 - Disclosure - COLLABORATIONS AND OTHER ARRANGEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTANDCREDITFACILITIES" roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIES">
        <link:definition>2144110 - Disclosure - DEBT AND CREDIT FACILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTANDCREDITFACILITIESTables" roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables">
        <link:definition>2345308 - Disclosure - DEBT AND CREDIT FACILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails">
        <link:definition>2446427 - Disclosure - DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTANDCREDITFACILITIESAdditionalInformationDetails" roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails">
        <link:definition>2447428 - Disclosure - DEBT AND CREDIT FACILITIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2148111 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>2449429 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITY">
        <link:definition>2150112 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>2351309 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYAdditionalInformationDetails" roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails">
        <link:definition>2452430 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2453431 - Disclosure - STOCKHOLDERS' EQUITY - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS" roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS">
        <link:definition>2154113 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables" roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables">
        <link:definition>2355310 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails" roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails">
        <link:definition>2456432 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails" roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails">
        <link:definition>2457433 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Schedule of the Calculation of Basic and Diluted EPS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.gilead.com/role/INCOMETAXES">
        <link:definition>2158114 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.gilead.com/role/INCOMETAXESTables">
        <link:definition>2359311 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESSummaryoftheProvisionforIncomeTaxesDetails" roleURI="http://www.gilead.com/role/INCOMETAXESSummaryoftheProvisionforIncomeTaxesDetails">
        <link:definition>2460434 - Disclosure - INCOME TAXES - Summary of the Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESAdditionalInformationDetails" roleURI="http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails">
        <link:definition>2461435 - Disclosure - INCOME TAXES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENT" roleURI="http://www.gilead.com/role/SUBSEQUENTEVENT">
        <link:definition>2162115 - Disclosure - SUBSEQUENT EVENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTDetails" roleURI="http://www.gilead.com/role/SUBSEQUENTEVENTDetails">
        <link:definition>2463436 - Disclosure - SUBSEQUENT EVENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="gild_MerckMember" abstract="true" name="MerckMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_HIVProductSalesMember" abstract="true" name="HIVProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" abstract="true" name="JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_PreExposureProphylaxisMember" abstract="true" name="PreExposureProphylaxisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_ProductLiabilityMember" abstract="true" name="ProductLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_InjectableFormulationProductMember" abstract="true" name="InjectableFormulationProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_HepcludexForHDVMember" abstract="true" name="HepcludexForHDVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_AccountsReceivableCashDiscountsAndOtherCurrent" abstract="false" name="AccountsReceivableCashDiscountsAndOtherCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_OtherHepatitisCVirusProductsMember" abstract="true" name="OtherHepatitisCVirusProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_OtherCollaborationArrangementsMember" abstract="true" name="OtherCollaborationArrangementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_LossContingencyPartiesFilingOppositionNumber" abstract="false" name="LossContingencyPartiesFilingOppositionNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_CollaborativeAndOtherArrangementsTextBlock" abstract="false" name="CollaborativeAndOtherArrangementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="gild_ForeignCurrencyDerivativeContractsMember" abstract="true" name="ForeignCurrencyDerivativeContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_HCVProductsSofosbuvirVelpatasvirMember" abstract="true" name="HCVProductsSofosbuvirVelpatasvirMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_JudgmentEnhancedDamagesOnPastSales" abstract="false" name="JudgmentEnhancedDamagesOnPastSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" abstract="false" name="EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gild_A350SeniorUnsecuredNotesDueFebruary2025Member" abstract="true" name="A350SeniorUnsecuredNotesDueFebruary2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_HIVProductsBiktarvyMember" abstract="true" name="HIVProductsBiktarvyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_OtherProductsTotalOtherProductSalesMember" abstract="true" name="OtherProductsTotalOtherProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" abstract="false" name="CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A440SeniorUnsecuredNotesDueDecember2021Member" abstract="true" name="A440SeniorUnsecuredNotesDueDecember2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_MarketableSecuritiesCurrentMember" abstract="true" name="MarketableSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_CumulativeEffectPeriodOfAdoptionAxis" abstract="true" name="CumulativeEffectPeriodOfAdoptionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="gild_ProductsOtherHIVMember" abstract="true" name="ProductsOtherHIVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A450SeniorUnsecuredNotesDueFebruary2045Member" abstract="true" name="A450SeniorUnsecuredNotesDueFebruary2045Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A475SeniorUnsecuredNotesDueMarch2046Member" abstract="true" name="A475SeniorUnsecuredNotesDueMarch2046Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_HIVProductsDescovyMember" abstract="true" name="HIVProductsDescovyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_OtherProductsOtherMember" abstract="true" name="OtherProductsOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_HIVProductsOdefseyMember" abstract="true" name="HIVProductsOdefseyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_ProductsRevenueShareSymtuzaMember" abstract="true" name="ProductsRevenueShareSymtuzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_CashPaymentsMadeRelatedToEquityInvestments" abstract="false" name="CashPaymentsMadeRelatedToEquityInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_VariableTermLoanNoteDueOctober2023Member" abstract="true" name="VariableTermLoanNoteDueOctober2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A260SeniorUnsecuredNotesDueOctober2040Member" abstract="true" name="A260SeniorUnsecuredNotesDueOctober2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A280SeniorUnsecuredNotesDueOctober2050Member" abstract="true" name="A280SeniorUnsecuredNotesDueOctober2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" abstract="true" name="A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_TrodelvyMember" abstract="true" name="TrodelvyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_LossContingencyEstimateOfPossibleLossPastSales" abstract="false" name="LossContingencyEstimateOfPossibleLossPastSales" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_OtherEquitySecuritiesMember" abstract="true" name="OtherEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" abstract="true" name="ThreeYearSeniorUnsecuredTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A415SeniorUnsecuredNotesDueMarch2047Member" abstract="true" name="A415SeniorUnsecuredNotesDueMarch2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_AccruedGovernmentAndOtherRebates" abstract="false" name="AccruedGovernmentAndOtherRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_A480SeniorUnsecuredNotesDueApril2044Member" abstract="true" name="A480SeniorUnsecuredNotesDueApril2044Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_OtherFinancialInformationAbstract" abstract="true" name="OtherFinancialInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNISharesAcquired" abstract="false" name="EquitySecuritiesFVNISharesAcquired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gild_EquitySecuritiesDonationMember" abstract="true" name="EquitySecuritiesDonationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_OtherProductsRanexaMember" abstract="true" name="OtherProductsRanexaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNoteIssuedNovember2014Member" abstract="true" name="SeniorUnsecuredNoteIssuedNovember2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" abstract="false" name="FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_CardinalHealthIncMember" abstract="true" name="CardinalHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_MckessonCorpMember" abstract="true" name="MckessonCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" abstract="true" name="A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_InventoryNetAndInventoryNoncurrent" abstract="false" name="InventoryNetAndInventoryNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_CumulativeEffectPeriodOfAdoptionAdjustmentMember" abstract="true" name="CumulativeEffectPeriodOfAdoptionAdjustmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A165SeniorUnsecuredNotesDueOctober2030Member" abstract="true" name="A165SeniorUnsecuredNotesDueOctober2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductVireadMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_CollaborationArrangementPercentOfGlobalProductRevenues" abstract="false" name="CollaborationArrangementPercentOfGlobalProductRevenues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" abstract="false" name="LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_SeniorNotesAndMediumTermNotesMember" abstract="true" name="SeniorNotesAndMediumTermNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_EquityinvestmentinGalapagosMember" abstract="true" name="EquityinvestmentinGalapagosMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A2020StockRepurchaseProgramMember" abstract="true" name="A2020StockRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A2016StockRepurchaseProgramMember" abstract="true" name="A2016StockRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIRestrictionPeriod" abstract="false" name="EquitySecuritiesFVNIRestrictionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_AccountsReceivableChargebacksCurrent" abstract="false" name="AccountsReceivableChargebacksCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_MYRGmbHMember" abstract="true" name="MYRGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" abstract="false" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_HCVProductSalesMember" abstract="true" name="HCVProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A565SeniorUnsecuredNotesDueDecember2041Member" abstract="true" name="A565SeniorUnsecuredNotesDueDecember2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_OtherProductsLetairisMember" abstract="true" name="OtherProductsLetairisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_ViiVHealthcareCompanyMember" abstract="true" name="ViiVHealthcareCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_CellTherapyProductsTotalCellTherapyProductSalesMember" abstract="true" name="CellTherapyProductsTotalCellTherapyProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_CreditFacilityDueJune2025Member" abstract="true" name="CreditFacilityDueJune2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_JudgmentRoyaltyRateFromOctober2017" abstract="false" name="JudgmentRoyaltyRateFromOctober2017" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gild_RoyaltyContractAndOtherMember" abstract="true" name="RoyaltyContractAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_LossContingencyPartiesAppealedNumber" abstract="false" name="LossContingencyPartiesAppealedNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_A195SeniorUnsecuredNotesDueMarch2022Member" abstract="true" name="A195SeniorUnsecuredNotesDueMarch2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A325SeniorUnsecuredNotesDueSeptember2022Member" abstract="true" name="A325SeniorUnsecuredNotesDueSeptember2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" abstract="true" name="MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_AxicabtageneciloleucelDLBCLMember" abstract="true" name="AxicabtageneciloleucelDLBCLMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_CellTherapyProductsYescartaMember" abstract="true" name="CellTherapyProductsYescartaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" abstract="false" name="TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements" abstract="false" name="UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_A400SeniorUnsecuredNotesDueSeptember2036Member" abstract="true" name="A400SeniorUnsecuredNotesDueSeptember2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_GalapagosNVMember" abstract="true" name="GalapagosNVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A120SeniorUnsecuredNotesDueOctober2027Member" abstract="true" name="A120SeniorUnsecuredNotesDueOctober2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A365SeniorUnsecuredNotesDueMarch2026Member" abstract="true" name="A365SeniorUnsecuredNotesDueMarch2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A450SeniorUnsecuredNotesDueApril2021Member" abstract="true" name="A450SeniorUnsecuredNotesDueApril2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_HIVProductsStribildMember" abstract="true" name="HIVProductsStribildMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_AmerisourcebergenCorpMember" abstract="true" name="AmerisourcebergenCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_ResidentialMortgageAndAssetBackedSecuritiesMember" abstract="true" name="ResidentialMortgageAndAssetBackedSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_MarketableSecuritiesNoncurrentMember" abstract="true" name="MarketableSecuritiesNoncurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_ImmunomedicsIncMember" abstract="true" name="ImmunomedicsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_OralFormulationProductMember" abstract="true" name="OralFormulationProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_LossContingencyMaterialTransferAgreementsNumber" abstract="false" name="LossContingencyMaterialTransferAgreementsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_OtherInternationalMember" abstract="true" name="OtherInternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_HIVProductsGenvoyaMember" abstract="true" name="HIVProductsGenvoyaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" abstract="false" name="IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIShares" abstract="false" name="EquitySecuritiesFVNIShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gild_FiniteLivedIntangibleAssetsGrossReclassified" abstract="false" name="FiniteLivedIntangibleAssetsGrossReclassified" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_HIVProductsTruvadaMember" abstract="true" name="HIVProductsTruvadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A370SeniorUnsecuredNotesDueApril2024Member" abstract="true" name="A370SeniorUnsecuredNotesDueApril2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_IntangibleAssetSofosbuvirMember" abstract="true" name="IntangibleAssetSofosbuvirMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_CollaborativeandOtherArrangementsAbstract" abstract="true" name="CollaborativeandOtherArrangementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIPurchasePeriod" abstract="false" name="EquitySecuritiesFVNIPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_QuiTamMember" abstract="true" name="QuiTamMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_CumulativeEffectPeriodOfAdoptionDomain" abstract="true" name="CumulativeEffectPeriodOfAdoptionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_CallTherapyProductsTecartusMember" abstract="true" name="CallTherapyProductsTecartusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A460SeniorUnsecuredNotesDueSeptember2035Member" abstract="true" name="A460SeniorUnsecuredNotesDueSeptember2035Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A295SeniorUnsecuredNotesDueMarch2027Member" abstract="true" name="A295SeniorUnsecuredNotesDueMarch2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_PaymentsToAcquireEquitySecuritiesFVNI" abstract="false" name="PaymentsToAcquireEquitySecuritiesFVNI" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_IntangibleAssetMeasurementInput" abstract="false" name="IntangibleAssetMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_CollaborationArrangementNetProductSalesThreshold" abstract="false" name="CollaborationArrangementNetProductSalesThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_HIVProductsAtriplaMember" abstract="true" name="HIVProductsAtriplaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_GileadFoundationMember" abstract="true" name="GileadFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A075SeniorUnsecuredNotesDueSeptember2023Member" abstract="true" name="A075SeniorUnsecuredNotesDueSeptember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_FiniteLivedIntangibleAssetsGrossTransfers" abstract="false" name="FiniteLivedIntangibleAssetsGrossTransfers" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember" abstract="true" name="CommonStockPurchaseAgreementAndInvestorRightsAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_DeferredCompensationPlanMember" abstract="true" name="DeferredCompensationPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" abstract="false" name="LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_VekluryMember" abstract="true" name="VekluryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" abstract="false" name="CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gild_WriteOffsInAccruedInterestReceivable" abstract="false" name="WriteOffsInAccruedInterestReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_LossContingencyEstimateOfPossibleLossRoyalties" abstract="false" name="LossContingencyEstimateOfPossibleLossRoyalties" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_OtherProductsZydeligMember" abstract="true" name="OtherProductsZydeligMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_HCVProductsLedipasvirSofosbuvirMember" abstract="true" name="HCVProductsLedipasvirSofosbuvirMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_TrodelvyForMTNBCMember" abstract="true" name="TrodelvyForMTNBCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_HIVProductsCompleraEvipleraMember" abstract="true" name="HIVProductsCompleraEvipleraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_JudgmentRoyaltyRateOnFutureSales" abstract="false" name="JudgmentRoyaltyRateOnFutureSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gild_ArcusBiosciencesIncMember" abstract="true" name="ArcusBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A250SeniorUnsecuredNotesDueSeptember2023Member" abstract="true" name="A250SeniorUnsecuredNotesDueSeptember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_OtherProductsAmBisomeMember" abstract="true" name="OtherProductsAmBisomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_EuropeanPatentClaimsMember" abstract="true" name="EuropeanPatentClaimsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_ArcusStockPurchaseAgreementMember" abstract="true" name="ArcusStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages" abstract="false" name="LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>gild-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:62245928-4256-4115-b52c-a224301f8b52,g:d7709fc8-9a45-40b0-bb7e-3c2cb616ef14-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.gilead.com/role/CoverPage" xlink:type="simple" xlink:href="gild-20210331.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="gild-20210331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4a103b65-51f6-4714-aa12-71e9537ae991" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_814a39a1-36b7-4b60-83a6-f7a898eff7f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4a103b65-51f6-4714-aa12-71e9537ae991" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_814a39a1-36b7-4b60-83a6-f7a898eff7f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_f83d814f-496f-4e3b-80b6-e0e2627e9a83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4a103b65-51f6-4714-aa12-71e9537ae991" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_f83d814f-496f-4e3b-80b6-e0e2627e9a83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_bf166fd3-ba14-40b8-b152-af697583945a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4a103b65-51f6-4714-aa12-71e9537ae991" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_bf166fd3-ba14-40b8-b152-af697583945a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d6059297-5254-4ad5-bee0-d318115fcae9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4a103b65-51f6-4714-aa12-71e9537ae991" xlink:to="loc_us-gaap_InventoryNet_d6059297-5254-4ad5-bee0-d318115fcae9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_27f72f47-0602-4ba0-a177-35928e3bdd7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4a103b65-51f6-4714-aa12-71e9537ae991" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_27f72f47-0602-4ba0-a177-35928e3bdd7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_11a1b0e0-37a1-4a02-abf6-b8f8a93435ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e3f9319a-1e5e-4ab8-9f74-c768af229529" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_11a1b0e0-37a1-4a02-abf6-b8f8a93435ce" xlink:to="loc_us-gaap_AccountsPayableCurrent_e3f9319a-1e5e-4ab8-9f74-c768af229529" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccruedGovernmentAndOtherRebates_ecc38ab6-8c4d-4ff8-a243-c8d6505f420c" xlink:href="gild-20210331.xsd#gild_AccruedGovernmentAndOtherRebates"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_11a1b0e0-37a1-4a02-abf6-b8f8a93435ce" xlink:to="loc_gild_AccruedGovernmentAndOtherRebates_ecc38ab6-8c4d-4ff8-a243-c8d6505f420c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b16506e0-96f5-4aa2-942b-786a2ef8e44d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_11a1b0e0-37a1-4a02-abf6-b8f8a93435ce" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b16506e0-96f5-4aa2-942b-786a2ef8e44d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_7bf4f98f-a2ed-4b9d-a220-a5b29e0d9440" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_11a1b0e0-37a1-4a02-abf6-b8f8a93435ce" xlink:to="loc_us-gaap_DebtCurrent_7bf4f98f-a2ed-4b9d-a220-a5b29e0d9440" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2fede411-bdb9-42e1-8a56-826e1792d636" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f9586a36-1efa-44cc-a774-32ed39eb3761" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2fede411-bdb9-42e1-8a56-826e1792d636" xlink:to="loc_us-gaap_AssetsCurrent_f9586a36-1efa-44cc-a774-32ed39eb3761" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_024022a8-b744-415e-9de6-dd4ac89704ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2fede411-bdb9-42e1-8a56-826e1792d636" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_024022a8-b744-415e-9de6-dd4ac89704ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_ecd5f2f5-ee42-4172-b44b-3dc85c24722c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2fede411-bdb9-42e1-8a56-826e1792d636" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_ecd5f2f5-ee42-4172-b44b-3dc85c24722c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5c7baaf5-f114-4cce-9609-37e3b3615147" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2fede411-bdb9-42e1-8a56-826e1792d636" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5c7baaf5-f114-4cce-9609-37e3b3615147" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4cb0754d-27b2-4870-a1c2-2e5283ca6597" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2fede411-bdb9-42e1-8a56-826e1792d636" xlink:to="loc_us-gaap_Goodwill_4cb0754d-27b2-4870-a1c2-2e5283ca6597" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_76d76c80-06ea-43a1-bae2-1cce6e1734a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2fede411-bdb9-42e1-8a56-826e1792d636" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_76d76c80-06ea-43a1-bae2-1cce6e1734a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9ad5a6c4-c98e-44d0-a8da-404cc3c57085" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_785a41d5-dd16-4ec4-96f6-97e897787ea1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9ad5a6c4-c98e-44d0-a8da-404cc3c57085" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_785a41d5-dd16-4ec4-96f6-97e897787ea1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_09d9cea4-d6f4-4d40-a5a3-d1058f550d29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9ad5a6c4-c98e-44d0-a8da-404cc3c57085" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_09d9cea4-d6f4-4d40-a5a3-d1058f550d29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6814f0fc-52ad-4584-9a02-e15500675c31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9ad5a6c4-c98e-44d0-a8da-404cc3c57085" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6814f0fc-52ad-4584-9a02-e15500675c31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_89fed165-426c-4f1d-9e1c-2b927cc3c1bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9ad5a6c4-c98e-44d0-a8da-404cc3c57085" xlink:to="loc_us-gaap_CommitmentsAndContingencies_89fed165-426c-4f1d-9e1c-2b927cc3c1bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_448cb088-d437-48c4-bdbe-658ec15c0f61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9ad5a6c4-c98e-44d0-a8da-404cc3c57085" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_448cb088-d437-48c4-bdbe-658ec15c0f61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e1358495-4ca7-4ab4-816b-92a5f2f1382c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9ad5a6c4-c98e-44d0-a8da-404cc3c57085" xlink:to="loc_us-gaap_LiabilitiesCurrent_e1358495-4ca7-4ab4-816b-92a5f2f1382c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_faa5715b-b949-4940-9533-a3ea45ef39a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9ad5a6c4-c98e-44d0-a8da-404cc3c57085" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_faa5715b-b949-4940-9533-a3ea45ef39a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_45fa137b-c320-468e-a8b9-f8c0cbec4f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2c46484e-a5e6-4b1f-a8d0-c0feb657324f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_45fa137b-c320-468e-a8b9-f8c0cbec4f5d" xlink:to="loc_us-gaap_StockholdersEquity_2c46484e-a5e6-4b1f-a8d0-c0feb657324f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_0eb5f683-b80f-45ab-916f-1e73043bc23f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_45fa137b-c320-468e-a8b9-f8c0cbec4f5d" xlink:to="loc_us-gaap_MinorityInterest_0eb5f683-b80f-45ab-916f-1e73043bc23f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3c7e5a09-a8eb-47be-88be-26e97f9c486e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_219d2323-436a-40d1-886f-7cc41ffed729" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3c7e5a09-a8eb-47be-88be-26e97f9c486e" xlink:to="loc_us-gaap_PreferredStockValue_219d2323-436a-40d1-886f-7cc41ffed729" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a8ce5d70-de4f-4d2e-92aa-4367598133bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3c7e5a09-a8eb-47be-88be-26e97f9c486e" xlink:to="loc_us-gaap_CommonStockValue_a8ce5d70-de4f-4d2e-92aa-4367598133bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_0a5e6acd-64ef-4ceb-9feb-aea7b5ffcade" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3c7e5a09-a8eb-47be-88be-26e97f9c486e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_0a5e6acd-64ef-4ceb-9feb-aea7b5ffcade" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_03401dbc-1f9a-4f40-88f1-9a4f574dd153" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3c7e5a09-a8eb-47be-88be-26e97f9c486e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_03401dbc-1f9a-4f40-88f1-9a4f574dd153" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_79a2b18b-f91f-404e-8b8a-773ba5bae679" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3c7e5a09-a8eb-47be-88be-26e97f9c486e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_79a2b18b-f91f-404e-8b8a-773ba5bae679" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="gild-20210331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="gild-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b3c1d0e3-3564-4de8-8022-20b0cc1306fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_c77aa1ac-cc65-4ec9-915d-6e3fc002f1f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b3c1d0e3-3564-4de8-8022-20b0cc1306fb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_c77aa1ac-cc65-4ec9-915d-6e3fc002f1f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9f105c9f-b292-4f3c-9f07-9a83142bba43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b3c1d0e3-3564-4de8-8022-20b0cc1306fb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9f105c9f-b292-4f3c-9f07-9a83142bba43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_7c46f83d-2b0c-4153-b08a-a35fdfbc91ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b3c1d0e3-3564-4de8-8022-20b0cc1306fb" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_7c46f83d-2b0c-4153-b08a-a35fdfbc91ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4f944a11-ff5d-4423-9243-195e67017f66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b3c1d0e3-3564-4de8-8022-20b0cc1306fb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4f944a11-ff5d-4423-9243-195e67017f66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_42efa69e-ff95-4d61-8df3-cef17e75eb6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_757ca440-ff8f-4621-bfaf-cc742423be6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_42efa69e-ff95-4d61-8df3-cef17e75eb6d" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_757ca440-ff8f-4621-bfaf-cc742423be6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e6f2d125-b990-4388-b627-e171507e34cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_42efa69e-ff95-4d61-8df3-cef17e75eb6d" xlink:to="loc_us-gaap_ProfitLoss_e6f2d125-b990-4388-b627-e171507e34cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d83cefc8-2cc0-40ac-974e-eebc443e7699" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_daa0f235-a291-484c-ab03-fb638d049452" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_d83cefc8-2cc0-40ac-974e-eebc443e7699" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_daa0f235-a291-484c-ab03-fb638d049452" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4a0209c6-15c8-4be5-a592-c31d29bd99f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_d83cefc8-2cc0-40ac-974e-eebc443e7699" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4a0209c6-15c8-4be5-a592-c31d29bd99f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_7d114d51-3a33-47dc-94ca-e512e27c93d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ac21fc41-e2fa-43ab-ad55-019120428975" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_7d114d51-3a33-47dc-94ca-e512e27c93d2" xlink:to="loc_us-gaap_OperatingIncomeLoss_ac21fc41-e2fa-43ab-ad55-019120428975" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_cea3f48e-d471-4147-9dae-e2b3ba3b1e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_7d114d51-3a33-47dc-94ca-e512e27c93d2" xlink:to="loc_us-gaap_InterestExpense_cea3f48e-d471-4147-9dae-e2b3ba3b1e7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9bbb1625-d65c-4430-87ec-4182370365b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_7d114d51-3a33-47dc-94ca-e512e27c93d2" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9bbb1625-d65c-4430-87ec-4182370365b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_59fe9278-d99d-4bfd-9d07-549b64b54c91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3f8e1340-86d2-49b8-a595-b255838d2076" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_59fe9278-d99d-4bfd-9d07-549b64b54c91" xlink:to="loc_us-gaap_CostsAndExpenses_3f8e1340-86d2-49b8-a595-b255838d2076" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ea91fa30-0026-409d-8622-875436fef483" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_59fe9278-d99d-4bfd-9d07-549b64b54c91" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ea91fa30-0026-409d-8622-875436fef483" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="gild-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_81ca8cc7-3576-4fb3-b2d3-4664d66959bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_46b5b614-101c-4591-9c43-a0ae333ce5b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_81ca8cc7-3576-4fb3-b2d3-4664d66959bb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_46b5b614-101c-4591-9c43-a0ae333ce5b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_af4d7533-02b5-4b99-bdd0-222946e0270a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_81ca8cc7-3576-4fb3-b2d3-4664d66959bb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_af4d7533-02b5-4b99-bdd0-222946e0270a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_78e357fa-0458-4288-920b-0b3130cb2809" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b4459f55-d042-43ca-8857-4684883756d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_78e357fa-0458-4288-920b-0b3130cb2809" xlink:to="loc_us-gaap_ProfitLoss_b4459f55-d042-43ca-8857-4684883756d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c5d80834-b1cf-48b9-8b3e-7eb2376164da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_78e357fa-0458-4288-920b-0b3130cb2809" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c5d80834-b1cf-48b9-8b3e-7eb2376164da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6d88460c-c40b-49a4-8ede-5dd4936426ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_565e81f2-0b6a-4e97-9d31-a39025899dfa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6d88460c-c40b-49a4-8ede-5dd4936426ab" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_565e81f2-0b6a-4e97-9d31-a39025899dfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ed611855-639f-433a-8dbc-b7d6143ef2e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6d88460c-c40b-49a4-8ede-5dd4936426ab" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ed611855-639f-433a-8dbc-b7d6143ef2e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_afe4bb20-85f3-49e8-afef-07b03f2a7cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ec00c106-870c-4dbf-8dd5-245c02656572" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_afe4bb20-85f3-49e8-afef-07b03f2a7cb5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ec00c106-870c-4dbf-8dd5-245c02656572" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_fcabf189-ae8c-4434-9e5b-0ffef00b6171" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_afe4bb20-85f3-49e8-afef-07b03f2a7cb5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_fcabf189-ae8c-4434-9e5b-0ffef00b6171" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_c491daac-8f70-4a52-90cf-ff7bf39d0349" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_afe4bb20-85f3-49e8-afef-07b03f2a7cb5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_c491daac-8f70-4a52-90cf-ff7bf39d0349" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_32564855-2ce3-4193-a6ba-a93d67fbbba3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_ec9ca110-21fe-49fb-8160-47b7fdde7b3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_32564855-2ce3-4193-a6ba-a93d67fbbba3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_ec9ca110-21fe-49fb-8160-47b7fdde7b3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_ec00bd70-546b-4429-9470-e0d4fc48bdab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_32564855-2ce3-4193-a6ba-a93d67fbbba3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_ec00bd70-546b-4429-9470-e0d4fc48bdab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="gild-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="gild-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="gild-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28dc6447-0296-4d92-bd7b-25ed8001ae20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_616ff28e-487e-474f-a867-873e206394fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28dc6447-0296-4d92-bd7b-25ed8001ae20" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_616ff28e-487e-474f-a867-873e206394fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_dbb2f42e-53b0-492f-b0c4-0272ee8a06cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28dc6447-0296-4d92-bd7b-25ed8001ae20" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_dbb2f42e-53b0-492f-b0c4-0272ee8a06cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2a6b21a3-91a1-4aa3-8611-89e8817b15db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28dc6447-0296-4d92-bd7b-25ed8001ae20" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2a6b21a3-91a1-4aa3-8611-89e8817b15db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_13ee9449-5a74-44f0-a9f6-15e456a4d229" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28dc6447-0296-4d92-bd7b-25ed8001ae20" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_13ee9449-5a74-44f0-a9f6-15e456a4d229" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_dd87a167-41f8-4ec4-8561-0dd3f837499a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28dc6447-0296-4d92-bd7b-25ed8001ae20" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_dd87a167-41f8-4ec4-8561-0dd3f837499a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_9ccc3f93-d967-4f12-a8d0-ccd5f524d541" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28dc6447-0296-4d92-bd7b-25ed8001ae20" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_9ccc3f93-d967-4f12-a8d0-ccd5f524d541" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_72252b14-139a-420c-87e0-d0bdd8532916" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28dc6447-0296-4d92-bd7b-25ed8001ae20" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_72252b14-139a-420c-87e0-d0bdd8532916" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_51bffc8d-10d9-40f8-87a8-dd3fbac7932a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_0432f3a1-b045-4584-9e87-9b957f97c2b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_51bffc8d-10d9-40f8-87a8-dd3fbac7932a" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_0432f3a1-b045-4584-9e87-9b957f97c2b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3f11d6de-1647-47cd-81d0-1aaf6f191a8e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_51bffc8d-10d9-40f8-87a8-dd3fbac7932a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3f11d6de-1647-47cd-81d0-1aaf6f191a8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d26c9350-ac83-4a0d-90c8-57fc60fb423a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_51bffc8d-10d9-40f8-87a8-dd3fbac7932a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d26c9350-ac83-4a0d-90c8-57fc60fb423a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_e01e9087-e464-4489-9d86-02f825a933d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_51bffc8d-10d9-40f8-87a8-dd3fbac7932a" xlink:to="loc_us-gaap_AdjustmentForAmortization_e01e9087-e464-4489-9d86-02f825a933d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_01da39f0-77eb-4cb2-80eb-47dd08361a54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_51bffc8d-10d9-40f8-87a8-dd3fbac7932a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_01da39f0-77eb-4cb2-80eb-47dd08361a54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_bd616a34-fa8c-4b17-acb8-bc0368b0b961" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_51bffc8d-10d9-40f8-87a8-dd3fbac7932a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_bd616a34-fa8c-4b17-acb8-bc0368b0b961" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_50c59b7e-c6fa-46a0-a1fa-5464804183aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_51bffc8d-10d9-40f8-87a8-dd3fbac7932a" xlink:to="loc_us-gaap_Depreciation_50c59b7e-c6fa-46a0-a1fa-5464804183aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_21970a20-069c-48e6-9015-36eeb4e8dc63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_51bffc8d-10d9-40f8-87a8-dd3fbac7932a" xlink:to="loc_us-gaap_ShareBasedCompensation_21970a20-069c-48e6-9015-36eeb4e8dc63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_190ddf2f-7ad1-481e-b436-0bcd4cfadbdb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_51bffc8d-10d9-40f8-87a8-dd3fbac7932a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_190ddf2f-7ad1-481e-b436-0bcd4cfadbdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_09a0cfdd-199e-4a5f-a1ae-7d37c2b52d1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_51bffc8d-10d9-40f8-87a8-dd3fbac7932a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_09a0cfdd-199e-4a5f-a1ae-7d37c2b52d1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f71399c9-4957-46fb-971c-3f2b18909eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_51bffc8d-10d9-40f8-87a8-dd3fbac7932a" xlink:to="loc_us-gaap_ProfitLoss_f71399c9-4957-46fb-971c-3f2b18909eb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_340880cb-1acf-4000-b7ea-8f91b4cbf150" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_51bffc8d-10d9-40f8-87a8-dd3fbac7932a" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_340880cb-1acf-4000-b7ea-8f91b4cbf150" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2ff4a1d8-4b3e-473b-aa41-9b3b25c1095a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_51bffc8d-10d9-40f8-87a8-dd3fbac7932a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2ff4a1d8-4b3e-473b-aa41-9b3b25c1095a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_85f22ed8-b7bc-4583-8b98-bbd44ba21c24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_51bffc8d-10d9-40f8-87a8-dd3fbac7932a" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_85f22ed8-b7bc-4583-8b98-bbd44ba21c24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_52962092-f7fe-4938-a270-387bfaad94bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4dbe1ade-accf-47c3-a117-abc1f1d915fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_52962092-f7fe-4938-a270-387bfaad94bc" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4dbe1ade-accf-47c3-a117-abc1f1d915fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_583751d5-2bc7-4370-bd33-5769ca54f77a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_52962092-f7fe-4938-a270-387bfaad94bc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_583751d5-2bc7-4370-bd33-5769ca54f77a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_359e47d9-c150-43b4-8895-2d7a365cd994" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_52962092-f7fe-4938-a270-387bfaad94bc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_359e47d9-c150-43b4-8895-2d7a365cd994" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f7117d12-2df2-4e8a-8565-78cd9e61e998" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_52962092-f7fe-4938-a270-387bfaad94bc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f7117d12-2df2-4e8a-8565-78cd9e61e998" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b548535-c127-461c-bd80-e49b1992e398" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_fdc59b88-9a08-4288-b2d5-4cf7590dc0f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b548535-c127-461c-bd80-e49b1992e398" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_fdc59b88-9a08-4288-b2d5-4cf7590dc0f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_48734c60-4d15-4748-a342-40c109a070b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b548535-c127-461c-bd80-e49b1992e398" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_48734c60-4d15-4748-a342-40c109a070b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_19282afe-2168-48f1-b2f4-eb1e887a5e8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b548535-c127-461c-bd80-e49b1992e398" xlink:to="loc_us-gaap_RepaymentsOfDebt_19282afe-2168-48f1-b2f4-eb1e887a5e8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_c0ea720f-767f-48bb-b226-5f506b7cc498" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b548535-c127-461c-bd80-e49b1992e398" xlink:to="loc_us-gaap_PaymentsOfDividends_c0ea720f-767f-48bb-b226-5f506b7cc498" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_98204351-c96f-4914-aa62-d08157befa41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b548535-c127-461c-bd80-e49b1992e398" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_98204351-c96f-4914-aa62-d08157befa41" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="gild-20210331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="gild-20210331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUES" xlink:type="simple" xlink:href="gild-20210331.xsd#REVENUES"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/REVENUES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESTables" xlink:type="simple" xlink:href="gild-20210331.xsd#REVENUESTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/REVENUESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#REVENUESDisaggregationofRevenuesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#REVENUESRevenuesfromMajorCustomersDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#REVENUESAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/REVENUESAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="gild-20210331.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="gild-20210331.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b36a64c5-dac8-48b7-8537-083425f708e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_3ad2be63-4073-4400-8c2a-2c2db8ac9a35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b36a64c5-dac8-48b7-8537-083425f708e8" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_3ad2be63-4073-4400-8c2a-2c2db8ac9a35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_d1a60d30-c72e-4da6-8272-de88bc4290be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b36a64c5-dac8-48b7-8537-083425f708e8" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_d1a60d30-c72e-4da6-8272-de88bc4290be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3980d675-fbaa-411c-88b4-cd661e627d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b36a64c5-dac8-48b7-8537-083425f708e8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3980d675-fbaa-411c-88b4-cd661e627d3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_8aecb7b1-407d-4633-9e01-624f1f887906" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_cc263557-53cf-4517-8c1f-47a3a33921bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_8aecb7b1-407d-4633-9e01-624f1f887906" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_cc263557-53cf-4517-8c1f-47a3a33921bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_780dd463-b48e-4aba-a0a7-6dcf4bb2bf39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_8aecb7b1-407d-4633-9e01-624f1f887906" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_780dd463-b48e-4aba-a0a7-6dcf4bb2bf39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_4ac9c187-d3bb-42f1-b32b-c559e7342fc9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_8aecb7b1-407d-4633-9e01-624f1f887906" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_4ac9c187-d3bb-42f1-b32b-c559e7342fc9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ecde1f6c-e3b0-41d7-9355-27cca5102f6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_98eef3af-258a-4011-a3a0-c4e0d2eb49d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_ecde1f6c-e3b0-41d7-9355-27cca5102f6a" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_98eef3af-258a-4011-a3a0-c4e0d2eb49d6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#FAIRVALUEMEASUREMENTSAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIES" xlink:type="simple" xlink:href="gild-20210331.xsd#AVAILABLEFORSALEDEBTSECURITIES"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESTables" xlink:type="simple" xlink:href="gild-20210331.xsd#AVAILABLEFORSALEDEBTSECURITIESTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d33cec14-db2d-4f4a-9022-9cab01e9d294" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fabe7e09-16be-443f-9079-7d3f6b22131e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d33cec14-db2d-4f4a-9022-9cab01e9d294" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fabe7e09-16be-443f-9079-7d3f6b22131e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_067389f3-b185-4899-a3ad-36b96356429e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d33cec14-db2d-4f4a-9022-9cab01e9d294" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_067389f3-b185-4899-a3ad-36b96356429e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_36ca7828-7462-4c6c-9bbc-a1d7198c59f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d33cec14-db2d-4f4a-9022-9cab01e9d294" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_36ca7828-7462-4c6c-9bbc-a1d7198c59f0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cf4cda59-1c39-43e6-be3a-292e46b32981" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_260feae5-3aee-40f1-ae14-964ebc3c73d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cf4cda59-1c39-43e6-be3a-292e46b32981" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_260feae5-3aee-40f1-ae14-964ebc3c73d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_57cbc2e7-1dfb-4ad6-afdd-168cbcdb8645" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cf4cda59-1c39-43e6-be3a-292e46b32981" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_57cbc2e7-1dfb-4ad6-afdd-168cbcdb8645" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_079057fd-20fe-4bbc-8757-d7c43ddc5cb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cf4cda59-1c39-43e6-be3a-292e46b32981" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_079057fd-20fe-4bbc-8757-d7c43ddc5cb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e2a2f319-c63f-4779-a506-23445916a4ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_901d6e93-59d8-48f6-8a45-74fd6f07266d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e2a2f319-c63f-4779-a506-23445916a4ed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_901d6e93-59d8-48f6-8a45-74fd6f07266d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_159865c4-69d9-4b57-ae5e-29ff67113aa6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e2a2f319-c63f-4779-a506-23445916a4ed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_159865c4-69d9-4b57-ae5e-29ff67113aa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_23ccf280-10ee-4872-9b40-82b77a193ab1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e2a2f319-c63f-4779-a506-23445916a4ed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_23ccf280-10ee-4872-9b40-82b77a193ab1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="gild-20210331.xsd#DERIVATIVEFINANCIALINSTRUMENTS"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="gild-20210331.xsd#DERIVATIVEFINANCIALINSTRUMENTSTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_10f877a8-2f54-4d6c-b0e4-309aa0a5c9cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_957d2032-be10-40f5-8a45-a1fb0052af71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_10f877a8-2f54-4d6c-b0e4-309aa0a5c9cd" xlink:to="loc_us-gaap_DerivativeLiabilities_957d2032-be10-40f5-8a45-a1fb0052af71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_99b77f49-b13c-4736-a46e-a354fd448810" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_10f877a8-2f54-4d6c-b0e4-309aa0a5c9cd" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_99b77f49-b13c-4736-a46e-a354fd448810" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_9df4b2b2-62db-4fd5-a821-fbeb460a1e5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_10f877a8-2f54-4d6c-b0e4-309aa0a5c9cd" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_9df4b2b2-62db-4fd5-a821-fbeb460a1e5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_d2199e41-8fa2-4d76-8d38-812fc18cb170" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_770e7ace-4e51-4365-bdaa-0d32733f7ab7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_d2199e41-8fa2-4d76-8d38-812fc18cb170" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_770e7ace-4e51-4365-bdaa-0d32733f7ab7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_c3f08dca-5703-406f-8342-7077c776bb23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_d2199e41-8fa2-4d76-8d38-812fc18cb170" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_c3f08dca-5703-406f-8342-7077c776bb23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_1c60485f-cc75-44e8-9c65-535aeb965502" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_bddfd36f-06e3-4d73-b5dd-82248dc8c2ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_1c60485f-cc75-44e8-9c65-535aeb965502" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_bddfd36f-06e3-4d73-b5dd-82248dc8c2ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_e73ff219-6f21-449b-8124-3b8eb1fe8b70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_1c60485f-cc75-44e8-9c65-535aeb965502" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_e73ff219-6f21-449b-8124-3b8eb1fe8b70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_72ab73a3-393f-4f36-b8ee-83bf507f9292" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_ee68b62b-0a77-4a51-b93e-751d92c1b7a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_72ab73a3-393f-4f36-b8ee-83bf507f9292" xlink:to="loc_us-gaap_DerivativeAssets_ee68b62b-0a77-4a51-b93e-751d92c1b7a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_f207e0bd-9de4-4c12-87b4-371a0e117657" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_72ab73a3-393f-4f36-b8ee-83bf507f9292" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_f207e0bd-9de4-4c12-87b4-371a0e117657" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_eab380f7-57d2-458d-a87d-0bc50f5ea743" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_72ab73a3-393f-4f36-b8ee-83bf507f9292" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_eab380f7-57d2-458d-a87d-0bc50f5ea743" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONS" xlink:type="simple" xlink:href="gild-20210331.xsd#ACQUISITIONS"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/ACQUISITIONS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONSTables" xlink:type="simple" xlink:href="gild-20210331.xsd#ACQUISITIONSTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/ACQUISITIONSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_99840009-de42-4045-81cd-e236d6639fef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_8ba811a5-5edf-49e3-bbad-edb2854d9c30" xlink:href="gild-20210331.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_99840009-de42-4045-81cd-e236d6639fef" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_8ba811a5-5edf-49e3-bbad-edb2854d9c30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_fb4bcf86-bcd6-4aa0-a9aa-975195d6775c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_99840009-de42-4045-81cd-e236d6639fef" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_fb4bcf86-bcd6-4aa0-a9aa-975195d6775c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d99c3596-56bb-4b95-aa75-9049f7587ffc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_99840009-de42-4045-81cd-e236d6639fef" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d99c3596-56bb-4b95-aa75-9049f7587ffc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_ca7440fc-d196-46b0-9f9c-7b289eb9fef1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_99840009-de42-4045-81cd-e236d6639fef" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_ca7440fc-d196-46b0-9f9c-7b289eb9fef1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_8760737d-b4aa-466a-8e25-ed927cdbcfc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_99840009-de42-4045-81cd-e236d6639fef" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_8760737d-b4aa-466a-8e25-ed927cdbcfc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_ad3881a6-3bf1-403c-a0ab-fa232112921b" xlink:href="gild-20210331.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_99840009-de42-4045-81cd-e236d6639fef" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_ad3881a6-3bf1-403c-a0ab-fa232112921b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_8fe95cde-61ba-446e-b589-1e201c8e164a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_99840009-de42-4045-81cd-e236d6639fef" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_8fe95cde-61ba-446e-b589-1e201c8e164a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5f0a323e-d2c7-47f1-ac76-1243aa830754" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_241e7967-e410-43a8-b196-ec88a027cfb5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5f0a323e-d2c7-47f1-ac76-1243aa830754" xlink:to="loc_us-gaap_GoodwillGross_241e7967-e410-43a8-b196-ec88a027cfb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_64b6dc87-869e-46cb-9b23-e0bd699fa34b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5f0a323e-d2c7-47f1-ac76-1243aa830754" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_64b6dc87-869e-46cb-9b23-e0bd699fa34b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS" xlink:type="simple" xlink:href="gild-20210331.xsd#GOODWILLANDINTANGIBLEASSETS"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables" xlink:type="simple" xlink:href="gild-20210331.xsd#GOODWILLANDINTANGIBLEASSETSTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#GOODWILLANDINTANGIBLEASSETSGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8e1f0de6-abc4-4c26-87d6-7bea1b4364aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3252818d-5ae3-4a61-97d9-617a0a3a7206" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8e1f0de6-abc4-4c26-87d6-7bea1b4364aa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3252818d-5ae3-4a61-97d9-617a0a3a7206" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_18470d02-e572-4242-898f-58430655702b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8e1f0de6-abc4-4c26-87d6-7bea1b4364aa" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_18470d02-e572-4242-898f-58430655702b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_89cade92-e1d2-4a1c-bc1d-65e90136cce7" xlink:href="gild-20210331.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_cc758012-9b4a-4fef-aacd-aed655d6342e" xlink:href="gild-20210331.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_89cade92-e1d2-4a1c-bc1d-65e90136cce7" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_cc758012-9b4a-4fef-aacd-aed655d6342e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_8818b499-69ee-4fa9-aa03-dcfbc907d743" xlink:href="gild-20210331.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_89cade92-e1d2-4a1c-bc1d-65e90136cce7" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_8818b499-69ee-4fa9-aa03-dcfbc907d743" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cade23d5-d5f9-49c9-bb38-b578d7a49cd7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_13a500d1-e62c-48f3-a3b5-d54ae47c707f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cade23d5-d5f9-49c9-bb38-b578d7a49cd7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_13a500d1-e62c-48f3-a3b5-d54ae47c707f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_51788473-d6f8-48aa-b775-b1569bb9ae55" xlink:href="gild-20210331.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cade23d5-d5f9-49c9-bb38-b578d7a49cd7" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_51788473-d6f8-48aa-b775-b1569bb9ae55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a0a4879f-261c-4dee-8add-fc5d27a2dc60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cade23d5-d5f9-49c9-bb38-b578d7a49cd7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a0a4879f-261c-4dee-8add-fc5d27a2dc60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_a2692ee3-acbc-4c3f-9bad-e00f27598251" xlink:href="gild-20210331.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_eef0d9f4-5253-4688-b849-3fa3db792f52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_a2692ee3-acbc-4c3f-9bad-e00f27598251" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_eef0d9f4-5253-4688-b849-3fa3db792f52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_716fedc2-0f18-495f-9e18-2393823a545f" xlink:href="gild-20210331.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_a2692ee3-acbc-4c3f-9bad-e00f27598251" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_716fedc2-0f18-495f-9e18-2393823a545f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4515eb23-ff5a-4925-9e1b-7a0670438ed3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_188aec0d-182c-43c2-af40-b53eb493119c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4515eb23-ff5a-4925-9e1b-7a0670438ed3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_188aec0d-182c-43c2-af40-b53eb493119c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_938b9558-69dc-4ceb-958a-7071493d527d" xlink:href="gild-20210331.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4515eb23-ff5a-4925-9e1b-7a0670438ed3" xlink:to="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_938b9558-69dc-4ceb-958a-7071493d527d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6fc692a0-de8c-42f1-b9e1-bcc790f5bdc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7584de9f-2469-4832-b0a2-c1c5a5986a87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6fc692a0-de8c-42f1-b9e1-bcc790f5bdc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7584de9f-2469-4832-b0a2-c1c5a5986a87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8800d68a-67e4-4694-a454-b9bcc24cd1ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6fc692a0-de8c-42f1-b9e1-bcc790f5bdc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8800d68a-67e4-4694-a454-b9bcc24cd1ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_b2616ea9-f291-4134-8df7-15ae82dbdd93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6fc692a0-de8c-42f1-b9e1-bcc790f5bdc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_b2616ea9-f291-4134-8df7-15ae82dbdd93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_429dacfa-e1a8-4aed-81f0-1a8df39fc54f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6fc692a0-de8c-42f1-b9e1-bcc790f5bdc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_429dacfa-e1a8-4aed-81f0-1a8df39fc54f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1405c65a-8df1-4138-b81f-a0312ed18565" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6fc692a0-de8c-42f1-b9e1-bcc790f5bdc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1405c65a-8df1-4138-b81f-a0312ed18565" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_b8d40a05-187c-4229-a9ac-a446c3377d4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6fc692a0-de8c-42f1-b9e1-bcc790f5bdc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_b8d40a05-187c-4229-a9ac-a446c3377d4e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATION" xlink:type="simple" xlink:href="gild-20210331.xsd#OTHERFINANCIALINFORMATION"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATION" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables" xlink:type="simple" xlink:href="gild-20210331.xsd#OTHERFINANCIALINFORMATIONTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_36e72076-91b9-4d72-9865-6f2326792565" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_0a384e9f-d7ea-4485-a548-4bbe1a801a60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_36e72076-91b9-4d72-9865-6f2326792565" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_0a384e9f-d7ea-4485-a548-4bbe1a801a60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_1e75ba51-1475-4977-9f84-dd1e3efa3a53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_36e72076-91b9-4d72-9865-6f2326792565" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_1e75ba51-1475-4977-9f84-dd1e3efa3a53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableChargebacksCurrent_e21bcce6-5278-49ba-88ab-7251509868a1" xlink:href="gild-20210331.xsd#gild_AccountsReceivableChargebacksCurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_36e72076-91b9-4d72-9865-6f2326792565" xlink:to="loc_gild_AccountsReceivableChargebacksCurrent_e21bcce6-5278-49ba-88ab-7251509868a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_18d46b06-4d9b-4c44-ad44-44b340c4fc21" xlink:href="gild-20210331.xsd#gild_AccountsReceivableCashDiscountsAndOtherCurrent"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_36e72076-91b9-4d72-9865-6f2326792565" xlink:to="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_18d46b06-4d9b-4c44-ad44-44b340c4fc21" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#OTHERFINANCIALINFORMATIONInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent_78848592-3328-456d-b79e-d1727f7520ff" xlink:href="gild-20210331.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7209e8cb-29c3-466e-85ce-8dc20834b772" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_78848592-3328-456d-b79e-d1727f7520ff" xlink:to="loc_us-gaap_InventoryNet_7209e8cb-29c3-466e-85ce-8dc20834b772" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_db8e7d5b-064f-4621-8489-82695f40f3ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_78848592-3328-456d-b79e-d1727f7520ff" xlink:to="loc_us-gaap_InventoryNoncurrent_db8e7d5b-064f-4621-8489-82695f40f3ef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1" xlink:type="simple" xlink:href="gild-20210331.xsd#OTHERFINANCIALINFORMATIONInventoriesDetails_1"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent_722b7f38-7645-4920-95b1-542afbb2901e" xlink:href="gild-20210331.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_373a1ce3-a59c-4cda-8ace-9c0d167a1a63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_722b7f38-7645-4920-95b1-542afbb2901e" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_373a1ce3-a59c-4cda-8ace-9c0d167a1a63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_145a83ae-6014-4f52-a158-acb7ea3aa28c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_722b7f38-7645-4920-95b1-542afbb2901e" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_145a83ae-6014-4f52-a158-acb7ea3aa28c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_bec93d7e-0657-4a67-9afe-27f9ae90c2c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_722b7f38-7645-4920-95b1-542afbb2901e" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_bec93d7e-0657-4a67-9afe-27f9ae90c2c4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cb3ba043-26fe-4636-a043-f302ab80ea73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a0b8cdc2-475a-468d-ac13-4a27cb831206" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_cb3ba043-26fe-4636-a043-f302ab80ea73" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a0b8cdc2-475a-468d-ac13-4a27cb831206" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_946b59e6-6bf8-47a5-b309-1537cab3cfd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_cb3ba043-26fe-4636-a043-f302ab80ea73" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_946b59e6-6bf8-47a5-b309-1537cab3cfd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_01ed46dd-ae73-4515-9df6-3174342b5ac1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_cb3ba043-26fe-4636-a043-f302ab80ea73" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_01ed46dd-ae73-4515-9df6-3174342b5ac1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a235241c-5022-4a4e-ba95-4d8a87925179" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_cb3ba043-26fe-4636-a043-f302ab80ea73" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a235241c-5022-4a4e-ba95-4d8a87925179" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTS" xlink:type="simple" xlink:href="gild-20210331.xsd#COLLABORATIONSANDOTHERARRANGEMENTS"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#COLLABORATIONSANDOTHERARRANGEMENTSDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIES" xlink:type="simple" xlink:href="gild-20210331.xsd#DEBTANDCREDITFACILITIES"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables" xlink:type="simple" xlink:href="gild-20210331.xsd#DEBTANDCREDITFACILITIESTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_483c5c57-33b0-488a-a7d9-b09f2987d56b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_6d4cea41-61d7-4035-bba2-3c0f4a80c370" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_483c5c57-33b0-488a-a7d9-b09f2987d56b" xlink:to="loc_us-gaap_LongTermDebtCurrent_6d4cea41-61d7-4035-bba2-3c0f4a80c370" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_5931ff5e-464e-463b-9b37-00abce16b849" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_483c5c57-33b0-488a-a7d9-b09f2987d56b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_5931ff5e-464e-463b-9b37-00abce16b849" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#DEBTANDCREDITFACILITIESAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="gild-20210331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="gild-20210331.xsd#STOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="gild-20210331.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#STOCKHOLDERSEQUITYAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e8aca271-d87f-4f79-a47d-e8ed7b4bfa6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_95c40bb5-531b-42af-925c-94c30815e0e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e8aca271-d87f-4f79-a47d-e8ed7b4bfa6f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_95c40bb5-531b-42af-925c-94c30815e0e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_c5fee49d-bb65-4c3f-a0a2-019d9b25234a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e8aca271-d87f-4f79-a47d-e8ed7b4bfa6f" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_c5fee49d-bb65-4c3f-a0a2-019d9b25234a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS" xlink:type="simple" xlink:href="gild-20210331.xsd#NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables" xlink:type="simple" xlink:href="gild-20210331.xsd#NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5e4849ed-7e74-41a7-be78-e28a5eee63b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_10a5bd0b-baa8-4087-a0c2-4315d4b12233" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5e4849ed-7e74-41a7-be78-e28a5eee63b2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_10a5bd0b-baa8-4087-a0c2-4315d4b12233" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_57319f33-d8b9-47d6-9b5e-16764bfc6766" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5e4849ed-7e74-41a7-be78-e28a5eee63b2" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_57319f33-d8b9-47d6-9b5e-16764bfc6766" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXES" xlink:type="simple" xlink:href="gild-20210331.xsd#INCOMETAXES"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/INCOMETAXES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="gild-20210331.xsd#INCOMETAXESTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/INCOMETAXESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXESSummaryoftheProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#INCOMETAXESSummaryoftheProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/INCOMETAXESSummaryoftheProvisionforIncomeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#INCOMETAXESAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/SUBSEQUENTEVENT" xlink:type="simple" xlink:href="gild-20210331.xsd#SUBSEQUENTEVENT"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/SUBSEQUENTEVENT" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/SUBSEQUENTEVENTDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#SUBSEQUENTEVENTDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/SUBSEQUENTEVENTDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>gild-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:62245928-4256-4115-b52c-a224301f8b52,g:d7709fc8-9a45-40b0-bb7e-3c2cb616ef14-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.gilead.com/role/CoverPage" xlink:type="simple" xlink:href="gild-20210331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CoverPage" xlink:type="extended" id="i225a5f034b76446591a0869ff648f158_CoverPage"/>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="gild-20210331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i779294304ec6403590453235a7014629_CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="gild-20210331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="ieda54e5d45404e178b65beae3b155bd4_CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="gild-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended" id="i476a872677b947afaf335e0529ec0f22_CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_7420e625-8298-4512-8d67-24667798519a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_RevenuesAbstract_7420e625-8298-4512-8d67-24667798519a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_595851c2-a25e-4121-bb2e-ecb5abca95cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_7420e625-8298-4512-8d67-24667798519a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_595851c2-a25e-4121-bb2e-ecb5abca95cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_1492b3e8-fe0f-44d6-b13f-a7a811102bed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_1492b3e8-fe0f-44d6-b13f-a7a811102bed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_07eeb70f-cb7c-4bb5-bd6d-7e3df9469e14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1492b3e8-fe0f-44d6-b13f-a7a811102bed" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_07eeb70f-cb7c-4bb5-bd6d-7e3df9469e14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_cf78aa91-1afb-4223-83a6-0edc83a228fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1492b3e8-fe0f-44d6-b13f-a7a811102bed" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_cf78aa91-1afb-4223-83a6-0edc83a228fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_138bc0c0-63b5-4768-a2fc-e3a288e02fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1492b3e8-fe0f-44d6-b13f-a7a811102bed" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_138bc0c0-63b5-4768-a2fc-e3a288e02fbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ca46ea8a-2b57-4b08-b0e3-5105265a5555" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1492b3e8-fe0f-44d6-b13f-a7a811102bed" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ca46ea8a-2b57-4b08-b0e3-5105265a5555" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7a541993-a919-4841-8a29-5a9e73294487" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1492b3e8-fe0f-44d6-b13f-a7a811102bed" xlink:to="loc_us-gaap_CostsAndExpenses_7a541993-a919-4841-8a29-5a9e73294487" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e077d700-17c8-4b49-ac61-3ac76d785e59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_OperatingIncomeLoss_e077d700-17c8-4b49-ac61-3ac76d785e59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4ef5ccde-aca9-4958-a186-b55c6bbddd84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_InterestExpense_4ef5ccde-aca9-4958-a186-b55c6bbddd84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_20ce56af-d074-40d7-b098-ca17ddbd5d22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_20ce56af-d074-40d7-b098-ca17ddbd5d22" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9b18765d-09cf-4e08-a331-f2a46363ca0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9b18765d-09cf-4e08-a331-f2a46363ca0d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dfecab72-d5bf-4fbf-8293-58de3bb5eef9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dfecab72-d5bf-4fbf-8293-58de3bb5eef9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1c7d02a9-7b91-4b72-832c-19f78b916b27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_ProfitLoss_1c7d02a9-7b91-4b72-832c-19f78b916b27" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_18d0b065-7873-485d-8b4c-adfb04d2bd11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_18d0b065-7873-485d-8b4c-adfb04d2bd11" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_229aadce-dfa3-40bf-9db4-c2d8747de89d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_NetIncomeLoss_229aadce-dfa3-40bf-9db4-c2d8747de89d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b2bebfbf-e39e-4edd-8cba-1ee86186a8a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_EarningsPerShareBasic_b2bebfbf-e39e-4edd-8cba-1ee86186a8a0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5133a5bb-80e8-4e7b-b004-5f709f7ac701" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5133a5bb-80e8-4e7b-b004-5f709f7ac701" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_bbd78c5c-a3f1-422e-9477-b4ba3ee35b1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_EarningsPerShareDiluted_bbd78c5c-a3f1-422e-9477-b4ba3ee35b1f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_69e36925-c8f5-4a23-924d-66f120cd008c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_69e36925-c8f5-4a23-924d-66f120cd008c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6a4e9861-7149-4f02-a8f8-e2186c5cc373" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_StatementTable_6a4e9861-7149-4f02-a8f8-e2186c5cc373" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a7e63845-96cd-40f2-aeab-a54a1c6db917" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6a4e9861-7149-4f02-a8f8-e2186c5cc373" xlink:to="loc_srt_ProductOrServiceAxis_a7e63845-96cd-40f2-aeab-a54a1c6db917" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a7e63845-96cd-40f2-aeab-a54a1c6db917_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a7e63845-96cd-40f2-aeab-a54a1c6db917" xlink:to="loc_srt_ProductsAndServicesDomain_a7e63845-96cd-40f2-aeab-a54a1c6db917_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_845f125a-6a08-4053-9333-56a482fac509" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a7e63845-96cd-40f2-aeab-a54a1c6db917" xlink:to="loc_srt_ProductsAndServicesDomain_845f125a-6a08-4053-9333-56a482fac509" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_37d87313-91f2-4f19-819b-3caeed7a6ca5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_845f125a-6a08-4053-9333-56a482fac509" xlink:to="loc_us-gaap_ProductMember_37d87313-91f2-4f19-819b-3caeed7a6ca5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_8b13b500-a35d-4d11-8c0a-61b386bbca12" xlink:href="gild-20210331.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_845f125a-6a08-4053-9333-56a482fac509" xlink:to="loc_gild_RoyaltyContractAndOtherMember_8b13b500-a35d-4d11-8c0a-61b386bbca12" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="gild-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended" id="i3f45eb5f500d47d1a045507270e25892_CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="gild-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="ie05f729a707e41a48a1b0de1c4ac636f_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f391129d-868c-4880-8de9-888c7e5fe6a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f391129d-868c-4880-8de9-888c7e5fe6a3" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0362aca8-01db-4fac-b1d6-bf8fe6b0408a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0362aca8-01db-4fac-b1d6-bf8fe6b0408a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53c187e7-6756-45f0-b7de-9b4d9666563c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53c187e7-6756-45f0-b7de-9b4d9666563c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d83dbde7-87b5-4017-b091-2e49c4fd5ed9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_ProfitLoss_d83dbde7-87b5-4017-b091-2e49c4fd5ed9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_852fc246-c200-4d7a-931b-8281352ef593" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_852fc246-c200-4d7a-931b-8281352ef593" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f1ab5cac-a3ba-42ea-9216-eef4ece188ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f1ab5cac-a3ba-42ea-9216-eef4ece188ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2d65615e-bf9f-4c6b-8354-84a63f7ea467" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2d65615e-bf9f-4c6b-8354-84a63f7ea467" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_42e20005-0739-44ec-b102-cb0bf494754c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_42e20005-0739-44ec-b102-cb0bf494754c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5039d06d-a879-4000-a4ec-5723deae486f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5039d06d-a879-4000-a4ec-5723deae486f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a9bfc45d-0b5f-4d6d-a809-2d9333383297" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a9bfc45d-0b5f-4d6d-a809-2d9333383297" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_720ee1f2-ffec-4431-8ad2-fa1964b07df9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_720ee1f2-ffec-4431-8ad2-fa1964b07df9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_88988ef6-833f-4927-bc26-3b038c1c53e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_88988ef6-833f-4927-bc26-3b038c1c53e4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_f643b631-7a51-4e76-99b9-8f9bf0c349a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_Dividends_f643b631-7a51-4e76-99b9-8f9bf0c349a1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7f313fb6-51b2-4d7d-9429-97c088d1f1db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_498fd961-35e9-4798-81aa-f94e725b82c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2f14ac72-a112-46c8-8be1-42d0ea05689f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f391129d-868c-4880-8de9-888c7e5fe6a3" xlink:to="loc_us-gaap_StatementTable_2f14ac72-a112-46c8-8be1-42d0ea05689f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c37035f9-f411-4f10-9f60-9896c15ec4b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2f14ac72-a112-46c8-8be1-42d0ea05689f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c37035f9-f411-4f10-9f60-9896c15ec4b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c37035f9-f411-4f10-9f60-9896c15ec4b8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c37035f9-f411-4f10-9f60-9896c15ec4b8" xlink:to="loc_us-gaap_EquityComponentDomain_c37035f9-f411-4f10-9f60-9896c15ec4b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6c2e1953-7a27-4170-ac2c-96b4764685e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c37035f9-f411-4f10-9f60-9896c15ec4b8" xlink:to="loc_us-gaap_EquityComponentDomain_6c2e1953-7a27-4170-ac2c-96b4764685e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1e2beb46-baf8-4a75-b6d5-207893a07e36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6c2e1953-7a27-4170-ac2c-96b4764685e3" xlink:to="loc_us-gaap_CommonStockMember_1e2beb46-baf8-4a75-b6d5-207893a07e36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_102b4dd6-6055-480e-b6e8-a717fd1ab97c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6c2e1953-7a27-4170-ac2c-96b4764685e3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_102b4dd6-6055-480e-b6e8-a717fd1ab97c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ad375572-8ed6-4df1-8c32-7afc4a6fc774" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6c2e1953-7a27-4170-ac2c-96b4764685e3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ad375572-8ed6-4df1-8c32-7afc4a6fc774" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ab7a9c10-f8dd-4f75-96bf-de664495ef1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6c2e1953-7a27-4170-ac2c-96b4764685e3" xlink:to="loc_us-gaap_RetainedEarningsMember_ab7a9c10-f8dd-4f75-96bf-de664495ef1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_666f1f1e-d99f-4a36-ab08-e4f6da029b8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6c2e1953-7a27-4170-ac2c-96b4764685e3" xlink:to="loc_us-gaap_NoncontrollingInterestMember_666f1f1e-d99f-4a36-ab08-e4f6da029b8a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CumulativeEffectPeriodOfAdoptionAxis_57442aa3-cc3d-4027-8e93-4adb58ec5517" xlink:href="gild-20210331.xsd#gild_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2f14ac72-a112-46c8-8be1-42d0ea05689f" xlink:to="loc_gild_CumulativeEffectPeriodOfAdoptionAxis_57442aa3-cc3d-4027-8e93-4adb58ec5517" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CumulativeEffectPeriodOfAdoptionDomain_57442aa3-cc3d-4027-8e93-4adb58ec5517_default" xlink:href="gild-20210331.xsd#gild_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gild_CumulativeEffectPeriodOfAdoptionAxis_57442aa3-cc3d-4027-8e93-4adb58ec5517" xlink:to="loc_gild_CumulativeEffectPeriodOfAdoptionDomain_57442aa3-cc3d-4027-8e93-4adb58ec5517_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CumulativeEffectPeriodOfAdoptionDomain_7f5332f9-2a69-41cb-b62d-80b63a97f3db" xlink:href="gild-20210331.xsd#gild_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gild_CumulativeEffectPeriodOfAdoptionAxis_57442aa3-cc3d-4027-8e93-4adb58ec5517" xlink:to="loc_gild_CumulativeEffectPeriodOfAdoptionDomain_7f5332f9-2a69-41cb-b62d-80b63a97f3db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ef5009a3-3de7-4616-b0ea-bfe24a698d22" xlink:href="gild-20210331.xsd#gild_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_CumulativeEffectPeriodOfAdoptionDomain_7f5332f9-2a69-41cb-b62d-80b63a97f3db" xlink:to="loc_gild_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ef5009a3-3de7-4616-b0ea-bfe24a698d22" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="gild-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended" id="ib42bd4b0e88b4587b9b083c8071f51cd_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="gild-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="if885b70a79d74cd684cfd09c186c9230_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:roleRef roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="gild-20210331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended" id="i71406130b9b04755900974b6a57dc6cb_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:roleRef roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="gild-20210331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended" id="i512ca8d400d34ca9af55dadd201321fc_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:roleRef roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended" id="ic9bcc96e541d447bb2644b9b9f50415d_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUES" xlink:type="simple" xlink:href="gild-20210331.xsd#REVENUES"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/REVENUES" xlink:type="extended" id="ib8d53d11b2c0446096b1038fb2ae23ba_REVENUES"/>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESTables" xlink:type="simple" xlink:href="gild-20210331.xsd#REVENUESTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/REVENUESTables" xlink:type="extended" id="ib35c353bdb9044158c61cc7a2b7d0efe_REVENUESTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#REVENUESDisaggregationofRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails" xlink:type="extended" id="ie5f2bb3148f040d9841bf9374af2e97f_REVENUESDisaggregationofRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f5b4617e-4a1e-4c13-a2ad-2404d89c63b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2e5fac2f-e6e4-456c-9577-051af03d5e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f5b4617e-4a1e-4c13-a2ad-2404d89c63b5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2e5fac2f-e6e4-456c-9577-051af03d5e5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_84309fde-2db9-40d9-87fd-6e9a5bbfaeb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f5b4617e-4a1e-4c13-a2ad-2404d89c63b5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_84309fde-2db9-40d9-87fd-6e9a5bbfaeb7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9511a0b3-7889-44cd-9d9d-1a152a273c80" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_84309fde-2db9-40d9-87fd-6e9a5bbfaeb7" xlink:to="loc_srt_ProductOrServiceAxis_9511a0b3-7889-44cd-9d9d-1a152a273c80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9511a0b3-7889-44cd-9d9d-1a152a273c80_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9511a0b3-7889-44cd-9d9d-1a152a273c80" xlink:to="loc_srt_ProductsAndServicesDomain_9511a0b3-7889-44cd-9d9d-1a152a273c80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_da2b7125-969b-48fe-9162-d40622155aff" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9511a0b3-7889-44cd-9d9d-1a152a273c80" xlink:to="loc_srt_ProductsAndServicesDomain_da2b7125-969b-48fe-9162-d40622155aff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_dbd8532f-13a3-4bc9-959f-b5055676c288" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_da2b7125-969b-48fe-9162-d40622155aff" xlink:to="loc_us-gaap_ProductMember_dbd8532f-13a3-4bc9-959f-b5055676c288" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:href="gild-20210331.xsd#gild_HIVProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_dbd8532f-13a3-4bc9-959f-b5055676c288" xlink:to="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsAtriplaMember_5f533c93-6fb5-4cf0-8827-0b8769703544" xlink:href="gild-20210331.xsd#gild_HIVProductsAtriplaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:to="loc_gild_HIVProductsAtriplaMember_5f533c93-6fb5-4cf0-8827-0b8769703544" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsBiktarvyMember_8fd410df-6903-469f-a876-07b9113ce8c3" xlink:href="gild-20210331.xsd#gild_HIVProductsBiktarvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:to="loc_gild_HIVProductsBiktarvyMember_8fd410df-6903-469f-a876-07b9113ce8c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsCompleraEvipleraMember_6ddb8a76-06c2-4bde-ba03-98f1b72f5498" xlink:href="gild-20210331.xsd#gild_HIVProductsCompleraEvipleraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:to="loc_gild_HIVProductsCompleraEvipleraMember_6ddb8a76-06c2-4bde-ba03-98f1b72f5498" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsDescovyMember_95ff3a53-b930-49d6-8934-d8730edf8237" xlink:href="gild-20210331.xsd#gild_HIVProductsDescovyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:to="loc_gild_HIVProductsDescovyMember_95ff3a53-b930-49d6-8934-d8730edf8237" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsGenvoyaMember_e22296ba-0c6b-4bb2-8ed0-19e4c84d7af1" xlink:href="gild-20210331.xsd#gild_HIVProductsGenvoyaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:to="loc_gild_HIVProductsGenvoyaMember_e22296ba-0c6b-4bb2-8ed0-19e4c84d7af1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsOdefseyMember_651b9b22-dcec-44e2-b70c-1609dd51f68b" xlink:href="gild-20210331.xsd#gild_HIVProductsOdefseyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:to="loc_gild_HIVProductsOdefseyMember_651b9b22-dcec-44e2-b70c-1609dd51f68b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsStribildMember_9aab7d71-118e-4a53-b136-784b19a590fe" xlink:href="gild-20210331.xsd#gild_HIVProductsStribildMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:to="loc_gild_HIVProductsStribildMember_9aab7d71-118e-4a53-b136-784b19a590fe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsTruvadaMember_810584ad-f676-4306-b8d4-5f3ce5545ba2" xlink:href="gild-20210331.xsd#gild_HIVProductsTruvadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:to="loc_gild_HIVProductsTruvadaMember_810584ad-f676-4306-b8d4-5f3ce5545ba2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsOtherHIVMember_cc109811-92f9-4776-8fbb-2ff90c614945" xlink:href="gild-20210331.xsd#gild_ProductsOtherHIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:to="loc_gild_ProductsOtherHIVMember_cc109811-92f9-4776-8fbb-2ff90c614945" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsRevenueShareSymtuzaMember_a7fdb178-e6dd-4051-a745-f9ef3e29044a" xlink:href="gild-20210331.xsd#gild_ProductsRevenueShareSymtuzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:to="loc_gild_ProductsRevenueShareSymtuzaMember_a7fdb178-e6dd-4051-a745-f9ef3e29044a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductSalesMember_a7557a12-d4bf-4c9b-950d-4b85ea75d28a" xlink:href="gild-20210331.xsd#gild_HCVProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_dbd8532f-13a3-4bc9-959f-b5055676c288" xlink:to="loc_gild_HCVProductSalesMember_a7557a12-d4bf-4c9b-950d-4b85ea75d28a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsLedipasvirSofosbuvirMember_a037393c-43b2-4189-927d-87321003f8fe" xlink:href="gild-20210331.xsd#gild_HCVProductsLedipasvirSofosbuvirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HCVProductSalesMember_a7557a12-d4bf-4c9b-950d-4b85ea75d28a" xlink:to="loc_gild_HCVProductsLedipasvirSofosbuvirMember_a037393c-43b2-4189-927d-87321003f8fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_6cdb80a0-95ac-43de-b0d2-cd38a822e174" xlink:href="gild-20210331.xsd#gild_HCVProductsSofosbuvirVelpatasvirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HCVProductSalesMember_a7557a12-d4bf-4c9b-950d-4b85ea75d28a" xlink:to="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_6cdb80a0-95ac-43de-b0d2-cd38a822e174" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherHepatitisCVirusProductsMember_7357c4c3-d325-4d07-a01f-f93062511ad1" xlink:href="gild-20210331.xsd#gild_OtherHepatitisCVirusProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HCVProductSalesMember_a7557a12-d4bf-4c9b-950d-4b85ea75d28a" xlink:to="loc_gild_OtherHepatitisCVirusProductsMember_7357c4c3-d325-4d07-a01f-f93062511ad1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_15bddf28-7822-4986-a372-9feaf494606e" xlink:href="gild-20210331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_dbd8532f-13a3-4bc9-959f-b5055676c288" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_15bddf28-7822-4986-a372-9feaf494606e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_8c0b0bc2-dfba-481b-bdd0-56497ea1f917" xlink:href="gild-20210331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_15bddf28-7822-4986-a372-9feaf494606e" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_8c0b0bc2-dfba-481b-bdd0-56497ea1f917" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_14ad78e4-2f02-4215-bb5c-24c9bc49634c" xlink:href="gild-20210331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_15bddf28-7822-4986-a372-9feaf494606e" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_14ad78e4-2f02-4215-bb5c-24c9bc49634c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_38b6fffc-7145-474c-a6be-c88663995d2a" xlink:href="gild-20210331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_15bddf28-7822-4986-a372-9feaf494606e" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_38b6fffc-7145-474c-a6be-c88663995d2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VekluryMember_5ed9f64c-fbff-48f8-8ea9-5510ef2800e3" xlink:href="gild-20210331.xsd#gild_VekluryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_dbd8532f-13a3-4bc9-959f-b5055676c288" xlink:to="loc_gild_VekluryMember_5ed9f64c-fbff-48f8-8ea9-5510ef2800e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_f915b8ec-e9e4-4c58-945f-a038fa26d031" xlink:href="gild-20210331.xsd#gild_CellTherapyProductsTotalCellTherapyProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_dbd8532f-13a3-4bc9-959f-b5055676c288" xlink:to="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_f915b8ec-e9e4-4c58-945f-a038fa26d031" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CallTherapyProductsTecartusMember_2cc2ba65-6162-4d0e-a5dc-34b82324f8c9" xlink:href="gild-20210331.xsd#gild_CallTherapyProductsTecartusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_f915b8ec-e9e4-4c58-945f-a038fa26d031" xlink:to="loc_gild_CallTherapyProductsTecartusMember_2cc2ba65-6162-4d0e-a5dc-34b82324f8c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsYescartaMember_eca1824b-b31b-4a07-b1ea-e4fa8d3ad815" xlink:href="gild-20210331.xsd#gild_CellTherapyProductsYescartaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_f915b8ec-e9e4-4c58-945f-a038fa26d031" xlink:to="loc_gild_CellTherapyProductsYescartaMember_eca1824b-b31b-4a07-b1ea-e4fa8d3ad815" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_db71fbd2-7985-407a-bb6e-8481b97e97cf" xlink:href="gild-20210331.xsd#gild_TrodelvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_dbd8532f-13a3-4bc9-959f-b5055676c288" xlink:to="loc_gild_TrodelvyMember_db71fbd2-7985-407a-bb6e-8481b97e97cf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsTotalOtherProductSalesMember_a082bb64-4772-49a7-8a89-3131ed0cc64b" xlink:href="gild-20210331.xsd#gild_OtherProductsTotalOtherProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_dbd8532f-13a3-4bc9-959f-b5055676c288" xlink:to="loc_gild_OtherProductsTotalOtherProductSalesMember_a082bb64-4772-49a7-8a89-3131ed0cc64b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsAmBisomeMember_311125c2-f331-4628-839c-7f3da07066d0" xlink:href="gild-20210331.xsd#gild_OtherProductsAmBisomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_a082bb64-4772-49a7-8a89-3131ed0cc64b" xlink:to="loc_gild_OtherProductsAmBisomeMember_311125c2-f331-4628-839c-7f3da07066d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsLetairisMember_10289a7e-c65c-490d-98ba-e1baa804c005" xlink:href="gild-20210331.xsd#gild_OtherProductsLetairisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_a082bb64-4772-49a7-8a89-3131ed0cc64b" xlink:to="loc_gild_OtherProductsLetairisMember_10289a7e-c65c-490d-98ba-e1baa804c005" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsRanexaMember_d0fb5de9-fa86-4c49-9bf9-e3c9550e02a4" xlink:href="gild-20210331.xsd#gild_OtherProductsRanexaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_a082bb64-4772-49a7-8a89-3131ed0cc64b" xlink:to="loc_gild_OtherProductsRanexaMember_d0fb5de9-fa86-4c49-9bf9-e3c9550e02a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsZydeligMember_fedee5c2-a5be-4d88-a3ac-35449cc740f2" xlink:href="gild-20210331.xsd#gild_OtherProductsZydeligMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_a082bb64-4772-49a7-8a89-3131ed0cc64b" xlink:to="loc_gild_OtherProductsZydeligMember_fedee5c2-a5be-4d88-a3ac-35449cc740f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsOtherMember_2e9ce5ee-d8d8-48e2-b646-6d574c89b556" xlink:href="gild-20210331.xsd#gild_OtherProductsOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_a082bb64-4772-49a7-8a89-3131ed0cc64b" xlink:to="loc_gild_OtherProductsOtherMember_2e9ce5ee-d8d8-48e2-b646-6d574c89b556" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_462f43af-55b1-4c2e-9eac-18e8f78eb943" xlink:href="gild-20210331.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_da2b7125-969b-48fe-9162-d40622155aff" xlink:to="loc_gild_RoyaltyContractAndOtherMember_462f43af-55b1-4c2e-9eac-18e8f78eb943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d7d83b0f-b27b-4e7a-83f7-3c24d3c525a8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_84309fde-2db9-40d9-87fd-6e9a5bbfaeb7" xlink:to="loc_srt_StatementGeographicalAxis_d7d83b0f-b27b-4e7a-83f7-3c24d3c525a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d7d83b0f-b27b-4e7a-83f7-3c24d3c525a8_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d7d83b0f-b27b-4e7a-83f7-3c24d3c525a8" xlink:to="loc_srt_SegmentGeographicalDomain_d7d83b0f-b27b-4e7a-83f7-3c24d3c525a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_003b2567-6c7a-48c0-a24e-bab7e05fd6e4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d7d83b0f-b27b-4e7a-83f7-3c24d3c525a8" xlink:to="loc_srt_SegmentGeographicalDomain_003b2567-6c7a-48c0-a24e-bab7e05fd6e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4d795df3-16eb-48c8-abf8-f216b4063372" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_003b2567-6c7a-48c0-a24e-bab7e05fd6e4" xlink:to="loc_country_US_4d795df3-16eb-48c8-abf8-f216b4063372" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_01fd634b-6c1e-4316-bfb1-7f7b1d7c9c18" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_003b2567-6c7a-48c0-a24e-bab7e05fd6e4" xlink:to="loc_srt_EuropeMember_01fd634b-6c1e-4316-bfb1-7f7b1d7c9c18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherInternationalMember_7f982560-1ea5-4972-a3db-b68bb26e55dd" xlink:href="gild-20210331.xsd#gild_OtherInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_003b2567-6c7a-48c0-a24e-bab7e05fd6e4" xlink:to="loc_gild_OtherInternationalMember_7f982560-1ea5-4972-a3db-b68bb26e55dd" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#REVENUESRevenuesfromMajorCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails" xlink:type="extended" id="i42deb713c2ce4e95b03d564280298f6d_REVENUESRevenuesfromMajorCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_ebd4dfe1-7436-488b-a1f2-d9cbb2b74adc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f692e8f2-d852-46e2-bee0-f9e5ba60867e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_ebd4dfe1-7436-488b-a1f2-d9cbb2b74adc" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f692e8f2-d852-46e2-bee0-f9e5ba60867e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_3caa45b8-66b0-4411-bb48-c63dc3d6cd1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_ebd4dfe1-7436-488b-a1f2-d9cbb2b74adc" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_3caa45b8-66b0-4411-bb48-c63dc3d6cd1c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3ecd2712-0375-4c81-b55a-39aba1e882f4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_3caa45b8-66b0-4411-bb48-c63dc3d6cd1c" xlink:to="loc_srt_MajorCustomersAxis_3ecd2712-0375-4c81-b55a-39aba1e882f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3ecd2712-0375-4c81-b55a-39aba1e882f4_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_3ecd2712-0375-4c81-b55a-39aba1e882f4" xlink:to="loc_srt_NameOfMajorCustomerDomain_3ecd2712-0375-4c81-b55a-39aba1e882f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4658a320-d281-4878-bb64-7a0edbf1db80" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_3ecd2712-0375-4c81-b55a-39aba1e882f4" xlink:to="loc_srt_NameOfMajorCustomerDomain_4658a320-d281-4878-bb64-7a0edbf1db80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmerisourcebergenCorpMember_43ca7f33-b0bc-42b5-b1ef-0464d1c22836" xlink:href="gild-20210331.xsd#gild_AmerisourcebergenCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4658a320-d281-4878-bb64-7a0edbf1db80" xlink:to="loc_gild_AmerisourcebergenCorpMember_43ca7f33-b0bc-42b5-b1ef-0464d1c22836" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CardinalHealthIncMember_92cbc9f1-6138-47ad-ac2a-65520642aec4" xlink:href="gild-20210331.xsd#gild_CardinalHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4658a320-d281-4878-bb64-7a0edbf1db80" xlink:to="loc_gild_CardinalHealthIncMember_92cbc9f1-6138-47ad-ac2a-65520642aec4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MckessonCorpMember_63cf8f75-fd48-4bf2-afe4-71dec4375409" xlink:href="gild-20210331.xsd#gild_MckessonCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4658a320-d281-4878-bb64-7a0edbf1db80" xlink:to="loc_gild_MckessonCorpMember_63cf8f75-fd48-4bf2-afe4-71dec4375409" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4f7de32a-7388-4eae-b9e2-4ad55aa7056b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_3caa45b8-66b0-4411-bb48-c63dc3d6cd1c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4f7de32a-7388-4eae-b9e2-4ad55aa7056b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4f7de32a-7388-4eae-b9e2-4ad55aa7056b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4f7de32a-7388-4eae-b9e2-4ad55aa7056b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4f7de32a-7388-4eae-b9e2-4ad55aa7056b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e6faaa1a-3e0c-478a-b710-97709bc56912" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4f7de32a-7388-4eae-b9e2-4ad55aa7056b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e6faaa1a-3e0c-478a-b710-97709bc56912" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_9924dbe9-98d1-4d17-a6ec-aa9b3868d20d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e6faaa1a-3e0c-478a-b710-97709bc56912" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_9924dbe9-98d1-4d17-a6ec-aa9b3868d20d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c073c506-340e-4037-a8b0-aa9906da8ae0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_3caa45b8-66b0-4411-bb48-c63dc3d6cd1c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c073c506-340e-4037-a8b0-aa9906da8ae0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c073c506-340e-4037-a8b0-aa9906da8ae0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c073c506-340e-4037-a8b0-aa9906da8ae0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c073c506-340e-4037-a8b0-aa9906da8ae0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_40c8c90c-3dff-48b6-b689-b02988005736" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c073c506-340e-4037-a8b0-aa9906da8ae0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_40c8c90c-3dff-48b6-b689-b02988005736" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_b1f0e26e-891f-404b-a299-00e82edd0c8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_40c8c90c-3dff-48b6-b689-b02988005736" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_b1f0e26e-891f-404b-a299-00e82edd0c8a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#REVENUESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/REVENUESAdditionalInformationDetails" xlink:type="extended" id="i7ef6fd16345f439084cdfd29a9132846_REVENUESAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_37f0cba7-d842-42aa-83a7-833bcf31bc45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_02bb2a38-26ec-46d0-8c05-9b6e2915c47f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_37f0cba7-d842-42aa-83a7-833bcf31bc45" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_02bb2a38-26ec-46d0-8c05-9b6e2915c47f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_59f02333-7ef6-470e-8239-0412bfb4445f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_37f0cba7-d842-42aa-83a7-833bcf31bc45" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_59f02333-7ef6-470e-8239-0412bfb4445f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_0441ada5-0642-42b1-a96b-f8528f756587" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_37f0cba7-d842-42aa-83a7-833bcf31bc45" xlink:to="loc_us-gaap_ContractWithCustomerLiability_0441ada5-0642-42b1-a96b-f8528f756587" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_64c2401a-c835-4846-aed2-f89dbe40655a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_37f0cba7-d842-42aa-83a7-833bcf31bc45" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_64c2401a-c835-4846-aed2-f89dbe40655a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7c002eb8-c8f5-450b-90fb-7f3f6bc03bae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_37f0cba7-d842-42aa-83a7-833bcf31bc45" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7c002eb8-c8f5-450b-90fb-7f3f6bc03bae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ca6e213e-a6f6-468f-a05f-8c234f982082" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7c002eb8-c8f5-450b-90fb-7f3f6bc03bae" xlink:to="loc_srt_ProductOrServiceAxis_ca6e213e-a6f6-468f-a05f-8c234f982082" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ca6e213e-a6f6-468f-a05f-8c234f982082_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ca6e213e-a6f6-468f-a05f-8c234f982082" xlink:to="loc_srt_ProductsAndServicesDomain_ca6e213e-a6f6-468f-a05f-8c234f982082_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_998dd5f6-0217-4183-ae0b-15ffd28a07d5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ca6e213e-a6f6-468f-a05f-8c234f982082" xlink:to="loc_srt_ProductsAndServicesDomain_998dd5f6-0217-4183-ae0b-15ffd28a07d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_62ce8b5a-167d-4253-a862-5328c8c04b20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_998dd5f6-0217-4183-ae0b-15ffd28a07d5" xlink:to="loc_us-gaap_RoyaltyMember_62ce8b5a-167d-4253-a862-5328c8c04b20" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="gild-20210331.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended" id="i83c66245e46b4479a25691220f6077c0_FAIRVALUEMEASUREMENTS"/>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="gild-20210331.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended" id="ia9e9a7173c314cc9ae893aa400f5ac30_FAIRVALUEMEASUREMENTSTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended" id="i2e5d00feceba4392a149a5d1930c452c_FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9050e530-39ff-4173-9948-cfd85827a3b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3a0d4d63-b2ad-4b7f-906a-dce8ea1e278c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9050e530-39ff-4173-9948-cfd85827a3b4" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_3a0d4d63-b2ad-4b7f-906a-dce8ea1e278c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e425cffc-81d7-4c52-ab4b-f4ca036b5e1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3a0d4d63-b2ad-4b7f-906a-dce8ea1e278c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e425cffc-81d7-4c52-ab4b-f4ca036b5e1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_7e3eb6a7-9cb0-4c92-9f94-7199c0800296" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3a0d4d63-b2ad-4b7f-906a-dce8ea1e278c" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_7e3eb6a7-9cb0-4c92-9f94-7199c0800296" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_9e4b09cd-9da5-4658-b0c3-516d31e296c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3a0d4d63-b2ad-4b7f-906a-dce8ea1e278c" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_9e4b09cd-9da5-4658-b0c3-516d31e296c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ea5bfa01-cc2b-44d3-b072-d1c6937aec05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3a0d4d63-b2ad-4b7f-906a-dce8ea1e278c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ea5bfa01-cc2b-44d3-b072-d1c6937aec05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a31cfdf7-e627-4dea-9ce3-2f711d8646e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9050e530-39ff-4173-9948-cfd85827a3b4" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a31cfdf7-e627-4dea-9ce3-2f711d8646e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e45a6cfa-7d45-474b-bff9-da1519835755" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a31cfdf7-e627-4dea-9ce3-2f711d8646e2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e45a6cfa-7d45-474b-bff9-da1519835755" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_4717aebe-9708-4819-9f54-8cd92bb8dc00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a31cfdf7-e627-4dea-9ce3-2f711d8646e2" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_4717aebe-9708-4819-9f54-8cd92bb8dc00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_47d416bb-6bfe-4677-823b-94c4a0e57328" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a31cfdf7-e627-4dea-9ce3-2f711d8646e2" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_47d416bb-6bfe-4677-823b-94c4a0e57328" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_a8d70d5f-2c0a-4585-b11d-587aa8262e8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a31cfdf7-e627-4dea-9ce3-2f711d8646e2" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_a8d70d5f-2c0a-4585-b11d-587aa8262e8f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8cf036e1-5423-4d05-b20d-600428bc2c09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9050e530-39ff-4173-9948-cfd85827a3b4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8cf036e1-5423-4d05-b20d-600428bc2c09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80b7274d-d040-4ece-a187-09a843e91d22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8cf036e1-5423-4d05-b20d-600428bc2c09" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80b7274d-d040-4ece-a187-09a843e91d22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_80b7274d-d040-4ece-a187-09a843e91d22_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80b7274d-d040-4ece-a187-09a843e91d22" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_80b7274d-d040-4ece-a187-09a843e91d22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_eb68ea90-6367-41a5-9518-c1ca18d60ca2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80b7274d-d040-4ece-a187-09a843e91d22" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_eb68ea90-6367-41a5-9518-c1ca18d60ca2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a0b53aeb-377b-49b0-9fa3-dac4f2a16388" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_eb68ea90-6367-41a5-9518-c1ca18d60ca2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a0b53aeb-377b-49b0-9fa3-dac4f2a16388" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_75d63900-85db-4b3d-a818-42b8acbab8b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8cf036e1-5423-4d05-b20d-600428bc2c09" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_75d63900-85db-4b3d-a818-42b8acbab8b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75d63900-85db-4b3d-a818-42b8acbab8b7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_75d63900-85db-4b3d-a818-42b8acbab8b7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75d63900-85db-4b3d-a818-42b8acbab8b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0020ef22-9514-4a3c-829e-4b46d49bd549" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_75d63900-85db-4b3d-a818-42b8acbab8b7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0020ef22-9514-4a3c-829e-4b46d49bd549" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_51f4e0ef-9f47-418f-b0c7-f0bb6485f521" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0020ef22-9514-4a3c-829e-4b46d49bd549" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_51f4e0ef-9f47-418f-b0c7-f0bb6485f521" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ac4061ef-5d25-4fa2-a2de-d5f2ef495b30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0020ef22-9514-4a3c-829e-4b46d49bd549" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ac4061ef-5d25-4fa2-a2de-d5f2ef495b30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e354db26-f71a-465e-90ef-94759d885d13" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0020ef22-9514-4a3c-829e-4b46d49bd549" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e354db26-f71a-465e-90ef-94759d885d13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_9cf98e57-44ea-4499-a084-7e5d92320c84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8cf036e1-5423-4d05-b20d-600428bc2c09" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_9cf98e57-44ea-4499-a084-7e5d92320c84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_9cf98e57-44ea-4499-a084-7e5d92320c84_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_9cf98e57-44ea-4499-a084-7e5d92320c84" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_9cf98e57-44ea-4499-a084-7e5d92320c84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ce102b9e-724f-4a47-889e-7809aa1ec75b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_9cf98e57-44ea-4499-a084-7e5d92320c84" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ce102b9e-724f-4a47-889e-7809aa1ec75b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_df61e737-d64a-459e-8cc3-31c9a9ac396c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ce102b9e-724f-4a47-889e-7809aa1ec75b" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_df61e737-d64a-459e-8cc3-31c9a9ac396c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_e1742f53-fb3f-4b68-8557-01b32d96723b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_df61e737-d64a-459e-8cc3-31c9a9ac396c" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_e1742f53-fb3f-4b68-8557-01b32d96723b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_76a3caef-a42d-48f4-b945-4e94a6f28825" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8cf036e1-5423-4d05-b20d-600428bc2c09" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_76a3caef-a42d-48f4-b945-4e94a6f28825" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_76a3caef-a42d-48f4-b945-4e94a6f28825_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_76a3caef-a42d-48f4-b945-4e94a6f28825" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_76a3caef-a42d-48f4-b945-4e94a6f28825_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_76a3caef-a42d-48f4-b945-4e94a6f28825" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_e115c7ad-7791-48a9-9e2e-c1cd51a852ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_e115c7ad-7791-48a9-9e2e-c1cd51a852ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_2a48ff77-53f2-468f-bb3a-9eab9fca29d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_2a48ff77-53f2-468f-bb3a-9eab9fca29d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_41d5eea0-67d1-4c9a-9b9a-72312da820ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_41d5eea0-67d1-4c9a-9b9a-72312da820ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_24bdbf55-b093-414e-90be-7b8eb11ad8e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_24bdbf55-b093-414e-90be-7b8eb11ad8e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_f95f699c-d9af-455f-a492-8aa66e34edc1" xlink:href="gild-20210331.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_f95f699c-d9af-455f-a492-8aa66e34edc1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3939a2ab-cceb-4937-a513-ba6ebdf435dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3939a2ab-cceb-4937-a513-ba6ebdf435dd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityinvestmentinGalapagosMember_9303c1f2-fd31-41fe-abad-a9d6a4fe21f5" xlink:href="gild-20210331.xsd#gild_EquityinvestmentinGalapagosMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:to="loc_gild_EquityinvestmentinGalapagosMember_9303c1f2-fd31-41fe-abad-a9d6a4fe21f5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_6ecd5bc3-3d2e-4c0b-8a7f-45ce767f4daf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:to="loc_us-gaap_EquitySecuritiesMember_6ecd5bc3-3d2e-4c0b-8a7f-45ce767f4daf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember_1b279e5d-2e15-417a-8df3-cfac5b552959" xlink:href="gild-20210331.xsd#gild_DeferredCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:to="loc_gild_DeferredCompensationPlanMember_1b279e5d-2e15-417a-8df3-cfac5b552959" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ForeignCurrencyDerivativeContractsMember_01ca74e8-ffad-4919-b50e-be5afc9a4278" xlink:href="gild-20210331.xsd#gild_ForeignCurrencyDerivativeContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:to="loc_gild_ForeignCurrencyDerivativeContractsMember_01ca74e8-ffad-4919-b50e-be5afc9a4278" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2a8e1765-2112-4990-b487-0e58a0677f14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8cf036e1-5423-4d05-b20d-600428bc2c09" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2a8e1765-2112-4990-b487-0e58a0677f14" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a8e1765-2112-4990-b487-0e58a0677f14_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2a8e1765-2112-4990-b487-0e58a0677f14" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2a8e1765-2112-4990-b487-0e58a0677f14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0de29832-8aaf-4999-a377-8417b7d4d2a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2a8e1765-2112-4990-b487-0e58a0677f14" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0de29832-8aaf-4999-a377-8417b7d4d2a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_ad323c5f-2991-44df-9200-b7a168c5d1ac" xlink:href="gild-20210331.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0de29832-8aaf-4999-a377-8417b7d4d2a8" xlink:to="loc_gild_MYRGmbHMember_ad323c5f-2991-44df-9200-b7a168c5d1ac" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails" xlink:type="extended" id="iea0cf9e49d27411f9c1482df998f38f7_FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fc8d1b6a-114d-4800-be92-c4dc01449e12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a04c2480-f264-4daf-b117-50d102e8d48f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fc8d1b6a-114d-4800-be92-c4dc01449e12" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a04c2480-f264-4daf-b117-50d102e8d48f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d5e8e646-c28f-4ffd-92ee-9f6fc419eb4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fc8d1b6a-114d-4800-be92-c4dc01449e12" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d5e8e646-c28f-4ffd-92ee-9f6fc419eb4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_17f936ef-6bb8-4b06-b275-214f8b5af778" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fc8d1b6a-114d-4800-be92-c4dc01449e12" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_17f936ef-6bb8-4b06-b275-214f8b5af778" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_11afe6b7-eec1-4d88-96ae-d704265fba3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_17f936ef-6bb8-4b06-b275-214f8b5af778" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_11afe6b7-eec1-4d88-96ae-d704265fba3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_11afe6b7-eec1-4d88-96ae-d704265fba3f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_11afe6b7-eec1-4d88-96ae-d704265fba3f" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_11afe6b7-eec1-4d88-96ae-d704265fba3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_482a6363-60f5-4375-9a57-3bb96f5687aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_11afe6b7-eec1-4d88-96ae-d704265fba3f" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_482a6363-60f5-4375-9a57-3bb96f5687aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherEquitySecuritiesMember_f103652e-f8ca-4eb7-9be4-14795497672c" xlink:href="gild-20210331.xsd#gild_OtherEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_482a6363-60f5-4375-9a57-3bb96f5687aa" xlink:to="loc_gild_OtherEquitySecuritiesMember_f103652e-f8ca-4eb7-9be4-14795497672c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e2d7ac1d-d22c-476d-8e69-547757029a82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_17f936ef-6bb8-4b06-b275-214f8b5af778" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e2d7ac1d-d22c-476d-8e69-547757029a82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e2d7ac1d-d22c-476d-8e69-547757029a82_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e2d7ac1d-d22c-476d-8e69-547757029a82" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e2d7ac1d-d22c-476d-8e69-547757029a82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fc33ef04-2936-43fd-af8c-48358e327587" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e2d7ac1d-d22c-476d-8e69-547757029a82" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fc33ef04-2936-43fd-af8c-48358e327587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_6c1b929c-19c2-4520-9712-70749f4619fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fc33ef04-2936-43fd-af8c-48358e327587" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_6c1b929c-19c2-4520-9712-70749f4619fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_b09e24e8-d3c2-40a2-afbd-89e5f3a34db2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fc33ef04-2936-43fd-af8c-48358e327587" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_b09e24e8-d3c2-40a2-afbd-89e5f3a34db2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_7369d9b7-67e2-4a7f-a4c0-69607394c4b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fc33ef04-2936-43fd-af8c-48358e327587" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_7369d9b7-67e2-4a7f-a4c0-69607394c4b2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#FAIRVALUEMEASUREMENTSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" xlink:type="extended" id="i0d3f730d0b7245e4ab11bb321a07d15c_FAIRVALUEMEASUREMENTSAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29107fa8-9b9b-486c-8771-960468449de8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_da3adf12-829d-4251-b966-bbc2ea78d50c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29107fa8-9b9b-486c-8771-960468449de8" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_da3adf12-829d-4251-b966-bbc2ea78d50c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9a4ed356-0bd9-4c69-8a61-8d1797d48bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29107fa8-9b9b-486c-8771-960468449de8" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9a4ed356-0bd9-4c69-8a61-8d1797d48bc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_ca5237cf-b8c2-47e7-a9dd-fbee4f6c86a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29107fa8-9b9b-486c-8771-960468449de8" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_ca5237cf-b8c2-47e7-a9dd-fbee4f6c86a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_111fae9a-7d76-4263-97e8-a4e8982a9ce7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29107fa8-9b9b-486c-8771-960468449de8" xlink:to="loc_us-gaap_LongTermDebtFairValue_111fae9a-7d76-4263-97e8-a4e8982a9ce7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_45a34122-b612-4d81-9abb-837a947f297a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29107fa8-9b9b-486c-8771-960468449de8" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_45a34122-b612-4d81-9abb-837a947f297a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b2357268-aa1e-4210-8eac-3a8614f3337b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29107fa8-9b9b-486c-8771-960468449de8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b2357268-aa1e-4210-8eac-3a8614f3337b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca73e69c-02cd-4c0b-aa36-6a232bdd8cb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29107fa8-9b9b-486c-8771-960468449de8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca73e69c-02cd-4c0b-aa36-6a232bdd8cb2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_2a7fe366-8f6d-490b-89c7-a841bb8fea61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca73e69c-02cd-4c0b-aa36-6a232bdd8cb2" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_2a7fe366-8f6d-490b-89c7-a841bb8fea61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2a7fe366-8f6d-490b-89c7-a841bb8fea61_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_2a7fe366-8f6d-490b-89c7-a841bb8fea61" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2a7fe366-8f6d-490b-89c7-a841bb8fea61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4541fd0d-fd4a-4a1b-9766-786e29f01c7d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_2a7fe366-8f6d-490b-89c7-a841bb8fea61" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4541fd0d-fd4a-4a1b-9766-786e29f01c7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_37ab41e8-a9c2-447f-8954-e3f83114b2b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4541fd0d-fd4a-4a1b-9766-786e29f01c7d" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_37ab41e8-a9c2-447f-8954-e3f83114b2b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9e55ba61-b5f1-490c-b582-1f3e12f3ebe6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_37ab41e8-a9c2-447f-8954-e3f83114b2b4" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9e55ba61-b5f1-490c-b582-1f3e12f3ebe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_0c3c22b1-0d71-48fa-9cb6-230b44408327" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_37ab41e8-a9c2-447f-8954-e3f83114b2b4" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_0c3c22b1-0d71-48fa-9cb6-230b44408327" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aa661d24-9cec-4201-bbb0-d630f51136c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca73e69c-02cd-4c0b-aa36-6a232bdd8cb2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aa661d24-9cec-4201-bbb0-d630f51136c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aa661d24-9cec-4201-bbb0-d630f51136c4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aa661d24-9cec-4201-bbb0-d630f51136c4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aa661d24-9cec-4201-bbb0-d630f51136c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8d542a69-c785-4375-b085-2ca1cf40c86a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aa661d24-9cec-4201-bbb0-d630f51136c4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8d542a69-c785-4375-b085-2ca1cf40c86a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6f79814a-5830-44fc-97e3-4d2fdae28dd3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8d542a69-c785-4375-b085-2ca1cf40c86a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6f79814a-5830-44fc-97e3-4d2fdae28dd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a3c678db-f2e5-4955-b452-7b97b207e7e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8d542a69-c785-4375-b085-2ca1cf40c86a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a3c678db-f2e5-4955-b452-7b97b207e7e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_02f63276-a3e5-4420-a5a3-229762572b8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca73e69c-02cd-4c0b-aa36-6a232bdd8cb2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_02f63276-a3e5-4420-a5a3-229762572b8f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_02f63276-a3e5-4420-a5a3-229762572b8f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_02f63276-a3e5-4420-a5a3-229762572b8f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_02f63276-a3e5-4420-a5a3-229762572b8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a808af1b-ea41-4846-8af4-fcc543297a49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_02f63276-a3e5-4420-a5a3-229762572b8f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a808af1b-ea41-4846-8af4-fcc543297a49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_eac454d3-2e97-45cb-b0fb-8d7848b1ec0f" xlink:href="gild-20210331.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a808af1b-ea41-4846-8af4-fcc543297a49" xlink:to="loc_gild_MYRGmbHMember_eac454d3-2e97-45cb-b0fb-8d7848b1ec0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9e2086b6-2cc9-489c-93ed-f6a7016293fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca73e69c-02cd-4c0b-aa36-6a232bdd8cb2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9e2086b6-2cc9-489c-93ed-f6a7016293fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9e2086b6-2cc9-489c-93ed-f6a7016293fe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9e2086b6-2cc9-489c-93ed-f6a7016293fe" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9e2086b6-2cc9-489c-93ed-f6a7016293fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca95dd8f-3678-4eca-95ba-eb7e586fc241" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9e2086b6-2cc9-489c-93ed-f6a7016293fe" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca95dd8f-3678-4eca-95ba-eb7e586fc241" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_591ac1fa-3943-44df-89f5-a6fdb1187184" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca95dd8f-3678-4eca-95ba-eb7e586fc241" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_591ac1fa-3943-44df-89f5-a6fdb1187184" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails" xlink:type="extended" id="idf8b2d613bb04b37813805d49ee571c2_FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6ef6200d-4d80-44d6-b5bf-d4dbb5f8343b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_fb68547b-8a7a-475d-9879-5ef15cb9d92c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6ef6200d-4d80-44d6-b5bf-d4dbb5f8343b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_fb68547b-8a7a-475d-9879-5ef15cb9d92c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8f7d3579-16e5-435c-9381-3387975de4c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6ef6200d-4d80-44d6-b5bf-d4dbb5f8343b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8f7d3579-16e5-435c-9381-3387975de4c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6841d6f3-8ebf-4c3b-acac-13ab59d52a2b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8f7d3579-16e5-435c-9381-3387975de4c3" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6841d6f3-8ebf-4c3b-acac-13ab59d52a2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6841d6f3-8ebf-4c3b-acac-13ab59d52a2b_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6841d6f3-8ebf-4c3b-acac-13ab59d52a2b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6841d6f3-8ebf-4c3b-acac-13ab59d52a2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_4e2cf3c2-95d4-460b-8c36-6ae9f1e29bab" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6841d6f3-8ebf-4c3b-acac-13ab59d52a2b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_4e2cf3c2-95d4-460b-8c36-6ae9f1e29bab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosNVMember_49c2509c-47a8-4d1a-b0f8-dc1c453579ad" xlink:href="gild-20210331.xsd#gild_GalapagosNVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_4e2cf3c2-95d4-460b-8c36-6ae9f1e29bab" xlink:to="loc_gild_GalapagosNVMember_49c2509c-47a8-4d1a-b0f8-dc1c453579ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e4b69943-bb22-4277-827c-de6d0321ea42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8f7d3579-16e5-435c-9381-3387975de4c3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e4b69943-bb22-4277-827c-de6d0321ea42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e4b69943-bb22-4277-827c-de6d0321ea42_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e4b69943-bb22-4277-827c-de6d0321ea42" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e4b69943-bb22-4277-827c-de6d0321ea42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3c8769b5-cb51-4b04-be14-6a91f44d63f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e4b69943-bb22-4277-827c-de6d0321ea42" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3c8769b5-cb51-4b04-be14-6a91f44d63f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_8bb8da3f-75e4-4032-b586-c831cc9a042d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3c8769b5-cb51-4b04-be14-6a91f44d63f0" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_8bb8da3f-75e4-4032-b586-c831cc9a042d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_06d23991-2542-441a-a1ab-483ab292cb03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3c8769b5-cb51-4b04-be14-6a91f44d63f0" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_06d23991-2542-441a-a1ab-483ab292cb03" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIES" xlink:type="simple" xlink:href="gild-20210331.xsd#AVAILABLEFORSALEDEBTSECURITIES"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIES" xlink:type="extended" id="idd8c57f57bfc40a8a7bd8ee81c327799_AVAILABLEFORSALEDEBTSECURITIES"/>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESTables" xlink:type="simple" xlink:href="gild-20210331.xsd#AVAILABLEFORSALEDEBTSECURITIESTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESTables" xlink:type="extended" id="i3deb1ef267f5481786d3845be15ee224_AVAILABLEFORSALEDEBTSECURITIESTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="extended" id="i1f7d98a9c6754f428289cfed0b13e13d_AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cca630a2-3824-49e1-90f0-c3d3aff710c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c08aff56-8b8f-4e31-9dd4-de6532c68ca5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cca630a2-3824-49e1-90f0-c3d3aff710c3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c08aff56-8b8f-4e31-9dd4-de6532c68ca5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_21720da2-718d-4b3f-baeb-ff2e92428bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cca630a2-3824-49e1-90f0-c3d3aff710c3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_21720da2-718d-4b3f-baeb-ff2e92428bd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7f5848b4-92dd-4dae-9a39-6a378ce8aac3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cca630a2-3824-49e1-90f0-c3d3aff710c3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7f5848b4-92dd-4dae-9a39-6a378ce8aac3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_153a3e9f-d9cf-4e1f-9cd8-3d5657be1f44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cca630a2-3824-49e1-90f0-c3d3aff710c3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_153a3e9f-d9cf-4e1f-9cd8-3d5657be1f44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_010e45af-f1d0-4885-93ca-1bb0ac52207f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cca630a2-3824-49e1-90f0-c3d3aff710c3" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_010e45af-f1d0-4885-93ca-1bb0ac52207f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_34d6917e-b810-4324-ae8a-4575580c0e01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_010e45af-f1d0-4885-93ca-1bb0ac52207f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_34d6917e-b810-4324-ae8a-4575580c0e01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_34d6917e-b810-4324-ae8a-4575580c0e01_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_34d6917e-b810-4324-ae8a-4575580c0e01" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_34d6917e-b810-4324-ae8a-4575580c0e01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10a59d90-3e75-40f3-b20a-638f448e033a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_34d6917e-b810-4324-ae8a-4575580c0e01" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10a59d90-3e75-40f3-b20a-638f448e033a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_311f1d74-0ddd-49fb-ba98-f8a4f4350dac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10a59d90-3e75-40f3-b20a-638f448e033a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_311f1d74-0ddd-49fb-ba98-f8a4f4350dac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_5306cfc3-2f2a-40b8-9e0e-9065e966e107" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10a59d90-3e75-40f3-b20a-638f448e033a" xlink:to="loc_us-gaap_CertificatesOfDepositMember_5306cfc3-2f2a-40b8-9e0e-9065e966e107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_8a9049c1-a66e-4273-9bcf-d0e117d649b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10a59d90-3e75-40f3-b20a-638f448e033a" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_8a9049c1-a66e-4273-9bcf-d0e117d649b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d762ad70-2abe-4c72-b490-02f666472dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10a59d90-3e75-40f3-b20a-638f448e033a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d762ad70-2abe-4c72-b490-02f666472dcd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_9fbd50d4-319f-47d7-835d-b2bb251287e8" xlink:href="gild-20210331.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10a59d90-3e75-40f3-b20a-638f448e033a" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_9fbd50d4-319f-47d7-835d-b2bb251287e8" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended" id="i372e8996860f43669d42e2929995c502_AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eff10df3-23b1-4a05-b196-d831ba98c4a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_132b3844-2cac-4c7b-ac4f-5ab95a9e5f9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eff10df3-23b1-4a05-b196-d831ba98c4a1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_132b3844-2cac-4c7b-ac4f-5ab95a9e5f9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_83aebf54-b4b3-4e8f-85ba-80023037cf93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eff10df3-23b1-4a05-b196-d831ba98c4a1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_83aebf54-b4b3-4e8f-85ba-80023037cf93" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7dd3258a-f01a-42eb-b762-1fd139172416" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_83aebf54-b4b3-4e8f-85ba-80023037cf93" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7dd3258a-f01a-42eb-b762-1fd139172416" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7dd3258a-f01a-42eb-b762-1fd139172416_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7dd3258a-f01a-42eb-b762-1fd139172416" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7dd3258a-f01a-42eb-b762-1fd139172416_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3c1d0bf8-417f-425a-8f9b-799233ce800c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7dd3258a-f01a-42eb-b762-1fd139172416" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3c1d0bf8-417f-425a-8f9b-799233ce800c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_277b45a4-2378-451c-8569-b86a9f1afc8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3c1d0bf8-417f-425a-8f9b-799233ce800c" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_277b45a4-2378-451c-8569-b86a9f1afc8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesCurrentMember_6095ef11-4681-46b7-8752-6df4f915a28b" xlink:href="gild-20210331.xsd#gild_MarketableSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3c1d0bf8-417f-425a-8f9b-799233ce800c" xlink:to="loc_gild_MarketableSecuritiesCurrentMember_6095ef11-4681-46b7-8752-6df4f915a28b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesNoncurrentMember_4667c518-67df-4e8d-ac02-6b99ae75ec1b" xlink:href="gild-20210331.xsd#gild_MarketableSecuritiesNoncurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3c1d0bf8-417f-425a-8f9b-799233ce800c" xlink:to="loc_gild_MarketableSecuritiesNoncurrentMember_4667c518-67df-4e8d-ac02-6b99ae75ec1b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails" xlink:type="extended" id="ife7c823135d64620903699418022116c_AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended" id="i061b84e6d1e6464597d29a48b3225e25_AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="gild-20210331.xsd#DERIVATIVEFINANCIALINSTRUMENTS"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS" xlink:type="extended" id="i1a688ac36b1544cbbb86c4958459ba2a_DERIVATIVEFINANCIALINSTRUMENTS"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="gild-20210331.xsd#DERIVATIVEFINANCIALINSTRUMENTSTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables" xlink:type="extended" id="iaf4f043f736d4f6a8c70ce60bfcded33_DERIVATIVEFINANCIALINSTRUMENTSTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails" xlink:type="extended" id="i2a93581fbe764e1aaaeae4ee9b32a5be_DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_d3929d1c-ed27-494f-bcf6-f2e603a8d286" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_f7d71973-70e1-43a5-b5db-d33f12ff53fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_d3929d1c-ed27-494f-bcf6-f2e603a8d286" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_f7d71973-70e1-43a5-b5db-d33f12ff53fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_ea1275d8-802c-446d-80bb-fdd0f2eea32a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_d3929d1c-ed27-494f-bcf6-f2e603a8d286" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_ea1275d8-802c-446d-80bb-fdd0f2eea32a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_12cf9d55-5bbe-4bd6-9b0f-0b359cd5b20c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_d3929d1c-ed27-494f-bcf6-f2e603a8d286" xlink:to="loc_us-gaap_DerivativeNotionalAmount_12cf9d55-5bbe-4bd6-9b0f-0b359cd5b20c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_481b1294-06b0-4f09-9272-4a0f31c2e0b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_d3929d1c-ed27-494f-bcf6-f2e603a8d286" xlink:to="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_481b1294-06b0-4f09-9272-4a0f31c2e0b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_9fc52806-e2eb-4386-96fc-b67cd5bf1ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_d3929d1c-ed27-494f-bcf6-f2e603a8d286" xlink:to="loc_us-gaap_DerivativeTable_9fc52806-e2eb-4386-96fc-b67cd5bf1ea4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8b805119-2c9e-4f92-9c5c-b31d4b5368bc" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_9fc52806-e2eb-4386-96fc-b67cd5bf1ea4" xlink:to="loc_srt_RangeAxis_8b805119-2c9e-4f92-9c5c-b31d4b5368bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8b805119-2c9e-4f92-9c5c-b31d4b5368bc_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8b805119-2c9e-4f92-9c5c-b31d4b5368bc" xlink:to="loc_srt_RangeMember_8b805119-2c9e-4f92-9c5c-b31d4b5368bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ada9a9db-0b60-49c5-89fc-c539abc3ac77" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8b805119-2c9e-4f92-9c5c-b31d4b5368bc" xlink:to="loc_srt_RangeMember_ada9a9db-0b60-49c5-89fc-c539abc3ac77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_649ddc93-f2d4-47bb-bc68-ef4e948da981" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ada9a9db-0b60-49c5-89fc-c539abc3ac77" xlink:to="loc_srt_MaximumMember_649ddc93-f2d4-47bb-bc68-ef4e948da981" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="extended" id="i55bf1e6eb6534e218c8cb0337fb0f3e5_DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_5ec226d1-d6d1-4a64-90ae-eba5d5eb22bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_324a374a-f14c-43b3-a63d-24579dda391d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_5ec226d1-d6d1-4a64-90ae-eba5d5eb22bd" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_324a374a-f14c-43b3-a63d-24579dda391d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_8eb6833a-1ca7-4375-b52d-d788da824cab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_5ec226d1-d6d1-4a64-90ae-eba5d5eb22bd" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_8eb6833a-1ca7-4375-b52d-d788da824cab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7dc58fdb-6c3a-4ba2-b4e0-bfafc57779bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_5ec226d1-d6d1-4a64-90ae-eba5d5eb22bd" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7dc58fdb-6c3a-4ba2-b4e0-bfafc57779bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_65c2343d-361a-4a3b-97b0-a0d4ce81d613" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7dc58fdb-6c3a-4ba2-b4e0-bfafc57779bf" xlink:to="loc_us-gaap_HedgingDesignationAxis_65c2343d-361a-4a3b-97b0-a0d4ce81d613" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_65c2343d-361a-4a3b-97b0-a0d4ce81d613_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_65c2343d-361a-4a3b-97b0-a0d4ce81d613" xlink:to="loc_us-gaap_HedgingDesignationDomain_65c2343d-361a-4a3b-97b0-a0d4ce81d613_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_522c9cae-88a8-4eb4-a3fb-42fbea9c7202" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_65c2343d-361a-4a3b-97b0-a0d4ce81d613" xlink:to="loc_us-gaap_HedgingDesignationDomain_522c9cae-88a8-4eb4-a3fb-42fbea9c7202" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_be08b9a5-7df9-4a16-bfba-169a5d62c871" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_522c9cae-88a8-4eb4-a3fb-42fbea9c7202" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_be08b9a5-7df9-4a16-bfba-169a5d62c871" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_1265e827-dbe1-4fe9-a26d-e63695088c1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_522c9cae-88a8-4eb4-a3fb-42fbea9c7202" xlink:to="loc_us-gaap_NondesignatedMember_1265e827-dbe1-4fe9-a26d-e63695088c1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ac0a8597-ee30-43aa-b633-474b76013737" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7dc58fdb-6c3a-4ba2-b4e0-bfafc57779bf" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ac0a8597-ee30-43aa-b633-474b76013737" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ac0a8597-ee30-43aa-b633-474b76013737_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ac0a8597-ee30-43aa-b633-474b76013737" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ac0a8597-ee30-43aa-b633-474b76013737_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c7193cbc-61d9-4d5c-8db5-862abd304986" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ac0a8597-ee30-43aa-b633-474b76013737" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c7193cbc-61d9-4d5c-8db5-862abd304986" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_0407c3db-b2de-4089-8eaa-34e2f83a001d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c7193cbc-61d9-4d5c-8db5-862abd304986" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_0407c3db-b2de-4089-8eaa-34e2f83a001d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_c0e33fd8-f202-474f-bc7e-c544fa9a7874" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c7193cbc-61d9-4d5c-8db5-862abd304986" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_c0e33fd8-f202-474f-bc7e-c544fa9a7874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_6c946424-d81e-4631-a090-e5d250c13a71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c7193cbc-61d9-4d5c-8db5-862abd304986" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_6c946424-d81e-4631-a090-e5d250c13a71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_bdd1b4e8-408a-4c7c-acad-448be5a6a521" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c7193cbc-61d9-4d5c-8db5-862abd304986" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_bdd1b4e8-408a-4c7c-acad-448be5a6a521" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails" xlink:type="extended" id="i3e23e424726b4357b0902b5abb85852f_DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="extended" id="i04f2d8f2a29b4bdb89564964ee4e05fd_DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONS" xlink:type="simple" xlink:href="gild-20210331.xsd#ACQUISITIONS"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/ACQUISITIONS" xlink:type="extended" id="i3ef5e032f5e54eadbd41062849089199_ACQUISITIONS"/>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONSTables" xlink:type="simple" xlink:href="gild-20210331.xsd#ACQUISITIONSTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/ACQUISITIONSTables" xlink:type="extended" id="i230bc82e4b8b4af4bccc284990ef40c4_ACQUISITIONSTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended" id="i31998c5581984bd78189d32893067d1b_ACQUISITIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_fb6a76d4-8a2a-4a0d-9e1c-7302e077fa10" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_fb6a76d4-8a2a-4a0d-9e1c-7302e077fa10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_60b6e235-d53f-46f1-b669-58a62afdbd87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_60b6e235-d53f-46f1-b669-58a62afdbd87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_54a379e8-9b42-4820-86e3-708ebdbbe188" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_54a379e8-9b42-4820-86e3-708ebdbbe188" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_bcd0bda7-b54f-41c6-99f1-0e2cb6d10061" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_bcd0bda7-b54f-41c6-99f1-0e2cb6d10061" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_6363cdeb-49c3-4700-8bf4-e435dfd3895a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_6363cdeb-49c3-4700-8bf4-e435dfd3895a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_a5e943e1-4995-45ee-a4c5-83d64a5805c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_a5e943e1-4995-45ee-a4c5-83d64a5805c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetMeasurementInput_25eb583d-71c9-4015-9493-65c794a5ebc7" xlink:href="gild-20210331.xsd#gild_IntangibleAssetMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_gild_IntangibleAssetMeasurementInput_25eb583d-71c9-4015-9493-65c794a5ebc7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_693149ef-0d1f-48df-979d-b861bfe15fc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_693149ef-0d1f-48df-979d-b861bfe15fc8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_ee22109f-2c29-4242-88a1-cb11e30a7f89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_ee22109f-2c29-4242-88a1-cb11e30a7f89" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_4dfa1d3f-bf9d-4018-87b5-3a9018afce49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_us-gaap_GoodwillGross_4dfa1d3f-bf9d-4018-87b5-3a9018afce49" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_c2505c89-455b-43ba-85a6-ecb89c5d6d05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_c2505c89-455b-43ba-85a6-ecb89c5d6d05" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_cfb6050a-e96a-47ee-ba73-e7aa16022a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_cfb6050a-e96a-47ee-ba73-e7aa16022a1c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_98711051-1e9c-4935-ae7d-9a3dd2cd409b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_98711051-1e9c-4935-ae7d-9a3dd2cd409b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_90ec6092-d146-4986-bcba-aa9b5f6d9584" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_98711051-1e9c-4935-ae7d-9a3dd2cd409b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_90ec6092-d146-4986-bcba-aa9b5f6d9584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_90ec6092-d146-4986-bcba-aa9b5f6d9584_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_90ec6092-d146-4986-bcba-aa9b5f6d9584" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_90ec6092-d146-4986-bcba-aa9b5f6d9584_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d02cfc7-750f-4405-9ef5-8cd8c3579021" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_90ec6092-d146-4986-bcba-aa9b5f6d9584" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d02cfc7-750f-4405-9ef5-8cd8c3579021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_cd08012d-7069-4051-892f-ca7093094f8f" xlink:href="gild-20210331.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d02cfc7-750f-4405-9ef5-8cd8c3579021" xlink:to="loc_gild_MYRGmbHMember_cd08012d-7069-4051-892f-ca7093094f8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_7ef6914c-38f8-4ef6-b112-3bebbd787f5a" xlink:href="gild-20210331.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d02cfc7-750f-4405-9ef5-8cd8c3579021" xlink:to="loc_gild_ImmunomedicsIncMember_7ef6914c-38f8-4ef6-b112-3bebbd787f5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_10e3edd1-af08-4a73-a713-cd9b596937e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_98711051-1e9c-4935-ae7d-9a3dd2cd409b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_10e3edd1-af08-4a73-a713-cd9b596937e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_10e3edd1-af08-4a73-a713-cd9b596937e6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_10e3edd1-af08-4a73-a713-cd9b596937e6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_10e3edd1-af08-4a73-a713-cd9b596937e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_95bc154a-eb8d-46cb-be72-514d6d62b178" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_10e3edd1-af08-4a73-a713-cd9b596937e6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_95bc154a-eb8d-46cb-be72-514d6d62b178" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_eb9d1513-0cda-449a-ab42-3db0c86f13bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_95bc154a-eb8d-46cb-be72-514d6d62b178" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_eb9d1513-0cda-449a-ab42-3db0c86f13bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e703f70b-6777-402b-9536-e1afd0dd502c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_98711051-1e9c-4935-ae7d-9a3dd2cd409b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e703f70b-6777-402b-9536-e1afd0dd502c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e703f70b-6777-402b-9536-e1afd0dd502c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e703f70b-6777-402b-9536-e1afd0dd502c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e703f70b-6777-402b-9536-e1afd0dd502c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c7290a32-e3f9-4459-84cf-9ab26b16e652" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e703f70b-6777-402b-9536-e1afd0dd502c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c7290a32-e3f9-4459-84cf-9ab26b16e652" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexForHDVMember_c537554b-667b-46cb-a779-5e8c02cb8e4d" xlink:href="gild-20210331.xsd#gild_HepcludexForHDVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c7290a32-e3f9-4459-84cf-9ab26b16e652" xlink:to="loc_gild_HepcludexForHDVMember_c537554b-667b-46cb-a779-5e8c02cb8e4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8a23e780-8739-4274-8d21-031f5d19009a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_98711051-1e9c-4935-ae7d-9a3dd2cd409b" xlink:to="loc_us-gaap_DebtInstrumentAxis_8a23e780-8739-4274-8d21-031f5d19009a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8a23e780-8739-4274-8d21-031f5d19009a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8a23e780-8739-4274-8d21-031f5d19009a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8a23e780-8739-4274-8d21-031f5d19009a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_422024b8-88df-4d26-ba6b-7606c7fc2165" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8a23e780-8739-4274-8d21-031f5d19009a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_422024b8-88df-4d26-ba6b-7606c7fc2165" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_3930b824-e4f9-4bbd-80b9-faeb78b28ff8" xlink:href="gild-20210331.xsd#gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_422024b8-88df-4d26-ba6b-7606c7fc2165" xlink:to="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_3930b824-e4f9-4bbd-80b9-faeb78b28ff8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_09b15254-d811-43c9-ade2-91748f35cca0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_98711051-1e9c-4935-ae7d-9a3dd2cd409b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_09b15254-d811-43c9-ade2-91748f35cca0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_09b15254-d811-43c9-ade2-91748f35cca0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_09b15254-d811-43c9-ade2-91748f35cca0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_09b15254-d811-43c9-ade2-91748f35cca0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_983f1c99-0ede-463e-9ea2-2c6058718ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_09b15254-d811-43c9-ade2-91748f35cca0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_983f1c99-0ede-463e-9ea2-2c6058718ea9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_d57f61d2-c2fa-402e-8593-4ff3da51f7e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_983f1c99-0ede-463e-9ea2-2c6058718ea9" xlink:to="loc_us-gaap_MediumTermNotesMember_d57f61d2-c2fa-402e-8593-4ff3da51f7e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_7ec3850a-dede-4f8a-863e-603dc4d47eb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_98711051-1e9c-4935-ae7d-9a3dd2cd409b" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_7ec3850a-dede-4f8a-863e-603dc4d47eb4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7ec3850a-dede-4f8a-863e-603dc4d47eb4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7ec3850a-dede-4f8a-863e-603dc4d47eb4" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7ec3850a-dede-4f8a-863e-603dc4d47eb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_95eeebfd-6d47-4189-9892-8cc8a315d46a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7ec3850a-dede-4f8a-863e-603dc4d47eb4" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_95eeebfd-6d47-4189-9892-8cc8a315d46a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_561d6caa-c774-4808-8ce2-ab55c1793d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_95eeebfd-6d47-4189-9892-8cc8a315d46a" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_561d6caa-c774-4808-8ce2-ab55c1793d5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_be3028a5-cb6c-485e-80b5-b79913fb64e2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_98711051-1e9c-4935-ae7d-9a3dd2cd409b" xlink:to="loc_srt_RangeAxis_be3028a5-cb6c-485e-80b5-b79913fb64e2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_be3028a5-cb6c-485e-80b5-b79913fb64e2_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_be3028a5-cb6c-485e-80b5-b79913fb64e2" xlink:to="loc_srt_RangeMember_be3028a5-cb6c-485e-80b5-b79913fb64e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4cc3d15a-90fa-4465-97cf-76831fc690a7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_be3028a5-cb6c-485e-80b5-b79913fb64e2" xlink:to="loc_srt_RangeMember_4cc3d15a-90fa-4465-97cf-76831fc690a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_808308ff-0ae3-4f79-a900-2254bee6fbf6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4cc3d15a-90fa-4465-97cf-76831fc690a7" xlink:to="loc_srt_MaximumMember_808308ff-0ae3-4f79-a900-2254bee6fbf6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="i38835635a5fc418ea3abd49714075adf_ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_01509134-7b73-41f3-a0bb-05f99ab85962" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_01509134-7b73-41f3-a0bb-05f99ab85962" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_ce128350-17f5-4eb4-8c04-8e88e3eba5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_ce128350-17f5-4eb4-8c04-8e88e3eba5ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_06edc8a0-249d-4b65-9905-1bd68636ba73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_06edc8a0-249d-4b65-9905-1bd68636ba73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_a6ef0e1a-4956-40e3-abc0-5d65757b64f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_a6ef0e1a-4956-40e3-abc0-5d65757b64f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_63aa4072-978e-44e2-8198-376c5ced62c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_63aa4072-978e-44e2-8198-376c5ced62c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_40caa884-2cdb-4a98-b2c3-2ff45fb53fd4" xlink:href="gild-20210331.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_40caa884-2cdb-4a98-b2c3-2ff45fb53fd4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_944a59ae-9f3d-4ca4-8587-94bf61164d3f" xlink:href="gild-20210331.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_944a59ae-9f3d-4ca4-8587-94bf61164d3f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8cb5efdc-6d3d-48b3-8a8d-744068de5ce9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8cb5efdc-6d3d-48b3-8a8d-744068de5ce9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_8d1037a7-49b7-4945-991a-7def5761f8ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:to="loc_us-gaap_GoodwillGross_8d1037a7-49b7-4945-991a-7def5761f8ba" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_b3580461-b7e5-4482-b0e0-e7f6865d15d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_b3580461-b7e5-4482-b0e0-e7f6865d15d0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_8ddf6812-554e-46f9-9f25-76ff88d8472a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_8ddf6812-554e-46f9-9f25-76ff88d8472a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6620d551-6b96-444a-b4a2-d9fff5261584" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_8ddf6812-554e-46f9-9f25-76ff88d8472a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6620d551-6b96-444a-b4a2-d9fff5261584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6620d551-6b96-444a-b4a2-d9fff5261584_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6620d551-6b96-444a-b4a2-d9fff5261584" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6620d551-6b96-444a-b4a2-d9fff5261584_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94fce756-724c-424d-a27d-83b9b631cbd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6620d551-6b96-444a-b4a2-d9fff5261584" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94fce756-724c-424d-a27d-83b9b631cbd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_97ca60e9-9216-4b69-9144-96a6cf952c38" xlink:href="gild-20210331.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94fce756-724c-424d-a27d-83b9b631cbd6" xlink:to="loc_gild_MYRGmbHMember_97ca60e9-9216-4b69-9144-96a6cf952c38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_866652e6-78f8-417e-ace7-ed1d39b9cc41" xlink:href="gild-20210331.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94fce756-724c-424d-a27d-83b9b631cbd6" xlink:to="loc_gild_ImmunomedicsIncMember_866652e6-78f8-417e-ace7-ed1d39b9cc41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70e8f066-60ac-41a0-b908-a6b103071af6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_8ddf6812-554e-46f9-9f25-76ff88d8472a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70e8f066-60ac-41a0-b908-a6b103071af6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_70e8f066-60ac-41a0-b908-a6b103071af6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70e8f066-60ac-41a0-b908-a6b103071af6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_70e8f066-60ac-41a0-b908-a6b103071af6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_814ec5e2-6dac-4d93-875c-9b70cbc4c331" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70e8f066-60ac-41a0-b908-a6b103071af6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_814ec5e2-6dac-4d93-875c-9b70cbc4c331" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyForMTNBCMember_b2dd6dbd-c27d-4e2b-9eb4-66d649639677" xlink:href="gild-20210331.xsd#gild_TrodelvyForMTNBCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_814ec5e2-6dac-4d93-875c-9b70cbc4c331" xlink:to="loc_gild_TrodelvyForMTNBCMember_b2dd6dbd-c27d-4e2b-9eb4-66d649639677" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_59938b74-8ee6-4347-af40-5c844e4e8b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_814ec5e2-6dac-4d93-875c-9b70cbc4c331" xlink:to="loc_us-gaap_LicensingAgreementsMember_59938b74-8ee6-4347-af40-5c844e4e8b7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_09bc5e37-a387-474d-82a5-3d0c0914e278" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_8ddf6812-554e-46f9-9f25-76ff88d8472a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_09bc5e37-a387-474d-82a5-3d0c0914e278" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_09bc5e37-a387-474d-82a5-3d0c0914e278_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_09bc5e37-a387-474d-82a5-3d0c0914e278" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_09bc5e37-a387-474d-82a5-3d0c0914e278_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a41c8f59-0ba4-42ee-8650-c09b09732630" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_09bc5e37-a387-474d-82a5-3d0c0914e278" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a41c8f59-0ba4-42ee-8650-c09b09732630" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_b19af511-1c37-4b50-a0b0-694d91e29d27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a41c8f59-0ba4-42ee-8650-c09b09732630" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_b19af511-1c37-4b50-a0b0-694d91e29d27" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS" xlink:type="simple" xlink:href="gild-20210331.xsd#GOODWILLANDINTANGIBLEASSETS"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS" xlink:type="extended" id="i62927e36939c4e9a9640adfe7a3246f3_GOODWILLANDINTANGIBLEASSETS"/>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables" xlink:type="simple" xlink:href="gild-20210331.xsd#GOODWILLANDINTANGIBLEASSETSTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables" xlink:type="extended" id="i7de5fcabfbb64f548de11de1a3ec27e3_GOODWILLANDINTANGIBLEASSETSTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#GOODWILLANDINTANGIBLEASSETSGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" xlink:type="extended" id="ic6e5e7305deb4e0b92087c0150c49d93_GOODWILLANDINTANGIBLEASSETSGoodwillDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="extended" id="ie5b8a3c399184c7eb1f7a7b541ac1232_GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16f01e38-8e88-4fe8-920a-98a893e25b14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4f1a3ed2-05d3-4e5f-80c1-f5e9dff563a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16f01e38-8e88-4fe8-920a-98a893e25b14" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4f1a3ed2-05d3-4e5f-80c1-f5e9dff563a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5c0577f2-31a9-428b-94cc-c55bd7fd8e77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16f01e38-8e88-4fe8-920a-98a893e25b14" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5c0577f2-31a9-428b-94cc-c55bd7fd8e77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_ecf25c37-60d3-49c5-acda-a0eed0419272" xlink:href="gild-20210331.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16f01e38-8e88-4fe8-920a-98a893e25b14" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_ecf25c37-60d3-49c5-acda-a0eed0419272" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_30a92b08-e190-4586-a705-16a3709e829a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16f01e38-8e88-4fe8-920a-98a893e25b14" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_30a92b08-e190-4586-a705-16a3709e829a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ac613651-d061-44d6-a585-c3bac2670ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16f01e38-8e88-4fe8-920a-98a893e25b14" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ac613651-d061-44d6-a585-c3bac2670ca6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e3df6af9-b10a-4fc2-9081-69e6fa140275" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ac613651-d061-44d6-a585-c3bac2670ca6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e3df6af9-b10a-4fc2-9081-69e6fa140275" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_dbfb39d7-8414-48ad-abda-c16f27eafba5" xlink:href="gild-20210331.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ac613651-d061-44d6-a585-c3bac2670ca6" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_dbfb39d7-8414-48ad-abda-c16f27eafba5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_ef323266-442d-4f77-9c3e-059fd58befa9" xlink:href="gild-20210331.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ac613651-d061-44d6-a585-c3bac2670ca6" xlink:to="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_ef323266-442d-4f77-9c3e-059fd58befa9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsGrossTransfers_37ebf3bc-7773-46a4-80d0-f31923832b73" xlink:href="gild-20210331.xsd#gild_FiniteLivedIntangibleAssetsGrossTransfers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16f01e38-8e88-4fe8-920a-98a893e25b14" xlink:to="loc_gild_FiniteLivedIntangibleAssetsGrossTransfers_37ebf3bc-7773-46a4-80d0-f31923832b73" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_7bab3ba7-8c7d-4a99-9e30-a672ee37c094" xlink:href="gild-20210331.xsd#gild_FiniteLivedIntangibleAssetsGrossReclassified"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16f01e38-8e88-4fe8-920a-98a893e25b14" xlink:to="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_7bab3ba7-8c7d-4a99-9e30-a672ee37c094" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1999862a-8a89-4a8d-a4ec-4e6d4b5d26e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16f01e38-8e88-4fe8-920a-98a893e25b14" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1999862a-8a89-4a8d-a4ec-4e6d4b5d26e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc1b02f2-47e9-44fa-b84e-a7f823947628" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1999862a-8a89-4a8d-a4ec-4e6d4b5d26e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc1b02f2-47e9-44fa-b84e-a7f823947628" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cc1b02f2-47e9-44fa-b84e-a7f823947628_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc1b02f2-47e9-44fa-b84e-a7f823947628" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cc1b02f2-47e9-44fa-b84e-a7f823947628_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fb399894-4593-4575-9edb-5e22d098b8ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc1b02f2-47e9-44fa-b84e-a7f823947628" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fb399894-4593-4575-9edb-5e22d098b8ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetSofosbuvirMember_6925e649-ac70-49c4-8b86-ea8a12789a2b" xlink:href="gild-20210331.xsd#gild_IntangibleAssetSofosbuvirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fb399894-4593-4575-9edb-5e22d098b8ba" xlink:to="loc_gild_IntangibleAssetSofosbuvirMember_6925e649-ac70-49c4-8b86-ea8a12789a2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AxicabtageneciloleucelDLBCLMember_8e7eda4a-57f8-45d7-a63f-e0c74e7e9952" xlink:href="gild-20210331.xsd#gild_AxicabtageneciloleucelDLBCLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fb399894-4593-4575-9edb-5e22d098b8ba" xlink:to="loc_gild_AxicabtageneciloleucelDLBCLMember_8e7eda4a-57f8-45d7-a63f-e0c74e7e9952" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyForMTNBCMember_24fa5e33-1235-4b17-9282-a9533084e620" xlink:href="gild-20210331.xsd#gild_TrodelvyForMTNBCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fb399894-4593-4575-9edb-5e22d098b8ba" xlink:to="loc_gild_TrodelvyForMTNBCMember_24fa5e33-1235-4b17-9282-a9533084e620" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexForHDVMember_d15acc76-a8b5-45f5-883c-b1d13640feda" xlink:href="gild-20210331.xsd#gild_HepcludexForHDVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fb399894-4593-4575-9edb-5e22d098b8ba" xlink:to="loc_gild_HepcludexForHDVMember_d15acc76-a8b5-45f5-883c-b1d13640feda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_e2cf6529-a72d-4950-afb9-e91631aa2759" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fb399894-4593-4575-9edb-5e22d098b8ba" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_e2cf6529-a72d-4950-afb9-e91631aa2759" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_5f020639-10c8-4546-96ce-752068430558" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1999862a-8a89-4a8d-a4ec-4e6d4b5d26e7" xlink:to="loc_srt_StatementScenarioAxis_5f020639-10c8-4546-96ce-752068430558" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_5f020639-10c8-4546-96ce-752068430558_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_5f020639-10c8-4546-96ce-752068430558" xlink:to="loc_srt_ScenarioUnspecifiedDomain_5f020639-10c8-4546-96ce-752068430558_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4eff968a-5cfa-45ae-b2f4-5a32b62220a6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_5f020639-10c8-4546-96ce-752068430558" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4eff968a-5cfa-45ae-b2f4-5a32b62220a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_e4d49d6a-b74e-41ce-b034-8f1599638f3c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_4eff968a-5cfa-45ae-b2f4-5a32b62220a6" xlink:to="loc_srt_ScenarioForecastMember_e4d49d6a-b74e-41ce-b034-8f1599638f3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_80cba838-f1bd-4ed3-9c80-deaa6cc29e09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1999862a-8a89-4a8d-a4ec-4e6d4b5d26e7" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_80cba838-f1bd-4ed3-9c80-deaa6cc29e09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_80cba838-f1bd-4ed3-9c80-deaa6cc29e09_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_80cba838-f1bd-4ed3-9c80-deaa6cc29e09" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_80cba838-f1bd-4ed3-9c80-deaa6cc29e09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_710cefa5-5bca-4285-9f0a-1b2626f4d0d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_80cba838-f1bd-4ed3-9c80-deaa6cc29e09" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_710cefa5-5bca-4285-9f0a-1b2626f4d0d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_128ace1b-0f6d-4b51-a250-2f850524155b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_710cefa5-5bca-4285-9f0a-1b2626f4d0d6" xlink:to="loc_us-gaap_SubsequentEventMember_128ace1b-0f6d-4b51-a250-2f850524155b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_88dfd5d4-51dc-4d6f-a3a0-827f9bc6e24f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1999862a-8a89-4a8d-a4ec-4e6d4b5d26e7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_88dfd5d4-51dc-4d6f-a3a0-827f9bc6e24f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_88dfd5d4-51dc-4d6f-a3a0-827f9bc6e24f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_88dfd5d4-51dc-4d6f-a3a0-827f9bc6e24f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_88dfd5d4-51dc-4d6f-a3a0-827f9bc6e24f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0cce5c31-9f7a-4799-8de8-c70b87c5a891" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_88dfd5d4-51dc-4d6f-a3a0-827f9bc6e24f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0cce5c31-9f7a-4799-8de8-c70b87c5a891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_c255612a-8a90-4e94-bc97-6406fed516a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0cce5c31-9f7a-4799-8de8-c70b87c5a891" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_c255612a-8a90-4e94-bc97-6406fed516a7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails" xlink:type="extended" id="iad49ff747d984bcd8e5eceb7a7ca26a2_GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails" xlink:type="extended" id="ib3e5894c6f97404d816ca91c12ffee2d_GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATION" xlink:type="simple" xlink:href="gild-20210331.xsd#OTHERFINANCIALINFORMATION"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATION" xlink:type="extended" id="i718c1ceee5fa41fba42836cfd7b90af9_OTHERFINANCIALINFORMATION"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables" xlink:type="simple" xlink:href="gild-20210331.xsd#OTHERFINANCIALINFORMATIONTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables" xlink:type="extended" id="i9e48d0e6727a40cf809949b50c50b27a_OTHERFINANCIALINFORMATIONTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails" xlink:type="extended" id="id9869e318ad243859651324148499c3f_OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#OTHERFINANCIALINFORMATIONInventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails" xlink:type="extended" id="i6db19429309f4f68b5e696d9177a7db9_OTHERFINANCIALINFORMATIONInventoriesDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails" xlink:type="extended" id="i0014b14b98a24793a0296797e82f6632_OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTS" xlink:type="simple" xlink:href="gild-20210331.xsd#COLLABORATIONSANDOTHERARRANGEMENTS"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTS" xlink:type="extended" id="ibd1779d7dda142a6bdfdbd98798a1070_COLLABORATIONSANDOTHERARRANGEMENTS"/>
  <link:roleRef roleURI="http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#COLLABORATIONSANDOTHERARRANGEMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails" xlink:type="extended" id="i1006e8329e4e4367bdabab06702068bd_COLLABORATIONSANDOTHERARRANGEMENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_f908eab5-81fc-4430-bace-50cd3ed538fc" xlink:href="gild-20210331.xsd#gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_f908eab5-81fc-4430-bace-50cd3ed538fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementNetProductSalesThreshold_6b368cfe-484d-42af-b9cd-8c520186da2d" xlink:href="gild-20210331.xsd#gild_CollaborationArrangementNetProductSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_CollaborationArrangementNetProductSalesThreshold_6b368cfe-484d-42af-b9cd-8c520186da2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues_079facb0-1234-4e18-9816-bb9aa44c3dae" xlink:href="gild-20210331.xsd#gild_CollaborationArrangementPercentOfGlobalProductRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues_079facb0-1234-4e18-9816-bb9aa44c3dae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_a46fff4d-130d-41fd-80b0-8becac1ecfa5" xlink:href="gild-20210331.xsd#gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_a46fff4d-130d-41fd-80b0-8becac1ecfa5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNISharesAcquired_ae3be076-8b92-43ab-b808-fb1abf9327ab" xlink:href="gild-20210331.xsd#gild_EquitySecuritiesFVNISharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_EquitySecuritiesFVNISharesAcquired_ae3be076-8b92-43ab-b808-fb1abf9327ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToAcquireEquitySecuritiesFVNI_49105777-1707-473d-8ce5-7f1c151347a4" xlink:href="gild-20210331.xsd#gild_PaymentsToAcquireEquitySecuritiesFVNI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_PaymentsToAcquireEquitySecuritiesFVNI_49105777-1707-473d-8ce5-7f1c151347a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIShares_de13c8b2-2d47-4aef-9e8b-57c3b7527bb6" xlink:href="gild-20210331.xsd#gild_EquitySecuritiesFVNIShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_EquitySecuritiesFVNIShares_de13c8b2-2d47-4aef-9e8b-57c3b7527bb6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_e759de60-a524-4ef5-8e0e-a50220eff0af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_e759de60-a524-4ef5-8e0e-a50220eff0af" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIPurchasePeriod_79e5bb4b-5757-4274-9704-eca63af0fe9e" xlink:href="gild-20210331.xsd#gild_EquitySecuritiesFVNIPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_EquitySecuritiesFVNIPurchasePeriod_79e5bb4b-5757-4274-9704-eca63af0fe9e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_94b0874c-650a-49b1-a7ed-dd861e3ae9b0" xlink:href="gild-20210331.xsd#gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_94b0874c-650a-49b1-a7ed-dd861e3ae9b0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIRestrictionPeriod_05b46c51-9357-469d-a3b9-73fe201dc214" xlink:href="gild-20210331.xsd#gild_EquitySecuritiesFVNIRestrictionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_EquitySecuritiesFVNIRestrictionPeriod_05b46c51-9357-469d-a3b9-73fe201dc214" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements_34b92d14-bd7a-460d-b499-2fd4255dbe9e" xlink:href="gild-20210331.xsd#gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements_34b92d14-bd7a-460d-b499-2fd4255dbe9e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CashPaymentsMadeRelatedToEquityInvestments_e4e0a9c7-3e06-481c-9246-d88642e6cc4e" xlink:href="gild-20210331.xsd#gild_CashPaymentsMadeRelatedToEquityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_CashPaymentsMadeRelatedToEquityInvestments_e4e0a9c7-3e06-481c-9246-d88642e6cc4e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3019a84e-7363-4893-bac8-4d7112c1ad11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3019a84e-7363-4893-bac8-4d7112c1ad11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3650823a-4df3-40ad-9437-83b90e06a2f6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3019a84e-7363-4893-bac8-4d7112c1ad11" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3650823a-4df3-40ad-9437-83b90e06a2f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3650823a-4df3-40ad-9437-83b90e06a2f6_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3650823a-4df3-40ad-9437-83b90e06a2f6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3650823a-4df3-40ad-9437-83b90e06a2f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_527b59e9-a38c-4304-840a-db1c7340558c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3650823a-4df3-40ad-9437-83b90e06a2f6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_527b59e9-a38c-4304-840a-db1c7340558c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_0f1bc52c-42d3-4b0e-b3eb-188c0eea3857" xlink:href="gild-20210331.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_527b59e9-a38c-4304-840a-db1c7340558c" xlink:to="loc_gild_ArcusBiosciencesIncMember_0f1bc52c-42d3-4b0e-b3eb-188c0eea3857" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bf6bf816-338a-4087-9b33-9df50f461137" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3019a84e-7363-4893-bac8-4d7112c1ad11" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bf6bf816-338a-4087-9b33-9df50f461137" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bf6bf816-338a-4087-9b33-9df50f461137_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bf6bf816-338a-4087-9b33-9df50f461137" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bf6bf816-338a-4087-9b33-9df50f461137_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b5dd41c2-6e1c-49d6-85f7-6c1c6a35898d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bf6bf816-338a-4087-9b33-9df50f461137" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b5dd41c2-6e1c-49d6-85f7-6c1c6a35898d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_06bea4ca-9b9d-478a-b6b4-947eb28c7dc3" xlink:href="gild-20210331.xsd#gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b5dd41c2-6e1c-49d6-85f7-6c1c6a35898d" xlink:to="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_06bea4ca-9b9d-478a-b6b4-947eb28c7dc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusStockPurchaseAgreementMember_91f1caf1-595c-4b36-917e-8912205a175b" xlink:href="gild-20210331.xsd#gild_ArcusStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b5dd41c2-6e1c-49d6-85f7-6c1c6a35898d" xlink:to="loc_gild_ArcusStockPurchaseAgreementMember_91f1caf1-595c-4b36-917e-8912205a175b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherCollaborationArrangementsMember_8cec2ec8-4d87-4356-b9b9-5d3d76f8ad23" xlink:href="gild-20210331.xsd#gild_OtherCollaborationArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b5dd41c2-6e1c-49d6-85f7-6c1c6a35898d" xlink:to="loc_gild_OtherCollaborationArrangementsMember_8cec2ec8-4d87-4356-b9b9-5d3d76f8ad23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember_3348faea-4f63-4b58-aaa6-2eb7f76d7dab" xlink:href="gild-20210331.xsd#gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b5dd41c2-6e1c-49d6-85f7-6c1c6a35898d" xlink:to="loc_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember_3348faea-4f63-4b58-aaa6-2eb7f76d7dab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_060fa409-6a71-4020-9caf-9accccf05f27" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3019a84e-7363-4893-bac8-4d7112c1ad11" xlink:to="loc_srt_OwnershipAxis_060fa409-6a71-4020-9caf-9accccf05f27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_060fa409-6a71-4020-9caf-9accccf05f27_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_060fa409-6a71-4020-9caf-9accccf05f27" xlink:to="loc_srt_OwnershipDomain_060fa409-6a71-4020-9caf-9accccf05f27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_ee1850d4-4d67-4f19-900c-178e5db8445f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_060fa409-6a71-4020-9caf-9accccf05f27" xlink:to="loc_srt_OwnershipDomain_ee1850d4-4d67-4f19-900c-178e5db8445f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_18a17d17-9042-4f2a-81ad-4d07bbdeb538" xlink:href="gild-20210331.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_ee1850d4-4d67-4f19-900c-178e5db8445f" xlink:to="loc_gild_ArcusBiosciencesIncMember_18a17d17-9042-4f2a-81ad-4d07bbdeb538" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5e1c8d5a-1ff0-4a97-9c61-5c11ac3e4fdf" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3019a84e-7363-4893-bac8-4d7112c1ad11" xlink:to="loc_srt_ProductOrServiceAxis_5e1c8d5a-1ff0-4a97-9c61-5c11ac3e4fdf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5e1c8d5a-1ff0-4a97-9c61-5c11ac3e4fdf_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5e1c8d5a-1ff0-4a97-9c61-5c11ac3e4fdf" xlink:to="loc_srt_ProductsAndServicesDomain_5e1c8d5a-1ff0-4a97-9c61-5c11ac3e4fdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3b74e9ae-cefb-4820-bce6-7d749884385f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5e1c8d5a-1ff0-4a97-9c61-5c11ac3e4fdf" xlink:to="loc_srt_ProductsAndServicesDomain_3b74e9ae-cefb-4820-bce6-7d749884385f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OralFormulationProductMember_76f03715-f82b-4431-aded-dbcfe5dc8b63" xlink:href="gild-20210331.xsd#gild_OralFormulationProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3b74e9ae-cefb-4820-bce6-7d749884385f" xlink:to="loc_gild_OralFormulationProductMember_76f03715-f82b-4431-aded-dbcfe5dc8b63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InjectableFormulationProductMember_faa26d03-5e2a-496f-b3da-ae612badbdfc" xlink:href="gild-20210331.xsd#gild_InjectableFormulationProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3b74e9ae-cefb-4820-bce6-7d749884385f" xlink:to="loc_gild_InjectableFormulationProductMember_faa26d03-5e2a-496f-b3da-ae612badbdfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2f539ae8-2fc2-4e5e-97c8-4449a6f512d3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3019a84e-7363-4893-bac8-4d7112c1ad11" xlink:to="loc_dei_LegalEntityAxis_2f539ae8-2fc2-4e5e-97c8-4449a6f512d3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2f539ae8-2fc2-4e5e-97c8-4449a6f512d3_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2f539ae8-2fc2-4e5e-97c8-4449a6f512d3" xlink:to="loc_dei_EntityDomain_2f539ae8-2fc2-4e5e-97c8-4449a6f512d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e0185278-f489-4274-a2a7-082e331432c2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2f539ae8-2fc2-4e5e-97c8-4449a6f512d3" xlink:to="loc_dei_EntityDomain_e0185278-f489-4274-a2a7-082e331432c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckMember_219a7ce9-610b-4a92-ba84-fb32fa80fa9d" xlink:href="gild-20210331.xsd#gild_MerckMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e0185278-f489-4274-a2a7-082e331432c2" xlink:to="loc_gild_MerckMember_219a7ce9-610b-4a92-ba84-fb32fa80fa9d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIES" xlink:type="simple" xlink:href="gild-20210331.xsd#DEBTANDCREDITFACILITIES"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIES" xlink:type="extended" id="i6a1f743f2ea041868130a40a5ce4d8d3_DEBTANDCREDITFACILITIES"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables" xlink:type="simple" xlink:href="gild-20210331.xsd#DEBTANDCREDITFACILITIESTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables" xlink:type="extended" id="i906e45891abf4653bd43c41b313e4cca_DEBTANDCREDITFACILITIESTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="extended" id="i45abf235b9a946efa8be64614f5a17e2_DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ba4c9052-b6c8-4229-8820-39fed3d18d1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dad9ce2c-c6ab-4fff-b391-c3bb72cb95f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba4c9052-b6c8-4229-8820-39fed3d18d1b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dad9ce2c-c6ab-4fff-b391-c3bb72cb95f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8b3dfc7c-df9e-4267-9a34-819d76b2f50b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba4c9052-b6c8-4229-8820-39fed3d18d1b" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8b3dfc7c-df9e-4267-9a34-819d76b2f50b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2993aca3-effc-4ff2-b022-184c13531e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba4c9052-b6c8-4229-8820-39fed3d18d1b" xlink:to="loc_us-gaap_LongTermDebt_2993aca3-effc-4ff2-b022-184c13531e5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_0f52e380-6df2-4358-9250-6d0d68cc0a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba4c9052-b6c8-4229-8820-39fed3d18d1b" xlink:to="loc_us-gaap_LongTermDebtCurrent_0f52e380-6df2-4358-9250-6d0d68cc0a4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_b85e48a3-b57f-446b-a8f6-02b77c937365" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba4c9052-b6c8-4229-8820-39fed3d18d1b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_b85e48a3-b57f-446b-a8f6-02b77c937365" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9a0e35c6-3648-4b71-9d21-3e99dc3864d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba4c9052-b6c8-4229-8820-39fed3d18d1b" xlink:to="loc_us-gaap_DebtInstrumentTable_9a0e35c6-3648-4b71-9d21-3e99dc3864d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_adcf7acd-5368-4522-8f10-0772e003feac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9a0e35c6-3648-4b71-9d21-3e99dc3864d8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_adcf7acd-5368-4522-8f10-0772e003feac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_adcf7acd-5368-4522-8f10-0772e003feac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_adcf7acd-5368-4522-8f10-0772e003feac" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_adcf7acd-5368-4522-8f10-0772e003feac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4ba0b438-08b8-4751-8a9e-af606b4e1dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_adcf7acd-5368-4522-8f10-0772e003feac" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4ba0b438-08b8-4751-8a9e-af606b4e1dc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorNotesAndMediumTermNotesMember_d4d1e84c-2d0d-4588-95a9-e7bff4c4e000" xlink:href="gild-20210331.xsd#gild_SeniorNotesAndMediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4ba0b438-08b8-4751-8a9e-af606b4e1dc6" xlink:to="loc_gild_SeniorNotesAndMediumTermNotesMember_d4d1e84c-2d0d-4588-95a9-e7bff4c4e000" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_4c9ae84e-1840-49ce-8136-0b16a89c58e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SeniorNotesAndMediumTermNotesMember_d4d1e84c-2d0d-4588-95a9-e7bff4c4e000" xlink:to="loc_us-gaap_SeniorNotesMember_4c9ae84e-1840-49ce-8136-0b16a89c58e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_420bfdc8-3348-4f6a-8e91-bdd47cc39c34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SeniorNotesAndMediumTermNotesMember_d4d1e84c-2d0d-4588-95a9-e7bff4c4e000" xlink:to="loc_us-gaap_MediumTermNotesMember_420bfdc8-3348-4f6a-8e91-bdd47cc39c34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_109040f3-32aa-4a71-9c8e-05e791fee16f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4ba0b438-08b8-4751-8a9e-af606b4e1dc6" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_109040f3-32aa-4a71-9c8e-05e791fee16f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2fede147-bbb3-4bbc-affd-7cbf462ed534" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9a0e35c6-3648-4b71-9d21-3e99dc3864d8" xlink:to="loc_us-gaap_DebtInstrumentAxis_2fede147-bbb3-4bbc-affd-7cbf462ed534" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2fede147-bbb3-4bbc-affd-7cbf462ed534_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2fede147-bbb3-4bbc-affd-7cbf462ed534" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2fede147-bbb3-4bbc-affd-7cbf462ed534_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2fede147-bbb3-4bbc-affd-7cbf462ed534" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A450SeniorUnsecuredNotesDueApril2021Member_bd0f0824-3b3c-4242-902e-b83b6b45b223" xlink:href="gild-20210331.xsd#gild_A450SeniorUnsecuredNotesDueApril2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A450SeniorUnsecuredNotesDueApril2021Member_bd0f0824-3b3c-4242-902e-b83b6b45b223" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_790f06b6-4df6-4d0b-8fbc-18f4e795ce99" xlink:href="gild-20210331.xsd#gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_790f06b6-4df6-4d0b-8fbc-18f4e795ce99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A440SeniorUnsecuredNotesDueDecember2021Member_d9e0c9c5-5818-40c2-b08e-fc3fe427ff99" xlink:href="gild-20210331.xsd#gild_A440SeniorUnsecuredNotesDueDecember2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A440SeniorUnsecuredNotesDueDecember2021Member_d9e0c9c5-5818-40c2-b08e-fc3fe427ff99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member_dfcae2ff-3cc1-44c6-b8d8-1c5bef989a4b" xlink:href="gild-20210331.xsd#gild_A195SeniorUnsecuredNotesDueMarch2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member_dfcae2ff-3cc1-44c6-b8d8-1c5bef989a4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_bcae7cd5-bf57-4080-8982-8a428c4eb556" xlink:href="gild-20210331.xsd#gild_A325SeniorUnsecuredNotesDueSeptember2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_bcae7cd5-bf57-4080-8982-8a428c4eb556" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_2dadd508-22a0-4201-a5cb-0dc76bc012a2" xlink:href="gild-20210331.xsd#gild_A250SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_2dadd508-22a0-4201-a5cb-0dc76bc012a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_c9ccc141-fad0-485e-965e-812fa74fe874" xlink:href="gild-20210331.xsd#gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_c9ccc141-fad0-485e-965e-812fa74fe874" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_6f4a3828-5811-40a2-a2db-3183e62105a8" xlink:href="gild-20210331.xsd#gild_A075SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_6f4a3828-5811-40a2-a2db-3183e62105a8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VariableTermLoanNoteDueOctober2023Member_06a93292-f180-4515-86f0-b2c20d110532" xlink:href="gild-20210331.xsd#gild_VariableTermLoanNoteDueOctober2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_VariableTermLoanNoteDueOctober2023Member_06a93292-f180-4515-86f0-b2c20d110532" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member_c15c80d7-e175-41c2-a357-999ea2795bbb" xlink:href="gild-20210331.xsd#gild_A370SeniorUnsecuredNotesDueApril2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member_c15c80d7-e175-41c2-a357-999ea2795bbb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_e75e9a83-3372-4d5c-85de-801125a0d667" xlink:href="gild-20210331.xsd#gild_A350SeniorUnsecuredNotesDueFebruary2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_e75e9a83-3372-4d5c-85de-801125a0d667" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member_a8ddf955-d3fe-436b-9cdd-d6aa849c2327" xlink:href="gild-20210331.xsd#gild_A365SeniorUnsecuredNotesDueMarch2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member_a8ddf955-d3fe-436b-9cdd-d6aa849c2327" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member_4e0609e3-c805-493c-bdb1-fe4a7e6c9c96" xlink:href="gild-20210331.xsd#gild_A295SeniorUnsecuredNotesDueMarch2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member_4e0609e3-c805-493c-bdb1-fe4a7e6c9c96" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_7260a8ef-14b6-45bc-9580-d68ee93f4634" xlink:href="gild-20210331.xsd#gild_A120SeniorUnsecuredNotesDueOctober2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_7260a8ef-14b6-45bc-9580-d68ee93f4634" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_e018e1b5-1ef9-47be-ad95-91910dc26ba8" xlink:href="gild-20210331.xsd#gild_A165SeniorUnsecuredNotesDueOctober2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_e018e1b5-1ef9-47be-ad95-91910dc26ba8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_329dc728-1a15-436a-be63-e427caa75d13" xlink:href="gild-20210331.xsd#gild_A460SeniorUnsecuredNotesDueSeptember2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_329dc728-1a15-436a-be63-e427caa75d13" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_fbe0fb42-abcc-42c0-be14-b8e3163c17aa" xlink:href="gild-20210331.xsd#gild_A400SeniorUnsecuredNotesDueSeptember2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_fbe0fb42-abcc-42c0-be14-b8e3163c17aa" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_e7eafb86-733c-4aa7-95ce-96cdb4e4b3d0" xlink:href="gild-20210331.xsd#gild_A260SeniorUnsecuredNotesDueOctober2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_e7eafb86-733c-4aa7-95ce-96cdb4e4b3d0" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member_9d343024-3d95-4491-9a77-e888ddde3e9f" xlink:href="gild-20210331.xsd#gild_A565SeniorUnsecuredNotesDueDecember2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member_9d343024-3d95-4491-9a77-e888ddde3e9f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member_99756489-465b-4216-866c-dc3909a65696" xlink:href="gild-20210331.xsd#gild_A480SeniorUnsecuredNotesDueApril2044Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member_99756489-465b-4216-866c-dc3909a65696" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_5da4d77c-1f23-4f78-a424-555cdf63e3a7" xlink:href="gild-20210331.xsd#gild_A450SeniorUnsecuredNotesDueFebruary2045Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_5da4d77c-1f23-4f78-a424-555cdf63e3a7" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member_ba5e4c8f-b49d-4842-b2a5-cde4c86345b2" xlink:href="gild-20210331.xsd#gild_A475SeniorUnsecuredNotesDueMarch2046Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member_ba5e4c8f-b49d-4842-b2a5-cde4c86345b2" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member_15206402-b632-4199-80da-5e34ab3f663b" xlink:href="gild-20210331.xsd#gild_A415SeniorUnsecuredNotesDueMarch2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member_15206402-b632-4199-80da-5e34ab3f663b" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_312d5952-b924-4867-b17e-14961fef84dd" xlink:href="gild-20210331.xsd#gild_A280SeniorUnsecuredNotesDueOctober2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_312d5952-b924-4867-b17e-14961fef84dd" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_9368ef66-f264-478b-93dd-35c11b84668f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9a0e35c6-3648-4b71-9d21-3e99dc3864d8" xlink:to="loc_us-gaap_VariableRateAxis_9368ef66-f264-478b-93dd-35c11b84668f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_9368ef66-f264-478b-93dd-35c11b84668f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_9368ef66-f264-478b-93dd-35c11b84668f" xlink:to="loc_us-gaap_VariableRateDomain_9368ef66-f264-478b-93dd-35c11b84668f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_c0c40524-0300-4767-bc43-8d3e710dfa65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_9368ef66-f264-478b-93dd-35c11b84668f" xlink:to="loc_us-gaap_VariableRateDomain_c0c40524-0300-4767-bc43-8d3e710dfa65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_6423b12b-d5ed-4122-b12c-81135ec35716" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_c0c40524-0300-4767-bc43-8d3e710dfa65" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_6423b12b-d5ed-4122-b12c-81135ec35716" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#DEBTANDCREDITFACILITIESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails" xlink:type="extended" id="i6b953bf73303402a9ec2dd5332603d33_DEBTANDCREDITFACILITIESAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_58d45c74-f3b5-4449-97ab-36a08b46f8ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_7fd07be8-1e40-4790-b0a9-4f8647a59398" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_58d45c74-f3b5-4449-97ab-36a08b46f8ad" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_7fd07be8-1e40-4790-b0a9-4f8647a59398" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfUnsecuredDebt_54fb2e40-72f4-406b-b4a4-564f9effcc39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_58d45c74-f3b5-4449-97ab-36a08b46f8ad" xlink:to="loc_us-gaap_RepaymentsOfUnsecuredDebt_54fb2e40-72f4-406b-b4a4-564f9effcc39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_33026302-774b-4c60-baba-d783174fc282" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_58d45c74-f3b5-4449-97ab-36a08b46f8ad" xlink:to="loc_us-gaap_DebtInstrumentTerm_33026302-774b-4c60-baba-d783174fc282" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_41b6e6d8-8cf9-41cd-a6dc-149a9061ebb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_58d45c74-f3b5-4449-97ab-36a08b46f8ad" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_41b6e6d8-8cf9-41cd-a6dc-149a9061ebb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_89a0a3db-0a57-40a4-9b93-2372ec8534a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_58d45c74-f3b5-4449-97ab-36a08b46f8ad" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_89a0a3db-0a57-40a4-9b93-2372ec8534a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_af1fb4ce-6ace-42c4-92fa-4dce53bfbe42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_58d45c74-f3b5-4449-97ab-36a08b46f8ad" xlink:to="loc_us-gaap_LineOfCredit_af1fb4ce-6ace-42c4-92fa-4dce53bfbe42" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_705ca7eb-4c47-441c-87f3-9b7070ee406d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_58d45c74-f3b5-4449-97ab-36a08b46f8ad" xlink:to="loc_us-gaap_DebtInstrumentTable_705ca7eb-4c47-441c-87f3-9b7070ee406d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_813e7320-bb04-427f-945a-7bd197317039" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_705ca7eb-4c47-441c-87f3-9b7070ee406d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_813e7320-bb04-427f-945a-7bd197317039" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_813e7320-bb04-427f-945a-7bd197317039_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_813e7320-bb04-427f-945a-7bd197317039" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_813e7320-bb04-427f-945a-7bd197317039_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_54fe2979-4223-4e84-a093-0e54d9caf80f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_813e7320-bb04-427f-945a-7bd197317039" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_54fe2979-4223-4e84-a093-0e54d9caf80f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_812de35f-2774-4b0d-9779-3190e566f704" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_54fe2979-4223-4e84-a093-0e54d9caf80f" xlink:to="loc_us-gaap_SeniorNotesMember_812de35f-2774-4b0d-9779-3190e566f704" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_2e42759a-c7fb-4184-a6e7-1b4c438979cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_54fe2979-4223-4e84-a093-0e54d9caf80f" xlink:to="loc_us-gaap_MediumTermNotesMember_2e42759a-c7fb-4184-a6e7-1b4c438979cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_dbe37445-0af7-4110-8daa-c7c498fbe4fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_705ca7eb-4c47-441c-87f3-9b7070ee406d" xlink:to="loc_us-gaap_CreditFacilityAxis_dbe37445-0af7-4110-8daa-c7c498fbe4fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_dbe37445-0af7-4110-8daa-c7c498fbe4fd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_dbe37445-0af7-4110-8daa-c7c498fbe4fd" xlink:to="loc_us-gaap_CreditFacilityDomain_dbe37445-0af7-4110-8daa-c7c498fbe4fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_6b699732-cb83-46d2-ae10-f5adf5bc4418" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_dbe37445-0af7-4110-8daa-c7c498fbe4fd" xlink:to="loc_us-gaap_CreditFacilityDomain_6b699732-cb83-46d2-ae10-f5adf5bc4418" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_61a0fc52-025e-4a6e-adf3-4f07ef927717" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_6b699732-cb83-46d2-ae10-f5adf5bc4418" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_61a0fc52-025e-4a6e-adf3-4f07ef927717" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3889e463-16d2-4436-b00f-a8d8807cc67d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_705ca7eb-4c47-441c-87f3-9b7070ee406d" xlink:to="loc_us-gaap_DebtInstrumentAxis_3889e463-16d2-4436-b00f-a8d8807cc67d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3889e463-16d2-4436-b00f-a8d8807cc67d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3889e463-16d2-4436-b00f-a8d8807cc67d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3889e463-16d2-4436-b00f-a8d8807cc67d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5a081ff7-a89e-4485-8036-4aac0aa83f23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3889e463-16d2-4436-b00f-a8d8807cc67d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5a081ff7-a89e-4485-8036-4aac0aa83f23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNoteIssuedNovember2014Member_121b1c6c-b223-4001-aff4-d0f0e1c3dd47" xlink:href="gild-20210331.xsd#gild_SeniorUnsecuredNoteIssuedNovember2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a081ff7-a89e-4485-8036-4aac0aa83f23" xlink:to="loc_gild_SeniorUnsecuredNoteIssuedNovember2014Member_121b1c6c-b223-4001-aff4-d0f0e1c3dd47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_b614a94d-8911-440e-85b5-5ccbda627425" xlink:href="gild-20210331.xsd#gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a081ff7-a89e-4485-8036-4aac0aa83f23" xlink:to="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_b614a94d-8911-440e-85b5-5ccbda627425" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueJune2025Member_cf1caacf-9152-4621-9a13-a04862c6906b" xlink:href="gild-20210331.xsd#gild_CreditFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a081ff7-a89e-4485-8036-4aac0aa83f23" xlink:to="loc_gild_CreditFacilityDueJune2025Member_cf1caacf-9152-4621-9a13-a04862c6906b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="gild-20210331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended" id="i1adc28937698423b934d7dfd579eb4e1_COMMITMENTSANDCONTINGENCIES"/>
  <link:roleRef roleURI="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended" id="i8f4c86eaaf474f3999b94f8f7bedbd61_COMMITMENTSANDCONTINGENCIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_fec63a83-969e-4fb2-aa11-ec2dc257aec1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_fec63a83-969e-4fb2-aa11-ec2dc257aec1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateFromOctober2017_cbbc19eb-0e6d-4202-a87e-dd261889ea0c" xlink:href="gild-20210331.xsd#gild_JudgmentRoyaltyRateFromOctober2017"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_gild_JudgmentRoyaltyRateFromOctober2017_cbbc19eb-0e6d-4202-a87e-dd261889ea0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentEnhancedDamagesOnPastSales_80042977-17c0-4daa-bf0a-5f1a8d998d70" xlink:href="gild-20210331.xsd#gild_JudgmentEnhancedDamagesOnPastSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_gild_JudgmentEnhancedDamagesOnPastSales_80042977-17c0-4daa-bf0a-5f1a8d998d70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateOnFutureSales_3e028e9b-16ed-42ab-8ce2-b01902a17f39" xlink:href="gild-20210331.xsd#gild_JudgmentRoyaltyRateOnFutureSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_gild_JudgmentRoyaltyRateOnFutureSales_3e028e9b-16ed-42ab-8ce2-b01902a17f39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_f08a5286-faa5-4556-bd9d-999fac1e8fa1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_f08a5286-faa5-4556-bd9d-999fac1e8fa1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyEstimateOfPossibleLossPastSales_437c0f7e-e2d0-46c4-b46f-7b861006b5b4" xlink:href="gild-20210331.xsd#gild_LossContingencyEstimateOfPossibleLossPastSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_gild_LossContingencyEstimateOfPossibleLossPastSales_437c0f7e-e2d0-46c4-b46f-7b861006b5b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages_dddfe224-49f4-413f-b10d-e9101e698e82" xlink:href="gild-20210331.xsd#gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages_dddfe224-49f4-413f-b10d-e9101e698e82" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyEstimateOfPossibleLossRoyalties_d72e5d23-d3d2-4a4c-9bb2-71df2279fd1b" xlink:href="gild-20210331.xsd#gild_LossContingencyEstimateOfPossibleLossRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_gild_LossContingencyEstimateOfPossibleLossRoyalties_d72e5d23-d3d2-4a4c-9bb2-71df2279fd1b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_cc0c6f9e-5242-4999-8b08-10d4e5595b84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_cc0c6f9e-5242-4999-8b08-10d4e5595b84" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyMaterialTransferAgreementsNumber_302cef26-697e-49cd-a4e7-5119191941a1" xlink:href="gild-20210331.xsd#gild_LossContingencyMaterialTransferAgreementsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_gild_LossContingencyMaterialTransferAgreementsNumber_302cef26-697e-49cd-a4e7-5119191941a1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_276fdf50-e387-436f-9471-3f162fe2dff7" xlink:href="gild-20210331.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_276fdf50-e387-436f-9471-3f162fe2dff7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_adadcdfa-f353-4974-86ed-936ac9fd090c" xlink:href="gild-20210331.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_adadcdfa-f353-4974-86ed-936ac9fd090c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_15c2d0cf-f2af-4125-9500-59bf2f08551b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_15c2d0cf-f2af-4125-9500-59bf2f08551b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesAppealedNumber_4e89c0a9-81f8-4586-ac3a-922288d692e0" xlink:href="gild-20210331.xsd#gild_LossContingencyPartiesAppealedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_gild_LossContingencyPartiesAppealedNumber_4e89c0a9-81f8-4586-ac3a-922288d692e0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesFilingOppositionNumber_456a77d6-ee52-46f4-94f4-81cf579f247f" xlink:href="gild-20210331.xsd#gild_LossContingencyPartiesFilingOppositionNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_gild_LossContingencyPartiesFilingOppositionNumber_456a77d6-ee52-46f4-94f4-81cf579f247f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_198aefbe-fb44-464c-b1b7-39ba995e5f70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_198aefbe-fb44-464c-b1b7-39ba995e5f70" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_1e924627-ceef-444b-aec0-f2f8577ee2b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_us-gaap_LossContingenciesTable_1e924627-ceef-444b-aec0-f2f8577ee2b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_816cb813-c9dc-48a0-bedf-5a605b89256a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1e924627-ceef-444b-aec0-f2f8577ee2b1" xlink:to="loc_srt_LitigationCaseAxis_816cb813-c9dc-48a0-bedf-5a605b89256a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_816cb813-c9dc-48a0-bedf-5a605b89256a_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_816cb813-c9dc-48a0-bedf-5a605b89256a" xlink:to="loc_srt_LitigationCaseTypeDomain_816cb813-c9dc-48a0-bedf-5a605b89256a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9b53222a-de77-4344-a5f7-4c285b21f23c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_816cb813-c9dc-48a0-bedf-5a605b89256a" xlink:to="loc_srt_LitigationCaseTypeDomain_9b53222a-de77-4344-a5f7-4c285b21f23c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_a58976ca-7bfe-4a20-a610-9bf46fe78f20" xlink:href="gild-20210331.xsd#gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_9b53222a-de77-4344-a5f7-4c285b21f23c" xlink:to="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_a58976ca-7bfe-4a20-a610-9bf46fe78f20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ViiVHealthcareCompanyMember_3e4e6fb5-29cf-4048-a2bf-22a10e0eb87b" xlink:href="gild-20210331.xsd#gild_ViiVHealthcareCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_9b53222a-de77-4344-a5f7-4c285b21f23c" xlink:to="loc_gild_ViiVHealthcareCompanyMember_3e4e6fb5-29cf-4048-a2bf-22a10e0eb87b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PreExposureProphylaxisMember_e72293ba-b0ec-4cd3-9680-8ef430617126" xlink:href="gild-20210331.xsd#gild_PreExposureProphylaxisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_9b53222a-de77-4344-a5f7-4c285b21f23c" xlink:to="loc_gild_PreExposureProphylaxisMember_e72293ba-b0ec-4cd3-9680-8ef430617126" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaimsMember_4aea65e5-6f0e-4bd2-8bca-488589075518" xlink:href="gild-20210331.xsd#gild_EuropeanPatentClaimsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_9b53222a-de77-4344-a5f7-4c285b21f23c" xlink:to="loc_gild_EuropeanPatentClaimsMember_4aea65e5-6f0e-4bd2-8bca-488589075518" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductLiabilityMember_5cf77a0e-e59a-4994-985f-ad05ea32c4da" xlink:href="gild-20210331.xsd#gild_ProductLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_9b53222a-de77-4344-a5f7-4c285b21f23c" xlink:to="loc_gild_ProductLiabilityMember_5cf77a0e-e59a-4994-985f-ad05ea32c4da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_QuiTamMember_be929d18-b0de-40ea-899b-f197246ee9d7" xlink:href="gild-20210331.xsd#gild_QuiTamMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_9b53222a-de77-4344-a5f7-4c285b21f23c" xlink:to="loc_gild_QuiTamMember_be929d18-b0de-40ea-899b-f197246ee9d7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b00e5d5a-5713-45b2-aa6c-2ae6d50785b2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1e924627-ceef-444b-aec0-f2f8577ee2b1" xlink:to="loc_srt_RangeAxis_b00e5d5a-5713-45b2-aa6c-2ae6d50785b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b00e5d5a-5713-45b2-aa6c-2ae6d50785b2_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b00e5d5a-5713-45b2-aa6c-2ae6d50785b2" xlink:to="loc_srt_RangeMember_b00e5d5a-5713-45b2-aa6c-2ae6d50785b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_807742b0-4b3b-42b9-95ed-3a93a47eae39" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b00e5d5a-5713-45b2-aa6c-2ae6d50785b2" xlink:to="loc_srt_RangeMember_807742b0-4b3b-42b9-95ed-3a93a47eae39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_76d48821-a481-4293-96dc-7ea73ca98d58" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_807742b0-4b3b-42b9-95ed-3a93a47eae39" xlink:to="loc_srt_MinimumMember_76d48821-a481-4293-96dc-7ea73ca98d58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b8a119e6-d11e-48b2-b98b-f149e77f7b14" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_807742b0-4b3b-42b9-95ed-3a93a47eae39" xlink:to="loc_srt_MaximumMember_b8a119e6-d11e-48b2-b98b-f149e77f7b14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_3ea17f1f-f86b-4316-a762-b91376e8d1c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1e924627-ceef-444b-aec0-f2f8577ee2b1" xlink:to="loc_us-gaap_LitigationStatusAxis_3ea17f1f-f86b-4316-a762-b91376e8d1c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_3ea17f1f-f86b-4316-a762-b91376e8d1c2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_3ea17f1f-f86b-4316-a762-b91376e8d1c2" xlink:to="loc_us-gaap_LitigationStatusDomain_3ea17f1f-f86b-4316-a762-b91376e8d1c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_13ac5bc2-e14c-4a15-8295-2a8f56f25600" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_3ea17f1f-f86b-4316-a762-b91376e8d1c2" xlink:to="loc_us-gaap_LitigationStatusDomain_13ac5bc2-e14c-4a15-8295-2a8f56f25600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_28cce448-db9f-4be8-878c-487543ce85a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_13ac5bc2-e14c-4a15-8295-2a8f56f25600" xlink:to="loc_us-gaap_PendingLitigationMember_28cce448-db9f-4be8-878c-487543ce85a4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="gild-20210331.xsd#STOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITY" xlink:type="extended" id="ic9813e26020a442b8371b9aa0f9e534a_STOCKHOLDERSEQUITY"/>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="gild-20210331.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended" id="iab8d21967c404225983be8ad358dae0b_STOCKHOLDERSEQUITYTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#STOCKHOLDERSEQUITYAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="extended" id="iff59355360b546a6a8f25071e6e3996f_STOCKHOLDERSEQUITYAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b82a91f3-7113-4220-a2ee-7179eb800a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_aa5c4d22-a0b5-43ad-9dae-102416483674" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b82a91f3-7113-4220-a2ee-7179eb800a3a" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_aa5c4d22-a0b5-43ad-9dae-102416483674" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_fd3a100f-7bc7-459e-8345-4ef7bb2b1f38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b82a91f3-7113-4220-a2ee-7179eb800a3a" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_fd3a100f-7bc7-459e-8345-4ef7bb2b1f38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_32bf0a5a-c948-443c-ad4a-58a555b93d0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b82a91f3-7113-4220-a2ee-7179eb800a3a" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_32bf0a5a-c948-443c-ad4a-58a555b93d0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c29b1882-3770-4354-afa6-169c92663e6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b82a91f3-7113-4220-a2ee-7179eb800a3a" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c29b1882-3770-4354-afa6-169c92663e6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_67b4e575-60a1-4f34-936a-dbf817bd3261" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_b82a91f3-7113-4220-a2ee-7179eb800a3a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_67b4e575-60a1-4f34-936a-dbf817bd3261" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_0262132f-1157-47b9-8769-57cb5e52ac83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_67b4e575-60a1-4f34-936a-dbf817bd3261" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_0262132f-1157-47b9-8769-57cb5e52ac83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_0262132f-1157-47b9-8769-57cb5e52ac83_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_0262132f-1157-47b9-8769-57cb5e52ac83" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_0262132f-1157-47b9-8769-57cb5e52ac83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_b4ab56a6-a8ad-4f72-ae44-2e240e68d25e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_0262132f-1157-47b9-8769-57cb5e52ac83" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_b4ab56a6-a8ad-4f72-ae44-2e240e68d25e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2016StockRepurchaseProgramMember_154848a8-0f4f-4f3d-861f-d6e3e7ce77e1" xlink:href="gild-20210331.xsd#gild_A2016StockRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b4ab56a6-a8ad-4f72-ae44-2e240e68d25e" xlink:to="loc_gild_A2016StockRepurchaseProgramMember_154848a8-0f4f-4f3d-861f-d6e3e7ce77e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2020StockRepurchaseProgramMember_181fc684-6d44-4147-b4ad-7058d51f6b26" xlink:href="gild-20210331.xsd#gild_A2020StockRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b4ab56a6-a8ad-4f72-ae44-2e240e68d25e" xlink:to="loc_gild_A2020StockRepurchaseProgramMember_181fc684-6d44-4147-b4ad-7058d51f6b26" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i2da7a56d902641d6bb5fb74cc7712cdf_STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5ca967ca-be9e-4f61-9542-a3f1ebb376f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_5a0694ee-93df-45cf-a8e7-73a40c93ffc0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5ca967ca-be9e-4f61-9542-a3f1ebb376f8" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_5a0694ee-93df-45cf-a8e7-73a40c93ffc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_63dfd15a-66da-4315-b589-4d39f4cb8dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_5a0694ee-93df-45cf-a8e7-73a40c93ffc0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_63dfd15a-66da-4315-b589-4d39f4cb8dcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_345d9cfa-1b6e-4f97-8b60-89e29ccb29fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_5a0694ee-93df-45cf-a8e7-73a40c93ffc0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_345d9cfa-1b6e-4f97-8b60-89e29ccb29fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_e13584bd-fe1b-440e-ae1c-649048f8d88a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_5a0694ee-93df-45cf-a8e7-73a40c93ffc0" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_e13584bd-fe1b-440e-ae1c-649048f8d88a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f1c8c4d7-e979-4d72-9d1e-d7568b236f9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_5a0694ee-93df-45cf-a8e7-73a40c93ffc0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f1c8c4d7-e979-4d72-9d1e-d7568b236f9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_41a8b95b-da6e-40c5-a5f7-34d443b29fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_64ca19aa-5ba3-4fe4-b2ec-1fbca9448883" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5ca967ca-be9e-4f61-9542-a3f1ebb376f8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_64ca19aa-5ba3-4fe4-b2ec-1fbca9448883" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e1170bb1-0519-4c6d-9dc7-33317295c6e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_64ca19aa-5ba3-4fe4-b2ec-1fbca9448883" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e1170bb1-0519-4c6d-9dc7-33317295c6e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e1170bb1-0519-4c6d-9dc7-33317295c6e5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e1170bb1-0519-4c6d-9dc7-33317295c6e5" xlink:to="loc_us-gaap_EquityComponentDomain_e1170bb1-0519-4c6d-9dc7-33317295c6e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bba31187-ceaf-4254-98ae-3e59dffa5c97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e1170bb1-0519-4c6d-9dc7-33317295c6e5" xlink:to="loc_us-gaap_EquityComponentDomain_bba31187-ceaf-4254-98ae-3e59dffa5c97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7ddab721-845a-4b0e-9635-0e4da0437021" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bba31187-ceaf-4254-98ae-3e59dffa5c97" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7ddab721-845a-4b0e-9635-0e4da0437021" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_501ec77c-a4a9-4eba-93b8-158c5111eb12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7ddab721-845a-4b0e-9635-0e4da0437021" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_501ec77c-a4a9-4eba-93b8-158c5111eb12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_a10ff298-4894-4f3d-9a00-ce1e9daee5b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7ddab721-845a-4b0e-9635-0e4da0437021" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_a10ff298-4894-4f3d-9a00-ce1e9daee5b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c3d8b008-d2e3-4fec-8723-94d0e9860d57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7ddab721-845a-4b0e-9635-0e4da0437021" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c3d8b008-d2e3-4fec-8723-94d0e9860d57" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS" xlink:type="simple" xlink:href="gild-20210331.xsd#NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS" xlink:type="extended" id="idd45c4326aed47c2bc571c7f9430bbf9_NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS"/>
  <link:roleRef roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables" xlink:type="simple" xlink:href="gild-20210331.xsd#NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables" xlink:type="extended" id="i654e594fa54e4392b3a8ccc48c9ce492_NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails" xlink:type="extended" id="ic42530ff39ce4135b7e54f60249e8c7c_NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails" xlink:type="extended" id="id0bd2df51fe446d5935a681d1f0e966b_NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXES" xlink:type="simple" xlink:href="gild-20210331.xsd#INCOMETAXES"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/INCOMETAXES" xlink:type="extended" id="i3f720ff3f38049aeac8c48e9a21e2f66_INCOMETAXES"/>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="gild-20210331.xsd#INCOMETAXESTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/INCOMETAXESTables" xlink:type="extended" id="i9457fa45a2694fbb82c732b586b49c6a_INCOMETAXESTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXESSummaryoftheProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#INCOMETAXESSummaryoftheProvisionforIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/INCOMETAXESSummaryoftheProvisionforIncomeTaxesDetails" xlink:type="extended" id="ia717440a293a4897933bb2170a07906a_INCOMETAXESSummaryoftheProvisionforIncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#INCOMETAXESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="extended" id="ie2793dbdc9964a69bef97c5d8353cfbb_INCOMETAXESAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/SUBSEQUENTEVENT" xlink:type="simple" xlink:href="gild-20210331.xsd#SUBSEQUENTEVENT"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/SUBSEQUENTEVENT" xlink:type="extended" id="if1787a061302464d8319bd0a77d710cf_SUBSEQUENTEVENT"/>
  <link:roleRef roleURI="http://www.gilead.com/role/SUBSEQUENTEVENTDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#SUBSEQUENTEVENTDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/SUBSEQUENTEVENTDetails" xlink:type="extended" id="ib4c56c013f4a4c2190819ba9f359f71e_SUBSEQUENTEVENTDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2b033ce8-bc53-418d-a44f-1cd1bc10de98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_68bae763-d48d-4a5a-b7fc-55d84ec91191" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b033ce8-bc53-418d-a44f-1cd1bc10de98" xlink:to="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_68bae763-d48d-4a5a-b7fc-55d84ec91191" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0ba1ba19-2f58-4637-ae97-d2a6b5531540" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b033ce8-bc53-418d-a44f-1cd1bc10de98" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0ba1ba19-2f58-4637-ae97-d2a6b5531540" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7dd1d85a-7708-431b-bdc0-e32e1369c264" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0ba1ba19-2f58-4637-ae97-d2a6b5531540" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7dd1d85a-7708-431b-bdc0-e32e1369c264" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7dd1d85a-7708-431b-bdc0-e32e1369c264_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7dd1d85a-7708-431b-bdc0-e32e1369c264" xlink:to="loc_us-gaap_RelatedPartyDomain_7dd1d85a-7708-431b-bdc0-e32e1369c264_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1d415f2c-1e12-4f72-9bf1-1bee48b2d344" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7dd1d85a-7708-431b-bdc0-e32e1369c264" xlink:to="loc_us-gaap_RelatedPartyDomain_1d415f2c-1e12-4f72-9bf1-1bee48b2d344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadFoundationMember_ff8f1849-613f-4396-aa94-4aa960c8d37a" xlink:href="gild-20210331.xsd#gild_GileadFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1d415f2c-1e12-4f72-9bf1-1bee48b2d344" xlink:to="loc_gild_GileadFoundationMember_ff8f1849-613f-4396-aa94-4aa960c8d37a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_800c23a9-1a63-47eb-a854-73932545851e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0ba1ba19-2f58-4637-ae97-d2a6b5531540" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_800c23a9-1a63-47eb-a854-73932545851e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_800c23a9-1a63-47eb-a854-73932545851e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_800c23a9-1a63-47eb-a854-73932545851e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_800c23a9-1a63-47eb-a854-73932545851e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3ee144d4-2407-4c58-98ed-fdfeccb0c4b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_800c23a9-1a63-47eb-a854-73932545851e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3ee144d4-2407-4c58-98ed-fdfeccb0c4b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_177f4510-53d3-4b03-bf90-7af93cb6a025" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3ee144d4-2407-4c58-98ed-fdfeccb0c4b8" xlink:to="loc_us-gaap_SubsequentEventMember_177f4510-53d3-4b03-bf90-7af93cb6a025" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_6af43121-25cc-4253-a715-164f5083d7ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0ba1ba19-2f58-4637-ae97-d2a6b5531540" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_6af43121-25cc-4253-a715-164f5083d7ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_6af43121-25cc-4253-a715-164f5083d7ee_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_6af43121-25cc-4253-a715-164f5083d7ee" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_6af43121-25cc-4253-a715-164f5083d7ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3eb809ed-93d7-4aa1-8249-a99c8fc99fa6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_6af43121-25cc-4253-a715-164f5083d7ee" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3eb809ed-93d7-4aa1-8249-a99c8fc99fa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesDonationMember_2390862f-aec5-43bb-a6f9-74ccdd41abd5" xlink:href="gild-20210331.xsd#gild_EquitySecuritiesDonationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3eb809ed-93d7-4aa1-8249-a99c8fc99fa6" xlink:to="loc_gild_EquitySecuritiesDonationMember_2390862f-aec5-43bb-a6f9-74ccdd41abd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_5ec3b8d6-599f-469e-a2df-b54c943c4d4c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0ba1ba19-2f58-4637-ae97-d2a6b5531540" xlink:to="loc_srt_StatementScenarioAxis_5ec3b8d6-599f-469e-a2df-b54c943c4d4c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_5ec3b8d6-599f-469e-a2df-b54c943c4d4c_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_5ec3b8d6-599f-469e-a2df-b54c943c4d4c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_5ec3b8d6-599f-469e-a2df-b54c943c4d4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f815d8f5-df56-4d9b-9a0f-6b7d4794e641" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_5ec3b8d6-599f-469e-a2df-b54c943c4d4c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f815d8f5-df56-4d9b-9a0f-6b7d4794e641" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_e52563c9-c5c5-4149-8af5-9f139c3bfb6c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f815d8f5-df56-4d9b-9a0f-6b7d4794e641" xlink:to="loc_srt_ScenarioForecastMember_e52563c9-c5c5-4149-8af5-9f139c3bfb6c" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>gild-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:62245928-4256-4115-b52c-a224301f8b52,g:d7709fc8-9a45-40b0-bb7e-3c2cb616ef14-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_gild_IntangibleAssetSofosbuvirMember_68941fae-918c-42bb-8108-0a3a555b543a_terseLabel_en-US" xlink:label="lab_gild_IntangibleAssetSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset - sofosbuvir</link:label>
    <link:label id="lab_gild_IntangibleAssetSofosbuvirMember_label_en-US" xlink:label="lab_gild_IntangibleAssetSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset - Sofosbuvir [Member]</link:label>
    <link:label id="lab_gild_IntangibleAssetSofosbuvirMember_documentation_en-US" xlink:label="lab_gild_IntangibleAssetSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sofosbuvir [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetSofosbuvirMember" xlink:href="gild-20210331.xsd#gild_IntangibleAssetSofosbuvirMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IntangibleAssetSofosbuvirMember" xlink:to="lab_gild_IntangibleAssetSofosbuvirMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2626b78d-2f98-4cc7-b8db-f15a7f8b2cd0_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c2d0f396-07ba-4a0b-b9b3-2502453a7937_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3d7fef10-b0dd-4e61-8e6c-1a9330336eb7_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_fef8be8a-377c-4020-84bd-20d9b86d1919_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_b2111a9d-1fc8-4ca7-8f87-3905b6e294b9_terseLabel_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents challenged, scenario two</link:label>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_label_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number, Scenario Two</link:label>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_documentation_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number, Scenario Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:href="gild-20210331.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:to="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_0778501d-78d0-44b3-a262-d8e602acfba4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_7e090578-055d-4e30-86b3-fdc7718ddbed_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) reclassified from AOCI into product sales</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_2fb87759-8f69-4672-a624-2578138d7f64_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts outstanding under revolving credit facilities</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7beac0ca-25af-4b5c-bb15-f504bd6bdea7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1cc48a60-d3c1-496b-a903-03ca7502e6c3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JudgmentRoyaltyRateOnFutureSales_aee139b4-1f33-4ebd-beb3-241cc3e86b31_terseLabel_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Running royalty rate on future sales</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateOnFutureSales_label_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate on Future Sales</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateOnFutureSales_documentation_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate on Future Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateOnFutureSales" xlink:href="gild-20210331.xsd#gild_JudgmentRoyaltyRateOnFutureSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JudgmentRoyaltyRateOnFutureSales" xlink:to="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_2250425f-7922-4bbd-8bfc-d3557b64daf3_terseLabel_en-US" xlink:label="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cell Therapy</link:label>
    <link:label id="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_label_en-US" xlink:label="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Total Cell Therapy Product Sales [Member]</link:label>
    <link:label id="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_documentation_en-US" xlink:label="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Total Cell Therapy Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:href="gild-20210331.xsd#gild_CellTherapyProductsTotalCellTherapyProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:to="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_ce5da2ce-b02b-4954-acf5-123bec0a89f2_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160; Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyMaterialTransferAgreementsNumber_d7c1ffda-ec57-4f3d-a57e-2ed8ac01533e_terseLabel_en-US" xlink:label="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of material transfer agreements</link:label>
    <link:label id="lab_gild_LossContingencyMaterialTransferAgreementsNumber_label_en-US" xlink:label="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Material Transfer Agreements, Number</link:label>
    <link:label id="lab_gild_LossContingencyMaterialTransferAgreementsNumber_documentation_en-US" xlink:label="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Material Transfer Agreements, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:href="gild-20210331.xsd#gild_LossContingencyMaterialTransferAgreementsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:to="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_781d8de6-7417-4233-94d4-694dadd82437_verboseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_b67bbb56-57a6-4091-87ad-07760dc1feff_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill resulting from the acquisition of MYR</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_646b4bf7-fdd6-4ec3-a3ea-3bb3e4bfc91e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A2020StockRepurchaseProgramMember_7b789d30-1280-4ebf-bf91-0e8cab0340c4_terseLabel_en-US" xlink:label="lab_gild_A2020StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Repurchase Program</link:label>
    <link:label id="lab_gild_A2020StockRepurchaseProgramMember_label_en-US" xlink:label="lab_gild_A2020StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Repurchase Program [Member]</link:label>
    <link:label id="lab_gild_A2020StockRepurchaseProgramMember_documentation_en-US" xlink:label="lab_gild_A2020StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2020StockRepurchaseProgramMember" xlink:href="gild-20210331.xsd#gild_A2020StockRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A2020StockRepurchaseProgramMember" xlink:to="lab_gild_A2020StockRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_9427acb4-763d-409d-9454-6a6d79b3acd0_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_9275c9bd-b576-410b-bc37-3b823b3a200a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of each exchange on which registered</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_3f6b82bc-95a3-4020-b869-c05c61e6ec08_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuances of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_InjectableFormulationProductMember_7d99957f-ede4-4c9f-9a18-5f7f092c7a4e_terseLabel_en-US" xlink:label="lab_gild_InjectableFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Injectable Formulation Product</link:label>
    <link:label id="lab_gild_InjectableFormulationProductMember_label_en-US" xlink:label="lab_gild_InjectableFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Injectable Formulation Product [Member]</link:label>
    <link:label id="lab_gild_InjectableFormulationProductMember_documentation_en-US" xlink:label="lab_gild_InjectableFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Injectable Formulation Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InjectableFormulationProductMember" xlink:href="gild-20210331.xsd#gild_InjectableFormulationProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_InjectableFormulationProductMember" xlink:to="lab_gild_InjectableFormulationProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_b25163a6-a896-4035-82f5-5d64ed7bd4b3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_bf311ecd-9c4d-48d5-a5af-ddbb531cf39d_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HBV/HBD</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Other [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:href="gild-20210331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_68d527ca-c376-4523-afe3-7d9a11dd3a56_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a413aac8-e2e9-454e-b32a-d4539a6ded6e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in per share calculation - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b2c1f655-0ad8-465b-82d5-8bbdb611be25_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in per share calculation - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_a4b80018-dafb-4a5c-a8ec-09e7b388e982_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_517b6b9b-fd97-45b7-a1a0-c17e33a862c8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Classification of Available-for-Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_f68dbb6d-ba3e-426e-af1c-cf015ebe45a6_terseLabel_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents challenged, scenario one</link:label>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_label_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number, Scenario One</link:label>
    <link:label id="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_documentation_en-US" xlink:label="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number, Scenario One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:href="gild-20210331.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:to="lab_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_fe8b7121-fff4-4cba-9b48-9f76975961af_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3eb64700-26c9-4545-a9e2-b8bc49a487aa_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MediumTermNotesMember_86d7794a-dee3-4ed1-bde4-2d79646b1221_terseLabel_en-US" xlink:label="lab_us-gaap_MediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medium-term Notes</link:label>
    <link:label id="lab_us-gaap_MediumTermNotesMember_label_en-US" xlink:label="lab_us-gaap_MediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medium-term Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MediumTermNotesMember" xlink:to="lab_us-gaap_MediumTermNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_867ca7d4-59cb-40b2-a4f8-9ae6951b2e08_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_d3897a9f-2b8e-47f0-b60b-26f9770c7016_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e1cdf6c7-1712-44c1-9ee6-c3330de6356a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d17d9590-918a-4adf-8d81-f1e99ed64a92_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8185711a-9af0-4a7e-9551-add0c20fc85b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_99e22b6d-6a82-45bf-8f27-4271434e621f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_555ff330-e35a-49f5-bbbc-b2365029ee28_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_05520129-f2f2-4ec4-aec0-08c5a025b4b5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_d903d3e1-2e77-4d19-bf6b-f26f2f9882f3_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cb4372a8-3144-431e-8375-4c9bfd76c170_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsAmBisomeMember_d8e28726-31df-4ffb-b9db-9b551a47a945_terseLabel_en-US" xlink:label="lab_gild_OtherProductsAmBisomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmBisome</link:label>
    <link:label id="lab_gild_OtherProductsAmBisomeMember_label_en-US" xlink:label="lab_gild_OtherProductsAmBisomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, AmBisome [Member]</link:label>
    <link:label id="lab_gild_OtherProductsAmBisomeMember_documentation_en-US" xlink:label="lab_gild_OtherProductsAmBisomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, AmBisome [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsAmBisomeMember" xlink:href="gild-20210331.xsd#gild_OtherProductsAmBisomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsAmBisomeMember" xlink:to="lab_gild_OtherProductsAmBisomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquityinvestmentinGalapagosMember_3600f412-f018-4ee2-88e8-83513097048c_terseLabel_en-US" xlink:label="lab_gild_EquityinvestmentinGalapagosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment in Galapagos</link:label>
    <link:label id="lab_gild_EquityinvestmentinGalapagosMember_label_en-US" xlink:label="lab_gild_EquityinvestmentinGalapagosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment in Galapagos [Member]</link:label>
    <link:label id="lab_gild_EquityinvestmentinGalapagosMember_documentation_en-US" xlink:label="lab_gild_EquityinvestmentinGalapagosMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment in Galapagos [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityinvestmentinGalapagosMember" xlink:href="gild-20210331.xsd#gild_EquityinvestmentinGalapagosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquityinvestmentinGalapagosMember" xlink:to="lab_gild_EquityinvestmentinGalapagosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_9d73c241-4875-4365-8776-c48e1558e99a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_66387c4b-1716-4528-b514-bfa56ab30266_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_c3fb2fc9-1252-4544-9fce-51063a90fef6_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_cb692f16-0fd6-4457-8f36-c95ed0cce6c9_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_30391203-47fa-4699-a7fe-a718e8476919_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_5f8a78ee-8bfd-4b15-b67e-80ddc96c0251_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for MYR contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_53f97b1e-06d4-4ab3-b01d-449851e9040d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_eda83076-342d-419b-bf8b-72a5f7ff218c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_acccacea-9a58-4078-811c-503c2da6c7a5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MerckMember_dfb37f15-3d67-4af2-a916-a822ead2ea0a_terseLabel_en-US" xlink:label="lab_gild_MerckMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck</link:label>
    <link:label id="lab_gild_MerckMember_label_en-US" xlink:label="lab_gild_MerckMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck [Member]</link:label>
    <link:label id="lab_gild_MerckMember_documentation_en-US" xlink:label="lab_gild_MerckMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckMember" xlink:href="gild-20210331.xsd#gild_MerckMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MerckMember" xlink:to="lab_gild_MerckMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_c4392367-af2a-46fc-973c-f990238c9c1a_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount (Legal Offset)</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_ae439b2c-17f8-4f0c-8b42-4d1c9b861178_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_42caa4fe-df3b-40bf-b062-a0677df07bfa_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_99a14048-4f89-43ae-9f04-fa5a2f8dd375_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_be136e2f-360e-4ea2-ada6-a0229b83b98a_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductSalesMember_c22fa4af-c969-4a07-b114-f09472bace11_terseLabel_en-US" xlink:label="lab_gild_HIVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total HIV</link:label>
    <link:label id="lab_gild_HIVProductSalesMember_label_en-US" xlink:label="lab_gild_HIVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Product Sales [Member]</link:label>
    <link:label id="lab_gild_HIVProductSalesMember_documentation_en-US" xlink:label="lab_gild_HIVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductSalesMember" xlink:href="gild-20210331.xsd#gild_HIVProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductSalesMember" xlink:to="lab_gild_HIVProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_f79cee8d-ac46-43da-9778-6b33219a4600_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. government securities</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_30e05082-37f6-4c59-9544-f1f48fae2492_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member_bfd4e01d-1ac2-4054-a0a4-5e63cec682cd_terseLabel_en-US" xlink:label="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.65% Senior Unsecured Notes Due March 2026</link:label>
    <link:label id="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member_label_en-US" xlink:label="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.65% Senior Unsecured Notes Due March 2026 [Member]</link:label>
    <link:label id="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member_documentation_en-US" xlink:label="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.65% Senior Unsecured Notes Due March 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:href="gild-20210331.xsd#gild_A365SeniorUnsecuredNotesDueMarch2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:to="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_83162446-b45a-4928-97fb-6c989d3a5518_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment recognized</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5fa8236c-4a52-4653-a8cb-cb5f276437d4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_fed6b6eb-a8d3-4e60-a7f7-aa4c83c995c0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_4b6f14ca-e350-4e78-a34b-9130491826e5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_7c41bb2a-d894-4165-a6d0-95e3c3e31524_terseLabel_en-US" xlink:label="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% Senior Unsecured Notes Due September 2036</link:label>
    <link:label id="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_label_en-US" xlink:label="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% Senior Unsecured Notes Due September 2036 [Member]</link:label>
    <link:label id="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_documentation_en-US" xlink:label="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% Senior Unsecured Notes Due September 2036</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:href="gild-20210331.xsd#gild_A400SeniorUnsecuredNotesDueSeptember2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:to="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_2959ea99-882c-4547-916b-4e6b43697760_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_c4d0056f-4789-468d-8584-ddbd40cc4162_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_d3fd5328-da09-4edb-80d1-ccb381b2317f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsRanexaMember_f5734d2c-2df9-4698-9071-021b8c1043bd_terseLabel_en-US" xlink:label="lab_gild_OtherProductsRanexaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranexa</link:label>
    <link:label id="lab_gild_OtherProductsRanexaMember_label_en-US" xlink:label="lab_gild_OtherProductsRanexaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Ranexa [Member]</link:label>
    <link:label id="lab_gild_OtherProductsRanexaMember_documentation_en-US" xlink:label="lab_gild_OtherProductsRanexaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Ranexa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsRanexaMember" xlink:href="gild-20210331.xsd#gild_OtherProductsRanexaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsRanexaMember" xlink:to="lab_gild_OtherProductsRanexaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_d7dad2a8-3323-44b0-b169-a4301ceec7a5_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MckessonCorpMember_73dbf991-ed96-466d-a239-5cf57f1486bf_terseLabel_en-US" xlink:label="lab_gild_MckessonCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:label id="lab_gild_MckessonCorpMember_label_en-US" xlink:label="lab_gild_MckessonCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corp [Member]</link:label>
    <link:label id="lab_gild_MckessonCorpMember_documentation_en-US" xlink:label="lab_gild_MckessonCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corp [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MckessonCorpMember" xlink:href="gild-20210331.xsd#gild_MckessonCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MckessonCorpMember" xlink:to="lab_gild_MckessonCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ad231b73-0da1-4618-88f7-77c090ccab61_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6b73a571-1fd6-4887-97d6-c0a4d5fc88c2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9156fd5b-202a-44c6-98c9-2ab70a9bcc27_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_41e7349d-301d-45a8-903f-1e948af97cce_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c89c13d4-d9de-497c-8981-6d6683a17ad4_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining authorized repurchase amount under stock repurchase programs</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_bd49be68-7497-4aea-b910-878a965e4827_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_72b553e2-5fbc-43ac-83b8-3fe2814ee505_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AccountsReceivableChargebacksCurrent_b5befc4a-dad7-4e70-b534-8106a94f4fa6_terseLabel_en-US" xlink:label="lab_gild_AccountsReceivableChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: chargebacks</link:label>
    <link:label id="lab_gild_AccountsReceivableChargebacksCurrent_label_en-US" xlink:label="lab_gild_AccountsReceivableChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Chargebacks, Current</link:label>
    <link:label id="lab_gild_AccountsReceivableChargebacksCurrent_documentation_en-US" xlink:label="lab_gild_AccountsReceivableChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Chargebacks, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableChargebacksCurrent" xlink:href="gild-20210331.xsd#gild_AccountsReceivableChargebacksCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AccountsReceivableChargebacksCurrent" xlink:to="lab_gild_AccountsReceivableChargebacksCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_e37d2ec9-c80b-4eff-901f-3995709a249e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time estimate for gains (losses) to be reclassified from AOCI to product sales</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimate of Time to Transfer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_392ff11d-0218-4c0b-b5a5-1c9ce970fc21_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_3ee3260b-6a64-4bc9-8b39-515c0ed4879c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member_48468e15-6036-40b2-bb97-cdd054b4a24c_terseLabel_en-US" xlink:label="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.95% Senior Unsecured Notes Due March 2022</link:label>
    <link:label id="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member_label_en-US" xlink:label="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.95% Senior Unsecured Notes Due March 2022 [Member]</link:label>
    <link:label id="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member_documentation_en-US" xlink:label="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.95% Senior Unsecured Notes Due March 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:href="gild-20210331.xsd#gild_A195SeniorUnsecuredNotesDueMarch2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:to="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_e532fd3d-06ad-4a17-b3bb-173b1b7464e5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIRestrictionPeriod_2cd240e2-dfc9-4483-932e-1a9a5f102210_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restriction period</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIRestrictionPeriod_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Restriction Period</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIRestrictionPeriod_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Restriction Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:href="gild-20210331.xsd#gild_EquitySecuritiesFVNIRestrictionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:to="lab_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_6c97c7d2-55cd-4d40-bd07-da7e7d942011_terseLabel_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_label_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_documentation_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:href="gild-20210331.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:to="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_4cf7180c-e41a-4bfd-b332-e8a93f1dd1ef_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Not Offset, Policy Election Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6e1f080f-ebf4-4510-bb9d-fefd9a540484_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AmerisourcebergenCorpMember_e386f17e-a34e-4716-b5d5-c5f1e4d85d86_terseLabel_en-US" xlink:label="lab_gild_AmerisourcebergenCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation</link:label>
    <link:label id="lab_gild_AmerisourcebergenCorpMember_label_en-US" xlink:label="lab_gild_AmerisourcebergenCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corp [Member]</link:label>
    <link:label id="lab_gild_AmerisourcebergenCorpMember_documentation_en-US" xlink:label="lab_gild_AmerisourcebergenCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corp [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmerisourcebergenCorpMember" xlink:href="gild-20210331.xsd#gild_AmerisourcebergenCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AmerisourcebergenCorpMember" xlink:to="lab_gild_AmerisourcebergenCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsGenvoyaMember_bc832dfb-a939-464b-be61-34cd193859a0_terseLabel_en-US" xlink:label="lab_gild_HIVProductsGenvoyaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genvoya</link:label>
    <link:label id="lab_gild_HIVProductsGenvoyaMember_label_en-US" xlink:label="lab_gild_HIVProductsGenvoyaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Genvoya [Member]</link:label>
    <link:label id="lab_gild_HIVProductsGenvoyaMember_documentation_en-US" xlink:label="lab_gild_HIVProductsGenvoyaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Genvoya [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsGenvoyaMember" xlink:href="gild-20210331.xsd#gild_HIVProductsGenvoyaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsGenvoyaMember" xlink:to="lab_gild_HIVProductsGenvoyaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9edd12c9-64d5-4c74-a41d-3ef942d68beb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_5178ae0b-51ca-4606-b93f-adc180fb9d9a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ArcusStockPurchaseAgreementMember_0c9ba374-bf6d-4d89-b1be-3f132d495c9a_terseLabel_en-US" xlink:label="lab_gild_ArcusStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus stock purchase agreement</link:label>
    <link:label id="lab_gild_ArcusStockPurchaseAgreementMember_label_en-US" xlink:label="lab_gild_ArcusStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_gild_ArcusStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_gild_ArcusStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusStockPurchaseAgreementMember" xlink:href="gild-20210331.xsd#gild_ArcusStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ArcusStockPurchaseAgreementMember" xlink:to="lab_gild_ArcusStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_6d571a59-7011-4fa9-bac8-d2e56d954891_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to net income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_143bb081-943b-446f-94ee-f062f2e38670_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_3d68b9ae-0c18-4c63-9332-9ed395458043_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_93fa82d4-a896-438d-9f4d-dc2b231769a6_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsOtherMember_3cf3463d-c348-419a-919a-bb708a839f9b_terseLabel_en-US" xlink:label="lab_gild_OtherProductsOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_gild_OtherProductsOtherMember_label_en-US" xlink:label="lab_gild_OtherProductsOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Other [Member]</link:label>
    <link:label id="lab_gild_OtherProductsOtherMember_documentation_en-US" xlink:label="lab_gild_OtherProductsOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsOtherMember" xlink:href="gild-20210331.xsd#gild_OtherProductsOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsOtherMember" xlink:to="lab_gild_OtherProductsOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3b016c6a-db30-4705-9dfb-42615e9c51c8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_916a756e-6bee-4576-a46b-e44cef6c0f1c_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_4f1a9bec-bcf4-4e78-ac58-4f2c73352a77_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_8ad09d26-844f-44db-8ec5-2f33d25d6f5e_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_594e1412-726f-4575-b9a8-fe311a7d9910_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_a9569c1c-f66e-4a24-87fd-c74eff62c7e5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_6ee29ad5-70cb-44ce-8a01-3e16da2e3b8f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_b0022ec7-4b58-40e9-95f7-ceda61febdcf_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f38109c5-33b6-4e9a-8381-2bdf1557a7b2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_47d16b23-6b37-4bef-89ea-48ff34fd476c_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenues</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_19fe7b9c-cfab-41df-8d52-032481b413da_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ab38a60f-38e7-4d5b-abef-82c4850e42a2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e2a65857-d434-448a-ae34-3ee6b6546ed4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_921ec9a4-21fd-466a-b82c-40a899ce2b16_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_4311f68e-b80b-423d-ad11-aed814c42e4c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share attributable to Gilead common stockholders - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_9b91fbc6-c511-453b-bac3-a121691afcbc_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share attributable to Gilead common stockholders - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_d193887b-a761-4774-8dcb-db30b68310bd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, dividends declared (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_81bd64ae-a712-42f5-8693-55adb9457442_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_18351fbc-b027-4904-bafb-528532efa73d_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to Gilead</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member_ff96693c-d61c-412f-883f-6c9d231878ff_terseLabel_en-US" xlink:label="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Senior Unsecured Notes Due April 2024</link:label>
    <link:label id="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member_label_en-US" xlink:label="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Senior Unsecured Notes Due April 2024 [Member]</link:label>
    <link:label id="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member_documentation_en-US" xlink:label="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Senior Unsecured Notes Due April 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:href="gild-20210331.xsd#gild_A370SeniorUnsecuredNotesDueApril2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:to="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_32b777a1-5b66-4ce4-8cf4-7d7feddebb29_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_53b4a5a3-3443-4109-8cda-66d8a398d497_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member_2c4235a6-29e5-40f0-a0fa-a35b40df0389_terseLabel_en-US" xlink:label="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Senior Unsecured Notes Due October 2030</link:label>
    <link:label id="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member_label_en-US" xlink:label="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Senior Unsecured Notes Due October 2030 [Member]</link:label>
    <link:label id="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member_documentation_en-US" xlink:label="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Senior Unsecured Notes Due October 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:href="gild-20210331.xsd#gild_A165SeniorUnsecuredNotesDueOctober2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:to="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_22f30742-417b-4a27-9fe0-31400ae638b0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Amounts Offset on our Condensed Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_dc28b0e4-7d0b-4ce6-9fc4-f681b5d98c04_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_3c407115-9c70-4a75-92da-481ec506d5fb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_d62ec226-b6e8-46e1-b3b8-2634c0174420_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_30cc33b9-5d28-4270-b5ae-15abc6620e5a_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outlicense contract</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TrodelvyMember_3f165c9b-366f-49d6-8024-31eb832f4c94_terseLabel_en-US" xlink:label="lab_gild_TrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy</link:label>
    <link:label id="lab_gild_TrodelvyMember_label_en-US" xlink:label="lab_gild_TrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy [Member]</link:label>
    <link:label id="lab_gild_TrodelvyMember_documentation_en-US" xlink:label="lab_gild_TrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember" xlink:href="gild-20210331.xsd#gild_TrodelvyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TrodelvyMember" xlink:to="lab_gild_TrodelvyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_VariableTermLoanNoteDueOctober2023Member_419bae3a-eb45-4847-8a06-cb2e1ff9ee30_terseLabel_en-US" xlink:label="lab_gild_VariableTermLoanNoteDueOctober2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Term Loan Note Due October 2023</link:label>
    <link:label id="lab_gild_VariableTermLoanNoteDueOctober2023Member_label_en-US" xlink:label="lab_gild_VariableTermLoanNoteDueOctober2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Term Loan Note Due October 2023 [Member]</link:label>
    <link:label id="lab_gild_VariableTermLoanNoteDueOctober2023Member_documentation_en-US" xlink:label="lab_gild_VariableTermLoanNoteDueOctober2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Term Loan Note Due October 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VariableTermLoanNoteDueOctober2023Member" xlink:href="gild-20210331.xsd#gild_VariableTermLoanNoteDueOctober2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_VariableTermLoanNoteDueOctober2023Member" xlink:to="lab_gild_VariableTermLoanNoteDueOctober2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a6c84485-c7dc-4092-9fc5-f3615e05ac40_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b1883a95-7048-4446-a2e9-44cee9ed6f49_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_21d21499-6554-4318-92d1-0e1b453d77bc_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_7141e1c2-a0f5-4a63-880b-98b0fc9a705e_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3cba5a19-c221-4c64-8bd6-b820ececc106_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7b410f00-a848-407a-80c3-0c30cbc3745a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0af71e8b-0398-4c49-a3c9-28a92cd6b885_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_89260806-0819-40d8-8c3e-7afeed9e2104_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_2bedf404-528e-4b3e-b0bc-98e6c0306372_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_47a662cf-0953-4e32-ad92-87b05feee6b4_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_a4a743ff-addb-42de-aacd-5812a53c417e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_5fa2f56f-f408-432e-a04c-1ae0ef921117_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborativeandOtherArrangementsAbstract_label_en-US" xlink:label="lab_gild_CollaborativeandOtherArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Arrangements [Abstract]</link:label>
    <link:label id="lab_gild_CollaborativeandOtherArrangementsAbstract_documentation_en-US" xlink:label="lab_gild_CollaborativeandOtherArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Arrangements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeandOtherArrangementsAbstract" xlink:href="gild-20210331.xsd#gild_CollaborativeandOtherArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborativeandOtherArrangementsAbstract" xlink:to="lab_gild_CollaborativeandOtherArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9965a374-b1ba-4921-af48-78d1902b0d99_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_01cee6e1-c5d0-4016-92a4-cc852ea36cca_terseLabel_en-US" xlink:label="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.60% Senior Unsecured Notes Due September 2035</link:label>
    <link:label id="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_label_en-US" xlink:label="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.60% Senior Unsecured Notes Due September 2035 [Member]</link:label>
    <link:label id="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_documentation_en-US" xlink:label="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.60% Senior Unsecured Notes Due September 2035</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:href="gild-20210331.xsd#gild_A460SeniorUnsecuredNotesDueSeptember2035Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:to="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_992e85e8-a919-469b-bef7-a28e1f4fb204_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_dbbe6473-60cd-40a6-b4c0-acb0b2fba19a_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies, Estimates and Judgments</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GalapagosNVMember_17591f0c-2b93-4248-8ec8-f3bdd0613c77_terseLabel_en-US" xlink:label="lab_gild_GalapagosNVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos NV</link:label>
    <link:label id="lab_gild_GalapagosNVMember_label_en-US" xlink:label="lab_gild_GalapagosNVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos NV [Member]</link:label>
    <link:label id="lab_gild_GalapagosNVMember_documentation_en-US" xlink:label="lab_gild_GalapagosNVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos NV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosNVMember" xlink:href="gild-20210331.xsd#gild_GalapagosNVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GalapagosNVMember" xlink:to="lab_gild_GalapagosNVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_d98fa3ab-4636-4d32-a938-565e019083dc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_e75ea0a8-5732-4141-b500-482136069d78_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_7cfc34cd-224b-4e8d-b4e3-5916bfb2a9ca_terseLabel_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_label_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_documentation_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:href="gild-20210331.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:to="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_40afc7c6-0f34-46cc-8058-3aaaf71b04b5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_a9a82bd6-aff7-444f-b386-4d97f6cd97b4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_ec0ee8e9-30c7-43bc-ba97-5b886323ccec_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_bca0d46b-0e9f-4813-a2dc-af33a8296526_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_1e1c10ce-093d-4f76-8a2b-b8517a49fb3b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_f40b23b2-8af2-4d2b-98af-30076d6ed8ee_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7a418032-27dc-410f-b819-d955a4736eb0_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_0ff3af1c-ac99-49b7-b297-373b6984b2b3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_a5ba63ac-4a5b-45a8-8db0-ea6ae0ebb209_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other publicly traded equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ProductsRevenueShareSymtuzaMember_1cec3780-0ec0-47ea-9eac-8a30ddbb8579_terseLabel_en-US" xlink:label="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue share - Symtuza</link:label>
    <link:label id="lab_gild_ProductsRevenueShareSymtuzaMember_label_en-US" xlink:label="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Revenue Share-Symtuza [Member]</link:label>
    <link:label id="lab_gild_ProductsRevenueShareSymtuzaMember_documentation_en-US" xlink:label="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Revenue Share-Symtuza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsRevenueShareSymtuzaMember" xlink:href="gild-20210331.xsd#gild_ProductsRevenueShareSymtuzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ProductsRevenueShareSymtuzaMember" xlink:to="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_91ad1ffb-2bce-41ad-890a-41f7ac80381a_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherInternationalMember_75f47e31-66c6-4537-bca9-8a0051fdaffb_terseLabel_en-US" xlink:label="lab_gild_OtherInternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International</link:label>
    <link:label id="lab_gild_OtherInternationalMember_label_en-US" xlink:label="lab_gild_OtherInternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International [Member]</link:label>
    <link:label id="lab_gild_OtherInternationalMember_documentation_en-US" xlink:label="lab_gild_OtherInternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherInternationalMember" xlink:href="gild-20210331.xsd#gild_OtherInternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherInternationalMember" xlink:to="lab_gild_OtherInternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ad30e6a6-b152-4e64-b26c-65fe4c745647_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_d9d6f6f9-f38e-4b3b-85b3-4f12801cab2e_terseLabel_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets (and liabilities), net</link:label>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_label_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net</link:label>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_documentation_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:href="gild-20210331.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:to="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_251a818c-7831-4dcd-a930-d4d1c35f23f5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_82609ff9-a1f9-4ae9-853e-a67de3c91a4a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiffs involved</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_2552a11c-0e0c-421c-b3ef-91aebebbd7c7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_aeee6ef5-4b97-496d-a57a-dd73e664785c_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_7c773591-412f-4377-86af-cc4c02de687e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_158a4dc8-ccf4-4348-b09c-4a880fb1bbac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Not Offset, Policy Election Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsTruvadaMember_212c3ae2-5b17-4458-a0d5-8e2eab825db7_terseLabel_en-US" xlink:label="lab_gild_HIVProductsTruvadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Truvada</link:label>
    <link:label id="lab_gild_HIVProductsTruvadaMember_label_en-US" xlink:label="lab_gild_HIVProductsTruvadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Truvada [Member]</link:label>
    <link:label id="lab_gild_HIVProductsTruvadaMember_documentation_en-US" xlink:label="lab_gild_HIVProductsTruvadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Truvada [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsTruvadaMember" xlink:href="gild-20210331.xsd#gild_HIVProductsTruvadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsTruvadaMember" xlink:to="lab_gild_HIVProductsTruvadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9f499965-6123-430f-826a-23759134889b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_b1b1e5d6-1dea-4dc3-8441-96163a9f33f0_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Gilead</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9e2aa2d9-e2d5-47ce-82c9-2afeab715bc2_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Gilead</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyPartiesFilingOppositionNumber_52baa74a-2720-4d19-89da-802a60da38d5_terseLabel_en-US" xlink:label="lab_gild_LossContingencyPartiesFilingOppositionNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of parties filing opposition</link:label>
    <link:label id="lab_gild_LossContingencyPartiesFilingOppositionNumber_label_en-US" xlink:label="lab_gild_LossContingencyPartiesFilingOppositionNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Parties Filing Opposition, Number</link:label>
    <link:label id="lab_gild_LossContingencyPartiesFilingOppositionNumber_documentation_en-US" xlink:label="lab_gild_LossContingencyPartiesFilingOppositionNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Parties Filing Opposition, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesFilingOppositionNumber" xlink:href="gild-20210331.xsd#gild_LossContingencyPartiesFilingOppositionNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyPartiesFilingOppositionNumber" xlink:to="lab_gild_LossContingencyPartiesFilingOppositionNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_4c51177c-4c53-481e-87ed-cd86914edb74_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_0fa60ccd-b2ee-4646-8eca-28c9af9f28c5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock&#160;</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6fbfeeb2-b868-46ab-8ca6-b3e2502c938f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember_8410bfe7-d78b-41e2-a59d-91431d898da6_terseLabel_en-US" xlink:label="lab_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">the &#8220;Stock Purchase Agreements&#8221;</link:label>
    <link:label id="lab_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember_label_en-US" xlink:label="lab_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchase Agreement and Investor Rights Agreement [Member]</link:label>
    <link:label id="lab_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember_documentation_en-US" xlink:label="lab_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchase Agreement and Investor Rights Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember" xlink:href="gild-20210331.xsd#gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember" xlink:to="lab_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_795827fa-8490-438d-87ef-4f2bba14ec0c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_4a55c428-f485-4378-b5ad-0d29a3f64e6c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of each class</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_e85a809b-6799-472f-9657-382317007c61_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_9bda41ec-2bc5-40db-96de-324e3267a3d8_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_32002e02-f31c-4928-9d75-b66cc17e7312_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_b7f00ae8-adf7-4ad1-8e7b-776749c7d2fa_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member_ccca6cf1-520b-4fb6-804e-8e31f21205d0_terseLabel_en-US" xlink:label="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% Senior Unsecured Notes Due October 2040</link:label>
    <link:label id="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member_label_en-US" xlink:label="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% Senior Unsecured Notes Due October 2040 [Member]</link:label>
    <link:label id="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member_documentation_en-US" xlink:label="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% Senior Unsecured Notes Due October 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:href="gild-20210331.xsd#gild_A260SeniorUnsecuredNotesDueOctober2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:to="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_8ee845b0-dc52-455a-a0f6-523deafb7f94_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_bd122973-adc1-45ab-81c9-06807ea30961_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_f95aaa99-1a39-467c-9fbf-5db1c155ebce_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MYRGmbHMember_2b6e8db5-64ab-4fd8-bcaa-bc03014c7e45_terseLabel_en-US" xlink:label="lab_gild_MYRGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYR GmbH</link:label>
    <link:label id="lab_gild_MYRGmbHMember_label_en-US" xlink:label="lab_gild_MYRGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYR GmbH [Member]</link:label>
    <link:label id="lab_gild_MYRGmbHMember_documentation_en-US" xlink:label="lab_gild_MYRGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYR GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember" xlink:href="gild-20210331.xsd#gild_MYRGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MYRGmbHMember" xlink:to="lab_gild_MYRGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_70f7c24a-1c5f-417e-bd07-25f4a2167250_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_QuiTamMember_b0110d38-dde6-4593-9928-1c6315f823c2_terseLabel_en-US" xlink:label="lab_gild_QuiTamMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qui Tam</link:label>
    <link:label id="lab_gild_QuiTamMember_label_en-US" xlink:label="lab_gild_QuiTamMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qui Tam [Member]</link:label>
    <link:label id="lab_gild_QuiTamMember_documentation_en-US" xlink:label="lab_gild_QuiTamMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qui Tam</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_QuiTamMember" xlink:href="gild-20210331.xsd#gild_QuiTamMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_QuiTamMember" xlink:to="lab_gild_QuiTamMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_11f981b9-5cd7-45e9-bd31-a3dbc675c1f0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_a6435180-4fbb-4b20-b203-720d1a7b0ea0_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_296fbea8-42f1-458b-9af2-bfdc07205c16_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized&#160;Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_894ab3d9-6af7-4144-bc61-1c16af09f461_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Reclassification Adjustments, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherHepatitisCVirusProductsMember_359f4225-a1b5-434b-8e2b-82683589c817_terseLabel_en-US" xlink:label="lab_gild_OtherHepatitisCVirusProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HCV</link:label>
    <link:label id="lab_gild_OtherHepatitisCVirusProductsMember_label_en-US" xlink:label="lab_gild_OtherHepatitisCVirusProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Hepatitis C Virus Products [Member]</link:label>
    <link:label id="lab_gild_OtherHepatitisCVirusProductsMember_documentation_en-US" xlink:label="lab_gild_OtherHepatitisCVirusProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Hepatitis C Virus Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherHepatitisCVirusProductsMember" xlink:href="gild-20210331.xsd#gild_OtherHepatitisCVirusProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherHepatitisCVirusProductsMember" xlink:to="lab_gild_OtherHepatitisCVirusProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherEquitySecuritiesMember_1b637184-7bbd-41be-b4ce-c9b1d8e2ce7b_terseLabel_en-US" xlink:label="lab_gild_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Equity Securities</link:label>
    <link:label id="lab_gild_OtherEquitySecuritiesMember_label_en-US" xlink:label="lab_gild_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Equity Securities [Member]</link:label>
    <link:label id="lab_gild_OtherEquitySecuritiesMember_documentation_en-US" xlink:label="lab_gild_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherEquitySecuritiesMember" xlink:href="gild-20210331.xsd#gild_OtherEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherEquitySecuritiesMember" xlink:to="lab_gild_OtherEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_9179dff0-4007-4748-9130-8053fa8bb9fb_terseLabel_en-US" xlink:label="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.50% Senior Unsecured Notes Due September 2023</link:label>
    <link:label id="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_label_en-US" xlink:label="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.50% Senior Unsecured Notes Due September 2023 [Member]</link:label>
    <link:label id="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_documentation_en-US" xlink:label="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.50% Senior Unsecured Notes Due September 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:href="gild-20210331.xsd#gild_A250SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:to="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_3d78591c-1b9f-4893-a88a-bca8e2aa2230_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_3195ce87-f674-4f27-9c42-9920c119fc27_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ProductLiabilityMember_ae589386-cc13-4e10-ba29-3968b164c328_terseLabel_en-US" xlink:label="lab_gild_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:label id="lab_gild_ProductLiabilityMember_label_en-US" xlink:label="lab_gild_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability [Member]</link:label>
    <link:label id="lab_gild_ProductLiabilityMember_documentation_en-US" xlink:label="lab_gild_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductLiabilityMember" xlink:href="gild-20210331.xsd#gild_ProductLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ProductLiabilityMember" xlink:to="lab_gild_ProductLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_16e18345-3e0a-4550-901e-6908ef99d456_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_4fb90400-253e-43d2-8511-97647009c945_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_b9f5a928-8a56-44d2-8efb-fc568b7d917e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1f3b50a0-8e77-4294-aa05-29143573612e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Effect of Foreign Currency Exchange Contracts</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_2f082e93-9ac8-44dd-9bb3-b7cc8e875ca3_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_de3f51ad-2d6d-4e31-9bcd-d1722c20dda9_verboseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_857415ab-7e97-4a96-8e60-6a85d3611815_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_eeedf6ba-144e-45e6-a1a6-9b4e7433c6a5_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_e1268069-f1b6-40c1-826b-178f9261e35d_terseLabel_en-US" xlink:label="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Sharp &amp; Dohme Corp agreement</link:label>
    <link:label id="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_label_en-US" xlink:label="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Sharp &amp; Dohme Corp License And Collaboration Agreement [Member]</link:label>
    <link:label id="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_documentation_en-US" xlink:label="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Sharp &amp; Dohme Corp License And Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:href="gild-20210331.xsd#gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:to="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_bc4e46e1-de81-4059-ad69-11584b00d40a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion of long-term debt and other obligations, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_6392e6c6-f13d-43b1-887f-de3de35ad4a1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_94d1b02f-6290-48e0-85eb-f76f1626b69a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_0d260ad1-e550-4809-976e-b445ca1ff938_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_6e4b9f48-b851-498e-b429-dc2193a47c86_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_3cdbe995-e772-40df-a9f1-290f456f4b6e_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborationArrangementNetProductSalesThreshold_2dee1247-ae55-48b1-b5d0-d08c9e282f65_terseLabel_en-US" xlink:label="lab_gild_CollaborationArrangementNetProductSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product sales threshold</link:label>
    <link:label id="lab_gild_CollaborationArrangementNetProductSalesThreshold_label_en-US" xlink:label="lab_gild_CollaborationArrangementNetProductSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Net Product Sales Threshold</link:label>
    <link:label id="lab_gild_CollaborationArrangementNetProductSalesThreshold_documentation_en-US" xlink:label="lab_gild_CollaborationArrangementNetProductSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Net Product Sales Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementNetProductSalesThreshold" xlink:href="gild-20210331.xsd#gild_CollaborationArrangementNetProductSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborationArrangementNetProductSalesThreshold" xlink:to="lab_gild_CollaborationArrangementNetProductSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CumulativeEffectPeriodOfAdoptionAxis_50906487-6150-4806-8236-a5627a247ee8_terseLabel_en-US" xlink:label="lab_gild_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period Of Adoption [Axis]</link:label>
    <link:label id="lab_gild_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_gild_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period Of Adoption [Axis]</link:label>
    <link:label id="lab_gild_CumulativeEffectPeriodOfAdoptionAxis_documentation_en-US" xlink:label="lab_gild_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period Of Adoption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="gild-20210331.xsd#gild_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_gild_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_7d4d4741-d701-4f4b-9b29-711663627303_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_a22101e6-49af-48f1-8538-6f41c290ccf0_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_58bd0a05-ef75-4746-ae7e-9c492faafd53_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_e362d3bf-1f02-474d-9fd3-b5744390044e_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total HBV/HDV</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:href="gild-20210331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_7d07ab2e-ab7b-4fce-b3b8-0002c6cde60c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_b05ca03e-24df-48b8-965f-f68050c53e5b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_8003a34d-05da-4ac1-886d-7b743500c21e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Classification of Equity Securities</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_eea11b06-3daf-44ed-b2e1-dc0902f4fe8c_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts of Assets/Liabilities Presented on our Condensed Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent_09c5867e-c4fb-4402-a600-8952b102388b_terseLabel_en-US" xlink:label="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: cash discounts and other</link:label>
    <link:label id="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent_label_en-US" xlink:label="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Cash Discounts and Other, Current</link:label>
    <link:label id="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent_documentation_en-US" xlink:label="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Cash Discounts and Other, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:href="gild-20210331.xsd#gild_AccountsReceivableCashDiscountsAndOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:to="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_e82b96aa-6879-4a98-a54d-6f2a1ba52162_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160; Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_c3c5d660-7f56-4c1b-aaf2-b93cd5b6e2af_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_9afcef81-9892-431f-ab2e-a0f9db4e19f7_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_049309c4-d2b9-4a99-815b-165a4d402fda_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Debt Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsAtriplaMember_0662108a-6bdd-4cf4-8d2e-d9f6e39801b0_terseLabel_en-US" xlink:label="lab_gild_HIVProductsAtriplaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Atripla</link:label>
    <link:label id="lab_gild_HIVProductsAtriplaMember_label_en-US" xlink:label="lab_gild_HIVProductsAtriplaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Atripla [Member]</link:label>
    <link:label id="lab_gild_HIVProductsAtriplaMember_documentation_en-US" xlink:label="lab_gild_HIVProductsAtriplaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Atripla [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsAtriplaMember" xlink:href="gild-20210331.xsd#gild_HIVProductsAtriplaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsAtriplaMember" xlink:to="lab_gild_HIVProductsAtriplaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AccruedGovernmentAndOtherRebates_b25080c3-2886-4f3a-81ea-409b14a0af1f_terseLabel_en-US" xlink:label="lab_gild_AccruedGovernmentAndOtherRebates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued government and other rebates</link:label>
    <link:label id="lab_gild_AccruedGovernmentAndOtherRebates_label_en-US" xlink:label="lab_gild_AccruedGovernmentAndOtherRebates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Government And Other Rebates</link:label>
    <link:label id="lab_gild_AccruedGovernmentAndOtherRebates_documentation_en-US" xlink:label="lab_gild_AccruedGovernmentAndOtherRebates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Government And Other Rebates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccruedGovernmentAndOtherRebates" xlink:href="gild-20210331.xsd#gild_AccruedGovernmentAndOtherRebates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AccruedGovernmentAndOtherRebates" xlink:to="lab_gild_AccruedGovernmentAndOtherRebates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_38582053-f447-4d1e-ab7a-c41f7ff98aa3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CumulativeEffectPeriodOfAdoptionAdjustmentMember_c1c7ae40-48f1-40e5-aeaa-a8da41513e40_terseLabel_en-US" xlink:label="lab_gild_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect from the adoption of new accounting standard</link:label>
    <link:label id="lab_gild_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_gild_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period Of Adoption, Adjustment [Member]</link:label>
    <link:label id="lab_gild_CumulativeEffectPeriodOfAdoptionAdjustmentMember_documentation_en-US" xlink:label="lab_gild_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period Of Adoption, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="gild-20210331.xsd#gild_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_gild_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member_a7f55d43-afc3-46a5-b333-61aea00accfe_terseLabel_en-US" xlink:label="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.65% Senior Unsecured Notes Due December 204</link:label>
    <link:label id="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member_label_en-US" xlink:label="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.65% Senior Unsecured Notes Due December 2041 [Member]</link:label>
    <link:label id="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member_documentation_en-US" xlink:label="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.65% Senior Unsecured Notes Due December 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:href="gild-20210331.xsd#gild_A565SeniorUnsecuredNotesDueDecember2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:to="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborativeAndOtherArrangementsTextBlock_3789c36a-ada3-43d2-833c-2206f361702c_terseLabel_en-US" xlink:label="lab_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATIONS AND OTHER ARRANGEMENTS</link:label>
    <link:label id="lab_gild_CollaborativeAndOtherArrangementsTextBlock_label_en-US" xlink:label="lab_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative And Other Arrangements [Text Block]</link:label>
    <link:label id="lab_gild_CollaborativeAndOtherArrangementsTextBlock_documentation_en-US" xlink:label="lab_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Arrangements [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:href="gild-20210331.xsd#gild_CollaborativeAndOtherArrangementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:to="lab_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_25fef93b-adf9-4ac4-a2b0-0916d36f7261_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: allowances for credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_d5f7e595-a47f-47fe-90eb-95cb3858109b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing from senior unsecured term loan facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_31ddb204-e706-432f-9f6f-debb87cd63f4_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_e4d9cd5c-412b-49f7-bff1-7dec196470a2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Amounts Offset on our Condensed Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_8cea2479-3b9f-4b87-8640-c62015c1394d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_9fe61568-167d-4847-9af1-1f85ae0512b6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENT</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_81ea53d2-22df-4c02-a029-dc0758cdab46_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of possible loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_b31bdccb-fcc6-4ec4-afd2-a11bdaef343c_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_InventoryNetAndInventoryNoncurrent_23d9691d-5aab-4359-99db-d4bbefa5d762_totalLabel_en-US" xlink:label="lab_gild_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_gild_InventoryNetAndInventoryNoncurrent_label_en-US" xlink:label="lab_gild_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Net And Inventory Noncurrent</link:label>
    <link:label id="lab_gild_InventoryNetAndInventoryNoncurrent_documentation_en-US" xlink:label="lab_gild_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Net And Inventory Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent" xlink:href="gild-20210331.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent" xlink:to="lab_gild_InventoryNetAndInventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_77b0544d-a2fa-49cd-807f-1d97bde7522e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5dbbf996-bd94-4e8a-978a-133c86c95a56_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_4cf54d4a-76f1-49b2-ae9d-ba6e56085e52_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_a3aa6d36-06b9-405c-a3d2-468e6a9733d4_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinuances of cash flow hedges</link:label>
    <link:label id="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_label_en-US" xlink:label="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Discontinuation of Foreign Currency Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:to="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_f2fa8504-8090-4925-8f69-03c51a0fb858_terseLabel_en-US" xlink:label="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes Due February 2045</link:label>
    <link:label id="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_label_en-US" xlink:label="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes Due February 2045 [Member]</link:label>
    <link:label id="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_documentation_en-US" xlink:label="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes Due February 2045 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:href="gild-20210331.xsd#gild_A450SeniorUnsecuredNotesDueFebruary2045Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:to="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_d3c3d141-b6e3-4bb5-9f72-15bcb8c468fe_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_47a9964f-0734-487c-969a-4e68cc29b9ff_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified_8a662c33-60cd-45c3-8c08-0a2f28105468_terseLabel_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassified amounts</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified_label_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross, Reclassified</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified_documentation_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross, Reclassified</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:href="gild-20210331.xsd#gild_FiniteLivedIntangibleAssetsGrossReclassified"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:to="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_93464a35-e707-4dbb-828a-be4224513c92_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CellTherapyProductsYescartaMember_0a5fff5e-edea-446f-bbd4-1a2385335a06_terseLabel_en-US" xlink:label="lab_gild_CellTherapyProductsYescartaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yescarta</link:label>
    <link:label id="lab_gild_CellTherapyProductsYescartaMember_label_en-US" xlink:label="lab_gild_CellTherapyProductsYescartaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Yescarta [Member]</link:label>
    <link:label id="lab_gild_CellTherapyProductsYescartaMember_documentation_en-US" xlink:label="lab_gild_CellTherapyProductsYescartaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Yescarta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsYescartaMember" xlink:href="gild-20210331.xsd#gild_CellTherapyProductsYescartaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CellTherapyProductsYescartaMember" xlink:to="lab_gild_CellTherapyProductsYescartaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_bee8f3d3-596d-4d27-9ef0-e79c5dd7977c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfUnsecuredDebt_4e1251ad-e278-40c6-9e71-0ad1b02d9d39_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfUnsecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of senior unsecured notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfUnsecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfUnsecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Unsecured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfUnsecuredDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfUnsecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfUnsecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_baf49c1b-f71b-4c64-b1d2-d797ac87bea9_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_78750e75-b5e2-4094-b712-2de0eb7b39e8_terseLabel_en-US" xlink:label="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.25% Senior Unsecured Notes Due September 2022</link:label>
    <link:label id="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_label_en-US" xlink:label="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.25% Senior Unsecured Notes Due September 2022 [Member]</link:label>
    <link:label id="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_documentation_en-US" xlink:label="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.25% Senior Unsecured Notes Due September 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:href="gild-20210331.xsd#gild_A325SeniorUnsecuredNotesDueSeptember2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:to="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_a86b018b-2410-4167-a499-f7bba4c4ff7e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of dividends</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MarketableSecuritiesCurrentMember_59195d9b-e18a-4b17-8027-72af41b459cb_terseLabel_en-US" xlink:label="lab_gild_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities</link:label>
    <link:label id="lab_gild_MarketableSecuritiesCurrentMember_label_en-US" xlink:label="lab_gild_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current [Member]</link:label>
    <link:label id="lab_gild_MarketableSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_gild_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesCurrentMember" xlink:href="gild-20210331.xsd#gild_MarketableSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MarketableSecuritiesCurrentMember" xlink:to="lab_gild_MarketableSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_3fc5420c-ad57-4082-8787-508575aa7676_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_f2f4b989-186c-4749-ab1c-f54d4c5aa4c7_totalLabel_en-US" xlink:label="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Indefinite Lived Intangible Assets Excluding Goodwill</link:label>
    <link:label id="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_documentation_en-US" xlink:label="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total carrying amount of assets (excluding financial assets) that lack physical substance, excluding goodwill, having a projected indefinite period of benefit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="gild-20210331.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_653745d7-0dad-47d1-aeeb-50872dc2df0b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GOODWILL AND INTANGIBLE ASSETS</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_f4c6e370-3d4b-46a2-8e70-3093838496c3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_23a101dc-557e-4b56-a4fb-b95f7fa2805a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, performance obligation satisfied in previous period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0933ea2c-a1ea-4e8b-9995-a7e6c53992fc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56d3fde2-15e0-42c5-8e7f-81b7fcbc835d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a94bafd7-0942-4b00-8fd8-439469aa928d_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_d8f5fd72-aa57-4800-a939-17508b0c00e9_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_VekluryMember_90c771f1-3cce-4789-915c-3eb2275f509e_terseLabel_en-US" xlink:label="lab_gild_VekluryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Veklury</link:label>
    <link:label id="lab_gild_VekluryMember_label_en-US" xlink:label="lab_gild_VekluryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Veklury [Member]</link:label>
    <link:label id="lab_gild_VekluryMember_documentation_en-US" xlink:label="lab_gild_VekluryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Veklury</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VekluryMember" xlink:href="gild-20210331.xsd#gild_VekluryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_VekluryMember" xlink:to="lab_gild_VekluryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a9aad34-5c73-4825-962f-0b597a465724_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_72e32cde-9e8d-45ec-9d8c-ca704effc498_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_8f3c8e72-38f8-48e4-aa66-1c293934ec67_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PaymentsToAcquireEquitySecuritiesFVNI_1c223370-b344-4fb0-8e70-a9f4e496cfa3_terseLabel_en-US" xlink:label="lab_gild_PaymentsToAcquireEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire equity securities</link:label>
    <link:label id="lab_gild_PaymentsToAcquireEquitySecuritiesFVNI_label_en-US" xlink:label="lab_gild_PaymentsToAcquireEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Securities, FV, NI</link:label>
    <link:label id="lab_gild_PaymentsToAcquireEquitySecuritiesFVNI_documentation_en-US" xlink:label="lab_gild_PaymentsToAcquireEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Securities, FV, NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToAcquireEquitySecuritiesFVNI" xlink:href="gild-20210331.xsd#gild_PaymentsToAcquireEquitySecuritiesFVNI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PaymentsToAcquireEquitySecuritiesFVNI" xlink:to="lab_gild_PaymentsToAcquireEquitySecuritiesFVNI" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_271984f2-652e-4885-8f5c-40d4c78c48af_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_ac1af422-552a-40d9-b822-efd6cbece932_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages amount</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MarketableSecuritiesNoncurrentMember_f1db7e02-10af-4db7-bc3e-6664bef52c97_terseLabel_en-US" xlink:label="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities</link:label>
    <link:label id="lab_gild_MarketableSecuritiesNoncurrentMember_label_en-US" xlink:label="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent [Member]</link:label>
    <link:label id="lab_gild_MarketableSecuritiesNoncurrentMember_documentation_en-US" xlink:label="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesNoncurrentMember" xlink:href="gild-20210331.xsd#gild_MarketableSecuritiesNoncurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MarketableSecuritiesNoncurrentMember" xlink:to="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_ebe4efc2-b9f0-49e5-8d92-767d21752618_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_4ee5deb5-6ced-45ea-bdd8-3ce2132d7e25_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_54260639-8ea6-4148-82f1-bff544b3a66f_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a91b476c-6af8-4e56-bbe4-5679a5c873ed_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value&#160;</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0e0f786b-8def-436f-9184-91b91380074e_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyEstimateOfPossibleLossPastSales_3bf75da7-da17-4c0e-9e21-3fd3d4608cbc_terseLabel_en-US" xlink:label="lab_gild_LossContingencyEstimateOfPossibleLossPastSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of possible loss representing past sales</link:label>
    <link:label id="lab_gild_LossContingencyEstimateOfPossibleLossPastSales_label_en-US" xlink:label="lab_gild_LossContingencyEstimateOfPossibleLossPastSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate Of Possible Loss (Past Sales)</link:label>
    <link:label id="lab_gild_LossContingencyEstimateOfPossibleLossPastSales_documentation_en-US" xlink:label="lab_gild_LossContingencyEstimateOfPossibleLossPastSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate Of Possible Loss (Past Sales)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyEstimateOfPossibleLossPastSales" xlink:href="gild-20210331.xsd#gild_LossContingencyEstimateOfPossibleLossPastSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyEstimateOfPossibleLossPastSales" xlink:to="lab_gild_LossContingencyEstimateOfPossibleLossPastSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_1fc20266-dc12-4d51-880d-305953db9e88_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount (Legal Offset)</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A440SeniorUnsecuredNotesDueDecember2021Member_57be208d-4f83-4841-a942-3a2110350eef_terseLabel_en-US" xlink:label="lab_gild_A440SeniorUnsecuredNotesDueDecember2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.40% Senior Unsecured Notes Due December 2021</link:label>
    <link:label id="lab_gild_A440SeniorUnsecuredNotesDueDecember2021Member_label_en-US" xlink:label="lab_gild_A440SeniorUnsecuredNotesDueDecember2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.40% Senior Unsecured Notes Due December 2021 [Member]</link:label>
    <link:label id="lab_gild_A440SeniorUnsecuredNotesDueDecember2021Member_documentation_en-US" xlink:label="lab_gild_A440SeniorUnsecuredNotesDueDecember2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.40% Senior Unsecured Notes Due December 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A440SeniorUnsecuredNotesDueDecember2021Member" xlink:href="gild-20210331.xsd#gild_A440SeniorUnsecuredNotesDueDecember2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A440SeniorUnsecuredNotesDueDecember2021Member" xlink:to="lab_gild_A440SeniorUnsecuredNotesDueDecember2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_49b7ce05-0559-4195-be9a-4e3114b2251d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_4b446bba-556f-4bc0-a824-949474552eee_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3e362e0a-51e6-49f8-a574-4e7605e95703_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_19bbd48a-728c-499b-8f59-0db349ee2328_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_08a5753a-7854-4968-909b-a09c836a9571_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7f6a0c5e-7a6e-4833-ace1-78046860581c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_af770118-cd48-4338-b5f6-30b86b995770_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ProductsOtherHIVMember_d2f8f0ad-24ad-40e9-8735-a58eb71f8fc1_terseLabel_en-US" xlink:label="lab_gild_ProductsOtherHIVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HIV</link:label>
    <link:label id="lab_gild_ProductsOtherHIVMember_label_en-US" xlink:label="lab_gild_ProductsOtherHIVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Other HIV [Member]</link:label>
    <link:label id="lab_gild_ProductsOtherHIVMember_documentation_en-US" xlink:label="lab_gild_ProductsOtherHIVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Other HIV [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsOtherHIVMember" xlink:href="gild-20210331.xsd#gild_ProductsOtherHIVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ProductsOtherHIVMember" xlink:to="lab_gild_ProductsOtherHIVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_3c3ce02a-8db6-4152-97c5-8dd5ad89ea9b_negatedTerseLabel_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties</link:label>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_label_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability</link:label>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_documentation_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:href="gild-20210331.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:to="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_fcef74c6-4a76-4aa7-bd0f-149101045cde_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5ca2b774-21d6-457e-9fdd-565b3a7aca3d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share attributable to Gilead common stockholders - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_264932e4-80c9-4d01-9a42-207af84a13b4_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share attributable to Gilead common stockholders - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A2016StockRepurchaseProgramMember_e7390926-9116-4506-943f-8bf08ce9817f_terseLabel_en-US" xlink:label="lab_gild_A2016StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Stock Repurchase Program</link:label>
    <link:label id="lab_gild_A2016StockRepurchaseProgramMember_label_en-US" xlink:label="lab_gild_A2016StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Stock Repurchase Program [Member]</link:label>
    <link:label id="lab_gild_A2016StockRepurchaseProgramMember_documentation_en-US" xlink:label="lab_gild_A2016StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Stock Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2016StockRepurchaseProgramMember" xlink:href="gild-20210331.xsd#gild_A2016StockRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A2016StockRepurchaseProgramMember" xlink:to="lab_gild_A2016StockRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_66d95c15-2073-438e-a8d3-d6947a5645b6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_88119771-721f-4298-bf38-5b223a1fb4e0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt and other obligations, net</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsZydeligMember_b587b396-06d7-4953-889d-74b9b9f3e351_terseLabel_en-US" xlink:label="lab_gild_OtherProductsZydeligMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zydelig</link:label>
    <link:label id="lab_gild_OtherProductsZydeligMember_label_en-US" xlink:label="lab_gild_OtherProductsZydeligMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Zydelig [Member]</link:label>
    <link:label id="lab_gild_OtherProductsZydeligMember_documentation_en-US" xlink:label="lab_gild_OtherProductsZydeligMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Zydelig [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsZydeligMember" xlink:href="gild-20210331.xsd#gild_OtherProductsZydeligMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsZydeligMember" xlink:to="lab_gild_OtherProductsZydeligMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_8a50a6cb-55ef-4c49-b2b0-6075b0e4a6e8_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_433ca0e3-eda3-48cb-b873-a5444dd64781_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_3cdd2dd7-49c8-4a48-8751-a62a2cc57294_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_3e72ad97-cf13-4655-ab51-f13256411d90_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CallTherapyProductsTecartusMember_850e9edf-7410-4d79-9ec4-f02870060111_terseLabel_en-US" xlink:label="lab_gild_CallTherapyProductsTecartusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tecartus</link:label>
    <link:label id="lab_gild_CallTherapyProductsTecartusMember_label_en-US" xlink:label="lab_gild_CallTherapyProductsTecartusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Therapy Products, Tecartus [Member]</link:label>
    <link:label id="lab_gild_CallTherapyProductsTecartusMember_documentation_en-US" xlink:label="lab_gild_CallTherapyProductsTecartusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Therapy Products, Tecartus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CallTherapyProductsTecartusMember" xlink:href="gild-20210331.xsd#gild_CallTherapyProductsTecartusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CallTherapyProductsTecartusMember" xlink:to="lab_gild_CallTherapyProductsTecartusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_88fb293b-5a1d-4dfb-a6ac-f3530d4883a5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c5d5038a-89d3-44f0-8447-30825195b3ab_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign currency translation gain (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_11e43911-8c98-4d5c-9ba8-c1eb50503826_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_ed46e32d-6b6e-4614-897d-ac54fc2f41a2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements_a98a452a-1caf-4345-b7e5-d6991b653011_terseLabel_en-US" xlink:label="lab_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront collaboration expenses related to other collaborative arrangements</link:label>
    <link:label id="lab_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements_label_en-US" xlink:label="lab_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Collaboration Expenses Related to Other Collaborative Arrangements</link:label>
    <link:label id="lab_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements_documentation_en-US" xlink:label="lab_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Collaboration Expenses Related to Other Collaborative Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements" xlink:href="gild-20210331.xsd#gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements" xlink:to="lab_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_02718d07-67ce-43cb-b0ee-31415ee48ce3_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member_a54153e3-55de-4aca-b74b-df84a70a15db_terseLabel_en-US" xlink:label="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.80% Senior Unsecured Notes Due April 2044</link:label>
    <link:label id="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member_label_en-US" xlink:label="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.80% Senior Unsecured Notes Due April 2044 [Member]</link:label>
    <link:label id="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member_documentation_en-US" xlink:label="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.80% Senior Unsecured Notes Due April 2044 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:href="gild-20210331.xsd#gild_A480SeniorUnsecuredNotesDueApril2044Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:to="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_0673c346-c002-4374-801f-fe651ca00c14_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CreditFacilityDueJune2025Member_d8a6e660-dc12-4b20-ad65-70e0deedf73d_terseLabel_en-US" xlink:label="lab_gild_CreditFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">the "2020 Revolving Credit Facility"</link:label>
    <link:label id="lab_gild_CreditFacilityDueJune2025Member_label_en-US" xlink:label="lab_gild_CreditFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Due June 2025 [Member]</link:label>
    <link:label id="lab_gild_CreditFacilityDueJune2025Member_documentation_en-US" xlink:label="lab_gild_CreditFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Due June 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueJune2025Member" xlink:href="gild-20210331.xsd#gild_CreditFacilityDueJune2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CreditFacilityDueJune2025Member" xlink:to="lab_gild_CreditFacilityDueJune2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_4f2ea850-0f2d-489a-9540-c3f107b68ed9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_4da2b75e-bb4e-4fe4-81fa-794ab970efa2_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6b0ef7c2-961e-47dc-a615-1c7b02bae7e5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_c44b659a-e2e3-42ff-8427-a71898eb151f_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_f56a8f74-89c4-4749-854f-18f174fca402_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains recognized in AOCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f7ce547-d888-4f40-8add-f98f57594360_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_82bfb9c3-3ad3-47d0-9a80-6548563da67c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER FINANCIAL INFORMATION</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_cb5a0394-66c2-4b2a-8513-b5f5cb41c17b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_3d0e3180-e307-4986-bcaf-c96d50af7f8e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments not measured at fair value</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_dc52cd36-0afb-4b7d-9750-e7a38e51ebd5_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_b5bd0be9-ef54-4ce9-bf6c-e987916a6481_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_8a3f8ff9-1efb-4de3-8bad-bcb6c9207174_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to net income</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_6266b003-9a39-430f-871e-181f3b6a240c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allocated and Single Maturity Date, Maturity, after 10 Years, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_9cd1f885-ba8d-4197-a5c5-24517eb821aa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Amounts of Recognized Assets/Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_b787f26f-edae-4cb8-92d1-54868c3557f9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_15efb7c8-c8a6-4f56-9695-7d6851bc53cc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CumulativeEffectPeriodOfAdoptionDomain_c6f08d4c-541d-46c5-8b8b-db09d289760a_terseLabel_en-US" xlink:label="lab_gild_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period Of Adoption [Domain]</link:label>
    <link:label id="lab_gild_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_gild_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period Of Adoption [Domain]</link:label>
    <link:label id="lab_gild_CumulativeEffectPeriodOfAdoptionDomain_documentation_en-US" xlink:label="lab_gild_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period Of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="gild-20210331.xsd#gild_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_gild_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNISharesAcquired_cf85b1d3-e843-4700-b6bb-90b8c8f9f732_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNISharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities acquired (in shares)</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNISharesAcquired_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNISharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Shares Acquired</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNISharesAcquired_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNISharesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Shares Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNISharesAcquired" xlink:href="gild-20210331.xsd#gild_EquitySecuritiesFVNISharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNISharesAcquired" xlink:to="lab_gild_EquitySecuritiesFVNISharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7387a025-97f7-4a2f-9567-881ea0652c2a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_d4614eea-bc8e-4375-b5cc-4a04bd267603_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_36c12f32-3397-4b30-ab1b-4871089f693a_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_568374ac-321e-427e-a976-e4758ea87f69_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_65286caa-dbcd-49f4-a31c-33ced63f4310_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_eb70a588-6a65-4980-a408-8e9ff4181965_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_6eacb632-9cf6-41a3-8f26-3239d84c2346_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_ebab630b-ffea-45b8-9744-694c65b0deff_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_4ccc08b0-a20e-4ead-8b88-b93011ea4154_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_076bcf81-39b7-4141-a9fc-47a2f13304e6_verboseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_7abb835e-1883-4e4b-8048-357cead05328_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_319efebe-a68a-40fb-b827-2b6dfa0824d7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_d2c8754b-96f2-4f69-973a-e5dc6b27636b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_b165d863-f0b4-4d32-a69c-77b986f6cc39_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_56a68fdc-2998-4c60-8e99-7893037a02d5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equity securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_02abe07a-b74f-4e0e-99ec-acc5d9d14dc6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions held in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8733426b-e7fb-42ab-a79a-c48c44c9de1f_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_63156940-dfb6-489f-88c4-d7c348751359_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term and long-term debt, carrying values</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_d890adb5-d39c-4f93-bbab-7d306c7e617a_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_WriteOffsInAccruedInterestReceivable_d0d4c36e-2d98-4222-b174-36c2d4618ff3_terseLabel_en-US" xlink:label="lab_gild_WriteOffsInAccruedInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-offs of accrued interest receivable</link:label>
    <link:label id="lab_gild_WriteOffsInAccruedInterestReceivable_label_en-US" xlink:label="lab_gild_WriteOffsInAccruedInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-Offs In Accrued Interest Receivable</link:label>
    <link:label id="lab_gild_WriteOffsInAccruedInterestReceivable_documentation_en-US" xlink:label="lab_gild_WriteOffsInAccruedInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off in accrued interest receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_WriteOffsInAccruedInterestReceivable" xlink:href="gild-20210331.xsd#gild_WriteOffsInAccruedInterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_WriteOffsInAccruedInterestReceivable" xlink:to="lab_gild_WriteOffsInAccruedInterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_89e85f8a-a8a7-40db-b4bc-fc5787adacff_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_45039315-2b8e-4f0d-a28c-ee0ba3aa138d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_df0cdd41-1051-4863-a9b8-6470ab8fd4f5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_1d670f8e-08ec-41b4-9a75-65c380a71ef0_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_d76b3c50-e9c0-4255-9ad9-f94e292229c6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_d4ce1fca-ed1c-42ab-95ed-68ad18ca9da0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected tax deductible goodwill</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JudgmentEnhancedDamagesOnPastSales_ec6184fd-423e-4355-8d82-60c10ea25027_terseLabel_en-US" xlink:label="lab_gild_JudgmentEnhancedDamagesOnPastSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enhancement rate on past damages</link:label>
    <link:label id="lab_gild_JudgmentEnhancedDamagesOnPastSales_label_en-US" xlink:label="lab_gild_JudgmentEnhancedDamagesOnPastSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Enhanced Damages On Past Sales</link:label>
    <link:label id="lab_gild_JudgmentEnhancedDamagesOnPastSales_documentation_en-US" xlink:label="lab_gild_JudgmentEnhancedDamagesOnPastSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Enhanced Damages On Past Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentEnhancedDamagesOnPastSales" xlink:href="gild-20210331.xsd#gild_JudgmentEnhancedDamagesOnPastSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JudgmentEnhancedDamagesOnPastSales" xlink:to="lab_gild_JudgmentEnhancedDamagesOnPastSales" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a1f05e78-17cd-454f-b6fa-9a52208dd80d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_97263d88-a2f3-4e81-aad9-5f8d7618f871_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Changes in Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7a7f0c52-d6f2-498b-8b88-66eae76f01a0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_e6e52a5c-dcce-410f-8304-912bd82caef4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net losses from equity securities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_9991c578-fda4-4f23-aacd-4156a95ce340_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net losses from equity securities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_036e12c9-ddee-4402-b2a9-37c8d3277ca0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5910b6e1-c9da-4d38-9f93-81685856a386_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_91f83eeb-c3c6-4980-bc7e-72af7292dd2c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVAILABLE-FOR-SALE DEBT SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_fe9733a0-227f-44ab-9e8f-38e92e83a95b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Collateral Received/ Pledged</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Collateral, Obligation to Return Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:to="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_1635b842-5aca-4419-95bd-01c1ef8b74ad_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_b573a9ac-6400-4eec-9e1f-4ba210882fa1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_213868d7-0b2c-49c3-9b3c-34bc42104b85_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_6f561e6c-1805-45ed-a9c1-6add7a06a97c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_f068e24d-941a-45ef-a3af-fee4ed3e8786_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt and other obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_553f7d44-5b43-466c-bbbf-bc220b35638a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_36fe2c37-7e83-43fc-9abe-d9d1c8882595_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_0d92adb1-89b7-4848-bb19-e85bcb0f29ff_terseLabel_en-US" xlink:label="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option period to license</link:label>
    <link:label id="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_label_en-US" xlink:label="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period</link:label>
    <link:label id="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_documentation_en-US" xlink:label="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:href="gild-20210331.xsd#gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:to="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OralFormulationProductMember_69ddba90-ee31-4a44-8783-52823bb991e7_terseLabel_en-US" xlink:label="lab_gild_OralFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Formulation Product</link:label>
    <link:label id="lab_gild_OralFormulationProductMember_label_en-US" xlink:label="lab_gild_OralFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Formulation Product [Member]</link:label>
    <link:label id="lab_gild_OralFormulationProductMember_documentation_en-US" xlink:label="lab_gild_OralFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Formulation Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OralFormulationProductMember" xlink:href="gild-20210331.xsd#gild_OralFormulationProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OralFormulationProductMember" xlink:to="lab_gild_OralFormulationProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_f4c9f596-cf96-486e-ab7a-2a2cf09d9088_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_0f43ed7d-a26b-4af2-a260-d776889f3ec9_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of outstanding stock allowed to be purchased</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:href="gild-20210331.xsd#gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:to="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_85943af8-e380-4b44-804d-abf74f775e39_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_4d5a7b98-25b8-4e8d-b982-bc0d230c13b3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_772d7bb5-7b25-452c-91c6-5adb7c54192f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherFinancialInformationAbstract_de046328-4c8b-4b4b-903f-ee0b6a233b19_terseLabel_en-US" xlink:label="lab_gild_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_gild_OtherFinancialInformationAbstract_label_en-US" xlink:label="lab_gild_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_gild_OtherFinancialInformationAbstract_documentation_en-US" xlink:label="lab_gild_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract" xlink:href="gild-20210331.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherFinancialInformationAbstract" xlink:to="lab_gild_OtherFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9492a733-04c2-4f37-9d44-3dcfdb562dab_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_51f15344-2932-4a80-acd3-98752535c25f_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsCompleraEvipleraMember_e4a70141-d146-4e4c-83ef-3141c7fd13ca_terseLabel_en-US" xlink:label="lab_gild_HIVProductsCompleraEvipleraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Complera/Eviplera</link:label>
    <link:label id="lab_gild_HIVProductsCompleraEvipleraMember_label_en-US" xlink:label="lab_gild_HIVProductsCompleraEvipleraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Complera/Eviplera [Member]</link:label>
    <link:label id="lab_gild_HIVProductsCompleraEvipleraMember_documentation_en-US" xlink:label="lab_gild_HIVProductsCompleraEvipleraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Complera/Eviplera [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsCompleraEvipleraMember" xlink:href="gild-20210331.xsd#gild_HIVProductsCompleraEvipleraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsCompleraEvipleraMember" xlink:to="lab_gild_HIVProductsCompleraEvipleraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a40d8525-dda1-4732-9e77-ad2b19934ff0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_62e06a54-2c40-4e44-81cb-2f57620ebc76_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_c1a2c78d-6b77-4209-bcd0-ed224b933dc3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1fbec260-88ae-4c53-9e03-dbc2aecda5ff_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_3dd5fdca-ef24-474c-a4e6-f18aa6366854_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_b9be60fb-9889-410e-bde8-a1243be96a6c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIPurchasePeriod_1212878b-1926-4808-92e3-3b325282e257_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase period</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIPurchasePeriod_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Purchase Period</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIPurchasePeriod_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:href="gild-20210331.xsd#gild_EquitySecuritiesFVNIPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:to="lab_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_31e6df27-fbbd-4020-8d0b-d1abdb4629eb_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JudgmentRoyaltyRateFromOctober2017_7017b556-3b57-4af2-a25c-e256e13d1d1d_terseLabel_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Running royalty rate from October 2017</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateFromOctober2017_label_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate from October 2017</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateFromOctober2017_documentation_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate from October 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateFromOctober2017" xlink:href="gild-20210331.xsd#gild_JudgmentRoyaltyRateFromOctober2017"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JudgmentRoyaltyRateFromOctober2017" xlink:to="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_d4d9d1f4-3bab-40ea-b28a-c7df046f045d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_4833c7c8-c619-4e86-aaa5-bb0f0713e9bd_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_e0779503-71b6-406e-a3fa-d220151a78f5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_d650ac44-1492-4342-b6e7-4deea362453d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_ce66ff33-3e2c-40e0-a75d-a436e401704e_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_f1a9aea5-8acf-4b44-ad4b-6412ae486a62_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_b2ff2e98-7f72-48f1-9981-c1c50439d0bf_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_f7701992-8b8d-4b3d-8a0d-b5931175efbe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEBT AND CREDIT FACILITIES</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_6fcf4799-682b-44ca-9df9-98a30b54c2b1_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-offs charged against allowance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_edc73964-deac-4e61-83c2-6c41e7c858f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_5a8e5e98-6c86-45c6-88d6-e98c051cfb5f_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_362c393f-4671-4be6-941f-941d7121af9b_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c44469ca-2cbd-49be-b1bd-0242610415fb_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_59bca131-6a18-4721-9cf7-cad18c37bd42_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f707a9bb-ff89-4d20-be14-2d357d4278cd_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_17fa7314-4e3d-49ef-b932-1dd533bbc26f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_83e8262c-7e38-4893-8659-1d24b9acc859_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_87b247f5-b6e1-4fac-b962-8926e876471e_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_0f6952e4-0ff5-482f-b943-670fea9aa4ec_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_442789f7-fd45-4d96-9515-6f39984157e5_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_07efbfff-53a3-4e81-866a-d3dcec12ec77_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_24ffac8d-8441-47ca-9013-fdb9df286004_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_08e5d926-f6a2-4e51-9816-39a50aea8e1a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Calculation of Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_bd7566e3-7f3d-436d-a490-4a9ade3749b9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DERIVATIVE FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_69a9066f-6f21-4d28-b43c-18574e8eef63_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_3491cca9-4798-4127-bd85-ac5e0f96e7ab_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_a1384e48-1157-48ae-8721-ba7f32953fb7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_b11e9e87-29a5-43f6-9795-943cc88fcb6c_terseLabel_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of global development and commercialization costs</link:label>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_label_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Percent Of Global Development And Commercialization Costs</link:label>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_documentation_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Percent Of Global Development And Commercialization Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:href="gild-20210331.xsd#gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:to="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_123165c8-2109-4416-a81c-3bf72b1dbd6f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b4c21dbd-9418-4d8c-92ee-ade8246c4b82_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_cd5acc0d-3dc5-4228-bd13-bed7bf0f432f_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_1d182bc4-e9ef-44e1-bed7-f737562f9973_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_dab159cb-c88c-4d1f-bc7d-a8e922c45c5e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_6c893b81-187a-4fd9-90f0-757c8c771653_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_218f8553-afcf-4b8f-af4a-6afa0cd45022_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased and retired (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesDonationMember_82e39808-be8d-4863-8c2e-084bc735e529_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesDonationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Donation</link:label>
    <link:label id="lab_gild_EquitySecuritiesDonationMember_label_en-US" xlink:label="lab_gild_EquitySecuritiesDonationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Donation [Member]</link:label>
    <link:label id="lab_gild_EquitySecuritiesDonationMember_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesDonationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Donation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesDonationMember" xlink:href="gild-20210331.xsd#gild_EquitySecuritiesDonationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesDonationMember" xlink:to="lab_gild_EquitySecuritiesDonationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PreExposureProphylaxisMember_d60a362e-3183-43de-8010-29c84e1d312a_terseLabel_en-US" xlink:label="lab_gild_PreExposureProphylaxisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Exposure Prophylaxis</link:label>
    <link:label id="lab_gild_PreExposureProphylaxisMember_label_en-US" xlink:label="lab_gild_PreExposureProphylaxisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Exposure Prophylaxis [Member]</link:label>
    <link:label id="lab_gild_PreExposureProphylaxisMember_documentation_en-US" xlink:label="lab_gild_PreExposureProphylaxisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Exposure Prophylaxis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PreExposureProphylaxisMember" xlink:href="gild-20210331.xsd#gild_PreExposureProphylaxisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PreExposureProphylaxisMember" xlink:to="lab_gild_PreExposureProphylaxisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ArcusBiosciencesIncMember_9326793c-df5d-42d1-bf0e-1a5e53f8cb31_terseLabel_en-US" xlink:label="lab_gild_ArcusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus</link:label>
    <link:label id="lab_gild_ArcusBiosciencesIncMember_label_en-US" xlink:label="lab_gild_ArcusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_gild_ArcusBiosciencesIncMember_documentation_en-US" xlink:label="lab_gild_ArcusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Biosciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember" xlink:href="gild-20210331.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ArcusBiosciencesIncMember" xlink:to="lab_gild_ArcusBiosciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_45cf13ba-45e4-4d05-9f66-23e504be7eef_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_82ff0de3-882b-400d-8883-54a5b3bbd3f2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_9d8efa2b-1641-4dc8-8f4f-1c120f627016_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_7d32da22-1705-4445-bebd-0cc4e65ac4db_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsDescovyMember_cb54061b-a8cd-405f-a2f2-686c26c13cc3_terseLabel_en-US" xlink:label="lab_gild_HIVProductsDescovyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Descovy</link:label>
    <link:label id="lab_gild_HIVProductsDescovyMember_label_en-US" xlink:label="lab_gild_HIVProductsDescovyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Descovy [Member]</link:label>
    <link:label id="lab_gild_HIVProductsDescovyMember_documentation_en-US" xlink:label="lab_gild_HIVProductsDescovyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Descovy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsDescovyMember" xlink:href="gild-20210331.xsd#gild_HIVProductsDescovyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsDescovyMember" xlink:to="lab_gild_HIVProductsDescovyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_df8fc2af-b80e-4432-8be8-c298ee1dfde0_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_b208d20b-97dc-4008-a13e-f68c17acb8f5_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ImmunomedicsIncMember_abc142c3-6a77-4290-8620-b8d9ba50228d_terseLabel_en-US" xlink:label="lab_gild_ImmunomedicsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics</link:label>
    <link:label id="lab_gild_ImmunomedicsIncMember_label_en-US" xlink:label="lab_gild_ImmunomedicsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics, Inc. [Member]</link:label>
    <link:label id="lab_gild_ImmunomedicsIncMember_documentation_en-US" xlink:label="lab_gild_ImmunomedicsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics, Inc. (&#8220;Immunomedics&#8221;), a leading company in antibody-drug conjugate (&#8220;ADC&#8221;) technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember" xlink:href="gild-20210331.xsd#gild_ImmunomedicsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ImmunomedicsIncMember" xlink:to="lab_gild_ImmunomedicsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_5cfc5527-45e4-491b-bc27-edd7ae4d8c7b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_1edeedbd-2f19-4528-83f3-fa430d699861_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_27cece70-80ca-44de-bd54-d589b876f266_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_308288c9-087c-4e4d-8dc4-a71f1e429859_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_05e67e63-7f6b-4e30-81c1-ad58919c20a6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a812c69a-272a-4e18-ab3c-bf9b6e5ead7c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance under equity incentive plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_a47a1896-afd0-4055-af18-1528c5996b9a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_477b22bf-8f94-4b2a-b162-ac43d90f03f0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bc84e064-c04f-4827-8127-ac17acc72b99_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_06e8b808-d46a-42fe-9827-f2b8a2554cf9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_81c9c66e-7df5-4513-93d3-dc233eec1a10_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_dc52a2ea-f8a6-42f4-b36e-cecfceb4867b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (remaining nine months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d9779bfc-25cf-43ce-b079-5e76aec30279_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_ccb57761-6b3b-4e39-9bd0-f22ef257cbbc_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_422b7dcd-e29c-436f-885a-bcdc548b1f43_terseLabel_en-US" xlink:label="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juno Therapeutics, Inc. and Sloan Kettering Cancer Center</link:label>
    <link:label id="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_label_en-US" xlink:label="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juno Therapeutics, Inc. and Sloan Kettering Cancer Center [Member]</link:label>
    <link:label id="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_documentation_en-US" xlink:label="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#8220;Juno&#8221;)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:href="gild-20210331.xsd#gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:to="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e23966af-b592-434c-8932-ac04b7a4307d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0b2f6f5a-0768-437a-b31e-f0a97bdcd956_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_a8c6cfe3-7abb-46a7-8b26-b0d63f1fb663_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages_1c82f0fe-83b8-4dad-bc32-ada93ff45588_terseLabel_en-US" xlink:label="lab_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of possible loss representing enhancement of past damages</link:label>
    <link:label id="lab_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages_label_en-US" xlink:label="lab_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss (50% Enhancement of Past Damages)</link:label>
    <link:label id="lab_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages_documentation_en-US" xlink:label="lab_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss (50% Enhancement of Past Damages)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages" xlink:href="gild-20210331.xsd#gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages" xlink:to="lab_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_1cf8733e-5000-4461-89f6-34ba6b8fef90_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_9e7f4291-b426-4cfe-8228-8c314494b077_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Classification and Fair Value of Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_fbf3124c-0af8-451a-948b-1d74bccead42_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GileadFoundationMember_fe02e35b-db8d-44cd-94b5-0df40ce2f039_terseLabel_en-US" xlink:label="lab_gild_GileadFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Foundation</link:label>
    <link:label id="lab_gild_GileadFoundationMember_label_en-US" xlink:label="lab_gild_GileadFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Foundation [Member]</link:label>
    <link:label id="lab_gild_GileadFoundationMember_documentation_en-US" xlink:label="lab_gild_GileadFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Foundation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadFoundationMember" xlink:href="gild-20210331.xsd#gild_GileadFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GileadFoundationMember" xlink:to="lab_gild_GileadFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_7accb8ec-8022-4d6c-89c6-841861b2736d_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts of Assets/Liabilities Presented on our Condensed Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_9a9e2152-43b3-4599-bb22-d6460acb8325_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vemlidy</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:href="gild-20210331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_d7aadd63-4dc5-494b-86a9-df354e3af036_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member_918f7c29-8b71-4e1b-aeea-0cabe79d67b1_terseLabel_en-US" xlink:label="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Senior Unsecured Notes Due March 2027</link:label>
    <link:label id="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member_label_en-US" xlink:label="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Senior Unsecured Notes Due March 2027 [Member]</link:label>
    <link:label id="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member_documentation_en-US" xlink:label="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Senior Unsecured Notes Due March 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:href="gild-20210331.xsd#gild_A295SeniorUnsecuredNotesDueMarch2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:to="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_ce4cfd95-0841-4880-8a4b-455b9585df33_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_450b54f9-52a7-4d78-80af-4d95d64df180_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4119d979-5404-438d-a784-881d4ebebd8f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_d767026e-4dcf-46d3-8209-40ceb06d2772_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TrodelvyForMTNBCMember_dfcd9748-3569-4229-8748-431a1c3a50ec_terseLabel_en-US" xlink:label="lab_gild_TrodelvyForMTNBCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy for mTNBC</link:label>
    <link:label id="lab_gild_TrodelvyForMTNBCMember_cc83c7a5-dc1b-41f7-890a-3bf54c1b847d_verboseLabel_en-US" xlink:label="lab_gild_TrodelvyForMTNBCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset - Trodelvy for mTNBC</link:label>
    <link:label id="lab_gild_TrodelvyForMTNBCMember_label_en-US" xlink:label="lab_gild_TrodelvyForMTNBCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy for mTNBC [Member]</link:label>
    <link:label id="lab_gild_TrodelvyForMTNBCMember_documentation_en-US" xlink:label="lab_gild_TrodelvyForMTNBCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy for mTNBC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyForMTNBCMember" xlink:href="gild-20210331.xsd#gild_TrodelvyForMTNBCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TrodelvyForMTNBCMember" xlink:to="lab_gild_TrodelvyForMTNBCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_de911f9d-7527-48c2-9f33-51794e3cd79e_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares repurchased and retired</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_08d3acd8-507c-439b-bdea-5f60737719bf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_a7b28927-8d3e-45f0-bef6-0a0aa58762d5_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_e3344202-fd6c-4329-9e9e-3ed56a1ffafd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_955ddf54-7050-4ebe-9ae5-f4be665c74a3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after 10 Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_213341f6-c6ec-4fa3-91a4-21ebda948fb0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, including in-process research and development, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ForeignCurrencyDerivativeContractsMember_c3521579-da27-46d9-9629-3b0c167046ab_terseLabel_en-US" xlink:label="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency derivative contracts</link:label>
    <link:label id="lab_gild_ForeignCurrencyDerivativeContractsMember_label_en-US" xlink:label="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Contracts [Member]</link:label>
    <link:label id="lab_gild_ForeignCurrencyDerivativeContractsMember_documentation_en-US" xlink:label="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ForeignCurrencyDerivativeContractsMember" xlink:href="gild-20210331.xsd#gild_ForeignCurrencyDerivativeContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ForeignCurrencyDerivativeContractsMember" xlink:to="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_54be9abc-3dfb-40eb-aa08-ed99dc269aec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_49a86436-4318-468f-84ed-b6a3de6382d9_terseLabel_en-US" xlink:label="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.52% LIBOR Senior Unsecured Notes Due September 2023</link:label>
    <link:label id="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_label_en-US" xlink:label="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.52% LIBOR Senior Unsecured Notes Due September 2023 [Member]</link:label>
    <link:label id="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_documentation_en-US" xlink:label="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.52% LIBOR Senior Unsecured Notes Due September 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:href="gild-20210331.xsd#gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:to="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member_06284398-ec4e-4361-8e71-bb0789798c8c_terseLabel_en-US" xlink:label="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.20% Senior Unsecured Notes Due October 2027</link:label>
    <link:label id="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member_label_en-US" xlink:label="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.20% Senior Unsecured Notes Due October 2027 [Member]</link:label>
    <link:label id="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member_documentation_en-US" xlink:label="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.20% Senior Unsecured Notes Due October 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:href="gild-20210331.xsd#gild_A120SeniorUnsecuredNotesDueOctober2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:to="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_81929804-d34f-4b38-a836-26714243afb5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9e08d211-0f39-437b-8cf1-39c4f26fd2e7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a39827e9-8dd3-42de-9ddc-58d57bd63872_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_16fc141d-9ed4-464a-82ad-f10fc3e28086_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_df6c8614-1d96-46ed-aa86-67560501d011_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_87e30a0c-6e74-411c-a04e-1143057aa92e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#160;long-term&#160;obligations</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_9a7af8ca-30dd-44df-ad0b-64c22dc22aca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to net income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_a6d0f163-0292-431e-ac53-049e696b7a30_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_1a9b1a89-a0f3-4a2b-8278-43a572cb68bd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_610386dd-c9f8-425f-b443-246e6fbbcf3a_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_6c7a81ad-83b7-4273-b311-15c0126c95fe_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available-for-Sale Debt Securities by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_3f3f24c6-08b0-4d4c-ac2e-5d5c7128598b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A450SeniorUnsecuredNotesDueApril2021Member_362158ff-1c86-483e-94bf-bcd172166456_terseLabel_en-US" xlink:label="lab_gild_A450SeniorUnsecuredNotesDueApril2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes Due April 2021</link:label>
    <link:label id="lab_gild_A450SeniorUnsecuredNotesDueApril2021Member_label_en-US" xlink:label="lab_gild_A450SeniorUnsecuredNotesDueApril2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes Due April 2021 [Member]</link:label>
    <link:label id="lab_gild_A450SeniorUnsecuredNotesDueApril2021Member_documentation_en-US" xlink:label="lab_gild_A450SeniorUnsecuredNotesDueApril2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes Due April 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A450SeniorUnsecuredNotesDueApril2021Member" xlink:href="gild-20210331.xsd#gild_A450SeniorUnsecuredNotesDueApril2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A450SeniorUnsecuredNotesDueApril2021Member" xlink:to="lab_gild_A450SeniorUnsecuredNotesDueApril2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5aa6ffe7-a728-4942-a3eb-fd427d6a390f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e290b633-c6dc-41bf-a029-fee5b6209f90_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_a512fab0-11f3-4737-bbf5-951c409f3102_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_a71dedbd-7c0f-4be9-89fe-69db378697de_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_ce7892f1-9d7b-4c49-96a8-608ceafdc7ce_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EuropeanPatentClaimsMember_23a03786-0bf3-4499-8a9d-a002c1ad0c11_terseLabel_en-US" xlink:label="lab_gild_EuropeanPatentClaimsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims</link:label>
    <link:label id="lab_gild_EuropeanPatentClaimsMember_label_en-US" xlink:label="lab_gild_EuropeanPatentClaimsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims [Member]</link:label>
    <link:label id="lab_gild_EuropeanPatentClaimsMember_documentation_en-US" xlink:label="lab_gild_EuropeanPatentClaimsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaimsMember" xlink:href="gild-20210331.xsd#gild_EuropeanPatentClaimsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EuropeanPatentClaimsMember" xlink:to="lab_gild_EuropeanPatentClaimsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_f4c214ae-aacc-4fa3-b74f-032594d4254a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues_6ca3fe20-f2e0-4c8b-8932-531ea2427f0f_terseLabel_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of global product revenues</link:label>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues_label_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Percent Of Global Product Revenues</link:label>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues_documentation_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Percent Of Global Product Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:href="gild-20210331.xsd#gild_CollaborationArrangementPercentOfGlobalProductRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:to="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_e4ecb2ce-56b9-4a3b-928a-1d7e800eec34_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Potential Effect of Offsetting Derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_f08ffef7-c7cf-42ec-895e-0b67a4d584a8_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DeferredCompensationPlanMember_86778cb7-7284-4a05-b7e6-22d75f22c58b_terseLabel_en-US" xlink:label="lab_gild_DeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan</link:label>
    <link:label id="lab_gild_DeferredCompensationPlanMember_label_en-US" xlink:label="lab_gild_DeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan [Member]</link:label>
    <link:label id="lab_gild_DeferredCompensationPlanMember_documentation_en-US" xlink:label="lab_gild_DeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember" xlink:href="gild-20210331.xsd#gild_DeferredCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DeferredCompensationPlanMember" xlink:to="lab_gild_DeferredCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_93efc2fa-b5f8-4d08-b64c-6a7516b3d572_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_c4d9bedf-d5f0-424b-8d43-3ba6c72cceb6_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for sales returns</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherCollaborationArrangementsMember_d1de999d-8e72-46be-9f95-451d09565f72_terseLabel_en-US" xlink:label="lab_gild_OtherCollaborationArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other collaboration arrangements</link:label>
    <link:label id="lab_gild_OtherCollaborationArrangementsMember_label_en-US" xlink:label="lab_gild_OtherCollaborationArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaboration Arrangements [Member]</link:label>
    <link:label id="lab_gild_OtherCollaborationArrangementsMember_documentation_en-US" xlink:label="lab_gild_OtherCollaborationArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaboration Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherCollaborationArrangementsMember" xlink:href="gild-20210331.xsd#gild_OtherCollaborationArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherCollaborationArrangementsMember" xlink:to="lab_gild_OtherCollaborationArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_30d02ec4-c2b2-4f0d-9068-1f4a0af3b920_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorNotesAndMediumTermNotesMember_978ecbf7-602c-48c4-a6ed-9cbfc1024df7_terseLabel_en-US" xlink:label="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes and Medium-Term Notes</link:label>
    <link:label id="lab_gild_SeniorNotesAndMediumTermNotesMember_label_en-US" xlink:label="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes And Medium-Term Notes [Member]</link:label>
    <link:label id="lab_gild_SeniorNotesAndMediumTermNotesMember_documentation_en-US" xlink:label="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes And Medium-Term Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorNotesAndMediumTermNotesMember" xlink:href="gild-20210331.xsd#gild_SeniorNotesAndMediumTermNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorNotesAndMediumTermNotesMember" xlink:to="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_0d3778f8-2631-4691-ac80-1a466a86fbc5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_74e046ab-1a77-4979-9f5a-4d2a9fff4533_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsStribildMember_c1a31037-f9de-42a7-b214-0eefd92ad431_terseLabel_en-US" xlink:label="lab_gild_HIVProductsStribildMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stribild</link:label>
    <link:label id="lab_gild_HIVProductsStribildMember_label_en-US" xlink:label="lab_gild_HIVProductsStribildMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Stribild [Member]</link:label>
    <link:label id="lab_gild_HIVProductsStribildMember_documentation_en-US" xlink:label="lab_gild_HIVProductsStribildMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Stribild [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsStribildMember" xlink:href="gild-20210331.xsd#gild_HIVProductsStribildMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsStribildMember" xlink:to="lab_gild_HIVProductsStribildMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_0c5542c2-32d1-481d-a862-e74bbb541375_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Donation expense</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0d378737-6225-4786-8c93-9d00a85ef4c8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_6e7a82cc-78c5-4666-bd57-1bf23697f89b_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9674f3e7-b81b-45e7-8636-dcefb7585906_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_2c112ee1-780f-405e-9f08-732118b10c60_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_ba501e2a-1155-4fc4-b8a9-c7ddaf83b537_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ed4dfee6-a5b9-401e-bb8e-918818bd4353_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsBiktarvyMember_39272bb3-b186-400a-a0f1-154bf1e5dd31_terseLabel_en-US" xlink:label="lab_gild_HIVProductsBiktarvyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biktarvy</link:label>
    <link:label id="lab_gild_HIVProductsBiktarvyMember_label_en-US" xlink:label="lab_gild_HIVProductsBiktarvyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Biktarvy [Member]</link:label>
    <link:label id="lab_gild_HIVProductsBiktarvyMember_documentation_en-US" xlink:label="lab_gild_HIVProductsBiktarvyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Biktarvy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsBiktarvyMember" xlink:href="gild-20210331.xsd#gild_HIVProductsBiktarvyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsBiktarvyMember" xlink:to="lab_gild_HIVProductsBiktarvyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_1cc3ca88-cec4-49bb-9127-3097060a5b85_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_e944ecf6-4cad-4f5c-aead-1075a67317a7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_fc4988be-ff3a-417c-bfa2-3b12b00230ca_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_b8cf65d6-eea1-4da0-a275-c95c55bb0f17_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in estimate of variable consideration</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_9d6a3535-1178-4005-aedd-2b7b8af16476_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HCVProductSalesMember_c2d69103-73b6-413d-aa54-b99c5957cb9d_terseLabel_en-US" xlink:label="lab_gild_HCVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total HCV</link:label>
    <link:label id="lab_gild_HCVProductSalesMember_label_en-US" xlink:label="lab_gild_HCVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Product Sales [Member]</link:label>
    <link:label id="lab_gild_HCVProductSalesMember_documentation_en-US" xlink:label="lab_gild_HCVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductSalesMember" xlink:href="gild-20210331.xsd#gild_HCVProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HCVProductSalesMember" xlink:to="lab_gild_HCVProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_7795c0e8-6fa5-4de4-8a0a-9aa88e6d3ccc_terseLabel_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential mortgage and asset-backed securities</link:label>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_d481d1a6-efe1-4181-bb96-45943b0fdb3a_verboseLabel_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential mortgage and asset-backed securities</link:label>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_label_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential Mortgage And Asset-Backed Securities [Member]</link:label>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_documentation_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential Mortgage And Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:href="gild-20210331.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:to="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_ae2d318d-b49f-4da9-b885-3af08eef5bf7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIShares_7cf6e3ca-ea16-478b-8fba-15f260ed6fd9_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities (in shares)</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIShares_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Shares</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIShares_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIShares" xlink:href="gild-20210331.xsd#gild_EquitySecuritiesFVNIShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIShares" xlink:to="lab_gild_EquitySecuritiesFVNIShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsAbstract_4c386c63-44f0-4a59-9194-42be21a95bdf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsAbstract" xlink:to="lab_us-gaap_DerivativeAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_6bfd5952-0cb9-4694-bf23-1bc570a4b084_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesAbstract_b846ae65-4a12-46d2-9861-d3112aa86e11_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract" xlink:to="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_dab49a20-c5cd-4e22-8b60-807fab884c84_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsOdefseyMember_86e15384-6c13-47c8-ab90-b9c1a1fac8f9_terseLabel_en-US" xlink:label="lab_gild_HIVProductsOdefseyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Odefsey</link:label>
    <link:label id="lab_gild_HIVProductsOdefseyMember_label_en-US" xlink:label="lab_gild_HIVProductsOdefseyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Odefsey [Member]</link:label>
    <link:label id="lab_gild_HIVProductsOdefseyMember_documentation_en-US" xlink:label="lab_gild_HIVProductsOdefseyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Odefsey [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsOdefseyMember" xlink:href="gild-20210331.xsd#gild_HIVProductsOdefseyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsOdefseyMember" xlink:to="lab_gild_HIVProductsOdefseyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8c5cbffc-fb77-41a3-993f-40b8758cfcaa_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_0191d3fd-cc00-4afb-8c5b-c4abc7f0df86_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IntangibleAssetMeasurementInput_b34abdfb-89d7-46bd-a5df-5e925b3e3a5d_terseLabel_en-US" xlink:label="lab_gild_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_gild_IntangibleAssetMeasurementInput_label_en-US" xlink:label="lab_gild_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset, Measurement Input</link:label>
    <link:label id="lab_gild_IntangibleAssetMeasurementInput_documentation_en-US" xlink:label="lab_gild_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetMeasurementInput" xlink:href="gild-20210331.xsd#gild_IntangibleAssetMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IntangibleAssetMeasurementInput" xlink:to="lab_gild_IntangibleAssetMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_80a15fb4-2e1e-4792-8e3a-8b0fa7a25b2b_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_58d5d31e-0bf1-4328-9c49-aad71a76d28c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_a3a5215f-6133-4b31-879e-9eb97b95db80_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CardinalHealthIncMember_853ee145-0169-4209-8f1b-8b5deb12e13e_terseLabel_en-US" xlink:label="lab_gild_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health, Inc.</link:label>
    <link:label id="lab_gild_CardinalHealthIncMember_label_en-US" xlink:label="lab_gild_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health Inc [Member]</link:label>
    <link:label id="lab_gild_CardinalHealthIncMember_documentation_en-US" xlink:label="lab_gild_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CardinalHealthIncMember" xlink:href="gild-20210331.xsd#gild_CardinalHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CardinalHealthIncMember" xlink:to="lab_gild_CardinalHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_3d903db2-bd2b-4ea2-99e9-3524aaa7b42e_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_e1bea1de-3964-4669-af1d-77e3e9983eba_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNoteIssuedNovember2014Member_de12398c-5d99-4cd9-aafe-ad6b1b03d9df_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNoteIssuedNovember2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">the "2014 Senior Notes"</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNoteIssuedNovember2014Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNoteIssuedNovember2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Note Issued November 2014 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNoteIssuedNovember2014Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNoteIssuedNovember2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Note Issued November 2014</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNoteIssuedNovember2014Member" xlink:href="gild-20210331.xsd#gild_SeniorUnsecuredNoteIssuedNovember2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNoteIssuedNovember2014Member" xlink:to="lab_gild_SeniorUnsecuredNoteIssuedNovember2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_b2460546-82da-49a5-b26d-a9e907ce323b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ViiVHealthcareCompanyMember_e196445a-ead2-4565-be16-8593edadbf26_terseLabel_en-US" xlink:label="lab_gild_ViiVHealthcareCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV Healthcare Company</link:label>
    <link:label id="lab_gild_ViiVHealthcareCompanyMember_label_en-US" xlink:label="lab_gild_ViiVHealthcareCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV Healthcare Company [Member]</link:label>
    <link:label id="lab_gild_ViiVHealthcareCompanyMember_documentation_en-US" xlink:label="lab_gild_ViiVHealthcareCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV Healthcare Company (&#8220;ViiV&#8221;)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ViiVHealthcareCompanyMember" xlink:href="gild-20210331.xsd#gild_ViiVHealthcareCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ViiVHealthcareCompanyMember" xlink:to="lab_gild_ViiVHealthcareCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a1d59058-e6c8-4f8a-bcfc-dd46af4bb311_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cc18aeb4-351f-4951-8d9a-b8f11da7147f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_c0a82df8-55d4-45ee-8293-82726c562415_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HCVProductsLedipasvirSofosbuvirMember_2173b8be-bb85-46f1-91a6-c252120ebb36_terseLabel_en-US" xlink:label="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ledipasvir/Sofosbuvir</link:label>
    <link:label id="lab_gild_HCVProductsLedipasvirSofosbuvirMember_label_en-US" xlink:label="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Ledipasvir/Sofosbuvir [Member]</link:label>
    <link:label id="lab_gild_HCVProductsLedipasvirSofosbuvirMember_documentation_en-US" xlink:label="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Ledipasvir/Sofosbuvir</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:href="gild-20210331.xsd#gild_HCVProductsLedipasvirSofosbuvirMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:to="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_30ddcc7a-6d55-4c64-aa4a-dcd5fe62c124_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term and long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_25bbcaa6-dc44-4d0c-a188-e4924b3df4a7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8a35cde9-f94c-4b26-8680-11eb490e7070_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_9c4fdbe7-f10a-4737-b8e2-9769469d0ea8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITIONS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_087c6c5a-8583-42da-9bf1-44e7a06bd170_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_53d56c4e-009e-4c0c-a5dd-87ba9e8d7ed6_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_a4739034-2c3a-4b3e-b481-852a1ebbd0df_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.001 per share; 5,600 shares authorized; 1,254 shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member_8f3ffb64-7f17-4313-9c83-9ef59be74f4d_terseLabel_en-US" xlink:label="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Senior Unsecured Notes Due October 2050</link:label>
    <link:label id="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member_label_en-US" xlink:label="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Senior Unsecured Notes Due October 2050 [Member]</link:label>
    <link:label id="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member_documentation_en-US" xlink:label="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Senior Unsecured Notes Due October 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:href="gild-20210331.xsd#gild_A280SeniorUnsecuredNotesDueOctober2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:to="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_c0127988-52fb-4a2b-a8e0-6b93a8d13ff6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_724195cf-32df-452d-b396-f34f75572b45_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_ddac39c1-67ca-4e74-9364-d4c1c411a248_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyEstimateOfPossibleLossRoyalties_6fbc301f-735b-4bb6-af98-2ca2dbcd774c_terseLabel_en-US" xlink:label="lab_gild_LossContingencyEstimateOfPossibleLossRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of possible loss representing royalties and prejudgment interest</link:label>
    <link:label id="lab_gild_LossContingencyEstimateOfPossibleLossRoyalties_label_en-US" xlink:label="lab_gild_LossContingencyEstimateOfPossibleLossRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate Of Possible Loss, Royalties</link:label>
    <link:label id="lab_gild_LossContingencyEstimateOfPossibleLossRoyalties_documentation_en-US" xlink:label="lab_gild_LossContingencyEstimateOfPossibleLossRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate Of Possible Loss, Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyEstimateOfPossibleLossRoyalties" xlink:href="gild-20210331.xsd#gild_LossContingencyEstimateOfPossibleLossRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyEstimateOfPossibleLossRoyalties" xlink:to="lab_gild_LossContingencyEstimateOfPossibleLossRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2674c9fe-33f6-4fdd-b1b2-a592cba89e3e_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of stock options and equivalents (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_1c74b5e6-b0b4-42ce-9588-dee1ca56104f_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member_5d35d123-4093-4dbf-a454-cf3615bfbab5_terseLabel_en-US" xlink:label="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% Senior Unsecured Notes Due March 2046</link:label>
    <link:label id="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member_label_en-US" xlink:label="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% Senior Unsecured Notes Due March 2046 [Member]</link:label>
    <link:label id="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member_documentation_en-US" xlink:label="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% Senior Unsecured Notes Due March 2046 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:href="gild-20210331.xsd#gild_A475SeniorUnsecuredNotesDueMarch2046Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:to="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_041f6a4a-3f9b-4cf9-b01d-54b3597664bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_96bdf18c-51be-4d87-9b4e-adc53a0fdb49_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in per share calculation - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b0d67de1-5055-43a3-9fdf-5671a716ac74_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in per share calculation - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_b9e49cca-4d08-4356-902b-5dd3cd3a4e41_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viread</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:href="gild-20210331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_0915c2bb-9edc-4a7a-acd7-eca0970702fd_terseLabel_en-US" xlink:label="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three-Year Senior Term Loan Facility</link:label>
    <link:label id="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_label_en-US" xlink:label="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Year Senior Unsecured Term Loan Facility [Member]</link:label>
    <link:label id="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_documentation_en-US" xlink:label="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Year Senior Unsecured Term Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:href="gild-20210331.xsd#gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:to="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_0d07258a-5194-410a-b639-d8281d9aa434_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_7d7f8db2-e420-4e73-9d74-c72f3e8bd489_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_23a69149-0e67-49c4-9ba7-7dda15013326_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsLetairisMember_a3a1e154-0f57-4b08-8a84-709d4e6a7847_terseLabel_en-US" xlink:label="lab_gild_OtherProductsLetairisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letairis</link:label>
    <link:label id="lab_gild_OtherProductsLetairisMember_label_en-US" xlink:label="lab_gild_OtherProductsLetairisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Letairis [Member]</link:label>
    <link:label id="lab_gild_OtherProductsLetairisMember_documentation_en-US" xlink:label="lab_gild_OtherProductsLetairisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Letairis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsLetairisMember" xlink:href="gild-20210331.xsd#gild_OtherProductsLetairisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsLetairisMember" xlink:to="lab_gild_OtherProductsLetairisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CashPaymentsMadeRelatedToEquityInvestments_b5a94237-1c75-43a7-a8af-3cb8cb460a8e_terseLabel_en-US" xlink:label="lab_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments made related to equity investments</link:label>
    <link:label id="lab_gild_CashPaymentsMadeRelatedToEquityInvestments_label_en-US" xlink:label="lab_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Payments Made Related to Equity Investments</link:label>
    <link:label id="lab_gild_CashPaymentsMadeRelatedToEquityInvestments_documentation_en-US" xlink:label="lab_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Payments Made Related to Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:href="gild-20210331.xsd#gild_CashPaymentsMadeRelatedToEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:to="lab_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_270c0c59-22b7-458a-badc-4534350e04ae_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Gilead stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_de5253f2-81b3-4abb-a2b9-5b10b6779e53_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amortization expense related to finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_48043d40-24c4-4da6-8850-a37b5ee5bc11_terseLabel_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due September 2023</link:label>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_label_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due September 2023 [Member]</link:label>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_documentation_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due in September 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:href="gild-20210331.xsd#gild_A075SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:to="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ff53fc58-a3cc-42d3-9f16-4366dff777f3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_b732c450-d3ba-4651-89ca-8ec32506540e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b6681a2d-c67b-4583-b8f6-487e72b2f50d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_9fe624e5-61fc-476e-aa6c-d3eaaa5abfdc_terseLabel_en-US" xlink:label="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.15% LIBOR Senior Unsecured Notes Due September 2021</link:label>
    <link:label id="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_label_en-US" xlink:label="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.15% LIBOR Senior Unsecured Notes Due September 2021 [Member]</link:label>
    <link:label id="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_documentation_en-US" xlink:label="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.15% LIBOR Senior Unsecured Notes Due September 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:href="gild-20210331.xsd#gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:to="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_62c20c73-bd73-4cb9-afee-8e1b86f9b6ae_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains recognized in Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_6f5159e3-cd83-4ba8-9e45-f46fbc8dd039_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e1f38d32-85d9-4e58-9158-c3c23152992a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_32f4c898-6b0d-41a3-b043-f27fbc606a70_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_dff22890-c277-49c4-8f37-0d07f5cbce45_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyPartiesAppealedNumber_59ec4868-61f5-431b-b434-6d4ab0bc1055_terseLabel_en-US" xlink:label="lab_gild_LossContingencyPartiesAppealedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of parties appealed</link:label>
    <link:label id="lab_gild_LossContingencyPartiesAppealedNumber_label_en-US" xlink:label="lab_gild_LossContingencyPartiesAppealedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Parties Appealed, Number</link:label>
    <link:label id="lab_gild_LossContingencyPartiesAppealedNumber_documentation_en-US" xlink:label="lab_gild_LossContingencyPartiesAppealedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Parties Appealed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesAppealedNumber" xlink:href="gild-20210331.xsd#gild_LossContingencyPartiesAppealedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyPartiesAppealedNumber" xlink:to="lab_gild_LossContingencyPartiesAppealedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_a40e154e-f03b-4831-8ad5-3670bfbe936c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_cf1e0de6-cd4c-46c4-8f63-1d7bf1c994a6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_e5ccf5ab-f623-4d8f-b033-cdbdccf424f6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_360c79d4-0221-424b-9259-b75ffc9c31b9_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_51a8559b-5d6f-4291-b33b-21984c043414_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_56f58db6-2d19-4d6b-bf4a-48c708902aaf_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_08ec88ca-36a1-4120-8043-785d0d55726d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_c91f4289-3bbe-488d-85e9-f2f4949d8ee3_verboseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_cfc7f7b8-6f28-4d5c-91a6-4ecf9ed6b669_totalLabel_en-US" xlink:label="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_label_en-US" xlink:label="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:label id="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_documentation_en-US" xlink:label="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:href="gild-20210331.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:to="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_1fd750a0-c914-4428-9559-9d84186af5eb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_d778ab47-64f0-4f80-ac39-115a75f024a5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160; Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_ebf9dc4d-9974-47b4-84ed-6867ab137ec2_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage by noncontrolling owners</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_e2a56d53-bfcd-44de-9bee-6ab726edc9e4_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_91876012-7123-4a24-ab6c-efa8832a5635_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from Major Customers</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_86e19f40-d021-43bc-b062-3a11abc5dde6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepcludexForHDVMember_6ec15080-e634-41d4-86fb-99051e6121d6_terseLabel_en-US" xlink:label="lab_gild_HepcludexForHDVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepcludex For HDV</link:label>
    <link:label id="lab_gild_HepcludexForHDVMember_0c58e65e-45fe-4c2c-ba0f-7db6f04b62d6_verboseLabel_en-US" xlink:label="lab_gild_HepcludexForHDVMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset - Hepcludex for HDV</link:label>
    <link:label id="lab_gild_HepcludexForHDVMember_label_en-US" xlink:label="lab_gild_HepcludexForHDVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepcludex For HDV [Member]</link:label>
    <link:label id="lab_gild_HepcludexForHDVMember_documentation_en-US" xlink:label="lab_gild_HepcludexForHDVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepcludex For HDV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexForHDVMember" xlink:href="gild-20210331.xsd#gild_HepcludexForHDVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepcludexForHDVMember" xlink:to="lab_gild_HepcludexForHDVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_4f9f57c0-7140-4735-a6ce-b94604800eee_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_12128e00-159c-4530-bdff-695a45ce1e1c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d54db873-8b0c-47f1-aa18-fa8277e819c3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from earnings per share computation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_5665bfb0-3e90-4cdb-a544-9a86456ef702_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AxicabtageneciloleucelDLBCLMember_d9aca756-42db-4f9b-8939-85a99e0272cc_terseLabel_en-US" xlink:label="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset - axicabtagene ciloleucel</link:label>
    <link:label id="lab_gild_AxicabtageneciloleucelDLBCLMember_label_en-US" xlink:label="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">axicabtagene ciloleucel (DLBCL) [Member]</link:label>
    <link:label id="lab_gild_AxicabtageneciloleucelDLBCLMember_documentation_en-US" xlink:label="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">axicabtagene ciloleucel (DLBCL) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AxicabtageneciloleucelDLBCLMember" xlink:href="gild-20210331.xsd#gild_AxicabtageneciloleucelDLBCLMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AxicabtageneciloleucelDLBCLMember" xlink:to="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_ff97498a-4533-4148-8e36-ba9d69363825_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_f72ee0d0-5f2b-4dec-aea0-89f033d7699a_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member_cf79d37b-a49c-4798-aef5-a3c7ecf02b3b_terseLabel_en-US" xlink:label="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Senior Unsecured Notes Due March 2047</link:label>
    <link:label id="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member_label_en-US" xlink:label="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Senior Unsecured Notes Due March 2047 [Member]</link:label>
    <link:label id="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member_documentation_en-US" xlink:label="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Senior Unsecured Notes Due March 2047 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:href="gild-20210331.xsd#gild_A415SeniorUnsecuredNotesDueMarch2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:to="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_7f465984-06af-4650-b8be-2c45516af947_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_fd1f1156-0b82-489c-b870-be61d96e8e0b_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8901aacc-e50f-4f88-83fe-818da3266b5d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_948265a3-4125-45f8-8806-d10631fb0e4b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Available-for-Sale Debt Securities from Cost Basis to Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_f59f49f4-b40b-4158-952b-de762e3a75df_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HCVProductsSofosbuvirVelpatasvirMember_b7117f7d-1fd3-459a-b0bc-83e9691c9ada_terseLabel_en-US" xlink:label="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sofosbuvir/Velpatasvir</link:label>
    <link:label id="lab_gild_HCVProductsSofosbuvirVelpatasvirMember_label_en-US" xlink:label="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Sofosbuvir/Velpatasvir [Member]</link:label>
    <link:label id="lab_gild_HCVProductsSofosbuvirVelpatasvirMember_documentation_en-US" xlink:label="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Sofosbuvir/Velpatasvir</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:href="gild-20210331.xsd#gild_HCVProductsSofosbuvirVelpatasvirMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:to="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsGrossTransfers_145e7e7d-4ddb-4642-84f6-e9ab809ac0d2_terseLabel_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsGrossTransfers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets reclassified from indefinite-lived assets</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsGrossTransfers_label_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsGrossTransfers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross, Transfers</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsGrossTransfers_documentation_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsGrossTransfers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross, Transfers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsGrossTransfers" xlink:href="gild-20210331.xsd#gild_FiniteLivedIntangibleAssetsGrossTransfers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FiniteLivedIntangibleAssetsGrossTransfers" xlink:to="lab_gild_FiniteLivedIntangibleAssetsGrossTransfers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_d5cce7e2-ddec-492d-9b3f-17cabd729ccb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#160;accrued&#160;liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_a619c670-a74c-49b3-90bf-5387573f79e0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of class action lawsuits</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_c484f5a2-6396-4a1c-9e87-580aa7a8f3fb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Collateral Received/ Pledged</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Collateral, Right to Reclaim Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:to="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3feba7ee-70c4-468b-ae19-9fa04b770bd6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol(s)</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_e1d67f9e-4dbd-4736-8bf8-e8b6fcdcf1c3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_58dd17cc-3efd-4287-9382-2d8d391923a2_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized amount under stock repurchase program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsTotalOtherProductSalesMember_4e19573f-0061-4b2c-bb94-f43d66342fef_terseLabel_en-US" xlink:label="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Other</link:label>
    <link:label id="lab_gild_OtherProductsTotalOtherProductSalesMember_label_en-US" xlink:label="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Total Other product sales [Member]</link:label>
    <link:label id="lab_gild_OtherProductsTotalOtherProductSalesMember_documentation_en-US" xlink:label="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Total Other product sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsTotalOtherProductSalesMember" xlink:href="gild-20210331.xsd#gild_OtherProductsTotalOtherProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember" xlink:to="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_62ddb796-d18e-4d0f-b256-d45e74fdec3c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_5712041d-68ac-4d4c-9fb8-5986972b53db_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_49cfd0c8-f3e4-41b8-bde5-76a03ebeaaf9_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_e1271207-d997-4c0a-8c2e-e0bf57b153c2_terseLabel_en-US" xlink:label="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.50% Senior Unsecured Notes Due February 2025</link:label>
    <link:label id="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_label_en-US" xlink:label="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.50% Senior Unsecured Notes Due February 2025 [Member]</link:label>
    <link:label id="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_documentation_en-US" xlink:label="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.50% Senior Unsecured Notes Due February 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:href="gild-20210331.xsd#gild_A350SeniorUnsecuredNotesDueFebruary2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:to="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_f7f36e72-f2dd-47d5-8a73-845e49b35bb4_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_9c281ae6-5cbd-4db0-ad76-1aa0705dc553_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_0aa7cc92-d0b1-4f0d-9ddf-dee565593ddc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_RoyaltyContractAndOtherMember_37c417ce-c2b7-490c-aa63-47fd5609e1e5_terseLabel_en-US" xlink:label="lab_gild_RoyaltyContractAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, contract and other revenues</link:label>
    <link:label id="lab_gild_RoyaltyContractAndOtherMember_label_en-US" xlink:label="lab_gild_RoyaltyContractAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Contract, And Other [Member]</link:label>
    <link:label id="lab_gild_RoyaltyContractAndOtherMember_documentation_en-US" xlink:label="lab_gild_RoyaltyContractAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Contract, And Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember" xlink:href="gild-20210331.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_RoyaltyContractAndOtherMember" xlink:to="lab_gild_RoyaltyContractAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fac3893b-6ef9-4d5d-a2d8-a3a8e2bff8fc_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_b406157b-0e9f-49b1-b6a3-8e20cb22648c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Amounts of Recognized Assets/Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_b7d35be6-4fb3-4b2c-9fd3-3b42c674316c_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillGross_ed64662f-4cb9-4363-86ed-1ae821c6c141_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_label_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillGross" xlink:to="lab_us-gaap_GoodwillGross" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>gild-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:62245928-4256-4115-b52c-a224301f8b52,g:d7709fc8-9a45-40b0-bb7e-3c2cb616ef14-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.gilead.com/role/CoverPage" xlink:type="simple" xlink:href="gild-20210331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_fe34fe0d-be60-4081-933f-dd1899ad4826" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_DocumentType_fe34fe0d-be60-4081-933f-dd1899ad4826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_a3625a34-fa2e-4537-9a42-d606a739e2c5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_DocumentQuarterlyReport_a3625a34-fa2e-4537-9a42-d606a739e2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_0a8982e5-dc13-47e7-afee-92ccbf8a3fdf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_DocumentPeriodEndDate_0a8982e5-dc13-47e7-afee-92ccbf8a3fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_3a78d150-64ea-43ec-bfdc-2ae3e269894c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_DocumentTransitionReport_3a78d150-64ea-43ec-bfdc-2ae3e269894c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_35c4a9ad-60fc-4995-ba80-e497a3a06b9e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_EntityFileNumber_35c4a9ad-60fc-4995-ba80-e497a3a06b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4a378e83-4f17-4d0e-b8c6-cf9cf0aecfb6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_EntityRegistrantName_4a378e83-4f17-4d0e-b8c6-cf9cf0aecfb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_216324eb-da5e-4e3f-95ee-db7a0f35e11f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_EntityIncorporationStateCountryCode_216324eb-da5e-4e3f-95ee-db7a0f35e11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_74fcff9f-e2cf-4847-b92c-4b4d9834b6f5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_EntityTaxIdentificationNumber_74fcff9f-e2cf-4847-b92c-4b4d9834b6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6a2b356f-2bfa-4ab9-aab1-9b7a501d8803" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_EntityAddressAddressLine1_6a2b356f-2bfa-4ab9-aab1-9b7a501d8803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_dececf61-34c7-4087-8a1a-3ada49c78185" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_EntityAddressCityOrTown_dececf61-34c7-4087-8a1a-3ada49c78185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_7d4e658a-4503-429f-b798-d1c7a9c2b4f7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_EntityAddressStateOrProvince_7d4e658a-4503-429f-b798-d1c7a9c2b4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9e7e9854-4058-4a23-98b4-c97731ca83af" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_EntityAddressPostalZipCode_9e7e9854-4058-4a23-98b4-c97731ca83af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d86e3922-0f5f-46d2-a79d-2f7dc857680e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_CityAreaCode_d86e3922-0f5f-46d2-a79d-2f7dc857680e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c8b534e9-9e36-4f60-9299-1263936fe26a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_LocalPhoneNumber_c8b534e9-9e36-4f60-9299-1263936fe26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_eeffbd52-666c-4d99-8310-72d6b996737e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_Security12bTitle_eeffbd52-666c-4d99-8310-72d6b996737e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1162e421-716e-462d-bc3a-917603cdfce1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_TradingSymbol_1162e421-716e-462d-bc3a-917603cdfce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_db6ab97c-4276-45d9-96cb-cfea7b61e93e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_SecurityExchangeName_db6ab97c-4276-45d9-96cb-cfea7b61e93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_e5711fc9-d88c-44c9-bb0a-1eda7e5051c4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_EntityCurrentReportingStatus_e5711fc9-d88c-44c9-bb0a-1eda7e5051c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_2b3a5792-c5d9-44ab-a6cb-4cf8e96122a7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_EntityInteractiveDataCurrent_2b3a5792-c5d9-44ab-a6cb-4cf8e96122a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_88d348fb-cc59-43f0-8405-14da7e616a39" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_EntityFilerCategory_88d348fb-cc59-43f0-8405-14da7e616a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_47ffb542-65c4-409c-98b7-ff4fce49545e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_EntitySmallBusiness_47ffb542-65c4-409c-98b7-ff4fce49545e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_66eaab0d-08aa-4b68-a15e-f2302dcb3b43" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_EntityEmergingGrowthCompany_66eaab0d-08aa-4b68-a15e-f2302dcb3b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_38842170-b609-4db5-bddb-5c555509ee6a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_EntityShellCompany_38842170-b609-4db5-bddb-5c555509ee6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_a6954c6a-7945-4d28-b6b0-f234dc48e6c5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_a6954c6a-7945-4d28-b6b0-f234dc48e6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_020fd6dc-7f47-4d49-9ae5-bd4a86fd8b36" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_EntityCentralIndexKey_020fd6dc-7f47-4d49-9ae5-bd4a86fd8b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_3adb74d0-d0aa-46c0-bd9f-aee88cd590e9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_CurrentFiscalYearEndDate_3adb74d0-d0aa-46c0-bd9f-aee88cd590e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_634eebd4-00d7-4785-80e7-2aa15f18968a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_DocumentFiscalYearFocus_634eebd4-00d7-4785-80e7-2aa15f18968a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6a381013-220e-4563-b5da-f608d1e27b6f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6a381013-220e-4563-b5da-f608d1e27b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1c96762f-099b-4844-ac31-f02d30840f79" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdf6dce1-f8cb-4313-8ef6-6150b2e2f3df" xlink:to="loc_dei_AmendmentFlag_1c96762f-099b-4844-ac31-f02d30840f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="gild-20210331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c23bbc49-c2bc-4dbe-a16c-808401f4889b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a4e85aa9-57d9-4522-a03b-82252a522572" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c23bbc49-c2bc-4dbe-a16c-808401f4889b" xlink:to="loc_us-gaap_AssetsAbstract_a4e85aa9-57d9-4522-a03b-82252a522572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_790077a0-ce61-4a19-a14e-0fc26eace504" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a4e85aa9-57d9-4522-a03b-82252a522572" xlink:to="loc_us-gaap_AssetsCurrentAbstract_790077a0-ce61-4a19-a14e-0fc26eace504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_df9faa6f-31d2-4c46-b625-54d5299f71e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_790077a0-ce61-4a19-a14e-0fc26eace504" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_df9faa6f-31d2-4c46-b625-54d5299f71e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_3d31f47f-b3ef-4083-87c3-b9adbb6da733" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_790077a0-ce61-4a19-a14e-0fc26eace504" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_3d31f47f-b3ef-4083-87c3-b9adbb6da733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_724b4d66-8afe-4dec-8e54-c700ddd07751" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_790077a0-ce61-4a19-a14e-0fc26eace504" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_724b4d66-8afe-4dec-8e54-c700ddd07751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7814ba05-936a-408d-bcbf-aef478400884" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_790077a0-ce61-4a19-a14e-0fc26eace504" xlink:to="loc_us-gaap_InventoryNet_7814ba05-936a-408d-bcbf-aef478400884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_352d19a8-50df-47b7-84e6-dab37644c46f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_790077a0-ce61-4a19-a14e-0fc26eace504" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_352d19a8-50df-47b7-84e6-dab37644c46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_37fb8cda-d3aa-4479-9644-3934937815a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_790077a0-ce61-4a19-a14e-0fc26eace504" xlink:to="loc_us-gaap_AssetsCurrent_37fb8cda-d3aa-4479-9644-3934937815a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a3aa08ac-c7f8-487e-80b2-3944008a38d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a4e85aa9-57d9-4522-a03b-82252a522572" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a3aa08ac-c7f8-487e-80b2-3944008a38d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_9802e5c8-efb5-4caa-94dc-2ecff64c8b07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a4e85aa9-57d9-4522-a03b-82252a522572" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_9802e5c8-efb5-4caa-94dc-2ecff64c8b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d966cba5-dd62-4d0d-9992-faff99f6f02b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a4e85aa9-57d9-4522-a03b-82252a522572" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d966cba5-dd62-4d0d-9992-faff99f6f02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7e9548cf-288c-4300-aa2f-11b85cb6a158" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a4e85aa9-57d9-4522-a03b-82252a522572" xlink:to="loc_us-gaap_Goodwill_7e9548cf-288c-4300-aa2f-11b85cb6a158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_988469f1-14f7-49ef-acd5-b52dc37dde9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a4e85aa9-57d9-4522-a03b-82252a522572" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_988469f1-14f7-49ef-acd5-b52dc37dde9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_347721ea-b7e9-42e6-a48b-54bed71629ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a4e85aa9-57d9-4522-a03b-82252a522572" xlink:to="loc_us-gaap_Assets_347721ea-b7e9-42e6-a48b-54bed71629ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a815978-daf8-44cd-ad73-870a0c3c1e96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c23bbc49-c2bc-4dbe-a16c-808401f4889b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a815978-daf8-44cd-ad73-870a0c3c1e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_676ed803-c34b-4fe1-ab34-000480fc1582" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a815978-daf8-44cd-ad73-870a0c3c1e96" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_676ed803-c34b-4fe1-ab34-000480fc1582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b464fe6b-bdef-48b0-b94f-31eeb32012e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_676ed803-c34b-4fe1-ab34-000480fc1582" xlink:to="loc_us-gaap_AccountsPayableCurrent_b464fe6b-bdef-48b0-b94f-31eeb32012e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccruedGovernmentAndOtherRebates_d13d3353-882f-4a42-a449-1a23bfa64b39" xlink:href="gild-20210331.xsd#gild_AccruedGovernmentAndOtherRebates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_676ed803-c34b-4fe1-ab34-000480fc1582" xlink:to="loc_gild_AccruedGovernmentAndOtherRebates_d13d3353-882f-4a42-a449-1a23bfa64b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_275334fb-1321-4294-8b92-1eafd93c6b8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_676ed803-c34b-4fe1-ab34-000480fc1582" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_275334fb-1321-4294-8b92-1eafd93c6b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_a56c01b9-d4cc-4566-94b4-a4f53811ed6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_676ed803-c34b-4fe1-ab34-000480fc1582" xlink:to="loc_us-gaap_DebtCurrent_a56c01b9-d4cc-4566-94b4-a4f53811ed6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a889f1dc-e8fe-485f-877d-2b8f466d8cf9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_676ed803-c34b-4fe1-ab34-000480fc1582" xlink:to="loc_us-gaap_LiabilitiesCurrent_a889f1dc-e8fe-485f-877d-2b8f466d8cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_35574101-7a71-4771-91da-966abf40a127" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a815978-daf8-44cd-ad73-870a0c3c1e96" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_35574101-7a71-4771-91da-966abf40a127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_212cd582-dcb0-4719-9faa-005a04161a92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a815978-daf8-44cd-ad73-870a0c3c1e96" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_212cd582-dcb0-4719-9faa-005a04161a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1a60551e-4839-4494-944c-8d65914b2636" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a815978-daf8-44cd-ad73-870a0c3c1e96" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1a60551e-4839-4494-944c-8d65914b2636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7cec00b9-9aba-41ad-925f-d0dd4bda33c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a815978-daf8-44cd-ad73-870a0c3c1e96" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7cec00b9-9aba-41ad-925f-d0dd4bda33c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3f3475ec-9823-470f-bedb-9a1688f912b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a815978-daf8-44cd-ad73-870a0c3c1e96" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3f3475ec-9823-470f-bedb-9a1688f912b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa00e26b-8cd9-484d-8186-525b8150e78b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a815978-daf8-44cd-ad73-870a0c3c1e96" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa00e26b-8cd9-484d-8186-525b8150e78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b5fcc967-5cd7-4f4f-bf13-ab6a77d1905e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa00e26b-8cd9-484d-8186-525b8150e78b" xlink:to="loc_us-gaap_PreferredStockValue_b5fcc967-5cd7-4f4f-bf13-ab6a77d1905e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_06bad6be-2d29-457e-ba73-ebff7a42be5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa00e26b-8cd9-484d-8186-525b8150e78b" xlink:to="loc_us-gaap_CommonStockValue_06bad6be-2d29-457e-ba73-ebff7a42be5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_38ad77a2-0933-489c-9b67-8826241f1fdc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa00e26b-8cd9-484d-8186-525b8150e78b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_38ad77a2-0933-489c-9b67-8826241f1fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_08c5ee7e-1c4f-4a2f-bc2b-badc58e46de5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa00e26b-8cd9-484d-8186-525b8150e78b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_08c5ee7e-1c4f-4a2f-bc2b-badc58e46de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e621ea3f-e3f6-4332-8fc6-9e7157a9331f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa00e26b-8cd9-484d-8186-525b8150e78b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e621ea3f-e3f6-4332-8fc6-9e7157a9331f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fc5dcd6d-300b-4d57-8b85-6288bb0720b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa00e26b-8cd9-484d-8186-525b8150e78b" xlink:to="loc_us-gaap_StockholdersEquity_fc5dcd6d-300b-4d57-8b85-6288bb0720b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_9c6ec3bc-a744-4a05-81b6-f1e376ba3419" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa00e26b-8cd9-484d-8186-525b8150e78b" xlink:to="loc_us-gaap_MinorityInterest_9c6ec3bc-a744-4a05-81b6-f1e376ba3419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0b25c911-6d91-4db0-bee0-a65139941bce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa00e26b-8cd9-484d-8186-525b8150e78b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0b25c911-6d91-4db0-bee0-a65139941bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_39c4420a-c745-4c76-8b41-249d52328e97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a815978-daf8-44cd-ad73-870a0c3c1e96" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_39c4420a-c745-4c76-8b41-249d52328e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="gild-20210331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_cd04588e-00aa-40c7-b03f-1a12cc93926c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bb92315a-a4c4-4d05-9900-05ee6b95be95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cd04588e-00aa-40c7-b03f-1a12cc93926c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bb92315a-a4c4-4d05-9900-05ee6b95be95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_2abda62f-fd63-480d-a62d-a5738cfe1a98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bb92315a-a4c4-4d05-9900-05ee6b95be95" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_2abda62f-fd63-480d-a62d-a5738cfe1a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_50f1e4d4-ac23-4a99-a206-b16aa7ab35f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_2abda62f-fd63-480d-a62d-a5738cfe1a98" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_50f1e4d4-ac23-4a99-a206-b16aa7ab35f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_30ad8cd0-8a4a-4436-ae8a-5c4ae0db95f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_2abda62f-fd63-480d-a62d-a5738cfe1a98" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_30ad8cd0-8a4a-4436-ae8a-5c4ae0db95f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_c7d032a8-f968-4556-84c4-8335c2d30efa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_2abda62f-fd63-480d-a62d-a5738cfe1a98" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_c7d032a8-f968-4556-84c4-8335c2d30efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e25e63d4-0840-4e3d-9b4c-bf48856f8132" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_2abda62f-fd63-480d-a62d-a5738cfe1a98" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e25e63d4-0840-4e3d-9b4c-bf48856f8132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_600b8242-0d8f-472a-aec2-c6202ba0818e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_2abda62f-fd63-480d-a62d-a5738cfe1a98" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_600b8242-0d8f-472a-aec2-c6202ba0818e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_99920194-b895-4526-a409-7d1b376459ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_2abda62f-fd63-480d-a62d-a5738cfe1a98" xlink:to="loc_us-gaap_CommonStockSharesIssued_99920194-b895-4526-a409-7d1b376459ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_788ae4f2-89d3-4c62-8aa8-41a6b8dc9016" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_2abda62f-fd63-480d-a62d-a5738cfe1a98" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_788ae4f2-89d3-4c62-8aa8-41a6b8dc9016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="gild-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_09dd5d97-07dd-437c-8cc7-2c408450bc17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6a4e9861-7149-4f02-a8f8-e2186c5cc373" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_09dd5d97-07dd-437c-8cc7-2c408450bc17" xlink:to="loc_us-gaap_StatementTable_6a4e9861-7149-4f02-a8f8-e2186c5cc373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a7e63845-96cd-40f2-aeab-a54a1c6db917" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6a4e9861-7149-4f02-a8f8-e2186c5cc373" xlink:to="loc_srt_ProductOrServiceAxis_a7e63845-96cd-40f2-aeab-a54a1c6db917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_845f125a-6a08-4053-9333-56a482fac509" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a7e63845-96cd-40f2-aeab-a54a1c6db917" xlink:to="loc_srt_ProductsAndServicesDomain_845f125a-6a08-4053-9333-56a482fac509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_37d87313-91f2-4f19-819b-3caeed7a6ca5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_845f125a-6a08-4053-9333-56a482fac509" xlink:to="loc_us-gaap_ProductMember_37d87313-91f2-4f19-819b-3caeed7a6ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_8b13b500-a35d-4d11-8c0a-61b386bbca12" xlink:href="gild-20210331.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_845f125a-6a08-4053-9333-56a482fac509" xlink:to="loc_gild_RoyaltyContractAndOtherMember_8b13b500-a35d-4d11-8c0a-61b386bbca12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6a4e9861-7149-4f02-a8f8-e2186c5cc373" xlink:to="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_7420e625-8298-4512-8d67-24667798519a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_RevenuesAbstract_7420e625-8298-4512-8d67-24667798519a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_595851c2-a25e-4121-bb2e-ecb5abca95cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_7420e625-8298-4512-8d67-24667798519a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_595851c2-a25e-4121-bb2e-ecb5abca95cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_1492b3e8-fe0f-44d6-b13f-a7a811102bed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_1492b3e8-fe0f-44d6-b13f-a7a811102bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_07eeb70f-cb7c-4bb5-bd6d-7e3df9469e14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1492b3e8-fe0f-44d6-b13f-a7a811102bed" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_07eeb70f-cb7c-4bb5-bd6d-7e3df9469e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_cf78aa91-1afb-4223-83a6-0edc83a228fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1492b3e8-fe0f-44d6-b13f-a7a811102bed" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_cf78aa91-1afb-4223-83a6-0edc83a228fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_138bc0c0-63b5-4768-a2fc-e3a288e02fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1492b3e8-fe0f-44d6-b13f-a7a811102bed" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_138bc0c0-63b5-4768-a2fc-e3a288e02fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ca46ea8a-2b57-4b08-b0e3-5105265a5555" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1492b3e8-fe0f-44d6-b13f-a7a811102bed" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ca46ea8a-2b57-4b08-b0e3-5105265a5555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7a541993-a919-4841-8a29-5a9e73294487" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1492b3e8-fe0f-44d6-b13f-a7a811102bed" xlink:to="loc_us-gaap_CostsAndExpenses_7a541993-a919-4841-8a29-5a9e73294487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e077d700-17c8-4b49-ac61-3ac76d785e59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_OperatingIncomeLoss_e077d700-17c8-4b49-ac61-3ac76d785e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4ef5ccde-aca9-4958-a186-b55c6bbddd84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_InterestExpense_4ef5ccde-aca9-4958-a186-b55c6bbddd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_20ce56af-d074-40d7-b098-ca17ddbd5d22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_20ce56af-d074-40d7-b098-ca17ddbd5d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9b18765d-09cf-4e08-a331-f2a46363ca0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9b18765d-09cf-4e08-a331-f2a46363ca0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dfecab72-d5bf-4fbf-8293-58de3bb5eef9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dfecab72-d5bf-4fbf-8293-58de3bb5eef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1c7d02a9-7b91-4b72-832c-19f78b916b27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_ProfitLoss_1c7d02a9-7b91-4b72-832c-19f78b916b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_18d0b065-7873-485d-8b4c-adfb04d2bd11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_18d0b065-7873-485d-8b4c-adfb04d2bd11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_229aadce-dfa3-40bf-9db4-c2d8747de89d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_NetIncomeLoss_229aadce-dfa3-40bf-9db4-c2d8747de89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b2bebfbf-e39e-4edd-8cba-1ee86186a8a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_EarningsPerShareBasic_b2bebfbf-e39e-4edd-8cba-1ee86186a8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5133a5bb-80e8-4e7b-b004-5f709f7ac701" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5133a5bb-80e8-4e7b-b004-5f709f7ac701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_bbd78c5c-a3f1-422e-9477-b4ba3ee35b1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_EarningsPerShareDiluted_bbd78c5c-a3f1-422e-9477-b4ba3ee35b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_69e36925-c8f5-4a23-924d-66f120cd008c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35c38121-e8d8-42de-a93c-7e37ccf92019" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_69e36925-c8f5-4a23-924d-66f120cd008c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="gild-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_876817e0-68a6-4cb9-b08f-f8e817264e05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9f29e74e-955c-4235-8c3d-31141af580bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_876817e0-68a6-4cb9-b08f-f8e817264e05" xlink:to="loc_us-gaap_ProfitLoss_9f29e74e-955c-4235-8c3d-31141af580bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3b3b1b01-2a1b-47a6-8f21-5d4193cbc35d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_876817e0-68a6-4cb9-b08f-f8e817264e05" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3b3b1b01-2a1b-47a6-8f21-5d4193cbc35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_385c8ea0-255a-4e43-8c72-84549528ab32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3b3b1b01-2a1b-47a6-8f21-5d4193cbc35d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_385c8ea0-255a-4e43-8c72-84549528ab32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_415623af-4108-449a-bdc5-bea997aca057" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3b3b1b01-2a1b-47a6-8f21-5d4193cbc35d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_415623af-4108-449a-bdc5-bea997aca057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_a9a73b62-e2bd-4a7a-a584-6b6a316fa0a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_415623af-4108-449a-bdc5-bea997aca057" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_a9a73b62-e2bd-4a7a-a584-6b6a316fa0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_8e7e2f6b-1c9f-411c-8f16-263f971528cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_415623af-4108-449a-bdc5-bea997aca057" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_8e7e2f6b-1c9f-411c-8f16-263f971528cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_12472e75-b99f-4351-8c48-6fd6085c76b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_415623af-4108-449a-bdc5-bea997aca057" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_12472e75-b99f-4351-8c48-6fd6085c76b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_a6ef8351-b175-4395-bdf3-4b087cfdc585" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3b3b1b01-2a1b-47a6-8f21-5d4193cbc35d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_a6ef8351-b175-4395-bdf3-4b087cfdc585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_2ab729e3-0d6d-4e33-9cc2-fb9a52ba42f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_a6ef8351-b175-4395-bdf3-4b087cfdc585" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_2ab729e3-0d6d-4e33-9cc2-fb9a52ba42f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_edb22eaf-b72d-4731-9965-5854c83eaa1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_a6ef8351-b175-4395-bdf3-4b087cfdc585" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_edb22eaf-b72d-4731-9965-5854c83eaa1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_ef43fad4-16c3-4f99-b613-45fbc0b40865" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_a6ef8351-b175-4395-bdf3-4b087cfdc585" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_ef43fad4-16c3-4f99-b613-45fbc0b40865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_182ff783-3e9c-4927-9248-cc9a10a16349" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3b3b1b01-2a1b-47a6-8f21-5d4193cbc35d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_182ff783-3e9c-4927-9248-cc9a10a16349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8dea14ca-27ad-43e5-8f25-0d0c893682b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_876817e0-68a6-4cb9-b08f-f8e817264e05" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8dea14ca-27ad-43e5-8f25-0d0c893682b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_3affd4a0-5f3e-4945-b9ac-39c2615b4460" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_876817e0-68a6-4cb9-b08f-f8e817264e05" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_3affd4a0-5f3e-4945-b9ac-39c2615b4460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9c07ef76-1566-4715-a1da-dc9e5f5489a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_876817e0-68a6-4cb9-b08f-f8e817264e05" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_9c07ef76-1566-4715-a1da-dc9e5f5489a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="gild-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_6f96c57d-f785-491e-b7b0-4eb87fca55c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2f14ac72-a112-46c8-8be1-42d0ea05689f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6f96c57d-f785-491e-b7b0-4eb87fca55c0" xlink:to="loc_us-gaap_StatementTable_2f14ac72-a112-46c8-8be1-42d0ea05689f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c37035f9-f411-4f10-9f60-9896c15ec4b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2f14ac72-a112-46c8-8be1-42d0ea05689f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c37035f9-f411-4f10-9f60-9896c15ec4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6c2e1953-7a27-4170-ac2c-96b4764685e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c37035f9-f411-4f10-9f60-9896c15ec4b8" xlink:to="loc_us-gaap_EquityComponentDomain_6c2e1953-7a27-4170-ac2c-96b4764685e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1e2beb46-baf8-4a75-b6d5-207893a07e36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6c2e1953-7a27-4170-ac2c-96b4764685e3" xlink:to="loc_us-gaap_CommonStockMember_1e2beb46-baf8-4a75-b6d5-207893a07e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_102b4dd6-6055-480e-b6e8-a717fd1ab97c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6c2e1953-7a27-4170-ac2c-96b4764685e3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_102b4dd6-6055-480e-b6e8-a717fd1ab97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ad375572-8ed6-4df1-8c32-7afc4a6fc774" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6c2e1953-7a27-4170-ac2c-96b4764685e3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ad375572-8ed6-4df1-8c32-7afc4a6fc774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ab7a9c10-f8dd-4f75-96bf-de664495ef1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6c2e1953-7a27-4170-ac2c-96b4764685e3" xlink:to="loc_us-gaap_RetainedEarningsMember_ab7a9c10-f8dd-4f75-96bf-de664495ef1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_666f1f1e-d99f-4a36-ab08-e4f6da029b8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6c2e1953-7a27-4170-ac2c-96b4764685e3" xlink:to="loc_us-gaap_NoncontrollingInterestMember_666f1f1e-d99f-4a36-ab08-e4f6da029b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CumulativeEffectPeriodOfAdoptionAxis_57442aa3-cc3d-4027-8e93-4adb58ec5517" xlink:href="gild-20210331.xsd#gild_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2f14ac72-a112-46c8-8be1-42d0ea05689f" xlink:to="loc_gild_CumulativeEffectPeriodOfAdoptionAxis_57442aa3-cc3d-4027-8e93-4adb58ec5517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CumulativeEffectPeriodOfAdoptionDomain_7f5332f9-2a69-41cb-b62d-80b63a97f3db" xlink:href="gild-20210331.xsd#gild_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CumulativeEffectPeriodOfAdoptionAxis_57442aa3-cc3d-4027-8e93-4adb58ec5517" xlink:to="loc_gild_CumulativeEffectPeriodOfAdoptionDomain_7f5332f9-2a69-41cb-b62d-80b63a97f3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ef5009a3-3de7-4616-b0ea-bfe24a698d22" xlink:href="gild-20210331.xsd#gild_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CumulativeEffectPeriodOfAdoptionDomain_7f5332f9-2a69-41cb-b62d-80b63a97f3db" xlink:to="loc_gild_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ef5009a3-3de7-4616-b0ea-bfe24a698d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f391129d-868c-4880-8de9-888c7e5fe6a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2f14ac72-a112-46c8-8be1-42d0ea05689f" xlink:to="loc_us-gaap_StatementLineItems_f391129d-868c-4880-8de9-888c7e5fe6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f391129d-868c-4880-8de9-888c7e5fe6a3" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0362aca8-01db-4fac-b1d6-bf8fe6b0408a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0362aca8-01db-4fac-b1d6-bf8fe6b0408a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53c187e7-6756-45f0-b7de-9b4d9666563c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53c187e7-6756-45f0-b7de-9b4d9666563c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d83dbde7-87b5-4017-b091-2e49c4fd5ed9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_ProfitLoss_d83dbde7-87b5-4017-b091-2e49c4fd5ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_852fc246-c200-4d7a-931b-8281352ef593" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_852fc246-c200-4d7a-931b-8281352ef593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f1ab5cac-a3ba-42ea-9216-eef4ece188ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f1ab5cac-a3ba-42ea-9216-eef4ece188ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2d65615e-bf9f-4c6b-8354-84a63f7ea467" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2d65615e-bf9f-4c6b-8354-84a63f7ea467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_42e20005-0739-44ec-b102-cb0bf494754c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_42e20005-0739-44ec-b102-cb0bf494754c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5039d06d-a879-4000-a4ec-5723deae486f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5039d06d-a879-4000-a4ec-5723deae486f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a9bfc45d-0b5f-4d6d-a809-2d9333383297" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a9bfc45d-0b5f-4d6d-a809-2d9333383297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_720ee1f2-ffec-4431-8ad2-fa1964b07df9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_720ee1f2-ffec-4431-8ad2-fa1964b07df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_88988ef6-833f-4927-bc26-3b038c1c53e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_88988ef6-833f-4927-bc26-3b038c1c53e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_f643b631-7a51-4e76-99b9-8f9bf0c349a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_Dividends_f643b631-7a51-4e76-99b9-8f9bf0c349a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7f313fb6-51b2-4d7d-9429-97c088d1f1db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7f313fb6-51b2-4d7d-9429-97c088d1f1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_498fd961-35e9-4798-81aa-f94e725b82c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3f6b700b-78ce-40cc-b090-7c7906b782b3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_498fd961-35e9-4798-81aa-f94e725b82c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="gild-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_dba61a67-db8a-4b27-b3ab-eee4e7b939b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_7de0e6a9-27a7-43bb-99c3-e9c2603a3a41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_dba61a67-db8a-4b27-b3ab-eee4e7b939b7" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_7de0e6a9-27a7-43bb-99c3-e9c2603a3a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="gild-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f8ce8124-4106-4d5c-92c5-60b46194851a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1af5efd9-9cf6-4781-9a47-03451547aa49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f8ce8124-4106-4d5c-92c5-60b46194851a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1af5efd9-9cf6-4781-9a47-03451547aa49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d3ca2c26-6c3f-42fb-949e-43df7e6e32c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1af5efd9-9cf6-4781-9a47-03451547aa49" xlink:to="loc_us-gaap_ProfitLoss_d3ca2c26-6c3f-42fb-949e-43df7e6e32c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0b625ac8-882e-446f-89d0-0faf846bb6ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1af5efd9-9cf6-4781-9a47-03451547aa49" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0b625ac8-882e-446f-89d0-0faf846bb6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b22b5855-9e34-4ace-b928-6850e6ea17f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0b625ac8-882e-446f-89d0-0faf846bb6ad" xlink:to="loc_us-gaap_Depreciation_b22b5855-9e34-4ace-b928-6850e6ea17f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_3d1d35d5-af8b-4d04-80fd-374aa10db867" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0b625ac8-882e-446f-89d0-0faf846bb6ad" xlink:to="loc_us-gaap_AdjustmentForAmortization_3d1d35d5-af8b-4d04-80fd-374aa10db867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_cc9178ed-faf7-49b1-bbbc-67a67168f193" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0b625ac8-882e-446f-89d0-0faf846bb6ad" xlink:to="loc_us-gaap_ShareBasedCompensation_cc9178ed-faf7-49b1-bbbc-67a67168f193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_941f3208-7569-46e6-9e6f-f5bb67e16f0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0b625ac8-882e-446f-89d0-0faf846bb6ad" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_941f3208-7569-46e6-9e6f-f5bb67e16f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ad5bea34-3b76-4f45-b0f4-0ee9b3605201" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0b625ac8-882e-446f-89d0-0faf846bb6ad" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ad5bea34-3b76-4f45-b0f4-0ee9b3605201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_de58d7a6-adf5-43c1-a622-e406e32081f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0b625ac8-882e-446f-89d0-0faf846bb6ad" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_de58d7a6-adf5-43c1-a622-e406e32081f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_25df2d88-cd83-4f5c-9eaf-5505daa9fe2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0b625ac8-882e-446f-89d0-0faf846bb6ad" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_25df2d88-cd83-4f5c-9eaf-5505daa9fe2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_804645a3-f6ba-4608-a572-2047f3fe1090" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1af5efd9-9cf6-4781-9a47-03451547aa49" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_804645a3-f6ba-4608-a572-2047f3fe1090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_59ab1bd4-af37-48aa-bf7f-1abbc69ebb1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_804645a3-f6ba-4608-a572-2047f3fe1090" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_59ab1bd4-af37-48aa-bf7f-1abbc69ebb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_dcd56cc7-e132-4a05-9e2b-a288ef1fc6a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_804645a3-f6ba-4608-a572-2047f3fe1090" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_dcd56cc7-e132-4a05-9e2b-a288ef1fc6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_65f4128b-947a-43bb-b4d4-3be862d948ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_804645a3-f6ba-4608-a572-2047f3fe1090" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_65f4128b-947a-43bb-b4d4-3be862d948ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4c288e90-453b-4ef4-98bc-d83f73525f4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_804645a3-f6ba-4608-a572-2047f3fe1090" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4c288e90-453b-4ef4-98bc-d83f73525f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3224e93c-2169-40c9-991f-f17a4ed2b2db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_804645a3-f6ba-4608-a572-2047f3fe1090" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3224e93c-2169-40c9-991f-f17a4ed2b2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7ff79693-46f7-4a97-8154-61364790d5d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_804645a3-f6ba-4608-a572-2047f3fe1090" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7ff79693-46f7-4a97-8154-61364790d5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d2e6dcc-5031-4cec-9749-c4ed886b568b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1af5efd9-9cf6-4781-9a47-03451547aa49" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d2e6dcc-5031-4cec-9749-c4ed886b568b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d14b58c6-919f-45a8-ad2a-2c1909afe505" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f8ce8124-4106-4d5c-92c5-60b46194851a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d14b58c6-919f-45a8-ad2a-2c1909afe505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f370d7d5-fdab-4be1-9964-f69f5c3bc811" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d14b58c6-919f-45a8-ad2a-2c1909afe505" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f370d7d5-fdab-4be1-9964-f69f5c3bc811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_06da7e6c-cc44-4822-9200-fa3b80636a78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d14b58c6-919f-45a8-ad2a-2c1909afe505" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_06da7e6c-cc44-4822-9200-fa3b80636a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_19c6ebe1-8c8d-4f28-a055-6df1e0a5e164" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d14b58c6-919f-45a8-ad2a-2c1909afe505" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_19c6ebe1-8c8d-4f28-a055-6df1e0a5e164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0e4509b1-9df1-4996-ac63-3ba370eea95d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d14b58c6-919f-45a8-ad2a-2c1909afe505" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0e4509b1-9df1-4996-ac63-3ba370eea95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_7b71ec3c-b692-4b59-8f36-bef8159b4cfc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d14b58c6-919f-45a8-ad2a-2c1909afe505" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_7b71ec3c-b692-4b59-8f36-bef8159b4cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f5899bc7-a2ed-45e2-a08d-fec70482fd76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d14b58c6-919f-45a8-ad2a-2c1909afe505" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f5899bc7-a2ed-45e2-a08d-fec70482fd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1efb95aa-a8e8-41f6-901d-6d16a5d84460" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d14b58c6-919f-45a8-ad2a-2c1909afe505" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1efb95aa-a8e8-41f6-901d-6d16a5d84460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_63f30dd3-eea1-4d7f-8a6d-c287be802e92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d14b58c6-919f-45a8-ad2a-2c1909afe505" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_63f30dd3-eea1-4d7f-8a6d-c287be802e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9c36b0b5-8da4-493d-8a14-8aab7562b878" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f8ce8124-4106-4d5c-92c5-60b46194851a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9c36b0b5-8da4-493d-8a14-8aab7562b878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_09af5da7-1edd-4197-82b6-1efc59e11f8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9c36b0b5-8da4-493d-8a14-8aab7562b878" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_09af5da7-1edd-4197-82b6-1efc59e11f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_107f2498-ffc7-4cea-bbf6-64436c5f37f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9c36b0b5-8da4-493d-8a14-8aab7562b878" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_107f2498-ffc7-4cea-bbf6-64436c5f37f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_9f960733-79d1-4c77-8503-43cfa1b8bb50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9c36b0b5-8da4-493d-8a14-8aab7562b878" xlink:to="loc_us-gaap_RepaymentsOfDebt_9f960733-79d1-4c77-8503-43cfa1b8bb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_895f8d91-f6cb-437c-b1b9-4acde4afa3a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9c36b0b5-8da4-493d-8a14-8aab7562b878" xlink:to="loc_us-gaap_PaymentsOfDividends_895f8d91-f6cb-437c-b1b9-4acde4afa3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_de127d86-3077-4a16-9cf5-ab71a284c8b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9c36b0b5-8da4-493d-8a14-8aab7562b878" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_de127d86-3077-4a16-9cf5-ab71a284c8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fbcc9c25-c7e6-416a-9c71-ad434df05f49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9c36b0b5-8da4-493d-8a14-8aab7562b878" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fbcc9c25-c7e6-416a-9c71-ad434df05f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_674257b8-71e3-42ea-a705-d46860e9cfaf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f8ce8124-4106-4d5c-92c5-60b46194851a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_674257b8-71e3-42ea-a705-d46860e9cfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1210e261-90ce-42bf-ba18-6758fb2c85ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f8ce8124-4106-4d5c-92c5-60b46194851a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1210e261-90ce-42bf-ba18-6758fb2c85ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0094db4f-a924-49f1-8c2f-7ba58b00ca60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f8ce8124-4106-4d5c-92c5-60b46194851a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0094db4f-a924-49f1-8c2f-7ba58b00ca60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0ed38ca9-f190-4649-bd41-445b039aef6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f8ce8124-4106-4d5c-92c5-60b46194851a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0ed38ca9-f190-4649-bd41-445b039aef6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="gild-20210331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4f4e06a9-5be5-4c79-a4f6-e6800b8ab7b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_ba19a4a0-ef41-4e33-94ed-9de4c029ff35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4f4e06a9-5be5-4c79-a4f6-e6800b8ab7b1" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_ba19a4a0-ef41-4e33-94ed-9de4c029ff35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="gild-20210331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b2fbd5f3-9b6d-4d36-967d-0037e3918245" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c483fcb9-11ce-43ea-a4a6-92113ac96ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b2fbd5f3-9b6d-4d36-967d-0037e3918245" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c483fcb9-11ce-43ea-a4a6-92113ac96ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_222913da-6b90-4632-91f0-bda07f0910d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b2fbd5f3-9b6d-4d36-967d-0037e3918245" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_222913da-6b90-4632-91f0-bda07f0910d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_55d7630d-1540-4551-8895-5b74ed5d9233" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b2fbd5f3-9b6d-4d36-967d-0037e3918245" xlink:to="loc_us-gaap_UseOfEstimates_55d7630d-1540-4551-8895-5b74ed5d9233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_10439bd9-215e-45e1-a8a9-4db0b472b6b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b2fbd5f3-9b6d-4d36-967d-0037e3918245" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_10439bd9-215e-45e1-a8a9-4db0b472b6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_c3e6417a-b15c-4724-9175-e1b0742175ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b2fbd5f3-9b6d-4d36-967d-0037e3918245" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_c3e6417a-b15c-4724-9175-e1b0742175ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_66631370-f440-41ef-ae44-d5b56e9278d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b2fbd5f3-9b6d-4d36-967d-0037e3918245" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_66631370-f440-41ef-ae44-d5b56e9278d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_335ac564-de50-4c3e-bd8d-6e907a7be1af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_2d38adf4-f3f6-4840-8a04-8e2cc4472f47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_335ac564-de50-4c3e-bd8d-6e907a7be1af" xlink:to="loc_us-gaap_NumberOfOperatingSegments_2d38adf4-f3f6-4840-8a04-8e2cc4472f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_362a6d85-0be7-4e6b-bdcc-b19efa958fb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_335ac564-de50-4c3e-bd8d-6e907a7be1af" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_362a6d85-0be7-4e6b-bdcc-b19efa958fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUES" xlink:type="simple" xlink:href="gild-20210331.xsd#REVENUES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/REVENUES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5a494166-90e0-4215-b6fe-c42f077b1697" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_bd4627ed-b27e-4eb5-b6f0-3b9337477e26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5a494166-90e0-4215-b6fe-c42f077b1697" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_bd4627ed-b27e-4eb5-b6f0-3b9337477e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESTables" xlink:type="simple" xlink:href="gild-20210331.xsd#REVENUESTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/REVENUESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_10396172-1e8d-4a63-9171-84ba3c71b80e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_ae7e1c2f-d45c-40e5-8a6f-c3b9c4feddec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_10396172-1e8d-4a63-9171-84ba3c71b80e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_ae7e1c2f-d45c-40e5-8a6f-c3b9c4feddec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_033dd577-ac92-442e-929f-3ce3e472a6f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_10396172-1e8d-4a63-9171-84ba3c71b80e" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_033dd577-ac92-442e-929f-3ce3e472a6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#REVENUESDisaggregationofRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bcfec689-4699-4e4d-83f1-fea129fb9716" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_84309fde-2db9-40d9-87fd-6e9a5bbfaeb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bcfec689-4699-4e4d-83f1-fea129fb9716" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_84309fde-2db9-40d9-87fd-6e9a5bbfaeb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9511a0b3-7889-44cd-9d9d-1a152a273c80" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_84309fde-2db9-40d9-87fd-6e9a5bbfaeb7" xlink:to="loc_srt_ProductOrServiceAxis_9511a0b3-7889-44cd-9d9d-1a152a273c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_da2b7125-969b-48fe-9162-d40622155aff" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9511a0b3-7889-44cd-9d9d-1a152a273c80" xlink:to="loc_srt_ProductsAndServicesDomain_da2b7125-969b-48fe-9162-d40622155aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_dbd8532f-13a3-4bc9-959f-b5055676c288" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_da2b7125-969b-48fe-9162-d40622155aff" xlink:to="loc_us-gaap_ProductMember_dbd8532f-13a3-4bc9-959f-b5055676c288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:href="gild-20210331.xsd#gild_HIVProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_dbd8532f-13a3-4bc9-959f-b5055676c288" xlink:to="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsAtriplaMember_5f533c93-6fb5-4cf0-8827-0b8769703544" xlink:href="gild-20210331.xsd#gild_HIVProductsAtriplaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:to="loc_gild_HIVProductsAtriplaMember_5f533c93-6fb5-4cf0-8827-0b8769703544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsBiktarvyMember_8fd410df-6903-469f-a876-07b9113ce8c3" xlink:href="gild-20210331.xsd#gild_HIVProductsBiktarvyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:to="loc_gild_HIVProductsBiktarvyMember_8fd410df-6903-469f-a876-07b9113ce8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsCompleraEvipleraMember_6ddb8a76-06c2-4bde-ba03-98f1b72f5498" xlink:href="gild-20210331.xsd#gild_HIVProductsCompleraEvipleraMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:to="loc_gild_HIVProductsCompleraEvipleraMember_6ddb8a76-06c2-4bde-ba03-98f1b72f5498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsDescovyMember_95ff3a53-b930-49d6-8934-d8730edf8237" xlink:href="gild-20210331.xsd#gild_HIVProductsDescovyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:to="loc_gild_HIVProductsDescovyMember_95ff3a53-b930-49d6-8934-d8730edf8237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsGenvoyaMember_e22296ba-0c6b-4bb2-8ed0-19e4c84d7af1" xlink:href="gild-20210331.xsd#gild_HIVProductsGenvoyaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:to="loc_gild_HIVProductsGenvoyaMember_e22296ba-0c6b-4bb2-8ed0-19e4c84d7af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsOdefseyMember_651b9b22-dcec-44e2-b70c-1609dd51f68b" xlink:href="gild-20210331.xsd#gild_HIVProductsOdefseyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:to="loc_gild_HIVProductsOdefseyMember_651b9b22-dcec-44e2-b70c-1609dd51f68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsStribildMember_9aab7d71-118e-4a53-b136-784b19a590fe" xlink:href="gild-20210331.xsd#gild_HIVProductsStribildMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:to="loc_gild_HIVProductsStribildMember_9aab7d71-118e-4a53-b136-784b19a590fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsTruvadaMember_810584ad-f676-4306-b8d4-5f3ce5545ba2" xlink:href="gild-20210331.xsd#gild_HIVProductsTruvadaMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:to="loc_gild_HIVProductsTruvadaMember_810584ad-f676-4306-b8d4-5f3ce5545ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsOtherHIVMember_cc109811-92f9-4776-8fbb-2ff90c614945" xlink:href="gild-20210331.xsd#gild_ProductsOtherHIVMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:to="loc_gild_ProductsOtherHIVMember_cc109811-92f9-4776-8fbb-2ff90c614945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsRevenueShareSymtuzaMember_a7fdb178-e6dd-4051-a745-f9ef3e29044a" xlink:href="gild-20210331.xsd#gild_ProductsRevenueShareSymtuzaMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_6cb36896-3268-4383-bb8e-1e9a0cde3887" xlink:to="loc_gild_ProductsRevenueShareSymtuzaMember_a7fdb178-e6dd-4051-a745-f9ef3e29044a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductSalesMember_a7557a12-d4bf-4c9b-950d-4b85ea75d28a" xlink:href="gild-20210331.xsd#gild_HCVProductSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_dbd8532f-13a3-4bc9-959f-b5055676c288" xlink:to="loc_gild_HCVProductSalesMember_a7557a12-d4bf-4c9b-950d-4b85ea75d28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsLedipasvirSofosbuvirMember_a037393c-43b2-4189-927d-87321003f8fe" xlink:href="gild-20210331.xsd#gild_HCVProductsLedipasvirSofosbuvirMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HCVProductSalesMember_a7557a12-d4bf-4c9b-950d-4b85ea75d28a" xlink:to="loc_gild_HCVProductsLedipasvirSofosbuvirMember_a037393c-43b2-4189-927d-87321003f8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_6cdb80a0-95ac-43de-b0d2-cd38a822e174" xlink:href="gild-20210331.xsd#gild_HCVProductsSofosbuvirVelpatasvirMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HCVProductSalesMember_a7557a12-d4bf-4c9b-950d-4b85ea75d28a" xlink:to="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_6cdb80a0-95ac-43de-b0d2-cd38a822e174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherHepatitisCVirusProductsMember_7357c4c3-d325-4d07-a01f-f93062511ad1" xlink:href="gild-20210331.xsd#gild_OtherHepatitisCVirusProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HCVProductSalesMember_a7557a12-d4bf-4c9b-950d-4b85ea75d28a" xlink:to="loc_gild_OtherHepatitisCVirusProductsMember_7357c4c3-d325-4d07-a01f-f93062511ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_15bddf28-7822-4986-a372-9feaf494606e" xlink:href="gild-20210331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_dbd8532f-13a3-4bc9-959f-b5055676c288" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_15bddf28-7822-4986-a372-9feaf494606e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_8c0b0bc2-dfba-481b-bdd0-56497ea1f917" xlink:href="gild-20210331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_15bddf28-7822-4986-a372-9feaf494606e" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_8c0b0bc2-dfba-481b-bdd0-56497ea1f917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_14ad78e4-2f02-4215-bb5c-24c9bc49634c" xlink:href="gild-20210331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_15bddf28-7822-4986-a372-9feaf494606e" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_14ad78e4-2f02-4215-bb5c-24c9bc49634c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_38b6fffc-7145-474c-a6be-c88663995d2a" xlink:href="gild-20210331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_15bddf28-7822-4986-a372-9feaf494606e" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_38b6fffc-7145-474c-a6be-c88663995d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VekluryMember_5ed9f64c-fbff-48f8-8ea9-5510ef2800e3" xlink:href="gild-20210331.xsd#gild_VekluryMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_dbd8532f-13a3-4bc9-959f-b5055676c288" xlink:to="loc_gild_VekluryMember_5ed9f64c-fbff-48f8-8ea9-5510ef2800e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_f915b8ec-e9e4-4c58-945f-a038fa26d031" xlink:href="gild-20210331.xsd#gild_CellTherapyProductsTotalCellTherapyProductSalesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_dbd8532f-13a3-4bc9-959f-b5055676c288" xlink:to="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_f915b8ec-e9e4-4c58-945f-a038fa26d031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CallTherapyProductsTecartusMember_2cc2ba65-6162-4d0e-a5dc-34b82324f8c9" xlink:href="gild-20210331.xsd#gild_CallTherapyProductsTecartusMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_f915b8ec-e9e4-4c58-945f-a038fa26d031" xlink:to="loc_gild_CallTherapyProductsTecartusMember_2cc2ba65-6162-4d0e-a5dc-34b82324f8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsYescartaMember_eca1824b-b31b-4a07-b1ea-e4fa8d3ad815" xlink:href="gild-20210331.xsd#gild_CellTherapyProductsYescartaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_f915b8ec-e9e4-4c58-945f-a038fa26d031" xlink:to="loc_gild_CellTherapyProductsYescartaMember_eca1824b-b31b-4a07-b1ea-e4fa8d3ad815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_db71fbd2-7985-407a-bb6e-8481b97e97cf" xlink:href="gild-20210331.xsd#gild_TrodelvyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_dbd8532f-13a3-4bc9-959f-b5055676c288" xlink:to="loc_gild_TrodelvyMember_db71fbd2-7985-407a-bb6e-8481b97e97cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsTotalOtherProductSalesMember_a082bb64-4772-49a7-8a89-3131ed0cc64b" xlink:href="gild-20210331.xsd#gild_OtherProductsTotalOtherProductSalesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_dbd8532f-13a3-4bc9-959f-b5055676c288" xlink:to="loc_gild_OtherProductsTotalOtherProductSalesMember_a082bb64-4772-49a7-8a89-3131ed0cc64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsAmBisomeMember_311125c2-f331-4628-839c-7f3da07066d0" xlink:href="gild-20210331.xsd#gild_OtherProductsAmBisomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_a082bb64-4772-49a7-8a89-3131ed0cc64b" xlink:to="loc_gild_OtherProductsAmBisomeMember_311125c2-f331-4628-839c-7f3da07066d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsLetairisMember_10289a7e-c65c-490d-98ba-e1baa804c005" xlink:href="gild-20210331.xsd#gild_OtherProductsLetairisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_a082bb64-4772-49a7-8a89-3131ed0cc64b" xlink:to="loc_gild_OtherProductsLetairisMember_10289a7e-c65c-490d-98ba-e1baa804c005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsRanexaMember_d0fb5de9-fa86-4c49-9bf9-e3c9550e02a4" xlink:href="gild-20210331.xsd#gild_OtherProductsRanexaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_a082bb64-4772-49a7-8a89-3131ed0cc64b" xlink:to="loc_gild_OtherProductsRanexaMember_d0fb5de9-fa86-4c49-9bf9-e3c9550e02a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsZydeligMember_fedee5c2-a5be-4d88-a3ac-35449cc740f2" xlink:href="gild-20210331.xsd#gild_OtherProductsZydeligMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_a082bb64-4772-49a7-8a89-3131ed0cc64b" xlink:to="loc_gild_OtherProductsZydeligMember_fedee5c2-a5be-4d88-a3ac-35449cc740f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsOtherMember_2e9ce5ee-d8d8-48e2-b646-6d574c89b556" xlink:href="gild-20210331.xsd#gild_OtherProductsOtherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_a082bb64-4772-49a7-8a89-3131ed0cc64b" xlink:to="loc_gild_OtherProductsOtherMember_2e9ce5ee-d8d8-48e2-b646-6d574c89b556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_462f43af-55b1-4c2e-9eac-18e8f78eb943" xlink:href="gild-20210331.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_da2b7125-969b-48fe-9162-d40622155aff" xlink:to="loc_gild_RoyaltyContractAndOtherMember_462f43af-55b1-4c2e-9eac-18e8f78eb943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d7d83b0f-b27b-4e7a-83f7-3c24d3c525a8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_84309fde-2db9-40d9-87fd-6e9a5bbfaeb7" xlink:to="loc_srt_StatementGeographicalAxis_d7d83b0f-b27b-4e7a-83f7-3c24d3c525a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_003b2567-6c7a-48c0-a24e-bab7e05fd6e4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d7d83b0f-b27b-4e7a-83f7-3c24d3c525a8" xlink:to="loc_srt_SegmentGeographicalDomain_003b2567-6c7a-48c0-a24e-bab7e05fd6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4d795df3-16eb-48c8-abf8-f216b4063372" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_003b2567-6c7a-48c0-a24e-bab7e05fd6e4" xlink:to="loc_country_US_4d795df3-16eb-48c8-abf8-f216b4063372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_01fd634b-6c1e-4316-bfb1-7f7b1d7c9c18" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_003b2567-6c7a-48c0-a24e-bab7e05fd6e4" xlink:to="loc_srt_EuropeMember_01fd634b-6c1e-4316-bfb1-7f7b1d7c9c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherInternationalMember_7f982560-1ea5-4972-a3db-b68bb26e55dd" xlink:href="gild-20210331.xsd#gild_OtherInternationalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_003b2567-6c7a-48c0-a24e-bab7e05fd6e4" xlink:to="loc_gild_OtherInternationalMember_7f982560-1ea5-4972-a3db-b68bb26e55dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f5b4617e-4a1e-4c13-a2ad-2404d89c63b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_84309fde-2db9-40d9-87fd-6e9a5bbfaeb7" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_f5b4617e-4a1e-4c13-a2ad-2404d89c63b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2e5fac2f-e6e4-456c-9577-051af03d5e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f5b4617e-4a1e-4c13-a2ad-2404d89c63b5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2e5fac2f-e6e4-456c-9577-051af03d5e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#REVENUESRevenuesfromMajorCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b2366be8-49dd-4205-9511-4735441a3db1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_3caa45b8-66b0-4411-bb48-c63dc3d6cd1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b2366be8-49dd-4205-9511-4735441a3db1" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_3caa45b8-66b0-4411-bb48-c63dc3d6cd1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3ecd2712-0375-4c81-b55a-39aba1e882f4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_3caa45b8-66b0-4411-bb48-c63dc3d6cd1c" xlink:to="loc_srt_MajorCustomersAxis_3ecd2712-0375-4c81-b55a-39aba1e882f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4658a320-d281-4878-bb64-7a0edbf1db80" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_3ecd2712-0375-4c81-b55a-39aba1e882f4" xlink:to="loc_srt_NameOfMajorCustomerDomain_4658a320-d281-4878-bb64-7a0edbf1db80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmerisourcebergenCorpMember_43ca7f33-b0bc-42b5-b1ef-0464d1c22836" xlink:href="gild-20210331.xsd#gild_AmerisourcebergenCorpMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4658a320-d281-4878-bb64-7a0edbf1db80" xlink:to="loc_gild_AmerisourcebergenCorpMember_43ca7f33-b0bc-42b5-b1ef-0464d1c22836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CardinalHealthIncMember_92cbc9f1-6138-47ad-ac2a-65520642aec4" xlink:href="gild-20210331.xsd#gild_CardinalHealthIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4658a320-d281-4878-bb64-7a0edbf1db80" xlink:to="loc_gild_CardinalHealthIncMember_92cbc9f1-6138-47ad-ac2a-65520642aec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MckessonCorpMember_63cf8f75-fd48-4bf2-afe4-71dec4375409" xlink:href="gild-20210331.xsd#gild_MckessonCorpMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4658a320-d281-4878-bb64-7a0edbf1db80" xlink:to="loc_gild_MckessonCorpMember_63cf8f75-fd48-4bf2-afe4-71dec4375409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4f7de32a-7388-4eae-b9e2-4ad55aa7056b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_3caa45b8-66b0-4411-bb48-c63dc3d6cd1c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4f7de32a-7388-4eae-b9e2-4ad55aa7056b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e6faaa1a-3e0c-478a-b710-97709bc56912" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4f7de32a-7388-4eae-b9e2-4ad55aa7056b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e6faaa1a-3e0c-478a-b710-97709bc56912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_9924dbe9-98d1-4d17-a6ec-aa9b3868d20d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e6faaa1a-3e0c-478a-b710-97709bc56912" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_9924dbe9-98d1-4d17-a6ec-aa9b3868d20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c073c506-340e-4037-a8b0-aa9906da8ae0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_3caa45b8-66b0-4411-bb48-c63dc3d6cd1c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c073c506-340e-4037-a8b0-aa9906da8ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_40c8c90c-3dff-48b6-b689-b02988005736" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c073c506-340e-4037-a8b0-aa9906da8ae0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_40c8c90c-3dff-48b6-b689-b02988005736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_b1f0e26e-891f-404b-a299-00e82edd0c8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_40c8c90c-3dff-48b6-b689-b02988005736" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_b1f0e26e-891f-404b-a299-00e82edd0c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_ebd4dfe1-7436-488b-a1f2-d9cbb2b74adc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_3caa45b8-66b0-4411-bb48-c63dc3d6cd1c" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_ebd4dfe1-7436-488b-a1f2-d9cbb2b74adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f692e8f2-d852-46e2-bee0-f9e5ba60867e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_ebd4dfe1-7436-488b-a1f2-d9cbb2b74adc" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f692e8f2-d852-46e2-bee0-f9e5ba60867e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#REVENUESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/REVENUESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d512955a-ed3a-434f-b68a-280f9d9893f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7c002eb8-c8f5-450b-90fb-7f3f6bc03bae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d512955a-ed3a-434f-b68a-280f9d9893f3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7c002eb8-c8f5-450b-90fb-7f3f6bc03bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ca6e213e-a6f6-468f-a05f-8c234f982082" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7c002eb8-c8f5-450b-90fb-7f3f6bc03bae" xlink:to="loc_srt_ProductOrServiceAxis_ca6e213e-a6f6-468f-a05f-8c234f982082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_998dd5f6-0217-4183-ae0b-15ffd28a07d5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ca6e213e-a6f6-468f-a05f-8c234f982082" xlink:to="loc_srt_ProductsAndServicesDomain_998dd5f6-0217-4183-ae0b-15ffd28a07d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_62ce8b5a-167d-4253-a862-5328c8c04b20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_998dd5f6-0217-4183-ae0b-15ffd28a07d5" xlink:to="loc_us-gaap_RoyaltyMember_62ce8b5a-167d-4253-a862-5328c8c04b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_37f0cba7-d842-42aa-83a7-833bcf31bc45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7c002eb8-c8f5-450b-90fb-7f3f6bc03bae" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_37f0cba7-d842-42aa-83a7-833bcf31bc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_02bb2a38-26ec-46d0-8c05-9b6e2915c47f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_37f0cba7-d842-42aa-83a7-833bcf31bc45" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_02bb2a38-26ec-46d0-8c05-9b6e2915c47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_59f02333-7ef6-470e-8239-0412bfb4445f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_37f0cba7-d842-42aa-83a7-833bcf31bc45" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_59f02333-7ef6-470e-8239-0412bfb4445f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_0441ada5-0642-42b1-a96b-f8528f756587" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_37f0cba7-d842-42aa-83a7-833bcf31bc45" xlink:to="loc_us-gaap_ContractWithCustomerLiability_0441ada5-0642-42b1-a96b-f8528f756587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_64c2401a-c835-4846-aed2-f89dbe40655a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_37f0cba7-d842-42aa-83a7-833bcf31bc45" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_64c2401a-c835-4846-aed2-f89dbe40655a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="gild-20210331.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a09b2a6e-8f0c-40b3-ba0c-067838d475fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_b05fb090-17ef-43e2-b533-206740ee7947" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a09b2a6e-8f0c-40b3-ba0c-067838d475fc" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_b05fb090-17ef-43e2-b533-206740ee7947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="gild-20210331.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_78152b6b-c4e9-43e8-933b-8a579936b8cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1137c587-e94a-46f1-b4be-903b8ffe64d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_78152b6b-c4e9-43e8-933b-8a579936b8cc" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1137c587-e94a-46f1-b4be-903b8ffe64d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_b0258d1e-f0c6-4307-8884-4480cb387acf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_78152b6b-c4e9-43e8-933b-8a579936b8cc" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_b0258d1e-f0c6-4307-8884-4480cb387acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_ce476de6-aaee-4793-8396-631257fc9a12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_78152b6b-c4e9-43e8-933b-8a579936b8cc" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_ce476de6-aaee-4793-8396-631257fc9a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f7756778-612e-4663-b787-bd8c77e2c17a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8cf036e1-5423-4d05-b20d-600428bc2c09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f7756778-612e-4663-b787-bd8c77e2c17a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8cf036e1-5423-4d05-b20d-600428bc2c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80b7274d-d040-4ece-a187-09a843e91d22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8cf036e1-5423-4d05-b20d-600428bc2c09" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80b7274d-d040-4ece-a187-09a843e91d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_eb68ea90-6367-41a5-9518-c1ca18d60ca2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_80b7274d-d040-4ece-a187-09a843e91d22" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_eb68ea90-6367-41a5-9518-c1ca18d60ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a0b53aeb-377b-49b0-9fa3-dac4f2a16388" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_eb68ea90-6367-41a5-9518-c1ca18d60ca2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a0b53aeb-377b-49b0-9fa3-dac4f2a16388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_75d63900-85db-4b3d-a818-42b8acbab8b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8cf036e1-5423-4d05-b20d-600428bc2c09" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_75d63900-85db-4b3d-a818-42b8acbab8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0020ef22-9514-4a3c-829e-4b46d49bd549" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_75d63900-85db-4b3d-a818-42b8acbab8b7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0020ef22-9514-4a3c-829e-4b46d49bd549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_51f4e0ef-9f47-418f-b0c7-f0bb6485f521" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0020ef22-9514-4a3c-829e-4b46d49bd549" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_51f4e0ef-9f47-418f-b0c7-f0bb6485f521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ac4061ef-5d25-4fa2-a2de-d5f2ef495b30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0020ef22-9514-4a3c-829e-4b46d49bd549" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ac4061ef-5d25-4fa2-a2de-d5f2ef495b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e354db26-f71a-465e-90ef-94759d885d13" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0020ef22-9514-4a3c-829e-4b46d49bd549" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e354db26-f71a-465e-90ef-94759d885d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_9cf98e57-44ea-4499-a084-7e5d92320c84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8cf036e1-5423-4d05-b20d-600428bc2c09" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_9cf98e57-44ea-4499-a084-7e5d92320c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ce102b9e-724f-4a47-889e-7809aa1ec75b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_9cf98e57-44ea-4499-a084-7e5d92320c84" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ce102b9e-724f-4a47-889e-7809aa1ec75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_df61e737-d64a-459e-8cc3-31c9a9ac396c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ce102b9e-724f-4a47-889e-7809aa1ec75b" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_df61e737-d64a-459e-8cc3-31c9a9ac396c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_e1742f53-fb3f-4b68-8557-01b32d96723b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_df61e737-d64a-459e-8cc3-31c9a9ac396c" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_e1742f53-fb3f-4b68-8557-01b32d96723b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_76a3caef-a42d-48f4-b945-4e94a6f28825" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8cf036e1-5423-4d05-b20d-600428bc2c09" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_76a3caef-a42d-48f4-b945-4e94a6f28825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_76a3caef-a42d-48f4-b945-4e94a6f28825" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_e115c7ad-7791-48a9-9e2e-c1cd51a852ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_e115c7ad-7791-48a9-9e2e-c1cd51a852ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_2a48ff77-53f2-468f-bb3a-9eab9fca29d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_2a48ff77-53f2-468f-bb3a-9eab9fca29d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_41d5eea0-67d1-4c9a-9b9a-72312da820ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_41d5eea0-67d1-4c9a-9b9a-72312da820ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_24bdbf55-b093-414e-90be-7b8eb11ad8e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_24bdbf55-b093-414e-90be-7b8eb11ad8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_f95f699c-d9af-455f-a492-8aa66e34edc1" xlink:href="gild-20210331.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_f95f699c-d9af-455f-a492-8aa66e34edc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3939a2ab-cceb-4937-a513-ba6ebdf435dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3939a2ab-cceb-4937-a513-ba6ebdf435dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityinvestmentinGalapagosMember_9303c1f2-fd31-41fe-abad-a9d6a4fe21f5" xlink:href="gild-20210331.xsd#gild_EquityinvestmentinGalapagosMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:to="loc_gild_EquityinvestmentinGalapagosMember_9303c1f2-fd31-41fe-abad-a9d6a4fe21f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_6ecd5bc3-3d2e-4c0b-8a7f-45ce767f4daf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:to="loc_us-gaap_EquitySecuritiesMember_6ecd5bc3-3d2e-4c0b-8a7f-45ce767f4daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember_1b279e5d-2e15-417a-8df3-cfac5b552959" xlink:href="gild-20210331.xsd#gild_DeferredCompensationPlanMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:to="loc_gild_DeferredCompensationPlanMember_1b279e5d-2e15-417a-8df3-cfac5b552959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ForeignCurrencyDerivativeContractsMember_01ca74e8-ffad-4919-b50e-be5afc9a4278" xlink:href="gild-20210331.xsd#gild_ForeignCurrencyDerivativeContractsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589251cd-efba-47ee-a1af-963466220d2f" xlink:to="loc_gild_ForeignCurrencyDerivativeContractsMember_01ca74e8-ffad-4919-b50e-be5afc9a4278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2a8e1765-2112-4990-b487-0e58a0677f14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8cf036e1-5423-4d05-b20d-600428bc2c09" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2a8e1765-2112-4990-b487-0e58a0677f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0de29832-8aaf-4999-a377-8417b7d4d2a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2a8e1765-2112-4990-b487-0e58a0677f14" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0de29832-8aaf-4999-a377-8417b7d4d2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_ad323c5f-2991-44df-9200-b7a168c5d1ac" xlink:href="gild-20210331.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0de29832-8aaf-4999-a377-8417b7d4d2a8" xlink:to="loc_gild_MYRGmbHMember_ad323c5f-2991-44df-9200-b7a168c5d1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9050e530-39ff-4173-9948-cfd85827a3b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8cf036e1-5423-4d05-b20d-600428bc2c09" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9050e530-39ff-4173-9948-cfd85827a3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3a0d4d63-b2ad-4b7f-906a-dce8ea1e278c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9050e530-39ff-4173-9948-cfd85827a3b4" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_3a0d4d63-b2ad-4b7f-906a-dce8ea1e278c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e425cffc-81d7-4c52-ab4b-f4ca036b5e1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3a0d4d63-b2ad-4b7f-906a-dce8ea1e278c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e425cffc-81d7-4c52-ab4b-f4ca036b5e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_7e3eb6a7-9cb0-4c92-9f94-7199c0800296" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3a0d4d63-b2ad-4b7f-906a-dce8ea1e278c" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_7e3eb6a7-9cb0-4c92-9f94-7199c0800296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_9e4b09cd-9da5-4658-b0c3-516d31e296c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3a0d4d63-b2ad-4b7f-906a-dce8ea1e278c" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_9e4b09cd-9da5-4658-b0c3-516d31e296c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ea5bfa01-cc2b-44d3-b072-d1c6937aec05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3a0d4d63-b2ad-4b7f-906a-dce8ea1e278c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ea5bfa01-cc2b-44d3-b072-d1c6937aec05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a31cfdf7-e627-4dea-9ce3-2f711d8646e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9050e530-39ff-4173-9948-cfd85827a3b4" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a31cfdf7-e627-4dea-9ce3-2f711d8646e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e45a6cfa-7d45-474b-bff9-da1519835755" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a31cfdf7-e627-4dea-9ce3-2f711d8646e2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e45a6cfa-7d45-474b-bff9-da1519835755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_4717aebe-9708-4819-9f54-8cd92bb8dc00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a31cfdf7-e627-4dea-9ce3-2f711d8646e2" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_4717aebe-9708-4819-9f54-8cd92bb8dc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_47d416bb-6bfe-4677-823b-94c4a0e57328" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a31cfdf7-e627-4dea-9ce3-2f711d8646e2" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_47d416bb-6bfe-4677-823b-94c4a0e57328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_a8d70d5f-2c0a-4585-b11d-587aa8262e8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a31cfdf7-e627-4dea-9ce3-2f711d8646e2" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_a8d70d5f-2c0a-4585-b11d-587aa8262e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c8de5b58-b1b6-4532-abeb-6872f4c2b098" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_17f936ef-6bb8-4b06-b275-214f8b5af778" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c8de5b58-b1b6-4532-abeb-6872f4c2b098" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_17f936ef-6bb8-4b06-b275-214f8b5af778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_11afe6b7-eec1-4d88-96ae-d704265fba3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_17f936ef-6bb8-4b06-b275-214f8b5af778" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_11afe6b7-eec1-4d88-96ae-d704265fba3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_482a6363-60f5-4375-9a57-3bb96f5687aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_11afe6b7-eec1-4d88-96ae-d704265fba3f" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_482a6363-60f5-4375-9a57-3bb96f5687aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherEquitySecuritiesMember_f103652e-f8ca-4eb7-9be4-14795497672c" xlink:href="gild-20210331.xsd#gild_OtherEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_482a6363-60f5-4375-9a57-3bb96f5687aa" xlink:to="loc_gild_OtherEquitySecuritiesMember_f103652e-f8ca-4eb7-9be4-14795497672c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e2d7ac1d-d22c-476d-8e69-547757029a82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_17f936ef-6bb8-4b06-b275-214f8b5af778" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e2d7ac1d-d22c-476d-8e69-547757029a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fc33ef04-2936-43fd-af8c-48358e327587" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e2d7ac1d-d22c-476d-8e69-547757029a82" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fc33ef04-2936-43fd-af8c-48358e327587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_6c1b929c-19c2-4520-9712-70749f4619fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fc33ef04-2936-43fd-af8c-48358e327587" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_6c1b929c-19c2-4520-9712-70749f4619fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_b09e24e8-d3c2-40a2-afbd-89e5f3a34db2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fc33ef04-2936-43fd-af8c-48358e327587" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_b09e24e8-d3c2-40a2-afbd-89e5f3a34db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_7369d9b7-67e2-4a7f-a4c0-69607394c4b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fc33ef04-2936-43fd-af8c-48358e327587" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_7369d9b7-67e2-4a7f-a4c0-69607394c4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fc8d1b6a-114d-4800-be92-c4dc01449e12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_17f936ef-6bb8-4b06-b275-214f8b5af778" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fc8d1b6a-114d-4800-be92-c4dc01449e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a04c2480-f264-4daf-b117-50d102e8d48f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fc8d1b6a-114d-4800-be92-c4dc01449e12" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a04c2480-f264-4daf-b117-50d102e8d48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d5e8e646-c28f-4ffd-92ee-9f6fc419eb4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fc8d1b6a-114d-4800-be92-c4dc01449e12" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d5e8e646-c28f-4ffd-92ee-9f6fc419eb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#FAIRVALUEMEASUREMENTSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3ece5bdd-ef2e-4556-97dd-7061c68f5e24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca73e69c-02cd-4c0b-aa36-6a232bdd8cb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3ece5bdd-ef2e-4556-97dd-7061c68f5e24" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca73e69c-02cd-4c0b-aa36-6a232bdd8cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_2a7fe366-8f6d-490b-89c7-a841bb8fea61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca73e69c-02cd-4c0b-aa36-6a232bdd8cb2" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_2a7fe366-8f6d-490b-89c7-a841bb8fea61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4541fd0d-fd4a-4a1b-9766-786e29f01c7d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_2a7fe366-8f6d-490b-89c7-a841bb8fea61" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4541fd0d-fd4a-4a1b-9766-786e29f01c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_37ab41e8-a9c2-447f-8954-e3f83114b2b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4541fd0d-fd4a-4a1b-9766-786e29f01c7d" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_37ab41e8-a9c2-447f-8954-e3f83114b2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9e55ba61-b5f1-490c-b582-1f3e12f3ebe6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_37ab41e8-a9c2-447f-8954-e3f83114b2b4" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9e55ba61-b5f1-490c-b582-1f3e12f3ebe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_0c3c22b1-0d71-48fa-9cb6-230b44408327" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_37ab41e8-a9c2-447f-8954-e3f83114b2b4" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_0c3c22b1-0d71-48fa-9cb6-230b44408327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aa661d24-9cec-4201-bbb0-d630f51136c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca73e69c-02cd-4c0b-aa36-6a232bdd8cb2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aa661d24-9cec-4201-bbb0-d630f51136c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8d542a69-c785-4375-b085-2ca1cf40c86a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aa661d24-9cec-4201-bbb0-d630f51136c4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8d542a69-c785-4375-b085-2ca1cf40c86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6f79814a-5830-44fc-97e3-4d2fdae28dd3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8d542a69-c785-4375-b085-2ca1cf40c86a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6f79814a-5830-44fc-97e3-4d2fdae28dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a3c678db-f2e5-4955-b452-7b97b207e7e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8d542a69-c785-4375-b085-2ca1cf40c86a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a3c678db-f2e5-4955-b452-7b97b207e7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_02f63276-a3e5-4420-a5a3-229762572b8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca73e69c-02cd-4c0b-aa36-6a232bdd8cb2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_02f63276-a3e5-4420-a5a3-229762572b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a808af1b-ea41-4846-8af4-fcc543297a49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_02f63276-a3e5-4420-a5a3-229762572b8f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a808af1b-ea41-4846-8af4-fcc543297a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_eac454d3-2e97-45cb-b0fb-8d7848b1ec0f" xlink:href="gild-20210331.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a808af1b-ea41-4846-8af4-fcc543297a49" xlink:to="loc_gild_MYRGmbHMember_eac454d3-2e97-45cb-b0fb-8d7848b1ec0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9e2086b6-2cc9-489c-93ed-f6a7016293fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca73e69c-02cd-4c0b-aa36-6a232bdd8cb2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9e2086b6-2cc9-489c-93ed-f6a7016293fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca95dd8f-3678-4eca-95ba-eb7e586fc241" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9e2086b6-2cc9-489c-93ed-f6a7016293fe" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca95dd8f-3678-4eca-95ba-eb7e586fc241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_591ac1fa-3943-44df-89f5-a6fdb1187184" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca95dd8f-3678-4eca-95ba-eb7e586fc241" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_591ac1fa-3943-44df-89f5-a6fdb1187184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29107fa8-9b9b-486c-8771-960468449de8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca73e69c-02cd-4c0b-aa36-6a232bdd8cb2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29107fa8-9b9b-486c-8771-960468449de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_da3adf12-829d-4251-b966-bbc2ea78d50c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29107fa8-9b9b-486c-8771-960468449de8" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_da3adf12-829d-4251-b966-bbc2ea78d50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9a4ed356-0bd9-4c69-8a61-8d1797d48bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29107fa8-9b9b-486c-8771-960468449de8" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9a4ed356-0bd9-4c69-8a61-8d1797d48bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_ca5237cf-b8c2-47e7-a9dd-fbee4f6c86a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29107fa8-9b9b-486c-8771-960468449de8" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_ca5237cf-b8c2-47e7-a9dd-fbee4f6c86a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_111fae9a-7d76-4263-97e8-a4e8982a9ce7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29107fa8-9b9b-486c-8771-960468449de8" xlink:to="loc_us-gaap_LongTermDebtFairValue_111fae9a-7d76-4263-97e8-a4e8982a9ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_45a34122-b612-4d81-9abb-837a947f297a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29107fa8-9b9b-486c-8771-960468449de8" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_45a34122-b612-4d81-9abb-837a947f297a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b2357268-aa1e-4210-8eac-3a8614f3337b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29107fa8-9b9b-486c-8771-960468449de8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b2357268-aa1e-4210-8eac-3a8614f3337b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1da7e62f-2c47-4753-b4d5-dfeed055f6c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8f7d3579-16e5-435c-9381-3387975de4c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1da7e62f-2c47-4753-b4d5-dfeed055f6c5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8f7d3579-16e5-435c-9381-3387975de4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6841d6f3-8ebf-4c3b-acac-13ab59d52a2b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8f7d3579-16e5-435c-9381-3387975de4c3" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6841d6f3-8ebf-4c3b-acac-13ab59d52a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_4e2cf3c2-95d4-460b-8c36-6ae9f1e29bab" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6841d6f3-8ebf-4c3b-acac-13ab59d52a2b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_4e2cf3c2-95d4-460b-8c36-6ae9f1e29bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosNVMember_49c2509c-47a8-4d1a-b0f8-dc1c453579ad" xlink:href="gild-20210331.xsd#gild_GalapagosNVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_4e2cf3c2-95d4-460b-8c36-6ae9f1e29bab" xlink:to="loc_gild_GalapagosNVMember_49c2509c-47a8-4d1a-b0f8-dc1c453579ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e4b69943-bb22-4277-827c-de6d0321ea42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8f7d3579-16e5-435c-9381-3387975de4c3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e4b69943-bb22-4277-827c-de6d0321ea42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3c8769b5-cb51-4b04-be14-6a91f44d63f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e4b69943-bb22-4277-827c-de6d0321ea42" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3c8769b5-cb51-4b04-be14-6a91f44d63f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_8bb8da3f-75e4-4032-b586-c831cc9a042d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3c8769b5-cb51-4b04-be14-6a91f44d63f0" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_8bb8da3f-75e4-4032-b586-c831cc9a042d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_06d23991-2542-441a-a1ab-483ab292cb03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3c8769b5-cb51-4b04-be14-6a91f44d63f0" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_06d23991-2542-441a-a1ab-483ab292cb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6ef6200d-4d80-44d6-b5bf-d4dbb5f8343b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8f7d3579-16e5-435c-9381-3387975de4c3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6ef6200d-4d80-44d6-b5bf-d4dbb5f8343b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_fb68547b-8a7a-475d-9879-5ef15cb9d92c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6ef6200d-4d80-44d6-b5bf-d4dbb5f8343b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_fb68547b-8a7a-475d-9879-5ef15cb9d92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIES" xlink:type="simple" xlink:href="gild-20210331.xsd#AVAILABLEFORSALEDEBTSECURITIES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_807a7528-5d86-4fdd-82b4-4d42ab241742" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_29837244-2ce1-43a4-9330-40bf12831833" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_807a7528-5d86-4fdd-82b4-4d42ab241742" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_29837244-2ce1-43a4-9330-40bf12831833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESTables" xlink:type="simple" xlink:href="gild-20210331.xsd#AVAILABLEFORSALEDEBTSECURITIESTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8b57b18b-5e1b-4b50-a900-ba74d3aa9511" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_04ce929a-fae6-4485-8bdd-d05745b0a341" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8b57b18b-5e1b-4b50-a900-ba74d3aa9511" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_04ce929a-fae6-4485-8bdd-d05745b0a341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_eada47a6-d26e-4299-85f9-226a4386b104" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8b57b18b-5e1b-4b50-a900-ba74d3aa9511" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_eada47a6-d26e-4299-85f9-226a4386b104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_e6c7904b-00b2-439b-97ef-8377838a645f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8b57b18b-5e1b-4b50-a900-ba74d3aa9511" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_e6c7904b-00b2-439b-97ef-8377838a645f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ec3fab84-06ce-4d84-9661-251328990bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_010e45af-f1d0-4885-93ca-1bb0ac52207f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ec3fab84-06ce-4d84-9661-251328990bf6" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_010e45af-f1d0-4885-93ca-1bb0ac52207f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_34d6917e-b810-4324-ae8a-4575580c0e01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_010e45af-f1d0-4885-93ca-1bb0ac52207f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_34d6917e-b810-4324-ae8a-4575580c0e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10a59d90-3e75-40f3-b20a-638f448e033a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_34d6917e-b810-4324-ae8a-4575580c0e01" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10a59d90-3e75-40f3-b20a-638f448e033a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_311f1d74-0ddd-49fb-ba98-f8a4f4350dac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10a59d90-3e75-40f3-b20a-638f448e033a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_311f1d74-0ddd-49fb-ba98-f8a4f4350dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_5306cfc3-2f2a-40b8-9e0e-9065e966e107" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10a59d90-3e75-40f3-b20a-638f448e033a" xlink:to="loc_us-gaap_CertificatesOfDepositMember_5306cfc3-2f2a-40b8-9e0e-9065e966e107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_8a9049c1-a66e-4273-9bcf-d0e117d649b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10a59d90-3e75-40f3-b20a-638f448e033a" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_8a9049c1-a66e-4273-9bcf-d0e117d649b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d762ad70-2abe-4c72-b490-02f666472dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10a59d90-3e75-40f3-b20a-638f448e033a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d762ad70-2abe-4c72-b490-02f666472dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_9fbd50d4-319f-47d7-835d-b2bb251287e8" xlink:href="gild-20210331.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10a59d90-3e75-40f3-b20a-638f448e033a" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_9fbd50d4-319f-47d7-835d-b2bb251287e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cca630a2-3824-49e1-90f0-c3d3aff710c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_010e45af-f1d0-4885-93ca-1bb0ac52207f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cca630a2-3824-49e1-90f0-c3d3aff710c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c08aff56-8b8f-4e31-9dd4-de6532c68ca5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cca630a2-3824-49e1-90f0-c3d3aff710c3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c08aff56-8b8f-4e31-9dd4-de6532c68ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_21720da2-718d-4b3f-baeb-ff2e92428bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cca630a2-3824-49e1-90f0-c3d3aff710c3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_21720da2-718d-4b3f-baeb-ff2e92428bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7f5848b4-92dd-4dae-9a39-6a378ce8aac3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cca630a2-3824-49e1-90f0-c3d3aff710c3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7f5848b4-92dd-4dae-9a39-6a378ce8aac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_153a3e9f-d9cf-4e1f-9cd8-3d5657be1f44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cca630a2-3824-49e1-90f0-c3d3aff710c3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_153a3e9f-d9cf-4e1f-9cd8-3d5657be1f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7a405034-ac7a-4e0d-8dc5-cde81e6924fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_83aebf54-b4b3-4e8f-85ba-80023037cf93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_7a405034-ac7a-4e0d-8dc5-cde81e6924fc" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_83aebf54-b4b3-4e8f-85ba-80023037cf93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7dd3258a-f01a-42eb-b762-1fd139172416" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_83aebf54-b4b3-4e8f-85ba-80023037cf93" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7dd3258a-f01a-42eb-b762-1fd139172416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3c1d0bf8-417f-425a-8f9b-799233ce800c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7dd3258a-f01a-42eb-b762-1fd139172416" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3c1d0bf8-417f-425a-8f9b-799233ce800c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_277b45a4-2378-451c-8569-b86a9f1afc8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3c1d0bf8-417f-425a-8f9b-799233ce800c" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_277b45a4-2378-451c-8569-b86a9f1afc8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesCurrentMember_6095ef11-4681-46b7-8752-6df4f915a28b" xlink:href="gild-20210331.xsd#gild_MarketableSecuritiesCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3c1d0bf8-417f-425a-8f9b-799233ce800c" xlink:to="loc_gild_MarketableSecuritiesCurrentMember_6095ef11-4681-46b7-8752-6df4f915a28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesNoncurrentMember_4667c518-67df-4e8d-ac02-6b99ae75ec1b" xlink:href="gild-20210331.xsd#gild_MarketableSecuritiesNoncurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3c1d0bf8-417f-425a-8f9b-799233ce800c" xlink:to="loc_gild_MarketableSecuritiesNoncurrentMember_4667c518-67df-4e8d-ac02-6b99ae75ec1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eff10df3-23b1-4a05-b196-d831ba98c4a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_83aebf54-b4b3-4e8f-85ba-80023037cf93" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eff10df3-23b1-4a05-b196-d831ba98c4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_132b3844-2cac-4c7b-ac4f-5ab95a9e5f9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_eff10df3-23b1-4a05-b196-d831ba98c4a1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_132b3844-2cac-4c7b-ac4f-5ab95a9e5f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0ef4b53d-5065-42bf-ac00-80cb1d6fed6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_b58483d8-b809-43f0-8de9-da4944cc856e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0ef4b53d-5065-42bf-ac00-80cb1d6fed6a" xlink:to="loc_us-gaap_InterestReceivableCurrent_b58483d8-b809-43f0-8de9-da4944cc856e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_WriteOffsInAccruedInterestReceivable_1c1cb3d3-0aae-45ec-b846-ce56b5706a96" xlink:href="gild-20210331.xsd#gild_WriteOffsInAccruedInterestReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0ef4b53d-5065-42bf-ac00-80cb1d6fed6a" xlink:to="loc_gild_WriteOffsInAccruedInterestReceivable_1c1cb3d3-0aae-45ec-b846-ce56b5706a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_b5a234d9-475e-4ed7-9469-75ded1b1226f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0ef4b53d-5065-42bf-ac00-80cb1d6fed6a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_b5a234d9-475e-4ed7-9469-75ded1b1226f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_e6d123a3-60e2-408f-bd2d-ead103113ff0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0ef4b53d-5065-42bf-ac00-80cb1d6fed6a" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_e6d123a3-60e2-408f-bd2d-ead103113ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_48e1f4f9-28b4-41b1-9b23-d595ac79f8d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_3542e8cc-8493-4e31-ace0-9b950b667132" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_48e1f4f9-28b4-41b1-9b23-d595ac79f8d7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_3542e8cc-8493-4e31-ace0-9b950b667132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0b4d0341-b9ce-4841-9d94-9b860d2f9288" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_3542e8cc-8493-4e31-ace0-9b950b667132" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0b4d0341-b9ce-4841-9d94-9b860d2f9288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_d02cc449-adb4-4966-b170-2a47b96c4986" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_3542e8cc-8493-4e31-ace0-9b950b667132" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_d02cc449-adb4-4966-b170-2a47b96c4986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_ca47b5b8-5227-463b-9c59-2e9c1a772038" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_3542e8cc-8493-4e31-ace0-9b950b667132" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_ca47b5b8-5227-463b-9c59-2e9c1a772038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3269aba7-dab1-45f0-9acc-664dc0590b6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_3542e8cc-8493-4e31-ace0-9b950b667132" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3269aba7-dab1-45f0-9acc-664dc0590b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_36a83a47-af40-46c8-9263-41774b967d2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_48e1f4f9-28b4-41b1-9b23-d595ac79f8d7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_36a83a47-af40-46c8-9263-41774b967d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_edb9a5bf-6b5e-442b-b9e3-75e2df77f2db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_36a83a47-af40-46c8-9263-41774b967d2c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_edb9a5bf-6b5e-442b-b9e3-75e2df77f2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_53d8e579-6644-4fb1-8267-ecf7b0f6b1e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_36a83a47-af40-46c8-9263-41774b967d2c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_53d8e579-6644-4fb1-8267-ecf7b0f6b1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_7d27c5f8-9f2c-4c70-b689-348366a9515f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_36a83a47-af40-46c8-9263-41774b967d2c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_7d27c5f8-9f2c-4c70-b689-348366a9515f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_acc9b1cc-d93c-4fdd-8c70-6bd495187c1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_36a83a47-af40-46c8-9263-41774b967d2c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_acc9b1cc-d93c-4fdd-8c70-6bd495187c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="gild-20210331.xsd#DERIVATIVEFINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_dd0c7d5f-3ef2-4c11-8e8c-35b0b8b7ed39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_34276344-0463-4bdc-bef4-48951aa5051d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_dd0c7d5f-3ef2-4c11-8e8c-35b0b8b7ed39" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_34276344-0463-4bdc-bef4-48951aa5051d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="gild-20210331.xsd#DERIVATIVEFINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b888f492-960d-4413-b07b-2450055368ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_18dcf6c2-a7c6-4b0d-975d-285a423d7a02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b888f492-960d-4413-b07b-2450055368ca" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_18dcf6c2-a7c6-4b0d-975d-285a423d7a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_6152107f-5bf3-4029-a122-c610f080fbbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b888f492-960d-4413-b07b-2450055368ca" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_6152107f-5bf3-4029-a122-c610f080fbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_b305b681-9b11-4a6f-90b9-5712a917f369" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b888f492-960d-4413-b07b-2450055368ca" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_b305b681-9b11-4a6f-90b9-5712a917f369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1ed83ff1-4306-4d0f-b5ae-7db1067405b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_9fc52806-e2eb-4386-96fc-b67cd5bf1ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1ed83ff1-4306-4d0f-b5ae-7db1067405b1" xlink:to="loc_us-gaap_DerivativeTable_9fc52806-e2eb-4386-96fc-b67cd5bf1ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8b805119-2c9e-4f92-9c5c-b31d4b5368bc" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_9fc52806-e2eb-4386-96fc-b67cd5bf1ea4" xlink:to="loc_srt_RangeAxis_8b805119-2c9e-4f92-9c5c-b31d4b5368bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ada9a9db-0b60-49c5-89fc-c539abc3ac77" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8b805119-2c9e-4f92-9c5c-b31d4b5368bc" xlink:to="loc_srt_RangeMember_ada9a9db-0b60-49c5-89fc-c539abc3ac77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_649ddc93-f2d4-47bb-bc68-ef4e948da981" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ada9a9db-0b60-49c5-89fc-c539abc3ac77" xlink:to="loc_srt_MaximumMember_649ddc93-f2d4-47bb-bc68-ef4e948da981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_d3929d1c-ed27-494f-bcf6-f2e603a8d286" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_9fc52806-e2eb-4386-96fc-b67cd5bf1ea4" xlink:to="loc_us-gaap_DerivativeLineItems_d3929d1c-ed27-494f-bcf6-f2e603a8d286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_f7d71973-70e1-43a5-b5db-d33f12ff53fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_d3929d1c-ed27-494f-bcf6-f2e603a8d286" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_f7d71973-70e1-43a5-b5db-d33f12ff53fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_ea1275d8-802c-446d-80bb-fdd0f2eea32a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_d3929d1c-ed27-494f-bcf6-f2e603a8d286" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_ea1275d8-802c-446d-80bb-fdd0f2eea32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_12cf9d55-5bbe-4bd6-9b0f-0b359cd5b20c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_d3929d1c-ed27-494f-bcf6-f2e603a8d286" xlink:to="loc_us-gaap_DerivativeNotionalAmount_12cf9d55-5bbe-4bd6-9b0f-0b359cd5b20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_481b1294-06b0-4f09-9272-4a0f31c2e0b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_d3929d1c-ed27-494f-bcf6-f2e603a8d286" xlink:to="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_481b1294-06b0-4f09-9272-4a0f31c2e0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d3bff260-7a03-4c93-a589-cbc580bafb8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7dc58fdb-6c3a-4ba2-b4e0-bfafc57779bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d3bff260-7a03-4c93-a589-cbc580bafb8d" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7dc58fdb-6c3a-4ba2-b4e0-bfafc57779bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_65c2343d-361a-4a3b-97b0-a0d4ce81d613" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7dc58fdb-6c3a-4ba2-b4e0-bfafc57779bf" xlink:to="loc_us-gaap_HedgingDesignationAxis_65c2343d-361a-4a3b-97b0-a0d4ce81d613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_522c9cae-88a8-4eb4-a3fb-42fbea9c7202" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_65c2343d-361a-4a3b-97b0-a0d4ce81d613" xlink:to="loc_us-gaap_HedgingDesignationDomain_522c9cae-88a8-4eb4-a3fb-42fbea9c7202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_be08b9a5-7df9-4a16-bfba-169a5d62c871" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_522c9cae-88a8-4eb4-a3fb-42fbea9c7202" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_be08b9a5-7df9-4a16-bfba-169a5d62c871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_1265e827-dbe1-4fe9-a26d-e63695088c1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_522c9cae-88a8-4eb4-a3fb-42fbea9c7202" xlink:to="loc_us-gaap_NondesignatedMember_1265e827-dbe1-4fe9-a26d-e63695088c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ac0a8597-ee30-43aa-b633-474b76013737" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7dc58fdb-6c3a-4ba2-b4e0-bfafc57779bf" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ac0a8597-ee30-43aa-b633-474b76013737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c7193cbc-61d9-4d5c-8db5-862abd304986" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ac0a8597-ee30-43aa-b633-474b76013737" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c7193cbc-61d9-4d5c-8db5-862abd304986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_0407c3db-b2de-4089-8eaa-34e2f83a001d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c7193cbc-61d9-4d5c-8db5-862abd304986" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_0407c3db-b2de-4089-8eaa-34e2f83a001d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_c0e33fd8-f202-474f-bc7e-c544fa9a7874" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c7193cbc-61d9-4d5c-8db5-862abd304986" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_c0e33fd8-f202-474f-bc7e-c544fa9a7874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_6c946424-d81e-4631-a090-e5d250c13a71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c7193cbc-61d9-4d5c-8db5-862abd304986" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_6c946424-d81e-4631-a090-e5d250c13a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_bdd1b4e8-408a-4c7c-acad-448be5a6a521" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c7193cbc-61d9-4d5c-8db5-862abd304986" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_bdd1b4e8-408a-4c7c-acad-448be5a6a521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_5ec226d1-d6d1-4a64-90ae-eba5d5eb22bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_7dc58fdb-6c3a-4ba2-b4e0-bfafc57779bf" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_5ec226d1-d6d1-4a64-90ae-eba5d5eb22bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_324a374a-f14c-43b3-a63d-24579dda391d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_5ec226d1-d6d1-4a64-90ae-eba5d5eb22bd" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_324a374a-f14c-43b3-a63d-24579dda391d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_8eb6833a-1ca7-4375-b52d-d788da824cab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_5ec226d1-d6d1-4a64-90ae-eba5d5eb22bd" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_8eb6833a-1ca7-4375-b52d-d788da824cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6bf12b97-fadc-4c91-9158-df65bdd7a45e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_0326182a-43cd-4dea-8e60-e368f5d853db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6bf12b97-fadc-4c91-9158-df65bdd7a45e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_0326182a-43cd-4dea-8e60-e368f5d853db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_9538d1e3-1e45-4cda-8f12-70fa5057f42e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6bf12b97-fadc-4c91-9158-df65bdd7a45e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_9538d1e3-1e45-4cda-8f12-70fa5057f42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_414c86dc-c8ee-44cf-949c-212c97e01109" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6bf12b97-fadc-4c91-9158-df65bdd7a45e" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_414c86dc-c8ee-44cf-949c-212c97e01109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_22b01907-3914-432e-9acb-4f644fe7f154" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsAbstract_76e2d4e7-1f47-4a3d-aed7-42d58cbba00a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_22b01907-3914-432e-9acb-4f644fe7f154" xlink:to="loc_us-gaap_DerivativeAssetsAbstract_76e2d4e7-1f47-4a3d-aed7-42d58cbba00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_643a1919-28ba-419c-996f-4013730b0fa2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_76e2d4e7-1f47-4a3d-aed7-42d58cbba00a" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_643a1919-28ba-419c-996f-4013730b0fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_3be659ef-d228-489e-a798-02af850f3e0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_76e2d4e7-1f47-4a3d-aed7-42d58cbba00a" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_3be659ef-d228-489e-a798-02af850f3e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_fdd18974-e5e7-46a7-b90f-b154220f3483" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_76e2d4e7-1f47-4a3d-aed7-42d58cbba00a" xlink:to="loc_us-gaap_DerivativeAssets_fdd18974-e5e7-46a7-b90f-b154220f3483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_70a1a643-0982-437a-b9a4-42be358e8535" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_76e2d4e7-1f47-4a3d-aed7-42d58cbba00a" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_70a1a643-0982-437a-b9a4-42be358e8535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_05cdc6ef-6e6d-4be5-9369-ca093818b969" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_76e2d4e7-1f47-4a3d-aed7-42d58cbba00a" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_05cdc6ef-6e6d-4be5-9369-ca093818b969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_224bfbde-f2ab-4943-a521-c10aa08bd149" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_76e2d4e7-1f47-4a3d-aed7-42d58cbba00a" xlink:to="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_224bfbde-f2ab-4943-a521-c10aa08bd149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesAbstract_72ebc1f7-4508-4470-8b30-01c8b3f3ca9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_22b01907-3914-432e-9acb-4f644fe7f154" xlink:to="loc_us-gaap_DerivativeLiabilitiesAbstract_72ebc1f7-4508-4470-8b30-01c8b3f3ca9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a831678c-2e4f-4abc-acc4-9d3b7dd16b3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_72ebc1f7-4508-4470-8b30-01c8b3f3ca9c" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a831678c-2e4f-4abc-acc4-9d3b7dd16b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_71de662d-8e0e-4cda-9e66-8c03c4ed9b65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_72ebc1f7-4508-4470-8b30-01c8b3f3ca9c" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_71de662d-8e0e-4cda-9e66-8c03c4ed9b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_51a74ccb-9765-4f93-a53b-4c89186bc817" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_72ebc1f7-4508-4470-8b30-01c8b3f3ca9c" xlink:to="loc_us-gaap_DerivativeLiabilities_51a74ccb-9765-4f93-a53b-4c89186bc817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_04bdc7cc-631e-49c7-9972-4321405fba8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_72ebc1f7-4508-4470-8b30-01c8b3f3ca9c" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_04bdc7cc-631e-49c7-9972-4321405fba8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_6eb8e427-6ab6-470c-a534-59df04c37536" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_72ebc1f7-4508-4470-8b30-01c8b3f3ca9c" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_6eb8e427-6ab6-470c-a534-59df04c37536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_0ed20664-fc1b-4daf-844d-dc9c4c7a089c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_72ebc1f7-4508-4470-8b30-01c8b3f3ca9c" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_0ed20664-fc1b-4daf-844d-dc9c4c7a089c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONS" xlink:type="simple" xlink:href="gild-20210331.xsd#ACQUISITIONS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ACQUISITIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_dbce388a-ccc4-4925-9770-13ddf5c14f30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_97131b91-f3ba-4dfe-8065-bcf2435d61e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_dbce388a-ccc4-4925-9770-13ddf5c14f30" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_97131b91-f3ba-4dfe-8065-bcf2435d61e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONSTables" xlink:type="simple" xlink:href="gild-20210331.xsd#ACQUISITIONSTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ACQUISITIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_8ab58f32-654e-429c-bc6a-48b802718deb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_68d8829e-b544-474b-b3af-7b4331de363d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8ab58f32-654e-429c-bc6a-48b802718deb" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_68d8829e-b544-474b-b3af-7b4331de363d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_b0f66893-7671-4c9e-b5f4-dba89cabf5bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_98711051-1e9c-4935-ae7d-9a3dd2cd409b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b0f66893-7671-4c9e-b5f4-dba89cabf5bf" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_98711051-1e9c-4935-ae7d-9a3dd2cd409b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_90ec6092-d146-4986-bcba-aa9b5f6d9584" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_98711051-1e9c-4935-ae7d-9a3dd2cd409b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_90ec6092-d146-4986-bcba-aa9b5f6d9584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d02cfc7-750f-4405-9ef5-8cd8c3579021" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_90ec6092-d146-4986-bcba-aa9b5f6d9584" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d02cfc7-750f-4405-9ef5-8cd8c3579021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_cd08012d-7069-4051-892f-ca7093094f8f" xlink:href="gild-20210331.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d02cfc7-750f-4405-9ef5-8cd8c3579021" xlink:to="loc_gild_MYRGmbHMember_cd08012d-7069-4051-892f-ca7093094f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_7ef6914c-38f8-4ef6-b112-3bebbd787f5a" xlink:href="gild-20210331.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d02cfc7-750f-4405-9ef5-8cd8c3579021" xlink:to="loc_gild_ImmunomedicsIncMember_7ef6914c-38f8-4ef6-b112-3bebbd787f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_10e3edd1-af08-4a73-a713-cd9b596937e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_98711051-1e9c-4935-ae7d-9a3dd2cd409b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_10e3edd1-af08-4a73-a713-cd9b596937e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_95bc154a-eb8d-46cb-be72-514d6d62b178" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_10e3edd1-af08-4a73-a713-cd9b596937e6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_95bc154a-eb8d-46cb-be72-514d6d62b178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_eb9d1513-0cda-449a-ab42-3db0c86f13bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_95bc154a-eb8d-46cb-be72-514d6d62b178" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_eb9d1513-0cda-449a-ab42-3db0c86f13bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e703f70b-6777-402b-9536-e1afd0dd502c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_98711051-1e9c-4935-ae7d-9a3dd2cd409b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e703f70b-6777-402b-9536-e1afd0dd502c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c7290a32-e3f9-4459-84cf-9ab26b16e652" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e703f70b-6777-402b-9536-e1afd0dd502c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c7290a32-e3f9-4459-84cf-9ab26b16e652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexForHDVMember_c537554b-667b-46cb-a779-5e8c02cb8e4d" xlink:href="gild-20210331.xsd#gild_HepcludexForHDVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c7290a32-e3f9-4459-84cf-9ab26b16e652" xlink:to="loc_gild_HepcludexForHDVMember_c537554b-667b-46cb-a779-5e8c02cb8e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8a23e780-8739-4274-8d21-031f5d19009a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_98711051-1e9c-4935-ae7d-9a3dd2cd409b" xlink:to="loc_us-gaap_DebtInstrumentAxis_8a23e780-8739-4274-8d21-031f5d19009a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_422024b8-88df-4d26-ba6b-7606c7fc2165" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8a23e780-8739-4274-8d21-031f5d19009a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_422024b8-88df-4d26-ba6b-7606c7fc2165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_3930b824-e4f9-4bbd-80b9-faeb78b28ff8" xlink:href="gild-20210331.xsd#gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_422024b8-88df-4d26-ba6b-7606c7fc2165" xlink:to="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_3930b824-e4f9-4bbd-80b9-faeb78b28ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_09b15254-d811-43c9-ade2-91748f35cca0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_98711051-1e9c-4935-ae7d-9a3dd2cd409b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_09b15254-d811-43c9-ade2-91748f35cca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_983f1c99-0ede-463e-9ea2-2c6058718ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_09b15254-d811-43c9-ade2-91748f35cca0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_983f1c99-0ede-463e-9ea2-2c6058718ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_d57f61d2-c2fa-402e-8593-4ff3da51f7e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_983f1c99-0ede-463e-9ea2-2c6058718ea9" xlink:to="loc_us-gaap_MediumTermNotesMember_d57f61d2-c2fa-402e-8593-4ff3da51f7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_7ec3850a-dede-4f8a-863e-603dc4d47eb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_98711051-1e9c-4935-ae7d-9a3dd2cd409b" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_7ec3850a-dede-4f8a-863e-603dc4d47eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_95eeebfd-6d47-4189-9892-8cc8a315d46a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7ec3850a-dede-4f8a-863e-603dc4d47eb4" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_95eeebfd-6d47-4189-9892-8cc8a315d46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_561d6caa-c774-4808-8ce2-ab55c1793d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_95eeebfd-6d47-4189-9892-8cc8a315d46a" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_561d6caa-c774-4808-8ce2-ab55c1793d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_be3028a5-cb6c-485e-80b5-b79913fb64e2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_98711051-1e9c-4935-ae7d-9a3dd2cd409b" xlink:to="loc_srt_RangeAxis_be3028a5-cb6c-485e-80b5-b79913fb64e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4cc3d15a-90fa-4465-97cf-76831fc690a7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_be3028a5-cb6c-485e-80b5-b79913fb64e2" xlink:to="loc_srt_RangeMember_4cc3d15a-90fa-4465-97cf-76831fc690a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_808308ff-0ae3-4f79-a900-2254bee6fbf6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4cc3d15a-90fa-4465-97cf-76831fc690a7" xlink:to="loc_srt_MaximumMember_808308ff-0ae3-4f79-a900-2254bee6fbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_98711051-1e9c-4935-ae7d-9a3dd2cd409b" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_fb6a76d4-8a2a-4a0d-9e1c-7302e077fa10" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_fb6a76d4-8a2a-4a0d-9e1c-7302e077fa10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_60b6e235-d53f-46f1-b669-58a62afdbd87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_60b6e235-d53f-46f1-b669-58a62afdbd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_54a379e8-9b42-4820-86e3-708ebdbbe188" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_54a379e8-9b42-4820-86e3-708ebdbbe188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_bcd0bda7-b54f-41c6-99f1-0e2cb6d10061" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_bcd0bda7-b54f-41c6-99f1-0e2cb6d10061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_6363cdeb-49c3-4700-8bf4-e435dfd3895a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_6363cdeb-49c3-4700-8bf4-e435dfd3895a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_a5e943e1-4995-45ee-a4c5-83d64a5805c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_a5e943e1-4995-45ee-a4c5-83d64a5805c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetMeasurementInput_25eb583d-71c9-4015-9493-65c794a5ebc7" xlink:href="gild-20210331.xsd#gild_IntangibleAssetMeasurementInput"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_gild_IntangibleAssetMeasurementInput_25eb583d-71c9-4015-9493-65c794a5ebc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_693149ef-0d1f-48df-979d-b861bfe15fc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_693149ef-0d1f-48df-979d-b861bfe15fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_ee22109f-2c29-4242-88a1-cb11e30a7f89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_ee22109f-2c29-4242-88a1-cb11e30a7f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_4dfa1d3f-bf9d-4018-87b5-3a9018afce49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_us-gaap_GoodwillGross_4dfa1d3f-bf9d-4018-87b5-3a9018afce49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_c2505c89-455b-43ba-85a6-ecb89c5d6d05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_c2505c89-455b-43ba-85a6-ecb89c5d6d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_cfb6050a-e96a-47ee-ba73-e7aa16022a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5710d590-f899-4520-8147-bf74408eca51" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_cfb6050a-e96a-47ee-ba73-e7aa16022a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_cb645289-c7c1-42df-90f9-8a31cbd728d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_8ddf6812-554e-46f9-9f25-76ff88d8472a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_cb645289-c7c1-42df-90f9-8a31cbd728d0" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_8ddf6812-554e-46f9-9f25-76ff88d8472a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6620d551-6b96-444a-b4a2-d9fff5261584" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_8ddf6812-554e-46f9-9f25-76ff88d8472a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6620d551-6b96-444a-b4a2-d9fff5261584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94fce756-724c-424d-a27d-83b9b631cbd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6620d551-6b96-444a-b4a2-d9fff5261584" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94fce756-724c-424d-a27d-83b9b631cbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_97ca60e9-9216-4b69-9144-96a6cf952c38" xlink:href="gild-20210331.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94fce756-724c-424d-a27d-83b9b631cbd6" xlink:to="loc_gild_MYRGmbHMember_97ca60e9-9216-4b69-9144-96a6cf952c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_866652e6-78f8-417e-ace7-ed1d39b9cc41" xlink:href="gild-20210331.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_94fce756-724c-424d-a27d-83b9b631cbd6" xlink:to="loc_gild_ImmunomedicsIncMember_866652e6-78f8-417e-ace7-ed1d39b9cc41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70e8f066-60ac-41a0-b908-a6b103071af6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_8ddf6812-554e-46f9-9f25-76ff88d8472a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70e8f066-60ac-41a0-b908-a6b103071af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_814ec5e2-6dac-4d93-875c-9b70cbc4c331" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70e8f066-60ac-41a0-b908-a6b103071af6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_814ec5e2-6dac-4d93-875c-9b70cbc4c331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyForMTNBCMember_b2dd6dbd-c27d-4e2b-9eb4-66d649639677" xlink:href="gild-20210331.xsd#gild_TrodelvyForMTNBCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_814ec5e2-6dac-4d93-875c-9b70cbc4c331" xlink:to="loc_gild_TrodelvyForMTNBCMember_b2dd6dbd-c27d-4e2b-9eb4-66d649639677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_59938b74-8ee6-4347-af40-5c844e4e8b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_814ec5e2-6dac-4d93-875c-9b70cbc4c331" xlink:to="loc_us-gaap_LicensingAgreementsMember_59938b74-8ee6-4347-af40-5c844e4e8b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_09bc5e37-a387-474d-82a5-3d0c0914e278" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_8ddf6812-554e-46f9-9f25-76ff88d8472a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_09bc5e37-a387-474d-82a5-3d0c0914e278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a41c8f59-0ba4-42ee-8650-c09b09732630" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_09bc5e37-a387-474d-82a5-3d0c0914e278" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a41c8f59-0ba4-42ee-8650-c09b09732630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_b19af511-1c37-4b50-a0b0-694d91e29d27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_a41c8f59-0ba4-42ee-8650-c09b09732630" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_b19af511-1c37-4b50-a0b0-694d91e29d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_8ddf6812-554e-46f9-9f25-76ff88d8472a" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_01509134-7b73-41f3-a0bb-05f99ab85962" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_01509134-7b73-41f3-a0bb-05f99ab85962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_ce128350-17f5-4eb4-8c04-8e88e3eba5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_ce128350-17f5-4eb4-8c04-8e88e3eba5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_06edc8a0-249d-4b65-9905-1bd68636ba73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_06edc8a0-249d-4b65-9905-1bd68636ba73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_a6ef0e1a-4956-40e3-abc0-5d65757b64f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_a6ef0e1a-4956-40e3-abc0-5d65757b64f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_63aa4072-978e-44e2-8198-376c5ced62c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_63aa4072-978e-44e2-8198-376c5ced62c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_40caa884-2cdb-4a98-b2c3-2ff45fb53fd4" xlink:href="gild-20210331.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_40caa884-2cdb-4a98-b2c3-2ff45fb53fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_944a59ae-9f3d-4ca4-8587-94bf61164d3f" xlink:href="gild-20210331.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_944a59ae-9f3d-4ca4-8587-94bf61164d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8cb5efdc-6d3d-48b3-8a8d-744068de5ce9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8cb5efdc-6d3d-48b3-8a8d-744068de5ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_8d1037a7-49b7-4945-991a-7def5761f8ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:to="loc_us-gaap_GoodwillGross_8d1037a7-49b7-4945-991a-7def5761f8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_b3580461-b7e5-4482-b0e0-e7f6865d15d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_04b2f8ab-23cb-4707-807e-9d8eb6951141" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_b3580461-b7e5-4482-b0e0-e7f6865d15d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS" xlink:type="simple" xlink:href="gild-20210331.xsd#GOODWILLANDINTANGIBLEASSETS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a426a5ef-e265-40c4-8012-1ad2d75b06e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_59899d33-3a09-4666-98a8-dc1ffcf4ae49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a426a5ef-e265-40c4-8012-1ad2d75b06e6" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_59899d33-3a09-4666-98a8-dc1ffcf4ae49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables" xlink:type="simple" xlink:href="gild-20210331.xsd#GOODWILLANDINTANGIBLEASSETSTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_762c7ab3-8bb5-4a8b-8f84-d938beb0ff15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_49a52e69-ee4e-4cff-a7d7-4c61ae6593ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_762c7ab3-8bb5-4a8b-8f84-d938beb0ff15" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_49a52e69-ee4e-4cff-a7d7-4c61ae6593ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_4d8094a8-e6af-4c39-af8d-a025f1e673c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_762c7ab3-8bb5-4a8b-8f84-d938beb0ff15" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_4d8094a8-e6af-4c39-af8d-a025f1e673c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_3207f792-ba3f-4cc1-95d7-407a0f3f5e38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_762c7ab3-8bb5-4a8b-8f84-d938beb0ff15" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_3207f792-ba3f-4cc1-95d7-407a0f3f5e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_774847f0-5de1-4741-a9aa-0965ed1d0d82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_762c7ab3-8bb5-4a8b-8f84-d938beb0ff15" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_774847f0-5de1-4741-a9aa-0965ed1d0d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#GOODWILLANDINTANGIBLEASSETSGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b79f9dd7-c8c9-4ffd-bac4-1a52536175da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_d5b3ebc0-a7f1-4a79-9c1d-e93a8e8e9bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b79f9dd7-c8c9-4ffd-bac4-1a52536175da" xlink:to="loc_us-gaap_GoodwillRollForward_d5b3ebc0-a7f1-4a79-9c1d-e93a8e8e9bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_026bfc90-c9c3-48db-9c0d-b4c676b9b437" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d5b3ebc0-a7f1-4a79-9c1d-e93a8e8e9bf3" xlink:to="loc_us-gaap_Goodwill_026bfc90-c9c3-48db-9c0d-b4c676b9b437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_81db5f96-4dd8-4d0b-9d56-b3e01bb8cae4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d5b3ebc0-a7f1-4a79-9c1d-e93a8e8e9bf3" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_81db5f96-4dd8-4d0b-9d56-b3e01bb8cae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_53c96427-890e-4647-b1dd-43f07b2e5b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d5b3ebc0-a7f1-4a79-9c1d-e93a8e8e9bf3" xlink:to="loc_us-gaap_Goodwill_53c96427-890e-4647-b1dd-43f07b2e5b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b191e7c8-68ba-414f-b99f-68a461722837" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1999862a-8a89-4a8d-a4ec-4e6d4b5d26e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b191e7c8-68ba-414f-b99f-68a461722837" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1999862a-8a89-4a8d-a4ec-4e6d4b5d26e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc1b02f2-47e9-44fa-b84e-a7f823947628" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1999862a-8a89-4a8d-a4ec-4e6d4b5d26e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc1b02f2-47e9-44fa-b84e-a7f823947628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fb399894-4593-4575-9edb-5e22d098b8ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc1b02f2-47e9-44fa-b84e-a7f823947628" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fb399894-4593-4575-9edb-5e22d098b8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetSofosbuvirMember_6925e649-ac70-49c4-8b86-ea8a12789a2b" xlink:href="gild-20210331.xsd#gild_IntangibleAssetSofosbuvirMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fb399894-4593-4575-9edb-5e22d098b8ba" xlink:to="loc_gild_IntangibleAssetSofosbuvirMember_6925e649-ac70-49c4-8b86-ea8a12789a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AxicabtageneciloleucelDLBCLMember_8e7eda4a-57f8-45d7-a63f-e0c74e7e9952" xlink:href="gild-20210331.xsd#gild_AxicabtageneciloleucelDLBCLMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fb399894-4593-4575-9edb-5e22d098b8ba" xlink:to="loc_gild_AxicabtageneciloleucelDLBCLMember_8e7eda4a-57f8-45d7-a63f-e0c74e7e9952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyForMTNBCMember_24fa5e33-1235-4b17-9282-a9533084e620" xlink:href="gild-20210331.xsd#gild_TrodelvyForMTNBCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fb399894-4593-4575-9edb-5e22d098b8ba" xlink:to="loc_gild_TrodelvyForMTNBCMember_24fa5e33-1235-4b17-9282-a9533084e620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexForHDVMember_d15acc76-a8b5-45f5-883c-b1d13640feda" xlink:href="gild-20210331.xsd#gild_HepcludexForHDVMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fb399894-4593-4575-9edb-5e22d098b8ba" xlink:to="loc_gild_HepcludexForHDVMember_d15acc76-a8b5-45f5-883c-b1d13640feda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_e2cf6529-a72d-4950-afb9-e91631aa2759" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fb399894-4593-4575-9edb-5e22d098b8ba" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_e2cf6529-a72d-4950-afb9-e91631aa2759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_5f020639-10c8-4546-96ce-752068430558" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1999862a-8a89-4a8d-a4ec-4e6d4b5d26e7" xlink:to="loc_srt_StatementScenarioAxis_5f020639-10c8-4546-96ce-752068430558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4eff968a-5cfa-45ae-b2f4-5a32b62220a6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_5f020639-10c8-4546-96ce-752068430558" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4eff968a-5cfa-45ae-b2f4-5a32b62220a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_e4d49d6a-b74e-41ce-b034-8f1599638f3c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_4eff968a-5cfa-45ae-b2f4-5a32b62220a6" xlink:to="loc_srt_ScenarioForecastMember_e4d49d6a-b74e-41ce-b034-8f1599638f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_80cba838-f1bd-4ed3-9c80-deaa6cc29e09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1999862a-8a89-4a8d-a4ec-4e6d4b5d26e7" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_80cba838-f1bd-4ed3-9c80-deaa6cc29e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_710cefa5-5bca-4285-9f0a-1b2626f4d0d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_80cba838-f1bd-4ed3-9c80-deaa6cc29e09" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_710cefa5-5bca-4285-9f0a-1b2626f4d0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_128ace1b-0f6d-4b51-a250-2f850524155b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_710cefa5-5bca-4285-9f0a-1b2626f4d0d6" xlink:to="loc_us-gaap_SubsequentEventMember_128ace1b-0f6d-4b51-a250-2f850524155b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_88dfd5d4-51dc-4d6f-a3a0-827f9bc6e24f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1999862a-8a89-4a8d-a4ec-4e6d4b5d26e7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_88dfd5d4-51dc-4d6f-a3a0-827f9bc6e24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0cce5c31-9f7a-4799-8de8-c70b87c5a891" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_88dfd5d4-51dc-4d6f-a3a0-827f9bc6e24f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0cce5c31-9f7a-4799-8de8-c70b87c5a891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_c255612a-8a90-4e94-bc97-6406fed516a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0cce5c31-9f7a-4799-8de8-c70b87c5a891" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_c255612a-8a90-4e94-bc97-6406fed516a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16f01e38-8e88-4fe8-920a-98a893e25b14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1999862a-8a89-4a8d-a4ec-4e6d4b5d26e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16f01e38-8e88-4fe8-920a-98a893e25b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4f1a3ed2-05d3-4e5f-80c1-f5e9dff563a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16f01e38-8e88-4fe8-920a-98a893e25b14" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4f1a3ed2-05d3-4e5f-80c1-f5e9dff563a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5c0577f2-31a9-428b-94cc-c55bd7fd8e77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16f01e38-8e88-4fe8-920a-98a893e25b14" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5c0577f2-31a9-428b-94cc-c55bd7fd8e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_ecf25c37-60d3-49c5-acda-a0eed0419272" xlink:href="gild-20210331.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16f01e38-8e88-4fe8-920a-98a893e25b14" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_ecf25c37-60d3-49c5-acda-a0eed0419272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_30a92b08-e190-4586-a705-16a3709e829a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16f01e38-8e88-4fe8-920a-98a893e25b14" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_30a92b08-e190-4586-a705-16a3709e829a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ac613651-d061-44d6-a585-c3bac2670ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16f01e38-8e88-4fe8-920a-98a893e25b14" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ac613651-d061-44d6-a585-c3bac2670ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e3df6af9-b10a-4fc2-9081-69e6fa140275" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ac613651-d061-44d6-a585-c3bac2670ca6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e3df6af9-b10a-4fc2-9081-69e6fa140275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_dbfb39d7-8414-48ad-abda-c16f27eafba5" xlink:href="gild-20210331.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ac613651-d061-44d6-a585-c3bac2670ca6" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_dbfb39d7-8414-48ad-abda-c16f27eafba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_ef323266-442d-4f77-9c3e-059fd58befa9" xlink:href="gild-20210331.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ac613651-d061-44d6-a585-c3bac2670ca6" xlink:to="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_ef323266-442d-4f77-9c3e-059fd58befa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsGrossTransfers_37ebf3bc-7773-46a4-80d0-f31923832b73" xlink:href="gild-20210331.xsd#gild_FiniteLivedIntangibleAssetsGrossTransfers"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16f01e38-8e88-4fe8-920a-98a893e25b14" xlink:to="loc_gild_FiniteLivedIntangibleAssetsGrossTransfers_37ebf3bc-7773-46a4-80d0-f31923832b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_7bab3ba7-8c7d-4a99-9e30-a672ee37c094" xlink:href="gild-20210331.xsd#gild_FiniteLivedIntangibleAssetsGrossReclassified"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16f01e38-8e88-4fe8-920a-98a893e25b14" xlink:to="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_7bab3ba7-8c7d-4a99-9e30-a672ee37c094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_5efef127-618b-4db1-a266-c527e0922ad0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b191e7c8-68ba-414f-b99f-68a461722837" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_5efef127-618b-4db1-a266-c527e0922ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c8293389-2446-4aea-987c-5a89f4093324" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b191e7c8-68ba-414f-b99f-68a461722837" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c8293389-2446-4aea-987c-5a89f4093324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_38c9e86b-2595-40f3-8819-6931e658587f" xlink:href="gild-20210331.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b191e7c8-68ba-414f-b99f-68a461722837" xlink:to="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_38c9e86b-2595-40f3-8819-6931e658587f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0cd33ba0-310b-4c22-bb48-65120b0bba08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b191e7c8-68ba-414f-b99f-68a461722837" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0cd33ba0-310b-4c22-bb48-65120b0bba08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_03fb843b-ea0d-4c21-8088-50ddb0a09a27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2298c574-87ea-4f5f-af96-d2adac7fe350" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_03fb843b-ea0d-4c21-8088-50ddb0a09a27" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2298c574-87ea-4f5f-af96-d2adac7fe350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a8446c63-a780-432c-966c-d78757447d81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_be15fc53-437d-4f70-af60-e2c09a8d943b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a8446c63-a780-432c-966c-d78757447d81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_be15fc53-437d-4f70-af60-e2c09a8d943b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ba54ddb7-bb00-4e47-bd23-0735e65a19b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a8446c63-a780-432c-966c-d78757447d81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ba54ddb7-bb00-4e47-bd23-0735e65a19b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e740cd86-3b34-4a8b-be47-981a2f441f7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a8446c63-a780-432c-966c-d78757447d81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e740cd86-3b34-4a8b-be47-981a2f441f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_23394c12-a0b5-4394-8339-c7b9be97293c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a8446c63-a780-432c-966c-d78757447d81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_23394c12-a0b5-4394-8339-c7b9be97293c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_00dcf1ea-a1dc-45dd-ba27-b79f92ba582b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a8446c63-a780-432c-966c-d78757447d81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_00dcf1ea-a1dc-45dd-ba27-b79f92ba582b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_a225b467-223d-49c9-a50b-fcc508cc1630" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a8446c63-a780-432c-966c-d78757447d81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_a225b467-223d-49c9-a50b-fcc508cc1630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4b5904bd-f288-49e9-bf9e-133cbeecaa28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a8446c63-a780-432c-966c-d78757447d81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4b5904bd-f288-49e9-bf9e-133cbeecaa28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATION" xlink:type="simple" xlink:href="gild-20210331.xsd#OTHERFINANCIALINFORMATION"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_416b4cb1-7df5-42d9-af95-3db99008d7e4" xlink:href="gild-20210331.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_4ca18e10-16ed-46fe-969e-91eeef70e088" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_416b4cb1-7df5-42d9-af95-3db99008d7e4" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_4ca18e10-16ed-46fe-969e-91eeef70e088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables" xlink:type="simple" xlink:href="gild-20210331.xsd#OTHERFINANCIALINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_0312e142-a86a-4f23-b282-947c979e2b7b" xlink:href="gild-20210331.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_e21781a7-8114-4da5-aca7-a06b5f7e66c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_0312e142-a86a-4f23-b282-947c979e2b7b" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_e21781a7-8114-4da5-aca7-a06b5f7e66c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_7bee7cdd-6e96-43f8-ace7-87b628ef946b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_0312e142-a86a-4f23-b282-947c979e2b7b" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_7bee7cdd-6e96-43f8-ace7-87b628ef946b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c638c9b8-a07e-46c9-9d5a-1b40d526dbee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_0312e142-a86a-4f23-b282-947c979e2b7b" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c638c9b8-a07e-46c9-9d5a-1b40d526dbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_8586a761-ca42-44bc-a090-bcae9dd4bff2" xlink:href="gild-20210331.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_311a1f8d-4e3c-43b4-a830-af92c76cb446" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_8586a761-ca42-44bc-a090-bcae9dd4bff2" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_311a1f8d-4e3c-43b4-a830-af92c76cb446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableChargebacksCurrent_0ae6139a-87e0-4dd0-8952-cb2d07741d42" xlink:href="gild-20210331.xsd#gild_AccountsReceivableChargebacksCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_8586a761-ca42-44bc-a090-bcae9dd4bff2" xlink:to="loc_gild_AccountsReceivableChargebacksCurrent_0ae6139a-87e0-4dd0-8952-cb2d07741d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_2cad5b54-65ea-4972-936c-3d1337a02722" xlink:href="gild-20210331.xsd#gild_AccountsReceivableCashDiscountsAndOtherCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_8586a761-ca42-44bc-a090-bcae9dd4bff2" xlink:to="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_2cad5b54-65ea-4972-936c-3d1337a02722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_663a25f7-027f-4404-b285-61688ba8eff6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_8586a761-ca42-44bc-a090-bcae9dd4bff2" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_663a25f7-027f-4404-b285-61688ba8eff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4d627f98-81dc-4f17-8cdc-b61700e48556" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_8586a761-ca42-44bc-a090-bcae9dd4bff2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4d627f98-81dc-4f17-8cdc-b61700e48556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#OTHERFINANCIALINFORMATIONInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_f43c23d7-4acb-4873-8f77-a6ef225a14c6" xlink:href="gild-20210331.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_c1fd9a52-6067-41c8-9442-d1295d152c50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_f43c23d7-4acb-4873-8f77-a6ef225a14c6" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_c1fd9a52-6067-41c8-9442-d1295d152c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f31238b3-0526-48c1-86e6-b0d8ccec8fdb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_f43c23d7-4acb-4873-8f77-a6ef225a14c6" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f31238b3-0526-48c1-86e6-b0d8ccec8fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_70af8125-a466-442a-9abc-d70b60196e53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_f43c23d7-4acb-4873-8f77-a6ef225a14c6" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_70af8125-a466-442a-9abc-d70b60196e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent_17e55dbc-eaf2-4f2b-94e1-92701ed5a171" xlink:href="gild-20210331.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_f43c23d7-4acb-4873-8f77-a6ef225a14c6" xlink:to="loc_gild_InventoryNetAndInventoryNoncurrent_17e55dbc-eaf2-4f2b-94e1-92701ed5a171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_efd7416d-eb15-4fad-9a5a-b58999e21b5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_f43c23d7-4acb-4873-8f77-a6ef225a14c6" xlink:to="loc_us-gaap_InventoryNet_efd7416d-eb15-4fad-9a5a-b58999e21b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_8e2dc170-3fe7-4de8-a839-29ec42660212" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_f43c23d7-4acb-4873-8f77-a6ef225a14c6" xlink:to="loc_us-gaap_InventoryNoncurrent_8e2dc170-3fe7-4de8-a839-29ec42660212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent_faedca05-3f9e-4ef3-81f3-9e08adef9bf6" xlink:href="gild-20210331.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1" xlink:type="simple" xlink:href="gild-20210331.xsd#OTHERFINANCIALINFORMATIONInventoriesDetails_1"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_51430757-c115-40f6-a003-2d59816fa6ca" xlink:href="gild-20210331.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d316ce80-670c-4c12-a31c-e0584db9d980" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_51430757-c115-40f6-a003-2d59816fa6ca" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d316ce80-670c-4c12-a31c-e0584db9d980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_c7793cf6-5b79-492a-b317-7e98c35fdc7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_51430757-c115-40f6-a003-2d59816fa6ca" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_c7793cf6-5b79-492a-b317-7e98c35fdc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_76eeef9f-17af-4878-b935-aab0d0b363cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_51430757-c115-40f6-a003-2d59816fa6ca" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_76eeef9f-17af-4878-b935-aab0d0b363cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b55315b0-a787-44c2-a61c-c49cba48cd63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_51430757-c115-40f6-a003-2d59816fa6ca" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b55315b0-a787-44c2-a61c-c49cba48cd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9441ba29-8995-4e86-9eb0-58837c2b16eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_51430757-c115-40f6-a003-2d59816fa6ca" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9441ba29-8995-4e86-9eb0-58837c2b16eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTS" xlink:type="simple" xlink:href="gild-20210331.xsd#COLLABORATIONSANDOTHERARRANGEMENTS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeandOtherArrangementsAbstract_e783a8eb-c66f-47ae-b981-abe3ee5ac2d0" xlink:href="gild-20210331.xsd#gild_CollaborativeandOtherArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeAndOtherArrangementsTextBlock_41490783-0a8d-4c91-afe1-41a6425f6a19" xlink:href="gild-20210331.xsd#gild_CollaborativeAndOtherArrangementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CollaborativeandOtherArrangementsAbstract_e783a8eb-c66f-47ae-b981-abe3ee5ac2d0" xlink:to="loc_gild_CollaborativeAndOtherArrangementsTextBlock_41490783-0a8d-4c91-afe1-41a6425f6a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#COLLABORATIONSANDOTHERARRANGEMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeandOtherArrangementsAbstract_b1f93ca7-3948-4b7b-83ab-7294889073fb" xlink:href="gild-20210331.xsd#gild_CollaborativeandOtherArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3019a84e-7363-4893-bac8-4d7112c1ad11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CollaborativeandOtherArrangementsAbstract_b1f93ca7-3948-4b7b-83ab-7294889073fb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3019a84e-7363-4893-bac8-4d7112c1ad11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3650823a-4df3-40ad-9437-83b90e06a2f6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3019a84e-7363-4893-bac8-4d7112c1ad11" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3650823a-4df3-40ad-9437-83b90e06a2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_527b59e9-a38c-4304-840a-db1c7340558c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3650823a-4df3-40ad-9437-83b90e06a2f6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_527b59e9-a38c-4304-840a-db1c7340558c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_0f1bc52c-42d3-4b0e-b3eb-188c0eea3857" xlink:href="gild-20210331.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_527b59e9-a38c-4304-840a-db1c7340558c" xlink:to="loc_gild_ArcusBiosciencesIncMember_0f1bc52c-42d3-4b0e-b3eb-188c0eea3857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bf6bf816-338a-4087-9b33-9df50f461137" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3019a84e-7363-4893-bac8-4d7112c1ad11" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bf6bf816-338a-4087-9b33-9df50f461137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b5dd41c2-6e1c-49d6-85f7-6c1c6a35898d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bf6bf816-338a-4087-9b33-9df50f461137" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b5dd41c2-6e1c-49d6-85f7-6c1c6a35898d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_06bea4ca-9b9d-478a-b6b4-947eb28c7dc3" xlink:href="gild-20210331.xsd#gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b5dd41c2-6e1c-49d6-85f7-6c1c6a35898d" xlink:to="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_06bea4ca-9b9d-478a-b6b4-947eb28c7dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusStockPurchaseAgreementMember_91f1caf1-595c-4b36-917e-8912205a175b" xlink:href="gild-20210331.xsd#gild_ArcusStockPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b5dd41c2-6e1c-49d6-85f7-6c1c6a35898d" xlink:to="loc_gild_ArcusStockPurchaseAgreementMember_91f1caf1-595c-4b36-917e-8912205a175b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherCollaborationArrangementsMember_8cec2ec8-4d87-4356-b9b9-5d3d76f8ad23" xlink:href="gild-20210331.xsd#gild_OtherCollaborationArrangementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b5dd41c2-6e1c-49d6-85f7-6c1c6a35898d" xlink:to="loc_gild_OtherCollaborationArrangementsMember_8cec2ec8-4d87-4356-b9b9-5d3d76f8ad23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember_3348faea-4f63-4b58-aaa6-2eb7f76d7dab" xlink:href="gild-20210331.xsd#gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b5dd41c2-6e1c-49d6-85f7-6c1c6a35898d" xlink:to="loc_gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember_3348faea-4f63-4b58-aaa6-2eb7f76d7dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_060fa409-6a71-4020-9caf-9accccf05f27" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3019a84e-7363-4893-bac8-4d7112c1ad11" xlink:to="loc_srt_OwnershipAxis_060fa409-6a71-4020-9caf-9accccf05f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_ee1850d4-4d67-4f19-900c-178e5db8445f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_060fa409-6a71-4020-9caf-9accccf05f27" xlink:to="loc_srt_OwnershipDomain_ee1850d4-4d67-4f19-900c-178e5db8445f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_18a17d17-9042-4f2a-81ad-4d07bbdeb538" xlink:href="gild-20210331.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_ee1850d4-4d67-4f19-900c-178e5db8445f" xlink:to="loc_gild_ArcusBiosciencesIncMember_18a17d17-9042-4f2a-81ad-4d07bbdeb538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5e1c8d5a-1ff0-4a97-9c61-5c11ac3e4fdf" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3019a84e-7363-4893-bac8-4d7112c1ad11" xlink:to="loc_srt_ProductOrServiceAxis_5e1c8d5a-1ff0-4a97-9c61-5c11ac3e4fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3b74e9ae-cefb-4820-bce6-7d749884385f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5e1c8d5a-1ff0-4a97-9c61-5c11ac3e4fdf" xlink:to="loc_srt_ProductsAndServicesDomain_3b74e9ae-cefb-4820-bce6-7d749884385f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OralFormulationProductMember_76f03715-f82b-4431-aded-dbcfe5dc8b63" xlink:href="gild-20210331.xsd#gild_OralFormulationProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3b74e9ae-cefb-4820-bce6-7d749884385f" xlink:to="loc_gild_OralFormulationProductMember_76f03715-f82b-4431-aded-dbcfe5dc8b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InjectableFormulationProductMember_faa26d03-5e2a-496f-b3da-ae612badbdfc" xlink:href="gild-20210331.xsd#gild_InjectableFormulationProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3b74e9ae-cefb-4820-bce6-7d749884385f" xlink:to="loc_gild_InjectableFormulationProductMember_faa26d03-5e2a-496f-b3da-ae612badbdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2f539ae8-2fc2-4e5e-97c8-4449a6f512d3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3019a84e-7363-4893-bac8-4d7112c1ad11" xlink:to="loc_dei_LegalEntityAxis_2f539ae8-2fc2-4e5e-97c8-4449a6f512d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e0185278-f489-4274-a2a7-082e331432c2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2f539ae8-2fc2-4e5e-97c8-4449a6f512d3" xlink:to="loc_dei_EntityDomain_e0185278-f489-4274-a2a7-082e331432c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckMember_219a7ce9-610b-4a92-ba84-fb32fa80fa9d" xlink:href="gild-20210331.xsd#gild_MerckMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e0185278-f489-4274-a2a7-082e331432c2" xlink:to="loc_gild_MerckMember_219a7ce9-610b-4a92-ba84-fb32fa80fa9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3019a84e-7363-4893-bac8-4d7112c1ad11" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_f908eab5-81fc-4430-bace-50cd3ed538fc" xlink:href="gild-20210331.xsd#gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_f908eab5-81fc-4430-bace-50cd3ed538fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementNetProductSalesThreshold_6b368cfe-484d-42af-b9cd-8c520186da2d" xlink:href="gild-20210331.xsd#gild_CollaborationArrangementNetProductSalesThreshold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_CollaborationArrangementNetProductSalesThreshold_6b368cfe-484d-42af-b9cd-8c520186da2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues_079facb0-1234-4e18-9816-bb9aa44c3dae" xlink:href="gild-20210331.xsd#gild_CollaborationArrangementPercentOfGlobalProductRevenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues_079facb0-1234-4e18-9816-bb9aa44c3dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_a46fff4d-130d-41fd-80b0-8becac1ecfa5" xlink:href="gild-20210331.xsd#gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_a46fff4d-130d-41fd-80b0-8becac1ecfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNISharesAcquired_ae3be076-8b92-43ab-b808-fb1abf9327ab" xlink:href="gild-20210331.xsd#gild_EquitySecuritiesFVNISharesAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_EquitySecuritiesFVNISharesAcquired_ae3be076-8b92-43ab-b808-fb1abf9327ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToAcquireEquitySecuritiesFVNI_49105777-1707-473d-8ce5-7f1c151347a4" xlink:href="gild-20210331.xsd#gild_PaymentsToAcquireEquitySecuritiesFVNI"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_PaymentsToAcquireEquitySecuritiesFVNI_49105777-1707-473d-8ce5-7f1c151347a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIShares_de13c8b2-2d47-4aef-9e8b-57c3b7527bb6" xlink:href="gild-20210331.xsd#gild_EquitySecuritiesFVNIShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_EquitySecuritiesFVNIShares_de13c8b2-2d47-4aef-9e8b-57c3b7527bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_e759de60-a524-4ef5-8e0e-a50220eff0af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_e759de60-a524-4ef5-8e0e-a50220eff0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIPurchasePeriod_79e5bb4b-5757-4274-9704-eca63af0fe9e" xlink:href="gild-20210331.xsd#gild_EquitySecuritiesFVNIPurchasePeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_EquitySecuritiesFVNIPurchasePeriod_79e5bb4b-5757-4274-9704-eca63af0fe9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_94b0874c-650a-49b1-a7ed-dd861e3ae9b0" xlink:href="gild-20210331.xsd#gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_94b0874c-650a-49b1-a7ed-dd861e3ae9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIRestrictionPeriod_05b46c51-9357-469d-a3b9-73fe201dc214" xlink:href="gild-20210331.xsd#gild_EquitySecuritiesFVNIRestrictionPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_EquitySecuritiesFVNIRestrictionPeriod_05b46c51-9357-469d-a3b9-73fe201dc214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements_34b92d14-bd7a-460d-b499-2fd4255dbe9e" xlink:href="gild-20210331.xsd#gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements_34b92d14-bd7a-460d-b499-2fd4255dbe9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CashPaymentsMadeRelatedToEquityInvestments_e4e0a9c7-3e06-481c-9246-d88642e6cc4e" xlink:href="gild-20210331.xsd#gild_CashPaymentsMadeRelatedToEquityInvestments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_63aeac30-8165-4a15-89bb-1aa723759590" xlink:to="loc_gild_CashPaymentsMadeRelatedToEquityInvestments_e4e0a9c7-3e06-481c-9246-d88642e6cc4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIES" xlink:type="simple" xlink:href="gild-20210331.xsd#DEBTANDCREDITFACILITIES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_60fd2c84-8a61-4c55-a69d-de9c4124dd53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_3a591486-930d-4a49-8f5a-5065d1467cb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_60fd2c84-8a61-4c55-a69d-de9c4124dd53" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_3a591486-930d-4a49-8f5a-5065d1467cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables" xlink:type="simple" xlink:href="gild-20210331.xsd#DEBTANDCREDITFACILITIESTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_831f93c6-cf3e-41e0-b484-f50773ef3470" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_730206b7-aa23-4d24-915a-8b50831ebdcb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_831f93c6-cf3e-41e0-b484-f50773ef3470" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_730206b7-aa23-4d24-915a-8b50831ebdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d8035895-700d-46cf-94c5-0ee02162bac2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9a0e35c6-3648-4b71-9d21-3e99dc3864d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d8035895-700d-46cf-94c5-0ee02162bac2" xlink:to="loc_us-gaap_DebtInstrumentTable_9a0e35c6-3648-4b71-9d21-3e99dc3864d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_adcf7acd-5368-4522-8f10-0772e003feac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9a0e35c6-3648-4b71-9d21-3e99dc3864d8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_adcf7acd-5368-4522-8f10-0772e003feac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4ba0b438-08b8-4751-8a9e-af606b4e1dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_adcf7acd-5368-4522-8f10-0772e003feac" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4ba0b438-08b8-4751-8a9e-af606b4e1dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorNotesAndMediumTermNotesMember_d4d1e84c-2d0d-4588-95a9-e7bff4c4e000" xlink:href="gild-20210331.xsd#gild_SeniorNotesAndMediumTermNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4ba0b438-08b8-4751-8a9e-af606b4e1dc6" xlink:to="loc_gild_SeniorNotesAndMediumTermNotesMember_d4d1e84c-2d0d-4588-95a9-e7bff4c4e000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_4c9ae84e-1840-49ce-8136-0b16a89c58e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SeniorNotesAndMediumTermNotesMember_d4d1e84c-2d0d-4588-95a9-e7bff4c4e000" xlink:to="loc_us-gaap_SeniorNotesMember_4c9ae84e-1840-49ce-8136-0b16a89c58e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_420bfdc8-3348-4f6a-8e91-bdd47cc39c34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SeniorNotesAndMediumTermNotesMember_d4d1e84c-2d0d-4588-95a9-e7bff4c4e000" xlink:to="loc_us-gaap_MediumTermNotesMember_420bfdc8-3348-4f6a-8e91-bdd47cc39c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_109040f3-32aa-4a71-9c8e-05e791fee16f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4ba0b438-08b8-4751-8a9e-af606b4e1dc6" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_109040f3-32aa-4a71-9c8e-05e791fee16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2fede147-bbb3-4bbc-affd-7cbf462ed534" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9a0e35c6-3648-4b71-9d21-3e99dc3864d8" xlink:to="loc_us-gaap_DebtInstrumentAxis_2fede147-bbb3-4bbc-affd-7cbf462ed534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2fede147-bbb3-4bbc-affd-7cbf462ed534" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A450SeniorUnsecuredNotesDueApril2021Member_bd0f0824-3b3c-4242-902e-b83b6b45b223" xlink:href="gild-20210331.xsd#gild_A450SeniorUnsecuredNotesDueApril2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A450SeniorUnsecuredNotesDueApril2021Member_bd0f0824-3b3c-4242-902e-b83b6b45b223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_790f06b6-4df6-4d0b-8fbc-18f4e795ce99" xlink:href="gild-20210331.xsd#gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_790f06b6-4df6-4d0b-8fbc-18f4e795ce99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A440SeniorUnsecuredNotesDueDecember2021Member_d9e0c9c5-5818-40c2-b08e-fc3fe427ff99" xlink:href="gild-20210331.xsd#gild_A440SeniorUnsecuredNotesDueDecember2021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A440SeniorUnsecuredNotesDueDecember2021Member_d9e0c9c5-5818-40c2-b08e-fc3fe427ff99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member_dfcae2ff-3cc1-44c6-b8d8-1c5bef989a4b" xlink:href="gild-20210331.xsd#gild_A195SeniorUnsecuredNotesDueMarch2022Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member_dfcae2ff-3cc1-44c6-b8d8-1c5bef989a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_bcae7cd5-bf57-4080-8982-8a428c4eb556" xlink:href="gild-20210331.xsd#gild_A325SeniorUnsecuredNotesDueSeptember2022Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_bcae7cd5-bf57-4080-8982-8a428c4eb556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_2dadd508-22a0-4201-a5cb-0dc76bc012a2" xlink:href="gild-20210331.xsd#gild_A250SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_2dadd508-22a0-4201-a5cb-0dc76bc012a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_c9ccc141-fad0-485e-965e-812fa74fe874" xlink:href="gild-20210331.xsd#gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_c9ccc141-fad0-485e-965e-812fa74fe874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_6f4a3828-5811-40a2-a2db-3183e62105a8" xlink:href="gild-20210331.xsd#gild_A075SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_6f4a3828-5811-40a2-a2db-3183e62105a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VariableTermLoanNoteDueOctober2023Member_06a93292-f180-4515-86f0-b2c20d110532" xlink:href="gild-20210331.xsd#gild_VariableTermLoanNoteDueOctober2023Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_VariableTermLoanNoteDueOctober2023Member_06a93292-f180-4515-86f0-b2c20d110532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member_c15c80d7-e175-41c2-a357-999ea2795bbb" xlink:href="gild-20210331.xsd#gild_A370SeniorUnsecuredNotesDueApril2024Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member_c15c80d7-e175-41c2-a357-999ea2795bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_e75e9a83-3372-4d5c-85de-801125a0d667" xlink:href="gild-20210331.xsd#gild_A350SeniorUnsecuredNotesDueFebruary2025Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_e75e9a83-3372-4d5c-85de-801125a0d667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member_a8ddf955-d3fe-436b-9cdd-d6aa849c2327" xlink:href="gild-20210331.xsd#gild_A365SeniorUnsecuredNotesDueMarch2026Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member_a8ddf955-d3fe-436b-9cdd-d6aa849c2327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member_4e0609e3-c805-493c-bdb1-fe4a7e6c9c96" xlink:href="gild-20210331.xsd#gild_A295SeniorUnsecuredNotesDueMarch2027Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member_4e0609e3-c805-493c-bdb1-fe4a7e6c9c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_7260a8ef-14b6-45bc-9580-d68ee93f4634" xlink:href="gild-20210331.xsd#gild_A120SeniorUnsecuredNotesDueOctober2027Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_7260a8ef-14b6-45bc-9580-d68ee93f4634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_e018e1b5-1ef9-47be-ad95-91910dc26ba8" xlink:href="gild-20210331.xsd#gild_A165SeniorUnsecuredNotesDueOctober2030Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_e018e1b5-1ef9-47be-ad95-91910dc26ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_329dc728-1a15-436a-be63-e427caa75d13" xlink:href="gild-20210331.xsd#gild_A460SeniorUnsecuredNotesDueSeptember2035Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_329dc728-1a15-436a-be63-e427caa75d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_fbe0fb42-abcc-42c0-be14-b8e3163c17aa" xlink:href="gild-20210331.xsd#gild_A400SeniorUnsecuredNotesDueSeptember2036Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_fbe0fb42-abcc-42c0-be14-b8e3163c17aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_e7eafb86-733c-4aa7-95ce-96cdb4e4b3d0" xlink:href="gild-20210331.xsd#gild_A260SeniorUnsecuredNotesDueOctober2040Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_e7eafb86-733c-4aa7-95ce-96cdb4e4b3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member_9d343024-3d95-4491-9a77-e888ddde3e9f" xlink:href="gild-20210331.xsd#gild_A565SeniorUnsecuredNotesDueDecember2041Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member_9d343024-3d95-4491-9a77-e888ddde3e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member_99756489-465b-4216-866c-dc3909a65696" xlink:href="gild-20210331.xsd#gild_A480SeniorUnsecuredNotesDueApril2044Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member_99756489-465b-4216-866c-dc3909a65696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_5da4d77c-1f23-4f78-a424-555cdf63e3a7" xlink:href="gild-20210331.xsd#gild_A450SeniorUnsecuredNotesDueFebruary2045Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_5da4d77c-1f23-4f78-a424-555cdf63e3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member_ba5e4c8f-b49d-4842-b2a5-cde4c86345b2" xlink:href="gild-20210331.xsd#gild_A475SeniorUnsecuredNotesDueMarch2046Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member_ba5e4c8f-b49d-4842-b2a5-cde4c86345b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member_15206402-b632-4199-80da-5e34ab3f663b" xlink:href="gild-20210331.xsd#gild_A415SeniorUnsecuredNotesDueMarch2047Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member_15206402-b632-4199-80da-5e34ab3f663b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_312d5952-b924-4867-b17e-14961fef84dd" xlink:href="gild-20210331.xsd#gild_A280SeniorUnsecuredNotesDueOctober2050Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_472d49f7-28d7-402a-9ae7-039b0659a6d5" xlink:to="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_312d5952-b924-4867-b17e-14961fef84dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_9368ef66-f264-478b-93dd-35c11b84668f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9a0e35c6-3648-4b71-9d21-3e99dc3864d8" xlink:to="loc_us-gaap_VariableRateAxis_9368ef66-f264-478b-93dd-35c11b84668f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_c0c40524-0300-4767-bc43-8d3e710dfa65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_9368ef66-f264-478b-93dd-35c11b84668f" xlink:to="loc_us-gaap_VariableRateDomain_c0c40524-0300-4767-bc43-8d3e710dfa65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_6423b12b-d5ed-4122-b12c-81135ec35716" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_c0c40524-0300-4767-bc43-8d3e710dfa65" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_6423b12b-d5ed-4122-b12c-81135ec35716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ba4c9052-b6c8-4229-8820-39fed3d18d1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9a0e35c6-3648-4b71-9d21-3e99dc3864d8" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ba4c9052-b6c8-4229-8820-39fed3d18d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dad9ce2c-c6ab-4fff-b391-c3bb72cb95f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba4c9052-b6c8-4229-8820-39fed3d18d1b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dad9ce2c-c6ab-4fff-b391-c3bb72cb95f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8b3dfc7c-df9e-4267-9a34-819d76b2f50b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba4c9052-b6c8-4229-8820-39fed3d18d1b" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8b3dfc7c-df9e-4267-9a34-819d76b2f50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2993aca3-effc-4ff2-b022-184c13531e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba4c9052-b6c8-4229-8820-39fed3d18d1b" xlink:to="loc_us-gaap_LongTermDebt_2993aca3-effc-4ff2-b022-184c13531e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_0f52e380-6df2-4358-9250-6d0d68cc0a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba4c9052-b6c8-4229-8820-39fed3d18d1b" xlink:to="loc_us-gaap_LongTermDebtCurrent_0f52e380-6df2-4358-9250-6d0d68cc0a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_b85e48a3-b57f-446b-a8f6-02b77c937365" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba4c9052-b6c8-4229-8820-39fed3d18d1b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_b85e48a3-b57f-446b-a8f6-02b77c937365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#DEBTANDCREDITFACILITIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_49b0748d-eb57-4f6c-9956-9368d29f68ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_705ca7eb-4c47-441c-87f3-9b7070ee406d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_49b0748d-eb57-4f6c-9956-9368d29f68ba" xlink:to="loc_us-gaap_DebtInstrumentTable_705ca7eb-4c47-441c-87f3-9b7070ee406d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_813e7320-bb04-427f-945a-7bd197317039" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_705ca7eb-4c47-441c-87f3-9b7070ee406d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_813e7320-bb04-427f-945a-7bd197317039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_54fe2979-4223-4e84-a093-0e54d9caf80f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_813e7320-bb04-427f-945a-7bd197317039" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_54fe2979-4223-4e84-a093-0e54d9caf80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_812de35f-2774-4b0d-9779-3190e566f704" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_54fe2979-4223-4e84-a093-0e54d9caf80f" xlink:to="loc_us-gaap_SeniorNotesMember_812de35f-2774-4b0d-9779-3190e566f704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_2e42759a-c7fb-4184-a6e7-1b4c438979cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_54fe2979-4223-4e84-a093-0e54d9caf80f" xlink:to="loc_us-gaap_MediumTermNotesMember_2e42759a-c7fb-4184-a6e7-1b4c438979cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_dbe37445-0af7-4110-8daa-c7c498fbe4fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_705ca7eb-4c47-441c-87f3-9b7070ee406d" xlink:to="loc_us-gaap_CreditFacilityAxis_dbe37445-0af7-4110-8daa-c7c498fbe4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_6b699732-cb83-46d2-ae10-f5adf5bc4418" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_dbe37445-0af7-4110-8daa-c7c498fbe4fd" xlink:to="loc_us-gaap_CreditFacilityDomain_6b699732-cb83-46d2-ae10-f5adf5bc4418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_61a0fc52-025e-4a6e-adf3-4f07ef927717" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_6b699732-cb83-46d2-ae10-f5adf5bc4418" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_61a0fc52-025e-4a6e-adf3-4f07ef927717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3889e463-16d2-4436-b00f-a8d8807cc67d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_705ca7eb-4c47-441c-87f3-9b7070ee406d" xlink:to="loc_us-gaap_DebtInstrumentAxis_3889e463-16d2-4436-b00f-a8d8807cc67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5a081ff7-a89e-4485-8036-4aac0aa83f23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3889e463-16d2-4436-b00f-a8d8807cc67d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5a081ff7-a89e-4485-8036-4aac0aa83f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNoteIssuedNovember2014Member_121b1c6c-b223-4001-aff4-d0f0e1c3dd47" xlink:href="gild-20210331.xsd#gild_SeniorUnsecuredNoteIssuedNovember2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a081ff7-a89e-4485-8036-4aac0aa83f23" xlink:to="loc_gild_SeniorUnsecuredNoteIssuedNovember2014Member_121b1c6c-b223-4001-aff4-d0f0e1c3dd47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_b614a94d-8911-440e-85b5-5ccbda627425" xlink:href="gild-20210331.xsd#gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a081ff7-a89e-4485-8036-4aac0aa83f23" xlink:to="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_b614a94d-8911-440e-85b5-5ccbda627425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueJune2025Member_cf1caacf-9152-4621-9a13-a04862c6906b" xlink:href="gild-20210331.xsd#gild_CreditFacilityDueJune2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5a081ff7-a89e-4485-8036-4aac0aa83f23" xlink:to="loc_gild_CreditFacilityDueJune2025Member_cf1caacf-9152-4621-9a13-a04862c6906b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_58d45c74-f3b5-4449-97ab-36a08b46f8ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_705ca7eb-4c47-441c-87f3-9b7070ee406d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_58d45c74-f3b5-4449-97ab-36a08b46f8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_7fd07be8-1e40-4790-b0a9-4f8647a59398" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_58d45c74-f3b5-4449-97ab-36a08b46f8ad" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_7fd07be8-1e40-4790-b0a9-4f8647a59398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfUnsecuredDebt_54fb2e40-72f4-406b-b4a4-564f9effcc39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_58d45c74-f3b5-4449-97ab-36a08b46f8ad" xlink:to="loc_us-gaap_RepaymentsOfUnsecuredDebt_54fb2e40-72f4-406b-b4a4-564f9effcc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_33026302-774b-4c60-baba-d783174fc282" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_58d45c74-f3b5-4449-97ab-36a08b46f8ad" xlink:to="loc_us-gaap_DebtInstrumentTerm_33026302-774b-4c60-baba-d783174fc282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_41b6e6d8-8cf9-41cd-a6dc-149a9061ebb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_58d45c74-f3b5-4449-97ab-36a08b46f8ad" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_41b6e6d8-8cf9-41cd-a6dc-149a9061ebb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_89a0a3db-0a57-40a4-9b93-2372ec8534a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_58d45c74-f3b5-4449-97ab-36a08b46f8ad" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_89a0a3db-0a57-40a4-9b93-2372ec8534a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_af1fb4ce-6ace-42c4-92fa-4dce53bfbe42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_58d45c74-f3b5-4449-97ab-36a08b46f8ad" xlink:to="loc_us-gaap_LineOfCredit_af1fb4ce-6ace-42c4-92fa-4dce53bfbe42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="gild-20210331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6922f317-49ad-4411-8a14-ada4d40dbdf0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_36a91dc6-f3b3-4df6-ac77-8bffa2f1b2ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6922f317-49ad-4411-8a14-ada4d40dbdf0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_36a91dc6-f3b3-4df6-ac77-8bffa2f1b2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6902ebf4-f757-4bd3-ba6d-dde886792e3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_1e924627-ceef-444b-aec0-f2f8577ee2b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6902ebf4-f757-4bd3-ba6d-dde886792e3a" xlink:to="loc_us-gaap_LossContingenciesTable_1e924627-ceef-444b-aec0-f2f8577ee2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_816cb813-c9dc-48a0-bedf-5a605b89256a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1e924627-ceef-444b-aec0-f2f8577ee2b1" xlink:to="loc_srt_LitigationCaseAxis_816cb813-c9dc-48a0-bedf-5a605b89256a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9b53222a-de77-4344-a5f7-4c285b21f23c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_816cb813-c9dc-48a0-bedf-5a605b89256a" xlink:to="loc_srt_LitigationCaseTypeDomain_9b53222a-de77-4344-a5f7-4c285b21f23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_a58976ca-7bfe-4a20-a610-9bf46fe78f20" xlink:href="gild-20210331.xsd#gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_9b53222a-de77-4344-a5f7-4c285b21f23c" xlink:to="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_a58976ca-7bfe-4a20-a610-9bf46fe78f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ViiVHealthcareCompanyMember_3e4e6fb5-29cf-4048-a2bf-22a10e0eb87b" xlink:href="gild-20210331.xsd#gild_ViiVHealthcareCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_9b53222a-de77-4344-a5f7-4c285b21f23c" xlink:to="loc_gild_ViiVHealthcareCompanyMember_3e4e6fb5-29cf-4048-a2bf-22a10e0eb87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PreExposureProphylaxisMember_e72293ba-b0ec-4cd3-9680-8ef430617126" xlink:href="gild-20210331.xsd#gild_PreExposureProphylaxisMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_9b53222a-de77-4344-a5f7-4c285b21f23c" xlink:to="loc_gild_PreExposureProphylaxisMember_e72293ba-b0ec-4cd3-9680-8ef430617126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaimsMember_4aea65e5-6f0e-4bd2-8bca-488589075518" xlink:href="gild-20210331.xsd#gild_EuropeanPatentClaimsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_9b53222a-de77-4344-a5f7-4c285b21f23c" xlink:to="loc_gild_EuropeanPatentClaimsMember_4aea65e5-6f0e-4bd2-8bca-488589075518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductLiabilityMember_5cf77a0e-e59a-4994-985f-ad05ea32c4da" xlink:href="gild-20210331.xsd#gild_ProductLiabilityMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_9b53222a-de77-4344-a5f7-4c285b21f23c" xlink:to="loc_gild_ProductLiabilityMember_5cf77a0e-e59a-4994-985f-ad05ea32c4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_QuiTamMember_be929d18-b0de-40ea-899b-f197246ee9d7" xlink:href="gild-20210331.xsd#gild_QuiTamMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_9b53222a-de77-4344-a5f7-4c285b21f23c" xlink:to="loc_gild_QuiTamMember_be929d18-b0de-40ea-899b-f197246ee9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b00e5d5a-5713-45b2-aa6c-2ae6d50785b2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1e924627-ceef-444b-aec0-f2f8577ee2b1" xlink:to="loc_srt_RangeAxis_b00e5d5a-5713-45b2-aa6c-2ae6d50785b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_807742b0-4b3b-42b9-95ed-3a93a47eae39" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b00e5d5a-5713-45b2-aa6c-2ae6d50785b2" xlink:to="loc_srt_RangeMember_807742b0-4b3b-42b9-95ed-3a93a47eae39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_76d48821-a481-4293-96dc-7ea73ca98d58" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_807742b0-4b3b-42b9-95ed-3a93a47eae39" xlink:to="loc_srt_MinimumMember_76d48821-a481-4293-96dc-7ea73ca98d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b8a119e6-d11e-48b2-b98b-f149e77f7b14" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_807742b0-4b3b-42b9-95ed-3a93a47eae39" xlink:to="loc_srt_MaximumMember_b8a119e6-d11e-48b2-b98b-f149e77f7b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_3ea17f1f-f86b-4316-a762-b91376e8d1c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1e924627-ceef-444b-aec0-f2f8577ee2b1" xlink:to="loc_us-gaap_LitigationStatusAxis_3ea17f1f-f86b-4316-a762-b91376e8d1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_13ac5bc2-e14c-4a15-8295-2a8f56f25600" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_3ea17f1f-f86b-4316-a762-b91376e8d1c2" xlink:to="loc_us-gaap_LitigationStatusDomain_13ac5bc2-e14c-4a15-8295-2a8f56f25600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_28cce448-db9f-4be8-878c-487543ce85a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_13ac5bc2-e14c-4a15-8295-2a8f56f25600" xlink:to="loc_us-gaap_PendingLitigationMember_28cce448-db9f-4be8-878c-487543ce85a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1e924627-ceef-444b-aec0-f2f8577ee2b1" xlink:to="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_fec63a83-969e-4fb2-aa11-ec2dc257aec1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_fec63a83-969e-4fb2-aa11-ec2dc257aec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateFromOctober2017_cbbc19eb-0e6d-4202-a87e-dd261889ea0c" xlink:href="gild-20210331.xsd#gild_JudgmentRoyaltyRateFromOctober2017"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_gild_JudgmentRoyaltyRateFromOctober2017_cbbc19eb-0e6d-4202-a87e-dd261889ea0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentEnhancedDamagesOnPastSales_80042977-17c0-4daa-bf0a-5f1a8d998d70" xlink:href="gild-20210331.xsd#gild_JudgmentEnhancedDamagesOnPastSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_gild_JudgmentEnhancedDamagesOnPastSales_80042977-17c0-4daa-bf0a-5f1a8d998d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateOnFutureSales_3e028e9b-16ed-42ab-8ce2-b01902a17f39" xlink:href="gild-20210331.xsd#gild_JudgmentRoyaltyRateOnFutureSales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_gild_JudgmentRoyaltyRateOnFutureSales_3e028e9b-16ed-42ab-8ce2-b01902a17f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_f08a5286-faa5-4556-bd9d-999fac1e8fa1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_f08a5286-faa5-4556-bd9d-999fac1e8fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyEstimateOfPossibleLossPastSales_437c0f7e-e2d0-46c4-b46f-7b861006b5b4" xlink:href="gild-20210331.xsd#gild_LossContingencyEstimateOfPossibleLossPastSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_gild_LossContingencyEstimateOfPossibleLossPastSales_437c0f7e-e2d0-46c4-b46f-7b861006b5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages_dddfe224-49f4-413f-b10d-e9101e698e82" xlink:href="gild-20210331.xsd#gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages_dddfe224-49f4-413f-b10d-e9101e698e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyEstimateOfPossibleLossRoyalties_d72e5d23-d3d2-4a4c-9bb2-71df2279fd1b" xlink:href="gild-20210331.xsd#gild_LossContingencyEstimateOfPossibleLossRoyalties"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_gild_LossContingencyEstimateOfPossibleLossRoyalties_d72e5d23-d3d2-4a4c-9bb2-71df2279fd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_cc0c6f9e-5242-4999-8b08-10d4e5595b84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_cc0c6f9e-5242-4999-8b08-10d4e5595b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyMaterialTransferAgreementsNumber_302cef26-697e-49cd-a4e7-5119191941a1" xlink:href="gild-20210331.xsd#gild_LossContingencyMaterialTransferAgreementsNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_gild_LossContingencyMaterialTransferAgreementsNumber_302cef26-697e-49cd-a4e7-5119191941a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_276fdf50-e387-436f-9471-3f162fe2dff7" xlink:href="gild-20210331.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne_276fdf50-e387-436f-9471-3f162fe2dff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_adadcdfa-f353-4974-86ed-936ac9fd090c" xlink:href="gild-20210331.xsd#gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo_adadcdfa-f353-4974-86ed-936ac9fd090c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_15c2d0cf-f2af-4125-9500-59bf2f08551b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_15c2d0cf-f2af-4125-9500-59bf2f08551b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesAppealedNumber_4e89c0a9-81f8-4586-ac3a-922288d692e0" xlink:href="gild-20210331.xsd#gild_LossContingencyPartiesAppealedNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_gild_LossContingencyPartiesAppealedNumber_4e89c0a9-81f8-4586-ac3a-922288d692e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesFilingOppositionNumber_456a77d6-ee52-46f4-94f4-81cf579f247f" xlink:href="gild-20210331.xsd#gild_LossContingencyPartiesFilingOppositionNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_gild_LossContingencyPartiesFilingOppositionNumber_456a77d6-ee52-46f4-94f4-81cf579f247f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_198aefbe-fb44-464c-b1b7-39ba995e5f70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_037c82bd-0c22-45ea-b5bf-022d66e5b9f5" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_198aefbe-fb44-464c-b1b7-39ba995e5f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="gild-20210331.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8cbbe653-8a19-482d-8a93-5a212354dfd3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_fc888885-086e-4888-b81e-44a28b9d3f3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8cbbe653-8a19-482d-8a93-5a212354dfd3" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_fc888885-086e-4888-b81e-44a28b9d3f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="gild-20210331.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5feeb09c-ee5d-4c15-bd0e-929750274eea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_db8344cf-b571-4534-85c8-c72e3e73e5c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5feeb09c-ee5d-4c15-bd0e-929750274eea" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_db8344cf-b571-4534-85c8-c72e3e73e5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#STOCKHOLDERSEQUITYAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f8e44f1f-5575-4e45-9099-b13a13cf53f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_67b4e575-60a1-4f34-936a-dbf817bd3261" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f8e44f1f-5575-4e45-9099-b13a13cf53f4" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_67b4e575-60a1-4f34-936a-dbf817bd3261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_0262132f-1157-47b9-8769-57cb5e52ac83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_67b4e575-60a1-4f34-936a-dbf817bd3261" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_0262132f-1157-47b9-8769-57cb5e52ac83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_b4ab56a6-a8ad-4f72-ae44-2e240e68d25e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_0262132f-1157-47b9-8769-57cb5e52ac83" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_b4ab56a6-a8ad-4f72-ae44-2e240e68d25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2016StockRepurchaseProgramMember_154848a8-0f4f-4f3d-861f-d6e3e7ce77e1" xlink:href="gild-20210331.xsd#gild_A2016StockRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b4ab56a6-a8ad-4f72-ae44-2e240e68d25e" xlink:to="loc_gild_A2016StockRepurchaseProgramMember_154848a8-0f4f-4f3d-861f-d6e3e7ce77e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2020StockRepurchaseProgramMember_181fc684-6d44-4147-b4ad-7058d51f6b26" xlink:href="gild-20210331.xsd#gild_A2020StockRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b4ab56a6-a8ad-4f72-ae44-2e240e68d25e" xlink:to="loc_gild_A2020StockRepurchaseProgramMember_181fc684-6d44-4147-b4ad-7058d51f6b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b82a91f3-7113-4220-a2ee-7179eb800a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_67b4e575-60a1-4f34-936a-dbf817bd3261" xlink:to="loc_us-gaap_ClassOfStockLineItems_b82a91f3-7113-4220-a2ee-7179eb800a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_aa5c4d22-a0b5-43ad-9dae-102416483674" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b82a91f3-7113-4220-a2ee-7179eb800a3a" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_aa5c4d22-a0b5-43ad-9dae-102416483674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_fd3a100f-7bc7-459e-8345-4ef7bb2b1f38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b82a91f3-7113-4220-a2ee-7179eb800a3a" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_fd3a100f-7bc7-459e-8345-4ef7bb2b1f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_32bf0a5a-c948-443c-ad4a-58a555b93d0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b82a91f3-7113-4220-a2ee-7179eb800a3a" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_32bf0a5a-c948-443c-ad4a-58a555b93d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c29b1882-3770-4354-afa6-169c92663e6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b82a91f3-7113-4220-a2ee-7179eb800a3a" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c29b1882-3770-4354-afa6-169c92663e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5afd8d89-0aa7-441c-9d1a-7d3f7b4af40c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_64ca19aa-5ba3-4fe4-b2ec-1fbca9448883" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5afd8d89-0aa7-441c-9d1a-7d3f7b4af40c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_64ca19aa-5ba3-4fe4-b2ec-1fbca9448883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e1170bb1-0519-4c6d-9dc7-33317295c6e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_64ca19aa-5ba3-4fe4-b2ec-1fbca9448883" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e1170bb1-0519-4c6d-9dc7-33317295c6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bba31187-ceaf-4254-98ae-3e59dffa5c97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e1170bb1-0519-4c6d-9dc7-33317295c6e5" xlink:to="loc_us-gaap_EquityComponentDomain_bba31187-ceaf-4254-98ae-3e59dffa5c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7ddab721-845a-4b0e-9635-0e4da0437021" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bba31187-ceaf-4254-98ae-3e59dffa5c97" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7ddab721-845a-4b0e-9635-0e4da0437021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_501ec77c-a4a9-4eba-93b8-158c5111eb12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7ddab721-845a-4b0e-9635-0e4da0437021" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_501ec77c-a4a9-4eba-93b8-158c5111eb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_a10ff298-4894-4f3d-9a00-ce1e9daee5b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7ddab721-845a-4b0e-9635-0e4da0437021" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_a10ff298-4894-4f3d-9a00-ce1e9daee5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c3d8b008-d2e3-4fec-8723-94d0e9860d57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7ddab721-845a-4b0e-9635-0e4da0437021" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c3d8b008-d2e3-4fec-8723-94d0e9860d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5ca967ca-be9e-4f61-9542-a3f1ebb376f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_64ca19aa-5ba3-4fe4-b2ec-1fbca9448883" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5ca967ca-be9e-4f61-9542-a3f1ebb376f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_5a0694ee-93df-45cf-a8e7-73a40c93ffc0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5ca967ca-be9e-4f61-9542-a3f1ebb376f8" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_5a0694ee-93df-45cf-a8e7-73a40c93ffc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_63dfd15a-66da-4315-b589-4d39f4cb8dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_5a0694ee-93df-45cf-a8e7-73a40c93ffc0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_63dfd15a-66da-4315-b589-4d39f4cb8dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_345d9cfa-1b6e-4f97-8b60-89e29ccb29fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_5a0694ee-93df-45cf-a8e7-73a40c93ffc0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_345d9cfa-1b6e-4f97-8b60-89e29ccb29fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_e13584bd-fe1b-440e-ae1c-649048f8d88a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_5a0694ee-93df-45cf-a8e7-73a40c93ffc0" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_e13584bd-fe1b-440e-ae1c-649048f8d88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f1c8c4d7-e979-4d72-9d1e-d7568b236f9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_5a0694ee-93df-45cf-a8e7-73a40c93ffc0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f1c8c4d7-e979-4d72-9d1e-d7568b236f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_41a8b95b-da6e-40c5-a5f7-34d443b29fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_5a0694ee-93df-45cf-a8e7-73a40c93ffc0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_41a8b95b-da6e-40c5-a5f7-34d443b29fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS" xlink:type="simple" xlink:href="gild-20210331.xsd#NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_601d978e-84a4-46bb-9a1c-0279c25d1cac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_61165b5e-cde3-4e03-8937-cd53fde0d867" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_601d978e-84a4-46bb-9a1c-0279c25d1cac" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_61165b5e-cde3-4e03-8937-cd53fde0d867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables" xlink:type="simple" xlink:href="gild-20210331.xsd#NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_199c6604-c286-4ec8-9abf-28743f3d5cdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_53ebc7f4-3574-4b5f-8709-5fb9e3ab46af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_199c6604-c286-4ec8-9abf-28743f3d5cdd" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_53ebc7f4-3574-4b5f-8709-5fb9e3ab46af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2cfb9895-6be1-421c-b67e-7e2ef69a39d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6ff94b56-57be-4b12-8698-0929d617fb21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2cfb9895-6be1-421c-b67e-7e2ef69a39d5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6ff94b56-57be-4b12-8698-0929d617fb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ea853b74-a53e-4f4a-9a32-daf5bbc5266b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1b7d43df-768a-4116-b6dc-d36008471722" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ea853b74-a53e-4f4a-9a32-daf5bbc5266b" xlink:to="loc_us-gaap_NetIncomeLoss_1b7d43df-768a-4116-b6dc-d36008471722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_00160f1a-ff39-4e78-ac44-90f36e8a63e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ea853b74-a53e-4f4a-9a32-daf5bbc5266b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_00160f1a-ff39-4e78-ac44-90f36e8a63e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9d26a9b3-194c-4a34-a210-0aac123eb345" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ea853b74-a53e-4f4a-9a32-daf5bbc5266b" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9d26a9b3-194c-4a34-a210-0aac123eb345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e1ddf7fe-9d79-4d45-8d64-f1b3a116e927" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ea853b74-a53e-4f4a-9a32-daf5bbc5266b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e1ddf7fe-9d79-4d45-8d64-f1b3a116e927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_beb510c6-88df-41a9-9e5b-e5c6466d3f7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ea853b74-a53e-4f4a-9a32-daf5bbc5266b" xlink:to="loc_us-gaap_EarningsPerShareBasic_beb510c6-88df-41a9-9e5b-e5c6466d3f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_37387f3a-1ab4-4a25-94d5-c5f8c80012b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ea853b74-a53e-4f4a-9a32-daf5bbc5266b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_37387f3a-1ab4-4a25-94d5-c5f8c80012b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXES" xlink:type="simple" xlink:href="gild-20210331.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_50a6f202-faf7-41b8-8578-11932ff8933c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_7b7c883d-9a97-4b91-9e9e-a205aa53da2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_50a6f202-faf7-41b8-8578-11932ff8933c" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_7b7c883d-9a97-4b91-9e9e-a205aa53da2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="gild-20210331.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c41757f7-f9d9-4576-8cb1-6cf6e5ab9115" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9cdeeb79-7741-4826-8c4c-cd9e1f979868" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c41757f7-f9d9-4576-8cb1-6cf6e5ab9115" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9cdeeb79-7741-4826-8c4c-cd9e1f979868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXESSummaryoftheProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#INCOMETAXESSummaryoftheProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/INCOMETAXESSummaryoftheProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3a3e1d9f-6f1e-41ab-8f1f-925b44a18880" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b6a31468-70d1-4e0f-9f84-ab831ec57a14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3a3e1d9f-6f1e-41ab-8f1f-925b44a18880" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b6a31468-70d1-4e0f-9f84-ab831ec57a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3b71a41a-71ff-478f-aa2d-78da932b0356" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3a3e1d9f-6f1e-41ab-8f1f-925b44a18880" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3b71a41a-71ff-478f-aa2d-78da932b0356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9f4fa64d-db0e-4622-b303-c0310b3b488c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3a3e1d9f-6f1e-41ab-8f1f-925b44a18880" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9f4fa64d-db0e-4622-b303-c0310b3b488c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#INCOMETAXESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f50836d6-fb66-441a-9e00-0207467b8378" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1b9c6ab7-5f3c-45c1-b7ae-539a65d5daf4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f50836d6-fb66-441a-9e00-0207467b8378" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1b9c6ab7-5f3c-45c1-b7ae-539a65d5daf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/SUBSEQUENTEVENT" xlink:type="simple" xlink:href="gild-20210331.xsd#SUBSEQUENTEVENT"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/SUBSEQUENTEVENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_934552cd-3fc9-4c5b-b369-590fa289f61c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_cce364a7-1e79-4614-9d61-1da71c6f8cb6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_934552cd-3fc9-4c5b-b369-590fa289f61c" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_cce364a7-1e79-4614-9d61-1da71c6f8cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/SUBSEQUENTEVENTDetails" xlink:type="simple" xlink:href="gild-20210331.xsd#SUBSEQUENTEVENTDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/SUBSEQUENTEVENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_59301aba-4791-4dfa-8fc6-4b25e2b5f537" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0ba1ba19-2f58-4637-ae97-d2a6b5531540" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_59301aba-4791-4dfa-8fc6-4b25e2b5f537" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0ba1ba19-2f58-4637-ae97-d2a6b5531540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7dd1d85a-7708-431b-bdc0-e32e1369c264" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0ba1ba19-2f58-4637-ae97-d2a6b5531540" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7dd1d85a-7708-431b-bdc0-e32e1369c264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1d415f2c-1e12-4f72-9bf1-1bee48b2d344" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7dd1d85a-7708-431b-bdc0-e32e1369c264" xlink:to="loc_us-gaap_RelatedPartyDomain_1d415f2c-1e12-4f72-9bf1-1bee48b2d344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadFoundationMember_ff8f1849-613f-4396-aa94-4aa960c8d37a" xlink:href="gild-20210331.xsd#gild_GileadFoundationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1d415f2c-1e12-4f72-9bf1-1bee48b2d344" xlink:to="loc_gild_GileadFoundationMember_ff8f1849-613f-4396-aa94-4aa960c8d37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_800c23a9-1a63-47eb-a854-73932545851e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0ba1ba19-2f58-4637-ae97-d2a6b5531540" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_800c23a9-1a63-47eb-a854-73932545851e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3ee144d4-2407-4c58-98ed-fdfeccb0c4b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_800c23a9-1a63-47eb-a854-73932545851e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3ee144d4-2407-4c58-98ed-fdfeccb0c4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_177f4510-53d3-4b03-bf90-7af93cb6a025" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3ee144d4-2407-4c58-98ed-fdfeccb0c4b8" xlink:to="loc_us-gaap_SubsequentEventMember_177f4510-53d3-4b03-bf90-7af93cb6a025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_6af43121-25cc-4253-a715-164f5083d7ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0ba1ba19-2f58-4637-ae97-d2a6b5531540" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_6af43121-25cc-4253-a715-164f5083d7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3eb809ed-93d7-4aa1-8249-a99c8fc99fa6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_6af43121-25cc-4253-a715-164f5083d7ee" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3eb809ed-93d7-4aa1-8249-a99c8fc99fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesDonationMember_2390862f-aec5-43bb-a6f9-74ccdd41abd5" xlink:href="gild-20210331.xsd#gild_EquitySecuritiesDonationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3eb809ed-93d7-4aa1-8249-a99c8fc99fa6" xlink:to="loc_gild_EquitySecuritiesDonationMember_2390862f-aec5-43bb-a6f9-74ccdd41abd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_5ec3b8d6-599f-469e-a2df-b54c943c4d4c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0ba1ba19-2f58-4637-ae97-d2a6b5531540" xlink:to="loc_srt_StatementScenarioAxis_5ec3b8d6-599f-469e-a2df-b54c943c4d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f815d8f5-df56-4d9b-9a0f-6b7d4794e641" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_5ec3b8d6-599f-469e-a2df-b54c943c4d4c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f815d8f5-df56-4d9b-9a0f-6b7d4794e641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_e52563c9-c5c5-4149-8af5-9f139c3bfb6c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f815d8f5-df56-4d9b-9a0f-6b7d4794e641" xlink:to="loc_srt_ScenarioForecastMember_e52563c9-c5c5-4149-8af5-9f139c3bfb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2b033ce8-bc53-418d-a44f-1cd1bc10de98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0ba1ba19-2f58-4637-ae97-d2a6b5531540" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_2b033ce8-bc53-418d-a44f-1cd1bc10de98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_68bae763-d48d-4a5a-b7fc-55d84ec91191" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b033ce8-bc53-418d-a44f-1cd1bc10de98" xlink:to="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_68bae763-d48d-4a5a-b7fc-55d84ec91191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>gild-20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:gild="http://www.gilead.com/20210331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gild-20210331.xsd" xlink:type="simple"/>
    <context id="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i59d6a509af4b42e1a99d44dee3d8c20f_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i857e1d9466cc45c0ad66d0661626a0bd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if18ad61a4d694b84a567b29c22cd074c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i869fada8dc15440fb186758025e4ea38_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i888db709f4bb4306aecd55be57d43e9e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3d0a665778d14bbb912aa93b2b6e4f2e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2e94052ecbb3480d9dda10de813ecacb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4491879c7fcd415288701f6b62e40e51_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i13bf16e2c0cc414ca0e4618b4219c2cb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id315795d1e774a6a845a09bd3c23f669_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i631a0304196e455e9a985f2aed12a21c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8ceb4b2138664055958fd36c771ef719_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i22e6def1ee614c1f88a734ccf8b57339_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i49ed492a453846c298f340cfb12aea93_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3f56585e4ce041a0a4818371afd20608_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2e9ec92ee61543dbb61d2f855c0a785c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i33e7b278cf744482b55f1a9184b9c0fb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4cad2b62afdf497cb6d680783df2564b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0e12da2f502648b1b1cfe3c2ce745770_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ideb5f8dc0c4442658f18eab50f25a677_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6aa770dc5dd844ef8a4c9f16bbad3843_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i59a30e5469c84cd78e03499a820d4cfa_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie0e06ce8778849a79902920387c413c1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic27cb3c440c3422fbad61655cb15c60c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6c7b9ebee1f549d198ceb53ea6813141_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i58c9bc44b74c412ea8a63c832add3283_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0484fdf9aa034ecd94e3797e7f978bdf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9a8779a54fef4be683c8d4f7e5b601ac_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i17fa9a1c26714f1587a2aa325624b533_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gild:CumulativeEffectPeriodOfAdoptionAxis">gild:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i48b7a28e035547fa89fcfc8c0593b301_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gild:CumulativeEffectPeriodOfAdoptionAxis">gild:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2835b80e3c7a4d00b23cdd84912a90e9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2f2d827efd2a4f4a91dee3811a501ecc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4dce18c9540c42d6ae4ba9bd85b66896_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6dd270c88164436597aad1b5ed3cb4ef_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic6ecd38b92444ed38d13e95fbd53341a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7ca6dc703a0d49718435076c33ed0dbc_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i887b76714c9c41c4a6db53d46bc0f6a7_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i51b7741d7f0241a9a5987bf6c4f4f41c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="icaa5a801f01b483992e5c3baa5e7844b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i118f3a03d85d40aba97d7091b6ac999f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic3f0f2350f9c47889d2e1afa48054b12_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie434694a2f304ecd94c3775324b4378d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ied66863fda3841ad881df6b37123aec9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibeff20e2f7ee495db92fa4c3484b89a8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib0438c7b3d8b44618b0023cd7a41ed6d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib5f03dade66d4049ac775a2ff2e95578_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iaffbd58e1c6444dbbb5947207f1292df_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1af19a68a52f40feb3f105f7566f6acb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id77a0ac827ef47e490fe49f7648d3b55_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8bcc8d5fc46645f296ca7a59cd624b53_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7754da6d6ec44b0e944fa8f87cfe572d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i93ea9ae384744892b920c309bb2dc11b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4b9480e8d66b4593ad97e4e5be56077d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i860dabfa33e143bbb52212212435f1ac_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i32acee5874f9459b9252142abdad455c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if8c9ead692aa4d9b810f9ec7db117251_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie8c7336c5e6147e7adf7d7c7affa6881_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2462c72487a94e59b5caf6a5a319777f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i926db54afaa349f6af84a0c3e2544b96_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6ec0f287f8ff4da3820bdba4ffc47bc2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib3fd650f8abb4697adb1f0f30c929d64_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i74acc5bbd8d34c738b16ae51a6075385_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i15469494cca5432aa408d46c88acabf0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9d5d49b7149047bab9ea616bba4640f0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8809e89136714bbbab87f233c9eadb83_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id32809760dcc4f69a8dab604473dba7f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib508419ccb58428e84530322853938fe_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i25554b833ac44de8ae88e315443d09c8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i78b9775b1d1b40319b1f9d7183321020_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i63920a1a040e417891a03f303d3bbcad_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia590ce34497d4eaa86fa2b29038aabb5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7eeed5ddca31468cb705d74685f56174_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i64b13d2f087c45bd9fc1acd32cd1ef64_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i63ae64a7b8094554852cb98b0a551090_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic110886142334d548f1d0723e44253d3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifdcd081c4a4c46029ac68f60d58be6aa_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if0410e8fcd4043e490ebbf9c80ae64b1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib630252d0da14149adffcae74b86e4e7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9bec6854dc6b4f04a8e737cd53521147_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia0ebb14b7645429db55c7da591d24c92_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2d00d8d104314587b42a25a2edff05da_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5a6f431e5de642bba69f6328f2961f14_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i99ccdd43f15d46bfbdc7e4ea02150055_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic5661ce6a8f840d1850cebad529dc17c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8af148cdc07347ba838fdffde80857bb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie65015860c764edfbb86c8af349ccd93_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9b044c57517f472a99248ee2666230e0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie915268dd561478f9d1b79082fe9e92c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2c5a0930911c499688e99f6e08ca653c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic4618b8d2431482ea6b2b45a2b50b865_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2ed385b62afc49599835c73bd497620e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0d7e6c0864674e51b116a0887e955135_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8f3c8b7a52cf49be80972340697e8657_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0a691facdde446d09127f1d0029b00a8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic621020502cb4461b3f507d17a78d96d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9944473064fa47dcbb264707adb1876b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if2e742eaf2b342098a385d2addbe3722_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i588d3a5b64fd4b7080b0056b85ea0150_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i33b30c8afa7d47e59e7da726ed9b9890_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i03098f2d9e664ef285eee0bbed328af7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i38535068021e4957bf196cb0586b1f95_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie91ab1070982497baf8fd021259bd6f4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i77d7d1bcb69242afbb3209274bf2e205_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib9079d3cc20b47f48f6dadc7048847b4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie5c79c7043994738bad7f7620e19bd9c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib54f9224b2d046a7ba0fb1790721cc77_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2f0e9b7992f04bd4b7a98d3c40e33e6c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia1bfaa1d7b2047c8b0243a6fe75777de_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic6a1884c73a14fabbeac29b5261925ce_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9213a6fb817f496f82175fdabab96f9f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id25b065da243414e834f92baa87571d1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="idd4289b827184b00ba7eb9735afd98c1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib7f221d836804ac0ac5bf313e85fb6d7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i38b3924c6f0c441c9eb7e6c652985a59_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i685ce820b15c48c5a1caa899b5612367_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ica58dd4564944ece805e2d3c625a68a5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9eac58164bb8445e95ecf5a632b200e5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id5a9b0307d9f4396804a48e8a8842af3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i405af8d2ac694bcba3c274ea467fe4c5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id4b1a067e082487a8eba535819944c84_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6ad7557b78564109823d84b4134cb07c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i19c918e9779d45728feb8d2f77e6f762_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i84672c37600c456ab352a9bd8d1c0bc1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1a8a43acfc2946a2bb710af0e9617ab5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i61244f5bb1eb4b01a880be330bb43ca1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9695a806ea324bfd8dc16e1026c867b1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i28b0923ec98c483796a4a281d6f4da09_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3f3114f39eea433da4c3f4769d416586_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia68c505daaab4913bbd9dbc115125ca6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i01820e105c11483b98e41dfe3ddbf458_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i46a4791353fb4785b0fd7e420b2475dd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if6903aaf9e2c46dd8097d605617899ff_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1cedb25ca5664766987bf8d01722d958_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibd6d40d2852e487fab1dc8033ea98643_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8f2e37e070de443485aa360d17396ef9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i926b41607fcf4d478d80f477c8e14d41_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib18a279ca38b432890071110c7674594_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0e7edf182cba4fe09b32a83db26b4422_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iec3036fbf5cb40bc8c7e26870944ae22_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i51bdb311ba0f467c84b98f56b3828ae6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i92d6c64051da48a8a8e6f80486b979bc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icb14461498914ac79e0457757c75dbd7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic8d0518889a34fa2998643c6c7727744_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iba550e7873fd45c6aff0245542583cad_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i63580e96633b4a5e805fcfb22890f21f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="idbe86121ebc04ad2a0dac3152347a17c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3261f10427f747079f2363eba0693663_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2f5059f19d2d404d9f5b485c545a5334_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if27f6ff654cf4f2aa404dd2e82fe05b3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idb4b9a4d69dc4a5b969be42cf4ab5ab8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i54a8ecbfe7104cffb328730f7e2f2ba8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icabba3a157cc4c89993c0a6f7b81fbf4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iec98ee45e5ad401eb35c35717992014d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8cab6459ae2e4342bcf14bb7f0922405_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if127a72225484fd3bd781db0b605a953_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0d2f28f5774846bcaefb219a74d26197_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1df4119b39b941c5a676e0d6e2524da4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if8d501a125774436b2320401b2dd5bfe_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id015d46967b94673ac7fb2ecc01b0237_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4660e6236c694b5ab8b1df8d62990e36_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib0789c28a8de462d9aaa999b30d2860d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i675d50c435a342b58fa7e73781175e88_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i360f92e56eee4f9cace9fa5368873470_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5bcf031777e242c49d6e3dcb11d0d8b4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie1a9d40b8bca4c5ebf598872fea64e39_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if969bdf4b849499da19c7f7222a8956b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i84671f49939d40bc886c4b2114546e68_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2772b321f6f54c0c86bea892e8380009_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic526ab60ae6e4f5793eb51c0321f5905_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id610eb3a322f41c8a749fe84d536e585_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ica526b4aef3a494aa2733999ba191001_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1bc50922e47b41d1ae940b37d4a22377_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i88ec94f0555e4aebb035ebb5e2f4925a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6cc4334126ed455ca10fd4f18e8f5b4c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4ff242a9f3684b65bdac58944556d71a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iab32fe9b37b248d29bd625882511a2bb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia54a8c84a9224b4aa1d3a5f8e35961cf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3432013787d441d5ac3a3a61b439dac3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib78feb1672bc421087bf1d5bd26b7f38_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0b34a41296624040be895c5b6d3289a3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i85236c36163f4119b8910a94fbd2562f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1912c5f855804d3eba84607a017c56ee_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6b6a5426bf9c42a6acc2bf5e17b270af_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i60e4866d36c54935ba04c29bb4fca09d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6db1d7fe6dbc4d6ca143fc475b93b204_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibc5ca7d98d3244549154eef3bc1137b9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5777618eff474b979c73d1e5bb0bcd06_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i20c40061142b4bff954eed33447b411c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib68625c89e0942cda48fef6469af6e0b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie8c748ed1b844524849ec04f66244abe_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i37dae4cebdb14befa776bdc7e3990bdc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i37cc9d8c63b54982bdae48850a893359_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i897fee00cdd84fe19bcc2cc8dff383b3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1b087aba23654283a5c4af9b69a0202e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibeb98b603f06451ead95cabe282463e2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id37d8e541c21407bb4a5f8243c09f13e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id7ec4f656f3842acbe27241f7f05ed2f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id69e1c2be46d4ab3b4309b0f917bbc46_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1667d7f2806e4f558140470b36628aa9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2328db06206c4fdd9af385e7c2173cc1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4f4ecee25efe4513b99dc58abd0fe3a2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if3005b97b85247b7bb0b10e165ad5a20_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icf31979b82854addb363f690711744a9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5c18a34a44ac4a6eb3e0df9bd9f9bbec_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie5b81cbd589447aeb09c7c7271354585_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0a2f8ebf252349c19b669e8c8082fec4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie7413a3522244628851987c3f80b566e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i13d9726cce774f76a579a5e8833f0a50_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id035c0dd020540dd9baeb1cf7dc147b5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ieffdb1acfae64cf3893370c95966b40f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib75a2669840e4d33ba162e40920c2dd7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i43c8f799fa3c418bb426643d8c44cd59_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i770b79af85df4a5682a9ba6a0d5ab1d8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie36eeb702c1740afbd92eef4087fa2b7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie528cd0b9cdf4dc5a97392412c208b8c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i95f4d058a72e4ceeb60de778690ef7c2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie77a01ccaa114972a96aa9c83d1e2ae4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1e328dc77d9945ddb8c8684f306018df_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i638557b5d8cb4470bf95e691ee5ce53b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i05bbfb8bf6fe4d4db64e6f86903a3437_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id31fed8e97de4275a24d7c4b6bdcd1ae_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i895202346b1e4f8e9fb49025b720a3e9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4a4bec7cd2a7469992b30486d0367128_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibd6d31d7996e46edbb7ee6b98031d951_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia884a4d361c549379ff1a1b4a3e743d1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3e124cdf64ce4d42808bbced06eee17f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i94c157660993467d933768c8d2aace75_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i765af031a6b7456b87400772e5870fad_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie9bec1aed1d4441e84196a0df4aef39e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0a6c817b9881419c843a0c4e6dc181a7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i72493ff81994417eb27d02d1509511da_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i84bc3ed5f80d4988b11e429d726f932f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if726dadc7df94416b6c217bdf80c23dd_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib6640c16387c47d3a3a2b9e3877f611f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9418ff206901445b9b29378a177c1078_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i95a67a6c1c934a8191082d5f097351ab_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic787aa223d5c4f5da13f043035ca0c4d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icbcfbd0d83fd490a88eb77e4164e8482_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i56ccd5f7a01343d2a2c516f6e998e3bc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i830a223d4ff2496b95fa59aa0e3e4797_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4a0e2be2410b432f83a8f28ad4956670_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i56d0c83af6c24195b5bf3247fc3a2a1d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8f5ba02898844d3ea4c5f499f95e5fb0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i20275018e0d44c51a225e199b4c27700_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic8ac1fc0d9b04f45841b68102ff7a077_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibc55defcbcf045f4926fb48eb0af8237_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie794e67f1815485d87eb5b97b42e3a28_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie4c01e5b99d04896a602aacda729c489_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icb5ad85e55c34064accc690566b965df_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i060769bd1274459796e6b5d21c6d2fcf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8116a166d7b441d2956497a975f03511_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i240d967d6df04f7b960c8bd653ebf8b2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i217f335d6069466ab81d2c9226caf8aa_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7fd3a3dc901f42628f9c5cdcd8c7c6a8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i416394b51cde4930982ba7a31e497d29_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if80f651125c7457f9c03c5bae809f7df_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i29de68ae484845bbbcc46d9cef9b77cc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie9cafed727b04b61a40c05a62b4478bb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i91466ff987d24072b25a05678b2c099c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i27f5ef98b94448b0b24ea64ee73bc0bd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i993d7e955bc24b07ac282e4ab68a7571_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1e949706c1134da999d6dae385652030_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6ec3ba3a461c4bb9a085047222875988_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib2a556c276af4966a1f10ac00b2afafe_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1608b354af974844a750d7bbff9d65bd_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie622129ad8eb43a190e8eff8fa687ae5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6f5fae6c59274f0c9e41875005ba8c44_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9e613c28bb364cccbb5a721e8f1d7d7a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6e45a6235b364a4bb66ea5322ed6de0c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i52538488633a4641a1fb75bd6ea77c00_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ife67fb52d10a4d4a9dc24e6e584d9f8f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i77b40277de7045d1be5c4072ff5a78d5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6d26210a184b4926ac141ab337c6d073_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib2bdbc28395e4c749de3966f3d490986_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i31d850a622e9469497772ed09d38381a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id1dde27099e04e999e1d57d292d9919d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iddfef4e9b501477bb8ed2bdd6115418a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i633cffc37fba44c896afe1666617e27b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i696ccf6fee89419a892324e7301d6a33_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if03f06d9abbc4d33994c24916cad8f2a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2da7f309c165427aaa64cd0d24fc46ec_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib0f41ed705fc47bdad91b627766f40c6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i242ad95eb87d4a50a40c74136ce45ce8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4208030b6e11411a8b65bb4461639e24_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i26be40f7eb5247d2a40cf54a35c01a00_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i53b279b4db0f4f1dbfbb9132a4d78da9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib6a7bd7ae51244859339deec6090a256_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3eb69f03734240adab1da5d621476341_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i718d3fcd575e4cfcb3f142a29edf8c39_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i776c29b6bd8246b799595de5c9c32a6c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia2d224f161354feb9e09b4ebb8e0cd9c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i001045f707f44a6f80dd8a8ca22a4bf3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iefd124be7cd14a8cb0d1429c3a487683_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i027a876acd5948e39aaa2a168d3de1fa_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8517e6b14d3e4e059d8471ac0f54ff42_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6c6a2a79dbe141ba9c759468a86cea51_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i85cbcbbe9efe43c6b5e7ac96bb4d64c1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4a72c3a2c01447b1ba0c68c97b289ee6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9f8b4813eba0494e93eda89e8d1553c8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0bd483f628534e979ee1ef8021838fb8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icbcb2718a9a24054beb14bb7fd018345_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ifd0ff86989784672bbacbf1f772f25fa_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id7f6740c84514432ac4d19cf79c9a9e6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia65096122500425d94f26b129443d35e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8763f2000062414b96d9bc6531fe8ab1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i77440dee8e4f4c28b9284a8c1b5ee20d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0658097ecd9f4ed7a6c2540f41f0c3ba_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7c6858c51c1e4711938e993b04877b4e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if96617e7cd54426a8d62efdc0b500ca3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id0ad9df8e3f742f8a9d13605d46cdb6f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i31c0a79638a0401ca700e01bc980c823_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7b3360b0081141b68f60fc04b739a94b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i93e1474c09ed43708fdbb6b69bc558b3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ief5d8a88cb0c498aa5bab8062cadc5e2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e340b8dc03c46e9847845ecc93cd50d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5a5e98f04e5240d491e0cc8b9dddefdb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i97d51408424340dda5bf1d3aa89904bb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibb8af5d71f544b89bc874338694fa854_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ied9f8a90eedf43f299e27e814d996911_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i07d6a99463d548be91dccf3d8477c710_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00c48252b08b4726a781e4f7f1713886_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i555b95565b354fac92b93a98e20786a0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie7f7eb5d72aa41e389a203f002990378_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iade14a2b611b4dc4a1182a5853afb334_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id4464d90589e45bda0d671fed402ff0e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6b417832f6cc49f191f7192d1a823352_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idc9df4486c8247a19dc93d1ed8ddc162_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic28662f110d3489097e5bfb6893f2427_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic05e70bbe4b3409dae83bc7d0776ac63_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e9200ff492148ae8c58c24ec1cd7a91_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d0c1157b3a14d309db0f095df92bde3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i152ea6395daa4d07b42285941bcfdf86_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i52d21135f58b461f951b28b78af74777_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i377ef2a3c67e4eddb0210c423899d36b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i25828069eb6f42dd8588993c039568a3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3222bce3d3fd40099ca0065f76398572_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7823458e96f5434ba771f22ab8eaabf9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i64c79cd884d64f78bc716dbc267e3aaa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00681abd09ab444f83e854d3a2172b8e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia0d37ded2b7640aa9128dac07431cd34_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3a4a45ef79134c3eb7aefea81863cd66_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6b6fb120815b4e528bfe5109cd7d6515_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib3664faeffef41cf8c6784e97bf9f9e9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia462feb041e340b58c473503f10bf35b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1db9c8c7496f46a8a743dffc446c7a18_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7f4efed1bea843dc869bb5263b87e2ad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00a4be1eea0d49da818f2dfc2e5cfec6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic3fb2529cb7c446b9a528d1a8b7febe6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i88a5a0a5260942a38c682ec567b73ed3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i30f95952d5ad4c11a2bb8bfb311497de_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i49e347d7180a4083bef177c0caac5662_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i19b688ee3c124c99aecfd55f3756946d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id0f6e93e4ace4564af67e889d7a1da32_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8ab32a7541324448912a25d6eb8375b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9a15e23f32af40a1b8c8859ebe00a14c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ee618b24da746db97c20d8ee326d75b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6ecc557b23e64f7f8b3e28f3bb1e98a7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9c9d39b9d99e449cb7beaed696f22f66_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9a792f48d4514975b5fc1c1b4ed9d133_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1b4ada8e24d54ee1b49c8cb41dc0bb2a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f6cb1f3baba4062821903054d8f7abe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifc6563b6f71a489583fb4e031963948f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5ad38733f4904e358d2e5a32c94b2371_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if9ddc669c48f47d4bd4a8213c2574ab2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ied694544bbe046f5abc557c39b011a0b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia3bc6d62c5104b8c8d39a0ae9f7af156_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id19a8a5f19494cf0b1f5311d3e01397e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i679d3266010f46df9faca1c635a05771_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie908d94aad8a48da9603237735f6394b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia516bf91deb6424abb224de23f37284b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4ea5455638c849c895022cdbce0f998c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i49ae8bae833b4b0296c3d14e93ef42cc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if4a3d53db4d24b249fa3b917fb325e05_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i86cb4e206c9e40978c991361828e2661_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic136b1c243ab4833b7ff10d92f76ed3b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i676cb8c8931248afb9e78b6bc23fc50a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if5e8131ea89e4f1490b4e83e0d880fa4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i972f4f0a16784ee889562e13a1463c5d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac1c2aeaca014e89ae0337e0d8ff78f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6227824f558c4cf0ba46ee925f4ba83c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iafe8c56a47ec438f9d41105497550c3a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia740610ef9fb41c794dfff273c3759dd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id021fadde4cf4151b8857bcbfbaa339f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idef828ce7dea449aa7d5797f8b58b3f6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i63e11f3f2e3d40369f3e6bd198c01b8f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i08cfe9d6b24b4cdfafdaa13b884170c0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e6608db0e98415cb580d29b81c635ca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i985051c2ebfb41d0b2027dcd0777c115_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i15435e6a628245f9a04322eb3570b28e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib612747a67f64d9b91c1ab19e54958ed_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id8330bb360aa481b97cd6a1b14847b1d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ief0436ce6e3d435288b49bb3c284e932_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia5405c11586b401189e38d818eda683a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iecff646d1fe84980876d9a9c81fd66c9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibdf1d864d25b418bb9159fa7600a42ac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a23cea7a9ba48798f1fd6bbaffb4921_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7fc48886b65840e5a1585ee67a7e5017_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i86da9eb4322542f1b0071e4a1ce91218_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i96f6368de4194af297dac9a63844f55e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i712971393ae14ae89870e173db5b2a1a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1244e3889c7843578e273ee679a43474_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i283158ca5b0642c59af33bc78f9e3655_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85636e0ea3524ff98a8b2e838f9c8141_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7819b77653554557af820a95339c1b48_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i82dd65450f234374bcea4a2190eb3484_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i69731411c56349848eae4d9b486db920_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6dee5b3f2c69441494dc09dbd6b1224c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i87d4f540cc2348449700aa4e9824ba95_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i842226164126495eb19a5f6e285f7a87_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i775975dd06c34a91977a0d26c3c7aad3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i31a2c0299c3f47b68f2ee84425bd6ba4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie4079e9eaf1b42a79cea9514877ac8eb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i707925a6e11e4e8b89cd1de5486dccd6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if9ff815d16ad4190a3c3cc2de4b5e390_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib2cfe856897d47a4a15c011727b132a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ccba16f84d64786acebdc56d30d2961_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3b637184cf1d4fd595b58c5754beb956_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5a4c7af7aa214730805797a174566133_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if73c04ebb10b4c1fb24efca2362f9a22_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89f38dcb82a5491dbb25812d7738c19b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iffef8ea761174ff198789287afe52e44_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1a97739a676441f385dd15bc5a05b29f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i69e005c46bfd4e5c8cfa65d68167b7ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icfa8675ac1aa4739beb924a027e71114_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3f6999e94a9b47b8836b7e7d12120eb3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i96932fa83e584390b3f1d56742823d34_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia27960115dde4e8db6988f723a792c47_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if12b94fde2df458b856419eb60f3749f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie29dcd6fa2fd430ab157b38ccbb28d3e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib5174f6004a743eb845f20ac1490f61a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4e49f98b54ce4b26af2d8166b46b66e9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2408fe312f9e4448b357064015614afc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i91624599719d473faf279a33da7ef5be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id1ff20f5b83944dba31b16c66a70e1a8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8a1a8f49d74c45eeaa8823dd49a9aebc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3ff3207761de4a358076755192646e75_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i278cbd93950247099589a8c54d16f788_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2964d55b3b0243efb3f22c4eed834d5f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7dcabcb1cbf9400c95b149a28f9172b6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia0315ed156fa4a999a216e7bf46cb806_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i15db68ece60c4907bce23168391fc549_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib316497f09074016814019469a1c5282_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9b3659e23b9d46dc913b50eb69f837b7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4a4bb5869b2a4a65965e0573d5a9fc0b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i15df5ed6d62b49e8bf563f685962e609_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ieb9b9032e3424975b8d41437080d8fd9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i37496332327e49d2bfd711461be5eee2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i84d63f6e0c374aa6a0d94624a78f5b37_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d0edd02c9c343938d862442b6afc2af_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i91c1249190d841d3ac8dc4919431731a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2a21b040839549338b52418d18bb1e17_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia692393a1fd94bbb97576f97ccd34cce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb12e9542cfd4e90b2dcab8f7f4c58d5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic8653fde001146e0bea68d8800992d8a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ied6ece005700482abaa15b4b44d0acab_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i638cafe3b48a4a748be6d8f1b169f897_D20210304-20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-04</startDate>
            <endDate>2021-03-04</endDate>
        </period>
    </context>
    <context id="ibedf080b94a2460fb4f0a3efc0a14793_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="i3a98f90b07b94f6c86e128d20787701b_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="iad268a44b5f2496ba16a02c95c0952e9_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="i4833c72c785b491e8f5afc3f5e83a942_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexForHDVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="i33549bbb2e014a6ab92f613d389caaf5_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexForHDVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="i0db85f8bde2e48919fd0edfbb47844d6_D20210304-20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexForHDVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-04</startDate>
            <endDate>2021-03-04</endDate>
        </period>
    </context>
    <context id="i1b3e846287d144f5a57024a1a2aaa1f4_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="i9f919867053e472aa6823a950ddff61b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i19a0802804904e31ba6efd10f1f3ea4b_D20201023-20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="idc1e9ade6e414ced9c63b109438a49e7_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9bbcce56feb74fe6a616f350aa562468_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="i3aa9165e8567484387ecc5acb5b3f1e9_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyForMTNBCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="iaf62e749ffee4dcc9a54082aaa23c3b8_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="i05a08140a83742d99cfbd0fcb20b09fa_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="i5d12086953934504ada4ca8bfb4497b1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia02e3e3eb61e4722a1d82ca5bfeafc26_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3231dad87cac437aaa04d35fce3d9824_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8222759ba26347c3a6f92ef2992fa9a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i56a8801e286d4710aab30d8ef3145cc8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyForMTNBCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib8a8bbb1048e4a4db06008d8d902d2a9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyForMTNBCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i42d240b01e18486db9a4e93c058e1eb9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexForHDVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i86ef6063e2dd483ebe6c5dcca3038c73_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexForHDVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if32750d98ae2460aa464be3d472d1042_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie0ac0434166243fdbe064ef57c4cf330_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaf9f311c0c5a450295b3455afad3eb99_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i04105952f21b49fe8cd9befd11b8c28b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4e6af3a3c95d4c1689521cc7dae5427c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9bba91958aca44f293ca49c63fbaafef_D20210313-20210313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-13</startDate>
            <endDate>2021-03-13</endDate>
        </period>
    </context>
    <context id="i37ff3780af8f4a3e8fb8ad3d11da24c2_D20210313-20210313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gild:MerckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-13</startDate>
            <endDate>2021-03-13</endDate>
        </period>
    </context>
    <context id="i2bb0786a7089452eab44f7d3f2844758_D20210313-20210313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OralFormulationProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-13</startDate>
            <endDate>2021-03-13</endDate>
        </period>
    </context>
    <context id="i32ac5282522a4590be96101bc1e207b1_D20210313-20210313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:InjectableFormulationProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-13</startDate>
            <endDate>2021-03-13</endDate>
        </period>
    </context>
    <context id="id660245607b543dea4f85f3873880146_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibdce32802a20413da082d4b864fd5089_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i410db304976646ba98567afb20cfa4a0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2a3b8026d52f4290b417e3f5e019a0ff_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8e3646c5f44b457faaf84b163f791ffc_D20200527-20200527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-27</startDate>
            <endDate>2020-05-27</endDate>
        </period>
    </context>
    <context id="i9a6c487393e2416988fed705f84d74ee_D20200527-20200527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:CommonStockPurchaseAgreementAndInvestorRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-27</startDate>
            <endDate>2020-05-27</endDate>
        </period>
    </context>
    <context id="if5fa445c6c284cf389eb387244e326c3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie247b2a21d0b41a8936b62106a17ef12_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id981d1fa90ad4e34a3646bf93d286389_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueApril2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iddf64755f5544f55a023159b39cd796c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueApril2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5ef8f9839275426e96e11272486fcf64_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i226f19faf322425f8f45de6324e4ddcc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia0682f9735fe421db3f9c49bed1595fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2e07919b5c964bd1a6f6261698386d5a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A440SeniorUnsecuredNotesDueDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie96a1150c9f54ebbb4aeeeac86d5d0b4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A440SeniorUnsecuredNotesDueDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4560703e7e434329b08f919b7ec93556_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A195SeniorUnsecuredNotesDueMarch2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2d7b8c0c53ce4856b17e0c17548ab01b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A195SeniorUnsecuredNotesDueMarch2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i42ab2dc4d1f3427799326322503aeb9f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A325SeniorUnsecuredNotesDueSeptember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8e00b7d5eead42bcba3eb2cf1ac7ef4e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A325SeniorUnsecuredNotesDueSeptember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i31c5d5f5c24240f88a2fbf3010130c04_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A250SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3a5500ac6a4a40b4a0ce85e93cb1be81_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A250SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i84c7098c5f6942d6aafc60e537b25ace_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8d84c0793a654adc835292e4057e62af_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icc91e8dffffa4c25b54f3376c5704709_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b064cf950804b14bb98c71681dbbe38_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie1cfc9d0baa34e13b8b793bd53072677_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5caff279b30742e699b0222a2e09750d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:VariableTermLoanNoteDueOctober2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9f01ef44785a49f0bc8f3ed2a594041b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:VariableTermLoanNoteDueOctober2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i82712a6fb96b40d1ba7af885131644a8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A370SeniorUnsecuredNotesDueApril2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i02153ca61e2240f8a5f4caff17673c80_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A370SeniorUnsecuredNotesDueApril2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifd2dbc82577249dda35b4d5bf8355af9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A350SeniorUnsecuredNotesDueFebruary2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie93b3397067946b99b504b92e01bc73e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A350SeniorUnsecuredNotesDueFebruary2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie111efaeb3a5493fb1836bdd7dd01efa_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A365SeniorUnsecuredNotesDueMarch2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i37798ead586444438d3256c1b09bc74c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A365SeniorUnsecuredNotesDueMarch2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ab5e1d8ed5a4d4ebb33b172197fddbc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A295SeniorUnsecuredNotesDueMarch2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1cc4906eaff642878b6f94791e6e1015_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A295SeniorUnsecuredNotesDueMarch2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i41f044c9e0ca469e8e21f44e347cf6f3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia277d47a2bbd47a4bda96e51633f0028_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i06b11f61f1c147e092d508e568092b9d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0607a5570b824496986ded1619166b26_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1bb341107e2a4b88b6060a86a8e386e2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A460SeniorUnsecuredNotesDueSeptember2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i649ba66e7c7f4344a91edbb3d0ed8c94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A460SeniorUnsecuredNotesDueSeptember2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i461c85d95d204d8b9943c1284aed4e98_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A400SeniorUnsecuredNotesDueSeptember2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic58ce72e2e4849669af1178aea5ff019_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A400SeniorUnsecuredNotesDueSeptember2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iefd9e7139a3441e891c9c8d8134e4c6d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8c5e44c87f514190914febaeb7ea34b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6bb3588ac15b409787bad99b65f13969_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A565SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id64726640cdc49ae9944b3cafdf07c69_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A565SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7030cc99c6824dc0a8042a4bed018068_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A480SeniorUnsecuredNotesDueApril2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if5dfe2f629c047abb4f613b421c5ea88_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A480SeniorUnsecuredNotesDueApril2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idaf8c9742e0b4ece8d7b8394db2ca224_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueFebruary2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0aa69e4a48d34c5da5aab157a2293340_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueFebruary2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i65459f3f8cdf4c0fbca4efc6938b38e0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A475SeniorUnsecuredNotesDueMarch2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7771d37672d44616baa7902fe05821c9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A475SeniorUnsecuredNotesDueMarch2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e2b6e7d9810413789463933aef23466_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A415SeniorUnsecuredNotesDueMarch2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iae31ed5d6fdc4498b6a90dbfc8b86b3a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A415SeniorUnsecuredNotesDueMarch2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia4e384c2073a40b39d85efcab4bf3ee9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i81921ac030614d4f83c0267cd19a94f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id10bca8646004217ad83ef4814b3a4a9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie72718e6c6b44809858a4b6a4ec81ed3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3dbd1bb43e241408c3dee0863ca9f87_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id9b223edf7794782b8bfe9faef909258_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i608d56f7947f4ed8a1369997dcdee599_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNoteIssuedNovember2014Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i5e2e8987386644709b5eece8fb454a57_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i970db95a26094960bfc48e49693d580f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i16cafbaeadde42a9815b149e242ae829_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7c3a790a1deb4b198ed2f54a96f31ccb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id6d3b14fdf7c4b5eb29edbe4dd41290f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id74ea6000e4640078ac1bb187f3e6b5c_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibff1240b05f74e8bbf297b65247ec996_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i2516fe8e62b244c1b6bc3ae3b23fb48c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i43d6693463d944d28b68b70f837d5ae1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7bf3308623744494a7125eb9515bdd4a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i190cbe2a2a9c446497a9e647b03a5b69_D20180207-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ViiVHealthcareCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-07</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibee266afb5b04b4db218d2019292d0cd_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:PreExposureProphylaxisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i9e2d7de5386e4c88ab9f4aaa94c77fe9_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib51fb29ce69647fcba6f2f052669fbed_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5ae8970b904f49c99fc9ef1c33c59098_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i0d4fda0dfd5c44b09d04f6e618870a0a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id9fd61e590a14210ba14b89a9af49a7a_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i6905d9942f5a4f50abf9170409131c14_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i39c4711339df49138fdbd03e8ed2571a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6e3291601bc74013bce40b293768f095_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:QuiTamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="ic57a1e59e1024277b33535c08ac1107b_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:QuiTamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i891c637afe3247688741c781d552db7a_I20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2016StockRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="i4e485618ab80414bb2d0af91dc1e3dde_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2020StockRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i90c7f28364e54993b67eae1023b738de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i157cdc9a965446c9969cd003d367f516_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i252e49a6c063428f959d1aefb1686cb7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i950fa40a56274ea0bb64105a4547be31_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i777694101d38407bb54ae3e8cd5cee81_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id773468e90654dd8b93c841e0cb1a4f1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i74a3340bf967422db6145ae553899ded_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i841123aefd8d43d8a410b8754e996cf9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic5050a35f97640609878001cc93224f3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3d8ba4328011413291632383906e71c4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i70187083484a4893bef3cc4b8f7bb49f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i01bc5741de984cbc967d805c30a354d1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic65478d3665c420fb62c02fb229595b5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib8ecd1344d59495b906912f07829d102_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iea5ded2b35d44d24932e27a42a2fd41d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i55db8ffa0e8944bfb28e03d449bbd545_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie621feabbb3c4e7e89573dd30bc4a6a9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i1502d914c22f4785a00d85c5a6112310_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i00cafa1b2c044278a85e4d45db30d3b1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gild:EquitySecuritiesDonationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gild:GileadFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>gild:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="position">
        <measure>gild:position</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="agreement">
        <measure>gild:agreement</measure>
    </unit>
    <unit id="patent">
        <measure>gild:patent</measure>
    </unit>
    <unit id="opposingparty">
        <measure>gild:opposingParty</measure>
    </unit>
    <unit id="party">
        <measure>gild:party</measure>
    </unit>
    <unit id="lawsuit">
        <measure>gild:lawsuit</measure>
    </unit>
    <unit id="plaintiff">
        <measure>gild:plaintiff</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180L2ZyYWc6YWMwZWVmMDk0N2U0NDE0NWEzYjkyNTc4NWE5NjgwMDAvdGFibGU6ZjQ3YzM2MjUyYzZkNDAwYzg3MmJlZDViMjEyMDBlYzkvdGFibGVyYW5nZTpmNDdjMzYyNTJjNmQ0MDBjODcyYmVkNWIyMTIwMGVjOV80LTEtMS0xLTA_fc272212-66ff-4d92-b214-19df2a24189e">0000882095</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180L2ZyYWc6YWMwZWVmMDk0N2U0NDE0NWEzYjkyNTc4NWE5NjgwMDAvdGFibGU6ZjQ3YzM2MjUyYzZkNDAwYzg3MmJlZDViMjEyMDBlYzkvdGFibGVyYW5nZTpmNDdjMzYyNTJjNmQ0MDBjODcyYmVkNWIyMTIwMGVjOV81LTEtMS0xLTA_fde70f86-f517-4697-9a8a-5b723368a602">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180L2ZyYWc6YWMwZWVmMDk0N2U0NDE0NWEzYjkyNTc4NWE5NjgwMDAvdGFibGU6ZjQ3YzM2MjUyYzZkNDAwYzg3MmJlZDViMjEyMDBlYzkvdGFibGVyYW5nZTpmNDdjMzYyNTJjNmQ0MDBjODcyYmVkNWIyMTIwMGVjOV85LTEtMS0xLTA_af1809d0-f2be-4f87-9f86-a8f8ea3ba598">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180L2ZyYWc6YWMwZWVmMDk0N2U0NDE0NWEzYjkyNTc4NWE5NjgwMDAvdGFibGU6ZjQ3YzM2MjUyYzZkNDAwYzg3MmJlZDViMjEyMDBlYzkvdGFibGVyYW5nZTpmNDdjMzYyNTJjNmQ0MDBjODcyYmVkNWIyMTIwMGVjOV8xMC0xLTEtMS0w_169a8f30-a9e0-4259-9cf3-6d54c74801a2">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180L2ZyYWc6YWMwZWVmMDk0N2U0NDE0NWEzYjkyNTc4NWE5NjgwMDAvdGFibGU6ZjQ3YzM2MjUyYzZkNDAwYzg3MmJlZDViMjEyMDBlYzkvdGFibGVyYW5nZTpmNDdjMzYyNTJjNmQ0MDBjODcyYmVkNWIyMTIwMGVjOV8xMy0xLTEtMS0w_d3354405-e710-45b1-ae0e-30990961483c">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN184OQ_71f71220-e2fa-4221-b331-73ae96c371b8">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGFibGU6YmQxNTJlM2IwYTllNGM5OTk3OWQ5YmRjZTdmNWExZjMvdGFibGVyYW5nZTpiZDE1MmUzYjBhOWU0Yzk5OTc5ZDliZGNlN2Y1YTFmM18wLTAtMS0xLTA_4c9c53fa-9974-46dc-b7dd-832cacbef8f6">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18xMTA_b812b608-6739-426c-bb31-45b161239c9c">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGFibGU6NWJhNDExYjhjOWI0NGY4Yjg5NDFiZGVhYjllZmEyYTYvdGFibGVyYW5nZTo1YmE0MTFiOGM5YjQ0ZjhiODk0MWJkZWFiOWVmYTJhNl8wLTAtMS0xLTA_2c4a7a4e-e97a-4e42-bd08-28ea303e19a6">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18xOTg_75466917-1bda-484a-a80c-f8eb60af5437">0-19731</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18yMDY_3e2f2de6-9862-4a4b-b0e4-2491214eaea5">GILEAD SCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGFibGU6YzdkOGIyZWNkMTc3NGNlMTg0NTMzZGE3MDE5ZWJiN2EvdGFibGVyYW5nZTpjN2Q4YjJlY2QxNzc0Y2UxODQ1MzNkYTcwMTllYmI3YV8wLTAtMS0xLTA_bcc76d95-99d5-46cd-9d23-8067beb01b27">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGFibGU6YzdkOGIyZWNkMTc3NGNlMTg0NTMzZGE3MDE5ZWJiN2EvdGFibGVyYW5nZTpjN2Q4YjJlY2QxNzc0Y2UxODQ1MzNkYTcwMTllYmI3YV8wLTEtMS0xLTA_bacb7874-6c63-4acf-9bad-4dc31bfbb876">94-3047598</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18yNzI_6a7d16f7-d820-4193-af97-0b8c9b1c9a1b">333 Lakeside Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18yNzY_909a5f00-15a2-4581-b945-260896eb7ce8">Foster City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18yODA_0f83cc37-f648-41d7-92da-56f65bd1cd86">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18yODM_5a858634-d2c7-4d5d-ab01-3cab5fc435e7">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18zMzk_28dece6e-31a9-465a-83bf-17ed012eebb6">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18zNDI_a40183d4-b028-4365-9d35-0963b135f19c">574-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGFibGU6YTEwZThlMjA2MTdlNDQyYmE3M2NlOGE3YTIxNzJjMWEvdGFibGVyYW5nZTphMTBlOGUyMDYxN2U0NDJiYTczY2U4YTdhMjE3MmMxYV8xLTAtMS0xLTA_61c7c803-256f-469f-9774-45459d8adb5a">Common Stock, par value, $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGFibGU6YTEwZThlMjA2MTdlNDQyYmE3M2NlOGE3YTIxNzJjMWEvdGFibGVyYW5nZTphMTBlOGUyMDYxN2U0NDJiYTczY2U4YTdhMjE3MmMxYV8xLTItMS0xLTA_45614642-2464-41cf-87ba-47cb011c7d3f">GILD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGFibGU6YTEwZThlMjA2MTdlNDQyYmE3M2NlOGE3YTIxNzJjMWEvdGFibGVyYW5nZTphMTBlOGUyMDYxN2U0NDJiYTczY2U4YTdhMjE3MmMxYV8xLTQtMS0xLTA_55cfb4a9-fd6b-4e94-a20a-5d0c9b2459f3">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN184MTI_b9dfc64e-7477-447c-8f2c-ef7c31ff51be">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18xMTMx_3fe0ee81-8b77-4abb-8cd4-1d8232651394">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18yMTEx_a1f8fb1f-2e4a-4d37-adc0-899e7594fe6f">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18yMTEy_69565f5c-2c29-4d36-9f7e-165f49027740">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18yMTEz_48b68f94-436a-48a9-b676-5519a14f4b33">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18yMTE0_985a2533-6e13-49b4-841c-9d4c0fb15d20">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i59d6a509af4b42e1a99d44dee3d8c20f_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xL2ZyYWc6MzExZTU0OGFlMjAwNGY2Y2ExODlhM2MxOTM5ZjUwMTcvdGV4dHJlZ2lvbjozMTFlNTQ4YWUyMDA0ZjZjYTE4OWEzYzE5MzlmNTAxN18yMTA3_9b29c6c3-867c-4f2b-bd58-bd83130fa405"
      unitRef="shares">1254178166</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMy0xLTEtMS0w_93f621d5-46cb-4dfb-9528-a48f77c0e940"
      unitRef="usd">4065000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMy0zLTEtMS0w_2fda4ce9-855a-4ef9-b140-5754f63f0d26"
      unitRef="usd">5997000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfNC0xLTEtMS0w_58c05262-2b89-459f-a39f-3a9f5d3e7364"
      unitRef="usd">1601000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfNC0zLTEtMS0w_b7672691-cce9-4bcb-beb4-74f1f8cc5010"
      unitRef="usd">1411000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfNS0xLTEtMS0w_c64279e7-ef97-4963-b0c0-339894c1e002"
      unitRef="usd">3925000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfNS0zLTEtMS0w_c73634a6-1916-464f-bee9-b381dcfde58e"
      unitRef="usd">4892000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfNi0xLTEtMS0w_940694de-679f-4703-95d0-1092df9b1e85"
      unitRef="usd">1779000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfNi0zLTEtMS0w_3eab0329-3699-4a63-a92c-16535f3de705"
      unitRef="usd">1683000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfNy0xLTEtMS0w_3b2651d1-027e-4e6c-9f6f-1711dd0b6fda"
      unitRef="usd">1908000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfNy0zLTEtMS0w_7bee398a-7ee2-43f5-a714-9b04754dfe3d"
      unitRef="usd">2013000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfOC0xLTEtMS0w_be93d1a9-4a43-47f6-be15-37eaf84a636e"
      unitRef="usd">13278000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfOC0zLTEtMS0w_0314f905-b3d6-43e5-8319-0803414d1844"
      unitRef="usd">15996000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfOS0xLTEtMS0w_b73408af-7b51-442d-ab19-e99a5c1be1fe"
      unitRef="usd">4990000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfOS0zLTEtMS0w_5581dbb5-6e66-4aab-a199-941e9d4e6b4f"
      unitRef="usd">4967000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTAtMS0xLTEtMA_94a94646-b527-45b8-9ce8-d91abb4d95cb"
      unitRef="usd">579000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTAtMy0xLTEtMA_347a9d2f-1e24-46a9-a208-4b7e78d9a441"
      unitRef="usd">502000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTEtMS0xLTEtMA_d21d0e2a-9653-4b3d-a2b8-597c9787bae5"
      unitRef="usd">34781000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTEtMy0xLTEtMA_f39f9692-e555-49fa-ad29-178caf3cfd95"
      unitRef="usd">33126000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTItMS0xLTEtMA_b30e43ee-acfe-473a-8bf0-bf3c77cd59ee"
      unitRef="usd">8334000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTItMy0xLTEtMA_829e67b5-ab5b-40eb-acba-5ea8066016fa"
      unitRef="usd">8108000000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTMtMS0xLTEtMA_aee62e7c-c3e8-4303-a1dd-2592662fc257"
      unitRef="usd">5530000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTMtMy0xLTEtMA_b7934ada-080e-4125-9093-a63fbd5fd01d"
      unitRef="usd">5708000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTQtMS0xLTEtMA_9cf33a0f-4387-4224-a568-8ff3ee7d1e83"
      unitRef="usd">67492000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTQtMy0xLTEtMA_680c05ae-6627-440c-901d-083c19483599"
      unitRef="usd">68407000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTctMS0xLTEtMA_c47e2410-2d86-43ec-8918-4d4fb3eae377"
      unitRef="usd">570000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTctMy0xLTEtMA_c51eb5b7-fb4f-4b1b-b68d-795a20fe08f1"
      unitRef="usd">844000000</us-gaap:AccountsPayableCurrent>
    <gild:AccruedGovernmentAndOtherRebates
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTgtMS0xLTEtMA_20ce39c1-6b8b-48e9-a40d-3ff56c39cfd9"
      unitRef="usd">3369000000</gild:AccruedGovernmentAndOtherRebates>
    <gild:AccruedGovernmentAndOtherRebates
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTgtMy0xLTEtMA_30498650-4bb6-4407-80e0-b3d74b3b773e"
      unitRef="usd">3460000000</gild:AccruedGovernmentAndOtherRebates>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTktMS0xLTEtMA_f026ace8-65ef-4c2a-bccc-d54be97758eb"
      unitRef="usd">3507000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMTktMy0xLTEtMA_0fb0e78b-4222-47ae-963f-b18e519b5fd2"
      unitRef="usd">4336000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtCurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjAtMS0xLTEtMA_5850bb1a-6dcb-4548-a40f-8202855222c1"
      unitRef="usd">2259000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjAtMy0xLTEtMA_99026f24-82ab-4bd8-b2fd-ea021a121092"
      unitRef="usd">2757000000</us-gaap:DebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjEtMS0xLTEtMA_8ab86197-9a98-4a48-8944-dba652ed39e2"
      unitRef="usd">9705000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjEtMy0xLTEtMA_8733d043-44b5-4ac8-9395-3fbafe02eebb"
      unitRef="usd">11397000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjItMS0xLTEtMA_82ccac92-2b2f-4c2c-9900-2884e2779db1"
      unitRef="usd">27907000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjItMy0xLTEtMA_13aa4064-2979-49ee-9575-c19ebe4b9a66"
      unitRef="usd">28645000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjMtMS0xLTEtMA_d94412ac-5e98-4073-8ef3-fd9c3f016439"
      unitRef="usd">5022000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjMtMy0xLTEtMA_da4434ba-c206-4a98-a9e4-50980ee4adcd"
      unitRef="usd">5016000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjQtMi0xLTEtNjIzNw_567728a1-4d46-4b3f-a7c9-24c06bdf02a2"
      unitRef="usd">4464000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjQtNC0xLTEtNjIzNw_62154c10-bf7d-4300-a71d-fe3b0fa80ac4"
      unitRef="usd">3914000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjQtMS0xLTEtMA_4a7f746c-a174-4778-aee6-f8dcc4751acf"
      unitRef="usd">1430000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjQtMy0xLTEtMA_7ada551c-26cd-4802-bd2a-7c5f347f98ff"
      unitRef="usd">1214000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjUtMS0xLTEtMA_e9e3993d-d0eb-4ffa-adc0-f294e345563f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjUtMy0xLTEtMA_1b1d72f5-d8c3-44fc-a2ae-c1736f2f6883"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjZjOTYxMjJhZjA4MTQxZDE5N2NiODU3ZTQzMWZlZGI4XzMx_72bce3da-4feb-4db0-b4f5-6131bcc2eb7c"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjZjOTYxMjJhZjA4MTQxZDE5N2NiODU3ZTQzMWZlZGI4XzMx_d3b10a9f-6fdf-45dd-a6d4-a941421f84fa"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjZjOTYxMjJhZjA4MTQxZDE5N2NiODU3ZTQzMWZlZGI4XzQ1_632b6792-6e74-41b4-901f-981e2e32739d"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjZjOTYxMjJhZjA4MTQxZDE5N2NiODU3ZTQzMWZlZGI4XzQ1_d5ac34ca-da14-4630-bf39-ee97ac0eb212"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjZjOTYxMjJhZjA4MTQxZDE5N2NiODU3ZTQzMWZlZGI4XzY3_0a831285-ff0f-4d1e-997b-3af30a9685c7"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjZjOTYxMjJhZjA4MTQxZDE5N2NiODU3ZTQzMWZlZGI4XzY3_7d797de1-fc21-483f-9870-11606a2e3b71"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjctMS0xLTEtMA_0a96520a-3254-4894-917c-b62afb7230c8"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjctMy0xLTEtMA_d8060898-f774-499b-9c4d-bc2b4c791f73"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjZlMWUzMDRlYzAzNTQzY2JhMDJiZTJjMmFhODM0MmJiXzI4_0b67891e-94f4-4f96-b739-7b02459b5954"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjZlMWUzMDRlYzAzNTQzY2JhMDJiZTJjMmFhODM0MmJiXzI4_19941b0c-5736-4310-a3a9-101badfefee6"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjZlMWUzMDRlYzAzNTQzY2JhMDJiZTJjMmFhODM0MmJiXzQy_49f702ac-7390-4f18-822c-65b29e4c99d0"
      unitRef="shares">5600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjZlMWUzMDRlYzAzNTQzY2JhMDJiZTJjMmFhODM0MmJiXzQy_86e2dfa8-bb83-48f9-95ce-11dc2fda9981"
      unitRef="shares">5600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjZlMWUzMDRlYzAzNTQzY2JhMDJiZTJjMmFhODM0MmJiXzY0_2cfdeea7-2663-44f8-a71f-40a1b268af6f"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjZlMWUzMDRlYzAzNTQzY2JhMDJiZTJjMmFhODM0MmJiXzY0_3d4155aa-1318-4d06-bbd3-4eb6af547bec"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjZlMWUzMDRlYzAzNTQzY2JhMDJiZTJjMmFhODM0MmJiXzY0_9a992112-7685-47e7-8345-f5ddc7b07b3f"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjZlMWUzMDRlYzAzNTQzY2JhMDJiZTJjMmFhODM0MmJiXzY0_d858bc28-e730-4af0-a940-eb2725709416"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjgtMS0xLTEtMA_faddfc89-4495-4bd1-9abc-3c6573803c2d"
      unitRef="usd">1000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjgtMy0xLTEtMA_3eb66a81-e838-4b02-890b-185dfe36e454"
      unitRef="usd">1000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjktMS0xLTEtMA_2e74b642-2882-44b2-9d78-58b59334ed55"
      unitRef="usd">4092000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMjktMy0xLTEtMA_4b3a1dab-a15a-4ddd-882f-7eb402cd07d3"
      unitRef="usd">3880000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzAtMS0xLTEtMA_e2ec33ea-72f7-4d7a-bd98-b8cff4fa22bd"
      unitRef="usd">38000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzAtMy0xLTEtMA_cba489cd-af93-4c9e-bd0c-397e667a8b00"
      unitRef="usd">-60000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzEtMS0xLTEtMA_d0e074f6-2110-4599-8d65-1618bc4259a5"
      unitRef="usd">14821000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzEtMy0xLTEtMA_cea355e0-67ab-4345-a045-7ba1db918534"
      unitRef="usd">14381000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzItMS0xLTEtMA_58a092df-d91d-47b2-9cf3-8ba2543ef339"
      unitRef="usd">18952000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzItMy0xLTEtMA_b3ddf38b-8097-4c2c-a6a6-e3571aa9f299"
      unitRef="usd">18202000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzMtMS0xLTEtMA_9b17c40b-7269-41ef-890a-a57607a97721"
      unitRef="usd">12000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzMtMy0xLTEtMA_17b618ee-eaad-4292-9e51-b532c8dfa6db"
      unitRef="usd">19000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzQtMS0xLTEtMA_19e703d1-6b59-4b40-aefd-6b57df527e33"
      unitRef="usd">18964000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzQtMy0xLTEtMA_93358cef-37b2-4746-bbce-f5456767521d"
      unitRef="usd">18221000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzUtMS0xLTEtMA_19937401-c7af-405e-a80d-96aae80189e8"
      unitRef="usd">67492000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xNi9mcmFnOjc5NGVhZTIwN2RlODRiYzc5YTMxNDA1NjY3ZTcwMmU4L3RhYmxlOmQ5NWVkNmQwMzM0NTRkYjVhMjkxYjE1ODFhNDZjNDIwL3RhYmxlcmFuZ2U6ZDk1ZWQ2ZDAzMzQ1NGRiNWEyOTFiMTU4MWE0NmM0MjBfMzUtMy0xLTEtMA_1f7bd31c-27e3-4c99-9431-2780c5788bd2"
      unitRef="usd">68407000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i869fada8dc15440fb186758025e4ea38_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfNC0yLTEtMS0w_1539724c-3a59-4ecb-bcd1-55d8be7cd3fa"
      unitRef="usd">6340000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i888db709f4bb4306aecd55be57d43e9e_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfNC00LTEtMS0w_2cb93b0f-f3bd-41c1-abe4-589694d872e1"
      unitRef="usd">5467000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d0a665778d14bbb912aa93b2b6e4f2e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfNS0yLTEtMS0w_9e2e8261-09e4-4748-bb4b-402f5d75fe51"
      unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e94052ecbb3480d9dda10de813ecacb_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfNS00LTEtMS0w_85212ebf-ebfe-4fbf-8fa5-cf196f15aeb2"
      unitRef="usd">81000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfNi0yLTEtMS0w_aaa9c345-ce60-41c2-bd26-587c8d5ff9f4"
      unitRef="usd">6423000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfNi00LTEtMS0w_09a7911a-5a61-4d4f-958a-315e6e926a5b"
      unitRef="usd">5548000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfOC0yLTEtMS0w_46d27953-a66f-4796-9f01-d0785bf74ce9"
      unitRef="usd">1361000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfOC00LTEtMS0w_e2fdf623-6af0-4acb-bfd1-8e5919bd606e"
      unitRef="usd">969000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfOS0yLTEtMS0w_b796dfb9-5e54-4ba2-8b9d-b44e6f27166d"
      unitRef="usd">1055000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfOS00LTEtMS0w_e61039ac-526d-4d9b-99ae-b53621856276"
      unitRef="usd">1004000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTAtMi0xLTEtMA_23b463bf-f810-40d2-973a-ebbf560f6ffc"
      unitRef="usd">62000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTAtNC0xLTEtMA_2f87f07b-9fb1-4428-957a-69bb03908945"
      unitRef="usd">97000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTEtMi0xLTEtMA_af777257-8432-4a90-b610-c13895f6ff9f"
      unitRef="usd">1055000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTEtNC0xLTEtMA_ed18d869-3692-498c-9d73-8c9246316ac1"
      unitRef="usd">1076000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTItMi0xLTEtMA_065e2137-1938-4c32-aebb-3c09578f5431"
      unitRef="usd">3533000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTItNC0xLTEtMA_a0b5c44c-359c-4c4c-be27-0a11ba044f4c"
      unitRef="usd">3146000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTMtMi0xLTEtMA_87ee0016-6dcb-4cd3-b449-8c395007916e"
      unitRef="usd">2890000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTMtNC0xLTEtMA_809ac0e2-1c99-430d-81d9-5a4fac403618"
      unitRef="usd">2402000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTQtMi0xLTEtMA_e5509fdd-f6df-4b58-843b-2ce9cf51802b"
      unitRef="usd">257000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTQtNC0xLTEtMA_cecdf21e-c6cc-455e-9232-12be392c5b6c"
      unitRef="usd">241000000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTUtMi0xLTEtMA_7409c852-f4e1-4fe1-b92c-24d425957988"
      unitRef="usd">-369000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTUtNC0xLTEtMA_bd1df6df-0913-4ec9-9ee3-215f221039d2"
      unitRef="usd">-158000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTYtMi0xLTEtMA_b942bcab-1ff0-4474-bbaa-52cc5468f9f6"
      unitRef="usd">2264000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTYtMi0xLTEtMA_c9777f9a-f878-420b-820f-b321e78079a1"
      unitRef="usd">2264000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTYtNC0xLTEtMA_184ab219-dfdf-4bcb-b1d2-5efa84b0a24a"
      unitRef="usd">2003000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTYtNC0xLTEtMA_7ba11f38-6c28-492a-a952-d1d7f3eb11ea"
      unitRef="usd">2003000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTctMi0xLTEtMA_d1b97bb7-88cd-4b11-bb64-5011cf02b82f"
      unitRef="usd">542000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTctNC0xLTEtMA_d1e7da64-5ce4-429a-9276-e3d404fd2381"
      unitRef="usd">465000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTgtMi0xLTEtMA_3749c92d-1abd-4115-ac57-17bfa85c550a"
      unitRef="usd">1722000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTgtNC0xLTEtMA_70cdd4af-de07-4c94-9132-4b6c472492eb"
      unitRef="usd">1538000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTktMi0xLTEtMA_076d6056-c32f-418d-8786-72fafb71fecc"
      unitRef="usd">-7000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMTktNC0xLTEtMA_1c70eb5e-187b-4961-bbc2-5c123bba777d"
      unitRef="usd">-13000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMjAtMi0xLTEtMA_10e882bf-6385-4a73-aced-c87aceefdcfb"
      unitRef="usd">1729000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMjAtNC0xLTEtMA_60eb6653-2a1e-42fa-b3bc-f864e3b37e78"
      unitRef="usd">1551000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMjEtMi0xLTEtMA_a2654a7b-059e-4993-ba09-4dc3d7951ea9"
      unitRef="usdPerShare">1.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMjEtNC0xLTEtMA_c29ef92a-ce5a-4d1f-9c12-9d87de5d715d"
      unitRef="usdPerShare">1.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMjItMi0xLTEtMA_a1ca49a0-6d74-4275-81cb-d05d9896884f"
      unitRef="shares">1256000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMjItNC0xLTEtMA_2ba753a6-cef7-4ba4-8f1a-373404742060"
      unitRef="shares">1262000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMjMtMi0xLTEtMA_8a558bff-3436-4104-8b6b-8a473594350b"
      unitRef="usdPerShare">1.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMjMtNC0xLTEtMA_20a09fa0-4927-4bfe-83dc-2d1d0c1d64ed"
      unitRef="usdPerShare">1.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMjQtMi0xLTEtMA_9b19c8e4-7223-45a0-b5d1-9899e0c163da"
      unitRef="shares">1262000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xOS9mcmFnOjlhMmMxNjIxNGM5MDQ5YmZhNGMyYmE1MDc4NmFjNzU0L3RhYmxlOjkwNjIzMzUwZTczYzQ5MGVhYTg1NWZlZDAwNzVmZmM1L3RhYmxlcmFuZ2U6OTA2MjMzNTBlNzNjNDkwZWFhODU1ZmVkMDA3NWZmYzVfMjQtNC0xLTEtMA_37f7c369-dc97-4596-bf78-6f6c4456d108"
      unitRef="shares">1270000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMy0yLTEtMS0w_3749c92d-1abd-4115-ac57-17bfa85c550a"
      unitRef="usd">1722000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMy00LTEtMS0w_70cdd4af-de07-4c94-9132-4b6c472492eb"
      unitRef="usd">1538000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfNS0yLTEtMS0w_9e7dbddb-fa44-44f9-9e52-83191323088c"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfNS00LTEtMS0w_87140515-c651-43e4-9ef6-a76a13777d6e"
      unitRef="usd">-39000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfNy0yLTEtMS0w_93801c46-9704-4ef5-a432-4fdd8d040adf"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfNy00LTEtMS0w_e46b5f19-5820-4208-9441-f50acfaf97c0"
      unitRef="usd">-23000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfOC0yLTEtMS0w_2ef1ac4b-a93e-4e51-ada1-a3ad25ff7dff"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfOC00LTEtMS0w_399f0645-3958-425d-a04c-04feb61bce5c"
      unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfOS0yLTEtMS0w_461b484b-ee9d-4474-9b5f-8d32e474707e"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfOS00LTEtMS0w_c971c920-a66e-43f1-bafa-c1ad8a60e0c6"
      unitRef="usd">-34000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTEtMi0xLTEtMA_02519809-a917-40e0-8298-a509e0fd5675"
      unitRef="usd">68000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTEtNC0xLTEtMA_a2c4d067-f673-47ef-a447-8386df22c770"
      unitRef="usd">57000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTItMi0xLTEtMA_eda07862-e7bb-4f91-9554-bdf80a161937"
      unitRef="usd">-22000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTItNC0xLTEtMA_a5c2b89c-c540-450a-b740-22335a14aaa4"
      unitRef="usd">23000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTMtMi0xLTEtMA_15474330-6aae-4946-ae74-c392370ee1be"
      unitRef="usd">90000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTMtNC0xLTEtMA_6c0d917a-d94d-4af0-b911-e16ccafb6cc4"
      unitRef="usd">34000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTQtMi0xLTEtMA_8defcab8-d7ac-413c-9042-15e4340e0035"
      unitRef="usd">98000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTQtNC0xLTEtMA_8aca2f57-f930-4708-8cf3-06d7f0df09f2"
      unitRef="usd">-39000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTUtMi0xLTEtMA_4858d924-4f9f-4d94-8627-43e3ce331649"
      unitRef="usd">1820000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTUtNC0xLTEtMA_33ffc505-a405-4b55-a320-e8158c34963c"
      unitRef="usd">1499000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTYtMi0xLTEtMA_506b6f31-9481-4d98-9134-4b3e26396bbd"
      unitRef="usd">-7000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTYtNC0xLTEtMA_268d496e-b589-4ab2-ab7d-f3510e2fa989"
      unitRef="usd">-13000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTctMi0xLTEtMA_a7fe52b6-7bcf-4592-910e-5b13088c82d3"
      unitRef="usd">1827000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yMi9mcmFnOjdmNWQyYjFiNWQ5OTRmZDM5YTY0Mjg0MTNhOWRhYjg1L3RhYmxlOmRkM2M0YTdiMWIxZTQ4NjRhOTE4MmIxNDk2NjY1OTgzL3RhYmxlcmFuZ2U6ZGQzYzRhN2IxYjFlNDg2NGE5MTgyYjE0OTY2NjU5ODNfMTctNC0xLTEtMA_327e96f0-e0e8-46b4-89cb-359b57f9361f"
      unitRef="usd">1512000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4491879c7fcd415288701f6b62e40e51_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNC0yLTEtMS0w_d54b098f-3fe4-42b7-a088-67f0968d943a"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4491879c7fcd415288701f6b62e40e51_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNC00LTEtMS0w_6513937e-d526-4d16-ac81-52fd7eb7a354"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i13bf16e2c0cc414ca0e4618b4219c2cb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNC02LTEtMS0w_31244ace-72ea-4cfa-8898-276d5292482f"
      unitRef="usd">3880000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id315795d1e774a6a845a09bd3c23f669_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNC04LTEtMS0w_acd87442-58ae-4953-83ad-8e9c336b06e8"
      unitRef="usd">-60000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i631a0304196e455e9a985f2aed12a21c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNC0xMC0xLTEtMA_9716f21c-27b7-4a91-a81f-ea1ec9236b4e"
      unitRef="usd">14381000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ceb4b2138664055958fd36c771ef719_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNC0xMi0xLTEtMA_fd608a8a-a19d-4481-8ac4-01b8f52c04d3"
      unitRef="usd">19000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNC0xNC0xLTEtMA_c926702a-62cd-4014-8daf-a77a1a81be3a"
      unitRef="usd">18221000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i22e6def1ee614c1f88a734ccf8b57339_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNi0xMC0xLTEtMA_10c21cfa-f294-46cd-8d19-aa7b45a55356"
      unitRef="usd">1729000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i49ed492a453846c298f340cfb12aea93_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNi0xMi0xLTEtMA_9423c53d-2b1f-4878-b048-3501a241b799"
      unitRef="usd">-7000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNi0xNC0xLTEtMA_a8101b3c-20f2-42d9-8ea0-2be0cdca3a52"
      unitRef="usd">1722000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3f56585e4ce041a0a4818371afd20608_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNy04LTEtMS0w_8641458a-7241-4c72-aff6-9cac27fa2215"
      unitRef="usd">98000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfNy0xNC0xLTEtMA_eb77ea4e-b20f-4f49-9576-18df511b0694"
      unitRef="usd">98000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i2e9ec92ee61543dbb61d2f855c0a785c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfOC0yLTEtMS0w_3cc52a0e-5433-43ab-bd31-633a8c4c76b1"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i33e7b278cf744482b55f1a9184b9c0fb_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfOC02LTEtMS0w_fd521fe9-5958-4652-b590-45d48cd65e44"
      unitRef="usd">76000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfOC0xNC0xLTEtMA_8b9dbd74-e0f6-47c0-b93e-9b9a9e9b78dd"
      unitRef="usd">76000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i2e9ec92ee61543dbb61d2f855c0a785c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfOS0yLTEtMS0w_e18bae09-3636-4308-a97c-214eaa6bee05"
      unitRef="shares">5000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i33e7b278cf744482b55f1a9184b9c0fb_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfOS02LTEtMS0w_264034db-2704-4acc-9037-ecae43959613"
      unitRef="usd">12000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfOS0xNC0xLTEtMA_000c74d0-dd02-4a6a-b28d-eb8e5e1a9900"
      unitRef="usd">12000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i33e7b278cf744482b55f1a9184b9c0fb_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTAtNi0xLTEtMA_15184ed4-17e7-40ec-9585-88f565d839fc"
      unitRef="usd">140000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTAtMTQtMS0xLTA_7c41d8cf-2f9f-41bc-9c0a-1519dd343d6d"
      unitRef="usd">140000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i2e9ec92ee61543dbb61d2f855c0a785c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTEtMi0xLTEtMA_ce3a90d8-8bfd-4217-b386-7f7490d985bf"
      unitRef="shares">6000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i33e7b278cf744482b55f1a9184b9c0fb_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTEtNi0xLTEtMA_a3e0ebdd-00fb-470e-8f23-d6a9f0662c3e"
      unitRef="usd">16000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i22e6def1ee614c1f88a734ccf8b57339_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTEtMTAtMS0xLTA_19186bde-c7af-46c2-aef6-cbd173248339"
      unitRef="usd">383000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTEtMTQtMS0xLTA_9b291cd2-9e14-4b7d-ad9c-c3a726af4cdb"
      unitRef="usd">399000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTItMC0xLTEtMC90ZXh0cmVnaW9uOjA4YzRmODQ1YThhNTRjMDU4OTUzZWExNmMzNTFhYzI0XzI0_834c6622-8706-4528-9440-091b76b3e92c"
      unitRef="usdPerShare">0.71</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="i22e6def1ee614c1f88a734ccf8b57339_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTItMTAtMS0xLTA_f0aaf4ed-882f-4cfc-a083-3e7874468ad3"
      unitRef="usd">906000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTItMTQtMS0xLTA_6c79d4de-a2fd-41f2-8ada-6f71bb6afcc7"
      unitRef="usd">906000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4cad2b62afdf497cb6d680783df2564b_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTMtMi0xLTEtMA_e16861b0-38e3-4ea1-8364-0fb6f6db0ea2"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4cad2b62afdf497cb6d680783df2564b_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTMtNC0xLTEtMA_21116aee-bf95-45bf-9a3d-0a4f6ca2fff5"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0e12da2f502648b1b1cfe3c2ce745770_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTMtNi0xLTEtMA_c86eeedb-8d7a-49b2-8f15-dbfd3cb06351"
      unitRef="usd">4092000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ideb5f8dc0c4442658f18eab50f25a677_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTMtOC0xLTEtMA_e7fb750f-f102-4cf3-a9a6-37c2d31a5f20"
      unitRef="usd">38000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6aa770dc5dd844ef8a4c9f16bbad3843_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTMtMTAtMS0xLTA_97270ab8-2600-4ca3-8df0-202c6841fc33"
      unitRef="usd">14821000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i59a30e5469c84cd78e03499a820d4cfa_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTMtMTItMS0xLTA_fc37bce0-8b98-4564-9ed3-33f182443737"
      unitRef="usd">12000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjdhNmZmNWFmMDJiZTQ0MWNiMzRkNzRmZGI1NjYxMDEyL3RhYmxlcmFuZ2U6N2E2ZmY1YWYwMmJlNDQxY2IzNGQ3NGZkYjU2NjEwMTJfMTMtMTQtMS0xLTA_b26df7ee-c67a-4341-92bf-0de3870a5232"
      unitRef="usd">18964000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie0e06ce8778849a79902920387c413c1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNC0yLTEtMS0w_bee312ad-e958-432b-aa56-93582b1b0cd6"
      unitRef="shares">1266000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie0e06ce8778849a79902920387c413c1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNC00LTEtMS0w_3cb14b06-6143-4ee2-8f9b-75ac20207809"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic27cb3c440c3422fbad61655cb15c60c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNC02LTEtMS0w_6a45caf5-7f54-48ff-870f-ab82bf4e1625"
      unitRef="usd">3051000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6c7b9ebee1f549d198ceb53ea6813141_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNC04LTEtMS0w_f317667f-f407-44ab-98ec-81f1e1503a7e"
      unitRef="usd">85000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i58c9bc44b74c412ea8a63c832add3283_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNC0xMC0xLTEtMA_6afa2aa9-76e9-4583-8c66-e08d0dda05f0"
      unitRef="usd">19388000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0484fdf9aa034ecd94e3797e7f978bdf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNC0xMi0xLTEtMA_276dce5e-a505-4080-a602-893a5d509b0b"
      unitRef="usd">125000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9a8779a54fef4be683c8d4f7e5b601ac_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNC0xNC0xLTEtMA_0d403869-083d-478e-92c5-2df8becac96b"
      unitRef="usd">22650000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i17fa9a1c26714f1587a2aa325624b533_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNS0xMC0xLTEtNDQ3OA_e4fb8b59-d5f6-45d5-aadb-35bdfb6143c1"
      unitRef="usd">-7000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i48b7a28e035547fa89fcfc8c0593b301_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNS0xNC0xLTEtNDQ3OA_058fc938-715c-4c39-82c1-e3668466653e"
      unitRef="usd">-7000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i2835b80e3c7a4d00b23cdd84912a90e9_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNS0xMC0xLTEtMA_25154e3a-dc1d-4c5b-8958-3b4f99f13d63"
      unitRef="usd">1551000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2f2d827efd2a4f4a91dee3811a501ecc_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNS0xMi0xLTEtMA_dd9fdad7-27b7-4a9d-a17f-0b91bce20c65"
      unitRef="usd">-13000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNS0xNC0xLTEtMA_58448976-8ac0-466f-8eaa-dcf6424407d1"
      unitRef="usd">1538000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4dce18c9540c42d6ae4ba9bd85b66896_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNi04LTEtMS0w_91145e53-eac3-45c0-b765-d16cae0bebd5"
      unitRef="usd">-39000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNi0xNC0xLTEtMA_a55219eb-4f67-4bc7-9670-66942f83f593"
      unitRef="usd">-39000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i6dd270c88164436597aad1b5ed3cb4ef_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNy0yLTEtMS0w_64ac541d-f100-4d1f-afcc-1d6c60ff2a13"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic6ecd38b92444ed38d13e95fbd53341a_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNy02LTEtMS0w_3261fb2b-e0ba-4cab-ad8e-2884dd9ee195"
      unitRef="usd">66000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfNy0xNC0xLTEtMA_b6ee1478-587d-4af5-8fc1-d6d2e99c3df6"
      unitRef="usd">66000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i6dd270c88164436597aad1b5ed3cb4ef_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfOC0yLTEtMS0w_dfddce5e-73f7-4f92-b3a2-a7d2272209a6"
      unitRef="shares">7000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic6ecd38b92444ed38d13e95fbd53341a_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfOC02LTEtMS0w_128f7d7e-914f-4653-b80f-483763e5f021"
      unitRef="usd">111000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfOC0xNC0xLTEtMA_ea8a3d81-984e-44ce-a540-7d50f2b243be"
      unitRef="usd">111000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic6ecd38b92444ed38d13e95fbd53341a_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfOS02LTEtMS0w_3c0392c6-5deb-4eda-976d-cd598ee20dd5"
      unitRef="usd">141000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfOS0xNC0xLTEtMA_420bc3d8-88d9-42be-b29e-664608cb9092"
      unitRef="usd">141000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i6dd270c88164436597aad1b5ed3cb4ef_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTAtMi0xLTEtMA_d7a9ebe1-9723-4c0c-ae96-6ade94b98c95"
      unitRef="shares">20000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ic6ecd38b92444ed38d13e95fbd53341a_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTAtNi0xLTEtMA_2507c1a3-6b68-4039-a7f3-aba3811a08e7"
      unitRef="usd">58000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i2835b80e3c7a4d00b23cdd84912a90e9_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTAtMTAtMS0xLTA_08d9ba21-a5d8-42a3-be0d-cd6a5e8eb06b"
      unitRef="usd">1356000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTAtMTQtMS0xLTA_27e0ded9-e495-45db-b43a-930ca0c55ac5"
      unitRef="usd">1414000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOmZjMDcxZGM2ZjExNTQwM2Q5YzViODJmNDQzM2JjZmUzXzI0_eb074dde-ed6d-48ee-b620-f47ab16c68b4"
      unitRef="usdPerShare">0.68</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="i2835b80e3c7a4d00b23cdd84912a90e9_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTEtMTAtMS0xLTA_8abc657a-1b66-4cc1-92b7-88c5a484deb2"
      unitRef="usd">867000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTEtMTQtMS0xLTA_94e33e50-d395-4f30-9ea0-7dc6c8a27d84"
      unitRef="usd">867000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7ca6dc703a0d49718435076c33ed0dbc_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTItMi0xLTEtMA_2953896f-f1ac-4c06-8842-66c1f0cb8b5d"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ca6dc703a0d49718435076c33ed0dbc_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTItNC0xLTEtMA_c3e18d44-5f22-4e0a-833d-e2acc1a40429"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i887b76714c9c41c4a6db53d46bc0f6a7_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTItNi0xLTEtMA_bf5bb91f-af09-4f7e-a84d-08d109533e60"
      unitRef="usd">3311000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i51b7741d7f0241a9a5987bf6c4f4f41c_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTItOC0xLTEtMA_d6608818-d4fc-41cd-b7cb-d6f715f15a17"
      unitRef="usd">46000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icaa5a801f01b483992e5c3baa5e7844b_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTItMTAtMS0xLTA_d335e586-b62f-44ae-90ac-2e679133bf33"
      unitRef="usd">18709000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i118f3a03d85d40aba97d7091b6ac999f_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTItMTItMS0xLTA_536b29a9-899a-4b2e-83c5-6d0c5bd4d833"
      unitRef="usd">112000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic3f0f2350f9c47889d2e1afa48054b12_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yNS9mcmFnOjBjM2U1NTVlZDE4ZTRmYWQ4N2RhYzA0NDBlNjBjMGRkL3RhYmxlOjYxYTM0YjAwOGUwZTRhMDY4ZGZmODhmYjJlNWVjMTk5L3RhYmxlcmFuZ2U6NjFhMzRiMDA4ZTBlNGEwNjhkZmY4OGZiMmU1ZWMxOTlfMTItMTQtMS0xLTA_13b44247-b56f-415b-a1a5-063b720433cd"
      unitRef="usd">22179000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfNC0yLTEtMS0w_e439bcd0-e2a7-49fe-92d2-142d9a472e79"
      unitRef="usd">1722000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfNC00LTEtMS0w_fb9fffe0-0dbb-4db8-8090-51f7ecfe97bc"
      unitRef="usd">1538000000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfNi0yLTEtMS0w_5b9d0eaa-94f3-4892-a090-e189d64a8a45"
      unitRef="usd">78000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfNi00LTEtMS0w_241cef25-d688-4516-ba37-4bdca23ec0aa"
      unitRef="usd">68000000</us-gaap:Depreciation>
    <us-gaap:AdjustmentForAmortization
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfNy0yLTEtMS0w_3050d4cc-8fe1-4372-b7d1-cb102ab5db9a"
      unitRef="usd">395000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfNy00LTEtMS0w_49870a82-89ed-4cb8-b686-ca8a774fe435"
      unitRef="usd">281000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfOC0yLTEtMS0w_11fac12b-4f99-4e99-8f1b-7c31f1f8c3d3"
      unitRef="usd">139000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfOC00LTEtMS0w_f3ec40cc-6ad2-4ebf-a17d-142c18f9732e"
      unitRef="usd">141000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfOS0yLTEtMS0w_3079cf48-06d8-4273-826b-4fc8c50a0425"
      unitRef="usd">62000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfOS00LTEtMS0w_87939393-3b81-4117-8b34-d287535aa83b"
      unitRef="usd">97000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTAtMi0xLTEtMA_d4b96577-20b0-481d-b105-539e6997c270"
      unitRef="usd">71000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTAtNC0xLTEtMA_b9de2a78-ee50-4577-935f-96af88cd39a9"
      unitRef="usd">56000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTEtMi0xLTEtMA_a281a611-e46e-46fe-84b8-4684db6ec90c"
      unitRef="usd">-351000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTEtNC0xLTEtMA_07082604-9388-43b2-8132-8f03400a8da6"
      unitRef="usd">-283000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTItMi0xLTEtMA_3b7bcb56-4a26-4746-802d-e9e6dc8842ed"
      unitRef="usd">-201000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTItNC0xLTEtMA_481ba22b-7777-44ef-ba6d-c5bbdb385ca4"
      unitRef="usd">-73000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTQtMi0xLTEtMA_567d4669-0eb9-47b3-8ffb-ae1210bc23e9"
      unitRef="usd">-975000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTQtNC0xLTEtMA_b86b984d-1b3b-4eac-a2b2-8701928fa902"
      unitRef="usd">376000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTUtMi0xLTEtMA_b1e51967-ebab-4ce6-ad15-26875637072e"
      unitRef="usd">69000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTUtNC0xLTEtMA_6d0ef71a-20de-4800-bf75-0a7c5de99848"
      unitRef="usd">-15000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTYtMi0xLTEtMA_3dfd0005-c405-4ae0-825d-68561ba38c7e"
      unitRef="usd">8000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTYtNC0xLTEtMA_adcd8474-c8c9-4e52-9f04-547c01931331"
      unitRef="usd">-46000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTctMi0xLTEtMA_6e9a5e69-eafa-44a1-8e3e-3ea6b0b4a153"
      unitRef="usd">-253000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTctNC0xLTEtMA_a5f4f2c2-2a5c-46fb-a05c-15510bb81446"
      unitRef="usd">-109000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTgtMi0xLTEtMA_c90c9431-0567-43f8-84ff-e672927e55b3"
      unitRef="usd">-316000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTgtNC0xLTEtMA_86a32a02-6685-4556-8643-e9386b7e9f4f"
      unitRef="usd">-127000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTktMi0xLTEtMA_5e238241-718b-4abb-8ce6-6f6824225430"
      unitRef="usd">-738000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMTktNC0xLTEtMA_a966de69-6199-4509-adc1-06f1a5277ef0"
      unitRef="usd">-550000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjAtMi0xLTEtMA_01d7f5a1-ced5-4e4b-8664-567809af9684"
      unitRef="usd">2610000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjAtNC0xLTEtMA_e1d6b864-5112-4bb5-b0f8-086c249f77e2"
      unitRef="usd">1436000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjItMi0xLTEtMA_9f56f33e-aba3-4514-a650-6b421c59cfd4"
      unitRef="usd">931000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjItNC0xLTEtMA_59ce7352-89cf-4b43-8a7c-52402f8b5025"
      unitRef="usd">13158000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjMtMi0xLTEtMA_ee411ae8-ee74-469f-b6d1-1df4171ff89b"
      unitRef="usd">60000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjMtNC0xLTEtMA_1933a687-70db-422f-9340-bcdd12c8c82b"
      unitRef="usd">9656000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjQtMi0xLTEtMA_58f31152-34ff-4b43-be47-7051e0505a79"
      unitRef="usd">619000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjQtNC0xLTEtMA_090b2908-1c4d-4560-bf86-8a4a68d1050f"
      unitRef="usd">3449000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjUtMi0xLTEtMA_eb8ea83d-4b43-4b7f-a024-f36231e19703"
      unitRef="usd">1255000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjUtNC0xLTEtMA_3a82f379-6f13-4acf-b917-37daf466732c"
      unitRef="usd">63000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjYtMi0xLTEtMA_39ea4e16-efda-41ea-803b-b41e5d5921ce"
      unitRef="usd">279000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjYtNC0xLTEtMA_15d3610b-e75d-4c95-87fd-a3abd44c9aef"
      unitRef="usd">8000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjctMi0xLTEtMA_36e1907f-8c09-48ef-9b2c-48e6694c3ef1"
      unitRef="usd">165000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjctNC0xLTEtMA_96057e36-c3c2-4f71-8d95-b15ed8af9d20"
      unitRef="usd">171000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjgtMi0xLTEtMA_fc6e8759-3e98-4ee2-a23e-725a37f8173e"
      unitRef="usd">91000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjgtNC0xLTEtMA_8b5884bd-24f3-4c58-ba77-c6624c86e4c2"
      unitRef="usd">49000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjktMi0xLTEtMA_3136de1c-a373-4153-8c70-cd0c2c796993"
      unitRef="usd">-2042000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMjktNC0xLTEtMA_04e8a874-40da-4d20-9b15-4f89e8b29d97"
      unitRef="usd">-344000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzItMi0xLTEtMA_295f5d6b-f979-4585-9b70-7acc2126fd70"
      unitRef="usd">88000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzItNC0xLTEtMA_75eca535-4858-4005-858c-a79bab16a536"
      unitRef="usd">177000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzMtMi0xLTEtMA_27bbf088-53ff-40cd-80fd-b4445ba268b8"
      unitRef="usd">309000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzMtNC0xLTEtMA_ab258b4e-cedb-4bfb-825b-1347c2bf656f"
      unitRef="usd">1328000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfDebt
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzQtMi0xLTEtMA_ec7da4ae-ea43-4af0-a24a-6041427d9494"
      unitRef="usd">1250000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzQtNC0xLTEtMA_ce382f2a-6283-4d56-90ca-cb7899063712"
      unitRef="usd">500000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:PaymentsOfDividends
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzUtMi0xLTEtMA_dc909efd-cf89-439b-9e68-b178b3edf4ec"
      unitRef="usd">917000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzUtNC0xLTEtMA_69840dec-7829-43d9-936e-aed6318e70aa"
      unitRef="usd">874000000</us-gaap:PaymentsOfDividends>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzYtMi0xLTEtMA_d6d6e3ed-24cd-4313-b1f5-f06eda8fbb78"
      unitRef="usd">-89000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzYtNC0xLTEtMA_22cb8f0c-4570-477e-9c8c-93f3cd7e3248"
      unitRef="usd">-86000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzctMi0xLTEtMA_66e62d91-b29e-4982-8f5c-751f7190f319"
      unitRef="usd">-2477000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzctNC0xLTEtMA_c4f9de68-a59b-4703-acec-736ee6aba1cb"
      unitRef="usd">-2611000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzgtMi0xLTEtMA_b1f68aa0-9935-4e59-a616-5dde4e8932a5"
      unitRef="usd">-23000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzgtNC0xLTEtMA_1e99870d-6bbe-4e9b-a911-2688dc7d8158"
      unitRef="usd">-61000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzktMi0xLTEtMA_02e9d9ef-aab0-4e8d-a513-2225ebc8dd37"
      unitRef="usd">-1932000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfMzktNC0xLTEtMA_089c1925-6fec-401b-b528-6c9f5cc762a3"
      unitRef="usd">-1580000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfNDAtMi0xLTEtMA_ee01aefc-2918-4f95-9133-1e83befd7a4f"
      unitRef="usd">5997000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9a8779a54fef4be683c8d4f7e5b601ac_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfNDAtNC0xLTEtMA_86f2975a-cf3f-41fd-b866-f6e201130865"
      unitRef="usd">11631000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfNDEtMi0xLTEtMA_446728af-b053-4721-99d5-914a7cad0c1a"
      unitRef="usd">4065000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic3f0f2350f9c47889d2e1afa48054b12_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18yOC9mcmFnOjA4NGI0MTgxMDBkZjQ1ZjBiNDM0NGI2YmNkNDhhNTJmL3RhYmxlOjYzMTFkMzhjMGQ0MDQyMDJiYmY2MmFhNGIzZTIyYjIxL3RhYmxlcmFuZ2U6NjMxMWQzOGMwZDQwNDIwMmJiZjYyYWE0YjNlMjJiMjFfNDEtNC0xLTEtMA_952ce7af-383b-43e2-8c54-82efb067c553"
      unitRef="usd">10051000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNC9mcmFnOjljYzQ3MTQ1ZmQyMzQzOTA5NzBjNDkzODBiYTFlMjAzL3RleHRyZWdpb246OWNjNDcxNDVmZDIzNDM5MDk3MGM0OTM4MGJhMWUyMDNfNzM1MA_df35cae8-7ded-472b-872c-c8f92de3ad29">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information. The financial statements include all adjustments consisting of normal recurring adjustments that the management of Gilead Sciences, Inc. (&#x201c;Gilead&#x201d;, &#x201c;we&#x201d;, &#x201c;our&#x201d; or &#x201c;us&#x201d;) believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and a variable interest entity (&#x201c;VIE&#x201d;) for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our Condensed Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess whether we are the primary beneficiary of a VIE at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have one operating segment, which focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (&#x201c;CODM&#x201d;), manages and allocates resources to the operations of the company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#x201c;R&amp;amp;D&#x201d;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;amp;D portfolio and external opportunities to best support the long-term growth of our business. See Note 2. Revenues for a summary of disaggregated revenues by product and geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Significant Accounting Policies, Estimates and Judgments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of these Condensed Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the coronavirus disease (&#x201c;COVID-19&#x201d;) could have on our significant accounting estimates. Actual results may differ significantly from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain amounts for the three months ended March 31, 2020 were reclassified to conform to the current period presentation. Beginning in the second quarter of 2020, acquired in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) expenses are reported separately from Research and development expenses on our Condensed Consolidated Statements of Income. Our Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2020, has also been conformed to separately present acquired IPR&amp;amp;D expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States, Europe and Japan. There were no material write-offs charged against the allowance for the three months ended March 31, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the raw materials and components that we utilize in our operations are obtained through single suppliers. Certain of the raw materials that we utilize in our operations are made at only one facility. Since the suppliers of key components and raw materials must be named in a new drug application filed with U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from our suppliers is interrupted for any reason, we may be unable to ship our commercial products or to supply our product candidates for clinical trials.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNC9mcmFnOjljYzQ3MTQ1ZmQyMzQzOTA5NzBjNDkzODBiYTFlMjAzL3RleHRyZWdpb246OWNjNDcxNDVmZDIzNDM5MDk3MGM0OTM4MGJhMWUyMDNfNzMzNQ_23087276-63be-44dd-8e33-889b843fcc8b">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information. The financial statements include all adjustments consisting of normal recurring adjustments that the management of Gilead Sciences, Inc. (&#x201c;Gilead&#x201d;, &#x201c;we&#x201d;, &#x201c;our&#x201d; or &#x201c;us&#x201d;) believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and a variable interest entity (&#x201c;VIE&#x201d;) for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our Condensed Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess whether we are the primary beneficiary of a VIE at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. &lt;/span&gt;&lt;/div&gt;The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNC9mcmFnOjljYzQ3MTQ1ZmQyMzQzOTA5NzBjNDkzODBiYTFlMjAzL3RleHRyZWdpb246OWNjNDcxNDVmZDIzNDM5MDk3MGM0OTM4MGJhMWUyMDNfNzM2Mg_b1b6b8a0-ff10-46a2-8725-6ad2da0180ef">We have one operating segment, which focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (&#x201c;CODM&#x201d;), manages and allocates resources to the operations of the company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#x201c;R&amp;amp;D&#x201d;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;amp;D portfolio and external opportunities to best support the long-term growth of our business.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNC9mcmFnOjljYzQ3MTQ1ZmQyMzQzOTA5NzBjNDkzODBiYTFlMjAzL3RleHRyZWdpb246OWNjNDcxNDVmZDIzNDM5MDk3MGM0OTM4MGJhMWUyMDNfMTgxMw_175aaa0a-3e26-4af8-9b00-df3c8e737a09"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNC9mcmFnOjljYzQ3MTQ1ZmQyMzQzOTA5NzBjNDkzODBiYTFlMjAzL3RleHRyZWdpb246OWNjNDcxNDVmZDIzNDM5MDk3MGM0OTM4MGJhMWUyMDNfNzM3Mw_8a7da416-826c-435f-8bf8-f022da2436b0">The preparation of these Condensed Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the coronavirus disease (&#x201c;COVID-19&#x201d;) could have on our significant accounting estimates. Actual results may differ significantly from these estimates.</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNC9mcmFnOjljYzQ3MTQ1ZmQyMzQzOTA5NzBjNDkzODBiYTFlMjAzL3RleHRyZWdpb246OWNjNDcxNDVmZDIzNDM5MDk3MGM0OTM4MGJhMWUyMDNfNzMzOA_f44b09ab-cf01-47d3-babc-6b86ed1eee4b">Certain amounts for the three months ended March 31, 2020 were reclassified to conform to the current period presentation. Beginning in the second quarter of 2020, acquired in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) expenses are reported separately from Research and development expenses on our Condensed Consolidated Statements of Income. Our Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2020, has also been conformed to separately present acquired IPR&amp;amp;D expenses.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNC9mcmFnOjljYzQ3MTQ1ZmQyMzQzOTA5NzBjNDkzODBiYTFlMjAzL3RleHRyZWdpb246OWNjNDcxNDVmZDIzNDM5MDk3MGM0OTM4MGJhMWUyMDNfNzM4Mw_e0c14bb0-9f1f-42f3-b7e2-da105f7c886a">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States, Europe and Japan. There were no material write-offs charged against the allowance for the three months ended March 31, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the raw materials and components that we utilize in our operations are obtained through single suppliers. Certain of the raw materials that we utilize in our operations are made at only one facility. Since the suppliers of key components and raw materials must be named in a new drug application filed with U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from our suppliers is interrupted for any reason, we may be unable to ship our commercial products or to supply our product candidates for clinical trials.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNC9mcmFnOjljYzQ3MTQ1ZmQyMzQzOTA5NzBjNDkzODBiYTFlMjAzL3RleHRyZWdpb246OWNjNDcxNDVmZDIzNDM5MDk3MGM0OTM4MGJhMWUyMDNfNTc0Ng_73f8a0b9-de5b-4413-806e-17aef02ce2b8"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNC9mcmFnOjljYzQ3MTQ1ZmQyMzQzOTA5NzBjNDkzODBiYTFlMjAzL3RleHRyZWdpb246OWNjNDcxNDVmZDIzNDM5MDk3MGM0OTM4MGJhMWUyMDNfNTc0Ng_d63d930b-2a79-49e7-84da-22b103ad3418"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RleHRyZWdpb246NWJjODQ4YzM4NzdjNGU5N2JjNDYxYWJlYjRhMTdhNDFfMjA3OA_12d6fa51-19dc-4f74-be4c-83052a91dc77">REVENUES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Disaggregation of Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Product Sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Atripla&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Biktarvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Complera/Eviplera&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Descovy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Genvoya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Odefsey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stribild&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Truvada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other HIV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenue share - Symtuza &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Hepatitis C virus (&#x201c;HCV&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ledipasvir/Sofosbuvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sofosbuvir/Velpatasvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other HCV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total HCV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Hepatitis B virus (&#x201c;HBV&#x201d;) / Hepatitis Delta virus (&#x201c;HDV&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vemlidy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Viread&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other HBV/HDV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total HBV/HDV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Veklury&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Cell Therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tecartus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Yescarta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Cell Therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Trodelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;AmBisome&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Letairis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ranexa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Zydelig&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Royalty, contract and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#x201c;C&#x201d;), emtricitabine (&#x201c;FTC&#x201d;) and tenofovir alafenamide (&#x201c;TAF&#x201d;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Cayston and Jyseleca.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenues from Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(as a percentage of total revenues)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenues Recognized from Performance Obligations Satisfied in Prior Periods &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized from performance obligations satisfied in prior years related to royalties for licenses of our intellectual property were $226 million and $188 million for the three months ended March 31, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable consideration is included in the net sales price only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with the variable consideration is subsequently resolved. Estimates are assessed each period and updated to reflect current information. Changes in estimates for variable consideration related to sales made in prior years resulted in a $332 million and $38 million increase in revenues for the three months ended March 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Balances &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $185 million and $198 million as of March&#160;31, 2021 and December&#160;31, 2020, respectively. Contract liabilities, which generally result from receipt of advance payment before our performance under the contract, were $91&#160;million and $97&#160;million as of March&#160;31, 2021 and December&#160;31, 2020, respectively. During the three months ended March 31, 2021 and 2020, revenue recognized that was included in the contract liability balance as of the beginning of the respective years was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RleHRyZWdpb246NWJjODQ4YzM4NzdjNGU5N2JjNDYxYWJlYjRhMTdhNDFfMjA3Mw_dba33174-2e36-4651-a7dd-1ecccbf5f8ef">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Product Sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Atripla&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Biktarvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Complera/Eviplera&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Descovy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Genvoya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Odefsey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stribild&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Truvada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other HIV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenue share - Symtuza &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Hepatitis C virus (&#x201c;HCV&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ledipasvir/Sofosbuvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sofosbuvir/Velpatasvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other HCV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total HCV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Hepatitis B virus (&#x201c;HBV&#x201d;) / Hepatitis Delta virus (&#x201c;HDV&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vemlidy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Viread&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other HBV/HDV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total HBV/HDV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Veklury&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Cell Therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tecartus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Yescarta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Cell Therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Trodelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;AmBisome&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Letairis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ranexa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Zydelig&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Royalty, contract and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#x201c;C&#x201d;), emtricitabine (&#x201c;FTC&#x201d;) and tenofovir alafenamide (&#x201c;TAF&#x201d;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Cayston and Jyseleca.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie434694a2f304ecd94c3775324b4378d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNC0yLTEtMS0yNzcz_4e7eca08-65cc-4677-b069-b9bc256826bb"
      unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied66863fda3841ad881df6b37123aec9_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNC00LTEtMS0yNzcz_36b6b515-90cb-43a4-8897-44f95b1e9797"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibeff20e2f7ee495db92fa4c3484b89a8_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNC02LTEtMS0yNzcz_556f2e28-b11a-4cc7-8886-1e2478e53d33"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0438c7b3d8b44618b0023cd7a41ed6d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNC04LTEtMS0yNzcz_1c39fb80-433a-404d-8ba9-7600bcbf2a97"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5f03dade66d4049ac775a2ff2e95578_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNC0xMC0xLTEtMjc3Mw_ed230a7e-bbe7-452d-b4a6-17148b3a1229"
      unitRef="usd">81000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaffbd58e1c6444dbbb5947207f1292df_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNC0xMi0xLTEtMjc3Mw_553c001d-85bb-4433-ab4a-c246be45bcb1"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1af19a68a52f40feb3f105f7566f6acb_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNC0xNC0xLTEtMjc3Mw_a194d1f0-364a-402e-9ab7-a864b4b873b1"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id77a0ac827ef47e490fe49f7648d3b55_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNC0xNi0xLTEtMjc3Mw_69a32e2f-ab38-465c-87f6-a086053cd1aa"
      unitRef="usd">95000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8bcc8d5fc46645f296ca7a59cd624b53_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNS0yLTEtMS0yNzcz_df73c08d-a49f-414e-9c14-d22d965111d8"
      unitRef="usd">1465000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7754da6d6ec44b0e944fa8f87cfe572d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNS00LTEtMS0yNzcz_d0c9ac2f-0071-4511-b02a-f34a6bcf71a1"
      unitRef="usd">216000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93ea9ae384744892b920c309bb2dc11b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNS02LTEtMS0yNzcz_a5c51f55-0bd2-4d0f-a9b7-dbdbc429dc6b"
      unitRef="usd">143000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b9480e8d66b4593ad97e4e5be56077d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNS04LTEtMS0yNzcz_2b7271c2-87c7-4dfa-8f9f-224c19d84048"
      unitRef="usd">1824000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i860dabfa33e143bbb52212212435f1ac_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNS0xMC0xLTEtMjc3Mw_da9c308c-a835-45f5-9cb8-3ef2296fe9ee"
      unitRef="usd">1412000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i32acee5874f9459b9252142abdad455c_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNS0xMi0xLTEtMjc3Mw_bcaed904-ea85-4c3b-8497-978e62363a0e"
      unitRef="usd">181000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8c9ead692aa4d9b810f9ec7db117251_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNS0xNC0xLTEtMjc3Mw_a8b32066-78a6-489d-8929-135efbcb43c4"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8c7336c5e6147e7adf7d7c7affa6881_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNS0xNi0xLTEtMjc3Mw_31a1e7d4-e92b-4a32-9ae0-10504deb0075"
      unitRef="usd">1693000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2462c72487a94e59b5caf6a5a319777f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNi0yLTEtMS0yNzcz_63911f95-0201-421a-9115-4abce9dbf6cd"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i926db54afaa349f6af84a0c3e2544b96_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNi00LTEtMS0yNzcz_6a956961-bf69-4061-8e32-bd0caced510b"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ec0f287f8ff4da3820bdba4ffc47bc2_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNi02LTEtMS0yNzcz_231ade34-e749-4c66-abbb-13d9dd6f723e"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3fd650f8abb4697adb1f0f30c929d64_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNi04LTEtMS0yNzcz_1de62d71-94d5-41a7-b533-50e36e615f8d"
      unitRef="usd">63000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74acc5bbd8d34c738b16ae51a6075385_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNi0xMC0xLTEtMjc3Mw_2e9f9c6c-ce1c-4dfe-9a01-4da5a58ebf3b"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15469494cca5432aa408d46c88acabf0_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNi0xMi0xLTEtMjc3Mw_9a37030c-1966-42bf-8fa4-0c411beb5875"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d5d49b7149047bab9ea616bba4640f0_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNi0xNC0xLTEtMjc3Mw_56911ec1-cb42-4742-baf1-a7cc3113f30c"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8809e89136714bbbab87f233c9eadb83_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNi0xNi0xLTEtMjc3Mw_763457af-2b96-4485-8b30-38a695676374"
      unitRef="usd">76000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id32809760dcc4f69a8dab604473dba7f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNy0yLTEtMS0yNzcz_bbd36bc8-9b74-4cfc-a682-9338a64a4fa3"
      unitRef="usd">282000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib508419ccb58428e84530322853938fe_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNy00LTEtMS0yNzcz_da980173-7f78-4b31-a3cc-1deba3f6758a"
      unitRef="usd">42000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25554b833ac44de8ae88e315443d09c8_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNy02LTEtMS0yNzcz_36b8eb90-edd4-4061-a905-1b7553b18f3a"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78b9775b1d1b40319b1f9d7183321020_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNy04LTEtMS0yNzcz_644381e3-b24f-4950-a762-43fba008b027"
      unitRef="usd">359000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63920a1a040e417891a03f303d3bbcad_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNy0xMC0xLTEtMjc3Mw_6d0e9e35-07ec-44e5-b7aa-339da9c32c06"
      unitRef="usd">363000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia590ce34497d4eaa86fa2b29038aabb5_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNy0xMi0xLTEtMjc3Mw_ee1adf49-f2c4-4a38-85ac-a7c69dec5283"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7eeed5ddca31468cb705d74685f56174_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNy0xNC0xLTEtMjc3Mw_43f2a462-2b53-4035-9c01-79a9ce4134e0"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64b13d2f087c45bd9fc1acd32cd1ef64_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNy0xNi0xLTEtMjc3Mw_920fedf1-b7f7-4ee2-a6fb-941157323b5f"
      unitRef="usd">458000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63ae64a7b8094554852cb98b0a551090_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOC0yLTEtMS0yNzcz_40569ab4-641d-4bef-9b1a-5012b51f3588"
      unitRef="usd">506000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic110886142334d548f1d0723e44253d3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOC00LTEtMS0yNzcz_c0a9c7c8-d900-4842-9f01-599ee6ee3494"
      unitRef="usd">106000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifdcd081c4a4c46029ac68f60d58be6aa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOC02LTEtMS0yNzcz_eb911201-bfaa-40e1-8be6-6d7077d193af"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0410e8fcd4043e490ebbf9c80ae64b1_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOC04LTEtMS0yNzcz_4605ec8b-5562-4b10-be0e-b58a0077a6be"
      unitRef="usd">673000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib630252d0da14149adffcae74b86e4e7_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOC0xMC0xLTEtMjc3Mw_689015fe-aa03-43c5-bb35-984ad0e494d9"
      unitRef="usd">612000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9bec6854dc6b4f04a8e737cd53521147_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOC0xMi0xLTEtMjc3Mw_e60a43cc-9150-4446-96b8-80e120ec2789"
      unitRef="usd">151000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0ebb14b7645429db55c7da591d24c92_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOC0xNC0xLTEtMjc3Mw_645a57a8-1977-4bfd-b9d7-9080b5772630"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d00d8d104314587b42a25a2edff05da_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOC0xNi0xLTEtMjc3Mw_19aee80a-a55d-4dfa-97aa-7e05b73aed5d"
      unitRef="usd">824000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a6f431e5de642bba69f6328f2961f14_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOS0yLTEtMS0yNzcz_c579baaf-9284-4b4c-9586-ae0209cb63e1"
      unitRef="usd">240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99ccdd43f15d46bfbdc7e4ea02150055_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOS00LTEtMS0yNzcz_8ab40e74-beeb-4018-84ff-62fceaa114bc"
      unitRef="usd">113000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5661ce6a8f840d1850cebad529dc17c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOS02LTEtMS0yNzcz_705e28f1-9d05-464e-b3ee-f441a4bd1f77"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8af148cdc07347ba838fdffde80857bb_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOS04LTEtMS0yNzcz_a29489ce-0872-48dc-a81f-6a7dc5e09ba9"
      unitRef="usd">367000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie65015860c764edfbb86c8af349ccd93_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOS0xMC0xLTEtMjc3Mw_c0a7cc5a-f6de-40ea-a731-8d2747b6131f"
      unitRef="usd">269000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b044c57517f472a99248ee2666230e0_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOS0xMi0xLTEtMjc3Mw_cb45f3a4-9cf0-4d93-bf8e-cf66177c36ce"
      unitRef="usd">127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie915268dd561478f9d1b79082fe9e92c_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOS0xNC0xLTEtMjc3Mw_9fe2994e-a39f-460a-a083-5d438d410127"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c5a0930911c499688e99f6e08ca653c_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfOS0xNi0xLTEtMjc3Mw_cf51877a-e8d3-47e9-962b-ea399cff015d"
      unitRef="usd">409000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4618b8d2431482ea6b2b45a2b50b865_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTAtMi0xLTEtMjc3Mw_7db08f94-d6a0-431c-84dd-f0e94c1616c3"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ed385b62afc49599835c73bd497620e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTAtNC0xLTEtMjc3Mw_49cf0793-c20d-4c1c-a445-96e74ace779b"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d7e6c0864674e51b116a0887e955135_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTAtNi0xLTEtMjc3Mw_939c83f3-803e-49fc-8189-a92ff1089e3e"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f3c8b7a52cf49be80972340697e8657_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTAtOC0xLTEtMjc3Mw_59587b6d-dcc5-4d9e-bbf5-dcd604bef9e5"
      unitRef="usd">46000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a691facdde446d09127f1d0029b00a8_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTAtMTAtMS0xLTI3NzM_1c5efb7a-5c5a-4677-8d85-78a6a2fc8038"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic621020502cb4461b3f507d17a78d96d_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTAtMTItMS0xLTI3NzM_23d867ec-f44c-41fb-9269-a2fe52217356"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9944473064fa47dcbb264707adb1876b_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTAtMTQtMS0xLTI3NzM_bcf40937-ad0c-4392-80c8-be349e11cbbf"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2e742eaf2b342098a385d2addbe3722_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTAtMTYtMS0xLTI3NzM_d1baf5cb-5164-43d9-9f13-21511918ab49"
      unitRef="usd">53000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i588d3a5b64fd4b7080b0056b85ea0150_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTEtMi0xLTEtMjc3Mw_fc8feeea-6ede-48db-b082-21d9ee9ecfd9"
      unitRef="usd">119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33b30c8afa7d47e59e7da726ed9b9890_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTEtNC0xLTEtMjc3Mw_89ec95a1-b704-4655-8d47-586434449fe3"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03098f2d9e664ef285eee0bbed328af7_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTEtNi0xLTEtMjc3Mw_58baedaa-eef0-4749-8e2f-8a78e2497ea6"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38535068021e4957bf196cb0586b1f95_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTEtOC0xLTEtMjc3Mw_66a6c0ab-3d15-416b-be62-ea49da25bbdd"
      unitRef="usd">135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie91ab1070982497baf8fd021259bd6f4_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTEtMTAtMS0xLTI3NzM_c7fbf4e6-b45d-44f8-aaa8-ca63ebb7fdf5"
      unitRef="usd">383000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77d7d1bcb69242afbb3209274bf2e205_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTEtMTItMS0xLTI3NzM_66017622-9b4f-4959-84e8-57a2a055f543"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9079d3cc20b47f48f6dadc7048847b4_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTEtMTQtMS0xLTI3NzM_6e5cb3ab-f426-476f-b0b6-ea897e7a0567"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5c79c7043994738bad7f7620e19bd9c_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTEtMTYtMS0xLTI3NzM_7313bd37-7c78-4c6a-a2e4-cf7dab6a65f9"
      unitRef="usd">406000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib54f9224b2d046a7ba0fb1790721cc77_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTItMi0xLTEtMjc3Mw_0e0a3303-ab23-4c37-9f44-a327db9ba2d2"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f0e9b7992f04bd4b7a98d3c40e33e6c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTItNC0xLTEtMjc3Mw_8e12ff06-0bd6-4032-81c6-4e864df54f57"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1bfaa1d7b2047c8b0243a6fe75777de_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTItNi0xLTEtMjc3Mw_311085c0-7196-4130-88d5-2c65b8352786"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6a1884c73a14fabbeac29b5261925ce_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTItOC0xLTEtMjc3Mw_a1177c27-f0f5-44f6-8e36-bcc07b2998fb"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9213a6fb817f496f82175fdabab96f9f_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTItMTAtMS0xLTI3NzM_1b421ea9-9a05-4cf7-97b4-45a796d9de51"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id25b065da243414e834f92baa87571d1_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTItMTItMS0xLTI3NzM_1f36b0ab-a1d5-4e84-b564-feda9aec6a29"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd4289b827184b00ba7eb9735afd98c1_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTItMTQtMS0xLTI3NzM_f5dbfba4-b793-4807-ad62-a531d2819f63"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7f221d836804ac0ac5bf313e85fb6d7_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTItMTYtMS0xLTI3NzM_93a8f6c9-5b19-428f-9961-f4a00fc2ebad"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38b3924c6f0c441c9eb7e6c652985a59_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTMtMi0xLTEtMjc3Mw_0958075f-bc77-46d4-9b7a-dbce2c3f9384"
      unitRef="usd">89000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i685ce820b15c48c5a1caa899b5612367_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTMtNC0xLTEtMjc3Mw_0cd3fd23-19c0-486c-a351-5da118f21de4"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica58dd4564944ece805e2d3c625a68a5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTMtNi0xLTEtMjc3Mw_2ff0c1da-1eb6-4bf5-acd9-8017c24036a3"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9eac58164bb8445e95ecf5a632b200e5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTMtOC0xLTEtMjc3Mw_b6e5c0d8-a562-4d83-92d4-78d3bfca00c6"
      unitRef="usd">135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5a9b0307d9f4396804a48e8a8842af3_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTMtMTAtMS0xLTI3NzM_c60a134b-8e2d-4461-9d1f-02c938a5488a"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i405af8d2ac694bcba3c274ea467fe4c5_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTMtMTItMS0xLTI3NzM_6f993038-26e7-4361-9b40-6e7a3ea96082"
      unitRef="usd">38000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4b1a067e082487a8eba535819944c84_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTMtMTQtMS0xLTI3NzM_9bae9ac5-8053-4c6b-9bb7-2e1b8554ec4a"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ad7557b78564109823d84b4134cb07c_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTMtMTYtMS0xLTI3NzM_51677838-50bc-4f88-a733-63b81c020f6d"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19c918e9779d45728feb8d2f77e6f762_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTQtMi0xLTEtMjk5NA_8e39148a-5251-494f-900a-4a3d5d187c5f"
      unitRef="usd">2786000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84672c37600c456ab352a9bd8d1c0bc1_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTQtNC0xLTEtMjk5Ng_1323a7f7-70c8-4a70-b95e-34d004e0738e"
      unitRef="usd">578000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a8a43acfc2946a2bb710af0e9617ab5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTQtNi0xLTEtMjk5OA_6146020b-d49a-418a-b638-419397e209a8"
      unitRef="usd">286000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61244f5bb1eb4b01a880be330bb43ca1_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTQtOC0xLTEtMzAwMA_8fb2ffac-66a8-40ad-a7c8-23ff5c1c4cfb"
      unitRef="usd">3650000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9695a806ea324bfd8dc16e1026c867b1_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTQtMTAtMS0xLTMwMDI_17def2a7-4d17-4d6c-a346-b5b6271d120c"
      unitRef="usd">3253000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28b0923ec98c483796a4a281d6f4da09_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTQtMTItMS0xLTMwMDQ_49e3febd-5e34-48af-aab4-e0943521fa4f"
      unitRef="usd">639000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f3114f39eea433da4c3f4769d416586_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTQtMTQtMS0xLTMwMDY_bf9381ab-2e5a-4f94-a3fd-fb6cddb4f73e"
      unitRef="usd">242000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia68c505daaab4913bbd9dbc115125ca6_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTQtMTYtMS0xLTMwMDg_6c4856dc-1510-470d-b645-e7e2f665e51e"
      unitRef="usd">4134000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01820e105c11483b98e41dfe3ddbf458_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTYtMi0xLTEtMjc3Mw_ae30d135-9cc3-4c62-8c00-6a53bbd78d13"
      unitRef="usd">19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46a4791353fb4785b0fd7e420b2475dd_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTYtNC0xLTEtMjc3Mw_c7503eae-c684-475e-baf5-fdcf46352708"
      unitRef="usd">16000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6903aaf9e2c46dd8097d605617899ff_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTYtNi0xLTEtMjc3Mw_fc871686-3c76-44c3-8b48-27991e26a057"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cedb25ca5664766987bf8d01722d958_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTYtOC0xLTEtMjc3Mw_790ac4f3-33c4-4da4-a563-7a519016d3b2"
      unitRef="usd">56000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd6d40d2852e487fab1dc8033ea98643_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTYtMTAtMS0xLTI3NzM_cb5b3684-8809-48b8-b4b2-8bacf5813070"
      unitRef="usd">53000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f2e37e070de443485aa360d17396ef9_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTYtMTItMS0xLTI3NzM_a1356533-d557-401a-998d-f73462e2b40d"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i926b41607fcf4d478d80f477c8e14d41_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTYtMTQtMS0xLTI3NzM_ab3e82c2-9ad2-4833-b934-dc3bd6211057"
      unitRef="usd">48000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib18a279ca38b432890071110c7674594_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTYtMTYtMS0xLTI3NzM_33260c1e-b7d8-491a-9a41-6adc16f7034f"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e7edf182cba4fe09b32a83db26b4422_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTctMi0xLTEtMjc3Mw_0f321698-761e-41f1-971e-337c5abd69b8"
      unitRef="usd">214000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec3036fbf5cb40bc8c7e26870944ae22_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTctNC0xLTEtMjc3Mw_f437a4ee-b5fc-4082-8e57-16861fff6fa0"
      unitRef="usd">75000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51bdb311ba0f467c84b98f56b3828ae6_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTctNi0xLTEtMjc3Mw_66b2d73a-f161-4e15-8bd9-df555499d4b9"
      unitRef="usd">92000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92d6c64051da48a8a8e6f80486b979bc_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTctOC0xLTEtMjc3Mw_78dfb53e-a86b-4595-8602-04d9561ddc79"
      unitRef="usd">381000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb14461498914ac79e0457757c75dbd7_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTctMTAtMS0xLTI3NzM_87628948-93c8-4bd5-a72a-f2190ef76764"
      unitRef="usd">311000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8d0518889a34fa2998643c6c7727744_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTctMTItMS0xLTI3NzM_b83adb5c-0fdd-4ade-92cc-0ec7849dacce"
      unitRef="usd">122000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba550e7873fd45c6aff0245542583cad_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTctMTQtMS0xLTI3NzM_1880f558-2372-44cd-87cf-f9904e3babfb"
      unitRef="usd">131000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63580e96633b4a5e805fcfb22890f21f_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTctMTYtMS0xLTI3NzM_d0e4d302-5ebb-4e4a-9d49-47e6477c6424"
      unitRef="usd">564000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idbe86121ebc04ad2a0dac3152347a17c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTgtMi0xLTEtMjc3Mw_ea44bcb3-363b-4ca8-92b1-9345a3ce6820"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3261f10427f747079f2363eba0693663_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTgtNC0xLTEtMjc3Mw_2dfdf4cd-8cff-46bd-9678-3237eb39bd45"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f5059f19d2d404d9f5b485c545a5334_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTgtNi0xLTEtMjc3Mw_0cec4da1-1d88-41b2-9b6d-31d02ed60855"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if27f6ff654cf4f2aa404dd2e82fe05b3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTgtOC0xLTEtMjc3Mw_8a170a75-0d75-458f-9b3a-3d0b7cfd5aa3"
      unitRef="usd">73000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb4b9a4d69dc4a5b969be42cf4ab5ab8_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTgtMTAtMS0xLTI3NzM_daba7b8f-66a4-4f97-b0d4-7bbf8c6dcf3d"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54a8ecbfe7104cffb328730f7e2f2ba8_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTgtMTItMS0xLTI3NzM_1cde2355-d11e-45ed-a24f-458a2abb8a0e"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icabba3a157cc4c89993c0a6f7b81fbf4_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTgtMTQtMS0xLTI3NzM_61134bd6-9028-40ba-a3ae-077434321fc9"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec98ee45e5ad401eb35c35717992014d_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTgtMTYtMS0xLTI3NzM_cb23620b-4d60-4d49-80c3-c4ebb28e87bb"
      unitRef="usd">53000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8cab6459ae2e4342bcf14bb7f0922405_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTktMi0xLTEtMzA1OA_aa2ce4a8-1f58-4315-9f84-f62dac4afa85"
      unitRef="usd">258000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if127a72225484fd3bd781db0b605a953_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTktNC0xLTEtMzA2MA_97873bbc-69cd-475e-9039-4486a95a121d"
      unitRef="usd">135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d2f28f5774846bcaefb219a74d26197_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTktNi0xLTEtMzA2Mg_db2862f0-4700-4b64-b184-a05f30730682"
      unitRef="usd">117000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1df4119b39b941c5a676e0d6e2524da4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTktOC0xLTEtMzA2NA_440f70dc-b419-492c-a4a6-6e5c3a825279"
      unitRef="usd">510000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8d501a125774436b2320401b2dd5bfe_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTktMTAtMS0xLTMwNjY_40867b21-57fd-406f-800f-47795715b782"
      unitRef="usd">398000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id015d46967b94673ac7fb2ecc01b0237_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTktMTItMS0xLTMwNjg_b6c1f888-a36c-4a56-88ac-1bd69d86b690"
      unitRef="usd">148000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4660e6236c694b5ab8b1df8d62990e36_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTktMTQtMS0xLTMwNzA_815596cd-91b2-4418-a153-85213cb5b6f3"
      unitRef="usd">183000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0789c28a8de462d9aaa999b30d2860d_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMTktMTYtMS0xLTMwNzI_ea130f25-00d5-4f36-bf79-b672adcc7cd0"
      unitRef="usd">729000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i675d50c435a342b58fa7e73781175e88_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtMi0xLTEtNTk1Mw_63d86441-6227-4b0d-8a52-51d28f34a584"
      unitRef="usd">77000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i360f92e56eee4f9cace9fa5368873470_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtNC0xLTEtNTk1Mw_a633b0fd-e44e-4827-856f-cd7f20f8b7ce"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5bcf031777e242c49d6e3dcb11d0d8b4_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtNi0xLTEtNTk1Mw_52ad593b-57e4-46fa-96a7-f6659c6a5102"
      unitRef="usd">96000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1a9d40b8bca4c5ebf598872fea64e39_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtOC0xLTEtNTk1Mw_160235b8-eb43-45aa-b019-71700f125506"
      unitRef="usd">181000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if969bdf4b849499da19c7f7222a8956b_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtMTAtMS0xLTU5NTM_94e3fd20-9f78-445b-a794-7d1a6ac7e677"
      unitRef="usd">73000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84671f49939d40bc886c4b2114546e68_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtMTItMS0xLTU5NTM_a95fd283-54ea-4f47-91e9-e17b4afb4895"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2772b321f6f54c0c86bea892e8380009_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtMTQtMS0xLTU5NTM_83d3a090-9f2b-42a0-b582-7b31c6db7c07"
      unitRef="usd">56000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic526ab60ae6e4f5793eb51c0321f5905_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtMTYtMS0xLTU5NTM_f81086d9-0821-4ab9-b513-8d2bf6170797"
      unitRef="usd">136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id610eb3a322f41c8a749fe84d536e585_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjItMi0xLTEtNTk1Mw_b38b37e2-f06c-4686-aace-e97c38127446"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica526b4aef3a494aa2733999ba191001_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjItNC0xLTEtNTk1Mw_7a0fcd85-a4d9-46c7-bb35-d0bf8ff63ae8"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1bc50922e47b41d1ae940b37d4a22377_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjItNi0xLTEtNTk1Mw_c8a10710-c97d-43e7-b133-c45f09935cc4"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88ec94f0555e4aebb035ebb5e2f4925a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjItOC0xLTEtNTk1Mw_c49ce4f2-2763-4285-a0c5-e63a133f19dd"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cc4334126ed455ca10fd4f18e8f5b4c_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjItMTAtMS0xLTU5NTM_6d0bb187-8f7b-4769-a75b-9700d93a0977"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ff242a9f3684b65bdac58944556d71a_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjItMTItMS0xLTU5NTM_e7b85306-b923-45e6-b930-4dc24b173082"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab32fe9b37b248d29bd625882511a2bb_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjItMTQtMS0xLTU5NTM_83c13532-f960-4199-842c-9cdb08890feb"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia54a8c84a9224b4aa1d3a5f8e35961cf_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjItMTYtMS0xLTU5NTM_7bad535f-dd9a-42f1-b12b-3710c77f3ec6"
      unitRef="usd">40000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3432013787d441d5ac3a3a61b439dac3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjMtMi0xLTEtNTk3Mg_0e802a50-c6e0-40be-9cd7-ebc52ecda825"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib78feb1672bc421087bf1d5bd26b7f38_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjMtNC0xLTEtNTk3NQ_00e1035f-6aa2-4a68-aee2-6688473dbb7b"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b34a41296624040be895c5b6d3289a3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjMtNi0xLTEtNTk3Nw_5a215b40-b05d-4f66-bdbc-1b55344dcd6a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85236c36163f4119b8910a94fbd2562f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjMtOC0xLTEtNTk3OQ_6989764b-86c6-4938-9d3e-f3f8863ac2fb"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1912c5f855804d3eba84607a017c56ee_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjMtMTAtMS0xLTU5ODE_9b135bd8-b982-45c0-a230-8e4e5808aaf7"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b6a5426bf9c42a6acc2bf5e17b270af_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjMtMTItMS0xLTU5ODM_8bd1844a-7c33-4a3f-b982-18581cb24c21"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60e4866d36c54935ba04c29bb4fca09d_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjMtMTQtMS0xLTU5ODU_83baa7da-6805-4544-95ba-f5d249508149"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6db1d7fe6dbc4d6ca143fc475b93b204_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjMtMTYtMS0xLTU5ODc_4961d162-7327-4d96-a462-3bb620efe4cc"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc5ca7d98d3244549154eef3bc1137b9_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjQtMi0xLTEtNTk4OQ_edd4f4b3-6a68-4dd4-9f2f-31ab300f08f8"
      unitRef="usd">81000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5777618eff474b979c73d1e5bb0bcd06_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjQtNC0xLTEtNTk5MQ_5d83ee67-fa4f-4501-ac25-d82bed4254b8"
      unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20c40061142b4bff954eed33447b411c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjQtNi0xLTEtNTk5Mw_cc1d7b66-a430-4504-ae23-549db8bc0735"
      unitRef="usd">116000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib68625c89e0942cda48fef6469af6e0b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjQtOC0xLTEtNTk5NQ_316d1284-3e45-4cdc-b035-86f26212f334"
      unitRef="usd">220000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8c748ed1b844524849ec04f66244abe_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjQtMTAtMS0xLTU5OTc_76010098-72f5-4014-812b-ca5bcaf27e3c"
      unitRef="usd">85000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37dae4cebdb14befa776bdc7e3990bdc_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjQtMTItMS0xLTU5OTk_11367815-8ec4-43b3-a2d5-0f77c573d6cb"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37cc9d8c63b54982bdae48850a893359_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjQtMTQtMS0xLTYwMDE_daa39985-3f8a-426a-bb7b-fb17bd4a4e08"
      unitRef="usd">81000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i897fee00cdd84fe19bcc2cc8dff383b3_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjQtMTYtMS0xLTYwMDM_91b01bd9-1058-41ca-884a-143150bbbb56"
      unitRef="usd">186000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b087aba23654283a5c4af9b69a0202e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtMi0xLTEtMjc3Mw_715fdf9f-e139-488c-adcc-9858c4f780c7"
      unitRef="usd">820000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibeb98b603f06451ead95cabe282463e2_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtNC0xLTEtMjc3Mw_79d83096-2aaa-4e6c-86df-d285048502e7"
      unitRef="usd">388000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id37d8e541c21407bb4a5f8243c09f13e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtNi0xLTEtMjc3Mw_f38e2a71-2a57-459f-ba02-7d1d4c592389"
      unitRef="usd">248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7ec4f656f3842acbe27241f7f05ed2f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtOC0xLTEtMjc3Mw_2d61f667-bc91-40a8-923e-0c78ede4fb5a"
      unitRef="usd">1456000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id69e1c2be46d4ab3b4309b0f917bbc46_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtMTAtMS0xLTI3NzM_cd88938f-13d1-414a-9c35-89ec4e53bf76"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1667d7f2806e4f558140470b36628aa9_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtMTItMS0xLTI3NzM_9bb820e7-5a57-43b8-b1d5-2f6a106658d0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2328db06206c4fdd9af385e7c2173cc1_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtMTQtMS0xLTI3NzM_dc9eafd2-9792-449d-9aee-7869ea096053"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f4ecee25efe4513b99dc58abd0fe3a2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjEtMTYtMS0xLTI3NzM_10c196ef-7e6a-4bae-9836-9e637725a051"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3005b97b85247b7bb0b10e165ad5a20_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjUtMi0xLTEtMjc3Mw_eb521c36-d767-4ea0-a16d-33b0515f4e5f"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf31979b82854addb363f690711744a9_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjUtNC0xLTEtMjc3Mw_3f18e9b6-e1cb-44d1-aa0f-31e819043ede"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c18a34a44ac4a6eb3e0df9bd9f9bbec_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjUtNi0xLTEtMjc3Mw_eff32e45-5831-4f1f-b136-e894d7aba59f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5b81cbd589447aeb09c7c7271354585_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjUtOC0xLTEtMjc3Mw_72e66b2f-1dcd-4499-bdff-18ceffa27969"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a2f8ebf252349c19b669e8c8082fec4_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjUtMTAtMS0xLTI3NzM_b686ef74-de91-4a4a-81fa-3dcf59aba8c6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7413a3522244628851987c3f80b566e_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjUtMTItMS0xLTI3NzM_8ce0d7a8-63e9-4e5f-b358-acdd413061e6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13d9726cce774f76a579a5e8833f0a50_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjUtMTQtMS0xLTI3NzM_66b4af77-ded0-4e59-8962-f6e2a224b135"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id035c0dd020540dd9baeb1cf7dc147b5_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjUtMTYtMS0xLTI3NzM_3b23f142-c4fc-4abc-9f78-255519373da3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieffdb1acfae64cf3893370c95966b40f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtMi0xLTEtMTA2NDI_9f30b233-f188-4224-9119-7bb9c9cff99a"
      unitRef="usd">92000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib75a2669840e4d33ba162e40920c2dd7_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtNC0xLTEtMTA2NDI_38c56c32-72f2-4a97-9531-168380b86a84"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43c8f799fa3c418bb426643d8c44cd59_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtNi0xLTEtMTA2NDI_9a397537-924d-4f0b-a68b-5ac0c23a22d2"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i770b79af85df4a5682a9ba6a0d5ab1d8_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtOC0xLTEtMTA2NDI_efe6ea16-a90f-4513-8774-6a160bc20e1d"
      unitRef="usd">160000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie36eeb702c1740afbd92eef4087fa2b7_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtMTAtMS0xLTEwNjQy_f87796b6-53d4-4453-94f1-d57d04e76374"
      unitRef="usd">103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie528cd0b9cdf4dc5a97392412c208b8c_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtMTItMS0xLTEwNjQy_62faf937-d56b-423f-8867-18d9fb1a0427"
      unitRef="usd">37000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95f4d058a72e4ceeb60de778690ef7c2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtMTQtMS0xLTEwNjQy_22ffa181-ece1-456b-bc31-f537903248ce"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie77a01ccaa114972a96aa9c83d1e2ae4_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtMTYtMS0xLTEwNjQy_8cada538-3938-4fd4-a8ec-386ba23e823e"
      unitRef="usd">140000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e328dc77d9945ddb8c8684f306018df_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjYtMi0xLTEtMzE1NA_fdd3392b-cc89-4ffe-b881-51db71f7ccfc"
      unitRef="usd">119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i638557b5d8cb4470bf95e691ee5ce53b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjYtNC0xLTEtMzE1Ng_344a9387-6cba-4506-81b7-26eb155d82ac"
      unitRef="usd">65000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05bbfb8bf6fe4d4db64e6f86903a3437_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjYtNi0xLTEtMzE1OA_e367c3ac-8a63-47a1-8b14-d6452504d33c"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id31fed8e97de4275a24d7c4b6bdcd1ae_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjYtOC0xLTEtMzE2MA_edeb1106-b321-48be-a1bc-e46c725db8b7"
      unitRef="usd">191000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i895202346b1e4f8e9fb49025b720a3e9_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjYtMTAtMS0xLTMxNjI_c0eb5368-59fa-4261-a970-eee1c1c8317a"
      unitRef="usd">103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a4bec7cd2a7469992b30486d0367128_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjYtMTItMS0xLTMxNjQ_820988d1-95de-4503-ab2b-b137c3e59769"
      unitRef="usd">37000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd6d31d7996e46edbb7ee6b98031d951_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjYtMTQtMS0xLTMxNjY_0211f545-c275-4543-9a96-1b006e820d2e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia884a4d361c549379ff1a1b4a3e743d1_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjYtMTYtMS0xLTMxNjg_5cb224f9-ecea-4ace-8e4f-16661b7626e4"
      unitRef="usd">140000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e124cdf64ce4d42808bbced06eee17f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjgtMi0xLTEtMjc3Mw_1a0874a8-e929-4ba5-97ae-e047e2e00a4b"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94c157660993467d933768c8d2aace75_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjgtNC0xLTEtMjc3Mw_2e2e1870-d56b-426a-b27e-a1e419383dd8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i765af031a6b7456b87400772e5870fad_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjgtNi0xLTEtMjc3Mw_36a152e6-7947-4dee-8cef-db6658335e2e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9bec1aed1d4441e84196a0df4aef39e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjgtOC0xLTEtMjc3Mw_ff7ec639-f1b7-4472-934c-128edb0c2962"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a6c817b9881419c843a0c4e6dc181a7_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjgtMTAtMS0xLTI3NzM_d14c439b-5087-4c33-b673-d28a826633a6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72493ff81994417eb27d02d1509511da_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjgtMTItMS0xLTI3NzM_f0d8e9b0-2c48-44f8-bf27-0b598b8d8c4b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84bc3ed5f80d4988b11e429d726f932f_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjgtMTQtMS0xLTI3NzM_6c30689e-5e7a-4201-9435-0ac4cafa6e28"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if726dadc7df94416b6c217bdf80c23dd_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMjgtMTYtMS0xLTI3NzM_7a350fc2-709a-42c6-8f9f-c980863290ef"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6640c16387c47d3a3a2b9e3877f611f_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtMi0xLTEtMjc3Mw_952fd121-f002-48b2-9cee-2fd38a69ef04"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9418ff206901445b9b29378a177c1078_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtNC0xLTEtMjc3Mw_95ffc414-7a6e-49c4-a717-af137492d88a"
      unitRef="usd">66000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95a67a6c1c934a8191082d5f097351ab_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtNi0xLTEtMjc3Mw_ebb0ccae-8a46-4e63-b26b-d57cf08cfd98"
      unitRef="usd">43000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic787aa223d5c4f5da13f043035ca0c4d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtOC0xLTEtMjc3Mw_010574e8-bb1f-467e-8eda-d74ad39a0516"
      unitRef="usd">121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icbcfbd0d83fd490a88eb77e4164e8482_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtMTAtMS0xLTI3NzM_330f54b7-2c5f-42cf-9df6-16bf544e40b8"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56ccd5f7a01343d2a2c516f6e998e3bc_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtMTItMS0xLTI3NzM_1a6769c3-c37b-4459-88d4-f19c5738055f"
      unitRef="usd">59000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i830a223d4ff2496b95fa59aa0e3e4797_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtMTQtMS0xLTI3NzM_121418c8-8802-4896-bbdf-bf6800562824"
      unitRef="usd">42000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a0e2be2410b432f83a8f28ad4956670_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzEtMTYtMS0xLTI3NzM_a36ec084-12ad-4b2c-813a-acb6dcb984c9"
      unitRef="usd">119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56d0c83af6c24195b5bf3247fc3a2a1d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzItMi0xLTEtMjc3Mw_49f8389c-32ba-4bf6-9c13-8993474f86b2"
      unitRef="usd">54000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f5ba02898844d3ea4c5f499f95e5fb0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctNC0xLTEtOTA2MQ_866801c3-8067-4b4c-8844-13d5ca0457ae"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20275018e0d44c51a225e199b4c27700_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctNi0xLTEtOTA2MQ_824634be-1072-4d0c-95dc-b56a79313512"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8ac1fc0d9b04f45841b68102ff7a077_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzItOC0xLTEtMjc3Mw_6179c4f7-c8ad-43fc-a4bd-57f5b8a5f32b"
      unitRef="usd">54000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc55defcbcf045f4926fb48eb0af8237_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzItMTAtMS0xLTI3NzM_c71dd5a5-e6b1-4592-b8cd-7cb7457eb237"
      unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie794e67f1815485d87eb5b97b42e3a28_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctMTItMS0xLTkwNjE_df03090a-aa2b-45a5-a51c-c15b80bbeead"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4c01e5b99d04896a602aacda729c489_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctMTQtMS0xLTkwNjE_9097ce8e-3aca-4b2c-81e8-1428b152082f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb5ad85e55c34064accc690566b965df_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzItMTYtMS0xLTI3NzM_81f5e0ca-6230-4234-bc5f-57ff32d637f9"
      unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i060769bd1274459796e6b5d21c6d2fcf_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzMtMi0xLTEtMjc3Mw_ea0d2c38-26de-43da-aabb-c7ac2609646c"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8116a166d7b441d2956497a975f03511_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtNC0xLTEtOTA2MQ_13e6c2a0-9765-4f6b-9208-06085bc808c2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i240d967d6df04f7b960c8bd653ebf8b2_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtNi0xLTEtOTA2MQ_a8c920c6-15f0-42b8-9b32-48d1178812cc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i217f335d6069466ab81d2c9226caf8aa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzMtOC0xLTEtMjc3Mw_ce3495e7-6681-48b7-9223-a0039b2f5475"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7fd3a3dc901f42628f9c5cdcd8c7c6a8_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzMtMTAtMS0xLTI3NzM_608cfe97-9251-429e-ae6e-009fd73d43c5"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i416394b51cde4930982ba7a31e497d29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtMTItMS0xLTkwNjE_02b61363-d391-4170-a878-046055d08613"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if80f651125c7457f9c03c5bae809f7df_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtMTQtMS0xLTkwNjE_752e6076-37a2-495f-b364-38f8f664ea7b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29de68ae484845bbbcc46d9cef9b77cc_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzMtMTYtMS0xLTI3NzM_61bf19c5-0ee7-49e7-976e-0b7eae367737"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9cafed727b04b61a40c05a62b4478bb_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzYtMi0xLTEtMjc3Mw_6c03b870-021b-4f28-b6b4-a99e5ed28e3b"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91466ff987d24072b25a05678b2c099c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzYtNC0xLTEtMjc3Mw_cc1f667e-6513-4912-b025-af1d8e522d22"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27f5ef98b94448b0b24ea64ee73bc0bd_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzYtNi0xLTEtMjc3Mw_659921d2-bd56-4821-9385-717a27418540"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i993d7e955bc24b07ac282e4ab68a7571_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzYtOC0xLTEtMjc3Mw_c3e0a5e3-f213-417d-a964-93e2cee17c42"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e949706c1134da999d6dae385652030_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzYtMTAtMS0xLTI3NzM_a504ef68-c814-4e72-94e7-682410b925a6"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ec3ba3a461c4bb9a085047222875988_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzYtMTItMS0xLTI3NzM_a29604d9-ac47-472a-890f-7ddcbaba39c8"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2a556c276af4966a1f10ac00b2afafe_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzYtMTQtMS0xLTI3NzM_901c222b-f345-455b-8011-e40658d64b95"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1608b354af974844a750d7bbff9d65bd_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzYtMTYtMS0xLTI3NzM_37b3af7f-23b0-40d2-bc4f-661c3dd6ac33"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie622129ad8eb43a190e8eff8fa687ae5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctMi0xLTEtMjc3Mw_cc5754b2-43e9-4b23-a636-00ab48f29a9f"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f5fae6c59274f0c9e41875005ba8c44_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctNC0xLTEtMjc3Mw_3cb8c14e-52f2-4096-9dc5-9599f6438cfe"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e613c28bb364cccbb5a721e8f1d7d7a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctNi0xLTEtMjc3Mw_dc2700ea-8a5f-47e8-8f7d-583c1705ec10"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e45a6235b364a4bb66ea5322ed6de0c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctOC0xLTEtMjc3Mw_2b00c2f1-cd94-4fd4-8222-41b18a75cae5"
      unitRef="usd">48000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52538488633a4641a1fb75bd6ea77c00_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctMTAtMS0xLTI3NzM_1920aa08-f387-4ce5-bda1-0b0fe0ece2d1"
      unitRef="usd">33000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife67fb52d10a4d4a9dc24e6e584d9f8f_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctMTItMS0xLTI3NzM_af020626-5f6e-43ea-a340-d1d2b86c6962"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77b40277de7045d1be5c4072ff5a78d5_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctMTQtMS0xLTI3NzM_47c025b5-cd1c-4071-a5ab-bb9978fb4eaa"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d26210a184b4926ac141ab337c6d073_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzctMTYtMS0xLTI3NzM_3d14a98a-4807-408b-a45f-b9101b4729ec"
      unitRef="usd">48000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2bdbc28395e4c749de3966f3d490986_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtMi0xLTEtMzI5MQ_93946360-66cd-4bfe-b15b-91d3d20f6a9d"
      unitRef="usd">104000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31d850a622e9469497772ed09d38381a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtNC0xLTEtMzI5Mw_ec7253ee-b72a-477f-8163-4794a100302f"
      unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1dde27099e04e999e1d57d292d9919d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtNi0xLTEtMzI5NQ_52f4b023-32de-426a-b5ea-d1f8a9eea0b8"
      unitRef="usd">51000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iddfef4e9b501477bb8ed2bdd6115418a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtOC0xLTEtMzI5Nw_a4934e98-93ae-40b6-8387-17587b509cb8"
      unitRef="usd">241000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i633cffc37fba44c896afe1666617e27b_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtMTAtMS0xLTMyOTk_00a5369f-62ba-4223-b12e-c4f3906c6cb3"
      unitRef="usd">150000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i696ccf6fee89419a892324e7301d6a33_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtMTItMS0xLTMzMDE_b6cb3b6f-abd5-41fd-9fec-57abd3766faa"
      unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if03f06d9abbc4d33994c24916cad8f2a_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtMTQtMS0xLTMzMDM_5e1845c2-125f-4368-a1c5-919cbf5dc8d0"
      unitRef="usd">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2da7f309c165427aaa64cd0d24fc46ec_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzgtMTYtMS0xLTMzMDU_3683b02e-6dbe-4541-942d-bed9ec36ae74"
      unitRef="usd">278000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0f41ed705fc47bdad91b627766f40c6_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzktMi0xLTEtMzI3NQ_7804ffa7-24cb-43c2-ae6f-d363cb5c0f71"
      unitRef="usd">4240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i242ad95eb87d4a50a40c74136ce45ce8_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzktNC0xLTEtMzI3Nw_b195c513-27e4-4721-a766-2cc0715fb79d"
      unitRef="usd">1275000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4208030b6e11411a8b65bb4461639e24_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzktNi0xLTEtMzI3OQ_f2db163d-e264-4407-a9e1-b0bab74e4f67"
      unitRef="usd">825000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i869fada8dc15440fb186758025e4ea38_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzktOC0xLTEtMzI4MQ_9843dd8c-bbd0-4459-8c70-9a735cff98ba"
      unitRef="usd">6340000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26be40f7eb5247d2a40cf54a35c01a00_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzktMTAtMS0xLTMyODM_bbe2ba4c-f61c-499c-aad3-d96619f7b373"
      unitRef="usd">3989000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53b279b4db0f4f1dbfbb9132a4d78da9_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzktMTItMS0xLTMyODU_f5436bdd-ec4b-4750-9654-a061d2e00958"
      unitRef="usd">927000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6a7bd7ae51244859339deec6090a256_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzktMTQtMS0xLTMyODc_27ce2ffd-d19b-44ff-9e87-2ba1f830abaf"
      unitRef="usd">551000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i888db709f4bb4306aecd55be57d43e9e_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfMzktMTYtMS0xLTMyODk_72508094-60e5-4f6f-9a20-48290b511691"
      unitRef="usd">5467000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3eb69f03734240adab1da5d621476341_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDAtMi0xLTEtMjc3Mw_0682e97a-33f0-44bc-92e1-a0f62e5641c9"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i718d3fcd575e4cfcb3f142a29edf8c39_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDAtNC0xLTEtMjc3Mw_97894a78-17af-4425-b9e6-1e94f89139c1"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i776c29b6bd8246b799595de5c9c32a6c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDAtNi0xLTEtMjc3Mw_c07b3535-fc08-4a33-85ee-f1b81c4d373e"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d0a665778d14bbb912aa93b2b6e4f2e_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDAtOC0xLTEtMjc3Mw_342185c1-4d8d-470a-bec7-488504b74b5e"
      unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2d224f161354feb9e09b4ebb8e0cd9c_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDAtMTAtMS0xLTI3NzM_d62747ec-0e25-49e9-8abf-885b2c13551b"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i001045f707f44a6f80dd8a8ca22a4bf3_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDAtMTItMS0xLTI3NzM_e5d1e6f1-4cd5-408e-8341-6c7a4391b136"
      unitRef="usd">48000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefd124be7cd14a8cb0d1429c3a487683_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDAtMTQtMS0xLTI3NzM_eaa91a8a-792a-4107-9813-3e516df929a6"
      unitRef="usd">16000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e94052ecbb3480d9dda10de813ecacb_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDAtMTYtMS0xLTI3NzM_2e6317c4-23ea-47ef-a12e-8de5ac124874"
      unitRef="usd">81000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i027a876acd5948e39aaa2a168d3de1fa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDEtMi0xLTEtMzMyNw_fde556d5-aeb5-4f2a-bc1f-7110f2c97654"
      unitRef="usd">4260000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8517e6b14d3e4e059d8471ac0f54ff42_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDEtNC0xLTEtMzMyOQ_b8846581-d8dd-4e74-9447-e8ea28e9b813"
      unitRef="usd">1336000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c6a2a79dbe141ba9c759468a86cea51_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDEtNi0xLTEtMzMzMQ_45b5e83a-1933-495a-a422-195a4ac33c1a"
      unitRef="usd">827000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDEtOC0xLTEtMzMzMw_d1cfd366-ea75-4b60-b5a2-3fbe183290d7"
      unitRef="usd">6423000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85cbcbbe9efe43c6b5e7ac96bb4d64c1_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDEtMTAtMS0xLTMzMzU_76f24eec-7767-4761-b913-3b61aca73025"
      unitRef="usd">4006000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a72c3a2c01447b1ba0c68c97b289ee6_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDEtMTItMS0xLTMzMzg_ce923f21-4c67-4cc6-9e6b-6a7a35083d49"
      unitRef="usd">975000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f8b4813eba0494e93eda89e8d1553c8_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDEtMTQtMS0xLTMzNDE_7587f29a-5d31-4b2a-8df7-6dd421c426cf"
      unitRef="usd">567000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjZlMjg1NmY5NmVmOTQ4ZGViODY5MjYxNmExMzA4YTE5L3RhYmxlcmFuZ2U6NmUyODU2Zjk2ZWY5NDhkZWI4NjkyNjE2YTEzMDhhMTlfNDEtMTYtMS0xLTMzNDQ_d524cecf-1960-432f-8bf7-df4ada0cd1b5"
      unitRef="usd">5548000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RleHRyZWdpb246NWJjODQ4YzM4NzdjNGU5N2JjNDYxYWJlYjRhMTdhNDFfMjA2OQ_99167eec-709e-4e01-8805-5e697bef69ff">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(as a percentage of total revenues)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0bd483f628534e979ee1ef8021838fb8_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjA4NDY0NzRkMTRiZDRmMzZiNjFmM2UxM2FjNGM4YWM4L3RhYmxlcmFuZ2U6MDg0NjQ3NGQxNGJkNGYzNmI2MWYzZTEzYWM0YzhhYzhfMy0yLTEtMS0w_a74fb8b4-cd56-4f11-ac02-f21ac231bf7d"
      unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icbcb2718a9a24054beb14bb7fd018345_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjA4NDY0NzRkMTRiZDRmMzZiNjFmM2UxM2FjNGM4YWM4L3RhYmxlcmFuZ2U6MDg0NjQ3NGQxNGJkNGYzNmI2MWYzZTEzYWM0YzhhYzhfMy00LTEtMS0w_796c172b-37d6-4eba-af9d-7524b941914b"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifd0ff86989784672bbacbf1f772f25fa_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjA4NDY0NzRkMTRiZDRmMzZiNjFmM2UxM2FjNGM4YWM4L3RhYmxlcmFuZ2U6MDg0NjQ3NGQxNGJkNGYzNmI2MWYzZTEzYWM0YzhhYzhfNC0yLTEtMS0w_8bf224b5-2ac7-4ec5-a3a7-84b81fcae100"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id7f6740c84514432ac4d19cf79c9a9e6_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjA4NDY0NzRkMTRiZDRmMzZiNjFmM2UxM2FjNGM4YWM4L3RhYmxlcmFuZ2U6MDg0NjQ3NGQxNGJkNGYzNmI2MWYzZTEzYWM0YzhhYzhfNC00LTEtMS0w_0fc2c078-b03a-426a-90ec-fa57ae6c07c2"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia65096122500425d94f26b129443d35e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjA4NDY0NzRkMTRiZDRmMzZiNjFmM2UxM2FjNGM4YWM4L3RhYmxlcmFuZ2U6MDg0NjQ3NGQxNGJkNGYzNmI2MWYzZTEzYWM0YzhhYzhfNS0yLTEtMS0w_d8529434-527f-45c6-babe-f338e98aae65"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8763f2000062414b96d9bc6531fe8ab1_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RhYmxlOjA4NDY0NzRkMTRiZDRmMzZiNjFmM2UxM2FjNGM4YWM4L3RhYmxlcmFuZ2U6MDg0NjQ3NGQxNGJkNGYzNmI2MWYzZTEzYWM0YzhhYzhfNS00LTEtMS0w_cf55ddbb-3306-4d8c-bf2f-27f96b6e6df9"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i77440dee8e4f4c28b9284a8c1b5ee20d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RleHRyZWdpb246NWJjODQ4YzM4NzdjNGU5N2JjNDYxYWJlYjRhMTdhNDFfNjUx_df18510d-2f0b-4ccd-b3b4-d945411e0d18"
      unitRef="usd">226000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i0658097ecd9f4ed7a6c2540f41f0c3ba_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RleHRyZWdpb246NWJjODQ4YzM4NzdjNGU5N2JjNDYxYWJlYjRhMTdhNDFfMTA5OTUxMTYyOTk1Ng_6d6c2aaf-7428-4921-990d-9891d3af8ff1"
      unitRef="usd">188000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RleHRyZWdpb246NWJjODQ4YzM4NzdjNGU5N2JjNDYxYWJlYjRhMTdhNDFfMTE3Mg_bf4bf008-72ac-47f1-9ce6-801a31b9161f"
      unitRef="usd">332000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RleHRyZWdpb246NWJjODQ4YzM4NzdjNGU5N2JjNDYxYWJlYjRhMTdhNDFfMTA5OTUxMTYzMDEwNg_8466e9dd-0e01-43c0-bcaf-ab4f7ff42c35"
      unitRef="usd">38000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RleHRyZWdpb246NWJjODQ4YzM4NzdjNGU5N2JjNDYxYWJlYjRhMTdhNDFfMTQ5OQ_9798345b-e647-40ba-b320-9f56839365f0"
      unitRef="usd">185000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RleHRyZWdpb246NWJjODQ4YzM4NzdjNGU5N2JjNDYxYWJlYjRhMTdhNDFfMTUwNg_2060e9a3-6e18-44ec-b71f-517071251ff7"
      unitRef="usd">198000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RleHRyZWdpb246NWJjODQ4YzM4NzdjNGU5N2JjNDYxYWJlYjRhMTdhNDFfMTY2NQ_cda4ec68-c1a3-4b89-8752-21b577f39bba"
      unitRef="usd">91000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18zNy9mcmFnOjViYzg0OGMzODc3YzRlOTdiYzQ2MWFiZWI0YTE3YTQxL3RleHRyZWdpb246NWJjODQ4YzM4NzdjNGU5N2JjNDYxYWJlYjRhMTdhNDFfMTY3Mg_fff4b9a7-5492-4536-8e29-a19039b7054b"
      unitRef="usd">97000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfNDc5NQ_28742a32-856a-4f32-8aa8-5c2ec49d6cb0">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 1 inputs include quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. For our marketable securities, we review trading activity and pricing as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments consist primarily of cash and cash equivalents, marketable debt securities, accounts receivable, foreign currency exchange contracts, equity securities, accounts payable and short-term and long-term debt. Cash and cash equivalents, marketable debt securities, certain equity securities and foreign currency exchange contracts are reported at their respective fair values on our Condensed Consolidated Balance Sheets. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Short-term and long-term debt are reported at their amortized costs on our Condensed Consolidated Balance Sheets. The remaining financial instruments are reported on our Condensed Consolidated Balance Sheets at amounts that approximate current fair values. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment in Galapagos&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability for MYR contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our equity securities measured at fair value on a recurring basis on our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes equity investment in Galapagos NV (&#x201c;Galapagos&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments not measured at fair value and excluded from the above tables were limited partnerships and other equity method investments of $69 million and $58 million at March&#160;31, 2021 and December&#160;31, 2020, respectively, and other equity investments without readily determinable fair values of $225 million and $204 million at March&#160;31, 2021 and December&#160;31, 2020, respectively. These amounts were included in Other long-term assets on our Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of equity securities resulted in net unrealized losses of $351&#160;million and $283&#160;million for the three months ended March 31, 2021 and 2020, respectively, which were included in Other income (expense), net on our Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our available-for-sale debt securities are classified as cash equivalents, short-term marketable securities and long-term marketable securities in our Condensed Consolidated Balance Sheets. See Note 4. Available-For-Sale Debt Securities for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Investment in Galapagos&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our equity investment in Galapagos in our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:9.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We elected and applied the fair value option to account for our equity investment in Galapagos whereby the investment is marked to market through earnings each reporting period based on the market price of Galapagos shares. We believe the fair value option best reflects the underlying economics of the investment. The portion of the investment subject to long-term contractual lock-up provisions is classified within Other long-term assets and the remainder is classified as Prepaid and other current assets on our Condensed Consolidated Balance Sheets. Subsequent to the first quarter of 2021, we amended the Galapagos subscription agreement to extend the initial lock-up provision for certain Galapagos shares from August 2021 to August 2024. As a result, all of our equity investment in Galapagos became subject to long-term contractual lock-up provisions and will be classified as Other long-term assets commencing in the second quarter of 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2 Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair values of Level 2 financial instruments by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;amp;P Global Ratings, Moody&#x2019;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, London Interbank Offered Rates and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total estimated fair values of our aggregate short-term and long-term debt, determined using Level 2 inputs based on their quoted market values, were approximately $31.6 billion and $34.6 billion as of March&#160;31, 2021 and December&#160;31, 2020, respectively, and the carrying values were $29.1 billion and $30.3 billion as of March&#160;31, 2021 and December&#160;31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3 Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2021, we measured assets acquired and liabilities assumed at fair value on a nonrecurring basis, in connection with our acquisition of MYR GmbH (&#x201c;MYR&#x201d;). Total consideration for the MYR acquisition included a liability for contingent consideration of $341 million as of the acquisition date. This contingent liability was measured at fair value using probability-weighted scenarios for FDA approval. See Note 6. Acquisitions for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021 and December&#160;31, 2020, the carrying value of the liability related to future royalties assumed from the fourth quarter 2020 Immunomedics, Inc. (&#x201c;Immunomedics&#x201d;) acquisition approximated fair value, determined using Level 3 inputs. See Note 10. Debt and Credit Facilities for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfNDc5Mw_298d15ae-c8e0-45ff-95f2-d119c2528a3b">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 1 inputs include quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. For our marketable securities, we review trading activity and pricing as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. &lt;/span&gt;&lt;/div&gt;Our financial instruments consist primarily of cash and cash equivalents, marketable debt securities, accounts receivable, foreign currency exchange contracts, equity securities, accounts payable and short-term and long-term debt. Cash and cash equivalents, marketable debt securities, certain equity securities and foreign currency exchange contracts are reported at their respective fair values on our Condensed Consolidated Balance Sheets. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Short-term and long-term debt are reported at their amortized costs on our Condensed Consolidated Balance Sheets. The remaining financial instruments are reported on our Condensed Consolidated Balance Sheets at amounts that approximate current fair values.&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We elected and applied the fair value option to account for our equity investment in Galapagos whereby the investment is marked to market through earnings each reporting period based on the market price of Galapagos shares. We believe the fair value option best reflects the underlying economics of the investment. The portion of the investment subject to long-term contractual lock-up provisions is classified within Other long-term assets and the remainder is classified as Prepaid and other current assets on our Condensed Consolidated Balance Sheets. Subsequent to the first quarter of 2021, we amended the Galapagos subscription agreement to extend the initial lock-up provision for certain Galapagos shares from August 2021 to August 2024. As a result, all of our equity investment in Galapagos became subject to long-term contractual lock-up provisions and will be classified as Other long-term assets commencing in the second quarter of 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2 Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair values of Level 2 financial instruments by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;amp;P Global Ratings, Moody&#x2019;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, London Interbank Offered Rates and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfNDgxNA_0390aa09-c3c1-47bc-9c5b-83f6a1e6553f">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment in Galapagos&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability for MYR contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7c6858c51c1e4711938e993b04877b4e_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNC0xLTEtMS0w_b671a63b-ddc3-4391-8b9c-b74fcabe9a4e"
      unitRef="usd">464000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if96617e7cd54426a8d62efdc0b500ca3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNC0zLTEtMS0w_fcd63d1a-4e67-40b4-b0b9-78cc4293dc42"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id0ad9df8e3f742f8a9d13605d46cdb6f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNC01LTEtMS0w_ead00879-345b-4939-836d-ce9b55b7a58b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i31c0a79638a0401ca700e01bc980c823_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNC03LTEtMS0w_04c5c87b-da58-4b1b-913a-2e82d429e5f9"
      unitRef="usd">464000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7b3360b0081141b68f60fc04b739a94b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNC05LTEtMS0w_3c91bb61-74a2-4b21-85d1-6effee925a43"
      unitRef="usd">309000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i93e1474c09ed43708fdbb6b69bc558b3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNC0xMS0xLTEtMA_da4475bd-daa4-486e-bc74-022cc6398110"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ief5d8a88cb0c498aa5bab8062cadc5e2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNC0xMy0xLTEtMA_15033581-4827-4372-9e92-84fedc00918a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1e340b8dc03c46e9847845ecc93cd50d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNC0xNS0xLTEtMA_0abce4cd-da47-4317-9105-d6a3b402e13a"
      unitRef="usd">309000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5a5e98f04e5240d491e0cc8b9dddefdb_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNS0xLTEtMS0w_33709120-8958-4192-a3e7-02c878fe8fa1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i97d51408424340dda5bf1d3aa89904bb_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNS0zLTEtMS0w_fbfdfb28-a162-4362-a590-b00b542d5f29"
      unitRef="usd">358000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibb8af5d71f544b89bc874338694fa854_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNS01LTEtMS0w_0ccb63a9-7733-4415-9d3a-8d71b21619c5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ied9f8a90eedf43f299e27e814d996911_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNS03LTEtMS0w_cdd19b40-7cdc-4854-a3ce-5d3b3f007df1"
      unitRef="usd">358000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i07d6a99463d548be91dccf3d8477c710_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNS05LTEtMS0w_ad359cd0-3c6c-453f-aad9-1fdb582c3b31"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i00c48252b08b4726a781e4f7f1713886_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNS0xMS0xLTEtMA_c07a31aa-3431-49f1-8187-fa4d97a9495e"
      unitRef="usd">216000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i555b95565b354fac92b93a98e20786a0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNS0xMy0xLTEtMA_82f442ca-1c42-4ce5-aba4-02ea7b025f81"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie7f7eb5d72aa41e389a203f002990378_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNS0xNS0xLTEtMA_5687f262-9576-4fa0-b44f-a3c0ba8cbf5c"
      unitRef="usd">216000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iade14a2b611b4dc4a1182a5853afb334_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNy0xLTEtMS0w_dc5aa362-dfc2-4fce-a6bb-e1935b4e7d11"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id4464d90589e45bda0d671fed402ff0e_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNy0zLTEtMS0w_59e6ed3b-2aac-4634-84a3-7c3e33408417"
      unitRef="usd">62000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6b417832f6cc49f191f7192d1a823352_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNy01LTEtMS0w_100f0305-bd02-4abd-9a48-053b3df862a1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idc9df4486c8247a19dc93d1ed8ddc162_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNy03LTEtMS0w_733d16e6-cd24-4d8b-b539-a2f7051df7e9"
      unitRef="usd">62000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic28662f110d3489097e5bfb6893f2427_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNy05LTEtMS0w_bbf04743-0be3-4aa2-8789-d231cb270262"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic05e70bbe4b3409dae83bc7d0776ac63_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNy0xMS0xLTEtMA_f3a7a913-5af3-4aeb-b522-20c3bdcebac1"
      unitRef="usd">43000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6e9200ff492148ae8c58c24ec1cd7a91_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNy0xMy0xLTEtMA_de7f33af-4432-481e-abc8-51c6ab2e24e6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6d0c1157b3a14d309db0f095df92bde3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfNy0xNS0xLTEtMA_b9393e1e-d25b-4768-b06d-3eac3c62bff9"
      unitRef="usd">43000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i152ea6395daa4d07b42285941bcfdf86_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOC0xLTEtMS0w_d40c60ff-8720-4d7c-8458-4c9a815aa181"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i52d21135f58b461f951b28b78af74777_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOC0zLTEtMS0w_ba4f916e-a04a-43e7-8bdf-4de081c1eba8"
      unitRef="usd">1247000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i377ef2a3c67e4eddb0210c423899d36b_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOC01LTEtMS0w_741e432b-4d0a-43fe-a934-701375768725"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i25828069eb6f42dd8588993c039568a3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOC03LTEtMS0w_f3c3daff-c64d-4bd5-871f-3cf1f94c7002"
      unitRef="usd">1247000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3222bce3d3fd40099ca0065f76398572_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOC05LTEtMS0w_cacaa7c1-8ade-493d-aa31-77d1de37f792"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7823458e96f5434ba771f22ab8eaabf9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOC0xMS0xLTEtMA_687245b2-f90d-4e0c-a3f7-2a62fd2c485b"
      unitRef="usd">1142000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i64c79cd884d64f78bc716dbc267e3aaa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOC0xMy0xLTEtMA_6090930d-9f64-4fd3-a932-e66f0586c7f9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i00681abd09ab444f83e854d3a2172b8e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOC0xNS0xLTEtMA_bf7989e7-ac9b-45a7-ad5c-9fc22163ac0f"
      unitRef="usd">1142000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia0d37ded2b7640aa9128dac07431cd34_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOS0xLTEtMS0w_20207623-4413-498d-b891-00dd0a0ed2ef"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3a4a45ef79134c3eb7aefea81863cd66_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOS0zLTEtMS0w_16057d94-2ed1-4e75-87e3-6de6299fcc35"
      unitRef="usd">347000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6b6fb120815b4e528bfe5109cd7d6515_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOS01LTEtMS0w_2abc5a0b-d3fa-4261-b024-63676ce31fe1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib3664faeffef41cf8c6784e97bf9f9e9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOS03LTEtMS0w_84cfcf26-9849-4130-b2c3-6b78c6d69099"
      unitRef="usd">347000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia462feb041e340b58c473503f10bf35b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOS05LTEtMS0w_f5832a5b-dbed-4752-8f8e-00027e2a33ea"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1db9c8c7496f46a8a743dffc446c7a18_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOS0xMS0xLTEtMA_1c632e66-09ba-4066-a287-35eb83079c64"
      unitRef="usd">316000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7f4efed1bea843dc869bb5263b87e2ad_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOS0xMy0xLTEtMA_cee29fa2-e107-45d2-862d-02e22f95d80e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i00a4be1eea0d49da818f2dfc2e5cfec6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfOS0xNS0xLTEtMA_7708c30e-2730-4b7c-8e7c-6cb624038181"
      unitRef="usd">316000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic3fb2529cb7c446b9a528d1a8b7febe6_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtMi0xLTEtNDc0Ng_31c82c7e-3871-41d1-870b-1d921f49b82f"
      unitRef="usd">2216000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i88a5a0a5260942a38c682ec567b73ed3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtNC0xLTEtNDc0Ng_d0beaee3-089c-4337-9d8f-6f6c321641b3"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i30f95952d5ad4c11a2bb8bfb311497de_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtNi0xLTEtNDc0Ng_712d4d76-ea88-44d9-8c46-2d0f38692242"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i49e347d7180a4083bef177c0caac5662_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtOC0xLTEtNDc0Ng_6f35eae5-61a5-4273-b9e5-345bb98e65d5"
      unitRef="usd">2216000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i19b688ee3c124c99aecfd55f3756946d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtMTAtMS0xLTQ3NDY_291d170d-2249-41a2-a141-cc0f406769b6"
      unitRef="usd">4361000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id0f6e93e4ace4564af67e889d7a1da32_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtMTItMS0xLTQ3NDY_e7ef12ed-d362-4542-8b09-98ff97a58342"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8ab32a7541324448912a25d6eb8375b8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtMTQtMS0xLTQ3NDY_c01121cf-e579-45d9-9575-63211d3d6f3e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9a15e23f32af40a1b8c8859ebe00a14c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtMTYtMS0xLTQ3NDY_6d538192-c448-4107-8700-b852fba0efcb"
      unitRef="usd">4361000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2ee618b24da746db97c20d8ee326d75b_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtMS0xLTEtMA_ea3f7d1d-aa6a-4f2f-9874-17b5b23acd4e"
      unitRef="usd">1302000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6ecc557b23e64f7f8b3e28f3bb1e98a7_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtMy0xLTEtMA_25150040-e3e1-4508-b935-c8f96c2473a0"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9c9d39b9d99e449cb7beaed696f22f66_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtNS0xLTEtMA_f1bb40ab-b972-41a7-ad3f-04b981fccd27"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9a792f48d4514975b5fc1c1b4ed9d133_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtNy0xLTEtMA_b3d310fc-b00b-4fa9-a308-30f24856f79e"
      unitRef="usd">1302000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1b4ada8e24d54ee1b49c8cb41dc0bb2a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtOS0xLTEtMA_6b2a400b-e1fb-4798-94cc-b2ce4b8de36e"
      unitRef="usd">1648000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9f6cb1f3baba4062821903054d8f7abe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtMTEtMS0xLTA_a7df6b79-336d-408d-8475-72003e75b715"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ifc6563b6f71a489583fb4e031963948f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtMTMtMS0xLTA_560ab51c-c7d9-4c3e-8840-5777f02b5ca9"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5ad38733f4904e358d2e5a32c94b2371_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTEtMTUtMS0xLTA_20eb8e6d-c32d-454b-bab0-c52a0809c187"
      unitRef="usd">1648000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if9ddc669c48f47d4bd4a8213c2574ab2_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTMtMS0xLTEtMA_091ac2df-1258-44c6-b958-e4ed13a821a2"
      unitRef="usd">968000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ied694544bbe046f5abc557c39b011a0b_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTMtMy0xLTEtMA_a3a478c4-e5c5-4370-b42c-64fb3241dba4"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia3bc6d62c5104b8c8d39a0ae9f7af156_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTMtNS0xLTEtMA_a2f5fa12-70f6-41ac-8a14-dff26afd6713"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id19a8a5f19494cf0b1f5311d3e01397e_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTMtNy0xLTEtMA_75219eaa-1c37-41ad-b8ef-af41efd88839"
      unitRef="usd">968000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i679d3266010f46df9faca1c635a05771_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTMtOS0xLTEtMA_864b085d-089e-43f7-8914-ef62112453b8"
      unitRef="usd">743000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie908d94aad8a48da9603237735f6394b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTMtMTEtMS0xLTA_6c09ef7b-d98f-4fda-baff-2e327bffcf3e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia516bf91deb6424abb224de23f37284b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTMtMTMtMS0xLTA_3930317f-713c-4073-82c0-cf66eb4cf8df"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4ea5455638c849c895022cdbce0f998c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTMtMTUtMS0xLTA_13cbd89b-ce25-4951-94bd-4faf5a7ee542"
      unitRef="usd">743000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i49ae8bae833b4b0296c3d14e93ef42cc_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTQtMS0xLTEtMA_3c16de01-881d-47ee-901f-b3b8cda3ddc0"
      unitRef="usd">235000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if4a3d53db4d24b249fa3b917fb325e05_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTQtMy0xLTEtMA_b20b7160-5a4e-48cc-aa6c-2a226309bbd7"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i86cb4e206c9e40978c991361828e2661_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTQtNS0xLTEtMA_da8eea13-809c-4ecc-8d6d-2311745152ca"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic136b1c243ab4833b7ff10d92f76ed3b_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTQtNy0xLTEtMA_3bcc33e4-3146-47d7-ba1d-aafbbfee33b7"
      unitRef="usd">235000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i676cb8c8931248afb9e78b6bc23fc50a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTQtOS0xLTEtMA_c9d1de4f-13b8-44ab-ab3b-02dc94da116a"
      unitRef="usd">218000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if5e8131ea89e4f1490b4e83e0d880fa4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTQtMTEtMS0xLTA_275d529a-8f51-40a2-8e0b-2ea9333b311e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i972f4f0a16784ee889562e13a1463c5d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTQtMTMtMS0xLTA_f0cf8a25-11d7-4b3d-8d4f-3ec8754b33d0"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iac1c2aeaca014e89ae0337e0d8ff78f8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTQtMTUtMS0xLTA_ab9e40e6-e2b1-4704-9ff0-cae9d48284cd"
      unitRef="usd">218000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i6227824f558c4cf0ba46ee925f4ba83c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTUtMS0xLTEtMA_63d35edb-c409-4cd0-b34c-256520ede597"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="iafe8c56a47ec438f9d41105497550c3a_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTUtMy0xLTEtMA_b3545b9f-1b0d-4d08-a584-f41b545a0d81"
      unitRef="usd">32000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ia740610ef9fb41c794dfff273c3759dd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTUtNS0xLTEtMA_b98420e7-a173-472a-a865-2c1705a31e43"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="id021fadde4cf4151b8857bcbfbaa339f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTUtNy0xLTEtMA_f7c5af96-7eb2-4c28-a0c4-fb9d7cf7f2c1"
      unitRef="usd">32000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="idef828ce7dea449aa7d5797f8b58b3f6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTUtOS0xLTEtMA_73876431-5b7b-4eb3-b756-c275daac63f2"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i63e11f3f2e3d40369f3e6bd198c01b8f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTUtMTEtMS0xLTA_e2aec4de-9ae9-44b7-a069-902f2ddacd2d"
      unitRef="usd">12000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i08cfe9d6b24b4cdfafdaa13b884170c0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTUtMTMtMS0xLTA_5389845f-ecd5-426e-9678-ffdeee96aef8"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i1e6608db0e98415cb580d29b81c635ca_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTUtMTUtMS0xLTA_4f16d221-0fd5-464c-829f-ac1201a31d9d"
      unitRef="usd">12000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i985051c2ebfb41d0b2027dcd0777c115_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTYtMS0xLTEtMA_29309456-5a39-43ef-887d-aabf46af9b15"
      unitRef="usd">5185000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i15435e6a628245f9a04322eb3570b28e_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTYtMy0xLTEtMA_40ac7583-ea68-4d8d-a452-0a0aed729c71"
      unitRef="usd">2046000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib612747a67f64d9b91c1ab19e54958ed_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTYtNS0xLTEtMA_c6c82094-5f0a-42db-b09d-c82ac266c605"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id8330bb360aa481b97cd6a1b14847b1d_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTYtNy0xLTEtMA_f4632d56-10a7-4639-be96-e75acc227659"
      unitRef="usd">7231000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ief0436ce6e3d435288b49bb3c284e932_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTYtOS0xLTEtMA_a15d952c-f600-462c-89ca-021a7ad06657"
      unitRef="usd">7279000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia5405c11586b401189e38d818eda683a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTYtMTEtMS0xLTA_d74e7875-05ca-46ea-821c-b9a2bedaaf55"
      unitRef="usd">1729000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iecff646d1fe84980876d9a9c81fd66c9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTYtMTMtMS0xLTA_5698044a-922e-462b-8a79-7cbed5183dcf"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibdf1d864d25b418bb9159fa7600a42ac_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTYtMTUtMS0xLTA_fd278263-7b43-4b6d-8d00-4433aefb25bd"
      unitRef="usd">9008000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8a23cea7a9ba48798f1fd6bbaffb4921_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtMi0xLTEtNjQxNw_7d2680ac-6889-480b-9abf-5bceb5fb0e93"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7fc48886b65840e5a1585ee67a7e5017_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtNC0xLTEtNjQxNw_1f15ba55-1014-4a07-9ea0-d2d7e6461a56"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i86da9eb4322542f1b0071e4a1ce91218_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtNi0xLTEtNjQxNw_4cb85237-fea7-42ea-8bcb-250f7a0c0f60"
      unitRef="usd">341000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i96f6368de4194af297dac9a63844f55e_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtOC0xLTEtNjQxNw_79bce34b-e081-462f-accb-323f46af583b"
      unitRef="usd">341000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i712971393ae14ae89870e173db5b2a1a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtMTAtMS0xLTY0MTc_b3249ae1-576d-4d88-a38a-27579e97cc20"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1244e3889c7843578e273ee679a43474_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtMTItMS0xLTY0MTc_c5ea76ed-0e68-40df-ad7a-bbc4ab6b284d"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i283158ca5b0642c59af33bc78f9e3655_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtMTQtMS0xLTY0MTc_243bf6db-5ac5-487b-97c5-fe56d137a9b0"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i85636e0ea3524ff98a8b2e838f9c8141_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtMTYtMS0xLTY0MTc_4d962893-0b29-4c97-9eda-f3dda8b2dd03"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i49ae8bae833b4b0296c3d14e93ef42cc_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtMS0xLTEtMA_4409fb88-4e7a-47cb-af70-f62a106c8863"
      unitRef="usd">235000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="if4a3d53db4d24b249fa3b917fb325e05_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtMy0xLTEtMA_ea1317f4-81f5-4582-bb46-34c539a582d8"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i86cb4e206c9e40978c991361828e2661_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtNS0xLTEtMA_c942cac9-1b5c-4ed7-9dfb-afe28a16062c"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="ic136b1c243ab4833b7ff10d92f76ed3b_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtNy0xLTEtMA_3de4b75b-4802-438c-916d-291dac75ff7b"
      unitRef="usd">235000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i676cb8c8931248afb9e78b6bc23fc50a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtOS0xLTEtMA_b8cd6ba0-9fca-4ff6-b167-590433d3a728"
      unitRef="usd">218000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="if5e8131ea89e4f1490b4e83e0d880fa4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtMTEtMS0xLTA_d00131c4-fdce-4b64-9042-ed646a337447"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i972f4f0a16784ee889562e13a1463c5d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtMTMtMS0xLTA_3021a8a7-2f33-4058-8c6f-88899230ec98"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="iac1c2aeaca014e89ae0337e0d8ff78f8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTgtMTUtMS0xLTA_b6d6a1b2-fd65-4b91-9bc6-926f742dcac0"
      unitRef="usd">218000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i6227824f558c4cf0ba46ee925f4ba83c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTktMS0xLTEtMA_9bff509d-6a9a-4fa4-b178-ca87ade1767e"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="iafe8c56a47ec438f9d41105497550c3a_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTktMy0xLTEtMA_980eaa6a-ab6b-494a-9126-a6dc36e3f733"
      unitRef="usd">41000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ia740610ef9fb41c794dfff273c3759dd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTktNS0xLTEtMA_e2e98c36-755b-4dc4-b79b-2eac9cefdf8f"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="id021fadde4cf4151b8857bcbfbaa339f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTktNy0xLTEtMA_761bb0fb-ff86-49ca-a2e7-2c9135f51899"
      unitRef="usd">41000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="idef828ce7dea449aa7d5797f8b58b3f6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTktOS0xLTEtMA_420cea65-50c8-45c5-9a2d-d8c7fd25f841"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i63e11f3f2e3d40369f3e6bd198c01b8f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTktMTEtMS0xLTA_b984346f-516d-4534-8eb4-bf4dfec19305"
      unitRef="usd">121000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i08cfe9d6b24b4cdfafdaa13b884170c0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTktMTMtMS0xLTA_303098f3-bc1b-443b-a623-96fc59b995c8"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i1e6608db0e98415cb580d29b81c635ca_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMTktMTUtMS0xLTA_5a86def0-4641-4b2b-a464-126b1bda2af1"
      unitRef="usd">121000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i985051c2ebfb41d0b2027dcd0777c115_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMjAtMS0xLTEtMA_90cc32d9-7358-46dc-8849-921169e0a521"
      unitRef="usd">235000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i15435e6a628245f9a04322eb3570b28e_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMjAtMy0xLTEtMA_9900458a-0c52-4f73-bac1-fde6f6c8e9bf"
      unitRef="usd">41000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib612747a67f64d9b91c1ab19e54958ed_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMjAtNS0xLTEtMA_0b13a6dc-cd76-4954-867d-723671c94ba6"
      unitRef="usd">341000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id8330bb360aa481b97cd6a1b14847b1d_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMjAtNy0xLTEtMA_9e89b42c-a376-4ce3-a5ab-0489c2e7ea16"
      unitRef="usd">617000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ief0436ce6e3d435288b49bb3c284e932_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMjAtOS0xLTEtMA_e0b74e86-9b14-46d5-8c8f-c47eb30dc9be"
      unitRef="usd">218000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia5405c11586b401189e38d818eda683a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMjAtMTEtMS0xLTA_2df2e355-fd9d-4366-9cea-b2634fc8383c"
      unitRef="usd">121000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iecff646d1fe84980876d9a9c81fd66c9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMjAtMTMtMS0xLTA_d69171d7-2ec9-4129-8941-4d31763be878"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ibdf1d864d25b418bb9159fa7600a42ac_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmU2ZWRlMzE3M2ViZDQ0MjQ5ZGI4NTFhNGVjMjA3MjkzL3RhYmxlcmFuZ2U6ZTZlZGUzMTczZWJkNDQyNDlkYjg1MWE0ZWMyMDcyOTNfMjAtMTUtMS0xLTA_9deccd9b-cbd0-44b0-b2b0-ca7611e521e4"
      unitRef="usd">339000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfOTg5NTYwNDY2OTEyMg_70d95b97-fe56-46f6-b7f6-d0eac36d35ea">&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our equity securities measured at fair value on a recurring basis on our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes equity investment in Galapagos NV (&#x201c;Galapagos&#x201d;)&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7819b77653554557af820a95339c1b48_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOjgyYTk4MGI0ODU3OTQzYWJhODgyZTQ0ZGU4ZmNmMmQyL3RhYmxlcmFuZ2U6ODJhOTgwYjQ4NTc5NDNhYmE4ODJlNDRkZThmY2YyZDJfMS0yLTEtMS00Njkz_35ff8fe9-93ea-47a7-bd05-78c589ed1872"
      unitRef="usd">2216000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i82dd65450f234374bcea4a2190eb3484_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOjgyYTk4MGI0ODU3OTQzYWJhODgyZTQ0ZGU4ZmNmMmQyL3RhYmxlcmFuZ2U6ODJhOTgwYjQ4NTc5NDNhYmE4ODJlNDRkZThmY2YyZDJfMS00LTEtMS00Njkz_2b32d83d-73dd-44e0-addf-46763c48e6dc"
      unitRef="usd">4361000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i69731411c56349848eae4d9b486db920_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOjgyYTk4MGI0ODU3OTQzYWJhODgyZTQ0ZGU4ZmNmMmQyL3RhYmxlcmFuZ2U6ODJhOTgwYjQ4NTc5NDNhYmE4ODJlNDRkZThmY2YyZDJfMi0yLTEtMS00Njkz_ae84953e-f655-4300-81fc-8005d6a28c14"
      unitRef="usd">797000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6dee5b3f2c69441494dc09dbd6b1224c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOjgyYTk4MGI0ODU3OTQzYWJhODgyZTQ0ZGU4ZmNmMmQyL3RhYmxlcmFuZ2U6ODJhOTgwYjQ4NTc5NDNhYmE4ODJlNDRkZThmY2YyZDJfMi00LTEtMS00Njkz_b1afeaf7-469c-408e-861c-8bd52c75d3dc"
      unitRef="usd">853000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i87d4f540cc2348449700aa4e9824ba95_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOjgyYTk4MGI0ODU3OTQzYWJhODgyZTQ0ZGU4ZmNmMmQyL3RhYmxlcmFuZ2U6ODJhOTgwYjQ4NTc5NDNhYmE4ODJlNDRkZThmY2YyZDJfMy0yLTEtMS00Njkz_2ddf770b-1236-4c02-82d8-68201fa9045b"
      unitRef="usd">1708000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i842226164126495eb19a5f6e285f7a87_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOjgyYTk4MGI0ODU3OTQzYWJhODgyZTQ0ZGU4ZmNmMmQyL3RhYmxlcmFuZ2U6ODJhOTgwYjQ4NTc5NDNhYmE4ODJlNDRkZThmY2YyZDJfMy00LTEtMS00Njkz_5cfa89d3-2ef6-4882-a4af-9175eac81139"
      unitRef="usd">1756000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i775975dd06c34a91977a0d26c3c7aad3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOjgyYTk4MGI0ODU3OTQzYWJhODgyZTQ0ZGU4ZmNmMmQyL3RhYmxlcmFuZ2U6ODJhOTgwYjQ4NTc5NDNhYmE4ODJlNDRkZThmY2YyZDJfNC0yLTEtMS00Njkz_48d4c97a-df99-4aa5-830a-96abbcceb902"
      unitRef="usd">4721000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i31a2c0299c3f47b68f2ee84425bd6ba4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOjgyYTk4MGI0ODU3OTQzYWJhODgyZTQ0ZGU4ZmNmMmQyL3RhYmxlcmFuZ2U6ODJhOTgwYjQ4NTc5NDNhYmE4ODJlNDRkZThmY2YyZDJfNC00LTEtMS00Njkz_24828fc1-215e-46bc-99be-9c56f184d45b"
      unitRef="usd">6970000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfMTA5OTUxMTYzNDc5NQ_aea03bf8-2e3e-4197-ab61-0d2400668053"
      unitRef="usd">69000000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfMTA5OTUxMTYzNDc3OA_353eb7dd-9bf8-4c78-89ad-fcb2333c61e9"
      unitRef="usd">58000000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfMTA5OTUxMTYzNDgzMw_d5077442-1d61-4db6-9bb3-b29bf5f21378"
      unitRef="usd">225000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfMTA5OTUxMTYzNDgxNQ_de16daaf-84fe-4465-b334-1ad3378d6db9"
      unitRef="usd">204000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfNDM5ODA0NjUzOTM2OQ_a281a611-e46e-46fe-84b8-4684db6ec90c"
      unitRef="usd">-351000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfNDM5ODA0NjUzOTM3Nw_07082604-9388-43b2-8132-8f03400a8da6"
      unitRef="usd">-283000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfOTg5NTYwNDY3ODI2Mw_b0a071bf-3ef1-4d79-a074-7057f13902d4">&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our equity investment in Galapagos in our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:9.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie4079e9eaf1b42a79cea9514877ac8eb_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmVlNmU5YjU5MjU4ZTRkZTY5YjA4ZGEzN2ZiNGYzNGViL3RhYmxlcmFuZ2U6ZWU2ZTliNTkyNThlNGRlNjliMDhkYTM3ZmI0ZjM0ZWJfMS0yLTEtMS0xMDI0NA_270c67ef-fb9a-46dd-8f3b-959fb7a4885b"
      unitRef="usd">276000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i707925a6e11e4e8b89cd1de5486dccd6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmVlNmU5YjU5MjU4ZTRkZTY5YjA4ZGEzN2ZiNGYzNGViL3RhYmxlcmFuZ2U6ZWU2ZTliNTkyNThlNGRlNjliMDhkYTM3ZmI0ZjM0ZWJfMS00LTEtMS0xMDI0NA_e438fd05-5eda-454d-89e3-f0f8a3405d72"
      unitRef="usd">351000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if9ff815d16ad4190a3c3cc2de4b5e390_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmVlNmU5YjU5MjU4ZTRkZTY5YjA4ZGEzN2ZiNGYzNGViL3RhYmxlcmFuZ2U6ZWU2ZTliNTkyNThlNGRlNjliMDhkYTM3ZmI0ZjM0ZWJfMi0yLTEtMS0xMDI0NA_f22198b1-ad66-45cc-92ce-0a90f6a8358d"
      unitRef="usd">1026000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib2cfe856897d47a4a15c011727b132a4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmVlNmU5YjU5MjU4ZTRkZTY5YjA4ZGEzN2ZiNGYzNGViL3RhYmxlcmFuZ2U6ZWU2ZTliNTkyNThlNGRlNjliMDhkYTM3ZmI0ZjM0ZWJfMi00LTEtMS0xMDI0NA_9a8dd7c9-bca6-4cff-8463-c4baf37d48be"
      unitRef="usd">1297000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9ccba16f84d64786acebdc56d30d2961_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmVlNmU5YjU5MjU4ZTRkZTY5YjA4ZGEzN2ZiNGYzNGViL3RhYmxlcmFuZ2U6ZWU2ZTliNTkyNThlNGRlNjliMDhkYTM3ZmI0ZjM0ZWJfMy0yLTEtMS0xMDI0NA_dfe9e179-8151-4f63-987b-b5c6b609da50"
      unitRef="usd">1302000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3b637184cf1d4fd595b58c5754beb956_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RhYmxlOmVlNmU5YjU5MjU4ZTRkZTY5YjA4ZGEzN2ZiNGYzNGViL3RhYmxlcmFuZ2U6ZWU2ZTliNTkyNThlNGRlNjliMDhkYTM3ZmI0ZjM0ZWJfMy00LTEtMS0xMDI0NA_eddbf162-55ae-4fc2-aada-a08292f2b169"
      unitRef="usd">1648000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:LongTermDebtFairValue
      contextRef="i5a4c7af7aa214730805797a174566133_I20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfNDY3Mw_f3bc261a-06bb-4971-a797-d80c749032c9"
      unitRef="usd">31600000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="if73c04ebb10b4c1fb24efca2362f9a22_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfNDY4MA_7fd11a31-18d7-40b3-b821-fa2a6fe3432d"
      unitRef="usd">34600000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i89f38dcb82a5491dbb25812d7738c19b_I20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfNDc0Mw_de6c4b1d-e66e-4884-bbf3-1bf7750227e7"
      unitRef="usd">29100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iffef8ea761174ff198789287afe52e44_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfNDc1MA_326587ca-64d0-4553-b1b2-c78ca939c07c"
      unitRef="usd">30300000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i86da9eb4322542f1b0071e4a1ce91218_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180MC9mcmFnOmIwNTQ4ZWU3M2IxYzQ3NTI5N2RlNjYwYWJhMWY0ZWYyL3RleHRyZWdpb246YjA1NDhlZTczYjFjNDc1Mjk3ZGU2NjBhYmExZjRlZjJfMTA5OTUxMTY0Mzk3Mw_fdf272d9-56e7-467b-8dce-2847e3c8f630"
      unitRef="usd">341000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RleHRyZWdpb246OTk1NjkwZmExZjI1NGY2ZDhhZTIyY2Q4ZjE0ZGI4ZTlfMTA2OQ_16c765be-fbb9-41a8-8393-8dc27d256258">AVAILABLE-FOR-SALE DEBT SECURITIES&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest receivable excluded from both the fair value and amortized cost basis of the available-for-sale debt securities was $9 million as of March&#160;31, 2021 and December&#160;31, 2020 and is recorded in Prepaid and other current assets on our Condensed Consolidated Balance Sheets. There were no write-offs of accrued interest receivable during the three months ended March 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities by contractual maturity: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;We held a total of 203 positions which were in an unrealized loss position as of March&#160;31, 2021. The unrealized losses are largely due to changes in interest rates. Aggregated gross unrealized losses on available-for-sale debt securities were not material, and accordingly, no impairment was recognized for the three months ended March 31, 2021. Gross realized gains and gross realized losses on available-for-sale debt securities were not material for the three months ended March 31, 2021.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RleHRyZWdpb246OTk1NjkwZmExZjI1NGY2ZDhhZTIyY2Q4ZjE0ZGI4ZTlfMTA4OQ_5c8f5c89-9ab2-4f66-ac4d-0cf9d91ab29d">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1a97739a676441f385dd15bc5a05b29f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMi0yLTEtMS0w_9ed8f495-9f2c-447b-8487-781257ea99b6"
      unitRef="usd">464000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1a97739a676441f385dd15bc5a05b29f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMi00LTEtMS0w_5c4eca4a-db58-4678-87ce-1e30d59512ac"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1a97739a676441f385dd15bc5a05b29f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMi02LTEtMS0w_7c0e148e-7153-4cac-a5fd-af617e6516de"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1a97739a676441f385dd15bc5a05b29f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMi04LTEtMS0w_24370252-1095-4a37-8c41-3deeedf7e06e"
      unitRef="usd">464000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i69e005c46bfd4e5c8cfa65d68167b7ff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMi0xMC0xLTEtMA_856d1588-9d16-4971-92ef-bc1ec2c9d57c"
      unitRef="usd">308000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i69e005c46bfd4e5c8cfa65d68167b7ff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMi0xMi0xLTEtMA_1ad64496-b9d0-4318-b965-0507159279d9"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i69e005c46bfd4e5c8cfa65d68167b7ff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMi0xNC0xLTEtMA_f2458107-6303-4e1d-9470-094dfe95145a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i69e005c46bfd4e5c8cfa65d68167b7ff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMi0xNi0xLTEtMA_5b9d9c2a-ddc7-45d9-a9e2-a1e711b924f7"
      unitRef="usd">309000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icfa8675ac1aa4739beb924a027e71114_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMy0yLTEtMS0w_302e031e-7537-44e1-b0a0-2db1031dd616"
      unitRef="usd">358000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icfa8675ac1aa4739beb924a027e71114_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMy00LTEtMS0w_5d26f44e-81f9-436a-80ee-aa31fc21b505"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icfa8675ac1aa4739beb924a027e71114_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMy02LTEtMS0w_9837c3b9-3102-4181-8f18-b7288834fca8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icfa8675ac1aa4739beb924a027e71114_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMy04LTEtMS0w_cf9f2d21-5033-4ad2-a200-de1a2d152820"
      unitRef="usd">358000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3f6999e94a9b47b8836b7e7d12120eb3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMy0xMC0xLTEtMA_ed2ae440-7d17-4469-acdb-8b530c954f9a"
      unitRef="usd">216000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3f6999e94a9b47b8836b7e7d12120eb3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMy0xMi0xLTEtMA_8a9826ca-987c-417d-a7cb-2fa14d5fc38a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3f6999e94a9b47b8836b7e7d12120eb3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMy0xNC0xLTEtMA_165703a4-b932-4cbb-8e08-d99f6b8279e5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3f6999e94a9b47b8836b7e7d12120eb3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfMy0xNi0xLTEtMA_47141dde-33c3-4d6c-afdc-108391dad515"
      unitRef="usd">216000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i96932fa83e584390b3f1d56742823d34_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNS0yLTEtMS0w_8089b467-b69c-41c6-ba1f-c95e12743d74"
      unitRef="usd">62000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i96932fa83e584390b3f1d56742823d34_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNS00LTEtMS0w_732443c1-535c-463e-9c48-6c9002f5ec9e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i96932fa83e584390b3f1d56742823d34_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNS02LTEtMS0w_f24c3ab9-1797-4d07-b106-bb9aaf390ca5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i96932fa83e584390b3f1d56742823d34_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNS04LTEtMS0w_47c2dd41-9319-4f60-b6c7-2701023e02a8"
      unitRef="usd">62000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia27960115dde4e8db6988f723a792c47_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNS0xMC0xLTEtMA_bcb1d4d9-1e26-4749-8707-3d15b096b0b7"
      unitRef="usd">43000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia27960115dde4e8db6988f723a792c47_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNS0xMi0xLTEtMA_148772fe-370c-4a77-96d8-3340e504024d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia27960115dde4e8db6988f723a792c47_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNS0xNC0xLTEtMA_27c1b1b4-9082-4cc5-ae85-4042b3625b16"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia27960115dde4e8db6988f723a792c47_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNS0xNi0xLTEtMA_8e01a46c-443a-4355-9e46-0c313fdfbd05"
      unitRef="usd">43000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if12b94fde2df458b856419eb60f3749f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNi0yLTEtMS0w_fcf1f3c0-7fbc-4ba7-b520-2e54aece2fe7"
      unitRef="usd">1247000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if12b94fde2df458b856419eb60f3749f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNi00LTEtMS0w_a2bfe9cd-9409-469a-a158-b35fd2c67f71"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if12b94fde2df458b856419eb60f3749f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNi02LTEtMS0w_27beec84-e799-4556-89b4-24a4e58aaf38"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if12b94fde2df458b856419eb60f3749f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNi04LTEtMS0w_7bcada81-7219-485f-8663-e8c000ad2c59"
      unitRef="usd">1247000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie29dcd6fa2fd430ab157b38ccbb28d3e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNi0xMC0xLTEtMA_ceb81169-9278-4ae5-9ba1-11fd20a184ae"
      unitRef="usd">1140000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie29dcd6fa2fd430ab157b38ccbb28d3e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNi0xMi0xLTEtMA_a5b86628-356c-41dd-8272-5b711faf51b0"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie29dcd6fa2fd430ab157b38ccbb28d3e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNi0xNC0xLTEtMA_79f77cdb-dd07-44b1-a1c7-70490568abaa"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie29dcd6fa2fd430ab157b38ccbb28d3e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNi0xNi0xLTEtMA_2537e578-5f3b-4d8a-a375-39ef72399792"
      unitRef="usd">1142000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib5174f6004a743eb845f20ac1490f61a_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNy0yLTEtMS0w_1e12fd61-9403-4f1d-9700-39e6999fddcc"
      unitRef="usd">347000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib5174f6004a743eb845f20ac1490f61a_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNy00LTEtMS0w_97a2228a-aa60-4d49-a3c9-d48ce48cab98"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib5174f6004a743eb845f20ac1490f61a_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNy02LTEtMS0w_59140796-5597-4e78-8e00-d7f6581e9866"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib5174f6004a743eb845f20ac1490f61a_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNy04LTEtMS0w_09df1c63-0f3c-4288-b6b2-228e634c6489"
      unitRef="usd">347000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4e49f98b54ce4b26af2d8166b46b66e9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNy0xMC0xLTEtMA_ed16f134-7cf5-47cf-9ee4-f906c609d452"
      unitRef="usd">316000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4e49f98b54ce4b26af2d8166b46b66e9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNy0xMi0xLTEtMA_9facdbb6-01dc-4a93-a875-5e884e23c42b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4e49f98b54ce4b26af2d8166b46b66e9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNy0xNC0xLTEtMA_5c57e42b-9b17-478e-9667-5377b3ea2719"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4e49f98b54ce4b26af2d8166b46b66e9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfNy0xNi0xLTEtMA_44248cfd-1e27-4847-8d76-051475443df8"
      unitRef="usd">316000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfOC0yLTEtMS0w_cce14dfc-11ec-40ec-b909-a72653cd84e3"
      unitRef="usd">2478000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfOC00LTEtMS0w_e9972a80-1035-475b-8d71-c7f78ab11718"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfOC02LTEtMS0w_745e8dc6-a1fa-4aec-8a21-c7b5edfdf976"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfOC04LTEtMS0w_7cf0e2c3-6aa8-4b35-a217-b927381d60ae"
      unitRef="usd">2478000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfOC0xMC0xLTEtMA_3ae9bec3-e744-47c8-b2f1-644c3318288b"
      unitRef="usd">2023000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfOC0xMi0xLTEtMA_b4ff1cff-6edb-4a11-926f-0c863970ba0c"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfOC0xNC0xLTEtMA_83ca511e-ddf0-44f6-a425-2bccc03d1969"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjUxYmU0MzBjYTcyNDRhMDI5ZTViMzA3NGY2NDI2ODEzL3RhYmxlcmFuZ2U6NTFiZTQzMGNhNzI0NGEwMjllNWIzMDc0ZjY0MjY4MTNfOC0xNi0xLTEtMA_464cc5fe-8e8c-4842-9e0d-54b59b3b344c"
      unitRef="usd">2026000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RleHRyZWdpb246OTk1NjkwZmExZjI1NGY2ZDhhZTIyY2Q4ZjE0ZGI4ZTlfMTA3OQ_44c58385-81bc-42f3-992c-df44be77a1e9">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2408fe312f9e4448b357064015614afc_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjk3ODQ2MGFlNGRiODQ3YTNiNDc0MmJjOGIzZmQ2MTVmL3RhYmxlcmFuZ2U6OTc4NDYwYWU0ZGI4NDdhM2I0NzQyYmM4YjNmZDYxNWZfMS0yLTEtMS0w_bcc2ffa5-d281-4422-aca3-6e683d5c8ef8"
      unitRef="usd">298000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i91624599719d473faf279a33da7ef5be_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjk3ODQ2MGFlNGRiODQ3YTNiNDc0MmJjOGIzZmQ2MTVmL3RhYmxlcmFuZ2U6OTc4NDYwYWU0ZGI4NDdhM2I0NzQyYmM4YjNmZDYxNWZfMS00LTEtMS0w_e354b82a-0189-4b65-ad0c-4be1abbd6d0a"
      unitRef="usd">113000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id1ff20f5b83944dba31b16c66a70e1a8_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjk3ODQ2MGFlNGRiODQ3YTNiNDc0MmJjOGIzZmQ2MTVmL3RhYmxlcmFuZ2U6OTc4NDYwYWU0ZGI4NDdhM2I0NzQyYmM4YjNmZDYxNWZfMi0yLTEtMS0w_4a473bab-cbda-4629-8a4a-fc090b8e46b9"
      unitRef="usd">1601000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8a1a8f49d74c45eeaa8823dd49a9aebc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjk3ODQ2MGFlNGRiODQ3YTNiNDc0MmJjOGIzZmQ2MTVmL3RhYmxlcmFuZ2U6OTc4NDYwYWU0ZGI4NDdhM2I0NzQyYmM4YjNmZDYxNWZfMi00LTEtMS0w_190eacc4-e6b6-4dbd-a012-24918f8e6578"
      unitRef="usd">1411000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3ff3207761de4a358076755192646e75_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjk3ODQ2MGFlNGRiODQ3YTNiNDc0MmJjOGIzZmQ2MTVmL3RhYmxlcmFuZ2U6OTc4NDYwYWU0ZGI4NDdhM2I0NzQyYmM4YjNmZDYxNWZfMy0yLTEtMS0w_31fe3c2a-6ed4-4ef4-b8d9-28669c4e529e"
      unitRef="usd">579000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i278cbd93950247099589a8c54d16f788_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjk3ODQ2MGFlNGRiODQ3YTNiNDc0MmJjOGIzZmQ2MTVmL3RhYmxlcmFuZ2U6OTc4NDYwYWU0ZGI4NDdhM2I0NzQyYmM4YjNmZDYxNWZfMy00LTEtMS0w_75d7931f-1b11-4089-a18e-6b3397de5667"
      unitRef="usd">502000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjk3ODQ2MGFlNGRiODQ3YTNiNDc0MmJjOGIzZmQ2MTVmL3RhYmxlcmFuZ2U6OTc4NDYwYWU0ZGI4NDdhM2I0NzQyYmM4YjNmZDYxNWZfNC0yLTEtMS0w_3b43d9ee-74e2-466a-ba83-ae45b05706e2"
      unitRef="usd">2478000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjk3ODQ2MGFlNGRiODQ3YTNiNDc0MmJjOGIzZmQ2MTVmL3RhYmxlcmFuZ2U6OTc4NDYwYWU0ZGI4NDdhM2I0NzQyYmM4YjNmZDYxNWZfNC00LTEtMS0w_2596c766-1ddc-4eb8-b4be-4ba959d60517"
      unitRef="usd">2026000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InterestReceivableCurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RleHRyZWdpb246OTk1NjkwZmExZjI1NGY2ZDhhZTIyY2Q4ZjE0ZGI4ZTlfMzUy_56328ccd-bb7e-4a24-86a9-542e216c4df0"
      unitRef="usd">9000000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RleHRyZWdpb246OTk1NjkwZmExZjI1NGY2ZDhhZTIyY2Q4ZjE0ZGI4ZTlfMzUy_8435301b-a4b3-46d1-b8a8-5245424c646b"
      unitRef="usd">9000000</us-gaap:InterestReceivableCurrent>
    <gild:WriteOffsInAccruedInterestReceivable
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RleHRyZWdpb246OTk1NjkwZmExZjI1NGY2ZDhhZTIyY2Q4ZjE0ZGI4ZTlfNDY3_3e4bc755-8551-4a29-8c16-ef76321ce728"
      unitRef="usd">0</gild:WriteOffsInAccruedInterestReceivable>
    <gild:WriteOffsInAccruedInterestReceivable
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RleHRyZWdpb246OTk1NjkwZmExZjI1NGY2ZDhhZTIyY2Q4ZjE0ZGI4ZTlfNDY3_a3b50a9d-d4d8-47fe-a84d-6f960f075383"
      unitRef="usd">0</gild:WriteOffsInAccruedInterestReceivable>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RleHRyZWdpb246OTk1NjkwZmExZjI1NGY2ZDhhZTIyY2Q4ZjE0ZGI4ZTlfMTA5Ng_c3bc1a82-2979-4b8e-947e-67cc89e97096">&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities by contractual maturity: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjdmOTc5YmUwMjJjYjQ1MTNhNTkxNDY5Y2MyZWM3YWIzL3RhYmxlcmFuZ2U6N2Y5NzliZTAyMmNiNDUxM2E1OTE0NjljYzJlYzdhYjNfMi0yLTEtMS0w_37942ee5-bfcb-4399-8be3-6105e3672f22"
      unitRef="usd">1898000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjdmOTc5YmUwMjJjYjQ1MTNhNTkxNDY5Y2MyZWM3YWIzL3RhYmxlcmFuZ2U6N2Y5NzliZTAyMmNiNDUxM2E1OTE0NjljYzJlYzdhYjNfMi00LTEtMS0w_642fad6b-08cc-40df-868d-a154b9086a32"
      unitRef="usd">1899000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjdmOTc5YmUwMjJjYjQ1MTNhNTkxNDY5Y2MyZWM3YWIzL3RhYmxlcmFuZ2U6N2Y5NzliZTAyMmNiNDUxM2E1OTE0NjljYzJlYzdhYjNfMy0yLTEtMS0w_2dc0f9a8-1aa8-48ce-8232-868dac6344d6"
      unitRef="usd">563000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjdmOTc5YmUwMjJjYjQ1MTNhNTkxNDY5Y2MyZWM3YWIzL3RhYmxlcmFuZ2U6N2Y5NzliZTAyMmNiNDUxM2E1OTE0NjljYzJlYzdhYjNfMy00LTEtMS0w_dc918503-d329-49d3-aabe-ad1881895aa1"
      unitRef="usd">562000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjdmOTc5YmUwMjJjYjQ1MTNhNTkxNDY5Y2MyZWM3YWIzL3RhYmxlcmFuZ2U6N2Y5NzliZTAyMmNiNDUxM2E1OTE0NjljYzJlYzdhYjNfNC0yLTEtMS0w_a11fbc5e-1960-49af-b958-68b7e1d839ab"
      unitRef="usd">17000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjdmOTc5YmUwMjJjYjQ1MTNhNTkxNDY5Y2MyZWM3YWIzL3RhYmxlcmFuZ2U6N2Y5NzliZTAyMmNiNDUxM2E1OTE0NjljYzJlYzdhYjNfNC00LTEtMS0w_d56ed335-78b4-4307-9834-8734194f0253"
      unitRef="usd">17000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjdmOTc5YmUwMjJjYjQ1MTNhNTkxNDY5Y2MyZWM3YWIzL3RhYmxlcmFuZ2U6N2Y5NzliZTAyMmNiNDUxM2E1OTE0NjljYzJlYzdhYjNfNS0yLTEtMS0w_7f5a186a-c17a-4ff2-8285-fecdfb19b159"
      unitRef="usd">2478000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RhYmxlOjdmOTc5YmUwMjJjYjQ1MTNhNTkxNDY5Y2MyZWM3YWIzL3RhYmxlcmFuZ2U6N2Y5NzliZTAyMmNiNDUxM2E1OTE0NjljYzJlYzdhYjNfNS00LTEtMS0w_ef246f36-c966-4021-9f70-b1134a2a63d0"
      unitRef="usd">2478000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RleHRyZWdpb246OTk1NjkwZmExZjI1NGY2ZDhhZTIyY2Q4ZjE0ZGI4ZTlfNzc2_87af183a-d4ee-44b4-8e8b-bf307a5f7e84"
      unitRef="position">203</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RleHRyZWdpb246OTk1NjkwZmExZjI1NGY2ZDhhZTIyY2Q4ZjE0ZGI4ZTlfMjc0ODc3OTA3MTA2MA_3fdc443a-76c6-4275-a395-6fc9784b4cc6"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180My9mcmFnOjk5NTY5MGZhMWYyNTRmNmQ4YWUyMmNkOGYxNGRiOGU5L3RleHRyZWdpb246OTk1NjkwZmExZjI1NGY2ZDhhZTIyY2Q4ZjE0ZGI4ZTlfMjc0ODc3OTA3MTA2MA_d6b344df-8ef5-46b6-8200-838ce78cba74"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RleHRyZWdpb246MTg2ODNjNjU1ZDNkNDY1ZDk2Mjk3NmQwZTVjNjJjMDFfMzM2MQ_29d462ae-cc83-493f-b562-ca6a27d9cb75">DERIVATIVE FINANCIAL INSTRUMENTSOur operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we may hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward or option contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes. &lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hedge our exposure to foreign currency exchange rate fluctuations for certain monetary assets and liabilities that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are not designated as hedges and, as a result, changes in their fair value are recorded in Other income (expense), net on our Condensed Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hedge our exposure to foreign currency exchange rate fluctuations for forecasted product sales that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are designated as cash flow hedges and have maturities of 18 months or less. Upon executing a hedging contract and quarterly thereafter, we assess hedge effectiveness using regression analysis. The unrealized gains or losses in Accumulated other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;AOCI&#x201d;) are reclassified into product sales when the respective hedged transactions affect earnings. The majority of gains and losses related to the hedged forecasted transactions reported in AOCI as of March&#160;31, 2021 are expected to be reclassified to product sales within 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cash flow effects of our derivative contracts for the three months ended March 31, 2021 and 2020 were included within Net cash provided by operating activities on our Condensed Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had notional amounts on foreign currency exchange contracts outstanding of $3.0 billion and $2.4 billion as of March&#160;31, 2021 and December&#160;31, 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts on a gross basis. The following table summarizes the classification and fair values of derivative instruments on our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability Derivatives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;accrued&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability Derivatives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;accrued&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of our foreign currency exchange contracts on our Condensed Consolidated Financial Statements: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) reclassified from AOCI into product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains recognized in Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we may discontinue cash flow hedges and, as a result, record related amounts in Other income (expense), net on our Condensed Consolidated Statements of Income. There were no discontinuances of cash flow hedges for the three months ended March 31, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021 and December&#160;31, 2020, we only held foreign currency exchange contracts. The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.899%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross Amounts Not Offset &lt;br/&gt;on our Condensed &lt;br/&gt;Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross Amounts&lt;br/&gt;&#160;of Recognized &lt;br/&gt;Assets/Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross Amounts&lt;br/&gt;&#160;Offset on our &lt;br/&gt;Condensed &lt;br/&gt;Consolidated &lt;br/&gt;Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amounts of Assets/Liabilities Presented&lt;br/&gt;&#160;on our Condensed Consolidated&lt;br/&gt;Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Derivative &lt;br/&gt;Financial &lt;br/&gt;Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Cash Collateral &lt;br/&gt;Received/&lt;br/&gt;Pledged&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net Amount&lt;br/&gt;&#160;(Legal Offset)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i2964d55b3b0243efb3f22c4eed834d5f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RleHRyZWdpb246MTg2ODNjNjU1ZDNkNDY1ZDk2Mjk3NmQwZTVjNjJjMDFfMTg3Ng_dacab751-7dc4-4ad3-aedd-ff8945273a13">P18M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1
      contextRef="i2964d55b3b0243efb3f22c4eed834d5f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RleHRyZWdpb246MTg2ODNjNjU1ZDNkNDY1ZDk2Mjk3NmQwZTVjNjJjMDFfMjM0MQ_62b78985-d651-4353-80f6-e7ecf2b87846">P12M</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RleHRyZWdpb246MTg2ODNjNjU1ZDNkNDY1ZDk2Mjk3NmQwZTVjNjJjMDFfMjU2NQ_80e71220-e254-4bd2-aaf7-0b7c3d85f89c"
      unitRef="usd">3000000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RleHRyZWdpb246MTg2ODNjNjU1ZDNkNDY1ZDk2Mjk3NmQwZTVjNjJjMDFfMjU3Mg_9ae4c43b-7e32-4608-bc55-3c65a616588a"
      unitRef="usd">2400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RleHRyZWdpb246MTg2ODNjNjU1ZDNkNDY1ZDk2Mjk3NmQwZTVjNjJjMDFfMzM3Ng_018e4c09-223f-4e9a-a71d-0895095d4192">The following table summarizes the classification and fair values of derivative instruments on our Condensed Consolidated Balance Sheets:&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability Derivatives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;accrued&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.508%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability Derivatives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;accrued&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i7dcabcb1cbf9400c95b149a28f9172b6_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfNC00LTEtMS0w_8c2ff02c-10b6-43e1-b3f5-a4001c38f87a"
      unitRef="usd">25000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="ia0315ed156fa4a999a216e7bf46cb806_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfNC04LTEtMS0w_9e509380-201a-424f-865e-867ce66b8ade"
      unitRef="usd">41000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i15db68ece60c4907bce23168391fc549_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfNS00LTEtMS0w_450787ed-1891-4a19-8921-bd17ac61728e"
      unitRef="usd">7000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="ib316497f09074016814019469a1c5282_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfNS04LTEtMS0w_320d2659-225f-4d43-8576-95db538823fb"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i9b3659e23b9d46dc913b50eb69f837b7_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfNi00LTEtMS0w_58d8d125-b815-43b4-bb7c-1fc7b89d60bb"
      unitRef="usd">32000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i9b3659e23b9d46dc913b50eb69f837b7_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfNi04LTEtMS0w_f4513b49-f133-4609-a2de-e9fc8a726019"
      unitRef="usd">41000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i4a4bb5869b2a4a65965e0573d5a9fc0b_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfOC00LTEtMS0w_c01d5e70-13d4-4ad0-9493-172635986185"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i15df5ed6d62b49e8bf563f685962e609_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfOC04LTEtMS0w_3e2c099d-4fe3-46ba-908f-1c26107f2282"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="ieb9b9032e3424975b8d41437080d8fd9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfOS00LTEtMS0w_f17e9418-f034-4819-b927-82b1d165c622"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="ieb9b9032e3424975b8d41437080d8fd9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfOS04LTEtMS0w_dc386720-2620-4875-b39a-f01b02013d52"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfMTAtNC0xLTEtMA_9ae5474c-1973-45b7-a091-b0ca2325154e"
      unitRef="usd">32000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjljYTE2MWIyZTQzNDRhMmE4YmM4MjZjMjkyMTRkZmVlL3RhYmxlcmFuZ2U6OWNhMTYxYjJlNDM0NGEyYThiYzgyNmMyOTIxNGRmZWVfMTAtOC0xLTEtMA_c64f8379-95f7-4cc5-82be-41464c83f536"
      unitRef="usd">41000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i37496332327e49d2bfd711461be5eee2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfNC00LTEtMS0w_42041b69-f45e-4a49-a1eb-47b1605b393c"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i84d63f6e0c374aa6a0d94624a78f5b37_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfNC04LTEtMS0w_7aa4cdd9-a769-41ac-93b0-8f069e3050fb"
      unitRef="usd">113000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i9d0edd02c9c343938d862442b6afc2af_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfNS00LTEtMS0w_47ea8131-1f92-410d-82a1-31061034c669"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i91c1249190d841d3ac8dc4919431731a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfNS04LTEtMS0w_ef012454-14d6-4051-be5f-980dcdfc23e6"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i2a21b040839549338b52418d18bb1e17_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfNi00LTEtMS0w_979840e7-d3a0-4fa8-a527-664c84d7b88f"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i2a21b040839549338b52418d18bb1e17_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfNi04LTEtMS0w_1ca3f612-e4f7-4d61-9383-da8e6266c70d"
      unitRef="usd">120000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="ia692393a1fd94bbb97576f97ccd34cce_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfOC00LTEtMS0w_ba9467ed-8795-4fa5-9e53-535bb8336de3"
      unitRef="usd">12000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="ieb12e9542cfd4e90b2dcab8f7f4c58d5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfOC04LTEtMS0w_741eb00e-0fe8-479c-997d-c32663606287"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="ic8653fde001146e0bea68d8800992d8a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfOS00LTEtMS0w_3547033d-041a-40fe-9bce-2b78e648ce2e"
      unitRef="usd">12000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="ic8653fde001146e0bea68d8800992d8a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfOS04LTEtMS0w_b64f2f91-9943-4594-a2c8-1d368bb41b8c"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfMTAtNC0xLTEtMA_770fba41-b9cd-4460-8e7b-9ef96566b7b5"
      unitRef="usd">12000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjE3YzQ4NGNkNzA4MzQ4ZjM4ODA0YjE1ZDBlYjY1NWFmL3RhYmxlcmFuZ2U6MTdjNDg0Y2Q3MDgzNDhmMzg4MDRiMTVkMGViNjU1YWZfMTAtOC0xLTEtMA_dabfbdc2-a2e5-435b-8f2a-418be0055aa8"
      unitRef="usd">121000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RleHRyZWdpb246MTg2ODNjNjU1ZDNkNDY1ZDk2Mjk3NmQwZTVjNjJjMDFfMzM2NA_c360e37b-ccc9-4080-8a16-451f4a777432">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of our foreign currency exchange contracts on our Condensed Consolidated Financial Statements: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains (losses) reclassified from AOCI into product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gains recognized in Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjI0Y2JjZDRjMzY5ZTRkM2U4MDY1MzE0OTQ1ZmQ5Zjk3L3RhYmxlcmFuZ2U6MjRjYmNkNGMzNjllNGQzZTgwNjUzMTQ5NDVmZDlmOTdfNC0yLTEtMS0w_5ce00dbb-9609-4cb2-9706-8985135060f2"
      unitRef="usd">78000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjI0Y2JjZDRjMzY5ZTRkM2U4MDY1MzE0OTQ1ZmQ5Zjk3L3RhYmxlcmFuZ2U6MjRjYmNkNGMzNjllNGQzZTgwNjUzMTQ5NDVmZDlmOTdfNC00LTEtMS0w_bd515551-c142-4972-9078-e12af128b7fa"
      unitRef="usd">66000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjI0Y2JjZDRjMzY5ZTRkM2U4MDY1MzE0OTQ1ZmQ5Zjk3L3RhYmxlcmFuZ2U6MjRjYmNkNGMzNjllNGQzZTgwNjUzMTQ5NDVmZDlmOTdfNS0yLTEtMS0w_b2b74ca5-c96c-47ae-a5cb-baf487bf52b3"
      unitRef="usd">-25000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjI0Y2JjZDRjMzY5ZTRkM2U4MDY1MzE0OTQ1ZmQ5Zjk3L3RhYmxlcmFuZ2U6MjRjYmNkNGMzNjllNGQzZTgwNjUzMTQ5NDVmZDlmOTdfNS00LTEtMS0w_9ad3a012-13c6-4c47-91a1-e6f1e1bd988b"
      unitRef="usd">27000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjI0Y2JjZDRjMzY5ZTRkM2U4MDY1MzE0OTQ1ZmQ5Zjk3L3RhYmxlcmFuZ2U6MjRjYmNkNGMzNjllNGQzZTgwNjUzMTQ5NDVmZDlmOTdfNy0yLTEtMS0w_d2720a8a-b38d-455d-aed1-155db2ad0aa1"
      unitRef="usd">34000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOjI0Y2JjZDRjMzY5ZTRkM2U4MDY1MzE0OTQ1ZmQ5Zjk3L3RhYmxlcmFuZ2U6MjRjYmNkNGMzNjllNGQzZTgwNjUzMTQ5NDVmZDlmOTdfNy00LTEtMS0w_6e718b02-456f-4184-88c8-5fb203a786bc"
      unitRef="usd">24000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RleHRyZWdpb246MTg2ODNjNjU1ZDNkNDY1ZDk2Mjk3NmQwZTVjNjJjMDFfMzA5OA_423875ec-52c5-4f6d-a65c-fc4230ea4e36"
      unitRef="usd">0</us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet>
    <us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RleHRyZWdpb246MTg2ODNjNjU1ZDNkNDY1ZDk2Mjk3NmQwZTVjNjJjMDFfMzA5OA_a6e0bce1-85f4-4f72-b081-e25848bb20ce"
      unitRef="usd">0</us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RleHRyZWdpb246MTg2ODNjNjU1ZDNkNDY1ZDk2Mjk3NmQwZTVjNjJjMDFfMzM5MQ_a1858e49-be2f-497b-988c-f4671e314215">The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Condensed Consolidated Balance Sheets:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.899%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross Amounts Not Offset &lt;br/&gt;on our Condensed &lt;br/&gt;Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross Amounts&lt;br/&gt;&#160;of Recognized &lt;br/&gt;Assets/Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross Amounts&lt;br/&gt;&#160;Offset on our &lt;br/&gt;Condensed &lt;br/&gt;Consolidated &lt;br/&gt;Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amounts of Assets/Liabilities Presented&lt;br/&gt;&#160;on our Condensed Consolidated&lt;br/&gt;Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Derivative &lt;br/&gt;Financial &lt;br/&gt;Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Cash Collateral &lt;br/&gt;Received/&lt;br/&gt;Pledged&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Net Amount&lt;br/&gt;&#160;(Legal Offset)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNC0yLTEtMS0w_d3f0d1b2-4e59-4e75-b26f-427cb28d4920"
      unitRef="usd">32000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNC00LTEtMS0w_6212de37-33f4-4d1b-b85e-2cc47108d3cb"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssets
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNC02LTEtMS0w_efe5ac38-69d0-4ce2-8139-a2b699e3a53a"
      unitRef="usd">32000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNC04LTEtMS0w_b4c161b8-9d29-49ec-8db5-3ec4c3ea06bf"
      unitRef="usd">22000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNC0xMC0xLTEtMA_59c97449-d5e7-4c7e-bb52-4bc9a15139f7"
      unitRef="usd">0</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNC0xMi0xLTEtMA_072ed9d0-5785-4a6e-8521-71c23234592f"
      unitRef="usd">10000000</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNS0yLTEtMS0w_1fc2dee6-8046-463b-9cc2-bd3cbf405b40"
      unitRef="usd">41000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNS00LTEtMS0w_44feee46-8cde-4774-b8cf-98c3bf19a0b2"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilities
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNS02LTEtMS0w_dd4c346b-b639-471c-9d40-39738a7ea4b1"
      unitRef="usd">41000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNS04LTEtMS0w_b5cd9526-beac-4e61-9d24-b7db07dcf10a"
      unitRef="usd">22000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNS0xMC0xLTEtMA_e6e95bdc-12dc-4325-a661-f10816821cc9"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNS0xMi0xLTEtMA_9c80296c-6ba9-4dc3-b3a3-72188c1cdf93"
      unitRef="usd">19000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNy0yLTEtMS0w_6bf76e22-a3a6-4640-9037-c9228642105e"
      unitRef="usd">12000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNy00LTEtMS0w_d3351b49-e326-4ce1-908e-3c5b7780c1ec"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssets
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNy02LTEtMS0w_bbd6c2bc-9db6-42f8-b9d4-4a7e88c29c57"
      unitRef="usd">12000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNy04LTEtMS0w_62f70df2-1788-4042-84ed-d3866fc6d411"
      unitRef="usd">12000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNy0xMC0xLTEtMA_da815b89-8b10-4a81-8009-113326cbec90"
      unitRef="usd">0</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfNy0xMi0xLTEtMA_083489ab-6aa5-4474-8eb1-28836ca5d069"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfOC0yLTEtMS0w_ef48c9db-e678-4d1b-9065-d22e36474a6e"
      unitRef="usd">121000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfOC00LTEtMS0w_4447c104-140b-43c3-83cf-5cb89b75655f"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilities
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfOC02LTEtMS0w_9a72ff3c-3ba0-4d3e-98fc-843e87c5d587"
      unitRef="usd">121000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfOC04LTEtMS0w_e4d23669-ff4e-4e8f-bd97-ba0caab945ea"
      unitRef="usd">12000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfOC0xMC0xLTEtMA_97a195ce-ccef-4799-8b36-88da13d04ad9"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180Ni9mcmFnOjE4NjgzYzY1NWQzZDQ2NWQ5NjI5NzZkMGU1YzYyYzAxL3RhYmxlOmNkZDMxZTljMjViZTRlNDJhYjFkNTQ4NDVmZGU0MWQ0L3RhYmxlcmFuZ2U6Y2RkMzFlOWMyNWJlNGU0MmFiMWQ1NDg0NWZkZTQxZDRfOC0xMi0xLTEtMA_2dc88c46-11e8-4735-a62d-c5284eab8f0f"
      unitRef="usd">109000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfMjA4OTg_e5e08a4a-5ceb-4c41-8f48-172e9bb77db6">ACQUISITIONS&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired and liabilities assumed be recorded at their fair values as of the acquisition date. Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. Transaction costs associated with business combinations are expensed as they are incurred. The first quarter 2021 acquisition of MYR and the fourth quarter 2020 acquisition of Immunomedics were accounted for as business combinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:155%"&gt;MYR &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 4, 2021, we completed the acquisition of MYR, a German biotechnology company. MYR focuses on the development and commercialization of therapeutics for the treatment of HDV. The acquisition provides Gilead with Hepcludex, which was conditionally approved by the European Medicines Agency (&#x201c;EMA&#x201d;) in July 2020 for the treatment of chronic HDV infection in adults with compensated liver disease. Upon closing, MYR became a wholly-owned subsidiary of Gilead. The financial results of MYR were included in our Condensed Consolidated Financial Statements from the date of the acquisition. MYR contributed an immaterial net loss from the date of acquisition through March 31, 2021. We recorded other acquisition-related expenses of $11 million, primarily representing closing costs and related fees, in Selling, general and administrative expenses on our Condensed Consolidated Statements of Income for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate consideration for this acquisition of approximately &#x20ac;1.3 billion (or $1.6 billion) primarily consists of &#x20ac;1.0 billion (or approximately $1.2 billion) paid upon closing and contingent consideration of up to &#x20ac;300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex. The estimated fair value of this contingent liability was $341 million as of the acquisition date and recorded in Other long-term obligations on our Condensed Consolidated Balance Sheets. The contingent consideration was estimated using probability-weighted scenarios for FDA approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value estimates for the assets acquired and liabilities assumed were based upon valuations using information known and knowable as of the date of this filing. Changes to these assumptions and estimates could cause an impact to the valuation of assets acquired, including intangible assets, goodwill and the related tax impacts of the acquisition, as well as legal and other contingencies. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets (and liabilities), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The finite-lived intangible asset of $845 million represents the estimated fair value of Hepcludex for HDV in Europe as of the acquisition date. The fair value was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to Hepcludex for HDV in Europe and a discount rate of 12%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired intangible assets related to IPR&amp;amp;D consist of Hepcludex for HDV in all other regions without regulatory approval, including the U.S. The estimated aggregate fair value of $1.2 billion as of the acquisition date was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to this asset and a discount rate of 12%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some of the more significant assumptions inherent in the development of intangible asset fair values include: estimates of projected future cash flows including revenues and operating profits; probability of success; the discount rate selected; the life of the potential commercialized products and the risks related to the viability of and potential alternative treatments in any future target markets, among other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived assets until the completion or abandonment of the associated R&amp;amp;D efforts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The inputs used for valuing these identifiable intangibles are unobservable and considered Level 3 under the fair value measurement and disclosure guidance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net deferred tax liability was based upon the difference between the estimated book basis and tax basis of net assets acquired and an estimate for the final pre-acquisition net operating losses of MYR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the consideration transferred over the fair values of assets acquired and liabilities assumed of $226 million was recorded as goodwill, which primarily reflects the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill recognized for MYR is not expected to be deductible for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Immunomedics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2020, we completed the acquisition of Immunomedics for cash consideration of $20.6 billion. Immunomedics is a wholly-owned subsidiary of Gilead. The acquisition was financed with the majority of the proceeds from the September 2020 senior unsecured notes offering, an additional $1.0 billion borrowing under a new senior unsecured term loan facility and cash on hand. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outlicense contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets (and liabilities), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no measurement period adjustments recorded to the fair values of assets acquired and liabilities assumed during the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="ied6ece005700482abaa15b4b44d0acab_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjYzMTYzMg_72894e38-84f9-4aa7-a1bb-a375f6c7951c"
      unitRef="usd">11000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i638cafe3b48a4a748be6d8f1b169f897_D20210304-20210304"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjYyNjE1OA_7a6d9ee9-c385-4220-a6a5-38177e23d797"
      unitRef="eur">1300000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i638cafe3b48a4a748be6d8f1b169f897_D20210304-20210304"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjYyNjE3NA_81dcf81b-839f-4123-8fc0-4b84fb790c7b"
      unitRef="usd">1600000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i638cafe3b48a4a748be6d8f1b169f897_D20210304-20210304"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjU5MTY3NQ_c2f29176-63e3-4ab4-b50f-50fd2525ccd0"
      unitRef="eur">1000000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i638cafe3b48a4a748be6d8f1b169f897_D20210304-20210304"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjU5MTY5MQ_2a2fa76d-2f7f-409d-b4f1-00bedab68204"
      unitRef="usd">1200000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ibedf080b94a2460fb4f0a3efc0a14793_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjU5MTY1Ng_2b9fde56-6897-4468-bda5-0e2f9ae828ee"
      unitRef="eur">300000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability
      contextRef="i3a98f90b07b94f6c86e128d20787701b_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfMTA5OTUxMTc2NDE5Mg_4b9c3e8d-d822-4a09-88a1-47ecf8530fa1"
      unitRef="usd">341000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfOTg5NTYwNDc3MTU1OA_652d7626-0603-46c9-a717-27cd9774c040">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets (and liabilities), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outlicense contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets (and liabilities), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i3a98f90b07b94f6c86e128d20787701b_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmRlMjI3ODg4ZWU1YTQ5NTg4MDFkZmJmNGQwNDI4NmJkL3RhYmxlcmFuZ2U6ZGUyMjc4ODhlZTVhNDk1ODgwMWRmYmY0ZDA0Mjg2YmRfMi0yLTEtMS01NTAz_0d4eedef-202c-4c46-b988-b612abbc3983"
      unitRef="usd">845000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="iad268a44b5f2496ba16a02c95c0952e9_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmRlMjI3ODg4ZWU1YTQ5NTg4MDFkZmJmNGQwNDI4NmJkL3RhYmxlcmFuZ2U6ZGUyMjc4ODhlZTVhNDk1ODgwMWRmYmY0ZDA0Mjg2YmRfMy0yLTEtMS01NTA3_ec9345a8-3dd9-4fa0-a0b1-8be4135e675a"
      unitRef="usd">1190000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i3a98f90b07b94f6c86e128d20787701b_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmRlMjI3ODg4ZWU1YTQ5NTg4MDFkZmJmNGQwNDI4NmJkL3RhYmxlcmFuZ2U6ZGUyMjc4ODhlZTVhNDk1ODgwMWRmYmY0ZDA0Mjg2YmRfNC0yLTEtMS01NTA3_31a21b32-b869-468e-8cce-826a771f6dbc"
      unitRef="usd">513000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet
      contextRef="i3a98f90b07b94f6c86e128d20787701b_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmRlMjI3ODg4ZWU1YTQ5NTg4MDFkZmJmNGQwNDI4NmJkL3RhYmxlcmFuZ2U6ZGUyMjc4ODhlZTVhNDk1ODgwMWRmYmY0ZDA0Mjg2YmRfNS0yLTEtMS01NTA3_ee1e3ae6-ead3-42a3-9999-db77cc2bf124"
      unitRef="usd">-187000000</gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i3a98f90b07b94f6c86e128d20787701b_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmRlMjI3ODg4ZWU1YTQ5NTg4MDFkZmJmNGQwNDI4NmJkL3RhYmxlcmFuZ2U6ZGUyMjc4ODhlZTVhNDk1ODgwMWRmYmY0ZDA0Mjg2YmRfNi0yLTEtMS01NTA3_da677983-1857-413d-b69d-abbba6666acf"
      unitRef="usd">1335000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillGross
      contextRef="i3a98f90b07b94f6c86e128d20787701b_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmRlMjI3ODg4ZWU1YTQ5NTg4MDFkZmJmNGQwNDI4NmJkL3RhYmxlcmFuZ2U6ZGUyMjc4ODhlZTVhNDk1ODgwMWRmYmY0ZDA0Mjg2YmRfNy0yLTEtMS01MzU3_861b1a5a-472c-4f8c-907d-f382906b5e25"
      unitRef="usd">226000000</us-gaap:GoodwillGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i3a98f90b07b94f6c86e128d20787701b_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmRlMjI3ODg4ZWU1YTQ5NTg4MDFkZmJmNGQwNDI4NmJkL3RhYmxlcmFuZ2U6ZGUyMjc4ODhlZTVhNDk1ODgwMWRmYmY0ZDA0Mjg2YmRfOC0yLTEtMS01NTA3_5e398c47-77a4-4159-90c0-5c831571458b"
      unitRef="usd">1561000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i4833c72c785b491e8f5afc3f5e83a942_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjU5MTgwMw_38f1cafa-6d99-4c07-ab68-bbe7d5e1fa0a"
      unitRef="usd">845000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <gild:IntangibleAssetMeasurementInput
      contextRef="i33549bbb2e014a6ab92f613d389caaf5_I20210304"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjU5MTgxMQ_f42e3e3a-7885-4970-855c-cb1e09c06415"
      unitRef="number">0.12</gild:IntangibleAssetMeasurementInput>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i0db85f8bde2e48919fd0edfbb47844d6_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjU5MTgxNg_72b0516f-b462-4e9e-8c7e-d1b67532db17">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="iad268a44b5f2496ba16a02c95c0952e9_I20210304"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjU5MTgyOQ_4434cf07-b839-447a-ab20-1bfad96183b6"
      unitRef="usd">1200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <gild:IntangibleAssetMeasurementInput
      contextRef="i1b3e846287d144f5a57024a1a2aaa1f4_I20210304"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjU5MTgzOA_b0dd25e2-dea5-4e69-8de5-381222c606b0"
      unitRef="number">0.12</gild:IntangibleAssetMeasurementInput>
    <us-gaap:GoodwillGross
      contextRef="i3a98f90b07b94f6c86e128d20787701b_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjYxOTA3MA_e69cd742-6235-4110-b594-6134129a0e80"
      unitRef="usd">226000000</us-gaap:GoodwillGross>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i9f919867053e472aa6823a950ddff61b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfOTg5NTYwNDc3ODExMA_5072e403-bd98-409d-b4f4-05139a222957"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i19a0802804904e31ba6efd10f1f3ea4b_D20201023-20201023"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNTQ5NzU1ODI2MDYwNA_d9d2a49a-ae22-4f57-88bf-df070cb344c7"
      unitRef="usd">20600000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="idc1e9ade6e414ced9c63b109438a49e7_D20201001-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RleHRyZWdpb246ZDJjYWZkMTUwNWNiNGU0NDgzYTQ4MjBhZjY1OWQ3NTZfNDM5ODA0NjYxMTA5MA_9d2c1e7d-92cc-4329-a428-bab7d2ebb277"
      unitRef="usd">1000000000.0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i9bbcce56feb74fe6a616f350aa562468_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmQ2MzQ5MmViZWI4OTRjYjI4YTQ2ZjlkZmEyYTlmMmU2L3RhYmxlcmFuZ2U6ZDYzNDkyZWJlYjg5NGNiMjhhNDZmOWRmYTJhOWYyZTZfMS0yLTEtMS05MTU3_1c789fce-a37c-4585-bae4-0a06e894523f"
      unitRef="usd">726000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i9bbcce56feb74fe6a616f350aa562468_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmQ2MzQ5MmViZWI4OTRjYjI4YTQ2ZjlkZmEyYTlmMmU2L3RhYmxlcmFuZ2U6ZDYzNDkyZWJlYjg5NGNiMjhhNDZmOWRmYTJhOWYyZTZfMi0yLTEtMS05MTU3_a3fb8aad-07ae-43ed-b074-9e6dead9404b"
      unitRef="usd">946000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i3aa9165e8567484387ecc5acb5b3f1e9_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmQ2MzQ5MmViZWI4OTRjYjI4YTQ2ZjlkZmEyYTlmMmU2L3RhYmxlcmFuZ2U6ZDYzNDkyZWJlYjg5NGNiMjhhNDZmOWRmYTJhOWYyZTZfNC0yLTEtMS05MTU3_7bb2e78f-4f8a-4a16-9e5b-31cb4ebf290c"
      unitRef="usd">4600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="iaf62e749ffee4dcc9a54082aaa23c3b8_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmQ2MzQ5MmViZWI4OTRjYjI4YTQ2ZjlkZmEyYTlmMmU2L3RhYmxlcmFuZ2U6ZDYzNDkyZWJlYjg5NGNiMjhhNDZmOWRmYTJhOWYyZTZfNS0yLTEtMS05MTU3_71ebd6de-a2f6-499a-b130-b2b76d586935"
      unitRef="usd">15760000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i05a08140a83742d99cfbd0fcb20b09fa_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmQ2MzQ5MmViZWI4OTRjYjI4YTQ2ZjlkZmEyYTlmMmU2L3RhYmxlcmFuZ2U6ZDYzNDkyZWJlYjg5NGNiMjhhNDZmOWRmYTJhOWYyZTZfNi0yLTEtMS05MTU3_33ed6a0d-6981-4623-b766-11b6c1f8e3c2"
      unitRef="usd">175000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i9bbcce56feb74fe6a616f350aa562468_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmQ2MzQ5MmViZWI4OTRjYjI4YTQ2ZjlkZmEyYTlmMmU2L3RhYmxlcmFuZ2U6ZDYzNDkyZWJlYjg5NGNiMjhhNDZmOWRmYTJhOWYyZTZfNy0yLTEtMS05MTU3_47302010-39f8-4fb9-bd79-924f66b219b1"
      unitRef="usd">4565000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability
      contextRef="i9bbcce56feb74fe6a616f350aa562468_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmQ2MzQ5MmViZWI4OTRjYjI4YTQ2ZjlkZmEyYTlmMmU2L3RhYmxlcmFuZ2U6ZDYzNDkyZWJlYjg5NGNiMjhhNDZmOWRmYTJhOWYyZTZfOC0yLTEtMS05MTU3_a35b2973-ff45-4ef5-b17c-a49520570942"
      unitRef="usd">1100000000</gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability>
    <gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet
      contextRef="i9bbcce56feb74fe6a616f350aa562468_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmQ2MzQ5MmViZWI4OTRjYjI4YTQ2ZjlkZmEyYTlmMmU2L3RhYmxlcmFuZ2U6ZDYzNDkyZWJlYjg5NGNiMjhhNDZmOWRmYTJhOWYyZTZfOS0yLTEtMS05MTU3_9e4a3735-b5a7-4bac-af5f-5c0e15cd5832"
      unitRef="usd">64000000</gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i9bbcce56feb74fe6a616f350aa562468_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmQ2MzQ5MmViZWI4OTRjYjI4YTQ2ZjlkZmEyYTlmMmU2L3RhYmxlcmFuZ2U6ZDYzNDkyZWJlYjg5NGNiMjhhNDZmOWRmYTJhOWYyZTZfMTAtMi0xLTEtOTE1Nw_4f1a144c-c508-45eb-ab80-9a1388a7386e"
      unitRef="usd">16606000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillGross
      contextRef="i9bbcce56feb74fe6a616f350aa562468_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmQ2MzQ5MmViZWI4OTRjYjI4YTQ2ZjlkZmEyYTlmMmU2L3RhYmxlcmFuZ2U6ZDYzNDkyZWJlYjg5NGNiMjhhNDZmOWRmYTJhOWYyZTZfMTEtMi0xLTEtOTE1Nw_209c2e3b-7b19-44dc-a65b-df46ab12eab2"
      unitRef="usd">3991000000</us-gaap:GoodwillGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i9bbcce56feb74fe6a616f350aa562468_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N180OS9mcmFnOmQyY2FmZDE1MDVjYjRlNDQ4M2E0ODIwYWY2NTlkNzU2L3RhYmxlOmQ2MzQ5MmViZWI4OTRjYjI4YTQ2ZjlkZmEyYTlmMmU2L3RhYmxlcmFuZ2U6ZDYzNDkyZWJlYjg5NGNiMjhhNDZmOWRmYTJhOWYyZTZfMTItMi0xLTEtOTE1Nw_a1676eea-9206-4c56-9695-337f0ad84ead"
      unitRef="usd">20597000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RleHRyZWdpb246NDNlMTg4M2UwYTk0NDI4NDlmMGVjYzlkNjAxNTcyYjRfNDUx_76637063-d539-45b9-90ef-92defef75a59">GOODWILL AND INTANGIBLE ASSETS&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill resulting from the acquisition of MYR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Intangible assets, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - sofosbuvir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - axicabtagene ciloleucel&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Trodelvy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Hepcludex for HDV &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite-lived assets - IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Gross carrying amount as of March&#160;31, 2021 includes $910&#160;million reclassified from indefinite-lived assets - IPR&amp;amp;D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts represent Trodelvy for metastatic triple-negative breast cancer.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Gross carrying amount as of March&#160;31, 2021 includes $1.2&#160;billion recognized from the first quarter 2021 MYR acquisition. See Note 6. Acquisitions for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;In April 2021, FDA granted accelerated approval of Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer, a new indication. Accordingly, the related amount of $1.0&#160;billion will be reclassified to finite-lived assets in the second quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate amortization expense related to finite-lived intangible assets was $395 million and $281 million for the three months ended March 31, 2021 and 2020, respectively, and was primarily included in Cost of goods sold on our Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of March&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RleHRyZWdpb246NDNlMTg4M2UwYTk0NDI4NDlmMGVjYzlkNjAxNTcyYjRfOTg5NTYwNDY1NjYyNQ_d9aa6bef-9657-4e11-b599-45addac6ec07">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill resulting from the acquisition of MYR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOmM1NTI4ZWYxOTBlNjQ3N2Q5ZDAwMWFiNDE4YjQ4MzMzL3RhYmxlcmFuZ2U6YzU1MjhlZjE5MGU2NDc3ZDlkMDAxYWI0MThiNDgzMzNfMS0yLTEtMS00NTg2_7360acdd-235f-4ed6-b595-464594e44bbe"
      unitRef="usd">8108000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOmM1NTI4ZWYxOTBlNjQ3N2Q5ZDAwMWFiNDE4YjQ4MzMzL3RhYmxlcmFuZ2U6YzU1MjhlZjE5MGU2NDc3ZDlkMDAxYWI0MThiNDgzMzNfMi0yLTEtMS00NTg2_eabf57f8-1074-4cc9-a3a4-3e4febaeedc5"
      unitRef="usd">226000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOmM1NTI4ZWYxOTBlNjQ3N2Q5ZDAwMWFiNDE4YjQ4MzMzL3RhYmxlcmFuZ2U6YzU1MjhlZjE5MGU2NDc3ZDlkMDAxYWI0MThiNDgzMzNfMy0yLTEtMS00NTg2_469dcf4c-19f1-41df-aea0-bc4bb5ded5c7"
      unitRef="usd">8334000000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RleHRyZWdpb246NDNlMTg4M2UwYTk0NDI4NDlmMGVjYzlkNjAxNTcyYjRfNDU5_2882025a-855b-4ec3-854b-f32d3715d655">&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Intangible assets, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - sofosbuvir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - axicabtagene ciloleucel&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Trodelvy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Hepcludex for HDV &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite-lived assets - IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Gross carrying amount as of March&#160;31, 2021 includes $910&#160;million reclassified from indefinite-lived assets - IPR&amp;amp;D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts represent Trodelvy for metastatic triple-negative breast cancer.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Gross carrying amount as of March&#160;31, 2021 includes $1.2&#160;billion recognized from the first quarter 2021 MYR acquisition. See Note 6. Acquisitions for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;In April 2021, FDA granted accelerated approval of Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer, a new indication. Accordingly, the related amount of $1.0&#160;billion will be reclassified to finite-lived assets in the second quarter of 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RleHRyZWdpb246NDNlMTg4M2UwYTk0NDI4NDlmMGVjYzlkNjAxNTcyYjRfNDc2_dbc1966f-a9a5-4659-95b5-349c9daef52b">&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Intangible assets, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - sofosbuvir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - axicabtagene ciloleucel&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Trodelvy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Hepcludex for HDV &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite-lived assets - IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Gross carrying amount as of March&#160;31, 2021 includes $910&#160;million reclassified from indefinite-lived assets - IPR&amp;amp;D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts represent Trodelvy for metastatic triple-negative breast cancer.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Gross carrying amount as of March&#160;31, 2021 includes $1.2&#160;billion recognized from the first quarter 2021 MYR acquisition. See Note 6. Acquisitions for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;In April 2021, FDA granted accelerated approval of Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer, a new indication. Accordingly, the related amount of $1.0&#160;billion will be reclassified to finite-lived assets in the second quarter of 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5d12086953934504ada4ca8bfb4497b1_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfMy0yLTEtMS0w_5cfcc58e-a27c-4159-b5bc-d92aeba04491"
      unitRef="usd">10720000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5d12086953934504ada4ca8bfb4497b1_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfMy00LTEtMS0w_c14ef391-c180-452b-b7b1-bc78322cfa4b"
      unitRef="usd">5127000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i5d12086953934504ada4ca8bfb4497b1_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfMy02LTEtMS0w_cb5950b8-992c-4f8c-8b6f-8f658c43abfb"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5d12086953934504ada4ca8bfb4497b1_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfMy04LTEtMS0w_7a9b357b-7461-4fbc-bdc8-17d855be57f5"
      unitRef="usd">5593000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia02e3e3eb61e4722a1d82ca5bfeafc26_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfMy0xMC0xLTEtMA_fecf73b3-c37c-4405-ad4e-0625f20341ed"
      unitRef="usd">10720000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia02e3e3eb61e4722a1d82ca5bfeafc26_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfMy0xMi0xLTEtMA_35a592b2-cc6c-4413-aabf-c983a0158361"
      unitRef="usd">4952000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ia02e3e3eb61e4722a1d82ca5bfeafc26_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfMy0xNC0xLTEtMA_87061e26-c0dc-4293-ac79-430a861360dd"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia02e3e3eb61e4722a1d82ca5bfeafc26_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfMy0xNi0xLTEtMA_6828d04b-1cc3-4b97-b122-3b87393f83ec"
      unitRef="usd">5768000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3231dad87cac437aaa04d35fce3d9824_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNC0yLTEtMS0w_40b5d317-22a2-41c1-b932-1abbf10c5b83"
      unitRef="usd">7110000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3231dad87cac437aaa04d35fce3d9824_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNC00LTEtMS0w_272890bf-29d9-45c8-af7c-6fc7cc3279d5"
      unitRef="usd">1196000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i3231dad87cac437aaa04d35fce3d9824_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNC02LTEtMS0w_069190e0-d9af-4d8e-9be9-8cfaa8638a59"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3231dad87cac437aaa04d35fce3d9824_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNC04LTEtMS0w_c5f49d4e-b45e-43ab-8484-064cc123fef1"
      unitRef="usd">5914000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8222759ba26347c3a6f92ef2992fa9a1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNC0xMC0xLTEtMA_6f1343fd-602d-4955-8bca-0fe7546f74bb"
      unitRef="usd">6200000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8222759ba26347c3a6f92ef2992fa9a1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNC0xMi0xLTEtMA_63f46210-e1b9-4733-9668-5206143cca68"
      unitRef="usd">1105000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i8222759ba26347c3a6f92ef2992fa9a1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNC0xNC0xLTEtMA_c2254a97-ae92-49a2-b489-227502a69dad"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8222759ba26347c3a6f92ef2992fa9a1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNC0xNi0xLTEtMA_f3bc6ac9-6055-486c-ab4a-91ac164e18b3"
      unitRef="usd">5095000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i56a8801e286d4710aab30d8ef3145cc8_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS0yLTEtMS0zNzQ5_b0d654c4-ed5e-4d3c-92b1-abef3213f81f"
      unitRef="usd">4600000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i56a8801e286d4710aab30d8ef3145cc8_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS00LTEtMS0zNzQ5_6124bbec-6c15-4f52-9966-6b3fa3f315f5"
      unitRef="usd">158000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i56a8801e286d4710aab30d8ef3145cc8_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS02LTEtMS0zNzQ5_c14156ae-5240-4e91-a3cb-70f9d8fcc2c3"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i56a8801e286d4710aab30d8ef3145cc8_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS04LTEtMS0zNzQ5_eb256a17-7a58-4ca0-9c51-76e3925f7f2d"
      unitRef="usd">4442000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib8a8bbb1048e4a4db06008d8d902d2a9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS0xMC0xLTEtMzc0Ng_604cece3-052e-4cf5-9c00-f3af6b701857"
      unitRef="usd">4600000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib8a8bbb1048e4a4db06008d8d902d2a9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS0xMi0xLTEtMzc0Ng_d9851673-df8e-4198-98e4-1058dde35cbe"
      unitRef="usd">63000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ib8a8bbb1048e4a4db06008d8d902d2a9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS0xNC0xLTEtMzc0Ng_8955a580-e5d0-4096-afc1-a5e6b6108832"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib8a8bbb1048e4a4db06008d8d902d2a9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS0xNi0xLTEtMzc0Ng_5b2ebd28-b8ef-4846-ae01-9ee770107c73"
      unitRef="usd">4537000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i42d240b01e18486db9a4e93c058e1eb9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi0yLTEtMS00ODk0_7ecf84d2-3a0c-41f3-9f23-fb8b27f33539"
      unitRef="usd">845000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i42d240b01e18486db9a4e93c058e1eb9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi00LTEtMS00ODk0_3d119f37-433d-4c7c-b090-77771aa1d975"
      unitRef="usd">7000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i42d240b01e18486db9a4e93c058e1eb9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi02LTEtMS00ODk0_a8a173fa-0617-4454-b360-9692741a00ed"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i42d240b01e18486db9a4e93c058e1eb9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi04LTEtMS00ODk0_4c6cafae-71ae-4dd5-a8c8-a989b3f9c4da"
      unitRef="usd">838000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i86ef6063e2dd483ebe6c5dcca3038c73_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi0xMC0xLTEtNDg5NA_9933a911-2d75-4d33-b2b1-a3e5355d7b0e"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i86ef6063e2dd483ebe6c5dcca3038c73_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi0xMi0xLTEtNDg5NA_04262c26-8864-4aef-8078-d2930d5b6eb8"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i86ef6063e2dd483ebe6c5dcca3038c73_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi0xNC0xLTEtNDg5NA_5b0e5169-a12d-4889-bebf-f4b4226daf65"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i86ef6063e2dd483ebe6c5dcca3038c73_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi0xNi0xLTEtNDg5NA_e4c8db31-cd92-4e25-8504-8f0ba9feea1c"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if32750d98ae2460aa464be3d472d1042_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS0yLTEtMS0w_a74953e6-d3b2-44a2-8afb-e2bfcdc46af9"
      unitRef="usd">1391000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if32750d98ae2460aa464be3d472d1042_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS00LTEtMS0w_3b06feb7-4848-43a9-a97c-ebc2518040a1"
      unitRef="usd">567000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="if32750d98ae2460aa464be3d472d1042_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS02LTEtMS0w_b57f9d9e-2bb6-4a92-a8f2-e8a9b4c10bb6"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if32750d98ae2460aa464be3d472d1042_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS04LTEtMS0w_6eb99dc1-1d69-43ad-ae07-78108b75044c"
      unitRef="usd">824000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie0ac0434166243fdbe064ef57c4cf330_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS0xMC0xLTEtMA_6cbf3cf8-755b-497c-b799-50e1cf4f1923"
      unitRef="usd">1377000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie0ac0434166243fdbe064ef57c4cf330_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS0xMi0xLTEtMA_95ea2d75-08b7-450d-9d9e-79c9b12a1aa3"
      unitRef="usd">540000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ie0ac0434166243fdbe064ef57c4cf330_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS0xNC0xLTEtMA_c3fc2494-7763-4e65-8aa7-344431ace8ab"
      unitRef="usd">-1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie0ac0434166243fdbe064ef57c4cf330_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNS0xNi0xLTEtMA_960747d0-4830-4934-9077-e974cb5b07ea"
      unitRef="usd">836000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi0yLTEtMS0w_c5730af7-cb74-4c33-9d1b-8f6f6cd127d7"
      unitRef="usd">24666000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi00LTEtMS0w_b6d8aef3-e478-42e9-a5d0-946d177ca9da"
      unitRef="usd">7055000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi02LTEtMS0w_220c7248-a0d7-4e15-a337-31bf1e6a1ed7"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi04LTEtMS0w_1989a335-8e55-4474-b044-ee33c413b70a"
      unitRef="usd">17611000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi0xMC0xLTEtMA_cdd9daff-5cda-46db-aeab-2e82d6947a9f"
      unitRef="usd">22897000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi0xMi0xLTEtMA_e778be42-1e02-405c-a333-9f15513f2800"
      unitRef="usd">6660000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi0xNC0xLTEtMA_50008000-7489-4014-83d0-976661114d21"
      unitRef="usd">-1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNi0xNi0xLTEtMA_16e19888-14be-49ec-9e75-a2d73b2d7d59"
      unitRef="usd">16236000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iaf9f311c0c5a450295b3455afad3eb99_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNy0yLTEtMS0w_ea4a2484-4efd-4220-98ff-df3c762805d7"
      unitRef="usd">17170000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="iaf9f311c0c5a450295b3455afad3eb99_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNy02LTEtMS0w_bd574b63-f497-4a53-ad9b-e0d5fa512725"
      unitRef="usd">0</gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iaf9f311c0c5a450295b3455afad3eb99_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNy04LTEtMS0w_b0944680-c778-462e-ae94-a160fb999726"
      unitRef="usd">17170000000</gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i04105952f21b49fe8cd9befd11b8c28b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNy0xMC0xLTEtMA_7e4e4565-7c3b-4f65-b498-9ab7647c19e5"
      unitRef="usd">16890000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i04105952f21b49fe8cd9befd11b8c28b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNy0xNC0xLTEtMA_c9739caa-6120-4bfd-8445-4799f66501ec"
      unitRef="usd">0</gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i04105952f21b49fe8cd9befd11b8c28b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfNy0xNi0xLTEtMA_5e6952ef-bd6c-4217-ab25-d27f42307d22"
      unitRef="usd">16890000000</gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfOC0yLTEtMS0w_e1992b89-7e3a-47d5-b994-22fd09ab129b"
      unitRef="usd">41836000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfOC00LTEtMS0w_05d336fa-6569-4960-9206-4837628b4a6c"
      unitRef="usd">7055000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfOC02LTEtMS0w_7700d5a8-e887-4952-88c7-d21e92de2edd"
      unitRef="usd">0</gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfOC04LTEtMS0w_e08fcbf0-cd8c-466d-be9b-0e5af6be5009"
      unitRef="usd">34781000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfOC0xMC0xLTEtMA_6f364bb2-9b68-4cf8-ba45-1e1dfcfc5d39"
      unitRef="usd">39787000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfOC0xMi0xLTEtMA_11464f85-07b2-48d6-a81c-665b209d3a5f"
      unitRef="usd">6660000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfOC0xNC0xLTEtMA_79f2d356-a072-4e5d-866a-79f2e4356481"
      unitRef="usd">-1000000</gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjk0ZDkzZDYxOWUxYjRiMGJiOTE3MDRhYTU4MDJjMTVhL3RhYmxlcmFuZ2U6OTRkOTNkNjE5ZTFiNGIwYmI5MTcwNGFhNTgwMmMxNWFfOC0xNi0xLTEtMA_7924fa5c-4c55-4c6e-92a3-dd3a20a14666"
      unitRef="usd">33126000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <gild:FiniteLivedIntangibleAssetsGrossTransfers
      contextRef="iaf9f311c0c5a450295b3455afad3eb99_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RleHRyZWdpb246NDNlMTg4M2UwYTk0NDI4NDlmMGVjYzlkNjAxNTcyYjRfNDM5ODA0NjUxNzA2OQ_3902499a-9b05-43b1-8a2a-ee0f1d4fee2c"
      unitRef="usd">-910000000</gild:FiniteLivedIntangibleAssetsGrossTransfers>
    <gild:FiniteLivedIntangibleAssetsGrossTransfers
      contextRef="i3231dad87cac437aaa04d35fce3d9824_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RleHRyZWdpb246NDNlMTg4M2UwYTk0NDI4NDlmMGVjYzlkNjAxNTcyYjRfNDM5ODA0NjUxNzA2OQ_f554ffa3-69d4-4af0-b969-a99aa02d8c60"
      unitRef="usd">910000000</gild:FiniteLivedIntangibleAssetsGrossTransfers>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="iad268a44b5f2496ba16a02c95c0952e9_I20210304"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RleHRyZWdpb246NDNlMTg4M2UwYTk0NDI4NDlmMGVjYzlkNjAxNTcyYjRfMTA5OTUxMTYzOTIyMQ_ec4eb230-8803-4a8a-9f89-9f419889e8e3"
      unitRef="usd">1200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <gild:FiniteLivedIntangibleAssetsGrossReclassified
      contextRef="i4e6af3a3c95d4c1689521cc7dae5427c_D20210401-20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RleHRyZWdpb246NDNlMTg4M2UwYTk0NDI4NDlmMGVjYzlkNjAxNTcyYjRfMTA5OTUxMTYzNzE4OQ_833d3094-88fa-471d-a2e6-f06c3e2f9207"
      unitRef="usd">1000000000.0</gild:FiniteLivedIntangibleAssetsGrossReclassified>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RleHRyZWdpb246NDNlMTg4M2UwYTk0NDI4NDlmMGVjYzlkNjAxNTcyYjRfMTY1_8f872083-eb26-4b45-8cee-5645e5cad050"
      unitRef="usd">395000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RleHRyZWdpb246NDNlMTg4M2UwYTk0NDI4NDlmMGVjYzlkNjAxNTcyYjRfMTY0OTI2NzQ0MjI0OQ_21435ae1-0399-4b3d-87f4-1f789855a962"
      unitRef="usd">281000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RleHRyZWdpb246NDNlMTg4M2UwYTk0NDI4NDlmMGVjYzlkNjAxNTcyYjRfNDY0_6c0a3346-4db7-4eeb-b488-0c2f25c52c03">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of March&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjczOGVlNTBmYmM0YjRhYjc5ZDJjNjFhMGQwM2NjZWI4L3RhYmxlcmFuZ2U6NzM4ZWU1MGZiYzRiNGFiNzlkMmM2MWEwZDAzY2NlYjhfMS0yLTEtMS0w_2aa82c9e-3683-4135-9eea-47d1fb08e93a"
      unitRef="usd">1256000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjczOGVlNTBmYmM0YjRhYjc5ZDJjNjFhMGQwM2NjZWI4L3RhYmxlcmFuZ2U6NzM4ZWU1MGZiYzRiNGFiNzlkMmM2MWEwZDAzY2NlYjhfMi0yLTEtMS0w_a39e7e92-8a5b-42f0-b15d-453529caac7c"
      unitRef="usd">1675000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjczOGVlNTBmYmM0YjRhYjc5ZDJjNjFhMGQwM2NjZWI4L3RhYmxlcmFuZ2U6NzM4ZWU1MGZiYzRiNGFiNzlkMmM2MWEwZDAzY2NlYjhfMy0yLTEtMS0w_0169d22b-9db1-4353-b040-a1843ea209cb"
      unitRef="usd">1675000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjczOGVlNTBmYmM0YjRhYjc5ZDJjNjFhMGQwM2NjZWI4L3RhYmxlcmFuZ2U6NzM4ZWU1MGZiYzRiNGFiNzlkMmM2MWEwZDAzY2NlYjhfNC0yLTEtMS0w_46741d72-c23c-47d3-8cb2-c9c3a3acdb76"
      unitRef="usd">1675000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjczOGVlNTBmYmM0YjRhYjc5ZDJjNjFhMGQwM2NjZWI4L3RhYmxlcmFuZ2U6NzM4ZWU1MGZiYzRiNGFiNzlkMmM2MWEwZDAzY2NlYjhfNS0yLTEtMS0w_1a09d761-7fe0-4345-9f3c-1c602b2cb5f6"
      unitRef="usd">1669000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjczOGVlNTBmYmM0YjRhYjc5ZDJjNjFhMGQwM2NjZWI4L3RhYmxlcmFuZ2U6NzM4ZWU1MGZiYzRiNGFiNzlkMmM2MWEwZDAzY2NlYjhfNi0yLTEtMS0w_01e6e724-e6b3-42cb-a83d-0efe0b0343e5"
      unitRef="usd">9661000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181NS9mcmFnOjQzZTE4ODNlMGE5NDQyODQ5ZjBlY2M5ZDYwMTU3MmI0L3RhYmxlOjczOGVlNTBmYmM0YjRhYjc5ZDJjNjFhMGQwM2NjZWI4L3RhYmxlcmFuZ2U6NzM4ZWU1MGZiYzRiNGFiNzlkMmM2MWEwZDAzY2NlYjhfNy0yLTEtMS0w_c1bd463a-89d9-418e-841f-d14a651b09ba"
      unitRef="usd">17611000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RleHRyZWdpb246ODkyNDc5YzcxNjMyNDY3NDk4OGViYWFiZTljZjg5YWZfMTg2_076e4ee3-fe00-41cc-9bc5-9caf1eda12f7">OTHER FINANCIAL INFORMATION&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Accounts receivable, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: cash discounts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowances for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Inventories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:96.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;________________________________&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts primarily consist of raw materials.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accrued and other current liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of Accrued and other current liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for sales returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RleHRyZWdpb246ODkyNDc5YzcxNjMyNDY3NDk4OGViYWFiZTljZjg5YWZfOTg5NTYwNDY1MDM5OA_1b68d03a-8f4d-4739-961d-596a653093df">&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Accounts receivable, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: cash discounts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowances for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmExY2I2ZGY3YjdiNTRmODI4ZmVlMGI1NDNhYWJjNjNiL3RhYmxlcmFuZ2U6YTFjYjZkZjdiN2I1NGY4MjhmZWUwYjU0M2FhYmM2M2JfMS0yLTEtMS0zOTg_2dd79fb3-440d-4819-9c2b-49b6cde6b755"
      unitRef="usd">4647000000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmExY2I2ZGY3YjdiNTRmODI4ZmVlMGI1NDNhYWJjNjNiL3RhYmxlcmFuZ2U6YTFjYjZkZjdiN2I1NGY4MjhmZWUwYjU0M2FhYmM2M2JfMS00LTEtMS0zOTg_4a884701-6fd8-4ee4-9755-927770047e1e"
      unitRef="usd">5560000000</us-gaap:AccountsReceivableGrossCurrent>
    <gild:AccountsReceivableChargebacksCurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmExY2I2ZGY3YjdiNTRmODI4ZmVlMGI1NDNhYWJjNjNiL3RhYmxlcmFuZ2U6YTFjYjZkZjdiN2I1NGY4MjhmZWUwYjU0M2FhYmM2M2JfMi0yLTEtMS0zOTg_8981a554-de6b-4a9c-993d-6ef0ab73f230"
      unitRef="usd">607000000</gild:AccountsReceivableChargebacksCurrent>
    <gild:AccountsReceivableChargebacksCurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmExY2I2ZGY3YjdiNTRmODI4ZmVlMGI1NDNhYWJjNjNiL3RhYmxlcmFuZ2U6YTFjYjZkZjdiN2I1NGY4MjhmZWUwYjU0M2FhYmM2M2JfMi00LTEtMS0zOTg_a9533c6a-a656-4a3f-96c0-7699872ffb8f"
      unitRef="usd">552000000</gild:AccountsReceivableChargebacksCurrent>
    <gild:AccountsReceivableCashDiscountsAndOtherCurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmExY2I2ZGY3YjdiNTRmODI4ZmVlMGI1NDNhYWJjNjNiL3RhYmxlcmFuZ2U6YTFjYjZkZjdiN2I1NGY4MjhmZWUwYjU0M2FhYmM2M2JfMy0yLTEtMS0zOTg_12a43dcd-805e-4f0b-bb2d-8dc168b0a300"
      unitRef="usd">64000000</gild:AccountsReceivableCashDiscountsAndOtherCurrent>
    <gild:AccountsReceivableCashDiscountsAndOtherCurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmExY2I2ZGY3YjdiNTRmODI4ZmVlMGI1NDNhYWJjNjNiL3RhYmxlcmFuZ2U6YTFjYjZkZjdiN2I1NGY4MjhmZWUwYjU0M2FhYmM2M2JfMy00LTEtMS0zOTg_06d21b53-fa28-4f0d-9124-ab360b6d15c3"
      unitRef="usd">72000000</gild:AccountsReceivableCashDiscountsAndOtherCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmExY2I2ZGY3YjdiNTRmODI4ZmVlMGI1NDNhYWJjNjNiL3RhYmxlcmFuZ2U6YTFjYjZkZjdiN2I1NGY4MjhmZWUwYjU0M2FhYmM2M2JfNC0yLTEtMS0zOTg_c3d487d6-d325-4d74-95f9-5193466c0cb7"
      unitRef="usd">51000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmExY2I2ZGY3YjdiNTRmODI4ZmVlMGI1NDNhYWJjNjNiL3RhYmxlcmFuZ2U6YTFjYjZkZjdiN2I1NGY4MjhmZWUwYjU0M2FhYmM2M2JfNC00LTEtMS0zOTg_992c1e7f-ce4f-4510-8049-018fbb865bf7"
      unitRef="usd">44000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmExY2I2ZGY3YjdiNTRmODI4ZmVlMGI1NDNhYWJjNjNiL3RhYmxlcmFuZ2U6YTFjYjZkZjdiN2I1NGY4MjhmZWUwYjU0M2FhYmM2M2JfNS0yLTEtMS0zOTg_e43e16f6-01d4-426a-8268-e81ebc0c3da9"
      unitRef="usd">3925000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmExY2I2ZGY3YjdiNTRmODI4ZmVlMGI1NDNhYWJjNjNiL3RhYmxlcmFuZ2U6YTFjYjZkZjdiN2I1NGY4MjhmZWUwYjU0M2FhYmM2M2JfNS00LTEtMS0zOTg_116b653c-c673-4e53-b458-3c83bf8e870b"
      unitRef="usd">4892000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RleHRyZWdpb246ODkyNDc5YzcxNjMyNDY3NDk4OGViYWFiZTljZjg5YWZfMTgx_3f45da58-044f-4980-9dd4-0c584d76013b">&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Inventories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:96.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;________________________________&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts primarily consist of raw materials.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfMS0yLTEtMS0w_bcc441f8-6a9f-4777-adab-69ae63081603"
      unitRef="usd">1023000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfMS00LTEtMS0w_4e9f5f62-3cd0-4481-b655-9b4fcc7486c7"
      unitRef="usd">1080000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfMi0yLTEtMS0w_14c9559f-349f-42e8-bf9c-cfb0d0d1123b"
      unitRef="usd">856000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfMi00LTEtMS0w_50c41fd3-7947-4d01-ad9b-b9110a8b04da"
      unitRef="usd">976000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfMy0yLTEtMS0w_7862e286-a554-4617-bb5e-9312726848d7"
      unitRef="usd">1117000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfMy00LTEtMS0w_e7c76f45-9f02-460e-8ebd-715570354469"
      unitRef="usd">958000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <gild:InventoryNetAndInventoryNoncurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfNC0yLTEtMS0w_ce99ae1c-4895-437a-8a2b-bd1f2ca243e6"
      unitRef="usd">2996000000</gild:InventoryNetAndInventoryNoncurrent>
    <gild:InventoryNetAndInventoryNoncurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfNC00LTEtMS0w_a3a8f044-df17-4639-911f-f77ea44d295d"
      unitRef="usd">3014000000</gild:InventoryNetAndInventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfNy0yLTEtMS0w_940694de-679f-4703-95d0-1092df9b1e85"
      unitRef="usd">1779000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfNy00LTEtMS0w_3eab0329-3699-4a63-a92c-16535f3de705"
      unitRef="usd">1683000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfOC0yLTEtMS0w_92f91b23-ddd3-4f1f-bdb1-edeac93ce9ac"
      unitRef="usd">1217000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfOC00LTEtMS0w_7b120dd1-6edf-407a-a44d-efc047962c01"
      unitRef="usd">1331000000</us-gaap:InventoryNoncurrent>
    <gild:InventoryNetAndInventoryNoncurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfOS0yLTEtMS0w_48c757ed-4606-4b0f-b81a-67cfb7f6bc05"
      unitRef="usd">2996000000</gild:InventoryNetAndInventoryNoncurrent>
    <gild:InventoryNetAndInventoryNoncurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOjk1NmFhODQyNjJjZjRiZWZiN2EwN2JhODhiNDQxODUyL3RhYmxlcmFuZ2U6OTU2YWE4NDI2MmNmNGJlZmI3YTA3YmE4OGI0NDE4NTJfOS00LTEtMS0w_7488bb6c-6057-45a9-ad22-cf436185c71d"
      unitRef="usd">3014000000</gild:InventoryNetAndInventoryNoncurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RleHRyZWdpb246ODkyNDc5YzcxNjMyNDY3NDk4OGViYWFiZTljZjg5YWZfMTg3_eccb508d-0194-48c8-bfbb-8e028a8c58ff">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of Accrued and other current liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for sales returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmQ1NGMyNzgyMTA4YTRjN2I5OWU0YzQ4MzgxZDdlNDFlL3RhYmxlcmFuZ2U6ZDU0YzI3ODIxMDhhNGM3Yjk5ZTRjNDgzODFkN2U0MWVfMS0yLTEtMS0w_bfc0065b-a2b5-41e2-ac1c-4c8b93e619ac"
      unitRef="usd">494000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmQ1NGMyNzgyMTA4YTRjN2I5OWU0YzQ4MzgxZDdlNDFlL3RhYmxlcmFuZ2U6ZDU0YzI3ODIxMDhhNGM3Yjk5ZTRjNDgzODFkN2U0MWVfMS00LTEtMS0w_0d7dd8d1-936b-45f2-9691-79b67f336770"
      unitRef="usd">864000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmQ1NGMyNzgyMTA4YTRjN2I5OWU0YzQ4MzgxZDdlNDFlL3RhYmxlcmFuZ2U6ZDU0YzI3ODIxMDhhNGM3Yjk5ZTRjNDgzODFkN2U0MWVfMi0yLTEtMS0w_9369320b-6733-4d73-8067-2b61f890c34a"
      unitRef="usd">215000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmQ1NGMyNzgyMTA4YTRjN2I5OWU0YzQ4MzgxZDdlNDFlL3RhYmxlcmFuZ2U6ZDU0YzI3ODIxMDhhNGM3Yjk5ZTRjNDgzODFkN2U0MWVfMi00LTEtMS0w_0e817143-3acf-4319-82f5-ea73e3f9df4c"
      unitRef="usd">598000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmQ1NGMyNzgyMTA4YTRjN2I5OWU0YzQ4MzgxZDdlNDFlL3RhYmxlcmFuZ2U6ZDU0YzI3ODIxMDhhNGM3Yjk5ZTRjNDgzODFkN2U0MWVfMy0yLTEtMS0zNjI_49fb7116-e6e2-4015-9eb1-4e646772bf64"
      unitRef="usd">524000000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmQ1NGMyNzgyMTA4YTRjN2I5OWU0YzQ4MzgxZDdlNDFlL3RhYmxlcmFuZ2U6ZDU0YzI3ODIxMDhhNGM3Yjk5ZTRjNDgzODFkN2U0MWVfMy00LTEtMS0zNjI_e2c2f942-dc02-4bfc-86c8-5acb8c963694"
      unitRef="usd">587000000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmQ1NGMyNzgyMTA4YTRjN2I5OWU0YzQ4MzgxZDdlNDFlL3RhYmxlcmFuZ2U6ZDU0YzI3ODIxMDhhNGM3Yjk5ZTRjNDgzODFkN2U0MWVfMy0yLTEtMS0w_95dfbf41-3d4a-4b65-b5a1-95b5df4fb04c"
      unitRef="usd">2274000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmQ1NGMyNzgyMTA4YTRjN2I5OWU0YzQ4MzgxZDdlNDFlL3RhYmxlcmFuZ2U6ZDU0YzI3ODIxMDhhNGM3Yjk5ZTRjNDgzODFkN2U0MWVfMy00LTEtMS0w_986c86b0-cbe5-4ab0-b804-e6e3a9a25c78"
      unitRef="usd">2287000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmQ1NGMyNzgyMTA4YTRjN2I5OWU0YzQ4MzgxZDdlNDFlL3RhYmxlcmFuZ2U6ZDU0YzI3ODIxMDhhNGM3Yjk5ZTRjNDgzODFkN2U0MWVfNC0yLTEtMS0w_fee650db-5d69-41bf-8843-1008d63b607a"
      unitRef="usd">3507000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181Mi9mcmFnOjg5MjQ3OWM3MTYzMjQ2NzQ5ODhlYmFhYmU5Y2Y4OWFmL3RhYmxlOmQ1NGMyNzgyMTA4YTRjN2I5OWU0YzQ4MzgxZDdlNDFlL3RhYmxlcmFuZ2U6ZDU0YzI3ODIxMDhhNGM3Yjk5ZTRjNDgzODFkN2U0MWVfNC00LTEtMS0w_77dfb11d-9f9a-419a-a405-bf6694c395d4"
      unitRef="usd">4336000000</us-gaap:AccruedLiabilitiesCurrent>
    <gild:CollaborativeAndOtherArrangementsTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF85ODk1NjA0NzA0MDQ0_c0430c72-7e7d-4c47-869f-0b8db12ad0af">COLLABORATIONS AND OTHER ARRANGEMENTS&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We continue to pursue licensing and strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain products and product candidates. These arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements and cost-sharing arrangements. We also continue to pursue equity investments in third parties focused on the development and commercialization of products and product candidates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Merck Sharp &amp;amp; Dohme Corp. (&#x201c;Merck&#x201d;) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 13, 2021, we entered into a license and collaboration agreement with Merck, a subsidiary of Merck &amp;amp; Co., Inc. to jointly develop and commercialize long-acting investigational treatments in HIV that combine Gilead&#x2019;s investigational capsid inhibitor, lenacapavir, and Merck&#x2019;s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir. The collaboration will initially focus on long-acting oral and injectable formulations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Gilead and Merck will share global development and commercialization costs at 60% and 40%, respectively, across the oral and injectable formulation programs. For long-acting oral products, Gilead will lead commercialization in the U.S. and Merck will lead commercialization in the European Union (&#x201c;EU&#x201d;) and rest of the world. For long-acting injectable products, Merck will lead commercialization in the U.S. and Gilead will lead commercialization in the EU and rest of the world. Gilead and Merck will jointly promote the combination products in the U.S. and certain other major markets. We will share global product revenues with Merck equally until product revenues surpass certain pre-determined per formulation revenue tiers. Upon passing $2.0 billion in net product sales for the oral combination in a given calendar year, our share of revenue will increase to 65% for any revenues above the threshold for such calendar year. Upon passing $3.5 billion in net product sales for the injectable combination in a given calendar year, our share of revenue will increase to 65% for any revenues above the threshold for such calendar year. There was no material impact from the agreement on our Condensed Consolidated Financial Statements for the three months ended March 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We will also have the option to license certain of Merck&#x2019;s investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of Gilead&#x2019;s investigational oral integrase inhibitors to develop in combination with islatravir. Each company may exercise its option for such investigational oral integrase inhibitor of the other company within the first five years after execution of the agreement, following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon exercise of an option, the companies will split development cost and revenues, unless the non-exercising company decides to opt-out, in which case the non-exercising company will be paid a royalty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Arcus Biosciences, Inc. (&#x201c;Arcus&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On&#160;May 27, 2020, we entered into a transaction with Arcus, which included entry into an option, license and collaboration agreement (the &#x201c;Collaboration Agreement&#x201d;) and a common stock purchase agreement and an investor rights agreement (together, and as subsequently amended the &#x201c;Stock Purchase Agreements&#x201d;). In 2020, pursuant to the Stock Purchase Agreements and a separate secondary equity offering, we acquired approximately 8.2&#160;million shares of Arcus common stock for approximately $261 million. In the first quarter of 2021, we amended and restated the common stock purchase agreement and acquired approximately 5.7&#160;million additional shares of Arcus common stock for $220 million. As a result, we currently own a total of 13.8&#160;million shares of Arcus, which represented approximately 19.5% of the issued and outstanding voting stock of Arcus immediately following the closing of the transaction. We recorded our equity investments in Arcus in Other long-term assets on our Condensed Consolidated Balance Sheets as the investments are subject to contractual lock-up provisions, subject to certain conditions. We account for our equity investments in Arcus at fair value with changes in fair value recognized in Other income (expense), net on our Condensed Consolidated Statements of Income for each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Stock Purchase Agreements, we have the right to purchase additional shares of Arcus from Arcus over the five year period beginning on the closing of the Stock Purchase Agreements, up to a maximum of 35% of the outstanding voting stock. We are subject to a three year standstill, which period began on the date the parties entered into the Stock Purchase Agreements, restricting our ability to acquire voting stock of Arcus exceeding more than 35% of the then issued and outstanding voting stock of Arcus, subject to certain exceptions. Additionally, we agreed not to dispose of any equity securities of Arcus prior to the second anniversary of the closing of the Stock Purchase Agreements without the prior consent of Arcus, subject to certain exceptions. The amendment and restatement of the common stock purchase agreement in the first quarter of 2021 did not modify any of these terms. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2021 and 2020, we entered into several collaborations, equity investments and licensing arrangements as well as other similar arrangements that we do not consider to be individually material. We recorded upfront collaboration expenses related to these arrangements of $62 million and $97 million for the three months ended March 31, 2021 and 2020, respectively, within Acquired in-process research and development expenses on our Condensed Consolidated Statements of Income. Cash payments made related to our equity investments were $59 million and $8 million for the three months ended March 31, 2021 and 2020, respectively, which were primarily recorded in Other long-term assets on our Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the financial terms of these arrangements, we may be required to make payments upon achievement of developmental, regulatory and commercial milestones, which could be significant. Future milestone payments, if any, will be reflected in our Condensed Consolidated Statements of Income when the corresponding events become probable. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurrence.&lt;/span&gt;&lt;/div&gt;</gild:CollaborativeAndOtherArrangementsTextBlock>
    <gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts
      contextRef="i9bba91958aca44f293ca49c63fbaafef_D20210313-20210313"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF8xMDk5NTExNjgxODUw_92985a5f-8e5b-4f25-a09d-3c672316a21f"
      unitRef="number">0.60</gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts>
    <gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts
      contextRef="i37ff3780af8f4a3e8fb8ad3d11da24c2_D20210313-20210313"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF8xMDk5NTExNjgxODU1_c73bcef4-6e01-460a-aca7-628284332b37"
      unitRef="number">0.40</gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts>
    <gild:CollaborationArrangementNetProductSalesThreshold
      contextRef="i2bb0786a7089452eab44f7d3f2844758_D20210313-20210313"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF8xMDk5NTExNjgxODcx_5490fd21-b7e4-44be-aa95-7c00a7ca5b52"
      unitRef="usd">2000000000.0</gild:CollaborationArrangementNetProductSalesThreshold>
    <gild:CollaborationArrangementPercentOfGlobalProductRevenues
      contextRef="i2bb0786a7089452eab44f7d3f2844758_D20210313-20210313"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF8xMDk5NTExNjgxODk1_839f2bec-3bc2-4309-ac5b-c4db82cb98ba"
      unitRef="number">0.65</gild:CollaborationArrangementPercentOfGlobalProductRevenues>
    <gild:CollaborationArrangementNetProductSalesThreshold
      contextRef="i32ac5282522a4590be96101bc1e207b1_D20210313-20210313"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF8xMDk5NTExNjgxODg3_20fd9541-9013-456c-86d3-4fc3e32b919a"
      unitRef="usd">3500000000</gild:CollaborationArrangementNetProductSalesThreshold>
    <gild:CollaborationArrangementPercentOfGlobalProductRevenues
      contextRef="i32ac5282522a4590be96101bc1e207b1_D20210313-20210313"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF8xMDk5NTExNjgxOTAx_874366f2-7497-4268-84bc-5348195bfb51"
      unitRef="number">0.65</gild:CollaborationArrangementPercentOfGlobalProductRevenues>
    <gild:CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod
      contextRef="i9bba91958aca44f293ca49c63fbaafef_D20210313-20210313"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF85ODk1NjA0NzE0MDQx_fc9c39cb-4508-4e42-8516-804dd22651fa">P5Y</gild:CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod>
    <gild:EquitySecuritiesFVNISharesAcquired
      contextRef="id660245607b543dea4f85f3873880146_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF80Mzk4MDQ2NTYyOTc3_34b6b31d-f4bb-4b8b-865c-a7c3100ac1d2"
      unitRef="shares">8200000</gild:EquitySecuritiesFVNISharesAcquired>
    <gild:PaymentsToAcquireEquitySecuritiesFVNI
      contextRef="id660245607b543dea4f85f3873880146_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF80Mzk4MDQ2NTYyOTky_d6c2b08f-4645-41b8-8de7-5d0174484e67"
      unitRef="usd">261000000</gild:PaymentsToAcquireEquitySecuritiesFVNI>
    <gild:EquitySecuritiesFVNISharesAcquired
      contextRef="ibdce32802a20413da082d4b864fd5089_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF80Mzk4MDQ2NTYyNjc1_332a5218-2f00-4005-9f26-679922c4e91d"
      unitRef="shares">5700000</gild:EquitySecuritiesFVNISharesAcquired>
    <gild:PaymentsToAcquireEquitySecuritiesFVNI
      contextRef="ibdce32802a20413da082d4b864fd5089_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF80Mzk4MDQ2NTYyNjkz_7c0cdb0b-ef24-4c30-8fca-ebd6b32904fe"
      unitRef="usd">220000000</gild:PaymentsToAcquireEquitySecuritiesFVNI>
    <gild:EquitySecuritiesFVNIShares
      contextRef="i410db304976646ba98567afb20cfa4a0_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF80Mzk4MDQ2NTYyNzA5_d5bdecfb-7008-4cab-8d44-1a646906eec8"
      unitRef="shares">13800000</gild:EquitySecuritiesFVNIShares>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i2a3b8026d52f4290b417e3f5e019a0ff_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF80Mzk4MDQ2NTYyNzI4_f70f23ff-8f28-4df8-a397-205e2ae26a45"
      unitRef="number">0.195</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <gild:EquitySecuritiesFVNIPurchasePeriod
      contextRef="i8e3646c5f44b457faaf84b163f791ffc_D20200527-20200527"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF85ODk1NjA0NzA0MDQy_d7489cf6-2c8b-4baa-926a-bbf5d2fc6ec7">P5Y</gild:EquitySecuritiesFVNIPurchasePeriod>
    <gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased
      contextRef="i9a6c487393e2416988fed705f84d74ee_D20200527-20200527"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF80Mzk4MDQ2NTU4MDgw_849166ad-312c-44f4-baf5-17c1e85d7c2d"
      unitRef="number">0.35</gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased>
    <gild:EquitySecuritiesFVNIRestrictionPeriod
      contextRef="i8e3646c5f44b457faaf84b163f791ffc_D20200527-20200527"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF85ODk1NjA0NzA0MDQz_71cafa10-5022-47be-939f-c6f3d417fd28">P3Y</gild:EquitySecuritiesFVNIRestrictionPeriod>
    <gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased
      contextRef="i9a6c487393e2416988fed705f84d74ee_D20200527-20200527"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF80Mzk4MDQ2NTU4MjM0_849166ad-312c-44f4-baf5-17c1e85d7c2d"
      unitRef="number">0.35</gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased>
    <gild:UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements
      contextRef="if5fa445c6c284cf389eb387244e326c3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF8xNjQ5MjY3NDU3MTI4_116c3fb9-f5fb-4b55-9d02-e347c129593d"
      unitRef="usd">62000000</gild:UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements>
    <gild:UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements
      contextRef="ie247b2a21d0b41a8936b62106a17ef12_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF80Mzk4MDQ2NTUxOTc3_eee563e2-0741-4be9-a76e-77020ec87d4d"
      unitRef="usd">97000000</gild:UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements>
    <gild:CashPaymentsMadeRelatedToEquityInvestments
      contextRef="if5fa445c6c284cf389eb387244e326c3_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF80Mzk4MDQ2NTUyMDIy_5e0d1100-e118-469d-a024-c67de542f9c5"
      unitRef="usd">59000000</gild:CashPaymentsMadeRelatedToEquityInvestments>
    <gild:CashPaymentsMadeRelatedToEquityInvestments
      contextRef="ie247b2a21d0b41a8936b62106a17ef12_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTAzL2ZyYWc6YTFlM2VjYWFhOWZjNDY5MmJhZGIxYjIyYjA2NDY4YjAvdGV4dHJlZ2lvbjphMWUzZWNhYWE5ZmM0NjkyYmFkYjFiMjJiMDY0NjhiMF80Mzk4MDQ2NTUyMDMz_ef0f76c7-130a-473b-a4a2-9b6480f11d6d"
      unitRef="usd">8000000</gild:CashPaymentsMadeRelatedToEquityInvestments>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RleHRyZWdpb246NTNlYTE3Mjc0OWU2NDk0YmFjNDM3NGU0MWFjNmU4ZTdfNTA2MQ_44e70e10-3092-426d-8c6e-f1ea5a6182d7">DEBT AND CREDIT FACILITIES&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amount of our borrowings under various financing arrangements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type of Borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issue Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-month LIBOR + 0.15%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-month LIBOR + 0.52%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;variable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2046&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2047&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total senior unsecured notes and term loan facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less: current portion of long-term debt and other obligations, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2021, we repaid $1.25 billion of debt. In January 2021, we repaid $1.0 billion of senior unsecured notes prior to the April 2021 maturity, by exercising a 3-month par call. In March 2021, we repaid $250 million principal amount under our three-year $1.0 billion senior unsecured term loan facility, leaving $750 million principal amount outstanding as of March&#160;31, 2021. No new debt was issued during the three months ended March 31, 2021. We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of March&#160;31, 2021, we were in compliance with all covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021 and December&#160;31, 2020, there were no amounts outstanding under our $2.5 billion revolving credit facility maturing in June 2025, and we were in compliance with all covenants.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RleHRyZWdpb246NTNlYTE3Mjc0OWU2NDk0YmFjNDM3NGU0MWFjNmU4ZTdfNTA2MA_45a9db6b-ef64-4065-9505-98c7b71c379b">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amount of our borrowings under various financing arrangements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type of Borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issue Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-month LIBOR + 0.15%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-month LIBOR + 0.52%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;variable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2046&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2047&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total senior unsecured notes and term loan facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less: current portion of long-term debt and other obligations, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id981d1fa90ad4e34a3646bf93d286389_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNC00LTEtMS0w_66d23960-ed97-4ff6-8222-7044a3914602"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="id981d1fa90ad4e34a3646bf93d286389_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNC02LTEtMS0w_b853b366-e466-4d8d-9c13-6bdd97a42a38"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iddf64755f5544f55a023159b39cd796c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNC04LTEtMS0w_b2c109dc-5c6c-4fa4-94cd-eb24edaed471"
      unitRef="usd">1000000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i5ef8f9839275426e96e11272486fcf64_D20210101-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNS00LTEtMS0wL3RleHRyZWdpb246MjZiNjVlNzM5NmY5NDE4MTg5NTM2ZTUwYzQwZGFmMTVfMjA_abaaa2da-51e8-4dd6-aa4e-ef5dd7d8e07e"
      unitRef="number">0.0015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="i226f19faf322425f8f45de6324e4ddcc_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNS02LTEtMS0w_59145635-7fb5-4fe8-825d-22c654b7240b"
      unitRef="usd">500000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ia0682f9735fe421db3f9c49bed1595fe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNS04LTEtMS0w_2ba67912-feeb-4a1e-af1a-f6b4a05d9a78"
      unitRef="usd">499000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2e07919b5c964bd1a6f6261698386d5a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNi00LTEtMS0w_d5c61b60-2b58-48b9-829c-b1ff46d58df2"
      unitRef="number">0.0440</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i2e07919b5c964bd1a6f6261698386d5a_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNi02LTEtMS0w_e3b03a3b-a7cc-4f24-a50a-50aacb17cd00"
      unitRef="usd">1249000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie96a1150c9f54ebbb4aeeeac86d5d0b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNi04LTEtMS0w_f0726e64-056b-4f7c-bc2d-f188bed88f4e"
      unitRef="usd">1249000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4560703e7e434329b08f919b7ec93556_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNy00LTEtMS0w_6110554d-62f1-4ca1-9ec0-8fe7343bdcb9"
      unitRef="number">0.0195</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i4560703e7e434329b08f919b7ec93556_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNy02LTEtMS0w_dd1d5d95-2993-435a-b639-1dd2c9f88aa9"
      unitRef="usd">499000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i2d7b8c0c53ce4856b17e0c17548ab01b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfNy04LTEtMS0w_624cc6c0-2d5f-4821-9fb8-d9b67a343a69"
      unitRef="usd">499000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i42ab2dc4d1f3427799326322503aeb9f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfOC00LTEtMS0w_079caba6-7b9f-430f-a2aa-d363f4908256"
      unitRef="number">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i42ab2dc4d1f3427799326322503aeb9f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfOC02LTEtMS0w_cf619de8-4d04-494b-a8fd-53a8d0c92f21"
      unitRef="usd">999000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i8e00b7d5eead42bcba3eb2cf1ac7ef4e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfOC04LTEtMS0w_91e68a58-a9ad-4cdf-9010-58c6fc493425"
      unitRef="usd">998000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i31c5d5f5c24240f88a2fbf3010130c04_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfOS00LTEtMS0w_6f065a6a-56e4-462d-ae9f-88c16d2fa591"
      unitRef="number">0.0250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i31c5d5f5c24240f88a2fbf3010130c04_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfOS02LTEtMS0w_bd6542bf-4685-4ef1-973a-653987bb7d53"
      unitRef="usd">748000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3a5500ac6a4a40b4a0ce85e93cb1be81_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfOS04LTEtMS0w_2925cc12-9db2-4e6d-aeda-b6486d3d3ae3"
      unitRef="usd">748000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i84c7098c5f6942d6aafc60e537b25ace_D20210101-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTAtNC0xLTEtMC90ZXh0cmVnaW9uOmNlZjRhYjNiZTE5NzQ4NDI5YjQ0NjVjMzQ2OWM3MTUwXzIw_dfd0bebc-49f1-4bc3-a8e8-fc81d25a92b2"
      unitRef="number">0.0052</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="i8d84c0793a654adc835292e4057e62af_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTAtNi0xLTEtMA_536f79ae-a382-414d-9152-e37871fbaa75"
      unitRef="usd">498000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="icc91e8dffffa4c25b54f3376c5704709_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTAtOC0xLTEtMA_42db4fc1-dda8-449a-9e45-8b8ddf9818b5"
      unitRef="usd">498000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7b064cf950804b14bb98c71681dbbe38_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTEtNC0xLTEtMA_7e6f48d7-5bf4-4021-97f0-af1e53564690"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7b064cf950804b14bb98c71681dbbe38_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTEtNC0xLTEtMA_c85dd233-9f86-46cc-87e4-7006ce2fd2ca"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i7b064cf950804b14bb98c71681dbbe38_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTEtNi0xLTEtMA_d0614edc-7068-4b24-8e7f-0b61a37d2c95"
      unitRef="usd">1993000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie1cfc9d0baa34e13b8b793bd53072677_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTEtOC0xLTEtMA_d8518a12-56f3-4d11-8b61-72337dcf7cf0"
      unitRef="usd">1992000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i5caff279b30742e699b0222a2e09750d_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTItOC0xLTEtMjAyMw_30aac413-4ba7-4e7d-8d5e-5be616583aa9"
      unitRef="usd">748000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i9f01ef44785a49f0bc8f3ed2a594041b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTItMTAtMS0xLTIwMjM_08a953c7-389e-4faf-888e-50ef30c54612"
      unitRef="usd">998000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i82712a6fb96b40d1ba7af885131644a8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTItNC0xLTEtMA_9452cae4-f745-4097-b48c-139a65a8a065"
      unitRef="number">0.0370</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i82712a6fb96b40d1ba7af885131644a8_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTItNi0xLTEtMA_90d4be5c-f1fa-4c66-aef6-decf8d9a00a4"
      unitRef="usd">1746000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i02153ca61e2240f8a5f4caff17673c80_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTItOC0xLTEtMA_8452d44a-9441-42b4-9e2d-bfafbfab56ab"
      unitRef="usd">1746000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifd2dbc82577249dda35b4d5bf8355af9_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTMtNC0xLTEtMA_3f981ad1-60e7-4b46-ac5e-c4a41f986333"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ifd2dbc82577249dda35b4d5bf8355af9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTMtNi0xLTEtMA_76ee837a-8a45-49f5-a88e-7fff68846f41"
      unitRef="usd">1747000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie93b3397067946b99b504b92e01bc73e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTMtOC0xLTEtMA_5777c0ad-3a5f-442a-a297-9de6065f9acd"
      unitRef="usd">1746000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie111efaeb3a5493fb1836bdd7dd01efa_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTQtNC0xLTEtMA_0ae17ea5-c560-4001-846c-b53c2e316866"
      unitRef="number">0.0365</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ie111efaeb3a5493fb1836bdd7dd01efa_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTQtNi0xLTEtMA_e5ccc906-6671-4899-9aee-4a4e383a823a"
      unitRef="usd">2737000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i37798ead586444438d3256c1b09bc74c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTQtOC0xLTEtMA_a0be197a-c1e6-46ff-94b6-fe7c1f1d0ea1"
      unitRef="usd">2737000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0ab5e1d8ed5a4d4ebb33b172197fddbc_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTUtNC0xLTEtMA_189541da-8d01-4ac9-9a9b-81a666486629"
      unitRef="number">0.0295</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i0ab5e1d8ed5a4d4ebb33b172197fddbc_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTUtNi0xLTEtMA_00fc2a8b-b09e-443a-b9b7-3514b8203d1c"
      unitRef="usd">1246000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i1cc4906eaff642878b6f94791e6e1015_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTUtOC0xLTEtMA_29505306-70d5-4ea6-9e58-cae9d57342c0"
      unitRef="usd">1246000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i41f044c9e0ca469e8e21f44e347cf6f3_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTYtNC0xLTEtMA_3f7299ff-d97f-406c-8e79-8e43ddda4e0e"
      unitRef="number">0.0120</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i41f044c9e0ca469e8e21f44e347cf6f3_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTYtNC0xLTEtMA_57e93a67-af39-4c59-aa90-9cc35cb1b6cf"
      unitRef="number">0.0120</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i41f044c9e0ca469e8e21f44e347cf6f3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTYtNi0xLTEtMA_f6008f65-229b-4bd6-9303-0d56134cc140"
      unitRef="usd">746000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ia277d47a2bbd47a4bda96e51633f0028_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTYtOC0xLTEtMA_eb64f955-a923-4b93-a14f-fa91fb794ef7"
      unitRef="usd">745000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i06b11f61f1c147e092d508e568092b9d_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTctNC0xLTEtMA_608b468b-036e-4056-9e5f-ef290c86ca79"
      unitRef="number">0.0165</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i06b11f61f1c147e092d508e568092b9d_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTctNC0xLTEtMA_69885d63-a034-4807-a08a-eda7cac65504"
      unitRef="number">0.0165</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i06b11f61f1c147e092d508e568092b9d_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTctNi0xLTEtMA_304d81df-e18d-49e6-b586-3216a5974eae"
      unitRef="usd">992000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i0607a5570b824496986ded1619166b26_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTctOC0xLTEtMA_187c70e9-3f6e-47c2-b94e-49592bf953ae"
      unitRef="usd">992000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1bb341107e2a4b88b6060a86a8e386e2_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTgtNC0xLTEtMA_86d3393c-5946-4467-8a4a-04627d66fa42"
      unitRef="number">0.0460</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i1bb341107e2a4b88b6060a86a8e386e2_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTgtNi0xLTEtMA_35c903f4-fccf-4b8e-9175-af5a83ef966f"
      unitRef="usd">992000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i649ba66e7c7f4344a91edbb3d0ed8c94_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTgtOC0xLTEtMA_00f2f230-efc4-4a6d-89cd-aa45c21a39e9"
      unitRef="usd">991000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i461c85d95d204d8b9943c1284aed4e98_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTktNC0xLTEtMA_ea7aa8a1-cd89-4e13-93e2-c650864b221e"
      unitRef="number">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i461c85d95d204d8b9943c1284aed4e98_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTktNi0xLTEtMA_ad5f158b-2a18-4101-a1e3-28005f119b61"
      unitRef="usd">742000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic58ce72e2e4849669af1178aea5ff019_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMTktOC0xLTEtMA_617e841c-07ed-45df-928e-7e947dd5d70b"
      unitRef="usd">741000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iefd9e7139a3441e891c9c8d8134e4c6d_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjAtNC0xLTEtMA_50d80719-12d4-4b0c-a5b7-b3d9a6c260c6"
      unitRef="number">0.0260</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iefd9e7139a3441e891c9c8d8134e4c6d_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjAtNC0xLTEtMA_e9495cc4-d7fb-4119-8bdf-1fdca4775612"
      unitRef="number">0.0260</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="iefd9e7139a3441e891c9c8d8134e4c6d_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjAtNi0xLTEtMA_812e8f77-898a-4b4b-960a-4fdd7ddd58da"
      unitRef="usd">986000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i8c5e44c87f514190914febaeb7ea34b2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjAtOC0xLTEtMA_4e90bbef-ccdb-4f40-9c9a-986d358dc167"
      unitRef="usd">986000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6bb3588ac15b409787bad99b65f13969_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjEtNC0xLTEtMA_9284187e-42df-4f3e-b468-78c0d4fb90a4"
      unitRef="number">0.0565</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i6bb3588ac15b409787bad99b65f13969_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjEtNi0xLTEtMA_59823b79-62af-48c6-94c5-93a758bc6945"
      unitRef="usd">996000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="id64726640cdc49ae9944b3cafdf07c69_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjEtOC0xLTEtMA_e0bd70cd-1a98-4111-a582-b615b01792fe"
      unitRef="usd">996000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7030cc99c6824dc0a8042a4bed018068_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjItNC0xLTEtMA_f190c5a0-1225-4f1b-bfc3-edef9d5cb948"
      unitRef="number">0.0480</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i7030cc99c6824dc0a8042a4bed018068_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjItNi0xLTEtMA_be0f43e2-d467-4cc6-9527-4fbc5ab67a8e"
      unitRef="usd">1735000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if5dfe2f629c047abb4f613b421c5ea88_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjItOC0xLTEtMA_8d92eafa-909f-44b4-8b70-ba141085ab55"
      unitRef="usd">1735000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idaf8c9742e0b4ece8d7b8394db2ca224_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjMtNC0xLTEtMA_44079ef8-a613-47a2-977b-b744075ea33a"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="idaf8c9742e0b4ece8d7b8394db2ca224_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjMtNi0xLTEtMA_2ed0dcb2-a1a3-4f43-813f-177f31741f65"
      unitRef="usd">1732000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i0aa69e4a48d34c5da5aab157a2293340_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjMtOC0xLTEtMA_cef56b93-ddc9-4cf3-8327-a1ee4f03a603"
      unitRef="usd">1732000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i65459f3f8cdf4c0fbca4efc6938b38e0_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjQtNC0xLTEtMA_4c5d120f-81eb-410e-8fcd-7ca83aa42ca9"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i65459f3f8cdf4c0fbca4efc6938b38e0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjQtNi0xLTEtMA_9f6acf5c-895e-4e8a-a629-79eb08be9f2f"
      unitRef="usd">2219000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i7771d37672d44616baa7902fe05821c9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjQtOC0xLTEtMA_45c98e23-cfa2-46d8-8ddc-3e18b3b99e1c"
      unitRef="usd">2219000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1e2b6e7d9810413789463933aef23466_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjUtNC0xLTEtMA_a5113a7d-3e3e-4ea2-bd32-9dec3a720544"
      unitRef="number">0.0415</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i1e2b6e7d9810413789463933aef23466_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjUtNi0xLTEtMA_11c9d113-d760-4b82-9780-bd682b349956"
      unitRef="usd">1726000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iae31ed5d6fdc4498b6a90dbfc8b86b3a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjUtOC0xLTEtMA_fae7ab97-c52f-4264-9278-d9682e4eaff3"
      unitRef="usd">1726000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia4e384c2073a40b39d85efcab4bf3ee9_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjYtNC0xLTEtMA_6bfbac93-035d-4358-8ba2-f598625889c8"
      unitRef="number">0.0280</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia4e384c2073a40b39d85efcab4bf3ee9_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjYtNC0xLTEtMA_b630c41f-180f-4543-a374-61ba444d697f"
      unitRef="number">0.0280</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ia4e384c2073a40b39d85efcab4bf3ee9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjYtNi0xLTEtMA_7f02984f-f548-41a0-b061-0c333f3247a6"
      unitRef="usd">1476000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i81921ac030614d4f83c0267cd19a94f9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjYtOC0xLTEtMA_3aa13df9-ada1-4f21-808c-c9afcf59bc8a"
      unitRef="usd">1476000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="id10bca8646004217ad83ef4814b3a4a9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjctNi0xLTEtMA_eebad571-883f-453c-ac52-8d40b9b76fef"
      unitRef="usd">29052000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie72718e6c6b44809858a4b6a4ec81ed3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjctOC0xLTEtMA_f1a27f73-16fb-4b28-831e-7561847ef826"
      unitRef="usd">30295000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if3dbd1bb43e241408c3dee0863ca9f87_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjctOC0xLTEtMjA3Mg_59a84f01-ef31-45ed-aa77-eca9ecf68a39"
      unitRef="usd">1114000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="id9b223edf7794782b8bfe9faef909258_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjctMTAtMS0xLTIwNzI_a6e58b69-f5f8-4244-af93-d963da2bde2d"
      unitRef="usd">1107000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjgtOC0xLTEtMjA3Mg_59a3c3ba-75bd-4e84-aef3-19f87342bd7b"
      unitRef="usd">30166000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjgtMTAtMS0xLTIwNzI_f336bb8d-0f24-411c-b7ed-7af72ac982e8"
      unitRef="usd">31402000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjgtNi0xLTEtMA_d4839ca2-e8ce-424b-830c-4c130b96ec75"
      unitRef="usd">2259000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjgtOC0xLTEtMA_d6ab8526-4812-4750-a653-21eead48ae5f"
      unitRef="usd">2757000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjktNi0xLTEtMA_ecd91c01-a467-4f61-92aa-70ff3212791f"
      unitRef="usd">27907000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if18ad61a4d694b84a567b29c22cd074c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RhYmxlOmMwMjQwMTlhNGViOTQwOTNhMzkwMTJmMjhkNzdhOTYxL3RhYmxlcmFuZ2U6YzAyNDAxOWE0ZWI5NDA5M2EzOTAxMmYyOGQ3N2E5NjFfMjktOC0xLTEtMA_7b8e3489-3f2b-4498-a5d9-856d5d98cf81"
      unitRef="usd">28645000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RleHRyZWdpb246NTNlYTE3Mjc0OWU2NDk0YmFjNDM3NGU0MWFjNmU4ZTdfMTA5OTUxMTY0MDYzOQ_d26f18d7-a0c2-474f-8321-8456f10adf21"
      unitRef="usd">1250000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="i608d56f7947f4ed8a1369997dcdee599_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RleHRyZWdpb246NTNlYTE3Mjc0OWU2NDk0YmFjNDM3NGU0MWFjNmU4ZTdfMTY0OTI2NzQ1MzY1OQ_312e956e-6f38-4c1e-b643-6d6d6990fed1"
      unitRef="usd">1000000000.0</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="i5e2e8987386644709b5eece8fb454a57_D20210301-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RleHRyZWdpb246NTNlYTE3Mjc0OWU2NDk0YmFjNDM3NGU0MWFjNmU4ZTdfMTY0OTI2NzQ1MzY3Nw_0f3871c6-af9d-4850-8a23-38a98a01da00"
      unitRef="usd">250000000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:DebtInstrumentTerm
      contextRef="i5e2e8987386644709b5eece8fb454a57_D20210301-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RleHRyZWdpb246NTNlYTE3Mjc0OWU2NDk0YmFjNDM3NGU0MWFjNmU4ZTdfOTg5NTYwNDY2MjYxMg_be6239ef-e509-4503-8a1a-cdfee0cd49fd">P3Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i970db95a26094960bfc48e49693d580f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RleHRyZWdpb246NTNlYTE3Mjc0OWU2NDk0YmFjNDM3NGU0MWFjNmU4ZTdfMTA5OTUxMTY0MDcyOQ_5e585c87-c51c-4709-8ddc-b43083405228"
      unitRef="usd">1000000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i970db95a26094960bfc48e49693d580f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RleHRyZWdpb246NTNlYTE3Mjc0OWU2NDk0YmFjNDM3NGU0MWFjNmU4ZTdfMTA5OTUxMTY0MDg2Ng_0e45bc89-007a-4398-8d5f-beb60eb977bb"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LineOfCredit
      contextRef="i16cafbaeadde42a9815b149e242ae829_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RleHRyZWdpb246NTNlYTE3Mjc0OWU2NDk0YmFjNDM3NGU0MWFjNmU4ZTdfMTY0OTI2NzQ0NzMxMA_90b2296d-e303-4b73-a189-c17ea7f47a5c"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i7c3a790a1deb4b198ed2f54a96f31ccb_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RleHRyZWdpb246NTNlYTE3Mjc0OWU2NDk0YmFjNDM3NGU0MWFjNmU4ZTdfMTY0OTI2NzQ0NzMxMA_98b22a2a-fe1d-4f9a-a9cb-e5dcedbd8ff0"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="id6d3b14fdf7c4b5eb29edbe4dd41290f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N181OC9mcmFnOjUzZWExNzI3NDllNjQ5NGJhYzQzNzRlNDFhYzZlOGU3L3RleHRyZWdpb246NTNlYTE3Mjc0OWU2NDk0YmFjNDM3NGU0MWFjNmU4ZTdfMTY0OTI2NzQ0NzQxMw_09d1d164-6782-4d8b-abf1-f9467aeb625d"
      unitRef="usd">2500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMjM5NDM_4338666e-7d42-4ce1-9955-c34223dcd241">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to various legal actions. The most significant of these are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. Unless otherwise noted, it is not possible to determine the outcome of these matters or the outcome (including in excess of any accrual) is not expected to be material, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not have any material accruals for the matters described below on our Condensed Consolidated Balance Sheets as of March&#160;31, 2021 and December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Related to Sofosbuvir&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2012, we acquired Pharmasset, Inc. Through the acquisition, we acquired sofosbuvir, a nucleotide analog that acts to inhibit the replication of the HCV. In 2013, we received approval from FDA for sofosbuvir, now known commercially as Sovaldi. Sofosbuvir is also included in all of our marketed HCV products. We have received a number of litigation claims regarding sofosbuvir. While we have carefully considered these claims both prior to and following the acquisition and believe they are without merit, we cannot predict the ultimate outcome of such claims or range of loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are aware of patents and patent applications owned by third parties that have been or may in the future be alleged by such parties to cover the use of our HCV products. If third parties obtain valid and enforceable patents, and successfully prove infringement of those patents by our HCV products, we could be required to pay significant monetary damages. We cannot predict the ultimate outcome of intellectual property claims related to our HCV products. We have spent, and will continue to spend, significant resources defending against these claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Litigation with Idenix Pharmaceuticals, Inc. (&#x201c;Idenix&#x201d;), Universita Degli Studi di Cagliari (&#x201c;UDSG&#x201d;), Centre National de la Recherche Scientifique and L&#x2019;Universit&#xe9; Montpellier II&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2013, Idenix and UDSG sued us in the U.S. District Court for the District of Massachusetts alleging that the commercialization of sofosbuvir infringes U.S. Patent Nos. 6,914,054 (the &#x201c;&#x2019;054 patent&#x201d;) and 7,608,597 (the &#x201c;&#x2019;597 patent&#x201d;). In 2014, the court transferred the Massachusetts litigation to the U.S. District Court for the District of Delaware. Prior to trial in 2016, Idenix committed to give us a covenant not to sue with respect to any claims arising out of the &#x2019;054 patent related to sofosbuvir and withdrew that patent from the trial. We prevailed at all phases of litigation concerning the &#x2019;597 patent, and in January 2021, the U.S. Supreme Court denied Idenix&#x2019;s petition for review, making the judgment against Idenix final. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Litigation with the University of Minnesota&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The University of Minnesota (the &#x201c;University&#x201d;) has obtained U.S. Patent No. 8,815,830 (the &#x201c;&#x2019;830 patent&#x201d;), which purports to broadly cover nucleosides with antiviral and anticancer activity. In 2016, the University filed a lawsuit against us in the U.S. District Court for the District of Minnesota, alleging that the commercialization of sofosbuvir-containing products infringes the &#x2019;830 patent. We believe the &#x2019;830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir. In 2017, the court granted our motion to transfer the case to California. We have also filed petitions for inter partes review with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (&#x201c;PTAB&#x201d;) alleging that all asserted claims are invalid for anticipation and obviousness. The PTAB instituted one of these petitions and a merits hearing was held in February 2021. In 2018, the U.S. District Court for the Northern District of California stayed the litigation until after the PTAB concludes the inter partes review that it has initiated, which we expect will occur in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Litigation with NuCana plc. (&#x201c;NuCana&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NuCana has obtained European Patent No. 2,955,190 (the &#x201c;EP &#x2019;190 patent&#x201d;) that allegedly covers sofosbuvir. In Opposition proceedings before the European Patent Office (&#x201c;EPO&#x201d;) held in February 2021, the EPO Opposition Division upheld the validity of the EP &#x2019;190 patent in amended form. We believe that the amended EP &#x2019;190 patent claims are invalid. Subsequently, we initiated proceedings to invalidate the UK counterpart of the EP &#x2019;190 patent in the High Court of England &amp;amp; Wales. In March 2021, NuCana filed a counterclaim against us in the High Court of England &amp;amp; Wales alleging patent infringement of the UK counterpart and seeking damages and other relief. In April 2021, NuCana also filed a lawsuit against us in Germany at the Landgericht D&#xfc;sseldorf alleging patent infringement of the German counterpart of the EP &#x2019;190 patent and seeking damages and relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Related to Axicabtagene Ciloleucel&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2017, Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#x201c;Juno&#x201d;) filed a lawsuit against us in the U.S. District Court for the Central District of California, alleging that the commercialization of axicabtagene ciloleucel, sold commercially as Yescarta, infringes on U.S. Patent No. 7,446,190 (the &#x201c;&#x2019;190 patent&#x201d;). A jury trial was held on the &#x2019;190 patent, and in December 2019, the jury found that the asserted claims of the &#x2019;190 patent were valid, and that we willfully infringed the asserted claims of the &#x2019;190 patent. The jury also awarded Juno damages in amounts of $585 million in an up-front payment and a 27.6% running royalty from October 2017 through the date of the jury&#x2019;s verdict. The parties filed post-trial motions in the first quarter of 2020, and the trial judge entered a judgment in April 2020. The trial judge affirmed the jury&#x2019;s verdict, enhanced the past damages by 50% and maintained the royalties on future Yescarta sales at 27.6%. In April 2020, we filed an appeal seeking to reverse the judgment or obtain a new trial due to errors made by the trial judge.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing whether we should accrue a liability for this litigation in our Condensed Consolidated Financial Statements, we considered various factors, including the legal and factual circumstances of the case, the jury&#x2019;s verdict, the district court&#x2019;s pre- and post-trial orders, the current status of the proceedings, applicable law, the views of legal counsel and the likelihood that the judgment will be upheld on appeal. As a result of this review, we have determined, in accordance with applicable accounting standards, that it is not probable that we will incur a material loss as a result of this litigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the judgment is reversed on appeal, the loss is expected to be zero. If the judgment is upheld in its entirety on appeal, we estimate a loss through the first quarter of 2021 to be approximately $1.4 billion, which consists primarily of (i) approximately $811 million, which represents damages on Yescarta revenues through December 12, 2019, and prejudgment interest thereon, (ii) approximately $389 million, which represents a 50% enhancement of past damages and (iii) approximately $225 million for royalties on Yescarta revenues from December 13, 2019 to March&#160;31, 2021. The estimated loss does not include post-judgment interest on the foregoing, which is not estimated to be material as of March 31, 2021. Although we cannot predict with certainty the ultimate outcome of this litigation on appeal, we believe the jury&#x2019;s verdict and the judgment to be in error. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Related to Bictegravir&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, ViiV Healthcare Company (&#x201c;ViiV&#x201d;) filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the commercialization of bictegravir, sold commercially in combination with tenofovir alafenamide and emtricitabine as Biktarvy, infringes ViiV&#x2019;s U.S. Patent No. 8,129,385 (the &#x201c;&#x2019;385 patent&#x201d;) covering ViiV&#x2019;s dolutegravir. Bictegravir is structurally different from dolutegravir, and we believe that bictegravir does not infringe the claims of the &#x2019;385 patent. The court has set a trial date of January 2022 for this lawsuit. ViiV is seeking billions of dollars for alleged damages comprised of ViiV&#x2019;s lost profits and a royalty on sales of bictegravir from launch through the trial. ViiV calculates these damages based on the cumulative U.S. revenues from Biktarvy since launch, which have totaled $12.9 billion through March&#160;31, 2021. In addition, should a court find that we are liable for infringement, we expect ViiV will seek a royalty on sales after the trial. Although we cannot predict with certainty the ultimate outcome of this litigation, an adverse judgment could result in substantial monetary damages, including ViiV&#x2019;s lost profits and royalties through trial, and a going-forward royalty stream on future sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, ViiV also filed a lawsuit against us in the Federal Court of Canada, alleging that our activities relating to our bictegravir compound have infringed ViiV&#x2019;s Canadian Patent No. 2,606,282 (the &#x201c;&#x2019;282 patent&#x201d;), which was issued to Shionogi &amp;amp; Co. Ltd. and ViiV. The &#x2019;282 patent is the compound patent covering ViiV&#x2019;s dolutegravir. We believe that bictegravir does not infringe the claims of the &#x2019;282 patent. In January 2020, the court held a summary trial to assess ViiV&#x2019;s infringement allegations. In April 2020, the court determined that bictegravir does not infringe the claims of the &#x2019;282 patent and dismissed the case. ViiV has appealed this decision. Argument on the appeal took place in April 2021, and a decision is expected in the second half of 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November and December 2019, ViiV filed lawsuits in France, Germany, Ireland and the UK asserting the relevant national designations of European Patent No. 3 045 206 (&#x201c;EP &#x2019;206&#x201d;); in Australia asserting Australian Patent No. 2006239177; in Japan asserting Japanese Patent No. 4295353; and in Korea asserting Korean Patent Nos. 1848819 (&#x201c;KR &#x2019;819&#x201d;) and 1363875. These patents all relate to molecules which ViiV claims would act as integrase inhibitors. We believe that bictegravir does not infringe the claims of any of ViiV&#x2019;s patents. In 2019, we filed an opposition in the EPO requesting revocation of EP &#x2019;206. The EPO hearing took place in January 2021, and the patent claims, which do not cover bictegravir, were maintained in amended form. Additionally, in 2020, we filed a petition in the Korean Intellectual Property Office requesting invalidation of KR &#x2019;819. Following a trial, a tribunal of the Korean Intellectual Property Trial and Appeal Board found KR &#x2019;819 to be invalid. In March 2021, ViiV appealed this decision. The court in Germany held a hearing on the issue of infringement in April 2021. In all jurisdictions, to the extent that the claims of ViiV&#x2019;s patents are interpreted to cover bictegravir, we believe that those claims are invalid. We cannot predict the ultimate outcome of intellectual property claims related to bictegravir. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Relating to Pre-Exposure Prophylaxis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, &#x201c;HHS Patents&#x201d;) by PTAB. The HHS Patents are assigned to the U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;) and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of emtricitabine and tenofovir or TDF prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis (&#x201c;PrEP&#x201d;). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the sale of Truvada and Descovy for use as PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a breach of contract lawsuit against the U.S. federal government in the Court of Federal Claims, alleging violations of four material transfer agreements (&#x201c;MTAs&#x201d;) related to the research underlying the HHS Patents and a clinical trial agreement (&#x201c;CTA&#x201d;) by the U.S. Centers for Disease Control and Prevention related to PrEP research. Although we cannot predict with certainty the ultimate outcome of these litigation matters, we believe that the U.S. federal government breached the MTAs and CTA, that Truvada and Descovy do not infringe the HHS Patents and that the HHS Patents are invalid over prior art descriptions of Truvada&#x2019;s use for PrEP and post-exposure prophylaxis as well because physicians and patients were using the claimed methods years before HHS filed the applications for the patents. A trial date for the lawsuit in the Court of Federal Claims has been set for June 2022, and a trial date for the lawsuit in the District Court of Delaware has been set for May 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation with Generic Manufacturers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the approval process for some of our products, FDA granted us a New Chemical Entity (&#x201c;NCE&#x201d;) exclusivity period during which other manufacturers&#x2019; applications for approval of generic versions of our product will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (&#x201c;ANDA&#x201d;), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products earlier than their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product&#x2019;s approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Starting in December 2019, we received letters from Lupin Ltd., Apotex Inc., Shilpa Medicare Ltd., Sunshine Lake Pharma Co. Ltd., Laurus Labs, Natco Pharma Ltd., Macleods Pharma Ltd., Hetero Labs Ltd. and Cipla Ltd. (collectively, &#x201c;generic manufacturers&#x201d;) indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of certain of our tenofovir alafenamide (&#x201c;TAF&#x201d;)-containing products. Between them, these generic manufacturers seek to market generic versions of Odefsey, Descovy and Vemlidy. Some generic manufacturers have challenged the validity of four patents listed on the Orange Book and associated with TAF, while others have challenged the validity of two of our Orange Book-listed patents associated with TAF. We filed lawsuits against the generic manufacturers, and we intend to enforce and defend our intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;European Patent Claims&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, several parties filed oppositions in the EPO requesting revocation of one of our granted European patents covering sofosbuvir that expires in 2028. In 2016, the EPO upheld the validity of certain claims of our sofosbuvir patent. We have appealed this decision, seeking to restore all of the original claims, and several of the original opposing parties have also appealed, requesting full revocation. The appeal hearing is scheduled for July 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to sofosbuvir that expires in 2024. The EPO conducted an oral hearing for this opposition in 2018 and upheld the claims. Two of the original opposing parties have appealed, requesting full revocation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, several parties filed oppositions in the EPO requesting revocation of our granted European patent covering TAF that expires in 2026. In 2017, the EPO upheld the validity of the claims of our TAF patent. Three parties have appealed this decision. The appeal hearing was held in March 2021, and the validity of all claims were upheld.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to TAF hemifumarate that expires in 2032. In 2019, the EPO upheld the validity of the claims of our TAF hemifumarate patent. Three parties have appealed this decision. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, three parties filed oppositions in the EPO requesting revocation of our granted European patent covering cobicistat that expires in 2027. In 2017, the EPO upheld the validity of the claims of our cobicistat patent. Two parties have appealed this decision. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The appeal process may take several years for all EPO opposition proceedings. While we are confident in the strength of our patents, we cannot predict the ultimate outcome of these oppositions. If we are unsuccessful in defending these oppositions, some or all of our patent claims may be narrowed or revoked and the patent protection for sofosbuvir, TAF, TAF hemifumarate and cobicistat in the European Union could be substantially shortened or eliminated entirely. If our patents are revoked, and no other European patents are granted covering these compounds, our exclusivity may be based entirely on regulatory exclusivity granted by EMA. If we lose patent protection for any of these compounds, our revenues and results of operations could be negatively impacted for the years including and succeeding the year in which such exclusivity is lost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Antitrust and Consumer Protection&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We (along with Japan Tobacco, Inc. (&#x201c;Japan Tobacco&#x201d;), Bristol-Myers Squibb Company (&#x201c;BMS&#x201d;) and Johnson &amp;amp; Johnson, Inc.)) have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV, including drugs used in combination antiretroviral therapy. Japan Tobacco was dismissed from the lawsuit after a favorable court ruling on the defendants&#x2019; motion to dismiss. Plaintiffs allege that we (and the other remaining defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been or may be consolidated, are all pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of two nationwide classes - one of direct purchasers consisting largely of wholesales, and another of end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we along with generic manufacturers Cipla Ltd. and Cipla USA Inc. (&#x201c;Cipla&#x201d;) were named as defendants in a class action lawsuit filed in the U.S. District Court for the Northern District of California by Jacksonville Police Officers and Fire Fighters Health Insurance Trust (&#x201c;Jacksonville Trust&#x201d;) on behalf of end-payor purchasers. Jacksonville Trust claims that the 2014 settlement agreement between us and Cipla, which settled a patent dispute relating to patents covering our Emtriva, Truvada, and Atripla products and permitted generic entry prior to patent expiry, violates certain federal and state antitrust and consumer protection laws. Plaintiffs seek damages, permanent injunctive relief and other relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, we along with BMS and generic manufacturer Teva Pharmaceuticals USA were named as defendants in a lawsuit filed in the First Judicial District Court for the State of New Mexico, county of Santa Fe by the New Mexico Attorney General. The New Mexico Attorney General alleges that we (and the other defendants) restrained competition in violation of New Mexico state antitrust and consumer protection laws. In March 2021, we removed the case to the U.S. District Court for the District of New Mexico. The New Mexico Attorney General seeks damages and other relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages or could be subject to permanent injunctive relief awarded in favor of plaintiffs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have been named as a defendant in two class action lawsuits and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to experience kidney, bone and/or tooth injuries. The lawsuits, which are pending in state or federal court in California, Delaware, Florida, New Jersey and Missouri, involve more than 21,000 plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, we received a subpoena from the U.S. Attorney&#x2019;s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Qui Tam Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Two former sales employees filed a qui tam lawsuit against Gilead in August 2017 in the U.S. District Court for the Eastern District of Pennsylvania. Following the government&#x2019;s decision not to intervene in the suit, the relators served us with a Second Amended Complaint in November 2019. The lawsuit alleges that Gilead&#x2019;s HBV speaker programs and advisory boards violated the federal False Claims Act and various state false claims acts. The relators seek all available relief under these statutes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Another former sales employee also filed a qui tam lawsuit against Gilead in March 2017 in U.S. District Court for the Eastern District of Pennsylvania. Following the government&#x2019;s decision not to intervene in the suit, the relator served us with a Second Amended Complaint in January 2021. The lawsuit alleges that Gilead&#x2019;s HCV patient access programs, clinical educator programs, speaker programs, and other sales and marketing programs violated the federal False Claims Act and various state false claims acts. The relator seeks all available relief under these statutes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Two former employees filed a qui tam lawsuit against Gilead in April 2020 in California state court. These same former employees had previously filed a qui tam lawsuit in federal court in California and the U.S. Department of Justice declined intervention and moved to dismiss relators&#x2019; federal False Claims Act claims. Relators subsequently voluntarily dismissed their federal lawsuit and refiled their lawsuit in California state court. Following the California Attorney General&#x2019;s Office&#x2019;s decision not to intervene, relators served Gilead with their complaint in August 2020. The complaint alleges violations of the California False Claims Act (&#x201d;CFCA&#x201d;) and employment law claims. Relators seek all available relief under the CFCA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Health Choice Advocates, LLC (&#x201c;Health Choice&#x201d;) filed a qui tam lawsuit against Gilead in April 2020 in New Jersey state court. Following the New Jersey Attorney General&#x2019;s Office&#x2019;s decision not to intervene in the suit, Health Choice served us with their original complaint in August 2020. The lawsuit alleges that Gilead violated the New Jersey False Claims Act through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the New Jersey False Claims Act. In April 2021, the trial court granted our motion to dismiss with prejudice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Health Choice filed another qui tam lawsuit against Gilead in May 2020 making similar allegations in Texas state court. Following the Texas Attorney General&#x2019;s Office&#x2019;s decision not to intervene in the suit, Health Choice served us with their original complaint in October 2020. The lawsuit alleges that Gilead violated the Texas Medicare Fraud Prevention Act (&#x201c;TMFPA&#x201d;) through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the TMFPA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcomes. If any of these plaintiffs are successful in their claims, we could be required to pay significant monetary damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunomedics and several of its former officers and directors have been named as defendants in putative class actions filed in 2018 and 2019. The lawsuits were consolidated in September 2019, and plaintiffs filed a consolidated complaint in November 2019. Plaintiffs allege that Immunomedics and the individual defendants violated the federal securities laws in connection with Immunomedics&#x2019; Biologics License Application for Trodelvy, and seek certification of a class of shareholders, damages and other relief. The consolidated lawsuit is pending in the United States District Court for the District of New Jersey. While we believe this case is without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that these other legal actions will have a material adverse impact on our consolidated business, financial position or results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="id74ea6000e4640078ac1bb187f3e6b5c_D20191201-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTA5OTUxMTgyMzIyNA_db350480-35eb-462f-939f-2c93fe5df077"
      unitRef="usd">585000000</us-gaap:LossContingencyDamagesAwardedValue>
    <gild:JudgmentRoyaltyRateFromOctober2017
      contextRef="id74ea6000e4640078ac1bb187f3e6b5c_D20191201-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTA5OTUxMTgyMzIzNQ_1171d0b8-a1f0-47c8-b0b7-ae7836f5bfa0"
      unitRef="number">0.276</gild:JudgmentRoyaltyRateFromOctober2017>
    <gild:JudgmentEnhancedDamagesOnPastSales
      contextRef="ibff1240b05f74e8bbf297b65247ec996_I20200430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTA5OTUxMTgyMzI1Nw_aa493e67-4432-47d7-a286-d5dc94e858f5"
      unitRef="number">0.50</gild:JudgmentEnhancedDamagesOnPastSales>
    <gild:JudgmentRoyaltyRateOnFutureSales
      contextRef="ibff1240b05f74e8bbf297b65247ec996_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTA5OTUxMTgyMzI0NA_5c4c3507-88a5-4247-a65a-1597f27ef9aa"
      unitRef="number">0.276</gild:JudgmentRoyaltyRateOnFutureSales>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i2516fe8e62b244c1b6bc3ae3b23fb48c_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTY0OTI2NzYzNzE1OA_a0876b49-d2da-4c60-9d39-ce530a1961f1"
      unitRef="usd">0</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i43d6693463d944d28b68b70f837d5ae1_I20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTY0OTI2NzYzNzE3Mw_f4b35ff8-69ef-45e6-843d-3bbade33baae"
      unitRef="usd">1400000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <gild:LossContingencyEstimateOfPossibleLossPastSales
      contextRef="i7bf3308623744494a7125eb9515bdd4a_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTY0OTI2NzYzNzE5MA_fa03bd8b-dddf-4bcf-b56a-1b95147557e6"
      unitRef="usd">811000000</gild:LossContingencyEstimateOfPossibleLossPastSales>
    <gild:LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages
      contextRef="i7bf3308623744494a7125eb9515bdd4a_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTY0OTI2NzYzNzIwOA_56271423-79c2-402f-aced-6af9ea618f5f"
      unitRef="usd">389000000</gild:LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages>
    <gild:JudgmentEnhancedDamagesOnPastSales
      contextRef="ibff1240b05f74e8bbf297b65247ec996_I20200430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTY0OTI2NzYzNzIxNA_aa493e67-4432-47d7-a286-d5dc94e858f5"
      unitRef="number">0.50</gild:JudgmentEnhancedDamagesOnPastSales>
    <gild:LossContingencyEstimateOfPossibleLossRoyalties
      contextRef="i7bf3308623744494a7125eb9515bdd4a_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTY0OTI2NzYzNzIyOQ_bee894b2-9872-48a2-b9a5-7927448b281d"
      unitRef="usd">225000000</gild:LossContingencyEstimateOfPossibleLossRoyalties>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i190cbe2a2a9c446497a9e647b03a5b69_D20180207-20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTA5OTUxMTgyMzExOQ_2eac2351-af2b-479b-94ce-9510d247deb5"
      unitRef="usd">12900000000</us-gaap:LossContingencyDamagesSoughtValue>
    <gild:LossContingencyMaterialTransferAgreementsNumber
      contextRef="ibee266afb5b04b4db218d2019292d0cd_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfOTg5NTYwNDg2MjYwNg_c125b14c-6bcd-46e2-a0af-a2b507595983"
      unitRef="agreement">4</gild:LossContingencyMaterialTransferAgreementsNumber>
    <gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioOne
      contextRef="i9e2d7de5386e4c88ab9f4aaa94c77fe9_D20191201-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfOTg5NTYwNDg2MjU4Mg_2b4a3826-202f-4152-88fe-9f9946c4d5b4"
      unitRef="patent">4</gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioOne>
    <gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo
      contextRef="i9e2d7de5386e4c88ab9f4aaa94c77fe9_D20191201-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfOTg5NTYwNDg2NDI4Ng_dca9320f-2a6d-4953-8cd9-4162b13dffce"
      unitRef="patent">2</gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo>
    <gild:LossContingencyPartiesAppealedNumber
      contextRef="ib51fb29ce69647fcba6f2f052669fbed_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfOTg5NTYwNDg2MjU3Mw_994ab95d-08de-45e4-b439-fc582948f653"
      unitRef="opposingparty">2</gild:LossContingencyPartiesAppealedNumber>
    <gild:LossContingencyPartiesAppealedNumber
      contextRef="i5ae8970b904f49c99fc9ef1c33c59098_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfOTg5NTYwNDg2MjU2Mg_7bb11694-5eaa-42ad-b326-42bf45df97e9"
      unitRef="opposingparty">3</gild:LossContingencyPartiesAppealedNumber>
    <gild:LossContingencyPartiesAppealedNumber
      contextRef="i0d4fda0dfd5c44b09d04f6e618870a0a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfOTg5NTYwNDg2MjU1MQ_089ce006-ed87-46ff-b8f9-367439248c95"
      unitRef="opposingparty">3</gild:LossContingencyPartiesAppealedNumber>
    <gild:LossContingencyPartiesFilingOppositionNumber
      contextRef="id9fd61e590a14210ba14b89a9af49a7a_D20160101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfOTg5NTYwNDg2MjUzMg_bbc42a23-b3eb-4a24-bffb-d545652c5111"
      unitRef="party">3</gild:LossContingencyPartiesFilingOppositionNumber>
    <gild:LossContingencyPartiesAppealedNumber
      contextRef="i6905d9942f5a4f50abf9170409131c14_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfOTg5NTYwNDg2MjU0Mg_ea8e452b-7285-4d91-8519-c924d808ffb9"
      unitRef="opposingparty">2</gild:LossContingencyPartiesAppealedNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i39c4711339df49138fdbd03e8ed2571a_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfOTg5NTYwNDg2MjUwMg_15022762-34b4-473f-b499-bab55f6ded64"
      unitRef="lawsuit">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i39c4711339df49138fdbd03e8ed2571a_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfMTA5OTUxMTgyMzY4MA_6cd64715-aa04-4b44-9f29-b5fdba772fc2"
      unitRef="plaintiff">21000</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i6e3291601bc74013bce40b293768f095_D20170801-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfOTg5NTYwNDg2MjQ5Mw_c4fa3687-a8b3-41d8-94ab-816c9f974217"
      unitRef="plaintiff">2</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="ic57a1e59e1024277b33535c08ac1107b_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182MS9mcmFnOjk1MWZmYzJhMmNiODQ1NjM4ZWQzYWM4OTg1NzY4MGY1L3RleHRyZWdpb246OTUxZmZjMmEyY2I4NDU2MzhlZDNhYzg5ODU3NjgwZjVfOTg5NTYwNDg2MzM5Ng_90e31b62-415d-43a7-9c50-4c1ec7c31c6a"
      unitRef="plaintiff">2</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RleHRyZWdpb246YWJkNDcxNjRhM2RhNDVlM2I5ZGEwMTNlZjM5ZWY0M2NfMTYxOA_4391a7d2-26d5-433a-9d52-95d40c8ccead">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Repurchase Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2016, our Board of Directors authorized a $12.0 billion stock repurchase program (&#x201c;2016 Program&#x201d;) under which repurchases may be made in the open market or in privately negotiated transactions. We started repurchases under the 2016 Program in April 2016. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2020, our Board of Directors authorized a new $5.0 billion&#160;stock repurchase program (&#x201c;2020 Program&#x201d;), which will commence upon the completion of the&#160;2016 Program. Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2021 and 2020, we repurchased and retired 4.8 million and 18.7 million shares of our common stock for $309 million and $1.3 billion, respectively, through open market transactions under the 2016 Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, the remaining authorized repurchase amount under both programs was $6.5 billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in AOCI by component, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts reclassified to net income for gains and losses on cash flow hedges are recorded as part of Product sales on our Condensed Consolidated Statements of Income. See Note 5. Derivative Financial Instruments for additional information. The amounts reclassified to net income for gains and losses on available-for-sale debt securities are recorded as part of Other income (expense), net on our Condensed Consolidated Statements of Income. Gross realized gains and losses on available-for-sale debt securities were not material for the three months ended March 31, 2021 and 2020. The income tax impact allocated to each component of other comprehensive income (loss) was not material for the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i891c637afe3247688741c781d552db7a_I20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RleHRyZWdpb246YWJkNDcxNjRhM2RhNDVlM2I5ZGEwMTNlZjM5ZWY0M2NfMTA0_93383c51-435d-4b2a-9487-eee902826b64"
      unitRef="usd">12000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i4e485618ab80414bb2d0af91dc1e3dde_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RleHRyZWdpb246YWJkNDcxNjRhM2RhNDVlM2I5ZGEwMTNlZjM5ZWY0M2NfMzU3_03011d68-f651-4e81-9202-65521c3e58d7"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RleHRyZWdpb246YWJkNDcxNjRhM2RhNDVlM2I5ZGEwMTNlZjM5ZWY0M2NfMTY0OTI2NzQ0MzQ3MA_f145facf-1fca-49dc-9e38-e58a68e52ef3"
      unitRef="shares">4800000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RleHRyZWdpb246YWJkNDcxNjRhM2RhNDVlM2I5ZGEwMTNlZjM5ZWY0M2NfMTY0OTI2NzQ0MzQ3Nw_ebbd636c-3d3e-4d17-a88e-b91fffaf2cf8"
      unitRef="shares">18700000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RleHRyZWdpb246YWJkNDcxNjRhM2RhNDVlM2I5ZGEwMTNlZjM5ZWY0M2NfMTY0OTI2NzQ0MzQ4Mw_e632ad17-45bd-4064-bd93-7f63aadadfca"
      unitRef="usd">309000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RleHRyZWdpb246YWJkNDcxNjRhM2RhNDVlM2I5ZGEwMTNlZjM5ZWY0M2NfMTY0OTI2NzQ0MzQ5MA_1fbc4c46-30c7-4648-8fc7-40ced7de99c1"
      unitRef="usd">1300000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i857e1d9466cc45c0ad66d0661626a0bd_I20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RleHRyZWdpb246YWJkNDcxNjRhM2RhNDVlM2I5ZGEwMTNlZjM5ZWY0M2NfODc5NjA5MzAyNDExNA_7546d6b0-ebd1-40d7-bca0-19a503345173"
      unitRef="usd">6500000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RleHRyZWdpb246YWJkNDcxNjRhM2RhNDVlM2I5ZGEwMTNlZjM5ZWY0M2NfMTYwNg_6df6b650-ba86-4eb1-adb6-e84be551bd95">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in AOCI by component, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i90c7f28364e54993b67eae1023b738de_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMS0yLTEtMS0w_be037fda-fead-4451-ad31-e8bfc8575ca1"
      unitRef="usd">51000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i157cdc9a965446c9969cd003d367f516_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMS00LTEtMS0w_60eeac72-641c-4567-9ab7-8a024f4824eb"
      unitRef="usd">2000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i252e49a6c063428f959d1aefb1686cb7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMS02LTEtMS0w_eeb17e99-1377-416b-8681-9d0ce4032d85"
      unitRef="usd">-113000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id315795d1e774a6a845a09bd3c23f669_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMS04LTEtMS0w_1dd71095-2d64-4cb8-a3c3-eeee25e825e0"
      unitRef="usd">-60000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i950fa40a56274ea0bb64105a4547be31_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMi0yLTEtMS0w_9536eb71-9976-431a-bed5-5c58c467a565"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i777694101d38407bb54ae3e8cd5cee81_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMi00LTEtMS0w_c10cd416-61b2-499f-92c6-a779fc653a42"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="id773468e90654dd8b93c841e0cb1a4f1_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMi02LTEtMS0w_234fb14c-60ac-40e0-a875-d6ed38cebe03"
      unitRef="usd">68000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i3f56585e4ce041a0a4818371afd20608_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMi04LTEtMS0w_bbe505ea-1d2d-48b2-bc45-95c5d1c38aec"
      unitRef="usd">76000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i950fa40a56274ea0bb64105a4547be31_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMy0yLTEtMS0w_1fe2c2d5-5343-48c5-8c61-f3320b944dc6"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i777694101d38407bb54ae3e8cd5cee81_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMy00LTEtMS0w_08250593-6a2b-4121-b91d-0f5db4a236c6"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="id773468e90654dd8b93c841e0cb1a4f1_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMy02LTEtMS0w_f74972c6-21cd-49b4-a5a7-17c8d76c7ae1"
      unitRef="usd">-22000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i3f56585e4ce041a0a4818371afd20608_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfMy04LTEtMS0w_922936fe-975e-49b6-bb0f-78d499100282"
      unitRef="usd">-22000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i950fa40a56274ea0bb64105a4547be31_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfNC0yLTEtMS0w_442534fd-b05d-40a8-b145-0860099939a2"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i777694101d38407bb54ae3e8cd5cee81_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfNC00LTEtMS0w_874a0098-cf5a-464b-9885-47154907ada2"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id773468e90654dd8b93c841e0cb1a4f1_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfNC02LTEtMS0w_d63a22d2-75ab-4d11-b3b6-b4d54c49c2f8"
      unitRef="usd">90000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3f56585e4ce041a0a4818371afd20608_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfNC04LTEtMS0w_ea52c3e5-5f52-48ed-9917-19e87a03b90b"
      unitRef="usd">98000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i74a3340bf967422db6145ae553899ded_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfNS0yLTEtMS0w_46e7d534-e850-491a-a13a-3e0a670a47b8"
      unitRef="usd">61000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i841123aefd8d43d8a410b8754e996cf9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfNS00LTEtMS0w_7eb81692-69f4-4570-b532-26c27c4e4aa4"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic5050a35f97640609878001cc93224f3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfNS02LTEtMS0w_fce385cc-a220-4a61-8eef-b77fe9ad0fe9"
      unitRef="usd">-23000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ideb5f8dc0c4442658f18eab50f25a677_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjAzYmZkMWQwYTk3ZTQ5N2Q5OWNiMDhiYzQwNTIzM2I0L3RhYmxlcmFuZ2U6MDNiZmQxZDBhOTdlNDk3ZDk5Y2IwOGJjNDA1MjMzYjRfNS04LTEtMS0w_80ee2ebf-e873-4218-b966-9fa57f588a2e"
      unitRef="usd">38000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3d8ba4328011413291632383906e71c4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMS0yLTEtMS0w_bbcdbbb4-617e-4532-b3de-5578a649da6a"
      unitRef="usd">53000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i70187083484a4893bef3cc4b8f7bb49f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMS00LTEtMS0w_b0243221-6c72-4db2-b57a-17aa0bfc56c3"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i01bc5741de984cbc967d805c30a354d1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMS02LTEtMS0w_63f61294-bdb8-4327-a053-53d4ce44f7c5"
      unitRef="usd">31000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6c7b9ebee1f549d198ceb53ea6813141_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMS04LTEtMS0w_d9781b8c-f74b-4198-b42e-53bf2f63beb5"
      unitRef="usd">85000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ic65478d3665c420fb62c02fb229595b5_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMi0yLTEtMS0w_8f44492c-e1dc-45ca-9099-b7372ae4fad1"
      unitRef="usd">-39000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ib8ecd1344d59495b906912f07829d102_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMi00LTEtMS0w_820d2d16-286e-4be4-89d5-86ab9dbc3717"
      unitRef="usd">-23000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="iea5ded2b35d44d24932e27a42a2fd41d_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMi02LTEtMS0w_db2650ae-8451-42bf-8635-f8725489dbc9"
      unitRef="usd">57000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i4dce18c9540c42d6ae4ba9bd85b66896_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMi04LTEtMS0w_58fa05c8-8ec7-4060-bf52-718c160324b2"
      unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ic65478d3665c420fb62c02fb229595b5_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMy0yLTEtMS0w_f830144f-8abe-42db-b523-ab83939d7dc9"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ib8ecd1344d59495b906912f07829d102_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMy00LTEtMS0w_898ffb0d-dbf2-4575-bcf6-5402c865d4a9"
      unitRef="usd">11000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="iea5ded2b35d44d24932e27a42a2fd41d_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMy02LTEtMS0w_654cc14e-e449-43b6-a48b-ffc4f4ca3b23"
      unitRef="usd">23000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i4dce18c9540c42d6ae4ba9bd85b66896_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfMy04LTEtMS0w_a24403f6-f724-4c7e-b492-61d63308dc2a"
      unitRef="usd">34000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic65478d3665c420fb62c02fb229595b5_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfNC0yLTEtMS0w_edf54034-bbd5-4db2-b17e-7c0cc4906e54"
      unitRef="usd">-39000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib8ecd1344d59495b906912f07829d102_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfNC00LTEtMS0w_cb24d851-42ad-4f95-93df-71f560b8947c"
      unitRef="usd">-34000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iea5ded2b35d44d24932e27a42a2fd41d_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfNC02LTEtMS0w_3f335a0b-bbf8-473f-96fc-469a511b5351"
      unitRef="usd">34000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4dce18c9540c42d6ae4ba9bd85b66896_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfNC04LTEtMS0w_15aa3e57-0418-447d-b4d2-78ef54d193d3"
      unitRef="usd">-39000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i55db8ffa0e8944bfb28e03d449bbd545_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfNS0yLTEtMS0w_e1a44c6c-68b5-4aa1-93d6-4a4f904460be"
      unitRef="usd">14000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie621feabbb3c4e7e89573dd30bc4a6a9_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfNS00LTEtMS0w_7f52f521-cfc9-4e61-880e-e87f09d33288"
      unitRef="usd">-33000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1502d914c22f4785a00d85c5a6112310_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfNS02LTEtMS0w_b72c64c7-6b3e-41b4-9793-6dcc80efd9b4"
      unitRef="usd">65000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i51b7741d7f0241a9a5987bf6c4f4f41c_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182NC9mcmFnOmFiZDQ3MTY0YTNkYTQ1ZTNiOWRhMDEzZWYzOWVmNDNjL3RhYmxlOjkyMmEwYTE1N2RlYzQ2ODU5ZTU5ZjE1ODEzNDgyZGM3L3RhYmxlcmFuZ2U6OTIyYTBhMTU3ZGVjNDY4NTllNTlmMTU4MTM0ODJkYzdfNS04LTEtMS0w_ab22ac43-cd2d-460f-9e61-cdbd0fd78889"
      unitRef="usd">46000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RleHRyZWdpb246ZTI2NzQ2MDBmMThiNGJlOTliY2RmZWI3ZDJjZDA1NjNfMTA3Nw_c00f55ed-bc31-407a-812d-4b72768194e0">NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income per share attributable to Gilead common stockholders is calculated based on the weighted average number of shares of our common stock outstanding during the period. Diluted net income per share attributable to Gilead common stockholders is calculated based on the weighted average number of shares of our common stock and other dilutive securities outstanding during the period. The potentially dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and equivalents were determined under the treasury stock metho&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential shares of common stock excluded from the computation of diluted net income per share attributable to Gilead common stockholders because their effect would have been antidilutive were 15 million and 14 million, for the three months ended March 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the calculation of basic and diluted net income per share attributable to Gilead common stockholders:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in per share calculation - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of stock options and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in per share calculation - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share attributable to Gilead common stockholders - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share attributable to Gilead common stockholders - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RleHRyZWdpb246ZTI2NzQ2MDBmMThiNGJlOTliY2RmZWI3ZDJjZDA1NjNfODA1_e4e517d1-7abf-44fe-8fc7-8a4fbdb5b7c8"
      unitRef="shares">15000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RleHRyZWdpb246ZTI2NzQ2MDBmMThiNGJlOTliY2RmZWI3ZDJjZDA1NjNfODQ1_8f27e3bc-c2a6-4600-9c2a-83be38734490"
      unitRef="shares">14000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RleHRyZWdpb246ZTI2NzQ2MDBmMThiNGJlOTliY2RmZWI3ZDJjZDA1NjNfMTA2OA_d69647d1-477f-4b20-a232-96e9570fe6ca">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the calculation of basic and diluted net income per share attributable to Gilead common stockholders:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in per share calculation - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of stock options and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in per share calculation - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share attributable to Gilead common stockholders - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share attributable to Gilead common stockholders - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfMy0yLTEtMS0w_10e882bf-6385-4a73-aced-c87aceefdcfb"
      unitRef="usd">1729000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfMy00LTEtMS0w_60eb6653-2a1e-42fa-b3bc-f864e3b37e78"
      unitRef="usd">1551000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfNC0yLTEtMS0w_d19ab1b8-0b2e-455e-91e5-c32c07e5c5ec"
      unitRef="shares">1256000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfNC00LTEtMS0w_268e9f67-bfe9-4e60-aada-82ae05ea3500"
      unitRef="shares">1262000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfNS0yLTEtMS0w_3c8a17d3-1ac6-4d8a-8d9b-45d1d5fb1d7f"
      unitRef="shares">6000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfNS00LTEtMS0w_3f278c78-979f-4558-a408-4ba8db1ca24e"
      unitRef="shares">8000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfNi0yLTEtMS0w_6019ac81-85e4-4817-ada9-e43844116100"
      unitRef="shares">1262000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfNi00LTEtMS0w_0bd47e82-ed7f-411f-9756-7e2637eb9f7d"
      unitRef="shares">1270000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfOC0yLTEtMS0w_a2654a7b-059e-4993-ba09-4dc3d7951ea9"
      unitRef="usdPerShare">1.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfOC00LTEtMS0w_c29ef92a-ce5a-4d1f-9c12-9d87de5d715d"
      unitRef="usdPerShare">1.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfOS0yLTEtMS0w_8a558bff-3436-4104-8b6b-8a473594350b"
      unitRef="usdPerShare">1.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N182Ny9mcmFnOmUyNjc0NjAwZjE4YjRiZTk5YmNkZmViN2QyY2QwNTYzL3RhYmxlOmVhMDJjMDMwZTQ0ZjQ1MzdiNTAwZTNhMjRiNjRkMmNhL3RhYmxlcmFuZ2U6ZWEwMmMwMzBlNDRmNDUzN2I1MDBlM2EyNGI2NGQyY2FfOS00LTEtMS0w_20a09fa0-4927-4bfe-83dc-2d1d0c1d64ed"
      unitRef="usdPerShare">1.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RleHRyZWdpb246NDExYjk4YTRlN2I2NGFiM2JlZTAyNzBiMzgzMmMyMmJfMjQwMg_9aef0e05-ecf3-49b6-a697-391995c4ebf1">INCOME TAXES &lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our income tax expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions, except percentages)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our effective income tax rate of 23.9% for the three months ended March 31, 2021 differed from the U.S. federal statutory rate of 21% primarily due to unfavorable changes in the fair value of our equity investment in Galapagos that are non-deductible for income tax purposes, partially offset by net discrete tax benefits related to settlements with taxing authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our effective income tax rate of 23.2% for the three months ended March 31, 2020 differed from the U.S. federal statutory rate of 21% primarily due to the Global Intangible Low-Taxed Income tax, state taxes and our portion of the non-deductible branded prescription drug fee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are currently under examination by the U.S. Internal Revenue Service for the tax years from 2016 to 2018 and by various state and foreign jurisdictions. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We regularly evaluate our exposures associated with our tax filing positions to determine our assessment of unrecognized tax benefits in accordance with the income tax guidance which clarifies the accounting for uncertainty in income taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RleHRyZWdpb246NDExYjk4YTRlN2I2NGFiM2JlZTAyNzBiMzgzMmMyMmJfMjM5NQ_20a91949-6545-453a-b3ff-9d7a4f204a0d">&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our income tax expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions, except percentages)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RhYmxlOjAwYzlhMzNjOGU3YjQ3NjdiMTI5YzMzZThmMjQ1YjA4L3RhYmxlcmFuZ2U6MDBjOWEzM2M4ZTdiNDc2N2IxMjljMzNlOGYyNDViMDhfMy0yLTEtMS0w_b942bcab-1ff0-4474-bbaa-52cc5468f9f6"
      unitRef="usd">2264000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RhYmxlOjAwYzlhMzNjOGU3YjQ3NjdiMTI5YzMzZThmMjQ1YjA4L3RhYmxlcmFuZ2U6MDBjOWEzM2M4ZTdiNDc2N2IxMjljMzNlOGYyNDViMDhfMy0yLTEtMS0w_c9777f9a-f878-420b-820f-b321e78079a1"
      unitRef="usd">2264000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RhYmxlOjAwYzlhMzNjOGU3YjQ3NjdiMTI5YzMzZThmMjQ1YjA4L3RhYmxlcmFuZ2U6MDBjOWEzM2M4ZTdiNDc2N2IxMjljMzNlOGYyNDViMDhfMy00LTEtMS0w_184ab219-dfdf-4bcb-b1d2-5efa84b0a24a"
      unitRef="usd">2003000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RhYmxlOjAwYzlhMzNjOGU3YjQ3NjdiMTI5YzMzZThmMjQ1YjA4L3RhYmxlcmFuZ2U6MDBjOWEzM2M4ZTdiNDc2N2IxMjljMzNlOGYyNDViMDhfMy00LTEtMS0w_7ba11f38-6c28-492a-a952-d1d7f3eb11ea"
      unitRef="usd">2003000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RhYmxlOjAwYzlhMzNjOGU3YjQ3NjdiMTI5YzMzZThmMjQ1YjA4L3RhYmxlcmFuZ2U6MDBjOWEzM2M4ZTdiNDc2N2IxMjljMzNlOGYyNDViMDhfNC0yLTEtMS0w_d1b97bb7-88cd-4b11-bb64-5011cf02b82f"
      unitRef="usd">542000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RhYmxlOjAwYzlhMzNjOGU3YjQ3NjdiMTI5YzMzZThmMjQ1YjA4L3RhYmxlcmFuZ2U6MDBjOWEzM2M4ZTdiNDc2N2IxMjljMzNlOGYyNDViMDhfNC00LTEtMS0w_d1e7da64-5ce4-429a-9276-e3d404fd2381"
      unitRef="usd">465000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RhYmxlOjAwYzlhMzNjOGU3YjQ3NjdiMTI5YzMzZThmMjQ1YjA4L3RhYmxlcmFuZ2U6MDBjOWEzM2M4ZTdiNDc2N2IxMjljMzNlOGYyNDViMDhfNS0yLTEtMS0w_d78fb845-bff4-4f01-91d1-84c20d389a2f"
      unitRef="number">0.239</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RhYmxlOjAwYzlhMzNjOGU3YjQ3NjdiMTI5YzMzZThmMjQ1YjA4L3RhYmxlcmFuZ2U6MDBjOWEzM2M4ZTdiNDc2N2IxMjljMzNlOGYyNDViMDhfNS00LTEtMS0w_feea88ec-e6ba-4077-a992-d60cfdd06468"
      unitRef="number">0.232</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RleHRyZWdpb246NDExYjk4YTRlN2I2NGFiM2JlZTAyNzBiMzgzMmMyMmJfMTQ4_d78fb845-bff4-4f01-91d1-84c20d389a2f"
      unitRef="number">0.239</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ie89ff5396a374d86aaf45a4df1e5ca29_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N183MC9mcmFnOjQxMWI5OGE0ZTdiNjRhYjNiZWUwMjcwYjM4MzJjMjJiL3RleHRyZWdpb246NDExYjk4YTRlN2I2NGFiM2JlZTAyNzBiMzgzMmMyMmJfOTQ2_feea88ec-e6ba-4077-a992-d60cfdd06468"
      unitRef="number">0.232</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTc0L2ZyYWc6ZTM4YzY4MGNmNWNkNGM4ZTllZjE2MzYwODg3MGExYTUvdGV4dHJlZ2lvbjplMzhjNjgwY2Y1Y2Q0YzhlOWVmMTYzNjA4ODcwYTFhNV85ODk1NjA0NjUwOTUz_c8280223-7005-4614-9bee-8a9b21a65f05">SUBSEQUENT EVENTIn April 2021, Gilead donated equity securities at fair value to the Gilead Foundation, a California nonprofit public benefit corporation (&#x201c;Foundation&#x201d;). The Foundation is a related party as certain officers of the Company also serve as directors of the Foundation. The donation expense of $206 million will be recorded within Selling, general and administrative expenses on our Condensed Consolidated Statements of Income in the second quarter of 2021.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="i00cafa1b2c044278a85e4d45db30d3b1_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVlOGIwZTE4NDE5ODQzMTU5ZWMwN2UxYjc5NGQwZDg3L3NlYzo1ZThiMGUxODQxOTg0MzE1OWVjMDdlMWI3OTRkMGQ4N18xMTc0L2ZyYWc6ZTM4YzY4MGNmNWNkNGM4ZTllZjE2MzYwODg3MGExYTUvdGV4dHJlZ2lvbjplMzhjNjgwY2Y1Y2Q0YzhlOWVmMTYzNjA4ODcwYTFhNV80Mzk4MDQ2NTEyMDcw_a687ef81-fefd-4950-8790-2d9ccab0095e"
      unitRef="usd">206000000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516367158328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GILEAD SCIENCES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3047598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">333 Lakeside Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Foster City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">574-3000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock, par value, $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol(s)</a></td>
<td class="text">GILD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,254,178,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516367660680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,065<span></span>
</td>
<td class="nump">$ 5,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term marketable securities</a></td>
<td class="nump">1,601<span></span>
</td>
<td class="nump">1,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">3,925<span></span>
</td>
<td class="nump">4,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">1,779<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">1,908<span></span>
</td>
<td class="nump">2,013<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">13,278<span></span>
</td>
<td class="nump">15,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">4,990<span></span>
</td>
<td class="nump">4,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="nump">579<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">34,781<span></span>
</td>
<td class="nump">33,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">8,334<span></span>
</td>
<td class="nump">8,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">5,530<span></span>
</td>
<td class="nump">5,708<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">67,492<span></span>
</td>
<td class="nump">68,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AccruedGovernmentAndOtherRebates', window );">Accrued government and other rebates</a></td>
<td class="nump">3,369<span></span>
</td>
<td class="nump">3,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">3,507<span></span>
</td>
<td class="nump">4,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of long-term debt and other obligations, net</a></td>
<td class="nump">2,259<span></span>
</td>
<td class="nump">2,757<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,705<span></span>
</td>
<td class="nump">11,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">27,907<span></span>
</td>
<td class="nump">28,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term income taxes payable</a></td>
<td class="nump">5,022<span></span>
</td>
<td class="nump">5,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">4,464<span></span>
</td>
<td class="nump">3,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">1,430<span></span>
</td>
<td class="nump">1,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001 per share; 5,600 shares authorized; 1,254 shares issued and outstanding</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">4,092<span></span>
</td>
<td class="nump">3,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">38<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">14,821<span></span>
</td>
<td class="nump">14,381<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Gilead stockholders&#8217; equity</a></td>
<td class="nump">18,952<span></span>
</td>
<td class="nump">18,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">18,964<span></span>
</td>
<td class="nump">18,221<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 67,492<span></span>
</td>
<td class="nump">$ 68,407<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AccruedGovernmentAndOtherRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Government And Other Rebates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AccruedGovernmentAndOtherRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516360835512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">5,600,000,000<span></span>
</td>
<td class="nump">5,600,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">1,254,000,000<span></span>
</td>
<td class="nump">1,254,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">1,254,000,000<span></span>
</td>
<td class="nump">1,254,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516368022856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 6,423<span></span>
</td>
<td class="nump">$ 5,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">1,361<span></span>
</td>
<td class="nump">969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="nump">1,055<span></span>
</td>
<td class="nump">1,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">1,055<span></span>
</td>
<td class="nump">1,076<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">3,533<span></span>
</td>
<td class="nump">3,146<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">2,890<span></span>
</td>
<td class="nump">2,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(257)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(369)<span></span>
</td>
<td class="num">(158)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">2,264<span></span>
</td>
<td class="nump">2,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">542<span></span>
</td>
<td class="nump">465<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,722<span></span>
</td>
<td class="nump">1,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Gilead</a></td>
<td class="nump">$ 1,729<span></span>
</td>
<td class="nump">$ 1,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share attributable to Gilead common stockholders - basic (in dollars per share)</a></td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in per share calculation - basic (in shares)</a></td>
<td class="nump">1,256<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share attributable to Gilead common stockholders - diluted (in dollars per share)</a></td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="nump">$ 1.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in per share calculation - diluted (in shares)</a></td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 6,340<span></span>
</td>
<td class="nump">$ 5,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516362944216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,722<span></span>
</td>
<td class="nump">$ 1,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Net foreign currency translation gain (loss), net of tax</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Net unrealized loss, net of tax</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassifications to net income, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net change</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Net unrealized gain, net of tax</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Reclassifications to net income, net of tax</a></td>
<td class="nump">22<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net change</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">98<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">1,820<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to noncontrolling interest</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Gilead</a></td>
<td class="nump">$ 1,827<span></span>
</td>
<td class="nump">$ 1,512<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities and unrealized holding gain (loss) related to transfers of securities into the available-for-sale classification and out of the held-to-maturity classification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516364667416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative effect from the adoption of new accounting standard</div></th>
<th class="th"><div>Common Stock&#160;</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th">
<div>Retained Earnings </div>
<div>Cumulative effect from the adoption of new accounting standard</div>
</th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,266,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 22,650<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 3,051<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 19,388<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">1,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuances under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuances under employee stock purchase plan</a></td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances under equity incentive plans</a></td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(1,414)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,356)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">(867)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(867)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,254,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">$ 22,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,311<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">18,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">1,254,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,254,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 18,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,880<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="nump">14,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">1,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuances under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuances under employee stock purchase plan</a></td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances under equity incentive plans</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(399)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(383)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">$ (906)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(906)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="nump">1,254,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,254,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 18,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 4,092<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 14,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516361165992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared (in dollars per share)</a></td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516366997832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,722<span></span>
</td>
<td class="nump">$ 1,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization expense</a></td>
<td class="nump">395<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">Net losses from equity securities</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">975<span></span>
</td>
<td class="num">(376)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(69)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(253)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="num">(316)<span></span>
</td>
<td class="num">(127)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="num">(738)<span></span>
</td>
<td class="num">(550)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">2,610<span></span>
</td>
<td class="nump">1,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable debt securities</a></td>
<td class="num">(931)<span></span>
</td>
<td class="num">(13,158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales of marketable debt securities</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">9,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable debt securities</a></td>
<td class="nump">619<span></span>
</td>
<td class="nump">3,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, including in-process research and development, net of cash acquired</a></td>
<td class="num">(1,255)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Purchases of equity securities</a></td>
<td class="num">(279)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(165)<span></span>
</td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(2,042)<span></span>
</td>
<td class="num">(344)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuances of common stock</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock</a></td>
<td class="num">(309)<span></span>
</td>
<td class="num">(1,328)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt and other obligations</a></td>
<td class="num">(1,250)<span></span>
</td>
<td class="num">(500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payments of dividends</a></td>
<td class="num">(917)<span></span>
</td>
<td class="num">(874)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(89)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(2,477)<span></span>
</td>
<td class="num">(2,611)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(1,932)<span></span>
</td>
<td class="num">(1,580)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">5,997<span></span>
</td>
<td class="nump">11,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 4,065<span></span>
</td>
<td class="nump">$ 10,051<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516361081848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information. The financial statements include all adjustments consisting of normal recurring adjustments that the management of Gilead Sciences, Inc. (&#8220;Gilead&#8221;, &#8220;we&#8221;, &#8220;our&#8221; or &#8220;us&#8221;) believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and a variable interest entity (&#8220;VIE&#8221;) for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our Condensed Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether we are the primary beneficiary of a VIE at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one operating segment, which focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (&#8220;CODM&#8221;), manages and allocates resources to the operations of the company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#8220;R&amp;D&#8221;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;D portfolio and external opportunities to best support the long-term growth of our business. See Note 2. Revenues for a summary of disaggregated revenues by product and geographic region.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies, Estimates and Judgments</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these Condensed Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the coronavirus disease (&#8220;COVID-19&#8221;) could have on our significant accounting estimates. Actual results may differ significantly from these estimates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts for the three months ended March 31, 2020 were reclassified to conform to the current period presentation. Beginning in the second quarter of 2020, acquired in-process research and development (&#8220;IPR&amp;D&#8221;) expenses are reported separately from Research and development expenses on our Condensed Consolidated Statements of Income. Our Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2020, has also been conformed to separately present acquired IPR&amp;D expenses. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Risk </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States, Europe and Japan. There were no material write-offs charged against the allowance for the three months ended March 31, 2021 and 2020. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the raw materials and components that we utilize in our operations are obtained through single suppliers. Certain of the raw materials that we utilize in our operations are made at only one facility. Since the suppliers of key components and raw materials must be named in a new drug application filed with U.S. Food and Drug Administration (&#8220;FDA&#8221;) for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from our suppliers is interrupted for any reason, we may be unable to ship our commercial products or to supply our product candidates for clinical trials.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516461924168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenues</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.660%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product Sales:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">HIV</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Atripla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue share - Symtuza </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HIV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,786&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Hepatitis C virus (&#8220;HCV&#8221;)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ledipasvir/Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HCV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Hepatitis B virus (&#8220;HBV&#8221;) / Hepatitis Delta virus (&#8220;HDV&#8221;)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Cell Therapy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Cell Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ranexa</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zydelig</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,260&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,423&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,006&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#8220;C&#8221;), emtricitabine (&#8220;FTC&#8221;) and tenofovir alafenamide (&#8220;TAF&#8221;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Cayston and Jyseleca.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues from Major Customers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:79.488%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(as a percentage of total revenues)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues Recognized from Performance Obligations Satisfied in Prior Periods </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized from performance obligations satisfied in prior years related to royalties for licenses of our intellectual property were $226 million and $188 million for the three months ended March 31, 2021 and 2020, respectively. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable consideration is included in the net sales price only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with the variable consideration is subsequently resolved. Estimates are assessed each period and updated to reflect current information. Changes in estimates for variable consideration related to sales made in prior years resulted in a $332 million and $38 million increase in revenues for the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $185 million and $198 million as of March&#160;31, 2021 and December&#160;31, 2020, respectively. Contract liabilities, which generally result from receipt of advance payment before our performance under the contract, were $91&#160;million and $97&#160;million as of March&#160;31, 2021 and December&#160;31, 2020, respectively. During the three months ended March 31, 2021 and 2020, revenue recognized that was included in the contract liability balance as of the beginning of the respective years was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516364920328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 1 inputs include quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. For our marketable securities, we review trading activity and pricing as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data; and </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist primarily of cash and cash equivalents, marketable debt securities, accounts receivable, foreign currency exchange contracts, equity securities, accounts payable and short-term and long-term debt. Cash and cash equivalents, marketable debt securities, certain equity securities and foreign currency exchange contracts are reported at their respective fair values on our Condensed Consolidated Balance Sheets. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Short-term and long-term debt are reported at their amortized costs on our Condensed Consolidated Balance Sheets. The remaining financial instruments are reported on our Condensed Consolidated Balance Sheets at amounts that approximate current fair values. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.661%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Galapagos</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,185&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,231&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,279&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,008&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for MYR contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Securities</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity securities measured at fair value on a recurring basis on our Condensed Consolidated Balance Sheets:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,721&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,970&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-bottom:4.5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes equity investment in Galapagos NV (&#8220;Galapagos&#8221;)</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments not measured at fair value and excluded from the above tables were limited partnerships and other equity method investments of $69 million and $58 million at March&#160;31, 2021 and December&#160;31, 2020, respectively, and other equity investments without readily determinable fair values of $225 million and $204 million at March&#160;31, 2021 and December&#160;31, 2020, respectively. These amounts were included in Other long-term assets on our Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of equity securities resulted in net unrealized losses of $351&#160;million and $283&#160;million for the three months ended March 31, 2021 and 2020, respectively, which were included in Other income (expense), net on our Condensed Consolidated Statements of Income.</span></div><div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale debt securities are classified as cash equivalents, short-term marketable securities and long-term marketable securities in our Condensed Consolidated Balance Sheets. See Note 4. Available-For-Sale Debt Securities for additional information. </span></div><div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Investment in Galapagos</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity investment in Galapagos in our Condensed Consolidated Balance Sheets:</span></div><div style="margin-bottom:11pt;margin-top:9.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,302&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected and applied the fair value option to account for our equity investment in Galapagos whereby the investment is marked to market through earnings each reporting period based on the market price of Galapagos shares. We believe the fair value option best reflects the underlying economics of the investment. The portion of the investment subject to long-term contractual lock-up provisions is classified within Other long-term assets and the remainder is classified as Prepaid and other current assets on our Condensed Consolidated Balance Sheets. Subsequent to the first quarter of 2021, we amended the Galapagos subscription agreement to extend the initial lock-up provision for certain Galapagos shares from August 2021 to August 2024. As a result, all of our equity investment in Galapagos became subject to long-term contractual lock-up provisions and will be classified as Other long-term assets commencing in the second quarter of 2021. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2 Inputs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair values of Level 2 financial instruments by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;P Global Ratings, Moody&#8217;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, London Interbank Offered Rates and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated fair values of our aggregate short-term and long-term debt, determined using Level 2 inputs based on their quoted market values, were approximately $31.6 billion and $34.6 billion as of March&#160;31, 2021 and December&#160;31, 2020, respectively, and the carrying values were $29.1 billion and $30.3 billion as of March&#160;31, 2021 and December&#160;31, 2020, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3 Inputs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, we measured assets acquired and liabilities assumed at fair value on a nonrecurring basis, in connection with our acquisition of MYR GmbH (&#8220;MYR&#8221;). Total consideration for the MYR acquisition included a liability for contingent consideration of $341 million as of the acquisition date. This contingent liability was measured at fair value using probability-weighted scenarios for FDA approval. See Note 6. Acquisitions for additional information. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021 and December&#160;31, 2020, the carrying value of the liability related to future royalties assumed from the fourth quarter 2020 Immunomedics, Inc. (&#8220;Immunomedics&#8221;) acquisition approximated fair value, determined using Level 3 inputs. See Note 10. Debt and Credit Facilities for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516360914216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">AVAILABLE-FOR-SALE DEBT SECURITIES</a></td>
<td class="text">AVAILABLE-FOR-SALE DEBT SECURITIES<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets:</span></div><div style="margin-bottom:11pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable excluded from both the fair value and amortized cost basis of the available-for-sale debt securities was $9 million as of March&#160;31, 2021 and December&#160;31, 2020 and is recorded in Prepaid and other current assets on our Condensed Consolidated Balance Sheets. There were no write-offs of accrued interest receivable during the three months ended March 31, 2021 and 2020.</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity: </span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>We held a total of 203 positions which were in an unrealized loss position as of March&#160;31, 2021. The unrealized losses are largely due to changes in interest rates. Aggregated gross unrealized losses on available-for-sale debt securities were not material, and accordingly, no impairment was recognized for the three months ended March 31, 2021. Gross realized gains and gross realized losses on available-for-sale debt securities were not material for the three months ended March 31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516361021928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">DERIVATIVE FINANCIAL INSTRUMENTS</a></td>
<td class="text">DERIVATIVE FINANCIAL INSTRUMENTSOur operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we may hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward or option contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes. <div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge our exposure to foreign currency exchange rate fluctuations for certain monetary assets and liabilities that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are not designated as hedges and, as a result, changes in their fair value are recorded in Other income (expense), net on our Condensed Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge our exposure to foreign currency exchange rate fluctuations for forecasted product sales that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are designated as cash flow hedges and have maturities of 18 months or less. Upon executing a hedging contract and quarterly thereafter, we assess hedge effectiveness using regression analysis. The unrealized gains or losses in Accumulated other comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;AOCI&#8221;) are reclassified into product sales when the respective hedged transactions affect earnings. The majority of gains and losses related to the hedged forecasted transactions reported in AOCI as of March&#160;31, 2021 are expected to be reclassified to product sales within 12 months.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flow effects of our derivative contracts for the three months ended March 31, 2021 and 2020 were included within Net cash provided by operating activities on our Condensed Consolidated Statements of Cash Flows.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had notional amounts on foreign currency exchange contracts outstanding of $3.0 billion and $2.4 billion as of March&#160;31, 2021 and December&#160;31, 2020, respectively. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts on a gross basis. The following table summarizes the classification and fair values of derivative instruments on our Condensed Consolidated Balance Sheets:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:33.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.380%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;accrued&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.338%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;accrued&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our foreign currency exchange contracts on our Condensed Consolidated Financial Statements: </span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains recognized in AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) reclassified from AOCI into product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains recognized in Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may discontinue cash flow hedges and, as a result, record related amounts in Other income (expense), net on our Condensed Consolidated Statements of Income. There were no discontinuances of cash flow hedges for the three months ended March 31, 2021 and 2020. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021 and December&#160;31, 2020, we only held foreign currency exchange contracts. The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Condensed Consolidated Balance Sheets:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:22.507%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Amounts Not Offset <br/>on our Condensed <br/>Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Amounts<br/>&#160;of Recognized <br/>Assets/Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Amounts<br/>&#160;Offset on our <br/>Condensed <br/>Consolidated <br/>Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amounts of Assets/Liabilities Presented<br/>&#160;on our Condensed Consolidated<br/>Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Derivative <br/>Financial <br/>Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Cash Collateral <br/>Received/<br/>Pledged</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net Amount<br/>&#160;(Legal Offset)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline">As of March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516362627176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITIONS</a></td>
<td class="text">ACQUISITIONS<div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired and liabilities assumed be recorded at their fair values as of the acquisition date. Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. Transaction costs associated with business combinations are expensed as they are incurred. The first quarter 2021 acquisition of MYR and the fourth quarter 2020 acquisition of Immunomedics were accounted for as business combinations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:155%">MYR </span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 4, 2021, we completed the acquisition of MYR, a German biotechnology company. MYR focuses on the development and commercialization of therapeutics for the treatment of HDV. The acquisition provides Gilead with Hepcludex, which was conditionally approved by the European Medicines Agency (&#8220;EMA&#8221;) in July 2020 for the treatment of chronic HDV infection in adults with compensated liver disease. Upon closing, MYR became a wholly-owned subsidiary of Gilead. The financial results of MYR were included in our Condensed Consolidated Financial Statements from the date of the acquisition. MYR contributed an immaterial net loss from the date of acquisition through March 31, 2021. We recorded other acquisition-related expenses of $11 million, primarily representing closing costs and related fees, in Selling, general and administrative expenses on our Condensed Consolidated Statements of Income for the three months ended March 31, 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate consideration for this acquisition of approximately &#8364;1.3 billion (or $1.6 billion) primarily consists of &#8364;1.0 billion (or approximately $1.2 billion) paid upon closing and contingent consideration of up to &#8364;300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex. The estimated fair value of this contingent liability was $341 million as of the acquisition date and recorded in Other long-term obligations on our Condensed Consolidated Balance Sheets. The contingent consideration was estimated using probability-weighted scenarios for FDA approval. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value estimates for the assets acquired and liabilities assumed were based upon valuations using information known and knowable as of the date of this filing. Changes to these assumptions and estimates could cause an impact to the valuation of assets acquired, including intangible assets, goodwill and the related tax impacts of the acquisition, as well as legal and other contingencies. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date: </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(513)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,335&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The finite-lived intangible asset of $845 million represents the estimated fair value of Hepcludex for HDV in Europe as of the acquisition date. The fair value was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to Hepcludex for HDV in Europe and a discount rate of 12%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of 10 years.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired intangible assets related to IPR&amp;D consist of Hepcludex for HDV in all other regions without regulatory approval, including the U.S. The estimated aggregate fair value of $1.2 billion as of the acquisition date was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to this asset and a discount rate of 12%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the more significant assumptions inherent in the development of intangible asset fair values include: estimates of projected future cash flows including revenues and operating profits; probability of success; the discount rate selected; the life of the potential commercialized products and the risks related to the viability of and potential alternative treatments in any future target markets, among other factors.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived assets until the completion or abandonment of the associated R&amp;D efforts. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The inputs used for valuing these identifiable intangibles are unobservable and considered Level 3 under the fair value measurement and disclosure guidance. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax liability was based upon the difference between the estimated book basis and tax basis of net assets acquired and an estimate for the final pre-acquisition net operating losses of MYR.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the consideration transferred over the fair values of assets acquired and liabilities assumed of $226 million was recorded as goodwill, which primarily reflects the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill recognized for MYR is not expected to be deductible for income tax purposes.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Immunomedics</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we completed the acquisition of Immunomedics for cash consideration of $20.6 billion. Immunomedics is a wholly-owned subsidiary of Gilead. The acquisition was financed with the majority of the proceeds from the September 2020 senior unsecured notes offering, an additional $1.0 billion borrowing under a new senior unsecured term loan facility and cash on hand. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outlicense contract</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,606&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,597&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no measurement period adjustments recorded to the fair values of assets acquired and liabilities assumed during the three months ended March 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516361105176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL AND INTANGIBLE ASSETS</a></td>
<td class="text">GOODWILL AND INTANGIBLE ASSETS<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill resulting from the acquisition of MYR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net: </span></div><div style="margin-top:1.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:22.360%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - axicabtagene ciloleucel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Hepcludex for HDV </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,666&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,055)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,611&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,897&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,236&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets - IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,836&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,055)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,781&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of March&#160;31, 2021 includes $910&#160;million reclassified from indefinite-lived assets - IPR&amp;D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts represent Trodelvy for metastatic triple-negative breast cancer.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of March&#160;31, 2021 includes $1.2&#160;billion recognized from the first quarter 2021 MYR acquisition. See Note 6. Acquisitions for additional information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;In April 2021, FDA granted accelerated approval of Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer, a new indication. Accordingly, the related amount of $1.0&#160;billion will be reclassified to finite-lived assets in the second quarter of 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense related to finite-lived intangible assets was $395 million and $281 million for the three months ended March 31, 2021 and 2020, respectively, and was primarily included in Cost of goods sold on our Condensed Consolidated Statements of Income.</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of March&#160;31, 2021:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining nine months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,611&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516362627176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">OTHER FINANCIAL INFORMATION</a></td>
<td class="text">OTHER FINANCIAL INFORMATION<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable, net</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Accounts receivable, net:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash discounts and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,925&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,892&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Inventories:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,014&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,014&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.415%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">________________________________</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts primarily consist of raw materials.</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued and other current liabilities </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of Accrued and other current liabilities:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,507&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,336&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516361046520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATIONS AND OTHER ARRANGEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborativeandOtherArrangementsAbstract', window );"><strong>Collaborative and Other Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborativeAndOtherArrangementsTextBlock', window );">COLLABORATIONS AND OTHER ARRANGEMENTS</a></td>
<td class="text">COLLABORATIONS AND OTHER ARRANGEMENTS<div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to pursue licensing and strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain products and product candidates. These arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements and cost-sharing arrangements. We also continue to pursue equity investments in third parties focused on the development and commercialization of products and product candidates. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Merck Sharp &amp; Dohme Corp. (&#8220;Merck&#8221;) </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 13, 2021, we entered into a license and collaboration agreement with Merck, a subsidiary of Merck &amp; Co., Inc. to jointly develop and commercialize long-acting investigational treatments in HIV that combine Gilead&#8217;s investigational capsid inhibitor, lenacapavir, and Merck&#8217;s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir. The collaboration will initially focus on long-acting oral and injectable formulations. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Gilead and Merck will share global development and commercialization costs at 60% and 40%, respectively, across the oral and injectable formulation programs. For long-acting oral products, Gilead will lead commercialization in the U.S. and Merck will lead commercialization in the European Union (&#8220;EU&#8221;) and rest of the world. For long-acting injectable products, Merck will lead commercialization in the U.S. and Gilead will lead commercialization in the EU and rest of the world. Gilead and Merck will jointly promote the combination products in the U.S. and certain other major markets. We will share global product revenues with Merck equally until product revenues surpass certain pre-determined per formulation revenue tiers. Upon passing $2.0 billion in net product sales for the oral combination in a given calendar year, our share of revenue will increase to 65% for any revenues above the threshold for such calendar year. Upon passing $3.5 billion in net product sales for the injectable combination in a given calendar year, our share of revenue will increase to 65% for any revenues above the threshold for such calendar year. There was no material impact from the agreement on our Condensed Consolidated Financial Statements for the three months ended March 31, 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also have the option to license certain of Merck&#8217;s investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of Gilead&#8217;s investigational oral integrase inhibitors to develop in combination with islatravir. Each company may exercise its option for such investigational oral integrase inhibitor of the other company within the first five years after execution of the agreement, following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon exercise of an option, the companies will split development cost and revenues, unless the non-exercising company decides to opt-out, in which case the non-exercising company will be paid a royalty.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arcus Biosciences, Inc. (&#8220;Arcus&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On&#160;May 27, 2020, we entered into a transaction with Arcus, which included entry into an option, license and collaboration agreement (the &#8220;Collaboration Agreement&#8221;) and a common stock purchase agreement and an investor rights agreement (together, and as subsequently amended the &#8220;Stock Purchase Agreements&#8221;). In 2020, pursuant to the Stock Purchase Agreements and a separate secondary equity offering, we acquired approximately 8.2&#160;million shares of Arcus common stock for approximately $261 million. In the first quarter of 2021, we amended and restated the common stock purchase agreement and acquired approximately 5.7&#160;million additional shares of Arcus common stock for $220 million. As a result, we currently own a total of 13.8&#160;million shares of Arcus, which represented approximately 19.5% of the issued and outstanding voting stock of Arcus immediately following the closing of the transaction. We recorded our equity investments in Arcus in Other long-term assets on our Condensed Consolidated Balance Sheets as the investments are subject to contractual lock-up provisions, subject to certain conditions. We account for our equity investments in Arcus at fair value with changes in fair value recognized in Other income (expense), net on our Condensed Consolidated Statements of Income for each reporting period. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Stock Purchase Agreements, we have the right to purchase additional shares of Arcus from Arcus over the five year period beginning on the closing of the Stock Purchase Agreements, up to a maximum of 35% of the outstanding voting stock. We are subject to a three year standstill, which period began on the date the parties entered into the Stock Purchase Agreements, restricting our ability to acquire voting stock of Arcus exceeding more than 35% of the then issued and outstanding voting stock of Arcus, subject to certain exceptions. Additionally, we agreed not to dispose of any equity securities of Arcus prior to the second anniversary of the closing of the Stock Purchase Agreements without the prior consent of Arcus, subject to certain exceptions. The amendment and restatement of the common stock purchase agreement in the first quarter of 2021 did not modify any of these terms. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Arrangements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021 and 2020, we entered into several collaborations, equity investments and licensing arrangements as well as other similar arrangements that we do not consider to be individually material. We recorded upfront collaboration expenses related to these arrangements of $62 million and $97 million for the three months ended March 31, 2021 and 2020, respectively, within Acquired in-process research and development expenses on our Condensed Consolidated Statements of Income. Cash payments made related to our equity investments were $59 million and $8 million for the three months ended March 31, 2021 and 2020, respectively, which were primarily recorded in Other long-term assets on our Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the financial terms of these arrangements, we may be required to make payments upon achievement of developmental, regulatory and commercial milestones, which could be significant. Future milestone payments, if any, will be reflected in our Condensed Consolidated Statements of Income when the corresponding events become probable. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurrence.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborativeAndOtherArrangementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative and Other Arrangements [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborativeAndOtherArrangementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborativeandOtherArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative and Other Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborativeandOtherArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516362627176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT AND CREDIT FACILITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT AND CREDIT FACILITIES</a></td>
<td class="text">DEBT AND CREDIT FACILITIES<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of our borrowings under various financing arrangements:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.382%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + 0.15%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + 0.52%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">variable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2036</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2044</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2046</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2047</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total senior unsecured notes and term loan facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: current portion of long-term debt and other obligations, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,259&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,757&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total long-term debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, we repaid $1.25 billion of debt. In January 2021, we repaid $1.0 billion of senior unsecured notes prior to the April 2021 maturity, by exercising a 3-month par call. In March 2021, we repaid $250 million principal amount under our three-year $1.0 billion senior unsecured term loan facility, leaving $750 million principal amount outstanding as of March&#160;31, 2021. No new debt was issued during the three months ended March 31, 2021. We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of March&#160;31, 2021, we were in compliance with all covenants.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021 and December&#160;31, 2020, there were no amounts outstanding under our $2.5 billion revolving credit facility maturing in June 2025, and we were in compliance with all covenants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516362446392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions. The most significant of these are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. Unless otherwise noted, it is not possible to determine the outcome of these matters or the outcome (including in excess of any accrual) is not expected to be material, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any material accruals for the matters described below on our Condensed Consolidated Balance Sheets as of March&#160;31, 2021 and December&#160;31, 2020. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Sofosbuvir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, we acquired Pharmasset, Inc. Through the acquisition, we acquired sofosbuvir, a nucleotide analog that acts to inhibit the replication of the HCV. In 2013, we received approval from FDA for sofosbuvir, now known commercially as Sovaldi. Sofosbuvir is also included in all of our marketed HCV products. We have received a number of litigation claims regarding sofosbuvir. While we have carefully considered these claims both prior to and following the acquisition and believe they are without merit, we cannot predict the ultimate outcome of such claims or range of loss.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patents and patent applications owned by third parties that have been or may in the future be alleged by such parties to cover the use of our HCV products. If third parties obtain valid and enforceable patents, and successfully prove infringement of those patents by our HCV products, we could be required to pay significant monetary damages. We cannot predict the ultimate outcome of intellectual property claims related to our HCV products. We have spent, and will continue to spend, significant resources defending against these claims.</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with Idenix Pharmaceuticals, Inc. (&#8220;Idenix&#8221;), Universita Degli Studi di Cagliari (&#8220;UDSG&#8221;), Centre National de la Recherche Scientifique and L&#8217;Universit&#233; Montpellier II</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2013, Idenix and UDSG sued us in the U.S. District Court for the District of Massachusetts alleging that the commercialization of sofosbuvir infringes U.S. Patent Nos. 6,914,054 (the &#8220;&#8217;054 patent&#8221;) and 7,608,597 (the &#8220;&#8217;597 patent&#8221;). In 2014, the court transferred the Massachusetts litigation to the U.S. District Court for the District of Delaware. Prior to trial in 2016, Idenix committed to give us a covenant not to sue with respect to any claims arising out of the &#8217;054 patent related to sofosbuvir and withdrew that patent from the trial. We prevailed at all phases of litigation concerning the &#8217;597 patent, and in January 2021, the U.S. Supreme Court denied Idenix&#8217;s petition for review, making the judgment against Idenix final. </span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with the University of Minnesota</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The University of Minnesota (the &#8220;University&#8221;) has obtained U.S. Patent No. 8,815,830 (the &#8220;&#8217;830 patent&#8221;), which purports to broadly cover nucleosides with antiviral and anticancer activity. In 2016, the University filed a lawsuit against us in the U.S. District Court for the District of Minnesota, alleging that the commercialization of sofosbuvir-containing products infringes the &#8217;830 patent. We believe the &#8217;830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir. In 2017, the court granted our motion to transfer the case to California. We have also filed petitions for inter partes review with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (&#8220;PTAB&#8221;) alleging that all asserted claims are invalid for anticipation and obviousness. The PTAB instituted one of these petitions and a merits hearing was held in February 2021. In 2018, the U.S. District Court for the Northern District of California stayed the litigation until after the PTAB concludes the inter partes review that it has initiated, which we expect will occur in 2021.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with NuCana plc. (&#8220;NuCana&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NuCana has obtained European Patent No. 2,955,190 (the &#8220;EP &#8217;190 patent&#8221;) that allegedly covers sofosbuvir. In Opposition proceedings before the European Patent Office (&#8220;EPO&#8221;) held in February 2021, the EPO Opposition Division upheld the validity of the EP &#8217;190 patent in amended form. We believe that the amended EP &#8217;190 patent claims are invalid. Subsequently, we initiated proceedings to invalidate the UK counterpart of the EP &#8217;190 patent in the High Court of England &amp; Wales. In March 2021, NuCana filed a counterclaim against us in the High Court of England &amp; Wales alleging patent infringement of the UK counterpart and seeking damages and other relief. In April 2021, NuCana also filed a lawsuit against us in Germany at the Landgericht D&#252;sseldorf alleging patent infringement of the German counterpart of the EP &#8217;190 patent and seeking damages and relief.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Axicabtagene Ciloleucel</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#8220;Juno&#8221;) filed a lawsuit against us in the U.S. District Court for the Central District of California, alleging that the commercialization of axicabtagene ciloleucel, sold commercially as Yescarta, infringes on U.S. Patent No. 7,446,190 (the &#8220;&#8217;190 patent&#8221;). A jury trial was held on the &#8217;190 patent, and in December 2019, the jury found that the asserted claims of the &#8217;190 patent were valid, and that we willfully infringed the asserted claims of the &#8217;190 patent. The jury also awarded Juno damages in amounts of $585 million in an up-front payment and a 27.6% running royalty from October 2017 through the date of the jury&#8217;s verdict. The parties filed post-trial motions in the first quarter of 2020, and the trial judge entered a judgment in April 2020. The trial judge affirmed the jury&#8217;s verdict, enhanced the past damages by 50% and maintained the royalties on future Yescarta sales at 27.6%. In April 2020, we filed an appeal seeking to reverse the judgment or obtain a new trial due to errors made by the trial judge.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing whether we should accrue a liability for this litigation in our Condensed Consolidated Financial Statements, we considered various factors, including the legal and factual circumstances of the case, the jury&#8217;s verdict, the district court&#8217;s pre- and post-trial orders, the current status of the proceedings, applicable law, the views of legal counsel and the likelihood that the judgment will be upheld on appeal. As a result of this review, we have determined, in accordance with applicable accounting standards, that it is not probable that we will incur a material loss as a result of this litigation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the judgment is reversed on appeal, the loss is expected to be zero. If the judgment is upheld in its entirety on appeal, we estimate a loss through the first quarter of 2021 to be approximately $1.4 billion, which consists primarily of (i) approximately $811 million, which represents damages on Yescarta revenues through December 12, 2019, and prejudgment interest thereon, (ii) approximately $389 million, which represents a 50% enhancement of past damages and (iii) approximately $225 million for royalties on Yescarta revenues from December 13, 2019 to March&#160;31, 2021. The estimated loss does not include post-judgment interest on the foregoing, which is not estimated to be material as of March 31, 2021. Although we cannot predict with certainty the ultimate outcome of this litigation on appeal, we believe the jury&#8217;s verdict and the judgment to be in error. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Bictegravir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, ViiV Healthcare Company (&#8220;ViiV&#8221;) filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the commercialization of bictegravir, sold commercially in combination with tenofovir alafenamide and emtricitabine as Biktarvy, infringes ViiV&#8217;s U.S. Patent No. 8,129,385 (the &#8220;&#8217;385 patent&#8221;) covering ViiV&#8217;s dolutegravir. Bictegravir is structurally different from dolutegravir, and we believe that bictegravir does not infringe the claims of the &#8217;385 patent. The court has set a trial date of January 2022 for this lawsuit. ViiV is seeking billions of dollars for alleged damages comprised of ViiV&#8217;s lost profits and a royalty on sales of bictegravir from launch through the trial. ViiV calculates these damages based on the cumulative U.S. revenues from Biktarvy since launch, which have totaled $12.9 billion through March&#160;31, 2021. In addition, should a court find that we are liable for infringement, we expect ViiV will seek a royalty on sales after the trial. Although we cannot predict with certainty the ultimate outcome of this litigation, an adverse judgment could result in substantial monetary damages, including ViiV&#8217;s lost profits and royalties through trial, and a going-forward royalty stream on future sales. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, ViiV also filed a lawsuit against us in the Federal Court of Canada, alleging that our activities relating to our bictegravir compound have infringed ViiV&#8217;s Canadian Patent No. 2,606,282 (the &#8220;&#8217;282 patent&#8221;), which was issued to Shionogi &amp; Co. Ltd. and ViiV. The &#8217;282 patent is the compound patent covering ViiV&#8217;s dolutegravir. We believe that bictegravir does not infringe the claims of the &#8217;282 patent. In January 2020, the court held a summary trial to assess ViiV&#8217;s infringement allegations. In April 2020, the court determined that bictegravir does not infringe the claims of the &#8217;282 patent and dismissed the case. ViiV has appealed this decision. Argument on the appeal took place in April 2021, and a decision is expected in the second half of 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November and December 2019, ViiV filed lawsuits in France, Germany, Ireland and the UK asserting the relevant national designations of European Patent No. 3 045 206 (&#8220;EP &#8217;206&#8221;); in Australia asserting Australian Patent No. 2006239177; in Japan asserting Japanese Patent No. 4295353; and in Korea asserting Korean Patent Nos. 1848819 (&#8220;KR &#8217;819&#8221;) and 1363875. These patents all relate to molecules which ViiV claims would act as integrase inhibitors. We believe that bictegravir does not infringe the claims of any of ViiV&#8217;s patents. In 2019, we filed an opposition in the EPO requesting revocation of EP &#8217;206. The EPO hearing took place in January 2021, and the patent claims, which do not cover bictegravir, were maintained in amended form. Additionally, in 2020, we filed a petition in the Korean Intellectual Property Office requesting invalidation of KR &#8217;819. Following a trial, a tribunal of the Korean Intellectual Property Trial and Appeal Board found KR &#8217;819 to be invalid. In March 2021, ViiV appealed this decision. The court in Germany held a hearing on the issue of infringement in April 2021. In all jurisdictions, to the extent that the claims of ViiV&#8217;s patents are interpreted to cover bictegravir, we believe that those claims are invalid. We cannot predict the ultimate outcome of intellectual property claims related to bictegravir. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Relating to Pre-Exposure Prophylaxis</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, &#8220;HHS Patents&#8221;) by PTAB. The HHS Patents are assigned to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of emtricitabine and tenofovir or TDF prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis (&#8220;PrEP&#8221;). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the sale of Truvada and Descovy for use as PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a breach of contract lawsuit against the U.S. federal government in the Court of Federal Claims, alleging violations of four material transfer agreements (&#8220;MTAs&#8221;) related to the research underlying the HHS Patents and a clinical trial agreement (&#8220;CTA&#8221;) by the U.S. Centers for Disease Control and Prevention related to PrEP research. Although we cannot predict with certainty the ultimate outcome of these litigation matters, we believe that the U.S. federal government breached the MTAs and CTA, that Truvada and Descovy do not infringe the HHS Patents and that the HHS Patents are invalid over prior art descriptions of Truvada&#8217;s use for PrEP and post-exposure prophylaxis as well because physicians and patients were using the claimed methods years before HHS filed the applications for the patents. A trial date for the lawsuit in the Court of Federal Claims has been set for June 2022, and a trial date for the lawsuit in the District Court of Delaware has been set for May 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Generic Manufacturers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the approval process for some of our products, FDA granted us a New Chemical Entity (&#8220;NCE&#8221;) exclusivity period during which other manufacturers&#8217; applications for approval of generic versions of our product will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (&#8220;ANDA&#8221;), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products earlier than their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product&#8217;s approval.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in December 2019, we received letters from Lupin Ltd., Apotex Inc., Shilpa Medicare Ltd., Sunshine Lake Pharma Co. Ltd., Laurus Labs, Natco Pharma Ltd., Macleods Pharma Ltd., Hetero Labs Ltd. and Cipla Ltd. (collectively, &#8220;generic manufacturers&#8221;) indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of certain of our tenofovir alafenamide (&#8220;TAF&#8221;)-containing products. Between them, these generic manufacturers seek to market generic versions of Odefsey, Descovy and Vemlidy. Some generic manufacturers have challenged the validity of four patents listed on the Orange Book and associated with TAF, while others have challenged the validity of two of our Orange Book-listed patents associated with TAF. We filed lawsuits against the generic manufacturers, and we intend to enforce and defend our intellectual property.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Claims</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, several parties filed oppositions in the EPO requesting revocation of one of our granted European patents covering sofosbuvir that expires in 2028. In 2016, the EPO upheld the validity of certain claims of our sofosbuvir patent. We have appealed this decision, seeking to restore all of the original claims, and several of the original opposing parties have also appealed, requesting full revocation. The appeal hearing is scheduled for July 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to sofosbuvir that expires in 2024. The EPO conducted an oral hearing for this opposition in 2018 and upheld the claims. Two of the original opposing parties have appealed, requesting full revocation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, several parties filed oppositions in the EPO requesting revocation of our granted European patent covering TAF that expires in 2026. In 2017, the EPO upheld the validity of the claims of our TAF patent. Three parties have appealed this decision. The appeal hearing was held in March 2021, and the validity of all claims were upheld.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to TAF hemifumarate that expires in 2032. In 2019, the EPO upheld the validity of the claims of our TAF hemifumarate patent. Three parties have appealed this decision. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, three parties filed oppositions in the EPO requesting revocation of our granted European patent covering cobicistat that expires in 2027. In 2017, the EPO upheld the validity of the claims of our cobicistat patent. Two parties have appealed this decision. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The appeal process may take several years for all EPO opposition proceedings. While we are confident in the strength of our patents, we cannot predict the ultimate outcome of these oppositions. If we are unsuccessful in defending these oppositions, some or all of our patent claims may be narrowed or revoked and the patent protection for sofosbuvir, TAF, TAF hemifumarate and cobicistat in the European Union could be substantially shortened or eliminated entirely. If our patents are revoked, and no other European patents are granted covering these compounds, our exclusivity may be based entirely on regulatory exclusivity granted by EMA. If we lose patent protection for any of these compounds, our revenues and results of operations could be negatively impacted for the years including and succeeding the year in which such exclusivity is lost.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust and Consumer Protection</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We (along with Japan Tobacco, Inc. (&#8220;Japan Tobacco&#8221;), Bristol-Myers Squibb Company (&#8220;BMS&#8221;) and Johnson &amp; Johnson, Inc.)) have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV, including drugs used in combination antiretroviral therapy. Japan Tobacco was dismissed from the lawsuit after a favorable court ruling on the defendants&#8217; motion to dismiss. Plaintiffs allege that we (and the other remaining defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been or may be consolidated, are all pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of two nationwide classes - one of direct purchasers consisting largely of wholesales, and another of end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we along with generic manufacturers Cipla Ltd. and Cipla USA Inc. (&#8220;Cipla&#8221;) were named as defendants in a class action lawsuit filed in the U.S. District Court for the Northern District of California by Jacksonville Police Officers and Fire Fighters Health Insurance Trust (&#8220;Jacksonville Trust&#8221;) on behalf of end-payor purchasers. Jacksonville Trust claims that the 2014 settlement agreement between us and Cipla, which settled a patent dispute relating to patents covering our Emtriva, Truvada, and Atripla products and permitted generic entry prior to patent expiry, violates certain federal and state antitrust and consumer protection laws. Plaintiffs seek damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we along with BMS and generic manufacturer Teva Pharmaceuticals USA were named as defendants in a lawsuit filed in the First Judicial District Court for the State of New Mexico, county of Santa Fe by the New Mexico Attorney General. The New Mexico Attorney General alleges that we (and the other defendants) restrained competition in violation of New Mexico state antitrust and consumer protection laws. In March 2021, we removed the case to the U.S. District Court for the District of New Mexico. The New Mexico Attorney General seeks damages and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages or could be subject to permanent injunctive relief awarded in favor of plaintiffs.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in two class action lawsuits and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to experience kidney, bone and/or tooth injuries. The lawsuits, which are pending in state or federal court in California, Delaware, Florida, New Jersey and Missouri, involve more than 21,000 plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Investigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Two former sales employees filed a qui tam lawsuit against Gilead in August 2017 in the U.S. District Court for the Eastern District of Pennsylvania. Following the government&#8217;s decision not to intervene in the suit, the relators served us with a Second Amended Complaint in November 2019. The lawsuit alleges that Gilead&#8217;s HBV speaker programs and advisory boards violated the federal False Claims Act and various state false claims acts. The relators seek all available relief under these statutes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Another former sales employee also filed a qui tam lawsuit against Gilead in March 2017 in U.S. District Court for the Eastern District of Pennsylvania. Following the government&#8217;s decision not to intervene in the suit, the relator served us with a Second Amended Complaint in January 2021. The lawsuit alleges that Gilead&#8217;s HCV patient access programs, clinical educator programs, speaker programs, and other sales and marketing programs violated the federal False Claims Act and various state false claims acts. The relator seeks all available relief under these statutes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Two former employees filed a qui tam lawsuit against Gilead in April 2020 in California state court. These same former employees had previously filed a qui tam lawsuit in federal court in California and the U.S. Department of Justice declined intervention and moved to dismiss relators&#8217; federal False Claims Act claims. Relators subsequently voluntarily dismissed their federal lawsuit and refiled their lawsuit in California state court. Following the California Attorney General&#8217;s Office&#8217;s decision not to intervene, relators served Gilead with their complaint in August 2020. The complaint alleges violations of the California False Claims Act (&#8221;CFCA&#8221;) and employment law claims. Relators seek all available relief under the CFCA.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice Advocates, LLC (&#8220;Health Choice&#8221;) filed a qui tam lawsuit against Gilead in April 2020 in New Jersey state court. Following the New Jersey Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in August 2020. The lawsuit alleges that Gilead violated the New Jersey False Claims Act through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the New Jersey False Claims Act. In April 2021, the trial court granted our motion to dismiss with prejudice.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice filed another qui tam lawsuit against Gilead in May 2020 making similar allegations in Texas state court. Following the Texas Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in October 2020. The lawsuit alleges that Gilead violated the Texas Medicare Fraud Prevention Act (&#8220;TMFPA&#8221;) through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the TMFPA.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcomes. If any of these plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunomedics and several of its former officers and directors have been named as defendants in putative class actions filed in 2018 and 2019. The lawsuits were consolidated in September 2019, and plaintiffs filed a consolidated complaint in November 2019. Plaintiffs allege that Immunomedics and the individual defendants violated the federal securities laws in connection with Immunomedics&#8217; Biologics License Application for Trodelvy, and seek certification of a class of shareholders, damages and other relief. The consolidated lawsuit is pending in the United States District Court for the District of New Jersey. While we believe this case is without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that these other legal actions will have a material adverse impact on our consolidated business, financial position or results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516362627176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Repurchase Programs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2016, our Board of Directors authorized a $12.0 billion stock repurchase program (&#8220;2016 Program&#8221;) under which repurchases may be made in the open market or in privately negotiated transactions. We started repurchases under the 2016 Program in April 2016. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, our Board of Directors authorized a new $5.0 billion&#160;stock repurchase program (&#8220;2020 Program&#8221;), which will commence upon the completion of the&#160;2016 Program. Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021 and 2020, we repurchased and retired 4.8 million and 18.7 million shares of our common stock for $309 million and $1.3 billion, respectively, through open market transactions under the 2016 Program.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the remaining authorized repurchase amount under both programs was $6.5 billion.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in AOCI by component, net of tax:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:11pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts reclassified to net income for gains and losses on cash flow hedges are recorded as part of Product sales on our Condensed Consolidated Statements of Income. See Note 5. Derivative Financial Instruments for additional information. The amounts reclassified to net income for gains and losses on available-for-sale debt securities are recorded as part of Other income (expense), net on our Condensed Consolidated Statements of Income. Gross realized gains and losses on available-for-sale debt securities were not material for the three months ended March 31, 2021 and 2020. The income tax impact allocated to each component of other comprehensive income (loss) was not material for the periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516360856104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS</a></td>
<td class="text">NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS<div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share attributable to Gilead common stockholders is calculated based on the weighted average number of shares of our common stock outstanding during the period. Diluted net income per share attributable to Gilead common stockholders is calculated based on the weighted average number of shares of our common stock and other dilutive securities outstanding during the period. The potentially dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and equivalents were determined under the treasury stock metho</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential shares of common stock excluded from the computation of diluted net income per share attributable to Gilead common stockholders because their effect would have been antidilutive were 15 million and 14 million, for the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the calculation of basic and diluted net income per share attributable to Gilead common stockholders:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.944%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516362583736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES <div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our income tax expense:</span></div><div style="margin-bottom:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,003&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate of 23.9% for the three months ended March 31, 2021 differed from the U.S. federal statutory rate of 21% primarily due to unfavorable changes in the fair value of our equity investment in Galapagos that are non-deductible for income tax purposes, partially offset by net discrete tax benefits related to settlements with taxing authorities.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate of 23.2% for the three months ended March 31, 2020 differed from the U.S. federal statutory rate of 21% primarily due to the Global Intangible Low-Taxed Income tax, state taxes and our portion of the non-deductible branded prescription drug fee.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently under examination by the U.S. Internal Revenue Service for the tax years from 2016 to 2018 and by various state and foreign jurisdictions. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We regularly evaluate our exposures associated with our tax filing positions to determine our assessment of unrecognized tax benefits in accordance with the income tax guidance which clarifies the accounting for uncertainty in income taxes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516361046520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">SUBSEQUENT EVENT</a></td>
<td class="text">SUBSEQUENT EVENTIn April 2021, Gilead donated equity securities at fair value to the Gilead Foundation, a California nonprofit public benefit corporation (&#8220;Foundation&#8221;). The Foundation is a related party as certain officers of the Company also serve as directors of the Foundation. The donation expense of $206 million will be recorded within Selling, general and administrative expenses on our Condensed Consolidated Statements of Income in the second quarter of 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516360879768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information. The financial statements include all adjustments consisting of normal recurring adjustments that the management of Gilead Sciences, Inc. (&#8220;Gilead&#8221;, &#8220;we&#8221;, &#8220;our&#8221; or &#8220;us&#8221;) believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and a variable interest entity (&#8220;VIE&#8221;) for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our Condensed Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether we are the primary beneficiary of a VIE at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. </span></div>The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">We have one operating segment, which focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (&#8220;CODM&#8221;), manages and allocates resources to the operations of the company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#8220;R&amp;D&#8221;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;D portfolio and external opportunities to best support the long-term growth of our business.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Significant Accounting Policies, Estimates and Judgments</a></td>
<td class="text">The preparation of these Condensed Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the coronavirus disease (&#8220;COVID-19&#8221;) could have on our significant accounting estimates. Actual results may differ significantly from these estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text">Certain amounts for the three months ended March 31, 2020 were reclassified to conform to the current period presentation. Beginning in the second quarter of 2020, acquired in-process research and development (&#8220;IPR&amp;D&#8221;) expenses are reported separately from Research and development expenses on our Condensed Consolidated Statements of Income. Our Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2020, has also been conformed to separately present acquired IPR&amp;D expenses.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risk</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States, Europe and Japan. There were no material write-offs charged against the allowance for the three months ended March 31, 2021 and 2020. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the raw materials and components that we utilize in our operations are obtained through single suppliers. Certain of the raw materials that we utilize in our operations are made at only one facility. Since the suppliers of key components and raw materials must be named in a new drug application filed with U.S. Food and Drug Administration (&#8220;FDA&#8221;) for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from our suppliers is interrupted for any reason, we may be unable to ship our commercial products or to supply our product candidates for clinical trials.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 1 inputs include quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. For our marketable securities, we review trading activity and pricing as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data; and </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. </span></div>Our financial instruments consist primarily of cash and cash equivalents, marketable debt securities, accounts receivable, foreign currency exchange contracts, equity securities, accounts payable and short-term and long-term debt. Cash and cash equivalents, marketable debt securities, certain equity securities and foreign currency exchange contracts are reported at their respective fair values on our Condensed Consolidated Balance Sheets. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Short-term and long-term debt are reported at their amortized costs on our Condensed Consolidated Balance Sheets. The remaining financial instruments are reported on our Condensed Consolidated Balance Sheets at amounts that approximate current fair values.<div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected and applied the fair value option to account for our equity investment in Galapagos whereby the investment is marked to market through earnings each reporting period based on the market price of Galapagos shares. We believe the fair value option best reflects the underlying economics of the investment. The portion of the investment subject to long-term contractual lock-up provisions is classified within Other long-term assets and the remainder is classified as Prepaid and other current assets on our Condensed Consolidated Balance Sheets. Subsequent to the first quarter of 2021, we amended the Galapagos subscription agreement to extend the initial lock-up provision for certain Galapagos shares from August 2021 to August 2024. As a result, all of our equity investment in Galapagos became subject to long-term contractual lock-up provisions and will be classified as Other long-term assets commencing in the second quarter of 2021. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2 Inputs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair values of Level 2 financial instruments by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;P Global Ratings, Moody&#8217;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, London Interbank Offered Rates and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516362384632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenues</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.660%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product Sales:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">HIV</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Atripla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue share - Symtuza </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HIV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,786&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Hepatitis C virus (&#8220;HCV&#8221;)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ledipasvir/Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HCV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Hepatitis B virus (&#8220;HBV&#8221;) / Hepatitis Delta virus (&#8220;HDV&#8221;)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Cell Therapy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Cell Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ranexa</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zydelig</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,260&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,423&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,006&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#8220;C&#8221;), emtricitabine (&#8220;FTC&#8221;) and tenofovir alafenamide (&#8220;TAF&#8221;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Cayston and Jyseleca.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Revenues from Major Customers</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:79.488%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(as a percentage of total revenues)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516361030408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.661%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Galapagos</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,185&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,231&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,279&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,008&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for MYR contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Summary of Classification of Equity Securities</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity securities measured at fair value on a recurring basis on our Condensed Consolidated Balance Sheets:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,721&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,970&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-bottom:4.5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes equity investment in Galapagos NV (&#8220;Galapagos&#8221;)</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Equity Method Investments</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity investment in Galapagos in our Condensed Consolidated Balance Sheets:</span></div><div style="margin-bottom:11pt;margin-top:9.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,302&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516361081848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Reconciliation of Available-for-Sale Debt Securities from Cost Basis to Fair Value</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Classification of Available-for-Sale Debt Securities</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets:</span></div><div style="margin-bottom:11pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of Available-for-Sale Debt Securities by Contractual Maturity</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity: </span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516461945480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of Classification and Fair Value of Derivative Instruments</a></td>
<td class="text">The following table summarizes the classification and fair values of derivative instruments on our Condensed Consolidated Balance Sheets:<div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:33.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.380%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;accrued&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.338%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;accrued&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of Effect of Foreign Currency Exchange Contracts</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our foreign currency exchange contracts on our Condensed Consolidated Financial Statements: </span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains recognized in AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) reclassified from AOCI into product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains recognized in Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Summary of Potential Effect of Offsetting Derivatives</a></td>
<td class="text">The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Condensed Consolidated Balance Sheets:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:22.507%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Amounts Not Offset <br/>on our Condensed <br/>Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Amounts<br/>&#160;of Recognized <br/>Assets/Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Amounts<br/>&#160;Offset on our <br/>Condensed <br/>Consolidated <br/>Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amounts of Assets/Liabilities Presented<br/>&#160;on our Condensed Consolidated<br/>Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Derivative <br/>Financial <br/>Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Cash Collateral <br/>Received/<br/>Pledged</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net Amount<br/>&#160;(Legal Offset)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline">As of March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516362472600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date: </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(513)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,335&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outlicense contract</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,606&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,597&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516362379992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill resulting from the acquisition of MYR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net: </span></div><div style="margin-top:1.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:22.360%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - axicabtagene ciloleucel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Hepcludex for HDV </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,666&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,055)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,611&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,897&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,236&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets - IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,836&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,055)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,781&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of March&#160;31, 2021 includes $910&#160;million reclassified from indefinite-lived assets - IPR&amp;D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts represent Trodelvy for metastatic triple-negative breast cancer.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of March&#160;31, 2021 includes $1.2&#160;billion recognized from the first quarter 2021 MYR acquisition. See Note 6. Acquisitions for additional information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;In April 2021, FDA granted accelerated approval of Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer, a new indication. Accordingly, the related amount of $1.0&#160;billion will be reclassified to finite-lived assets in the second quarter of 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net: </span></div><div style="margin-top:1.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:22.360%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,952)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - axicabtagene ciloleucel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Hepcludex for HDV </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,666&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,055)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,611&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,897&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,236&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets - IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,836&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,055)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,781&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of March&#160;31, 2021 includes $910&#160;million reclassified from indefinite-lived assets - IPR&amp;D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts represent Trodelvy for metastatic triple-negative breast cancer.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Gross carrying amount as of March&#160;31, 2021 includes $1.2&#160;billion recognized from the first quarter 2021 MYR acquisition. See Note 6. Acquisitions for additional information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;In April 2021, FDA granted accelerated approval of Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer, a new indication. Accordingly, the related amount of $1.0&#160;billion will be reclassified to finite-lived assets in the second quarter of 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of March&#160;31, 2021:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining nine months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,611&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516363196632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Accounts receivable, net:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash discounts and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,925&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,892&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Inventories:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,014&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,014&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.415%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">________________________________</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts primarily consist of raw materials.</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Other Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of Accrued and other current liabilities:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,507&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,336&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516361078456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT AND CREDIT FACILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Debt Carrying Amount</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of our borrowings under various financing arrangements:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.382%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + 0.15%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + 0.52%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">variable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2036</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2044</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2046</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2047</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total senior unsecured notes and term loan facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: current portion of long-term debt and other obligations, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,259&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,757&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total long-term debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516361015816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of Changes in Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in AOCI by component, net of tax:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:11pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516362296600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of the Calculation of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the calculation of basic and diluted net income per share attributable to Gilead common stockholders:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.944%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516361105176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of the Provision for Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our income tax expense:</span></div><div style="margin-bottom:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,003&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516366564616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-offs charged against allowance | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516355860216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Disaggregation of Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 6,423<span></span>
</td>
<td class="nump">$ 5,548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4,260<span></span>
</td>
<td class="nump">4,006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,336<span></span>
</td>
<td class="nump">975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=gild_OtherInternationalMember', window );">Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">827<span></span>
</td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6,340<span></span>
</td>
<td class="nump">5,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total product sales | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4,240<span></span>
</td>
<td class="nump">3,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total product sales | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,275<span></span>
</td>
<td class="nump">927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total product sales | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">825<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3,650<span></span>
</td>
<td class="nump">4,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,786<span></span>
</td>
<td class="nump">3,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">578<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember', window );">Atripla</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember', window );">Atripla | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember', window );">Atripla | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember', window );">Atripla | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,824<span></span>
</td>
<td class="nump">1,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,465<span></span>
</td>
<td class="nump">1,412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">359<span></span>
</td>
<td class="nump">458<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">673<span></span>
</td>
<td class="nump">824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">506<span></span>
</td>
<td class="nump">612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">510<span></span>
</td>
<td class="nump">729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember', window );">Other HCV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember', window );">Other HCV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember', window );">Other HCV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember', window );">Other HCV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HBV/HBD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HBV/HBD | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HBV/HBD | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HBV/HBD | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,456<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">820<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">388<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total Cell Therapy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">191<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total Cell Therapy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total Cell Therapy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total Cell Therapy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CallTherapyProductsTecartusMember', window );">Tecartus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CallTherapyProductsTecartusMember', window );">Tecartus | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CallTherapyProductsTecartusMember', window );">Tecartus | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CallTherapyProductsTecartusMember', window );">Tecartus | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember', window );">Yescarta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember', window );">Yescarta | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember', window );">Yescarta | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember', window );">Yescarta | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember', window );">Ranexa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember', window );">Ranexa | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember', window );">Ranexa | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember', window );">Ranexa | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember', window );">Zydelig</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember', window );">Zydelig | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember', window );">Zydelig | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember', window );">Zydelig | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=gild_OtherInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=gild_OtherInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsStribildMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HCVProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_VekluryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_VekluryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_CallTherapyProductsTecartusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_CallTherapyProductsTecartusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_TrodelvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_TrodelvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516360837112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Revenues from Major Customers (Details) - Revenue from Contract with Customer Benchmark - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gild_AmerisourcebergenCorpMember', window );">AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gild_CardinalHealthIncMember', window );">Cardinal Health, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=gild_MckessonCorpMember', window );">McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gild_AmerisourcebergenCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gild_AmerisourcebergenCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gild_CardinalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gild_CardinalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gild_MckessonCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gild_MckessonCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516360796872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Change in estimate of variable consideration</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Contract with customer, performance obligation satisfied in previous period</a></td>
<td class="nump">$ 226<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516364595896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 2,478<span></span>
</td>
<td class="nump">$ 2,026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">7,231<span></span>
</td>
<td class="nump">9,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">617<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR contingent consideration</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">464<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">1,247<span></span>
</td>
<td class="nump">1,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">2,216<span></span>
</td>
<td class="nump">4,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Equity investment in Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">1,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">968<span></span>
</td>
<td class="nump">743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,185<span></span>
</td>
<td class="nump">7,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">464<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">2,216<span></span>
</td>
<td class="nump">4,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Equity investment in Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">1,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">968<span></span>
</td>
<td class="nump">743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">2,046<span></span>
</td>
<td class="nump">1,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">1,247<span></span>
</td>
<td class="nump">1,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Equity investment in Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR contingent consideration</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Equity investment in Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_EquityinvestmentinGalapagosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_EquityinvestmentinGalapagosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_ForeignCurrencyDerivativeContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_ForeignCurrencyDerivativeContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516367722776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Summary of Classification of Equity Securities (Details) - Other Equity Securities - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 4,721<span></span>
</td>
<td class="nump">$ 6,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=gild_OtherEquitySecuritiesMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">2,216<span></span>
</td>
<td class="nump">4,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=gild_OtherEquitySecuritiesMember', window );">Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">797<span></span>
</td>
<td class="nump">853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=gild_OtherEquitySecuritiesMember', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">$ 1,708<span></span>
</td>
<td class="nump">$ 1,756<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_OtherEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_OtherEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516368075912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity investments not measured at fair value</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments without readily determinable fair values</a></td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">Net losses from equity securities</a></td>
<td class="num">(351)<span></span>
</td>
<td class="num">$ (283)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | MYR GmbH | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | MYR GmbH | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR contingent consideration</a></td>
<td class="nump">341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Market value | MYR GmbH | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR contingent consideration</a></td>
<td class="nump">341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Market value | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Short-term and long-term debt</a></td>
<td class="nump">31,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying value | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Short-term and long-term debt, carrying values</a></td>
<td class="nump">$ 29,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516364685304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Equity Investment In Galapagos (Details) - Galapagos NV - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investment</a></td>
<td class="nump">$ 1,302<span></span>
</td>
<td class="nump">$ 1,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosNVMember', window );">Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investment</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosNVMember', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investment</a></td>
<td class="nump">$ 1,026<span></span>
</td>
<td class="nump">$ 1,297<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosNVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosNVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516368258680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 2,478<span></span>
</td>
<td class="nump">$ 2,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">2,478<span></span>
</td>
<td class="nump">2,026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">464<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">464<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,247<span></span>
</td>
<td class="nump">1,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">1,247<span></span>
</td>
<td class="nump">1,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember', window );">Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">$ 347<span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516367314776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 2,478<span></span>
</td>
<td class="nump">$ 2,026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesCurrentMember', window );">Short-term marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">1,601<span></span>
</td>
<td class="nump">1,411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesNoncurrentMember', window );">Long-term marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 579<span></span>
</td>
<td class="nump">$ 502<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesNoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesNoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516448960936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivable</a></td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_WriteOffsInAccruedInterestReceivable', window );">Write-offs of accrued interest receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of positions held in an unrealized loss position | position</a></td>
<td class="nump">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Impairment recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_WriteOffsInAccruedInterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-off in accrued interest receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_WriteOffsInAccruedInterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516367292600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized&#160;Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Within one year</a></td>
<td class="nump">$ 1,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">After one year through five years</a></td>
<td class="nump">563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost', window );">After five years</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,478<span></span>
</td>
<td class="nump">$ 2,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Within one year</a></td>
<td class="nump">1,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">After one year through five years</a></td>
<td class="nump">562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">After five years</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 2,478<span></span>
</td>
<td class="nump">$ 2,026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516366325416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 3,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet', window );">Discontinuances of cash flow hedges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Maturities of derivative instruments</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1', window );">Time estimate for gains (losses) to be reclassified from AOCI to product sales</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period for the anticipated transfer of gain (loss), net, from accumulated other comprehensive income into earnings, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net gain (loss) reclassified into earnings when foreign currency cash flow hedge is discontinued because it is probable that the original forecasted transactions will not occur by the end of the original period or an additional two month time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=112277219&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516368132136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative asset, fair value</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative liability, fair value</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative asset, fair value</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative liability, fair value</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative asset, fair value</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Other&#160;accrued&#160;liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative liability, fair value</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative asset, fair value</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Other&#160;long-term&#160;obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative liability, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative asset, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative liability, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative asset, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Other&#160;accrued&#160;liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative liability, fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and elected not to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516366474952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Gains recognized in AOCI</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Gains (losses) reclassified from AOCI into product sales</a></td>
<td class="num">(25)<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Gains recognized in Other income (expense), net</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109974929&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516368263464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Potential Effect of Offsetting Derivatives (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsAbstract', window );"><strong>Derivative assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Gross Amounts of Recognized Assets/Liabilities</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossLiability', window );">Gross Amounts Offset on our Condensed Consolidated Balance Sheets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Amounts of Assets/Liabilities Presented on our Condensed Consolidated Balance Sheets</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction', window );">Derivative Financial Instruments</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCollateralObligationToReturnCash', window );">Cash Collateral Received/ Pledged</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net Amount (Legal Offset)</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Gross Amounts of Recognized Assets/Liabilities</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossAsset', window );">Gross Amounts Offset on our Condensed Consolidated Balance Sheets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Amounts of Assets/Liabilities Presented on our Condensed Consolidated Balance Sheets</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction', window );">Derivative Financial Instruments</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCollateralRightToReclaimCash', window );">Cash Collateral Received/ Pledged</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net Amount (Legal Offset)</a></td>
<td class="num">$ (19)<span></span>
</td>
<td class="num">$ (109)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralObligationToReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41678-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralObligationToReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralRightToReclaimCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41678-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralRightToReclaimCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118948506&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118948506&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516364913896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS - Narrative (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 04, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 04, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 23, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 04, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember', window );">Three-Year Senior Term Loan Facility | Medium-term Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Borrowing from senior unsecured term loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Acquisition consideration transferred</a></td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="nump">&#8364; 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition</a></td>
<td class="nump">1,200,000,000<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability', window );">Fair value of contingent liability</a></td>
<td class="nump">341,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible assets</a></td>
<td class="nump">845,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="nump">226,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Expected tax deductible goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR GmbH | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR contingent consideration | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR GmbH | Hepcludex For HDV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible assets</a></td>
<td class="nump">$ 845,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR GmbH | Hepcludex For HDV | Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_IntangibleAssetMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR GmbH | Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquired IPR&amp;D</a></td>
<td class="nump">$ 1,190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR GmbH | Acquired IPR&amp;D | Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_IntangibleAssetMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Acquisition consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,991,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics | Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,760,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_IntangibleAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_IntangibleAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=116868678&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexForHDVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexForHDVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516461761688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACQUISITIONS - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 04, 2021</div></th>
<th class="th"><div>Oct. 23, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible assets</a></td>
<td class="nump">$ 845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income taxes</a></td>
<td class="num">(513)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet', window );">Other assets (and liabilities), net</a></td>
<td class="num">(187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="nump">1,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total consideration transferred</a></td>
<td class="nump">1,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR GmbH | Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquired IPR&amp;D</a></td>
<td class="nump">$ 1,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,565)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability', window );">Liability related to future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet', window );">Other assets (and liabilities), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,991<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics | Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics | Trodelvy for mTNBC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics | Outlicense contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyForMTNBCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyForMTNBCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516461902264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 8,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill resulting from the acquisition of MYR</a></td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 8,334<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516364963880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS - Summary of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,666<span></span>
</td>
<td class="nump">$ 22,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,055)<span></span>
</td>
<td class="num">(6,660)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,611<span></span>
</td>
<td class="nump">16,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross&#160; Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,836<span></span>
</td>
<td class="nump">39,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,055)<span></span>
</td>
<td class="num">(6,660)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,781<span></span>
</td>
<td class="nump">33,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross&#160; Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,170<span></span>
</td>
<td class="nump">16,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,170<span></span>
</td>
<td class="nump">16,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsGrossTransfers', window );">Intangible assets reclassified from indefinite-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(910)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | Subsequent Event | Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsGrossReclassified', window );">Reclassified amounts</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_IntangibleAssetSofosbuvirMember', window );">Intangible asset - sofosbuvir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,720<span></span>
</td>
<td class="nump">10,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,127)<span></span>
</td>
<td class="num">(4,952)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,593<span></span>
</td>
<td class="nump">5,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,127)<span></span>
</td>
<td class="num">(4,952)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_AxicabtageneciloleucelDLBCLMember', window );">Intangible asset - axicabtagene ciloleucel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,110<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,196)<span></span>
</td>
<td class="num">(1,105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,914<span></span>
</td>
<td class="nump">5,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsGrossTransfers', window );">Intangible assets reclassified from indefinite-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,196)<span></span>
</td>
<td class="num">(1,105)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyForMTNBCMember', window );">Intangible asset - Trodelvy for mTNBC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(158)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,442<span></span>
</td>
<td class="nump">4,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(158)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexForHDVMember', window );">Intangible asset - Hepcludex for HDV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">845<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,391<span></span>
</td>
<td class="nump">1,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(567)<span></span>
</td>
<td class="num">(540)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">824<span></span>
</td>
<td class="nump">836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (567)<span></span>
</td>
<td class="num">$ (540)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedIntangibleAssetsGrossReclassified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Gross, Reclassified</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedIntangibleAssetsGrossReclassified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedIntangibleAssetsGrossTransfers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Gross, Transfers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedIntangibleAssetsGrossTransfers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total carrying amount of assets (excluding financial assets) that lack physical substance, excluding goodwill, having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_IntangibleAssetSofosbuvirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_IntangibleAssetSofosbuvirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_AxicabtageneciloleucelDLBCLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_AxicabtageneciloleucelDLBCLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyForMTNBCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyForMTNBCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexForHDVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexForHDVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516361024424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Aggregate amortization expense related to finite-lived intangible assets</a></td>
<td class="nump">$ 395<span></span>
</td>
<td class="nump">$ 281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516366373320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2021 (remaining nine months)</a></td>
<td class="nump">$ 1,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">1,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">1,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">1,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2025</a></td>
<td class="nump">1,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">9,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 17,611<span></span>
</td>
<td class="nump">$ 16,236<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516360856936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Accounts Receivable, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 4,647<span></span>
</td>
<td class="nump">$ 5,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AccountsReceivableChargebacksCurrent', window );">Less: chargebacks</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AccountsReceivableCashDiscountsAndOtherCurrent', window );">Less: cash discounts and other</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less: allowances for credit losses</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 3,925<span></span>
</td>
<td class="nump">$ 4,892<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AccountsReceivableCashDiscountsAndOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Cash Discounts and Other, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AccountsReceivableCashDiscountsAndOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AccountsReceivableChargebacksCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Chargebacks, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AccountsReceivableChargebacksCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516359107608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,023<span></span>
</td>
<td class="nump">$ 1,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">856<span></span>
</td>
<td class="nump">976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">958<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_InventoryNetAndInventoryNoncurrent', window );">Total</a></td>
<td class="nump">2,996<span></span>
</td>
<td class="nump">3,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">1,779<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">$ 1,217<span></span>
</td>
<td class="nump">$ 1,331<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_InventoryNetAndInventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory Net And Inventory Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_InventoryNetAndInventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516365858760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Other Accrued Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and employee benefits</a></td>
<td class="nump">$ 494<span></span>
</td>
<td class="nump">$ 864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent', window );">Allowance for sales returns</a></td>
<td class="nump">524<span></span>
</td>
<td class="nump">587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">2,274<span></span>
</td>
<td class="nump">2,287<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 3,507<span></span>
</td>
<td class="nump">$ 4,336<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=118944142&amp;loc=SL49130611-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516368181096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATIONS AND OTHER ARRANGEMENTS (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 13, 2021</div></th>
<th class="th"><div>May 27, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember', window );">Merck Sharp &amp; Dohme Corp agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts', window );">Percent of global development and commercialization costs</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod', window );">Option period to license</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember', window );">Merck Sharp &amp; Dohme Corp agreement | Merck</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts', window );">Percent of global development and commercialization costs</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember', window );">Merck Sharp &amp; Dohme Corp agreement | Oral Formulation Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborationArrangementNetProductSalesThreshold', window );">Net product sales threshold</a></td>
<td class="nump">$ 2,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborationArrangementPercentOfGlobalProductRevenues', window );">Percent of global product revenues</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember', window );">Merck Sharp &amp; Dohme Corp agreement | Injectable Formulation Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborationArrangementNetProductSalesThreshold', window );">Net product sales threshold</a></td>
<td class="nump">$ 3,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborationArrangementPercentOfGlobalProductRevenues', window );">Percent of global product revenues</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_ArcusStockPurchaseAgreementMember', window );">Arcus stock purchase agreement | Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage by noncontrolling owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_OtherCollaborationArrangementsMember', window );">Other collaboration arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements', window );">Upfront collaboration expenses related to other collaborative arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,000,000<span></span>
</td>
<td class="nump">$ 97,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CashPaymentsMadeRelatedToEquityInvestments', window );">Cash payments made related to equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,000,000<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember', window );">Arcus | Arcus stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNISharesAcquired', window );">Equity securities acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PaymentsToAcquireEquitySecuritiesFVNI', window );">Payments to acquire equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIShares', window );">Equity securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIPurchasePeriod', window );">Purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIRestrictionPeriod', window );">Restriction period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember', window );">Arcus | the &#8220;Stock Purchase Agreements&#8221;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased', window );">Maximum percentage of outstanding stock allowed to be purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CashPaymentsMadeRelatedToEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Payments Made Related to Equity Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CashPaymentsMadeRelatedToEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborationArrangementNetProductSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Net Product Sales Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborationArrangementNetProductSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Percent Of Global Development And Commercialization Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborationArrangementPercentOfGlobalProductRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Percent Of Global Product Revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborationArrangementPercentOfGlobalProductRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIRestrictionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Restriction Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIRestrictionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNISharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Shares Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNISharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PaymentsToAcquireEquitySecuritiesFVNI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Equity Securities, FV, NI</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PaymentsToAcquireEquitySecuritiesFVNI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Collaboration Expenses Related to Other Collaborative Arrangements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gild_MerckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gild_MerckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OralFormulationProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OralFormulationProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_InjectableFormulationProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_InjectableFormulationProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_ArcusStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_ArcusStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gild_ArcusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gild_ArcusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_OtherCollaborationArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_OtherCollaborationArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516364638152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 30,166<span></span>
</td>
<td class="nump">$ 31,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion of long-term debt and other obligations, net</a></td>
<td class="nump">2,259<span></span>
</td>
<td class="nump">2,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt, net</a></td>
<td class="nump">27,907<span></span>
</td>
<td class="nump">28,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=gild_SeniorNotesAndMediumTermNotesMember', window );">Senior Notes and Medium-Term Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 29,052<span></span>
</td>
<td class="nump">30,295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.50% Senior Unsecured Notes Due April 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.15% LIBOR Senior Unsecured Notes Due September 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.15% LIBOR Senior Unsecured Notes Due September 2021 | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.40% Senior Unsecured Notes Due December 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,249<span></span>
</td>
<td class="nump">1,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.95% Senior Unsecured Notes Due March 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 499<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.25% Senior Unsecured Notes Due September 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 999<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.50% Senior Unsecured Notes Due September 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 748<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.52% LIBOR Senior Unsecured Notes Due September 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 498<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.52% LIBOR Senior Unsecured Notes Due September 2023 | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.75% Senior Unsecured Notes Due September 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,993<span></span>
</td>
<td class="nump">1,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.70% Senior Unsecured Notes Due April 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,746<span></span>
</td>
<td class="nump">1,746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.50% Senior Unsecured Notes Due February 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,747<span></span>
</td>
<td class="nump">1,746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.65% Senior Unsecured Notes Due March 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 2,737<span></span>
</td>
<td class="nump">2,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.95% Senior Unsecured Notes Due March 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,246<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.20% Senior Unsecured Notes Due October 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 746<span></span>
</td>
<td class="nump">745<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.65% Senior Unsecured Notes Due October 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 992<span></span>
</td>
<td class="nump">992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.60% Senior Unsecured Notes Due September 2035</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 992<span></span>
</td>
<td class="nump">991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.00% Senior Unsecured Notes Due September 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 742<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.60% Senior Unsecured Notes Due October 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 986<span></span>
</td>
<td class="nump">986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.65% Senior Unsecured Notes Due December 204</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 996<span></span>
</td>
<td class="nump">996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.80% Senior Unsecured Notes Due April 2044</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,735<span></span>
</td>
<td class="nump">1,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.50% Senior Unsecured Notes Due February 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,732<span></span>
</td>
<td class="nump">1,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.75% Senior Unsecured Notes Due March 2046</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 2,219<span></span>
</td>
<td class="nump">2,219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.15% Senior Unsecured Notes Due March 2047</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,726<span></span>
</td>
<td class="nump">1,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.80% Senior Unsecured Notes Due October 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,476<span></span>
</td>
<td class="nump">1,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Medium-term Notes | Variable Term Loan Note Due October 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">748<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes Payable, Other Payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,114<span></span>
</td>
<td class="nump">$ 1,107<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=gild_SeniorNotesAndMediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=gild_SeniorNotesAndMediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A450SeniorUnsecuredNotesDueApril2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A450SeniorUnsecuredNotesDueApril2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A440SeniorUnsecuredNotesDueDecember2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A440SeniorUnsecuredNotesDueDecember2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A195SeniorUnsecuredNotesDueMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A195SeniorUnsecuredNotesDueMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A325SeniorUnsecuredNotesDueSeptember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A325SeniorUnsecuredNotesDueSeptember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A250SeniorUnsecuredNotesDueSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A250SeniorUnsecuredNotesDueSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A370SeniorUnsecuredNotesDueApril2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A370SeniorUnsecuredNotesDueApril2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A350SeniorUnsecuredNotesDueFebruary2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A350SeniorUnsecuredNotesDueFebruary2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A365SeniorUnsecuredNotesDueMarch2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A365SeniorUnsecuredNotesDueMarch2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A295SeniorUnsecuredNotesDueMarch2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A295SeniorUnsecuredNotesDueMarch2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A120SeniorUnsecuredNotesDueOctober2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A120SeniorUnsecuredNotesDueOctober2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A165SeniorUnsecuredNotesDueOctober2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A165SeniorUnsecuredNotesDueOctober2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A460SeniorUnsecuredNotesDueSeptember2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A460SeniorUnsecuredNotesDueSeptember2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A400SeniorUnsecuredNotesDueSeptember2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A400SeniorUnsecuredNotesDueSeptember2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A260SeniorUnsecuredNotesDueOctober2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A260SeniorUnsecuredNotesDueOctober2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A565SeniorUnsecuredNotesDueDecember2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A565SeniorUnsecuredNotesDueDecember2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A480SeniorUnsecuredNotesDueApril2044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A480SeniorUnsecuredNotesDueApril2044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A450SeniorUnsecuredNotesDueFebruary2045Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A450SeniorUnsecuredNotesDueFebruary2045Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A475SeniorUnsecuredNotesDueMarch2046Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A475SeniorUnsecuredNotesDueMarch2046Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A415SeniorUnsecuredNotesDueMarch2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A415SeniorUnsecuredNotesDueMarch2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A280SeniorUnsecuredNotesDueOctober2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A280SeniorUnsecuredNotesDueOctober2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_VariableTermLoanNoteDueOctober2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_VariableTermLoanNoteDueOctober2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516461763288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT AND CREDIT FACILITIES - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amounts outstanding under revolving credit facilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | the "2020 Revolving Credit Facility"</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | the "2014 Senior Notes"</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Repayments of senior unsecured notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Medium-term Notes | Three-Year Senior Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Repayments of senior unsecured notes</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Contractual term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Remaining outstanding</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_CreditFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_CreditFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNoteIssuedNovember2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNoteIssuedNovember2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516364551512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">38 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>plaintiff </div>
<div>agreement</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>patent </div>
<div>opposingParty</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>plaintiff</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>plaintiff </div>
<div>opposingParty </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>party</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>opposingParty</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>opposingParty</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>opposingParty</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne', window );">Number of patents challenged, scenario one | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo', window );">Number of patents challenged, scenario two | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember', window );">Juno Therapeutics, Inc. and Sloan Kettering Cancer Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 585,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_JudgmentRoyaltyRateFromOctober2017', window );">Running royalty rate from October 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_JudgmentEnhancedDamagesOnPastSales', window );">Enhancement rate on past damages</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_JudgmentRoyaltyRateOnFutureSales', window );">Running royalty rate on future sales</a></td>
<td class="nump">27.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyEstimateOfPossibleLossPastSales', window );">Estimate of possible loss representing past sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 811,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 811,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages', window );">Estimate of possible loss representing enhancement of past damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">389,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">389,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyEstimateOfPossibleLossRoyalties', window );">Estimate of possible loss representing royalties and prejudgment interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember', window );">Juno Therapeutics, Inc. and Sloan Kettering Cancer Center | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember', window );">Juno Therapeutics, Inc. and Sloan Kettering Cancer Center | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_ViiVHealthcareCompanyMember', window );">ViiV Healthcare Company | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_PreExposureProphylaxisMember', window );">Pre-Exposure Prophylaxis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyMaterialTransferAgreementsNumber', window );">Number of material transfer agreements | agreement</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaimsMember', window );">European Patent Claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPartiesAppealedNumber', window );">Number of parties appealed | opposingParty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyPartiesFilingOppositionNumber', window );">Number of parties filing opposition | party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_ProductLiabilityMember', window );">Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of class action lawsuits | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs involved | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_QuiTamMember', window );">Qui Tam</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs involved | plaintiff</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_JudgmentEnhancedDamagesOnPastSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Judgment: Enhanced Damages On Past Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_JudgmentEnhancedDamagesOnPastSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_JudgmentRoyaltyRateFromOctober2017">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Judgment: Royalty Rate from October 2017</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_JudgmentRoyaltyRateFromOctober2017</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_JudgmentRoyaltyRateOnFutureSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Judgment: Royalty Rate on Future Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_JudgmentRoyaltyRateOnFutureSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyEstimateOfPossibleLossPastSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Estimate Of Possible Loss (Past Sales)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyEstimateOfPossibleLossPastSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyEstimateOfPossibleLossRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Estimate Of Possible Loss, Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyEstimateOfPossibleLossRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Estimate of Possible Loss (50% Enhancement of Past Damages)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyMaterialTransferAgreementsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Material Transfer Agreements, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyMaterialTransferAgreementsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyPartiesAppealedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Parties Appealed, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyPartiesAppealedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyPartiesFilingOppositionNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Parties Filing Opposition, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyPartiesFilingOppositionNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Patents Allegedly Infringed, Number, Scenario One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Patents Allegedly Infringed, Number, Scenario Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118943654&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_ViiVHealthcareCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_ViiVHealthcareCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_PreExposureProphylaxisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_PreExposureProphylaxisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaimsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_EuropeanPatentClaimsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_ProductLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_ProductLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_QuiTamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_QuiTamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516367338184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Additional Information (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Shares repurchased and retired (in shares)</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">18.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Value of shares repurchased and retired</a></td>
<td class="nump">$ 309,000,000<span></span>
</td>
<td class="nump">$ 1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized repurchase amount under stock repurchase programs</a></td>
<td class="nump">$ 6,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2016StockRepurchaseProgramMember', window );">2016 Stock Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount under stock repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2020StockRepurchaseProgramMember', window );">2020 Stock Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount under stock repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2016StockRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=gild_A2016StockRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2020StockRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=gild_A2020StockRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516366735992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">$ 18,221<span></span>
</td>
<td class="nump">$ 22,650<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">98<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">18,964<span></span>
</td>
<td class="nump">22,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(60)<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="nump">76<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="nump">22<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">98<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(113)<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="nump">22<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">$ (23)<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724394-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516362619960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Additional Information (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from earnings per share computation (in shares)</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516448983576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Schedule of the Calculation of Basic and Diluted EPS (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Gilead</a></td>
<td class="nump">$ 1,729<span></span>
</td>
<td class="nump">$ 1,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in per share calculation - basic (in shares)</a></td>
<td class="nump">1,256<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of stock options and equivalents (in shares)</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in per share calculation - diluted (in shares)</a></td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share attributable to Gilead common stockholders - basic (in dollars per share)</a></td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share attributable to Gilead common stockholders - diluted (in dollars per share)</a></td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="nump">$ 1.22<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516366411528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Summary of the Provision for Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">$ 2,264<span></span>
</td>
<td class="nump">$ 2,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 542<span></span>
</td>
<td class="nump">$ 465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">23.90%<span></span>
</td>
<td class="nump">23.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516367440680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">23.90%<span></span>
</td>
<td class="nump">23.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140516362383160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gild_GileadFoundationMember', window );">Gilead Foundation | Subsequent Event | Equity Securities Donation | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty', window );">Donation expense</a></td>
<td class="nump">$ 206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gild_GileadFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gild_GileadFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=gild_EquitySecuritiesDonationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=gild_EquitySecuritiesDonationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>86
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M:18K"+'KY(MZQ" _8FX.)MDYG<@$!YJE1G+8S)(XC!PJ!XV)GR^]2E9EO*1
MDE_4NVL@DR<*R.,-TVH%'<F,>NH@/W6NZ#U5:Y]KF=WR/UEEFCP)PW@,1XL5
M3J%C>T,]=9"?.F,X#NK*JM76SAB$M%DAI]8>0<C?]ESRLF12;\'UOJ'DE635
MBE:9*BOP]I9+"B!\9]7M]:S?#)W6&Y+1\\E&T)J*'9W,@:T;_Q\<'4;?<Q+%
M7@ O),\>UKS(J:C__"-!</:^.6?+)Q^'40\Z]&)?U&9LK9^DCO-$ -6J;REX
M$YP$ 03JF _J-1'T/8CV%VH=ME)USNQ?FK\'%:\HX%M9JQ-KKA;&NA F\(SL
M\9D<!M<#$?F!J%-'$>4UD1W%06"+#AZA*'S^@M5UQ]<7 K8T7>. ?2:' ?<L
M17Z67N0YTU6L&*2[W6-6@8QLF&*25:2ETPJ,HZ7%"B>)8VUP3TKL)Z4ZK&S+
M;:$.4MUAA9>J>M;ZU>B./F_W;PM>U];BQB87\;CUM=@<N\Y9N"<G]I/SF^H>
MU4>JX26B4@E@?Z=E A&&"1IG@=4,)XY,P#TWL9^;^X/(1U90TI:V=1.Q*C?1
M"),T&N>%U0RY6E\\>''H1^@MK_06+WBAOEFI/%"$HK7U;()-.D)#IL4F=6CL
M^8E?T[7]YK1:\)BD!O&M9@BY$J+'*/9C="]Y<")MMK'?#"$RWL':FE&;F:49
MG0[>UNN?2KX0L6)5#0IZK\8%)S/E1NQ_?=C?2+YI7N ON92\;"[7*KVIT ;J
M^WNNS@+MC?Y-H/L-:/X?4$L#!!0    ( 'B!IE*;3Y*EO@(  .<(   8
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MSLKQAH"V),$Q KU/0YY0M!8\03 OY%D=:NE.#P">3.TN3(V59^,!F+B!B?\
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M2O&DN-Q"+Z(B-X#_KSE7GS?Y"^ICP?E_4$L#!!0    ( 'B!IE*&Z(#%_0,
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M4Z!.E36 [QLIS=O )BAO<J-_ 5!+ P04    " !X@:928[E"0&<&  "X'0
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M)$YS'0R3GABVZHG-\OF4L;HGI!K55+>XB>M!V.Y26I7%9IE]; KOH1^H6QU
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MFUHC-"'E,(R))J;32!.&GL["(UZOC(:FT@0J3"16VIAR].2')W[T*AS.X$B
M2YK2J7;9ZE5$"1PME]ZZI: \H"-C(3LB+?06:BG->4KN06 ;9[M]K5!R;0U3
M H6&47RIIEKFV&/#'RQU,L"IEA>\PGF>1'^- +]F79>4-I)S"GYZ.YC(!+DA
M<0C&=O<%&L4LC%J9J!55*E3+L,A0J(CLB OXLULBZ(FN',\R@-6YN,Z,H8JY
MY5RB3"&:B:(^_#N@M<6ZHB<WSSMJ53%?2)N7#]6:<A/*=YWVGIOBG5IQ_BW&
M3DE5P0AD#?Y#FDC.6Q]7SA+"-19<D]+"\($UH-UNE-O-P' W8.Y]*0&$M$-Q
MPS_Z/Z4#:6/L)K:-3J&#H)(]LP"XG]-[,!VPB-_!9*,( :\)8-9:-; %MO'N
MZP:YI-P,Q<2*5/Q^5+M6E293#SMY#^=FV#Z_OKC*N#U+73MA?MM:-#3\ H#
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M28[(-)\]FP>G-_Y3XT([3!3^=HW#K31,@/=+K5WWP +Z;\^O_P-02P,$%
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MZY31(J-NVZ9]SP8OYM;F*UV60_')2>-E+/',^L!FVTQC\QRU%!9WA%$Z!;O
M;3YJA!EK?JA-5CML"=5DF78^B&^U= &V$BHW?(2U[_[SD2/'?MC:8<?>\M'V
M\LNJJHU%6'7FQ4JY-N4P@Y(.4W8:/.2-WAN!$D%.3V*)(,6*EBU+10JV4Q#-
M&P@IWBA0F!$S;8/*%L:6=KYF06G6475A03=()L1(3:ZNP=A+\&]@]["V4@YQ
M+?6?LE&.A4XN51W(&;*>) .:0V YK'C[\O<8R+Y92V>O@0(OWN@2C22FZ:U:
M9F6=JYL&MBM)$3 YRS!\Y9(D"9%KWNE5[="=X-8["B?%3%P [-E:'/SRCP>3
MR>CQJW<7_&G\^!")%;_6T,)9V6ELMG#6Z(R,QNHB-0[(R1PD[Z.=%#2@AO%5
M:D)PKKU"8QB*STL"86D]%Q\%=:8R6<%YN&3AP9%=&8CY>H8JT&B"M&L,0@,W
M(PT%&6CWO&="&",%T*0(Y602D 92 ^TR@/')VU+G;-7K5LE5P /R#MEQMHJ)
MQ:,=Y1I!@'@'IV=U8#H0&IT:0"955)3P;(>B?F8#(EC/%PFD#9$/B=G:\K6$
MFK[4D5,E&Y[JD9W>'X_1[\H2OP\ &(V103.#8?;PBOFM"753]T!IHZE0R@\H
M3%?H]YR-1(*\2N;HI)I: (T$O6WO#6LOF%3'!D!0'8X63BE1Q6ZHJ!O>B@%7
MP7SNU)P"M\F$48WVV]7+B+_1E 4X#RA/STX>CX=3%#*'1AQ <'\\/&L>'/9B
MQ5OX:&XK.MH0W=0/19.>(JES4?<@G7B 8T\5LT7F!1:+8)NMIJ-1ET @_@O*
MB7Z.0PUA7^9?\)DC.MA,K!1+\!0^(V%%'6I@'ZH4!(V"76LN6#;M]<N+1 M8
M2GS3L$B,-T38N7RKQ7"L>ZXT;6_-K+,_/6G!=T]S2XA+L ;8WC.R2VOF1ZB:
M2MA9J>>IW]R/K>>R1,DJ<46#G(^VWQEI,K%S+,X#B, LN7"TXE&4>"93!E"P
MD9O[H4ILT\6DT=?1^(].!\Q,-!@GL)"^C5$%3,KS,YG^U8 !615]DK-2]>+;
M,1.24VBJVZ%XL9"(@2?D8(U7<=]E:N)0U%F.-EH"H+*F541>2QDA1\I;L[BL
M-GT;)&:-U@9LJ*-EM&K0#AMMFV]8)LB;M,LNC S(M94B.2]*5'U4$.FO36Z&
M6"9NJ&@,B'/.W.@_>7Z!]"RVA9*?Q$EE(Z9&T71%!475E6:!: RDUJ  FI[L
M+."(1KZ"W86Q@ER@3"-25%5K)4$'14@3V>U!C@&#)F97/']R[N)1#H;YG97F
M=\3Z3AS=76>/Q &**]6C/Q07'"@P\%:FJ/'IH(ZH*^>W$BGVQ8.34W'1V''Y
MX>,OLEH^?BG&@_'#D7BI"N5XU(S,CN12#Z&^=W ZGAZFZDY;'6RY<9A6CA^<
M'XI/-B#9*%CDN- <J=Y,.QY,IZ?B30.JR>0L"6Q6^3X6GIZ-^VY>1 5I4+C'
M5>J?Y&S#82VY1O3<Q8HM>3()Q"DH#5GWSOA;7$+\E"MB0 (<#6N@G7+='%M2
M?)F*)#ID9 D,Q3.OW#5'2YME';CF&U-W$QQ%-9-^(0K $E *<7AA'1"^UQ^:
M VATB^<ME[AG//EG]&?SEYKH[<XH\A(^4J$:OL*F)>9_#*08KFEJ9%HB4H))
M,4+,<-M9HWUW/*;BG2GNBI6%6F(!/CBA</M=0!5U"406T8T1%S28I<7[+6+K
M:,SVBB$-#7?" 8-XHC ,,DS"-!5;< J^UU!HW;IM,WUBI9!]'EYM]^5N(MK$
M8G\6N:\'_S1@B^,;9^QGQ-85A2$%$3@"=VLTF4)GTH2-GJH-DDM#A[Y]$(3\
M+7CVZ3X=4![UFC)$$$T:_HANXBS7BV*'#X=]#-\F4)-<,@W&P:;0P3_NYX24
M^CJCMO<XVK@1T'CGI_+X6U,2]+F;*OO'61@&Y7F=I4,$MWCMOVY4",\0NF<
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MQU;8_,#C,G4+#Q6 "/"AI9>:+':4Q8@#Z^P)<NW@K[<>/0VT(6</IV,TI^\
M]2FQC7:8"]PA7Q;?DD2J.?CJVH$(#P")I#&[ ."9SQYQ<MVUF+!T'G8>_^T_
MCO?W=U_((/YE[\4W$U@?Z%P#25? O'EILNL6=@) G)TI_ JW)#[Z\=7U#_V#
M9]@5I.@]$P#> )Q*!61$E (T!<+"@<-&9^;73DSF.WIV[_F+N.+?_F/_X. %
M.ZA+\-A WBXN>J3RVZ%':67(##@-%\E+\<>=ZQWR#]N&CN\,/&NC;8@?,[@[
MI_(%I+@E/2*)%R57<N@]L)E_1=QT":AYN72RXI4HX7N+ W@V.=D[G.P>'6:/
M:2;/)K]-^EBD-_",M_)\\FSW>')T\GS3,_3Q\)F W(<33RQM$VYP[6:Z\:@V
MVF("F=[)>RBK7D&<"7BPRX",+1M?PS0\BV>2L]/N)7^.XZ1S48P9-<DP*19)
M=R<X23)-/H5 ;=0>R):CHR 8];9JC7>IBB6'(LK4+HH&828?I1_.EHQF8L)9
M":'AMPK6 9#4LCE:+A UNK%U@>>KFSK@_]J!B *#$6]5W1&6D*LPZ=E[W6$=
M0(9PE]B$!7MEPUPN6^I6+ HQ'U0AHIT F#^%1?_9%7.&OZ#OGMTS4]->QOK.
M:P=E6K&LF[H&?$"7;^[Y+A6\?DR4TH4*2(X=#&5^)SN>'.\=38X/=C>)+WT\
M%%]@],*08>F:I6W$79DV5A5LFLG"B&]#-EIB K"Y-3AB<OGJ@G_+R6-K)%\
M0H-*/)N,.3"34P8.W;G.]&S\#: 1F#7Y>L1X0@"/A>F98 T2%$FDJ^<7"VKB
M8ZR/(.?*U+UI95-">C;M3:=W!'0T,<67: V\?)["RQSP0BK'/IN-0.)!1P8J
MQ_;K#/."?[51O;UC%U".(@B\>.UD2AMV%K3SXI\(<B)HM+^;1A6:/,;LPPR6
M48?O;B0:P(C3Y5+CQY<6[F"T45<WIR][O!T<':D^.>(-[2U"D(Y<)1)9W,Q2
M1;_/3F\I+H<P^&B<%LA(JDS;,9/J)/KJ]\NR*\ZARQ9:T?ED=XI^+AE&SO6T
MB3@2CN%X\D4I?0\U@H6M!^+:'T/F6K7R9B%!-P3 !KN?M?[\>!<AV!>9W'0Z
MS#?3,B1 H!'-24#+.GVG?:@HLFCSO&O$4M"&QF#UOCM#[)(MR\07D<_B<?DA
M _QYW9'+A9 ZP:#]R<G1T63O9(A!KZ^"TM W(\L;!("\W0 ];JP''Y8(2 6@
METFR9JK!6M'*,35>-!]'$C[T*+KIG.5X,2Q=ZQ50C5.JW9(?HB$LD1ZXY9'U
MS7%T!7-!@18E@T<8XL$JC-@XP[H6D"&;.OC2^+I<L8L=#W[ %8X[^9$0^'_\
MD?"#I(B$Z$N4<V1J$ >+>&/TZWI>DMK\357+%]DOJB1''<<BT;FPSXM( 'J_
M'F]C ]I_<?X>(2)AXR!D;5\<OFC-1MO'$X(4I);DKA@]8[I/$5Z60[H3:-QF
MI7[0<-XI*R/']PY3SX$B^:+-7L%A/MI_ 0@K"]O,'D2\3/?@@]FVN;"MS3F0
MT\^PT=#8N088GIG2EKK+=<DZE;>60GFQ,6^[VA**-FK)X4D(3FB)Z]*"T!\Y
MO4?+GXG5IS #_SW.+4=AL/4DEE[A:+ZH<;_/^G,X W.R&58?[ :HE!5Y9 5"
M/%L6:TF4?VB7XT@P?>\?8)ZQT_5\<GCX; WPMJ+=3G8*5Q*0(\Y[M#JV3EV+
M_KGHVL:D%T[K9.)=4LPS@_04":2,C.C0=T^DZ4XW'LHF/FDJ66:R%Q+Z]Y[+
MUTPLEIA)8XVBH(4PCL4KB"VC(XD]S_.7H^.CK,*Z=$[T%<'M$T0+-84.JRH(
MO\KVG^\\^VO6=#4[<(U=J9)<2XHK4F$&97T>K_"Y[<"QZ/'#S%!V00@.:1+O
M&UG7/I$3$B<KBNG,-!#;7SLRQ9P$H_QCX*"/;#A6@ $FY6"IC[&#29!G5Q9.
MGU P64WE&;Z)U@DF79#NR9"E BV!IW OCW;_RI10?=';:,X[,I^,R*]/, 7I
MSIQ@;2N\'8+C+ML8K[LU);?(J0L8!'!IJ"S@,^=QDU!:GVQ264V."N^PD*0*
M F,+ZU[!@0P.<<(!7IXDS7'P>;?0#-P@PBTXF>1+"  2HZ:FY,""0<(,8FMS
M;Y[Y'"%;38J>7;?XH)+4EU180D(RU'QFB&Q \"3KD_3LODDIB%*32M)/N6GR
MKH*'5^<Z:@>YXI-[3I/E,X :._A]/-KH)Y)9[&710I.(%IZZ:QKB-E9LN[A@
MX@5,0C*2D_CJ3AXCUU'":]X!V1Z8K+YL8C[!FBRL32 E'BR[D@AIO"]D@T0
MTRC#T&C7E=Z$&1=CZ)#WC<41*I]0A3G'=CC?+Z%E3RQ]U7&ED797%P 0WK3X
MNZ'N$@I>*7#1*>'<Q[4BM8&\7EI\LC39J%!/DIWL<M+7E?#]J!#S+]W8C?-X
M7F'#%&Q0TJW1Y#KVL][U]:A0?TOA:Q/@[/E5N4;PF1\%7O]E;^<PFPJ,ACB
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M+<:L),'D@BO W8ZN#+I-2I% 2FFD_TCW!W&M(^O4=@=4D85PEPM%H]L_#EM
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M+G'G V%S.LW1: LTOJX##N3%1CD,%2J7*?;F"W)4FQAP(EHPJ3)JV$9+&4'
M\1&;;)@K2*?8>#;14!A^D^+%MRL^_I\4SWZOK5_ XPTJTBU%HU_]^AF:%L'O
M"^U80NX*4KM*-J'S+,<[XN=0C[1>L!;H^&%!0].):<5I"9@T5!])-JA,S! /
MH!*L(=.=QE&KQ1A[L*<&@,0.2-_3BASPWQ"O3$GWHD'.#6D.O2;%>'*:.6)\
M+H 1; 7V/H4MESR9F\TLG?H[L0F5D;\5]@N' ??P>J'SAIH, %RB8 M"&BFM
M7O>","V3[=>.94)C'K,!_RC(ARRF-J5V4E-=BM"QU1LD,>C?OG(:"CV/@^+)
M)>[M2A"$D"CLU(ZFE3K+F5J?$!<+6_DS/EG >5;>X]T6'LSAN!,CYWM$'UO3
MLV%L"^6^DRK*17S7R3&.\"'XTD@7"/B\FD/5QF98,#-]7NQ!A09BH.UCP)-"
MD)X%IN282@]QON1^.FPRD^\-I>=*N_)>H</N62:S76P,NJ,$8&A,0>RR+U3)
M8'*))-AQQ$U)3HT'!^SPW_Y$HX/_>DN\E-M+4!*S_\7O9_<7I(O^7G!OWM^N
MT+M+ R4LU7 =#W\\&2CN;RS]1_2=W!(6/N+.(:\-+GG$V0#KM?=Q]Y$3[*^-
M\W\ 4$L#!!0    ( 'B!IE+_1A*CZ0(  !X&   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;*55WV_:,!#^5T[9-&T2(A#:KFL!"1C=^M"I*VWW,.W!
M)!=BU;%3^P+M?[^S X%):Z5I+_YQOOON^QS?9;@Q]L$5B 1/I=)N%!5$U5D<
MN[3 4KBNJ5#S26YL*8BW=A6[RJ+(0E"IXJ37.XE+(74T'@;;M1T/34U*:KRV
MX.JR%/9YBLIL1E$_VAENY*H@;XC'PTJL<(%T5UU;WL4M2B9+U$X:#1;S433I
MGTV/O']PN)>X<0=K\$J6QCSXS64VBGJ>$"I,R2,(GM8X0Z4\$--XW&)&;4H?
M>+C>H5\$[:QE*1S.C/HA,RI&T6D$&>:B5G1C-E]QJ^?8XZ5&N3#"IO%-/D60
MUHY,N0UF!J74S2R>MO=P$'#:>R$@V08D@7>3*+#\+$B,A]9LP'IO1O.+(#5$
M,SFI_4=9D.53R7$T7MQ-%_/O=_-OMS"_YW$8$Z/ZLSC=(DP;A.0%A %<&4V%
M@[G.,/LS/F8V+:5D1VF:O IX)6P7!OT.)+VD_PK>H)4X"'B#ER362X>/-6J"
M^9I'!S\G2T>6'\2O5^"/6OBC '_T'S?X;PB7&B:5E2I<0 >^2,75!IG1@C #
MEB+I&1RFM94DT8$@R(6TL!:J1B #5. NZL+4.A.^ #H@8":4Y$+64H VNK(F
MEP15O50RA25J]-O4V,K8$ +OW[TY39+>^1XE&/KG'[IPRTGV=I#,@ZM4!8Z5
ML$Q1.$C1$G<&,'DN>>UX$=C-3%D)S2[*&99BU^B],VFY6,W>;8_?Y MWX+/A
M$W<EA][O;=([X<I0RMLW/+,2)L(R^#FR@0K.O^"REWK5@16KM$*!T!F(C M*
M^I?@.\,.DY,SW]HR1W[0;,C\RADELZ!M03R5X1UQ]DN=FA*!4WB^_%$X"!YK
MUH_6G_M/V/W;*XL/:K9$NPJ=B2^,%5-3OJVU;7Z3IN;W[DWGY()92>U 8<ZA
MO>['XPALTXV:#9DJ=("E(>XG85GPXT#K'?@\-X9V&Y^@_26,?P-02P,$%
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MS^!#T]Q)FXW3:W\/G&D')_CE"B.(- R [PNMW7[##-I_#)S^ 5!+ P04
M" !X@:92@;;9_T0%  #<#@  &0   'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6S%5WMO(C<0_RHC&E6)1,*^6 B7(!&2:T\ZKE%(4E5559E= U:\]I[M)4<_
M?<?>96\Y'KE6JLH?>#RVY^7?S*RO7J5ZT4M*#7S)N-#7K:4Q^:#3T<F29D1?
MR)P*7)E+E1&#4[7HZ%Q1DKI#&>\$GA=W,L)$:WCE>/=J>"4+PYF@]PITD65$
MK6\HEZ_7+;^U83RPQ=)81F=XE9,%G5+SE-\KG'5J*2G+J-!,"E!T?MT:^8.;
MV.YW&YX9?=4-&JPG,RE?[.1#>MWRK$&4T\18"02'%1U3SJT@-.-S);-5J[0'
MF_1&^GOG._HR(YJ.)?^5I69YW>JW(*5S4G#S(%]_II4_72LOD5R[?W@M]W9[
M+4@*;616'48+,B;*D7RIXM XT/<.' BJ X&SNU3DK+PEA@ROE'P%97>C-$LX
M5]UI-(X)>RE3HW"5X3DS?#_Z\ #/HX]/=S"Y&TV?'NXF=Y\>IW#Z2&:<ZK.K
MCD$M=F\GJ23>E!*# Q)#F$AAEAKN1$K3[?,=M*XV,=B8>!,<%3@AZ@)"OPV!
M%_A'Y(6URZ&3%QYRF3 %SX07%&Z93KC4A:(:?A_-M%&(DC^.Z(AJ'9'3$1W0
M,2TQ#G(.(ZVIT4!$"A\9F3'.#$-U$TJLWA2(@:\6[0OW44TV:0<Z)PF];F%6
M:JI6M#5\7%*82XX9Q\0"C+W**NW87ZC;X+)9YTBA?>2K?;QA7]:P;V[M6[F(
MV43"9$P*I:QH3 BF8;8&3E?48M<LF7#R&V>6C"JBDN5Z !,[UI<)MS2AV8RJ
M#<>#4SR>,<XQ8_49?'12_6H,JC&$1VD(?V.UC/L 1BO"N(W .9:P<TTP%"F=
M&=#6">?K )XNIA=@E'-YW5B!$XCB"/]__*$?^,&[+:I<";W+ ^MV94R587.6
M$%,&.Z6YU,S4N\)N?R\=^/$6_4F*<V?D0JZH$E@5FP[46^-@'QF%37(L52X5
M&O1M&.I-?CN(>@=G?A1\,WN@FJ5H$<.H9U*9!59SAR<'K?,925X01WL4A0W!
M6W3#>TO??2Z866_=&-88NL9"J%ZP<<T+D6H(VLVHU=%SW*@=QO[.6LFMI#.Q
MHMJXR"(&?R*<8%>2&GT,O6#G:,GUVW'4W[-FN;]@%BC(BQEG"5\CN@B60Z#?
MN@*7\:X$R^LUKFTS6MXMG5-E$S.1&;9F35QWRSD1$(3=7?^1%_B[*BP/^QIV
M+0$VFZE(UH@(Q5;$]DF4+EPU;-Q6L(_TM\@R]4Z@V_;[71R#MA?%6UG1:P>A
M7XX]FSE^NQ=L9]!EV_/ZS5HYJ"=KK&H*)K\]./.P -G;0M+B3Y6!.)"+D5__
M[UO?I?ZW,$?^/M(/MNE-H*W>$VAX%_L]RT:U)V[C5A3"2SC2W+IU<^M^;W,;
M<\SQLL#9\""GRJ9I#?!]+>VX_._H7LF.7EFH/<GU3[J8E8-"QA*_6X3&,TAI
MR5F*M3*%&RP((J$PM9]:",GM1O5F7QL3O70U,;&$-10M0?1JER2V1)U4Y>A>
MT9RPU&V6KH:4N#&;3GWJGT'OL@?];E@5&2[%XMQ0E36W8&)A&N%_-Z[1$F&R
M.9"T+WL>_/G&SXGY(!)>I!A*>KQ,?GJ&4XNTP'M7,]W<?W=V!'-QC;GX*"8J
M6$VH6<H4C=H8L1=>1T7]ZR^FHY@[%!;V7X+J3:@@MGH666'7/P05O^T%L6WR
MB*@-3,KF=E(ULGVWUVF\.#*J%NY=I;&:%<*4CX^:6S_=1N6+Y>OV\MV'7BZ8
MT/@%.<>CWD4/BX,JWU+EQ,C<O5]FTN!KR)%+?'Y293?@^EQ*LYE8!?6#=O@W
M4$L#!!0    ( 'B!IE+68]VW.00  "T+   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;+56;6_B.!#^*Z/<ZM1*4/("].4 "2C=K=3>5=!V/YSN@TD&
M8M6Q6=LIV_WU-TY"2DM+JY-.@M@>>V:>>;.GMU;ZP:2(%GYF0IJ^EUJ[.FNU
M3)QBQLR16J&DG872&;.TU,N666ED2<&4B5;H^]U6QKCT!KV"=J,'/95;P27>
M:#!YEC']-$*AUGTO\#:$*5^FUA%:@]Z*+7&&]FYUHVG5JJ4D/$-IN)*@<='W
MAL'9J.O.%P?N.:[-UAR<)7.E'MSB,NE[O@.$ F/K)# :'G&,0CA!!.-')=.K
M53K&[?E&^D5A.]DR9P;'2GSGB4W[WHD'"2Y8+NQ4K;]A94_'R8N5,,47UM59
MWX,X-U9E%3,AR+@L1_:S\L-G&,**(2QPEXH*E.?,LD%/JS5H=YJDN4EA:L%-
MX+AT09E93;N<^.Q@>#^\O!J.KB;-B[^FS=GP:@+GD]$MS";CN^GE[>5D!@>W
M;"[0'/9:EA0ZME9<"1^5PL-WA$=PK:1-#4QD@LE+_A8!K=&&&[2C<*_ :Z:/
M( H:$/IAL$=>5%L?%?*B=^2=X]S"#.-<<\O1-&#XR+APYC8IWYN&"82_AW-C
M-67//WL4MFN%[4)A^QV%4XR5C+G@K,A)M7BE<>8TOD(%"ZTR&"MC8<0,-V 5
M7#"NX9Z)'-^*REX,KLS/S(K%V/>HC@WJ1_0&MRG"0@FJ42Z78!V@JE#Y+X*@
M<@ULUS>)0VIJI&=  8K3.D)D28S9'/6&XL,!EY3&0I#UYA"&F=*6%"3P52MC
MJN_$6$[U1M2/]N^.9D=@Z3(RN7[: @)?H-UMT_?WWT["(/SCQ:S<B?P3^@8O
M=B+_%,9(&A<\)OG&Q2?!E3+<0M0YJ4]N1D<+@^X.W='^5+)9P%NJ1]22[K%M
M3T$WW.$B4CO:H1)IK/1*:0+TVM\0-,+V,1EQ$!QNYHV@[<.S<+<.88J&)X2
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MC:>C.S*=+9:/7^\GL^6"-)=TQ4&W^HY!=U;)\7/3-YEI[X#I#KF7PL2:3$0
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M/U./E[Z!MV@,G1@#2U5ON&3N21CX?;XQ5M/+^.,=$]G)1.9-9&^86%/!E(U
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M*2ON>9[;6+=I$D>WQII1,S:Z-6XL*X?[0>&:EU.SYM6$S>MO-]WMN@NM<AM
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M.MW[Q")/!QX"LIZBR'HK])DN#9 \F<2!D8"<IZANZ&'5)4!U>"E*JO+UF"*
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M'MK@8T#/N4@=]X ^9Z45>X2LA<!\#F45:GPK-Z#56:'5][)&^#! YERD#G;
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M\Q&E_)G!F:^&78H#.)%3?1#I?!,M:1*Q3*F(!@AP =^!'C9Q@,@4\$'8U,I
MH':2.RJB'5+]%=$ H2\PT7)&^\\N>P:(?H%N=SE [ KX:&RR+]1^<D?9LTNJ
MM^P9(#@&)MK.Z O]VF: 0!GH]IH#,F3#1VV3G:)VE]7:9H=0;VTS0+@,3+2@
MT26S"I@!HF6@VV,.$?)"/J:;ZH5P3%K;)=27UH:(J"$?ZXT=RT+4"WG4FU;
M#-40K^/D'4*])T<L#,U&@KI5RA"1-=2-"D,$OO#_5*(+AZ-&5N147P3#D ?#
ML=<C(F(XD,?.-H"*>HH!.)%3?<E<HSE8%)R%$/E"7>2+$/FBF96[J .];+<=
MB75(02#Z1C,1Y"(C(!<AR$4SL]I(A2JEL-TATUO8CA#.(G-P)L;5)R-$K,A(
M9R%"V(IXV-*K3T;#V,6*G"J-V!69RWC%O/IDA+@7Z6:V$6)2-#.SC88S6U;D
M5!\R:VTNLQ7S)D5M.F&MF^""3<:K;3[%[9\6M3MFI]5QT0ZI_GE1F\Q/V^:R
M6:$U%FJ386E;>UK:)N/2]MQY:5O-2I79T"ZAOBP);#(P;9M+7<7,BB789#+:
MUAZ-MLELM#UW.-I6@ZN.0=!.L=Y)4+#)A+1M,! S6[\$FXQ&V[K1&U"V",R,
MWPX+^:G/3JE>]#DAG9CKOHJIM4R@-!+0G2 !2O8 /FB;6B@X[,<]<'F9EJH$
M' ?()%,],+N:"91, KI-6*"<#^#CM^G>4#NOJC<XF9:J!#8'."53O:%?SP1*
M+@'=?BU0\@>8'8,^[,>[970K%PBW! ;()5/=,JNF"81: D*WE0N$_P'"[*3S
M83_6$ZQ,2U6"K(*/#,?R'@DW! ;((=,JFX?=^+-S,BU%"2H*LQ&C;F43"*D$
MA';T2.@@,,0'F5O<.VS,#F%V"?5-80*AB,  1V3TM4DP<H JHF&(#CJ(0LCM
M$.HM60'AC( 1TLCN2G58?BV!1&WJ!Q#N!PR0/_H#Y@X"AW+_LS(MG2B%V SV
M$?H%.'-38Z>#)JQ>0!U2O0<E0#? Y)AT^8QDUA-R!CA&>A5 6!3@\("FR:YW
M.E"MPQFCVQ9 2!LPP-J8ZHQ9-'J"B /,C#%$>@)4 [0,ADJO9KS*;<[*M'0B
M0&:$@8$&GU$%)<P*T*96 .%6P "Y@K'WB R8E6GI1-^F8"X#=K0JH(2! :YV
M!DS($3# CF#,/B+5965:.A%(=,VENL[<^B>A8("KG=P2Z@2X,\>1#PMYBX_/
M8@G[ @;H%U,M;K+R20@9X&D'<H1A =[<0,X;$<BQ,BV=" H.L#0FQS>3JIZ$
M> &>[D0*>/05,&8)N(?]> ^,;N@"(6;  #-CJ@?F5ST),P,\W=8N$&X%>&;9
MMH?]>&^,[OH"H6[  '=CJC<,5#T)D0-\[3XPX6" ;W;4^; ?ZQ96IJ4J@<X!
MCL=4M\RK>A*.!_C:;6'"T0#?[*#S83_>$^,38D(! 9^/!L=FI#Y]$1:/@!.K
MGOZ(.)&5:2E*4-$W&R=J5ST),P1\[9B1\#I@B-@QN]CGCX@I69E3G0D)! 98
M(&.O3,(%@0$RR'PS[#?V.3.P,CN=%^0MM/4[@"N@N$\VA97*NVJ-_:;F).2[
MM^KN/I39MGDQ[6U6EMFZ^?%!5L^DO!:H?G^79>7A0_VNV^/+C2_^!U!+ P04
M    " !X@:92BJG2B0$#  "5"0  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6S-5LMNXC 4_96K:!:MU#8/'H$*D"A03:4R@Z!T%J-9F' !JTY,;0?:
MOQ_;2=.4U\RBBVX2V[GGYMQS_&IMN7B2*T0%+S%+9-M9*;6^=ET9K3 F\HJO
M,=%?%ES$1.FN6+IR+9#,+2AF;N!Y=3<F-'$Z+3LV$IT63Q6C"8X$R#2.B7B]
M0<:W;<=WW@;&=+E29L#MM-9DB1-4T_5(Z)Y;9)G3&!-)>0("%VVGZU_W_,
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M^$%)I3' ]PLA]-O$+) W]-U_ %!+ P04    " !X@:92)5&@V+$"  #4!P
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M!SQ7696>G Q=D'V&6I0ANG1EE2.XU]\"PL%-#7NM]M M]WVJ4G,63Q17D6_
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M8(DKDC(YX[L?F ?4U'P+SA+S"[O\K&/!(DTDCW*P<A#1./LG;WDBC@!NXPS
MRP'>1P'U'% W@6;.3%AC(DF_*_@.A#ZMV/3 Y,:@530TUF4,I%"[5.%D?_ \
MF-X-AG>3VNW/62T8W$U@/!D^0C 9/<VFC]-) #4(LAH#7\%@2R@C<X8UU4*U
M@#"$,<XE!+A(!944$YCO8<1C*52%4L+@GDB]LX?+,4H%3JX4XU,PALN+*[@
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MT.YAM0>33(C5V&9MIW3__=I.2(%"NH?E /Z8]^;-V)ZAOQ;R1:6(&MY8QM7
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M39]PP]2T?I36P.PG0NC-Q#JH_DP,_P)02P,$%     @ >(&F4BE'_7+G P
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M)5)7[;6:6#7W'>I)6>IW?IC3C83:!=#W5"G[-G$_J.^X_E]02P,$%     @
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M'5X_17BA\ =IPB''U-;U)^Q7U?*N#2/73E)+:5"@;EO@BPC*!N!Y+J79&[9
M\\8FOP!02P,$%     @ >(&F4C"Z<+SC!@  T"<  !D   !X;"]W;W)K<VAE
M971S+W-H965T-34N>&ULQ5K;;MLX$/T5PEL4+;"IQ9MDMTX )T[;+)(T2-+V
MH=@'6:9M;75Q*3J713]^*5D1;8FDXZW2O"2^G!D=DC-GQB,-;E/^/9LS)L!=
M'"79?F<NQ.)MMYL%<Q;[V9MTP1+YS33EL2_D6S[K9@O._$EA%$==Y#AN-_;#
MI',P*#Z[X >#="FB,&$7'&3+./;Y_2&+TMO]#NP\?' 9SN8B_Z![,%CX,W;%
MQ.?%!9?ONI6721BS) O3!' VW>\,X=N1BW*# O$E9+?9VFN0+V6<IM_S-R>3
M_8Z3,V(1"T3NPI?_;M@1BZ+<D^3QHW3:J:Z9&ZZ_?O#^OEB\7,S8S]A1&GT-
M)V*^W^EUP(1-_64D+M/;CZQ<$,W]!6F4%7_!;8EU.B!89B*-2V/)( Z3U7__
MKMR(-0/I1V^ 2@-4-R & UP:X,<:D-* %#NS6DJQ#R-?^ <#GMX"GJ.EM_Q%
ML9F%M5Q^F.3G?B6X_#:4=N+@PZ=/HZ\GIZ=@>#X")^?7P_,/)X>GQV!X=75\
M?07VP-4J($ Z!2>)\)-9.(X8&&89$QEX-6+"#Z/LM01^OAJ!5R]>@Q<@3,!9
M&$7R6+-!5TB2^:6Z04GH<$4(&0AA<)8F8IZ!XV3")IOV7;FX:H7H886'R.KP
MKV7R!F#G3X <!#5\CNSF9SZ7YM!H/K*;CUA0F3N6U>#JO'#A#QO\O0^34+"]
M4YDL$\V!?#N5>' B6)S];;D:J:Y&BJL14W3P-,M>_@%=YQTX\CF_#Y,9&,;I
M,A&ZG5PY<PMGN>#<'"#BNNZ@>[.^81H4ZO6]"K7!E%9,J97I, B6\3+RA=P6
M29"+\%\_%Q8=S94GND9@SW,HK='4H.1:'#U-MZ+I6FE*K9)*E("C)><L">[!
M-?>3+"JH@N'D'YGP4E2UF^LV^#@UQDW$'M33]2JZGI7NN2P\CSAWKW%AZ+D0
MUNAI4"["KIYAKV+8L^;#B52)Z2HG(D-.O#J^"Z+E)%_"AS2=W$II>@V^#<>9
MX++JV-*D7Y'HMYDF_<9&$-C#]31IHG#?ZQG2!#I*[YW6$J5TM2U3=#!SJL"U
MT@2?*EE*S[9LT4!,Z0*1HHS:2)C2R\;A$J]7SQ@=#$-D2!FH:@C$6V+@QS+D
M>;)<7+[TX\6[D24)H"H6D#Q?+D)5":"]%.R8C; I]-"#7B-<-#"WUS<%N2H(
M\,DJ MQ>$JR03<:J)L!6B@+4507-ONK*@GE?55V /2O+M=CS5[''61#)E^$T
ME*$YY6DL&]5:P*Z0VM7TFFK1AR:6JG! >^7(3S_P,P%^RD9[G+$?2WG6X/@F
M__L3[)2G2)4 Y#Q?GB(E[\@N[Y?KY^$7<:3]O5"Z66\8H>,8MAXIJ49VJ:X'
MB/P)DZ73-!LO;T)N6Z"26?0[>G6D]!>UVJV7WC8RS_%0/4&WPC;9*IE&[77L
M2-.,4XB\.E4-C/0I,E!5&HV>3*/1=HVV0C89*XU&K6@T:HHOI7U<)ZA!>6[/
MP%$I-'K&UATI"49V"=XI#IM-N38.-3!S'&(EW-C>NVLDR[\+ W\L_!F36A*$
M41JQ9< BVZ1!"32&OT&_L%)D;%?D'?4+-[MC#\)Z=FE0+C)5#[PVAMG60C\^
M:DI7F[\T8+_^@T\/<ZB!JBH+V%X6?D&]<%/[&_MK@VPR5J4!VTO#(]4+-^6>
M]B&I$]2@G+YI5U5-P.[SJ1=60H_M0M]RFXN;4F_L<K%2>FSOQ7=*%DVCK4L6
M+<R8+*H:8'LUT$CL-4\G++JY!].4@_CZ_/#(-EE58D[L77A+DUREYL3>;N\Z
MRVV.1XCKU+-_&VJ3JZH$Q%X)=@D8TA3X/4A[=:(:E(L-/%45(/8J\ O22IIJ
MW]A<&V23\=I WUX,'BFMI*GJA!!4)ZA!46P841(E_X0^G[02I?#$WO7O%(2Z
MV7LS"#4H8Q"J$D!V*P%2LCZR1;X][*[0K(^C+[8-43).[ U[2XJEM)BT.E8G
MS:Z[1^JS:@W(D%-4*3EM;Z1.=2/U^IVG)L;$4:D_?;)9.MT^2[="-AFK&D!;
M&:73IK#W<#WQ-" 3/Z7]U#[=>5*5HDK0J5W0=PJ^IEXW@^_1_3Q=NS=K[^<_
MB3FSC=2HTF1J[[K;D2"JM)7:M75'":*:83;NUV_K:%&>Z0:XDF?:7I=-->TS
M=1NQH$,14S@H7:?;A][_5XML\EV2U@Q?#/?U7"7QKEWB'RE&;E.Y>ZC^@U0'
M,MT&=Y7 N_9AS9/*D:M4VVVO<R]=N?8@U*(:0=A=>P0J9GQ6/$J6@2 _J=73
M4-6GU>-JP^(AK:Z"KYYU._/Y+$PR$+&I-'7>>/*D^.KQL=4;D2Z*!ZK&J1!I
M7+R<,W_"> Z0WT_35#R\R2]0/<1W\!]02P,$%     @ >(&F4E?/1:^# @
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MLC0E\O4<F=CT',]Y7[BCJT3;!;??79,5SE _K&^EF;F5EYBFR!45'"0N>\[
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MA"R6F?F'H;0 \WXIA'[?V#%9_Q4'_P!02P,$%     @ >(&F4GHH^&JY @
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MJ;M(40[M0 ?0% +!%Z7-(-76L=K,S/,T@ DH^_4;3V6^%/R'W01X")*M9Q+
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M+]]L^7$O-VKR'A4"^W($X$OX)#D"."3'\- ^#:XQ#1P;$V%2D G1,0\ 03*
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M*>^QYJ,'WE+*=^<'D)</*N6=N7MD*>_:PE-YXC1)*<\!COSTI7R/21TCFW.
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M$U>$>_WM-.LR>',\K5X=UO1XK*X%:Z<H42$ * 5'%>"W3 @P4H6N,$GD42+
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M 4_G1_9//G?*9<L,3I3XQC.;#X./ 62X8Y6P*W6XPR:?&\>7*F'\%PY-;">
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M_ARHK -]3Z0T1\,&J/Y%_;]02P,$%     @ >(&F4EQG4C(L @  * 4  !D
M  !X;"]W;W)K<VAE971S+W-H965T-S N>&ULC53;CILP$/T5"ZE2*[6! +VM
M"%)N5?.0-MIL+U+5!P>&8*VQJ3V4].]K&T+3*$G[ AY[SCDSXQDGK52/N@1
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MM/6\2 _UZ:$^SLN'C*H/%L?OD]C+O](DB:(XQC(Z&GD5C+"\Q3%\_6R8-O#
MXD"D/\LU7FV\0P[W 5;30QV"K13O1&RE>*X!\><-/)+$7VTL#GA@5<!Z!^+[
MXT!/^7VB"*J*:</>8!Q)$@R!7O3W:!PCV8GAXZ\/]I9$49+X$<#\"J((0^!M
MQ!%, 6C D"BJ]L&]_2A<[U/AYO>OX6]02P,$%     @ >(&F4I>*NQS
M$P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B
M#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z1
M0J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ
M0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?V
MD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !X@:92
MK@T72X@%   M+P  #P   'AL+W=O<FMB;V]K+GAM;,6:6W.C-A2 _XK&+TT?
M4MO<LIN)=T8&G&B*(07L=I\ZQ)8=NABR B?=_?45>-T<4N=,7\[XR>$RY$,2
M^HZ.SLU+I;X\5-47]O>N*.O)X+%IGJZ'PWKU*'=9_4OU)$M]95.I7=;H0[4=
MUD]*9NOZ4<IF5PR-T<@9[K*\''RZ.3[K7@WA0=7(59-7I3[9GECF\J5^O=X>
MLN>\SA_R(F^^30;=WX4<L%U>YKO\NUQ/!J,!JQ^KE[M*Y=^KLLF*9*6JHI@,
MQH<+2ZF:?/6?TTD+F68/=7>FR1[B3(-,!LY(/W"3J[KI[NB>GVG&9ZEO/ASM
MFVJ6%XU47M;(6U7MG_)RVSY&O\40O$;7#L??0R->J__3C-5FDZ^D5ZWV.UDV
MAW94LF@!R_HQ?ZH'K,QV<C)PJV>IV'VVE>U+Z?\BUH<7;#09:"YUG>L+2JP[
M1D*>*/3\,/$]IO]*HD!X/-4'4Q[PT/49@#002..,D'\: -)$(,VS0":I_IG[
M(8"T$$CKC)"]EK012/N<D": =!!(YYR0%H"\0B"OS@EI \@/".0'6LAD,9_S
M^#.+9BP1MZ&8"9>'*>.N&RW"5 #(CPCD1UK(V%_ZX<)/X*P]PJ;M$2W/C(N8
M+7FP\-G<Y\DB;N>8M(>'6H58*WS)1<"G@7\YB^++A <^\_QIRA+?7<0BA9B8
M5\;$8O'\6"QY*I8^FXE0RT3P@(DP2>-%VYP0$S/+F%@MW/UM(1*1"OT10R9,
M)&-BD]Q&D?>[" +&0T\W6<K#6Z'[F_$D\?OC$#/)F%@E47KGQ[V^U>-QSMN6
MA(B81\;D(@GTEQ+%'532->>!FL>Q;E2(B9ED3*R2[O-MX=S8]T3*9MP5@1Z2
M_2D1T\B8V"-N-)^+M)L&#Z"1MD=XZ^N>[T-B&AD3>R1)(_?7NRC0,T_R$_/U
M=YU^AD$VYA2#V"FAG^H/1#>CS^[U^$ON>*R_YS2-Q721\BG$Q-QB$+OE!V+*
M_^AUJX$N4(A%DBRFB>Y,/?98&RA <QB8.0QB<Z"Q52_>-S"9&,0R.497[$(O
MV0M9_PS!,'\8Q/YX)\PZ<D),S"$&L4/0<*O?S9A##'*'(.%6'Q,3B4$L$AAN
MG1R1F$ ,8H'@<1=,V)B82TQBER"!5]ND$!-SB4GLDO>CFJ[C(2:F%Y-:+R>B
MAE,CTT3S7\2N0<.'?I8.<XU)[!H8/IQL0\PW)K%O<%_#U)>)^<8D]LV_OKYD
M7EYGVZV2V^XN5FU8#%/;)N8;D]@W #.6S[+<RYIM5+5C\^RO2O7F2LPW)K%O
M "9?K_/V>E8P41X>ED-,S#PFL7G>BX4N6;+?[>"4;F'FL<Z3&3M@]J8A"S./
M16R>]S&[,0 Q,?-8Q.9Y']/_NN]C8NZQJ#-D:  ,YTT+W7TA=@^."3<-+,Q"
M%K&%<$RX;6!A%K+.NNIQ("9F(>NLJY[>V,0L9!%;",?LC4W,0A:QA7!,.#9M
MS$(VL85P3#@V;<Q"-O4^#5SJ7K(P4RIK*R?8A2>;#(8>-F8AF]A";S 3_<CU
MOI!MM#G+<@4Q,0O9Q!9"U^;]W77,0O8YMVYZ$Y*-5@$06PC'A!.2C5G()K80
MCMF;D# +V<06PA(R.N:$F)B%;&(+X9BP&,#&+&036PC'C&")"F8AA]A"Z-YB
M;T)R, LYY\O"M:LVB(E9R"&O%D P^1IB8A9RR O1D'U0=@$Q,0LYQ!8ZF=-\
MS8! 3,Q"#G5&[C1FE_)0WV .R4&KT8@MA"=?>S5SF(4<8@OAF-#I#F8AA]A"
MO1SQ:V?K<+-YE.P>8F(6<H@M] ;S;?(0UB!B%KHBMM#;S?$?BXNBEW:_P@1T
M=:C4[FZN/]VLY28OY3K43Z_U^556K.X5:W\.%666W=9X;/9%X>IS41E4V?I8
M[7VL5/_T#U!+ P04    " !X@:92L 4 O38"   <*@  &@   'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QSS=I+;J- %(7AK5@L(+CNBZ059]233*-L #GE
MAV(;1-%*LONVG(%]4 ]Z$G%&J$!<?C'XA(#'EWQHQWUW*KM]7Q:?Q\.IK*K=
M./:_ZKJL=_G8EKNNSZ?SD4TW'-OQO!RV==^NW]MMKF6YC'JXG5$]/=[.7+Q^
M]?E_)G:;S7Z=?W?K/\=\&O\QN/[HAO>RRWFL%J_ML,WCJJH_#]?=I;YLTMUY
M<K5X?EM5P_-;JNJY@P2"9/X@A2"=/\@@R.8/<@CR^8,"@F+^H :"FOF#[B'H
M?OZ@!PAZF#\H+5'&)4'2!&L"K1-RG0B\3@AV(A [(=F)P.R$:"<"M1.RG0C<
M3@AW(I [(=V)P.Z$>"<"O07U%@*]!?46 KUE\K!-H+>@WD*@MZ#>0J"WH-Y"
MH+>@WD*@MZ#>0J"WH-Y"H+>@WD*@MZ+>2J"WHMY*H+>BWDJ@MTY>EA#HK:BW
M$NBMJ+<2Z*VHMQ+HK:BW$NBMJ+<2Z*VHMQ+H;:BW$>AMJ+<1Z&VHMQ'H;:BW
M$>AMDY?=!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z.^KM!'H[ZNT$>COJ
M[01Z.^KM!'H[ZNT$>OOD8R6!WHYZ.X'>CGH[@=Z.>CN!WHYZ.X'>@7H'@=Z!
M>@>!WH%Z!X'>@7H'@=Z!>@>!WH%Z!X'>,?G9A$#O0+V#0.] O8- [T"]@T#O
M!O5N"/1N4._F)_4NX]<AEVO/]QJO_Y-4C^=S\_7RE^7WSLE-N.!<WU:4I[]0
M2P,$%     @ >(&F4N'+1LC] 0  /2D  !,   !;0V]N=&5N=%]4>7!E<UTN
M>&ULS=I-3L,P$ 7@JU39HL;U;P%1-L 66' !DTS;J$ELV0;*[7%20 )!!2H2
M;].HM3UOXI&^5<_NGCW%R;9K^[@HUBGY4\9BM:;.QM)YZO/*TH7.IOPUK)BW
MU<:NB(G9S+#*]8GZ-$U#C>+\[)*6]J%-DZMM_CDVKE\4@=I83"YV&X>L16&]
M;YO*IKS.'OOZ4\KT-:',)\<]<=WX>)0W%.S+A&'E^X#7<S>/%$)3T^36AG1M
MN[R+;5L6TW-+L=Q?XHL>W7+95%2[ZJ'+1\KH ]DZKHE2UY:[HD?[DU.^8=I]
M\H/SQS+[ O/.V^!\S!,+]/NXMY$,IZ<^%Z*0FOVO^)Z82Q_\?C1,NZ;ZA]GY
M>I]<V(SSB&Q\''[''V?\7O^7?0B0/B1('PJD#PW2AP'I8P[2QS%('R<@?? 9
M2B,HHG(44CF*J1P%58ZB*D=AE:.XRE%@Y2BR"A19!8JL D56@2*K0)%5H,@J
M4&05*+(*%%D%BJP215:)(JM$D56BR"I19)4HLDH4626*K!)%5HDBJT*15:'(
MJE!D52BR*A19%8JL"D56A2*K0I%5H<BJ4635*+)J%%DUBJP:15:-(JM&D56C
MR*I19-4HLAH460V*K 9%5H,BJT&1U:#(:E!D-2BR&A19#8JL<Q19Y_\IZ[US
MFS^.'Y]E9YO^+9^-_YH\?P%02P$"% ,4    " !X@:92!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M 'B!IE(G0J=,[@   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( 'B!IE*97)PC$ 8  )PG   3
M  "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ >(&F4M3"
MAF%#!0  >A4  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( 'B!IE+:+*\+708   \:   8
M  " @88-  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !X
M@:92FT^2I;X"  #G"   &               @($9%   >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ >(&F4DIH5, B!0  (A0  !@
M         ("!#1<  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( 'B!IE*&Z(#%_0,  -4-   8              " @64<  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !X@:928[E"0&<&  "X'0
M&               @(&8(   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ >(&F4N%P4'!] @  8 4  !@              ("!-2<  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( 'B!IE)^V5/<OP8
M +$<   8              " @>@I  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    " !X@:924UM%P#4,  #&'@  &               @('=
M,   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ >(&F4M44
MQ=2K"0  AQ8  !D              ("!2#T  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    " !X@:926N\B/%T-   Z*0  &0
M    @($J1P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M 'B!IE*Y]+4T=P0   L+   9              " @;Y4  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ >(&F4C$[3L.="   /1L  !D
M             ("!;%D  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    " !X@:92ISAVY^ *   S'@  &0              @(% 8@  >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( 'B!IE*'9>?".@8
M .@.   9              " @5=M  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ >(&F4DV"I'.Y P  M @  !D              ("!
MR',  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " !X@:92
M93QMV5P+   %(0  &0              @(&X=P  >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( 'B!IE*H6> ANP4  (T/   9
M      " @4N#  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ >(&F4CW092DD(0  L&L  !D              ("!/8D  'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !X@:92E0:X:J$%  #^#@
M&0              @(&8J@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( 'B!IE*!UG%)_P,  *\*   9              " @7"P  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ >(&F4O/])*69
M!   0@H  !D              ("!IK0  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    " !X@:92_T82H^D"   >!@  &0
M@(%VN0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( 'B!
MIE(OPO,EKQ   "DN   9              " @9:\  !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ >(&F4B5T1>!1!P  )!   !D
M         ("!?,T  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M    " !X@:92@;;9_T0%  #<#@  &0              @($$U0  >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( 'B!IE+68]VW.00  "T+
M   9              " @7_:  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L! A0#%     @ >(&F4BH 4_+=!   LP\  !D              ("![]X
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " !X@:92D9-S
M0',#   %"   &0              @($#Y   >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+ 0(4 Q0    ( 'B!IE)_HL0(- 8  +86   9
M  " @:WG  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
M>(&F4O:X;]3M P  E D  !D              ("!&.X  'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    " !X@:92[X8Z$Z$$   L#   &0
M            @($\\@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( 'B!IE(VGM&'@ ,  '8(   9              " @13W  !X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ >(&F4BX<5OTA P
M&P<  !D              ("!R_H  'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    " !X@:92D_"TT7P"  !)!0  &0              @($C
M_@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( 'B!IE(>
M N<<? (  +4%   9              " @=8  0!X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ >(&F4I1F>X/W%   );P  !D
M     ("!B0,! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
M" !X@:92 R@;QL4"  #W"   &0              @(&W& $ >&PO=V]R:W-H
M965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( 'B!IE+V ;)5^ (  &,(   9
M              " @;,; 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L!
M A0#%     @ >(&F4M32+V4O"P  Z%@  !D              ("!XAX! 'AL
M+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " !X@:92BJG2B0$#
M  "5"0  &0              @(%(*@$ >&PO=V]R:W-H965T<R]S:&5E=#0Q
M+GAM;%!+ 0(4 Q0    ( 'B!IE) >;2E"P0  -P/   9              "
M@8 M 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ >(&F
M4B51H-BQ @  U <  !D              ("!PC$! 'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    " !X@:92VA7!;;($  "S%P  &0
M        @(&J- $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( 'B!IE*<#Z9#S@(  ,<(   9              " @9,Y 0!X;"]W;W)K
M<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ >(&F4BC=60?@ @  E0<
M !D              ("!F#P! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"% ,4    " !X@:92_@2MJ=X"  !["   &0              @(&O/P$
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( 'B!IE((2]^$
M @,  %@(   9              " @<1" 0!X;"]W;W)K<VAE971S+W-H965T
M-#@N>&UL4$L! A0#%     @ >(&F4BE'_7+G P  61,  !D
M ("!_44! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " !X
M@:92G7#3<.P"  #O!@  &0              @($;2@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( 'B!IE(IW[)1B0,  !4-   9
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M970U-2YX;6Q02P$"% ,4    " !X@:925\]%KX,"  !T!0  &0
M    @('M9 $ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    (
M 'B!IE*_,=)AQ (  & '   9              " @:=G 0!X;"]W;W)K<VAE
M971S+W-H965T-3<N>&UL4$L! A0#%     @ >(&F4GTPIU*Q @  (0<  !D
M             ("!HFH! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"
M% ,4    " !X@:92>BCX:KD"  !\!P  &0              @(&*;0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( 'B!IE+MITNXP@(
M "4'   9              " @7IP 0!X;"]W;W)K<VAE971S+W-H965T-C N
M>&UL4$L! A0#%     @ >(&F4D[R-&$G!0  [A4  !D              ("!
M<W,! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " !X@:92
MH4DOF/H(  "//0  &0              @('1> $ >&PO=V]R:W-H965T<R]S
M:&5E=#8R+GAM;%!+ 0(4 Q0    ( 'B!IE)U?$$XU ,  !T.   9
M      " @0*" 0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%
M  @ >(&F4O*!(BP-!@  UQH  !D              ("!#88! 'AL+W=O<FMS
M:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " !X@:92][,GCB #  #?"0
M&0              @(%1C $ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+
M 0(4 Q0    ( 'B!IE(I^1%F)@4  /H7   9              " @:B/ 0!X
M;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ >(&F4HV,N\2(
M @  B 4  !D              ("!!94! 'AL+W=O<FMS:&5E=',O<VAE970V
M-RYX;6Q02P$"% ,4    " !X@:92X/DWUW(#  #'"0  &0
M@('$EP$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( 'B!
MIE+S5NY2D0(  )<&   9              " @6V; 0!X;"]W;W)K<VAE971S
M+W-H965T-CDN>&UL4$L! A0#%     @ >(&F4EQG4C(L @  * 4  !D
M         ("!-9X! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"% ,4
M    " !X@:92P:J.NTT"  #G!   &0              @(&8H $ >&PO=V]R
M:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( 'B!IE)K?-E1-P,   P3
M   -              "  1RC 0!X;"]S='EL97,N>&UL4$L! A0#%     @
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H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !/ $\ H!4  +BQ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>594</ContextCount>
  <ElementCount>396</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>149</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/REVENUES</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2109103 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2115104 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIES</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2121105 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2127106 - Disclosure - ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ACQUISITIONS</Role>
      <ShortName>ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2131107 - Disclosure - GOODWILL AND INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2137108 - Disclosure - OTHER FINANCIAL INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OTHERFINANCIALINFORMATION</Role>
      <ShortName>OTHER FINANCIAL INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2142109 - Disclosure - COLLABORATIONS AND OTHER ARRANGEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTS</Role>
      <ShortName>COLLABORATIONS AND OTHER ARRANGEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2144110 - Disclosure - DEBT AND CREDIT FACILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DEBTANDCREDITFACILITIES</Role>
      <ShortName>DEBT AND CREDIT FACILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2148111 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2150112 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2154113 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS</Role>
      <ShortName>NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2158114 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2162115 - Disclosure - SUBSEQUENT EVENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/SUBSEQUENTEVENT</Role>
      <ShortName>SUBSEQUENT EVENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/REVENUESTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/REVENUES</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESTables</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIES</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2328305 - Disclosure - ACQUISITIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ACQUISITIONSTables</Role>
      <ShortName>ACQUISITIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/ACQUISITIONS</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2332306 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2338307 - Disclosure - OTHER FINANCIAL INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables</Role>
      <ShortName>OTHER FINANCIAL INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/OTHERFINANCIALINFORMATION</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2345308 - Disclosure - DEBT AND CREDIT FACILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables</Role>
      <ShortName>DEBT AND CREDIT FACILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/DEBTANDCREDITFACILITIES</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2351309 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2355310 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables</Role>
      <ShortName>NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2359311 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/INCOMETAXES</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - REVENUES - Disaggregation of Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails</Role>
      <ShortName>REVENUES - Disaggregation of Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - REVENUES - Revenues from Major Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails</Role>
      <ShortName>REVENUES - Revenues from Major Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - REVENUES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/REVENUESAdditionalInformationDetails</Role>
      <ShortName>REVENUES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Classification of Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Summary of Classification of Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - FAIR VALUE MEASUREMENTS - Equity Investment In Galapagos (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Equity Investment In Galapagos (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2420412 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2424414 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2425415 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2426416 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Potential Effect of Offsetting Derivatives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Potential Effect of Offsetting Derivatives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2429417 - Disclosure - ACQUISITIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ACQUISITIONSNarrativeDetails</Role>
      <ShortName>ACQUISITIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2430418 - Disclosure - ACQUISITIONS - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>ACQUISITIONS - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2433419 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2434420 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS - Summary of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2435421 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2436422 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2439423 - Disclosure - OTHER FINANCIAL INFORMATION - Accounts Receivable, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Accounts Receivable, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2440424 - Disclosure - OTHER FINANCIAL INFORMATION - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2441425 - Disclosure - OTHER FINANCIAL INFORMATION - Other Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Other Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2443426 - Disclosure - COLLABORATIONS AND OTHER ARRANGEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails</Role>
      <ShortName>COLLABORATIONS AND OTHER ARRANGEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTS</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails</Role>
      <ShortName>DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2447428 - Disclosure - DEBT AND CREDIT FACILITIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails</Role>
      <ShortName>DEBT AND CREDIT FACILITIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2449429 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2452430 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2453431 - Disclosure - STOCKHOLDERS' EQUITY - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2456432 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails</Role>
      <ShortName>NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2457433 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Schedule of the Calculation of Basic and Diluted EPS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails</Role>
      <ShortName>NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Schedule of the Calculation of Basic and Diluted EPS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2460434 - Disclosure - INCOME TAXES - Summary of the Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/INCOMETAXESSummaryoftheProvisionforIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES - Summary of the Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2461435 - Disclosure - INCOME TAXES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails</Role>
      <ShortName>INCOME TAXES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="gild-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2463436 - Disclosure - SUBSEQUENT EVENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/SUBSEQUENTEVENTDetails</Role>
      <ShortName>SUBSEQUENT EVENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/SUBSEQUENTEVENT</ParentRole>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="gild-20210331.htm">gild-20210331.htm</File>
    <File>gild-20210331.xsd</File>
    <File>gild-20210331_cal.xml</File>
    <File>gild-20210331_def.xml</File>
    <File>gild-20210331_lab.xml</File>
    <File>gild-20210331_pre.xml</File>
    <File>gildq12021ex10162021psuagr.htm</File>
    <File>gildq12021ex10192021psuagr.htm</File>
    <File>gildq12021ex10242021employ.htm</File>
    <File>gildq12021ex1072021employe.htm</File>
    <File>gildq12021ex311ceocertific.htm</File>
    <File>gildq12021ex312cfocertific.htm</File>
    <File>gildq12021ex32section906ce.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>91
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "gild-20210331.htm": {
   "axisCustom": 1,
   "axisStandard": 33,
   "contextCount": 594,
   "dts": {
    "calculationLink": {
     "local": [
      "gild-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gild-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "gild-20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gild-20210331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gild-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "gild-20210331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 617,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 38,
   "keyStandard": 358,
   "memberCustom": 96,
   "memberStandard": 47,
   "nsprefix": "gild",
   "nsuri": "http://www.gilead.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.gilead.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - REVENUES",
     "role": "http://www.gilead.com/role/REVENUES",
     "shortName": "REVENUES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109103 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://www.gilead.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115104 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIES",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121105 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS",
     "role": "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127106 - Disclosure - ACQUISITIONS",
     "role": "http://www.gilead.com/role/ACQUISITIONS",
     "shortName": "ACQUISITIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131107 - Disclosure - GOODWILL AND INTANGIBLE ASSETS",
     "role": "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137108 - Disclosure - OTHER FINANCIAL INFORMATION",
     "role": "http://www.gilead.com/role/OTHERFINANCIALINFORMATION",
     "shortName": "OTHER FINANCIAL INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gild:CollaborativeAndOtherArrangementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142109 - Disclosure - COLLABORATIONS AND OTHER ARRANGEMENTS",
     "role": "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTS",
     "shortName": "COLLABORATIONS AND OTHER ARRANGEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gild:CollaborativeAndOtherArrangementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144110 - Disclosure - DEBT AND CREDIT FACILITIES",
     "role": "http://www.gilead.com/role/DEBTANDCREDITFACILITIES",
     "shortName": "DEBT AND CREDIT FACILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148111 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150112 - Disclosure - STOCKHOLDERS' EQUITY",
     "role": "http://www.gilead.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2154113 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS",
     "role": "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS",
     "shortName": "NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2158114 - Disclosure - INCOME TAXES",
     "role": "http://www.gilead.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2162115 - Disclosure - SUBSEQUENT EVENT",
     "role": "http://www.gilead.com/role/SUBSEQUENTEVENT",
     "shortName": "SUBSEQUENT EVENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - REVENUES (Tables)",
     "role": "http://www.gilead.com/role/REVENUESTables",
     "shortName": "REVENUES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES (Tables)",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESTables",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS (Tables)",
     "role": "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328305 - Disclosure - ACQUISITIONS (Tables)",
     "role": "http://www.gilead.com/role/ACQUISITIONSTables",
     "shortName": "ACQUISITIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332306 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)",
     "role": "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338307 - Disclosure - OTHER FINANCIAL INFORMATION (Tables)",
     "role": "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables",
     "shortName": "OTHER FINANCIAL INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345308 - Disclosure - DEBT AND CREDIT FACILITIES (Tables)",
     "role": "http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables",
     "shortName": "DEBT AND CREDIT FACILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2351309 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "role": "http://www.gilead.com/role/STOCKHOLDERSEQUITYTables",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2355310 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS (Tables)",
     "role": "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables",
     "shortName": "NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2359311 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://www.gilead.com/role/INCOMETAXESTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - REVENUES - Disaggregation of Revenues (Details)",
     "role": "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails",
     "shortName": "REVENUES - Disaggregation of Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i027a876acd5948e39aaa2a168d3de1fa_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i0bd483f628534e979ee1ef8021838fb8_D20210101-20210331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - REVENUES - Revenues from Major Customers (Details)",
     "role": "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails",
     "shortName": "REVENUES - Revenues from Major Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i0bd483f628534e979ee1ef8021838fb8_D20210101-20210331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - REVENUES - Additional Information (Details)",
     "role": "http://www.gilead.com/role/REVENUESAdditionalInformationDetails",
     "shortName": "REVENUES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details)",
     "role": "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "id8330bb360aa481b97cd6a1b14847b1d_I20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i775975dd06c34a91977a0d26c3c7aad3_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Classification of Equity Securities (Details)",
     "role": "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Summary of Classification of Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i775975dd06c34a91977a0d26c3c7aad3_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details)",
     "role": "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i9ccba16f84d64786acebdc56d30d2961_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - FAIR VALUE MEASUREMENTS - Equity Investment In Galapagos (Details)",
     "role": "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Equity Investment In Galapagos (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i9ccba16f84d64786acebdc56d30d2961_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i2408fe312f9e4448b357064015614afc_I20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Additional Information (Details)",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420412 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details)",
     "role": "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424414 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details)",
     "role": "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425415 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details)",
     "role": "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426416 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Potential Effect of Offsetting Derivatives (Details)",
     "role": "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Potential Effect of Offsetting Derivatives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "idc1e9ade6e414ced9c63b109438a49e7_D20201001-20201231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromLongTermLinesOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429417 - Disclosure - ACQUISITIONS - Narrative (Details)",
     "role": "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
     "shortName": "ACQUISITIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "idc1e9ade6e414ced9c63b109438a49e7_D20201001-20201231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromLongTermLinesOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i3a98f90b07b94f6c86e128d20787701b_I20210304",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430418 - Disclosure - ACQUISITIONS - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "ACQUISITIONS - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i3a98f90b07b94f6c86e128d20787701b_I20210304",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "if18ad61a4d694b84a567b29c22cd074c_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433419 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)",
     "role": "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434420 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Intangible Assets (Details)",
     "role": "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS - Summary of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435421 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details)",
     "role": "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436422 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense (Details)",
     "role": "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439423 - Disclosure - OTHER FINANCIAL INFORMATION - Accounts Receivable, Net (Details)",
     "role": "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails",
     "shortName": "OTHER FINANCIAL INFORMATION - Accounts Receivable, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440424 - Disclosure - OTHER FINANCIAL INFORMATION - Inventories (Details)",
     "role": "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails",
     "shortName": "OTHER FINANCIAL INFORMATION - Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "ie0e06ce8778849a79902920387c413c1_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "ie0e06ce8778849a79902920387c413c1_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441425 - Disclosure - OTHER FINANCIAL INFORMATION - Other Accrued Liabilities (Details)",
     "role": "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails",
     "shortName": "OTHER FINANCIAL INFORMATION - Other Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i9bba91958aca44f293ca49c63fbaafef_D20210313-20210313",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443426 - Disclosure - COLLABORATIONS AND OTHER ARRANGEMENTS (Details)",
     "role": "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails",
     "shortName": "COLLABORATIONS AND OTHER ARRANGEMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i9bba91958aca44f293ca49c63fbaafef_D20210313-20210313",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details)",
     "role": "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails",
     "shortName": "DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i857e1d9466cc45c0ad66d0661626a0bd_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "-7",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447428 - Disclosure - DEBT AND CREDIT FACILITIES - Additional Information (Details)",
     "role": "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
     "shortName": "DEBT AND CREDIT FACILITIES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "-7",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i9e2d7de5386e4c88ab9f4aaa94c77fe9_D20191201-20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449429 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "role": "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i9e2d7de5386e4c88ab9f4aaa94c77fe9_D20191201-20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "gild:LossContingencyPatentsAllegedlyInfringedNumberScenarioOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452430 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)",
     "role": "http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "if18ad61a4d694b84a567b29c22cd074c_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453431 - Disclosure - STOCKHOLDERS' EQUITY - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Summary of Changes in Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i3f56585e4ce041a0a4818371afd20608_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456432 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Additional Information (Details)",
     "role": "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails",
     "shortName": "NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457433 - Disclosure - NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Schedule of the Calculation of Basic and Diluted EPS (Details)",
     "role": "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails",
     "shortName": "NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS - Schedule of the Calculation of Basic and Diluted EPS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460434 - Disclosure - INCOME TAXES - Summary of the Provision for Income Taxes (Details)",
     "role": "http://www.gilead.com/role/INCOMETAXESSummaryoftheProvisionforIncomeTaxesDetails",
     "shortName": "INCOME TAXES - Summary of the Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461435 - Disclosure - INCOME TAXES - Additional Information (Details)",
     "role": "http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails",
     "shortName": "INCOME TAXES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i00cafa1b2c044278a85e4d45db30d3b1_D20210401-20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463436 - Disclosure - SUBSEQUENT EVENT (Details)",
     "role": "http://www.gilead.com/role/SUBSEQUENTEVENTDetails",
     "shortName": "SUBSEQUENT EVENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "i00cafa1b2c044278a85e4d45db30d3b1_D20210401-20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20210331.htm",
      "contextRef": "iaacdf45eb5fe4ea3902e8b0178bdedaa_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 149,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol(s)"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.15% LIBOR Senior Unsecured Notes Due September 2021",
        "label": "0.15% LIBOR Senior Unsecured Notes Due September 2021 [Member]",
        "terseLabel": "0.15% LIBOR Senior Unsecured Notes Due September 2021"
       }
      }
     },
     "localname": "A015LIBORSeniorUnsecuredNotesDueSeptember2021Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.52% LIBOR Senior Unsecured Notes Due September 2023",
        "label": "0.52% LIBOR Senior Unsecured Notes Due September 2023 [Member]",
        "terseLabel": "0.52% LIBOR Senior Unsecured Notes Due September 2023"
       }
      }
     },
     "localname": "A052LIBORSeniorUnsecuredNotesDueSeptember2023Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A075SeniorUnsecuredNotesDueSeptember2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.75% Senior Unsecured Notes Due in September 2023 [Member]",
        "label": "0.75% Senior Unsecured Notes Due September 2023 [Member]",
        "terseLabel": "0.75% Senior Unsecured Notes Due September 2023"
       }
      }
     },
     "localname": "A075SeniorUnsecuredNotesDueSeptember2023Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A120SeniorUnsecuredNotesDueOctober2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.20% Senior Unsecured Notes Due October 2027",
        "label": "1.20% Senior Unsecured Notes Due October 2027 [Member]",
        "terseLabel": "1.20% Senior Unsecured Notes Due October 2027"
       }
      }
     },
     "localname": "A120SeniorUnsecuredNotesDueOctober2027Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A165SeniorUnsecuredNotesDueOctober2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.65% Senior Unsecured Notes Due October 2030",
        "label": "1.65% Senior Unsecured Notes Due October 2030 [Member]",
        "terseLabel": "1.65% Senior Unsecured Notes Due October 2030"
       }
      }
     },
     "localname": "A165SeniorUnsecuredNotesDueOctober2030Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A195SeniorUnsecuredNotesDueMarch2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.95% Senior Unsecured Notes Due March 2022 [Member]",
        "label": "1.95% Senior Unsecured Notes Due March 2022 [Member]",
        "terseLabel": "1.95% Senior Unsecured Notes Due March 2022"
       }
      }
     },
     "localname": "A195SeniorUnsecuredNotesDueMarch2022Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A2016StockRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Stock Repurchase Program [Member]",
        "label": "2016 Stock Repurchase Program [Member]",
        "terseLabel": "2016 Stock Repurchase Program"
       }
      }
     },
     "localname": "A2016StockRepurchaseProgramMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A2020StockRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Stock Repurchase Program [Member]",
        "label": "2020 Stock Repurchase Program [Member]",
        "terseLabel": "2020 Stock Repurchase Program"
       }
      }
     },
     "localname": "A2020StockRepurchaseProgramMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A250SeniorUnsecuredNotesDueSeptember2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.50% Senior Unsecured Notes Due September 2023",
        "label": "2.50% Senior Unsecured Notes Due September 2023 [Member]",
        "terseLabel": "2.50% Senior Unsecured Notes Due September 2023"
       }
      }
     },
     "localname": "A250SeniorUnsecuredNotesDueSeptember2023Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A260SeniorUnsecuredNotesDueOctober2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.60% Senior Unsecured Notes Due October 2040",
        "label": "2.60% Senior Unsecured Notes Due October 2040 [Member]",
        "terseLabel": "2.60% Senior Unsecured Notes Due October 2040"
       }
      }
     },
     "localname": "A260SeniorUnsecuredNotesDueOctober2040Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A280SeniorUnsecuredNotesDueOctober2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.80% Senior Unsecured Notes Due October 2050",
        "label": "2.80% Senior Unsecured Notes Due October 2050 [Member]",
        "terseLabel": "2.80% Senior Unsecured Notes Due October 2050"
       }
      }
     },
     "localname": "A280SeniorUnsecuredNotesDueOctober2050Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A295SeniorUnsecuredNotesDueMarch2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.95% Senior Unsecured Notes Due March 2027 [Member]",
        "label": "2.95% Senior Unsecured Notes Due March 2027 [Member]",
        "terseLabel": "2.95% Senior Unsecured Notes Due March 2027"
       }
      }
     },
     "localname": "A295SeniorUnsecuredNotesDueMarch2027Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A325SeniorUnsecuredNotesDueSeptember2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.25% Senior Unsecured Notes Due September 2022",
        "label": "3.25% Senior Unsecured Notes Due September 2022 [Member]",
        "terseLabel": "3.25% Senior Unsecured Notes Due September 2022"
       }
      }
     },
     "localname": "A325SeniorUnsecuredNotesDueSeptember2022Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A350SeniorUnsecuredNotesDueFebruary2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.50% Senior Unsecured Notes Due February 2025 [Member]",
        "label": "3.50% Senior Unsecured Notes Due February 2025 [Member]",
        "terseLabel": "3.50% Senior Unsecured Notes Due February 2025"
       }
      }
     },
     "localname": "A350SeniorUnsecuredNotesDueFebruary2025Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A365SeniorUnsecuredNotesDueMarch2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.65% Senior Unsecured Notes Due March 2026",
        "label": "3.65% Senior Unsecured Notes Due March 2026 [Member]",
        "terseLabel": "3.65% Senior Unsecured Notes Due March 2026"
       }
      }
     },
     "localname": "A365SeniorUnsecuredNotesDueMarch2026Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A370SeniorUnsecuredNotesDueApril2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.70% Senior Unsecured Notes Due April 2024 [Member]",
        "label": "3.70% Senior Unsecured Notes Due April 2024 [Member]",
        "terseLabel": "3.70% Senior Unsecured Notes Due April 2024"
       }
      }
     },
     "localname": "A370SeniorUnsecuredNotesDueApril2024Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A400SeniorUnsecuredNotesDueSeptember2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.00% Senior Unsecured Notes Due September 2036",
        "label": "4.00% Senior Unsecured Notes Due September 2036 [Member]",
        "terseLabel": "4.00% Senior Unsecured Notes Due September 2036"
       }
      }
     },
     "localname": "A400SeniorUnsecuredNotesDueSeptember2036Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A415SeniorUnsecuredNotesDueMarch2047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.15% Senior Unsecured Notes Due March 2047 [Member]",
        "label": "4.15% Senior Unsecured Notes Due March 2047 [Member]",
        "terseLabel": "4.15% Senior Unsecured Notes Due March 2047"
       }
      }
     },
     "localname": "A415SeniorUnsecuredNotesDueMarch2047Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A440SeniorUnsecuredNotesDueDecember2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.40% Senior Unsecured Notes Due December 2021",
        "label": "4.40% Senior Unsecured Notes Due December 2021 [Member]",
        "terseLabel": "4.40% Senior Unsecured Notes Due December 2021"
       }
      }
     },
     "localname": "A440SeniorUnsecuredNotesDueDecember2021Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A450SeniorUnsecuredNotesDueApril2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Senior Unsecured Notes Due April 2021 [Member]",
        "label": "4.50% Senior Unsecured Notes Due April 2021 [Member]",
        "terseLabel": "4.50% Senior Unsecured Notes Due April 2021"
       }
      }
     },
     "localname": "A450SeniorUnsecuredNotesDueApril2021Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A450SeniorUnsecuredNotesDueFebruary2045Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Senior Unsecured Notes Due February 2045 [Member]",
        "label": "4.50% Senior Unsecured Notes Due February 2045 [Member]",
        "terseLabel": "4.50% Senior Unsecured Notes Due February 2045"
       }
      }
     },
     "localname": "A450SeniorUnsecuredNotesDueFebruary2045Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A460SeniorUnsecuredNotesDueSeptember2035Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.60% Senior Unsecured Notes Due September 2035",
        "label": "4.60% Senior Unsecured Notes Due September 2035 [Member]",
        "terseLabel": "4.60% Senior Unsecured Notes Due September 2035"
       }
      }
     },
     "localname": "A460SeniorUnsecuredNotesDueSeptember2035Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A475SeniorUnsecuredNotesDueMarch2046Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.75% Senior Unsecured Notes Due March 2046 [Member]",
        "label": "4.75% Senior Unsecured Notes Due March 2046 [Member]",
        "terseLabel": "4.75% Senior Unsecured Notes Due March 2046"
       }
      }
     },
     "localname": "A475SeniorUnsecuredNotesDueMarch2046Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A480SeniorUnsecuredNotesDueApril2044Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.80% Senior Unsecured Notes Due April 2044 [Member]",
        "label": "4.80% Senior Unsecured Notes Due April 2044 [Member]",
        "terseLabel": "4.80% Senior Unsecured Notes Due April 2044"
       }
      }
     },
     "localname": "A480SeniorUnsecuredNotesDueApril2044Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A565SeniorUnsecuredNotesDueDecember2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.65% Senior Unsecured Notes Due December 2041 [Member]",
        "label": "5.65% Senior Unsecured Notes Due December 2041 [Member]",
        "terseLabel": "5.65% Senior Unsecured Notes Due December 204"
       }
      }
     },
     "localname": "A565SeniorUnsecuredNotesDueDecember2041Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AccountsReceivableCashDiscountsAndOtherCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Cash Discounts and Other, Current",
        "label": "Accounts Receivable, Cash Discounts and Other, Current",
        "terseLabel": "Less: cash discounts and other"
       }
      }
     },
     "localname": "AccountsReceivableCashDiscountsAndOtherCurrent",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AccountsReceivableChargebacksCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Chargebacks, Current",
        "label": "Accounts Receivable, Chargebacks, Current",
        "terseLabel": "Less: chargebacks"
       }
      }
     },
     "localname": "AccountsReceivableChargebacksCurrent",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AccruedGovernmentAndOtherRebates": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Government And Other Rebates",
        "label": "Accrued Government And Other Rebates",
        "terseLabel": "Accrued government and other rebates"
       }
      }
     },
     "localname": "AccruedGovernmentAndOtherRebates",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AmerisourcebergenCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AmerisourceBergen Corp [Member]",
        "label": "AmerisourceBergen Corp [Member]",
        "terseLabel": "AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AmerisourcebergenCorpMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ArcusBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcus Biosciences, Inc.",
        "label": "Arcus Biosciences, Inc. [Member]",
        "terseLabel": "Arcus"
       }
      }
     },
     "localname": "ArcusBiosciencesIncMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ArcusStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcus Stock Purchase Agreement",
        "label": "Arcus Stock Purchase Agreement [Member]",
        "terseLabel": "Arcus stock purchase agreement"
       }
      }
     },
     "localname": "ArcusStockPurchaseAgreementMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AxicabtageneciloleucelDLBCLMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "axicabtagene ciloleucel (DLBCL) [Member]",
        "label": "axicabtagene ciloleucel (DLBCL) [Member]",
        "terseLabel": "Intangible asset - axicabtagene ciloleucel"
       }
      }
     },
     "localname": "AxicabtageneciloleucelDLBCLMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability",
        "negatedTerseLabel": "Liability related to future royalties"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net",
        "terseLabel": "Other assets (and liabilities), net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_CallTherapyProductsTecartusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Call Therapy Products, Tecartus",
        "label": "Call Therapy Products, Tecartus [Member]",
        "terseLabel": "Tecartus"
       }
      }
     },
     "localname": "CallTherapyProductsTecartusMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CardinalHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health Inc [Member]",
        "label": "Cardinal Health Inc [Member]",
        "terseLabel": "Cardinal Health, Inc."
       }
      }
     },
     "localname": "CardinalHealthIncMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CashPaymentsMadeRelatedToEquityInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Payments Made Related to Equity Investments",
        "label": "Cash Payments Made Related to Equity Investments",
        "terseLabel": "Cash payments made related to equity investments"
       }
      }
     },
     "localname": "CashPaymentsMadeRelatedToEquityInvestments",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_CellTherapyProductsTotalCellTherapyProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cell Therapy Products, Total Cell Therapy Product Sales",
        "label": "Cell Therapy Products, Total Cell Therapy Product Sales [Member]",
        "terseLabel": "Total Cell Therapy"
       }
      }
     },
     "localname": "CellTherapyProductsTotalCellTherapyProductSalesMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CellTherapyProductsYescartaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cell Therapy Products, Yescarta [Member]",
        "label": "Cell Therapy Products, Yescarta [Member]",
        "terseLabel": "Yescarta"
       }
      }
     },
     "localname": "CellTherapyProductsYescartaMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period",
        "label": "Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period",
        "terseLabel": "Option period to license"
       }
      }
     },
     "localname": "CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_CollaborationArrangementNetProductSalesThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Net Product Sales Threshold",
        "label": "Collaboration Arrangement, Net Product Sales Threshold",
        "terseLabel": "Net product sales threshold"
       }
      }
     },
     "localname": "CollaborationArrangementNetProductSalesThreshold",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Percent Of Global Development And Commercialization Costs",
        "label": "Collaboration Arrangement, Percent Of Global Development And Commercialization Costs",
        "terseLabel": "Percent of global development and commercialization costs"
       }
      }
     },
     "localname": "CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_CollaborationArrangementPercentOfGlobalProductRevenues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Percent Of Global Product Revenues",
        "label": "Collaboration Arrangement, Percent Of Global Product Revenues",
        "terseLabel": "Percent of global product revenues"
       }
      }
     },
     "localname": "CollaborationArrangementPercentOfGlobalProductRevenues",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_CollaborativeAndOtherArrangementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative and Other Arrangements [Text Block]",
        "label": "Collaborative And Other Arrangements [Text Block]",
        "terseLabel": "COLLABORATIONS AND OTHER ARRANGEMENTS"
       }
      }
     },
     "localname": "CollaborativeAndOtherArrangementsTextBlock",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gild_CollaborativeandOtherArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative and Other Arrangements [Abstract]",
        "label": "Collaborative and Other Arrangements [Abstract]"
       }
      }
     },
     "localname": "CollaborativeandOtherArrangementsAbstract",
     "nsuri": "http://www.gilead.com/20210331",
     "xbrltype": "stringItemType"
    },
    "gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Purchase Agreement and Investor Rights Agreement",
        "label": "Common Stock Purchase Agreement and Investor Rights Agreement [Member]",
        "terseLabel": "the \u201cStock Purchase Agreements\u201d"
       }
      }
     },
     "localname": "CommonStockPurchaseAgreementAndInvestorRightsAgreementMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CreditFacilityDueJune2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility Due June 2025",
        "label": "Credit Facility Due June 2025 [Member]",
        "terseLabel": "the \"2020 Revolving Credit Facility\""
       }
      }
     },
     "localname": "CreditFacilityDueJune2025Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative Effect, Period Of Adoption, Adjustment",
        "label": "Cumulative Effect, Period Of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative effect from the adoption of new accounting standard"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative Effect, Period Of Adoption",
        "label": "Cumulative Effect, Period Of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period Of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative Effect, Period Of Adoption [Domain]",
        "label": "Cumulative Effect, Period Of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period Of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_DeferredCompensationPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Compensation Plan [Member]",
        "label": "Deferred Compensation Plan [Member]",
        "terseLabel": "Deferred compensation plan"
       }
      }
     },
     "localname": "DeferredCompensationPlanMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EquitySecuritiesDonationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Donation",
        "label": "Equity Securities Donation [Member]",
        "terseLabel": "Equity Securities Donation"
       }
      }
     },
     "localname": "EquitySecuritiesDonationMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased",
        "label": "Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased",
        "terseLabel": "Maximum percentage of outstanding stock allowed to be purchased"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_EquitySecuritiesFVNIPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Purchase Period",
        "label": "Equity Securities, FV-NI, Purchase Period",
        "terseLabel": "Purchase period"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIPurchasePeriod",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_EquitySecuritiesFVNIRestrictionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Restriction Period",
        "label": "Equity Securities, FV-NI, Restriction Period",
        "terseLabel": "Restriction period"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIRestrictionPeriod",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_EquitySecuritiesFVNIShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Shares",
        "label": "Equity Securities, FV-NI, Shares",
        "terseLabel": "Equity securities (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIShares",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gild_EquitySecuritiesFVNISharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Shares Acquired",
        "label": "Equity Securities, FV-NI, Shares Acquired",
        "terseLabel": "Equity securities acquired (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesFVNISharesAcquired",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gild_EquityinvestmentinGalapagosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity investment in Galapagos [Member]",
        "label": "Equity investment in Galapagos [Member]",
        "terseLabel": "Equity investment in Galapagos"
       }
      }
     },
     "localname": "EquityinvestmentinGalapagosMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EuropeanPatentClaimsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "European Patent Claims",
        "label": "European Patent Claims [Member]",
        "terseLabel": "European Patent Claims"
       }
      }
     },
     "localname": "EuropeanPatentClaimsMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "label": "Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "totalLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "label": "Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "terseLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_FiniteLivedIntangibleAssetsGrossReclassified": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Gross, Reclassified",
        "label": "Finite-Lived Intangible Assets, Gross, Reclassified",
        "terseLabel": "Reclassified amounts"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGrossReclassified",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_FiniteLivedIntangibleAssetsGrossTransfers": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Gross, Transfers",
        "label": "Finite-Lived Intangible Assets, Gross, Transfers",
        "terseLabel": "Intangible assets reclassified from indefinite-lived assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGrossTransfers",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_ForeignCurrencyDerivativeContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Derivative Contracts [Member]",
        "label": "Foreign Currency Derivative Contracts [Member]",
        "terseLabel": "Foreign currency derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeContractsMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GalapagosNVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Galapagos NV",
        "label": "Galapagos NV [Member]",
        "terseLabel": "Galapagos NV"
       }
      }
     },
     "localname": "GalapagosNVMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GileadFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gilead Foundation",
        "label": "Gilead Foundation [Member]",
        "terseLabel": "Gilead Foundation"
       }
      }
     },
     "localname": "GileadFoundationMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HCVProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HCV Product Sales",
        "label": "HCV Product Sales [Member]",
        "terseLabel": "Total HCV"
       }
      }
     },
     "localname": "HCVProductSalesMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HCVProductsLedipasvirSofosbuvirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HCV Products, Ledipasvir/Sofosbuvir",
        "label": "HCV Products, Ledipasvir/Sofosbuvir [Member]",
        "terseLabel": "Ledipasvir/Sofosbuvir"
       }
      }
     },
     "localname": "HCVProductsLedipasvirSofosbuvirMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HCVProductsSofosbuvirVelpatasvirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HCV Products, Sofosbuvir/Velpatasvir",
        "label": "HCV Products, Sofosbuvir/Velpatasvir [Member]",
        "terseLabel": "Sofosbuvir/Velpatasvir"
       }
      }
     },
     "localname": "HCVProductsSofosbuvirVelpatasvirMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Product Sales",
        "label": "HIV Product Sales [Member]",
        "terseLabel": "Total HIV"
       }
      }
     },
     "localname": "HIVProductSalesMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsAtriplaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Atripla [Member]",
        "label": "HIV Products, Atripla [Member]",
        "terseLabel": "Atripla"
       }
      }
     },
     "localname": "HIVProductsAtriplaMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsBiktarvyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Biktarvy [Member]",
        "label": "HIV Products, Biktarvy [Member]",
        "terseLabel": "Biktarvy"
       }
      }
     },
     "localname": "HIVProductsBiktarvyMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsCompleraEvipleraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Complera/Eviplera [Member]",
        "label": "HIV Products, Complera/Eviplera [Member]",
        "terseLabel": "Complera/Eviplera"
       }
      }
     },
     "localname": "HIVProductsCompleraEvipleraMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsDescovyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Descovy [Member]",
        "label": "HIV Products, Descovy [Member]",
        "terseLabel": "Descovy"
       }
      }
     },
     "localname": "HIVProductsDescovyMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsGenvoyaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Genvoya [Member]",
        "label": "HIV Products, Genvoya [Member]",
        "terseLabel": "Genvoya"
       }
      }
     },
     "localname": "HIVProductsGenvoyaMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsOdefseyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Odefsey [Member]",
        "label": "HIV Products, Odefsey [Member]",
        "terseLabel": "Odefsey"
       }
      }
     },
     "localname": "HIVProductsOdefseyMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsStribildMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Stribild [Member]",
        "label": "HIV Products, Stribild [Member]",
        "terseLabel": "Stribild"
       }
      }
     },
     "localname": "HIVProductsStribildMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsTruvadaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Truvada [Member]",
        "label": "HIV Products, Truvada [Member]",
        "terseLabel": "Truvada"
       }
      }
     },
     "localname": "HIVProductsTruvadaMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product [Member]",
        "terseLabel": "Total HBV/HDV"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product, Other",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product, Other [Member]",
        "terseLabel": "Other HBV/HBD"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductOtherMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]",
        "terseLabel": "Vemlidy"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]",
        "terseLabel": "Viread"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductVireadMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepcludexForHDVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepcludex For HDV",
        "label": "Hepcludex For HDV [Member]",
        "terseLabel": "Hepcludex For HDV",
        "verboseLabel": "Intangible asset - Hepcludex for HDV"
       }
      }
     },
     "localname": "HepcludexForHDVMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ImmunomedicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunomedics, Inc. (\u201cImmunomedics\u201d), a leading company in antibody-drug conjugate (\u201cADC\u201d) technology",
        "label": "Immunomedics, Inc. [Member]",
        "terseLabel": "Immunomedics"
       }
      }
     },
     "localname": "ImmunomedicsIncMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "label": "Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "terseLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_InjectableFormulationProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Injectable Formulation Product",
        "label": "Injectable Formulation Product [Member]",
        "terseLabel": "Injectable Formulation Product"
       }
      }
     },
     "localname": "InjectableFormulationProductMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_IntangibleAssetMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Asset, Measurement Input",
        "label": "Intangible Asset, Measurement Input",
        "terseLabel": "Measurement input"
       }
      }
     },
     "localname": "IntangibleAssetMeasurementInput",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "gild_IntangibleAssetSofosbuvirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sofosbuvir [Member]",
        "label": "Intangible Asset - Sofosbuvir [Member]",
        "terseLabel": "Intangible asset - sofosbuvir"
       }
      }
     },
     "localname": "IntangibleAssetSofosbuvirMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_InventoryNetAndInventoryNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory Net And Inventory Noncurrent",
        "label": "Inventory Net And Inventory Noncurrent",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryNetAndInventoryNoncurrent",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_JudgmentEnhancedDamagesOnPastSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judgment: Enhanced Damages On Past Sales",
        "label": "Judgment: Enhanced Damages On Past Sales",
        "terseLabel": "Enhancement rate on past damages"
       }
      }
     },
     "localname": "JudgmentEnhancedDamagesOnPastSales",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_JudgmentRoyaltyRateFromOctober2017": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judgment: Royalty Rate from October 2017",
        "label": "Judgment: Royalty Rate from October 2017",
        "terseLabel": "Running royalty rate from October 2017"
       }
      }
     },
     "localname": "JudgmentRoyaltyRateFromOctober2017",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_JudgmentRoyaltyRateOnFutureSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judgment: Royalty Rate on Future Sales",
        "label": "Judgment: Royalty Rate on Future Sales",
        "terseLabel": "Running royalty rate on future sales"
       }
      }
     },
     "localname": "JudgmentRoyaltyRateOnFutureSales",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, \u201cJuno\u201d)",
        "label": "Juno Therapeutics, Inc. and Sloan Kettering Cancer Center [Member]",
        "terseLabel": "Juno Therapeutics, Inc. and Sloan Kettering Cancer Center"
       }
      }
     },
     "localname": "JunoTherapeuticsIncAndSloanKetteringCancerCenterMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_LossContingencyEstimateOfPossibleLossPastSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Estimate Of Possible Loss (Past Sales)",
        "label": "Loss Contingency, Estimate Of Possible Loss (Past Sales)",
        "terseLabel": "Estimate of possible loss representing past sales"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLossPastSales",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_LossContingencyEstimateOfPossibleLossRoyalties": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Estimate Of Possible Loss, Royalties",
        "label": "Loss Contingency, Estimate Of Possible Loss, Royalties",
        "terseLabel": "Estimate of possible loss representing royalties and prejudgment interest"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLossRoyalties",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Estimate of Possible Loss (50% Enhancement of Past Damages)",
        "label": "Loss Contingency, Estimate of Possible Loss (50% Enhancement of Past Damages)",
        "terseLabel": "Estimate of possible loss representing enhancement of past damages"
       }
      }
     },
     "localname": "LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_LossContingencyMaterialTransferAgreementsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Material Transfer Agreements, Number",
        "label": "Loss Contingency, Material Transfer Agreements, Number",
        "terseLabel": "Number of material transfer agreements"
       }
      }
     },
     "localname": "LossContingencyMaterialTransferAgreementsNumber",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyPartiesAppealedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Parties Appealed, Number",
        "label": "Loss Contingency, Parties Appealed, Number",
        "terseLabel": "Number of parties appealed"
       }
      }
     },
     "localname": "LossContingencyPartiesAppealedNumber",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyPartiesFilingOppositionNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Parties Filing Opposition, Number",
        "label": "Loss Contingency, Parties Filing Opposition, Number",
        "terseLabel": "Number of parties filing opposition"
       }
      }
     },
     "localname": "LossContingencyPartiesFilingOppositionNumber",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Patents Allegedly Infringed, Number, Scenario One",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number, Scenario One",
        "terseLabel": "Number of patents challenged, scenario one"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumberScenarioOne",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Patents Allegedly Infringed, Number, Scenario Two",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number, Scenario Two",
        "terseLabel": "Number of patents challenged, scenario two"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumberScenarioTwo",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_MYRGmbHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MYR GmbH",
        "label": "MYR GmbH [Member]",
        "terseLabel": "MYR GmbH"
       }
      }
     },
     "localname": "MYRGmbHMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MarketableSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Current [Member]",
        "label": "Marketable Securities, Current [Member]",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrentMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MarketableSecuritiesNoncurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Noncurrent [Member]",
        "label": "Marketable Securities, Noncurrent [Member]",
        "terseLabel": "Long-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrentMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MckessonCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson Corp [Member]",
        "label": "McKesson Corp [Member]",
        "terseLabel": "McKesson Corporation"
       }
      }
     },
     "localname": "MckessonCorpMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MerckMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck",
        "label": "Merck [Member]",
        "terseLabel": "Merck"
       }
      }
     },
     "localname": "MerckMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck Sharp &amp; Dohme Corp License And Collaboration Agreement",
        "label": "Merck Sharp &amp; Dohme Corp License And Collaboration Agreement [Member]",
        "terseLabel": "Merck Sharp &amp; Dohme Corp agreement"
       }
      }
     },
     "localname": "MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OralFormulationProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oral Formulation Product",
        "label": "Oral Formulation Product [Member]",
        "terseLabel": "Oral Formulation Product"
       }
      }
     },
     "localname": "OralFormulationProductMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherCollaborationArrangementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Collaboration Arrangements [Member]",
        "label": "Other Collaboration Arrangements [Member]",
        "terseLabel": "Other collaboration arrangements"
       }
      }
     },
     "localname": "OtherCollaborationArrangementsMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Equity Securities [Member]",
        "label": "Other Equity Securities [Member]",
        "terseLabel": "Other Equity Securities"
       }
      }
     },
     "localname": "OtherEquitySecuritiesMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Financial Information",
        "label": "Other Financial Information [Abstract]",
        "terseLabel": "Other Financial Information [Abstract]"
       }
      }
     },
     "localname": "OtherFinancialInformationAbstract",
     "nsuri": "http://www.gilead.com/20210331",
     "xbrltype": "stringItemType"
    },
    "gild_OtherHepatitisCVirusProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Hepatitis C Virus Products",
        "label": "Other Hepatitis C Virus Products [Member]",
        "terseLabel": "Other HCV"
       }
      }
     },
     "localname": "OtherHepatitisCVirusProductsMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherInternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other International [Member]",
        "label": "Other International [Member]",
        "terseLabel": "Other International"
       }
      }
     },
     "localname": "OtherInternationalMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsAmBisomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, AmBisome [Member]",
        "label": "Other Products, AmBisome [Member]",
        "terseLabel": "AmBisome"
       }
      }
     },
     "localname": "OtherProductsAmBisomeMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsLetairisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Letairis [Member]",
        "label": "Other Products, Letairis [Member]",
        "terseLabel": "Letairis"
       }
      }
     },
     "localname": "OtherProductsLetairisMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Other [Member]",
        "label": "Other Products, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductsOtherMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsRanexaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Ranexa [Member]",
        "label": "Other Products, Ranexa [Member]",
        "terseLabel": "Ranexa"
       }
      }
     },
     "localname": "OtherProductsRanexaMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsTotalOtherProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Total Other product sales",
        "label": "Other Products, Total Other product sales [Member]",
        "terseLabel": "Total Other"
       }
      }
     },
     "localname": "OtherProductsTotalOtherProductSalesMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsZydeligMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Zydelig [Member]",
        "label": "Other Products, Zydelig [Member]",
        "terseLabel": "Zydelig"
       }
      }
     },
     "localname": "OtherProductsZydeligMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_PaymentsToAcquireEquitySecuritiesFVNI": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Equity Securities, FV, NI",
        "label": "Payments To Acquire Equity Securities, FV, NI",
        "terseLabel": "Payments to acquire equity securities"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesFVNI",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PreExposureProphylaxisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Exposure Prophylaxis",
        "label": "Pre-Exposure Prophylaxis [Member]",
        "terseLabel": "Pre-Exposure Prophylaxis"
       }
      }
     },
     "localname": "PreExposureProphylaxisMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ProductLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Liability",
        "label": "Product Liability [Member]",
        "terseLabel": "Product Liability"
       }
      }
     },
     "localname": "ProductLiabilityMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ProductsOtherHIVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products, Other HIV [Member]",
        "label": "Products, Other HIV [Member]",
        "terseLabel": "Other HIV"
       }
      }
     },
     "localname": "ProductsOtherHIVMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ProductsRevenueShareSymtuzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products, Revenue Share-Symtuza [Member]",
        "label": "Products, Revenue Share-Symtuza [Member]",
        "terseLabel": "Revenue share - Symtuza"
       }
      }
     },
     "localname": "ProductsRevenueShareSymtuzaMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_QuiTamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qui Tam",
        "label": "Qui Tam [Member]",
        "terseLabel": "Qui Tam"
       }
      }
     },
     "localname": "QuiTamMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ResidentialMortgageAndAssetBackedSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Residential Mortgage And Asset-Backed Securities [Member]",
        "label": "Residential Mortgage And Asset-Backed Securities [Member]",
        "terseLabel": "Residential mortgage and asset-backed securities",
        "verboseLabel": "Residential mortgage and asset-backed securities"
       }
      }
     },
     "localname": "ResidentialMortgageAndAssetBackedSecuritiesMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_RoyaltyContractAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty, Contract, And Other [Member]",
        "label": "Royalty, Contract, And Other [Member]",
        "terseLabel": "Royalty, contract and other revenues"
       }
      }
     },
     "localname": "RoyaltyContractAndOtherMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorNotesAndMediumTermNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes And Medium-Term Notes",
        "label": "Senior Notes And Medium-Term Notes [Member]",
        "terseLabel": "Senior Notes and Medium-Term Notes"
       }
      }
     },
     "localname": "SeniorNotesAndMediumTermNotesMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNoteIssuedNovember2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Note Issued November 2014",
        "label": "Senior Unsecured Note Issued November 2014 [Member]",
        "terseLabel": "the \"2014 Senior Notes\""
       }
      }
     },
     "localname": "SeniorUnsecuredNoteIssuedNovember2014Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Year Senior Unsecured Term Loan Facility",
        "label": "Three Year Senior Unsecured Term Loan Facility [Member]",
        "terseLabel": "Three-Year Senior Term Loan Facility"
       }
      }
     },
     "localname": "ThreeYearSeniorUnsecuredTermLoanFacilityMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total carrying amount of assets (excluding financial assets) that lack physical substance, excluding goodwill, having a projected indefinite period of benefit.",
        "label": "Total Indefinite Lived Intangible Assets Excluding Goodwill",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_TrodelvyForMTNBCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trodelvy for mTNBC [Member]",
        "label": "Trodelvy for mTNBC [Member]",
        "terseLabel": "Trodelvy for mTNBC",
        "verboseLabel": "Intangible asset - Trodelvy for mTNBC"
       }
      }
     },
     "localname": "TrodelvyForMTNBCMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_TrodelvyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trodelvy",
        "label": "Trodelvy [Member]",
        "terseLabel": "Trodelvy"
       }
      }
     },
     "localname": "TrodelvyMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Collaboration Expenses Related to Other Collaborative Arrangements",
        "label": "Upfront Collaboration Expenses Related to Other Collaborative Arrangements",
        "terseLabel": "Upfront collaboration expenses related to other collaborative arrangements"
       }
      }
     },
     "localname": "UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_VariableTermLoanNoteDueOctober2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Term Loan Note Due October 2023",
        "label": "Variable Term Loan Note Due October 2023 [Member]",
        "terseLabel": "Variable Term Loan Note Due October 2023"
       }
      }
     },
     "localname": "VariableTermLoanNoteDueOctober2023Member",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_VekluryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Veklury",
        "label": "Veklury [Member]",
        "terseLabel": "Veklury"
       }
      }
     },
     "localname": "VekluryMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ViiVHealthcareCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ViiV Healthcare Company (\u201cViiV\u201d)",
        "label": "ViiV Healthcare Company [Member]",
        "terseLabel": "ViiV Healthcare Company"
       }
      }
     },
     "localname": "ViiVHealthcareCompanyMember",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_WriteOffsInAccruedInterestReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-off in accrued interest receivable",
        "label": "Write-Offs In Accrued Interest Receivable",
        "terseLabel": "Write-offs of accrued interest receivable"
       }
      }
     },
     "localname": "WriteOffsInAccruedInterestReceivable",
     "nsuri": "http://www.gilead.com/20210331",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r153",
      "r258",
      "r263",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r151",
      "r258",
      "r261",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/REVENUESAdditionalInformationDetails",
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/REVENUESAdditionalInformationDetails",
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails",
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails",
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r152",
      "r258",
      "r262",
      "r432",
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r223",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails",
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r154",
      "r155"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r2",
      "r20",
      "r154",
      "r155",
      "r259"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "totalLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r15",
      "r398",
      "r421"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r17",
      "r398",
      "r421"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r74",
      "r84",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r68",
      "r69",
      "r70",
      "r74",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r72",
      "r73",
      "r74"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r71",
      "r74",
      "r77",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r66",
      "r74",
      "r77",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "OTHER FINANCIAL INFORMATION"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r110",
      "r213"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r269",
      "r270",
      "r273",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r26",
      "r156",
      "r181"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Less: allowances for credit losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Write-offs charged against allowance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r110",
      "r205",
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Aggregate amortization expense related to finite-lived intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from earnings per share computation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "verboseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r149",
      "r396",
      "r420"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r54"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r343"
     ],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r164"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r161",
      "r188"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r168"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost",
        "terseLabel": "After one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r165",
      "r168",
      "r410"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value",
        "terseLabel": "After one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": {
     "auth_ref": [
      "r169"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Allocated and Single Maturity Date, Maturity, after 10 Years, Amortized Cost",
        "terseLabel": "After five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "auth_ref": [
      "r165",
      "r169",
      "r411"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after 10 Years, Fair Value",
        "terseLabel": "After five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]",
        "terseLabel": "Amortized\u00a0Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r167"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost",
        "terseLabel": "Within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r165",
      "r167",
      "r409"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value",
        "terseLabel": "Within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r158",
      "r162",
      "r188"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Total",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r323",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Expected tax deductible goodwill"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition-related expenses"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r295",
      "r296",
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Acquisition consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r294",
      "r297",
      "r300"
     ],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Liability for MYR contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ACQUISITIONS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability": {
     "auth_ref": [
      "r290",
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability",
        "verboseLabel": "Fair value of contingent liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r276",
      "r291"
     ],
     "calculation": {
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r290",
      "r291"
     ],
     "calculation": {
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Finite-lived intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r290",
      "r291"
     ],
     "calculation": {
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r290",
      "r291"
     ],
     "calculation": {
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total identifiable net assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Total consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Combination, Separately Recognized Transactions [Line Items]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Line Items]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing the disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Table]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Table]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying value"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r107",
      "r112",
      "r113"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r107",
      "r361"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit",
        "verboseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r46",
      "r222",
      "r404",
      "r427"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r221",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, dividends declared (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value $0.001 per share; 5,600 shares authorized; 1,254 shares issued and outstanding"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r80",
      "r82",
      "r83"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to Gilead"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r80",
      "r82",
      "r307",
      "r308",
      "r316"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive loss attributable to noncontrolling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r80",
      "r82",
      "r306",
      "r316"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r142",
      "r143",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r142",
      "r143",
      "r359",
      "r360",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r142",
      "r143",
      "r359",
      "r360",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r138",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r142",
      "r143",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r142",
      "r143",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r252",
      "r254",
      "r259"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r252",
      "r253",
      "r259"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "terseLabel": "Change in estimate of variable consideration"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Contract with customer, performance obligation satisfied in previous period"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerRefundLiabilityCurrent": {
     "auth_ref": [
      "r260"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.",
        "label": "Contract with Customer, Refund Liability, Current",
        "terseLabel": "Allowance for sales returns"
       }
      }
     },
     "localname": "ContractWithCustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r265",
      "r268",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "terseLabel": "Current portion of long-term debt and other obligations, net"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "DEBT AND CREDIT FACILITIES"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r15",
      "r16",
      "r397",
      "r399",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r16",
      "r237",
      "r399",
      "r418"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Short-term and long-term debt, carrying values",
        "verboseLabel": "Remaining outstanding"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate, stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r44",
      "r118",
      "r244",
      "r247",
      "r248",
      "r249",
      "r364",
      "r365",
      "r367",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Contractual term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Summary of Classification of Available-for-Sale Debt Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r171",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of positions held in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r110",
      "r115",
      "r281",
      "r283"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r277",
      "r280"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r110",
      "r219"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and elected not to be offset.",
        "label": "Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement",
        "terseLabel": "Derivative asset, fair value"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossLiability": {
     "auth_ref": [
      "r56",
      "r64",
      "r326"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Asset, Fair Value, Gross Liability",
        "negatedTerseLabel": "Gross Amounts Offset on our Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r60",
      "r62"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.",
        "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "totalLabel": "Net Amount (Legal Offset)"
       }
      }
     },
     "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r58",
      "r62"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative assets.",
        "label": "Derivative Asset, Not Offset, Policy Election Deduction",
        "negatedTerseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r57",
      "r61",
      "r356"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "totalLabel": "Amounts of Assets/Liabilities Presented on our Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Asset [Abstract]",
        "terseLabel": "Derivative assets"
       }
      }
     },
     "localname": "DerivativeAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeCollateralObligationToReturnCash": {
     "auth_ref": [
      "r59",
      "r62",
      "r336"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.",
        "label": "Derivative, Collateral, Obligation to Return Cash",
        "negatedTerseLabel": "Cash Collateral Received/ Pledged"
       }
      }
     },
     "localname": "DerivativeCollateralObligationToReturnCash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeCollateralRightToReclaimCash": {
     "auth_ref": [
      "r59",
      "r62",
      "r336"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.",
        "label": "Derivative, Collateral, Right to Reclaim Cash",
        "terseLabel": "Cash Collateral Received/ Pledged"
       }
      }
     },
     "localname": "DerivativeCollateralRightToReclaimCash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r55",
      "r63",
      "r326",
      "r380"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Gross Amounts of Recognized Assets/Liabilities"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r55",
      "r63",
      "r326",
      "r380"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "negatedTerseLabel": "Gross Amounts of Recognized Assets/Liabilities"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "DERIVATIVE FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period for the anticipated transfer of gain (loss), net, from accumulated other comprehensive income into earnings, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimate of Time to Transfer",
        "terseLabel": "Time estimate for gains (losses) to be reclassified from AOCI to product sales"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r331",
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Gains recognized in Other income (expense), net"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r57",
      "r61",
      "r356"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "negatedTotalLabel": "Amounts of Assets/Liabilities Presented on our Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability [Abstract]",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossAsset": {
     "auth_ref": [
      "r56",
      "r64",
      "r326"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Liability, Fair Value, Gross Asset",
        "terseLabel": "Gross Amounts Offset on our Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset.",
        "label": "Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement",
        "negatedLabel": "Derivative liability, fair value"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r60",
      "r62"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.",
        "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "negatedTotalLabel": "Net Amount (Legal Offset)"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r58",
      "r62"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative liabilities.",
        "label": "Derivative Liability, Not Offset, Policy Election Deduction",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r318",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "verboseLabel": "Maturities of derivative instruments"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r121",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r328",
      "r332",
      "r335",
      "r337",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESAdditionalInformationDetails",
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESAdditionalInformationDetails",
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r250",
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "negatedTerseLabel": "Dividends declared"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r87",
      "r124",
      "r127",
      "r129",
      "r130",
      "r131",
      "r134",
      "r406",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income per share attributable to Gilead common stockholders - basic (in dollars per share)",
        "verboseLabel": "Net income per share attributable to Gilead common stockholders - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r87",
      "r124",
      "r127",
      "r129",
      "r130",
      "r131",
      "r134",
      "r406",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income per share attributable to Gilead common stockholders - diluted (in dollars per share)",
        "verboseLabel": "Net income per share attributable to Gilead common stockholders - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r120",
      "r278",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://www.gilead.com/role/INCOMETAXESSummaryoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Marketable equity securities",
        "verboseLabel": "Equity investment"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r10",
      "r14",
      "r177",
      "r403",
      "r419",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Other publicly traded equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity investments without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of Fair Value Measurement",
        "verboseLabel": "Market value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r343",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r343",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Summary of Classification of Equity Securities"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r265",
      "r266",
      "r268",
      "r344",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r343",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r343",
      "r344",
      "r347",
      "r348",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r265",
      "r266",
      "r268",
      "r344",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r265",
      "r266",
      "r268",
      "r344",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r265",
      "r266",
      "r268",
      "r344",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r350",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r323",
      "r328",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r182",
      "r184",
      "r185",
      "r186",
      "r187",
      "r190",
      "r191",
      "r192",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r212"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year",
        "terseLabel": "2021 (remaining nine months)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r214"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r214"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r214"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r214"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r206",
      "r209",
      "r212",
      "r216",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r212",
      "r382"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross\u00a0 Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r206",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r212"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "terseLabel": "Foreign currency derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "terseLabel": "Foreign currency derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r265",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Non-U.S. government securities"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net gain (loss) reclassified into earnings when foreign currency cash flow hedge is discontinued because it is probable that the original forecasted transactions will not occur by the end of the original period or an additional two month time period.",
        "label": "Gain (Loss) on Discontinuation of Foreign Currency Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring, Net",
        "terseLabel": "Discontinuances of cash flow hedges"
       }
      }
     },
     "localname": "GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r197",
      "r198"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill resulting from the acquisition of MYR"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "GOODWILL AND INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillGross": {
     "auth_ref": [
      "r199",
      "r201"
     ],
     "calculation": {
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Gross",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r321",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income before income taxes",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/INCOMETAXESSummaryoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r148",
      "r284"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/INCOMETAXESSummaryoftheProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "negatedTerseLabel": "Net losses from equity securities",
        "terseLabel": "Net losses from equity securities"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r128",
      "r133"
     ],
     "calculation": {
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Dilutive effect of stock options and equivalents (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r208",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Gross\u00a0 Carrying Amount"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r208",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Gross\u00a0 Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r204",
      "r210"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r85",
      "r147",
      "r363",
      "r366",
      "r407"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Accrued interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r27",
      "r196"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1": {
       "order": 3.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r1",
      "r51",
      "r195"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails": {
       "order": 1.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails": {
       "order": 2.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r29",
      "r196"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1": {
       "order": 1.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r28",
      "r196"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails_1": {
       "order": 2.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Summary of Available-for-Sale Debt Securities by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Equity investments not measured at fair value"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r177",
      "r395",
      "r413",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "AVAILABLE-FOR-SALE DEBT SECURITIES"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r401",
      "r425"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r343"
     ],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Outlicense contract"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSScheduleofFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r16",
      "r399",
      "r418"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Amounts outstanding under revolving credit facilities"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r16",
      "r238",
      "r399",
      "r422"
     ],
     "calculation": {
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total debt, net"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Less: current portion of long-term debt and other obligations, net"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Short-term and long-term debt"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net",
        "verboseLabel": "Total long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r44",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r227",
      "r228",
      "r229",
      "r232",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r222",
      "r225",
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r222",
      "r225",
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Damages amount"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r226",
      "r231",
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Estimate of possible loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Number of class action lawsuits"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Number of plaintiffs involved"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r3",
      "r40"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "verboseLabel": "Long-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MediumTermNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instruments with maturities ranging from five to ten years.",
        "label": "Medium-term Notes [Member]",
        "terseLabel": "Medium-term Notes"
       }
      }
     },
     "localname": "MediumTermNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r50",
      "r400",
      "r424"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Ownership percentage by noncontrolling owners"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r107",
      "r108",
      "r111"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r78",
      "r81",
      "r86",
      "r111",
      "r133",
      "r405",
      "r428"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income attributable to Gilead",
        "totalLabel": "Net income attributable to Gilead"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r78",
      "r81",
      "r310",
      "r315"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Notes Payable, Other Payables"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r41"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Available-for-sale debt securities:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]",
        "terseLabel": "Cash flow hedges:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "auth_ref": [
      "r68",
      "r69"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities and unrealized holding gain (loss) related to transfers of securities into the available-for-sale classification and out of the held-to-maturity classification.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Reclassification Adjustments, after Tax",
        "terseLabel": "Net unrealized loss, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r68",
      "r69",
      "r72"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r74",
      "r84"
     ],
     "calculation": {
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "verboseLabel": "Net unrealized gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r67",
      "r72"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r67",
      "r72"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "verboseLabel": "Net unrealized gain, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r67",
      "r72",
      "r325",
      "r329",
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Gains recognized in AOCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r72",
      "r75"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "negatedTerseLabel": "Reclassifications to net income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r72",
      "r75",
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Gains (losses) reclassified from AOCI into product sales"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r65",
      "r362"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Net foreign currency translation gain (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r79",
      "r82",
      "r84",
      "r243"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive income (loss)",
        "verboseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r72",
      "r75",
      "r76",
      "r176"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedLabel": "Reclassifications to net income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other\u00a0accrued\u00a0liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of other liabilities.",
        "label": "Other Liabilities, Fair Value Disclosure",
        "terseLabel": "Deferred compensation plan"
       }
      }
     },
     "localname": "OtherLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other\u00a0long-term\u00a0obligations"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r160"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale",
        "terseLabel": "Impairment recognized"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r94",
      "r98",
      "r122"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedTerseLabel": "Payments of dividends"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r92",
      "r95",
      "r159"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable debt securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r96",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash paid for acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisitions, including in-process research and development, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedTerseLabel": "Purchases of equity securities"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r33",
      "r34"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSEquityInvestmentInGalapagosDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofClassificationofEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.",
        "label": "Reclassification, Policy [Policy Text Block]",
        "terseLabel": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuances of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-term Lines of Credit",
        "terseLabel": "Borrowing from senior unsecured term loan facility"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r92",
      "r93",
      "r159"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities of marketable debt securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r101",
      "r104",
      "r122"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r92",
      "r93",
      "r159"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sales of marketable debt securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales",
        "verboseLabel": "Total product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r78",
      "r81",
      "r106",
      "r149",
      "r150",
      "r306",
      "r309",
      "r311",
      "r315",
      "r316"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r220",
      "r426"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r74",
      "r77",
      "r84"
     ],
     "calculation": {
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Reclassifications to net income"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r267",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.",
        "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party",
        "terseLabel": "Donation expense"
       }
      }
     },
     "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r267",
      "r368",
      "r369",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "SUBSEQUENT EVENT"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUBSEQUENTEVENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Repayments of debt and other obligations"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "terseLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfUnsecuredDebt": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.",
        "label": "Repayments of Unsecured Debt",
        "terseLabel": "Repayments of senior unsecured notes"
       }
      }
     },
     "localname": "RepaymentsOfUnsecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r275"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r250",
      "r423"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r257",
      "r258"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/REVENUESDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer Benchmark"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of Changes in Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Available-for-Sale Debt Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Available-for-Sale Debt Securities from Cost Basis to Fair Value"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r166",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r408",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Summary of the Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Summary of Debt Carrying Amount"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r324",
      "r332",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of Effect of Foreign Currency Exchange Contracts"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Summary of Classification and Fair Value of Derivative Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r121",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r328",
      "r332",
      "r335",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "terseLabel": "Summary of Potential Effect of Offsetting Derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of the Calculation of Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r206",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r206",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r202",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r215",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r30",
      "r31",
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r116",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "terseLabel": "Revenues from Major Customers"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/REVENUESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r47",
      "r117",
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Estimated Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r90",
      "r194"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r48",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r18",
      "r19",
      "r243",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "verboseLabel": "Issuances under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r243",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance under equity incentive plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r18",
      "r19",
      "r243",
      "r250"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuances under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r250",
      "r271",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuances under equity incentive plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Authorized amount under stock repurchase program"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Remaining authorized repurchase amount under stock repurchase programs"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r18",
      "r19",
      "r243",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "terseLabel": "Shares repurchased and retired (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r18",
      "r19",
      "r243",
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "terseLabel": "Value of shares repurchased and retired"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r18",
      "r19",
      "r243",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchases of common stock (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r18",
      "r19",
      "r243",
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r23",
      "r24",
      "r157"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Gilead stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r304",
      "r305",
      "r314"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.gilead.com/role/STOCKHOLDERSEQUITYSummaryofChangesinAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails",
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails",
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GOODWILLANDINTANGIBLEASSETSSummaryofIntangibleAssetsDetails",
      "http://www.gilead.com/role/SUBSEQUENTEVENTDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "verboseLabel": "Collaborative Arrangements and Non-collaborative Arrangements [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r265",
      "r268",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r136",
      "r137",
      "r139",
      "r140",
      "r144",
      "r145",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Significant Accounting Policies, Estimates and Judgments"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/COLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r126",
      "r131"
     ],
     "calculation": {
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Shares used in per share calculation - diluted (in shares)",
        "totalLabel": "Shares used in per share calculation - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r125",
      "r131"
     ],
     "calculation": {
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used in per share calculation - basic (in shares)",
        "verboseLabel": "Shares used in per share calculation - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/NETINCOMEPERSHAREATTRIBUTABLETOGILEADCOMMONSTOCKHOLDERSScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 13
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3444-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=SL6284422-111562"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117539-209714"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL108322424-203045"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130611-203046-203046"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998890-113959"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109974929&loc=SL110061190-113977"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b,c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r441": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r442": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r443": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r444": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r445": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)(i)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724391-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>92
<FILENAME>0000882095-21-000013-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000882095-21-000013-xbrl.zip
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M@GH&H&;@S%@[)TD4,C*++, EMER&L9\Z1^YNQ4PY1ZBHTD*Q-CZ57FIL,!/
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MW4)U]]CFXJO9[XK1%V.7GSY>9&HX@<;2:@U$@_LVF^*:*BH.^L+J;2[Q\H=
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MBC8H;>B6D+4(.P;J;7'FZ()9QGY:')-Y17; \:>(B"I4(_5.TIHN+3QLN7K
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M+KZ,0]("2PW-Z%.FB91DPQ@% R;3!%Z](!@-3CH3J!PEP]A/N=@F$%)KYBU
ML2A>=%ILZWTP#;0R$\ <DFXY(B]&M50'<>"((%,:)&L<TY/DW+1::/D(T3-+
M.4H2DV%G9"H.VH#,,]7:\U2[B[ NC"E>MYMY^9N%=%;;"SO-T;"$86<D)ZC3
MJMO4@,("6<:,<6DVZEZPL^RZH1;-/+5 Y &<QC_1RA1(G(PHTM*B-O:"H"-R
M>YAU[P-'4D*$P6\%W<;\9C7& A%7A317P=:<M7?-P\)E )WRXKO'.OZ+;>@/
M61C;7"I+V8^E0E5U:D+N2!")D5).X"V':)7STBR59;.4_;C60NZA&K&(@N5,
M!)J 8E4V[&DNC74.&D%'Y#I)QJWG0!IK@=28N8):L 1=H?K2<EKVPE+VXTL)
M':);"V4(LHFQ492:6JNU0]!Y^U*N+DX>,#^ZV3M_,K*GH@MIH**X8#/@$J8T
MJ 8Q5W4HZG-IKK+G59I?A\59 @52P)"#5(\18F246D0 ZI2![6DN 4.'H$N.
MR &2JCB$/M493- L3>JE%^!<-$2>>;S XF:@_11,SY(:"=C$5GHTZ2(4\X"*
M-31>2S@<X RTIZZ!/#CL%,<<$P 6&H:ON6L-%#B5.A.@'((N.2+C-KM4ZB&W
M# D"&TLT+E93A%8S+""/\K/SIWQZ^?3N^-5;ULOWSFPA86O[J3X5T7)7*VV*
M/^@JN<=A(R5RZZB99H*70PA;^VW G"=J6M5$4L4P095&5*B8%R4=3*8N(+YY
M/UKFB$PE3I;2(, UY@+=A3P,5NS3FG%0HP5X81<[4>VG&/.  I3>0NL 7#L&
M,V143L-TDCZ79<3CG:CVDR+:;5A/XDTMPD"+A/%O&K,4 [:*<T'-P6F9([*H
M0FH\L,*#(Q.@9V*>.MO5P9O-8Y]+4-,1VC988O,J<>HT!QX*&4*+K*$/QM%A
M+A6V#R'N8S]19UK'2&MDXA&B,&D;0[".6;^J<YF++^/@U.B>!J.*BCAY=\A:
MI7ACI2H"5D'C3&;B(V3>P"U-W5PU1( F8R &K:C4)"&YS\41?0AJ="_RHXX"
M&+,/P0&!4W;C(3FT6$K6!=386C8;O3K;/)/DV=7TX"]D\]#YXFKK[SZ_QOAX
M<X&;/3?;TQ5^GMN* >9>$Y8\@-'&<(X^3.L4,6.7N83#W.?OSK=WKRXNSQ_Z
M]N(E3+PWMC<7YU=;]7': S^[>[Y]]'M-HYNUJV%RJ4]6UX2VSS87W[__]'T_
MTV\?\O;[5U>Y/O/'?G;E?]Z>/[RQT_Z^N?SVYHG?X -]\?31OZVXW=ST)P<O
MD71,E".UB$R<(!00']: 2.L6!L)A+CG6*[X/']_[B8RWT#M60FH(M2415NFQ
MMY9Z*K/P31P<VO[C@+O+6]L,:O$7Y]/+;S\ZTZ/ ]GZ2"5NO#8(BE&%WY,0*
M%DE[(R6F69@=*[8/']M[T=M<2Z :4RHA0"I&T%.5F&@ W7+Q56\?*-I^WPB[
MK]_[Q<7YZ["T6:IL;#7W-.&L)AA$FZJ1:"TY=D>6.?CX5E@?-*SW5*D+()@[
M.G28:H)2PFDQ.4IQ3V'>53)>P/C9.O(2U5*H!0,U5Z,.;HVKI@)3LF /4_N!
M&:BE0Y'??L:?5BRH)6IT:#%21B?*$@"G(GK^CX\.==C=".?/O-E^Q:=7_OX0
MT+5O=KK G[?^SZLQJ3Q]59(O#G[IT(O/7*^VV\W9[VX$\#./].+C7\:/Y*U^
M^_3C,:>=_L)3?73VZ.KRXOJ(^ 8>YKV+"[^\>\H7%Z_>_\O/O]A>OX^GGT^O
M8G.Y>1-)S)NS >EQ[$_US\V>W^*EH>LZ*4VM *3*:#5Y-PTRZ+]R7O%[,)"Y
MU>&39H)?"VQD'3WW!JDCD\5<0S&H:E+[BM\] 2@?]F Z%/SFJ($;U8P<($3E
M%H*'*$H8%-.J?W\G9%ZZS_M\L?DWX'QP<;EY.)C?I_W%*2\^W-M<Z.GY=/**
MY-=BPI*'XI4!L:DJ@53L-70-("T3$\@UDD-,*Y)7)KP[_(:3F':#7\H>H8$&
M<H/< G83J5))M!24O.+W8""S(":\._QZ+U/2T91'HD#(7(0%0TW*IL73BM^5
M"1\R?J-G"(*F(4^E[@BA(117I:Q6@JWX79GP/)!<N SX]@!>$@0#BAY44<C,
M?+"*U:8[ B9\U[>3%'2,J8M/^SU_='YQ<\6#-^6H68D0$!(,G6PVJ$2/EIF1
M:!AT*X /"#,+XL*[ [ (\J##+?8"(#A,.&R0,U:"SEA@!? 1<.$Y:V"?^O(Q
M!7?KD'LB\M0<(QA1I1A7 !\5&9XSE$.SRD10LQ5 <8JFVO.4[]ZTQ;#:=2L;
M/FAS+@0%3"5)0(&6*C>,#KWUV&)&K"N #P<S"V+#._1'E")42BTRE3-CI224
MF=!3:%AYU< K&SYL 'N[+EMN+3%#](S$:>J[$P8O#KGA"N"5#<\$RFP>@9/4
M& 5,@6/$Q 5+YBXYKYZ)8V##?S[?^N;!V8?GCWU[-KV2>RZ7LPOX,8 *1J$@
M.10Q#E9;[&X04N]A#7T_2/0LB"'O#LI5(#;,J5=5H!XI]A8I661,.9>T0OD(
M&/)"M+*2=0"LB@D:1QI?9(MN:*:QKE ^+JZ\#%!KPEI3CS%8!J0I8;)(EXJ4
M>X+45@-P9<TS,0 U%&]!Q$$R!#)VS*+-0IOJ.-<US/@@T;,@UKP[*%>G%$+O
M0"D"#B!K04W@&M4:4URAO++FN4#9@L98FF2>2K(/O2RA#[!9IR3FJU9>6?/\
M0!U+<JYYH)@9!L$02 D+013MUI\O7,_%%/S%Q8#S[:/S[0#/&Y_/#W!8O3'>
M?BB&7TF68LRE%Q2HL5.)DE :<F_06ELA?+00GHMO.;?F/7'6VAS<!K$8@%5(
M&8DLUWD%TZ\0ODV>?B@03@43ADHNM4,RPX(#O%G#X!859U8D:(7P?OCYH8 Y
MIY1$/5ON!B$0*8=02V^#*6-I\\J37L$\'U:\.\.N8<I0T*GV AF$6XL])19T
M9NFT0OAH(3P;WS%H(S7$J<-:;RC:8C71-%AR9N85PD<+X3?+BG>9%U(QLE@@
M%@#HF!T+6.846QJJ>(7PW"%\\*QXAW')P7(SMR2M0F"FF-!80X,<U=:XY(/E
MI+L8[,^:=?O%,S'PZ?WS[>4#?N#OG=GUH>^S?N\VNZBAS,!0O#>*&32[-/;N
MC!%K5JOS6O\X0$R_81@MB#?O,E*Y=HDI8"PRU1="Z5YB&%2Z62VQK)@^4-9Z
M@ /L4# MN0X;<.CF[AVB=M3:<&KY*ITZ.:V8/G@:NZ+[EYDUU-1= CPK<%A0
MH>42<H]!>BYK7>256<\OLLB$%+4!U0Z5D8>9:+TK0-7&<4W(/FP8+8A9[W!1
MI<.P#BW*L! 'FA4KB914LV#SQ&O]V959STY/A\ @'MUY*D-KD^NC)^N:O&AW
M74L7K<QZQNC6W"651"IM8AY"7!)..=O2!N'V>?GW?FD!YO[YF3^]S]OO_?+/
M5V=V)"LO!QK"L3NK$)$+AP'8&@@29]2*R;74)BV[+2.D;L7N 3'E':ZKA$Z%
M2K+"!AHC)Q&4+CE&H&;S*ORR8G<&01N[PRZ09VC6(@YJ'#"+]]B:!F4>RG=F
MY3%6[,XJ6F-W*(XD%=$]:TR@1.S:K92>6ZD$=5Z^BA7%,V"^N[/:+/3JE!U8
M'4H%[K4Y(EGC:)R7$7^_8O> F._NL(LL.7$K$'," *28.!6K+CA4K\QKW6/%
M[@R8[P[[FW(LGG(? .X0. HJ8B$7#V,+=,7N;+%[\,QW=RA.[C6B)#!N@^@*
M-4W!)BJ<JK4R[VSJ:S_]!_^\&H^[.7OL%Y?3I3=G'_(I/^('YT>"Y@-EP#N,
MX7354IJD[%/N4T?)GK!GD>B$/.^B%BN&#Y@)[[!%I))E$C(B!YB6X,39K5+M
M*?69Q=:O&)X1(]XAAKE1ZH &95JX*%*Z1HT";F0QSWL-;L7P+)CQ#GW" FR,
M/JAQ ?>Q.85H"D33()+FG5&]HOF F?$.?12]JL3!A%D80DV8(H4<"ACVQC+O
ME.H5PP?,C'>'X:ZUU"RUM\B 5##WP2A"CE0S ?85P\>+X;GXB@M;QI9S!PK@
MN: E+YR3$DC*;5Z5O5<,SY(9[U CDYG62CJT+S0#,>#!++*FTH!E7C$_!PBE
M@\[ >X'HZP$_N^S1R:4&!4#$ ]1>6";7L6:2$".'>:UW'"!V=P27!3'A'68^
M9]%J-6F) :;E9LO$@9V&+==CF9>/^ "Q>] 9=3/7NQ:)D4N/! 3:@\1><HR6
M/<1,;5XQ[@>(W3WJW8-GOCM<:6YD.=4:8NA0K5-GY:@U%PZES<R..T 4K\SW
MS5EM3@&-@-F0 8VIAIQR:[GTR9&VUDTY#+@LB/GNL)IFB54Z17.ID(!%4@*[
MCKYL"5?LKLSW<+$+S@5*J7D8;-,2,I60DIJHATZ$\XH3/D#LKLSW5E!,["A3
M<]TL("%1U6P1IL2C#DEUM=\6S'RO5WCN>??MUNWN^<-'XUR^'&?_]93/9F*Z
M=>!L)9N )9 $PW3+0K%UR:EX6 N]'A!F%L2!=UCAI*J IU"5' (U5**8:\2$
MGFJ-*X 7S(&7H(%UH%6B)L@L,/&(UGL,1JFWZI;7I;?#9Z,KE&_\P$,9#WN.
M<DR W(6\H531E+N6,*_8X .$\LJ&WW0(3W&,.3KC(!,] H7!+3![,,30&58
M'PYF%L2&=QC9WE*''CA>MS:8ZIV4FCQFCE"SEGE5[#E  *]L^$TO:>B@PNRL
M'.)0O<0^F&^;%'#O#?N\2I\<((!7-GQK4*XI-4S0R]2+8XKM8:CNE$H'8<RK
M;WCQ;/C/YUO?/#B[.U[!]+[N#>P\'BA^['<'3K:LEW,)4^/NJ*4R-%?(V,D@
MQE"F;.82-/,*Y4-$SX(8\@ZAW"#4&+Q3%XC:"*SWGEK6W J9K5!>.D->C%:V
M<;'.9C[8!<02!;$T4>G"G#/U%<K'PY67 VKOF%"]F3, ,3<KC:;J504E][67
MS,J:YQ+B5K/'V'-/G@U"KM2S5[%(J&$HZWFEZ!\@E%?6?&M0#JC=R:HD$%#K
MW(TYYL$X(+:@887RRIIG N7HM08T"4X#O$4'KPB62/ Z84G71>J5-<\/U(0E
ME*C)9?)J6)!Q]69JH;6F,:YAG(?*F@_%[(H%<O'*4S$T*)TX0$X#3KFT 29<
M$Y&7R1!W!R"I,35H7%NO8"04-;)$\@)4T.?E5STH.O:&T7PH #+,.8CD&I@!
MXU1RWRI'B8#0),X+0 >H@0X^*VN'U8SZF+VJ>IT<+[DD1 $:T-*$4VK6O'H_
M'2"4#I0-[3*Q&D*9>#-6@1 CDF<TC&,>XXIYM1&7R89V6%5"^Z!!U6)W!,*
MK1HQ*<9NM2K-"D K&[I] (GU:#B8="K#H$<9?+I0YU9#8$B\IL<OG0WMLIM@
MRNK<F&00ZT;8)R4DPKT/6I36#,G? J7WKRXV9WYQ\9[^\VISL9E"4U_R*][_
M^K,/'\I?#FGFG(LCJG4%Q,&[:D$(7GB0L.)>&S<O(<ZK:]6*UH/D>;O,/C<F
ME\E76B#U*"&TZ,!1G6**N*)U[NNBNQ@ZAX)6JKWFBN80";@G:L9*7#/"E*:P
M.OGGI%L/GL'ND!/$ =68*;-'8$?"%CRV;%(D<5S=,7/"[8$RV!T&F"0 SXBD
M#2&7AIY:GA@L,61H:Q+Y4:!U+I[*A'E86,I%0H6DA;CG+ .ZG3S74E:TK@SV
M<-"*91!8#\ZY).B=D%&2XY22J!AAK30^)]UZ\ QV=[AM&$E:JR67J>IMXSZ
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M21K<8 BL%@^E92M,7<,,(F7_FY3&0+87@EKYXV\C!GWPQVHU"9"C]%)SKSC
MD@99F $Q.'C^^&M >BBP<"&AD)-G2(,2%$&#"+D%#(;=9@"+)4IEBD&I.:><
MF@-9DFXM1JA1O+C[#/)G9L+B]Z[@=Y@N S8I= \ZT,-<.=B@] FX82^29Q![
M=O *?G]<<8>QI!;<+"0ES9!I:D$Y0 ))*G=-/(,X^9FHEEFGVD>-@PY$&B0
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M6396D+PN6#'-6!QF>(0B]=3>$,VH(L$@2;AQ3CB7.&D%RA6723/XKVI,>$4
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MZS9%FB@*/CE-JC(MJ;8/@QNF>G;07N^U=+OXV&G9KO-%?7=6VO&# Q])=-&
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M]H?BQ/>*?A+HG\6M2E>^WW\<?2N5J[\^'!QV>Q&.72;63Z)G'] 73K#A0F'
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M@Q ",P$D)1A0K2 P,3@#%A&I6*(I*N2,R[,WZL?,N&2C?A"CGB(SWB$9A:@
MX2H:M9(6*"<(D%;A&)4@KBTJC5KP)3+J%U)!;G^HBWKJK,D+KAA][.J6M%8^
M!K@<KLV'<%O3M 5RYC$B B!%)* V<A?MC0'$PABVR<!H%-1KLLI(+A7/AO_$
MA"<;_CT-?XK::&B8I:G;"%,V&GY\93P6 &J$C(:4!FJ3X2-Z;VJ3*\$79)9;
M'=L]]D7H=8^+[HE/-+_;>?(LS0L&O\=D/=LC@:<#LY(6O.OF//6<^%>?)CY2
M>!_=$@?<61/QSY%4'*-B:$<4@U HE$H$\:I4]^ZV-*^=5"B9\X)M_S&)3[;]
M^]O^%/>14&D+/08HG<1!"71 (J= %%_0ED+"D4RV3^&"3S=:(NY3M9S/Y)C(
M2;+GJ7,]%02WWYZR1&8BOYR5O@M\?9BF+IXQJ()S(' 7 #5,ID4G [#UR@:&
M),0FPA?[<8W]AU;=N1RFBL:Y\'J8;)SW,\XI;F%]!$Z,/+#<6D 9\T!A$JD&
M-IXH;)GA-AHG_7&3X),8Y[//F6R7W0Y;H\S);V/R\/MJT?&#ITZ</'.46@"%
MZ,<'CJ^NPU6CV^E>C8@R<-T%N#Y.LPI!H;*281"H1X"&^,-$O *8.HJ98D+)
M&!21&_9,S@Y<N7)EB>UU :PBV^L#V^L4T3 .N3( @ J1U"Y> >4] 1BQ@!.<
MJG2F*&(_-O)Y$GM] 0F*DF(8'[H]/R$< WV:RU)>R +-96YVTLNLU1G&J=V^
M6*G[J]2-T77-I!GU5J?;:PW.)O'7>L==O<OHZ.6Z'QQVXSO?XB5IHT)._LZ'
MFWO3/,<HBHW5!J"0>D-008$Q6@.&K664RZ "SSJ6=>P^.F:5$"(H#8(4$E ,
M#9 8!F (1EY(*)1&:8$!\Q^WY5:EVB([LN>ZVIA!9GE!9BH 0))J@Y$"+I3+
M *G)$7(8,!^TI 9J3'76L:QC]]$Q831"@4C +8Z.3&$-M&(8Q-A3!.(-0EXG
M1Q:5H;*.[-FGP+<N8M%[+9Z_[$S:TZZ=CT%PG#;[RW=\:.6V.?,!FYUFZ X9
M)8P10$KKHO-$*$:!G (&$;(!8B-Q6'G-Z*(*@'+*>PD-]0'6T;.A+L)0IQB(
MBP&ST\DR;3J#"\>@6F'!@2>.0AH<)C*&TI0OTZ[J9Y_K;OC!.,.=<]M5IADS
MAVOO>]V(8[GN>&XL.Y@F'='+**NP TB71Z8B!K1E B!A8LC.+&-0I^WD B^J
MG57. CXKDW_,#$TV^3N;_'0"!5KGJ [ >2@ M8H"A5*#&,,M%9@J[$TR>4;R
M@3O+Q&[:4>\+/1CT6F8XT*;MBT&WB,(I3U+NEGU7(@,:)2)S-J6J=81^<)E!
M7I\2=K/;N"+J2<HY(^%<2/CU2J<)P1V'C -+</C_['UK4QO)LNU?47!WW)@=
M03'U?GAV$,$ ]F;N(#P&CX_]9:*>1K:0.'K8QK_^9G5+(%XV @$MJ'-B,QBI
MNZLS*U>MS,K*!/*C ])*2Z1HLLDIDJ+W*^MW.;-00BT-MN)[S"XL5GS/5CR[
MZ>@5!B2.B&CE$#<RQTT]1<(3RIRS2JG<6.#R;E!).KS?0,PELO*JTXWV7GJZ
MW:^#=I6 'Q7E_G5O#'R.Z=QPQ_0A8U'G\+Y@^3Q8_NE<:76"H];4)229%HA;
MQ9#U$6:S5C;/Y."3J\-1B^J3M2SAJ()P!>$>,?16$.XN"#?#5B5P52D%0]22
MB#AXFL@QYU'2DD?FF(I*5]$WL:B>G4\E^O:H9CG#:H_CH#4\M(/K^"W(X.BH
MGT?8]Y\/^UT0_K"%6LX.._X^XG)S%'IAH.'0'^?A/H>E87X!+._:\#H.]O.D
M7"P+IA?7@6T[Z(&TAM/'_9YG]>EZ@,MZ<(/UX'R1?BH%\%R'L#"P'AC#D+/8
M(!X\"\H($FWNX;QV]\V8N:WAD2.5!=<*KEV+:W?DO@77[@779HO.4!-33L[W
M45A ,Y*0\80B$[0*401%1([*KM$[%_%^,%Q[H-#MHYIB-?F'K?&PZ@XYPW5A
M?'[<K<[!W(G,/N^26M<B727DX2.&,-]5PXQA \1E/\;V^,C%P5ZJY\/>>#0<
MV5Z6]GE@+ & FP#CN?8&EGC+C<5(!I6SAY5 FGB' A;!:".UYE57)BH65>6\
M05',8MZ/%+\KYGV?YCW;;-)9)9B5P'N2RFWN.=*)6,04XY@K3K'$E7DWJC]L
M">'=)(07.MTQV-!C!/&>@3O[M!W6^P[$;=5SL[BL<T'W^?X+5@CM4D*,,XDX
MP0#=3CJD+5=,&,X$=E4H[LZ=@IN7%ECPYXGCSWT'S K^W Y_9JDCMM@D\ RY
MH9DZIH@T"Q[10 +V)$@>ZY!9DTZ EZ#8:5#L+O2P^,U+%1:;H-TE][EXSG/!
MW[D>$L81XW7D2%'*$"Q.&#D1"#+:F CX)UFPS?.<BX$_R<!8,? %&?@,OV$J
M*<^D0<$;X#?"2.22TD@FZ3D7,A!<I;Y1=>?^=HL.C?U:!8C@OZ'S9?T_\&/Z
MZ)E[^9@/\TP,;/T_;O#K^NEXRV7ELG)9N6P)+GM :D KYRK&EO6^?P3//LEG
MV'O]41RN73ONR<6<KBD!#SCN#SMYA7@QB-D1^Q)_^]H)H\,I[YBYL(;U%_CL
M$NN&_;S,7WO)D1U\[/2F.26_-45D[+QP9G_FP5>\1&27*!+-B=&<$6&BQRH2
MIPP/.&CU#Z4KTXL.!],W. 8*A-P@VL_()GC!%[;[U9X,5WX]+Q:0R04U7"?!
MBVOM#^9F V:HNE+<K5<[?VYO;+7V-W>VVYO;^ZNMG?;F]1.T*</>W />V=[?
MWFK!;_M[?^YL;1S /_8/X#^[V^V#_=;>2_AH]_6;[?_"]W;^WL[OM;>[_7AO
M9FXT_7\9]^PX=(">__O:H4XL=V+S\@?&^Q.8/'^C/-5G0$%<<]]Z._$4=ZK$
M-!!.UQX/XXOI+[^%SO"X:T]>='K5.U8777&.]\RVUG!M7Y-PV^3^DX_7JH\N
M,./Z,TW6#+_^8[Q&;OF98+>[ZX\&*]<DU\LS5D%O=->?A$E_&A:8XZOFTE>O
M"!'44_4!3HVK-?$SM*HF]<'A (C +GSO<-C:[H4+<=0BOY_(;]<._&&+D=7;
MB.U1@_ W?<-?.KT6W+>;*[%?*MUPMSDQSQ&YG\^"QQ53#GG?9 OB)J_\_$2'
MYS&?A1RY;/3.U_U655V8&)]:1L+S/=/^O"O(GNQVIE']<-1^]]?)^T\O._!?
M =\Y^K"U*]X?O,>[G^ >!^W#O7=O#M]_^G@:H=\[@OO07?S^('3@OM\^', ]
M/[TYW(.Q[A[M?&MO?:;M3^\)C.'[Q:C^AU=_?7___<UAF^[ .[SLMK<^TO:K
M;;%[\!'&L(WW#M[#M6_A?=MI]P2?5!']??RUU(\MX%; K8D%.PJXW1;<\"FX
ME4JY2YGHOS<ZC(.<PG\\B(>Q-^Q\.6U^^TLNHOOO%_=:'G?9[[&@C+YZU:)K
M5#1\NF0?)_=U@X&T_'@PB#U_TAH-X(Z3S+Z/MM.;S)S55@^^W4^Y<U7)\VNX
M(W!^0:Q087,6%&9:]=7JWYQH_R KOQ[B1B\<G$V%C?!I7+?P@TFSEP[LM[*X
MSK&XMO=G/ <357 A.)AIG"/.4VX6+RC2C.1%EF&M/2RN34H%*D:^/"68B[DW
MP=S/N+16A&-!!/)2$,19!"X=DT1624M8KM$LX\HZNUS6\^95FIMW'G9I.-#&
M%]OIYOUG!$P(#6&*@Y4Y<$ B,*+.J!.'A3,_%&>FHDZI:?)\R9QYW!M$&,KW
M&*K6)(4:/X'V(S]:-4\Q I;/?4"(_5-L.%LGZP[9;Z+OVN&PDT"XY]?185E(
M;[.0SD;<#=.8>"Z141AX<TP"69Z#4BD$'3#'-J25]<O1]D=91XOM/PW&7&S_
M$6W_C$1'+@'SB4%"4XPXQ1H9S@E* EN?;#+*8[#]N[0Z:2B)OB$I>KRV)Q?G
M_;#JSG::/G%G=O2\VSH]7@;!]SCH!SL\G <MK\? EX/^T<;>YLX$1O?2&9 6
M=+P%.NYMSC C&A.QGCMD#8O C 1!-ECXP6R@(B45$C"C__M_-"7TMP:54"@0
MT$"25*R]D=9^QH68,0E++A S0@,7$@%9S#W"/$4GB?.@ZI5U<KF+QE-N^W;Z
MT)D3+)-;H/S]T_-:U7TZO0"S] 4RQZ-'C"/Y0]O[&"^<!2N-O$M4J>R^W DL
M9S=;.0 BUT"-8C0!<:XX,J!GI .C$?ZEL(H+"1HM2W9F 85E#S<54+@=*)PQ
M*&\4\89B9*4$?XDE@IQ-%GEB@[821^SERCKC2X *SVV_=M,.#UNIV__:.HSA
M8P-V9Q=VG*Q9@WSF^[HY\W$V<MDJ&[L-#UW>?(W-$/(2$.2_&4!>@:+S'Z_9
MP\FE0,I2.^=)@H-S?=XP%<1H;) U1"$.BRO2U&AD!381IR"D$BOK<E$'"9:4
M:C]M^W[0L&2Q[_NW[YGBAI9Z'K!4*$G%$%<Q(0M^-M),RY H]4KAE75QY]+Q
M97^V[,\N-0@^3ICQ2C0L.+@0'#S7W@Q4B)66%$7E'.+)$&2$X,B%I+$EDABF
M5M8;5<*^F'@#HX;%M)MAVK,41WCJM/'("XX1%]@BI^ W2AD3EG!K+;]C]EG9
M<2T[KLN]N;)4X9X*%2]!92\4H)P7*,\U$B."*\X81K#P1<0-E\A&Q9%GAC*%
M8R0NKJR;11UM+7NN3PH6'I\\%5A8'"S,\"?I<3!$610,#XC;A)$SA*!(I/<V
M.?C)K]QO;2@LE%HRPQL5(KU73_(9 ^6#\J>2;G(K #S7X4N'F+QU&@5E/>*$
M>60PIXB(R%G>$L-, "^Z\Q[8O*:Q1(&CIV;NS<]%*X9_2\.?83[:@GZ24"@9
M\(JXPAIIGQC",JB$0\(FT3L6_W@HFW\._4XWKZ [CYWY\]2 KZ$UD:\ P2D
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M'X0X0+5L7C#08.B/73>VIB*9?&'4/WZ1]3OL=SNA^G )H6V^=#_N;:!.4IL
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MXY$%:1_TV_U>'L>@WX7A?]R!$0&PC@J<S@FG,^=)/(M$!\Z12)0B'K%%FK&
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M/@PKQST?Z<E?&/>.@'A7G\$BT(N9[N]E-GW8B0G0'="^NGHO >.(@U6@7-5
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M!J;\B*/3,%S&]Q&85K=C7:=;(=GJ&:#4<'><W_*\(Y@77_#EQX,<P-FKUA.
MNGX>=+665.&L^,5VQQED,^3-NNJSKS@Q[OI1TQ=9:[VK%J7ZTK/W _$?=H:C
M_J""]SRR016:KH,.O2I0V!]G(0T^1["^8UB*X9DS/>#@!6!8>0Q#P-/C>O&I
M!/4U3B/1-93G56+8KY9$6%9"K+U*WQGX\=%P9.N ^"3$506-09I3HC*H@Q?U
MLIK1&_24W_9,-];UQ[56O!T,*J<\2RO.**4:]8Q>)OJ<!+&S+YT#V/8X;T'
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M.T\7X&>XQ&"&)Z_^W%\\^L-O__00+0R_H!W&\"-,"?4NG'+J7N/L";+%V0A
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MA\]?V2>O>Q1^*K_8SW?.G,S*BI'4>NYS$<Y>1T+W,J+FC)'V_<K#*?)?O_4
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M2\ %2@ RQ\YYOG18\=;HZ+,UD,99-7;@+0&'E("GWTK /]Z[D42D7%O0=?X
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M*6 T"5,*>IA=@/36<3C9U77Z)=[;'.\M#!<B#*Q]%@3>D1N:@^,L+3T.3;-
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M0$L]6[^+G7?3_./3_-$IS5*M&8$$T/D&QZR]37H-(+R&+'69_\ZR&X_?0%^
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M,L#IFA[$<9O"@,+'ICNKI!<Q*",,6>5*C3HB,X#JNK.= 3Z2/TT1I-644S+
M#D L!94LQ!.(,N8N.K>>#'"Z'(@F9Y3/('0KS,7Q0!781.="(8N9&3XT08GP
MC6\$W((TCO/T)/0W4BOD4LD;GTFO^]SW#F?>HA.^,]QU9;*?MFF8?9=D\77K
M[?_ZT@2J577.;3%M4GMD+Q8Y+HH0R$1$U*A<**:0JA=15.XIBFMC]7Y<4N38
M.-A\]ZJR<;..8UZDU#(4V?=-657AE9)5Y^B=A4&1PZWJ_-^* ';#*<R=8SO'
MKBX-W"I/+BDHAH"DC26 5YAEM5 KZ,ZQWQ;'G@BB;!P\^^55"@&<#4J44(H
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M-S\QX6:U\>9/\_+GW_7FFQ^V7NS\^-?+-[]NOWSSS\KO6;:W.GC0:+0(UJ&
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M<^D^2S!>K'D<>V;ET*LZ@M_.I+"O=']4.,(\5$?,.-L:5?:"^#)\_<(#]WK
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MJL-_WVS*U>/V+$U&<KX0#BHTB#5^5<;5F:[X]''^+^O.C_+S-TUB%BTS5Y5
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MWS;GNF&^]5!F=SHH3$5&3 !0@Z%@H1C4RFNVSMTPKR^>ES?;V9,.D;S '),
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MUZZ-M'Y9WFDV6;E"4HD05"O!2"2B5%4DCMQS05-*EO<>:F/7*%6F@W/5:2#
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MO8;N74"T,Z14Y=$F4T :%ZLAEXJ*(4NVRN<H"W?L7FM$O+0Q3AHI0R$1D:(
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M4M->=Y;K+'?'68YRK0Y<494"Q""#=R5BS$'5XER.E\MXZP2W.H);RFUS/%
M**+6U-RX) +Z*'QF>K,JF))75W2D4URGN&^;XE*IJ@0'1=L$*J04E8T5/<=
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M#'=W&"[H4AQSFZS:@/&0,B&@5E%2,A N6)6E,]P5,YP\Q7 Z&5V"*<*;4@0
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MA=6P["P8R">3:* $"=@-Q&V@R%*,48C$TD $U107U?N1LRM+TA@3#;?&<>4
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M>H70\U,[:/S7>NEJV^.U>#]=BE>C?A^VZJ'CR,W3+;Y_//LL)*/:^X"<4X
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M7R-L;(9MS?'\-JOI38\ZS9-#IX^T^>ZSQE$1D,@H4@'ZF L469L4PDYY%K0
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MT]Z#9UHJBA&5\(-K)9!CQ@+D$I=+>[,@'A[&/LGPRA))N0Z!0%>,7AA7%F5
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M/M*X"MVZ="59"U8O 'K?*OCJ$;2HX/>(I#,5W$F>:#($%&^>"Z$;CBSU&I'
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M$ 1YPBGB1@%48:51)-0F0K53R3Y[*>4:0=6*$I0>M.+Y6QLX(@[^E370,3^
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M")Y2\<>%@_5'_5X75 48-%R=:E4ZWV?#J T\7HTS+QKP;\7I[5;&DM :1#L
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M;F'J.,%0L641T,X2K@R;U'Y=(IY?M#]>36>R((_6+\OAGNF)- \_4V=2B *
M!I@:<2XU<@%T%!QI,C9JJF-\]I+A"X!F:HD,ZK.X3"(>='-0J,&0MR'KZ15?
M/U^T4&SCI#?,OX/ED4;#$1CR\*@(-W8CT&:%!35YOMG:'/LXX-+L/)FX1&KG
M -Q205M8\EQ6^O8<.4^\J6>5"^4Z*,BLT<E@AQ60,-AE6D9"=:!8::4P<;=#
MO^^C[QUVP0 )V]FX::56/LRJ2^.,$3)L=L-<Z.IF[2.>$7ZA]9V]3;&[]_';
MSIZG>3Y@='-G/(LZH* I!:&*#=+:$L15!(5,,)PL 5J_H//,A-9_X&,?F]IC
MGPY8V;N56Z?=ZQZB8>QW&KUI5O_/C.H_;-MV?6Q\.(JPXS6M7XK.F:1GC% ?
M2P#'N/'^CRW7[&3SL0LJ8Z]V3,ZSUL:2@_CBP]&Q43VV?#G=4-DN/^G5:_"B
M\C*TOL;?3UMA>#0)=IJ[<>QDQK-;K(,YCX:7WS+G!6"+/@"8"RSJ/=G[1"RM
MU]S/H_ZLQ.YA1*X?[1=D$PSVA6V?VK/!LW\O3A'FM[2DRZM13_+E_[K^OU]>
M].(+3_-^>CJW=)KG%-'18Q^%Q=PY8KB1/!(G0 X$P?FE&_,PW#-S F+"+#,'
M_55/X"J?L[.97ROQE)^W<!S8ZM:PGW?A2[=WVJT>E7_+ #X''C.?,TBJU,K>
MN(W&JZ,<NS+(8A2N&<3ZO2?C@S)XT&SDOC=J@\9F1_FJ[)8^L;7\S0^?#JOR
M,RW.[?G89UZ/=@@O;-4CRU<]GQ[H38_2)K[#H?TV?LM% /@\3^TTYOL&C78\
M'+L4:\?V%+D\K.7X[*.3C]KJL\1:T#6JM[K:X=^N/JE/ Q?6M!OS"6;6+K*J
M,3[EJ0<#=YV!'9Q/*'MN:($(8*YN-&QT>XTJ="@?ML**@(IQ%BU81FDX/O4\
M=UAZ[JS\%H,F/OBC&$;MN)O."WW@S)^+_+U,64\UN@+&(YI[^Z?-+<_@^NQS
MDX(&):E$6&(PG*4WR"JB$%4^&*6XQQPO8Y]06"<6A+&$\<2HT6!D$:6L94Q$
M9I<#+1XV$O;:[=YI%;Q0@1)04?8D?8^#"_7IP04@<BE 7JX=O;CJ&;1</(&^
M]"A]//B):@%*5S_'DK7MR2"^F/SR>V@-3MKV[$6K6RU&==-R]!B\9B9R-W M
M=L>U*<;/'W^]47VU%,M6?Z?IAE3DTJ_QQDV_ ZWT1G?^:+"$;S!CKO38A] @
M0U^A/<:SE[^!2C[6X@?GXA)7TTSA@E6H]=1U6H?-2O8N+,!-^SZ,V:X*>3P9
M-BH#II$G\*#JM&POJT&WT1%BM<OZ:UT[?A!KJVH+9)VWZTVKVQI&E"--PCD5
MME37>>II#'?BW+L]#]X,C!Y\N,PX9>%]>^<8GK=UR \^?22@Q8/&?LAWMMY\
M.>C\V<GC:FYM\V;GSR_+*0L';S^>[1Q[OKMUU#[8^^>HN?6%P'-.=SZ][^QW
M]O'!UB;>.3ZD^YWW::<UK<5#FGN;WS_CP&,,,67+R^> :XF<T1HY2:AUSC.C
MV;.7FHLURKM:4?^EAX+D$T9H;/_]_G]LY^3WK5N5O/1Z"WDAE#]HO+.!2FTY
M=R)1;J2S1%I@#B,\-H)&LV:'&=M@,*=*V/^59?T,&=>L1\"#@,>S!7ADGZ,W
MC NK$0O!()XL1A8[@K2+G# 1I1(Y6_XY,></_DK9R-LM&UF'3&5';0ZF'-IO
M.6RS>SO*[970\:J*[OJAXW626M=1'9P0PY[]MHZ%BAX"]#5?+4$?(Y82QRAR
M6@+T21V1!HQ"FDJK%$DR./_LI2#GHS+7L47MHVC*61^5C[W,ORUYE_]U<_![
MVJKAW8#? .8)OTU0\+#5#BN%P(HVFFM4#?)!@-Z'97TODLALE"C:P!"GEB$#
M_T/!*>4]=8G0'#:HU7KT9%FE3Y/0#;KNIO!>;VC;0-8SSIA+O[UOO>]2?_2R
MI_^!X.+CC?\K,'E-F&PMP62P4BFC&2):* 26<$!.FH"L<\Y*^)_UN=3)<\96
MY3>\,G,5_?%RCGX[#ELJ2N)Z@N$BXDUV:S&WH^#5%?!JSHVW\_TC^ZPE<<0*
MB[C*IQQ)>V2P"B@Q30V6.7I3/'M)Z?E4L@?OQ'M@NMU"T/9]'%./!<TXS(K!
M H;>*"N:563!K^EX:[?FUS[A7M7J%+"_=<UW(CZ*!KP"B;*[[!T5D1GMN4)*
M60X:L# @43Q&PFM&A")<Z)R<_%S(\UDROZ0!_RKKK:9<X#3_9;YVVGI4>:J>
M^*(%PJ3EKQ#K.Q?65O//3R-P'U ,\X]BP*Y;+(=KQCRH3TH+QPV).@F;/$LB
M:@!!3M?,QG]$$4(KRF,%9#O]S'0BWB:+9# &<8\5RMG0R+FH@H@D66POCO>9
MYO9-DU3KQ)/+LDNG2:A5_E!=&FM<>>N')?B6TI!RWEZ(.3,PYZKD"E[VY*1]
M-JDJ.#[]K5+TK#\:)QB-NCT'?/.U\A"VNB>C894N-!GJQ8E_V9/H[>"HD=J]
MTT'##NN*5M4SX.8?SB<7!LKUO.IRB/UQVM*EW 5<X.)R$CAC@AOG'(V8<"NM
M,S1)P@+3QEN;Q,4,1A=.%):B/W:BS55%<Z;P=EZ%*2<@^K19X=O.N\^)T\@B
MLTCI7';&*(RT$!YY1R(V'DN0ZA=V0OCOFD@7MWN4T]TN98WJDJJ,)0B1+T!H
M)S;+VA8(AEP?KDI3RTEJ0&<UV5<9;\N0G=][P<<YF<O%*F6\TX/'YJRPJE@E
M2)WYE->81NU&NY7F:?/"A"T<G!8I9V?1R+4A)@4<0W*.*\UYD!<6M9A#>9!9
M_D48]7,&V3+&3T#[S>4A2Y_&'+D)<["'\6,U\+]@W$^<9INY'IK#@LB$')<4
M\6CRH;R**! GE6 T.))+)>%EW:Q*YKM:5<[U5VVF 9'G,C-G>9B]6;3DI/3/
MI4+)MMOC',Q^/*RR2'/!QMYHF/\>P0-[_;-I$OA\9FCF\8\;'Y:K+,QJG"U*
MQ.MH6S<,0OS%NE2W'H3XM"O3')[MOOO,.>,^@=[E-#.Y%[4%#8QB1%RRP4BB
MF9,_KDSSH^H*:Z,NU<7\*O&T$NV(.!8U@)Y6@7 .MH=0F')+++76DL2+=K0Z
M,OV^N_G9X1"HB!2%F%NF1VF0#K$JRD<I]1)+A]=,.WH<TNU#9M Q>X,Z%ZO(
M(4!B;[O#A5('K2Z(K%SHI'6^\C+<?TY+G$]6'E<$?C%7*P%N 3[/!8JR*5?7
M&YKC[YG4Z\-[NE4A]5R[X*3RU=?%5%)K./A]'BWR0P<CGZL1_%Z/<8$J!K%=
MO:[^;J*9YM]GE8_FZT?#P.#AN07<8%9YH37XLB#WJ](.K;D!Y"MGS[-M ,=N
M7;QU6L1Y4*D!W;/)O(= ,'%"C8/G6:^&&=8Z0@(Z[ST&78J(B[(Z+U:AQI11
M%Z*?G-'4%[DL,B;2?^QK&C\J%_9O5QLR+D)1%=L N\3!GO2Z$TH=UQ:9E,&?
MO#,F4&5R79_'L=)[1U/96J%A5D S-XY%,\#;0ES3C'WK15^0T>,Z=)-=^"MS
M?H/!->%\BX+.3,I5]X5ILY'&X:@5<@6EJRWQFCMRIPD!X^K*>SDAX,&3SM27
MF]6M,)EB+C.S6*UMKMQ.C;,I9>'@(_#G\#3&[I+(=;W>EWQ3:XRD\,#ZKTLZ
M6E0ZW,R=,*T)5-6A 7B(:%X5S4^8289<_CU.*M*O96>(:Y+:<AS-?=#$PT?%
M*6G/&J[4HF*^;-MP5ASYH@8LURJ[<DT3_ Z.=A]5B,\J:C_#V#;9SN9G,#=\
M4)PB21E8'X1@Y(3A2!+&"3461XTO#MB9'E-D5+RH"<^D3<A\7X#4KI2;BK9J
M#1!N[/8Z+0_PV8U9KP4AW*J,Y:J/16\^$V-*>)4)4]<<Z_:&8\VH];451E4;
MDM:T8%5%HH,(9DY=<7A6X&NC,:&)^:I?&6USFPW YVL0L$F&&"T5%BQR!7:R
MU!2(6H!EEW*KJ@D!+W:UV&Z^.>_,!2H^A94$X^TR+])<,XN_1WU_!/+H[W[+
MQ\UVN^<K7IY,[/6WDTKK!P$][N><#?*JW,J4!? 38X'Y"EV[6Z^_ 0L(K&CD
MF.7VS'I:P9@C+ @S%FQP(]2SE]W>.0X85DTI_'"JGH?I*E>$-$N8;)R,^B<]
MD,UK*91_V+YOOC'5XY"$V]V+FG*!S,I]AW[>KVFA4U?>YLIV/U>A^CH"D #.
M:DPUY@;SR(BS,J9 <"*)1<OK]CB88,K0Y)?2).%6!66.;OK^D< SZ<X6H,7F
MYV "M=Q89&.NU9N$0EJ[A$+""GO'./> $A3_H$O"QB+M9(O@JFVGYFDPR]NZ
M#=6DE5WEP;+'O?[8$5,Y=OH]'V.8:P?U(9X,8W;XU@VV0,2T@'I'71 [HRQ4
M09)6:AYL?M6,Q^:V6I/F7M>BY^!)-#9$&3GA,$KC)7,D]W+4L(113>BYKD-Y
MOB_OM6KUC^?Y!J;Y5Z][N!?[G;\RA>^F5S"KUO#I$O&<MI>+3^<&X('"UJB
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M+I8B^'=<!#])8 IN4HJ1!^^-%1SKG&M#F6?N!_KX6N>?%8"\ D NNRT4B2Z
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M1GW^BKJ"H@5%ZXJB3Z!4%Q1=$(I.U"4KL(@)"<@D Q8Q,;D[$ :S.$FX1L_
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MJ'-8:6D5UH8+&JT#":8"2T#^7 G]"YS::KV[:Q/7VT"L%4__/3B,3]EVVCF
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MA7RNR.?;Q5Z0GCJL$^*2YX[ #JS&$!42 1/%N>91JI5U*F].J!TUZ:\ ;*S
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MXWL9&3-5[TQP)T/5>^-*0\OI'>=#1VQH''>KM^21PMU1@/DJU-2_(HXQ%9\
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M._#<G;>L>>CQ]I?/H()]PZ!:@7K69*WWN0\Z?'_TF7_=":FULT&;'_; V%'
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M( %V*[B8*\,UFG(4Z[-LC"G7<>U-6R#:,L:#CT6A1:&8538&'4V(.M-,=I7
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M0S,X1J@_-),$D8N!PD..!D.TPLM'.1"Y<8XC!4DYA75+!P8)>:NG5)*R"J5
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M/0,U$328WE,#OX)5TMSZU^[K7Q<W/H5= R[92P-(%8YZ0P-2V($6"W]ZK]T
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M"6-I206VI:7<HGI9*CS[LX8Q_&9%8:U9$DWY6AA,5Y%I_Z2.:D DK8^; /*
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M1_.PP*?&1XO)&J6?-BE<D]!R$J#?H Q6G@1\U4^#^TB'XR4ZE%GE(\ YPE=
MEI6SH"/,1)@O3D&6RIP55#!."HU%7C,6B7'!D]Q$'4Q.5<3.+ER=;^+T!<*\
MJF.T<PS=ZKY_VMOY%L=06+!5F>_2\@DBM !XW$?T6)9BKVI75P<6)=%@^44;
M@M+",J)5 42C#"-6&PG8P6"KE&6*8LV9=06AZ^.4%*'==B.>EUS)N[X06[P4
M6ZA.KRVXAS[M)K.YU,W].)3V<Y6<5[H7SLN[ZH 3XZD.QT .-9356<?-4Y?3
MCMO)K:VB?3M#S)([/%J3']>NVC<[NS!S:=7#LVR!M"-DUWE:&O]&,]%RV)A=
MC6ZU!YQ>^P2F'PXGYJ'EUZJMWM^#P=^]WX &9D>8Z=E[.CX^P8"L.L@/O__&
MD(96ALJEXQ;L8L77Q2J4U:'L8-3..PBC<1RG+).AB0$0N4SR];UPC,,!&K!8
M1 "XZ\G@P\Q,/IZUXQSJB2:2/Q^93YG>XDJNBWC CU<",%/$)<YRZ:D^Q765
ML]IN$Q4B E9==;/Y),W/#V(,DR8QIGUC4Y1@*?:QM5YM>"HG5R[SNAB&Q=!+
MH"MCU#$D=1JP.$3E/*].'%LI-*SE,BZ)8;LD)9Q)Y:&O+-+T3IC!T$S*4/4Z
MQ[06ZECG:S)(#K:XO&!#K ,"<CX.9G74=WU&BJ5VTXG0,K&4ZS4T\Y$[6O*A
M5'E%:8P@<-T<F7M:A98W1XZF<O.5SN'C>1F\5Y+#L@"I2:@W':#[M7QC#?#)
M5SO#KGCA:G7@J<Z<#5BH3SLA<J$+HT,N"IMQ(VV>^@]0!<IJL;X._#<X9RJ%
M]C6NV&PYTN/'<\RT3[6>?0+5A 7C&)>4F-0EI]"6:.$" :TQ\V!'^&!!GZ5L
M>XTA4]?#J\EQK9J!9S;>5^4+ZH.:BA_CH!6LA""-!S?#4.5]+*)@MUII XG0
MDSL?V7$=XRP2%BK>N'$%8RL=V_GRD*[1&LH$[>HD 8!\.K=X0C$K@Q.6\[+;
M1T9?1H:%TM=P_:*$B^DE_8O @F$D4[,6@+G!'+=.FZ=E&/:#%/*7B,;&?7T>
M?,# PT9V8RBW/Q=QB$>#5=+8(%1Y[]6Q+'[5AF3$]Q2QEV!Q$6*WM*'I+8/5
MS(<\R[>88NND+GZ\/A^N518;2Z,< 26.#P=5(/Q3>.X?,U_&>.((2L%W[J$H
MR"KMI!Q\G4-P"<F^FIAP3>&\&,QJ?YNLG5&6#A<,L-'QL6F"+#%C-QT!+X]S
M*68^;:BIRFZM'+PO'K\X<KRAR:25]X/I,>Q1%?B!1[R5;$;=HS1*TG>#:1)O
MTW3$N#,YG)=N@9)4JXB V7C\H7<R-"XLQ2/1FO?K!RR=U574/@T@?Y$RA[$^
M6'E([+\'U)K,W'95I,I-FY:[Q(,*#1(&@-P"A6:KSLS8ZKU WA[YQOS[ZS]5
M8&Q]C@_?AX\I?7Q1&0'K5]0%2>+:M";>RX2$H>2M?**&6+*\9NI?TI["V@(F
M#4SKS<UGRY"19=C+@Q;%+V72-Z[[XJ;T.VI\K5L$TY)+_DL==?P?,-?;+TJ_
MCY8*"% EE**Z&?E_7C4YI50OE0V@/.>JD ED6L5+,%VRS)!'3CT>#P,HI)BD
MFP"L5%)++CJM0C9FO90FF%AO&NHZ1>/)]-O@)M636]&ZJT'6>9-Z.0QGO$CE
MJG@($[RPV KZ,S"*,7P<+ZHF+6UJB;5X?9VUN<R[RSGZ-<$M96_5(._':5IE
MGO.2M9BBO%N19>?RQG8J/0LMK:TJJ7(IUFB1\%_-L"*!%^W*+W_6E5^JK+C6
M"C298M4:+)''=N]Y4QW)-$H*_F#GR#L5;'[QE1?DZ99Q\4MO:WPT5;K;2H)9
MJ1A< +<+@["5J%5)FWK_*B1.XK8LCM,2,$MH7*JX0PRU F,/M4I$AZUU51F7
M270=;58Y?)CC-0FSNH/%&E)8S1 <+\I6+:4!WGSYG]9 5B5*ETGVE4PROOF9
M9%_-#%LMG>LL%T'FN6=<V"Q:JV1PS/&HI33!?ZD4[7URF%8VP)^30)[513 1
MMX[.AN;3X*%4LT5M>7X(PUH5D(LB!4ORX'SV/R#)N;I$>BL38DMF\$"])0N]
MQ3G''S4OMJ@N2UO2##Z56X+Q"W+0?OOM=?70::.)V+-4E*"$]-8%966Y*2IK
M)6@M7+@!AUN?P97^X?3^W^:88/LZ3#X.,$;SI\5;E_2>JB9)PN4R7;D,JRQK
ML,*/,QQX$H$I0 4P]@A-^N1; R$22E<9#!S>-C@^GH_&/H"<':"K"M9P-D%/
M[SQE"1B/=6^G59Z>6?(,P\M6O+^H5#2>XO&D=[#[?%&\<%&WM93":4S5NGQA
M%%NMZ:&?>CP:GE6U'DT9A=H\^&3!"XNZ&I-G?RX5CFK4]D7BVYI=^1W9PH7O
MXY5'3PA><S"9?P3SOS(@IB!DRVAAK $(<\.AK]1?:=%7FDR[) "H6:DZ!B@9
MPT%%<TV]C^0X^'I5D[H4Y\IKUH>-]U! @+H#-R$>HT_NW#HU*Q0KUT?9TZI6
M85(V9KUDC7>D4D:;A?LX& \7!L^%+E]S. E).5H-40B!Y;F)5MI,6.$MH\KC
M[C/-?.;\^A"%2T:"KCN6[E>'C0=5Y9F=>F#3O2J$X@<-"%WTASS$_I"G>X?O
M'&78>,J1W#I/1!X8,9F)Q# KLT)JJ15_]!BT[\F:@^GZ4+<I\=.0P ( ^@<[
M"[!NZ9"E=3T-26,O:Z:<U5;W$HPG/P>R%!9 K%Q S7N:USP]V&F+A(;NRYSF
MDN, )0(:F$@JDW%I9/R9CCYF94^79G")]>O1W8SW&$WDUOET52EZG1Y_,<>6
M#%]7V#O8*5<'IEY%OZ\#M,J87+*15]>W>?&J_*Q+'"7SHY0D)OG-L+SU20,)
MU7L;2P8!%!<\+6.3H[!63@#.GH:4-N ,W@9?3$$(F5%3!7:01I,LW_FTII D
M>&$AC@/LC)_VL'5I4]\%9U%B9.5)6U20K5/0&S_ 3OL<L/ZV1M$O(V3RYZ6*
MLWB@B/?6_7Y8[9[[^K,OEESG']\W2=#PC6P7>'W=.K'0KV&4^J7TS6B>4F8F
MP!T/1*/>F?;:Y5J:<MJU6E56TSYN"@\O:OYBK>VZJEHJ9XDC>GH4CA,6/@/<
MFBW"&?:>/FL@,'QR0^ 6+'L':@<P;M-&LW0QE25NCMN+77'O>7YIQ@O#.ZRV
M*57.J[B_->2EZG+E?<%O-YN[]+Y4I-D=H991XU+M 6GIT$TAO)4BS_6JP*27
M)HMEU1 ,EON?AY&O5W_UAG)U+AIC6=,XG1M769UGRR6-\0 2=VE1(QU7K#<=
M !V9I(0/D +3?OG)_+ YPD/?K;6H]R6ADQJ?XO>MY6]V=F=O=V=Q$K0":DE)
MZLW.3O =H)O/IV4]O^6)U($+[<TTS7;BFTL+JM:-O[+1TQZL<2KRFUIWP) &
MD]J9"3@_F%2LG3R\976_I;K/HW0Z Q^'B/90W2"AB4,H*Q7A,6KY9MBE^C3G
MH%KUE15?&7 YOYHLC\J>Q+CW93[<5NL.5X4%X=Y.Y_88P1E>BXN.6US6NX?!
ME3)F<;1L@01]64L+7])(OWI@#R7E\O7,3"I;?_6<I=TE8!C*WA?)S/UC?@)7
MXV'D%E@OP,V?4O69+3RR')Z87A^U)Q1RY26OYZ/I$9JP?Y@/H:IYW1QG;L&G
M<[2'_S 6-F[/@%957U-^WS=8"Q34@*5/?\/3O7&Z:W$L^G1P,BPON,#'<+@.
M!QI<A0U);-<R)\\JD$B4@ZR,A#.M*:?E*CG!L\;IM"J+678YJ$"E>=5:OJM[
M%E<LN#X8K,:*@YWG]6C7%13=[CT)LU-$4!CZ\5:EF*Z==,EFBZ&N&]J^#W$:
M8/5J=3,=/8=C4!K/L.?#\47/+OLOU.A_OE3>A59F"3*K#<0#\X4/DJL\"*>4
ML3H*8XP6KBABT%\I#_(-MF:E+>_4!0E?U"$ I:GYVL'^@(#9'X7.ZDQ6YU^B
M?_B.66&X8CE&>D4BJ&1$J1B(CEJ+W DOK;C(ZJR5A"&ZQ9J(MOVR0<83/'-+
MNO=T.G:E:$WZ);!%.EY#Z8:ZSP]'@0>GXXX"L<7]+EQ[^,X[HSG+(F$F]T1H
MR8ER7@,MYLQ2[F-TX='CV>GY/-@:AEL41RI:;$[PSA-?.H9;B4AH.^G6HF03
M#XN^PE'R3%1-1LI D]0R(PUF[<G=0[ 35\,K2M/[@6A691""W ))^S$Y%I8K
M&RW"$::7BD>H2DHC/=3F4;-\-6DV,5ZMS@5)DTE:>UG+#4!9K11+Q_=>4-2V
MUDX6I]HX@-;C6Y7*2TM@[9G\UG+UD^D,/3E55RA\Y7@R.,2> TVL1%G@M%RW
MU6O*E4OU5,L%7108K]^^U5Y'K)#76LS2%*I"L.IP (S^1N?;?%A&6_1^GP_/
MOKUH]<:18W%CY'@Q'2[%5'Z9$L4BL ;#V>8IP@UC=2:MO6D"]I<C>#!"--%)
MBW2K?D(7B_>:=E(SS]6C#$FC9=J%7.>BB,Z:/+*829;G.MJ0CC*HNE'AGG9@
MIR+:[ORBK4EB50'0%T'5DIYDR@>L*B"(%5R3Z*1B6JB82_[H\<$%<OPRH'$I
MO'A0")#?!@(T@@B4HW5\GZ^TF/B"!%J.J<*7XC-KL7,M1I<F*%UD5F<B"NVT
MCDZ'2!WG3NI,J\3H1<?HM\/H#$S&PEI*<RV(#,80P8PGEH,%*9B-0OJHBZ"Q
M?<TDA'4VXQJ.7A<3N"+SVXTWVK&%=?AFFPI15ZD#6]-A52+63C?X)MT &1F/
M.^(<EJML3["*%)RUHGFOA11++_@FV,B\B-YD/GKIA+"9]H ?><BI4D5FLI1_
M?\/&?P<;%\(&[;]\ERG0UK(L)\&K@H@\1F)5U(3G!:@)3"BGY;?!QH-B<!#]
M7_![G2=XKZ//:0"9:*A@-+/PCU7:: -BTQ0FN;WRC)9NK_SF*?_Y *9RN.C!
MTG% FP,^@^"TUH&T9!S$)1;R-@PTY!@M\5+(7#(G*:6/'L^^S '?4?]S8SL
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ME9E%2ZDGW3G7I8X:7@<WGY3],A_<:<.+U!WE&,EFNEIV+&5AE*;%N!U>7(;
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M#)\4)^/C]#A0;8"P?2]\"A,WF(;ROL6;JQ4^*2LZX(@#V%,?04M 32,I!CZ
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M4<R$3 +XRRQ+P)"S>P,,-]JSZ1ZH5KMU#%85IX4ABU^*^>OZ.&V^ K4,AF!
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M%/J@\^8ER>?4TT$PDJ05M@]:3#,4OI+?H^$$>H(?"TZLI&<N7.($:";Y8#3
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M TTTHW.B$B=.7#>BZ%[>I/A/'.'#Z)Z,Z;[G)L?8?1+6%03UH'DBWBY?+^Q
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M8%%/I^7-H; 1AC&*?-&("1/=\0Q2=QD:@T?&@<'NX'/R=,F&E_<<A#H>P]#
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M54I35CT<KC,N[-UN%3?OFU_6I+7W3$U:%6#3X%C*V)\+3JHOZ*+%/=<:!'8
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M0)J'AMCDVW\-?;AUP8OI!Z$K1T8 #X=- _Y:_?+&LH.IPV:O;9=V13?E^0)
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MP$67MQ>'+Y]DT>L!;7$D2Y0#:-5_73FKARE4&T$]G2=5.H**:DZ=(YV'LZU
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M(>)LR$$:W,4( ]FCV!_BV8&7-.'^"6HY]Z">RD8EPR@ D@U6L,*=.FV+NCX
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M(%Z()"S(*QY8N9G7'^,E2'^YAB!T/ (ZTY;!AM[=5D<NE8K5$Y.FO6+TTN0
M)@&5I6C:"#T8VQ#34H/4+-'4&X/T(+B%#+\V\!:MIYAI^A'.J$U.1P[J1]V$
M1VX&=#G!EB+:2M"1#,0#,Q>$?A@#.\>&29G[@*'5O8IUDKJ3BAD7"EL^6S.:
MX^/6T:"W42^:0>OP8+WH6M%0X&;SHU8M]K@U.'J:_BY/L=:C(]W?Y5GZNV@
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M.OB)5L(?I80OI4N=XO2V=[0\Q:D 9SS\I1IY4;O)C/M+F?'IY<7-U>5GH7*
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MZ  U]6#\E]LG\S%0@8HY6>3_RUD>M@*QF09Q$NSR%8@E*9H4!<GX?50N4LI
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M@[XPOT(0<Y@)-J8Q* "N6&+Z;G-FHN<B0*7"1^2(XO7A;$D\.1"1-QD+;8C
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MUB"\AVI]8K^Q+/<)TL:3#3J<'49S2764MFV<G+^_EJDT 0XP(M;U5<0>9.(
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MAE-@7#G4XHA(KJ;\TN(.Y=*@52;&T[%ZGU5&'R2;6"JDJLOE(K4B.IJ,9*/
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MA\#NC@58ZTZL+J!>,Y#GK1Z#I=#IXK)./18D['(5I3PZ<OWE?5O$M*ESQP%
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M2&_=J)DU&FM7H6PLRYTN64H5-QV':]Y'((+U_;K4,6:ST&J7?HQW7,7C6#.
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M1K\,V/5$L&0&@8&(,*,R5/8-.B#LC =C ,7)ELX5)Z>B_^;W] I2?ZO$2G-
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M1=(#SC?"5_R3S@PYW5%2.[XR-V-[]? QT8>"=?O@.;YV]N>Z_3ET<IDUD>K
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M7^JB>9O'FC1"ARG NLV6$W8D3,8RE8)S07SA:!HGB;I$10/#XL?0WY5;K_N
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M4I<)"K,JQ<T)D2DB>2SW &^P$DVJ7#:!:E_XJEI4_0WY]^W&^I:Y53?U_KJ
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M7:'A_J$A:XG^ /YN-E!+_+T)?C^$Q:=!Q4$%A-L%A#M<!BV!L%,!X;X#88^
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M]"Z"J 1]@UDBE51;FRV"G\YTR#"U\TNZR'+OS\%L_M8[EG\FXS"(O N17DF
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MIHKSD(/B< /0OYDDQ#__J=_T>V\S[WB1IN#Z.Q?S),T]B2C8N:E_\),WP8>
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MR/Y5=@$M3\!W0:[,XET'J589^7&VLHJ/4"3CS_O7]>(29;[%CW$2S[5A_L;
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M#++>9PB\:-;Q';ZQE!;7;ACWSA<8AH'?#/!"L(>RI:1V]NVJV9"-'46;8;M
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M7BZ)=H&>$'I*%I@<@"&]UQ+X@HT^+HEV@9K0\Y*CXZ]K^?K%YQ)];T<P_8W
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M[7M]A6_VZT4EYJ%65_62)=FIU;+DEN3,KB<N# &;G13I)BFG?;_^!DC-(P>
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MOO7Q:6]_?)J4GCWSDP&S-C[3_K>9F>MQFZ*6TA#*G28R.4[0V@7"%21+*?/
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MXD!KCCY6YRB4 VG0D8@87R"^((FU#N$FXX56,3G7Q"];]8SG=DM$7C]'U^7
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M^0R&C^"FQE%E<G$D2G>K$L)8HPQ))DJ14E2Q3;/]]:&_ZAAU8\1=7^N;SXX
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M:,K08<Z*$\^4+0<\#&"X[;EM4J^_ +97M3C5H$\E-=7G3]G[FGR9]P.]!RQ
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MY@VTX0-.D![XF6"]HM7L9/2EO@$7D[]:P-)_GPW&F ^'OXY'A'Q2)W2<BO,
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M[%6R5FJ#VD:M70 Y"UB0O%CN:),^OA?IUO*;&00;G<??];@VLER&=4&B$#"
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MEFV]_:M'?L!JW-9N"1=KOC@N+CL1G&*.(_D@"@R+)D=&KU,1LA2C2I,#H+M
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M,=I@A-#/H3G#YO5>85*#M%_31[["22W"?<R%X;1;:.:BH^5#%,6 Q\BX*2%
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M2Z94V ,1#A5(J*2MYSFP@Z@;V!';]FNQ-N6D$II-+)7^9SH3+SPEEIOL0M3
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MR&08XY'YQ)H4/M1_E7UU=6[I<QU8P8=N_'S?A&$I@OOO[QU,;T;I^U?X]*<
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MCZ JNCCRRG:(OX7(%V??=4HI R]]@5PIHV0BD\!H(N 898 .-ZP6+6['DZY
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M^O_Y%+@SL;MVA& 3)/C [..$^F&[S[9;?5JRYTPX;E3@*7%<*FK(*KFUG_X
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M%->66!C&+,*"JL":CCN),#6.KDPS(S*H979@E&Z#8$'3@T,[,'=OXPD:#:[
M(=C-'RORZ7+3K=L8.%#]X&,Q$O]W').>%H2+4&Q=);JU/-[2<9'F.^O)92UU
M\]\_+(14Z2)=RH_ILQ1[U_^*]U_KN/<?LTS\D<[G,RY#07TN(?-\IKW[$$/*
M50B1'S#)/9H0Y;OL![L*,+4%YL<\*XI__C.*O'\%;VF>OQB/H#IM<O/^G4?"
M;F]@2'P'7F4VHL.YD1WL7Z,NP#=K^4&CP+?];2YTQ:[/K0=G&4;=F.B*T/ZV
M1>=V+@_U_UF;[7E*YW<Y711*YM?WN2PW]XLJ6',F8HZ4$A1*'L80JT! &L82
M^E(DE'LH# +9-<#_7.=38[M-6/]C+3E8UJ(#NI:]>PSYV<&P,*X'A'CP<_?]
M^/!&>-!(#S;B-P'B Z+=/4Z_3]1?+3K_(O0O"LBWA<\E#/]LFZ\6?&^K;5O(
MO74;'>,L-H>^Q?5"?,H6=/.;LD_*S>?9.*!Q@D0B9 1CC/2BX0<!)%A@&.G_
M4B$2'P?Q[%GF++,.G'"3P&6";<LQH(.:S;4^6:ZG\;/</D4O %T(<P,;\E./
M@&T%P6_OLD>:+BRW$;H.H65(Q'##,O0FSDFPS7!L_[N*CET^T 78?>GL0+@'
M.G2#L]>X!4<1Q@U#Z(;/051!QV:ZD6=CM5_S?ZS27(IW*W,;JHI'F+$H9HR%
M$0QC&D'L$023F KHQ7'D"6UZ2Z5<-A3:.IN:.=W("G2CJ[E9RJJ; 7J^ <JK
M\ V3K4+;VS__[8L;W;6";L=M?4$Y,)$U8EZ!1E!020HJ4?MC)QM ^J2BUOY&
MY1T;S?=)QNJ="^\]OGDI=PC>FFCYZZ]I,8MPQ#!3,51":#J1/( TD!0&C 52
M_X$39.6MG^UI:EQ2)18LQ0._&0$=S:/3D-J112] #<P4#AAUO^AX2O]!KCD>
M=/8ZEQQ/Z7SRBN/)%SILZ%V;;"5EG/47^:0_E0=:R,]Y=I_3Q\8;8W%"1.!!
MY">>"5-2D"EM:'@RX91Y ?:XU4T7N^ZFQ@Q&7E *##82@UIDA]VC\SA;[,[U
MBM[ =-$*7)?#[/,(.NRX]8KD2'ML%R+JMJ=F#5#K+MKY5L;;-[/6:&>GS/ZM
M;L:8N?9PHXRU9WS).MJ\N,UTUP3[,>4,PS@*A''N!"0XQ#"BD8@)"VB9J=7>
M&CO=U=1(M[P+HOVV>R,K*+2$;N98"ZAV]E@_4 V^!U6A5(I9[CLU@H+;-LB<
MK;/S:/1IGK7T-JI]=E[K?0/-X@WW=(:WDFO7;_GR_JOFGL6]_*2_B!GQXY 3
M$S >QJ86C,D$S(-8.VJ)'VAFT/I:)=$_U<'4",'(9#YU2?D#D+6@)CSWCX=4
M_R:7]VEA$D=:\L1)7-O9H0^T!N:$1CS0R >,@/WD1&Q3_8+<B$>;'2U'8IM2
MV[D26Y_KMO1K,X)+*8H?M$ ?BF)ETAW?J+?9XV.V*"V.6: B/:$9AR2D096]
ME"41@=P+>81D)+F7N%@ 9WN<VKQO!*YV=M-:Y,)0 2^EKE*TNUD'YW&W,Q)Z
M17-@7M@%LI&VS$Y0X7C;BJ.SR6"-39^6P_E.1S4@K#'8MR/L7^RPX?-A\7?)
MR]S+/V3YXVI>.JUU:&RSXR,((6&LH!020\R)@H2B!(8J5A[Q>4RQ?=#6^?ZF
M1CH;B<&6R$WDMU.AF;-06VSZ] O@P#S3CEVW:CUG070JV-,GF"-M_'3\(%W+
M]]@B<Z:"S]EFQBSB8ZO37AT?Z]>Z67[O9)X^EU$@'].%_+"4C\6,^2&* AI!
MFA!SE!^$,/%5"$,182EB)C"SNG[6TL?4B'8C(OC-" E**1V/WHYA:6>_78C0
MP$SJ"HZSB=:B?I]&V;%N1C7#6O3<-[S:'NU@:OTDGW1CR[1X\VN:KXKU/]]I
MW&CYJYI4RABQ>C%C*D!(<@$)QP+B1(20FNQ10C 6!HBK@%CE".TLP=18H@J@
M^^G-K]__].:=@^'0"7T+>VQH3 ?FE;6\X THI07?@\WO2B7JW]=J7-4AC!UL
MMTY#X&#-#3T4(]EW78>D)\OO$A1;;<%.#8]G'5ZB]XZ]>%%#W2S(GVG^NRQ-
MU'IC<BOO4:37##_F%/+ ' Z$?@"ID@'4;CU%2(B AI&+)=G2U]36BMN'+%]6
MV3<?UU*#8BVVFVG9!K*=B=D3= ,O"1LIP4;, ?)-6:#1I^79UMVH%JB%WON6
MJ,TKW9CCKS*]?UA*<?TL<WHOJPL^-^I=.E_IWY;9\(J;3:+?&<4HH)0G4/J2
M:#;!$K+ IU#@," T$E)$3C&ACOU/CV&,@&!EDEJF"_"D#:/"_ IP.N?-S@P$
MHE('?*.?*?]>G+Y:W<LP,9\C%84A]*A(((Y"!A-?^PX)8X)%"#'IARZ) X<<
MIA&R"DYUF.R6C0'!'W@I:20'M>A@<^FY'I(MN:] K5%_2TQ'Y/I<=EQ%&'4I
MZHC/_O+4M9F.,7)U:I O\DF;=[K7,D/(.ASZ75KP>5:L<EE[D!2SQ/-0 @55
M#&(:<D@3R:%'9,R"))$D<4JSXMC_U):L=6:59R.M8R2=(_1V_#8@H /S6R-Q
M50,*_"RI$;.\Z-E_^:>.,/4:C.<HPK@1>MWP.0C;Z]A,U[,?MMS8]-?/-)W7
M)TTF,=5=6119?EV^F9M E!#%+&*$025(K(UO%D.*J <YBF40T"3RN5, D$OG
M4Z.QV]6C]NE?RIB5G?HNYC=K5:#*<FB4 4;7+7_6]53)891LCYN&P7[P<Z@=
M&*_VH#:)>L%OI?3 B ]*^7L]IG*'K=_S*X?^1S[8<D?F\,2K0QNCE8B^6<B9
MBA+!6"0@HX&$V(\DI IQR)6'0LDD#JG5;N9E8DR-#"U+1&<+2WOOPD&R.#8;
M!?J!N?#2&L0W(PW'X"6B'8?EOTF)Z+;A&:-$]!:J Y2(-JU/O43T%@(]E(C>
M;NWRDG\_5*7M7GZF7]/'U>.;+,^S/W2O;ZG^'/7O9THF+$8^@DHI$S;+*"0,
M)Y"H.")Q2")$G9*QN'0^M?6IEA.P1E# :TF[UP4\.P!V=OA0L Z]]NQ4$P2-
MY";17@7U6GCP]AS4%Y4<M,5LJ)*$9_M_M9*%MLBTE32T;J/SG:,GF2]?/NMO
M:WF]$.__L4J?S-+\22YG@601CCT/^A$OC_I"2(GT(4L8QX3B)*96MPIM.IL:
M836R7H$G(VUYG58V\EZ!A73,2-T*M!U1]07?P,2T0>[S&KGW&^0^M2#7Y5K1
M64AZOE%TNK^Q+Q.=U?S(/:+S[W2,/])<M7J\D_GCIVRYKAR11"*.":902&DJ
M6@D$F;E"Y(N8F-Q2R/>M*EJU]C(UYJB$K(*.2C$=@XR.(FG'$!?C,S U'$ S
MP"%)*P:]AA,=[6C<0*(V70]"B%H?[CKMU^=='Q9/JZ4Y&S&'):9\TYH#8DYC
M@6%(.(/88SZD6&DOB,J(A(CYTNW.\ODNIT8(C81E#3%7,CB+KRTS](G:X#2Q
M.44MI36!(5L8#L(:MOCT2R%G>QV93VQ1."07ZS<[[KQD"Y$M/BSTA&5T\?N-
M4B:]AVG^XX<W-U^:NP)!0F)*%/19(B&.E0=9Y#'MP"@2QQZ//>04ZFS5Z]3X
MIA3-<5O%"EW+_92^,1M\$]_("]8"@UKBBFJ^*87^=@#*<<*IU\T3JX['W35Q
MP>)@N\3IY8XE"SA?E3=_I2@O;9C:X+E\D(LB?98?%CQ[;-9CB;A0$8\ABI$/
M,>8($BDCR(,@\(2,@C!RVC2Q[GEJ-+0E>'UC;$=T4,FN)UA6N$;9VH^&0+$@
M(?$@00F%F H%$Y$@J) D1(H(4^([EHX88CS&*1I1%L ;"FF[Q6$0] 9>(*YO
MWGX U\MEGK)5=2MFF8'/-!\FR,\9H5[+-5AW/FZA!E=,#DHT.#?0/9COPZ)8
MYN7Q]AM:I,6M[HB*F\6O-$_-QV/6)31+4!+&"%'M!FL;%=-80A*&"%(A/.Y[
MBB<A<PWDL^EX:HM$*2DH2E%-_K[G6MBR_KM[B)X5]G9,-02B Q-5&9JWD?D*
M5.C>KM%M!&_?B>@4DN<"5=_A>%9]CQZ*YX+(L3 \I_>[T=4M?Y!B-9<W:C_2
M;Q,#^'&=144;3+YO(N\BFO@F^%C;4LHW!;EBA ,L(Q\YQ3,X]3XUXNH[P-AM
M*.PH;#" Q^"Q<R'&'X?(@=,)L3[IS$V 43FM$S;[Q-:MD8X^>UGN=A:&H5+:
M]X8R"+4+2%0(&6,<,C^(0L_7SKF?N-R$K9IUXJ,1+KA6I>EI*9NCBU?!9.F_
M.2L_M'/6KK&[^[6C8*^^5=7RN([3CC8'7M'N7]USD;]?+-/ER[40>D2+VZ6V
M2&[RSWGVG&KA9EX8:B1\ I6O?%,\"D,JN0>]A(?4\T.&66B;D[RMHZE9!I6L
MH!;V"I3B:DA!([!]3O)6?-LG;)^H#3R%NP/FE*[<!HT+TI:W-C]:^G(;);?3
MF%L]WS&T4)9WO3_J-?V^#/1OMF2)%XA (NC+6#L/0I,E4Q'3-!%IIB!)XBNG
MQ)8G^ID:+=1B@HV<C@&$)^"T6[=[ &E@%CC$9X#-U3,P]!HJ>**K<:,$V_4]
M"! \\WA'.WS/TM^[8[C9FOTQSXKBET4NZ3S]+RG,P= ;J3T^>4>_SCC#0>S3
M1..,,<0!DC )XM"D(V=*Q!%'L3=;R'O3D*4AWX=<5C.(5#-H6[KA)E(I+=B(
M"XR\KML1_8R9I4\QVCA,9OO"5-?=G(X>';$KP$K=@%:N1_>F3ZQ[]8YZ$6Q<
MYZI/+ ]\LUX;[W!#NSPGJ_-4%M>/;])BZU0]D7X2^Y$>1*$@5HI!1@2#A(4A
MHCBF!%NY=N<ZFIH-UTCG<&FW#<9V>NP3G($9KPKO:,34Y%8+VB5'<.MW9W^/
MN2?@1KJIW!U MWO(%JBTWC1N>W^\N\066NS<%K9YO@-#FNLSRY=T\2R+I?E&
MTL6/=$Z?Z'W6W-H((L]3&/E0F>QC6$H?)HE,M.$:HL CL8<3;LV39[N;&EM6
M H.-Q";SXEIF!THX#[0%D_8*W] [8JW(=6'5\Q Z<&NO4([$L)="ZL:SU@BU
MLNWY5L;C7&N-=IC7_JV. 0PK5LA_K'3+[Y_U?^I/F8@XX#Y&$"=F@R"(0IC$
M<00Y3B0*PT02XA2">[27J;'M1DA02ND8?G 42#O__6)X!F;3?60&V%=LA:#7
M^("C'8T;!]"FZ\%Y?^O#7:\";2=_V8F+B:(@B3EF)OB^+'600!8B#)FB8419
MX/F1X_V?4UU-;?KOY3I*S=W:CUUK:+4@;$<)_> V,"]TA:S#39]S:/1[O>=D
M;R/?Z3FG]>%%GK-O=&.,+_*)OAC[H[A1'[/%O;D$;3;49CQ0S%><0.2')J01
M8T@4ES!$7A10XBFIG/CB5$=38XN-G":%T%Q+6EW*%UI6-ZHX":T=4?0!V, T
ML8O5QS56[]JP<N:(<T#TR1 G^QJ5'\YIO,\.9Y_OQ@W;\=3OLD>:+F:<1<17
MVH#PE-!6! YCF*A ^P\DE,+C7$:<N+#"81=3XX.=BP'@MTI(1Z/A")!V'' 9
M/ //?D=DG.?]:>7[G/%'>AEUKI_6<G^6MSSI-K^+?#EK$C_^LBB>)$]5*D7]
M909>0)#O!29' (4X(@326$G]'Y3(!,<10593O+67J<WR=6)3MPG>CF3['.\-
MGZ'W"*RAL9[A5JJW3'+]_M8$U__:G]SM'8PROZUT;*:XW</=5O$WJT+["L9]
M>&3IHMQ+7GL22_U3D>JVRE]_U/129E2<A2JA<2(E3)@2$#,40A;%^I^>$)Q$
MW/-#I^QD'628&D.L!0,JR\'/?_L"^%H#\^-&!3?;H,OPV!D/ X,^,.TTTH,M
M\:\V>Q)+L*/!%5CKT)\!<@& ?5HH7<08U82Y *=]&^>2IOK8,GUY1Q_IO2RN
M_Z"Z#5%6M9F%@2(Q0Q)ZD< 04Q9 YB'-BY@D(9+$PYY5G7'[+J=&?K6(@%8R
M7K)E>A3A+ENGE^(V[A;JRQ5H0*P%OJH*8PVUE]H&SW![JD=[?<6]U384VO=8
M6]_LG"DI7TE1)=6XHU\W)9*EH$G@Q1$,L*]Y!1$&F4H8C'T:JE@I']E%PYSM
M:6K$4F<Z6AH1P1-],?ZM<QJ>$Z#:D4HO4 W,);6,35ZH4LH!BDZ?A:+G?#HG
M.AL[?TZ[SD?RY9QYH6M^G#Q]UI:-2;K39+<HKA?B)RGN-2-=<_VG,L!Y4V3O
MFND'*5_.*.=<?SDF94Z80.S%"4P0XC#T NX+&O&86@4=]R#+U AFH\I6^I>B
MS+Q>:P,VZH"-/N"W1B/'O=Y+QM&.L48:G8$Y;<B!Z9"FYV)(^\W<TUV<D9/Y
M7(S;87Z?RYOL$+'\L\SY[TV\IV)!K% ( Q'%VM]3/J0$19 FOB^IT/_O607)
M[3<\-6XL17.(E-W&J)VJ+M%\8-XII>H2)[SSA=A'!'=$8:38W_9/P"VR]XBF
MK3&\V\^/%ZU[1,J=N-QC?[_4HBNSB:RK)-\HI?]Y?4]337!OL[FYJY;3^2>Y
MO%&?LN7MBOU=\N5=]C,M]!_TKXU'>IWG>MS*+.*?LWG*7][/]4/FZ^,X('Z@
MB4KSE#FO4QR2..!0$>+Y0<()1]0EB<\X8CMQX0A)@K2\H*IF#;[Y*._I'%3Z
M.J;?'6G,70W%J8SD>#9EJ?$5,#I7^VQ7]8""6F^P4;RLO&0BF+3RH-;>)+*M
M] <U & +@2M080 :$(8P1<<8M&&LUD$E?R4#=XS1.&T+C])[MV7NPX+GDA;R
MG:S^]\/BFI<%+HHODDLM/YO+&95ZE6(^ARA6"<3*XS!AV#<Y;CAA2810G#0I
M*N[L-RIL^K;BI]TT%'=C7)BN!07Y6M(.M?.LP+=;+7K#<ARN;\0%WS0"?VON
MK:UAW0C='S>[0-0GLUKU.RHONB"QSVI.[_9UTO))ZU6?"V"?4XJ5A$(%9=DM
M!9D7:1_?B^)8*"]FRK4,Q<G.IN;R;V*TTP%.7K9 [GKXT@VZ5SE_V8@ZY!',
M(2##GL)L]??*!S&'FI\_BSGR3M=RYE5X2;H^WUGOTA-"$?:P,6,2 G% )23*
MPU#1D/HJ$2*(G4Y;3G<U-?:HQ0/SC<1_<2U2?A)6.\;H!ZR!^6)+R/4Q[2#G
M%N?1Z+>T^,G>1BXD?D[KP[+A9]_H1A.[E<BOOZ;%C$D41-)7,(@\";&DVK(0
M--+FA>]K5R=@)'$R+PZ[F!PME!*"1D3]I6LA'8]-CP!I1PB7P3,P$3@BXSS_
M3RO?Y[P_TLNH\_VTEOOSO.7)#F>"/WWXM4Z-9-+,-=E@N.\KBJF"G$1Z^:=>
M#!E">OGW"(Y]IC\$9!4;?[J+J<WO*H&^%M7AM.PX=A:GAA<C,O"4UO(UV<A
M*6&7L\3CZ#B<*EZ,TDCGBP=H]736V*I_ZZGC\3?'.W]LE7SG)++]R6[VR@]9
M+M/[Q8_9L\P79OQWDV?6'Z**"9<R$9!R'&D/1U!(XCB!$0L"'Q&*(\]S,6&L
M>IT:ZVE7$O[RW>UWX'XM-B@ZEC"R@]W.X.D=S,$/Y38Y?U^NP$;N<@=%/S)
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M+3;AEJ;$QZW,GU.S(W:CUG-[:VJ;A/_%\3_5<7211,I+/ 4E4QCB$'GFQ%9
M)94@-,0>3IR2E_0IW-2(]"A[=@R,['40[?CUM89F8.+M."K.W#H$?'V2;J_R
MC<K&0R"[3].#]-$EF.91KQ?5Q\]D?B^W$SS+((D4BJ4I%R\ACE$$62A"R$.%
M)!9)*!*'6[6G.YH:KVZ)^J84M6,>\39L;2)B^D%L8+H[#E:G:)<6N%S"6_J!
M;:RKLAWA<PQ=.8])>ZQ*R_LC!J><UV(W&L7B^0Z4^=.'7YO2+3_*Q7/VTI0
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M;]P$OA::'^3PM7FG&V]_RA;K1/M5QKSF]BKCU!,X8M"31)E*[0&DON":PX-
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M2056G:@6=]36:]!OQKPCZSN0NW^QO)7]"FB\.[Z96GYP/P;>%JD /G$?*0/
M,?YV]_Y#\>N][K<>=+Q;_J'Z[EWN#QYDR(:Q?EHOZES1IKCSJRCG!;^5U[QX
MKJ?736>3( ]2A#.8ADWH+84XBE-(DC3*B-H]A#!G4S.9<6H;PU;FM@:VSDA7
M8H-;"3K!K3K\FH-OLCLXAM3WCO"&:-K8?L>HCF7O3=!U9=XM(.HWZ28#C6C&
M+?3:-]TV#PZMLBJ?]=X@='CUH*M(QA%'&0HAS]0!"TE$84ZC'&9AF*:Q,M=Q
M8%?ZVC?;Y,QT)VR3?559MK@Q0YA$ZLL;BA2BG&AR<QE"G,08IA*%+,H#QF1@
M60#K"N.12F#'0-DLM.,,.>]GH ZR5[VB?22SF&#BMJZM;\*1"]L,=#^L;#-Y
MZ%(.FSIB_>[EO6XRV=RV)ICR0-//")DENHF.<JA%)C2E>1Y)0B1/K$QUSUQ3
M,]2[E[2UL("^@%K<89?9?3";61)'X'FV(Q?@=@%[RTE$_/"P'$[W1HPJ)_4^
MS8UR^I$!9_--<\1W=7/$S3\_*#S);K_$KC!,^7<\IA*&,HBT0>$PESR&-,D0
MBO,@0,CH4FK(Y%.S, V#Y]_?_?;7OW^PZ2AKB[G!Z=PCDI[-S;8=ZKNV'>I?
M=UJDUO+OMTD=4M)EB[C%"=XC\B,=YJU7P-'!?B!RO6=\VS''.^X/U';OY#]T
M#$=4*^]+P><K_;=9QH.,T$A 0C,*D60"TIAB& 1!Q%+&11JPBYA6MG--S>KO
MB5I3#FDI+R1:V8'6]%3J!##O9])#FI5&T(YSI5C,V0OXO?VO%XI  ZB\4K#L
M3/>V#"R'>I\E8#GRR-"LRH()P:M/2DQ]LW0KK[^3^4*[KY^*4O]D>RK69^09
M#1)&@EC "'$= E/&)4\3"66*@R1@22P2H_:O0P68FMGIY =ZH=O, 65[GDCY
MAUC5_)H71<JLU\?,3/E$W;/MV@=<B]K0R^W%UJ[ 1A\HBQ+J=7&9OCD,/;<)
MG98RC)SB.0RAPZ3/@>,,9*/J\K+>O;PC"TU9>O<HQ.J7LE@_SW6];$<PC!4F
M)%:'["#A!"*B>5APRF%&,Q0G0<"BT"H'U'3BJ5F_'8+H.N[1D NV!?$';> M
MB:A,%\/,Y/F V+.IVR9_7NE@7RLVJ.4&G>!>:9QM07-*.F4Z][AL4Y:('-!,
MV3X_M(JNXX';Z?(Q$X*$(0U2&'-]?XD$A^JP&$+.@CR())("L]E2/.CN0_?F
M+7Z.3F;T'N7->W0PI;]WZOJI6.LB,&6?FCZ4?]UM4/-53:4<;<&!-F'K4E>7
M<DVMHDEREI4Z#?&Z;=;>JVAIUXXOC9D1&X[TZ+3S#IL(&FGOMM+NV$0CU]KU
MZ'I8;=?WX0'7#]>,U:_)-\&$&EGM+[KD7V>KUS^^7O*ZIVO'1Q/D+,%I)B!#
MDBJ[$D20I$$ <9Y$- RB&&.C0^& N:?F$;7T0)JX@G<B;[F +&+CEDM@<!GA
M#UC/5J43'&PEOVJX03[L05R+?[Y1_,586UQ#^,-\I%L(Q]C;744,0Z_W)L)R
MR/$N(H;ING</,7"(H>W=5NI[,E>3-'Z4\F"KZN,/MEASY<?^4A3\S_E"620<
MT3PE!*8XRS7W.X8D40?G5$8DI"2)PC2R:2=I-JW5KC""UUE+^:__$J;!OZF7
MIRQ?],&M<45M^[T9H6[F3;K'TO-&L!6X==ZO0"TS^&DC->C$/EWL/J EG U.
M;KO#&<T\<J,X&S0.>\99/3VT:7;39F'3"I'%+.%I&L!,ZGZ3+*20$!E!FL>,
M)S05$9%V?;+W)YB:%]K)]S?;#MBO<#.S(Y>@X=EB=*)Y:15Y2F^WO:Q?S3%R
M^^KC&AYVK#[Q.;OWMRI7L\_J\-JPI2KG1=RK =H&[#F13$@<PASG$41Q*&&3
MZA#(G%,DPEQF)N]PWR13>X^W<FJ?6U@VMN^%L__5=@62Y]?;&A_C=]P$@)[W
M7#V^\XZK?[U^OWO''^4=-]&P>\^-/GMYJU?:,$5MKW8"E,=!SA#DZA2A3P\Y
MQ&%"89@F!'$41));L3_V33:U=W_G;JV^W;[HW-"+LMDN[PH[SR9A-T^^QFVL
M-J>G,/'5L?1@OC=K/GI*\[X^HB>?&9(L?_-;FV!97:_*^?."M/G"09I&88 )
M3"GGRNV7"&*N7 :>RU3$.0Y"&IAGQ9^896IVHQ7.)@W[%'X&0647J'BV"$K$
M+D5:)P8U4@Y*5S^%DTU>N@.\QDI 'X:;9;;Y&3SZT\I//3QB_O@9^?<3Q<]]
M>-A57;D6_)?BNRB7^EO1A7F_":K[?,YHE 0X8#&,,$XADC%1/I0@$ 4Y#1$)
MB R-8A]&LTW.&#;R@H>-P#N-.<I&9KN+HGZPS:[AG$'H_^*M1F\K:]TOJ)86
M?'./GMW%FC,4Q[M*&XZF]<69$3KGKLKZ!QGU<LQ(G]?7868/79@LND/,J*_>
MUF6I3FD=62A.<!0D,90(91#QL"[-(9"A4&92YIC8M:,WF71J-G@WC7%7["NP
M$7Q@9F@?\F:'6M=X>C;(NU!NI/1 )&$#BY><S[YYWR;?TP")D[F>)L_Z('#C
M_[6N5CN-$%G(,B)0T%#7H$ DD A"(,&<H# )8_4[=V1NKV:?FEG:(<L2M0)-
M18G:( #IB,@*"9;B3T":Q K]KE4KY3^2THJDTG:9#)Q(G^![MF%&)&7JO+G1
M8,A1W1ISE^1P%V _):*XW348BS3N!'27$<B]'G1"9'(G]+4CECLUR)!H0I(F
M=V(Y+\I_+.N:1<&_%,I7_K 6'P2KAX\"%'9\:)E,$HYB2"2+(4I) FD<QS -
MU;82!,IL2G/6$:NII[:9)'])D_\-&O'!1GY0*P ^Z,[PK0I Z6!S9+9:#Y/H
M@R^4/>\:5@"'0[8,.ZAM0A6^(!]ILW -O64H8PAZ_7$-JQ%'#'(,T70_XC%H
MA,MZ#7P775AEAZZZVEXNQQG.69RJ0P8G:H^(>01Q'#,814$JXS3,@LB(DL1R
MWJEM$.]O/W^^?G?[[?K^YO;+';C^\@'<WO_]XS=P_>W;]9=?/O[Z\<O]W3#F
M^W,K8'*<\(*K[X/$KM [H=1=N<'O)O?^%\$[K*6 0YC';R:@X"87P#VXCX A
M:*8=!,X-]R:] PQU/-4UP/3Q83'OZ\6B^%-7OGXJR@_%FJ[D>G&DZJ2MDXH2
M*60>4V7ZI<[>8@B2B 8PR,.4QZG,HM2JZ;?5[%/; )K"0-*I4 &IO"G6D"XM
MBJJRI4>P6PJS:+@W@/W?4QX6J6V4J9%NZ:UTRUJ'56H7 ><R<&XGP*@1]$'8
MO ZE#QOD<DXLW4;V7I1/G^=+4=W*YELTXXG,1)(GD*!,0O4_ ?- 4)@GC.H;
MOS#(!Y-@'9UQ:L;L75&6Q9\Z'M[07C5GP_7F;%@WWET49 DD8?TL  .7P,R@
M.076LQ';)[;:]B^NY:T9=FJ)_=!8]8+CB[?J^*1O1E35BT$?,U7_@\.,T+MU
MI4>KWA=/=+YLB/\$*QZ6NMOI#5=6;B[G9%-&=\W^>SU7\RKG;X<"0OU.G0SX
MID?[:D/*,8M#SFD4("BR(%7'\DC"7*82<D$ISAA/8XGL6EEXEMCF31VG&49]
M&?^][LVIWDZV$1DLSE*?O,F2FYG,"2VC9X/;:0IV5*W3*EIEP:ZV;<$QZ/2M
M#\"[U$&MRE=@J[0/#IR1EL>ER?<M\J@;QDCXO]YNQIK6%=O8RR;WI2[PKJ6:
M"<1SQA,&41A1B'*902IE"#,N6)BG* M(9.,VFTT[-=^Y82SH>,ANI50RCDHW
M=G1MS#8']XA[MO''",FNP&X:7;L<6FZ?3&5]./FE+CLZ\QMSF?6A<9[<K/?I
M@:3ZFKVT[>&BW?B;E7BJ9I@)W>(TAS'-U3E?.<80IRB +%7H)RR,<\2MZ/2/
MS3(U^]3T%-IT&?I="PIJ22T[,QW'U,S07(R4[[NG 2#9,^3W@>"4&__H1..R
MXO?I>L"'W_OA@77H:UJ)_UXKK^CC=WUE8LF!<NKQ"7UGMR*"1D8OI"CG@'!:
M#GUJKG%+H<]H?% &?>[S0TF/%MI9_$K*U<M]29:5&E*W0M'\;XM"YY]O[ZQS
M*=(P23$,TXQ#A%$&<Z(\\5#BA(@@4?YY:L>'9#SWU+:[NW^\N_OX'__X^.4>
M?/Q-_6G+F&0.NIDA\02E9]O22@UJL<&NW& KN./L@ L0<\O09#[]R.1-UK@<
M\CK9#S',>NF+V4U@@KU\K%;S)S7UK?RJ?J'IXO0'9KIP.=$I9%&DN\\P330<
M1+DF,,\2S#BAR,IN&<TZ-8O52:G=S^=6SCJ%P,YTF2%N9K2<X^C97&EQP([
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M]-@SK$8/7)K1_TT\$75063YTV37A3"*6RR1/(9/J#X13 0G-"(Q(Q&20\SS
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M@7E (0\)Y12E42ZL2D/,IIV:,6YZ@A42?%6C=N^=97C0#&_#:)]S%'T'[SH
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M$Y%$1BDZ!G.-C;XJ:<%&7-#(:Q'R<@3>;G;R#%K?SIB#>!T_2UD#9Q'^XP_
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M*OSE'V> @*D@98%DW96*S-[ 1.>Z+R=TSM\@7ZST'V;_7#V1I5@/=7YYT8P
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MTL"G.^#R]$R]6E#04N4,M->J40>4'_LI"?X&KK;72&L%:K4,H]:\+)*%PW?
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M!BF/LLPJ!-ETXK'1R]W5'U<WOU_=VY&),<QFO-('>#U33"TRT.\$:(0NZZ*
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MNNB><N <#"/]WZ=DF#UFQRIE--WB[?'W^T>2T0CGROA1!"(@2F0 J9 I#$A
M2(*S-.)&"1>;(<?&#;__?/^S&1.T8.E^V=V4[?E]_OWF^N'J$MP_G#]T^"R-
M7]SW.G9<X]4?UN]FUOQ#OY99Z[5L#3C(F_=>@>;EVO.7$QO-7$X*-IWK5A#7
M2_%2Y_\U_67B&"%U3H-2)SZB.,IA+G(!8\&3E(12$NG67Z9CTK&]@ZTZ/ZV6
M&<=;G[BC;K9;^\:RYU?<%4;W#C(&N/32.*9KWH_I%V. Q,$V,2;/.D8'?">3
M:5E.?+ZX)U.QJ3Q^*>CR*UG6_SJ72^VMG^E6M9M.-8]YDG N$P2S( F@#AB
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MG-9.JG7S5?O>11W2A,,\RG& ((^1A(C&&!*L3B!1FH4H0C&1U"A4TWC&L>T
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M7'TB[YV%O0@W/%W[Q'0OKWN=P+5%&Q?RL"_]ZD>=&_[K?,[_FDRGZZMKDO)
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M08T!*<(HSC&#"<_5@85Q[>>6 A*>TI"JS3PWJPE@._'8WNCELP#_2XL'*B5
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M?N-\U'(#+3AH)+?@.\N%,-AN^H.WYWVF%!RTD=VX==]C[+*Y6()ML:OT!_I
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M90$+6)+#**+*,M87#I3H*^@D1G$2B  11?3S)9F:^@-WI[#B]/5$/5[$Z3G
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M^:S.KWZD:8I#$G'(THQJ]W\,*=95<7$FLHA&,@F,\L[V#3XV=BCE Z6 =>T
M,S[8"UPW 9P*1\]OO 42QN]XE\J;E[IHWFIU8/CY:?[]W]5C2N\HT#_H\U/0
M>H_W#CG(B]NE3/.F=G[&R3D6)E^N/]W>&9RIPMH_D$N11D@D, VE.N5DJ8"$
MI$QM_8(0DA JN7FS! <!QO:*!S^'R=] J82Q'R>T<M_8KY&1QZQ7Y'MWFSF
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M_A\];OC(9"@"+E+(.&(0I>6Y,XUAR#,J0Y;GB!C50.V<96S<4PD*:A'/FA]
M^8+<SH1Y4/5A8+L9QAM</5.*,U)60=='D3@A^OKPV(.%81]5KQV/??S#CB53
MF#)R5U55)GUE4/5W/.?_7%6%F>I@4Y$P)A-"H4RC6+<QE9 J8U#1 ^7J+RA"
MTJHFLMFT8R.(S_.%F#S-P$59SI[5EVS3NH[OC5CJT^4#^6%9(L5L"<QL$__
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MAU\^7M-5_M)F[::9YV-,*>2Q)Y2!7@K34'"8^BG#88 0B9F)V.LW/3<=5\)
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MVYR;N+2HU&I^$S^";E=Z@7_4ZUPW6C3A7$]>+#/I6&046K '5V7[_  M8M!
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MF/8_43*Z>=X3R4F>6NR&GH=\&!%50(QD$111R! *HT!PK6Q8LV;G)EH-5M"
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ME@Q<R$P6EY,WSGH^1/+C^IK;P:#C].C> AQ9\?7.=?;ZPV)^F;%)/AJE,;"
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MDI^YIPQR@#/S$:+&Z232#DN#*: #,#V??R:J%\LOQ,+$>:$C<,."LE W0BT
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M%C<WS3_C')<P(Z9.\L?I?%H%M9Y^Q@O131)HB^"!R6@<V7;N6>2HF!'<2&O
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M21.]3$W,VQ'OR=N- /T.+\IWT?>@2!^[3<EY>_8/N)XFF-WDL%G/DIMKCM/
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M>HF?8)HO8[0+_^)D?M[[_62UPO5J8DW10OIZ7>K@O*(HZEP#-O16YJ!]PN.
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MG-XG''#&.! U%1\+TRE$%@PG7J(W2'^9I=\.&/=^_+@%0$/EH@\67#^J7[W
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MUNA?!PT\G:^GZR]_G6;<<>3 1"4 ;:)G)"C.2"B"Q:@]H]V;D\HV9=%DOLD
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MRLDNR&LWY607#7=PO#_<XD((*&@C'4^8!!U/WK-@ 1F=+%I:4R*HUN/S]NB
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M)"G*DYP%)R1SW.E0M!6A-"F!?8RH_M"TC^)OMX492@L=(.KU$C_!-#_]HSY
MQ6KI-Z?]>>)^?>F";#B+/*"LSP&SJISQ.CBC1-J' 4U1H.K,@Q;XVI[$<0_-
M1FAKI*$.L+?A@_R&= \K3MF0 WF3UB&Q4M_5@TZ<V6"Y4_5&J W8'J%IW$N[
M1N@:2@<=P&G86J62?!;1 A-"USZV]<$8!LF2SHD+K0.*MJ-BC_9PZCN8D3)(
M8O#HL.A@3]Q;J Y<)TFDLR*M9K5-2;T#=<SP++A$GW6;F^F]7PETG;K>$QO;
MO"C815$=@.WAPN%LD*(U;5F2OC!=Z(0*$I&%8DO2(F#4;9Y '52_W75Z91C8
M#:.R[ZA0XB3GS5-SF#V?E\7RX[D?-7!1Q*.+M"J V)ZS8Q0[*$QH8J[=:6IS
M+&,LA<'TK>-6).N+H4#E'[?8(8%3:$-B7*9\WCH,@'QW"U))DII/;:*;?X1B
MAUV0UZ[881<-=W!T?VMTG*3@#Y6US!=;6T'57G<A.09>"W+)"X)M.RWY@!F0
M77N/>Z!EQQF0NZBN)R0^-D=.&RU*YIF57*=V@8BTQXE%YRW*4+A(KDV/_^]^
M!N1.:-AG!N0NJND ;KO,BE,.HA;H&6Q2^]H5DIW1#%7QBISO*-OTTOG[F@&Y
M$T .F &YB[8Z .).PP0#&A-II[)HBJB[.-%77C)1% 5[]$?$-GT>_BYG0.Z$
ME$-F0.ZBMBZ:C)S"<OF%7)4W^(GDB?E\)S_,($\J21D%X]G5Z5:E/MR(EDG%
MH]::>R6;E#/L2.>XV9]C0;.E\CHPF-<\G:LO_S+%)1'UX<L+_(RSC<-31UZ(
M+'5]0928)@"Q&"-GV2I>C!#*IM;3ZQ\A[_O/0PX:P RER)[@><T-7]WE[\(I
M\MEH"3:PY/Q%;6;D])5,(%+1/'G;MC9[&RH[<2X'A,E#2!Q<9ST!<E,MO-I(
M3%X6+147O"!WW'C%Z9@IB7QRK"TJ9<F TN<VHQP?H:D3L V/A(<P=Z!:.D68
MNFS"JY)U/D=6))*(0AV;IHUD+@87)7?HL&T"\2Y-G9R]HR!L'[5T@+"'^H9S
M62QYIY:!JFR0U6=@0#$I@[/2.!G;5#0<TN+_.RB[.<2K&T)5G2+N9I=R\-Q#
M$9$AZ!HV:<OH>\U*2D8KX@IT.!;VOH,6_SOI?^<6_[LH8^QG;C>[U",D;6I'
M/8G!U1E2D2Q\B<QGY[6/ A._9<+^'EK\[Z2OAUO\[R*\#HS*_9<TSY;X7V>U
M6\YFGP24W-N:?DDID&3("@>%F14+C@LK@RK8U&%ZF+:N)@6/G[081(4]H?(^
MAB[V:X)@2#"%*7(;F<8$+)@(#*-#XVU)4K=UXQ^FK9. <2@\;)&:.$0YG>)M
M=;5M+RR["0*2*,!4T.I\>(L/Q3"P)4<AO!.^;?KV$>(Z0=Q0B-@F&7:(>GJ"
MW""%MS(([@IX%F*(M)]M8MXYP8+EVGJM0\9N6Q:]V.F)R'<PCFZ0P_SHL.A@
M3SR_&K"\>CX_*67300)7;\_B:IJGL"01D%@6:?-3XOQ_+:;S]6_TZ[7J<I)!
M02Y",B\#B5T:P6*PEL68)(+SV? FCXX/HKH3PWU\M"W&4GT'.+_]PN:OT_6'
M16V; GDZ^_($::6/T_EF5LR5@C8WYI, &K,REO&8R6]+-E"0:@5%E\(%ERG
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M')1Q]8]HP5DMP.2BBN<Z"!=?"B"&+=5Q[Z+MD=) NCUBY;8KTZ8SIC$V:>[
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M3XBE]7>N'QYEE3DZE4#D:HRU<^!U\( VEJ*2(C$-NVT;L%A?"-E%H8N&TNW
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M"29R[7YF>[WP_':0<0S+9OWN7P-J9,,NN,9?ZP3#$!(8=Q:H4QQM@^3!&2E
M<\N9%-)(6F?N['9Z6AG<?JYSJP^VM(FN.['C*5$AH@ FB"XNL0%K4H0<<PK!
MDR!\G9*@710U99X?Q^^?8^B(S6\/17>*EFJ=A:0$)(^\S-+@X+,EH%VV/'CE
M"*LSY7 ;-<VAYQA.OXR?([:] >SL4-B=<"F7T>)C%)@,H<Q/X^ TE4"5Z'($
M4:<J9]P+- V;]FW&/SN8/>TB[4$0O2$6)<\BW<48I& 86HG.VF!RL#:[<P;/
M6SCS>N/]?I@Z@A%#NVCKXJ['_C"_S*9/70W&+3&*912W(-'5\&@<J&Q!BQ!B
M+)49FZV.=KAJ+[^G290<P\U9G:T=$"6+^?)Q!NU52%,WG\PZ 9(I<&^B HE[
M@$JYNUH2,W@I@A4\H$VP3Z(27_!$U^!7FWIF)P7#7E,^WTG6#PN&QM =W9^F
MBZ\I3/(DQ3L!RX;*:+*$F*4"$6UILTHRJ-)015N1E-BG<=A^.-I%Q3 :J"?.
MSOK>YD:P\NMLGH);W/L%23*I>+ 09-&8%)6P<;@@FRFWN%W9J_X4SE82!D1)
M/WS=@I03-KE=D_B/AR%LI8:8AV3 ![3P!#41G! 9:(C4!TIBLE6B0#\C;-AV
M",VX8<<QJEW@7:5N3,%O:9KF[G8TC:/X93*=E$QXJ>F[*W_O[E4\W>V_398W
M3Y\X5L:[I!6'*' CA),.O,X!),JZ2,%2:JMTTZR[K";M_",AN!^^A\!#_;JK
MNV^4#^\6Z=__[?\!4$L#!!0    ( 'B!IE+TU+O*V#(  "I0 0 >    9VEL
M9'$Q,C R,65X,3 Q-C(P,C%P<W5A9W(N:'1M[7U9<QO'EN;[_(IJ.<9-1H#@
M(HJ4)5]'T!0M<T*B-23OU?331 *5(,HJ5&%J(87^]7.VS,JL!0!I65@N.V[+
M)('*RN7DV<]W?OZ/=W^<W_[7IXM@7$SBX-,_?_UP>1Z\V-O?__SR?'__W>V[
MX/?;CQ^"X_[!87";J22/BBA-5+R_?W'U(G@Q+HKIF_W]AX>'_L/+?IK=[=]>
M[^-0Q_MQFN:Z'Q;ABU]^QK_ OUJ%O_R/G_]C;R]XEP[+B4Z*8)AI5>@P*/,H
MN0L^ASK_$NSMR;?.T^DLB^[&17!T<'08?$ZS+]&]XL^+J(CU+V:<G_?Y]Y_W
MZ24_#])P]LO/870?1.$_7D0GX6CPTY$Z.GP]&A[#C^KUZ8'2KX='!^'AX>CX
MY/\>PB3WX>O\3%[,8OV/%Y,HV1MK?/^;TZ-I\?8A"HOQF\.#@__YPOM>H;\6
M>RJ.[I(W-%OX=)0F!<PB@U'YQ\;@'0^9CX=IG&9O?CB@_WN+G^R-U"2*9V_^
M\S::Z#RXT@_!=3I1R7_V<CB6O5QGT8B_F$?_K=\<XHSIUP=9 HP31XDV2SH\
MPG5<_)_?+W^]O T.#_J')_YD5SAE&O%-5,#+ADLLXO;F.OAT<?W;']<?SZ[.
M+X+W?YQ]Z-SXB<KNX&"+=,HO=%8U!$K2V8I.XOWEAXNS=\'-^>4%K.&F%UQ>
MG?<7K6*0%D4Z6:>%\#1"/4PSA:SB39F$.L-OO?C%/:.;W\^N+X*SSV?7[X*S
M]]<7%Q\OKFZ?N-P_R[R(1K,5'=SUQ?GE[=F'FZ=0G,R<_Q3!3B7,:_[VI1RW
M+N6L_^,/AR<';YO_OH]B8*S!S3#2R5#G0)W)L!_L%&,=_/C#ZZ.C@[=F^>O!
M$L[3R50EL[]Y4G,WD_;E\.UN,%9Y$$VFL49)!;(.-ZU]/X\.#HZ#B_]71L4,
M_P!?C^YU\"E622^ 010,$,( Z[OM.-6UV/-1FM$^3\ML"GI(D(Z":9;>1R&J
M&9'9VCPHTD 51::&12_(=*&B)%!)&$Q2^!@4DT##-8T&L0XNX #3F<:C>A=E
M>EBD64Y?/4^3O(P+E10TVA#F&"6EQK='60#KN(^&&L:.B1WFXV@:/$3%F&8G
M5+J0S6\ Z_BUDW7<CJ,\.+O+--%_ +_HKWI8XDV T\E+V#G8N!YM)GP8P1TA
M*L?-5%DV"]*R<,\RA\/LT1^0VN#[N.<)G AL;V-KD2 .3]_"L#F^:4B4D(]5
M1L/@MR;PU$V1#K_@"S^IK(B&T93F--:9)NFU#>=SWGD^9W$,&SVE._[?N.\Z
MF^ QP ; <7S2&=RE"6W=#>Y;</:@LM YT!WZWEJR(SO)M>!)0':PU6-U3\PA
MF&B5(#=2>0[TP@0/?Y\$2'>P_<#!Z! T<B@U',,WSJ93N!O1U^"L'YPWCBQ)
MBR#4HPC'6F:,C@GES1G)&'C?OME=..Z_^@Z7H9TNKO[XW MN?[^XO@!]]&*5
MQ-$+(F*)>%Z#6:"08$.4]:,TCM.'_,<?7KU^NU'LIWW'#_O?9Y=;39*I"E'N
M[\5Z5+PY.C4;U6ZDO,^0^8-L:'"^?)6$T@^"VTJL67I!7IS7)!?IBK  O++,
MK-^A*@-$$ W)V3+00%HH</GY-=8G:?IKP;Q;"2(@NJEX8U#3=5CE1#43O^'H
M%E9-8?<6G!^HE!J5_331R+4G*4C:#CTE96X,X\)%IP.URDV(!\VZ+VJ]/$ O
M&*@<?6Q3>1*(7Y/2%3R,H^$XT" 96@0]Z,>@TSHZ&CW,L@;I+QWUB29O@0OI
MPFQ)7@[^!&6,OXZ[@4?(^IJ:3N'8%:K3T^IM>_@>$H2L3:/ZG)9Y<".JL_DX
MTV 89;2QN:S1'YX6#W_'_^:X2[PZ_*A+XQNK@L8/K*XG0G$ O&&B>6-QOC@W
M.B\] 1L!I\/[@'\']3,DMV@>W*7W.N./G<F!O1&7(?_5VP6[\N%0QYIY$1--
MCL/U[&3P1N>PQ[!L(!RCFUE">Y)07JFWBQT_-__\^/'L^K^6<9+:V1:T<_*%
M09K!F>W!K&,US?4;\\/;,,JGL9J]B1)Z-SWTUO<B@?KQ%DX+[J2*Y27T/OZX
M\O;V#]CC6V3P_Z%YLWS<IX_VB[#YV=%I__3XI//C@_YAYV?SACV%";TZ7FK8
M?9HR3QMV)@?6\X\7+U^8!T0LOCF:?@T.?=I 2=G8G'2Z$MMEKD>QXJF^IB1;
M,V?5![CF?Y^=JA2!YXV:NU$BS:[*R0"D0:O8?^P./FHWB >N0M5!4:Z&1:GB
M(+&+GR<X)VK6D)-U;:%%9VHH"%9=LM(NU"A=R9!%A]P0SBFD(:S>] 3]H9*K
MN!QK#]_@OR5,_;(?_ ;:@^-EJHMK.*IA*7X\4?VJIUD'*9AZDCG4@PN'-99%
MQ,8[;('L\OKJX9Z*MP[Z>$WCJ7C3/HGZ%EU"ACDY[K^&-\$1D\KVAAVS][HS
MNBO:PD'UB!KD:5P6W8]TAJ9:0L+NO^.LXAQW>F^0:?5E3XW@+KQ1\8.:Y2_^
M:GQZR>D\JV#KK(*M75STL2+V7\*1#?-<+4-I.-@V2:(_DH^;G;]V;.E^L,K]
MO^U0$HPJX&D+?]UOX!G1+3H #<8O)[^ >$S.\5Q'Z#Y#"YW<:3M@DAMO.XQ5
MN=5WJPV=9XZ__#M]L8^-EH]5<H<>0MK'+(T#(935TT:' LK<9&9\*BT4A-JI
MBO/4GJ-**C\+.D%53M'&5O72]51Y:B,8G.HN4]-Q<,P*8DV!3<LX#%30W-!T
M."RS@(0Y>Z1 4RR"08E.P@B=64S?H$U/8TU4)OJGNS3X.4I#=W;=:K8$P)N4
MVZDZ%5E-5_J)2/01UN&S(>E(N4OCE'V*T;WFZYY[-]GMRJ9D/./[AVSU*;:B
M$0/XT!QKT+NCM4O9O"U3\AJ!)9<%PR@;EA.XC)B%(S8=SS\OX1\C0^CVYGWO
M .>;&YL3FCO:F-#<AV@2(>NF1.01\/$!F-#%2I.\^D'PR>7?XD!QLTWFQ!^8
MTOP 1,\+%*$4P[A^(4L.,/B'*3(9/F3B\DLX6<C])S+!$9Y=(:8L #$4WE$\
M)<5,F(<HUS!)_!,M2,6R.(PSM8N?QFO<2,@.7E[,[(GQ4.FH=VEQ($-!,/+X
MO%PU! 6.;6\*[X!=F9I?1_2-*8P#GPR16:13\T6:-[PR+S).-B\BF],0W*NX
MM,>S<$/ZP>_I@[['T^$Y+GV<).*K'>3X$;Q0&)KBU*8":%+4B\J?+9E+H5;
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M0_<U51/IX<!<-6619J[SP&C;524DH[2,HP$!;<>I2F2:-Z+<'!\<F7V\4=E
M)3K?^^-KK&?!&?OICPX.CK9#OUW#2JQ+OZC**K$2*.#JZ4ZB7>1[\G *LGJT
MHR*<$>B9N2-(6*$B^=24:BHWN(@BK5VG<HO' FS87H>-WF/A:E :28L?R15:
M,O^0>VTMV*>A2KRKW5ZXVP@VB7H0\KUDT8M%BVGF..D7>TTJA? ARJKF@+@4
M-.GS%A6RP?:6\A-C[&KF>5B8<?%S]!9FM0\*0U%.>;WS<DJ_1S?&?95W,]<^
M<)3[PB]W1A4IRS!OG_3]Y?2>*C_OD9R^2DCB53MOG@ GHIDF#+$45>=.,4G'
MW^2V(:>UAMIAE3^=;0<GC-:'$Q[W3WZ:&S];,@CVETW)P#2A<K$?".:,VVH4
M%L"SZRKX=Z]FE=5:AG2%@!93>06PBV[(FN7GO8*-IRKAVGPW3ZWKJ^=:.DYS
M'/3D>8MQ;I/*:S*KUBVGB]MOQ]7YLCY79ZF6@UUE47EPLA-6,=@3X D<$I,D
M!%TGK9'&LKRX)[WD**^.HEK\ /N[)5=/U ,FP'I2FX_6XF60&?\NX0+Z3G_6
M6EU/ 'H0U$.^NT!#D,03,3*D.5#5^7=]@ZL7U;[2U5^'H*I!LD\H*Y)TA'R!
M/\POM\#=)GRZ>MU'T:SU2+R^6.9XL]I1$K+6\L1B3[Z/8+A4UWD7SZRI:3MR
M=A<BD(;BMK><W]Y+U!F/,_L-*?WU<+20JT=)_-!F. F+!H[QJ9O5 @9"F5!Y
M:EQE+4Y1+E@=Z%$J:8.//42O-UG[M*2%9UTA5,%PK'TX*)0N7)**V5.=BG5M
M(.M#EUY;(G4]25R_=)W,;&Y%17V!0&LQ$&="WK.8?<R/,9"*U _Y?O<%+&L]
M?%=]@NJ.YZ*6G>S\Z0 D.1>ZI0N4%Q(G,\'IZ%=C)5X4>Y[)\/+PZ'#G?K?_
MR$K+^C(D:=F/G<"BW$*W)>%R^382TZS'<OSJ<@F*1EWZ[C,$N",?3[?->[PN
MY>VG&U/>?B,MDM^A"PL4Y>!"XL<K!KGY9-A,+=-9!?_LW_1-7C0W7ZEGJAHW
M8#F8( -64F#A056'9KW:Q,LKH]FRN+HZ,<>C1*9R/>S<K$%KEH;5[?9YY67<
M5;0^\YZ;:]+F$:S[I&K>HZ:7@EFLP\FW 7+B]<;<R0]:W3.)G;%;<H6V^YQI
M?J?][ #M#'ZK-9FGSCK&D7"OL@@KF9<N:JX'!%H38YQ051>*M*098ED3GAS=
M=0,7B/<NQK.E7\3CC,R+$GY2J<KKZ.E&68IY"TZ!\=/1R#VJTYL6-2VQ4M^L
M7LUWW/&"H*%I3 VW] (S5#)=Y\/B;Z&ZCGJ%N0-1@1'#V5^ IR LBHV"I^A"
MI^B$K5A :8\@"H-C*XT(QT#,P<Y+MPVA2?^XQQH]G>54_MP@23?9F\?*T6<2
M[)SZ8\V" 0P 7PEU<Q"O U7G:W<=Y(#E+A@EQS!IUSL&N>:.6?P>39C+-64-
M\B>^/LM+MG\WNG0":KU@;-(1^*A<FK7'QBE8EKT:UFQ=5[V%Y#S0LU0J4M?+
MJ6F JE<I\5*GO49%^EY3S_HE[)ET$+]U:%%F";F9%$>&V\189G+$+9.I^=)4
M(?@F#4SJ);O:M;S"5I3;CG=Y9UN&JN\=Y@ATM,'CV'+K\W,[%VU%2_:?-D;A
M/:^%MS^@*H*"X5K?"?[&JD%7;\=+U?375:&:B\HQU)R0?BW"5#=G.>(/ S@=
M\6B'V#7%VB#<ZG0;K+3#@_6AVL/Y5'NE&/IY%+S'6O$5FT.7B23ZU@ KNFJZ
M>VP!4/B5+QOU<N04KL=I[.L<^%X_^$(\&\)X02LJ1[34*$<T+2/!8!8-QU-D
M4CPDB(!R#E2HA"F0@#.X[ K=X&E(KO->H,"NH^*LO,RG]"-YZ8UL;82VG>ZL
M]<@B)>L5SC.X J"2GQ92B7&/]VG+-HETUA!_SMYK'XH"*8G,?L*SZCFZ$24J
M#X<J9Z0K2L:WT"O4 YV!KF ZF31UJ!!^"4#?;8]3$KG1!-@]A6_/>ZP7)GH4
M<5\'TP+-?$R&5V1^=XKJ:*0J"6^J\H)H:J'VM;E$M7ZH;JA98 $WN\+J\54Y
M<SDZ2QM, Q2 )P9ERG$D=[=>Z>9W8=AROK'F$&C +%Q1XV"0@>+@8) MN(G_
MAN'2UUL=+GU&QFFH:2Q=#4C:<H7>#LPD%00D%!+$7VT? &PGUZ-:;NY>4VA3
MLI_I::R&@@*E$V3)+(:)]:+)"'\D0V0I'KH11[^&T!C?[>Q-IY\$$U](]=)?
MIYR1Z!ZVU+;.C%/5@9^H>F@B EEAFK88X%)3X(S.6T4>P4RJ7;D!0>4KZQ&:
M68*AYQEU+<+B'%0F@3CWTA'N+[GMIHK"13GZA+$K!$H0>&"0)B7A)V!1M_VR
M$@V0')-[!@VS&L+0>(K])&R;5?CM0<<CW"2K5J(#'Q:(^6/F\>54Q8VX VN(
M84#!'U;^O 8F[ "9S>E?0AB.Z&A(D$YMAPTJ[<*>&2H1@*(I4%Q$Q$Y:)R)@
M*^"&LRTZV#4LWDM2;*<235I:Y7D\!UO%J EE34H]5495=YA2"?QHI"/C_JK8
M90U#V22O./U5E@P.[!B.)[[[A[$J\I1#4#6D#$[3'B'"LB2+1@E0;!1R8"!
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MSM$N8]5:^W&1 /3EF\#\5KZ/5OE#CHVXG$QAE1,3CEO 6[\UA1/9BGCIS9L
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MKA!6O()4- %QP2"8.JU!D+QT K\.;?>0+J+DAK25[4[EO7(M;@HQ"M^!!?V
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MO,X[_Q<5]>]BMCT.>:7KWV=/N>,I?]GM*=\?I.$,_C,N)O$O_Q]02P,$%
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MV=<%LFW@Z@V&5:Y1?P(BOW;RR)(Z<M"R)G)(NX'Q(\MA%OL*U1"@PF1(1OQ
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MHJW]LJIYR:"/W_2@F*& E $/L1@JAG',-?SPHQP@.89:6W  DJ4"T"I#OB:
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M>T7%JQT<BK<SR=9O4O"5;C/Y'1HPEPG)'.0C/A;WD@X;06]>%*D7C4TTG+?
MIT6['9RM8=FA8:7^_<U+R'2@Y[E4.#VL5'K!+UVG@/*Q4SV2#N[3JA^NGLE&
M"&_MJF9%1CX,Q>'0-K%3F(Q=RSQJCAI5":1! R9UQ;MK6KJP%8KV7INR$VK=
MW6Y#EV6W7W;# =76]Q=>L_&4I^IKE$\.YH>FY/_X:)3\LUJX_@UJA2C++_6-
M%,VO&3WP>KQ2]6]=*:TY?CSSU,M0J 4'ZT8\)S!  ][=3K1 S$Y8+P=^G6^(
M;;J_]W#H=G\QW;Y3#&0ZBEYCL?(:QPVB?YT'Y"*37--:87U7/7./+4&*V\NU
M'V@%<S[<AET'WJ4ZXS(1+ 0:MB5"2B8E8B09)04&T_"[)29A1J(0J,J EIPQ
M'5*M/=<YH9<YC\DSW8L4F-I4#57.RBG]2DYPHSXUTA.\:_;JD4E*0JR\=W &
ML&$_;LR&=4-Y6;H.80AP^\C]00@P/4_GI/SCX5"5C U#^= 6(@%A+1AM8 B#
M*@2GVV&/-NY_F-$>TP#8'X:]ESW6MS,]2ABJV]S<9+XF0S4Q?WNE8]22R^B;
MJK+:J(WLAL)"88IENNR'JX<B9:%EO>R&\,)3J)J.HBE#D.S;>H5/B*&]40N[
M&B@/' N?DWFH." B/%2<C5J:;G )QR\,/,MJ!9H>U!3E2V<46,$_+>@RW@#3
MHQI,!G:OM"FU+?0T54/!--$9TCLS%J)K5$'A0])J-FH7NB__^6J[8.#H,PP4
M$UO7'Z><,.<ONY0NS8TCS*O@=M> (;)-97#%#8R8J5]#AYLB+XYWDV[/]V_T
M""4GPU#:G*#UL8H !160R4X^PE4F5\M4D4N^1#\>8F'CF847!GDVHPIDK-FS
M#RN1+N1,VC&(6*X)0VTYHFC;Z^[@KSN=CG"1K,A"9RI,$#-*S.L;18S=4 ?D
M$6=A$P"H>]BQG85Q\!!JTQD2C 7XIF(0A.Q6F<!>3&'K$Z(ZDG*(&*J 06R6
M/.JNQLURA%5/)BUWC02G$"'CU80RBZ04HJ""&4P[@A,ZTHFQ\QP#J6'\F?"T
MA[.^HHMSR_  \4#>@0E4YNQ(KY4&<U[M"!$ ):$JR8!TDIC=FQ'ZR##K:?1Y
M0FQ!R+VU=,;UHEP44ZZK%>ROK'8A6(CN5</S:B+2)GY*#ZZ![&,-VR$I"GV;
M#ZGL1$S)3$LV7^+JU5#;)H)0-PB55X76%7Y]*:SL'+N9FU4XMPA;=RJYU>T8
M>^(6=BHB;E%A.37A\F/G/:EEQ)L_0^2HUB$8H6/!,2RFI&N2SC/TVP;A$"#F
MA*]1'@F&3=F>4[!5LT*N>X#C019?"%"&=5]43MNISRV.8OO[9*\&POVR\6AR
MH6E_D-8]0"1B:F"-JXR4^7PXXQ2X((_.%-):F4<""%8G+D!^I3:1Q"WADT??
M<Q\_>?0?GJSKKC&5()YCEG)D;/*45WPBR Z]Z*OIP\;9H,J:. #>U!/I52N)
M$69E;BRN ?E(:AK?&,-%FWQWMS]5RLX.V2ES2ACIIF@_W15^#8KP,V*M]Y&C
MGS4"0<7<3P1OTHG5WS65_@W;RH2!+]=]734MC/B_:UP4(6+*M@.36,]9Y#VY
MU&LVH1Z12.0")(LN4HAN9"Y;BGM4NH<ZS8QL$((V((T@9OKK ) =YF"4$=15
M@(417+'DSHNWA)L2B=E_/)&8/#J-B5%<6O3@KQF3Z4C'\(ML31D_'4*C%5;J
M8X\QH9$P\?JEC)*0%4VF1]2<A"4*$X))%HN!4_YB05)VR,GW J;NR:TU38T6
MP899;Z%SX\$3+S52ZT G!-Q#=PFG57<Q/H*:VZ0N;W&0[82K4^;%)T_8)JBX
MI93#[6%[^QS2LJA-.=D'C^AD(Q!F^>W&5D])J!$::*V:ZB;!V XZ+[ATS=&M
MX16N!&7IO0(>X!>957$,A[IL-HDU^WA'#!BV>+123TKFHQ%M573?(;=:C(L&
M%,25V8J?Y&#IR3TRYF$R5]%#1I?D,%9:R\7C#40SDW&&_%6"0)XA:P;N@)8X
M'2T<UOTAT_SJ-4+@WD%B\$&-$L1F"J"X_)WQ@)4(T,7I) U(+;\,E4%R<>,:
MUKJ[1Y<292UCEC68>QLY_\0)4\.Q)O/8L&@J;,'G>A%\7N'4IX6>JL2"YG(1
M2X-&D>$;#"X#9;<I'/OYH^'85WB/6$GR&;?KM,2XQ-=BX!V*V/GB H70,FI
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M7>D\\_>QSCZC)?B%7_*-\F_#?W+XV?TGNX,\GL,_XVJ2_O+_ 5!+ P04
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M*'2@W4G?HMB=X071*SPD0122&;EL4PVB..Z38)H/J_(GT3GHD^YKX2)517!
MPZ^L_H93 507GMS@UH4Z/H?#>Z;A1(_R3//!T#H79+N42SU+YHF.W5D2XTNP
MQ0!/K>'Y$YJ2K%Y,X;%PHPL^:LIZ^@\XH41)\AS!C;I?E[>X6B[!>U!H0N#K
MX#8M48O6J7DDFB=\?_X%CJ;$T=Y>)[-KN0!_B[>7<9 2GX*D+32_!MZ_H2!0
M#^#]"KT LZ9//T17^8TN^&N[JN;^N-REKG"@<!ZW#I.-!\ TKZI\P8+H:1KZ
M>Q@.!)B8OYV]>W6?^R^Z/RWVZ-N+O_W\\]F[O[<6\MMO*I(I&<XT!T$O]F%4
MJ5J6^KGYQXLX*9>I6CU/,KHW_>A%N/JH&4'$0"Y5*@M.:\]?NPC*Y("C*%4!
M_S\V3Y:O)_35XRIN?W=T,#D]/NG]^F!RV/O=NML^?3HY>O)DJ]L^IB'SL&%F
M2MA^?WUT_,C\0(Z*YT?+#]%A*/EX>C0GA^?E7L[4=2>8IUK(IK B([.SYL4/
M\+7_5)/E#L<O<[5IKMXT3]D+=\K2/-YU"N\Z':3N^.Y3F.NV*KP/Q=SCW([P
MD$9O^.C@!4\7_7'X8J\19?STX@,G]^!DYU<QJ2[$I/I,HG)?K_[H6S1#95N0
MSZ[ %JN+_9561<N>G$1'I_].GQI;=YX4)1J"&5C&1:DP"-,TWMG2G:J4+&&R
ML.D.3R9XLW_6H/5ALE<<1E%S^ ,,Y"I)HWF=PL=LETZB'_-;#<\8D_T-9NTB
M+^S %VJ%MJ1G/*O93*>Z()?!O 4&&V:PQK$,1 ) %+4KR5*%L<,AI*X*M;R.
MCO$II_P^W3;IGV,'O#9.C-D".RK]B?&'?!>''<0>R7F3%PN51DT5T>,\>3%,
M%Y24;>3Y<+"7:I5:H45?;=QT"YLQ2S26):XIV\^[X6\PW.L\I;CTI?J@RTGT
M.HNR/(+M!*.A#5EMF(8REYF8\@O!KN*=BC],5<6GZRC9HP]FJ03$Z0^5ZBP&
M94(:)7%.IWTB:8/F[/3-+>S)42+/F2<P!GB'ZVAT>%I=[\%D6?T#>Q;TS^BX
MB/?<$."4@XM=.*NL823^3+.N HTP@Z?AV/QAN8&OF]T((P-P-<R4+ M.%GP6
MN+E.S3S=2L,\)K^GPP\6:7YR,J'H6LZI\N>%AE4!G=R;/A;7Z<#]1$W+/*VK
M_I_\\?YT3U2N*]W)_[TNG :ZTOM3.%#>[Y.D/E?IK5J5C^Z4:^\UVM9%.>DM
M'E28\^@!A3E_2A8)[BB"A<SAA)\F:5*M[CF\^;9(,-*&=D>%VIMBA<O**"-1
M=*Q 2-W9D.,XT+-HR&0Y:!MYNPCCI9CH*O!'DB9ATTK2CSPU*]*18M 7T3+5
M\17IRARMJML$U/$U?43Q296*=O8#@TDV2VM28R,\X#"7EN)<TPKLT4#*:U!?
M\G,>FIK]LTY8?^!'&*O)S9]SNF()]X%O9G@BYDMS(0T+'EE6!2-RJL1FAJ(;
ME=;V^&B]GV<)XOW73&TTA6?S%VX:.%:)(5@YQCAE6(% B/GG8A!RNL9:@=(6
M&].L3!%F);LMR=:MZ+#-S;%Y2]<E&8P-YAE,B\E6:92'IV".'Y"">:G+4AD)
MOM#%33+3]ZI=MA:)#>M_>/#UO0G 2.W=WQRV). ISL/YAYD&#8WI)JL<&,"A
M8YN(:'B#@>%V:G)1H!;K- [T^$RK$LUT\&.S.J]+(TB4D$&U!89)"2*V-.>&
MYZ-V^+=;&L>4W?'/"%(W:+(O%CI.P+X%?WJ&B@;LTIC]&+C]TGH6>![469 )
M&MLLC\M5]23?S-- -=8S5*WD,L$ T]4D]";(/V+8!.:8>;9@!!R P.DA_"7,
M@N3B^(QP.3A/\YN4'X[=O1NFV+9#RPQ^ZTR'M'4.Z!"Y:$L\^GZ]4@^'; K?
MP1+>ZA26;W1XM,?.6.F#"\*<+\H=N7JCPSWQ-A$@PHE&L.ZCTU/)-"[ WJ&-
MX)X#VV!T>+!'3J?$.%NC0E?RJ/O63TYE+[7%=L8WTF;71F1-A-G3*\S%PY_.
M%+EC! &T4C)G]]0?P;6*Q8!A'=5^*?#MYUWY]%>P<6C['A^.HZ.#PZ_'T>C#
M7G2KR.&_4"F&[GXH5*RCXU.R[J;Y#2B4T6J/GBJ3S :3S/$UN*O@8:^=9%8?
MHW^QPU[6BS[+B.<?[W^E_66%3]:MH?XGF-MD\VK0YSK&;#*&-5;1Z*E9_C&L
M UY17KO0#!AUH%3(Y,33OIRO)),-]FQ!ZH:>6-;3I57XL!-1'B?16:?=&2KI
MA+(,[L?VP38>U,Q\NY/ED&=_ N)1H:B48!S&9H? ]?HJA[_&*"(^QD>4(^;?
MP=0&868;9I;76:E3AAZ0TB5 XU2#>"M8RRL0P'_4\17I6'C07[XZ>?H"IHN_
MB6$ZTWS)B+RL<^G^41=)&2<<?Z*GW))Z2)/W>.# --6I=5[FZ@:,+@(3( B?
M'^K"*7+ L1IHS6AS.> E*'+#:UEG8%+/Z]1_"?!(9@6X,9FJ\F+E'9!FTNC0
M0I<+!['BQW2.<;.?,/,MQ[ZMT#Z<*RE&:,I#(#['8$%-HN_K A<030-:?5\W
MP+C3G#$R\.,S.,4*.-#4&-PEF*+_RE%@2.5HO$4*8X&- 3-TJ9);E;7W",[)
MU(.G6KQKX.2T!?T8U^5N;THN<NMM=^+PG@WI\":[MZE3<!.P.VY7ELXMQ,ZV
M+5LK[!VZ&%<8A!/W&BPRRLM+58-!,()_D=UKK%[2$4E)*EX5=M_+;W$ [L=\
M?&K"1M-&)+=9A";0/+>DVAI;@G^H;;B$ 4H]&]A[BC*Q6-IG,$=[8]X>+<-'
M9U=X9!&2U<PD@I]J!'S#\9#J[I,ZHEDQML]&W6'F;('!]D1A9BS68(7C&$%-
MB]Z<8D43W(I.\/E<)85%TQF%-Q(/Y!U&B&%BSM'"QM=3&.G@1= 6DEOF,'Y2
MHMI/+YS%<%6"*@;4JM6J&,/^"+\#M8UQ-F 1:09AD*B Q*SRE._0/(D_8?S]
MZ$O\_=-.Z,D#"H^1PX\)+]@J[_ N#/=\E6#@!/YQ#@;T#>;;[AERO!/6P_"B
M9I@>E=6W:4L/T(LZVZK>TA,54L-!EN$FK\B)B8WDH,N1@/3$? Z:7[2C5+H'
M+,T#8>R(?TAP(KX4!P^=\. 57!+$5CPDA4GD6 1W&*;XG0GXG1#. <:E-OO+
MY)BPN, \DBW ;K$59/A'7E?V%@+0$+FQ.'Z4;U]RV>Z+T21*IC4*@K-EX/EU
MJ@H.4H#)1$%1C+?@8,Q%2[4B8<$J-55>@^VM9V#=5@E,V8CO#B/- JS>GGLR
MV.Y+750K=C([0LC!7K$O"W>B()/_>K1_<2.[N+@QP[*8PP8Q>(4WNF!73@0>
M7H!L*SM%=&-_COS9H7O%>>,YQBA;_]-1,M&3<;AS$6 1WLMS-DVJ#^_E+2T.
MTBL5;%J(5"G1-P8_- $WK"B=-PY=#'D+[U=^0G9/S&;%]2*@:Z9Y_IZBA+6U
M;-$!+Q'ZD937XE,U"S# ,H\I(TZ*4D5+D!*P+-W0C>>@[<ELJTM8Q_6^) >W
M.)A#4D&+OU2)$QPS_5YTI%O2,(@(EZSX'CTK@G_+*L@VA1OW#6\2G97!(.#!
M);PDW$!@@WZ6G42T.35N2DJ$.-FIM,D0AXDB[ZJ]0/@8$]CQJFBZGV!CC^8M
M^%%A&-V4W!44*D4UQ]P77GH_D<GGK4^7JK+MEU%<K,23")1#@6Z85Q\U2XI9
MO2@I[5SNH<<*ZJ;@N;/A:;\6EC+S093;@T3AJZ^=7?*'3&"WP.,\SS@U1-$@
M7Y0*>ONYII4@Z(!SQ7CT5J@^TZ).^T8@!64=&WO>]?Q(+?"NWLK?"<>'9TP'
MO*P1+*4=XN^*RY8<-"IRFSX]W,8Z_JSUL/:F<#B,YF$7:D)2!^Z :@@P'V94
MY%NY  .;>'9:,*=2P$/A+:7\^$V^9D+=#_GA1;"C^,9=T/8.^8'9:PD<?>H.
M$CFE2*'@>YBC1G08[D<3TF\^8#<,O>'%,#ORC[VY1P-FZLFPAPBM[K-KY+R6
M%N3(V#"%RR2$=I,!RJKW_'0&IY,8$X*J7;UIL>MB,DC&D?_VPN\]V:,^W/J>
ME_U8JS3;&K.9WW0;UVA&WN)W"\W-.9O1&Z)K1N)$FVZ_J1Y4$.CT 06!7H+X
M7-FX-FCN^X5?[H26'5ZLYXRR!)U0GVX]V<B1JJ@E)P9%B6@1!:?F0L>!4V31
M%92 P (@U' S-ASU?([/G*X$2P#Z_89R)SGX<"RD8T:,%'J9JIGUB;((I#C+
M%UAQDJ[V/7L"70;0.74EI?927M"^!=DQR-^#.HK5,&C;A3D^P"+$# XI:SL8
MZWEA;L@856+!$&[!F('?JZ2(?E;%>U#HO_K@5S\QP1A8UHD]JS("4_I+HL*#
MG3Z 1,4],-=T3]8"SN<:0SI^TL[B$\E;:>YFSO,+:+*T" 'GASN3!J]3*[3#
M2+31:0GV0P\^JE0+'=S$>J2>'>1!3IPBF=) 164T:3 LX1 ,U'-O6R](E5(4
M*Z12*1/3(<VU[#3/@NI'$P037;*0>_C B/7JR>JD;NTSQBJNKDI'>4B?\B;+
M+)^!P]]4V3VSL"&N"J.@]^S1D;VAK'5C[#Q@PL@M/=,\I&/]'<0+IM>J>?A8
MX/L(/]"9I-U54>!K+^14\+WT)BCL91Z#((F??G+P[,S"72X+VD1X;&+(MQ+Q
MO!,]V. -E0'&_8-=ZK87R,UF(X-5Q'AK86PSV,2X1 W%Z:HC4?;JQ2)0#VV[
MJ,PIA)<;&!H_22#7%#5+5<E199<7(&>R54[9LA8(P7 'M=Z*^,(K8,$NSU?[
M?4"'M._!\5X_0D_!YG1# -CD8PCI<=E(U-B(-:?O;.K!OT,0\#'Y!%),.' X
MIPJ',.),7_"+SA?LF*/Q&K,/$39+A;%4]FA7>VCVCOL("#>?)G<12W\&.<%D
MGX-Q8#A8>C \GBGLQT=<* T?F=_B.]!\47;76,>(-(*7) N6PX;M;$/'(E#X
M;@D23C)B3N6V,%'1E9JQA6^+-(RMP:..PX$E&'-6<8*;J5 Q!5@H[12<0G^;
M7$S\':4_S.CANZ&IAQ>X6^-2LAYSQ=/;:NY>7L^6%&':UMY^K8L8;6^#=5FN
M7HT0N/6=T?\[\%,XY(&U>4,2DCN%P8Z?;!;:?;QH8'SB??]]W0WE-&2ZE)RM
M,06,QR Q%= ">T!5)/<U('5*=L!"W("#FU68H_?S%7X>?D[Y-2P,Q9PL7*0R
ME)9722D5R7LV\DQ 5H*/-B#;\%!8 G"<BGS!UFQSV#'7F2CB *Z*>H:N>G3I
MQC1&A8_!5-+W,>@Q,<]!JR8YINM!%*BLQ<H3D^KB^U"J7DX#L(KA-*#;6^RK
M8RQ<JY(E;1N'3U%%FH2T$/Y46B^PZ[%FXKK,)YJFSKUM:2'TAV52A.Z8"[*?
M^<'UMSQ)(;9GNR?VU@?Y=I:I#Y)(>"N.;K"XOH/HG49&Z1 ?A8[+O<UY=D[_
M?>SM+2=FN_3"UVFSO;"<17?EX$BH1,"Z=NB%1NPWVV(H_R9?TZ'.:04:TM/<
M*?BJF.]%<42V;FO;@&B1Q8NR*FE32S0TIA+QQ&-#82X3VN'X I_Y_+PC_3\-
M[EZ)).](\L)Y_9Z%I@!$^6D)77RAZWSXE_"H!SM^ .'1;6R7>YH^6W%YN0'N
MV8*PDF3:2*:'@C!T06MMRK6$00_978F'Y*Y(8&E[![PO"];MBQ@0R6?S<O#F
M'^GCV.85V_LX%EK@XDV.Z*\W\H1'B!>N[@@\>\9,,-D>U*[V8MH,);*Q*A._
M)7R!5_.#9JVV0"Z./=AL0R-"88,3!J K-V57P(.XMPJMMHZ5,7:"(^@]#]\&
M.FCI^BLY00_P!+4587B4A@?EL(P;=AA 7.[3P($IY;R(9^B0/6'CJWYPM!\@
M+59QD[?C5R^3U:)57%,.WDY7]3DEUI3Z"--[[++?;(PAM:? N8W<J.B_:UC0
M.867.Y2/3^\7P 1GH'Y ?A?(,&#\.X+]J1L)J C0T#M)PU+C5MIE$EVT@)@?
MA[2L-IW@&YF>S-F\&R>Q'M))+'5''3UF"(7)=;=@DV+!*ZVX5?D-A8R!%,K5
M8",FRJ? I.._\^)*93# QBDLTHV(.&Y[@]];?<KAF+J@7\&M%[JX@BV$&CQ/
M$Z;M!-&$/Y!'PU0V<9&]%A8PR_+&?Q-?&NQ7$VT/JGE+T Z[BGU[\H"P;V<D
M0H8/@XV3>V8?%#@LBH\(K=&T3ONY%-?4LD^)QN6$20GJ#W8&_V%PH;133,\G
M"3C.\L74"\244KEM4B?^9^421#*?S\,$3E@$U0LLM[5-<E_>WL9XZ<WY43B7
MLZ5^'+%Y '@,C8'1Y9?Y4\F#P6/U/G J62@X'K@NW_)?-0++G=/!^W[+.6D,
MKM &Q0&K2/JG\!50,(E6R\E;DKV.+@!WX5!6JCU;FD1(X'9A18'(596C5G19
M:L.ZTIFL[N9!=G5W.%B"SZ.A/L?366QBSL@A%&?!(&H&X;@1CSM&*/!C]5YW
M8*ZE+$-8>CVX<Y>U%!2(,,+?'?@GR';2XYL%0F\@(F$%1%<JUBM"@<O IILF
MKCH*ZW12.!9N=!N;U(&W'*^U5DZ[*S!VE(3RZ0,Z9%Y[A5>N[NL7VLEG++U?
MJNMW#W']"Q\'A!VB  5;C,:IZBCK=0EM<3E[DLCZP[) 2[*#O>G,4=WXUK)D
ML_"N^ 0\2-"#@T_G#;\2SUOD\Y]3B[9HQ(,5I#=&L%"7%WF6S*@J;*\-QZ3X
MAV'7<W6(+MC1[CRV6E_#TLUM:?)BG[[(\DM>P:MD>0!YA<%D$;:ISG7]'W W
MH5Y YFS:X)^F(<1.J/,!XE(#E35[G^6W1,S.D'7TK:[ \DTUV\K,IRZ%(TX/
M>V8U?BQY[X)-VQ:5%E*0<3RA'<0JA/&KQ\Y=FL]H"*(BJ4D)JF=B@TQ7C?+C
M@&F4$ YIE2R(#B$1' S3970.*&'-SXRF9>>@N%*\3.1>U#D;#A8F^V3!Y@("
M"R_%*;G6X"")XV+FL3%_(8^8*45L+=)62X&1X@4N1X:N"QZT2,K&Z.^\X&W-
M]9^EK+GQ8AV_9&^]=X=S06/A-??+"7QV'?R06&C'KB@  T^5J:\,?XC_3-HV
MYZC%+[+':8:U-_+J/TRK 8L!)B1]&!@/LZ&NIZCUS_WR\])?A'46P%^^.GWV
MPG$(2YDN0D03UT4<K2=6NK!R^13TFA1NY6,OOF>P2S;#<\6M=HN^A6 7%H,
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MOY8^/.1B:[X5GEX-N+#JHW7;4?/UV0,R7U\VTK\_H9F")Y'7)^AA\'G<N9?
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M"4("8WKO"/&S5^%3D(HW$ +)G03PS8:LJ<J$3:,+1X\>SHOQ(/V^Z1:W2\)
MT35C"YX</#L3_O6 6J!A6^H/H,NQ!;C7Q8J[5TF-+R9E0["L3%6'%,U;TBGU
MF9/^UHD/1^G_]V"4_F9#U.B/P9BA#5.!+(]=L 3>#48H-H1\S=DR&(EP\"WQ
M0.1,9".V">$<=>K^O;'?3D)@*)2O1&W)9JB7OO?.D89RY[Z:TUP 1[=Y\5XR
MYYYG(T4", V9,! NP 9@"(!G2^R"6%\,1JPW&[@BV8/1=1U@I(:TL8B+P0AG
M+M@;^(=WR.Z"#%T.1H8V)\2^5^ :_ZR*][J*?E5I_0>IR0'FPI:ZX"086Y1^
MGI"5=J%3?8-V(!5B!Z79!N&[+- :[+_32+:%N7Z:Q&,N>"30=\GX'&[+A9Z3
MP&GIB90V_F>=5XY]IL&ZP85:98#G,6$0Q:5;##Y9&>(-4.FT\IZ_80?[)6:U
M7<R*VS87U&0]R^WB-60"\UYNT9WWPRM;74O![+H?,6[ .D%CNVHIHL+,BI)P
M6OX5;L"T;B2W3JI:/$?,76SP+2U5P8$SSRV3^_!S[-V([5<F)<GN<8^OTX/X
M)K_A@"^J0L,+_F=>(X#C7L7+--"2WJ5$+&XV<NC;8J"#V((27(==.$/_-I@S
M=+//:>#T0[+#"(9TX7!L]I XXPI6'+,/1!(X.4% <_K?79"B7Q^0%+U!+RJ-
M?M4<4;V87>NX3@?CMA+J4L84,L.O8Z$9]T!0^XARQ-/D:2%'P70NXRKP&UUR
MU;974I%D)=@/J30)0XAZ9],T"UIOQ^^^0$ \",CQ%PC([YB_WP:C<8XG3[Y>
MKW%@FPR(\=46*BYI6 &*S)8M]N2>T/YFN+F7>*+CC=C5V?"T"8*CDY'><Z&Q
M>">.NO\9C.!M/NH\_3P4Z7/% WQ026V=;<)"'(&]9&V[($!_?T@"E*HA -5Z
MN=:.#@Y.HO-_UACS?)WA@8Z.-+=:]6QN-'>01H9KPG;1 /]_@Q&JS:'0MQK3
M&'CTO,("YR2%U1N2D"69#*I!Y8/RPIQ&!EK@8:FC*Y5D2+%D.8Z"TDJ\&@$0
M,T)=V[@/$0E?KTK\G$HOL9%5*B10Q!7$ICR2#7U8"L6(3WP5:P7. 5=+3:45
MD[6ZX[JPE5-^!:FK&L523].,NR>'OVW^OF-1B7I,,!YQ1^Y^UPA>S\XF?U#4
M[:Y]??Z[A@F;DY_W(#AW"!SD>'<:P)CFE8XHL8>>AWGKNAA]YMQ)P^YBJ7-<
M3^TR9G(#HH+CBL0;UW+9XZY'+3&#Y8@) &;))@+F\7EC;.8-^):!_V]!V!.$
MWNP?CY*]T>C4&MB7!1$S8 ;[JDZ5810:?F[A?AMK2[G\'24*"?6B/$M7777+
M?J:BR=W@48?X!.L]1"5C*LOWQ;6;1>2/I0'9";#5=]\-55F'N?RAJ&=$7J+D
M<S"#:CJ#^G5_=Z"]38A)8O/TRM#(;HKJ;%KD[\%H@$U'[ C^-:7'^=!B?<0;
M-[E[&O>GC^B^W1A-43\>3E25VT!CQ^:7,2O^QF,Y <CO<TL]/>T^M2U**3]L
MV"5@RV?^3CUJ[=2.@OE@L_8PSI"UR:FL!I>!8%?#T4HH6+05-L> VR 9)P'^
M*_4AFH+YER&]B%AO-+$+]9Z[>]H.JB'?ZD[HB)<OAZLC.N+Z0U$57D GLQP.
M;&O1<0HN4HT=6/#G[,[,-)ZUDH(PS,1!HSW>R'3LDABGNNF:F;L@BXT\H1L<
M@K"1[E97%IB.#=C*N6I@^UIPY!O)(0467=@WA7;:[D"47[T:ZHZXT$CO2PM&
M$9[/6HIR]SW1V?D1E*IUT,WY$TDWJR!\X-,LH\<_1E"?2!QY_R%GN^,:GFPJ
MV&"<OOP<SS9'4SPWN BC]^'LXJI0#)X)/B(%"SYM#'&:9PH,T5B[,[8%=0W.
M7 ;?EJP?Y+P5AAJ]U"3T5G/DQ1[>AX,-%$M!?AXIK5 R'H/0POHU9QNO.W)A
M&@J,[-CWL4,W]%"X% 6SO;?&+TQ2%#T*B&Q )TGO[Z2H5B ]'Z+1\1,;@AF9
M*2ZO$;=3F.RI,UVN"4A4$BIXQ:ME!Q$4F.Q-HHL\Q:<V RW&(R6K"6,U*NK9
M+.R_E&&5#^G<L,@GEWH34.^22S(S8>OX6(A)A+A$!Z>,G%\L?NG 8OOD8U_2
MQ"Y-?/(@T\3W-%V&FDTVM0%N1S\@)^O=H/S:_%9_!@!_8]O( ,WFP0.C;/D]
MO<Z7^;+3YK?&>\#C.K9_2F)W.T97R?2N"W!=&++ D\,3[/&(@\-_SH)$L)VI
MKJ 5NR,THC&&GS61B"C&HX!QQ7 5\YS#TR?'H\.],:AS?MKH.'S4.G7H20%.
MC.7W#?Q1GAN;U:;WXFE97A=8[BB+:5V[TP-SQH1ES2 K=4G35E9(J (/:O[T
MZ]9/R=E<IDH($6&.Z)S@)\-T:%64UJ4KM6$Z%4:WYGQA\)!68_]H7=QP_:05
M*N9V$$:XM-=GH5.2FK?S)W,VP,F\VVQ-HC,FWKGV$;W,. DJHN>P;;$B3C5G
MOWO"QIY?06X_]6-<MX;(8*OCIO@>/#L+(!G1:Z1JB"4\&5;>FG[F7J]+.]3$
M4"UR"!LF ":=4<QPNE)-;Z4PR#-=A>;$=8*>D8L;)$&8\7=PX#_U/R'G<O@T
MM8,AJ;6T^!?7>9W&!J<A4#Z2;5Y?GYH<R9)MLH^^WB.%C;8I6KK6T!7D_09?
M),DP>MYOG5KW7']8)EYJDW*V">5OS&/WHX#OFZYBO7 #&Z_.B"[7'PX721$/
MN0M+['O>$&^CL*VMD)(;UZ0=KS1%A=U!4\-@VB@YW#X5^N#%?T#R;QH)=,I_
M6]"-G+-/N9]A(GQT].P/%_CF\_<?L-P3^80?<1AW3;RK=VF?.#&3('PTVH+[
M4H%FF^HM !=4#R0)7!<<=%./T0>:<%*6H48D VV&G-%E,Y")EDUFXH>&SP%G
MU_3AXF"+3QWNK=>G60O#A!&R!98)[$)5]#QZ%R <Y^>#C6]2+/LW6%U#0_TS
MN99#"7#B_]55CES-,X[DDRB:P8().=/Q9JYLBC:9'XY#GFOVB;U"A<#"M5D'
MU!H!C@-CE_(KVAVJ76(7C6Q;"V6M:ML" FO]P++Y)^84)':@%GF=539ZZ-2C
MOT*7ZH/>B>ZOWW\_V&T1E.8.93.0+"[@/GB6A$-D'^N-*F/US^B'-)_R623_
MNB#^?R.:4G>* _P[QIO".WVIIO'"I*</,DPZE/W]PP^#W=_65AG*WK;U,U[_
MAL]:0S/?N1J:'W\<JKBU3N_!2)W) C ]9H[E"SB^:.1(5ZD6>:[A950ZIA2<
MYD!PFJ/'@U@>^.LO7YT\?0%RB,1O(!O!W?9L8-XR?380L<W;\ZT[;NNY)*V!
MECF%%<'OK LTL,;14JTP!H^7TA^<V.9 :,U>B\2=U(=]T]LKJ?2BW#/H"VK]
M@YEA;G3-CA19DM*"RS<S&6F;R2YCJQ!;!JH/9,3E]*# @)5.-@UJ"%5513*M
M*^.N.>A+WE,>:S[S\6I;,2G+\;P^X=9Q+/VY[8(G_7;!XVD>K^!_KJM%^NW_
M!U!+ P04    " !X@:92YWINZ?Y*  #<^P$ '@   &=I;&1Q,3(P,C%E>#$P
M-S(P,C%E;7!L;WEE+FAT;>U]Z7,;1Y;G]_TK:N48#[D!0KQU=7<$+=&V9F19
M*[+MF?TRD4 EB+(*57 =I-!__;XKKSI Z#*+D"8FVB)0R,KCY;O?[_WM?[_X
M]?GE?[\YC^;5(HW>_/.'5R^?1P_V'C[\_>CYPX<O+E]$/U_^\BHZ'N\?1)>%
MRLJD2O),I0\?GK]^$#V85]7RZ<.'-S<WXYNC<5Y</;Q\^Q"'.GZ8YGFIQW$5
M/_C'W_ 3^%^MXG_\K[_][[V]Z$4^K1<ZJZ)IH56EXZ@ND^PJ^CW6Y;MH;T^>
M>IXO5T5R-:^BP_W#@^CWO'B77"O^ODJJ5/_#C/.WA_SWWQ[22_XVR>/5/_X6
M)]=1$O_]03(Y5M/#R?'A\<&!/M8GQ^KD=/_H!#Y1)T].]D]G_W, DWP(C_-O
MRFJ5ZK\_6"39WESC^Y\^.EQ6SVZ2N)H_/=C?_[<'P7.5?E_MJ32YRI[2;.';
M69Y5,(L"1N5_M@;O^9'Y>IJG>?'TNWWZOV?XS=Y,+9)T]?3?+Y.%+J/7^B9Z
MFR]4]N^C$HYEK]1%,N,'R^1?^NG! <R8_KR1)< X:9)ILZ2#0US'^7_]_/*'
MEY?1P?[X43C7=3.>PI;KXK-/^7"C*?_T\M7YV8OHXOG+\]?/SR]&T<O7S\>;
M[/,=SOH932/6T[Q0>(&>UEFL"WP*UO/JUQ_.7D47E[\^_\_HUS>7+W]]'9W]
M]/;\_)?SUY=1[\(6JK@" JWR)4_!6^@?=5DEL]7@5OKV_/G+R[-7%Y^P)OXH
M@3$SOI5??)''G41X-O[^NX/3_6?M_[V<)V5T=E5H30P._M#O];1&)K>LB[)6
M\&&5CR*5Q?AE C0)JXGALVBJBF(5Y34\,-?X]!)8:!GELQ%]\"95&3P?3?,L
MTU/<W.@FJ>;TW?-\L539ZOOO'A\>/'I61E<%OB>?P6NB?$G/P@M^I7]IW7]=
M[L\)_-![ F=I"ENY3"J8][]P9W6Q*$'"P#\GL+=9#AL#>U;<)*6.8CV#H6/<
MURH\N7*N8*"YNM:TPPNM,I11JBQA-_C X/,%_U)'JJK4= Z?GRV7<*+)^T_9
MY#MBK:]__7T47?Y\_O;\QU_?GIOYW\7ICGRJCN"P]&3%1%UVDW14+W,^B%F>
MIOD-'A4?/%XTN#(Q:2[E]]^=/'ZV\<DL51S#2'NIGL%,QR>#OA$'X[_FQ#K9
M?K!3AX=NJWJ$GN%/?'YW26KCZ+*7U'P""\@.F/-TKH!_ )<HB$?C" OX\J+*
MI^\B6JKEVOP*7O,+T'>9NGGDZ()&X(_.W^MBBFSI39%,Y;'?-% 94/,%<I<Z
MU430_/ RX9VE02,8!IA1G$Q)H\Z;#(TG(4N +Q1PPFROK%155SG*'?[&S?R?
MXXMQ--/PITIAX&F^ $ZHWD>INBEYL$(O5)+U7;7H*K_6!7^-,Y$7,%^=P'S+
MJ-05W-<"A%B+_WX4^[Q3Q51TMY_>GH'>=O$&E)T?7S[O5W;ZIKW>;I#%3_*J
MRA=/3XG95&H"9"$/3/("3FP/%IVJ9:F?FG\\BY-RF:K5TR2CJ=./GH7#X:6%
M(ZN A%*9&LV2OW8&T'B?C: *)EK%YLWR]9B^>EC%[>^.]L=/3@YZO]X?]W^W
M;MC3T_'CXR<;#?N0ILS3AITIX<[__<'1 _,#X6)/#Y?OHX.0M)"QM38G7PY.
MR7ZMX)I:QJIU*/!D?]8L?1\7_O5LEV/*WS9J/5W5BPD(!DM9(K>^[=K:76L*
M[P_=K@$MO5M[<CI%R;:2 H%>%WLKK8KH6E9?RNK'T>')O]&GD5'6DP+^4%F6
MP(I*!6I(C*H,4%D5:$RL;TP4*%-3#68O:! TS.D81_RS5@4(T'2%ORJTFL$?
MH,A421K-ZA0^QF=U/(Y^SF\TO&@$KX>7%-$B!YV)"3E:J!5J)64]^0.L:U3R
MU'2J4]!^4)TR2P$]!3X&&2L3$?M[6>3724F[ '-_HPH%&N1R'AWA6TYX/=W:
MS==Q#QJZZJ=SC8>DOVRB(#V[UT;=X3TRZD0P7((M</<&'5HD]MX%I@<8,G %
MX?8*#W)<QA@P<--KC1Q@@A95I&<SY C,4/ 7TS0OB4E-,&ZAR](,E2K@2?;#
M&#C*LDB  ["OJ&FQC6#(%!\L<^!'!4TYR8C==+ 9QU1.D*F<PN32_*;?3+I7
M9'YTC\B<XF SD N3)$VJU5\T\^Y]BRZ[+.M,)R@(H\K.%.S##(B&G9?TYV3E
M7!LY/SU7&7Y,TC4OA*!O2*(E&3R15$2-SL'F; QQ.\=: :7B+1)IJL6A$8^B
MN"XZ?Y,F,UW!GJ!0!E'MS6MS%\"]HO7C>T3KR*:( (QG:FC43EH@$MQ$DX-*
M"(Y(?"9$'!@LQ%HCG( 6RBXK& B5LK)/NVNYX)S?BMUE\@:6)!=+/4UFR;0<
M1V<E_5YFC',MO<F6K=F6]70>S A=@"AK@EGRRF&B]:).28X8EV"P->R=Z]P1
M]]LX'-K)N \39<@OT'W:D&3XM>CRQG>*8IDW[4,%FI#"Z?'X,5[YG',1GA8:
MU@'F0V]\7E3!??<3-2GSM*[Z?_+7NQ1[7/JMS>CU$?K_.R^<$G"E]R9@$KW;
M(ZOHJ4IOU*I\\$&)#K>\<UOX\LD]XLO/X5+:ZW6AB^MDJN]>Y_;O>,E<D'59
M=]4/(S7)K[6P**OQ1CO,PEJZNL8@"VOB>5T!I\IPFW;7,Z-RGM=I3 Q)N(_3
M63Q+742&6BY3,)\G3>_,)\;&#_8?WQDI[ZC=NZ.&%BT_PGTX?S_5RPJ#/B[X
MKM\O02*7Z8I/)69B*>O)TM!+&>U,=N$$B[R^FD<[LUUKTGG28V0.W"JTEFQ$
M!L+_/V>S+J]+<U](&B*- 'LL,9EBGJ0ZH$'\ER,Z"L=E[B5>@L"GFX;:D;"0
M[!<^0!KQ*25)3#<(;FD%G$<7=ZK]P<;L)+L]VP4T F>R<[2[MX"1YM$27I+'
MF+91U@40UJS(%_2@<3"2KC7U^6B;1$:HF.PD\M*6^2XF#1 .# 4'::R=@(@,
ME>%_T+":=>BD^(R,$I(?.RY)O_/U.,4I0F@VA;$>L:EN6=8X^J?)E@@WDO8D
M318)OM2NAK=RU,&>'?\FSTDWL[8[X*^@?_U6C,R!5X3).A.M,V=2?K8LICOE
MU),A<>I]TKY>"FE<8QI4R%/++CXZL2P42(AHI, \"O$&;,A6_0?:SH,!7J(1
MKMOP([@B)>9%PT:@2(.-(YND<UR-.1<ZX"S\<_R(_T69)S=SX5AN)<:A4X39
MA.UW?*H/!TQ7M.:0'7 &=A]W8SY &0;&#-U0AQNYE*V/%9K?1&27B#SK%9$W
M.@6:W#DXW%A(]GCXD'9_Z!2*WT3+<$3+=$BBA8R BTX]_3:1\@9(064HC%[@
M$9/7_8ZU=;[J1B/]+%=MB_3139;RC5$,AU'$0V(4K(,V.05>LUYN >27:KRQ
MWK6+Z-J5?CIX.]9+5VGG_6[$*2.8P\_YK.I*1R<G$@]>+%--_G_W'J"!G8/]
MW0C37,IN J>KNNH>^O2DFSWM'.P&\6>*;F!0 BBWSN3RF70;RE&&OS'EA3WJ
MGS=\@;Z:1.ZCG>=<Q>)486=->]W??W?RY!GO+IS"9V*XWS2]MJ9'WDI2]]KR
M9X;&Q\X)$^CGE#W=6M_]$CWX?A.!ZQG5<8V-!@POWK<(EI>_=,\C6'=0F]6]
MD<+-X2+X_O$(9/<X>ND,M1%YV&?1"SW5E+![=#"*#O</'H^BG9>[7'$87:@4
M4RV!W\<Z.J+H*T5E\)F7NZ3TB-3#JV&%GO&PKI-Z[ 2 85XRHRCK1:<=R?(0
MA[_2OIB%3];)5/UGK5)R,.GW4ZUC+"%!-]4JVGEDQ/$HFM,5+^?:I<3$F'=)
M17MXD<L9I8J")/NS3@K-L6_B'N'6DGY 6S..7N<5GH'5*#FL5.BKG*R-9!:4
MK!6P_W"EI5H-)#_SCFE>9Z5&6<A\J]"TVZ14*MCG*Y5&?]3Q%54@PHN^_^[X
MT3-8"W\3PUK3?,F%I5E[4_\ )ES&"=>&TBMN2(M*DW<ZQ3F5=5J9@L69NLXY
M,ZC"(GQ^HPV%&<$K_-=W-G42(2P!-T6VN<Y2=3.K4W\)<5).BX14];Q86:^?
MVS+R6:&RC;-8\6LZ)_FI?KM&M@2]=R)O0(ILU269#*DP,M49B8(?NTW<#NM
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M=9=$]KLP?,VUFQS'D<N3"I30"T%\.4%=VT\;JI!/[ AW,%EWK)J HC+/"\)
MF:S:=R;0@TC04C96= /"&1V<EOFP<'<69ML';^Z7\ZRTTH[QOGN:40/\P-S5
MIFJ6Y<4"GOY8#Z;P6MH5E=HB/EO81Z9-3^F>Y"./UL7*OT2,@T,\,Q-CVOWT
M,'G+67=O@RCW*I_X]![E$U_(#3GS;\8PX%FV0K8.+Q_WTE>50FGB7_F&LP7-
MVVF%5NQSD()75J\L\K0#7(N+KSUN,>HTH5V=->AZQC76X%"C0!<+@_%DD6+
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M@%,/?K>K(W03F2S)* -!NI\R0 P;/,3C#/"+;>/GF^QH<93A_BG>O^"F=(
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M_J[1,GE9N_LNYT7O[]?VI]Y6P_ ^U;V?6<^FB;&_5MPM>>:2E0;080W]&ER
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MA?WY]E#Q?)A4+&JMI<UV^ T[]67H^Z#& 2:9TN9?.GC-)48SB&XMV,,4.QH
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M3J:_.^IH8$\1,F26K AZ8>/^(A'N_@;6+0>C;O+BG41L/8U:<KQA&S*!^UJ
MV.?0LZ<^; -E_]_!4/;M[$XH>S#LKB,)ID%M3.*B(X+(!5T#_S R=AL(Z.U@
M".@6#^"YZ<_T D[H6^S%P")7C8+YW&](Y:63^-VP$"&[B%U_%%>7]J15E+8-
M-'XQ&!K?0/P;,G]3#,@&9P-$9K;$F45+M6+,"&VPOJ(+C 92GQ$$!YLE%G%3
MOO\)<1:B"_YRNA5U\Y>#(:W;8RCG[Y>)1-#^.AZZ&6T1']N,:LA\Y:1= T6Z
M4.^3!6+6H5?2^1(\=L@=K,A7X&7L; ,!_G,P!'B[ OBC2HKH%U6\TU7TFTKK
MNZ1 9ER4O]!JDB$M- J=ZFND/:9.XYOS:S.$%?:.M"-ZI7E^DL0C1F>@<IV2
M4RJYB1IZ&Z40@MY(B3Y_UGGE\*(:2#E<J%H&*9C&DZ^X=)7S!5<&+ <N NV^
MYZFSD^5@PQ<^$QKQ:5+!79INH&NU0Q]WRK5XPV=<V4NM4')[> V:P)0%=^C.
M>\@G6\T%VF/=CSC3RSH11_;44DSG-2<:JH#<'6O=3&X<5;60R;A9BTE);%Y7
MS;$?SZTIX_![[&B$4"V; @P7?_,[?G51@4Y91?^1UY3<9GIY<<(K0YD;L@T]
MH>@-)T"K!-^Z#5S[MWO$M5G^#E)CZ+)\'-S[Z'.HHE]E L;1MP2,3]B_WP=S
MN8_&IX_77VY3TC>DJTTYT!<NB][J.V<,1H%S]K.@I:2-"E!R^N\VB(C_&@P5
MW2XB7N?9'E:@U-2JG5GL4"B*NET0S^<\&(=7P_WE.74G[,'7C- >'FX#1?WW
MO:*H2MJ0&(?84.@)J26SLQ/2LKXQB8TQ%IOK9A<FB&T#,?V_P1#3[8XOWSTY
M*-C>K#;A]IYVG8V@J6GS^35Y6,_.Q@/%Q3-AP"%1E,E4PU/;P)=*E9V"!]!N
ME^47@(9!H6@+".N''X9*6&^ %PPH(]HD^BYI6D&AC@6&Z<FK1#\95_)Z296D
MNU.+(G80.37K>$?ONAR0>"OT^.?/!TMF&O-@\$A?(#)+DGK8?7=-=$@!22:3
M\A$[D1<QH*')2/5JP*(KE62(L&@!#@- "'P:DV:YG:!U>E(4TT-W10X'_V($
M2(:;)2=34A)BY=1!Q0O<9:Q5-9>Z^HGTSK-9EW%=V$IO'_?"85T@0 6[5GL3
M0#=,_NPZ40(<E;S@N"/WTT]%WH+K]N+%8*];J@9C%'=5ZQ[N[Q]'YV & \V\
MS- #B?3&W>&WW=ER?CY4JNF&5KUK^L&J >2FK*D@$[L(<#_\U#K,OZ2$?\(2
M]LIXB7^#?CHI\G? O*9S"L_/_&=*#S&G!3V+ S>ASQKCTT<T;D>)@007O1H'
M)//;"SI&MB(K(@CBQCLY!,>+N:$>L-:36>@E2 V\61BA-< \(!4R'^OLL(5U
MUH$R$L"=]8!UD<CC\%H# $;J+L+92MXL1S85]I2!81 .F*K&*O4^FH ,RA"9
M240(YV*H=YR(X5KND@'A(SYO X_X\<>A\H@P+6 H/((LQ@6,,U59(W.!RUU>
MJS)6?YJF;$!)ICT;P469R+/$O'&"_XW9WN%(VT!8/_TT6,*R3'TH1&6-40]G
MZHL:I+.M,TA__GFHY/:;YG.ZF,*AU.F@.%DI<_+ZZ*SSK(UZT-.<DPV!11%1
M'Z4N8ZFU0%+Q!X'OFE0F#Q4TR8"(TU2B5M>ZH^NN UUL5P)^RWH(LAZ.OV4]
M? KLV\NALI7?P3@P*(>7ZOUP0D#&B!&T!&0!J&7O.-P)2H60'HS2<Y'!D=(<
MG57X-/SU_7?'CYYA/ZB\@%=EWEBZW+7E<!;V06 /&RT>[? \=,>P7I\R&MJ?
M:)D3HC0PI+K PI(1U@<@T#8^2G]P1QDN/JG99A18</5^S\ ;)Y5>P)0E&D_H
MITMT<%7B<YMPQ8I!(6Y8@V;"^+$I-B,PTSS+1*3?<#NL%;Z5^"S5PH,M5A7)
MI*Y,9TB/57>U,D?$X62:+ ,[LQO(I_>J?^W<]J2?VSZ<Y/$*_C.O%ND__C]0
M2P,$%     @ >(&F4N)JJM>Z!P  MA\  !X   !G:6QD<3$R,#(Q97@S,3%C
M96]C97)T:69I8RYH=&W=66USVS82_MY?@2IS:3RC=\NQ)#N><2WW3C-ITLNI
MD^FG&Y  1=04P0*@9-VOOV<!ZL66E"B]].)Q9D*+Y&*QV&?WV05Q^?WH_<WD
MMU]N6>IF&?OEUQ_?CF]8K=%J?3R]:;5&DQ'[Q^3GMZS7;'?8Q/#<*J=TSK-6
MZ_9=C=52YXIAJ[58+)J+TZ8VT];D0XM4]5J9UE8VA1.UJTMZ@JODXNJ[R^\;
M#3;2<3F3N6.QD=Q)P4JK\BG[**2]8XU&)76CBZ51T]2Q;KO;81^UN5-S'MX[
MY3)YM=)SV0KWERT_R66DQ?+J4J@Y4^)-324BZ73;I]UNO_^ZEYQV(Q$E2;\S
MB,[.Q3E/VO_NP,@6Q,,8ZY:9?%.;J;R12II_V.LVS\\*=[%0PJ7#3KO]MYH7
MO;I,=.XPG\'X\#.HV57&S13ZG"Z& RAR\MXU>*:F^="OL!8TK:1CG6DS?-'V
M_R[H32/A,Y4MAS],U$Q:]DXNV <]X_D/=0M4&E8:E01!J_XC82(F\;>+L()S
MZ,E4+E<K@C^PAMO[5$7*L=-.L\,>KN HVV/X7IIO9/S-[8?)^*?QS?5D_/[=
MD<;_Y:;V]IHZKK,1SY5$BC79^Y<O^MW.^<6(+^LLEL:I9,E<RMW+%V?]BV,6
M<O80A=]+2SK"(Y4+@#+L]GS$?J/U=IILS%(^E\S(N9(+9+A+E65_E-P@8+(E
MGA?:.*9S]I,V,]9I-_[)=,+^KC(D,/M7K&0>2UMGXSQNPB^#H_PR>.I^Z3;9
MC]S"&UCW;,GN<KW(I)C*>G!/Y12A,6.NP8Y0R%7.>+YD9>Y,*6$P^-)3)[S%
MV0QW1O&,)3S&(\/T#.GL=)#;$<@EG&JY69+(C-])S+NET^*9@#&8,O.\BSE(
M(%8&/ LQP@26"&G8(E5QRFQ)E\WXA32R4D(+F"E+>!*W+Y1+L4!;R-@;2'H+
MF*8%ECG',,&BY;8;G@_JIY] 7;)$Y? K0;3Q8QV00QROS=9[E2?(%4X5&+_C
MK!30":RVG%8'SHKRJX"K*4HH>K)L$P85 O;1U(@TX4M[G23*# + 7@,@/YWU
M]L3<IBS)],*N L/(J;(.?8%CG!X&NV%E?0M?NS)FQ]KG W&OR28/_%%QO*U
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MF<N=^\&-;WT.=C=3> P'5^[I*4_=NCUYV5C_AJM/?PE[\5]02P,$%     @
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M2@PY2*[0!"=2? MK[B'!^D/N<\4*PW+9#),L UR&>V.=X$".!!>NBI+;^D%
M:C_,MNQPUBQS09(Y4W;/XEYM>8]1.Y9:RVGK$'W</$*?B<8><F#K&3-XX=+K
MT*7OEB=?V,#FD^QS)CV1U?!HD];ZCN^J)N.,K2#&4E&F*NA/1O*"M5;_M"DO
M\HPL6EQ8L^RB]K4Y+F.2+2%QEV7STFQZC7K5]"\:FQ9-5_#+UL:SK8VOZ?88
M-D&-J+IS./#"G6-_!1OB8#WZXK#6VOJ38'W+A&,#62VP0%Z7JJ75@IQ0BMUI
M*\IO('PH4O?)=E'^TH72>"P/ Y>'-?PTV*=+R>UG[^1LT'^ST0*<?+S-W"59
M?X^'C"7ZVV)A[>X_\^R[C/#)6>^B?VD;KT'WU\'9\/QL@X5'$GYYTIB3"=F
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M,2YH=&U02P$"% ,4    " !X@:928AF/$Y\8  "[#P$ $0
M@ $?%P, 9VEL9"TR,#(Q,#,S,2YX<V102P$"% ,4    " !X@:927AV-9% O
M  #8  ( %0              @ 'M+P, 9VEL9"TR,#(Q,#,S,5]C86PN>&UL
M4$L! A0#%     @ >(&F4LC83E%$>@  0B4% !4              ( !<%\#
M &=I;&0M,C R,3 S,S%?9&5F+GAM;%!+ 0(4 Q0    ( 'B!IE+($$E#3B0!
M  T+#  5              "  >?9 P!G:6QD+3(P,C$P,S,Q7VQA8BYX;6Q0
M2P$"% ,4    " !X@:92_Z>C3AFN  !6T < %0              @ %H_@0
M9VEL9"TR,#(Q,#,S,5]P<F4N>&UL4$L! A0#%     @ >(&F4O34N\K8,@
M*E ! !X              ( !M*P% &=I;&1Q,3(P,C%E>#$P,38R,#(Q<'-U
M86=R+FAT;5!+ 0(4 Q0    ( 'B!IE+,9:\.1#,  $=% 0 >
M  "  <C?!0!G:6QD<3$R,#(Q97@Q,#$Y,C R,7!S=6%G<BYH=&U02P$"% ,4
M    " !X@:92HK%%$EI4   0(0( '@              @ %($P8 9VEL9'$Q
M,C R,65X,3 R-#(P,C%E;7!L;WDN:'1M4$L! A0#%     @ >(&F4N=Z;NG^
M2@  W/L! !X              ( !WF<& &=I;&1Q,3(P,C%E>#$P-S(P,C%E
M;7!L;WEE+FAT;5!+ 0(4 Q0    ( 'B!IE+B:JK7N@<  +8?   >
M      "  1BS!@!G:6QD<3$R,#(Q97@S,3%C96]C97)T:69I8RYH=&U02P$"
M% ,4    " !X@:92*%QVU)<'  #?'0  '@              @ $.NP8 9VEL
M9'$Q,C R,65X,S$R8V9O8V5R=&EF:6,N:'1M4$L! A0#%     @ >(&F4M;3
M!4N.!0  %Q8  !X              ( !X<(& &=I;&1Q,3(P,C%E>#,R<V5C
C=&EO;CDP-F-E+FAT;5!+!08     #0 - )X#  "KR 8    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
